<SEC-DOCUMENT>0001193125-14-074001.txt : 20140228
<SEC-HEADER>0001193125-14-074001.hdr.sgml : 20140228
<ACCEPTANCE-DATETIME>20140227213735
ACCESSION NUMBER:		0001193125-14-074001
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20131231
FILED AS OF DATE:		20140228
DATE AS OF CHANGE:		20140227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Regulus Therapeutics Inc.
		CENTRAL INDEX KEY:			0001505512
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				264738379
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35670
		FILM NUMBER:		14651255

	BUSINESS ADDRESS:	
		STREET 1:		3545 JOHN HOPKINS COURT
		STREET 2:		SUITE 210
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-202-6300

	MAIL ADDRESS:	
		STREET 1:		3545 JOHN HOPKINS COURT
		STREET 2:		SUITE 210
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d652681d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Form 10-K
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT&nbsp;OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2013 </B></P>
 <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>or </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: 001-35670 </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-4738379</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>3545 John Hopkins Ct., Suite 210, San Diego CA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>92121</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(858) 202-6300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:64.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:156.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Each Exchange on Which Registered</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, par value $0.001 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be
contained, to the best of the registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form
10-K.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of &#147;large accelerated filer&#148;, &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange
Act.: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities
Exchange Act of 1934).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">As of June&nbsp;28, 2013, the last business day of the registrant&#146;s most recently completed second fiscal quarter, the aggregate market
value of the registrant&#146;s common stock held by non-affiliates of the registrant was approximately $125.1&nbsp;million, based on the closing price of the registrant&#146;s common stock on the NASDAQ Global Market on June&nbsp;28, 2013 of $9.81
per share. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">The number of outstanding shares of the registrant&#146;s common stock, par value $0.001 per share, as of February&nbsp;7, 2014
was 43,168,034. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Portions of the registrant&#146;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in
connection with the registrant&#146;s 2014 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part&nbsp;III of this Form 10-K. Such proxy statement will be filed with the Securities
and Exchange Commission not later than 120 days following the end of the registrant&#146;s fiscal year ended December&nbsp;31, 2013. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-K </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Fiscal
Year Ended December&nbsp;31, 2013 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;I</B></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_1">Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_2">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_3">Unresolved Staff Comments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_4">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_5">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_6">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;II</B></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_7">Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_8">Selected Financial Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;7A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_10">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_11">Financial Statements and Supplementary Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_12">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_13">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;9B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_14">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;III</B></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_15">Directors, Executive Officers and Corporate Governance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_16">Executive Compensation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_17">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_18">Certain Relationships and Related Transactions, and Director Independence</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_19">Principal Accounting Fees and Services</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;IV</B></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#toc652681_20">Exhibits, Financial Statement Schedules</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc652681_21">Signatures</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Regulus Therapeutics logo is a trademark of Regulus Therapeutics Inc. All other product and company names
are trademarks of their respective companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Annual
Report on Form 10-K, or this Annual Report, may contain &#147;forward-looking statements&#148; within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our
actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part&nbsp;I, Item&nbsp;1A, &#147;Risk Factors&#148; in this Annual Report. Except
as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various
future events, may contain words such as &#147;may,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;estimate&#148; or other words indicating future results. Such
statements may include, but are not limited to, statements concerning the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, cost, timing, progress and results of our research and development activities, preclinical studies and future clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain regulatory approval of our future product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain funding for our operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to research, develop and commercialize our future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our strategic alliance partners&#146; election to pursue development and commercialization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract collaborators with development, regulatory and commercialization expertise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain intellectual property protection for our future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and growth potential of the markets for our future product candidates, and our ability to serve those markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully commercialize our future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance of our future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments in the United States and foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the performance of our third-party suppliers and manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competing therapies that are or become available; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the loss of key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully secure and deploy capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to satisfy our debt obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the proceeds from our initial public offering and concurrent private placement or our subsequent public offering in July 2013; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy of our estimates regarding expenses, future revenues, capital requirements and need for additional financing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the additional risks and other factors described under the caption &#147;Risk Factors&#148; under Item&nbsp;1A of this Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2013, as filed with the
Securities and Exchange Commission. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_1"></A>Business. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on
discovering and developing first-in-class drugs that target <I>micro</I>RNAs to treat a broad range of diseases. We were formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Isis Pharmaceuticals, Inc., or Isis, contributed significant
intellectual property, know-how and financial and human capital to pursue the development of drugs targeting <I>micro</I>RNAs pursuant to a license and collaboration agreement. <I>micro</I>RNAs are recently discovered, naturally occurring
ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown that the improper balance, or dysregulation, of <I>micro</I>RNAs is directly linked to many diseases. We believe we
have assembled the leading position in the <I>micro</I>RNA field, including expertise in <I>micro</I>RNA biology and oligonucleotide chemistry, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development
processes. We refer to these assets as our <I>micro</I>RNA product platform. We are using our <I>micro</I>RNA product platform to develop chemically modified, single-stranded oligonucleotides that we call anti-miRs. We use these anti-miRs to
modulate <I>micro</I>RNAs and by doing so return diseased cells to their healthy state. We are pursuing several <I>micro</I>RNA targets and are focusing our proprietary efforts in oncology and orphan diseases. We believe <I>micro</I>RNAs may be
transformative in the field of drug discovery and that anti-miRs may become a new and major class of drugs with broad therapeutic application much like small molecules, biologics and monoclonal antibodies. Additionally, we believe that
<I>micro</I>RNA biomarkers may be used to select optimal patient segments in clinical trials and to monitor disease progression or relapse. We believe these <I>micro</I>RNA biomarkers can be applied toward drugs that we develop and drugs developed
by other companies with which we partner or collaborate, including small molecules and monoclonal antibodies. In January 2014, we expanded our biomarkers efforts and established <I>micro</I>Markers&#153;, a research and development division focused
on identifying <I>micro</I>RNAs as biomarkers of human disease, which is designed to support our therapeutic pipeline, collaborators and strategic partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RNA plays an essential role in the process used by cells to encode and translate genetic information from DNA to proteins. RNA is comprised of
subunits called nucleotides and is synthesized from a DNA template by a process known as transcription. Transcription generates different types of RNA, including messenger RNAs that carry the information for proteins in the sequence of their
nucleotides. In contrast, <I>micro</I>RNAs are small RNAs that do not code for proteins but rather are responsible for regulating gene expression by affecting the translation of target messenger RNAs. By interacting with many messenger RNAs, a
single <I>micro</I>RNA can regulate several genes that are instrumental for the normal function of a biological pathway. More than 500 <I>micro</I>RNAs have been identified to date in humans, each of which is believed to interact with a specific set
of genes that control key aspects of cell biology. Since most diseases are multi-factorial and involve multiple targets in a pathway, the ability to modulate gene networks by targeting a single <I>micro</I>RNA provides a new therapeutic approach for
treating complex diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that <I>micro</I>RNA therapeutics have the potential to become a new and major class of drugs with broad
therapeutic application for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>micro</I>RNAs are a recent discovery in biology and, until recently, have not been a focus of pharmaceutical research; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>micro</I>RNAs play a critical role in regulating biological pathways by controlling the translation of many target genes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>micro</I>RNA therapeutics target entire disease pathways which may result in more effective treatment of complex multi-factorial diseases; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>micro</I>RNA therapeutics can be produced with a more efficient rational drug design process; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>micro</I>RNA therapeutics may be synergistic with other therapies because of their different mechanism of action. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently optimizing anti-miRs in several distinct programs, both independently and with our strategic alliance partners, AstraZeneca
AB, or AstraZeneca, GlaxoSmithKline plc, or GSK, and Sanofi. We also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have a collaboration agreement with Biogen Idec MA Inc., or Biogen Idec, to evaluate the potential use of <I>micro</I>RNA signatures as a biomarker for human patients with multiple sclerosis, or
MS. Under these strategic alliances, we are eligible to receive up to approximately $1.5 billion in milestone payments upon successful commercialization of <I>micro</I>RNA therapeutics for the programs contemplated by our agreements. These payments
include up to $128.0&nbsp;million upon achievement of preclinical and investigational new drug application, or IND, milestones, up to $254.0&nbsp;million upon achievement of clinical development milestones, up to $380.0&nbsp;million upon achievement
of regulatory milestones and up to $730.0 million upon achievement of commercialization milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, we set forth certain
corporate goals that seek to advance our <I>micro</I>RNA therapeutic pipeline toward the clinic under our &#145;Road to the Clinic&#146; strategy. Specifically, we set the goal of nominating two <I>micro</I>RNA candidates for clinical development in
2013, be positioned to file our first applications with regulatory authorities by the first half of 2014 and maintain a strong year-end cash position to support these goals. We successfully achieved all of these goals under our &#145;Road to the
Clinic&#146; strategy. Our first clinical candidate, RG-101, for which we have full ownership and commercial rights, is a GalNAc-conjugated anti-miR, which targets <I>micro</I>RNA-122, for the treatment of patients with chronic hepatitis C virus
infection, or HCV. We filed our first application for RG-101 with regulatory authorities in the Netherlands and recently received approval to commence a Phase I clinical trial. Additionally, we nominated RG-012, an anti-miR targeting miR-21 for the
treatment of Alport Syndrome, an orphan, life-threatening kidney disease driven by genetic mutations, as our second <I>micro</I>RNA candidate for clinical development. We are responsible for advancing RG-012 to proof-of-concept and Sanofi will have
the exclusive option, exercisable after proof-of-concept, to take over further development and commercialization of the RG-012 program. Lastly, our strong financial position supported our &#145;Road to the Clinic&#146; goals as we ended 2013 with
$114.0 million in cash, cash equivalents and short-term investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2014, we launched our &#145;Clinical Map
Initiative&#146;, which outlines certain corporate goals and objectives to advance our <I>micro</I>RNA therapeutics pipeline over the next several years. Specifically, we intend to demonstrate human proof-of-concept results in the Phase I clinical
study of RG-101 by the end of 2014, initiate a Phase I clinical study of RG-012 for the treatment of Alport Syndrome in the first half of 2015 and nominate a third <I>micro</I>RNA candidate for clinical development by the end of 2014. In order to
achieve these objectives, we intend to maintain a strong financial position and end 2014 with at least $75.0 million in cash, cash equivalents and short-term investments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OUR </B><B><I>micro</I></B><B>RNA PRODUCT PLATFORM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are the leading company in the field of <I>micro</I>RNA therapeutics. Backed by our founding companies, Alnylam and Isis, we are uniquely
positioned to leverage oligonucleotide technologies that have been proven in clinical trials. Central to achieving our goals is the know-how that we have accumulated in oligonucleotide design and how the specific chemistries behave in the clinical
setting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We view the following as providing a competitive advantage for our <I>micro</I>RNA product platform: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a mature platform selectively producing multiple development candidates advancing to the clinic; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scientific advisors who are pioneers in the <I>micro</I>RNA field; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exclusive access to proven RNA therapeutic technologies through our founding companies, as well as approximately 850 patents and patent applications relating to oligonucleotide technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a leading <I>micro</I>RNA intellectual property estate with access to approximately 200 patents and patent applications covering compositions and therapeutic uses; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">development expertise and financial resources provided by our three major strategic alliances with AstraZeneca, GSK and Sanofi; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">over 30 academic collaborations that help us identify new <I>micro</I>RNA targets and support our early stage discovery efforts. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The disciplined approach we take for the discovery and development of <I>micro</I>RNA therapeutics is as
important as the assets assembled to execute our plans and is based on the following four steps: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Step 1&#151;Evaluation of microRNA therapeutic
opportunities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initiation of our <I>micro</I>RNA discovery and development efforts is based on rigorous scientific and business criteria,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">existence of significant scientific evidence to support the role of a specific <I>micro</I>RNA in a disease; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of predictive preclinical disease models to test our <I>micro</I>RNA development candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to effectively deliver anti-miRs to the diseased cells or tissues; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">existence of a reasonable unmet medical need and commercial opportunity. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Step 2&#151;Identification of
microRNA targets </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We identify <I>micro</I>RNA targets through bioinformatic analysis of public and proprietary <I>micro</I>RNA
expression profiling data sets from samples of diseased human tissues. The analysis of such data sets can immediately highlight a potential role for specific <I>micro</I>RNAs in the disease being studied. Further investigation of animal models that
are predictive of human diseases in which those same <I>micro</I>RNAs are also dysregulated provides additional data to support a new program. We have applied this strategy successfully in our existing programs and we believe that this approach will
continue to help us identify clinically relevant <I>micro</I>RNA targets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Step 3&#151;Validation of microRNA targets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our validation strategy is based on two distinct steps. First, using genetic tools, we determine whether up-regulation, or overproduction, of
the <I>micro</I>RNA in healthy animals can create the specific disease state and inhibition of the <I>micro</I>RNA can lead to a therapeutic benefit. Second, using animal models predictive of human diseases, we determine whether pharmacological
modulation of the up-regulated <I>micro</I>RNA target with our anti-miRs can also lead to a therapeutic benefit. This validation process enables us to prioritize the best <I>micro</I>RNA targets that appear to be key drivers of disease and not
simply correlating markers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Step 4&#151;Optimization of microRNA development candidates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed a proprietary process that allows us to rapidly generate an optimized development candidate. Unlike traditional drug classes,
such as small molecules, in which thousands of compounds must be screened to identify prospective leads, the fact that anti-miRs are mirror images of their target <I>micro</I>RNAs allows for a more efficient rational design process. The optimization
process incorporates our extensive knowledge base around oligonucleotide chemistry and anti-miR design to efficiently synthesize a starting pool of rationally designed anti-miRs to be evaluated in a series of proven assays and models. We also
enhance our anti-miRs for distribution to the tissues where the specific <I>micro</I>RNA target is causing disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulus
</B><B><I>micro</I></B><B>Markers<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2014, we established Regulus
<I>micro</I>Markers&#153;, a research and development division focused on identifying <I>micro</I>RNAs as biomarkers of human disease, which is designed to support our therapeutic pipeline, collaborators and strategic partners.&nbsp;Through our
<I>micro</I>RNA target identification and validation efforts we have developed proprietary technologies for <I>micro</I>RNA profiling and analysis of human clinical samples such as tissue. More recently, <I>micro</I>RNAs have been detected in bodily
fluids such as blood, and emerging data generated by us and others have demonstrated that <I>micro</I>RNA signatures in blood can mimic the expression profile observed in disease tissues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The identification of dysregulated <I>micro</I>RNAs from various human tissues and blood helps us
identify and validate potential <I>micro</I>RNA targets for therapeutic development. Equally important, such <I>micro</I>RNAs may become biomarkers that can be used to select optimal patient segments for our clinical trials and the clinical trials
of our strategic alliance partners and collaborators. In August 2012, we entered into an agreement with Biogen Idec MA Inc. to collaborate on <I>micro</I>RNA biomarkers for MS and more recently, we entered into an arrangement with another leading,
commercial-stage pharmaceutical company to explore <I>micro</I>RNAs as biomarkers for specific patient populations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OUR INITIAL DEVELOPMENT CANDIDATES
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing single-stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of
specific target <I>micro</I>RNAs. We incorporate proprietary chemical modifications to enhance drug properties such as potency, stability and tissue distribution. We refer to these chemically modified oligonucleotides as anti-miRs. Each anti-miR is
designed to bind with and inhibit a specific <I>micro</I>RNA target that is up-regulated in a cell and that is involved in the disease state. In binding to the <I>micro</I>RNA, anti-miRs correct the dysregulation and return diseased cells to their
healthy state. We have demonstrated therapeutic benefits of our anti-miRs in over 20 different preclinical models of human diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have identified and validated several <I>micro</I>RNA targets across a number of disease categories and are working independently and with our strategic alliance partners to optimize anti-miR development candidates. Our distinct therapeutic
development programs are shown in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><B></B><B><I>micro</I></B><B>RNA&nbsp;target</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>anti-miR&nbsp;program&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt"><B>Commercial&nbsp;rights</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">miR-122</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">RG-101 for HCV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">Regulus*</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">miR-21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">RG-012 for Alport Syndrome</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">Sanofi/Regulus**</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">miR-221</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Hepatocellular&nbsp;carcinoma</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">Sanofi/Regulus**</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">miR-21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Oncology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">Sanofi/Regulus**</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">miR-19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Oncology</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">AstraZeneca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">miR-103/107</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Metabolic Disease</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">AstraZeneca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">miR-10b</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Glioblastoma</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Regulus</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">With the exception of RG-101, commercial rights for miR-122 target licensed to GSK. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Sanofi will have the exclusive option, exercisable after proof-of-concept, to take over further development and commercialization of these programs. At this stage, Regulus will have the option to co-promote any
<I>micro</I>RNA therapeutic product in the United States. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One aspect of our strategy is to pursue a balanced approach
between product candidates that we develop ourselves and those that we develop with partners. We intend to focus our own resources on proprietary product opportunities in therapeutic areas where development and commercialization activities are
appropriate for our size and financial resources, which we anticipate will include niche indications and orphan diseases. In therapeutic areas where costs are more significant, development timelines are longer or markets are too large for our
capabilities, we will seek to secure partners with requisite expertise and resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach has been validated to date by the following strategic
alliances and collaborations with large pharmaceutical companies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In April 2008, we formed a strategic alliance with GSK to discover and develop <I>micro</I>RNA therapeutics for immuno-inflammatory diseases. In February 2010, we and GSK expanded the alliance to include potential
<I>micro</I>RNA therapeutics for the treatment of HCV. In June 2013, we amended our agreement with GSK and agreed that RG-101 is fully-owned by us and that miR-122 remains a collaboration target under the agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In June 2010, we formed a strategic alliance with Sanofi to discover and develop <I>micro</I>RNA therapeutics for fibrotic diseases. In July 2012, we expanded the alliance to include potential <I>micro</I>RNA
therapeutics in oncology. The original research term for this strategic alliance expired in June 2013, upon which we and Sanofi entered into an option agreement pursuant to which we granted Sanofi an exclusive right to negotiate the co-development
and commercialization of certain of our unencumbered <I>micro</I>RNA programs, for which Sanofi paid us an upfront option fee of $2.5 million. In addition, Sanofi granted us an exclusive option to negotiate the co-development and commercialization
of miR-21. In February 2014, we and Sanofi extended our strategic alliance and Sanofi concurrently made a $10.0 million investment in our common stock at a purchase price of $7.67 per share, representing the average of the daily volume weighted
average price per share of our common stock during the 30 trading days ending on the date immediately preceding the date of investment. Under the terms of our extended alliance, Sanofi will have opt-in rights to our miR-21 pre-clinical fibrosis
program targeting miR-21 for the treatment of Alport Syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical programs targeting miR-221/222 for oncology indications, each of which is to be led by us. If
Sanofi chooses to exercise its option on any of these programs, Sanofi will reimburse us for a significant portion of our preclinical and clinical development costs and will also pay us an option exercise fee for any such program, provided that
$1.25 million of the $2.5 million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will be creditable against such option exercise fee. In addition, we will be eligible to receive clinical and regulatory
milestone payments under these programs and potentially commercial milestone payments. We also continue to be eligible to receive royalties on <I>micro</I>RNA therapeutic products commercialized by Sanofi or will have the right to co-promote these
products. For additional information, see Notes 5 and 15 to our financial statements under Item&nbsp;8 of Part II of this Annual Report. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In August 2012, we formed a strategic alliance with AstraZeneca to discover and develop <I>micro</I>RNA therapeutics for cardiovascular diseases, metabolic diseases and oncology. Pursuant to this alliance, we were
investigating targeting <I>micro</I>RNA- 33 (&#147;miR-33&#148;) for the treatment of atherosclerosis.&nbsp;We and AstraZeneca recently agreed to terminate this program as a collaboration target.&nbsp;We continue to work towards the identification
of development candidates on our other programs partnered with AstraZeneca, such as our program targeting <I>micro</I>RNA 103/107 (&#147;miR-103/107&#148;) for the treatment of metabolic diseases and <I>micro</I>RNA-19 (&#147;miR-19&#148;) in
oncology, a target selected by AstraZeneca in October 2013. In addition, AstraZeneca has a contractual right to substitute a new target for miR-33. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In August 2012, we entered into a collaboration agreement with Biogen Idec to evaluate the potential use of <I>micro</I>RNA signatures as a biomarker for human patients with MS. In June 2013, we and Biogen Idec amended
the collaboration agreement to update the research plan and criteria for success. We have also entered into an arrangement with another leading, commercial-stage pharmaceutical company to explore <I>micro</I>RNAs as biomarkers for specific patient
populations. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OUR STRATEGY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are building the leading biopharmaceutical company focused on the discovery and development of first-in-class, targeted drugs based on our
proprietary <I>micro</I>RNA product platform. The key elements of our strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Execute on our &#147;Clinical Map Initiative&#148;; rapidly advance our initial programs into clinical development.</I>&nbsp;We are currently optimizing our proprietary and partnered anti-miRs for development
candidate selection. We expect to commence our first clinical trial in the first quarter of 2014, a Phase I clinical trial of RG-101, our GalNAc-conjugated anti-miR for the treatment of HCV. Additionally, we nominated RG-012, an anti-miR targeting
miR-21 for the treatment of Alport Syndrome, an orphan, life-threatening kidney disease driven by genetic mutations, as our second <I>micro</I>RNA candidate for clinical development. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Focus our resources on developing drugs for niche indications or orphan diseases</I>.&nbsp;We believe that <I>micro</I>RNA therapeutics have
utility in many diseases as they regulate pathways, not single targets. We </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
intend to focus on proprietary product opportunities in niche therapeutic areas where the development and commercialization activities are appropriate for our size and financial resources, such
as our kidney fibrosis program targeting miR-21 for the treatment of Alport Syndrome. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Selectively form strategic alliances to augment our expertise and accelerate development and commercialization</I>.&nbsp;We have established strategic alliances with AstraZeneca, GSK and Sanofi and we will continue
to seek partners who can bring therapeutic expertise, development and commercialization capabilities and funding to allow us to maximize the potential of our <I>micro</I>RNA product platform. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Selectively use our micro</I>RNA<I> product platform to develop additional targets.</I>&nbsp;We have identified several other <I>micro</I>RNA targets with potential for therapeutic modulation and will apply our
rigorous scientific and business criteria to develop them. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Develop micro</I>RNA<I> biomarkers to support therapeutic product candidates</I>.&nbsp;We believe that <I>micro</I>RNA biomarkers may be used to select optimal patient segments in clinical trials and to monitor
disease progression or relapse. We believe these <I>micro</I>RNA biomarkers can be applied toward drugs that we develop and drugs developed by other companies with which we partner or collaborate, including small molecules and monoclonal antibodies.
In January 2014, we expanded our biomarkers efforts and established <I>micro</I>Markers&#153;, a research and development division focused on identifying <I>micro</I>RNAs as biomarkers of human disease, which is designed to support our therapeutic
pipeline, collaborators and strategic partners. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Maintain scientific and intellectual leadership in the microRNA field</I>.&nbsp;We will continue to conduct research in the <I>micro</I>RNA field to better understand this new biology and characterize the specific
mechanism of action for our future drugs. This includes building on our strong network of key opinion leaders and securing additional intellectual property rights to broaden our existing proprietary asset estate. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Our Intellectual Property and Technology Licenses </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to
protect and enhance the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to cover our products and compositions, their methods of use and any other inventions that are
important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we have a strong intellectual property position and substantial know-how relating to the development and commercialization of
<I>micro</I>RNA therapeutics, composed of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately 200 patents or patent applications that we own or have in-licensed from academic institutions and third parties including our founding companies, Alnylam and Isis, related to <I>micro</I>RNA and
<I>micro</I>RNA drug products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately 850 patents or patent applications exclusively licensed from our founding companies, Alnylam and Isis, related to RNA technologies, including patent and patent applications relating to chemical
modification of oligonucleotides that are useful for <I>micro</I>RNA therapeutics. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our objective is to continue to expand
our intellectual property estate through our multiple layer approach in order to protect our <I>micro</I>RNA therapeutics and to maintain our leading position in the <I>micro</I>RNA therapeutics field. Examples of the technologies covered by our
patent portfolio are described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have exclusively licensed patent rights from Julius-Maximilians-Universit&auml;t W&uuml;rzburg
and Bayerische Patent Allianz GmBH, which we collectively refer to herein as the University of W&uuml;rzburg, which rights encompass the use of anti-miR therapeutics targeting miR-21 for the treatment of fibrosis, including kidney, liver, lung and
cardiac fibrosis. In collaboration with us, investigators at the University of W&uuml;rzburg demonstrated that targeting miR-21 in a disease model resulted in beneficial phenotypic effects, including the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inhibition of the development of fibrosis. The W&uuml;rzburg-licensed patent portfolio includes more than 20 U.S. and foreign patents and patent applications. Any patents within this portfolio
that have issued or may yet issue would have a statutory expiration date in 2029. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Alnylam have a co-exclusive license from
Stanford University, or Stanford, to patent rights concerning the use of anti-miR therapeutics targeting miR-122 for the treatment of HCV. This patent portfolio is based upon research conducted by Peter Sarnow, Ph.D. and colleagues at Stanford,
demonstrating that miR-122 is required for HCV replication in mammalian cells. The Stanford-licensed portfolio includes more than 12 U.S and foreign patents and patent applications. Any patents within this portfolio that have issued or may yet issue
would have a statutory expiration date in 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have exclusively licensed from New York University, or NYU, patent rights encompassing
the use of an anti-miR therapeutic targeting miR-33 for the treatment of atherosclerosis, metabolic syndrome and elevated triglycerides. In collaboration with us, Kathryn Moore, Ph.D. and colleagues at NYU demonstrated that inhibiting miR-33 has
several therapeutic benefits, including reduction of atherosclerotic plaque size in an experimental model of atherosclerosis, in addition to reduction of serum triglycerides in non-human primates. The NYU-licensed patent rights include five U.S. and
foreign patent applications. Any patents that may issue from these applications would have a statutory expiration date in 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
portfolio of exclusively and jointly owned patent and patent applications is currently composed of approximately 15 U.S. and foreign patents and approximately 80 U.S. and foreign applications with claims to methods of composition-of-matter related
to our <I>micro</I>RNA drug products and <I>micro</I>RNA product platform. We jointly own approximately 10 of the patents and pending applications including those claiming methods for treating liver cancer, including hepatocellular carcinoma, or
HCC, using anti-miRs targeting miR-21. The patents have statutory expiration dates in 2024, 2025, 2026, or 2029. Any patents that may issue from the pending applications would have statutory expiration dates between 2024 and 2033. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our founding companies, Alnylam and Isis, each own or otherwise have rights to numerous patents and patent applications concerning
oligonucleotide technologies and a substantial number of these patents and applications have been exclusively licensed to us for use in the <I>micro</I>RNA field. The technologies covered in these patents and applications include various chemical
modifications that are applicable to <I>micro</I>RNA therapeutics. Due to patent expiration and strategic patent portfolio decisions, the total number licensed to Regulus will fluctuate from year to year. Among the licensed patents or patent
applications, those covering key chemical modifications for use in <I>micro</I>RNA drug products have statutory expiration dates in 2016, 2023, 2027 and 2029. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a co-exclusive license to the patent portfolio owned by Max-Planck-Gesellschaft, or MPG, which has been granted to us by
Max-Planck-Innovation GmbH, or MI, a wholly-owned subsidiary of MPG acting as MPG&#146;s technology transfer agency. MPG and MI are collectively referred to herein as Max-Planck. This patent portfolio is based on the pioneering <I>micro</I>RNA
research conducted by Thomas&nbsp;Tuschl, Ph.D. and colleagues at the Max-Planck Institute of Biophysical Chemistry, which led to the discovery of over 100 human <I>micro</I>RNA sequences, including <I>micro</I>RNAs that are the focus of several of
our programs. The patent rights encompass the <I>micro</I>RNA gene sequences as well as the antisense sequences that are complementary to the <I>micro</I>RNAs and thus cover both <I>micro</I>RNA mimic and anti-miR products. Our license is
co-exclusive with our founding companies, Alnylam and Isis, for the exploitation of the Max-Planck patent rights for therapeutic uses. In addition, we also have a co-exclusive license to develop and commercialize diagnostics based upon the
Max-Planck patent rights contained in these applications. The Max-Planck licensed patent portfolio, referred to herein as the Tuschl 3 patents, includes at least 25 U.S. and foreign patents and patent applications. Any patents within this portfolio
that have issued or may yet issue would have a statutory expiration date in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal
term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing the non-provisional application. In the United States, a patent&#146;s term may be lengthened by
patent term adjustment, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed
patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term
restoration of a U.S. patent as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent
term extension is related to the length of time the drug is under regulatory review. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to
an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. When possible, depending upon the length of clinical trials and other factors
involved in the filing of a new drug application, or NDA, we expect to apply for patent term extensions for patents covering our <I>micro</I>RNA product candidates and their methods of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to
protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and
trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
Technology Licenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Max-Planck </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Therapeutic license </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to 2011, our
access to the Tuschl 3 patents was derived from agreements between Max-Planck and our founding companies, Alnylam and Isis, for exclusive use in <I>micro</I>RNA therapeutics. In April 2011, we entered into a direct, co-exclusive license with
Max-Planck. The license provides to us, Alnylam and Isis, co-exclusively, access to the Tuschl 3 patents for therapeutic use. Max-Planck retains the right to practice the intellectual property licensed under the agreement for non-commercial
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the license, we are permitted to sublicense our rights outright or as part of an alliance. The license
requires that we use commercially reasonable diligence in developing and commercializing a product. In order to secure the license, we made an upfront payment of $400,000 to Max-Planck. We will be required to make payments based upon the initiation
of clinical trials and/or product approval milestones totaling up to $1.6 million for each licensed product reaching such clinical stage. In addition to milestone payments, we will be required to pay royalties of a percentage of cumulative annual
net sales of a licensed product commercialized by us or one of our strategic alliance partners. The percentage is in the low single digits, with the exact percentage depending upon whether the licensed product incorporates intellectual property
covered by a Tuschl&nbsp;3 patent that is still a pending application or, alternatively, an issued patent, and also upon the volume of annual sales. The royalties payable to Max-Planck are subject to reduction for any third party payments required
to be made, with a minimum floor in the low single digits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The longest lived patent rights licensed to us under the agreement have a
statutory expiration date of September 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Diagnostic license </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in June 2009, we entered into a co-exclusive license with Max-Planck for use of the Tuschl 3 patents for diagnostic purposes.
Under the terms of the license, we made an aggregate initial payment to Max-Planck of &#128;175,000 in three installments, with &#128;75,000 paid in June 2009 and &#128;50,000 paid in each of June 2010 and June 2011. In addition, we made annual
maintenance payments of &#128;10,000 in 2011, &#128;20,000 in 2012 and &#128;30,000 in 2013 and will make annual maintenance payments in this amount thereafter during the term of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement. In addition to maintenance payments, we will be required to pay royalties of a percentage of net sales of licensed products. The percentage is in the mid-single digits in the event we
market the product and low end of the 10 to 20% range in the event we sell the product through a distributor. The royalties payable to Max-Planck are reduced by the royalties payable to third parties but only if aggregate royalties payable to
Max-Planck and third parties exceed a percentage in the mid-10 to 20% range. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to use commercially reasonable efforts to
develop and commercialize products under the agreement. Under the terms of the agreement, Max-Planck is permitted to provide up to three additional co-exclusive licenses to its diagnostic patent rights. The longest lived patent rights licensed to us
under the agreement have a statutory expiration date of September 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Max-Planck retains the right to practice the intellectual
property licensed under the agreement for non-commercial purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>University of W&uuml;rzburg </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2010, we exclusively licensed patent rights from the University of W&uuml;rzburg which encompass the use of anti-miR therapeutics
targeting miR-21 for the treatment of fibrosis, including kidney, liver, lung and cardiac fibrosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The University of W&uuml;rzburg has
reserved the right to use the licensed intellectual property for academic and non-commercial purposes. We have the right to grant sublicenses to third parties under the agreement provided such sublicense is for the purpose of developing or
commercializing a product. We must obtain the University of W&uuml;rzburg&#146;s written consent to any such sublicense, which may not be unreasonably withheld. We must use commercially reasonable diligence in our efforts to develop, manufacture and
commercialize a licensed product. We have assumed certain development milestone obligations and must report on our progress in achieving these milestones on an annual basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a license issuance fee, we paid the University of W&uuml;rzburg &#128;300,000. In addition, upon commercialization of a product, we will
pay to the University of W&uuml;rzburg a percentage of net sales as a royalty. This royalty is in the low single digits and is reduced upon expiration of all patent claims covering the product. We also paid the University of W&uuml;rzburg a
partnership bonus of &#128;200,000 upon entering into our strategic alliance agreement with Sanofi. Under the agreement, beginning January&nbsp;1, 2020 and ending on the date we receive NDA approval for a licensed product, we will accrue a minimum
royalty obligation of &#128;150,000&nbsp;per year, which will become payable upon approval of an NDA for a licensed product. After approval of an NDA for a licensed product, we will be required to pay the University of W&uuml;rzburg an annual
minimum royalty, which increases in the five years following approval up to a maximum of &#128;3.0&nbsp;million&nbsp;per year. The minimum royalties are creditable against actual royalties due and payable for the same calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we will be required to pay the University of W&uuml;rzburg milestone payments of up to an aggregate of &#128;1.75&nbsp;million,
based upon achievement of specified clinical and regulatory events. In the event we initiate a Phase 2 clinical trial for another indication with the same licensed product, we will be required to pay 50% of the milestone payments applicable to such
milestone events. These milestone events are also tied to the due dates set forth in the commercialization plan but may be extended by delays caused by scientific challenges, regulatory requirements or other circumstances outside of our control. We
must request an extension in writing explaining the cause for the delay and proposing new due dates. The University of W&uuml;rzburg may accept the revised dates or reject them, in which case an arbitrator will set the revised dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The last to expire patent licensed to us under the agreement is currently expected to expire in February 2029. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stanford University </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August
2005, Alnylam and Isis entered into a co-exclusive license agreement with Stanford, relating to its patent applications claiming the use of miR-122 to reduce the replication of HCV. Upon our formation, we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received access to the Stanford technology as an affiliate of Alnylam and Isis. In July 2009, Isis assigned its rights and obligations under the license agreement to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the license agreement, we are permitted to research, develop, manufacture and commercialize therapeutics for the treatment and
prevention of HCV and related conditions. Diagnostics and reagents are specifically excluded from the license. In addition, the license provides a non-exclusive right to research, develop, manufacture and commercialize therapeutics for all
conditions or diseases other than HCV. Stanford retained the right, on behalf of itself and all other non-profit academic institutions, to practice the licensed patents for non-profit purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are permitted to sublicense our rights under the agreement in connection with a bona fide partnership seeking to research and/or develop
products under a jointly prepared research plan and which also includes a license to our intellectual property or in association with providing services to a sublicensee. In the event we receive an upfront payment in connection with a sublicense, we
are obligated to pay to Stanford a one-time fixed payment amount, which amount will vary depending upon the size of upfront payment we receive. We must also make an annual license maintenance payment during the term of the agreement. The maintenance
payments are creditable against royalty payments made in the same year. We will be required to pay milestones for an exclusively licensed product which will be payable upon achievement of specified regulatory and clinical milestones in an aggregate
amount of up to $400,000. Milestones for a non-exclusively licensed product will be payable upon achievement of the same milestones in an aggregate amount of up to $300,000 for the first such product and up to $200,000 for the second such product.
Upon commercialization of a product, we will be required to pay to Stanford a percentage of net sales as a royalty. This percentage is in the low single digits. The payment will be reduced by other payments we are required to make to third parties
until a minimum royalty has been reached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement requires that we use commercially reasonable efforts to develop, manufacture and
commercialize a licensed product and we have agreed to meet certain development and commercialization milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The last to expire
patent licensed to us under the agreement is currently expected to expire in May 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New York University </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2011, we entered into an exclusive license with NYU related to our miR-33 program. The license provides us the right to develop,
manufacture and commercialize therapeutics for the treatment or prevention of atherosclerotic plaque and/or other metabolic disorders under NYU&#146;s patents. We are entitled to grant sublicenses under the agreement. NYU retains the right to
practice the intellectual property licensed under the agreement for non-commercial purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we paid to
NYU an upfront payment of $25,000. An equal additional payment will be required upon issuance of a patent containing a claim of treating or preventing disease. We will be required to make payments to NYU upon achievement of specified clinical and
regulatory milestones of up to an aggregate of $925,000. These milestone payments will only be made after issuance of a therapeutic claim under the NYU patent applications. We are also required to pay royalties of a percentage of net sales for any
product sold by us or a strategic alliance partner. The royalty rate is in the low single digits and is subject to reduction to a minimum amount in the event we are required to pay royalties to a third party. In the event we sublicense the NYU
patents, NYU is also entitled to receive a percentage of the sublicense income received by us. The percentage payable depends upon the development stage of the program when the sublicense is completed with the highest percentage paid with submission
of the first IND. The percentage thereafter declines until completion of the first Phase 2 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required, under the
terms of the agreement, to use reasonable diligence to develop and commercialize a product and are required to provide NYU with annual reports detailing our progress in this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regard. In particular, we are required to fulfill specific development and regulatory milestones by particular dates. The longest-lived patent rights covered by the agreement is currently
expected to expire in August 2031. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We contract with third parties to manufacture our compounds and intend to do so in the future. We do not own or operate and we do not expect to
own or operate, facilities for product manufacturing, storage and distribution, or testing. We have personnel with extensive technical, manufacturing, analytical and quality experience and strong project management discipline to oversee contract
manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing
is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Our systems and
contractors are required to be in compliance with these regulations, and this is assessed regularly through monitoring of performance and a formal audit program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
2013, 2012 and 2011, research and development expenses were $29.9 million, $20.3 million and $17.3 million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by intense and rapidly changing competition to develop new technologies and
proprietary products. While we believe that our proprietary asset estate and scientific expertise in the <I>micro</I>RNA field provide us with competitive advantages, we face potential competition from many different sources, including larger and
better-funded pharmaceutical companies. Not only must we compete with other companies that are focused on <I>micro</I>RNA therapeutics but any products that we may commercialize will have to compete with existing therapies and new therapies that may
become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware of several companies that are working specifically to develop <I>micro</I>RNA therapeutics.
These include the biotechnology companies Groove Biopharma, Inc., InteRNA Technologies B.V., miRagen Therapeutics, Inc., MiReven Pty Ltd, Mirna Therapeutics, Inc., Microlin Bio, Inc. and Santaris Pharma A/S. These competitors also compete with us in
recruiting human capital and securing licenses to complementary technologies or specific <I>micro</I>RNAs that may be critical to the success of our business. They also compete with us for potential funding from the pharmaceutical industry. In
addition, we expect that for each disease category for which we determine to develop and apply our <I>micro</I>RNA therapeutics there are other biotechnology companies that will compete against us by applying marketed products and development
programs using technology other than <I>micro</I>RNA therapeutics. The key competitive factors that will affect the success of any of our development candidates, if commercialized, are likely to be their efficacy relative to such competing
technologies, safety, convenience, price and the availability of reimbursement from government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our competitors have products which are better in one or more
of these categories. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our&nbsp;Leadership </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive team has more than 50 years of collective experience leading the discovery and development of innovative therapeutics, including
significant operational and financial experience with emerging biotechnology companies, which we believe is the ideal combination of talent to execute our strategy.&nbsp;In addition, our experienced board of directors, which includes representatives
of our founding companies, Alnylam and Isis, provides significant support and guidance in all aspects of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive officers are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Kleanthis G. Xanthopoulos, Ph.D., our President and Chief Executive Officer, is an entrepreneur who has been involved in founding several companies, including Anadys Pharmaceuticals, Inc. (acquired by
F.&nbsp;Hoffmann-La Roche Inc. in 2011), which he started as President and Chief Executive Officer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Neil W. Gibson, Ph.D., our Chief Scientific Officer, is experienced in the discovery and development of novel therapeutics who previously served as Chief Scientific Officer of the Oncology Research Unit at Pfizer Inc.
and as Chief Scientific Officer of OSI Pharmaceuticals, Inc. He was involved in the discovery and development of several commercial cancer drugs including Xalkori<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (crizotinib), Nexavar<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (sorafenib) and Tarceva<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (erlotinib). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive team is supported by the following key personnel: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">David Szekeres, our Chief Business Officer and General Counsel, is an experienced transactional advisor with over a decade of experience in the global life sciences industry and who previously served in leadership roles
at several companies, including Life Technologies Corporation, Invitrogen Corporation, Latham&nbsp;&amp; Watkins LLP and Robertson Stephens. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mary Glanville, our Senior Vice President of Human Capital, is an accomplished human resources executive in the life sciences industry who previously served in management roles at Anadys Pharmaceuticals, Inc. (acquired
by F. Hoffman-La Roche Inc. in 2011), Inflazyme Inc. and Inex Pharmaceuticals Corp. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Victor Knopov, Ph.D., our Vice President, Pharmaceutical Development, is a leader in oligonucleotide drug delivery and pharmaceutical development who has held positions at Nitto Denko Technical Corporation, Bio-Medics,
Inc., EnGene, Inc., Marina Biotech, Inc. and Inex Pharmaceuticals Corporation. Dr.&nbsp;Knopov has extensive knowledge of Chemistry, Manufacturing and Control, or CMC, development for various technology platforms including commercial production of
enzymes, anticancer liposomal products as well as advanced delivery systems for antisense, plasmids and siRNA based on lipids, polymer nanoparticles and conjugated systems. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Daniel R. Chevallard, CPA, our Vice President, Finance and Accounting, is a corporate finance leader with public accounting expertise who previously held senior roles in corporate finance, accounting and financial
reporting as Controller and Senior Director, Finance at Prometheus Laboratories Inc. and who was a senior financial auditor at Ernst&nbsp;&amp; Young LLP. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of
products such as those we are developing. Any product candidate that we develop must be approved by the FDA before it may be legally marketed in the United States and by the appropriate foreign regulatory agency before it may be legally marketed in
foreign countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. drug development process </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations. Drugs are
also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure
of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial civil
or criminal sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning letters, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, debarment, restitution, disgorgement or civil
or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of nonclinical laboratory tests, animal studies and formulation studies according to good laboratory practices, or GLP, or other applicable regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an application for an IND, which must become effective before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations commonly referred to as current good clinical practices, or GCPs, to establish the safety and efficacy of the
proposed drug for its intended use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an NDA for a new drug; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with the FDA&#146;s current good manufacturing practice standards, or cGMP, to
assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA review and approval of the NDA. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lengthy process of seeking required approvals and the
continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources and approvals are inherently uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any compounds with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage. Preclinical
tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate. The conduct of the
preclinical tests must comply with federal regulations and requirements including GLP. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature
and a proposed clinical protocol, to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that 30-day time period. In such a case,
the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance.
Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the drug candidate to healthy volunteers or patients under the supervision of qualified
investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection
and exclusion criteria, and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted in accordance with the FDA&#146;s regulations comprising the good
clinical practices requirements. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with
protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the
form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 1.&nbsp;The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or
life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2.&nbsp;The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to
determine dosage tolerance, optimal dosage and dosing schedule. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 3.&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are
intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing
approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual progress reports detailing the results of the clinical trials must be submitted to the FDA and written IND safety reports must be
promptly submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not
be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are
being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has
been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with clinical trials, companies usually complete additional animal
studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The
manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. review and approval processes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
results of product development, nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to
the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA must contain data to assess the safety and
effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for
submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all NDAs submitted to determine if they are substantially complete before it
accepts them for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA has 10&nbsp;months in
which to complete its initial review of a standard NDA and respond to the applicant, and six months for a priority NDA. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs. The review process and the PDUFA goal date may
be extended by three months if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is
safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, strength, quality and purity. The FDA may refer applications for novel drug or
biological products or drug or biological products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to
whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the
FDA also will determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve
the NDA without a REMS, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured.
The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.
Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements. If the FDA determines that the application, manufacturing
process or manufacturing facilities are not acceptable it will outline the deficiencies in the submission and often will request additional testing or information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NDA review and approval process is lengthy and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria
are not satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from
clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides not to approve the NDA. The complete response letter usually
describes all of the specific deficiencies in the NDA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete
response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the
deficiencies identified in the letter, or withdraw the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be
significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or
precautions be included in the product labeling. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials testing, which involves clinical trials designed to further assess a drug safety and
effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan drug designation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or
biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting an NDA. After the FDA grants orphan product
designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for
the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same drug or
biological product as defined by the FDA or if our drug candidate is determined to be contained within the competitor&#146;s product for the same indication or disease. If a drug or biological product designated as an orphan product receives
marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status has similar but not identical benefits in the European Union. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expedited development and review programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that
meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the
condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may consider for review sections of the NDA on a rolling basis before the
complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user
fees upon submission of the first section of the NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including a Fast Track program, may
also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective therapy
where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an
application for a new drug or biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and
effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and
well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible
morbidity. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as
a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the standards
for approval but may expedite the development or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Post-approval requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any drug products for which we or our strategic alliance partners receive FDA approvals are subject to continuing regulation by the FDA,
including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain
electronic records and signature requirements and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, promoting drugs for uses or in patient populations that are not
described in the drug&#146;s approved labeling (known as &#147;off-label use&#148;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with FDA requirements can have
negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs for
off-label uses, manufacturers may not market or promote such off-label uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will rely, and expect to continue to rely, on third
parties for the production of clinical and commercial quantities of any products that we may commercialize. Our strategic alliance partners may also utilize third parties for some or all of a product we are developing with such strategic alliance
partner. Manufacturers of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&#146;s cGMP regulations. cGMP regulations require among other things, quality control and quality assurance as well as
the corresponding maintenance of records and documentation. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies,
and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality
control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA, including withdrawal of the product from the market. In addition, changes
to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require post-marketing testing, known as Phase 4 testing, risk minimization action plans and surveillance to
monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. patent
term restoration and marketing exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of the FDA approval of the use of our
drug candidates, some of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent
beyond a total of 14 years from the product&#146;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of
an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and
Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed
patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications of other companies seeking
to reference another company&#146;s NDA. The FDCA provides a five-year </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has
not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug
application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be
submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or
supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new
indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active
agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and
adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to
existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued
&#147;Written Request&#148; for such a trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>U.S. Foreign Corrupt Practices Act </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits certain individuals and entities, including us, from promising, paying, offering to
pay, or authorizing the payment of anything of value to any foreign government official, directly or indirectly, to obtain or retain business or an improper advantage. The U.S. Department of Justice and the U.S. Securities and Exchange Commission,
or SEC, have increased their enforcement efforts with respect to the FCPA. Violations of the FCPA may result in large civil and criminal penalties and could result in an adverse effect on a company&#146;s reputation, operations, and financial
condition. A company may also face collateral consequences such as debarment and the loss of export privileges. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal and state fraud and abuse laws
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been
applied to restrict certain business practices in the biopharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving
remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The term
&#147;remuneration&#148; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payment, ownership interests and
providing anything at less than its fair market value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other.
Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and our practices may not in all cases meet all of the
criteria for statutory exemptions or safe harbor protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an
exemption or safe harbor. Several courts have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has
been violated. The reach of the Anti-Kickback Statute was also broadened by the Patient Protection and Affordable Health Care Act, as amended by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Health Care and Education Affordability Reconciliation Act, or collectively the PPACA, which, among other things, amends the intent requirement of the federal Anti-Kickback Statute. Pursuant
to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the PPACA provides that the government may assert that a
claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute, which
imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or
fraudulent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for
payment to the federal government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal
programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, and thus non-reimbursable, uses. Many states also have statutes or
regulations similar to the federal Anti-Kickback Statute and False Claims Act, which state laws apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. Also, the federal
Health Insurance Portability and Accountability Act of 1996, or HIPAA, created new federal criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payers and
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the federal Anti-Kickback Statute&#146;s safe harbors, it is possible that some of
our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition and results of operations. If we obtain FDA approval for any of our
product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers, distributors, or other business partners, subject to various federal and state fraud and abuse
laws, including, without limitation, anti-kickback statutes and false claims statutes. These laws may impact, among other things, our proposed sales, marketing and education programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our
business. HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable
health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to &#147;business associates&#148;&#151;independent contractors or agents of covered entities that receive or obtain protected
health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave
state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. In addition, state
laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that
apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion of products from reimbursement under government programs, and the curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our product candidates are ultimately sold in a foreign country, we may be subject to similar foreign laws
and regulations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and
reporting of payments or transfers of value to healthcare professionals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and foreign jurisdictions, there have been
a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that
seek to reduce healthcare costs. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D,
Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug
coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its
own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all
the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for
our products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to
drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from Medicare Part&nbsp;D may result in a similar
reduction in payments from non-governmental payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The American Recovery and Reinvestment Act of 2009 provides funding for the federal
government to compare the effectiveness of different treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National
Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or
private payors, it is not clear what effect, if any, the research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness
research demonstrating benefits in a competitor&#146;s product could adversely affect the sales of our product candidates. If third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not
cover our products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most recently, in March 2010 the PPACA was enacted, which includes measures to significantly change the way healthcare is financed by both
governmental and private insurers. Among the provisions of the PPACA of greatest importance to the pharmaceutical and biotechnology industry are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government
healthcare programs, that began in 2011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain
individuals with income at or below 133% of the Federal Poverty Level beginning in 2014, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new requirements to report certain financial arrangements with physicians and teaching hospitals, as defined in the PPACA and its implementing regulations, including reporting any &#147;transfer of value&#148; made or
distributed to teaching hospitals, prescribers and other healthcare providers and reporting any ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations during the
preceding calendar year, with data collection to be required beginning August&nbsp;1, 2013 and reporting to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, to be required by March&nbsp;31, 2014 and by the 90th day of each subsequent
calendar year; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians, effective April&nbsp;1, 2012; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of health care fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a licensure framework for follow-on biologic products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">creation of the Independent Payment Advisory Board which, beginning in 2014, will have authority to recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs and
those recommendations could have the effect of law even if Congress does not act on the recommendations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on
January&nbsp;1, 2011. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the details regarding the implementation of the PPACA are yet to be determined, and at this
time, it remains unclear the full effect that the PPACA would have on our business. On June&nbsp;28, 2012, the US Supreme Court upheld the constitutionality of the PPACA, excepting certain provisions that would have required each state to expand its
Medicaid programs or risk losing all of the state&#146;s Medicaid funding. At this time, it remains unclear whether there will be any further changes made to the PPACA, whether in part or in its entirety. Some states have indicated that they intend
to not implement certain sections of the PPACA, and some members of the US Congress are still working to repeal the PPACA. We cannot predict whether these challenges will continue or other proposals will be made or adopted, or what impact these
efforts may have on us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Europe / rest of world government regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we and our strategic alliance partners will be subject to a variety of regulations in other
jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we
or our collaborators obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain
countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a clinical trial
application, or CTA, must be submitted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to each country&#146;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#146;s
requirements, clinical trial development may proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials, product
licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration
of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of an investigational drug or biological product under European Union regulatory systems, we
or our strategic alliance partners must submit a marketing authorization application. The application used to file the NDA or BLA in the United States is similar to that required in the European Union, with the exception of, among other things,
country-specific document requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union, such as countries in Eastern Europe, Latin
America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable
regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our strategic alliance
partners fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal
prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2013, we had 76 employees, of which 73 were full-time employees. Of these full-time employees, 59 employees are engaged in research and development activities and 14 employees are engaged in finance, legal, human resources,
facilities and general management. We have no collective bargaining agreements with our employees and we have not experienced any work stoppages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were originally
formed as a limited liability company under the name Regulus Therapeutics LLC in the State of Delaware in September 2007. In January 2009, we converted Regulus Therapeutics LLC to a Delaware corporation and changed our name to Regulus Therapeutics
Inc. Our principal executive offices are located at 3545 John Hopkins Court, Suite 210, San&nbsp;Diego, California 92121, and our telephone number is (858)&nbsp;202-6300. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate website address is www.regulusrx.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form
8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available free of charge on our website as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC. The SEC maintains an internet site that contains our public filings with the SEC and other information regarding the Company, at www.sec.gov. These reports and other information concerning the
Company may also be accessed at the SEC&#146;s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The contents of
these websites are not incorporated into this Annual Report. Further, our references to the URLs for these websites are intended to be inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use &#147;Regulus Therapeutics&#148; as a trademark in the United States and other countries. We have registered this trademark in the
United States and have also registered it in the European Union and Switzerland. This Annual Report contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to
in this Annual Report, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">&#153; </SUP>symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licensor to these trademarks and trade names. We do not intend our use or display of other companies&#146; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of
us by, any other companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. We will remain an emerging growth
company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of our initial public offering in October 2012, (b)&nbsp;in which we have total annual gross revenue of at least $1.0&nbsp;billion, or
(c)&nbsp;in which we are deemed to be a large accelerated filer, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three-year period. References herein to &#147;emerging growth
company&#148; shall have the meaning associated with it in the JOBS Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_2"></A>Risk Factors. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except for the historical information contained herein or
incorporated by reference, this Annual Report and the information incorporated by reference contains forward-looking statements that involve risks and uncertainties. These statements include projections about our accounting and finances, plans and
objectives for the future, future operating and economic performance and other statements regarding future performance. These statements are not guarantees of future performance or events. Our actual results may differ materially from those
discussed here. Factors that could cause or contribute to differences in our actual results include those discussed in the following section, as well as those discussed in Part II, Item&nbsp;7 entitled &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; and elsewhere throughout this Annual Report and in any other documents incorporated by reference into this Annual Report. You should consider carefully the following risk factors, together with
all of the other information included or incorporated in this Annual Report. Each of these risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affect the
value of an investment in our common stock. There may be additional risks that we do not presently know of or that we currently believe are immaterial which could also impair our business and financial position. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO OUR FINANCIAL CONDITION AND NEED FOR ADDITIONAL CAPITAL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses
for the foreseeable future. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a preclinical-stage, biopharmaceutical discovery and development company, formed in 2007, with a
limited operating history. Since inception, our operations have been primarily limited to organizing and staffing our company, acquiring and in-licensing intellectual property rights, developing our <I>micro</I>RNA product platform, undertaking
basic research around <I>micro</I>RNA targets and conducting preclinical studies for our initial programs. We have not yet initiated a clinical trial or obtained regulatory approval for any product candidates. Consequently, any predictions about our
future success or viability, or any evaluation of our business and prospects, may not be accurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred losses in each year
since our inception in September 2007. Our net losses were $18.7 million, $17.4 million and $7.6 million for the years ended December&nbsp;31, 2013, 2012 and 2011, respectively. As of December&nbsp;31, 2013, we had an accumulated deficit of $79.1
million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have devoted most of our financial resources to research and development, including our preclinical development activities.
To date, we have financed our operations primarily through the sale of equity securities and convertible debt and from revenue received from our strategic alliance partners. We have entered into strategic alliances with Sanofi relating to the
development of our miR-21 programs for HCC and kidney fibrosis and our miR-221/222 program for oncology indications, with GSK to develop our miR-122 program for HCV, and with AstraZeneca, to develop metabolic and oncology programs. Under our
agreements with Sanofi and GSK, Sanofi and GSK each have an option to obtain exclusive worldwide licenses for the development, manufacture and commercialization of potential product candidates selected from our programs. If either of Sanofi or GSK
exercises their respective options to obtain a license to develop, manufacture and commercialize such product candidates, such party will assume responsibility for funding and conducting further clinical development and commercialization activities
for such product candidates. However, if either of these parties does not exercise its option within the timeframes that we expect, or at all, we will be responsible for funding further development of the applicable product candidates and may not
have the resources to do so unless we are able to enter into another strategic alliance for these product candidates. The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to obtain funding
through equity or debt financings, strategic alliances or grants. We have only recently initiated clinical development of any product candidate and it will be several years, if ever, before we have a product candidate ready for commercialization.
Even if we or our strategic alliance partners successfully obtain regulatory approval to market a product candidate, our revenues will also depend upon the size of any markets in which our product candidates have received market approval, and our
ability to achieve sufficient market acceptance and adequate market share for our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasing operating losses for the
foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we: continue our research and preclinical development of our future product
candidates, both independently and under our strategic alliance agreements; seek to identify additional <I>micro</I>RNA targets and product candidates; acquire or in-license other products and technologies; initiate clinical trials for our product
candidates; seek marketing approvals for our product candidates that successfully complete clinical trials; ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing
approval; maintain, expand and protect our intellectual property portfolio; hire additional clinical, quality control and scientific personnel; and create additional infrastructure to support our operations as a public company and our product
development and planned future commercialization efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have never generated any revenue from product sales and may never be profitable. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic alliance partners, to successfully
complete the development of, obtain the necessary regulatory approvals for and commercialize product candidates. We do not anticipate generating revenues from sales of products for the foreseeable future, if ever. Our ability to generate future
revenues from product sales depends heavily on our success in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and validating new <I>micro</I>RNAs as therapeutic targets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completing our research and preclinical development of future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiating and completing clinical trials for future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seeking and obtaining marketing approvals for future product candidates that successfully complete clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing and maintaining supply and manufacturing relationships with third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching and commercializing future product candidates for which we obtain marketing approval, with an alliance partner or, if launched independently, successfully establishing a sales force, marketing and distribution
infrastructure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining, protecting and expanding our intellectual property portfolio; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attracting, hiring and retaining qualified personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and
uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of increased expenses and when we will be able to achieve or maintain profitability, if ever. In addition, our expenses could increase
beyond expectations if we are required by the FDA or foreign regulatory agencies to perform studies and trials in addition to those that we currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if one or more of the future product candidates that we independently develop is approved for commercial sale, we anticipate incurring
significant costs associated with commercializing any approved product candidate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may need to raise additional capital, which may not be available on acceptable terms, or at all. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research and
development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidates toward clinical programs. We will need to raise additional capital to support our operations and such funding
may not be available to us on acceptable terms, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we move our lead compounds through toxicology and other preclinical studies, also referred to
as nonclinical studies, required to file an IND, and as we conduct clinical development of RG-101, RG-012 and any other future product candidates, we may have adverse results requiring mitigation strategies that may cause us to consume additional
capital. Additionally, our strategic alliance partners may not elect to pursue the development and commercialization of any of our <I>micro</I>RNA product candidates that are subject to their respective strategic alliance agreements with us. Any of
these events may increase our development costs more than we expect. We may need to raise additional capital or otherwise obtain funding through strategic alliances if we choose to initiate clinical trials for new product candidates other than
programs currently partnered. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, future product candidates. Raising funds in the current economic environment, when the capital markets have been
affected by the global recession, may present additional challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to secure additional financing, such additional
fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize future product candidates. In addition, we cannot guarantee that future financing will be available in
sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significantly delay, scale back or discontinue the development or commercialization of any future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek strategic alliances for research and development programs at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional fundraising activities and we are unable to raise additional capital in sufficient amounts or on
terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in
additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that
significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock,
convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction,
investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. Pursuant to our 2012 Equity Incentive
Plan, or the 2012 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2012 Plan will automatically increase
each year by up to 4% of all shares of our capital stock outstanding as of December&nbsp;31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Any such
increase, of the maximum amount or a lesser amount, will cause our stockholders to experience additional dilution, which could cause our stock price to fall. Currently, we plan to register the increased number of shares available for issuance under
the 2012 Plan each year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO THE DISCOVERY AND DEVELOPMENT OF PRODUCT CANDIDATES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The approach we are taking to discover and develop drugs is novel and may never lead to marketable products. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have concentrated our therapeutic product research and development efforts on <I>micro</I>RNA technology, and our future success depends on
the successful development of this technology and products based on our <I>micro</I>RNA product platform. Neither we nor any other company has received regulatory approval to market therapeutics targeting <I>micro</I>RNAs. The scientific discoveries
that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we
do not successfully develop and commercialize product candidates based upon our technological approach, we may not become profitable and the value of our common stock may decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our focus solely on <I>micro</I>RNA technology for developing drugs as opposed to multiple, more proven technologies for drug
development increases the risks associated with the ownership of our common stock. If we are not successful in developing any product candidates using <I>micro</I>RNA technology, we may be required to change the scope and direction of our product
development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may
not be successful in our efforts to identify or discover potential product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily
upon our ability to identify, develop and commercialize <I>micro</I>RNA therapeutics. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a
number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our research methodology or that of our strategic alliance partners may be unsuccessful in identifying potential product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our strategic alliance partners may change their development profiles for potential product candidates or abandon a therapeutic area. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material
adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential
programs or product candidates that ultimately prove to be unsuccessful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preclinical testing and clinical trials of our future product candidates may
not be successful. If we are unable to successfully complete preclinical testing and clinical trials of our product candidates or experience significant delays in doing so, our business will be materially harmed. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our efforts and financial resources in the identification and preclinical development of product
candidates that target <I>micro</I>RNAs. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our future product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our future product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of preclinical studies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from applicable regulatory authorities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining patent and trade secret protection for future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully commercializing our products, if and when approved, whether alone or in collaboration with others. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully complete the development of, or commercialize, our product candidates, which would materially harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If clinical trials of
our future product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be
unable to complete, the development and commercialization of our future product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from
regulatory authorities for the sale of future product candidates, we or our strategic alliance partners must then conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is
expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early clinical trials
may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses,
and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Events which may result in a delay or unsuccessful completion of clinical development include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching an agreement with the FDA or other regulatory authorities on final trial design; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to adhere to clinical trial requirements directly or with third parties such as CROs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining required institutional review board approval at each clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in recruiting suitable patients to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in having patients complete participation in a trial or return for post-treatment follow-up; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays caused by patients dropping out of a trial due to product side effects or disease progression; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical sites dropping out of a trial to the detriment of enrollment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">time required to add new clinical sites; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our strategic alliance partners are required to conduct additional clinical trials or other testing of any future product candidates
beyond those that are currently contemplated, are unable to successfully complete clinical trials of any such product candidates or other testing, or if the results of these trials or tests are not positive or are only modestly positive or if there
are safety concerns, we or our strategic alliance partners may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval at all; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have the product removed from the market after obtaining marketing approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant
clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to
successfully commercialize our product candidates and may harm our business and results of operations. Any inability to successfully complete preclinical and clinical development, whether independently or with our strategic alliance partners, could
result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any of our future product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the
scope of any approved label or market acceptance. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse events, or AEs, caused by our future product candidates could cause us,
other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. Certain oligonucleotide therapeutics have shown injection site reactions and
pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our future product candidates may induce similar adverse events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If AEs are observed in any clinical trials of our future product candidates, including those that our strategic partners may develop under our
alliance agreements, our or our partners&#146; ability to obtain regulatory approval for product candidates may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if any of our future products, if and when approved for commercial sale, cause serious or unexpected side effects, a number of
potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered or conduct additional clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients;&nbsp;or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us or our partners from
achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products either by
us or by our strategic alliance partners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when
we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor our strategic alliance partners can commercialize a product until the appropriate regulatory authorities, such as the FDA, have
reviewed and approved the product candidate. The regulatory agencies may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee recommends restrictions on
approval or recommends non-approval. In addition, we or our strategic alliance partners may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency
policy during the period of product development, clinical trials and the review process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Even if we obtain regulatory approval for a product
candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or
marketing of our future product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to
meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and
promotional materials must comply with FDA rules and are subject to FDA review,&nbsp;in addition to other potentially applicable federal and state laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, and adherence to commitments made in the NDA. If we or a regulatory agency discovers previously unknown problems with a product such as
AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal
of the product from the market or suspension of manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our partners fail to comply with applicable regulatory requirements following
approval of any of our future product candidates, a regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue a warning letter asserting that we are in violation of the law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek an injunction or impose civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve a pending NDA or supplements to an NDA submitted by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize product; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to allow us to enter into supply contracts, including government contracts. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to
commercialize our future products and generate revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may not be successful in obtaining or maintaining necessary rights to</B><B><I>
micro</I></B><B>RNA targets, drug compounds and processes for our development pipeline through acquisitions and in-licenses. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently
we have rights to the intellectual property, through licenses from third parties and under patents that we own, to modulate only a subset of the known <I>micro</I>RNA targets. Because our programs may involve a range of <I>micro</I>RNA targets,
including targets that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our future product
candidates may require specific formulations to work effectively and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from
third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual
property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under
written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such right of first
negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other
parties, potentially blocking our ability to pursue our program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be
unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain
rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may use our
financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and human resources, we intend to leverage our existing strategic alliance agreements and enter into new
strategic alliance agreements for the development and commercialization of our programs and potential product candidates in indications with potentially large commercial markets such as HCC, fibrosis and HCV, while focusing our internal development
resources and any internal sales and marketing organization that we may establish on research programs and future product candidates for selected markets, such as orphan diseases. As a result, we may forego or delay pursuit of opportunities with
other programs or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Our spending on current and future research and development programs and future product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or
target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic alliance, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain
sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
have a material adverse effect on the success of our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and
regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and
biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the
event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal
fines and penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we
may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in
order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations
also may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We will depend upon our strategic alliances for the development and eventual commercialization of certain future</B><B><I> micro</I></B><B>RNA product
candidates. If these strategic alliances are unsuccessful or are terminated, we may be unable to commercialize certain product candidates and we may be unable to generate revenues from our development programs. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are likely to depend upon third party alliance partners for financial and scientific resources for the clinical development and
commercialization of certain of our <I>micro</I>RNA product candidates. These strategic alliances will likely provide us with limited control over the course of development of a future <I>micro</I>RNA product candidate, especially once a candidate
has reached the stage of clinical development. For example, in our alliances with Sanofi and GSK, Sanofi and GSK each have the option to obtain an exclusive worldwide license to develop, manufacture and commercialize product candidates upon the
achievement of relevant endpoints in clinical trials. However, neither Sanofi nor GSK is under any obligation to exercise these options to progress any of our <I>micro</I>RNA development candidates. While each of AstraZeneca, GSK and Sanofi have
development obligations with respect to programs that they may elect to pursue under their respective agreements, our ability to ultimately recognize revenue from these relationships will depend upon the ability and willingness of our alliance
partners to successfully meet their respective responsibilities under our agreements with them. Our ability to recognize revenues from successful strategic alliances may be impaired by several factors including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an alliance partner may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an alliance partner may cease development in therapeutic areas which are the subject of our strategic alliances; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an alliance partner may change the success criteria for a particular program or potential product candidate thereby delaying or ceasing development of such program or candidate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a significant delay in initiation of certain development activities by an alliance partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an alliance partner could develop a product that competes, either directly or indirectly, with an alliance product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an alliance partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an alliance partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an alliance partner may exercise its rights under the agreement to terminate a strategic alliance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a dispute may arise between us and an alliance partner concerning the research, development or commercialization of a program or product candidate resulting in a delay in milestones, royalty payments or termination of a
program and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an alliance partner may use our proprietary information or intellectual property in such a way as to invite litigation from a third party or fail to maintain or prosecute intellectual property rights such that our
rights in such property are jeopardized. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, with respect to termination rights, Sanofi may terminate the entire alliance or its
current alliance target program for any or no reason upon 30 days&#146; written notice to us. The agreement with Sanofi may also be terminated by either party for material breach by the other party, including a failure to comply with such
party&#146;s diligence obligations that remains uncured after 120 days. Similarly, GSK may terminate the entire alliance or any alliance target program for any or no reason upon 90&nbsp;days&#146; written notice to us and the agreement may also be
terminated by either party for material breach by the other party, including a failure to comply with such party&#146;s diligence obligations that remains uncured after a specified notice period. The agreement with AstraZeneca may be terminated by
either party in the event of the other party&#146;s material breach which remains uncured after 40 business days following notice thereof (or 30 business days in the case of nonpayment). In addition, AstraZeneca may terminate the agreement in its
entirety for any reason upon 60 business days&#146; written notice to us. Depending on the timing of any such termination, we may not be entitled to receive the option exercise fees or milestone payments, as these payments terminate with termination
of the respective program or agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our alliance partners do not elect to pursue the development and commercialization of our
<I>micro</I>RNA development candidates or if they terminate the strategic alliance, then, depending on the event: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of Sanofi, under certain circumstances, we may owe Sanofi royalties with respect to product candidates covered by our agreement with Sanofi that we elect to continue to commercialize, depending upon the
stage of development at which such product commercialization rights reverted back to us, or additional payments if we license such product candidates to third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of our product candidates subject to the AstraZeneca agreement, the GSK agreement or the Sanofi agreement, as applicable, may be terminated or significantly delayed; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates that were previously
funded, or expected to be funded, by AstraZeneca, GSK or Sanofi, as applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the AstraZeneca agreement, the GSK agreement or the Sanofi
agreement, as applicable, including the reimbursement of third parties; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in order to fund further development and commercialization, we may need to seek out and establish alternative strategic alliances with third-party partners; this may not be possible, or we may not be able to do so on
terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events would have a material adverse effect on our results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We expect to rely on third parties to conduct some aspects of our compound formulation, research and preclinical testing, and those third parties may not
perform satisfactorily, including failing to meet deadlines for the completion of such formulation, research or testing. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
expect to independently conduct all aspects of our drug discovery activities, compound formulation research or preclinical testing of product candidates. We currently rely and expect to continue to rely on third parties to conduct some aspects of
our preclinical testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these third parties may terminate their engagements with us at any time. If we need to enter into
alternative arrangements, it would delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities.
For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols for the
trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully carry out their contractual duties, meet expected
deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us or our strategic
alliance partners to select viable product candidates for IND submissions and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We intend to rely on third-party manufacturers to produce our preclinical supplies, and we intend to rely on third parties to produce clinical supplies of
any product candidates that we advance into clinical trials and commercial supplies of any approved product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on
third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to meet any product specifications and quality requirements consistently; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a delay or inability to procure or expand sufficient manufacturing capacity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing and product quality issues related to scale-up of manufacturing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs and validation of new equipment and facilities required for scale-up; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a failure to comply with cGMP and similar foreign standards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the reliance on a limited number of sources, and in some cases, single sources for raw materials, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture
and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">carrier disruptions or increased costs that are beyond our control; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure to deliver products under specified storage conditions and in a timely manner. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could lead to clinical study delays or failure to obtain regulatory approval, or impact our ability to successfully
commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We expect to rely on limited sources of supply for the drug substance of future product candidates and any disruption in the chain of supply may cause a
delay in developing and commercializing these product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to establish manufacturing relationships with a limited
number of suppliers to manufacture raw materials and the drug substance of any product candidate for which we are responsible for preclinical or clinical development. Each supplier may require licenses to manufacture such components if such
processes are not owned by the supplier or in the public domain. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to commercialization. If supply from the approved vendor is
interrupted, there could be a significant disruption in commercial supply. An alternative vendor would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new
supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if our alliance partners elect to pursue the development and commercialization of certain programs, we will lose control over the
manufacturing of the product candidate subject to the agreement. For example, if Sanofi elects to develop and commercialize a product candidate targeting miR-21 or miR-221/222 for oncology indications or RG-012 for kidney fibrosis under its
strategic alliance with us, Sanofi will be responsible for the manufacture of the product candidates for further clinical trials. Sanofi will be free to use a manufacturer of its own choosing or manufacture the product candidates in its own
manufacturing facilities. In such a case, we will have no control over Sanofi&#146;s processes or supply chains to ensure the timely manufacture and supply of the product candidates. In addition, we will not be able to ensure that the product
candidates will be manufactured under the correct conditions to permit the product candidates to be used in such clinical trials. Each of AstraZeneca and GSK will have similar obligations to manufacture product candidates which it takes into
clinical trials under its strategic alliance with us and we will face similar risks as to those product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors could
cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our future product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our
suppliers fail to deliver the required commercial quantities of active pharmaceutical ingredients on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production at a
substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing issues may arise that could
increase product and regulatory approval costs or delay commercialization. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we scale-up manufacturing of future product candidates
and conduct required stability testing, product, packaging, equipment and process-related issues may require refinement or resolution in order to proceed with any clinical trials and obtain regulatory approval for commercial marketing. We may
identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical programs and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for future
product candidates or any approved products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We expect to rely on third parties to conduct, supervise and monitor our clinical trials, and if those
third parties perform in an unsatisfactory manner, it may harm our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our strategic alliance partners commence
clinical trials, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we will have agreements governing their activities, we and our strategic alliance partners will have limited
influence over their actual performance. We will control only certain aspects of our CROs&#146; activities. Nevertheless, we or our strategic alliance partners will be responsible for ensuring that each of our clinical trials is conducted in
accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our alliance partners and our CROs are required to comply with the FDA&#146;s current good clinical practices, or cGCPs, for conducting,
recording and reporting the results of IND-enabling studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The
FDA enforces these cGCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our future clinical trials may be
deemed unreliable and the FDA may require us to perform additional clinical trials before approving any marketing applications. Upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inspection, the FDA may determine that our clinical trials did not comply with cGCPs. In addition, our future clinical trials will require a sufficiently large number of test subjects to evaluate
the safety and effectiveness of a potential drug product. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the
regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CROs will not be our employees, and we will not be able to control whether or not they devote sufficient
time and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities
which could harm our competitive position. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the
failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our
future product candidates. As a result, our financial results and the commercial prospects for such products and any future product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be
delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and distribute drug products for any clinical trials that we may conduct.
Any performance failure on the part of our distributors could delay clinical development or marketing approval of our future product candidates or commercialization of our products, if approved, producing additional losses and depriving us of
potential product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO OUR INTELLECTUAL PROPERTY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are unable to obtain or protect intellectual property rights related to our future products and product candidates, we may not be able to compete
effectively in our markets. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect
the intellectual property related to our future products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that
we own or in-license may fail to result in patents with claims that cover the products in the United States or in other countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications
has been found; such prior art can invalidate a patent or prevent a patent from issuing based on a pending patent application. Even if patents do successfully issue, third parties may challenge their validity, enforceability or scope, which may
result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue or if their breadth or
strength of protection is threatened, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. We cannot offer any assurances about which, if any, patents will
issue or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. In particular, we are aware that Santaris Pharma A/S, or Santaris, has initiated reexamination of and filed oppositions to patents
owned by Stanford University and licensed to us, in each case relating to miR-122, and has filed oppositions to a patent owned by us relating to miR-122 and to a patent owned by Isis relating to chemical modification of oligonucleotides. Any
successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we or our strategic alliance partners may develop. Since
patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product
candidate. Furthermore, in certain situations, if we and one or more third parties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have filed patent applications in the United States and claiming the same subject matter, an administrative proceeding can be initiated to determine which applicant is entitled to the patent on
that subject matter. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection
it affords, is limited. Once the patent life has expired for a product, we may be open to competition from generic medications. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product
candidate under patent protection could be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection
and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how,
information or technology that is not covered by patents. Although each of our employees agrees to assign their inventions to us through an employee inventions agreement, and all of our employees, consultants, advisors and any third parties who have
access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary
information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, others may independently discover our trade secrets
and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade
secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the
United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property
related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially
adversely affect our business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third-party claims of intellectual property infringement may prevent or
delay our development and commercialization efforts. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the
patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries,
including patent infringement lawsuits, as well as interferences, oppositions and inter partes reexamination proceedings before the U.S. Patent and Trademark Office, or U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign
issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our strategic alliance partners are pursuing development candidates. For example, we are aware that Santaris has patents and patent
applications in the <I>micro</I>RNA therapeutics space, including patents and patent applications related to targeting <I>micro</I>RNAs, such as miR-122, for the treatment of disease. As the biotechnology and pharmaceutical industries expand and
more patents are issued, the risk increases that our future product candidates may be subject to claims of infringement of the patent rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent
applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our future product candidates. Because patent applications can take many years to issue, there may be currently
pending patent applications which may later result in patents that our future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any
third-party patents were held </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by a court of competent jurisdiction to cover the manufacturing process of any of our future product candidates, any molecules formed during the manufacturing process or any final product itself,
the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a
court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the
applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the
event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more
licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we fail to comply with our obligations
in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional
license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. For example, under our exclusive license
agreement for Max-Planck-Innovation GmbH&#146;s proprietary technology and know-how covering <I>micro</I>RNA sequences, we are required to use commercially reasonable diligence to develop and commercialize a product and to satisfy specified payment
obligations. If we fail to comply with our obligations under our agreement with Max-Planck-Innovation GmbH or our other license agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event
we, or our strategic alliance partners, would not be able to market products covered by the license. In addition, our exclusive license agreements with our founding companies, Alnylam and Isis, provide us with rights to nucleotide technologies in
the field of <I>micro</I>RNA therapeutics based on oligonucleotides that modulate up-regulated <I>micro</I>RNAs. Some of these technologies, such as intellectual property relating to the chemical modification of oligonucleotides, are relevant to our
product candidate development programs. If our license agreements with Alnylam or Isis are terminated, or our business relationships with either of these companies or our other licensors are disrupted by events that may include the acquisition of
either company, our access to critical intellectual property rights will be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to obtain
licenses from third parties to advance our research or allow commercialization of our future product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at
all. In that event, we would be unable to further develop and commercialize one or more of our future product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might
be enforced against our future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and
unsuccessful. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we
may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any
litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to
our patents or patent applications or those of our alliance partners or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be
harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and
other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may be subject to
claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or
our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#146; former employers or other third parties. We may also be subject to claims that former employers
or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we are successful, litigation could result in
substantial cost and be a distraction to our management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO COMMERCIALIZATION OF PRODUCT CANDIDATES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The commercial success of our programs that are part of our strategic alliance agreements with Sanofi, GSK and AstraZeneca, will depend in large part on the
development and marketing efforts of our alliance partners. If our alliance partners are unable to perform in accordance with the terms of our agreements, our potential to generate future revenue from these programs would be significantly reduced
and our business would be materially and adversely harmed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of Sanofi, GSK or AstraZeneca elects to pursue the development and
commercialization of any of the <I>micro</I>RNA product candidates that are subject to their respective strategic alliance agreements with us, we will have limited influence and/or control over their approaches to development and commercialization.
If Sanofi, GSK, AstraZeneca or any potential future strategic alliance partners do not perform in the manner that we expect or fail to fulfill their responsibilities in a timely manner, or at all, the clinical development, regulatory approval and
commercialization efforts related to product candidates we have licensed to such strategic alliance partners could be delayed or terminated. If we terminate any of our strategic alliances or any program thereunder due to a material breach by Sanofi,
GSK or AstraZeneca, we have the right to assume the responsibility at our own expense for the development of the applicable <I>micro</I>RNA product candidates. Assuming sole responsibility for further development will increase our expenditures, and
may mean we will need to limit the size and scope of one or more of our programs, seek additional funding and/or choose to stop work altogether on one or more of the affected product candidates. This could result in a limited potential to generate
future revenue from such <I>micro</I>RNA product candidates and our business could be materially and adversely affected. Further, under certain circumstances, we may owe Sanofi, GSK or AstraZeneca, as applicable, royalties on any product candidate
that we may successfully commercialize. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We face significant competition from other biotechnology and pharmaceutical companies and our operating
results will suffer if we fail to compete effectively. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are intensely competitive. We
have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. We are aware of several companies that are working
specifically to develop <I>micro</I>RNA therapeutics including Groove Biopharma, Inc., InteRNA Technologies B.V., miRagen Therapeutics, Inc., MiReven Pty Ltd, Mirna Therapeutics, Inc., Microlin Bio, Inc. and Santaris. Our competitors may have
substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these
industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, drug products that are more effective or less costly than any product candidate that we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our programs are in a preclinical development stage and are targeted toward indications for which there are approved products on the
market or product candidates in clinical development. We will face competition from other drugs currently approved or that will be approved in the future for the same therapeutic indications. Our ability to compete successfully will depend largely
on our ability to leverage our experience in drug discovery and development to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discover and develop therapeutics that are superior to other products in the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract qualified scientific, product development and commercial personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain patent and/or other proprietary protection for our <I>micro</I>RNA product platform and future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain required regulatory approvals; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new therapeutics. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability of our competitors&#146; products could limit the demand, and the price we are able to charge, for any products that we may
develop and commercialize. We will not achieve our business plan if the acceptance of any of these products is inhibited by price competition or the reluctance of physicians to switch from existing drug products to our products, or if physicians
switch to other new drug products or choose to reserve our future products for use in limited circumstances. The inability to compete with existing or subsequently introduced drug products would have a material adverse impact on our business,
financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of
novel compounds or to in-license novel compounds that could make our future product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience,
tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing product
candidates before we do, which would have a material adverse impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The commercial success of our product candidates will depend upon the acceptance of these product candidates
by the medical community, including physicians, patients and healthcare payors. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of market acceptance of any product candidates will depend
on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstration of clinical safety and efficacy compared to other products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative convenience, ease of administration and acceptance by physicians, patients and healthcare payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any AEs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the FDA-approved label for such products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing and cost-effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our or any collaborators&#146; sales and marketing strategies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain hospital formulary approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain sufficient third party coverage or reimbursement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of patients to pay out-of-pocket in the absence of third party coverage. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless other formulations are developed in the future, we expect our compounds to be formulated in an injectable form. Injectable medications
may be disfavored by patients or their physicians in the event drugs which are easy to administer, such as oral medications, are available. If a product is approved, but does not achieve an adequate level of acceptance by physicians, patients and
healthcare payors, we may not generate sufficient revenues from such product and we may not become or remain profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are unable to establish
sales and marketing capabilities or enter into agreements with third parties to market and sell our future product candidates, we may be unable to generate any revenues. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and
maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third
parties to perform these services. For example, we have co-promotion rights with Sanofi with respect to our miR-21 and <FONT STYLE="white-space:nowrap">miR-221/222</FONT> programs, but would need to build our sales, marketing, managerial and other
non-technical capabilities in order to effectively carry out co-promotion activities with respect to any approved products that are developed through these programs. With respect to certain of our current programs that are the subject of existing
strategic alliances, such as miR-122 with GSK and the metabolic and oncology programs with AstraZeneca, we intend to rely completely on our alliance partner for sales and marketing. In addition, we intend to enter into strategic alliances with third
parties to commercialize other future product candidates, including in markets outside of the United States or for other large markets that are beyond our resources. Although we intend to establish a sales organization if we are able to obtain
approval to market any product candidates for niche markets in the United States, we will also consider the option to enter into strategic alliances for future product candidates in the United States if commercialization requirements exceed our
available resources. This will reduce the revenue generated from the sales of these products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future strategic alliance
partners, if any, may not dedicate sufficient resources to the commercialization of our future product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective alliances
to enable the sale of our future product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future strategic alliance
partners do not successfully commercialize the product candidates, our ability to generate revenues from product sales will be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish adequate sales, marketing and distribution capabilities, whether
independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations.
Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations
could materially adversely affect our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategic alliance agreements with Sanofi, GSK and AstraZeneca provide that our
partners will be responsible for the commercialization of future product candidates, if any, from their respective programs, as applicable. If any other future product candidates that we may develop are approved for commercialization, we may also
enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different regulatory requirements for drug approvals in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign taxes, including withholding of payroll taxes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Coverage and adequate reimbursement may not be available for our future product candidates, which could make it difficult for us to sell products
profitably. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market acceptance and sales of any future product candidates that we develop will depend on coverage and reimbursement
policies and may be affected by future healthcare reform measures. Government authorities and third party payors, such as private health insurers, hospitals and health maintenance organizations, decide which drugs they will pay for and establish
reimbursement levels. We cannot be sure that coverage and adequate reimbursement will be available for any future product candidates. Also, inadequate reimbursement amounts may reduce the demand for, or the price of, our future products. If
reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize future product candidates that we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we cannot be certain if and when we will obtain formulary approval to allow us to sell any products that we may develop and
commercialize into our target markets. Obtaining formulary approval from hospitals and from payers can be an expensive and time consuming process. Failure to obtain timely formulary approval will limit our commercial success. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been a number of legislative and regulatory proposals to change the healthcare system
in the United States and in some foreign jurisdictions that could affect our ability to sell products profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for drug products, following approval. The
availability of numerous generic treatments may also substantially reduce the likelihood of reimbursement for our future products. The potential application of user fees to generic drug products may expedite the approval of additional generic drug
treatments. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative
changes. If we fail to successfully secure and maintain reimbursement coverage for our future products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our future products and our business will be
harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed.
The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company
placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our
products. Historically, products launched in the EU do not follow price structures of the U.S. and generally tend to be priced significantly lower. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED TO OUR BUSINESS OPERATIONS AND INDUSTRY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our
objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#147;at will&#148; employees. Recruiting and retaining other qualified
employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled
personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition,
failure to succeed in preclinical studies and clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee might impede the progress of our
research, development and commercialization objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may need to expand our organization and may experience difficulties in managing this
growth, which could disrupt our operations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, we had 73 full-time employees. As our company matures, we
expect to expand our employee base to increase our managerial, scientific and operational, commercial, financial and other resources and to hire more consultants and contractors. Future growth would impose significant additional responsibilities on
our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day
activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational
mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our
growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize future
product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our employees may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S.
regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business
arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of
pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which
could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions
are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any future relationships with customers and third party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse
laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face criminal sanctions, civil penalties, contractual damages, reputational harm and
diminished profits and future earnings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain FDA approval for any of our product candidates and begin commercializing those
products in the United States, our operations may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False
Claims Act. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by the federal government and by the U.S. states and foreign jurisdictions in
which we conduct our business. The laws that may affect our ability to operate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for,
either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from
Medicare, Medicaid, or other third party payers that are false or fraudulent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false
statements relating to healthcare matters; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology and Clinical Health Act of 2009, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission
of individually identifiable health information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payer, including commercial insurers,
and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations
that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, possible exclusion from Medicare, Medicaid and other government healthcare programs, and curtailment or restructuring of
our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We face potential product
liability, and, if successful claims are brought against us, we may incur substantial liability and costs. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of our future
product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers,
pharmaceutical companies or others selling or otherwise coming into contact with our products. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver
function. There is a risk that our future product candidates may induce similar adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or
eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairment of our business reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs due to related litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of management&#146;s attention from our primary business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our future product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our future product candidates, if approved for commercial sale. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do
not currently have any product liability insurance coverage. We anticipate obtaining such insurance prior to the commencement of any clinical trials but any such insurance coverage that we obtain may not be sufficient to reimburse us for any
expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to
liability. If and when we obtain marketing approval for future product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially
reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could
cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cyber security risks and the failure to maintain the confidentiality, integrity, and availability of our
computer hardware, software, and Internet applications and related tools and functions could result in damage to our reputation and/or subject us to costs, fines or lawsuits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business requires manipulating, analyzing and storing large amounts of data. In addition, we rely on a global enterprise software system to
operate and manage our business. We also maintain personally identifiable information about our employees. Our business therefore depends on the continuous, effective, reliable, and secure operation of our computer hardware, software, networks,
Internet servers, and related infrastructure. To the extent that our hardware or software malfunctions or access to our data by internal research personnel is interrupted, our business could suffer. The integrity and protection of our employee and
Company data is critical to our business and employees have a high expectation that we will adequately protect their personal information. The regulatory environment governing information, security and privacy laws is increasingly demanding and
continues to evolve. Maintaining compliance with applicable security and privacy regulations may increase our operating costs. Although our computer and communications hardware is protected through physical and software safeguards, it is still
vulnerable to fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, software viruses, and similar events. These events could lead to the unauthorized access, disclosure and use of non-public
information. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques
proactively or implement adequate preventative measures. If our computer systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our
business. In addition, any sustained disruption in internet access provided by other companies could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business interruptions could
delay us in the process of developing our future products. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our headquarters are located in San Diego County. We are vulnerable to
natural disasters such as earthquakes and wild fires, as well as other events that could disrupt our operations. We do not carry insurance for earthquakes or other natural disasters and we may not carry sufficient business interruption insurance to
compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RISKS RELATED
TO OUR COMMON STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The market price of our common stock may be highly volatile. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since shares of our common stock were sold in our initial public offering in October 2012 at a price of $4.00 per share, our closing stock
price as reported on The NASDAQ Global Market has ranged from $4.15 to $12.41, through February&nbsp;7, 2014. The trading price of our common stock is likely to continue to be volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse results or delays in preclinical testing or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain additional funding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delay in filing an IND or NDA for any of our future product candidates and any adverse development or perceived adverse development with respect to the FDA&#146;s review of that IND or NDA; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to maintain our existing strategic alliances or enter into new alliances; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our strategic alliance partners to elect to develop and commercialize product candidates under our alliance agreements or the termination of any programs under our alliance agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us or our licensors and strategic alliance partners to prosecute, maintain or enforce our intellectual property rights; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to successfully develop and commercialize our future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in laws or regulations applicable to our preclinical and clinical development activities, product candidates or future products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain adequate product supply for our future product candidates or the inability to do so at acceptable prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse regulatory decisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of new products, services or technologies by our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed financial projections we may provide to the public; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed the estimates and projections of the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic alliance partners or our competitors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant lawsuits, including patent or stockholder litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the market valuations of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us or our stockholders in the future; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trading volume of our common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies trading in the stock market in
general, and The NASDAQ Global Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may
negatively affect the market price of our common stock, regardless of our actual operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our principal stockholders and management own
a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of February&nbsp;7, 2014, our executive officers, directors, 5% stockholders and their affiliates beneficially owned approximately 78% of our outstanding voting stock. Therefore, these stockholders will have the ability to influence us through this
ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents,
or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our
stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging growth company,&#148; and we cannot be certain if the reduced reporting requirements applicable to emerging
growth companies will make our common stock less attractive to investors. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in
the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148;
including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic
reports </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved. We could be an emerging growth company through December&nbsp;31, 2017, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0&nbsp;million
as of any June&nbsp;30 before that time or if we have total annual gross revenue of $1.0 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&nbsp;31
or, if we issue more than $1.0&nbsp;billion in non-convertible debt during any three year period before that time, we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may
still qualify as a &#147;smaller reporting company&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may
rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that
are not emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The requirements of being a public company may strain our resources and divert management&#146;s attention.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we have incurred, and will continue to incur, significant legal, accounting and other expenses that we did not
incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The NASDAQ Global Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform
and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these
areas such as &#147;say on pay&#148; and proxy access. Recent legislation permits smaller &#147;emerging growth companies&#148; to implement many of these requirements over a longer period and up to five years from the pricing of our initial public
offering. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current
political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we
operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and
financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we
may be required to incur substantial costs to maintain our current levels of such coverage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales of a substantial number of shares of our common
stock in the public market by our existing stockholders could cause our stock price to fall. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or
indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. Certain lock-up agreements pertaining to our recently completed public offering expired on
October&nbsp;14, 2013 and certain lock-up agreements pertaining to our initial public offering expired on October&nbsp;4, 2013. Upon the expiration of these lock-up agreements, a substantial number of shares of common stock became eligible for sale
in the public market, subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the Securities Act, with respect to any of these shares held by directors, executive officers and other affiliates. In connection
with our private placement of 1,303,780 shares to Aventis Holdings Inc., or Aventis, an entity affiliated with Sanofi, in February </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2014, Aventis has agreed that for a period of 12 months after the date on which the shares were issued, subject to specified exceptions, Aventis will not offer, sell, contract to sell, pledge or
otherwise dispose of, directly or indirectly, any of the shares of our common stock issued to Aventis in the private placement. Subject to certain limitations, all of the&nbsp;shares issued to Aventis in the private placement will become eligible
for sale upon expiration of the lock-up period. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans are or may become eligible for sale in the public
market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public
market, the trading price of our common stock could decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of our securities are entitled to rights with respect to the
registration of their shares under the Securities Act, subject to the applicable lock-up arrangement described above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under
the Securities Act, except for shares held by our affiliates as defined in Rule 144 under the Securities Act. We currently plan to file a registration statement that will provide for the sale of shares of common stock by us or by selling
stockholders.&nbsp;In addition, we may file additional registration statements in the future to provide for the further sale of shares of common stock by us or by selling shareholders. Any sales of securities by these stockholders could have a
material adverse effect on the trading price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future sales and issuances of our common stock or rights to purchase common stock,
including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise
additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine
from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing
stockholders, and new investors could gain rights superior to our existing stockholders. We currently plan to file a registration statement that will provide for the sale of shares of common stock by us or by selling stockholders.&nbsp;In addition,
we may file additional registration statements in the future to provide for the further sale of shares of common stock by us or by selling shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our 2012 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and
consultants. The number of shares available for future grant under the 2012 Plan will automatically increase each year by up to 4% of all shares of our capital stock outstanding as of December&nbsp;31 of the prior calendar year, subject to the
ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2012 Plan each year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We could be subject to securities class action litigation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of
management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our ability to use our net operating loss carryforwards and certain other
tax attributes may be limited. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an
&#147;ownership change,&#148; generally defined as a greater than 50% change (by value) in its equity ownership over a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
three year period, the corporation&#146;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its
post-change income may be limited. We believe that, with our initial public offering and other transactions that have occurred over the past three years, we may have triggered an &#147;ownership change&#148; limitation. We may also experience
ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during
which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We do not intend to pay
dividends on our common stock so any returns will be limited to the value of our stock. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash
dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any
return to stockholders will therefore be limited to the appreciation of their stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions in our amended and restated certificate of
incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by
others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorizing the issuance of &#147;blank check&#148; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limiting the removal of directors by the stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminating the ability of stockholders to call a special meeting of stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are subject to Section&nbsp;203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from
engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of
directors. This provision could have the effect of delaying or preventing a change in control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone
from acquiring us or merging with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_3"></A>Unresolved Staff Comments. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_4"></A>Properties. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our administrative offices and research
laboratory is located in La Jolla, California. As of December&nbsp;31, 2013, we had a lease for approximately 29,000 square feet for office and laboratory space. Our lease currently expires in June 2017, subject to our option to renew for up to two
additional three-year terms. We believe that our facility is sufficient to meet our needs and that suitable additional space will be available as and when needed. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_5"></A>Legal Proceedings. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_6"></A>Mine Safety Disclosures. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_7"></A>Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock began
trading on The NASDAQ Global Market on October&nbsp;4, 2012 under the symbol &#147;RGLS.&#148; Prior to such time, there was no public market for our common stock. The following table sets forth the high and low sales prices per share of our common
stock as reported on The NASDAQ Global Market for the periods indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price Range</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Year Ended December&nbsp;31, 2012:</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter (commencing October&nbsp;4, 2012)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Year Ended December&nbsp;31, 2013:</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders of Record </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&nbsp;7, 2014, there were approximately 16 holders of record of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared
or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our
common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition,
capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities Authorized
for Issuance Under Equity Compensation Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about our equity compensation plans is incorporated herein by reference to
Item&nbsp;12 of Part&nbsp;III of this Annual Report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Performance Graph </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following graph shows a comparison from October&nbsp;4, 2012 (the date our common stock commenced trading on The NASDAQ Global Market)
through December&nbsp;31, 2013 of the cumulative total return for our common stock, the NASDAQ Biotechnology Index (NBI) and the NASDAQ Composite Index (CCMP). The graph assumes an initial investment of $100 on October&nbsp;4, 2012. The comparisons
in the graph are not intended to forecast or be indicative of possible future performance of our common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g652681g80f67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;4, 2012, we commenced our initial public offering pursuant to a registration statement on Form&nbsp;S-1 (File
No.&nbsp;333-183384) that was declared effective by the SEC on October&nbsp;4, 2012 and that registered an aggregate of 12,937,500 shares of our common stock for sale to the public at a price of $4.00 per share and an aggregate offering price of
$51.8 million. On October&nbsp;10, 2012 and October&nbsp;23, 2012, we sold 11,250,000 shares and 1,480,982 shares of our common stock, respectively, to the public at a price of $4.00 per share for an aggregate gross offering price of $50.9 million.
Lazard&nbsp;Capital&nbsp;Markets, Cowen and Company and BMO Capital Markets acted as joint book-running managers for the offering, and Needham&nbsp;&amp; Company and Wedbush PacGrow Life&nbsp;Sciences served as co-managers for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting discounts and commissions in connection with the offering totaled approximately $3.4 million. We incurred additional costs of
approximately $2.6&nbsp;million in offering expenses, which when added to the underwriting discounts and commissions paid by us, amounts to total fees and costs of approximately $6.0&nbsp;million. Thus, the net offering proceeds to us, after
deducting underwriting discounts, commissions and offering costs, were approximately $44.9 million. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of
any class of our equity securities or to any other affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, we have used approximately $5.3 million of
the net proceeds from the offering for preclinical and clinical development of our initial <I>micro</I> RNA development candidates, for the identification and validation of additional <I>micro</I>RNA targets, and for capital expenditures, working
capital and other general corporate purposes, including costs and expenses associated with being a public company. We may also use a portion of the remaining net proceeds to in-license, acquire or invest in complementary <I>micro</I>RNA businesses,
technologies, products or assets. We cannot specify with certainty all of the particular uses for the remaining net proceeds from our initial public offering. Accordingly, our management will continue to have broad discretion in the application of
the remaining net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_8"></A>Selected Financial Data. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The selected financial data set forth below is
derived from our audited financial statements and may not be indicative of future operating results. The following selected financial data should be read in conjunction with the financial statements and notes thereto and Item&nbsp;7,
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this Annual Report. The selected financial data in this section are not intended to replace our financial statements and the
related notes. Our historical results are not necessarily indicative of our future results. Amounts are in thousands, except share and per share data. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:98.30pt; font-size:8pt; font-family:Times New Roman"><B>Statement of operations data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue under strategic alliances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,738</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in value of convertible note payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,969</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other expense, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(85.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute basic and diluted net loss per share<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,479,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,212,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>See Note 2 of our Notes to Financial Statements appearing elsewhere in this Annual Report for an explanation of the method used to calculate the basic and diluted net loss per common share and the number of shares
used in the computation of the share and per share data. </I></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:63.50pt; font-size:8pt; font-family:Times New Roman"><B>Balance sheet data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,011</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_9"></A>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis together with &#147;Item 6. Selected Financial Data&#148; and our financial statements
and related notes included elsewhere in this Annual Report. The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those expressed or implied in any
forward-looking statements as a result of various factors, including those set forth under the caption &#147;Item 1A. Risk Factors.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on discovering and developing first-in-class drugs that target <I>micro</I>RNAs to treat a
broad range of diseases. We were formed in 2007 when Alnylam and Isis contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting <I>micro</I>RNAs pursuant to a license and
collaboration agreement. <I>micro</I>RNAs are recently discovered, naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown that the improper balance, or
dysregulation, of <I>micro</I>RNAs is directly linked to many diseases. We believe we have assembled the leading position in the <I>micro</I>RNA field, including expertise in <I>micro</I>RNA biology and oligonucleotide chemistry, a broad
intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. We refer to these assets as our <I>micro</I>RNA product platform. We are using our <I>micro</I>RNA product platform to develop chemically
modified, single-stranded oligonucleotides that we call anti-miRs. We use these anti-miRs to modulate <I>micro</I>RNAs and by doing so return diseased cells to their healthy state. We are pursuing several <I>micro</I>RNA targets and are focusing our
proprietary efforts in oncology and orphan diseases. We believe <I>micro</I>RNAs may be transformative in the field of drug discovery and that anti-miRs may become a new and major class of drugs with broad therapeutic application much like small
molecules, biologics and monoclonal antibodies. Additionally, we believe that <I>micro</I>RNA biomarkers may be used to select optimal patient segments in clinical trials and to monitor disease progression or relapse. We believe these
<I>micro</I>RNA biomarkers can be applied toward drugs that we develop and drugs developed by other companies with which we partner or collaborate, including small molecules and monoclonal antibodies. In January 2014, we expanded our biomarkers
efforts and established <I>micro</I>Markers&#153;, a research and development division focused on identifying <I>micro</I>RNAs as biomarkers of human disease, which is designed to support our therapeutic pipeline, collaborators and strategic
partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently optimizing anti-miRs in several distinct programs, both independently and with our strategic alliance
partners, AstraZeneca, GSK and Sanofi. We also have a collaboration agreement with Biogen Idec to evaluate the potential use of <I>micro</I>RNA signatures as a biomarker for human patients with MS. Under these strategic alliances, we are eligible to
receive up to approximately $1.5 billion in milestone payments upon successful commercialization of <I>micro</I>RNA therapeutics for the programs contemplated by our agreements. These payments include up to $128.0&nbsp;million upon achievement of
preclinical and IND milestones, up to $254.0&nbsp;million upon achievement of clinical development milestones, up to $380.0&nbsp;million upon achievement of regulatory milestones and up to $730.0 million upon achievement of commercialization
milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, we set forth certain corporate goals that seek to advance our <I>micro</I>RNA therapeutic pipeline toward the clinic
under our &#145;Road to the Clinic&#146; strategy. Specifically, we set the goal of nominating two <I>micro</I>RNA candidates for clinical development in 2013, be positioned to file our first applications with regulatory authorities by the first
half of 2014 and maintain a strong year-end cash position to support these goals. We successfully achieved all of these goals under our &#145;Road to the Clinic&#146; strategy: (i)&nbsp;our first clinical candidate, RG-101, for which we have full
ownership and commercial rights, is a GalNAc-conjugated anti-miR, which targets <I>micro</I>RNA-122, for the treatment of patients with chronic HCV. We filed our first application for RG-101 with regulatory authorities in the Netherlands and
recently received approval to commence a Phase I clinical trial. Additionally, we nominated RG-012, an anti-miR targeting miR-21 for the treatment of Alport Syndrome, an orphan, life-threatening kidney disease driven by genetic mutations, as our
second <I>micro</I>RNA candidate for clinical development. We are responsible for advancing RG-012 to proof-of-concept and Sanofi will have the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exclusive option, exercisable after proof-of-concept, to take over further development and commercialization of RG-012 program. Lastly, our strong financial position supported our &#145;Road to
the Clinic&#146; goals as we ended 2013 with $114.0 million in cash, cash equivalents and short-term investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2014, we
launched our &#145;Clinical Map Initiative&#146;, which outlines certain corporate goals and objectives to advance our <I>micro</I>RNA therapeutics pipeline over the next several years. Specifically, we intend to demonstrate human proof-of-concept
results in the Phase I clinical study of RG-101 by the end of 2014, initiate a Phase I clinical study of RG-012 for the treatment of Alport Syndrome in the first half of 2015 and nominate a third <I>micro</I>RNA candidate for clinical development by
the end of 2014. In order to achieve these objectives, we intend to maintain a strong financial position and end 2014 with at least $75.0 million in cash, cash equivalents and short-term investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2013, we completed a public offering whereby we sold 5,175,000 shares of common stock at $9.50 per share and received net
proceeds of $45.8 million, after deducting underwriting discounts, commissions and other offering expenses. On October&nbsp;10, 2012, we completed our initial public offering whereby we issued and sold 11,250,000 shares of common stock at a public
offering price of $4.00 per share, resulting in net proceeds to us of approximately $39.5 million. Concurrently with the completion of our initial public offering on October&nbsp;10, 2012, $5.0 million of outstanding principal plus accrued interest
of $0.8 million underlying a convertible note that we issued to GSK in April 2008 and amended and restated in July 2012, together with $5.0&nbsp;million of outstanding principal plus accrued interest of $25,000 underlying a convertible note that we
issued to Biogen Idec in August 2012, was automatically converted upon the closing of our initial public offering into an aggregate of 2,703,269 shares of our common stock. Upon the closing of our initial public offering, all shares of our
outstanding convertible preferred stock automatically converted into an aggregate of 13,699,999 shares of common stock. On October&nbsp;23, 2012, the underwriters for our initial public offering partially exercised an over-allotment option to
purchase 1,480,982 shares of our common stock at $4.00 per share, resulting in net proceeds to us of approximately $5.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2014, we and Sanofi entered into a second amended and restated collaboration and license agreement to extend our strategic alliance. Under the terms of our extended alliance, Sanofi will have opt-in rights to our miR-21 pre-clinical
fibrosis program targeting miR-21for the treatment of Alport Syndrome, our preclinical program targeting miR-21 for oncology indications, and our preclinical programs targeting miR-221/222 for oncology indications, each of which is to be led by us.
If Sanofi chooses to exercise its option on any of these programs, Sanofi will reimburse us for a significant portion of our preclinical and clinical development costs and will also pay us an option exercise fee for any such program, provided that
$1.25 million of the $2.5 million upfront option fee paid to us by Sanofi in connection with the June 2013 option agreement will be creditable against such option exercise fee. In addition, we will be eligible to receive clinical and regulatory
milestone payments under these programs and potentially commercial milestone payments. We also continue to be eligible to receive royalties on <I>micro</I>RNA therapeutic products commercialized by Sanofi or will have the right to co-promote these
products. For additional information, see Notes 5 and 15 to our financial statements under Item&nbsp;8 of Part II of this Annual Report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our entry into the second amended and restated collaboration and license agreement with Sanofi, we sold and issued
1,303,780 shares of our common stock to Aventis, an entity affiliated with Sanofi, in a private placement at a price per share of $7.67 for an aggregate purchase price of $10.0 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenues </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding
and milestone payments under strategic alliance agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may generate revenue from a combination of license fees and other upfront
payments, research and development payments, milestone payments, product sales and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our
achievement of preclinical, clinical, regulatory and commercialization milestones, if at all, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized by
us or our strategic alliance partners. If our strategic alliance partners do not elect or otherwise agree to fund our development costs pursuant to our strategic alliance agreements, or we or our strategic alliance partners fail to develop product
candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues, and our results of operations and financial position would be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and development expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs associated with our research activities, including our drug discovery efforts, the
preclinical development of our therapeutic programs, and our <I>micro</I>Markers<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> division. Our research and development expenses include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee-related expenses, including salaries, benefits, travel and stock-based compensation expense; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, or CROs, contract manufacturing organizations, or CMOs, consultants and our scientific
advisory board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">license fees; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory and other
supplies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. We account for nonrefundable advance payments for goods
and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have conducted research on many different <I>micro</I>RNAs with the goal of understanding how they function and identifying those
that might be targets for therapeutic modulation. At any given time we are working on multiple targets, primarily within our five therapeutic areas of focus. Our organization is structured to allow the rapid deployment and shifting of resources to
focus on the best targets based on our ongoing research. As a result, in the early phase of our development, our research and development costs are not tied to any specific target. However, we are currently spending the vast majority of our research
and development resources on our lead development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in January 2009, we have grown from 15 research and
development personnel to 59 and have spent a total of approximately $96.8 million in research and development expenses through December&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase for the foreseeable future as we advance our research programs toward the clinic
and initiate clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We or our strategic alliance partners may never succeed in achieving marketing
approval for any of our product candidates. The probability of success for each product candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Under
our strategic alliance with GSK, we may be responsible for the development of product candidates through clinical proof-of-concept, depending on the time at which GSK may choose to exercise its option to obtain an exclusive license to develop,
manufacture and commercialize product candidates on a program-by-program basis. Under our strategic alliance with Sanofi, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are responsible for the development of product candidates up through proof-of-concept, after which time Sanofi would be responsible for the costs of clinical development and commercialization and
all related costs. Under our strategic alliance agreement with AstraZeneca, we are responsible for certain research and development activities with respect to each alliance target under a mutually agreed upon research and development plan until the
earlier to occur of IND approval in a major market or the end of the research term under the agreement. We also have several independent programs for which we are responsible for all of the research and development costs, unless and until we partner
any of these programs in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of our product development programs are at an early stage, and successful development of future
product candidates from these programs is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We anticipate we will
make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to maintain or enter into new strategic alliances with respect to each program or potential product
candidate, the scientific and clinical success of each future product candidate, as well as ongoing assessments as to each future product candidate&#146;s commercial potential. We will need to raise additional capital and may seek additional
strategic alliances in the future in order to advance our various programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and administrative expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our
executive, finance, legal, business development and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses and professional
fees for auditing, tax and legal services. We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a publicly-traded company. These
increases will likely include legal fees, accounting fees, directors&#146; and officers&#146; liability insurance premiums and fees associated with investor relations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other income (expense), net </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income
(expense) consists primarily of interest income and expense, and on occasion income or expense of a non-recurring nature, including changes in debt valuation each reporting period. We earn interest income from interest-bearing accounts and money
market funds for cash and cash equivalents and marketable securities, such as interest-bearing bonds, for our short-term investments. Interest expense has historically represented the amounts payable to under the convertible notes payable and
interest payable under equipment and tenant improvement financing arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities, and the revenues and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in the notes to our financial statements appearing elsewhere in this
Annual Report, we believe that the following critical accounting policies relating to revenue recognition and stock-based compensation are most important to understanding and evaluating our reported financial results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding
and milestone payments under strategic alliance agreements, as well as funding received under government grants. We recognize revenues when all four of the following criteria are met: (1)&nbsp;persuasive evidence that an arrangement exists;
(2)&nbsp;delivery of the products and/or services has occurred; (3)&nbsp;the selling price is fixed or determinable; and (4)&nbsp;collectability is reasonably assured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multiple element arrangements, such as our strategic alliance agreements with GSK, and Sanofi, are analyzed to determine whether the
deliverables within the agreement can be separated or whether they must be accounted for as a single unit of accounting. Deliverables under the agreement will be accounted for as separate units of accounting provided that (i)&nbsp;a delivered item
has value to the customer on a stand-alone basis; and (ii)&nbsp;if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the
control of the vendor. The allocation of consideration amongst the deliverables under the agreement is derived using a &#147;best estimate of selling price&#148; if vendor specific objective evidence and third-party evidence of fair value is not
available. If the delivered element does not have stand-alone value or if the fair value of any of the undelivered elements cannot be determined, the arrangement is then accounted for as a single unit of accounting, and we recognize the
consideration received under the arrangement as revenue on a straight-line basis over our estimated period of performance, which for us is often the expected term of the research and development plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestones </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue from
milestone payments when earned, provided that (i)&nbsp;the milestone event is substantive in that it can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance
and its achievability was not reasonably assured at the inception of the agreement, (ii)&nbsp;we do not have ongoing performance obligations related to the achievement of the milestone and (iii)&nbsp;it would result in the receipt of additional
payments. A milestone payment is considered substantive if all of the following conditions are met: (i)&nbsp;the milestone payment is non-refundable; (ii)&nbsp;achievement of the milestone was not reasonably assured at the inception of the
arrangement; (iii)&nbsp;substantive effort is involved to achieve the milestone; and (iv)&nbsp;the amount of the milestone payments appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk
associated with the achievement of the milestone. Any amounts received under the agreements in advance of performance, if deemed substantive, are recorded as deferred revenue and recognized as revenue as we complete our performance obligations. The
adoption of this guidance did not materially change our previous method for recognizing milestone payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, the milestone
events contained in our strategic alliance agreements coincide with the progression of our product candidates from target selection, to clinical candidate selection, to clinical trial, to regulatory approval and then to commercialization. The
process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve.
Therefore, as a product candidate progresses through the stages of its life-cycle, the value of the product candidate generally increases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair
Value Option </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting standards for fair value measurements establishes a three-level hierarchy for disclosure of financial
instruments measured at fair value. The classification of assets and liabilities within the hierarchy is based on whether the inputs to the measurement valuation methodology are observable or unobservable. Observable inputs reflect market-derived or
market-based information obtained from independent sources, while unobservable inputs reflect our estimates about market data. The following three-level fair value hierarchy is based on the transparency of the inputs used to measure the fair value
of the financial instruments: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2 includes financial instruments for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable in determining fair values of the instruments. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable accounting policies permit entities to choose, at specified election dates, to measure specified items at fair value if the
decision about the election is: 1) applied instrument by instrument, 2) irrevocable, and 3) applied to an entire instrument. In July&nbsp;2012, we amended and restated the 2010 GSK note, which resulted in a debt extinguishment for accounting
purposes. Concurrently with the debt extinguishment, we elected the fair value option for the 2010 GSK note. We performed valuations at the extinguishment date and subsequently on a quarterly basis with changes in fair value recorded in
non-operating earnings. This instrument has been classified in Level 3 within the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our valuation technique uses an
income approach in the form of a convertible bond valuation model to value the note. The convertible bond model considers the debt and option characteristics of the note. The key inputs to the model are volatility, risk-free rate and credit spread.
The absolute stock and strike price are not key inputs because upon an initial public offering, the conversion option was assumed to be set at-the-money. The estimated fair value of the note was based on the probability weighted average of an
initial public offering and a non-initial public offering scenario for the initial valuation in July 2012 and subsequent valuation in September 2012. The For valuations subsequent to our initial public offering, the valuation did not consider a
probability weighting, as the initial public offering was completed in October 2012. The volatility inputs are based on historical and implied volatility of peer companies. Peer companies are materially consistent with those used previously in our
409A analyses. The risk-free rate inputs are based on the yield of US Treasury Strips as of each date. The credit spread inputs are based on a creditworthiness analysis of the Company and market rates for comparable straight debt instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our significant accounting policies and estimates are more fully described in Note 1 to the Financial Statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a
discussion of recently issued accounting pronouncements, refer to the section titled &#147;Recently Issued Accounting Pronouncements&#148; within &#147;The Business, Basis of Presentation and Summary of Significant Accounting Policies&#148; of our
Financial Statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the years ended December&nbsp;31, 2013 and 2012 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the results of our operations for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;2013&nbsp;vs.&nbsp;2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue under strategic alliances</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from changes in valuation of convertible note payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue&nbsp;under strategic alliances </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues are generated from ongoing strategic alliance and collaborations, and generally consist of upfront payments for licenses or
options to obtain licenses in the future, research and development funding and milestone payments. The following table summarizes our total revenues for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanofi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GSK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AstraZeneca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biogen Idec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenues from strategic alliances</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue under strategic alliances was $19.6 million for the year ended December&nbsp;31, 2013 compared to
$12.7 million for the year ended December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2013, the research term expired under the Sanofi alliance, at which time
we entered into an option agreement pursuant to which Sanofi was granted an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered <I>micro</I>RNA programs, and we were granted the exclusive right to
negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport Syndrome. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts
payable by Sanofi to us under our second amended and restated collaboration and license agreement with Sanofi. The non-creditable portion of this payment, $1.25 million, is being recognized as revenue over the option period from the effective date
of the option agreement in June 2013 through the expiration of the option period. Revenue associated with the creditable portion of this option payment will be deferred until its application to a creditable transaction. In addition, we agreed to
continue specified research on the miR-21 programs during the option period. As a result of the expiration of the original research term and subsequent option agreement, we re-evaluated our estimated period of performance and amortized the remaining
deferred revenue of $10.1 million associated with the initial upfront payment of $25.0 million ratably from June 2013 through the expiration of the option period. As a result of the change in our estimated period of performance in June 2013 and
recognition of the non-creditable portion of the option payment, revenue associated with the Sanofi alliance increased to $15.3 million for the year ended December&nbsp;31, 2013, compared to $10.0 million for the year ended December&nbsp;31, 2012.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2013, the product development and commercialization agreement with GSK was amended to state that RG-101, and other formulations
thereof, will be developed by us independently of our alliance with GSK for the treatment of chronic HCV infection. As a result, we accelerated the remaining unamortized deferred revenue of $1.1 million associated with the upfront payment from the
February 2010 amendment that expanded our agreement with GSK to include potential <I>micro</I>RNA therapeutics for the treatment of HCV, due to the completion of our remaining performance obligations. As such, revenue of $1.8 million was recognized
for the year ended December&nbsp;31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2012, we amended our product development and commercialization agreement with GSK to
extend the target selection period for the fourth collaboration target under the agreement. As a result of the extension of the target selection period, we extended our estimated period of performance for the then remaining deferred revenue to
approximately eight years, which represented our new estimated performance period under the amended agreement. As such, revenue of $2.0 was recognized for the year ended December&nbsp;31, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2012, we entered into a strategic alliance and concurrent Common Stock Purchase Agreement, or CSPA, with AstraZeneca. The strategic
alliance included an upfront payment of $3.0 million and is being amortized over an estimated performance period of 48 months, which resulted in approximately $0.8 million and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$0.3 million for the years ended December&nbsp;31, 2013 and 2012, respectively. In October 2012, pursuant to the CSPA, we sold AstraZeneca 6,250,000 shares of our common stock at a price per
share of $4.00. Accounting guidance for multiple element arrangements contains a presumption that separate contracts negotiated and/or entered into at or near the same time with the same entity were negotiated as a package and should be evaluated as
a single agreement. We valued the discount applied to the shares of common stock due to the one-year restriction. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the lack of marketability discount,
$4.3&nbsp;million was attributed to the collaboration and license agreement, which is being amortized over the estimated period of performance of the collaboration. As such, revenue of $1.1 million and $0.3 million was recognized for the years ended
December&nbsp;31, 2013 and 2012, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2012, we entered into a collaboration and license agreement with Biogen Idec,
which included an upfront payment of $0.8 million. We are recognizing revenue related to the upfront payment over our estimated period of performance, which is approximately two years. As such, revenue associated with the upfront payment of $0.3
million and $0.1 million was recognized for the years ended December&nbsp;31, 2013 and 2012, respectively. Additionally research milestone payments totaling $0.3 million were received for the year ended December&nbsp;31, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased to $29.9 million for the year ended December&nbsp;31, 2013 compared to $20.3 million for the year
ended December&nbsp;31, 2012. The increase was primarily driven by IND-enabling activities for RG-101 and other programs of $5.9 million, and an increase in salaries and related benefits, including stock based compensation, of $3.3 million.
Employees engaged in research and development activities increased to 59 as of December&nbsp;31, 2013, compared to 52 as of December&nbsp;31, 2012. We expect our research and development expenses to continue to increase to the extent we commence
clinical studies and initiate additional IND-enabling activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased to $7.4&nbsp;million for the year ended December&nbsp;31, 2013 compared to $4.9&nbsp;million for
the year ended December&nbsp;31, 2012. The increase was primarily driven by an increase in salaries and related benefits, including stock based compensation, of $0.9 million, in addition to external service costs and other general operating expenses
of $0.9 million associated with the growth of the business and other costs associated with being a public reporting company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Loss on extinguishment of
debt </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2012, we amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK, or
the 2010 GSK note, which resulted in a debt extinguishment for accounting purposes. We valued the 2010 GSK note at the extinguishment date and recorded a $1.7 million loss on extinguishment of debt (the difference between the original $5.0 million
carrying value and the fair value) in the statements of operations and comprehensive loss for the year ended December&nbsp;31, 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Loss from change
in value of convertible note payable </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amended and restated 2010 GSK Note provided for a rollover into a new promissory note,
effective as of the closing date of a qualifying initial public offering (the &#147;Post-IPO GSK Note&#148;). The Post-IPO GSK Note would be equivalent to the aggregate amount of principal and accrued but unpaid interest as of the initial public
offering date. In October 2012, upon our initial public offering, the 2010 GSK Note was simultaneously cancelled and obligations thereto were terminated. Subsequent to the debt extinguishment previously described, changes in the fair value of the
2010 GSK Note (through October 2012) and the Post-IPO GSK Note (subsequent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the initial public offering) have been recorded on a periodic basis with changes in fair value recorded in non-operating earnings. We recorded a loss from changes in value of convertible notes
payable of $1.1 million and $3.0 million in the statements of operations and comprehensive loss for the years ended December&nbsp;31, 2013 and 2012, respectively. Changes in value were primarily driven by fluctuations in our stock price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the years ended December&nbsp;31, 2012 and 2011 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the results of our operations for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;2012&nbsp;vs.&nbsp;2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2011&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue under strategic alliances and grants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from changes in valuation of convertible note payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue&nbsp;under strategic alliances and grants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our total revenues for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanofi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GSK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AstraZeneca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biogen Idec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognized revenue of $12.7 million for the year ended December&nbsp;31, 2012 compared to $13.8 million for
the year ended December&nbsp;31, 2011. Our revenue during these periods consisted primarily of amortization of upfront payments received from the Sanofi and GSK strategic alliances, which we amortize monthly on a straight-line basis over our
estimated period of performance. Revenue recognized from the amortization of payments from the Sanofi strategic alliance was $10.0 million for each of the years ended December&nbsp;31, 2012 and 2011. Revenue recognized from the amortization of
payments from the GSK strategic alliance decreased to $2.0 million for the year ended December&nbsp;31, 2012 from $3.7 million for the year ended December&nbsp;31, 2011. This reduction was due to the June 2012 amendment of the collaboration
agreement which extended our estimated period of performance and the resulting amortization period, applied on a prospective basis. In addition, we entered into a strategic alliance with AstraZeneca, which included an upfront payment of $3.0 million
which is being amortized over an estimated performance period of 48 months. This resulted in approximately $0.3 million in revenue for the year ended December&nbsp;31, 2012. Revenue associated with the CSPA (as discussed above) was approximately
$0.3 million for the year ended December&nbsp;31, 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased to $20.3 million for the year ended December&nbsp;31, 2012 compared to $17.3 million for the year
ended December&nbsp;31, 2011. This change was primarily driven by an increase in salaries and related benefits of $1.1 million in response to the incremental research and development personnel required to support the growth in activity within the
strategic alliances and collaborations. In conjunction with the increased personnel costs, laboratory supplies and external services costs increased by $1.2&nbsp;million and $1.6 million, respectively over 2011. These increases were offset by a
decrease of approximately $0.8 million in pre-clinical study costs from 2011. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased to $4.9&nbsp;million for the year ended December&nbsp;31, 2012 compared to $3.6&nbsp;million for
the year ended December&nbsp;31, 2011. This change was primarily driven by an increase in salaries and related benefits of $0.9 million, in addition to increases in legal and external service costs of $0.3 million and $0.2 million, respectively,
attributable to costs associated with the growth of the business and preparations associated with our initial public offering in October 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Loss on
extinguishment of debt </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded a loss on extinguishment of debt of $1.7 million (as noted above) in conjunction with the 2010 GSK
note, in the statement of operations and comprehensive loss for the year ended December&nbsp;31, 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Loss from change in value of convertible note
payable </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded a loss from change in value of convertible notes payable of $3.0 million (as noted above) in the statements of
operations and comprehensive loss for the year ended December&nbsp;31, 2012. The loss from change in value was primarily driven by an increase in our stock price from the period of the extinguishment of debt through December&nbsp;31, 2012. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
our inception through December&nbsp;31, 2013, we have received $66.3&nbsp;million principally from upfront payments, research funding and preclinical milestones from our strategic alliances, collaborations, government grants and loans, and
$170.7&nbsp;million from the sale of our equity and convertible debt securities, including $70.0 million in net proceeds from our initial public offering and concurrent private placement of our common stock in October 2012 and $45.8 million in net
proceeds from our public offering in July 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, we had approximately $114.0&nbsp;million in cash and cash
equivalents and short-term investments. The following table shows a summary of our cash flows for the years ended December&nbsp;31, 2013, 2012 and 2011: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Net cash provided by (used in):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities have increased to $28.3&nbsp;million for the year ended December&nbsp;31, 2013, compared to
$8.7&nbsp;million and $15.1 million for the years ended December&nbsp;31, 2012 and 2011, respectively. Increases in cash used in operating activities has been attributable in part to an increase in net loss to $18.7 million in 2013, compared to
$17.4 million and $7.6 million in 2012 and 2011, respectively. Adjustments for non-cash charges, including stock-based compensation, loss on extinguishment of debt and subsequent changes in value of the 2010 GSK Note have also increased to $7.4
million, compared to $7.7 million and $2.3 million in 2012 and 2011, respectively. Changes in working capital, including deferred revenue, resulted in net cash used in operating activities of $17.0 million and $9.7 million in 2013 and 2011,
respectively, compared to net cash provided by operating activities of $1.0 million in 2012. These changes primarily relate to the timing of upfront payments and milestones, compared to the period of revenue recognition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in or provided by investing activities for the periods presented primarily related to the purchase, sale or maturity of
investments used to fund the day-to-day needs of our business. Increases in cash used in investment activities in 2013 and 2012 were primarily the result of net investments in short-term securities of $40.1 million and $29.0 million, offset by
investments in property, equipment and intangible assets of $0.8 million and $1.4 million, respectively. These investments were funded by proceeds from our July 2013 financing and October 2012 initial public offering, respectively. In 2011,
investing activities included net cash provided from investment activities of $3.3 million, primarily as a result of the net maturities of short-term investments of $3.9 million, offset by investments in property, equipment and intangible assets of
$0.6 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was approximately $46.5 and $70.5 million for the years ended December&nbsp;31, 2013 and 2012,
respectively. Net cash used in financing activities was $0.4 million for the year ended December&nbsp;31, 2011. In 2013, financing activities included a public offering that resulted in net proceeds of approximately $45.8 million. In 2012, financing
activities included our initial public offering and concurrent private placement of common stock, which resulted in net proceeds of approximately $65.8, in addition to proceeds of $5.0 million from the issuance of a promissory note to Biogen Idec in
conjunction with our license and collaboration agreement in August 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, we had approximately $114.0&nbsp;million in cash and cash equivalents and short-term investments. We expect our
research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidates in or towards clinical programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements are difficult to forecast and will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the achievement of milestones under our strategic alliance agreements with GSK, Sanofi and AstraZeneca; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any other strategic alliance, licensing and other arrangements that we may establish; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing and completion of preclinical studies and clinical trials for our potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress, costs and results of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and cost of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays that may be caused by changing regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of hiring new employees to support our continued growth; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and timing of procuring clinical and commercial supplies of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and timing of establishing sales, marketing and distribution capabilities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or invest in businesses, products or technologies. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of our long-term contractual obligations as of December&nbsp;31, 2013 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014<BR>&lt;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">2015-2016</FONT><BR>2-3 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR><FONT STYLE="white-space:nowrap">4-5&nbsp;Years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&gt;5&nbsp;Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligation relating to facility<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal under convertible notes payable, excluding accrued interest<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We lease approximately 29,000 square feet for office and laboratory space in La Jolla, California under an operating lease that expires in June 2017. Obligations under all lease agreements are included in the above
table. </I></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(2)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>In October 2012, in conjunction with our initial public offering we issued GSK a convertible promissory note, or the Post-IPO GSK Note, in the principal amount of $5.4 million. The Post-IPO GSK Note has a maturity
date of October&nbsp;9, 2015. At GSK&#146;s option, the Post-IPO GSK Note may be converted into shares of our common stocks at any time prior to the maturity date with a conversion equal to the quotient of all outstanding principal and interest
divided by the initial public offering price of $4.00 per share, regardless of the then fair market value of our common stock. </I></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to 2011, our
access to the Tuschl 3 patents was derived from agreements between Max-Planck-Innovation GmbH, or Max-Planck, and our founding companies, Alnylam and Isis, for exclusive use in <I>micro</I>RNA therapeutics. In April 2011, we entered into a direct,
co-exclusive license with Max-Planck. The license provides to us, Alnylam and Isis, co-exclusively, access to the Tuschl 3 patents for therapeutic use. We will be required to make payments based upon the initiation of clinical trials and/or product
approval milestones totaling up to $1.6 million for each licensed product reaching such clinical stage. In addition to milestone payments, we will be required to pay royalties of a percentage of cumulative annual net sales of a licensed product
commercialized by us or one of our strategic alliance partners. The percentage is in the low single digits, with the exact percentage depending upon whether the licensed product incorporates intellectual property covered by a Tuschl 3 patent that is
still subject to a pending application or, alternatively an issued patent, and also upon the volume of annual sales. Reduction in the royalties paid to Max-Planck is made for any third party payments also required to be made with a minimum floor in
the low single digits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2009, we entered into a co-exclusive license for use of the Tuschl 3 patents for diagnostic purposes with
Max-Planck.&nbsp;Under the terms of the license, we made an aggregate initial payment to Max-Planck of &#128;175,000 in three installments together with interest, with &#128;75,000 paid in June 2009 and &#128;50,000 plus interest paid in each of
June 2010 and December 2010. In addition, we made annual maintenance payments of &#128;10,000 in 2011, &#128;20,000 in 2012 and &#128;30,000 in 2013 and will make annual maintenance payments thereafter during the term of the agreement. In addition
to maintenance payments, we will be required to pay royalties of a percentage of net sales of licensed products. The percentage is in the mid-single digits in the event we market the product and low double digits in the event we sell the product
through a distributor. The royalties payable to Max-Planck are reduced by the royalties payable to third parties but only if aggregate royalties payable to Max-Planck and third parties exceed a percentage in the mid-10 to 20% range. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2010, we exclusively licensed patent rights from Julius-Maximilians-Universit&auml;t W&uuml;rzburg and Bayerische Patent Allianz GmBH,
which we collectively refer to herein as the University of W&uuml;rzburg, which rights encompass the use of anti-miR therapeutics targeting miR-21 for the treatment of fibrosis, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
kidney, liver, lung and cardiac fibrosis. As a license issuance fee, we paid the University of W&uuml;rzburg &#128;300,000. In addition, upon commercialization of a product, we will pay to the
University of W&uuml;rzburg a percentage of net sales as a royalty. This royalty is in the low single digits and is reduced upon expiration of all patent claims covering the product. We also paid the University of W&uuml;rzburg a partnership bonus
of &#128;200,000 upon entering into our strategic alliance agreement with Sanofi. Under the agreement, beginning January&nbsp;1, 2020 and ending on the date we receive NDA approval for a licensed product, we will accrue a minimum royalty obligation
of &#128;150,000&nbsp;per year, which will become payable upon approval of an NDA for a licensed product. After approval of an NDA for a licensed product, we will pay the University of W&uuml;rzburg an annual minimum royalty, which increases in the
five years following approval up to a maximum of &#128;3.0&nbsp;million&nbsp;per year. The minimum royalties are creditable against actual royalties due and payable for the same calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2005, Alnylam and Isis entered into a co-exclusive license agreement with Stanford University, or Stanford, relating to its patent
applications claiming the use of miR-122 to reduce the replication of HCV. Upon our formation, we received access to the Stanford technology as an affiliate of Alnylam and Isis. In July 2009, Isis assigned its rights and obligations under the
license agreement to us. We are permitted to sublicense our rights under the agreement in connection with a bona fide partnership seeking to research and/or develop products under a jointly prepared research plan and which also includes a license to
our intellectual property or in association with providing services to a sublicensee. In the event we receive an upfront payment in connection with a sublicense, we are obligated to pay to Stanford a one-time payment, the amount of which will vary
depending upon the size of upfront payment we receive. We must also make an annual license maintenance payment during the term of the agreement. The maintenance payments are creditable against royalty payments made in the same year. We will be
required to pay milestones for an exclusively licensed product which will be payable upon achievement of specified regulatory and clinical milestones in an aggregate amount of up to $400,000. Milestones for a non-exclusively licensed product will be
payable upon achievement of the same milestones in an aggregate amount of up to $200,000. Upon commercialization of a product, we will be required to pay to Stanford a percentage of net sales as a royalty. This percentage is in the low single
digits. The payment will be reduced by other payments we are required to make to third parties until a minimum royalty has been reached. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2011, we entered into an exclusive license with NYU related to our miR-33 program. Under the terms of the agreement, we paid to NYU
an upfront payment of $25,000. An equal additional payment will be required upon issuance of a patent containing a claim of treating or preventing disease. We will be required to make payments to NYU upon achievement of specified clinical and
regulatory milestones of up to an aggregate of $925,000. These milestone payments will only be made after issuance of a therapeutic claim under the NYU patent applications. We are also required to pay royalties of a percentage of net sales for any
product sold by us or a strategic alliance partner. The royalty rate is in the low single digits and is reduced down to a minimum floor in the event we are required to pay royalties to a third party. In the event we sublicense the NYU patents, NYU
is also entitled to receive a percentage of the sublicense income received by us. The percentage payable depends upon the development stage of the program when the sublicense is completed with the highest percentage paid with submission of the first
IND. The percentage thereafter declines until completion of the first Phase 2 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal
course of business with contract research organizations for preclinical research studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are
cancelable contracts and not included in the table of contractual obligations and commitments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any off-balance sheet arrangements (as defined by applicable SEC regulations) that are reasonably likely to have a current or
future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2012, the JOBS Act was enacted. Section&nbsp;107 of the JOBS Act provides that an emerging growth company can take advantage of the
extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those
standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption
of such standards is required for other companies. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_10"></A>Quantitative and Qualitative Disclosures About Market Risk </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the securities that we invest in have market risk in that a change in prevailing interest rates may cause the principal amount of the
marketable securities to fluctuate. Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We invest our excess cash primarily in
commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at
the same time maximizing the income we receive from our marketable securities without significantly increasing risk. Additionally, we established guidelines regarding approved investments and maturities of investments, which are designed to maintain
safety and liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the short-term maturities of our cash equivalents and marketable securities, we do not believe that an
increase in market rates would have any significant impact on the realized value of our marketable securities. If a 10% change in interest rates were to have occurred on December&nbsp;31, 2013, this change would not have had a material effect on the
fair value of our investment portfolio as of that date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_11"></A>Financial Statements and Supplementary Data </B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx652681_100"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders of Regulus Therapeutics Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of Regulus Therapeutics Inc. as of December&nbsp;31, 2013 and 2012, and the related statements of operations
and comprehensive loss, convertible preferred stock and stockholders&#146; equity (deficit), and cash flows for each of the three years in the period ended December&nbsp;31, 2013. These financial statements are the responsibility of the
Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in
accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material
respects, the financial position of Regulus Therapeutics Inc. at December&nbsp;31, 2013 and 2012, and the results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2013, in conformity with U.S.
generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;27, 2014 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx652681_101"></A>BALANCE SHEETS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracts and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable, at fair value</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, less current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 200,000,000 shares authorized at December&nbsp;31, 2013 and 2012, 41,787,326 and 35,831,808 shares
issued and outstanding at December&nbsp;31, 2013 and 2012, respectively</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx652681_102"></A>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue under strategic alliances and collaborations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,574</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,738</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in value of convertible note payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,969</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain (loss) on short-term investments, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,682</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(85.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,479,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,212,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx652681_103"></A>STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>paid-in<BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income (loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;<BR>equity&nbsp;(deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2010</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Unrealized loss on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,011</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Impact of initial public offering on stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Effect of 2-for-1 split on shares of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,450,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of shares of preferred stock to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,450,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,249,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,699,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Initial public offering of common stock, net of $5,886 of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,730,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock in private placement concurrently with initial public offering, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of notes payable to common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,703,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Unrealized loss on short-term investments, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,831,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">732,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock under Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of common stock, net of $434 of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,175,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Unrealized loss on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,787,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">172,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(79,087</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx652681_104"></A>STATEMENTS OF CASH FLOWS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in value of convertible note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of premium on investments, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracts and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities and sales of short-term investments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of intangibles</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible notes payable and other long-term obligations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments on other long-term obligations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes paid</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures of non-cash investing and financing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of notes payable to common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allowance for tenant improvements</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts accrued for patent expenditures</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx652681_105"></A>Notes to Financial Statements </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. The Business, Basis of Presentation and Summary of Significant Accounting Policies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulus Therapeutics Inc. was originally formed as a Delaware limited liability company under the name Regulus Therapeutics
LLC on September&nbsp;6, 2007, when Alnylam Pharmaceuticals, Inc. (&#147;Alnylam&#148;) and Isis Pharmaceuticals, Inc. (&#147;Isis&#148;) contributed significant intellectual property, know-how and financial and human capital to pursue the
development of drugs targeting <I>micro</I>RNAs pursuant to a license and collaboration agreement. Regulus Therapeutics Inc. was converted to a Delaware corporation on January&nbsp;2, 2009. As used in this report, unless the context suggests
otherwise, &#147;the Company,&#148; &#147;our,&#148; &#147;us&#148; and &#147;we&#148; means Regulus Therapeutics Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
biopharmaceutical company focused on discovering and developing first-in-class drugs that target <I>micro</I>RNAs to treat a broad range of diseases. We believe we have assembled the leading position in the <I>micro</I>RNA field, including expertise
in <I>micro</I>RNA biology and oligonucleotide chemistry, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. We refer to these assets as our <I>micro</I>RNA product platform. We are
using our <I>micro</I>RNA product platform to develop chemically modified, single-stranded oligonucleotides that we call anti-miRs. We use these anti-miRs to modulate <I>micro</I>RNAs and by doing so return diseased cells to their healthy state. We
are pursuing several <I>micro</I>RNA targets and are focusing our proprietary efforts in oncology and orphan diseases. We believe <I>micro</I>RNAs may be transformative in the field of drug discovery and that anti-miRs may become a new and major
class of drugs with broad therapeutic application much like small molecules, biologics and monoclonal antibodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements are prepared in accordance with U.S. generally accepted accounting principles. The preparation of our financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes.
Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues
generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments under strategic alliance agreements, as well as funding received under government grants. We
recognize revenues when all four of the following criteria are met: (1)&nbsp;persuasive evidence that an arrangement exists; (2)&nbsp;delivery of the products and/or services has occurred; (3)&nbsp;the selling price is fixed or determinable; and
(4)&nbsp;collectability is reasonably assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multiple element arrangements, such as our strategic alliance agreements with Sanofi,
AstraZeneca AB (&#147;AstraZeneca&#148;) and GlaxoSmithKline plc (&#147;GSK&#148;), are analyzed to determine whether the deliverables within the agreement can be separated or whether they must be accounted for as a single unit of accounting.
Deliverables under the agreement will be accounted for as separate units of accounting provided that (i)&nbsp;a delivered item has value to the customer on a stand-alone basis; and (ii)&nbsp;if the agreement includes a general right of return
relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the deliverables under the agreement is derived using a
&#147;best estimate of selling price&#148; if vendor specific objective evidence and third-party evidence of fair value is not available. If the delivered element does not have stand-alone value, the arrangement is then accounted for as a single
unit of accounting, and we recognize the consideration received under the arrangement as revenue on a straight-line basis over our estimated period of performance, which for us is often the expected term of the research and development plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestones </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue from milestone payments when earned, provided that (i)&nbsp;the milestone event is substantive in that it can only be
achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance and its achievability was not reasonably assured at the inception of the agreement, (ii)&nbsp;we do not have
ongoing performance obligations related to the achievement of the milestone and (iii)&nbsp;it would result in the receipt of additional payments. A milestone payment is considered substantive if all of the following conditions are met: (i)&nbsp;the
milestone payment is non-refundable; (ii)&nbsp;achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii)&nbsp;substantive effort is involved to achieve the milestone; and (iv)&nbsp;the amount of the milestone
payments appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone. Any amounts received under the agreements in advance of performance, if
deemed substantive, are recorded as deferred revenue and recognized as revenue as we complete our performance obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, the
milestone events contained in our strategic alliance agreements coincide with the progression of our product candidates from target selection, to clinical candidate selection, to clinical trial, to regulatory approval and then to commercialization.
The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to
achieve. Therefore, as a product candidate progresses through the stages of its life-cycle, the value of the product candidate generally increases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grant Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue from
government and private agency grants as the related research expenses are incurred and to the extent that funding is approved. Any amounts received in advance of performance are recorded as deferred revenue until earned. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received prior
to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the black-scholes model. We recognize
stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each
separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for stock options granted to non-employees, which primarily consist of members of our scientific advisory board, using the fair
value approach. Stock options granted to non-employees are subject to periodic revaluation over their vesting terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred and include compensation and related benefits, non-cash stock-based compensation,
license fees, laboratory supplies and associated overhead and facilities costs. In certain circumstances, we make non-refundable advance payments to purchase goods and services for future use in research and development activities pursuant to
contractual arrangements. In those instances, we capitalize these amounts and record expense in the period that we receive the goods or when services are performed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting
guidance for accounting for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For
those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are
measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. We provide a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more
likely than not that the deferred tax assets will be realized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Option </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable accounting policies permit entities to choose, at specified election dates, to measure specified items at fair value if the decision
about the election is: 1) applied instrument by instrument, 2) irrevocable, and 3) applied to an entire instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2012, we
amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK (&#147;2010 GSK note&#148;), which was accounted for as a debt extinguishment of the original note. We elected to measure the amended note
under the fair value option. The difference between the carrying value of the original note and the fair value of the amended note was recorded as a loss on extinguishment of debt to non-operating earnings. Thereafter, any change to the fair value
of the amended note is recorded as gain (loss) from valuation of convertible note payable to non-operating earnings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We classify time deposits and other investments that are highly liquid and have maturities of 90 days or less at the date of
purchase as cash equivalents. The carrying amounts approximate fair value due to the short maturities of these instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Short-Term Investments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry short-term investments classified as available-for-sale at fair value as determined by prices for identical or similar
securities at the balance sheet date. Our short-term investments consist of both Level 1 and Level 2 financial instruments in the fair value hierarchy. We record unrealized gains and losses as a component of other comprehensive loss within the
statements of operations and comprehensive loss and as a separate component of stockholders&#146; equity (deficit). We determine the realized gains or losses of available-for-sale securities using the specific identification method and include net
realized gains and losses in interest income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each balance sheet date, we assess available-for-sale securities in an unrealized loss
position to determine whether the unrealized loss is other-than-temporary. We consider factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities
in a single asset class, the length of time the market value of the security has been less than its cost basis, the security&#146;s relative performance versus its peers, sector or asset class, expected market volatility and the market and economy
in general. When we determine that a decline in the fair value below its cost basis is other-than-temporary, we recognize an impairment loss in the year in which the other-than-temporary decline occurred. We determined that there were no
other-than-temporary declines in the value of short-term investments as of December&nbsp;31, 2013 and 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash
equivalents and short-term investments. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have not experienced any losses in such accounts and believe we are not exposed to significant risk.
We maintain our cash equivalents and short-term investments with three financial institutions. We invest our excess cash primarily in commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies
and the U.S. Treasury. Additionally, we established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry
our property and equipment at cost, which consists of lab equipment, computer equipment and software, furniture and fixtures and leasehold improvements. Property and equipment is depreciated using the straight-line method over the estimated useful
lives (generally three to five years). Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured. Repair and maintenance costs that
do not improve service potential or extend economic life are expensed as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intangibles </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We capitalize costs which consist principally of outside legal costs and filing fees related to obtaining patents. We review our capitalized
patent costs periodically to determine that they include costs for patent applications that have future value and an alternative future use. We evaluate costs related to patents that we are not actively pursuing and write off these costs. We
amortize patent costs over their patent lives, beginning with the date the patents are issued. The weighted average remaining life of the issued patents was 12 years at December&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We obtain licenses from third parties and capitalize the costs related to exclusive licenses that have alternative future use within multiple
potential programs. We amortize capitalized licenses over their estimated useful life or term of the agreement, which for current licenses is 10 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly review the carrying amount of our property, equipment and intangible assets to determine whether indicators of impairment may
exist which warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the
asset&#146;s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. No impairment charges were recorded during the years ended
December&nbsp;31, 2013, 2012 and 2011. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trial and Pre-Clinical Study Accruals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on the facts and circumstances known
to us at that time. Our accrued expenses for clinical trials are based on estimates of the fees associated with services provided by clinical trial investigational sites and CROs. Payments under some of the contracts we have with such parties depend
on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended
in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or
overestimate the activity or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated
actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for
evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed our business as one segment operating primarily in the United States.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner
sources. Our only component of other comprehensive loss is unrealized gains (losses) on available-for-sale securities. Comprehensive gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate
component of the statements of convertible preferred stock and stockholders&#146; equity (deficit) for all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reclassifications
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain current and non-current liabilities in prior period financial statements have been reclassified or consolidated to conform
to the current period presentation. These reclassifications had no impact on our statements of operations, statements of preferred stock and stockholders&#146; equity (deficit) or statements of cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2013, the FASB issued Accounting Standards Update No.&nbsp;2013-11, <I>Presentation of an Unrecognized Tax Benefit When a Net Operating
Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists</I> (&#147;ASU 2013-11&#148;). This update provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss
carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2013, with an option for early adoption. We
intend to adopt this guidance in 2014, and do not believe the adoption of this standard will have a material impact on our financial condition, results of operations or related financial statement disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Net Loss Per Share </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding
for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the
treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock and options outstanding under our stock option plan. For all periods presented, there is no difference in the number of shares used to calculate
basic and diluted shares outstanding due to our net loss position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Potentially dilutive securities not included in the calculation of
diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Years ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,699,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,639,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,883,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,338,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,411,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,366,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,050,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,250,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,038,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2012, all convertible preferred stock converted in conjunction with our initial public offering.
For the year ended December&nbsp;31, 2011 we had convertible notes payable outstanding of $10.0 million that were convertible into convertible preferred stock upon the occurrence of various future preferred stock financing events at prices that were
not determinable until the occurrence of the future events. As such, we have excluded those convertible notes payable from the table above. For the years ended December&nbsp;31, 2013 and 2012 we had a convertible note payable outstanding with a
principal balance of $5.4 million that was convertible into common shares at $4.00 per share, at the option of the note holder. Those shares are included for the years ended December&nbsp;31, 2013 and 2012. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Investments </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We invest our excess cash in commercial paper and debt instruments of financial institutions, corporations and U.S.
government-sponsored agencies. As of December&nbsp;31, 2013, our short-term investments had a weighted average maturity of less than two years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following tables summarize our short-term investments (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maturity<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2&nbsp;or&nbsp;less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 or less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 or less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt securities of U.S. government-sponsored agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1 or less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maturity<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>cost</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>fair&nbsp;value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 or less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;or&nbsp;less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2 or less</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Fair Value Measurements </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within
the fair value hierarchy as described in the accounting standards for fair value measurements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable accounting guidance defines
fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of
the measurement date. Market participants are buyers and sellers in the principal market that are (i)&nbsp;independent, (ii)&nbsp;knowledgeable, (iii)&nbsp;able to transact, and (iv)&nbsp;willing to transact. The guidance provides an established
hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market
participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in
valuing the asset or liability. The guidance prioritizes the inputs used in measuring the fair value into the following hierarchy: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets,
quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or
corroborated by, observable market data. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management&#146;s own assumptions. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents our fair value hierarchy for assets and liabilities measured at fair value on a
recurring basis at December&nbsp;31, 2013 and 2012 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value as of December&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt securities of U.S. government-sponsored agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">113,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value as of December&nbsp;31, 2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificates of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of the liabilities measured at fair value on a quarterly basis using significant
unobservable inputs (Level 3) from December&nbsp;31, 2012 to December&nbsp;31, 2013 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements<BR>Using Significant<BR>Unobservable Inputs<BR>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in estimated fair value of convertible notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We obtain pricing information from quoted market prices or quotes from brokers/dealers. We generally determine
the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July&nbsp;2012, we amended and restated the 2010 GSK Note, which resulted in a debt extinguishment for accounting purposes. Concurrently
with the debt extinguishment, we elected the fair value option for the 2010 GSK Note. The amended and restated 2010 GSK Note provided for a rollover into a new promissory note, effective as of the closing date of a qualifying initial public offering
(the &#147;Post-IPO GSK Note&#148;). In October 2012, upon our initial public offering, the Post-IPO GSK Note was established, and the 2010 GSK Note was simultaneously cancelled and obligations thereto were terminated. We valued the 2010 GSK Note at
July 2012,&nbsp;September 2012 and at the extinguishment date. We valued the Post-IPO GSK Note each quarter since that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date. We recorded a $1.7 million loss on extinguishment of debt (the difference between the original $5.0 million carrying value and the then fair value) in July 2012. In subsequent periods,
changes in fair value have been recorded on a quarterly basis in non-operating earnings. We recorded a loss from change in value of the convertible note payable of $1.1 million and $3.0 million on the statements of operations and comprehensive loss
for the years ended December&nbsp;31, 2013 and 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We used an income approach in the form of a convertible bond valuation model to
value the note. The convertible bond model considered the debt and option characteristics of the note. The key inputs to the model as of December&nbsp;31, 2013 and 2012 was volatility (66% and 75%, respectively), risk-free rate (0.325% and 0.421%,
respectively), and credit spread (7.4% and 9.5%, respectively). The volatility inputs were based on historical and implied volatility of peer companies. Peer companies were consistent with those used previously for purposes of determining volatility
for stock-based compensation. The risk-free rate inputs were based on the yield of US Treasury Strips as of each date. The credit spread inputs were based on a creditworthiness analysis of the Company and market rates for comparable straight debt
instruments. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Strategic Alliances and Collaborations </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the amounts included in our revenues which resulted from our strategic alliances and
collaboration (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sanofi-Aventis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GSK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AstraZeneca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biogen Idec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sanofi </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of
the <I>micro</I>RNA alliance targets to be developed under such agreement. The modification made to the agreement was considered a material modification, which required the application of the new authoritative guidance adopted by us in January 2011
for multiple element arrangements. We determined that the elements within the strategic alliance agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The
following elements were delivered as part of the strategic alliance with Sanofi: (1)&nbsp;a license for up to four <I>micro</I>RNA targets; and (2)&nbsp;a research license under our technology alliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which we granted
Sanofi an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered <I>micro</I>RNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of
certain miR-21 anti-miRs in oncology and Alport&#146;s Syndrome. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and
commercialization agreement we enter pursuant to the option agreement. The non-creditable portion of this payment, $1.25 million, is being recognized as revenue over the option period from the effective date of the option agreement in June 2013
through the expiration of the option period. Revenue associated with the creditable portion of this option payment will be deferred until its application to a creditable transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In addition, we agreed to continue specified research on the miR-21 programs during the option period. As a result of the expiration of the original research term and subsequent option agreement,
we re-evaluated our estimated period of performance and are now amortizing the remaining deferred revenue associated with the initial upfront payment of $25.0 million ratably from June 2013 through the expiration of the option period. Deferred
revenue at December&nbsp;31, 2013 was $2.2 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated the remaining contingent event-based payments under our strategic
alliance agreement with Sanofi and determined that the preclinical payments meet the definition of a substantive milestone. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved
and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of Sanofi&#146;s performance will not be accounted for using the milestone
method. Such payments will be recognized as revenue over our remaining estimated period of performance, if any, and when collectability is reasonably assured. As of the expiration of the research term in June 2013, Sanofi no longer had rights to
select additional <I>micro</I>RNA targets. We can earn a preclinical milestone of $15.0&nbsp;million upon the filing of an Investigational New Drug application (&#147;IND&#148;) for the selected <I>micro</I>RNA target. We can also receive milestone
payments of up to $33.0 million for clinical milestones and up to $165.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales which will range from 8 to 12%, depending
upon the volume of sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GSK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April 2008, we entered into a strategic alliance with GSK to discover, develop and commercialize novel <I>micro</I>RNA-targeted therapeutics to treat inflammatory diseases (the &#147;immuno-inflammatory alliance&#148;). In February 2010, we and GSK
expanded the strategic alliance to include hepatitis C virus infection (&#147;HCV&#148;) to discover, develop and commercialize <I>micro</I>RNA therapeutics targeting miR-122 for the treatment of HCV (the &#147;HCV alliance&#148;). In June 2012, we
amended our immuno-inflammatory alliance to extend the target selection period for the fourth collaboration target. The modification made to the agreement was considered a material modification, which required the application of the new
authoritative guidance adopted by us in January 2011 for multiple element arrangements. We determined that the elements within the immuno-inflammatory alliance should be treated as a single unit of accounting because the delivered elements, the
opt-in licenses for <I>micro</I>RNA product candidates, did not have stand-alone value to GSK. As a result of the extension of the target selection period, we extended the amortization period for the remaining deferred revenue to approximately eight
years, which represented our new estimated period of performance. As of December&nbsp;31, 2013, deferred revenue associated with the immuno-inflammatory alliance was $3.5 million, which we are expecting to recognize over the remaining estimated
period of performance of approximately 6 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2013, the HCV alliance was amended to state that RG-101, and other formulations
thereof, will be developed by us independently of our alliance for the treatment of chronic HCV infection.&nbsp;This amendment removed any further milestone or royalty obligations owed by GSK to us as it relates only to RG-101. Concurrent with the
amendment, we recorded the remaining $1.1 million in deferred revenue associated with the upfront payment from the HCV alliance, as our estimated period of performance was complete. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Immuno-Inflammatory Alliance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
immuno-inflammatory alliance includes contractual milestones. If all the product candidates are successfully developed and commercialized through pre-agreed sales targets we could receive milestone payments up to $432.5&nbsp;million, including up to
$15.5 million for preclinical milestones, up to $87.0&nbsp;million for clinical milestones, up to $150.0&nbsp;million for regulatory milestones and up to $180.0&nbsp;million for commercialization milestones. We are also entitled to receive tiered
royalties as a percentage of annual sales which can increase up to the low end of the 10 to 20% range. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated the remaining contingent event-based payments under our immuno-inflammatory
alliance and determined that the preclinical and clinical payments meet the definition of a substantive milestone. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and
collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of GSK&#146;s performance will not be accounted for using the milestone method. Such
payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. We can earn the following preclinical milestones: $0.5 million upon the selection of a fourth
<I>micro</I>RNA target and $5.0 million upon the selection of a development candidate for each of the selected three targets. We can also earn the following clinical milestones for each of the selected three targets: $4.0 million for the initiation
of a Phase 1 clinical trial; $5.0 million for the initiation of a Phase 2 clinical trial; and $20.0 million if GSK chooses to opt-in to the program following the completion of a proof-of-concept trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>HCV Alliance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, GSK has retained its interest in the miR-122 program in HCV, and <FONT STYLE="white-space:nowrap">miR-122&nbsp;remains</FONT> a collaboration target under the alliance. If the HCV program is successful, we could receive contractual
milestone payments up to $144.5&nbsp;million, including up to $5.5&nbsp;million for preclinical milestones, up to $29.0&nbsp;million for clinical milestones, up to $50.0&nbsp;million for regulatory milestones and up to $60.0&nbsp;million for
commercialization milestones. In addition, we will receive tiered royalties which can increase up to the low end of the 10 to 20% range on sales from any product that GSK successfully commercializes under this alliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated the remaining contingent event-based payments under the HCV alliance and determined that the preclinical and clinical
payments meet the definition of a substantive milestone. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent
event-based payments under the strategic alliance agreement for which payment is contingent upon the results of GSK&#146;s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the
remaining estimated period of performance, if any, and when collectability is reasonably assured. We can earn a preclinical milestone of $5.5&nbsp;million upon the selection of a development candidate. We can also earn the following clinical
milestones: $4.0&nbsp;million for initiation of a Phase&nbsp;1 clinical trial; $5.0&nbsp;million for the initiation of a Phase&nbsp;2 clinical trial; and $20.0&nbsp;million if GSK chooses to opt-in to the program following the completion of a
proof-of-concept trial. We have no obligation to perform any research or development activities unless mutually agreed upon by the parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AstraZeneca </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2012, we entered
into a collaboration and license agreement with AstraZeneca. Under the terms of the agreement, we have agreed to collaborate with AstraZeneca to identify, research and develop compounds targeting three <I>micro</I>RNA alliance targets primarily in
the fields of cardiovascular diseases, metabolic diseases and oncology. Pursuant to the agreement, we granted AstraZeneca an exclusive, worldwide license to thereafter develop, manufacture and commercialize lead compounds designated by AstraZeneca
in the course of the collaboration activities against the alliance targets for all human therapeutic uses. Under the terms of the agreement we are required to use commercially reasonable efforts to perform all research, development and manufacturing
activities described in the research plan, at our cost, until the acceptance of an IND or the end of the research term, which extends until the fourth anniversary of the date of the agreement, and may be extended only by mutual written agreement of
us and AstraZeneca. Following the earlier to occur of the acceptance of an IND in a major market or the end of the research term, AstraZeneca will assume all costs, responsibilities and obligations for further development, manufacture and
commercialization of alliance product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we received an upfront payment of $3.0 million in October
2012. We determined the elements within the strategic alliance agreement should be treated as a single unit of accounting because the delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue related to
the upfront payment on a straight-line basis over our estimated period of performance, which is four years based on the expected term of the research and development plan. If all three targets are successfully developed and commercialized through
pre-agreed sales targets, we could receive milestone payments up to $498.0&nbsp;million, including preclinical milestones of up to $5.0&nbsp;million upon lead compound identification, up to $123.0 million for clinical milestones, and up to
$370.0&nbsp;million for commercialization milestones. In addition, we are entitled to receive royalties based on a percentage of net sales which will range from the mid-single digits to the low end of 10 to 20%, depending upon the product and the
volume of sales, which royalties may be reduced in certain, limited circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated the contingent event-based payments
under our strategic alliance agreement with AstraZeneca and determined that the preclinical payments meet the definition of substantive milestones. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the
milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of AstraZeneca&#146;s performance will not be accounted for
using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the collaboration and license agreement, we entered into a Common Stock Purchase Agreement (&#147;CSPA&#148;) with
AstraZeneca, pursuant to which we agreed to sell to AstraZeneca an aggregate of $25.0&nbsp;million of our common stock in a private placement concurrently with our initial public offering, at a price per share equal to the initial public offering
price. In October 2012, in accordance with the CSPA, we sold AstraZeneca 6,250,000 shares of our common stock at a price per share of $4.00. Further, the CSPA stipulated that AstraZeneca could not sell, transfer, make any short sale of, or grant any
option for the sale of any common stock for a 365-day period following the effective date of our initial public offering. Accounting guidance for multiple element arrangements contains a presumption that separate contracts negotiated and/or entered
into at or near the same time with the same entity were negotiated as a package and should be evaluated as a single agreement. We valued the discount applied to the shares of common stock due to the one-year restriction. Based upon restricted stock
studies of similar duration and a Black-Scholes valuation to measure the lack of marketability discount, $4.3 million was attributed to the collaboration and license agreement. We continue to recognize the $4.3 million into revenue ratably over the
estimated period of performance of the collaboration. As of December&nbsp;31, 2013, deferred revenue associated with the collaboration and license agreement and CSPA was $2.0 million and $2.9 million, respectively, which we are expecting to
recognize over the remaining contractual term and corresponding estimated period of performance of approximately 2.5 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biogen Idec </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2012, we entered into a collaboration and license agreement with Biogen Idec pursuant to which we and Biogen Idec have agreed to
collaborate on <I>micro</I>RNA biomarkers for multiple sclerosis (&#147;MS&#148;). Under the terms of the agreement, we granted Biogen Idec an exclusive, royalty free, worldwide license to our interest in the collaboration intellectual property for
the purpose of commercializing non-<I>micro</I>RNA products for the treatment, diagnosis and prevention of MS and non-MS diseases and disorders. We also granted Biogen Idec an exclusive, royalty-free, worldwide license, with the right to sublicense,
to our interest in the collaboration intellectual property (and a non-exclusive license to our background intellectual property) for the purpose of commercializing products for the diagnosis of MS. We also granted Biogen Idec a right of first
negotiation on certain commercial transactions relating to <I>micro</I>RNA products which utilize intellectual property developed during the collaboration. Pursuant to the terms of the agreement, in August 2012 we received an upfront payment of $0.8
million. We are also eligible to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive research milestone payments up to an aggregate of $1.3&nbsp;million. We considered the elements within the collaboration and license agreement as a single unit of accounting because the
delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue relating to the upfront payment of $0.8 million on a straight-line basis over our estimated period of performance, which is approximately two
years based on the expected term of the research and development plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2013, we amended the collaboration and license agreement
to provide for revised terms with respect to Phase 1 of the research plan and related milestone payment provisions. The Biogen Idec amendment does not modify the maximum dollar amount we were originally eligible to receive in connection with Phase 1
milestones under the Biogen Idec agreement, or our estimated period of performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated the contingent event-based payments
under our collaboration and license agreement with Biogen Idec and determined that the research payments meet the definition of substantive milestones. Accordingly, revenue for these achievements will be recognized in its entirety in the period when
the milestone is achieved and collectability is reasonably assured. In October 2013 and November 2013, we received research milestone payments totaling $0.3 million. In addition, we can earn the following research milestones: $0.5&nbsp;million for
validation of the <I>micro</I>RNA biomarker in a second independent sample set; and $0.5 million upon the refinement of the <I>micro</I>RNA biomarker signature from a longitudinal study of patient samples on MS therapy. As of December&nbsp;31, 2013,
deferred revenue associated with the collaboration and license agreement was $0.3 million, which we are expecting to recognize over the remaining contractual term and corresponding estimated period of performance of 10 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the collaboration and license agreement, we entered into a note purchase agreement with Biogen Idec, pursuant to which we
issued a convertible promissory note in the principal amount of $5.0 million. The $5.0 million note plus accrued interest converted into 1,256,232 shares of our common stock upon the closing of our initial public offering in October 2012 at a
conversion price of $4.00 per share. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Property and Equipment, net </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our major classes of property and equipment (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization of property and equipment of $1.3 million, $0.9&nbsp;million and $0.8 million
was recorded for the years ended December&nbsp;31, 2013, 2012 and 2011, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Intangible Assets, net </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our major classes of intangible assets (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible asset amortization of $0.1 million, $0.1 million and $0.1 million was recorded for the years ended
December&nbsp;31, 2013, 2012 and 2011, respectively. Amortization of these intangible assets over the next five years is expected to be approximately $0.1 million per year. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Commitments and Contingencies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Lease </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
lease office and laboratory space located at 3545 John Hopkins Court, La Jolla, California (the &#147;Facility&#148;) for our corporate headquarters and research facility under an operating lease agreement (the &#147;Lease&#148;). The Lease
commenced in July 2010 and provided for approximately 22,000 square feet of office and laboratory space, expiring in June 2017. In November 2012, we amended the Lease to expand our laboratory and office space by approximately 7,000 square feet,
including the addition of an approximately 3,000 square foot dedicated research and development laboratory. Lease payments for this additional space began October 2013. We have an option to terminate and cancel the lease in June&nbsp;2015 upon six
months&#146; written notice to our landlord. We also have two options to extend the lease for successive three-year periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with the inception of the Lease, we were provided tenant incentives of $0.1 million which was used to construct a leasehold improvement. In addition, we were provided and fully utilized a tenant improvement allowance of approximately $0.6
million, which was used to fund additional leasehold improvements. In January 2011, the Lease was amended to memorialize the payback of the allowance into our base rent. In conjunction with the amendment of the Lease in November 2012, we were
provided an additional tenant improvement allowance of approximately $0.7 million, which was utilized in 2013 to fund leasehold improvements in the newly occupied space. We are obligated to repay our landlord the tenant improvement allowance, plus
interest at a fixed rate of 8%, on a monthly basis over the remaining term of the Lease. The future minimum payment summary below includes our amended base rents over the remaining period of the lease agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cumulative rent to be paid over the lease term is being amortized on a straight-line basis over the term of the Lease. Rent expense for the
years ended December&nbsp;31, 2013, 2012 and 2011 was approximately $0.7 million, $0.6 million and $0.5 million, respectively. We account for the difference between the minimum lease payments and the straight-line amount as deferred rent. Deferred
rent at December&nbsp;31, 2013 and 2012 was approximately $0.9 million and $0.5 million, respectively. We also pay property taxes, maintenance and insurance, which are expensed as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, future annual minimum lease payments for our operating leases
are as follows (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have license agreements with third parties that require us to make annual license maintenance payments and future payments upon the success
of licensed products that include milestones and/or royalties. Minimum future payments over the next five years are not material. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Convertible Notes Payable </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our strategic alliance with GSK established in April&nbsp;2008, we issued a three-year convertible note in
exchange for $5.0&nbsp;million (&#147;2008 GSK Note&#148;). In February 2010 and in connection with the subsequent expansion of that strategic alliance, we issued a convertible promissory note in exchange for $5.0 million (&#147;2010&nbsp;GSK
Note&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2012 Amendment of the 2008 GSK Note </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2012, we amended and restated the 2008 GSK Note. We accounted for the amended and restated note as a debt modification. The amended and
restated note provided that the principal amount plus interest under the note will, upon completion of our initial public offering in which we receive a minimum level of proceeds from new investors or that results in certain of our current
stockholders together owning less than 50% of our voting securities, automatically convert into shares of our common stock at the initial public offering price. The $5.0 million note plus accrued interest converted into 1,447,037 shares of our
common stock upon the closing of our initial public offering in October 2012 at a conversion price of $4.00 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2012 Amendment of the 2010 GSK
Note </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2012, we amended and restated our 2010 GSK Note. The amended and restated 2010 GSK Note provided for a rollover into a
new promissory note, effective as of the closing date of a qualifying initial public offering (the &#147;Post-IPO GSK Note&#148;). The Post-IPO GSK Note would be equivalent to the aggregate amount of principal and accrued but unpaid interest as of
the initial public offering date. The 2010 GSK Note would then be simultaneously cancelled and obligations thereto would be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2012, in conjunction with our initial public offering, the Post-IPO GSK Note was established in the principal amount of $5.4
million, which was equivalent to the original principal amount of $5.0 million plus accrued but unpaid interest of approximately $0.4 million. The Post-IPO GSK Note has a maturity date of three years from the anniversary date of the agreement, or
October 2015. At GSK&#146;s option, the Post-IPO GSK Note shall be convertible into shares of common stock of Regulus at any time prior to the maturity date with a conversion equal to the quotient of all outstanding principal and interest divided by
the initial public offering price of $4.00 per share. Concurrently with our initial public offering, we accounted cancellation of the 2010 GSK Note as a debt extinguishment and recorded a loss on the extinguishment of debt of $1.7 million and
elected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the fair value option for the Post-IPO GSK Note. As of December&nbsp;31, 2013, the fair value of the Post-IPO GSK Note was $11.3 million, and is classified as &#147;Convertible notes payable, at
fair value&#148; on the balance sheet (see&nbsp;Note 4). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Note payable to Biogen Idec </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2012, we entered into a note purchase agreement with Biogen Idec, pursuant to which we issued Biogen Idec a convertible promissory
note in the principal amount of $5.0 million. The $5.0 million note plus accrued interest converted into 1,256,232 shares of our common stock upon the closing of our initial public offering in October 2012 at a conversion price of $4.00 per share.
</P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Convertible Preferred Stock, Common Stock and Stockholders&#146; Deficit </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reverse stock split </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;7, 2012, our board of directors approved a one-for-two reverse stock split of our common stock. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse split of our common
stock for all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the conversion in the initial public offering in October 2012, our convertible preferred stock was classified as temporary equity on
the accompanying balance sheets instead of in stockholders&#146; equity (deficit) in accordance with authoritative guidance for the classification and measurement of redeemable securities. Upon certain change in control events that were outside of
our control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock could cause its redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2012, all Series A Preferred Stock and Series B Preferred Stock had converted to common stock in conjunction with the
initial public offering. Following our initial public offering, we filed an amended and restated certificate of incorporation to authorize 10,000,000 shares of undesignated preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Public Offerings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2012, we
completed our initial public offering whereby we issued and sold 11,250,000 shares of common stock at a public offering price of $4.00 per share, resulting in net proceeds to the Company of $39.5&nbsp;million. Concurrently with the completion of our
initial public offering, we sold 6,250,000 shares of common stock in a private placement to AstraZeneca at the initial public offering price of $4.00 per share, resulting in net proceeds to the Company of $25.0 million. In addition, $5.0 million of
outstanding principal plus accrued interest of $0.8 million underlying a convertible note that we issued to GSK in April 2008, which was amended and restated in July 2012, together with $5.0&nbsp;million of outstanding principal plus accrued
interest underlying a convertible note that we issued to Biogen Idec in August 2012, was automatically converted upon the closing of our initial public offering into an aggregate of 2,703,269 shares of our common stock. Upon the closing of the
initial public offering, all shares of the Company&#146;s then-outstanding convertible preferred stock automatically converted into an aggregate of 13,699,999 shares of common stock. Underwriters for our initial public offering exercised an
over-allotment option to purchase 1,480,982 additional shares of our common stock at $4.00 per share, resulting in net proceeds of $5.5 million. Inclusive of the initial public offering, underwriters&#146; exercise of their over-allotment option and
concurrent private placement, we raised a total of $70.0 million in net proceeds after deducting underwriter discounts, commissions and other offering expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July&nbsp;2013, we completed a public offering whereby we sold 5,175,000 shares of common stock at $9.50&nbsp;per share and received net
proceeds of $45.8 million, after deducting underwriting discounts, commissions and other offering expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, there were 41,787,326 shares of common stock outstanding. Each share of common stock is entitled to one vote. The
holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by our Board of Directors. Following our initial public offering, we filed an amended and restated certificate of incorporation
to authorize 200,000,000 shares of common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Reserved for Future Issuance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following shares of common stock are reserved for future issuance at December&nbsp;31, 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,598,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options available for future grant</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible note payable (Post-IPO GSK Note)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,411,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common shares reserved for future issuance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,180,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combined total number of shares reserved for issuance under the 2012 Plan is 710,534 shares as of
December&nbsp;31, 2013. The following table summarizes our stock option activity under the 2012 Plan for the year ended December&nbsp;31, 2013 (in thousands, except per share and contractual term data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>remaining<BR>contractual<BR>term<BR>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>intrinsic<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canceled/forfeited/expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested or expected to vest at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value per share of employee stock options granted during the years ended
December&nbsp;31, 2013, 2012 and 2011 was $4.14, $2.97 and $1.14, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total intrinsic value of stock options exercised was
$5.7 million, $0.8 million and $0.2 million during the years ended December&nbsp;31, 2013, 2012 and 2011, respectively. Cash received from the exercise of stock options was approximately $0.6 million, $0.1 million and $0.1 million for the years
ended December&nbsp;31, 2013, 2012 and 2011, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used to estimate the fair value of stock options using the Black-Scholes
option pricing model were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;2013&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;2012&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;2011&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee Stock Options:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk-free interest rate</I>&#151;The risk-free interest rate assumption is based on observed interest rates appropriate for
the expected term of the stock option grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected dividend yield</I>&#151;The expected dividend yield assumption is based on the fact that we
have never paid cash dividends and have no present intention to pay cash dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected volatility</I>&#151;The expected volatility assumption is
based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected term</I>&#151;The expected term represents the period of time that options are expected to be outstanding. Because we do not have historic
exercise behavior, we determine the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forfeitures</I>&#151;We reduce stock-based compensation expense for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if
necessary, in subsequent periods if actual forfeitures differ from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation is reflected in the
statement of operations and comprehensive loss as follows (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total compensation cost related to non-vested awards not yet recognized was $7.8 million as of
December&nbsp;31, 2013. The weighted-average period over which this expense is expected to be recognized is approximately 2.3 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Stock
Purchase Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2012, we adopted the 2012 Employee Stock Purchase Plan (&#147;2012 Purchase Plan&#148;), which enables
participants to contribute up to 15% of such participant&#146;s eligible compensation during a defined rolling six-month periods to purchase our common stock. The purchase price of common stock under the 2012 Purchase Plan will be the lesser of:
(i)&nbsp;85% of the fair market value of our common stock at the inception of the enrollment period or (ii)&nbsp;85% of the fair market value of our common stock at the applicable purchase date. We issued 48,035 shares of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock under the 2012 Purchase Plan for the year ended December&nbsp;31, 2013. As of December&nbsp;31, 2013 460,283 shares of our common stock were reserved for future issuance and have
been authorized for purchase under the 2012 Purchase Plan. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Defined Contribution Plan </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2009, we established an employee 401(k) salary deferral plan (&#147;401(k) Plan&#148;) covering all eligible employees.
Active employees who are at least 18 years old and are not otherwise disqualified under the terms of the 401(k) Plan are eligible to participate. Employees may contribute up to 50% of their compensation per year (subject to a maximum limit
prescribed by federal tax law). Under the 401(k) Plan, we may elect to match a discretionary percentage of employee contributions. We have elected to match 25% of employees&#146; contributions up to 6% of the employees&#146; eligible salary. We made
$0.1 million, $0.1 million and $0.1 million in matching contributions for the years ended December&nbsp;31, 2013, 2012 and 2011, respectively. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income Taxes </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the components of our income tax (benefit) expense (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a reconciliation of the expected statutory federal income tax provision to our actual income
tax provision (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected income tax benefit at federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,923</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(432</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior year true-up</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the significant components of our deferred tax assets and
liabilities (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryovers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development and other tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles and property and equipment basis difference</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all periods presented, we have determined that it is more likely than not that our deferred tax asset will
not be realized. Accordingly, we have recorded a valuation allowance to fully offset the net deferred tax asset of $28.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of December&nbsp;31, 2013, we had federal and California tax net operating loss carryforwards of $44.2&nbsp;million and $52.6 million, respectively, which begin to expire in 2030 and 2031. At December&nbsp;31, 2013, approximately $1.6 million of the
net operating loss carryforwards relate to stock option exercises, which will result in an increase to additional paid-in capital and a decrease in income taxes payable at the time when the tax loss carryforwards are utilized. As of
December&nbsp;31, 2013, we also had federal and California research and development tax credit carryforwards of $3.6&nbsp;million and $2.8&nbsp;million, respectively. The federal research and development tax credit carryforwards will begin to expire
in 2029. The California research and development tax credit carryforwards are available indefinitely. As of December 31, 2013, we also had $0.2 million of Federal Alternative Minimum Tax Credit carryforwards that are available indefinitely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The future utilization of our research and development credit carryforwards and net operating loss carryforwards to offset future taxable
income may be subject to an annual limitation as a result of ownership changes that may have occurred previously or may occur in the future. The Tax Reform Act of 1986 (the Act) limits a company&#146;s ability to utilize certain tax credit
carryforwards and net operating loss carryforwards in the event of a cumulative change in ownerships in excess of 50% as defined in the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the changes in the amount of our unrecognized tax benefits (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance of unrecognized tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) for prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Included in the balance of unrecognized tax benefits at December&nbsp;31, 2013, is $1.1
million that, if recognized, would not impact our income tax benefit or effective tax rate as long as our deferred tax asset remains subject to a full valuation allowance. We do not expect any significant increases or decreases to our unrecognized
tax benefits within the next 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to taxation in the United States and California. We are subject to income tax
examination by tax authorities in those jurisdictions for 2009 and forward. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is our practice to recognize interest and/or penalties
related to income tax matters in income tax expense. For the years ended December&nbsp;31, 2013, 2012 and 2011, we have not recognized any interest or penalties related to income taxes. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Related-Party Transactions </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into several agreements with related parties in the ordinary course of business to license intellectual
property and to procure administrative and research and development support services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2013, we entered into an amendment to the
Amended and Restated License and Collaboration Agreement with Isis and Alnylam dated January&nbsp;1, 2009, as amended in June 2010 and October 2011 (as&nbsp;amended, the &#147;Amendment&#148;). Under the terms of the Amendment, the parties agreed to
our use of certain Alnylam-controlled intellectual property concerning the use and manufacture of GalNAc conjugates (&#147;GalNAc&nbsp;Process Technology&#148;) on a non-exclusive basis. We will generally not be permitted to sublicense or otherwise
transfer the GalNAc Process Technology and other Alnylam licensed intellectual property rights relating to GalNAc conjugate technology without the prior written consent of Alnylam, subject to certain limited exceptions for sublicenses to third party
collaboration partners. There were no financial terms related to this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the amounts included in
our operating expenses as a result of costs incurred from services provided under the Services Agreement (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services performed or out-of-pocket expenses paid to Alnylam</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Selected Quarterly Financial Data (Unaudited) </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management,
necessary for a fair statement of the results of the interim periods. Summarized quarterly data for 2013 and 2012 are as follows (in thousands, except per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the quarters ending</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2013:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net loss per share<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2012:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Applicable accounting guidance provides that a contract (such as the 2010 GSK Note) that is reported as an asset or liability for accounting purposes may require an adjustment to the numerator of the diluted earnings
per share calculation for any changes in income or loss that would result if the contract had been reported as an equity instrument during the period. For these periods, adjustments were made to the numerator of the diluted earnings per share
calculation to adjust net loss to remove the gain from the change in value of the convertible note payable. Adjustments to the denominator were made to add the number of shares to be issued upon conversion of the convertible note payable.
</TD></TR></TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Subsequent Events </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2014, we and Sanofi entered into a second amended and restated collaboration and license agreement to extend our
strategic alliance. Under the terms of our extended alliance, Sanofi will have opt-in rights to our miR-21 pre-clinical fibrosis program targeting miR-21 for the treatment of Alport Syndrome, our preclinical program targeting miR-21 for oncology
indications, and our preclinical programs targeting <FONT STYLE="white-space:nowrap">miR-221/222</FONT> for oncology indications, each of which is to be led by us. If Sanofi chooses to exercise its option on any of these programs, Sanofi will
reimburse us for a significant portion of our preclinical and clinical development costs and will also pay us an option exercise fee for any such program, provided that $1.25 million of the $2.5 million upfront option fee paid to us by Sanofi in
connection with the June 2013 option agreement will be creditable against such option exercise fee. In addition, we will be eligible to receive clinical and regulatory milestone payments under these programs and potentially commercial milestone
payments. We also continue to be eligible to receive royalties on <I>micro</I>RNA therapeutic products commercialized by Sanofi and will have the right to co-promote these products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our entry into the second amended and restated collaboration and license agreement with Sanofi, we sold and issued
1,303,780 shares of our common stock to Aventis, an entity affiliated with Sanofi, in a private placement at a price per share of $7.67 for an aggregate purchase price of $10.0 million. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_12"></A>Changes in and Disagreements With Accountants on Accounting and Financial Disclosure </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_13"></A>Controls and Procedures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic
and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms, and that such information is accumulated and communicated to our management, including
our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and
procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its
judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no
assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may
deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, we carried out an evaluation, under the supervision and with the participation of our management, including our
chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our
chief executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&nbsp;31, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Report on Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in
Exchange Act Rule&nbsp;13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive and financial officer, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013, our management assessed the effectiveness of our internal control over financial reporting using the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (1992 Framework). Based on this assessment, our management concluded that, as of December&nbsp;31, 2013, our internal control
over financial reporting was effective based on those criteria. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no changes in our internal control over financial reporting identified in management&#146;s evaluation pursuant to Rules 13a-15(d)
or 15d-15(d) of the Exchange Act during the quarter ended December&nbsp;31, 2013 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_14"></A>Other Information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART III </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_15"></A>Directors, Executive Officers and Corporate Governance </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
information required by this item and not set forth below will be set forth in the section headed &#147;Election of Directors&#148; and &#147;Executive Officers&#148; in our Proxy Statement for our 2014 Annual Meeting of Stockholders, or Proxy
Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended December&nbsp;31, 2013, and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a code of ethics for directors, officers (including our principal executive officer, principal financial officer and principal
accounting officer) and employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at <I>http://www.regulusrx.com</I> under the Corporate Governance section of our Investor
Relations page. We will promptly disclose on our website (i)&nbsp;the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons
performing similar functions and (ii)&nbsp;the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals that is required to be disclosed pursuant to SEC rules and
regulations, the name of such person who is granted the waiver and the date of the waiver. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_16"></A>Executive Compensation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item
will be set forth in the section headed &#147;Executed Compensation&#148; in our Proxy Statement and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_17"></A>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item will be set forth in the section headed &#147;Security Ownership of Certain Beneficial Owners and
Management&#148; in our Proxy Statement and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by Item&nbsp;201(d) of
Regulation S-K will be set forth in the section headed &#147;Executive Compensation&#148; in our Proxy Statement and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_18"></A>Certain Relationships and Related Transactions, and Director Independence </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item will be set forth in the section headed &#147;Transactions With Related Persons&#148; in our Proxy
Statement and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_19"></A>Principal Accounting Fees and Services </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information
required by this item will be set forth in the section headed &#147;Ratification of Selection of Independent Registered Public Accounting Firm&#148; in our Proxy Statement and is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART IV </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="toc652681_20"></A>Exhibits, Financial Statement Schedules </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Financial
Statements.</I> We have filed the following documents as part of this Annual Report: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><A NAME="index"></A>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx652681_100">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx652681_101">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx652681_102">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx652681_103">Statements of Convertible Preferred Stock and Stockholders&#146; Equity (Deficit)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx652681_104">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx652681_105">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Financial Statement Schedules.</I> None. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Exhibits.</I> For a list of exhibits filed with this Annual Report on Form 10-K, refer to the exhibit index. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc652681_21"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual
Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Regulus Therapeutics Inc.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;27, 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/&nbsp;&nbsp;&nbsp;&nbsp;Kleanthis G. Xanthopoulos&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kleanthis G. Xanthopoulos, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President &amp; Chief Executive Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kleanthis G. Xanthopoulos, Ph.D.
his or her true and lawful attorney-in-fact, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his substitute or substitutes may do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following
persons on behalf of the registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Kleanthis G.
Xanthopoulos&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kleanthis G. Xanthopoulos, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, President &amp; Chief&nbsp;Executive&nbsp;Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer, Principal</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial Officer and
Principal Accounting</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;27, 2014</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Stelios
Papadopoulos&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Stelios Papadopoulos, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">February&nbsp;27, 2014</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;David
Baltimore&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">David Baltimore, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;27, 2014</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Bruce L.A.
Carter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Bruce L.A. Carter, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;27, 2014</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Mark G.
Foletta&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Mark G. Foletta</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;27, 2014</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;John M.
Maraganore&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">John M. Maraganore, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;27, 2014</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;B. Lynne
Parshall&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">B. Lynne Parshall</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;27, 2014</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;William H.
Rastetter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">William H. Rastetter, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;27, 2014</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Douglas E.
Williams&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Douglas E. Williams, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">February&nbsp;27, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form 8-K, filed with the SEC on October 11, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#146;s Current Report on Form 8-K, filed with the SEC on October 11, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits 3.1 and 3.2.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17,
2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement between the Registrant and its directors and officers (incorporated by reference to Exhibit 10.1 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File&nbsp;No. 333-183384),
originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Regulus Therapeutics Inc. 2009 Equity Incentive Plan, as amended, and Form of Stock Option Grant Notice, Option Agreement and Form of Notice of Exercise (incorporated by reference to Exhibit 10.2 to the Registrant&#146;s
Registration Statement on Form S-1, as amended <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-183384),</FONT> originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2012 Equity Incentive Plan and Form of Stock Option Agreement and Form of Stock Option Grant Notice thereunder (incorporated by reference to Exhibit 10.3 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File
No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Non-Employee Director Compensation Policy, as amended.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2012 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>

<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement between the Registrant and Kleanthis G. Xanthopoulos, Ph.D., dated June 15, 2012 (incorporated by reference to Exhibit 10.6 to the Registrant&#146;s Registration Statement on Form S-1, as
amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement between the Registrant and Garry&nbsp;E.&nbsp;Menzel, Ph.D., dated June 15, 2012 (incorporated by reference to Exhibit 10.7 to the Registrant&#146;s Registration Statement on Form S-1, as
amended (File No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement between the Registrant and Neil W. Gibson, Ph.D., dated June&nbsp;15, 2012 (incorporated by reference to Exhibit 10.8 to the Registrant&#146;s Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> as amended (File No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Neil W. Gibson, Ph.D. Yearly Discretionary Merit Bonus Percentage Increase, effective January&nbsp;1, 2014.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lease between the Registrant and BMR-John Hopkins Court LLC, a Delaware limited liability company, dated March 19, 2010 (incorporated by reference to Exhibit 10.9 to the Registrant&#146;s Registration Statement on Form S-1, as
amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">First Amendment to Lease between the Registrant and BMR-John Hopkins Court LLC, a Delaware limited liability company, dated April 26, 2010 (incorporated by reference to Exhibit&nbsp;10.10 to the Registrant&#146;s Registration
Statement on Form S-1, as amended <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-183384),</FONT> originally filed with the SEC on August 17, 2012).</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Lease between the Registrant and BMR-John Hopkins Court LLC, a Delaware limited liability company, dated January 26, 2011 (incorporated by reference to Exhibit&nbsp;10.11 to the Registrant&#146;s Registration
Statement on Form S-1, as amended <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-183384),</FONT> originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Third Amendment to Lease between the Registrant and BMR-3545-3575 John Hopkins LP, a Delaware limited partnership (formerly known as BMR-John Hopkins Court LLC), dated February&nbsp;27, 2012 (incorporated by reference to Exhibit
10.12 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fourth Amendment to Lease between the Registrant and BMR-3545-3575 John Hopkins LP, a Delaware limited partnership (formerly known as BMR-John Hopkins Court LLC), dated November&nbsp;19, 2012 (incorporated by reference to
Exhibit&nbsp;10.13 to the Registrant&#146;s Annual Report on Form&nbsp;10-K, filed with the SEC on February&nbsp;19, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Founding Investor Rights Agreement among the Registrant, Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., dated January&nbsp;1, 2009 (incorporated by reference to Exhibit 10.13 to the Registrant&#146;s Registration
Statement on Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment Number One to the Founding Investor Rights Agreement among the Registrant, Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., dated June&nbsp;7, 2010 (incorporated by reference to Exhibit 10.14 to the
Registrant&#146;s Registration Statement on Form S-1, as amended (File&nbsp;No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment Number Two to the Founding Investor Rights Agreement among the Registrant, Alnylam Pharmaceuticals,&nbsp;Inc. and Isis Pharmaceuticals, Inc., dated October&nbsp;27, 2010 (incorporated by reference to Exhibit 10.15 to the
Registrant&#146;s Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated License and Collaboration Agreement among the Registrant, Alnylam Pharmaceuticals,&nbsp;Inc. and Isis Pharmaceuticals, Inc., dated January&nbsp;1, 2009 (incorporated by reference to Exhibit 10.17 to the
Registrant&#146;s Registration Statement on Form S-1, as amended (File&nbsp;No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment Number One to the Amended and Restated License and Collaboration Agreement among the Registrant, Alnylam Pharmaceuticals,&nbsp;Inc. and Isis Pharmaceuticals, Inc., dated June&nbsp;10, 2010 (incorporated by reference to
Exhibit 10.18 to the Registrant&#146;s Registration Statement on Form&nbsp;S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment Number Two to the Amended and Restated License and Collaboration Agreement among the Registrant, Alnylam Pharmaceuticals,&nbsp;Inc. and Isis Pharmaceuticals, Inc., dated October&nbsp;25, 2011 (incorporated by reference to
Exhibit 10.19 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Product Development and Commercialization Agreement between the Registrant and Glaxo Group Limited, dated April&nbsp;17, 2008 (incorporated by reference to Exhibit 10.20 to the Registrant&#146;s Registration Statement on Form S-1,
as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment #1 to the Product Development and Commercialization Agreement between the Registrant and Glaxo Group Limited, dated February&nbsp;24, 2010 (incorporated by reference to Exhibit&nbsp;10.21 to the Registrant&#146;s
Registration Statement on Form S-1, as amended <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-183384),</FONT> originally filed with the SEC on August&nbsp;17, 2012).</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment #2 to the Product Development and Commercialization Agreement between the Registrant and Glaxo Group Limited, dated June 16, 2010 (incorporated by reference to Exhibit&nbsp;10.22 to the Registrant&#146;s Registration
Statement on Form S-1, as amended <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-183384),</FONT> originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment #3 to the Product Development and Commercialization Agreement between the Registrant and Glaxo Group Limited, dated June 30, 2011 (incorporated by reference to Exhibit&nbsp;10.23 to the Registrant&#146;s Registration
Statement on Form S-1, as amended <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-183384),</FONT> originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exclusive License and Nonexclusive Option Agreement between the Registrant and Glaxo Group Limited, dated February&nbsp;24, 2010 (incorporated by reference to Exhibit 10.24 to the Registrant&#146;s Registration Statement on Form
S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Co-Exclusive License Agreement among the Board of Trustees of the Leland Stanford Junior University, Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., dated August 31, 2005 (incorporated by reference to Exhibit 10.25 to
the Registrant&#146;s Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Assignment Agreement between the Registrant and Isis Pharmaceuticals, Inc., dated July 13, 2009 (incorporated by reference to Exhibit 10.26 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File No.
333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License Agreement between the Registrant and Max-Planck-Innovation GmbH, dated June 5, 2009 (incorporated by reference to Exhibit 10.27 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File No. 333-183384),
originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated License Agreement among Max-Planck-Innovation GmbH, the Registrant, Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals,&nbsp;Inc., dated April 18, 2011 (incorporated by reference to Exhibit 10.28 to the
Registrant&#146;s Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> as amended (File&nbsp;No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NYU-Regulus License Agreement by and between the Registrant and New York University, dated March 28, 2011 (incorporated by reference to Exhibit 10.29 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File No.
333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exclusive Patent License Agreement between the Registrant and Bayerische Patent Allianz GmbH, dated May 18, 2010 (incorporated by reference to Exhibit 10.30 to the Registrant&#146;s Registration Statement on Form S-1, as amended
(File No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Collaboration and License Agreement between the Registrant and Sanofi, dated July 16, 2012 (incorporated by reference to Exhibit 10.31 to the Registrant&#146;s Registration Statement on Form S-1, as amended
(File No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.33&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Non-Exclusive Technology Alliance and Option Agreement between the Registrant and Sanofi, dated June&nbsp;21, 2010 (incorporated by reference to Exhibit 10.32 to the Registrant&#146;s Registration Statement on Form S-1, as amended
(File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.34</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Convertible Promissory Note No. 1 made by the Registrant in favor of Glaxo Group Limited, dated July&nbsp;27, 2012 (incorporated by reference to Exhibit 10.33 to the Registrant&#146;s Registration Statement on
Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.35</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Convertible Promissory Note No. 2 made by the Registrant in favor of Glaxo Group Limited, dated July&nbsp;27, 2012 (incorporated by reference to Exhibit 10.34 to the Registrant&#146;s Registration Statement on
Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.36&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment #4 to the Product Development and Commercialization Agreement between the Registrant and Glaxo Group Limited, dated June&nbsp;29, 2012 (incorporated by reference to Exhibit&nbsp;10.35 to the Registrant&#146;s Registration
Statement on Form S-1, as amended <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-183384),</FONT> originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.37</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment Number Three to the Founding Investor Rights Agreement among the Registrant, Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., dated July&nbsp;24, 2012 (incorporated by reference to Exhibit 10.36 to the
Registrant&#146;s Registration Statement on Form S-1, as amended (File&nbsp;No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.38&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Collaboration and License Agreement between the Registrant and AstraZeneca AB, dated August 14, 2012 (incorporated by reference to Exhibit 10.37 to the Registrant&#146;s Registration Statement on Form&nbsp;S-1, as amended (File No.
333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.39</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Common Stock Purchase Agreement between the Registrant and AstraZeneca AB, dated August 14, 2012 (incorporated by reference to Exhibit 10.38 to the Registrant&#146;s Registration Statement on Form&nbsp;S-1, as amended (File No.
333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.40&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Collaboration and License Agreement between the Registrant and Biogen Idec MA Inc., dated August&nbsp;15, 2012 (incorporated by reference to Exhibit 10.39 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File
No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.41</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Note Purchase Agreement between the Registrant and Biogen Idec MA Inc., dated August&nbsp;15, 2012 (incorporated by reference to Exhibit 10.40 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File No.
333-183384), originally filed with the SEC on August 17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.42</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Convertible Promissory Note made by the Registrant in favor of Biogen Idec MA Inc., dated August&nbsp;15, 2012 (incorporated by reference to Exhibit 10.41 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File
No. 333-183384), originally filed with the SEC on August&nbsp;17, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.43</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Investor Rights Agreement, dated October&nbsp;10, 2012, between AstraZeneca AB and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#146;s Current Report on Form 8-K, filed with the SEC on October 11,
2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.44</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Convertible Promissory Note, dated October 10, 2012, made by the Registrant in favor of Glaxo Group Limited (incorporated by reference to Exhibit 10.2 to the Registrant&#146;s Current Report on Form&nbsp;8-K, filed with the SEC on
October&nbsp;11, 2012).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.45&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment #5 to the Product Development and Commercialization Agreement between the Registrant and Glaxo Group Limited, dated June&nbsp;6, 2013 (incorporated by reference to Exhibit&nbsp;10.46 to the Registrant&#146;s Registration
Statement on Form S-1, as amended <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-189607),</FONT> originally filed with the SEC on June 26, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.46</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter Agreement dated April 26, 2013 between the Registrant and Sanofi (incorporated by reference to Exhibit 10.47 to the Registrant&#146;s Registration Statement on Form S-1, as amended
<FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-189607),</FONT> originally filed with the SEC on June 26, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.47&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Option Letter Agreement dated June 21, 2013 between the Registrant and Sanofi (incorporated by reference to Exhibit 10.48 to the Registrant&#146;s Registration Statement on Form S-1, as amended (File&nbsp;No. 333-189607), originally
filed with the SEC on June 26, 2013).</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.48</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment to Option Letter Agreement dated January 30, 2014 between the Registrant and Sanofi (incorporated by reference to Exhibit 99.1 to the Registrant&#146;s Current Report on Form 8-K, filed with the SEC on February 5,
2014).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.49&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 (to Collaboration and License Agreement) between the Registrant and AstraZeneca AB, dated April 30, 2013 (incorporated by reference to Exhibit 10.49 to the Registrant&#146;s Registration Statement on Form S-1, as
amended (File No. 333-189607), originally filed with the SEC on June 26, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.50&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. 1 to Collaboration and License Agreement between the Registrant and Biogen Idec MA Inc., dated June 24, 2013 (incorporated by reference to Exhibit 10.50 to the Registrant&#146;s Registration Statement on Form S-1, as
amended (File No. 333-189607), originally filed with the SEC on June 26, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.51&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment Number Three to the Amended and Restated License and Collaboration Agreement among the Company, Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., dated August&nbsp;2, 2013 (incorporated by reference to Exhibit
99.1 to the Registrant&#146;s Current Report on Form&nbsp;8-K, filed with the SEC on August 7, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.52&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Second Amended and Restated Collaboration and License Agreement dated February 4, 2014 between the Registrant and Sanofi.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.53</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Common Stock Purchase Agreement dated February 4, 2014 between the Registrant and Aventis Holdings Inc. (incorporated by reference to Exhibit 99.2 to the Registrant&#146;s Current Report on Form 8-K, filed with the SEC on February
5, 2014).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.54</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Registration Rights Agreement dated February 4, 2014 between the Registrant and Aventis Holdings Inc. (incorporated by reference to Exhibit 99.3 to the Registrant&#146;s Current Report on Form 8-K, filed with the SEC on February 5,
2014).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Independent Registered Public Accounting Firm.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Power of Attorney. Reference is made to the signature page hereto.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to Rule&nbsp;13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document.</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">We have requested or received confidential treatment for certain portions of this agreement, which have been omitted and filed separately with the SEC pursuant to Rule 406 under the Securities Act of 1933, as amended,
or Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">This certification is being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section&nbsp;1350, and is not being filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 and is
not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of
interactive data files in such exhibits and are not subject to liability under </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files
after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 460T, these interactive data files are deemed not filed and otherwise are not subject to
liability. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>d652681dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>ON</SMALL>-E<SMALL>MPLOYEE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>OLICY</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) who is not also serving as an employee of Regulus Therapeutics Inc.
(&#147;<B><I>Regulus</I></B>&#148;) or any of its subsidiaries and who is designated by the Compensation Committee of the Board as eligible to receive compensation for his or her services as a member of the Board (each such member, an
&#147;<B><I>Eligible Director</I></B>&#148;) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service following the closing of the initial public offering of Regulus&#146; common stock
(the &#147;<B><I>IPO</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This policy will be effective upon the date of the underwriting agreement between the Regulus and the underwriters
managing the initial public offering of the common stock of Regulus (the &#147;<B><I>Common Stock</I></B>&#148;), pursuant to which the Common Stock is priced in the IPO. This policy may be amended at any time in the sole discretion of the
Compensation Committee of the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Cash Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in
which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer and fee set forth below will be pro-rated based on days
served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><U>Annual Board Service Retainer</U>: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">All Eligible Directors: $32,000 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Chairman of the Board $60,000 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><U>Annual Committee Chair Service Fee</U>: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Chairman of the Audit Committee: $20,000 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Chairman of the Compensation Committee: $10,000 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Chairman of the Nominating&nbsp;&amp; Corporate Governance Committee: $7,500 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><U>Annual Committee Member (non-Chair) Service Fee</U>: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Audit Committee: $5,000 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Compensation Committee: $5,000 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Nominating&nbsp;&amp; Corporate Governance Committee: $2,500 </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The equity compensation set forth below will be granted under the Regulus 2012 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;), subject to the
Regulus stockholders&#146; approval of the Plan. All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying
Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Initial Grant</U>: On the date of the Eligible Director&#146;s initial election to the Board (or, if such date is not a market trading day, the first
market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 30,000 shares of Common Stock. One-third of the shares will vest
on the one year anniversary of the date of grant and the balance of the shares will vest in a series of 24 equal monthly installments therafter, such that the option is fully vested on the third anniversary of the date of grant, subject to the
Eligible Director&#146;s Continuous Service (as defined in the Plan) through each such vesting date. An Eligible Director who, in the one year prior to his or her initial election to serve on the Board as a non-employee director, served as an
employee of Regulus or one of its subsidiaries will not be eligible for an initial grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Annual Grant</U>: On the date of each Regulus annual
stockholder meeting held after the effective date of the IPO, each Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 17,500 shares of Common Stock.
One-third of the shares will vest on the one year anniversary of the date of grant and the balance of the shares will vest in a series of 24 equal monthly installments therafter, such that the option is fully vested on the third anniversary of the
date of grant, subject to the Eligible Director&#146;s Continuous Service (as defined in the Plan) through each such vesting date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>d652681dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Therapeutics Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Yearly Discretionary Merit Bonus Percentage of Neil W. Gibson, Ph.D. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors (the &#147;Board&#148;) of Regulus Therapeutics Inc., upon the recommendation of the Compensation Committee of the Board, approved an
increase in the yearly discretionary merit bonus percentage for Neil&nbsp;W.&nbsp;Gibson, Ph.D. from 25% to 35% of Dr.&nbsp;Gibson&#146;s base salary, effective January&nbsp;1, 2014. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.52
<SEQUENCE>4
<FILENAME>d652681dex1052.htm
<DESCRIPTION>EX-10.52
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.52</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.52 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>**Text Omitted and Filed Separately </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>with the Securities and Exchange Commission </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Confidential Treatment Requested </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Under 17 C.F.R. Sections 200.80(b)(4) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>and 240.24b-2 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION COPY
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULUS
THERAPEUTICS INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>And </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS</B> <B>SECOND AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT</B> (the <B><I>&#147;Agreement&#148;</I></B>) is made and
entered into this February&nbsp;4, 2014 (the <B><I>&#147;Second Restatement Date&#148;</I></B>), by and between <B>S<SMALL>ANOFI</SMALL></B><SMALL></SMALL> (formerly, <B>S<SMALL>ANOFI</SMALL>-A<SMALL>VENTIS</SMALL></B><SMALL></SMALL>), a French
Corporation (<B><I>&#147;Sanofi&#148;</I></B>) having a place of business at 54, rue la Bo&eacute;tie, 75008, Paris, France, registered in the Paris Trade and Company Register under no.&nbsp;395&nbsp;030&nbsp;844, and <B>R<SMALL>EGULUS</SMALL>
T<SMALL>HERAPEUTICS</SMALL> I<SMALL>NC</SMALL>.</B>, a Delaware Corporation (<B><I>&#147;Regulus&#148;</I></B>) having a place of business at 3545&nbsp;John Hopkins Court, Suite&nbsp;210, San Diego, California 92121-1121. Sanofi and Regulus each may
be referred to herein individually as a <B><I>&#147;Party,&#148;</I></B> or collectively as the <B><I>&#147;Parties.&#148;</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Regulus possesses certain patent rights, know-how and technology with respect to therapeutic microRNA Compounds; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Regulus and Sanofi entered into a Collaboration and License Agreement (the <B><I>&#147;Original Agreement&#148;</I></B>) dated
June&nbsp;21, 2010 (the <B><I>&#147;Effective Date&#148;</I></B>), under which the Parties agreed to conduct a Research Program to identify one or more Licensed Compounds for a limited number of Collaboration Targets and Regulus granted Sanofi
exclusive rights to Licensed Compounds and Products arising from the Research Program; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Regulus and Sanofi amended and
restated the Original Agreement pursuant to an Amended and Restated Collaboration and License Agreement (the <B><I>&#147;First Restated Agreement&#148;</I></B>) dated July&nbsp;16, 2012 (the <B><I>&#147;First Restatement Date&#148;</I></B>), under
which the Parties agreed to expand the scope of the Research Program; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Sanofi and Regulus now desire to amend and restate
the Restated Agreement with this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with the execution of this Agreement, the Parties are
entering into a Stock Purchase Agreement dated as of the Second Restatement Date, pursuant to which Sanofi is purchasing $10&nbsp;million of shares of Regulus&#146; common stock (the <B><I>&#147;Stock Purchase Agreement&#148;</I></B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B><B>,</B> in consideration of the foregoing and the mutual covenants herein contained, the Parties do hereby agree as
follows. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms
used in this Agreement with initial letters capitalized, whether used in the singular or the plural, will have the meaning set forth in <B>A<SMALL>PPENDIX</SMALL>&nbsp;1,</B> or if not listed in <B>A<SMALL>PPENDIX</SMALL> 1,</B> the meaning
designated in places throughout the Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRANT OF RIGHTS; EXCLUSIVITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.1 Mir-21 Licenses and Options.</B> <B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.1.1 License to Mir-21 Compounds and Products.</B> Subject to the terms and conditions of this Agreement (including, without limitation,
Section&nbsp;2.1.3, Section&nbsp;2.1.4, Section&nbsp;2.3, Section&nbsp;3.4.3(a) and Section&nbsp;9.4.1), Regulus hereby grants to Sanofi a worldwide, royalty-bearing, exclusive license, with the right to grant sublicenses as set forth in
Section&nbsp;2.4 below, under the Regulus Know-How and Regulus Patents to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import <FONT STYLE="white-space:nowrap">Mir-21</FONT>
Compounds, <FONT STYLE="white-space:nowrap">Mir-21</FONT> Products, and Companion Diagnostics for use with <FONT STYLE="white-space:nowrap">Mir-21</FONT> Products; in each case, in the Product Field (the <B><I>&#147;Mir-21 License&#148;</I></B>).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.1.2 Mir-21 POC Program Research License.</B> Subject to the terms and conditions of this Agreement, Sanofi hereby grants to Regulus,
(i)&nbsp;a worldwide, royalty-free, <FONT STYLE="white-space:nowrap">co-exclusive</FONT> (with Sanofi) sublicense, without the right to grant further sublicenses (other than in connection with the use of subcontractors or consultants in accordance
with Section&nbsp;3.9.4), under the Regulus Know-How and Regulus Patents licensed to Sanofi under Section&nbsp;2.1.1, and (ii)&nbsp;a worldwide, royalty-free, <FONT STYLE="white-space:nowrap">co-exclusive</FONT> (with Sanofi) license, without the
right to grant further sublicenses (other than in connection with the use of subcontractors or consultants in accordance with Section&nbsp;3.9.4), under Sanofi Inventions and Sanofi Program Patents; in each case, solely to perform the Mir-21 POC
Program activities for which Regulus is responsible as specified in the applicable Mir-21 POC Program Plan during the applicable Mir-21 POC Program Term. For clarity, upon termination of a Mir-21 POC Program pursuant to Section&nbsp;3.4, the license
granted by Sanofi to Regulus under this Section&nbsp;2.1.2 shall terminate and be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.1.3 Mir-21 POC
Program Options.</B> On a Mir-21 POC Program-by Mir-21 POC Program basis, upon expiration of the POC Program Term for a particular Mir-21 POC Program, Regulus shall deliver to Sanofi the POC Study Report for such Mir-21 POC Program, and an invoice
for both the Option Exercise Fee and POC Program Reimbursement Amount for such POC Program (which invoices shall be payable in accordance with Section&nbsp;6.5 and Section&nbsp;6.7, respectively, only in the event Sanofi exercises the Mir-21 Option
in accordance with this Section&nbsp;2.1.3), and Sanofi may elect to continue the Development of any Mir-21 POC Program Product that is the subject of such Mir-21 POC Program, the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound(s) contained
in any such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product, and Companion Diagnostics for use with any such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product after expiration of the applicable POC Program Term,
in accordance with the terms and conditions of this Agreement (each, a <B><I>&#147;Mir-21 Option&#148;</I></B>), by: (a)&nbsp;delivering written notice of such election to Regulus prior to expiration of the Option Period for such POC Program; and
(b)&nbsp;paying to Regulus the applicable Option Exercise Fee and POC Program Reimbursement Amount for such POC Program in accordance with Section&nbsp;6.5 and Section&nbsp;6.7, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.1.4 Consequences of Failure to Exercise <FONT STYLE="white-space:nowrap">Mir-21</FONT> Option.</B> On a
<FONT STYLE="white-space:nowrap">Mir-21</FONT> POC <FONT STYLE="white-space:nowrap">Program-by-Mir-21</FONT> POC Program basis, in the event that Sanofi fails to exercise its <FONT STYLE="white-space:nowrap">Mir-21</FONT> Option with respect to a
particular <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program in accordance with Section&nbsp;2.1.3 prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to expiration of the applicable Option Period, then, effective as of expiration of such Option Period: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the Mir-21 Option with respect to such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program shall terminate and be of no
further force or effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> the Mir-21 License shall terminate solely with respect to any
<FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product that was the subject of such Mir-21 POC Program, the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound(s) contained in any such <FONT STYLE="white-space:nowrap">Mir-21</FONT>
POC Program Product, and Companion Diagnostics for use with any such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product (collectively, <B><I>&#147;Expired <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program
Products&#148;</I></B>), but shall otherwise continue in full force and effect in accordance with its terms; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Sanofi
shall, and it hereby does, grant to Regulus an exclusive, worldwide, <FONT STYLE="white-space:nowrap">royalty-free,</FONT> <FONT STYLE="white-space:nowrap">fully-paid,</FONT> irrevocable, perpetual license, with the right to grant sublicenses, under
Sanofi&#146;s intellectual property rights in or to the Research Results from the Sanofi Program Activities in the POC Program Plan for such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program and from the Sanofi Independent Activities (in
each case, including, without limitation, Sanofi Product Specific Patents and Program Patents claiming or disclosing any such Research Results existing as of expiration of such Option Period), solely to Research, Develop, make, have made, use, gain
Approval, Commercialize, sell, offer for sale, have sold, export and import the applicable Expired <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Products in the Product Field. In addition, Sanofi shall promptly disclose to Regulus any and
all Research Results from the Sanofi Program Activities in the POC Program Plan for such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program, to the extent not previously disclosed to Regulus pursuant to Section&nbsp;3.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Notwithstanding the survival of the <FONT STYLE="white-space:nowrap">Mir-21</FONT> License with respect to <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Compounds, <FONT STYLE="white-space:nowrap">Mir-21</FONT> Products and associated Companion Diagnostics other than the Expired Program Products as provided in the preceding paragraph, from and after
expiration of the Option Period for such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program and for as long as Regulus (or any of its Affiliates or sublicensees) is using Commercially Reasonable Efforts to Develop or Commercialize such
Expired Program Products, Sanofi covenants that neither it nor any of its Affiliates will, directly or indirectly, itself or through any of its sublicensees, submit or cause to be submitted to any Regulatory Authority any preclinical or clinical
data generated by or on behalf of Regulus (other than by Sanofi) in the performance of such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program in support of any IND, Approval or application for Approval of any
<FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound, <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product or associated Companion Diagnostic; <I>provided, however,</I> that Sanofi (and its Affiliates and sublicensees) shall not be prohibited
from submitting to any Regulatory Authority any safety data (but not efficacy data) generated by or on behalf of Regulus (other than by Sanofi) in the performance of such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program that is legally
required to be submitted to or is otherwise requested by a Regulatory Authority in connection with any IND, Approval or application for Approval with respect to any <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound, <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Product or associated Companion Diagnostic that, in each case, is not an Expired Program Product.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.2 Mir-221/222 Licenses and Option. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.2.1 Mir-221/222 POC Program Research License.</B> Subject to the terms and conditions of this Agreement, Regulus hereby grants to Sanofi,
a worldwide, royalty-free, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">co-exclusive</FONT> (with Regulus) license, without the right to grant sublicenses (other than in connection with the use of subcontractors or consultants in
accordance with Section&nbsp;3.9.4), under the Regulus Know-How and Regulus Patents solely to perform the Mir-221/222 POC Program activities for which Sanofi is responsible as specified in the Mir-221/222 POC Program Plan during the applicable POC
Program Term. For clarity, upon termination of the Mir-221/222 POC Program pursuant to Section&nbsp;3.4, the license granted by Regulus to Sanofi under this Section&nbsp;2.1.2 shall terminate and be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.2.2 Mir-221/222 POC Program Option.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) Option Grant.</B> Subject to the terms and conditions of this Agreement (including, without limitation, Section&nbsp;2.1.3,
Section&nbsp;3.4.3(a) or Section&nbsp;3.4.3(b), as applicable), Regulus hereby grants to Sanofi an exclusive, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in connection with a permitted assignment of this Agreement pursuant to
Section&nbsp;13.1) option (the <B><I>&#147;Mir-221/222 Option&#148;</I></B>), exercisable during the Option Period in accordance with Section&nbsp;2.2.2(a), to obtain a worldwide, royalty-bearing, exclusive license, with the right to grant
sublicenses as set forth in Section&nbsp;2.4 below, under the Regulus Know-How and Regulus Patents to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import Mir-221/222 Compounds,
Mir-221/222 Products, and Companion Diagnostics for use with Mir-221/222 Products; in each case, in the Product Field (the <B><I>&#147;Mir-221/222 License&#148;</I></B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) Option Exercise.</B> Upon expiration of the POC Program Term for the Mir-221/222 POC Program, Regulus shall deliver to Sanofi the POC
Study Report for such Mir-21 POC Program, and an invoice for both the Option Exercise Fee and POC Program Reimbursement Amount for such POC Program (which invoices shall be payable in accordance with Section&nbsp;6.5 and Section&nbsp;6.7,
respectively, only in the event Sanofi exercises the Mir-221/222 Option in accordance with this Section&nbsp;2.2.2(b)), and Sanofi may exercise its Mir-221/222 Option by: (i)&nbsp;delivering written notice of such exercise to Regulus prior to
expiration of the Option Period for the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program; and (ii)&nbsp;paying to Regulus the applicable Option Exercise Fee and POC Program Reimbursement Amount for the
<FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program in accordance with Section&nbsp;6.5 and Section&nbsp;6.7, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) Program License Grant Upon Option Exercise.</B> Subject to the terms and conditions of this Agreement (including, without limitation,
Section&nbsp;9.4.1 or 9.4.2, as applicable), and effective only upon exercise of the Option for the Mir-221/222 POC Program in accordance with Section&nbsp;2.2.2(a) (including timely payment of the Option Exercise Fee and POC Program Reimbursement
Amount), Regulus hereby grants to Sanofi the Mir-221/222 License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.2.3 Consequences of Failure to Exercise <FONT
STYLE="white-space:nowrap">Mir-221/222</FONT> Option.</B> In the event that Sanofi fails to exercise its Mir-221/222 Option in accordance with Section&nbsp;2.2.2(a) prior to expiration of the applicable Option Period, then, effective as of
expiration of such Option Period: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the Mir-221/222 Option and all licenses and rights granted by Regulus to Sanofi under this
Agreement with respect to <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Compounds, <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Products and associated Companion Diagnostics shall terminate and be of no further force or effect; and </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Sanofi shall, and it hereby does, grant to Regulus an exclusive, worldwide, <FONT
STYLE="white-space:nowrap">royalty-free,</FONT> <FONT STYLE="white-space:nowrap">fully-paid,</FONT> irrevocable, perpetual license, with the right to grant sublicenses, under Sanofi&#146;s intellectual property rights in or to the Research Results
from the Sanofi Program Activities in the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program Plan (including, without limitation, Sanofi Product Specific Patents and Program Patents claiming or disclosing any such Research Results
existing as of expiration of such Option Period), solely to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Compounds, <FONT
STYLE="white-space:nowrap">Mir-221/222</FONT> Products and associated Companion Diagnostics; in each case, in the Product Field. In addition, Sanofi shall promptly disclose to Regulus any and all Research Results from the Sanofi Program Activities
in the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program Plan, to the extent not previously disclosed to Regulus pursuant to Section 3.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.3 Regulus Co-Promotion Option.</B> Subject to the terms and conditions of this Agreement, on a POC Program-by-POC Program
basis, Sanofi hereby grants to Regulus an exclusive, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (even in connection with a permitted assignment of this Agreement pursuant to Section&nbsp;13.1) option with respect to each POC Program
Product (each, a <B></B><B><I>&#147;Co-Promote Option&#148;</I></B><B></B>), exercisable [&#133;***&#133;] for such POC Program Product as set forth below, to obtain a <FONT STYLE="white-space:nowrap">co-exclusive</FONT> (with Sanofi),
royalty-bearing right and license, without the right to sublicense, under the Regulus Know-How, Regulus Patents, Sanofi Inventions, Sanofi Program Patents and other necessary Patents or know-how Controlled by Sanofi, in each case, solely to promote
each POC Program Product in the U.S. in accordance with <B>A<SMALL>PPENDIX</SMALL>&nbsp;10</B> (such right and license, a <B></B><B><I>&#147;Co-Promote Right&#148;</I></B><B></B>). Sanofi shall deliver written notice of its intent to file the first
NDA for each POC Program Product at least [&#133;***&#133;]&nbsp;months before the date Sanofi anticipates filing such NDA. Regulus may exercise its <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option with respect to such POC Program Product
by delivering written notice of such exercise to Sanofi within [&#133;***&#133;]&nbsp;months after Sanofi delivers written notice of its intent to file such NDA. Effective upon Regulus&#146; exercise of its
<FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option for a POC Program Product, Sanofi hereby grants to Regulus the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Right for such POC Program Product, and the Parties shall negotiate in good
faith and enter into a Co-Promotion Agreement governing such co-promotion activities no later than [&#133;***&#133;]&nbsp;months prior to Sanofi&#146;s good faith estimate of the POC Program Product launch date in the U.S. Such Co-Promotion
Agreement shall include, without limitation, the terms set forth in <B>A<SMALL>PPENDIX</SMALL>&nbsp;10</B> hereto.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.4 Sublicenses.</B> Each Program License is sublicensable only in connection with a sublicense of a Licensed Compound,
Product or Companion Diagnostic licensed to Sanofi under such Program License to any Affiliate of Sanofi or to any Third Party, in each case to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold,
export and import such Licensed Compound, Product or Companion Diagnostic in the Product Field in accordance with the terms of this Agreement; provided, however, that Sanofi shall not have the right to sublicense a POC Program Product in the U.S.
unless and until [&#133;***&#133;]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment
Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.5 Exclusivity. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.5.1 </B>During the Term, on a Collaboration Target-by-Collaboration Target basis, so long as any Program License or Option with respect
to a Collaboration Target is in effect, Regulus agrees that it will not [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.5.2 </B>During the Term, on a
Collaboration Target-by-Collaboration Target basis, so long as any Program License with respect to a Collaboration Target is in effect, Sanofi may, subject to the terms and conditions of this Agreement (including the financial provisions set forth
in Article 6), [&#133;***&#133;], <I>provided</I>, <I>however</I>, that, on a POC Program-by-POC Program basis, during the applicable POC Program Term , Sanofi agrees that it will not [&#133;***&#133;]; and (ii)&nbsp;with respect to a POC Program
Product that is the subject of such POC Program where the applicable POC Program Product [&#133;***&#133;]; in each case (both (i)&nbsp;and (ii)&nbsp;above), only in the [&#133;***&#133;] for which the applicable POC Program Product is being
developed and/or commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.6 License Conditions; Limitations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.6.1 </B>If Sanofi fails to meet its obligations to use Commercially Reasonable Efforts under ARTICLE 5 for a particular Licensed Compound
or Product, Regulus will have the termination rights set forth in Section&nbsp;9.4.1 or 9.4.2, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.6.2 </B>Each Program
License, and the exclusivity granted under Section&nbsp;2.5 with respect to the applicable Collaboration Target, are subject to and limited by the (i)&nbsp;[&#133;***&#133;], <I>solely</I> to the extent Regulus has, prior to the Effective Date,
provided Sanofi the provisions of such agreements in unredacted form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.6.3 </B>Without limiting this Section&nbsp;2.6, Regulus&#146;
ability to conduct research and development on [&#133;***&#133;], and [&#133;***&#133;] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;.]. To the extent the [&#133;***&#133;] POC Program Plan contemplates the potential research and
development of [&#133;***&#133;], Regulus will use commercially reasonable efforts (and will exercise its rights under the [&#133;***&#133;]) to secure the right to conduct research and development on [&#133;***&#133;], and grant Sanofi a
[&#133;***&#133;] Option under Section&nbsp;2.2.1 to obtain a [&#133;***&#133;] under Section&nbsp;2.2.2(b) with respect to [&#133;***&#133;], and to grant such [&#133;***&#133;] upon exercise of such [&#133;***&#133;], to the fullest extent
contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.6.4 </B>Pursuant to the [&#133;***&#133;], Regulus has a non-exclusive license under certain Patents
and Know How of [&#133;***&#133;]. Regulus has the right to request from [&#133;***&#133;] permission to grant a sublicense to Sanofi and its Affiliates under the [&#133;***&#133;], and to provide Sanofi and its Affiliates access to the
[&#133;***&#133;], in connection with the development, manufacture and commercialization of Products that are Development Candidates, on a Development Candidate-by-Development Candidate basis. On a Development Candidate-by-Development Candidate
basis: (a)&nbsp;with respect to Development Candidates that are POC Program Products, promptly following IND filing for such Development Candidate, Regulus shall use commercially reasonable efforts (and will exercise its rights under the
[&#133;***&#133;]) to obtain [&#133;***&#133;] permission (i)&nbsp;to grant to Sanofi and its Affiliates a sublicense under the [&#133;***&#133;] for such POC Program Products, and (ii)&nbsp;to provide Sanofi and its Affiliates access to the
[&#133;***&#133;] pursuant to Section&nbsp;4.3 for such POC Program Products; <I>provided, however,</I> that, notwithstanding Regulus&#146; receipt of such permission from [&#133;***&#133;], such sublicense grant to Sanofi under the
[&#133;***&#133;] would not become effective, and Regulus would not be obligated to provide such access to the [&#133;***&#133;] to Sanofi, in each case ((i) and (ii)) unless and until [&#133;***&#133;]; and (b)&nbsp;with respect to Products that
are not POC Program Products, [&#133;***&#133;], Regulus shall use commercially reasonable efforts (and will exercise its rights under the [&#133;***&#133;]) to grant to Sanofi and its Affiliates a sublicense under the [&#133;***&#133;], and to
provide Sanofi and its Affiliates access to the [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.6.5 </B>Subject to Section&nbsp;2.5, Regulus retains the right to
grant Permitted Licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.6.6 </B>The [&#133;***&#133;] granted to Sanofi under the [&#133;***&#133;] Agreement is subject to the
terms of the [&#133;***&#133;] Agreement (including for the avoidance of doubt the [&#133;***&#133;] obligation vis-&agrave;-vis [&#133;***&#133;] to provide reports in accordance with [&#133;***&#133;]Agreement, and to keep records as set forth in
Article&nbsp;10 of the [&#133;***&#133;] Agreement, <I>provided</I> that Regulus agrees to directly comply with the reporting obligations under the [&#133;***&#133;] Agreement with respect to progress of research and development). To the extent
necessary to comply with the reporting obligations under the [&#133;***&#133;] Agreement, Sanofi agrees to provide Regulus with reports of Sanofi&#146;s progress through the JSC for so long as the </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
JSC in place, and thereafter as reasonably requested by Regulus, in each case, at intervals and with reasonable lead-times reasonably necessary for Regulus to comply with the [&#133;***&#133;]
Agreement. Based on the information reported by Sanofi pursuant to the preceding sentence, Regulus will prepare the necessary reports and submit them to [&#133;***&#133;]. However, if [&#133;***&#133;] insists that Sanofi provide written progress,
Sanofi agrees to do so. The Parties shall cooperate in good faith to facilitate compliance with the Existing Regulus Agreements. Notwithstanding the foregoing, Regulus shall make a good faith effort to [&#133;***&#133;] that the [&#133;***&#133;] of
the [&#133;***&#133;] the reporting obligations that Sanofi has to Regulus under this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.1 Objective.</B> During the Research Term, the Parties collaborated in carrying out a program to discover and preclinically
develop certain Licensed Compounds (as further provided for in the R&amp;D Plan, the <B></B><B><I>&#147;Research Program&#148;</I></B><B></B>). Beginning as of the Second Restatement Date, Regulus will carry out, in cooperation with Sanofi, each of
the following development programs, for the potential further clinical Development and Commercialization of Licensed Compounds from such POC Program by Sanofi as Products. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.1.1</B> a program to develop certain Mir-21 Compounds meeting the applicable Development Candidate Criteria in one or more Indications in
the Fibrosis Field with the objective of demonstrating Proof of Concept with respect to a <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound Development Candidate in such Indication(s) (as further provided for in the <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Fibrosis POC Program Plan, the <B><I>&#147;Mir-21 Fibrosis POC Program&#148;</I></B>). The <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Fibrosis Program will be carried out in accordance with a written
research and development plan (the <B><I>&#147;Mir-21 Fibrosis POC Program Plan&#148;</I></B>). The initial <FONT STYLE="white-space:nowrap">Mir-21</FONT> Fibrosis POC Program Plan that has been agreed to by the Parties as of the Second Restatement
Date is attached as <B>A<SMALL>PPENDIX</SMALL>&nbsp;6A</B> hereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.1.2</B> a program to develop certain Mir-21 Compounds meeting the
applicable Development Candidate Criteria in one or more Indications in the Oncology Field with the objective of demonstrating Proof of Concept with respect to a <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound Development Candidate in such
Indication(s) (as further provided for in the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Oncology POC Program Plan, the <B><I>&#147;Mir-21 Oncology POC Program&#148;</I></B>). The <FONT STYLE="white-space:nowrap">Mir-21</FONT> Oncology POC
Program will be carried out in accordance with a written research and development plan (the <B><I>&#147;Mir-21 Oncology POC Program Plan&#148;</I></B>). The initial <FONT STYLE="white-space:nowrap">Mir-21</FONT> Oncology POC Program Plan that has
been agreed to by the Parties as of the Second Restatement Date is attached as <B>A<SMALL>PPENDIX</SMALL>&nbsp;6B</B> hereto; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.1.3</B> a program to develop certain Mir-221/222 Compounds meeting the applicable Development Candidate Criteria in one or more
Indications in the Oncology Field with the objective of demonstrating Proof of Concept with respect to a Mir-221/222 Compound Development Candidate in such Indication(s) (as further provided for in the Mir-221/222 POC Program Plan, the
<B><I>&#147;Mir-221/222 POC Program&#148;</I></B>). The Mir-221/222 POC Program will be carried out in accordance with a written research and development plan (the <B><I>&#147;Mir-221/222 POC </I></B> </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B><I>Program Plan&#148;</I></B>). The initial Mir-221/222 POC Program Plan that has been agreed to by the Parties as of the Second Restatement Date is attached as Appendix&nbsp;6C hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.2 POC Program Plans.</B> Each POC Program will be carried out in accordance with a written program plan (each, a
<B><I>&#147;POC Program Plan&#148;</I></B>). The initial POC Program Plans have been agreed to by the Parties as of the Effective Date and are attached as <B>A<SMALL>PPENDIX</SMALL> 6</B> hereto. The purpose of each POC Program Plan is: (a)&nbsp;to
detail the responsibilities and activities of Regulus with respect to carrying out the applicable POC Program, including the Development Candidate Criteria, POC Criteria and Target Product Profile for such POC Program; and (b)&nbsp;if applicable, to
detail those specific studies and/or activities under such POC Program that are to be carried out by Sanofi (<B><I>&#147;Sanofi Program Activities&#148;</I></B>). Regulus will be responsible for all activities under each POC Program Plan through
Achievement of Proof of Concept (except for Sanofi Program Activities, if any), and Sanofi will be responsible for all Sanofi Program Activities (if any) under each POC Program Plan. A POC Program Plan, including the Development Candidate Criteria,
POC Criteria, Target Product Profile and Sanofi Program Activities for such POC Program, may be amended with the approval of the JSC, subject to paragraph&nbsp;8 of the JSC Charter. Each POC Program Plan will be updated and amended from time to time
as necessary. In addition, at such time (if ever) as Sanofi exercises its Option with respect to a POC Program in accordance with Section&nbsp;2.2.2(a), the JSC will meet to update the applicable POC Program Plan to implement the Manufacturing
Technology transfer under Section&nbsp;4.3 and to secure supply of API to support further clinical trials after the Achievement of Proof of Concept, the cost of which will be borne solely by Sanofi. If the Parties cannot agree to updates or
amendments to a POC Program Plan, the Parties will first pursue the dispute resolution provisions of the JSC Charter and thereafter follow the provisions of Section&nbsp;13.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.3 POC Program Term.</B> Each POC Program will be carried out during the applicable POC Program Term, subject to the earlier
termination of such POC Program pursuant to Section&nbsp;3.4.1 or Section&nbsp;3.4.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.4 Early Termination of POC
Program. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.4.1 By Sanofi.</B> On a POC Program-by-POC Program basis, Sanofi will have the right to terminate a POC Program at any
time upon written notice to Regulus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.4.2 By the Parties.</B> On a POC Program-by-POC Program basis, the Parties may mutually agree
in writing to terminate a POC Program if they determine in good faith, and after consultation via the JSC, that, based on the results generated under the POC Program Plan, the further pursuit of such POC Program would be scientifically or clinically
unwarranted (<I>e.g.</I>, due to target validation issues, Development Candidate delivery issues, potency issues or safety issues); <I>provided, however,</I> that, in the event Regulus believes, on the basis of results generated under the POC
Program Plan, that further pursuit of such POC Program is not scientifically justifiable, but Sanofi does not agree to terminate such POC Program, then, upon Regulus&#146; written request, the matter shall be submitted to the Expert Panel as set
forth in Section&nbsp;13.4.5 of this Agreement for resolution of whether or not further pursuit of such POC Program is scientifically justifiable, and if the Expert Panel rules in favor of Regulus, such POC Program shall be deemed terminated by such
ruling. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.4.3 Consequences of Early Termination of POC Program.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program.</B> On a <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC <FONT
STYLE="white-space:nowrap">Program-by-Mir-21</FONT> POC Program basis, in the event of termination of a particular <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program pursuant to Section&nbsp;3.4.1 or Section&nbsp;3.4.2 (such <FONT
STYLE="white-space:nowrap">Mir-21</FONT> POC Program, the <B><I>&#147;Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program&#148;</I></B>), then, effective as of termination of such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC
Program: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the Mir-21 POC Program research license granted to Regulus pursuant to Section&nbsp;2.1.2 with respect to the
Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program shall terminate and be of no further force or effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>
the Mir-21 Option with respect to the Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program shall terminate and be of no further force or effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Mir-21 License shall terminate solely with respect to any Mir-21 POC Program Product that was the subject of the Terminated
Mir-21 POC Program, the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound(s) contained in any such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product, and Companion Diagnostics for use with any such <FONT
STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product (collectively, <B><I>&#147;Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Products&#148;</I></B>), but shall otherwise continue in full force and effect in accordance
with its terms; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> Sanofi shall, and it hereby does, grant to Regulus an exclusive, worldwide, <FONT
STYLE="white-space:nowrap">royalty-free,</FONT> <FONT STYLE="white-space:nowrap">fully-paid,</FONT> irrevocable, perpetual license, with the right to grant sublicenses, under Sanofi&#146;s intellectual property rights in or to the Research Results
from the Sanofi Program Activities in the POC Program Plan for the Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program and from the Sanofi Independent Activities (in each case, including, without limitation, Sanofi Product Specific
Patents and Program Patents claiming or disclosing any such Research Results existing as of termination of such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program), solely to Research, Develop, make, have made, use, gain Approval,
Commercialize, sell, offer for sale, have sold, export and import the applicable Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Products in the Product Field. In addition, Sanofi shall promptly disclose to Regulus any and all
Research Results from the Sanofi Program Activities in the POC Program Plan for such Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program, to the extent not previously disclosed to Regulus pursuant to Section&nbsp;3.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the survival of the <FONT STYLE="white-space:nowrap">Mir-21</FONT> License with respect to
<FONT STYLE="white-space:nowrap">Mir-21</FONT> Compounds, <FONT STYLE="white-space:nowrap">Mir-21</FONT> Products and associated Companion Diagnostics other than the Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Products as
provided in the preceding paragraph, from and after termination of the Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program and for as long as Regulus (or any of its Affiliates or sublicensees) is using Commercially Reasonable
Efforts to Develop or Commercialize such Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Products, Sanofi covenants that neither it nor any of its Affiliates will, directly or indirectly, itself or through any of its sublicensees,
submit or cause to be submitted to any Regulatory Authority any preclinical or clinical data generated by or on behalf of Regulus (other than by Sanofi) in the performance of such Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program
in support of any IND, Approval or application for Approval of any <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound, <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product or associated Companion Diagnostic; <I>provided, however,</I> that
Sanofi (and its Affiliates and sublicensees) shall not be prohibited from submitting to any Regulatory Authority any safety data (but not efficacy data) generated by or on behalf of Regulus (other than by Sanofi) in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance of such Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program that is legally required to be submitted to or is otherwise requested by a Regulatory Authority in
connection with any IND, Approval or application for Approval with respect to any <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound, <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product or associated Companion Diagnostic that, in each case,
is not a Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)
<FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program.</B> In the event of termination of the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program pursuant to Section&nbsp;3.4.1 or Section&nbsp;3.4.2, then, effective as of
termination of the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the Option with respect to the <FONT
STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program and all licenses and rights granted by Regulus to Sanofi under this Agreement with respect to <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Compounds,
<FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Products and associated Companion Diagnostics shall terminate and be of no further force or effect; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Sanofi shall, and it hereby does, grant to Regulus an exclusive, worldwide, <FONT STYLE="white-space:nowrap">royalty-free,</FONT>
<FONT STYLE="white-space:nowrap">fully-paid,</FONT> irrevocable, perpetual license, with the right to grant sublicenses, under Sanofi&#146;s intellectual property rights in or to the Research Results from the Sanofi Program Activities in the POC
Program Plan for the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program (including, without limitation, Sanofi Product Specific Patents and Program Patents claiming or disclosing any such Research Results existing as of termination of
such Mir-221/222 Program), solely to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Compounds, <FONT
STYLE="white-space:nowrap">Mir-221/222</FONT> Products and associated Companion Diagnostics; in each case, in the Product Field. In addition, Sanofi shall promptly disclose to Regulus any and all Research Results from the Sanofi Program Activities
in the POC Program Plan for the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program, to the extent not previously disclosed to Regulus pursuant to Section 3.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.4.4 End of POC Program Term.</B> Upon the expiration of the POC Program Term for such POC Program (whether as a result of termination of
such POC Program or otherwise), Regulus will not be obligated to continue to perform work under the POC Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.5
Joint Steering Committee.</B> The Parties will establish and maintain a joint steering committee (the <B><I>&#147;JSC&#148;</I></B>) to oversee the conduct of the POC Programs, including, but not limited to approving any changes to the POC Program
Plans. The JSC will be established, operated and governed in accordance with the policies and procedures set forth in <B>A<SMALL>PPENDIX</SMALL>&nbsp;4</B> attached hereto (the <B><I>&#147;JSC Charter&#148;</I></B>). The JSC Charter may be amended
with the unanimous approval of the JSC members. As needed, the JSC will establish subcommittees and working groups that will report to the JSC to further the objectives of the POC Programs. The JSC and any subcommittees and working groups
established by the JSC will automatically dissolve at such time as all of the Options granted hereunder either have been exercised, or have expired or terminated without exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.6 Program Contributions.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.6.1 Research Program.</B> The Parties acknowledge and agree that their respective staffing, funding and performance obligations with
respect to the Research Program have been fulfilled prior to the Second Restatement Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.6.2 POC Program Contributions By Regulus.</B> During the POC Program Term for a POC Program,
Regulus will dedicate Regulus employees and/or Third Party contractors to perform activities in support of and in accordance with the then-current POC Program Plan. Regulus will bear all costs, including costs related to research supplies,
consumables and animals, incurred in performing its obligations under each POC Program Plan. For clarity, during the POC Program Term for a POC Program, Regulus will perform, and bear all costs of performing, all IND-Enabling Studies to the extent
required by the FDA to support the IND for the Target Product Profile for such POC Program as set forth in the version of the POC Program Plan in effect immediately prior to the start of such IND-Enabling Studies; <I>provided, however,</I> that
Regulus shall not be responsible for performing, or for the costs of performing, any IND-Enabling Study that is identified as a Sanofi Program Activity in the applicable POC Program Plan. During the applicable POC Program Term, Regulus shall use
Commercially Reasonable Efforts to develop to Proof of Concept (i)&nbsp;at least one Mir-21 Compound in an Indication in the Fibrosis Field, (ii)&nbsp;at least one Mir-21 Compound in an Indication in the Oncology Field, and (iii)&nbsp;at least one <FONT
STYLE="white-space:nowrap">Mir-221/222</FONT> Compound in an Indication in the Oncology Field; in each case consistent with the applicable POC Program Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.6.3 POC Program Contributions By Sanofi.</B> During the applicable POC Program Term, Sanofi shall use Commercially Reasonable Efforts to
conduct and complete the Sanofi Program Activities (if any) for each POC Program in accordance with the then-current POC Program Plan. Sanofi will bear all costs, including costs related to research supplies, consumables and animals, incurred in
performing Sanofi Program Activities under each POC Program Plan, subject to Section&nbsp;4.1 and Section 6.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.7
Records.</B> Each Party and its contractors will maintain complete and accurate records of all work conducted in the performance of the Research Program and each POC Program, and all results, data, inventions and developments made in the performance
of the Research Program and each POC Program. All such records maintained by each Party and its contractors will be in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Upon reasonable prior written
notice, Regulus will provide Sanofi the right to inspect such records, and will provide copies of all requested records, to the extent reasonably required for the performance of Sanofi&#146;s obligations or the exercise of Sanofi&#146;s rights under
this Agreement. Upon reasonable prior written notice, and solely with respect to Sanofi Program Activities and/or Discontinued Products, Sanofi will provide Regulus the right to inspect such records, and will provide copies of all requested records,
to the extent reasonably required for the performance of Regulus&#146; obligations or the exercise of Regulus&#146; rights under this Agreement. In addition, Sanofi and its contractors will maintain complete and accurate records of all work
conducted by or on behalf of Sanofi with respect to <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compounds and Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Products independently of the <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC
Programs during the applicable Option Period(s) (<B><I>&#147;Sanofi Independent Activities&#148;</I></B>). In each case, each Party will maintain such records and the information it receives from the other Party in confidence in accordance with
Article&nbsp;7 hereof and will not use such records or information except to the extent otherwise permitted by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.8 Disclosure of Results.</B> The results of all work performed by the Parties as part of the Research Program and each POC
Program will be promptly disclosed to the other Party in a reasonable manner as such results are obtained. In addition, Regulus will periodically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide Sanofi with written reports of the work performed under the Research Program and each POC Program, and the results achieved by Regulus, and Sanofi will periodically provide Regulus with
written reports of Sanofi Program Activities performed under each POC Program, and the results achieved by Sanofi. Regulus and Sanofi will provide reports and analyses at each JSC meeting, and more frequently on reasonable request by the JSC,
detailing the current status of each POC Program. The results, reports, analyses and other information regarding the Research Program and each POC Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with
the rights granted and other terms and conditions under this Agreement. Upon reasonable request by Sanofi, Regulus will provide Sanofi with additional data, results and other information with respect to the work performed by Regulus in the
performance of the Research Program and each POC Program. Upon reasonable request by Regulus, Sanofi will provide Regulus with additional data, results and other information with respect to the work performed by Sanofi in the performance of the
Sanofi Program Activities. Any reports required, excluding reports needed for submission to a Regulatory Agency, under this Section&nbsp;3.8 may take the form of and be recorded in minutes of the JSC that will contain copies of any slides relating
to the results and presented to the JSC. Reports needed to support regulatory submissions and updates to a Regulatory Agency will be provided in a timely manner and in a format as agreed upon by the JSC. During the POC Program Term for any <FONT
STYLE="white-space:nowrap">Mir-21</FONT> POC Program, Sanofi will provide [&#133;***&#133;] written summaries of the Sanofi Independent Activities performed (if any) and the results obtained over the past [&#133;***&#133;] with respect to Other <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Products. Sanofi will provide to Regulus such additional information regarding such Sanofi Independent Activities and results obtained as Sanofi may determine to be necessary or useful for the performance of
the <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program(s), which information may be used by Regulus only in accordance with the rights granted and other terms and conditions under this Agreement. Except as expressly set forth in this
Section&nbsp;3.8 or as otherwise expressly provided in Section&nbsp;3.11 or Section&nbsp;5.2, Sanofi shall not be required to disclose to Regulus the results of work performed by Sanofi as part of the Sanofi Independent Activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.9 Research Efforts; Resources, Scientific Manner.</B> Each Party will use Commercially Reasonable Efforts to perform each
POC Program, including its responsibilities under each POC Program Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.9.1 </B>Throughout each POC Program Term, each Party will
assign qualified and reasonably sufficient personnel resources to the performance of such Party&#146;s obligations under the applicable POC Program Plan. The mixture of skills and levels of such employees will be appropriate to the objectives of
such Party&#146;s responsibilities under such POC Program Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.9.2 </B>Each Party will maintain laboratories, offices,
administrative support and all other facilities at its own expense and risk necessary to carry out its responsibilities under each POC Program Plan. Each Party agrees to make its employees reasonably available at their respective places of
employment to consult with the other Party on issues arising during the performance of each POC Program. Sanofi and Regulus will cooperate with each other in carrying out each POC Program, and each Party will contribute its relevant know-how and
experience necessary to carry out each POC Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.9.3 </B>Each POC Program will be conducted by each Party in good scientific
manner, and in compliance with all applicable GCP, GLP and GMP, and applicable legal </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements, to attempt to achieve efficiently and expeditiously the objectives of such POC Program. Each Party will comply with all Applicable Laws, in the performance of work under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.9.4 </B>Neither Party will perform any of its obligations under any POC Program Plan through subcontractors or
consultants, without the prior written approval of the other Party, such approval not to be unreasonably withheld; <I>except</I> that (i)&nbsp;Regulus may enter Permitted Licenses; and (ii)&nbsp;each Party may engage consultants and subcontractors
in the ordinary course that generally support such Party&#146;s research and development infrastructure, <I>provided</I> that (a)&nbsp;each such consultant and subcontractor agrees in writing to assign to such Party all Know-How and Patents
conceived made or reduced to practice in performing services for such Party, and (b)&nbsp;subject to Section&nbsp;6.6 and Section&nbsp;6.7.2, such Party will solely bear any costs associated with such Party&#146;s use of such consultants and
subcontractors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.10 Materials Transfer.</B> In order to facilitate the Programs, either Party may provide to the other
Party certain materials for use by the other Party in furtherance of the Programs. All such materials will be used by the receiving Party in accordance with the terms and conditions of this Agreement solely for purposes of performing its rights and
obligations under this Agreement, and the receiving Party will not transfer such materials to any Third Party unless expressly contemplated by this Agreement or upon the written consent of the supplying Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.11 Pharmacovigilance; Safety Database.</B> If Sanofi exercises its Option with respect to any POC Program, then prior to IND
transfer with respect to any Product under such POC Program, designated staff from the respective Headquarter Pharmacovigilance Department shall be requested by the Joint Steering Committee to establish a detailed Safety Data Exchange Agreement
(<B><I>&#147;SDEA&#148;</I></B>) for the Products to be in place prior to Sanofi starting any clinical development. Notwithstanding the foregoing, the Parties agree to the following principles: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.11.1 </B>If Sanofi exercises its Option with respect to a POC Program, Sanofi will establish the global safety database for the
applicable Licensed Compounds/Products that will be used for regulatory reporting and responses to safety queries from Regulatory Authorities. For that purpose, Regulus will promptly transfer all safety information regarding the applicable Licensed
Compounds or Products, including, if applicable, adverse events, and drug exposure during pregnancy data that it has regarding the Licensed Compounds or Products to Sanofi for entry into the global safety database upon request from Sanofi. The
timelines, format and content of such transfer shall be agreed in the SDEA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.11.2 </B>Regulus maintains a database that includes
information regarding the safety and tolerability of its drug compounds, individually and as a class, including information discovered during pre-clinical and clinical development (the <B><I>&#147;Regulus Database&#148;</I></B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.11.3 </B><I>Safety Monitoring</I>. In an effort to maximize understanding of the safety profile and pharmacokinetics of Regulus
compounds, Sanofi will cooperate with Regulus and forward safety information to Regulus designated contact persons. This includes transmission of serious adverse events collected from Sanofi sponsored studies in a timely fashion as agreed in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the SDEA. <I>Vice versa</I> Regulus shall promptly inform Sanofi on any safety issue or class effect that may come to its attention including those from other license partners to the extent
Regulus is not precluded by written agreement with the applicable partner from sharing such information with Sanofi. This includes also nonclinical safety information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.11.4 </B><I>Studies/Regulatory Documents</I>. To the extent collected by Sanofi and in the form in which Sanofi uses/stores such
information for its own purposes, Sanofi will provide Regulus with the results from each of the nonclinical (<I>e.g.</I>, toxicology, pharmacokinetics, and safety pharmacology studies) and the clinical studies of each Licensed Compound and Product
as soon as practicable following the date such information is available to Sanofi (but not later than [&#133;***&#133;]&nbsp;days after Sanofi&#146;s receipt of such information). The clinical results will include, but will not be limited to,
subject demographics and characteristics, medical history, prior and concomitant medication usage, adverse event reports and laboratory test results. The clinical results will be accompanied by the clinical study protocol (original and all
amendments) and an annotated case report form (CRF) that identifies the variable names in the transferred data associated with each of the data fields in the CRF. In connection with any reported serious adverse event, Sanofi will provide Regulus all
serious adverse event reports (including initial, interim, follow-up, amended, and final reports) promptly following the time these reports are submitted to Regulatory Authorities. In addition, with respect to each Licensed Compound and Product,
Sanofi will provide Regulus with copies of annual safety updates filed with each IND and the safety sections of any final clinical study reports within [&#133;***&#133;]&nbsp;days following the date such information is filed or is available to
Sanofi, as applicable. Furthermore, Sanofi will promptly provide Regulus with any supporting data and answer any follow-up questions reasonably requested by Regulus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.11.5 </B><I>Confidentiality.</I> All such information disclosed by Sanofi to Regulus will be Sanofi Confidential Information;
<I>provided, however</I>, that Regulus may disclose any such Sanofi Confidential Information to Regulus&#146; other partners pursuant to ARTICLE 7 below if such information is regarding class generic properties of microRNA Compounds, and/or any
Third Party, in each case, so long as Regulus does not disclose the identity of the Product, or Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.11.6 </B><I>Contacts.</I>
Sanofi will deliver all such information to Regulus for the Regulus Database to 3545&nbsp;John Hopkins Court, Suite&nbsp;210, San Diego, California 92121-1121, Attention: Chief Medical Officer (or to such other address/contact designated in writing
by Regulus). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANUFACTURING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.1 Supply of microRNA Compound for Programs.</B> Regulus agrees to manufacture and supply all microRNA Compounds for use in
support of each POC Program until the exercise by Sanofi of its Option with respect to such POC Program in accordance with Section&nbsp;2.1.3 or Section&nbsp;2.2.2(b), as applicable. Regulus will bear its own costs for the manufacture of all
microRNA Compound needed for POC Program Plan activities for each POC Program until such Option exercise, including the costs of manufacture of all microRNA </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Compound needed for Sanofi Program Activities. For clarity, Regulus will not be required to manufacture and supply API or drug product for any human clinical trial of any Licensed Compound or
Product conducted by Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.1.1 Contract Manufacture.</B> If Regulus intends to contract one or more Third Parties to conduct any
manufacturing activities with respect to any Licensed Compound or Product in support of a POC Program, and prior to entering into a definitive agreement with a Third Party with respect to the conduct of such manufacturing activities, in each case,
Regulus shall so notify Sanofi no later than the time Regulus submits a request for quotation or proposal to any such Third Party(ies) for those manufacturing activities, shall provide Sanofi with the same information that Regulus provides to any
such Third Party(ies) for the purpose of such Third Party&#146;s(ies&#146;) preparation of such quotation or proposal, and shall inform Sanofi of the date by which Regulus expects to select a contract manufacturer to perform such manufacturing
activities (collectively, the <B><I>&#147;Request for Proposal&#148;</I></B>). If Sanofi is interested in performing, or having one of its Affiliates perform, such manufacturing activities, Sanofi may, in its sole discretion, submit a quotation or
proposal to Regulus. Regulus shall consider in good faith such quotation or proposal from Sanofi, but Regulus shall be free to select the quotation or proposal (whether of Sanofi or of any Third Party) that Regulus, in its sole discretion, deems to
be in Regulus&#146; best interests, <I>provided</I>, <I>however</I>, that Regulus shall not select any Third Party quotation or proposal that (taken as a whole) is less favorable to Regulus than the last quotation or proposal received from Sanofi
and Regulus shall give Sanofi the opportunity to match any Third Party quotation or proposal that (taken as a whole) is more favorable to Regulus than the last quotation or proposal received from Sanofi. If Regulus accepts a quotation or proposal
provided by Sanofi, the Parties shall negotiate and enter into a separate agreement governing the performance such manufacturing activities. If Sanofi does not submit a quotation or proposal to Regulus within [&#133;***&#133;] days after the Request
for Proposal, or notify Regulus that it wishes to match a more favorable Third Party quotation or proposal within [&#133;***&#133;] days after Regulus communicates such Third Party proposal to Sanofi, then Regulus shall be free to enter into a
definitive agreement with a Third Party with respect to the conduct of such manufacturing activities. For clarity, this Section&nbsp;4.1.1 shall not apply to any manufacturing activities with respect to which Regulus has contracted with any Third
Party as of the Second Restatement Date, and in the case of any manufacturing activities with respect to which Regulus is in discussions with any Third Party as of the Second Restatement Date, Regulus shall not be obligated to wait more than
[&#133;***&#133;] days after the Request for Proposal to receive a quotation or proposal from Sanofi, or to consider accepting a quotation or proposal provided by Sanofi, for such manufacturing activities if doing so would delay Regulus&#146;
timeline for initiation of such manufacturing activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.2 Clinical and Commercial Manufacturing and Supply of
Licensed Compound and Product. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.2.1 Product Manufacturing Responsibility.</B> Except as otherwise provided in Section&nbsp;4.1 or
elsewhere in this Agreement, the Parties acknowledge and agree that Sanofi will be solely responsible for the manufacturing of Licensed Compound and Product for all clinical trials and commercial supply, including management of the overall
manufacturing strategy and tactics, formulation, internal or contract manufacturer selection for API and finished </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Product, associated audits, stability testing, pricing, relationship with contract manufacturer(s) and any work proposals or contract negotiations or contracts themselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>4.2.2 Supply of Finished Drug Product.</B> Except as otherwise specified in the R&amp;D Plan or a POC Program Plan, the Parties acknowledge
and agree that Sanofi will be solely responsible for the manufacturing, stability testing and supply of finished drug Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.3 Transfer of Manufacturing Technology and Assistance.</B> On a Product-by-Product basis (a)&nbsp;with respect to POC
Program Products, if Sanofi exercises its Option with respect to a particular POC Program pursuant to Section&nbsp;2.1.3 or Section&nbsp;2.2.2(b) (as applicable); and (b)&nbsp;with respect to Products that are not POC Program Products, upon
Sanofi&#146;s written notice to Regulus that such Product meets Sanofi&#146;s internal criteria as a development candidate, in each case ((a) or (b)), promptly after such Option exercise or notice that a Product meets Sanofi&#146;s internal criteria
as a development candidate, as applicable, Regulus shall disclose (and provide copies, as applicable) to either Sanofi or a Third Party manufacturer designated by Sanofi all Manufacturing Technology that is required for the manufacture (including
the development of the manufacturing process) of Products (including the Licensed Compound(s) contained therein) and is reasonably necessary or useful to enable Sanofi or such Third Party manufacturer (as appropriate) to manufacture such Licensed
Compounds and Products. The steps, planning and obligations of the Parties regarding the transfer of the Manufacturing Technology for each Product (including the Licensed Compound(s) contained therein) will be set forth in a &#147;Technology
Transfer Master Plan API&#148; to be executed between the Parties promptly after Sanofi&#146;s exercise of the Option for such POC Program or notice that a Product meets Sanofi&#146;s internal criteria as a development candidate, as applicable. Upon
request, Regulus will at all times use diligent efforts to provide Sanofi with any additional information or on-site support as may be required by Sanofi and its Affiliates in connection with the transfer of the Manufacturing Technology for such
Product. Sanofi shall reimburse Regulus for any on-site support rendered at the FTE-Day Rate per FTE-day, provided further Regulus shall in no event be obliged to provide more than [&#133;***&#133;] in total, unless the Parties otherwise agree in
writing. For purposes of this Agreement <B><I>&#147;Manufacturing Technology&#148;</I></B> shall mean, with respect to a particular Product, the Know-How Controlled by Regulus that is reasonably available and reasonably necessary for the Manufacture
(including formulation, processing, filling and packaging) of such Product (including the Licensed Compound(s) contained therein). Sanofi and its Third Party manufacturer may use the Manufacturing Technology only in support of the applicable Program
License(s) and only for so long as such Program License(s) are in effect, and will not use the Manufacturing Technology in connection with any other compound or product. Sanofi will be responsible and liable to Regulus for any practice of the
Manufacturing Technology by Sanofi&#146;s Third Party manufacturer that breaches this Section&nbsp;4.3. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT&nbsp;&amp; COMMERCIALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.1 Development, Commercialization and Regulatory Responsibilities.</B> Except as otherwise specified in a POC Program Plan or
a Co-Promotion Agreement, (a)&nbsp;in the case of a <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product, during such time from and after exercise of the Option for the applicable <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC
Program as Program License for such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Product is in effect, and (b)&nbsp;in the case of any other Product for a particular Collaboration Target, during such time as a Program License with respect to such Collaboration Target is in
effect pursuant to Section&nbsp;2.1 or Section&nbsp;2.2, Sanofi will have sole responsibility, including without limitation sole responsibility for all funding, resourcing and <FONT STYLE="white-space:nowrap">decision-making,</FONT> for all
Development and Commercialization with respect to the Licensed Compounds and Products licensed to Sanofi under such Program License, and Sanofi hereby assumes all regulatory responsibilities in connection with Licensed Compounds and Products
licensed to Sanofi under such Program License, including sole responsibility for all Regulatory Documentation and for obtaining all Approvals. Sanofi will comply with all Applicable Laws in connection with the Development and Commercialization of
Licensed Compounds and Products. Sanofi (by itself or through its Affiliates, sublicensees, (sub)contractors or agents, as applicable) will use Commercially Reasonable Efforts to achieve Initiation of a Phase&nbsp;2 Trial or Phase&nbsp;3 Trial as
soon as practicable following Sanofi&#146;s exercise of its Option (or at least one of its Options) for a given Collaboration Target, and will use Commercially Reasonable Efforts to Develop and Commercialize at least one Licensed Compound or Product
for each such Collaboration Target; <I>provided, however,</I> that if the <FONT STYLE="white-space:nowrap">Mir-21</FONT> License terminates with respect to <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Products from both <FONT
STYLE="white-space:nowrap">Mir-21</FONT> POC Programs, then Sanofi (by itself or through its Affiliates, sublicensees, (sub)contractors or agents, as applicable) will use Commercially Reasonable Efforts to identify an Other <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Product as a candidate for Development as soon as practicable thereafter, and will use Commercially Reasonable Efforts to Develop and Commercialize at least one <FONT STYLE="white-space:nowrap">Mir-21</FONT>
Compound (other than a <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound that was the subject of a <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program) or Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product. Regulus will make
all IND filings for POC Program Products in accordance with the POC Program Plans in Regulus&#146; name. Once Sanofi pays Regulus the applicable Option Exercise Fee and POC Program Reimbursement Amount under Section&nbsp;6.5 and Section&nbsp;6.7.2,
respectively, for a POC Program, Regulus will and hereby does assign to Sanofi, and Sanofi will own, all INDs, NDAs, MAAs and other regulatory filings and Approvals for POC Program Products that are the subject of such POC Program, subject to
Regulus reversion rights under ARTICLE 10. Sanofi will be solely responsible for making all IND filings for Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Products licensed to Sanofi under the <FONT STYLE="white-space:nowrap">Mir-21</FONT>
License and will own all INDs, NDAs, MAAs and other regulatory filings and Approvals for Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Products, subject to Regulus reversion rights under ARTICLE 10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.2 Reports by Sanofi after Option Exercise.</B> After Sanofi&#146;s exercise of its Option (or at least one of its Options)
for a given POC Program with respect to POC Program Products, and for as long as Sanofi is conducting Sanofi Independent Activities with respect to Other Mir-21 Products, Sanofi will provide a reasonably detailed [&#133;***&#133;] report to Regulus
summarizing Sanofi&#146;s activities over the past [&#133;***&#133;] with respect to such Licensed Compounds and Products and an appropriate number of representatives from each Party will meet at least once every year to review Development
activities. Sanofi will provide to Regulus such additional information regarding such activities as Regulus may reasonably request to allow Regulus to ascertain whether Sanofi is in compliance with its obligations to use Commercially Reasonable
Efforts under Section&nbsp;5.1, and will consider Regulus&#146; input regarding such activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.3 Product Development
Plans; Integrated Product Plans.</B> For each Product that Sanofi is clinically developing under this Agreement, Sanofi will prepare a development plan outlining key aspects of the clinical development of such Product through Approval. Each
development plan will contain information customarily contained in Sanofi&#146;s </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development plans for its similar products at similar stages of development (each a <B><I>&#147;Product Development Plan&#148;</I></B><I>)</I>. In addition, prior to the launch of a Product,
Sanofi will prepare a global integrated Product plan outlining the key aspects of market launch and commercialization (the <B><I>&#147;Integrated Product Plan&#148;</I></B> or <B><I>&#147;IPP&#148;</I></B>). Sanofi will prepare each IPP at the same
time and containing information and target markets as customarily contained in Sanofi&#146;s Commercialization plans for its similar products at similar stages of development. Each Product Development Plan and IPP will be updated annually by Sanofi.
Sanofi will provide to Regulus a copy of the final draft of the Product Development Plans and IPPs (original and updates) for each of the U.S., each Major European Country and Japan, if available. Such copies of Product Development Plans and IPPs
provided to Regulus may be redacted to the extent necessary to preserve the confidentiality of Sanofi confidential information related to products that are not Products. Sanofi and Regulus will meet on a yearly basis to discuss the draft of each
Product Development Plan and IPP and Sanofi will consider, in its sole discretion, any proposals and comments made by Regulus for incorporation in the final Product Development Plan or IPP (as the case may be). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.4 Class Generic Claims.</B> To the extent Sanofi intends to make any claims in a Product label that are class generic to
microRNA Compounds, Sanofi will provide such claims to Regulus in advance and will consider any proposals and comments made by Regulus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL
PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.1 Up-Front Payment.</B> The Parties acknowledge that, in consideration for the licenses and other rights
granted under this Agreement, Sanofi paid to Regulus, prior to the First Restatement Date, an irrevocable, non-creditable and nonrefundable technology access fee equal to $25,000,000 ($[&#133;***&#133;] of which Regulus allocated to the access to
Mir-21 in the detailed amounts set forth on <B>A<SMALL>PPENDIX</SMALL>&nbsp;9</B>, and $[&#133;***&#133;] of which Regulus allocated to the rest of the Research Program in the detailed amounts set forth on <B>A<SMALL>PPENDIX</SMALL>&nbsp;9</B>). The
Parties hereby agree that, as of the First Restatement Date, neither Party shall owe any obligation to the other Party under this Section&nbsp;6.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.2 Research Program Funding.</B> The Parties acknowledge that all Research Program funding payments due Regulus under the
Original Agreement and the First Restated Agreement were made prior to the Second Restatement Date, and the Parties hereby agree that, as of the Second Restatement Date, neither Party shall owe any obligation to the other Party under this
Section&nbsp;6.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.3 No Target Designation Milestone.</B> The Parties acknowledge that, prior to the Second Restatement
Date, no microRNA other than <FONT STYLE="white-space:nowrap">Mir-21</FONT> was designated as a Collaboration Target, and the Parties hereby agree that, as of the Second Restatement Date, neither Party shall owe any obligation to the other Party
under this Section&nbsp;6.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.4 Stock Purchase.</B> In partial consideration for the Options and the performance by
Regulus of the POC Program, on the Second Restatement Date, Sanofi shall </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase from Regulus, and Regulus shall issue and sell to Sanofi, $10&nbsp;million of shares of Regulus&#146; common stock on the terms and conditions set forth in the Stock Purchase Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.5 Option Exercise Fee.</B> On a POC Program-by-POC Program basis, if Sanofi exercises its Option with respect to a POC
Program, then Sanofi shall pay Regulus an irrevocable, <FONT STYLE="white-space:nowrap">non-creditable,</FONT> and <FONT STYLE="white-space:nowrap">non-refundable</FONT> Option exercise payment in the applicable amount for such POC Program set forth
below (the <B><I>&#147;Option Exercise Fee&#148;</I></B>), subject to Section&nbsp;6.6 (to the extent applicable), which Option Exercise Fee must be paid to Regulus prior to expiration of the applicable Option Period: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:49.55pt; font-size:8pt; font-family:Times New Roman"><B>POC Program</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Exercise&nbsp;Fee</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program with respect to which Sanofi exercises its Option (<B><I>&#147;First <FONT
STYLE="white-space:nowrap">Mir-21</FONT> POC Program&#148;</I></B>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program with respect to which Sanofi exercises its Option (<B><I>&#147;Second
<FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program&#148;</I></B>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Mir-221/222</FONT> POC Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.6 Option Exercise Fee Credits.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) Option Letter Credit.</B> Regulus hereby grants to Sanofi a one-time credit in the amount of $1.25&nbsp;million which may be applied
solely to the first Option Exercise Fee payable hereunder, and which is in full satisfaction of Regulus&#146; obligations to Sanofi with respect to the creditable portion of the <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee of
$2.5&nbsp;million paid by Sanofi to Regulus pursuant to the Option Letter; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) Sanofi Program Cost Credit.</B> On a POC
Program-by-POC Program basis, Regulus hereby grants to Sanofi a one-time credit in an amount equal to the reasonable and documented internal and external costs and expenses actually incurred by Sanofi in performing Sanofi Program Activities
completed by Sanofi for a POC Program (<B><I>&#147;Sanofi Program Costs&#148;</I></B>), which credit may be applied solely to the Option Exercise Fee for such POC Program; <I>provided, however,</I> that the aggregate amount of Sanofi Program Costs
that may be credited under this Section&nbsp;6.6(b) against the aggregate Option Exercise Fees for all POC Programs is $[&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(i) Ongoing Sanofi Program Cost Reporting.</B> On a POC Program-by-POC Program basis, within [&#133;***&#133;]&nbsp;days after the end of
each Calendar Quarter during which any Sanofi Program Activities for a POC Program are performed by Sanofi, Sanofi shall provide to Regulus an itemised statement reflecting all Sanofi Program Costs incurred by Sanofi or for its account during such
Calendar Quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(ii) Sanofi Program Credit Amount.</B> On a POC Program-by-POC Program basis, if Sanofi elects to exercise its
Option with respect to a POC Program, Sanofi&#146;s notice of exercise of such Option shall be accompanied by a final report of the total Sanofi Program Costs incurred by Sanofi for such POC Program that Sanofi is entitled to credit against the
Option Exercise Fee for such POC Program pursuant to, and subject to the limitation set forth in, the first paragraph of this Section&nbsp;6.6(b) (the <B><I>&#147;Sanofi Program Credit Amount&#148;</I></B>). </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman"><B>(iii) Audit.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman"><B>(1) Records.</B> On a POC Program-by-POC Program basis until one year after Sanofi&#146;s exercise of its Option with respect to a POC
Program (or, if Sanofi does not exercise its Option with respect to a POC Program, until expiration of the applicable Option Period), Sanofi shall keep complete and accurate records pertaining to Sanofi Program Costs for such POC Program in
sufficient detail to permit Regulus (A)&nbsp;prior to exercise of such Option, to confirm the accuracy of Sanofi&#146;s reports delivered pursuant to Section&nbsp;6.6(b)(i), and (B)&nbsp;after exercise of such Option, to confirm the accuracy of the
Sanofi Program Credit Amount taken by Sanofi against the Option Exercise Fee for such POC Program pursuant to the first paragraph of this Section&nbsp;6.6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman"><B>(2) Sanofi Program Cost Reports.</B> On a POC Program-by-POC Program basis, upon the written request of Regulus and not more than once in
each Calendar Year during the applicable POC Program Term for a POC Program (but prior to Sanofi&#146;s delivery of notice of exercise of its Option for such POC Program), Sanofi will permit an independent certified public accounting firm of
nationally recognized standing selected by Regulus and reasonably acceptable to Sanofi, at Regulus&#146; expense, to have access during normal business hours to such records of Sanofi as may be reasonably necessary to verify the accuracy of
Sanofi&#146;s reports delivered pursuant to Section&nbsp;6.6(b)(i). Regulus will provide Sanofi with a copy of the accounting firm&#146;s written report within 30&nbsp;days of completion of such report. These audit rights will terminate upon
Sanofi&#146;s delivery of notice of exercise of its Option for such POC Program, whereupon Regulus shall have the audit rights set forth in Section 6.6(b)(iii)(3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman"><B>(3) Sanofi Program Credit Amount.</B> On a POC Program-by-POC Program basis, upon the written request of Regulus not more than once after
Sanofi&#146;s delivery of notice of exercise of its Option for such POC Program, Sanofi will permit an independent certified public accounting firm of nationally recognized standing selected by Regulus and reasonably acceptable to Sanofi, at
Regulus&#146; expense, to have access during normal business hours to such records of Sanofi as may be reasonably necessary to verify the accuracy of the Sanofi Program Credit Amount taken by Sanofi against the Option Exercise Fee for such POC
Program. These audit rights will terminate on the first anniversary of Sanofi&#146;s delivery of notice of exercise of its Option for such POC Program. Regulus will provide Sanofi with a copy of the accounting firm&#146;s written report within
[&#133;***&#133;]&nbsp;days of completion of such report. If such accounting firm concludes that the amount credited by Sanofi against such Option Exercise Fee was higher or lower than the actual Sanofi Program Costs that Sanofi was entitled to
credit against such Option Exercise Fee in accordance with the first paragraph of this Section&nbsp;6.6(b), then the owing Party will pay the amount due within 30&nbsp;days of the date Regulus delivers to Sanofi such accounting firm&#146;s written
report so concluding. Regulus will bear the full cost of such audit unless such audit discloses that the amount credited by Sanofi against such Option Exercise Fee was equal to or greater than [&#133;***&#133;]% of the actual Sanofi Program Costs
that Sanofi was entitled to credit against such Option Exercise Fee in accordance with the first paragraph of this Section&nbsp;6.6(b), in which case Sanofi will pay the reasonable fees and expenses charged by the accounting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman"><B>(4) Confidentiality.</B> All financial information subject to review under this Section&nbsp;6.6(b) will be the Confidential Information
of Sanofi hereunder and </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be treated in accordance with the confidentiality provisions of this Agreement. As a condition precedent to Regulus&#146; audit rights under this Section&nbsp;6.6(b)(iii), Regulus&#146;
accounting firm will enter into a confidentiality agreement with Sanofi obligating it to treat all such financial information in confidence pursuant to such confidentiality agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.7 POC Program Costs.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.7.1 Ongoing POC Program Cost Reporting.</B> On a POC Program Plan-by-POC Program Plan basis, within [&#133;***&#133;]&nbsp;days after the
end of each Calendar Quarter during which any POC Program activities are performed, Regulus shall provide to Sanofi an itemised statement reflecting all POC Program Costs incurred by Regulus or for its account during such Calendar Quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.7.2 POC Program Cost Reimbursement.</B> On a POC Program-by-POC Program basis, within [&#133;***&#133;]&nbsp;days after Achievement of
Proof of Concept for a POC Program (or, if earlier, within [&#133;***&#133;]&nbsp;days after Sanofi&#146;s written request in the event that Sanofi wishes to exercise its Option for such POC Program at any time prior to Achievement of Proof of
Concept), Regulus shall deliver to Sanofi a written invoice for an amount equal to [&#133;***&#133;]% of Regulus&#146; POC Program Costs for such POC Program (the <B><I>&#147;POC Program Reimbursement Amount&#148;</I></B>). If Sanofi does exercise
its Option with respect to such POC Program, Sanofi shall pay Regulus the applicable POC Program Reimbursement Amount, which POC Program Reimbursement Amount must be paid to Regulus prior to expiration of the applicable Option Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.7.3 Audit.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) Records.</B> On a POC Program-by-POC Program basis until one year after Sanofi&#146;s exercise of its Option with respect to a POC
Program (or, if Sanofi does not exercise its Option with respect to a POC Program, until one year after expiration of the applicable Option Period), Regulus shall keep complete and accurate records pertaining to POC Program Costs for such POC
Program in sufficient detail to permit Sanofi (i)&nbsp;prior to exercise of such Option, to confirm the accuracy of Regulus&#146; reports delivered pursuant to Section&nbsp;6.7.1, and (ii)&nbsp;after exercise of such Option, to confirm the accuracy
of the POC Program Reimbursement Amount invoiced by Regulus pursuant to Section&nbsp;6.7.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) POC Program Cost Reports.</B> On a
POC Program-by-POC Program basis, upon the written request of Sanofi and not more than once in each Calendar Year during the applicable POC Program Term for a POC Program (but prior to Sanofi&#146;s delivery of notice of exercise of its Option for
such POC Program), Regulus will permit an independent certified public accounting firm of nationally recognized standing selected by Sanofi and reasonably acceptable to Regulus, at Sanofi&#146;s expense, to have access during normal business hours
to such records of Regulus as may be reasonably necessary to verify the accuracy of Regulus&#146; reports delivered pursuant to Section&nbsp;6.7.1. Sanofi will provide Regulus with a copy of the accounting firm&#146;s written report within
[&#133;***&#133;]&nbsp;days of completion of such report. These audit rights will terminate upon Sanofi&#146;s delivery of notice of exercise of its Option for such POC Program, whereupon Sanofi shall have the audit rights set forth in
Section&nbsp;6.7.3(c). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) POC Program Reimbursement Amount.</B> On a POC Program-by-POC Program basis, upon the
written request of Sanofi not more than once after Sanofi&#146;s delivery of notice of exercise of its Option for such POC Program, Regulus will permit an independent certified public accounting firm of nationally recognized standing selected by
Sanofi and reasonably acceptable to Regulus, at Sanofi&#146;s expense, to have access during normal business hours to such records of Regulus as may be reasonably necessary to verify the accuracy of the POC Program Reimbursement Amount invoiced by
Regulus pursuant to Section&nbsp;6.7.2. These audit rights will terminate on the first anniversary of Sanofi&#146;s delivery of notice of exercise of its Option for such POC Program. Sanofi will provide Regulus with a copy of the accounting
firm&#146;s written report within 30&nbsp;days of completion of such report. If such accounting firm concludes that the POC Program Reimbursement Amount invoiced by Regulus was higher or lower than [&#133;***&#133;]% of Regulus&#146; POC Program
Costs for such POC Program, then the owing Party will pay the amount due within [&#133;***&#133;]&nbsp;days of the date Sanofi delivers to Regulus such accounting firm&#146;s written report so concluding. Sanofi will bear the full cost of such audit
unless such audit discloses that the POC Program Reimbursement Amount invoiced by Regulus was equal to or greater than [&#133;***&#133;]% of Regulus&#146; POC Program Costs for such POC Program, in which case Regulus will pay the reasonable fees and
expenses charged by the accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d) Confidentiality.</B> All financial information subject to review under this
Section&nbsp;6.7.3 will be the Confidential Information of Regulus hereunder and will be treated in accordance with the confidentiality provisions of this Agreement. As a condition precedent to Sanofi&#146;s audit rights under this
Section&nbsp;6.7.3, Sanofi&#146;s accounting firm will enter into a confidentiality agreement with Regulus obligating it to treat all such financial information in confidence pursuant to such confidentiality agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.8 Milestone Payments by Sanofi.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.8.1 <FONT STYLE="white-space:nowrap">Mir-21.</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) Mir-21 POC Program Products.</B> Sanofi will give Regulus written notice of the first achievement (by Sanofi, its sublicensees or
their respective Affiliates) of each of the milestone events set forth below for the first <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product to achieve such milestone event within [&#133;***&#133;] after such achievement. After
receiving such written notice of the achievement of any such milestone event, Regulus shall submit an invoice to Sanofi for the amount of the milestone payment corresponding to the applicable milestone event set forth below, and Sanofi will pay
Regulus such milestone payment amount within [&#133;***&#133;]&nbsp;days after receipt of such invoice. Subject to Section&nbsp;6.8.2, each of the milestone payments set forth below in this Section&nbsp;6.8.1 shall be payable only one time, and only
for the first <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product to achieve the applicable milestone event (whether or not such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product is the same <FONT
STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product that achieved any preceding milestone event, except in the case of the second Approval milestone event below, which may only be achieved by a <FONT STYLE="white-space:nowrap">Mir-21</FONT>
POC Program Product other than the <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product that achieved the First <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product Approval. Any
<FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product that contains more than one <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound will be counted as a single <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product. If
the first POC Program Product to achieve NDA Filing or Approval contains both a <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound and a <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Compound, such POC Program Product shall be considered
a <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product for purposes of this Section&nbsp;6.8.1 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(and not a <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product for purposes of Section&nbsp;6.8.2), and only the milestone payment corresponding to such milestone event under this
Section&nbsp;6.8.1 shall be payable with respect to achievement of such milestone by such POC Program Product. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, after the first achievement of milestone event&nbsp;4 in the table above, if a
<FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product (whether the same or a different <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product that first achieved milestone&nbsp;2, 3 and/or 4 in the table above) subsequently
achieves milestone event&nbsp;2 and/or 3 for any Indication(s) other than the Indication(s) for which a <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product previously achieved milestone event&nbsp;2, 3 and/or 4 (each, an
<B><I>&#147;Additional <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product Indication&#148;</I></B>), then Sanofi will promptly notify Regulus and will pay Regulus an additional milestone payment in an amount equal to
[&#133;***&#133;]% of the applicable milestone payment(s) set forth in the table above for the achievement of milestone event 2 and/or 3 in the table above by such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product for each
Additional <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product Indication. For clarity, the milestone payment corresponding to milestone event&nbsp;4 in the table above shall be payable one time only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Products.</B> Sanofi will give Regulus written notice of the first achievement
(by Sanofi, its sublicensees or their respective Affiliates) of each of the milestone events set forth below for the first Mir-21 Product that is not a <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product (an <B><I>&#147;Other Mir-21
Product&#148;</I></B>) to achieve such milestone event within [&#133;***&#133;] after such achievement. After receiving such written notice of the achievement of any such milestone event, Regulus shall submit an invoice to Sanofi for the amount of
the milestone payment corresponding to the applicable milestone event set forth below, and Sanofi will pay Regulus such milestone payment amount within [&#133;***&#133;]&nbsp;days after receipt of such invoice. Except as expressly set forth in the
last paragraph of this Section&nbsp;6.8.1(b) with respect to milestone events&nbsp;5 and 6, each of the milestone payments set forth below in this Section&nbsp;6.8.1(b) shall be payable only one time, and only for the first Other <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Product to achieve the applicable milestone event (whether or not such Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product is the same Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product
that achieved any preceding milestone event). </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6. [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B>In addition, after the first achievement of milestone event 5 and/or 6 in the table above by the first Other <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Product for any Indication, if an Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product (whether the same or a different Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product) subsequently
achieves such milestone event(s) for any additional Indication(s) (each, an <B><I>&#147;Additional Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Indication&#148;</I></B>), then Sanofi will promptly notify Regulus and will pay Regulus an
additional milestone payment in an amount equal to [&#133;***&#133;]% of the applicable milestone payment(s) set forth in the table above for the achievement of milestone event 5 and/or 6 in the table above by such Other <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Product for each Additional Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Indication.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.8.2 <FONT STYLE="white-space:nowrap">Mir-221/222.</FONT></B> Sanofi will give Regulus written notice of the first achievement (by Sanofi,
its sublicensees or their respective Affiliates) of each of the milestone events set forth below for the first <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product to achieve such milestone event within [&#133;***&#133;] after such
achievement. After receiving such written notice of the achievement of any such milestone event, Regulus shall submit an invoice to Sanofi for the amount of the milestone payment corresponding to the applicable milestone event set forth below, and
Sanofi will pay Regulus such milestone payment amount within [&#133;***&#133;]&nbsp;days after receipt of such invoice. Each of the milestone payments set forth below in this Section&nbsp;6.8.1(b) shall be payable only one time, and only for the
first <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product to achieve the applicable milestone event (whether or not such <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product is the same
<FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product that achieved the preceding milestone event). Any <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product that contains more than one <FONT STYLE="white-space:nowrap">Mir-221/222</FONT>
Compound will be counted as a single <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.8.3 Sales Milestones.</B> Each of the milestone payments set forth below will be payable by
Sanofi to Regulus for the first achievement of the specified milestone events by Sanofi, its sublicensees or their Affiliates for (i)&nbsp;the first Mir-21 Product to achieve the specified milestone event; and (ii)&nbsp;the first Mir-221/222 Product
to achieve the specified milestone event. If the first POC Program Product to achieve an annual Net Sales milestone event set forth below contains both a <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound and a
<FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Compound, the milestone payment corresponding to such milestone event below shall be payable only one time with respect to achievement of such milestone by such POC Program Product, and such
milestone payment would only be paid a second time if the corresponding milestone event is subsequently achieved by a <I><U>different</U></I> POC Program Product (whether such POC Program Product is a <FONT STYLE="white-space:nowrap">Mir-21</FONT>
POC Program Product, a <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product, or a combination thereof). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1. Annual Net Sales [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2. Annual Net Sales [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.9 Royalty Payments by Sanofi.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.9.1 U.S. Net Sales.</B> Subject to the other provisions of this Agreement, during the Royalty Term, Sanofi will pay to Regulus royalties
on Net Sales of each POC Program Product in the U.S., including its territories and possessions (<B><I>&#147;U.S.&nbsp;Net Sales&#148;</I></B>) at the rate of [&#133;***&#133;]%. On a POC Program Product-by- POC Program Product basis, in the case of
any POC Program Product with respect to which Regulus exercises its Co-Promote Option, Regulus may, in its sole discretion, elect to receive [&#133;***&#133;]% of U.S. Profits (as defined in <B>A<SMALL>PPENDIX</SMALL>&nbsp;11</B>) for such POC
Program Product in lieu of royalties under this Section&nbsp;6.9.1; <I>provided, however,</I> that, unless Regulus&#146; notice of exercise of such Co-Promote Option expressly states that Regulus elects to receive [&#133;***&#133;]% of U.S. Profits
in lieu of royalties under this Section&nbsp;6.9.1, Sanofi will pay royalties to Regulus on U.S. Net Sales of such POC Program Product in accordance with this Section&nbsp;6.9.1, and <B>A<SMALL>PPENDIX</SMALL>&nbsp;11</B> shall not apply to such POC
Program Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.9.2 Ex-U.S. Net Sales.</B> Subject to the other provisions of this Agreement, during the Royalty Term, Sanofi will
pay to Regulus royalties on worldwide Net Sales of each POC Program Product other than U.S.&nbsp;Net Sales of such Product (<B><FONT STYLE="white-space:nowrap">&#147;Ex-U.S.&nbsp;Net</FONT> Sales&#148;</B>) at the applicable rate(s) set forth below
based on the level of <FONT STYLE="white-space:nowrap">Ex-U.S.</FONT> Net Sales of such POC Program Product in a given Calendar Year period by Sanofi, its Affiliates and sublicensees, with the royalty rate tiered based upon the level of such <FONT
STYLE="white-space:nowrap">Ex-U.S.</FONT> Net Sales in such Calendar Year period of such Product as set forth in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:88.90pt; font-size:8pt; font-family:Times New Roman"><B>Annual Ex.-U.S. Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion of Ex-U.S. Net Sales that is [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion of Ex-U.S. Net Sales that is [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, in the instance of a full Calendar Year, if annual Ex-U.S. Net Sales of a POC Program Product in such Calendar
Year worldwide are $[&#133;***&#133;], the royalty due will be </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$[&#133;***&#133;] ([&#133;***&#133;]% of the first $[&#133;***&#133;] in the first increment, plus [&#133;***&#133;]% of the next $[&#133;***&#133;] in the second increment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.9.3 Other Mir-21 Products. </B>Subject to the other provisions of this Agreement, during the Royalty Term, Sanofi will pay to Regulus
royalties on Net Sales of each Other Mir-21 Product at the applicable rate(s) set forth in the table below. The royalty rate payable with respect to each particular Other Mir-21 Product will be based on the level of annual worldwide Net Sales of
such Other Mir-21 Product in a given Calendar Year period by Sanofi, its Affiliates and sublicensees, with the royalty rate tiered based upon the level of such worldwide Net Sales in such Calendar Year period of such Other Mir-21 Product as set
forth in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:98.85pt; font-size:8pt; font-family:Times New Roman"><B>Annual Worldwide Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion that is [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion that is [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">For the portion that is [&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, in the instance of a full Calendar Year, if annual worldwide Net Sales of an Other Mir-21 Product in such
Calendar Year worldwide are $[&#133;***&#133;], the royalty due will be $[&#133;***&#133;] in the first increment, plus [&#133;***&#133;]% of the next $[&#133;***&#133;] in the second increment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.10 Existing Third Party Payment Obligations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.10.1 Existing Regulus Agreements.</B> Sanofi acknowledges that certain of the Regulus Technology Controlled by Regulus as of the
Effective Date were in-licensed, or otherwise acquired by Regulus, from Third Parties under the Existing Regulus Agreements, and that Regulus is obligated to pay In-License Royalties and/or In-License Milestones to the Licensor(s) under such
Existing Regulus Agreements as a result of the Development or Commercialization of Products by Sanofi or any of its Affiliates or sublicensees to the extent that such Products are covered by the applicable Third Party Patents. The Parties
acknowledge and agree that Regulus will be responsible for paying [&#133;***&#133;]% of the In-License Royalties, In-License Milestones and Other In-License Payments that become due to the Licensor(s) under the Existing Regulus Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.10.2 Existing Sanofi Agreements.</B> The Parties acknowledge and agree that, if and to the extent that there are any Existing Sanofi
Agreements, Sanofi will be responsible for paying [&#133;***&#133;]% of the In-License Royalties, In-License Milestones and Other In-License Payments that become due to the Licensor(s) under such Existing Sanofi Agreements, and [&#133;***&#133;] of
such payments will be creditable against any payment due to Regulus hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.11 Future Third Party Agreements.</B>
<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.11.1 Identification of Necessary Patents.</B> Subject to Section&nbsp;6.11.5, if, after the Effective Date, a Party
identifies any Patent that: </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>is not Controlled by either Party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>covers (i)&nbsp;the [&#133;***&#133;](each, a <B><I>&#147;[</I></B>&#133;***&#133;<B><I>] Invention&#148;</I></B>), (ii)&nbsp;the
[&#133;***&#133;] (each, a <B><I>&#147;[</I></B>&#133;***&#133;<B><I>] Invention&#148;</I></B>), (iii)&nbsp;a [&#133;***&#133;] (each, a <B><I>&#147;[</I></B>&#133;***&#133;<B><I>] Invention&#148;</I></B>), or (iv)&nbsp;[&#133;***&#133;] that is
necessary to [&#133;***&#133;] to the [&#133;***&#133;] in order to [&#133;***&#133;], excluding [&#133;***&#133;] (each, a <B><I>&#147;[</I></B>&#133;***&#133;<B><I>] Invention&#148;</I></B>); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>such Party believes in good faith is, or is likely to be, necessary for the Development or Commercialization of a Product; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, such Party will inform the other Party thereof, and the Parties (via the JSC for so long as the JSC is in place) shall promptly confer with each other,
and attempt in good faith to reach consensus regarding, as to whether in-licensing or acquiring other rights to such Patent is, or is likely to be, necessary for the Development or Commercialization of a Product. [&#133;***&#133;] with respect to
either or both Parties. The [&#133;***&#133;], as well as [&#133;***&#133;]. The Parties will initially [&#133;***&#133;] the [&#133;***&#133;], provided that promptly after the [&#133;***&#133;], the Party whose [&#133;***&#133;] the other Party an
[&#133;***&#133;] of the [&#133;***&#133;] (such that the [&#133;***&#133;] the other Party), and each Party [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
[&#133;***&#133;] the Party that [&#133;***&#133;], then such Party shall be [&#133;***&#133;], provided that (1)&nbsp;such Party shall be responsible for [&#133;***&#133;] of the [&#133;***&#133;], (2)&nbsp;if such Party is Sanofi, none of such
payments will be creditable against any payment due to Regulus hereunder, and (3)&nbsp;if such Party is Regulus, then notwithstanding any other provision of this Agreement to the contrary, such [&#133;***&#133;]. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.11.2 Responsible Party.</B> If the Parties mutually agree, or [&#133;***&#133;], that
in-licensing or acquiring other rights to a Patent meeting the criteria set forth in Section&nbsp;6.11.1 is necessary for the Development or Commercialization of a Product (each, a <B><I>&#147;Necessary Patent&#148;</I></B>), the Party that will be
responsible for in-licensing or acquiring other rights to such Necessary Patent (the <B><I>&#147;Responsible Party&#148;</I></B>) will be determined based on whether such Necessary Patent covers a Target Invention, a Compound Invention, a Method
Invention, or a Formulation Invention, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Mir-21</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U><FONT
STYLE="white-space:nowrap">Mir-221/222</FONT></U>: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any agreement entered into by a Responsible Party pursuant to this Section&nbsp;6.11.2 shall be deemed a <B></B><B><I>&#147;Future Regulus
Agreement&#148;</I></B><B></B> if Regulus is the Responsible Party, and a <B><I>&#147;Future Sanofi Agreement&#148;</I></B> if Sanofi is the Responsible Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.11.3 Consultation; Cooperation.</B> The Responsible Party will consult with the other Party and consider in good faith the reasonable
comments and suggestions of the other Party regarding the financial terms of any Future Regulus Agreement or Future Sanofi Agreement (as applicable), and in negotiating such Future Regulus Agreement or Future Sanofi Agreement with the applicable
Licensor(s) shall use commercially reasonable efforts to minimize any In-License Royalties, In-License Milestones and Other In-License Payments that (a)&nbsp;are to be borne, in whole or in part, by the other Party pursuant to Section&nbsp;6.12,
(b)&nbsp;are creditable against any amounts payable to Regulus hereunder in accordance with Section&nbsp;6.14.1 or Section&nbsp;6.14.4, and/or (c)&nbsp;in the case of In-License Royalties, are to be considered in [&#133;***&#133;]. Except as set
forth in Section&nbsp;6.11.2 or Section&nbsp;6.13, Regulus will not enter any Future Regulus Agreement that would impose any additional financial </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations on Sanofi beyond those set forth in this Agreement without first obtaining Sanofi&#146;s prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.11.4 Copy of Agreement.</B> Upon entering into any Future Regulus Agreement or Future Sanofi Agreement that includes In-License
Royalties, In-License Milestones and/or Other In-License Payments that (a)&nbsp;are to be borne, in whole or in part, by the other Party pursuant to Section&nbsp;6.12, (b)&nbsp;where Sanofi is the Responsible Party, are creditable against any
amounts payable to Regulus hereunder in accordance with Section&nbsp;6.14.1 or Section&nbsp;6.14.4, and/or (c)&nbsp;in the case of In-License Royalties, are to be considered [&#133;***&#133;], the Responsible Party shall provide to the other Party a
copy of the portion of such agreement which sets forth the relevant In-License Royalties, In-License Milestones and/or Other In-License Payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.11.5 Sanofi Sole Responsibility for [</B>&#133;***&#133;<B>] and [</B>&#133;***&#133;<B>].</B> In the event that after the Effective
Date, Sanofi identifies any Patent not Controlled by either Party that covers any [&#133;***&#133;] that Sanofi determines, in its sole discretion, to be necessary for the Development or Commercialization of a Product, Sanofi shall have the sole
responsibility for in-licensing or acquiring other rights to such Patent, including sole responsibility for negotiation and execution of a license or other agreement with respect thereto. Sanofi will be solely responsible for paying 100% of the
In-License Royalties, In-License Milestones and Other In-License Payments that become due to the Licensor(s) under such agreement, and no such payments, nor any portion thereof, will be creditable against any of Sanofi&#146;s payment obligations to
Regulus under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.12 Allocation of Payments. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.12.1 In-License Royalties.</B> In-License Royalties payable to Licensors under any Future Regulus Agreement or Future Sanofi Agreement
shall be allocated between the Parties based on (a)&nbsp;whether the applicable Third Party Patents cover a Target Invention, a Compound Invention, a Method Invention, or a Formulation Invention, (b)&nbsp;the identity of the Licensor(s), and/or
(c)&nbsp;Indication, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Mir-21</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U><FONT STYLE="white-space:nowrap">Mir-221/222</FONT></U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.12.2
In-License Milestones.</B> In-License Milestones payable to Licensors under any Future Regulus Agreement or Future Sanofi Agreement shall be allocated between the Parties based on (a)&nbsp;whether the applicable Third Party Patents cover a Target
Invention, a Compound Invention, a Method Invention, or a Formulation Invention, (b)&nbsp;the identity of the Licensor(s), and/or (c)&nbsp;Indication, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Mir-21</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Mir-221/222</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.12.3
Other In-License Payments.</B> Other In-License Payments payable to Licensors under any Future Regulus Agreement or Future Sanofi Agreement shall be allocated between the Parties, or among the Parties and one or more Third Parties (as applicable)
based on </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(a)&nbsp;whether the applicable Third Party Patents cover a Target Invention, a Compound Invention, a Method Invention, or a Formulation Invention, (b)&nbsp;the identity of the Licensor(s),
(c)&nbsp;Indication, and/or (d)&nbsp;whether the applicable Third Party Patents are licensed to any Third Party(ies) as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Mir-21</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U><FONT
STYLE="white-space:nowrap">Mir-221/222</FONT></U>: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.12.4 Payment Process.</B> Sanofi will directly pay to Regulus any amounts payable under a Future Regulus In-License in connection with a
Product to the extent such amounts are allocated to Sanofi under this Section&nbsp;6.12. Sanofi will pay directly the applicable Third Party any amounts payable under a Future Sanofi In-License in connection with a Product; <I>provided</I>, to the
extent any royalty payments are allocated to Regulus under this Section&nbsp;6.12, Sanofi will be entitled to the royalty reduction as further set forth in Section&nbsp;6.14.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.13 New Core Technology.</B> After the Effective Date, Regulus may wish to in-license or acquire rights to Patents from a
Third Party, which Patents, if in-licensed or acquired, would be within the scope of the definition of [&#133;***&#133;] Patent (<B><I>&#147;New Core Patents&#148;</I></B>), with or without associated Know-How. In such event, Regulus shall
[&#133;***&#133;] </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] Sanofi&#146;s consent, to negotiate and enter into an in-license or other agreement with the
Third Party with respect to such New Core Patents and related Know-How, if any (collectively, <B><I>&#147;New Core Technology&#148;</I></B>). In such event (and to the extent permitted by Regulus&#146; confidentiality agreement with the applicable
Third Party), Regulus will notify Sanofi regarding the nature of the [&#133;***&#133;] Technology and status of negotiations related to the New Core Technology through the JSC. Once Regulus and such Third Party have executed an agreement with
respect to such New Core Technology (<B><I>&#147;New Core Technology Agreement&#148;</I></B>), Regulus will offer such New Core Technology to Sanofi (including a description of the upfront and other ongoing non-royalty, non-milestone payments and,
except as set forth in Section&nbsp;6.13.2(b), the royalties and milestone payments paid or potentially payable by Regulus thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.13.1 </B>In the case of any such New Core Technology comprising a Target Invention, Compound Invention, Method Invention or Formulation
Invention or patent rights claiming any of the foregoing (in each case, <B><I>&#147;Section&nbsp;6.9.1 Technology&#148;</I></B>), if Sanofi wishes to include such Section&nbsp;6.9.1 Technology in the Regulus Technology licensed to Sanofi under
Section&nbsp;2.1, Sanofi will notify Regulus of its desire to do so within [&#133;***&#133;]&nbsp;days after receipt of notice from Regulus, whereupon such Section&nbsp;6.9.1 Technology shall be included in the Regulus Technology licensed to Sanofi
under Section&nbsp;2.1, and the upfront, royalty, milestone and other ongoing payments paid or potentially payable by Regulus under such New Core Technology Agreement shall be [&#133;***&#133;] in accordance with [&#133;***&#133;], <I>mutatis
mutandis</I>. If Sanofi [&#133;***&#133;] such notification to Regulus within such [&#133;***&#133;]-day period, then notwithstanding any other provision of this Agreement to the contrary, the applicable Section&nbsp;6.9.1 Technology will
[&#133;***&#133;] the Regulus Technology licensed to Sanofi under Section&nbsp;2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.13.2 </B>In the case of any New Core Technology
other than Section&nbsp;6.9.1 Technology (<B><I>&#147;Section&nbsp;6.9.2 Technology&#148;</I></B>), if Sanofi wishes to include such Section&nbsp;6.9.2 Technology in the Regulus Technology licensed to Sanofi under Section&nbsp;2.1, Sanofi will
notify Regulus of its desire to do so within [&#133;***&#133;]&nbsp;days after receipt of notice from Regulus, whereupon the Parties will negotiate in good faith regarding: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>a fair and commercially reasonable [&#133;***&#133;] (and/or among the Parties and any Regulus Third Party sublicensee(s) of such
Section&nbsp;6.9.2 Technology) of upfront and other ongoing <FONT STYLE="white-space:nowrap">non-royalty,</FONT> <FONT STYLE="white-space:nowrap">non-milestone</FONT> payment obligations (which [&#133;***&#133;] of such payment obligations). As part
of this [&#133;***&#133;], Regulus will share with Sanofi, in reasonable detail, the assumptions and methodology Regulus used to create the [&#133;***&#133;]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>the royalties and milestone payments to be [&#133;***&#133;] with respect to Licensed Compounds and Products, the Development,
manufacture or Commercialization of which is within the scope of Regulus&#146; in-license or other rights to the applicable Section&nbsp;6.9.2 Technology. For the avoidance of doubt, Regulus will [&#133;***&#133;] to Sanofi the nature or amount of
any of Regulus&#146; royalty and milestone payment obligations to such Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Parties mutually agree in writing to the
[&#133;***&#133;] in Section&nbsp;6.13.2(a) and the royalties and milestone payments to be [&#133;***&#133;] as described in </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;6.13.2(b), then the applicable Section&nbsp;6.9.2 Technology will be included in the Regulus Technology licensed to Sanofi under Section 2.1. If the Parties [&#133;***&#133;] to the
foregoing, then notwithstanding any other provision of this Agreement to the contrary, the applicable Section&nbsp;6.9.2 Technology will [&#133;***&#133;] the Regulus Technology licensed to Sanofi under Section 2.1. For purposes of clarification,
any payment obligations [&#133;***&#133;] under this Section&nbsp;6.13.2 will be in addition to, and will not be creditable in whole or in part against, Sanofi&#146;s payment obligations set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.13.3 </B>In the event of a dispute between the Parties as to whether a particular Patent of a Third Party constitutes a New Core Patent,
or whether any particular New Core Technology constitutes Section&nbsp;6.9.1 Technology or Section&nbsp;6.9.2 Technology, such dispute shall be referred to an Intellectual Property Panel for resolution in accordance with the provisions of
Section&nbsp;6.11.1, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.14 Royalty Reductions; [</B>&#133;***&#133;<B>] Royalty. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.14.1 Reduction for Third Party Royalties.</B> Subject to Section&nbsp;6.14.3, Sanofi&#146;s royalty obligations under Section&nbsp;6.9
above with respect to a particular Product in a particular country will be reduced by the applicable percentage (if any) of the amount of aggregate In-License Royalties paid by Sanofi to Licensor(s) under Future Sanofi-Agreements on sales of such
Product in such country for which Regulus is responsible, as set forth in Section&nbsp;6.12; <I>provided, however</I>, that the application of any such reduction shall not reduce the royalties payable by Sanofi under this Agreement with respect to
such Product in such country for any given Calendar Quarter below the greater of (i)&nbsp;50% of the applicable royalty rates stated in Section&nbsp;6.9; [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.14.2 Generic Competition.</B> Subject to Section&nbsp;6.14.3, if a Generic Product corresponding to a Product is approved for sale by the
applicable Regulatory Authority and then sold in a particular country and the Percentage Reduction of Net Sales is greater than [&#133;***&#133;]% for any given Calendar Quarter in such country, then the royalty rate applicable to such Product and
such country under Section&nbsp;6.9 for such Calendar Quarter will be reduced to [&#133;***&#133;]%; [&#133;***&#133;]. As used herein, the <B><I>&#147;Percentage Reduction of Net Sales&#148;</I></B> of a Product in a country for any particular
Calendar Quarter means the quotient (expressed as a percentage) obtained by dividing (A)&nbsp;the difference obtained by subtracting the [&#133;***&#133;] such applicable Calendar Quarter from the [&#133;***&#133;] by (B)&nbsp;the [&#133;***&#133;].
For clarity, this Section&nbsp;6.14.2 will operate and will be applied on a Calendar Quarter-by-Calendar Quarter Basis such that, for example, in the first Calendar Quarter in a year the royalty rate set forth in Section&nbsp;6.9 applicable to a
particular Product and particular country for such Calendar Quarter may be reduced to [&#133;***&#133;]%; but, in the second Calendar Quarter in such year the full royalty rate set forth in Section&nbsp;6.9 will be </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable to a particular Product if the [&#133;***&#133;]% in such country for such second Calendar Quarter. In addition, if (i)&nbsp;there [&#133;***&#133;] Generic Product sold by a Third
Party, and (ii)&nbsp;[&#133;***&#133;], then such Generic Product will [&#133;***&#133;] the royalty reduction under this Section&nbsp;6.14.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.14.3 [</B>&#133;***&#133;<B>] Royalties.</B> Notwithstanding any other provision of this Agreement to the contrary (including, without
limitation, Sections&nbsp;6.14.1 and 6.14.2), in no event shall the royalties payable by Sanofi to Regulus with respect to Net Sales of a particular Product in a particular country for any Calendar Quarter [&#133;***&#133;] the sum of:
(a)&nbsp;[&#133;***&#133;], and (b)&nbsp;[&#133;***&#133;] ([&#133;***&#133;]<B><I> Royalties&#148;</I></B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.14.4 Credit for Excess
Royalties Paid by Sanofi.</B> If Sanofi&#146;s obligation to pay [&#133;***&#133;] Royalties with respect to a Product in a country under Section&nbsp;6.14.3 is triggered and, as a result, the sum of all royalties Sanofi pays to Regulus on sales of
such Product in such country (the <B><I>&#147;Supported Amount&#148;</I></B>) exceeds the amount of royalties Sanofi would, but for the operation of Section&nbsp;6.14.3, otherwise be responsible under this ARTICLE 6 in connection with sales of such
Product in such country (the <B><I>&#147;Base Amount&#148;</I></B>), then Sanofi shall be entitled to credit such excess amount (<I>i.e.</I>, the Supported Amount <I>minus</I> the Base Amount) against any future sales milestone payment payable by
Sanofi to Regulus under Section&nbsp;6.8.3, regardless of which Product triggers such sales milestone payment obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.14.5 No
Payments to Sanofi.</B> For purposes of clarification, and notwithstanding any other provision of this Agreement, in no event shall the credits to which Sanofi may be entitled under this Section&nbsp;6.14 result in Regulus being obligated to make
any payment to Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.15 Royalty Term.</B> Royalties payable under Section&nbsp;6.9 (subject to and including any
applicable reductions under Section&nbsp;6.14) will be payable on a Product-by-Product and country-by-country basis from the First Commercial Sale of a Product in a country until the date that is the later of (i)&nbsp;10&nbsp;years after the First
Commercial Sale of such Product in such country or (ii)&nbsp;the expiration of the last to expire Valid Claim within the Regulus Patents which would be infringed by the sale of such Product in such country by an unauthorized party. Such period
during which royalties are payable with respect to a Product in a country, including giving effect to any applicable reductions under Section&nbsp;6.14, is referred to herein as the <B><I>&#147;Royalty Term&#148;</I></B> for such Product in such
country. Notwithstanding expiration of the Royalty Term with respect to a particular Product in a country, Sanofi will continue to pay to Regulus all royalties payable by Regulus to Licensor(s) under the Existing Regulus Agreements with respect to
Net Sales of such Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.16 Royalty Report and Payment.</B> During the Royalty Term following the
First Commercial Sale of any Product, within [&#133;***&#133;]&nbsp;days after the end of each Calendar Quarter, </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sanofi will provide Regulus with a royalty report for such Quarter showing, on a Product-by-Product and country-by-country basis: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>the Net Sales of Products sold by Sanofi, its sublicensees and their respective Affiliates during such Calendar Quarter reporting
period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>the royalties which will have accrued hereunder with respect to such Net Sales; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>the amount of any applicable credits taken against royalties under Section&nbsp;6.14.1 and the amount of any applicable credits
accrued against future sales milestone payments under Section&nbsp;6.14.4; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>any adjustment for Generic Products under
Section&nbsp;6.14.2; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>any other information related to the calculation of Net Sales of Products reasonably requested by
Regulus that (i)&nbsp;is contained in a report and format that is regularly generated by Sanofi&#146;s accounting department in its normal course of business and (ii)&nbsp;is reasonably necessary for Regulus to comply with an Existing Regulus
Agreement or an Additional Regulus Third Party Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sanofi will keep, and will require its sublicensees and their respective
Affiliates to keep, complete, true and accurate books of account and records for the purpose of determining the payments to be made under this Agreement. Upon reasonable request by Regulus (but no more frequently than once in any
[&#133;***&#133;]-month period), Sanofi will report to Regulus the quantity of Product not subject to royalties distributed by Sanofi, its Affiliates or sublicensees as part of an expanded access program to include compassionate use, named patients
or other similar use or as part of Phase&nbsp;4 Trials or as bona fide samples. All information disclosed by Sanofi to Regulus under this Section&nbsp;6.16 will be Sanofi Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.17 Manner of Payment and Exchange Rate.</B> Except as otherwise provided in this Agreement, Regulus shall invoice Sanofi for
all milestone, royalty and other payments hereunder and Sanofi shall pay all such milestone, royalty and other payments that are due within thirty (30)&nbsp;days after the receipt of the applicable invoice. All payments to be made by Sanofi to
Regulus hereunder will be made by deposit of U.S. Dollars by wire transfer in immediately available funds in the requisite amount to such bank account Regulus may from time to time designate by notice to Sanofi. For sales that were made in a
currency other than U.S. Dollars, such amounts will be converted into U.S. Dollars using the average exchange rates as calculated and utilized by Sanofi&#146;s group reporting system and published accounts for the applicable royalty period. All
invoices to be provided by Regulus to Sanofi under this Agreement shall include a breakdown of the goods, services and/or activities for which payment is due, as well is payment instructions and shall be sent by express courier service to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Sanofi </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Direction Comptable
Holding </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">54 rue la Bo&eacute;tie </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">75008 Paris </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">France </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.18 Audits, including Audits of Royalty Reports. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.18.1 Audits of Royalty Reports.</B> Upon the written request of Regulus and not more than once in each Calendar Year, Sanofi will permit
an independent certified public accounting firm of nationally recognized standing selected by Regulus and reasonably acceptable to Sanofi, at Regulus&#146; expense to have access during normal business hours to such records of Sanofi and/or its
Affiliates as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any Calendar Year ending not more than 36&nbsp;months prior to the date of such request. These audit rights (but not any obligation to pay unpaid
royalties for such periods) with respect to any Calendar Year will terminate 3 years after the end of such Calendar Year. Regulus will provide Sanofi with a copy of the accounting firm&#146;s written report within 30&nbsp;days of completion of such
report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.18.2 </B>If such accounting firm concludes that an overpayment or underpayment was made, then the owing Party will pay the
amount due within 30&nbsp;days of the date Regulus delivers to Sanofi such accounting firm&#146;s written report so correctly concluding. Regulus will bear the full cost of such audit unless such audit correctly discloses that the additional payment
payable by Sanofi for the audited period is more than [&#133;***&#133;]% of the amount of the royalties paid for that audited period, in which case Sanofi will pay the reasonable fees and expenses charged by the accounting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.18.3 </B>Sanofi will use Commercially Reasonable Efforts to include in each sublicense granted by it to any sublicensee a provision
requiring the sublicensee to maintain records of sales made pursuant to such license and to grant access to such records by Sanofi&#146;s independent accountant to the same extent and under substantially similar obligations as required of Sanofi
under this Agreement. Sanofi will advise Regulus in advance of each audit of any sublicensee with respect to Product sales. Sanofi will provide Regulus with a summary of the results received from the audit and, if Regulus so requests, a copy of the
audit report with respect to Product sales. Sanofi will pay the reasonable fees and expenses charged by the accounting firm, except that Regulus will pay for all additional services requested exclusively by Regulus from Sanofi&#146;s independent
accountant unless the audit discloses that the additional payments payable to Regulus for the audited period differ by more than [&#133;***&#133;]% from the amount of the royalties otherwise paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.18.4 </B>All financial information subject to review under this Section&nbsp;or under any license agreement with a sublicensee will be
Sanofi Confidential Information and will be treated in accordance with the confidentiality provisions of this Agreement. As a condition precedent to Regulus&#146; audit rights under this Section, Regulus&#146; accounting firm will enter into a
confidentiality agreement with Sanofi obligating it to treat all such financial information in confidence pursuant to such confidentiality agreement. Regulus may provide Third Parties to which Regulus owes royalties on Products information in such
audit report that are relevant and required to comply with such Third Party&#146;s audit rights under the applicable license agreement between Regulus and such Third Party, <I>provided</I> that such Third Party agrees in writing to keep such
information confidential under terms no less restrictive than Regulus&#146; obligations of confidentiality under this Agreement. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.19 Taxes. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.19.1 </B>Sanofi will make all payments to Regulus under this Agreement without deduction or withholding for taxes except to the extent
that any such deduction or withholding is required by Applicable Law in effect at the time of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.19.2 </B>Sanofi will promptly
pay on behalf of Regulus any tax required to be withheld on amounts payable under this Agreement to the appropriate governmental authority, and Sanofi will furnish Regulus with proof of payment of such tax. Any such tax required to be withheld will
be an expense of and borne by Regulus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.19.3 </B>Sanofi and Regulus will cooperate with respect to all documentation required by any
taxing authority or reasonably requested by Sanofi to secure a reduction in the rate of applicable withholding taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.20 Sublicenses.</B> In the event Sanofi grants licenses or sublicenses to a sublicensee to sell Products which are subject
to royalties under Section&nbsp;6.9, such licenses or sublicenses will include an obligation for the sublicensee to account for and report its sales of Products on the same basis as if such sales were Net Sales by Sanofi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.21 Interest.</B> If Sanofi fails to make any payment due to Regulus under this Agreement, then interest will accrue on a
daily basis at the greater of an annual rate equal to the [&#133;***&#133;] (or such lower interest rate to the extent necessary to comply with Applicable Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.22 Sanofi Founding Company License.</B> Notwithstanding any other provision in this Agreement, in the event that Sanofi is
granted a license (each such license a <B><I>&#147;Sanofi Founding Company License&#148;</I></B>) pursuant to Section&nbsp;15.3 of the Founding Company License Agreement (entitled &#147;Effects of Termination&#148;) from either of the Founding
Companies, then, in addition to, and not in lieu of, any other or remedies available to Sanofi: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.22.1 </B>[&#133;***&#133;] amounts
payable to either of the Founding Companies pursuant to proviso &#147;(ii)&#148; of the final sentence of Section&nbsp;15.3, [&#133;***&#133;]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>6.22.2 </B>subject to Section&nbsp;6.14.3, any royalty or milestone amounts (including both sales milestones and development milestones)
payable to either of the Founding Companies under any Sanofi Parent License, to the extent not [&#133;***&#133;] than were Regulus&#146; royalty and milestone payment obligations under the Founding Company License Agreement, [&#133;***&#133;] under
this Agreement. If royalty or milestone amounts payable by Sanofi to either of the Founding Companies under any Sanofi Parent License [&#133;***&#133;] Regulus&#146; royalty or milestone payment obligations under the Founding Company License
Agreement, Sanofi [&#133;***&#133;]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment
Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY; PRESS RELEASES&nbsp;&amp; PUBLICATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.1 Confidentiality; Exceptions.</B> Except to the extent expressly authorized by this Agreement or otherwise agreed in
writing, the Parties agree that, during the Term and for five (5)&nbsp;years thereafter, the receiving Party (the <B><I>&#147;Receiving Party&#148;</I></B>) and its Affiliates will keep confidential and will not publish or otherwise disclose or use
for any purpose other than as provided for in this Agreement any Know-How or other confidential and proprietary information and materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise) which
is disclosed to it by the other Party (the <B><I>&#147;Disclosing Party&#148;</I></B>) or its Affiliates or otherwise received or accessed by a Receiving Party in the course of performing its obligations or exercising its rights under this
Agreement, including, but not limited to, trade secrets, Know-How, inventions or discoveries, proprietary information, formulae, processes, techniques and information relating to the past, present and future marketing, financial, and research and
development activities of any product or potential product or useful technology of the Disclosing Party or its Affiliates and the pricing thereof (collectively, <B><I>&#147;Confidential Information&#148;</I></B>), except to the extent that it can be
established by the Receiving Party that such Confidential Information: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>7.1.1 </B>was in the lawful knowledge and possession of the
Receiving Party or its Affiliates prior to the time it was disclosed to, or learned by, the Receiving Party or its Affiliates, or was otherwise developed independently by the Receiving Party or its Affiliates, as evidenced by written records kept in
the ordinary course of business, or other documentary proof of actual use by the Receiving Party or its Affiliates; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>7.1.2 </B>was
generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party or its Affiliates; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>7.1.3 </B>became generally available to the public or otherwise part of the public domain after its disclosure and other than through any
act or omission of the Receiving Party or its Affiliates in breach of this Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>7.1.4 </B>was disclosed to the Receiving
Party or its Affiliates, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party or its Affiliates not to disclose such information to others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.2 Authorized Disclosure.</B> Except as expressly provided otherwise in this Agreement, a Receiving Party or its Affiliates
may use and disclose to Third Parties Confidential Information of the Disclosing Party as follows: (i)&nbsp;with respect to any such disclosure of Confidential Information, under confidentiality provisions no less restrictive than those in this
Agreement, and solely in connection with the performance of its obligations or exercise of its rights granted or reserved in this Agreement (including, without limitation, the rights to Develop and Commercialize Licensed Compounds, Products, and/or
Discontinued Products, and to grant licenses and sublicenses hereunder), <I>provided</I>, that Confidential Information may be disclosed by a Receiving Party to a governmental entity or agency without requiring such entity or agency to enter into a
confidentiality agreement with such Receiving Party if such Receiving Party has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
used reasonable efforts to impose such requirement without success and disclosure to such governmental entity or agency is necessary for the performance of the Receiving Party&#146;s obligations
hereunder; (ii)&nbsp;to the extent such disclosure is reasonably necessary in filing or prosecuting patent, copyright and trademark applications (subject to Section&nbsp;8.6 below) that the Disclosing Party has the right to file or prosecute under
Section&nbsp;8.2; complying with applicable governmental regulations; obtaining Approvals, conducting clinical trials, and marketing Products, in each case, for Products that the Disclosing Party has the right to Develop and Commercialize; or as
otherwise required by applicable law, regulation, rule or legal process (including the rules of the SEC and any stock exchange); <I>provided, however</I>, that if a Receiving Party or any of its Affiliates is required by law or regulation to make
any such disclosure of a Disclosing Party&#146;s Confidential Information it will, except where impracticable for necessary disclosures, for example, but without limitation, in the event of a medical emergency, give reasonable advance notice to the
Disclosing Party of such disclosure requirement and will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed; (iii)&nbsp;in communication with actual or potential lenders,
arm&#146;s-length financial investors, merger partners, acquirers, consultants, or professional advisors on a need-to-know basis, in each case under confidentiality provisions no less restrictive than those of this Agreement; (iv)&nbsp;to the extent
and only to the extent that such disclosure is required to comply with existing expressly stated contractual obligations owed to such Party&#146;s or its Affiliates&#146; licensor with respect to any intellectual property licensed to the other Party
under this Agreement; (v)&nbsp;to prosecute or defend litigation as permitted by this Agreement; or (vi)&nbsp;to the extent mutually agreed to in writing by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.3 Press Release; Disclosure of Agreement.</B> Sanofi agrees that Regulus may issue a press release (which will not be a
joint press release) announcing the execution of this Agreement in substantially the form attached as <B>A<SMALL>PPENDIX</SMALL>&nbsp;12</B> (the <B><I>&#147;Second Restatement Press Release&#148;</I></B>). From and after the Second Restatement
Date, except for the Second Restatement Press Release, or to the extent required to comply with applicable law, regulation, rule or legal process or as otherwise permitted in accordance with this Section&nbsp;7.3, neither Party nor such Party&#146;s
Affiliates will make any public announcements, press releases or other public disclosures concerning this Agreement or the terms or the subject matter hereof without the prior written consent of the other, which will not be unreasonably withheld.
Notwithstanding the foregoing, (a)&nbsp;except for scientific presentations and publications (which will be governed by Section&nbsp;7.5 below) each Party or its Affiliates may, without the other Party&#146;s approval, make disclosures pertaining
solely to Products (as to Sanofi) licensed to Sanofi or Discontinued Products (as to Regulus), provided, however, that Sanofi will immediately notify (and provide as much advance notice as possible to) Regulus of any event materially related to
Products (including in such notice any disclosure of clinical data or results, material regulatory filings or Approval) so that the Parties may analyze the need for or desirability of publicly disclosing or reporting such event, any press release or
other similar public communication by Sanofi related to efficacy or safety data and/or results regarding a Licensed Compound or Product will be submitted to Regulus for review at least five (5)&nbsp;Business Days (to the extent permitted by law) in
advance of such proposed public disclosure, Regulus will have the right to expeditiously review and recommend changes to such communication and Sanofi will in good faith consider any changes that are timely recommended by Regulus and (b)&nbsp;to the
extent information regarding this Agreement, a Licensed Compound or Product has already been publicly disclosed, either Party (or its Affiliates) may subsequently disclose the same information to the public without the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent of the other Party. Each Party will give the other Party a reasonable opportunity (to the extent consistent with law) to review all material filings with the SEC describing the terms of
this Agreement prior to submission of such filings, and will give due consideration to any reasonable comments by the non-filing Party relating to such filing, including without limitation the provisions of this Agreement for which confidential
treatment should be sought. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.4 Remedies.</B> Notwithstanding Section&nbsp;12.4, each Party will be entitled to seek, in
addition to any other right or remedy it may have, at law or in equity, a temporary injunction, without the posting of any bond or other security, enjoining or restraining the other Party from any violation or threatened violation of this
Article&nbsp;7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.5 Publications. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>7.5.1 Prior to Mir-221/222 Option Exercise.</B> Prior to Sanofi&#146;s exercise of its Mir-221/222 Option, Regulus may, consistent with its
practice with its other compounds and products, publish and present data regarding such Collaboration Target and Licensed Compounds and/or Products directed to such Collaboration Target; <I>provided, however</I>, that Regulus will provide any such
proposed publication to Sanofi at least [&#133;***&#133;]&nbsp;days prior to submission for publication or presentation. During such [&#133;***&#133;]-day period, Sanofi will have the right to review and comment on any such publications and Regulus
will give due consideration to Sanofi&#146;s requested changes. In addition, if Sanofi identifies potentially patentable Program Inventions disclosed within such proposed publication or presentation for which Sanofi desires that a patent application
be filed in accordance with the applicable provision of Section&nbsp;8.2, then by written notice to Regulus delivered within such [&#133;***&#133;]-day period, Sanofi may require Regulus to delay such publication or presentation for up to an
additional [&#133;***&#133;]&nbsp;days to permit the preparation and filing of such patent application in accordance with Section&nbsp;8.2. <I>Notwithstanding the foregoing</I>, Regulus may not publish or present any data or information that
contains any of Sanofi&#146;s Confidential Information without Sanofi&#146;s prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>7.5.2 During Term of Program
License.</B> During such time as a Program License with respect to a particular Collaboration Target is effective, and subject to this Section&nbsp;7.5.2, Sanofi will have the right to publish summaries of results from any human clinical trials
conducted by or on behalf of Sanofi with respect to the Licensed Compounds or Products for such Collaboration Target without obtaining the consent of Regulus and, except as required under Law, Regulus may not publish any of such data, without the
prior consent of Sanofi; <I>provided, however,</I> that, prior to Sanofi&#146;s exercise of its Option with respect to a <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program, Sanofi will not have the right to publish summaries of results from
any human clinical trial conducted by or on behalf of Sanofi with respect to a <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound or <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product that is the subject of such <FONT
STYLE="white-space:nowrap">Mir-21</FONT> POC Program, without obtaining the consent of Regulus (which Regulus may withhold in its sole discretion). The Parties acknowledge that scientific lead time is a key element of the value of the Research
Program and Products under this Agreement and further agree to use commercially reasonable efforts to control public scientific disclosures of the results of the research and Development activities under this Agreement (including but not limited to
any such summaries of human clinical trials data and results as required on the clinical trial registry) to prevent any potential adverse effect of any premature public disclosure of such results. The Parties will establish a procedure for
publication review and each Party will first submit to the other Party an early draft of all such publications, whether </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
they are to be presented orally or in written form, at least [&#133;***&#133;]&nbsp;days prior to submission for publication including, without limitation, to facilitate the publication of any
summaries of human clinical trials data and results as required on the clinical trial registry of each respective Party. Each Party will review such proposed publication in order to avoid the unauthorized disclosure of a Party&#146;s Confidential
Information and to preserve the patentability of inventions arising from the Research Program. If, as soon as reasonably possible, but no longer than [&#133;***&#133;]&nbsp;days following receipt of an advance copy of a Party&#146;s proposed
publication, the other Party informs such Party that its proposed publication contains Confidential Information of the other Party, then such Party will delete such Confidential Information from its proposed publication. In addition, if at any time
during such [&#133;***&#133;]-day period, the other Party informs such Party that its proposed publication discloses inventions made by either Party in the course of the Research Program under this Agreement that have not yet been protected through
the filing of a patent application, or the public disclosure of such proposed publication could be expected to have a material adverse effect on any Patents or Know-How solely owned or Controlled by such other Party, then such Party will either
(a)&nbsp;delay such proposed publication, for up to [&#133;***&#133;]&nbsp;days from the date the other Party informed such Party of its objection to the proposed publication, to permit the timely preparation and first filing of patent
application(s) on the information involved or (b)&nbsp;remove the identified disclosures prior to publication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.6
Acknowledgment.</B> Unless otherwise agreed upon in writing by the Parties, each Party will acknowledge in any press release, public presentation or publication regarding a Collaboration Target, Licensed Compound and/or Product, the other
Party&#146;s role in discovering and developing the Collaboration Target, Licensed Compound or Product, as applicable, and that such Collaboration Targets, Licensed Compounds or Products are under license from Regulus (including, if requested by
Regulus, Regulus&#146; stock ticker) and otherwise acknowledge the contributions from the other Party. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PATENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions
of this Article&nbsp;8 (excluding Section&nbsp;8.1) as they relate to Regulus Patents that are licensed to Regulus under any Existing Regulus Agreement are subject in all respects to the terms of such Existing Regulus Agreement. In the event of any
inconsistency between Regulus&#146; obligations under any Existing Regulus Agreement and the rights conferred on Sanofi by this Article&nbsp;8 (excluding Section&nbsp;8.1) with respect to the Regulus Patents that are subject to such Existing
Regulus, the Existing Regulus Agreement shall control, and the provisions of this Article&nbsp;8 shall, to the extent inconsistent with the Existing Regulus Agreement, be of no force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.1 Ownership of Inventions and Patents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.1.1 </B>Title to inventions, discoveries, improvements and other technology, whether or not patentable, conceived, made or reduced to
practice in the performance of the Research Program or the POC Programs under this Agreement (collectively, the <B><I>&#147;Program Inventions&#148;</I></B>) and any Patents claiming such Program Inventions (<B><I>&#147;Program
Patents&#148;</I></B>), are retained by the Party that is the employer of the inventor(s) (or, in the case of consultants and </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(sub)contractors, the Party for which the consultant or (sub)contractor is providing its services). Each Party will ensure that every employee, consultant, and (sub)contractor employed or
contracted by that Party in the performance of the Research Program and the POC Programs has a written obligation to assign all Know-How and Patents conceived, made or reduced to practice by each such employee, consultant, and (sub)contractor to
such Party. The Parties agree that the United States federal patent law on inventorship will determine the inventorship of any Program Invention and the names of the inventors on any Program Patent filings, whether sole or joint inventions, which
arise in connection with activities conducted pursuant to this Agreement. Sanofi will own Program Inventions invented solely by employees, consultants and/or (sub)contractors of Sanofi (the <B><I>&#147;Sanofi Inventions&#148;</I></B>) and any
Patents claiming such Program Inventions (the <B><I>&#147;Sanofi Program Patents&#148;</I></B>). Regulus will own Program Inventions invented solely by employees, consultants and/or (sub)contractors of Regulus (the <B><I>&#147;Regulus
Inventions&#148;</I></B>) and any Patents claiming such Program Inventions (the <B><I>&#147;Regulus Program Patents&#148;</I></B>). Regulus and Sanofi will own jointly such Program Inventions invented jointly by employees, consultants and/or
(sub)contractors of Regulus and Sanofi (the <B><I>&#147;Joint Inventions&#148;</I></B>) and any Patents claiming such Program Inventions (the <B><I>&#147;Joint Patents&#148;</I></B>). Regulus will promptly disclose to Sanofi any such Regulus
Invention or Joint Invention, and Sanofi will promptly disclose to Regulus any Sanofi Invention or Joint Invention, arising from or made in the performance of the Research Program and any patent or patent application claiming such Program Invention.
It is understood that except as otherwise provided in this Agreement or as the Parties may otherwise agree in writing, neither Party will have any obligation to account to the other Party for profits, or to obtain any approval of the other Party to
license, assign, mortgage or exploit a Joint Invention by reason of joint ownership of any such Joint Invention, and may otherwise undertake all activities a sole owner might undertake with respect to such inventions without the consent of and
without accounting to the other joint owner, and each Party hereby waives any right it may have under the laws of any jurisdiction to require such consent or accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.1.2 CREATE Act.</B> Notwithstanding anything to the contrary in this Article&nbsp;8, neither Party will have the right to make an
election under the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. &#167; 103(c)(2)-(c)(3) (the <B><I>&#147;CREATE Act&#148;</I></B>) when exercising its rights under this Article&nbsp;8 without the prior written consent of
the other Party, which will not be unreasonably withheld, conditioned or delayed. With respect to any such permitted election, the Parties will use reasonable efforts to cooperate and coordinate their activities with respect to any submissions,
filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a &#147;joint research agreement&#148; as defined in the CREATE Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.2 Filing, Prosecution and Maintenance of Patents.</B> For purposes of this Section&nbsp;8.2, the terms
&#147;prosecute,&#148; &#147;prosecuting&#148; and &#147;prosecution,&#148; when used in reference to any Patent, shall be deemed to include, without limitation, the control of any interferences, reissue proceedings, oppositions and reexaminations
with respect to such Patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.2.1 Product Specific Patents.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) Before Option Exercise.</B> On a Collaboration Target-by-Collaboration Target basis, for Product Specific Patents filed prior to
Sanofi&#146;s exercise of its Option (or at least one of its Options) for a given Collaboration Target (and Sanofi&#146;s payment to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulus of the applicable Option Exercise Fee and POC Program Reimbursement Amount), Regulus will be responsible for the preparation, filing, prosecution and maintenance of Product Specific
Patents (including Product Specific Patents that are Joint Patents) directed to such Collaboration Target or to Licensed Compounds or Products that target or mimic (as applicable) such Collaboration Target. Regulus will use Commercially Reasonable
Efforts to prepare, file, prosecute and maintain such Product Specific Patents in at least the countries listed in <B>A<SMALL>PPENDIX</SMALL>&nbsp;7</B> (each, a <B><I>&#147;Listed Country&#148;</I></B>), at Regulus&#146; expense; <I>provided,
however,</I> that if the applicable patent office in any Listed Country, other than [&#133;***&#133;] and [&#133;***&#133;], requires [&#133;***&#133;] of patent applications [&#133;***&#133;], Sanofi shall reimburse Regulus for costs incurred by
Regulus for [&#133;***&#133;] of Product Specific Patents [&#133;***&#133;]. If Sanofi requests in writing that Regulus prepare, file, prosecute and maintain any Product Specific Patent in any country that is not a Listed Country (each, a
<B><I>&#147;Sanofi Nominated Country&#148;</I></B>), Regulus will use Commercially Reasonable Efforts to prepare, file, prosecute and maintain such Product Specific Patent in such Sanofi Nominated Country, at Sanofi&#146;s expense, <I>provided,
however</I>, that if Sanofi is not the sole licensee or sublicensee of Regulus under such Product Specific Patent, Regulus will be responsible for such expenses and Sanofi will reimburse Regulus for the amount that is equal to the total of such
expenses divided by the number of licensee(s) or sublicense(s) under such product specific patent (such number to also include Regulus). Regulus, or its outside counsel, will provide Sanofi with (i)&nbsp;a reasonably detailed annual update of the
filing, prosecution and maintenance status for each such Product Specific Patent and (ii)&nbsp;any further information reasonably requested by Sanofi from time to time regarding such Product Specific Patent; <I>provided, however,</I> that if such
Product Specific Patent is licensed to Regulus by a Third Party, Regulus will not be obligated to make disclosure of information regarding such Product Specific Patent to the extent that such disclosure would constitute a breach of Regulus&#146;
confidentiality obligations to the Third Party licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) After Option Exercise.</B> On a Collaboration Target-by-Collaboration
Target basis, for Product Specific Patents filed after Sanofi&#146;s exercise of its Option (or at least one of its Options) for a given Collaboration Target (and Sanofi&#146;s payment to Regulus of the applicable Option Exercise Fee and POC Program
Reimbursement Amount), Sanofi will be responsible for the preparation, filing, prosecution and maintenance of such Product Specific Patents (including Product Specific Patents that are Joint Patents) directed to such Collaboration Target or to
Licensed Compounds or Products that target or mimic (as applicable) such Collaboration Target, at Sanofi&#146;s expense; <I>provided, however</I>, that if Sanofi is not the sole licensee or sublicensee of Regulus under such Product Specific Patent,
Regulus will be responsible for such expenses and Sanofi will reimburse Regulus for the amount that is equal to the total of such expenses divided by the number of licensee(s) or sublicense(s) under such product specific patent (such number to also
include Regulus). Sanofi, or its outside counsel, will provide Regulus with (i)&nbsp;a reasonably detailed monthly update of the filing, prosecution and maintenance status for each such Product Specific Patent and (ii)&nbsp;any further information
reasonably requested by Regulus from time to time regarding such Product Specific Patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) Cooperation.</B> The Party responsible
for preparing, filing, prosecuting and maintaining any Product Specific Patent (including any Product Specific Patent that is a Joint Patent) under Section&nbsp;8.2.1(a) or Section&nbsp;8.2.1(b) above (the <B><I>&#147;Lead Party&#148;</I></B>) will
consider in good faith all reasonable requests or recommendations of the other Party regarding the preparation, filing, prosecution and maintenance of Product Specific Patents. During such </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time as a Program License with respect to a particular Collaboration Target is effective, Regulus will consider in good faith, and give effect to, all reasonable requests or recommendations of
Sanofi regarding the preparation, filing, prosecution and maintenance of the applicable Product Specific Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d) Election Not to
File, Prosecute, or Maintain Product Specific Patents.</B> In the event that the Lead Party decides not to pursue or continue the filing, prosecution or maintenance of any Product Specific Patent in any country, the Lead Party, or its outside
counsel, will provide the other Party with written notice of such decision at least 60&nbsp;days in advance of any relevant filing, prosecution or maintenance deadline, and the other Party will provide the Lead Party with prompt notice as to whether
the other Party desires to assume responsibility and costs for such filing, prosecution or maintenance of such Product Specific Patent. The Lead Party will not knowingly permit any such Product Specific Patent to be abandoned in any Listed Country
(or, in the case of Regulus, any Sanofi Nominated Country for which Sanofi is bearing the expense of preparation, filing, prosecution and maintenance of Product Specific Patents), or elect not to file a new patent application claiming priority to a
patent application within the Product Specific Patents either before such patent application&#146;s issuance or within the time period required for the filing of an international (<I>i.e.</I>, Patent Cooperation Treaty), regional (including European
Patent Office) or national application, without the other Party&#146;s written consent or without the other Party otherwise first being given an opportunity to assume full responsibility (at the other Party&#146;s expense) for the continued
prosecution and maintenance of such Product Specific Patents, or the filing of such new patent application. In the event that the other Party assumes responsibility for the preparation, filing, prosecution or maintenance of any patent or patent
application as set forth above, the other Party will not be liable to the Lead Party in any way with respect to its handling of, or the results obtained from, the filing, prosecution, issuance, extension or maintenance of such application or any
resulting patent or any failure by it to so file, prosecute, extend or maintain. In the event that Sanofi assumes responsibility for the preparation, filing, prosecution or maintenance of any such Product Specific Patent as set forth above, Regulus
will assign such Product Specific Patent to Sanofi, for no additional consideration, and such Product Specific Patent (if later granted) will be disregarded for the purposes of calculating the Royalty Term under Section&nbsp;6.15. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.2.2 Regulus Core Technology Patents Other Than Joint Patents.</B> Regulus (or its Third Party licensors of Regulus Core Technology
Patents, as applicable) will be solely responsible for the preparation, filing, prosecution and maintenance of Regulus Core Technology Patents (other than Joint Patents that are Regulus Core Technology Patents), at Regulus&#146; sole expense. At
Sanofi&#146;s reasonable request from time to time, Regulus, or its outside counsel, will promptly provide Sanofi with an update of the filing, prosecution and maintenance status for each of such Regulus Core Technology Patents, including without
limitation an update of <B>A<SMALL>PPENDIX</SMALL>&nbsp;3</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.2.3 Joint Core Technology Patents.</B> This Section&nbsp;8.2.3 will
apply only to: (i)&nbsp;Regulus Core Technology Patents that are Joint Patents (each, a <B><I>&#147;Joint Core Technology Patent&#148;</I></B>); and (ii)&nbsp;any Joint Invention that is not claimed by any patent application in a country, provided
that if a patent application claiming such Joint Invention were filed in such country, such patent application would be a Joint Core Technology Patent (such Joint Invention, a <B><I>&#147;Joint Core Technology Invention&#148;</I></B>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) Regulus First Right to File, Prosecute and Maintain.</B> Regulus will have the first
right to prepare, file, prosecute and maintain any new patent application claiming a Joint Core Technology Invention, at Regulus&#146; expense. Regulus shall consult with Sanofi as to the preparation, filing, prosecution and maintenance of Joint
Core Technology Patents and draft patent applications claiming Joint Core Technology Inventions reasonably prior to any deadline or action with any patent office, shall furnish to Sanofi copies of all relevant documents reasonably in advance of such
consultation, and shall consider in good faith the reasonable comments and suggestions of Sanofi. Regulus, or its outside counsel, will provide Sanofi with an update of the filing, prosecution and maintenance status for each Joint Core Technology
Patent on a periodic basis, and will provide to Sanofi copies of any papers relating to the filing, prosecution and maintenance of such Joint Core Technology Patents promptly upon their being filed or received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) Disclosure; Cooperation.</B> Regulus or its outside counsel, will provide Sanofi with (i)&nbsp;a reasonably detailed monthly update of
the filing, prosecution and maintenance status for such Joint Core Technology Patent and (ii)&nbsp;any further information reasonably requested by Sanofi from time to time regarding such Joint Core Technology Patent. Regulus will consider in good
faith all reasonable requests or recommendations of Sanofi regarding the preparation, filing, prosecution and maintenance of Joint Core Technology Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) Election Not to File, Prosecute, or Maintain Joint Core Technology Patents.</B> In the event that Regulus decides not to pursue or
continue the filing, prosecution or maintenance of any Joint Core Technology Patent in any country, Regulus, or its outside counsel, will provide Sanofi with written notice of such decision at least 60&nbsp;days in advance of any relevant filing,
prosecution or maintenance deadline, and Sanofi will provide Regulus with prompt notice as to whether Sanofi desires to assume responsibility and costs for such filing, prosecution or maintenance of such Joint Core Technology Patent. Regulus will
not knowingly permit any such Joint Core Technology Patent to be abandoned, or elect not to file a new patent application claiming priority to a patent application within the Joint Core Technology Patents either before such patent application&#146;s
issuance or within the time period required for the filing of an international (<I>i.e.</I>, Patent Cooperation Treaty), regional (including European Patent Office) or national application, without Sanofi&#146;s written consent or without Sanofi
otherwise first being given an opportunity to assume full responsibility (at Sanofi&#146;s expense) for the continued prosecution and maintenance of such Joint Core Technology Patent, or the filing of such new patent application. In the event that
Sanofi assumes responsibility for the preparation, filing, prosecution or maintenance of any Joint Core Technology Patent as set forth above, such Joint Core Technology Patent (if later granted) will be disregarded for the purposes of calculating
the Royalty Term under Section&nbsp;6.11, provided that Regulus shall retain its joint ownership interest in such Joint Core Technology Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.2.4 Joint Patents Other Than Joint Core Technology Patents and Product Specific Patents.</B> This Section&nbsp;8.2.4 will apply only to:
(i)&nbsp;Joint Patents that are neither Joint Core Technology Patents nor Product Specific Patents (each, an <B><I>&#147;Other Joint Patent&#148;</I></B>); and (ii)&nbsp;any Joint Invention that is not claimed by any patent application in a country,
provided that if a patent application claiming such Joint Invention were filed in such country, such patent application would be neither a Joint Core Technology Patent nor a Product Specific Patent (such Joint Invention, an <B><I>&#147;Other Joint
Invention&#148;</I></B>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) Sanofi First Right to File, Prosecute and Maintain.</B> Sanofi will have the first right
to prepare, file, prosecute and maintain any new patent application claiming an Other Joint Invention, at Sanofi&#146;s expense. Sanofi shall consult with Regulus as to the preparation, filing, prosecution and maintenance of Other Joint Patents and
draft patent applications claiming Other Joint Inventions reasonably prior to any deadline or action with any patent office, shall furnish to Regulus copies of all relevant documents reasonably in advance of such consultation, and shall consider in
good faith the reasonable comments and suggestions of Regulus. Sanofi, or its outside counsel, will provide Regulus with an update of the filing, prosecution and maintenance status for each Other Joint Patent on a periodic basis, and will provide to
Regulus copies of any papers relating to the filing, prosecution and maintenance of such Other Joint Patents promptly upon their being filed or received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) Election Not to File, Prosecute, or Maintain Other Joint Patents.</B> In the event that Sanofi decides not to pursue or continue the
filing, prosecution or maintenance of any Other Joint Patent in any country, Sanofi, or its outside counsel, will provide Regulus with written notice of such decision at least 60&nbsp;days in advance of any relevant filing, prosecution or
maintenance deadline, and Regulus will provide Sanofi with prompt notice as to whether Regulus desires to assume responsibility and costs for such filing, prosecution or maintenance of such Other Joint Patent. Sanofi will not knowingly permit any
such Other Joint Patent to be abandoned, or elect not to file a new patent application claiming priority to a patent application within the Other Joint Patents either before such patent application&#146;s issuance or within the time period required
for the filing of an international (<I>i.e.</I>, Patent Cooperation Treaty), regional (including European Patent Office) or national application, without Regulus&#146; written consent or without Regulus otherwise first being given an opportunity to
assume full responsibility (at Regulus&#146; expense) for the continued prosecution and maintenance of such Other Joint Patent, or the filing of such new patent application. In the event that Regulus assumes responsibility for the preparation,
filing, prosecution or maintenance of any patent or patent application as set forth above, Regulus will not be liable to Sanofi in any way with respect to its handling of, or the results obtained from, the filing, prosecution, issuance, extension or
maintenance of such application or any resulting patent or any failure by it to so file, prosecute, extend or maintain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.2.5
Cooperation.</B> Each Party agrees to cooperate fully in the preparation, filing, prosecution and maintenance of Patents pursuant to this Section&nbsp;8.2. Such cooperation includes, but is not limited to: (a)&nbsp;executing all papers and
instruments, or requiring its employees or contractors, to execute such papers and instruments, so as to enable the other Party to exercise its rights and perform its obligations under this Section&nbsp;8.2; and (b)&nbsp;promptly informing the other
Party of any matters coming to such Party&#146;s attention that may affect the preparation, filing, prosecution or maintenance of any such patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.3 Patent Term Extension.</B> Regulus and Sanofi will each cooperate with one another and will use Commercially Reasonable
Efforts in obtaining patent term restorations and/or extensions (including without limitation, any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in any country with respect to
patent rights covering those Products licensed by Sanofi hereunder. If elections with respect to obtaining such patent term extensions or supplemental protection are to be made, Sanofi will have the right to make such election, <I>provided</I> that
(i)&nbsp;such election will be made in accordance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with applicable Law so as to maximize the period of marketing exclusivity for the Product, and (ii)&nbsp;Sanofi may not elect to extend a Regulus Core Technology Patent (other than a Joint Core
Technology Patent) under this Section&nbsp;8.3 without Regulus&#146; prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.4 Enforcement of Patents
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.4.1 Product Specific Patents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) Enforcement by Sanofi.</B> In the event that Regulus or Sanofi becomes aware of a suspected infringement of any Product Specific
Patent, or any such Product Specific Patent is challenged in any action or proceeding (other than any interferences, reissue proceedings, oppositions or reexaminations, which are addressed above), such Party will notify the other Party promptly, and
following such notification, the Parties will confer and determine an appropriate course of action in response to such suspected infringement or action or proceeding. During such time as a Program License with respect to a particular Collaboration
Target is effective, Sanofi will have the right, but will not be obligated, to defend any such action or proceeding or bring an infringement action with respect to such suspected infringement at its own expense, in its own name and entirely under
its own direction and control, or settle any such action, proceeding or dispute by license (to the extent such sublicense is permitted under this Agreement). Regulus will reasonably assist Sanofi in any action or proceeding being defended or
prosecuted if so requested, and will lend its name to such actions or proceedings if reasonably requested by Sanofi or required by Applicable Law. Sanofi will reimburse Regulus for the documented out-of-pocket costs Regulus reasonably incurs in
providing such assistance as specifically requested in writing by Sanofi. In the event Regulus is a required party to the proceeding or action, Regulus will have the right to be represented by its own counsel (such selection to be subject to
Sanofi&#146;s approval, such approval not to be unreasonably withheld), and Sanofi will reimburse Regulus for the documented external costs Regulus reasonably incurs that are reasonably related to the proceeding or action, including attorneys fees,
<I>provided</I> that Sanofi will retain overall responsibility for the prosecution of such action or proceeding in such event. In the event that Regulus is not a necessary party to the proceeding or action, Regulus will have the right to participate
and be represented in any such suit by its own counsel at its own expense, <I>provided</I> that Sanofi will retain overall responsibility for the prosecution of such action or proceedings in such event. Sanofi may not enter any settlement of any
such action or proceeding which restricts the scope, or adversely affects the enforceability, of a Product Specific Patent, or which could be reasonably expected to have a material adverse financial impact on Regulus, without Regulus&#146; prior
written consent, which consent will not be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) Enforcement by Regulus.</B> If Sanofi
elects not to settle, defend or bring any action for infringement described in Section&nbsp;8.4.1(a) and so notifies Regulus, including following any request by Regulus to do so, then Regulus may defend or bring such action at its own expense, in
its own name, <I>provided however</I> that, Regulus agrees not to so settle, defend or bring any action for infringement of a Product Specific Patent Right upon Sanofi&#146;s request based on Sanofi&#146;s good faith reasonable determination, the
basis for which will be provided to Regulus, that it is not in the best interest of the Parties to so settle, defend or bring such action for infringement. In the case where Regulus proceeds to settle, defend or bring an action for such
infringement, the following will apply: (i)&nbsp;Sanofi will reasonably assist Regulus in any action or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeding being defended or prosecuted if so requested, and will lend its name to such actions or proceedings if requested by Regulus or required by Applicable Law; (ii)&nbsp;Regulus will
reimburse Sanofi for the documented external costs Sanofi reasonably incurs, including attorneys fees, in providing such assistance as specifically requested in writing by Regulus; (iii)&nbsp;Sanofi will have the right to participate and be
represented in any such suit by its own counsel at its own expense, <I>provided</I> that Regulus will retain overall responsibility for the prosecution of such suit or proceedings in such event; and (iv)&nbsp;Regulus may not enter any settlement of
any action or proceeding defended or brought by Regulus with respect to a Product Specific Patent, which restricts the scope, or adversely affects the enforceability, of a Product Specific Patent, or which could be reasonably expected to have a
material adverse financial impact on Sanofi without Sanofi&#146;s prior written consent, which consent will not be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) Withdrawal.</B> If either Party brings an action or proceeding under this Section&nbsp;8.4.1 and subsequently ceases to pursue or
withdraws from such action or proceeding, it will promptly notify the other Party and the other Party may substitute itself for the withdrawing Party and pursue such action or proceeding in accordance with the terms of this Section&nbsp;8.4.1
(including but not limited to the proviso in the first sentence of Section&nbsp;8.4.1(b)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d) Damages.</B> In the event that either
Party exercises the rights conferred above in this Section&nbsp;8.4.1 and recovers any damages or other sums in such action, suit or proceeding or in settlement thereof, such damages or other sums recovered will first be applied to all out-of-pocket
costs and expenses incurred by the Party which initiated such action, suit or proceeding, including, without limitation, attorneys fees, and second to any out-of-pocket costs and expenses incurred by the other Party and not previously reimbursed by
the Party which initiated such action, suit or proceeding according to this Section&nbsp;8.4.1. Any remaining amounts will: (i)&nbsp;if recovered by Sanofi, be divided as follows: (A)&nbsp;as to ordinary damages based on lost sales or profit, Sanofi
will retain such funds and such funds will be treated as Net Sales and royalties will be payable by Sanofi to Regulus with respect to such Net Sales in accordance with Section&nbsp;6.9 of this Agreement and (B)&nbsp;as to special or punitive
damages, Sanofi will receive [&#133;***&#133;]% of the amount of such special or punitive damages and Regulus will receive [&#133;***&#133;]% of the amount of such special or punitive damages; or (ii)&nbsp;if recovered by Regulus, [&#133;***&#133;].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.4.2 Regulus Core Technology Patents Other Than Joint Core Technology Patents.</B> Regulus will have the sole right to enforce
Regulus Core Technology Patents (other than Joint Core Technology Patents) and to defend Regulus Core Technology Patents (other than Joint Core Technology Patents) against challenge in any action or proceeding (other than any interferences, reissue
proceedings, oppositions or reexaminations, which are addressed above). In the event of suspected infringement of a Regulus Core Technology Patent (other than a Joint Core Technology Patent) by a Third Party in a country, wherein (a)&nbsp;the
suspected infringing activity competes with a Product being Commercialized by or on behalf of Sanofi in such country, and (b)&nbsp;no other Patent Controlled by Sanofi (whether by license under this Agreement or otherwise) is infringed or suspected
to be infringed by the suspected infringing activity, Section&nbsp;[&#133;***&#133;] to such Product in such country (with the suspected infringing product [&#133;***&#133;]), unless Regulus permits Sanofi to enforce the applicable Regulus Core
Technology Patent against such Third Party. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.4.3 Joint Core Technology Patents.</B> In the event of suspected infringement of a Joint
Core Technology Patent by a Third Party in a country, wherein the suspected infringing activity competes with a Product being commercialized by or on behalf of Sanofi in such country, the Parties&#146; respective rights and obligations with respect
to enforcement of such Joint Core Technology Patent in such country (including damages or settlement amounts received as a result thereof) shall be as set forth in Section&nbsp;8.4.1, <I>mutatis mutandis</I>. In the event of any other suspected
infringement of a Joint Core Technology Patent, the Parties&#146; respective rights and obligations with respect to enforcement of such Joint Core Technology Patent in such country will be the reverse of their respective rights and obligations under
Section&nbsp;8.4.1, <I>mutatis mutandis</I>; <I>provided, however,</I> that after reimbursement of costs, any remaining damages or other amounts recovered will be allocated [&#133;***&#133;]% to the Party that brought and controlled the action, and
[&#133;***&#133;]% to the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.4.4 Other Joint Patents.</B> In the event of suspected infringement of an Other Joint Patent
by a Third Party in a country, wherein the suspected infringing activity competes with a Product being commercialized by or on behalf of Sanofi in such country, the Parties&#146; respective rights and obligations with respect to enforcement of such
Other Joint Patent in such country shall be as set forth in Section&nbsp;8.4.1, <I>mutatis mutandis</I>. In the event of any other suspected infringement of an Other Joint Patent, the Parties shall mutually agree in good faith on a case-by-case
basis on the course of action to be taken and the allocation of costs and recovered amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>8.4.5 Cooperation.</B> The Party not
enforcing a particular Patent under any of the preceding provisions of this Section&nbsp;8.4 will provide reasonable assistance to the other Party (at such other Party&#146;s expense), including providing access to relevant documents and other
evidence, making its employees available at reasonable business hours, and joining the action to the extent necessary to allow the enforcing Party to initiate or maintain the action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.5 Determination of Certain Patent Matters.</B> The Parties, acting in good faith and on the advice of their respective
internal or external patent counsel, agree in good faith on: (i)&nbsp;the inventorship of Program Inventions under Section&nbsp;8.1.1, consistent with U.S. patent laws; (ii)&nbsp;whether any particular Regulus Patent is a Regulus Core Technology
Patent or a Product Specific Patent, taking into full consideration the definitions of such terms set forth in <B>A<SMALL>PPENDIX</SMALL>&nbsp;1</B> and the Regulus Patents listed in <B>A<SMALL>PPENDIX</SMALL>&nbsp;2</B> and
<B>A<SMALL>PPENDIX</SMALL>&nbsp;3</B> hereto; and (iii)&nbsp;whether there exists a Product Specific Patent that is suspected to be infringed by a suspected infringement under Section&nbsp;8.4.1. If the Parties cannot agree upon any such matter
within 30&nbsp;days of good faith discussions, the Parties will refer such matter to independent patent counsel, not engaged by either Party or any of its Affiliates for any matter in the previous three (3)&nbsp;years and reasonably acceptable to
both Parties. The determination of the independent patent counsel with respect to such matter will be binding on the Parties. The costs and expenses of the independent patent counsel will be shared equally between the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.6 Data Exclusivity and Orange Book Listings.</B> With respect to data exclusivity periods (such as those periods listed in
the FDA&#146;s Orange Book (including without limitation any available pediatric extensions) or periods under national implementations of Article&nbsp;11.1(a)(iii) of Directive 2001/EC/83, or similar periods as may be applicable to a biologic, and
all international equivalents), Sanofi will use Commercially Reasonable Efforts </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consistent with its obligations under applicable law (including any applicable consent order) to seek, maintain and enforce all such data exclusivity periods available for the Products
exclusively licensed by Sanofi hereunder. With respect to filings in the FDA Orange Book or other similar filings or listings as may be applicable (and foreign equivalents) for issued patents for a Product, upon reasonable request by Sanofi, Regulus
will provide reasonable cooperation to Sanofi in filing and maintaining any such listing and filings. All listing and filing decisions will be at the sole discretion of Sanofi; <I>provided, however</I> that Sanofi will not list Regulus Core
Technology Patents in the FDA Orange Book without Regulus&#146; prior written consent, such consent not to be unreasonably withheld or delayed. In no event will Regulus withhold or delay such consent where the listing of such Regulus Core Technology
Patent is required under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.7 Further Actions.</B> Each Party will, upon the reasonable request of the
other Party, provide such assistance and execute such documents as are reasonably necessary for such Party to exercise its rights and/or perform its obligations pursuant to this Article&nbsp;8; <I>provided however</I>, that neither Party will be
required to take any action pursuant to Article&nbsp;8 that such Party reasonably determines in its sole judgment and discretion conflicts with or violates any applicable court or government order or decree. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.8 Infringement Claims; Oppositions.</B> Sanofi and Regulus will promptly inform the other in writing of any written notice
to it of alleged infringement or misappropriation, based on the research, development, making, using, importing, exporting or selling of a Licensed Compound or Product, of a Third Party&#146;s intellectual property rights of which it will become
aware. The Parties will confer on the handling of such matter. Regulus will not acknowledge to a Third Party the validity of any such allegation or admit liability without the prior written consent of Sanofi, and Sanofi will not acknowledge to a
Third Party the validity of any such allegation or admit liability without the prior written consent of Regulus. Sanofi and Regulus will each keep the other advised of all material developments in the conduct of any proceedings in defending any
claim of such alleged infringement or misappropriation and will cooperate with the other in the conduct of such defense. In no event may either Party settle any such infringement or misappropriation claim in a manner that would limit the rights of
the other Party or impose any obligation on the other Party, without such other Party&#146;s prior written consent, such consent not to be unreasonably withheld or delayed. Sanofi and Regulus will promptly inform the other in writing of any written
notice to it of actual or threatened opposition related to the Product Specific Patents. The Parties will confer on the handling of such matter and such matters will be handled in accordance with Section&nbsp;8.2 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.9 Records Regarding Regulus Patents.</B> Each Party will assign patent counsel representatives who will be responsible for
coordinating activities between the Parties in accordance with this Article&nbsp;8. Such representatives will use commercially reasonable efforts to maintain a report listing the Regulus Patents that are subject to the license granted to Sanofi
under Section&nbsp;2.1. Such report will be used to facilitate the identification and tracking of the Regulus Patents licensed under this Agreement, but will not, unless specifically agreed to in a separate written agreement signed by authorized
representatives of both Parties, be considered to be a then-current complete and binding list of the Regulus Patents licensed under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.10 Challenge.</B> As a material inducement for entering into this Agreement,
Sanofi acknowledges and agrees that during the term of this Agreement, solely with respect to claims within the Regulus Patents that are included in the license granted to Sanofi under Section&nbsp;2.1, in any of the Options or in any of the Program
Licenses, in the event that Sanofi, its Affiliates or sublicensees (a)&nbsp;commences or otherwise voluntarily determines to participate in (other than as may be necessary or reasonably required to respond to a court request or order or
administrative law request or order) any action or proceeding, challenging or denying the validity of any claim within an issued patent or patent application within the Regulus Patents, or (b)&nbsp;directs, supports or actively assists any other
Person (other than as may be necessary or reasonably required to respond to a court request or order or administrative law request or order) in bringing or prosecuting any action or proceeding challenging or denying the validity of any claim within
an issued patent or patent application within the Regulus Patents, then, in each case, Sanofi will be deemed to have materially breached this Agreement, and Regulus shall be deemed to have grounds for termination of this Agreement under
Section&nbsp;9.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.11 Amendments to Third Party Agreements.</B> Regulus will not amend or agree to amend any Existing
Regulus Agreement, Future Regulus Agreement, or New Core Technology Agreement for New Core Technology included in the Regulus Technology licensed to Sanofi under Section&nbsp;2.1 or under any Program License, in any manner that would increase
Sanofi&#146;s payment obligations or reduce the scope of Sanofi&#146;s license under Section&nbsp;2.1 or any Program License, without the prior written consent of Sanofi. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND
TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.1 Term.</B> The term of this Agreement (the <B><I>&#147;Term&#148;</I></B>) commences upon the
Effective Date and, unless earlier terminated in accordance with the provisions of this Article&nbsp;9, will continue until the expiration of all payment obligations on all Products to Regulus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.2 Sanofi Right to Terminate.</B> Sanofi may terminate this Agreement (including its license rights under this Agreement) in
full, or on a Product-by-Product basis, effective upon 30&nbsp;days prior written notice. For purposes of clarification, milestone and royalty payments will be due on milestones achieved and Products sold during the period between notice of
termination and the effective date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.3 Material Breach. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>If either Party believes that the other is in material breach of this Agreement (other than with respect to a breach of
Sanofi&#146;s obligations under Section&nbsp;5.1, which is governed by Section&nbsp;9.4), then the non-breaching Party may deliver notice of such breach to the other Party. In such notice the non-breaching Party will identify the actions or conduct
that it wishes such Party to take for an acceptable and prompt cure of such breach (or will otherwise state its good faith belief that such breach is incurable); <I>provided</I> that such identified actions or conduct will not be binding upon the
other Party with respect to the actions that it may need to take to cure such breach. If the breach is curable, the allegedly breaching Party will have 120&nbsp;days to either cure such breach (except to the extent such breach involves the failure
to make </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a payment when due, which breach must be cured within 30&nbsp;days following such notice) or, if a cure cannot be reasonably effected within such 120-day period, to deliver to the non-breaching
Party a plan for curing such breach which is reasonably sufficient to effect a cure within a reasonable period. If the breaching Party fails to (i)&nbsp;cure such breach within the 120-day (or 30-day, as applicable) period or (ii)&nbsp;use
Commercially Reasonable Efforts to carry out the plan and cure the breach, the non-breaching Party may terminate this Agreement on a Product-by-Product basis by providing written notice to the breaching Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Notwithstanding the foregoing, if the allegedly breaching Party disputes in good faith the existence, materiality, or failure to
cure of any such breach which is not a payment breach, and provides notice to the non-breaching Party (the <B><I>&#147;Other Party&#148;</I></B>) of such dispute within such 120-day period, the Other Party will not have the right to terminate this
Agreement in accordance with this Section&nbsp;9.3 unless and until it has been determined in accordance with Section&nbsp;12.4 that this Agreement was materially breached by the allegedly breaching Party and that Party fails to cure such breach
within 120&nbsp;days following such determination. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of
their respective obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>This Section&nbsp;9.3 will be subject to and will not limit the provisions of
Section&nbsp;9.4 and Section&nbsp;9.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.4 Termination by Regulus For Failure of Sanofi to Use Commercially Reasonable
Efforts. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>9.4.1 </B>Subject to Sections&nbsp;9.4.3 and 9.4.4, at any time after the earlier of (a)&nbsp;exercise of the Option for
at least one of the <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Programs and (b)&nbsp;the expiration of the Option Periods with respect to both of the <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Programs without Sanofi&#146;s exercise
of either of such Options, Regulus will have the right to terminate the license granted under Section&nbsp;2.1 and the Program Licenses for <FONT STYLE="white-space:nowrap">Mir-21</FONT> (and the corresponding exclusivity obligation under
Section&nbsp;2.5) on a <FONT STYLE="white-space:nowrap">Mir-21</FONT> <FONT STYLE="white-space:nowrap">Product-by-Mir-21</FONT> Product basis and country-by-country basis, if Sanofi is in breach of its obligations to use Commercially Reasonable
Efforts as set forth in Section&nbsp;5.1, <I>provided however</I>, that the Agreement will not so terminate unless (i)&nbsp;Sanofi is given 30&nbsp;days prior written notice by Regulus of Regulus&#146; intent to terminate, stating the reasons and
justification for such termination and recommending steps which Sanofi should take, and (ii)&nbsp;Sanofi, or its sublicensee, has not used Commercially Reasonable Efforts during the 120-day period following such notice to pursue the Development
and/or Commercialization of at least one <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound or <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product in the applicable country. Any such termination will be limited in force and effect to the
country or countries and Products to which such breach relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>9.4.2 </B>Subject to Sections&nbsp;9.4.3 and 9.4.4, at any time after
the exercise of the Option for the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Oncology POC Program, Regulus will have the right to terminate the Program License for <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> (and the corresponding
exclusivity obligation under Section&nbsp;2.5) on a <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> <FONT STYLE="white-space:nowrap">Product-by-Mir-221/222</FONT> Product basis and country-by-country basis, if Sanofi is in breach of its
obligations to use Commercially Reasonable Efforts as set forth in Section&nbsp;5.1, <I>provided however</I>, that the Agreement will not so terminate unless (i)&nbsp;Sanofi is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
given 30&nbsp;days prior written notice by Regulus of Regulus&#146; intent to terminate, stating the reasons and justification for such termination and recommending steps which Sanofi should
take, and (ii)&nbsp;Sanofi, or its sublicensee, has not used Commercially Reasonable Efforts during the 120-day period following such notice to pursue the Development and/or Commercialization of at least one
<FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Compound or <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product in the applicable country. Any such termination will be limited in force and effect to the country or countries and Products
to which such breach relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>9.4.3 </B>It is understood and acknowledged that if Sanofi (by itself or through its Affiliates or
sublicensees) uses Commercially Reasonable Efforts to Develop and Commercialize a Product for each Collaboration Target in each and every Major Market Country, Sanofi will be deemed to be in compliance with its obligation under Section&nbsp;5.1 to
use Commercially Reasonable Efforts to Develop and Commercialize a Product for such Collaboration Target with respect to all countries in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>9.4.4 </B>If Sanofi disputes in good faith the existence or materiality of an alleged breach specified in a notice provided by Regulus
pursuant to Section&nbsp;9.4.1 or 9.4.2, and provides notice to Regulus of such dispute within the 30&nbsp;days following such notice provided by Regulus, Regulus will not have the right to terminate this Agreement unless and until the existence of
such material breach or failure by Sanofi has been determined in accordance with Section&nbsp;12.4 and Sanofi fails to cure such breach within 30&nbsp;days following such determination. It is understood and acknowledged that during the pendency of
such a dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.5 Automatic Termination.</B> If, at any time, (a)&nbsp;no Option for any POC Program remains exercisable (whether due to
expiration of the applicable Option Period or early termination of the applicable POC Program), (b)&nbsp;the license granted by Regulus to Sanofi pursuant to Section&nbsp;2.1.1 has terminated in its entirety, and (c)&nbsp;no Program License for any
POC Program is in effect, then, effective upon the last to occur of (a), (b)&nbsp;and (c), this Agreement shall automatically terminate in its entirety. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.6 Consequences of Termination. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>9.6.1 Licenses.</B> Upon termination of this Agreement in its entirety by either Party pursuant to this Article&nbsp;9 or automatic
termination of this Agreement in its entirety pursuant to Section&nbsp;9.5, the licenses granted by Regulus to Sanofi hereunder will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>9.6.2 Return of Information and Materials.</B> Upon termination of this Agreement in its entirety by either Party pursuant to this
Article&nbsp;9 or automatic termination of this Agreement in its entirety pursuant to Section&nbsp;9.5, the Parties will return (or destroy, as directed by the other Party) all data, files, records and other materials containing or comprising the
other Party&#146;s Confidential Information. Notwithstanding the foregoing, the Parties will be permitted to retain one copy of such data, files, records, and other materials for archival purposes, and with respect to Regulus, to practice its rights
under Section&nbsp;10.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.7 Accrued Rights; Surviving Obligations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>9.7.1 Accrued Rights.</B> Termination or expiration of this Agreement for any reason will be without prejudice to any rights or financial
compensation that will have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration will not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>9.7.2 Survival.</B> Articles&nbsp;7,&nbsp;9,&nbsp;10, 11 and 13; and Section&nbsp;6.18, Section&nbsp;6.21, and
Section&nbsp;12.4 of this Agreement will survive expiration or termination of this Agreement for any reason. Furthermore, Regulus hereby grants to Sanofi a worldwide non-exclusive license, with the right to grant sublicenses under Section&nbsp;2.4,
to Regulus Know-How existing now or in the future and disclosed to Sanofi during the Term, solely for the further manufacture and sale of Licensed Compounds and Products after the expiration (but not the termination) of the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.8 Rights in Bankruptcy.</B> All rights and licenses granted under or pursuant to this Agreement by Regulus or Sanofi are,
and will otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the U.S. Bankruptcy Code (<I>i.e.</I>, Title 11 of the U.S. Code) or analogous provisions of Applicable Law outside the United States, licenses of rights to
&#147;intellectual property&#148; as defined under Section&nbsp;101 of the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States. The Parties agree that each Party, as licensee of such rights under this Agreement,
will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or any other provisions of Applicable Law outside the United States that provide similar protection for &#145;intellectual property.&#146; The Parties
further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of Applicable Law outside the United States, the Party that is not subject to such
proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in the non subject Party&#146;s possession, will be
promptly delivered to it upon the non subject Party&#146;s written request therefor. Any agreements supplemental hereto will be deemed to be &#147;agreements supplementary to&#148; this Agreement for purposes of Section&nbsp;365(n) of the U.S.
Bankruptcy Code. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULUS REVERSION RIGHT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;10.1 Regulus Reversion Rights.</B> For clarity, the Parties&#146; rights and obligations under this Section&nbsp;10.1 are in
addition to their rights and obligations under Sections&nbsp;2.1.4, 2.2.3, 3.4.3(a) and 3.4.3(b), and this Article&nbsp;10 shall not apply to any Expired <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Product, Terminated <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Program Product, or any <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Product that is the subject of a license granted to Regulus pursuant to Section&nbsp;2.2.3(b) or Section&nbsp;3.4.3(b)(ii). If
(i)&nbsp;Sanofi terminates the Agreement (in full or on a Product-by-Product basis) under Section&nbsp;9.2, (ii)&nbsp;Sanofi&#146;s Program License with respect to a POC Program Product is terminated after Sanofi&#146;s exercise of its Option with
respect to such POC Program, or (iii)&nbsp;Regulus terminates the Agreement under Section&nbsp;9.3 or Section&nbsp;9.4, Regulus may continue to Develop and Commercialize any Licensed Compound or Product that is the subject of such termination or
expiration (a <B><I>&#147;Discontinued</I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B><I></I></B><B><I>Product&#148;</I></B>). If Regulus provides a notice in writing to Sanofi within 90&nbsp;days of such termination (an <B><I>&#147;Election Notice&#148;</I></B>) that Regulus
is exercising its rights under this Section&nbsp;10.1, subject to Regulus&#146; payment obligations (if applicable) under Section&nbsp;10.2, Sanofi will, and it hereby does: (x)&nbsp;grant to Regulus a sublicensable, worldwide license or sublicense,
as the case may be, to all Sanofi Product Specific Patents, Program Patents and Research Results Controlled by Sanofi as of the date of the Election Notice solely as they are necessary to make, have made, use, sell, offer for sale, have sold and
import Discontinued Products, (y)&nbsp;transfer to Regulus, for Regulus&#146; use with respect to the Development and Commercialization of the Discontinued Products, any data, results, regulatory information and files in the possession of Sanofi as
of the date of the Election Notice that relate to such Discontinued Products, and (z)&nbsp;transfer and assign to Regulus all Regulatory Documentation with respect to such Discontinued Product (including but not limited to identifying for Regulus,
and authorizing Regulus to reference, any Drug Master File with a Regulatory Authority related to such Discontinued Product). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;10.2 Regulus Payment Obligations for Reversion Rights.</B> If, after Sanofi has paid the Option Exercise Fee and the POC
Program Reimbursement Amount for a POC Program, both (a)&nbsp;Regulus provides an Election Notice for any Discontinued Product and (b)&nbsp;prior to the applicable termination under this Agreement, such Discontinued Product had completed
[&#133;***&#133;] with respect to the applicable POC Program, then Regulus shall pay to Sanofi (i)&nbsp;[&#133;***&#133;] of any [&#133;***&#133;] such Discontinued Product [&#133;***&#133;]; or (ii)&nbsp;if [&#133;***&#133;] with the provisions of
Section&nbsp;6.10 through Section&nbsp;6.21 applying <B></B><I>mutatis mutandis</I><B></B>. For purposes of this Agreement, <B></B><B><I>&#147;Licensing Revenues&#148;</I></B><B></B> will mean any payments that Regulus receives from a Third Party in
consideration of a license to further the Development and Commercialization of a Discontinued <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product, in each case including, but not limited to, upfront payments, license fees, regulatory or sales
milestone payments, royalties and/or profit sharing payments, but <B></B><I>excluding</I><B></B>: (i)&nbsp;payments made in consideration of [&#133;***&#133;], (ii)&nbsp;payments to [&#133;***&#133;], and (iii)&nbsp;payments to [&#133;***&#133;].
<B> </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION, INSURANCE AND LIMITATION OF LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.1 Indemnification of Regulus.</B> Sanofi agrees to defend Regulus, its Affiliates and their respective directors, officers,
stockholders, employees and agents, and their respective successors, heirs and assigns (collectively, the <B><I>&#147;Regulus Indemnitees&#148;</I></B>), and will indemnify and hold harmless the Regulus Indemnitees, from and against any liabilities,
losses, costs, damages, fees or expenses payable to a Third Party, and reasonable attorneys&#146; fees and other legal expenses with respect thereto (collectively, <B><I>&#147;Losses&#148;</I></B>) arising out of any claim, action, lawsuit or other
proceeding by a Third Party (collectively, <B><I>&#147;Third Party Claims&#148;</I></B>) brought against any Regulus Indemnitee and resulting from or occurring as a result of: (a)&nbsp;any Sanofi </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Program Activities conducted by a Sanofi employee, consultant or (sub)contractor in the performance of a POC Program; (b)&nbsp;the Development, manufacture, use, handling, storage, sale or other
Commercialization or disposition of any Licensed Compound or Product in the Territory by Sanofi or its Affiliates, sublicensees or contractors, (c)&nbsp;any breach by Sanofi of any of its representations, warranties or covenants pursuant to this
Agreement or (d)&nbsp;the negligence or willful misconduct of Sanofi or any Sanofi Affiliate or sublicensee in connection with this Agreement; <I>except</I> in any such case to the extent such Losses result from: (i)&nbsp;the negligence or willful
misconduct of any Regulus Indemnitee, (ii)&nbsp;any breach by Regulus of any of its representations, warranties, covenants or obligations pursuant to this Agreement, or (iii)&nbsp;any breach of Applicable Law by any Regulus Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.2 Indemnification of Sanofi.</B> Regulus agrees to defend Sanofi, its Affiliates and their respective directors, officers,
stockholders, employees and agents, and their respective successors, heirs and assigns (collectively, the <B><I>&#147;Sanofi Indemnitees&#148;</I></B>), and will indemnify and hold harmless the Sanofi Indemnitees, from and against any Losses and
Third Party Claims brought against any Sanofi Indemnitee and resulting from or occurring as a result of: (a)&nbsp;any activities conducted by a Regulus employee, consultant or (sub)contractor in the performance of the Research Program or a POC
Program (unless such activities were the subject of a dispute between Regulus&#146; and Sanofi&#146;s representatives on the JSC that was finally resolved by Sanofi&#146;s Senior Representative, as reflected in the minutes of JSC proceedings);
(b)&nbsp;the Development, manufacture, use, handling, storage, sale or other Commercialization or disposition of any Licensed Compound or Product in the Territory by Regulus or its Affiliates, sublicensees or contractors; (c)&nbsp;any breach by
Regulus of any of its representations, warranties or covenants pursuant to this Agreement or (d)&nbsp;the negligence or willful misconduct of any Regulus Indemnitee or any (sub)contractor of Sanofi in connection with this Agreement; <I>except</I> in
any such case to the extent such Losses result from: (i)&nbsp;the negligence or willful misconduct of any Sanofi Indemnitee, (ii)&nbsp;any breach by Sanofi of any of its representations, warranties, covenants or obligations pursuant to this
Agreement, or (iii)&nbsp;any breach of Applicable Law by any Sanofi Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.3 Notice of Claim.</B> All
indemnification claims provided for in Sections&nbsp;11.1 and 11.2 will be made solely by such Party to this Agreement (the <B><I>&#147;Indemnified Party&#148;</I></B>). The Indemnified Party will give the indemnifying Party prompt written notice
(an <B><I>&#147;Indemnification Claim Notice&#148;</I></B>) of any Losses or the discovery of any fact upon which the Indemnified Party intends to base a request for indemnification under Section&nbsp;11.1 or 11.2, but in no event will the
indemnifying Party be liable for any Losses to the extent such Losses result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent
that the nature and amount of such Loss is known at such time). The Indemnified Party will furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.4 Defense, Settlement, Cooperation and Expenses. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>11.4.1 Control of Defense.</B> At its option, the indemnifying Party may assume the defense of any Third Party Claim by giving written
notice to the Indemnified Party within 30 calendar days after the indemnifying Party&#146;s receipt of an Indemnification Claim Notice. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumption of the defense of a Third Party Claim by the indemnifying Party will not be construed as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in
respect of the Third Party Claim, nor will it constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified Party&#146;s claim for indemnification. Upon assuming the defense of a Third Party Claim, the
indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party. In the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party will
as soon as is reasonably possible deliver to the indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume the
defense of a Third Party Claim, except as provided in Section&nbsp;11.4.1, the Indemnified Party will be responsible for the legal costs or expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or
settlement of the Third Party Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>11.4.2 Right to Participate in Defense.</B> Without limiting Section&nbsp;11.4.1, any Indemnified
Party will be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; <I>provided, however</I>, that such employment will be at the Indemnified Party&#146;s own cost
and expense unless (i)&nbsp;the employment thereof has been specifically authorized by the indemnifying Party in writing, (ii)&nbsp;the indemnifying Party has failed to assume the defense and employ counsel in accordance with Section&nbsp;11.4.1 (in
which case the Indemnified Party will control the defense) or (iii)&nbsp;the interests of the Indemnified Party and the indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same
counsel of both Parties under Applicable Law, ethical rules or equitable principles in which case the indemnifying Party will be responsible for any such costs and expenses of counsel for the Indemnified Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>11.4.3 Settlement.</B> With respect to any Third Party Claims relating solely to the payment of money damages in connection with a Third
Party Claim and that will not admit liability or violation of Law on the part of the Indemnified Party or result in the Indemnified Party&#146;s becoming subject to injunctive or other relief or otherwise adversely affecting the business of the
Indemnified Party in any manner (such as granting a license or admitting the invalidity of a Patent Controlled by an Indemnified Party), and as to which the indemnifying Party will have acknowledged in writing the obligation to indemnify the
Indemnified Party hereunder, the indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, will
deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section&nbsp;11.4.1, the indemnifying Party will have
authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will not be unreasonably withheld). The indemnifying
Party will not be liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached without the written consent of the indemnifying Party. Regardless of whether the indemnifying Party chooses to defend or prosecute any
Third Party Claim, no Indemnified Party will admit any liability with respect to or settle, compromise or discharge, any Third Party Claim without the prior written consent of the indemnifying Party, such consent not to be unreasonably withheld.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>11.4.4 Cooperation.</B> Regardless of whether the indemnifying Party chooses to defend or
prosecute any Third Party Claim, the Indemnified Party will, and will cause each other Indemnified Party to, cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend
such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation will include access during normal business hours afforded to indemnifying Party to, and reasonable
retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide additional
information and explanation of any material provided hereunder, and the indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket costs and expenses in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>11.4.5 Costs and Expenses.</B> Except as provided above in this Section&nbsp;11.4, the costs and expenses, including attorneys&#146; fees
and expenses, incurred by the Indemnified Party in connection with any claim will be reimbursed on a Calendar Quarter basis by the indemnifying Party, without prejudice to the indemnifying Party&#146;s right to contest the Indemnified Party&#146;s
right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.5 Insurance.</B> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>11.5.1 Regulus&#146; Insurance Obligations</B><B>.</B> Regulus shall maintain, at its cost, reasonable insurance against liability and
other risks associated with its activities contemplated by this Agreement, including but not limited to its indemnification obligations herein, in such amounts and on such terms as are customary for prudent practices for biotech companies of similar
size and with similar resources in the pharmaceutical industry for the activities to be conducted by it under this Agreement taking into account the scope of development of products, provided, that, at a minimum, Regulus shall maintain, in force at
its sole cost, a general liability insurance policy providing coverage of at least $[&#133;***&#133;] per claim and $[&#133;***&#133;] annual aggregate. In addition to the foregoing, in the event that Regulus plans to Commercialize any Discontinued
Product, then Regulus shall increase its insurance coverage commensurate with the additional liability and other risks associated with Commercialization activities, and at a minimum provide that the annual aggregate amount of such coverage is
increased to at least $[&#133;***&#133;] at least thirty (30)&nbsp;days before Regulus initiates the First Commercial Sale of any Discontinued Product hereunder. Regulus shall furnish to Sanofi evidence of any insurance required under this
Section&nbsp;11.5, upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>11.5.2 Sanofi&#146;s Insurance Obligations</B><B>.</B> Sanofi hereby represents and warrants to
Regulus that it is self-insured against liability and other risks associated with its activities and obligations under this Agreement in such amounts and on such terms as are customary for prudent practices for large companies in the pharmaceutical
industry for the activities to be conducted by Sanofi under this Agreement. Sanofi shall maintain such self insurance throughout the term of this Agreement and shall furnish to Regulus evidence of such self-insurance, upon request. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12.1 Representations, Warranties and Covenants.</B> Each Party hereby represents and warrants as of the Effective Date and
covenants to the other Party that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.1.1 </B>it has the power and authority and the legal right to enter into this Agreement and
perform its obligations hereunder, and that it has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.1.2 </B>this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding
obligation of such Party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting
the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.1.3 </B>all necessary consents, approvals and authorizations of all Regulatory Authorities and other Parties required to be obtained by
such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.1.4 </B>the execution and delivery of this Agreement and the performance of such Party&#146;s obligations hereunder (i)&nbsp;do not
conflict with or violate any requirement of Applicable Law or any provision of the certificate of incorporation, bylaws or any similar instrument of such Party, as applicable, in any material way, and (ii)&nbsp;do not conflict with, violate, or
breach or constitute a default or require any consent not already obtained under, any contractual obligation or court or administrative order by which such Party is bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12.2 Regulus Representations, Warranties, and Covenants</B><B>.</B> Regulus hereby represents and warrants to Sanofi as of the
Effective Date that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.1 </B>Regulus is the owner of, or otherwise has the right to grant all rights and licenses it purports to
grant to Sanofi with respect to the Regulus Patents under this Agreement for Mir-21 and Licensed Compounds identified by Regulus on or before the Effective Date that target Mir-21; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.2 </B>To the best of its knowledge and belief, Regulus does not require any additional licenses or other intellectual property rights
in order for Regulus to conduct its obligation under the R&amp;D Plan with respect to Mir-21 and Licensed Compounds identified by Regulus on or before the Effective Date that target Mir-21; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.3 </B>Regulus has not received any written claim alleging that any of the Regulus Patents are invalid or unenforceable; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.4 </B>Regulus has not received any written claim alleging that any of Regulus&#146;
activities relating to Mir-21 and Licensed Compounds identified by Regulus on or before the Effective Date that target Mir-21, or any of Regulus&#146; activities of the type proposed to be undertaken pursuant to the R&amp;D Plan, infringe any
intellectual property rights of a Third Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.5 </B>All employees, consultants, or (sub)contractors of Regulus or Affiliates
performing Development activities hereunder on behalf of Regulus are, and Regulus hereby covenants to Sanofi that they will be, obligated to assign all right, title and interest in and to any inventions developed by them, whether or not patentable,
to Regulus or Affiliate, respectively, as the sole owner thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.6 </B>Regulus will, and Regulus hereby covenants to, as
appropriate, hire and maintain sufficient staff and management to support and conduct the Research Program and each POC Program hereunder in a timely fashion; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.7 </B>If reasonably requested by Sanofi in writing, Regulus will, and Regulus hereby covenants to, take reasonable, good faith
measures and cooperate with Sanofi to help to facilitate a good faith negotiation between Sanofi and any Existing Regulus Agreement in the event that Sanofi desires to pursue the Development or Commercialization of any Licensed Compound or Product
and would require a license directly from any such Third Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.8 </B>Regulus will not, and Regulus hereby covenants to Sanofi
not to, withhold from Sanofi any material information or correspondence, including to or from any Regulatory Authority, that would be material and relevant to a reasonable assessment of the scientific, commercial, safety, and regulatory liabilities
or commercial value of the Licensed Compounds; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.9 </B>Regulus will, and Regulus hereby covenants to Sanofi that it will, perform
its activities pursuant to this Agreement in compliance with good laboratory and clinical practices and cGMP, in each case as applicable under the laws and regulations of the country and the state and local government wherein such activities are
conducted, and with respect to the care, handling and use in Development activities hereunder of any non-human animals by or on behalf of Regulus, will at all times comply (and will ensure compliance by any of its subcontractors) with all applicable
federal, state and local laws, regulations and ordinances and the guiding principles of the &#147;3R&#146;s&#148;, namely, wherever reasonably possible, reducing the number of animals used, replacing animals with non-animal methods and refining the
research techniques used for the proper care, handling and use of animals in pharmaceutical research and development activities; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>12.2.10 </B>The licenses granted to Regulus under the Existing Regulus Agreements are in full force and effect and Regulus has not received
any written notice, and is not aware, of any breach by any party to the Existing Regulus Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12.3 Sanofi
Covenants.</B> Sanofi hereby covenants to Regulus that it will perform its activities pursuant to this Agreement in compliance with good laboratory and clinical practices and cGMP, in each case as applicable under the laws and regulations of the
country and the state and local government wherein such activities are conducted, and with respect to the care, handling and use in Development activities hereunder of any non-human animals by or on </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
behalf of Sanofi, will at all times comply (and will ensure compliance by any of its subcontractors) with all Applicable Laws and the guiding principles of the &#147;3R&#146;s&#148;, namely,
wherever reasonably possible, reducing the number of animals used, replacing animals with non-animal methods and refining the research techniques used for the proper care, handling and use of animals in pharmaceutical research and development
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12.4 DISCLAIMER OF WARRANTY.</B> EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS ARTICLE 12, SANOFI AND
REGULUS MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND SANOFI AND REGULUS EACH SPECIFICALLY DISCLAIM ANY WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.1 Assignment; Sanofi Affiliates.</B> Except as expressly set forth in this Agreement, without the prior written consent of
the other Party hereto, neither Party will sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; <I>provided,
however,</I> that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>either Party may assign this Agreement and its rights and obligations hereunder without the other
Party&#146;s consent in connection with the transfer or sale of all or substantially all of the business of such Party to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise, provided that in
the event of such a sale or transfer (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (<I>e.g.</I>, in the context of a reverse triangular merger)), intellectual property rights of the acquiring
party in such sale or transfer (if other than one of the Parties to this Agreement) shall not be included in the technology licensed hereunder or otherwise subject to this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Sanofi may, without Regulus&#146; consent, assign this Agreement and its rights and obligations hereunder to an Affiliate of
Sanofi, provided that such Affiliate agrees to be bound by the terms and conditions of this Agreement and that no such assignment to an Affiliate will relieve Sanofi of its obligations hereunder; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Regulus may assign or transfer its rights under Article&nbsp;6 (but no liabilities) to a Third Party in connection with a royalty
factoring transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of
the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#146;s successors and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permitted assigns to the extent necessary to carry out the intent of this section. Any purported assignment or transfer in violation of this Section&nbsp;13.1 will be void <I>ab initio</I> and of
no force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.2 Severability.</B> If any provision of this Agreement is held to be illegal, invalid or
unenforceable by a court of competent jurisdiction, such adjudication will not affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement. All remaining portions will remain in full
force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.3 Governing Law; Jurisdiction.</B> This Agreement will be governed by and construed and enforced in accordance with the
laws of the State of New York, USA without reference to any rules of conflicts of laws. For clarification, any dispute relating to the scope, validity, enforceability or infringement of any Patents will be governed by and construed and enforced in
accordance with the patent laws of the applicable jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.4 Dispute Resolution. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.4.1 Resolution by Senior Representatives.</B> The Parties will seek to settle amicably any and all disputes, controversies or claims
arising out of or in connection with this Agreement. Any dispute within the JSC&#146;s decision-making authority will be finally decided as set forth in <B>A<SMALL>PPENDIX</SMALL>&nbsp;5</B>. Any dispute between the Parties which is outside the
JSC&#146;s <FONT STYLE="white-space:nowrap">decision-making</FONT> authority and is not subject to resolution under Section&nbsp;6.11.1 or Section&nbsp;13.4.5 will be promptly presented to each Party&#146;s respective co-chair of the JSC for
resolution, and if the co-chairs of the JSC are unable to resolve such dispute, such dispute will then be presented to the Executive VP of R&amp;D of Sanofi and the Executive Vice President of Regulus (the <B><I>&#147;Senior
Representatives&#148;</I></B>), or their respective designees, for resolution. Such Senior Representatives, or their respective designees, will meet in-person or by teleconference as soon as reasonably possible thereafter, and use their good faith
efforts to mutually agree upon the resolution of the dispute, controversy or claim. Any dispute within the JSC&#146;s decision-making authority will not be subject to arbitration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.4.2 Request for Arbitration.</B> If after negotiating in good faith pursuant to Section&nbsp;13.4.1, after good faith discussions
undertaken within reasonable promptness, to reach an amicable agreement within 90&nbsp;days, then either Party may upon written notice to the other submit to binding arbitration pursuant to Section&nbsp;13.4.3 below. No statements made by either
Party during such discussions will be used by the other Party or admissible in arbitration or any other subsequent proceeding for resolving the dispute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.4.3 Arbitration. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Any dispute, claim or controversy arising from or related in any way to this Agreement or the interpretation, application, breach,
termination or validity thereof, including any claim of inducement of this Agreement by fraud or otherwise, not resolved under the provisions of Section&nbsp;13.4.1 will be resolved by final and binding arbitration conducted in accordance with the
terms of this Section&nbsp;13.4.3. The arbitration will be held in New York, New York, USA according to Rules of Arbitration of the International Chamber of Commerce </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(<B><I>&#147;ICC&#148;</I></B>). The arbitration will be conducted by a panel of three (3)&nbsp;arbitrators with significant experience in the pharmaceutical industry, unless otherwise agreed by
the Parties, appointed in accordance with applicable ICC rules. Any arbitration herewith will be conducted in the English language to the maximum extent possible. The arbitrators will render a written decision no later than six (6)&nbsp;months
following the selection of the arbitrators, including a basis for any damages awarded and a statement of how the damages were calculated. Any award will be promptly paid in U.S. dollars free of any tax, deduction or offset. Each Party agrees to
abide by the award rendered in any arbitration conducted pursuant to this Section&nbsp;13.4.3. With respect to money damages, nothing contained herein will be construed to permit the arbitrator or any court or any other forum to award punitive or
exemplary damages, except in the case of breach of Article&nbsp;7. By entering into this agreement to arbitrate, the Parties expressly waive any claim for punitive or exemplary damages, except in the case of breach of Article&nbsp;7. Each Party will
pay its legal fees and costs related to the arbitration (including witness and expert fees). Judgment on the award so rendered will be final and may be entered in any court having jurisdiction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY. EACH PARTY HERETO WAIVES ANY CLAIM FOR ATTORNEYS&#146; FEES AND
COSTS AND PREJUDGMENT INTEREST FROM THE OTHER. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>EXCEPT FOR LOSSES COVERED BY THE INDEMNITIES PROVIDED UNDER ARTICLE 11, AND
ANY BREACH OF THE CONFIDENTIALITY RESTRICTIONS UNDER ARTICLE 7, EACH PARTY HERETO WAIVES (1)&nbsp;ANY CLAIM TO PUNITIVE, EXEMPLARY OR MULTIPLIED DAMAGES FROM THE OTHER; AND (2)&nbsp;ANY CLAIM OF CONSEQUENTIAL, INDIRECT OR INCIDENTAL DAMAGES FROM THE
OTHER. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.4.4 Disputes Regarding Material Breach.</B> If the Parties are in dispute as to whether one Party is in material breach of
this Agreement, then the arbitrator will first determine if material breach has in fact occurred, and if so, will grant the defaulting Party the cure period provided pursuant to Section&nbsp;9.3 (or 9.2, as applicable). If the material breach is not
cured within the time period provided pursuant to Section&nbsp;9.3 (or 9.2, as applicable), the arbitration will continue and the arbitrator will, as part of the same arbitration, award actual direct damages to the
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.4.5 Certain Matters Subject to Expert Panel.</B> If, at any time
during the Research Term, the Parties disagree on any matter arising from the a POC Program, the Parties may elect by mutual agreement to submit such matter to a panel of three (3)&nbsp;experts who are experienced in the field of biopharmaceuticals
(an <B><I>&#147;Expert Panel&#148;</I></B>). All members of the Expert Panel must be mutually agreed by the Parties in good faith and as promptly as possible and must be free of any conflicts of interest with respect to either or both Parties. The
Expert Panel will promptly hold a hearing to review the matter, at which they will consider briefs submitted by each Party at least 15&nbsp;days before the hearing, as well as reasonable presentations that each Party may present. The determination
of the relevant Expert Panel as to such dispute will be binding on both Parties. The Parties will share equally in the costs of the Expert Panel, and each Party will bear its own costs associated with preparing for and presenting to the Expert
Panel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.4.6 Court Actions.</B> Nothing contained in this Agreement shall deny either Party the
right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a <I>bona fide</I> emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing
dispute resolution discussions or arbitration proceeding. In addition, either Party may bring an action in any court of competent jurisdiction to resolve disputes pertaining to the validity, construction, scope, enforceability, infringement or other
violations of patents or other proprietary or intellectual property rights, and no such claim shall be subject to arbitration pursuant to Section&nbsp;13.4.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.5 Notices.</B> Except as otherwise provided for in this Agreement, all notices or other communications that are required or
permitted hereunder will be in the English Language and in writing and delivered personally with acknowledgement of receipt, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier as
provided herein), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Sanofi, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">54, rue la Bo&eacute;tie </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">75008
Paris, France </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile No.: +33 1 53 77 43 03 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">9 Rue du Pr&eacute;sident Allende, 94256 Gentilly&nbsp;Cedex, France </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: License Management </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile No.: +33 1 53 77 48 51 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Regulus,
to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Regulus Therapeutics Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">3545 John Hopkins Court, Suite 210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">San Diego, California 92121-1121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">USA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Chief Scientific
Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: +1 (858)&nbsp;202-6363 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: +1 (858)&nbsp;202-6363 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such
communication will be deemed to have been given (i)&nbsp;when delivered, if personally delivered or sent by facsimile on a Business Day, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;on the Business Day after dispatch, if sent by nationally-recognized overnight courier, and (iii)&nbsp;on the third Business Day following the date of mailing, if sent by mail. It is
understood and agreed that this Section&nbsp;13.5 is not intended to govern the day-to-day business communications necessary between the Parties in performing their duties, in due course, under the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.6 Entire Agreement; Modifications.</B> This Agreement (including the attached Appendices and the POC Program Plans),
together with the Stock Purchase Agreement, sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and thereof, and all prior agreements, understanding, promises and
representations, whether written or oral, with respect thereto are superseded hereby. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth herein. No amendment,
modification, release or discharge will be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.7 Headings.</B> The headings of Articles and Sections&nbsp;of this Agreement are for ease of reference only and will not
affect the meaning or interpretation of this Agreement in any way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.8 Relationship of the Parties.</B> It is expressly
agreed that the Parties will be independent contractors of one another and that the relationship between the Parties will not constitute a partnership, joint venture or agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.9 Waiver.</B> Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the
benefit thereof, but no such waiver will be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. Any such waiver will not be deemed a waiver of any other right or breach
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.10 Counterparts.</B> This Agreement may be executed in two or more counterparts, each of which will be
deemed an original, but all of which together will constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.11 No Benefit to Third
Parties.</B> The representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they will not be construed as conferring any rights on
any other parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.12 Further Assurances.</B> Each Party will duly execute and deliver, or cause to be duly executed
and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary to carry out the provisions and purposes of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.13 Force Majeure.</B> Neither Party will be charged with any liability for delay in performance of an
obligation under this Agreement to the extent such delay is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor disturbances, fire, explosion, earthquake, and compliance in good faith with any governmental
Law, regulation or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
order. The Party affected will give prompt written notice to the other Party of any material delay due to such causes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.14 Interpretation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.14.1 </B>Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between
them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their
counsel. Accordingly, in the event an ambiguity or a question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the Parties and no presumption or burden of proof will arise favoring or disfavoring any
Party by virtue of the authorship of any provisions of this Agreement. This Agreement has been prepared in the English language and the English language shall control its interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.14.2 </B>The definitions of the terms herein will apply equally to the singular and plural forms of the terms defined. Whenever the
context may require, any pronoun will include the corresponding masculine, feminine and neuter forms. The words &#147;include&#148;, &#147;includes&#148; and &#147;including&#148; will be deemed to be followed by the phrase &#147;without
limitation&#148;. The word &#147;will&#148; will be construed to have the same meaning and effect as the word &#147;will&#148;. The word &#147;any&#148; will mean &#147;any and all&#148; unless otherwise clearly indicated by context. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.14.3 </B>Unless the context requires otherwise, (i)&nbsp;any definition of or reference to any agreement, instrument or other document
herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or
therein), (ii)&nbsp;any reference to any Applicable Laws herein will be construed as referring to such Applicable Laws as from time to time enacted, repealed or amended, (iii)&nbsp;any reference herein to any person will be construed to include the
person&#146;s successors and assigns, (iv)&nbsp;the words &#147;herein&#148;, &#147;hereof&#148; and &#147;hereunder&#148;, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision
hereof, and (v)&nbsp;all references herein to Articles, Sections&nbsp;or Appendices, unless otherwise specifically provided, will be construed to refer to Articles, Sections&nbsp;and Appendices of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>13.14.4 </B>References to sections of the Code of Federal Regulations and to the United States Code will mean the cited sections, as these
may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Parties hereto have caused this Agreement to be executed by their
duly authorized representatives as of the date first above written.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>EGULUS</SMALL> T<SMALL>HERAPEUTICS</SMALL> I<SMALL>NC</SMALL>.
</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kleanthis G. Xanthopoulos</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Kleanthis G. Xanthopoulos, Ph.D.</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>S<SMALL>ANOFI</SMALL></B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Philippe Goupit</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Philippe Goupit</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Vice President, Corporate Licenses</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>SIGNATURE PAGE
&#150;SECOND AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT</I> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Appendices </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;1:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Definitions</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;2:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Product Specific Patents</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;3:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Regulus Core Technology Patents</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;4:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Charter of JSC</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;5:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Existing Regulus Agreements</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;6:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Initial POC Program Plans</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;6A:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Initial <FONT STYLE="white-space:nowrap">Mir-21</FONT> Fibrosis POC Program Plan</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;6B:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Initial <FONT STYLE="white-space:nowrap">Mir-21</FONT> Oncology POC Program Plan</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;6C:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Initial <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Oncology POC Program Plan</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;7:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Listed Countries</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;8:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">R&amp;D Plan</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;9:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Regulus Detailed Allocation of Upfront Payments</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;10:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Co-Promotion</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;11:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Profit-Sharing</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appendix&nbsp;12:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Regulus Second Restatement Press Release</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Achievement of Proof of Concept&#148;</B> means, with respect to a particular POC Program, a determination by the JSC or an Expert
Panel (as applicable) that a POC Program Product that is the subject of such POC Program has demonstrated Proof of Concept in the applicable POC Study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Affiliate&#148;</B> means any Person, whether <I>de jure </I>or<I> de facto</I>, which directly or indirectly through one (1)&nbsp;or
more intermediaries controls, is controlled by or is under common control with another Person. A Person will be deemed to &#147;control&#148; another Person if it (a)&nbsp;owns, directly or indirectly, beneficially or legally, at least 50% of the
outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a Person in a particular jurisdiction) of such other Person, or has other comparable ownership interest with respect to any Person
other than a corporation; or (b)&nbsp;has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of the Person. Notwithstanding the above, neither of the Founding Companies of Regulus
will be deemed an Affiliate of Regulus for the purposes of this Agreement under any circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Agreement&#148;</B> means
this Second Amended and Restated Collaboration and License Agreement, together with all Appendices attached hereto, and the Program Plans, as the same may be amended or supplemented from time to time in accordance with the terms of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;API&#148;</B> means, with respect to a Product, the bulk active pharmaceutical ingredient for a Licensed Compound manufactured
in accordance with GMP for such Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Applicable Law&#148;</B> or <B>&#147;Law&#148;</B> means all applicable laws, statutes,
rules, regulations and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, agency or other body, domestic or foreign, including but not limited to any
applicable rules, regulations, guidelines, or other requirements of the Regulatory Authorities that may be in effect from time to time, but excluding patent laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Approval&#148;</B> means, with respect to any Product in any regulatory jurisdiction, approval from the applicable Regulatory
Authority sufficient for the manufacture, distribution, use and sale of the Product in such jurisdiction in accordance with Applicable Laws. In jurisdictions where the applicable Regulatory Authority sets the pricing authorizations necessary for a
Product, Approval will not be deemed to have occurred if the final approval to market and sell the Product is being withheld because Sanofi (or its Affiliates or sublicensee) and the Regulatory Authority have not yet determined pricing;
<I>provided</I><I>,</I> <I>however</I>, that the First Commercial Sale in such jurisdiction will be considered Approval in such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Business Day&#148;</B> means a day on which banking institutions in New York, New York, United States and Paris, France are both open
for business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Calendar Quarter&#148;</B> means the respective periods of three consecutive calendar months ending on
March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 and December 31. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Collaboration Target&#148;</B> means either:
<FONT STYLE="white-space:nowrap">(i)&nbsp;Mir-21;</FONT> or <FONT STYLE="white-space:nowrap">(ii)&nbsp;Mir-221</FONT> and/or <FONT STYLE="white-space:nowrap">Mir-222.</FONT><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Combination Product&#148;</B> means a Product that includes at least one additional active ingredient (whether coformulated or
copackaged) which is not a Licensed Compound.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Commercialize&#148;</B>, <B>&#147;Commercializing&#148;</B> and
<B>&#147;Commercialization&#148;</B> means activities directed to manufacturing, obtaining pricing and reimbursement approvals, for, marketing, promoting, distributing, importing or selling a Product, including, without limitation, conducting
pre-and post-Approval activities, including studies reasonably required to increase the market potential of the Product and studies to provide improved formulation and Product delivery.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Commercially Reasonable Efforts&#148;</B> means, with respect to a Licensed Compound and Product, the carrying out of discovery,
research, Development or Commercialization activities using the efforts that the applicable Party would reasonably devote to a compound or product of similar market potential at a similar stage in development or product life resulting from its own
research efforts, taking into account product profile, the competitive landscape and other relevant scientific, technical and commercial factors.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Companion Diagnostic&#148;</B> means, with respect to a Product, any product or method useful for detecting the applicable
Collaboration Target as a biomarker for identifying patient populations that are better suited to respond to the corresponding Product in the treatment and/or prophylaxis of an approved Indication for the Product.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Confidential Information&#148; </B>has the meaning set forth in Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Control&#148;</B> means, with respect to any Know-How, Patent or other intellectual property right, possession by a Party (including
its Affiliates) of the right (whether by ownership, license or otherwise) to grant to the other Party ownership, a license, sublicense and/or other right to practice under such Know How, Patent or other intellectual property right as provided for
herein without violating the terms of any agreement or other arrangement with any Third Party. Notwithstanding anything to the contrary under this Agreement, with respect to any Third Party acquirer that later becomes an Affiliate of Regulus after
the Effective Date, no intellectual property of such Third Party acquirer will be included in the licenses granted hereunder by virtue of such Third Party acquirer becoming an Affiliate of Regulus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Co-Promote Option&#148;</B> has the meaning set forth in Section&nbsp;Section 2.3.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Co-Promote Right&#148;</B> has the meaning set forth in Section&nbsp;Section 2.3.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Cover&#148;</B>, <B>&#147;Covered&#148;</B> or <B>&#147;Covering&#148;</B> means, with respect to a Patent, that, but for rights
granted to a Person under such Patent, the practice by such Person of an invention claimed in such Patent would infringe a Valid Claim included in such Patent, or in the case of a Patent that is a patent application, would infringe a Valid Claim in
such patent application if it were to issue as a patent.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Development&#148;</B> means non-clinical (such as, but not
limited to, IND-enabling toxicology and production of GMP quality Product) and clinical development activities reasonably related to the development and submission of information to a Regulatory Authority, including, without <B>
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
</B>limitation, chemical synthesis, toxicology, pharmacology, test method development and stability testing, manufacturing process development, formulation development, delivery system
development, quality assurance and quality control development, manufacturing, statistical analysis, and clinical studies. When used as a verb, <B>&#147;Develop&#148;</B> means to engage in Development.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Development Candidate&#148;</B> means, on a POC Program-by-POC Program basis, a Licensed Compound meeting the Development Candidate
Criteria set forth in the applicable POC Program Plan.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Development Candidate Criteria&#148;</B> means, on a POC
Program-by-POC Program basis, with respect to the Collaboration Target that is the subject of a POC Program, the description, as set forth in the applicable POC Program Plan, of the characteristics that shall be used by Regulus to guide the
selection of a Licensed Compound from such POC Program as a candidate for the filing of an IND in an Indication in the applicable Target Field. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Disclosing Party&#148;</B> has the meaning set forth in Section 7.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Discontinued Product&#148;</B> has the meaning set forth in Section 10.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Dollars&#148;</B> or <B>&#147;$&#148;</B> means the lawful currency of the United States.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Effective Date&#148;</B> has the meaning set forth in the recitals on the first page of this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Election Notice&#148;</B> has the meaning set forth in Section 10.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;EMEA&#148;</B> means the European Regulatory Authority known as the European Medicines Agency and any successor agency thereto.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;EU&#148;</B> means the European Union, as its membership may be altered from time to time, and any successor thereto, and
which, as of the Effective Date, consists of Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Slovakia, Slovenia,
Spain, Sweden and the United Kingdom, and that certain portion of Cyprus included in such organization.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Existing Regulus
Agreement&#148;</B> means any of the agreements listed on <B>A<SMALL>PPENDIX</SMALL>&nbsp;5</B>.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Existing Sanofi
Agreement&#148;</B> means any agreement to which Sanofi is a party as of the Effective Date under which Sanofi has in-licensed or acquired rights to Patents from a Third Party.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Expired <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Product&#148;</B> has the meaning provided in
Section&nbsp;2.1.4(b).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Ex-U.S.</FONT> Net Sales&#148;</B> has the meaning set forth in
Section&nbsp;6.9.2.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;FDA&#148;</B> means the United States Food and Drug Administration and any successor
agency thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Fibrosis&#148;</B> means any organ and/or tissue injury or repair encompassing multiple biological processes
and/or disorders associated with organs and/or tissues as well as wound repair. Examples include, but are not limited to, fibrotic disorders, dermal scarring, wound healing, burns and post-operative adhesions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Fibrosis Field&#148;</B> has the meaning set forth in subparagraph&nbsp;(a) of the definition of Target Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;First Commercial Sale&#148;</B> means the first sale of a Product by Sanofi, its Affiliates or a sublicensee to a Third Party in a
particular country after Approval of such Product has been obtained in such country.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;First Restated Agreement&#148;</B>
has the meaning set forth in the recitals on the first page of this Agreement.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;First Restatement Date&#148;</B> has the
meaning set forth in the recitals on the first page of this Agreement.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Founding Company&#148; </B>means individually,
either Isis Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.; and collectively, both Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Founding Company License Agreement&#148; </B>means the Amended and Restated License and Collaboration Agreement among Regulus and the
Founding Companies dated January&nbsp;1, 2009, as amended as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;FTE-Day Rate&#148;</B> means
US&nbsp;$[&#133;***&#133;] per FTE-day, subject to adjustment on an annual basis as of January&nbsp;1 of each year beginning in 2011 by a factor which reflects changes in the Consumer Price Index for San Diego, California as reported as of
January&nbsp;1 by the U.S. Department of Labor&#146;s Bureau of Labor Statistics in each applicable year during the Research Term when compared to the comparable statistic for January&nbsp;1 of the preceding year. The FTE-Day Rate shall be inclusive
of all allocated overhead costs, administrative expenses and other expenses for the employee(s) providing services under this Agreement, excluding [&#133;***&#133;] costs (which Sanofi will either pay directly or reimburse to Regulus within
30&nbsp;days of invoice). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Future Regulus Agreement&#148;</B> has the meaning provided in Section&nbsp;6.11.2.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Future Sanofi Agreement&#148;</B> has the meaning provided in Section&nbsp;6.11.2.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;[</B>&#133;***&#133;<B>]&#148;</B> means [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;[</B>&#133;***&#133;<B>] Agreement&#148;</B> means the License Agreement among [&#133;***&#133;] and [&#133;***&#133;] dated
[&#133;***&#133;]. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Generic Product(s)&#148;</B> means a Third Party&#146;s product(s) or Third
Parties&#146; product(s) that has the same or substantially the same active pharmaceutical ingredient as a Product and receives Approval through a regulatory approval process in which either: (i)&nbsp;the applicant for, or sponsor of such Approval;
or (ii)&nbsp;the Regulatory Authority that granted such Approval, relied, in whole or in part, upon [&#133;***&#133;] submitted by, or on behalf of, Sanofi (or its Affiliate or sublicensee), to any Regulatory Authority, to support the Approval of a
Product.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Good Clinical Practice&#148;</B> or <B>&#147;GCP&#148;</B> will mean the then current standards for clinical
trials for pharmaceuticals, as set forth in the United States Code of Federal Regulations, ICH guidelines and applicable regulations, laws or rules as promulgated thereunder, as amended from time to time, and such standards of good clinical practice
as are required by the European Union and other organizations and governmental agencies in countries in which a Licensed Product is intended to be sold to the extent such standards are not less stringent than United States GCP.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Good Laboratory Practice&#148;</B> or <B>&#147;GLP&#148;</B> will mean the then current standards for laboratory activities for
pharmaceuticals, as set forth in the FDA&#146;s GLP regulations and/or ICH guidelines and applicable regulations.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Good
Manufacturing Practice(s)&#148;</B> or <B>&#147;GMP&#148;</B> will mean the regulatory requirements for current good manufacturing practices promulgated in the United States Code of Federal Regulations including those rules promulgated by the United
States Food and Drug Administration under the U.S. Food, Drug and Cosmetic Act, 21 C.F.R. &#167; 210 et seq., and ICH Guidelines and applicable regulations, as the same may be amended from time to time.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;[</B>&#133;***&#133;<B>]&#148;</B> means the [&#133;***&#133;] Agreement dated [&#133;***&#133;], between [&#133;***&#133;] and
[&#133;***&#133;], as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;IND&#148;</B> means an Investigational New Drug Application (as defined in the Food, Drug and
Cosmetic Act, as amended) filed with the FDA or its foreign counterparts.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;IND Approval&#148;</B> means the acceptance (or
deemed acceptance) of the filing of an IND by the applicable Regulatory Authority. For purposes of clarity, acceptance (or deemed acceptance) of the filing of the foreign equivalent of an IND by the applicable Regulatory Authority in such country
will be an IND Approval.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Indemnified Party&#148;</B> has the meaning set forth in Section 11.3.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Indemnification Claim Notice&#148;</B> has the meaning set forth in Section 11.3.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Indication&#148;</B> means mean any human or animal disease or condition, or sign or symptom of a human or animal disease or
condition.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Initiation of Phase&nbsp;1 Trial&#148;</B> means the dosing of the first human subject in a Phase&nbsp;1
Trial.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Initiation of Phase&nbsp;2 Trial&#148;</B> means the dosing of the first human subject in the first Phase&nbsp;2
Trial.<B> </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Initiation of Phase&nbsp;3 Trial&#148; </B>means the dosing of the first human subject
in a Phase&nbsp;3 Trial. In the case where a Phase&nbsp;2b/3 Trial precedes any Phase&nbsp;3 Trial for a given Product, the first dosing of such Product in a human subject following the review of interim data and decision to extend the period of
such Phase&nbsp;2b/3 Trial in order to provide sufficient evidence of safety and efficacy to be included as a Phase&nbsp;3 Trial in filings with Regulatory Authorities will be deemed to be the &#147;start of Phase&nbsp;3 Trial&#148; for such
Product.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;In-License Milestones&#148;</B> means, with respect to a particular Third Party Agreement, all milestone
payments that become payable by a Party to the Licensor(s) under such Third Party Agreement with respect to the applicable Third Party Patents as a result of the achievement of Development, regulatory and/or Commercialization events by a Product.
For clarity, &#147;In-License Milestones&#148; shall not include any upfront payments under Third Party Agreements.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;In-License Royalties&#148;</B> means, with respect to a particular Third Party Agreement, all royalties on sales of Products by
Sanofi, its Affiliates and its sublicensees that become payable by a Party to the Licensor(s) under such Third Party Agreement with respect to the applicable Third Party Patents.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Integrated Product Plan&#148; </B>or<B> &#147;IPP&#148;</B> has the meaning set forth in Section 5.3.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Intellectual Property Panel&#148;</B> has the meaning set forth in Section&nbsp;6.11.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Joint Invention&#148; </B>has the meaning set forth in Section 8.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Joint Patent&#148;</B> means any Patent that claims, and only to the extent that it claims, a Joint Invention(s).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;JSC Charter&#148;</B> has the meaning set forth in 3.4.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;JSC&#148;</B> has the meaning set forth in 3.4.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Know-How&#148;</B> means technical information and materials, including without limitation, technology, software, instrumentation,
devices, data, biological materials, assays, constructs, compounds, inventions, practices, methods, knowledge, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, skill and experience.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Licensed Compound&#148;</B> means any <FONT STYLE="white-space:nowrap">Mir-21</FONT> Compound or
<FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Compound.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Licensing Revenues&#148;</B> has the meaning set forth in
Section&nbsp;10.2.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Licensor&#148;</B> means, with respect to a particular Third Party Agreement, any Third Party that is
a party to such Third Party Agreement.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Losses&#148;</B> has the meaning set forth in Section 11.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Major European Country&#148;</B> means France, Germany, Italy, Spain or the United Kingdom.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Major Market Country&#148;</B> means Canada, France, Germany, Italy, Japan, Spain, the
United Kingdom, and the United States.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Manufacturing Technology&#148; </B>has the meaning set forth in
Section&nbsp;4.3.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;microRNA&#148;</B> means a structurally defined functional RNA molecule usually between 21 and 25
nucleotides in length, which is derived from genetically-encoded non-coding RNA which is predicted to be processed into a hairpin RNA structure that is a substrate for the double-stranded RNA-specific ribonuclease Drosha and subsequently is
predicted to serve as a substrate for the enzyme Dicer, a member of the RNase III enzyme family; including, without limitation, those microRNAs exemplified in miRBase (http://microrna.sanger.ac.uk/). To the extent that [&#133;***&#133;] for purposes
of this Agreement; <I>provided, however</I>, that nothing contained herein will require any Party hereto to [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;microRNA Antagonist&#148;</B> means a single-stranded oligonucleotide (or a single stranded analog thereof) that is designed to
interfere with or inhibit a particular microRNA. For purposes of clarity, the definition of &#147;microRNA Antagonist&#148; excludes oligonucleotides that function predominantly through the RNAi mechanism of action or the RNase H mechanism of
action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;microRNA Compound&#148;</B> means a compound consisting of (a)&nbsp;a microRNA Antagonist, or (b)&nbsp;a microRNA Mimic.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;microRNA Mimic&#148;</B> means a double-stranded or single-stranded oligonucleotide or analog thereof with a substantially
similar base composition as a particular microRNA and which is designed to mimic the activity of such microRNA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Mir-21&#148;</B>
means the microRNA having (i)&nbsp;miRBase ID: hsa-miR-21; (ii)&nbsp;the miRBase Accession Number MIMAT0000076, and (iii)&nbsp;the sequence UAGCUUAUCAGACUGAUGUUGA.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Mir-21 Compound&#148;</B> means any microRNA Antagonist that modulates the expression of Mir-21 whose primary mechanism of action is
through [&#133;***&#133;] to Mir-21.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Mir-21</FONT> Fibrosis POC Program&#148;</B> has
the meaning set forth in Section&nbsp;3.1.1.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Mir-21</FONT> Fibrosis POC Program
Plan&#148;</B> has the meaning set forth in Section&nbsp;3.1.1.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Mir-21</FONT> Oncology
POC Program&#148;</B> has the meaning set forth in Section&nbsp;3.1.2.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Mir-21</FONT>
Oncology POC Program Plan&#148;</B> has the meaning set forth in Section&nbsp;3.1.2.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Mir-21</FONT> POC Program&#148;</B> means the <FONT STYLE="white-space:nowrap">Mir-21</FONT>
Fibrosis POC Program or the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Oncology POC Program, as applicable.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">&#147;Mir-21</FONT> POC Program Product&#148;</B> means, with respect to a <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program, any <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product that is or was the subject
of such <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program.<B> </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Mir-21 Product&#148;</B> means any pharmaceutical product containing a Mir-21 Compound
(alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Mir-221&#148;</B>
means the microRNA having (i)&nbsp;miRBase ID: hsa-miR-221; (ii)&nbsp;the miRBase Accession Number MIMAT0000278, and (iii)&nbsp;the sequence AGCUACAUUGUCUGCUGGGUUUC.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Mir-221/222 Compound&#148;</B> means (a)&nbsp;any microRNA Antagonist that modulates the expression of Mir-221 and/or Mir-222 whose
primary mechanism of action is through its hybridization to Mir-221 and/or Mir-222, or (b)&nbsp;any microRNA Mimic with a substantially similar base composition as <FONT STYLE="white-space:nowrap">Mir-221</FONT> and/or
<FONT STYLE="white-space:nowrap">Mir-222</FONT> and which is designed to mimic the activity of <FONT STYLE="white-space:nowrap">Mir-221</FONT> and/or <FONT STYLE="white-space:nowrap">Mir-222.</FONT><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Mir-221/222</FONT> POC Program&#148;</B> has the meaning set forth in Section&nbsp;3.1.3.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">&#147;Mir-221/222</FONT> POC Program Plan&#148;</B> has the meaning set forth in
Section&nbsp;3.1.3.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Mir-221/222 Product&#148;</B> means any pharmaceutical product containing a Mir-221/222 Compound
(alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Mir-222&#148;</B>
means the microRNA having (i)&nbsp;miRBase ID: hsa-miR-222; (ii)&nbsp;the miRBase Accession Number MIMAT0000279, and (iii)&nbsp;the sequence AGCUACAUCUGGCUACUGGGU.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;NDA&#148; </B>means a New Drug Application filed with the FDA after completion of clinical trials to obtain marketing approval for
the applicable Product in the United States.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;NDA Filing&#148;</B> means the acceptance by the FDA of the filing of an NDA
for the applicable Product, or the acceptance of the foreign equivalent of an NDA by the applicable Regulatory Authority.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Necessary Patent&#148;</B> has the meaning provided in Section&nbsp;6.11.1. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Net Sales&#148;</B> means, with respect to a Product, the gross invoice price of all units of such Products sold by Sanofi, its
Affiliates and/or their sublicensees to any Third Party, less the following items: (a)&nbsp;trade discounts, credits or allowances, (b)&nbsp;credits or allowances additionally granted upon returns, rejections or recalls, (c)&nbsp;freight, shipping
and insurance charges, (d)&nbsp;taxes, duties or other governmental tariffs (other than income taxes), (e)&nbsp;government-mandated rebates, and (f)&nbsp;a reasonable reserve for bad debts. &#147;Net Sales&#148; under the following circumstances
will mean the fair market value of such Product: (i)&nbsp;Products which are used by Sanofi, its Affiliates or sublicensees for any commercial purpose without charge or provision of invoice, (ii)&nbsp;Products which are sold or disposed of in whole
or in part for non cash consideration, or (iii)&nbsp;Products which are provided to a Third Party by Sanofi, its Affiliates or sublicensees without charge or provision of invoice and used by such Third Party except in the cases of Products used to
conduct clinical trials, reasonable amounts of Products used as marketing samples and Product provided without charge for compassionate or similar uses.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net Sales will not include any transfer between or among Sanofi and any of its Affiliates or
sublicensees for resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event a Product is sold as part of a Combination Product, the Net Sales from the Combination Product, for
the purposes of determining royalty payments, will be determined by multiplying the Net Sales (as determined without reference to this paragraph) of the Combination Product, by the fraction, A/(A+B), where A is the average sale price of the Product
when sold separately in finished form and B is the average sale price of the other therapeutically active pharmaceutical compound(s) included in the Combination Product when sold separately in finished form, each during the applicable royalty period
or, if sales of all compounds did not occur in such period, then in the most recent royalty reporting period in which sales of all occurred. In the event that such average sale price cannot be determined for both the Product and all other
therapeutically active pharmaceutical compounds included in the Combination Product, Net Sales for the purposes of determining royalty payments will be calculated as above, but the average sales price in the above equation will be replaced by a good
faith estimate of the fair market value of the compound(s) for which no such price exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;New Core Patents&#148; </B>has the
meaning set forth in Section&nbsp;6.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;New Core Technology&#148; </B>has the meaning set forth in Section&nbsp;6.9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;New Core Technology Agreement&#148; </B>has the meaning set forth in Section&nbsp;6.9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Oncology&#148;</B> means any malignant neoplasm, and/or disorders associated with any malignant neoplasm. Examples include, but are
not limited to, carcinomas, melanomas, sarcomas, lymphomas, leukemias and gliomas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Oncology Field&#148;</B> has the meaning set
forth in subparagraph&nbsp;(b) of the definition of Target Field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Option&#148;</B> means the Mir-21 Option or the Mir-221/222
Option.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Option Letter&#148;</B> means the letter agreement between Regulus and Sanofi dated June&nbsp;21, 2013.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Option Period&#148;</B> means, with respect to any POC Program, the POC Program Term and, subject to Achievement of Proof of
Concept for such POC Program, the <FONT STYLE="white-space:nowrap">90-day</FONT> period beginning upon Achievement of Proof of Concept.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Original Agreement&#148;</B> has the meaning set forth in the recitals on the first page of this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Other In-License Payments&#148;</B> means, with respect to a particular Third Party Agreement, all payments
(<B></B><I><U>excluding</U></I><B></B> In-License Royalties and In-License Milestones) that become payable by a Party to the applicable Licensor(s) under such Third Party Agreement with respect to the applicable Third Party Patents.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Other Licensor&#148; </B>means any Licensor that is not a Founding Company.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Other <FONT STYLE="white-space:nowrap">Mir-21</FONT> Product&#148;</B> has the meaning
set forth in Section&nbsp;6.8.1(b).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Other Party&#148;</B> has the meaning set forth in Section 9.3.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Party(ies)&#148;</B> has the meaning set forth in the opening paragraph of this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Patents&#148;</B> means (a)&nbsp;patents and patent applications in any country or jurisdiction, (b)&nbsp;all priority applications,
divisionals, continuations, and continuations-in-part of any of the foregoing, and (c)&nbsp;all patents issuing on any of the foregoing patent applications, together with all registrations, reissues, renewals,
<FONT STYLE="white-space:nowrap">re-examinations,</FONT> confirmations, supplementary protection certificates, and extensions of any of (a), (b)&nbsp;or (c).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Permitted License&#148; </B>means&nbsp;a license granted by Regulus to a Third Party (i)&nbsp;under the Regulus Core Technology
Patents (but not under the Product Specific Patents) to [&#133;***&#133;] (or [&#133;***&#133;] to [&#133;***&#133;]) solely to conduct Research, or (ii)&nbsp;under the Regulus Core Technology Patents (but not under the Product Specific Patents) to
enable such Third Party to [&#133;***&#133;] or [&#133;***&#133;] microRNA Compounds, where such Third Party is [&#133;***&#133;] and is not [&#133;***&#133;] or [&#133;***&#133;].<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Person&#148;</B> means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint
venture company, governmental authority, association or other entity.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Phase&nbsp;1 Trial&#148; </B>means the initial
clinical testing of a Product in humans (first-in-humans study) with the intention of gaining a preliminary assessment of the safety of such Product.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Phase&nbsp;2 Trial&#148;</B> means a human clinical trial of a Product, the principal purpose of which is a determination of
preliminary short-term safety and efficacy in the target patient population, as described in 21 C.F.R. 312.21(b) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Phase&nbsp;2b/3 Trial&#148;</B> means a human clinical trial of a Product, the principal purpose of which is a further determination
of efficacy and safety, in the target population, at the intended clinical dose or doses or range of doses, on a sufficient number of subjects and for a sufficient period of time to confirm the optimal manner of use of the Product (dose and dose
regimen) prior to initiation of the pivotal Phase&nbsp;3 Trials, and which itself provides sufficient evidence of safety and efficacy to be included as a Phase&nbsp;3 Trial in filings with Regulatory Authorities.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Phase&nbsp;3 Trial&#148;</B> means a human clinical trial of a Product on a sufficient number of subjects that is designed to
establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial
is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Phase&nbsp;4 Trial&#148;</B> means a human clinical trial for a Product commenced after receipt of Approval in the country for which
such trial is being conducted and that is conducted within the parameters of the Approval for the Product. Phase&nbsp;4 Trials may include, without limitation, </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
epidemiological studies, modeling and pharmacoeconomic studies, investigator sponsored clinical trials of Product and post-marketing surveillance studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;POC Program&#148;</B> means any of the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Fibrosis POC Program, the <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Oncology POC Program and the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Oncology POC Program.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;POC Program Costs&#148;</B> means, with respect to any POC Program, the [&#133;***&#133;] incurred (including [&#133;***&#133;]) by
Regulus or for its account in connection with the performance of such POC Program during the applicable POC Program Term, including [&#133;***&#133;] (defined below). POC Program Costs will include, but not be limited to the following, in each case
to the extent attributable to POC Program Plan activities: (i)&nbsp;costs of [&#133;***&#133;] (collectively, <B><I>&#147;[</I></B>&#133;***&#133;<B><I>]&#148;</I></B>), [&#133;***&#133;] and/or having such [&#133;***&#133;];
(ii)&nbsp;[&#133;***&#133;]; (iii)&nbsp;costs of [&#133;***&#133;]; (iv)&nbsp;[&#133;***&#133;]; and (v)&nbsp;the costs of [&#133;***&#133;]. Notwithstanding the foregoing, POC Program Costs shall [&#133;***&#133;] amounts actually paid or
reimbursed by Sanofi to Regulus pursuant to Section&nbsp;3.6.3 with respect to Sanofi Program Activities that Regulus elects to have performed by any Third Party pursuant to Section&nbsp;3.6.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this definition: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>&#147;[</I></B>&#133;***&#133;<B><I>]&#148;</I></B> means [&#133;***&#133;]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>&#147;[</I></B>&#133;***&#133;<B><I>]&#148;</I></B> shall mean, with respect to any [&#133;***&#133;], but subject to the
last sentence of this paragraph, the </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment
Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
[&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;POC Program Plan&#148;</B> means any of any of the <FONT
STYLE="white-space:nowrap">Mir-21</FONT> Fibrosis POC Program Plan, the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Oncology POC Program Plan and the <FONT STYLE="white-space:nowrap">Mir-221/222</FONT> Oncology POC Program Plan.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;POC Program Product&#148;</B> means (i)&nbsp;any <FONT STYLE="white-space:nowrap">Mir-21</FONT> POC Program Product or (ii)&nbsp;any <FONT
STYLE="white-space:nowrap">Mir-221/222</FONT> Product, as applicable.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;POC Program Term&#148;</B> means, with respect to
any POC Program, the period beginning on the Second Restatement Date and, subject to earlier termination of such POC Program pursuant to Section&nbsp;3.4.1 or Section&nbsp;3.4.2 or earlier termination of this Agreement pursuant to ARTICLE 9, ending
90&nbsp;days after Regulus&#146; delivery to Sanofi of the POC Study Report (whether or not the results of the POC Study demonstrate Proof of Concept). <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;POC Study&#148;</B> means, with respect to a POC Program, the clinical trial described in the applicable POC Program Plan that is
designed to demonstrate Proof of Concept and is identified as a &#147;POC Study&#148; in such POC Program Plan. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;POC
Study Report&#148;</B> means, with respect to a POC Program, the final report from the POC Study under such POC Program.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Product&#148;</B> means any pharmaceutical product containing a Licensed Compound (alone or with other active ingredients), in all
forms, presentations, formulations and dosage forms.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Product Development Plan&#148;</B> has the meaning set forth in
Section 5.3.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Product Field&#148;</B> means (a)&nbsp;with respect to Licensed Compounds and Products, the treatment and/or
prophylaxis of any Indication and (b)&nbsp;with respect to Companion Diagnostics,&nbsp;to the extent that Regulus Controls [&#133;***&#133;] the applicable Collaboration Target as [&#133;***&#133;] for [&#133;***&#133;] to the corresponding Product
in the treatment and/or prophylaxis of an approved Indication for the Product. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Product Specific Patents</B>&#148; means
all Patents (including all claims and the entire scope of claims therein) Controlled by Regulus or its Affiliates on the Effective Date and/or at any time thereafter, in each case claiming (a)&nbsp;a Collaboration Target gene sequence or a portion
thereof, (b)&nbsp;the specific compositions of matter of Licensed Compounds or Products, or (c)&nbsp;methods of using Licensed Compounds or Products as therapeutics; <B></B><I>provided however</I><B></B>, that: <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1) </B>unless the Parties otherwise agree in writing, Patents that include claims that are directed to subject matter and have a scope
that is applicable to microRNA Compounds in general, and not directed solely to [&#133;***&#133;] or [&#133;***&#133;] or to the </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
[&#133;***&#133;] thereof, will be considered to be [&#133;***&#133;] Patents; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2) </B>unless the Parties otherwise agree in writing, Patents that include claims that are directed to the identification or isolation of
microRNAs that are not [&#133;***&#133;], or to the production, composition, or use of [&#133;***&#133;] that are not [&#133;***&#133;] or [&#133;***&#133;] will be considered to be [&#133;***&#133;] Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clarification, any Regulus Program Patent or any Joint Patent satisfying the definition above, will be considered a Product Specific
Patent. The Product Specific Patents as of the Effective Date are listed in <B>A<SMALL>PPENDIX</SMALL>&nbsp;2</B> attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Program&#148;</B> means the Research Program or any POC Program.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Program Inventions</B>&#148; has the meaning set forth in Section 8.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Program License&#148;</B> means the Mir-21 License or the Mir-221/222 License.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Program Patents</B>&#148; has the meaning set forth in Section 8.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Program Plan&#148;</B> means the R&amp;D Plan or any POC Program Plan.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Proof of Concept&#148;</B> with respect to a particular POC Program has the meaning provided in the applicable POC Program Plan.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;R&amp;D Plan&#148;</B> means the written research and development plan attached as <B>A<SMALL>PPENDIX</SMALL>&nbsp;8</B>
hereto. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Receiving Party&#148;</B> has the meaning set forth in Section 7.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulatory Authority&#148;</B> means any governmental authority, including without limitation FDA, EMEA or Koseisho
(<B></B><I>i.e.</I><B></B>, the Japanese Ministry of Health, Labour and Welfare, or any successor agency thereto), that has responsibility for granting any licenses or approvals or granting pricing and/or reimbursement approvals necessary for the
marketing and sale of a Product in any country.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulatory Documentation&#148;</B> means all applications, registrations,
licenses, authorizations and approvals (including all Approvals), all correspondence submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority),
all supporting documents and all clinical studies and tests, including the manufacturing batch records, relating to the Product, and all data contained in any of the foregoing, including all regulatory drug lists, advertising and promotion
documents, adverse event files and complaint files.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulus Confidential Information&#148;</B> means any Confidential
Information for which Regulus is the Disclosing Party.<B> </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulus Core Technology Patents&#148;</B> means, subject to 6.12.3, Patents Controlled
by Regulus or its Affiliates on the Effective Date and/or at any time thereafter, in each case that are useful or necessary for the Development and Commercialization of Licensed Compound and Products. Regulus Core Technology Patents will exclude the
Product Specific Patents. A representative list of the Regulus Core Technology Patents as of the Effective Date is listed in <B>A<SMALL>PPENDIX</SMALL>&nbsp;3</B> hereto. For clarification, any Regulus Program Patent or any Joint Patent satisfying
the definition above will be considered a Regulus Core Technology Patent. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulus Database&#148;</B> has the meaning set
forth in Section 3.11.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulus Inventions&#148;</B> has the meaning set forth in Section 8.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulus Know-How&#148;</B> means all Know-How Controlled by Regulus or its Affiliates as of the Effective Date and/or at any time
thereafter that is useful for the Research, discovery, Development, Approval, manufacturing and Commercialization of microRNA Compounds. <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulus Patents&#148;</B> means the Regulus Core Technology Patents and the Product Specific Patents (including patents licensed to
Regulus under an Existing Regulus Agreement, or under a Future Regulus Agreement in accordance with Section 6.11).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulus Program Patent&#148;</B> has the meaning set forth in Section 8.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulus Technology&#148;</B> means collectively, the Regulus Know-How and the Regulus Patents.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Research&#148;</B> means pre-clinical research including gene function, gene expression and target validation research using cells
and animals, which may include small pilot toxicology studies but excludes <FONT STYLE="white-space:nowrap">IND-Enabling</FONT> Studies, clinical development and commercialization.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Research Program&#148; </B>has the meaning set forth in Section 3.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Research Results&#148; </B>means all data, information, trade secrets, inventions and
<FONT STYLE="white-space:nowrap">Know-How</FONT> which are discovered, made, reduced to practice, identified or developed in whole or in part by Regulus in the course of the performance of the Research Program or any POC Program.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Research Term&#148;</B> means the period that began on the Effective Date and ended on the Second Restatement Date.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Royalty Term&#148; </B>has the meaning set forth in Section 6.15.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Sanofi Confidential Information&#148;</B> means any Confidential Information for which Sanofi is the Disclosing Party.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Sanofi Indemnitees&#148;</B> has the meaning set forth in Section 11.2.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Sanofi Inventions&#148;</B> has the meaning set forth in Section 8.1.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Sanofi Product Specific Patent&#148;</B> means any Patents (including all claims and the
entire scope of claims therein) Controlled by Sanofi or its Affiliates on the Effective Date and/or at any time thereafter, in each case claiming (a)&nbsp;the sequence or a portion thereof corresponding to the Collaboration Target gene sequence or a
portion thereof, (b)&nbsp;the specific composition of matter of a Product, (c)&nbsp;methods of using a Licensed Compound or Product as a therapeutic or (d)&nbsp;methods of using a Licensed Compound as a therapeutic).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Sanofi Independent Activities&#148;</B> has the meaning set forth in Section 3.7.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Sanofi Program Activities&#148;</B> has the meaning set forth in Section 3.2.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Sanofi Program Patents&#148;</B> has the meaning set forth in Section 8.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Second Restatement Date&#148;</B> has the meaning set forth in the opening paragraph of this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Senior Representatives&#148; </B>has the meaning set forth in Section&nbsp;13.4.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock Purchase Agreement&#148; </B>has the meaning set forth in the recitals on the first page of this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Target Field&#148; </B>means: <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(a) </B><B><I></I></B>in the case of the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Fibrosis POC Program, (i)&nbsp;the
treatment and/or prophylaxis of any or all Indications in Fibrosis and (ii)&nbsp;to the extent that Regulus Controls [&#133;***&#133;] the applicable Collaboration Target as [&#133;***&#133;] to the corresponding Licensed Compound in the treatment
and/or prophylaxis of an Indication in Fibrosis (collectively, the <B><I>&#147;Fibrosis Field&#148;</I></B>); or<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(b) </B><B><I></I></B>in the case of the <FONT STYLE="white-space:nowrap">Mir-21</FONT> Oncology POC Program or the <FONT
STYLE="white-space:nowrap">Mir-221/222</FONT> Oncology POC Program, (i)&nbsp;the treatment and/or prophylaxis of any or all Indications in Oncology and (ii)&nbsp;to the extent that Regulus Controls [&#133;***&#133;] the applicable Collaboration
Target as [&#133;***&#133;] to the corresponding Licensed Compound in the treatment and/or prophylaxis of an Indication in Oncology (collectively, the <B><I>&#147;Oncology Field&#148;</I></B>). <B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Target Product Profile&#148;</B> means, on a POC Program-by-POC Program basis, with respect to the Collaboration Target that is the
subject of a POC Program, the description, as set forth in the applicable POC Program Plan, of the commercially relevant range of acceptable product performance of a Licensed Compound against key product characteristics (including but not limited to
efficacy, safety, quality, side effects, tolerability, route of administration, contraindications and clinical endpoints), and which shall be used by Regulus to guide and shape the progression of and development decisions for such Licensed Compound
in the applicable Target Field.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Technology Alliance Agreement&#148;</B> means the Non-Exclusive Technology Alliance and
Option Agreement between the Parties dated as of the Effective Date. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Term&#148; </B>has the meaning set forth in Section 9.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Terminated <FONT STYLE="white-space:nowrap">Mir-21</FONT> Program Product&#148;</B> has the meaning provided in
Section&nbsp;3.4.3(a)(iii).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Territory&#148; </B>means all countries and jurisdictions throughout the world.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Therapeutic Field&#148; </B>means any field concerning the remediation of a health problem, including Fibrosis, Oncology,
[&#133;***&#133;], diabetes, cardiovascular, ophthalmology, central nervous system, internal medicine, thrombosis, and vaccines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Third Party&#148;</B> means any Person other than Regulus or Sanofi or their respective Affiliates.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Third Party Agreement&#148;</B> means an Existing Regulus Agreement, Future Regulus Agreement, Existing Sanofi Agreement or Future
Sanofi Agreement, as applicable.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Third Party Claims&#148;</B> has the meaning set forth in Section 11.1.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Third Party Patents&#148;</B> means, with respect to a particular Third Party Agreement, all Necessary Patents that a Party
in-licenses or acquires from the Licensor(s) under such Third Party Agreement.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;[</B>&#133;***&#133;<B>] Patents&#148;
</B>means all Patents licensed under the [&#133;***&#133;] Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;U.S. Net Sales&#148;</B> has the meaning set forth in
Section&nbsp;6.9.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Valid Claim&#148;</B> means a claim of any issued, unexpired patent that has not been revoked or held
unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been
disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;[</B>&#133;***&#133;<B>]&#148;</B> means [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;[</B>&#133;***&#133;<B>] Agreement&#148;</B> means the [&#133;***&#133;] Agreement by and between the [&#133;***&#133;], commissioned
by [&#133;***&#133;], and [&#133;***&#133;] dated [&#133;***&#133;].<B> </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRODUCT-SPECIFIC PATENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Attached] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Product-Specific Patents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(as of the Second Restatement Date) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#133;***&#133;]* </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Pages 1 through 3 of this Appendix 2 have been redacted and omitted pursuant to a confidential treatment request filed with the Securities and Exchange Commission. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULUS CORE TECHNOLOGY PATENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Attached] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULUS CORE TECHNOLOGY PATENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(as of the Second Restatement Date) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patents and Patent Applications owned by or licensed to Regulus </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#133;***&#133;]* </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Pages 1 through 6 of this Appendix 3 have been redacted and omitted pursuant to a confidential treatment request filed with the Securities and Exchange Commission. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULUS CORE TECHNOLOGY PATENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patents and Patent Applications Licensed to Regulus by Isis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#133;***&#133;]* </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Pages 1 through 48 of this Appendix 3 have been redacted and omitted pursuant to a confidential treatment request filed with the Securities and Exchange Commission. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULUS CORE TECHNOLOGY PATENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patents and Patent Applications Licensed to Regulus by Alnylam </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#133;***&#133;]* </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Pages 1 through 19 of this Appendix 3 have been redacted and omitted pursuant to a confidential treatment request filed with the Securities and Exchange Commission. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential Treatment Requested </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHARTER OF THE JOINT STEERING COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purpose </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Joint Steering Committee is
established by Regulus and Sanofi to oversee the POC Programs under the Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Responsibilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The JSC will, using each POC Program Plan initially agreed to on the Second Restatement Date as a basis, continue to develop and refine such POC Program
Plan, as needed, and will conduct a comprehensive review of the POC Program Plan as needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The JSC will be responsible for oversight of the POC
Program Plans. The JSC will (i)&nbsp;evaluate the data generated by the Parties in the course of carrying out the POC Program Plans, (ii)&nbsp;discuss and resolve any overarching issues or significant changes in the POC Program Plans,
(iii)&nbsp;make revisions to the POC Program Plans as necessary, (iv)&nbsp;evaluate and approve additional studies to be conducted by Sanofi (and at its sole expense) for the purpose of expanding the applications of a Compound or Product and
(v)&nbsp;consistent with Article&nbsp;7 of the Agreement, review and approve all public communications and disclosures, including but not limited to data presented at external meetings and journals on the joint Research Results. Except for
amendments to the POC Program Plans (as adopted in accordance with this charter and the Agreement), in no event will the JSC have the power or authority to amend any provision of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The JSC will have the power to delegate its authority and duties to <FONT STYLE="white-space:nowrap">sub-committees</FONT> as it deems appropriate and to
establish working groups to facilitate ongoing informal exchange of information regarding progress and results of each POC Program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Composition
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The JSC will at all times have an equal number of members designated by each Party. Each Party may replace its appointed JSC representatives at
any time upon written notice to the other Party. The size and composition of the JSC provided herein may not be changed without the consent of both Regulus and Sanofi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Each JSC member will have the requisite background, experience and training to carry out the duties and obligations of the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Each Party will designate one of its representatives as co-chairperson of the JSC. Each of the co-chairpersons will be responsible, on an alternating basis
with the Sanofi co-chairperson having responsibility with respect to the initial meeting, for scheduling meetings, preparing and circulating an agenda in advance of each meeting, and preparing the minutes of each meeting. Each Party will appoint an
individual employee representative to serve as liaisons between the Parties with respect to the POC Programs and to promote effective communication between the Parties and coordination of the Parties&#146; activities and responsibilities in
furtherance of the POC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Program Plans (the <B></B><B><I>&#147;Alliance Managers&#148;</I></B><B></B>). The Alliance Managers will manage and oversee the governance of the Agreement and will serve as the primary contact
person concerning on-going interactions between the Parties under this Agreement. The Alliance Managers shall be non-voting JSC members and will coordinate and attend all meetings of the JSC and will be responsible for the preparation and
circulation of JSC meeting minutes for approval and will facilitate the scheduling and conduct of JSC meetings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Decisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Each Party&#146;s JSC members will collectively have one vote, regardless of the number of its JSC members participating in any meeting. No votes will be
taken unless there is at least one JSC member representing each of Regulus and Sanofi participating in such meeting. Unless otherwise specified herein, all actions taken by the JSC as a committee will be by unanimous vote. If the JSC members reach a
deadlock on any vote, then the deadlock will be resolved in accordance with Paragraph 8 below. Notwithstanding anything to the contrary, no decision by the JSC will require the other Party to: (i)&nbsp;breach any written agreement that such other
Party may have with a Third Party (except where such agreement is entered into in breach of any representation, warranty, covenant or obligation of such Party under to this Agreement); (ii)&nbsp;perform any activities that are outside the scope of
the POC Programs; or (iii)&nbsp;violate any Applicable Law or principles of scientific integrity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. If the JSC is unable to decide by unanimous vote on
any issue within the scope of its authority and duties, then the JSC will promptly raise such issue to each Party&#146;s co-chairperson on the JSC, and such co-chairs will have 10&nbsp;days to mutually agree on how to resolve such issue. If the <FONT
STYLE="white-space:nowrap">co-chairs</FONT> are unable to resolve such issue within the 10&nbsp;day period, then such issue will be brought to each Party&#146;s Senior Representatives, or their designees. The Senior Representatives will have
10&nbsp;days to mutually agree on how to resolve such issue. If the Senior Representatives are unable to resolve such issue within the 10-day period, then, except as otherwise expressly set forth in the Agreement, such issue will be finally resolved
in accordance with the applicable subparagraph below, and the resolution of such issue in accordance with the applicable subparagraph will be binding on Sanofi and Regulus: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Parties hereby agree to submit the following matters to an Expert Panel for final resolution in accordance with Section&nbsp;13.4.5 of
the Agreement: (i)&nbsp;any issue relating to the Sanofi Program Activities performed or to be performed by Sanofi that are necessary for Achievement of Proof of Concept; and (ii)&nbsp;any dispute concerning the Achievement of Proof of Concept; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any issue relating to Sanofi Program Activities performed or to be performed by Sanofi that are not necessary for Achievement of Proof of
Concept shall be finally resolved by the Senior Representative of Sanofi; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) any issue relating to the POC Programs other than those
expressly set forth in subparagraphs&nbsp;(a) and (b)&nbsp;above shall be finally resolved by the Senior Representative of Regulus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clarity, no study not already contemplated by the initial POC Program Plan may be added to
such POC Program Plan as a Sanofi Program Activity without the written approval of both the Regulus and Sanofi representatives on the JSC, which approval may be withheld at the discretion of such representatives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operations; Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I>9. From the Second
Restatement Date until the expiration or termination of the last-to-expire or &#150;terminate of the POC Program Terms, the JSC will meet twice per year, unless otherwise agreed by the Parties&#146; Senior Representatives. Either Party may request
and require and <I>ad hoc</I> meeting of the JSC, at any time. Meetings may be held in person or by audio or video teleconference as appropriate. It is understood that the JSC will establish one or more working groups which will meet for the purpose
of facilitating the formal and informal exchange of information between the Parties regarding the progress and results of the POC Program activities on a monthly basis, unless otherwise agreed by the JSC.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. Meetings of the JSC will be effective only if at least one JSC representative of each Party is present or participating. Each Party will be responsible
for all of its own expenses of participating in the JSC meetings. The Parties will endeavor to schedule meetings of the JSC with at least 30&nbsp;days advance notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. Each Party may bring additional employees to each meeting as non-voting observers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B>12. If required, the co-chair responsible for each meeting (the <B><I>&#147;Responsible Chair&#148;</I></B>) will, in consultation with other
members of the JSC, develop and set the JSC&#146;s agenda for each meeting. The Responsible Chair will include on such agenda each item requested within a reasonable time in advance of such meeting by a JSC member. The agenda and information
concerning the business to be conducted at each meeting will be communicated in writing to the members of the JSC within a reasonable time in advance of such meeting to permit meaningful review. <B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. The Responsible Chair, or such person as the Responsible Chair may designate, will prepare, and distribute to all JSC members, draft committee minutes
within 2 weeks following each meeting and such minutes will be finalized by the JSC promptly thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXISTING REGULUS AGREEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Appendix&nbsp;5 contains a list of certain agreements in effect as of the Effective Date between Regulus and certain Third Parties that
may, as applicable, place certain encumbrances or limitations on the licenses or sublicenses granted to Sanofi, the exclusivity covenants, and the representations and warranties, where specified in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As set forth in the Agreement, the information and disclosures contained in this Appendix&nbsp;5 are intended only to qualify and limit the
licenses granted by Regulus to Sanofi, the exclusivity covenants, and the representations and warranties given by Regulus under the Agreement and do not expand in any way the scope or effect of any such licenses, representations or warranties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing herein constitutes an admission of any liability or obligation of Regulus nor an admission against any interest of Regulus. The
inclusion of this Appendix&nbsp;5 or the information contained in this Appendix&nbsp;5 does not indicate that Regulus has determined that this Appendix&nbsp;5 or the information contained in this Appendix&nbsp;5, when considered individually or in
the aggregate, is necessarily material to Regulus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Existing Regulus Agreements </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***...] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POC PROGRAM PLANS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are two main projects being prosecuted within the ongoing collaboration between Sanofi and Regulus Therapeutics, miR-21 and miR-221. Within the miR-21
project there are two therapeutic areas being evaluated. The first area is focused on renal fibrosis, specifically a human condition known as Alport Syndrome. The second therapeutic area of interest is Oncology. For the miR-221 project the sole
therapeutic area of interest in Oncology. This document will frame the ongoing activities and the planned activities within these collaborations with a more detailed overview of the miR-21 fibrosis program given that this is [&#133;***&#133;]. The
miR-21 and miR-221 Oncology projects are focused on [&#133;***&#133;] and the [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>The initial POC Program Plans for the <FONT
STYLE="white-space:nowrap">miR-21</FONT> fibrosis program, the <FONT STYLE="white-space:nowrap">miR-21</FONT> oncology program and the <FONT STYLE="white-space:nowrap">miR-221/222</FONT> oncology program are attached hereto as
<B>Appendix&nbsp;6A</B>, <B>Appendix&nbsp;6B</B> and <B>Appendix&nbsp;6C</B>, respectively.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 6A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INITIAL MIR-21 FIBROSIS POC PROGRAM PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>miR-21 Fibrosis focusing on Alport Syndrome </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] has been [&#133;***&#133;] within the miR-21 fibrosis program. In non GLP toxicology experiments [&#133;***&#133;]. The [&#133;***&#133;] by
comparing the [&#133;***&#133;] required for efficacy with the [&#133;***&#133;] that is achieved as adverse findings are being observed. This [&#133;***&#133;] is considered appropriate for a [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following activities will be performed within the miR-21 fibrosis program by Regulus. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following translational studies will be performed within the miR-21 fibrosis program
by Sanofi. Regulus will provide the compounds required for performing these studies: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT></TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Definition of Proof of Concept for [</U>&#133;***&#133;<U>] in patients with Alport Syndrome</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Study Design: [&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 6B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INITIAL MIR-21 ONCOLOGY POC PROGRAM PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>miR-21 Oncology </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At this time the
[&#133;***&#133;] in Oncology is [&#133;***&#133;]. The current focus of the project is on hepatocellular cancer although if translation results support the pursuit of an indication other than HCC the project team may proceed in that direction. The
following activities are ongoing and/or planned by Regulus. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should the studies discussed above identify a [&#133;***&#133;] the following studies will
be performed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Definition of Proof of Concept for the lead clinical candidate in the miR-21 Oncology
Project </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proposed proof of concept criteria that have been agreed to between Regulus and Sanofi are described in detail below. These criteria
specifically relate to a clinical study to be performed in advanced HCC patients who have [&#133;***&#133;]. Should the clinical plan change based on emerging findings from translational studies a new definition of proof of concept will need to be
developed by the steering committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proof of concept criteria are defined as </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Postdoctoral research project ([&#133;***&#133;]) </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following postdoc project will be performed at Sanofi, and Regulus will provide anti-miR-21 and relevant control compounds required for these studies. The
goal of the postdoctoral project is to contribute to better understanding [<U>&#133;***&#133;</U>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]. Deliverables for this project include scientific publications in peer-reviewed journals and
presentations at conferences/meetings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specific Aim I: [&#133;***&#133;]: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specific Aim II: [&#133;***&#133;]: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Additional studies</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional studies, performed either
internally by Sanofi or through academic collaborators, may be proposed to the JSC in the future based on emerging data on the target and indication of interest. Regulus and Sanofi have agreed that anti-miR-21 efficacy will be investigated in animal
models of [&#133;***&#133;], where upregulation of miR-21 has been documented. These studies will be performed by external academic collaborators at [&#133;***&#133;] and [&#133;***&#133;]. Regulus will provide the anti-miR-21 compounds and relevant
control compounds for these studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of these Sanofi activities is considered as [&#133;***&#133;]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 6C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INITIAL MIR-221/222 ONCOLOGY POC PROGRAM PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>miR-221 in Oncology </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The miR-221 project will follow the
plan laid out for the miR-21 project. As both programs may focus on HCC a key set of translational studies that evaluate the microRNA expression in HCC is necessary in order to define whether the proposed clinical studies will be focused on two
distinct segments of HCC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ongoing activities at Regulus include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;]. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LISTED COUNTRIES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:72.90pt; font-size:8pt; font-family:Times New Roman"><B>Patent Country Code</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:127.40pt; font-size:8pt; font-family:Times New Roman"><B>Patent Filing Country or Jurisdiction</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">World Intellectual Property Organization (WIPO)</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">European Patent Office (EPO)</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eurasian Patent Organization (EAPO)</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Office of the Co-operation Council for the Arab States of the Gulf (GCC)</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AU</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Australia</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brazil</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canada</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">China</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Hong Kong Special Administrative Region of the People&#146;s Republic of China</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ID</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indonesia</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Israel</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IN</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">India</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Japan</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Korea</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MX</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mexico</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malaysia</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">NZ</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Zealand</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippines</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">RU</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russian Federation</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thailand</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TW</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taiwan</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">UA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ukraine</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States of America</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ZA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">South Africa</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INITIAL R&amp;D PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Attached] </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESEARCH AND DEVELOPMENT PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULUS
THERAPEUTICS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI-AVENTIS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulus and Sanofi Collaboration on Fibrosis and [&#133;***&#133;] </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial research and development plan (the
&#147;R&amp;D Plan&#148;) described below outlines the current research objectives under the Collaboration and License Agreement dated June&nbsp;14, 2010 between Sanofi and Regulus. Capitalized terms used and not defined herein shall have the
meanings set forth in the Agreement. In case of any conflicts between this initial R&amp;D Plan and the Agreement, the terms of the Agreement shall govern. As stated in the Agreement, the Joint Steering Committee (JSC) has the right to amend the
R&amp;D Plan at any time during the Research Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Objective:</B> Regulus and Sanofi will collaborate in the discovery and preclinical development of
microRNA therapeutics for the clinical development and commercialization of such microRNA therapeutics by Sanofi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purpose of the initial R&amp;D Plan:
</B>The purpose of this R&amp;D Plan is to outline the responsibilities and activities of Regulus and Sanofi with respect to carrying out the research and preclinical development of microRNA therapeutics so as to provide broad guidance to the
scientific team in carrying out their work. The initial R&amp;D Plan contains a summary description of the potential specific activities, deliverables, and projected timelines for completion of such activities; and is subject to the modification by
the JSC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Management:</B> The R&amp;D Plan will be overseen and managed by the JSC. The R&amp;D Plan may only be amended with the
unanimous approval of the JSC (as permitted by the JSC Charter). The R&amp;D Plan may be amended at any time, and is expected to be reviewed at least annually. The Parties have created and agreed to the initial R&amp;D Plan as a basis for the
research and preclinical development of microRNA therapeutics and it is the intent of Regulus and Sanofi to subsequently modify the initial R&amp;D Plan in a manner to successfully develop microRNA therapeutics. Both Parties shall use Commercially
Reasonable Efforts to complete the activities listed in the R&amp;D Plan as promptly and diligently as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research Term:</B> The R&amp;D Plan
will be carried out during the period following the Effective Date and ending on the third anniversary of the Effective Date, unless otherwise extended as described in the Agreement. For any extension of the Research Term, the JSC will amend and
restate the R&amp;D Plan as necessary, subject to the provisions of the JSC Charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research Program Staffing and Resources:</B> As described in the
Agreement, Regulus will dedicate Regulus employees during the Research Term to perform the activities of the R&amp;D Plan. Regulus resources will include the following: bioinformatics, basic mechanisms, exploratory biology, <I>in vitro</I> and <I>in
vivo</I> biology, chemistry, and translational medicine. Sanofi and Regulus will cooperate with each other in carrying out the R&amp;D Plan and each Party will contribute its relevant know-how and experience necessary. It is contemplated that the
Parties will work closely together and, where applicable, Sanofi will contribute scientific expertise, assays and animal models, as defined in the Agreement (Article 3.5.2). If appropriate, experts from Sanofi are invited to visit the laboratories
of Regulus and participate in the ongoing research activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definitions:</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Program Candidates &#150; [&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research
Candidates &#150; [&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development Candidate &#150; [&#133;***&#133;] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXECUTIVE SUMMARY: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The overall goal of the R&amp;D Plan
is to provide the framework for a microRNA therapeutic &#147;IND Engine&#148; that can achieve an IND for miR-21 in [&#133;***&#133;] followed by several other potential INDs for microRNA therapeutics in [&#133;***&#133;]. We have provided a
proposed timeline of these activities shown in the figure below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial R&amp;D Plan is organized into four sections, which may have activities that overlap. Each section has clearly defined objectives,
tasks/activities, and deliverables to achieve the goals of selecting [&#133;***&#133;] Collaboration Targets (other than miR-21) and an IND for anti-miR-21 by [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial R&amp;D Plan has been written to reflect a flow from early stage to late stage activities within any given program. The timeline highlights when
these activities actually occur across the programs and emphasizes that the first key task of the Collaboration is to produce an IND for miR-21. That being said, the four sections of the R&amp;D Plan are: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section I. Designating Collaboration Targets in Fibrosis; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section II. [&#133;***&#133;]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section III. [&#133;***&#133;]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section IV. [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Briefly,
Sections I [&#133;***&#133;] describe efforts to identify and designate Collaboration Targets in Fibrosis and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]. A detailed R&amp;D plan for projects in [&#133;***&#133;] will be written and approved by the
JSC by [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As per the Agreement, Sanofi will designate its four Collaboration Targets within [&#133;***&#133;] of the Research Term (the
Target Designation Period). Regulus will be responsible for identifying and validating the Collaboration Targets using the criteria listed below [&#133;***&#133;]. In addition, Regulus will perform [&#133;***&#133;]. Following Collaboration Target
selection, Sanofi will have the right to substitute Collaboration Targets during a period of [&#133;***&#133;] months following designation and in accordance with the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section III describes the basic workflow for [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, Section IV describes [&#133;***&#133;]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DETAILS OF
THE INITIAL R&amp;D PLAN: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section I. Designating Collaboration Targets in Fibrosis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview:</I> The basic hypothesis is that microRNAs [&#133;***&#133;]. Regulus scientists have been working closely with a network of leading academic
collaborators [&#133;***&#133;]. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REGULUS NETWORK OF ACADEMIC COLLABORATORS FOR FIBROSIS</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:59.45pt; font-size:8pt; font-family:Times New Roman"><B>Name &amp; Institute</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:64.35pt; font-size:8pt; font-family:Times New Roman"><B>Fibrosis area focus</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From these collaborations [&#133;***&#133;]. We have determined microRNA [&#133;***&#133;]. We have also
[&#133;***&#133;]. The [&#133;***&#133;] offers the advantage that [&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Specific Activities: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Goal 1: </B>Identify
Collaboration Targets in Fibrosis </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(I)</TD>
<TD ALIGN="left" VALIGN="top">Identify potential microRNA therapeutic targets in Fibrosis </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deliverable 1:</B> [&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Goal 2:</B> [&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deliverable 2:</B>
[&#133;***&#133;] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section II. [</B>&#133;***&#133;<B>]</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview:</I> [&#133;***&#133;]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;].. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Specific Activities: </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Goal 3</B>:
[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deliverable 3: </B>[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Goal 4: </B>[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deliverable 4:</B> [&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The basic workflow for
Sections I and II is shown below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 1. Workflow for identification and validation of Collaboration Targets in Fibrosis [&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deliverables for Sections I and II: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:42.15pt; font-size:8pt; font-family:Times New Roman"><B>Deliverables</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman"><B>Timing</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section III. </B><B></B>[<B></B>&#133;***&#133;<B></B>]<B></B><B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview:</I> [&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deliverables for Sections III: [&#133;***&#133;] </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:42.15pt; font-size:8pt; font-family:Times New Roman"><B>Deliverables</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman"><B>Timing</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[&#133;***&#133;]</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section IV.</B> [&#133;***&#133;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.05pt; font-size:8pt; font-family:Times New Roman"><B>Deliverable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Criteria</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman"><B>Timing</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development Candidate Selection Criteria </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the miRNA antagonist or miRNA mimetic achieves the following profile, it will be considered for Development Candidate status: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.35pt; font-size:8pt; font-family:Times New Roman">Criteria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Regulus</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#133;***&#133;]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Table 1. Considerations for Development Candidate selection </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Key IND-Enabling Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a Development
Candidate has been selected, Regulus will conduct appropriate IND-enabling activities to support the miRNA antagonist for clinical trials. The Workflow is provided below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Figure 4: Workflow for key
IND-enabling activities of Development Candidate (timing: 12 months) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 8-A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R&amp;D PLAN UPDATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Attached] </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 8-A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R&amp;D PLAN UPDATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R&amp;D Plan for miR-21 in Fibrosis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R&amp;D
Plan for miR-21 and miR-221 in Hepatocellular Carcinoma (HCC) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Introduction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Extensive discussions have occurred between Sanofi and Regulus with regards to [&#133;***&#133;] &#150; miR-21 and miR-221. Both of these projects will now be
part of the ongoing R&amp;D collaboration between Sanofi and Regulus and will require additional studies in order to achieve the next project milestones. For the miR-21 project the next key milestone is [&#133;***&#133;]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of key R&amp;D activities for miR-21 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key
activities for miR-21 project will be as follows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aforementioned studies will be planned and executed over the next [&#133;***&#133;] months with the goal to [&#133;***&#133;]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposed research plan and resource allocation for miR-21 ONC project up to DC nomination </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="7%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:16.90pt; font-size:8pt; font-family:Times New Roman"><B>Task</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Responsible</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#133;***&#133;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>[&#133;***&#133;]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#133;***&#133;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of key R&amp;D activities for miR-221 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
attached slide set was prepared during the earlier discussions between Sanofi and Regulus and highlight the rational and justification for miR-221 as a target in hepatocellular carcinoma and the detailed activities that are needed to generate
pre-clinical proof of concept for the miR-221 program. These activities will be executed by Regulus during the next [&#133;***&#133;] months as part of the R&amp;D activities associated with [&#133;***&#133;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[&#133;***&#133;] </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposed validation plan for miR-221 in HCC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Detailed Allocation of Upfront Payments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Mir-21 Program </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allocation of the
$[&#133;***&#133;] payment pursuant to Section&nbsp;6.1 related to Regulus&#146; Mir-21 Program: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:71.20pt; font-size:8pt; font-family:Times New Roman"><B>Intellectual Property</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Other Programs </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allocation of the $[&#133;***&#133;] payment pursuant to Section&nbsp;6.1 related to Other Programs: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:71.20pt; font-size:8pt; font-family:Times New Roman"><B>Intellectual Property</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$[&#133;***&#133;</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Co-Promotion </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><B>General.</B> This Appendix sets out the principal terms under which Regulus may co-promote, with Sanofi, a Product with respect to which Regulus has exercised its Co-Promote Option in the U.S., subject to the
negotiation and execution of a definitive Co-Promotion Agreement as described herein. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><B>Certain Defined Terms.</B> Capitalized terms used but not otherwise defined herein shall have the meanings provided in the Agreement. In addition, the following terms, whether used in the singular or plural, shall
have the respective meanings set forth below: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;Detail&#148;</B> shall mean a product presentation in a face-to-face meeting in an individual or group practice setting between a professional sales representative and a Target Prescriber in which one or more
key product benefits are verbally presented. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;Detailing&#148;</B> shall mean the act of presenting a Detail. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;Target Prescriber&#148;</B> shall mean a medical or health care professional authorized to prescribe Products under the laws of the jurisdiction in which such medical or health care professional is practicing,
who is identified as a member of the target audience to whom Regulus shall direct a Detail. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><B>Co-Promotion Agreement.</B> Upon exercise by Regulus of the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option, the Parties shall enter into an agreement relating to the Detailing of Products to Target
Prescribers (the <B></B><B><I>&#147;Co-Promotion Agreement&#148;</I></B><B></B>). In conjunction with the negotiation and execution of the Co-Promotion Agreement, and no later than [&#133;***&#133;] months prior to the First Commercial Sale of a POC
Program Product, the Parties shall also negotiate and enter into an agreement setting forth mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of adverse
event reports, pregnancy reports, and any other information concerning the safety of Products. Such guidelines and procedures will be in accordance with, and will enable the Parties and their Affiliates to fulfill, local and international regulatory
reporting obligations to government authorities. For purposes of clarification, notwithstanding the exercise of the <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option or the execution of the Co-Promotion Agreement, Sanofi shall at all times
during the Term remain obligated to pay the applicable amounts specified under Article&nbsp;6 of the Agreement with respect to each Product (whether or not such Product is co promoted by Regulus). The Co-Promotion Agreement shall include but not be
limited to the following provisions: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Recruitment.</B> The Regulus Sales Force shall be recruited by Regulus at [&#133;***&#133;]. At the request of Regulus, Sanofi will support the
recruitment of the Regulus Sales Force. Regulus shall recruit the Regulus Sales Force with a profile to be consistent with that of Sanofi&#146;s sales force and reasonably agreed to by Sanofi. The Regulus Sales Force shall have a number of
representatives to be jointly determined by Sanofi and Regulus in good faith. The </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Parties agree that the Regulus Sales Force will operate throughout the U.S., but the specific territories and alignment throughout the U.S. allocated to the Regulus Sales Force shall be
reasonably determined by Sanofi following good faith consultations with Regulus. For purposes of clarification, should Regulus exercise its <FONT STYLE="white-space:nowrap">Co-Promote</FONT> Option with respect to a particular Product, as well as
its Co-Promote Option with respect to one or more other Products, there will be only one Regulus sales force for all Products co-promoted by Sanofi and Regulus, assuming the target audience for all such products is the same and that the number of
products is manageable by one sales force (2 to 3 products). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"><B>Training.</B> Sanofi shall provide the Regulus Sales Force with appropriate training with respect to promotion of the Product. In addition, at Regulus&#146; reasonable request, Sanofi shall provide general sales
training to the Regulus Sales Force. Regulus [&#133;***&#133;]. Sanofi [&#133;***&#133;]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"><B>Timing.</B> Hiring of the Regulus Sales Force shall begin no later than [&#133;***&#133;] months before the then-current estimated Product launch date in the U.S., and be completed no later than [&#133;***&#133;]
months before the then-current estimated Product launch date in the U.S., so that Sanofi may initiate training of the Regulus Sales Force in accordance with paragraph 3(b) above. Sanofi agrees to complete such training within two months following
initiation of such training. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"><B>Launch Meeting.</B> The Regulus Sales Force will attend the same launch meeting as the Sanofi U.S. sales force for Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"><B>Target Prescribers.</B> The Target Prescribers of the Product shall be reasonably determined by Sanofi following good faith consultations with Regulus. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"><B>Position of Details.</B> Details to be delivered by Regulus for the Product shall be reasonably determined by Sanofi following good faith consultations with Regulus. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"><B>Content of Details.</B> The form and content of all information communicated in all Details or other communications to health care professionals by Regulus for the Product shall be those developed by Sanofi at its
sole expense and in use by the corresponding Sanofi sales force in the U.S. Regulus will limit its claims of efficacy and safety for the Product to those which are consistent with Sanofi&#146;s approved labeling for the applicable product and shall
provide appropriate balance in all communications regarding such products. Regulus shall Detail the Product in strict adherence to all applicable legal, regulatory, professional and policy requirements, including, but not limited to, all applicable
Sanofi policies that have been communicated to Regulus, as they exist at the time of the Detail. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"><B>Compensation.</B> Commencing upon the completion of the training of the Regulus Sales Force on the Product, Sanofi shall [&#133;***&#133;], <I>provided</I> that the Regulus Sales Force details only Product. If there
is a product other than a Product also being detailed by the Regulus Sales Force, then Sanofi [&#133;***&#133;] of the Regulus Sales Force&#146;s cost. All [&#133;***&#133;] pursuant to this paragraph shall [&#133;***&#133;]. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"><B>Schedule of Payments.</B> Within 30&nbsp;days of the end of each Calendar Quarter, Regulus shall submit to Sanofi an invoice containing a schedule of Regulus Sales Force activities and expenses for review and
approval. Sanofi shall make the required payments to Regulus within 30&nbsp;days of receipt. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">j.</TD>
<TD ALIGN="left" VALIGN="top"><B>Performance Criteria.</B> The Parties shall agree on a minimum number of total Details to be conducted by Regulus each year for Product based on industry standard performance expectations of a similar specialty sales
representative. Compensation to Regulus as provided above will be subject to adjustment if the minimum level of such Details is not achieved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">k.</TD>
<TD ALIGN="left" VALIGN="top"><B>Regulus Trademarks.</B> All advertising and promotional material used by Regulus and Sanofi in connection with any co-promoted Product in the U.S. shall feature Regulus&#146; corporate trade name and logo if feasible
under applicable U.S. regulations (collectively, the <B><I>&#147;Regulus Marks&#148;</I></B>). Such use shall be in accordance with a separate trademark license agreement, under which Regulus would grant to Sanofi a non exclusive, royalty-free
license to use the Regulus Marks on Product advertising and promotional material. Regulus shall retain the ownership of the entire right, title and interest in and to the Regulus Marks, and all goodwill associated with or attached to the Regulus
Marks arising out of the use thereof by Sanofi shall inure to the benefit of Regulus. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">l.</TD>
<TD ALIGN="left" VALIGN="top"><B>Sampling and Promotional Materials.</B> With respect to Product, the Regulus Sales Force shall be required to use only promotional materials provided to it by Sanofi. Sanofi shall provide samples and promotional
material to Regulus Sales Force in a manner and quantity consistent with its provision of samples and promotional material to its own corresponding sales force. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">m.</TD>
<TD ALIGN="left" VALIGN="top"><B>Maintenance and Audit of Records.</B> Under the Co-Promotion Agreement, Regulus will be responsible for the maintenance of accurate records corresponding to the invoice of the expenses and activities of the Regulus
Sales Force, including, without limitation, an accurate monthly record of the number of Details, by position. Sanofi shall have the right to review and audit all such records. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">n.</TD>
<TD ALIGN="left" VALIGN="top"><B>Coordination.</B> The Regulus Sales Force shall work in a coordinated fashion with Sanofi&#146;s sales force for the applicable Product. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o.</TD>
<TD ALIGN="left" VALIGN="top"><B>Joint Commercialization Committee.</B> The Parties shall establish a joint commercialization committee (<B><I>&#147;JCC&#148;</I></B>) with an equal number of representatives of each party. The JCC shall meet in
accordance with a schedule established by mutual agreement of the Parties, but no less frequently than once per Calendar Quarter, with the location for such meetings alternating between Regulus and Sanofi facilities in the U.S. (or such other
locations as may be determined by the JCC). Alternatively, the JCC may meet by means of teleconference, videoconference or other similar communications equipment. Each party shall bear its own expenses related to the attendance of such meetings by
its representatives. The JCC shall be chaired by a representative of Sanofi. The JCC will review marketing plans and coordinate implementation of field activities. Sanofi&#146;s representatives on the JCC shall disclose to Regulus&#146;
representatives on the JCC such information as is reasonably necessary for Regulus&#146; representatives to participate in the proceedings of the JCC. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">p.</TD>
<TD ALIGN="left" VALIGN="top"><B>Term and Termination.</B> The term of the Co-Promotion Agreement shall continue until the last to expire Valid Claim covering the applicable Product in the U.S., or as long as Sanofi Details such Product in the U.S.,
whichever occurs later. The Co-Promotion Agreement shall be subject to termination: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top">by Sanofi in the event of Regulus&#146; assignment of the Agreement to a Third Party pursuant to Section 13.1(a); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top">by Sanofi at any time, if Regulus fails to meet an average of [&#133;***&#133;]% of the target level of Details for the Product over any [&#133;***&#133;]-month period, or if Regulus fails to meet [&#133;***&#133;]% of
the target level of Details for the Product during a rolling [&#133;***&#133;]-month period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top">by either party upon 60&nbsp;days&#146; prior written notice to the other party if the other party breaches any material provision of the Co-Promotion Agreement and has not cured such breach within the sixty (60)-day
period following written notice of termination by the non-breaching party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top">by either party immediately in the event of termination or expiration of the Agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Profit-Sharing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Appendix addresses
the accounting policies and procedures to be followed in determining U.S. Profits with respect to any Product with respect to which (a)&nbsp;Regulus exercises its Co-Promote Option and (b)&nbsp;Regulus&#146; notice of exercise of such Co-Promote
Option expressly states that Regulus elects to receive [&#133;***&#133;]% of U.S. Profits in lieu of royalties under Section&nbsp;<B></B>6.9.1 of the Agreement (such Product, an <B><I>&#147;Elected Product&#148;</I></B>). Terms not defined in this
Appendix will have the meanings set forth in the Agreement or in Appendix&nbsp;1 thereto. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><B>Calculation of U.S. Profits.</B><B><I> &#147;U.S. Profit&#148;</I></B> for an Elected Product means: (i)&nbsp;U.S.&nbsp;Net Sales of such Elected Product, less (ii)&nbsp;Allowable Costs and Expenses in connection
with the post-marketing development, commercial manufacturing, marketing or selling of such Elected Product in the U.S., plus or minus (iii)&nbsp;Net Interest Income, all as more fully described below. All calculations hereunder will be made using,
and all defined and undefined terms will be construed in accordance with, International Financial Reporting Standards, consistently applied, and consistent with generally accepted methods for activity-based project costing for similar products in
similar industries. Without limiting the foregoing, no cost item included in the calculation of U.S. Profits for a particular Elected Product will be included more than once in calculating U.S. Profits for such Elected Product. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">U.S. Profits will be calculated on an Elected Product-by-Elected Product basis; <I>provided, however,</I> that no cost item included in the
calculation of U.S. Profits for a particular Elected Product will be included in the calculation of U.S. Profits for any other Elected Product. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><B>Frequency of Reporting; Payments.</B> The fiscal year for purposes of U.S. Profits calculations will be a Calendar Year or such portion thereof as will be applicable. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Reporting by Sanofi for revenues and expenses will be performed as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:52.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Reporting Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Frequency</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:71.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Timing of Submission</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Actuals</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Quarterly</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45&nbsp;days&nbsp;following&nbsp;the&nbsp;end&nbsp;of&nbsp;each&nbsp;quarter</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Adjustment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Annual</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45&nbsp;days&nbsp;following&nbsp;Sanofi&#146;s&nbsp;fiscal&nbsp;year&nbsp;end</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, prior to the beginning of a financial period (i.e. a given year), Sanofi will provide Regulus a
quarterly forecast estimate of US Profits based upon projected Net Sales and budgeted Allowable Costs and Expenses and Sanofi will cause appropriate personnel to be available for a preliminary results conference call with Regulus finance within
30-days of quarter-end to discuss results and draft estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sanofi will be responsible for the preparation of reports and calculation of U.S. Profits. Sanofi
will provide to Regulus, by the submission dates shown above, a statement showing the results for the preceding Calendar Quarter and Calendar Year-to-date, comparing Calendar Quarter and Calendar Year-to-date results to revenue forecasts and expense
budgets, calculating the U.S. Profits as provided in paragraph&nbsp;1 above, and determining the cash payments to be made by Sanofi to Regulus; <I>provided</I>, <I>however</I>, that until such time as U.S. Profits are greater than
$[&#133;***&#133;], Sanofi shall not be obligated to make any payment to Regulus pursuant to this Appendix&nbsp;11; and <I>provided</I>, <I>further</I>, that in no event shall Regulus be obligated to make any payment to Sanofi pursuant to this
Appendix&nbsp;11. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For any Calendar Quarter in which U.S. Profits are greater than $[&#133;***&#133;], Sanofi shall pay to Regulus
[&#133;***&#133;]% of U.S. Profits no later than 30 days after the date of Regulus&#146; invoice for such amount, which invoice shall be issued after receipt of Sanofi&#146;s report for such Calendar Quarter under this paragraph&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To the extent any year-end adjustments are determined in good faith by Sanofi to be appropriate, an appropriate adjustment to U.S. Profits for
the applicable year will be made. In the case of an upward adjustment, Sanofi will make an appropriate payment to Regulus within 30&nbsp;days following receipt of Regulus&#146; invoice for such payment, which invoice shall be issued after receipt of
the report describing such upward adjustment, and in the case of a downward adjustment, Sanofi will be entitled to an appropriate credit to be applied against future payments to Regulus of U.S. Profits with respect to the applicable Elected Product;
<I>provided, however,</I> that in the event of a dispute between the parties with respect to whether any such adjustment or any other adjustment requested by Regulus is appropriate, such dispute will be referred to the Senior Representatives of the
Parties for resolution pursuant to Section 13.4 of the Agreement. Any such adjustment payment with respect to an upward adjustment will: (a)&nbsp;be without interest if such amount is less than [&#133;***&#133;]% of U.S. Profits for such year; and
(b)&nbsp;bear interest at the rate set forth in Section 6.21 of the Agreement if such amount is greater than or equal to [&#133;***&#133;]% of U.S. Profits for such year. Any such adjustment credit with respect to a downward adjustment will be
without interest. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><B>Definitions.</B> As used herein, the term &#147;operating unit&#148; will mean the standard operating unit in which a profit and loss statement is prepared for management accounting purposes in the party&#146;s
normal accounting procedures, consistently applied within and across its operating units. In addition, as a supplement to the definitions provided in the Agreement and in Appendix&nbsp;1 thereto, the following terms shall have the meanings set forth
below: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;Allowable Costs and Expenses&#148;</B> means those costs and expenses incurred by the parties or for their account after the applicable Product becomes an Elected Product that are specifically attributable or
related to the post-marketing development, commercial manufacturing, marketing or selling of an Elected Product in the U.S., and consisting of: (i)&nbsp;Cost of Goods Sold, <FONT STYLE="white-space:nowrap">(ii)&nbsp;Post-Marketing</FONT> Development
Expenses, (iii)&nbsp;Sales and Marketing Expenses and (iv)&nbsp;General and Administrative Expenses. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;Cost of Goods Sold&#148;</B> means the actual fully-burdened cost of Elected Products shipped in final form for commercial distribution in the U.S. As used herein, the cost of Elected Products means (i)&nbsp;in
the case of products and services acquired from Third Parties, payments made to such Third Parties, (ii)&nbsp;in the case of manufacturing and supply services performed by Sanofi or its Affiliate, the actual unit costs of manufacture in bulk form or
final manufacturing, as the case may be, plus the variances and other costs specifically provided for herein, and (iii)&nbsp;production costs associated with specific packaging and labeling requirements. Actual unit costs shall consist of direct
material and direct labor costs, plus manufacturing overhead reasonably allocable to manufacturing and supply services, of Sanofi or its Affiliate, in each case in accordance with reasonable cost accounting methods, consistently applied. Direct
material costs shall include the costs incurred in purchasing materials, including sales and excise taxes imposed thereon and customs duty and charges levied by governmental authorities in the U.S., and all costs of packaging components. Direct
labor shall include the cost of employees engaged in direct manufacturing or supply activities and direct or indirect quality control and quality assurance activities who are directly employed in manufacturing and packaging of Elected Products for
commercial distribution in the U.S. Manufacturing overhead allocable to manufacturing and supply services may include indirect labor, facilities&#146; start-up costs, unsuccessful or low yielding production runs, excess or idle capacity, the costs
of audits, insurance, and manufacturing and supply administrative and facilities costs, including allocable depreciation and repairs and maintenance of existing capital assets. Such allocations shall be in accordance with reasonable cost accounting
methods, consistently applied, of the party performing the work. Costs of Goods Sold will also include manufacturing variances and other attributable costs not in standard (but excluding capacity not incorporated into standard manufacturing unit
costs) such as, but not limited to, material price variances, labor hour variances, material usage variances, excess and obsolescence, inventory reserves and batches that do not conform to specification. Cost of Goods Sold shall exclude Third Party
royalty expenses (which are handled separately in Article&nbsp;6 of the Agreement). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"><B><FONT STYLE="white-space:nowrap">&#147;Post-Marketing</FONT> Development Expenses&#148;</B> means the expenses incurred by a party or for its account that are attributable to the development of an Elected Product for
the U.S. after First Commercial Sale of such Elected Product in the U.S., calculated on a fully burdened basis. Without limiting the generality of the foregoing, <FONT STYLE="white-space:nowrap">&#147;Post-Marketing</FONT> Development Expenses&#148;
will mean amounts paid by a party to Third Parties and internal costs (calculated on a full-time equivalent basis) incurred by a party, in each case, in support of or for extension of the applicable Elected Product in the U.S. after the First
Commercial Sale in the U.S.: Phase&nbsp;4 Trials; ongoing product development (<I>e.g.</I>, new formulations and routes of administration); ongoing product support; ongoing medical affairs; and fees and expenses of outside consultants and counsel in
respect of regulatory affairs. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>&#147;Sales and Marketing Expenses&#148;</B> means the costs which are incurred by a party or for its account attributable to the distribution,
sale, promotion and marketing of </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
an Elected Product in the U.S., calculated on a fully burdened basis. Sales and Marketing Expenses will mean the sum of Selling Expenses, Marketing Management, Market and Consumer Research,
Advertising, Trade Promotion, Consumer Promotion, Education Expenses and Freight and Transportation&#150;Out, each of which is specified below. The costs of activities which promote a party&#146;s business as a whole without being product specific
(such as corporate image advertising) are specifically excluded from Sales and Marketing Expenses. To the extent multiple products are involved and some of such products are not an Elected Product, then such allowances will be allocated on a <I>pro
rata</I> basis based upon net sales of each respective product by such operating unit during the most recent quarter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"><B><I>&#147;Advertising&#148;</I></B> will include, but not be limited to, all media costs associated with Elected Product advertising in the U.S. as follows: production expense/artwork including set up; design and art
work for an advertisement; the cost of securing print space, air time, etc. in newspapers, magazines, trade journals, television, radio, billboards, etc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"><B><I>&#147;Consumer Promotion&#148;</I></B> will include, but not be limited to, the expenses associated with programs to promote an Elected Product in the U.S. directly to the prescriber or end user. This category
will include, but not be limited to, expenses associated with promoting products directly to the professional community such as professional samples, professional literature, promotional material costs, patient aids and detailing aids. To the extent
multiple products are involved and some of such products are not the applicable Elected Product, then such allowances will be allocated on a <I>pro rata </I>basis based upon net sales of each respective product by such operating unit during the most
recent quarter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"><B><I>&#147;Education&#148;</I></B> will include, but not be limited to, expenses associated with professional education with respect to an Elected Product in the U.S. through any means not covered above, including, but
not limited to, articles appearing in journals, newspapers, magazines or other media; seminars, scientific exhibits, and conventions; and symposia, advisory boards and opinion leader development activities. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"><B><I>&#147;Freight and Transportation&#150;Out&#148;</I></B> will include (to the extent not already recovered in the calculation of Net Sales), but not limited to, the portion of distribution costs relating to moving
Elected Product goods in the U.S. from a warehouse to the customer as follows: outbound transportation costs; costs of moving goods from a manufacturing point to a warehouse at another location from which it is ultimately to be distributed to a
customer; the costs of the traffic department where there is a separate department that has responsibility for administration of freight costs. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B><I>&#147;Market and Consumer Research&#148;</I></B> will include, but not be limited to, compensation and departmental expenses for market and
consumer </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
research personnel and payments to Third Parties related to conducting and monitoring professional and consumer appraisals of existing, new or proposed Elected Products in the U.S., such as
market share services (<I>e.g</I>., IMS data), special research testing and focus groups. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>&#147;Marketing Management&#148;</I></B><B></B> will include, but not be limited to, product management and sales promotion management compensation and departmental expenses. This will include, but not be
limited to, costs associated with developing overall sales and marketing strategies (<I>e.g.</I>, product line or customer segment), as well as planning and programs for Elected Products in the U.S. In addition, payments to Third Parties in
connection with trademark selection, filing, prosecution and enforcement in the U.S. will be included in this category. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vii.</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>&#147;Selling Expenses&#148;</I></B><B></B> will include, but not be limited to, the following costs directly associated with the efforts of field sales representatives with respect to Elected Products in
the U.S.: field sales force; field sales offices; home offices; staffs directly involved in the management of and the performance of the selling functions; and payments to Third Parties under contract sales and marketing agreements. The costs of
detailing sales calls will be allocated on a weighted average basis based on the proportionate time and effort given to the detailing of Elected Products versus product other than an Elected Product at an accounting charge rate consistently applied
within and across a party&#146;s or a Third Party&#146;s operating units and which is no less favorable than the internal charge rate used by such party or such Third Party for its own internal cost accounting purposes for products other than the
Elected Product (excluding internal profit margins and markups). Without limiting the foregoing, &#147;Selling Expenses&#148; shall include all compensation paid by Sanofi to Regulus in accordance with paragraph 3h. of Appendix 10.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">viii.</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>&#147;Trade Promotion&#148;</I></B><B></B> will include, but not be limited to, the allowances given to retailers, brokers, distributors, hospital buying groups, etc. for purchasing, promoting, and
distribution of Elected Products in the U.S. This will include, but not be limited to, purchasing, advertising, new distribution, and display allowances as well as free goods, wholesale allowances and reasonable field sales samples.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>&#147;General and Administrative Expenses</B> means a party&#146;s customary allocation, based on direct project headcount or other generally
accepted activity-based accounting methods, of the costs of the following corporate general and administrative functions of such party or any of its operating units incurred to support or facilitate the post-marketing development, commercial
manufacturing, marketing or selling of Elected Products in the U.S.: finance and accounting; purchasing and receiving; management information systems; facilities; human resources; executive management; and legal, patent and trademark. Such costs
include, but not limited to, the costs of employees performing such functions, the </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
direct costs of supporting such individuals in the performance of their jobs (<I>e.g</I>., travel, floor space, computers and other supplies and telephones) and the actual cost of outside
services (<I>e.g</I>., consulting and audit services). General and administrative expenses of a party or operating unit that are incurred in the development, manufacturing, marketing or selling of an Elected Product outside the U.S. will be excluded
from General and Administrative Expenses. In view of the manner in which General and Administrative Expenses are calculated, administration expenses will be excluded from the definition of each of the other cost items that make up Allowable Costs
and Expenses. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Agreement, total General and Administrative
Expenses for an Elected Product in the U.S. shall not exceed [&#133;***&#133;]% of U.S. Net Sales of such Elected Product in any quarter. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;Net Interest Income&#148;</B> means interest income less interest expense and adjusted for realized gains and losses from the sale of investments. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"><B>&#147;U.S. Profits&#148;</B> will have the meaning ascribed to it in paragraph&nbsp;1 above. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><B>Foreign Exchange.</B> The functional currency for accounting for U.S. Profits will be U.S. Dollars. The statement of U.S. Profits will be translated into U.S. Dollars using, for each currency, the methodology
specified in Section 6.17 of the Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><B>Audits.</B> Regulus will have the right to request that an independent public accounting firm perform an audit of Sanofi&#146;s books of accounts for the purpose of verifying compliance with this Appendix in
accordance with Sections&nbsp;6.18.1 and 6.18.4, <I>mutatis mutandis</I>. Such audits will be conducted at the expense of Regulus; <I>provided, however, </I>that if the audit results in an upward adjustment exceeding [&#133;***&#133;]% of U.S.
Profits for such year the reasonable cost of the audit will be borne by Sanofi. Any disputes with regard to the foregoing will be resolved in accordance with Section 13.4 of the Agreement. Audit results will be shared with both parties.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>***Confidential
Treatment Requested </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX 12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Second Restatement Press Release </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g652681ex10_52pg133.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DRAFT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regulus Renews Strategic Alliance with Sanofi to Focus on Orphan Disease and Oncology Targets and Receives Additional $10 Million Equity
Investment </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>-Regulus to Develop microRNA-21 for Alport Syndrome, </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>a Life-Threatening Orphan Kidney Disease, and microRNA-21 in Oncology, to Human Proof-of-Concept- </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>-Sanofi Obtains Exclusive Option to Regulus&#146; Program Targeting microRNA-221/microRNA-222- </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Regulus Milestones Remain with Upside in Potential Royalties </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LA JOLLA, Calif., February&nbsp;5, 2014</B> &#150;Regulus Therapeutics Inc. (<I>NASDAQ:RGLS</I>) announced today that it has renewed its strategic alliance
with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Regulus will lead development of its fibrosis program targeting microRNA-21 (&#147;miR-21&#148;) for the treatment of
Alport Syndrome, an orphan, life-threatening genetic kidney disease with no approved therapy, and for its microRNA-21 (&#147;miR-21&#148;) program in oncology. Sanofi has retained its interest in these microRNA-21 programs and has gained rights to
Regulus&#146; preclinical program targeting microRNA-221/microRNA-222 (&#147;miR-221/222&#148;). Regulus is responsible for advancing the clinical candidates in these programs to proof-of-concept. Sanofi shall have the exclusive option, exercisable
after proof-of-concept, to take over further development and commercialization of each microRNA therapeutic program. At this stage, Regulus will have the option to co-promote any microRNA therapeutic product in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The renewal of our strategic relationship with Sanofi further underscores the commitment of both companies to realize the tremendous promise of RNA
therapeutics and the possibility to transform the field of drug discovery by targeting microRNAs,&#148; said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. &#147;We believe that Regulus&#146; microRNA therapeutic platform, coupled
with our focus on orphan diseases and oncology indications, combine perfectly with Sanofi&#146;s resources and their proven capabilities as a global-healthcare leader to bring innovative medicines to patients in need. We look forward to advancing
our programs together and building a meaningful clinical portfolio.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The refocused relationship allows Sanofi and Regulus to continue to collaborate
on several meaningful microRNA therapeutic programs, with a greater focus on orphan diseases and oncology. Under the original agreement from 2010, Sanofi had rights on up to four microRNA targets, which included Regulus&#146; lead fibrosis program
targeting miR-21.&nbsp;In 2012, the companies expanded the alliance to collaborate on an oncology program targeting miR-21. In 2013, the companies entered into an option letter agreement to allow for negotiation of the extended strategic alliance
announced today. Sanofi retained its interest in developing microRNA-21 therapeutics for fibrosis and oncology indications and now has opt-in rights to Regulus&#146; miR-21 and miR-221/222 program. If Sanofi chooses to exercise its
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option on any of these programs, Sanofi will reimburse Regulus for a significant portion of its preclinical and clinical development costs. Regulus continues to be eligible to receive royalties
on microRNA therapeutic products commercialized by Sanofi.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, Sanofi has increased its ownership stake in Regulus through an additional $10
million common stock investment at $7.67 per share, which represents the volume-weighted average share price over the last 30 trading days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Regulus </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulus Therapeutics Inc. (<I>NASDAQ:RGLS</I>) is a biopharmaceutical company leading the discovery and development of innovative medicines
targeting microRNAs.&nbsp;Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which
founded the company.&nbsp;Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its
leadership in the microRNA field.&nbsp;Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in
oncology, fibrosis and metabolic diseases.&nbsp;Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment of chronic hepatitis C virus infection. Regulus&#146; commitment to innovation and its
leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi. In addition, the Company has established Regulus microMarkers&#153;, a research and development division focused on
identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
more information, please visit&nbsp;http://www.regulusrx.com.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements contained in this press release regarding matters that are not historical facts are &#147;forward-looking statements&#148; within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements associated with Regulus&#146; expectations regarding future therapeutic and commercial potential of Regulus&#146; business plans, technologies and intellectual property related
to microRNA therapeutics being discovered and developed by Regulus.&nbsp;Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words
such as &#147;believes,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;will,&#148; &#147;goal,&#148; &#147;potential&#148; and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon Regulus&#146; current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from
those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of building a business around such drugs.&nbsp;These and other risks concerning Regulus&#146; programs are described in additional detail in Regulus&#146; SEC filings.&nbsp;All
forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which
they were made. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Conrad </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Investor Relations and Corporate
Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">aconrad@regulusrx.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">858-202-6321 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Liz Bryan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spectrum Science </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lbryan@spectrumscience.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">202-955-6222 x2526 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>d652681dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-184324 and 333-188606) of Regulus
Therapeutics&nbsp;Inc. and in the related Prospectus of our report dated February&nbsp;27, 2014, with respect to the financial statements of Regulus Therapeutics&nbsp;Inc. included in this Annual Report (Form&nbsp;10-K) for the year ended
December&nbsp;31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;27, 2014 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>d652681dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SARBANES-OXLEY ACT OF 2002 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Kleanthis
G. Xanthopoulos, Ph.D., certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2013 of Regulus
Therapeutics Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. I am responsible for
establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
<FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(f)</FONT> and 15d-15(f)) for the registrant and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) Evaluated the effectiveness of the registrant&#146;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#146;s
auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial
information; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant&#146;s internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="45%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kleanthis G. Xanthopoulos</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kleanthis G. Xanthopoulos, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive
Officer and Principal Financial Officer)</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February&nbsp;27, 2014 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>d652681dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Subsections (a)&nbsp;and (b)&nbsp;of Section&nbsp;1350, Chapter 63 of Title
18, United States Code) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report on Form 10-K of Regulus Therapeutics Inc. (the &#147;Company&#148;) for
the year ended December&nbsp;31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I,&nbsp;Kleanthis G. Xanthopoulos, Ph.D., as President and Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;27, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kleanthis&nbsp;G. Xanthopoulos</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Kleanthis&nbsp;G. Xanthopoulos, Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President &amp; Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP>(Principal Executive Officer and Principal Financial Officer)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167;
1350, and is not being filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of
any general incorporation language in such filing. A signed original of this written statement required by Section&nbsp;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>rgls-20131231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-02-27T18:35:01Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:rgls="http://www.regulusrx.com/20131231" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="rgls-20131231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:AreaOfRealEstateProperty contextRef="eol_PE841390--1310-K0016_STD_0_20121130_0_843826x726565" unitRef="sqft" decimals="INF" id="id_3156006_E6FAD7EB-C5DA-4AA5-88B1-E9744521041B_2002_7">3000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty contextRef="eol_PE841390--1310-K0016_STD_0_20121130_0_843826x823826" unitRef="sqft" decimals="INF" id="id_3156006_E6FAD7EB-C5DA-4AA5-88B1-E9744521041B_3002_6">7000</us-gaap:AreaOfRealEstateProperty>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20140207_0" unitRef="shares" decimals="INF" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_2_500008">43168034</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CustomerAdvancesCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20140228_0_710720x714667_711298x770834_759964x766452" unitRef="iso4217_USD" decimals="-4" id="id_3156006_FBB17B85-588B-4C14-AB76-2955B8B8181E_2001_0">1250000</us-gaap:CustomerAdvancesCurrent>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE841390--1310-K0016_STD_0_20140228_0_710720x714667_714777x709629_759964x766452" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_FC95A15C-3F18-406B-874E-79169FB9D11B_2001_1">7.67</us-gaap:SaleOfStockPricePerShare>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131130_0_712375x879645_759964x827281" unitRef="iso4217_USD" decimals="-5" id="id_3156006_71B7B13A-7970-47B6-BFBA-CFA86B919432_4001_0">300000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <us-gaap:ConvertibleNotesPayable contextRef="eol_PE841390--1310-K0016_STD_0_20120731_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_57C3D7C4-FC8F-41A1-AD0D-BDD26C594D4D_1001_0">5000000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE841390--1310-K0016_STD_0_20120731_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_BB1A1A43-BBB4-478D-B272-BF32F1933797_1003_1">5000000</us-gaap:DebtInstrumentCarryingAmount>
  <dei:EntityPublicFloat contextRef="eol_PE841390--1310-K0016_STD_0_20130628_0" unitRef="iso4217_USD" decimals="0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_3_600009">125100000</dei:EntityPublicFloat>
  <us-gaap:CustomerAdvancesCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20130731_0_711298x770834_759964x766452" unitRef="iso4217_USD" decimals="-4" id="id_3156006_9CD6A2C0-447F-4EEB-BDE6-0BB1E8B4D9B9_4002_1">1250000</us-gaap:CustomerAdvancesCurrent>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE841390--1310-K0016_STD_0_20120831_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_72A3246B-2577-4FF6-B664-6C775BF81CFE_1001_2">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:ConvertibleNotesPayable contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_710552x734047_759964x778268" unitRef="iso4217_USD" decimals="-5" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_6001_6">5000000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_710552x734047_759964x778268" unitRef="iso4217_USD" decimals="-5" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_6001_7">800000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:ConvertibleNotesPayable contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_710552x734047_759964x827281" unitRef="iso4217_USD" decimals="-5" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_7001_8">5000000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_713115x818265" unitRef="pure" decimals="2" id="id_3156006_AF0FEC6E-C215-402E-9F7C-DF715B62A90E_4001_0">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_714378x757334" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_A721273B-877F-4A34-A65B-B8CF6C8E5091_4001_5">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:ConvertibleNotesPayable contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_714378x757334" unitRef="iso4217_USD" decimals="-5" id="id_3156006_A721273B-877F-4A34-A65B-B8CF6C8E5091_4001_1">5000000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_714378x823469" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_A8E837E7-7A55-4CB6-BB2A-6F9673EDF292_3002_4">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_714378x823469" unitRef="iso4217_USD" decimals="-5" id="id_3156006_A8E837E7-7A55-4CB6-BB2A-6F9673EDF292_3002_2">5000000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_759964x826261" unitRef="shares" decimals="INF" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_3001_1">6250000</us-gaap:CommonStockSharesIssued>
  <us-gaap:DeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_0_20121031_0_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_3001_5">4300000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_0_20130930_0_711298x770834_759964x778268" unitRef="iso4217_USD" decimals="-5" id="id_3156006_E464BB75-E831-4CC1-8441-CEDD9804A7CA_2002_1">3500000</us-gaap:DeferredRevenue>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_2001_0">288000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_1006_900001">-34695000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2001_32">21268000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_1003_600001">701000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_1005_800001">-35409000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0_709650x716406" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_1004_700001">13000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0_711196x710990" unitRef="shares" decimals="INF" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_1003_600001">2499999</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0_711196x710990" unitRef="iso4217_USD" decimals="-3" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_1003_700002">10000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0_711196x713505" unitRef="shares" decimals="INF" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_1001_400001">24900000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE841390--1310-K0016_STD_0_20101231_0_711196x713505" unitRef="iso4217_USD" decimals="-3" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_1001_500002">32691000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_1003_0">406000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_3006_900006">-41494000</us-gaap:StockholdersEquity>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_0D4F8623-3219-4862-862B-3F9060D49F48_3_0">10000000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1003_32">9175000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_3003_600006">1584000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_3001_400006">153184</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_3005_800006">-43011000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0_709650x716406" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_3004_700006">-67000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0_711196x710990" unitRef="shares" decimals="INF" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_3003_600003">2499999</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0_711196x710990" unitRef="iso4217_USD" decimals="-3" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_3003_700004">10000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0_711196x713505" unitRef="shares" decimals="INF" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_3001_400003">24900000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE841390--1310-K0016_STD_0_20111231_0_711196x713505" unitRef="iso4217_USD" decimals="-3" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_3001_500004">32691000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_0D4F8623-3219-4862-862B-3F9060D49F48_2_1">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_26">35831808</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_C0B9FCE4-9F94-4676-8F7E-7DC0434704D7_2001_1">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="shares" decimals="-3" id="id_3156006_09612DD9-C5AA-4193-9C75-5DDB5A4DCA35_2001_1">4720000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_25">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_24">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3156006_4200EACB-88C9-4FC1-A418-C76C1B57CBA8_1_0">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_27">35831808</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_19">17756000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_17">12768000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_29">-52000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_1002_0">569000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_15">1348000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_2_6">2442000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_28">122528000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_13">311000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_9">19279000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_20">767000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_31">62093000</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_30">-60419000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_16">10451000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredTaxLiabilities contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_7">226000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_14">658000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_0D4F8623-3219-4862-862B-3F9060D49F48_2_0">5400000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:Liabilities contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_21">41425000</us-gaap:Liabilities>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_36C95308-8BC8-4267-B4A9-F19F4F271C19_2_3">163000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_43F3CC12-6573-40AE-A31F-2D49699BF00A_1002_1">500000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_23">36000</us-gaap:CommonStockValue>
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_18">10134000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_32">103518000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_9">125000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_1">8528000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_6">19505000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_8">1154000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_10" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_2_5">5752000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_1_4">96911000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_5">459000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_7">3310000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_10">103518000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_2">40552000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_3">57548000</us-gaap:ShortTermInvestments>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_8">19279000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_2">1983000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_3">7322000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_36C95308-8BC8-4267-B4A9-F19F4F271C19_2_2">1317000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_5">829000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_2_6">98929000</us-gaap:AssetsCurrent>
  <rgls:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1002_4">1213000</rgls:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_2004_2">57590000</rgls:ShortTermInvestmentsAmortizedCost>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_5003_600017">122528000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_5001_400017">35831808</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_5001_500017">36000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_5005_800017">-60419000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x716406" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_5004_700017">-52000</us-gaap:StockholdersEquity>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x709312" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_2002_5">6200000</us-gaap:ShortTermInvestments>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x709312" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_2002_2">6200000</rgls:ShortTermInvestmentsAmortizedCost>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x712703" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_2003_5">6492000</us-gaap:ShortTermInvestments>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x712703" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_2003_2">6492000</rgls:ShortTermInvestmentsAmortizedCost>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_2001_5">44856000</us-gaap:ShortTermInvestments>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_2001_2">44898000</rgls:ShortTermInvestmentsAmortizedCost>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x709312" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_1001_2">6200000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x709312_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_1003_2">6200000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x711008" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_2001_0">39363000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x711008_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_2002_0">39363000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x712703" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_3001_3">6492000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x712703_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_3003_3">6492000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_4001_1">44856000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x712929_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_4003_1">44856000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_714938x711305" unitRef="iso4217_USD" decimals="-3" id="id_3156006_36C95308-8BC8-4267-B4A9-F19F4F271C19_1002_0">913000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_714938x766191" unitRef="iso4217_USD" decimals="-3" id="id_3156006_36C95308-8BC8-4267-B4A9-F19F4F271C19_2002_1">404000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_2_4">39363000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_3_4">57548000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715757x715798" unitRef="iso4217_USD" decimals="-3" id="id_3156006_83B2BA16-5767-4BC7-A15A-DFB8CB5B8F67_3001_0">10134000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715757x715798_716819x708807" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_5004_6">10134000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x710442" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_1002_2">93000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x710555" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_2002_4">211000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x716297" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_3002_3">751000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x761833" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_4002_1">114000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x833191" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_5002_0">4583000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20121231_0_716819x708807" unitRef="iso4217_USD" decimals="-3" id="id_3156006_26800EE6-72E2-4D4A-9F7E-40580531F5C0_5001_6">10134000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_0D4F8623-3219-4862-862B-3F9060D49F48_1_1">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_26">41787326</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3156006_5A1C1CF4-916D-4D22-9C1A-A00461098075_1_4">8180683</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_3156006_09612DD9-C5AA-4193-9C75-5DDB5A4DCA35_1001_7">2244000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_C0B9FCE4-9F94-4676-8F7E-7DC0434704D7_1001_5">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_3156006_09612DD9-C5AA-4193-9C75-5DDB5A4DCA35_1001_5">5598000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_C0B9FCE4-9F94-4676-8F7E-7DC0434704D7_1001_6">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_C0B9FCE4-9F94-4676-8F7E-7DC0434704D7_1001_7">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:AreaOfRealEstateProperty contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="sqft" decimals="INF" id="id_3156006_E6FAD7EB-C5DA-4AA5-88B1-E9744521041B_1001_5">22000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_25">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_24">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_3156006_09612DD9-C5AA-4193-9C75-5DDB5A4DCA35_1001_6">5382000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_27">41787326</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_19">6500000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_2019FD1F-D9AD-47EC-86FB-C6104E74DA02_1_0">1066000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_17">10370000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_29">-16000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3156006_2019FD1F-D9AD-47EC-86FB-C6104E74DA02_1_4" />
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_1001_3">1092000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_15">1297000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_1_6">3731000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_28">172518000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_2019FD1F-D9AD-47EC-86FB-C6104E74DA02_1_5">4039000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_13">1172000</us-gaap:AccountsPayableCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_2019FD1F-D9AD-47EC-86FB-C6104E74DA02_1_3">624000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_9">28306000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_20">1459000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_31">93457000</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_30">-79087000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_16">4888000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredTaxLiabilities contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_7">973000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_14">3013000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_2019FD1F-D9AD-47EC-86FB-C6104E74DA02_1_1">1138000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_0D4F8623-3219-4862-862B-3F9060D49F48_1_0">5400000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:Liabilities contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_21">29608000</us-gaap:Liabilities>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_2019FD1F-D9AD-47EC-86FB-C6104E74DA02_1_2">1211000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:IncentiveFromLessor contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F02DAB0A-6862-4DBE-A39B-986A6C4FA171_1001_0">100000</us-gaap:IncentiveFromLessor>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_36C95308-8BC8-4267-B4A9-F19F4F271C19_1_3">236000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_43F3CC12-6573-40AE-A31F-2D49699BF00A_1001_1">900000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_23">42000</us-gaap:CommonStockValue>
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_18">11279000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_32">123065000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_9">987000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_1">17460000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8C20D543-4BE9-4D72-9105-57D953E540B5_1001_1">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_6">29279000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_4">79000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_8">1128000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8C20D543-4BE9-4D72-9105-57D953E540B5_1001_2">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_10" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_1_5">7499000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8C20D543-4BE9-4D72-9105-57D953E540B5_1001_4">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_1_6">113368000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_5">1297000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_7">3768000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8C20D543-4BE9-4D72-9105-57D953E540B5_1001_5">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:Assets contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_10">123065000</us-gaap:Assets>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B62357EF-8DA8-4509-BCE6-7DD82492D26A_1001_2">20800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_2">17807000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_3">96198000</us-gaap:ShortTermInvestments>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_8">28306000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_2">4727000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B62357EF-8DA8-4509-BCE6-7DD82492D26A_1001_3">13842000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B62357EF-8DA8-4509-BCE6-7DD82492D26A_1001_1">21162000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8C20D543-4BE9-4D72-9105-57D953E540B5_1001_3">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8B1B8DA5-8B15-4A23-9B4A-5F5BAF54F224_1_0">7800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_3">3999000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_36C95308-8BC8-4267-B4A9-F19F4F271C19_1_2">1364000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_5">3098000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_34B50EBC-D278-4A9F-89BE-142857648C2E_1_6">117182000</us-gaap:AssetsCurrent>
  <rgls:LeaseTerminationNoticePeriod contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" id="id_3156006_E6FAD7EB-C5DA-4AA5-88B1-E9744521041B_1001_2">P6M</rgls:LeaseTerminationNoticePeriod>
  <rgls:CommonStockVotesPerShare contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="Vote" decimals="INF" id="id_3156006_7A559FF6-A9A7-42E2-8337-FA3C6D4763B6_1_1">1</rgls:CommonStockVotesPerShare>
  <rgls:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_4B72ADF4-A95A-4975-9C3F-18573591EEBE_1001_4">1796000</rgls:DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2005_2">96181000</rgls:ShortTermInvestmentsAmortizedCost>
  <rgls:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_B5B827BC-25F4-483B-B12F-03143732F06D_1_0">1100000</rgls:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_707402x714598_710844x707112" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FD9FA894-3F05-4F74-A5C2-DAB245AF51AF_2001_6">2800000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_707402x714598_710844x745434" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FD9FA894-3F05-4F74-A5C2-DAB245AF51AF_3001_5">3600000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_9003_600025">172518000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_9001_400025">41787326</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_9001_500025">42000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_9005_800025">-79087000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x716406" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_9004_700025">-16000</us-gaap:StockholdersEquity>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x709312" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2002_5">11710000</us-gaap:ShortTermInvestments>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x709312" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2002_2">11710000</rgls:ShortTermInvestmentsAmortizedCost>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x712703" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2003_5">6071000</us-gaap:ShortTermInvestments>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x712703" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2003_2">6069000</rgls:ShortTermInvestmentsAmortizedCost>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2001_5">71416000</us-gaap:ShortTermInvestments>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2001_2">71402000</rgls:ShortTermInvestmentsAmortizedCost>
  <us-gaap:ShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x717071" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2004_5">7001000</us-gaap:ShortTermInvestments>
  <rgls:ShortTermInvestmentsAmortizedCost contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x717071" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2004_2">7000000</rgls:ShortTermInvestmentsAmortizedCost>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710844x707112" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FD9FA894-3F05-4F74-A5C2-DAB245AF51AF_1001_1">52600000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710844x707398" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FD9FA894-3F05-4F74-A5C2-DAB245AF51AF_5001_7">200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_710844x707398" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FD9FA894-3F05-4F74-A5C2-DAB245AF51AF_5001_0">44200000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_711196x708807" unitRef="shares" decimals="INF" id="id_3156006_5A1C1CF4-916D-4D22-9C1A-A00461098075_1001_3">1411659</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_711196x713713" unitRef="shares" decimals="INF" id="id_3156006_5A1C1CF4-916D-4D22-9C1A-A00461098075_2001_0">5598207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_711196x713713" unitRef="shares" decimals="INF" id="id_3156006_5A1C1CF4-916D-4D22-9C1A-A00461098075_2001_1">710534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_711196x715677" unitRef="shares" decimals="INF" id="id_3156006_5A1C1CF4-916D-4D22-9C1A-A00461098075_3001_2">460283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:DeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_711298x726565_759964x766452" unitRef="iso4217_USD" decimals="-5" id="id_3156006_9CD6A2C0-447F-4EEB-BDE6-0BB1E8B4D9B9_3001_3">2200000</us-gaap:DeferredRevenue>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x709312" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_1001_3">11710000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x709312_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_1003_3">11710000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x711008" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_2001_1">17170000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x711008_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_2002_1">17170000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x712703" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_3001_5">6071000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x712703_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_3003_5">6071000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_4001_2">71416000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x712929_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_4003_2">71416000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x717071" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_5001_4">7001000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x717071_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_5003_4">7001000</us-gaap:AssetsFairValueDisclosureRecurring>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x714598_759964x827281" unitRef="iso4217_USD" decimals="-5" id="id_3156006_BAAAD986-79F4-4F22-8F7A-EECB8B4262F4_2001_2">1300000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x742023_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F21F6296-A875-4611-8199-443F8AC4EAAF_3001_4">180000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x742023_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_02AF28BD-BB45-4A2F-B872-6197C178E5C9_2001_3">370000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x754265_759964x778268_853143x832174" unitRef="iso4217_USD" decimals="-5" id="id_3156006_9FD38356-75C7-4EE9-A433-48564CF19D1F_3001_3">50000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x754265_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F21F6296-A875-4611-8199-443F8AC4EAAF_4001_3">150000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x772189_759964x827281" unitRef="iso4217_USD" decimals="-5" id="id_3156006_71B7B13A-7970-47B6-BFBA-CFA86B919432_2002_1">500000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x784252_759964x778268_853143x832174" unitRef="iso4217_USD" decimals="-5" id="id_3156006_59009F41-CD00-4956-8D40-E6104E1CDF96_1001_1">4000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x784252_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_2B068FAF-CBB7-4250-B6D9-5E0D6FC9DE1E_1001_2">4000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x788356_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_2B068FAF-CBB7-4250-B6D9-5E0D6FC9DE1E_2001_0">500000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x790602_759964x766452" unitRef="iso4217_USD" decimals="-5" id="id_3156006_20230DF7-3D01-4BFE-9213-83269643F824_3001_0">15000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x790602_759964x778268_853143x832174" unitRef="iso4217_USD" decimals="-5" id="id_3156006_9FD38356-75C7-4EE9-A433-48564CF19D1F_4001_1">5500000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x790602_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F21F6296-A875-4611-8199-443F8AC4EAAF_5001_1">15500000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x790602_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_02AF28BD-BB45-4A2F-B872-6197C178E5C9_3001_1">5000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x795445_759964x778268_853143x832174" unitRef="iso4217_USD" decimals="-5" id="id_3156006_9FD38356-75C7-4EE9-A433-48564CF19D1F_5001_4">60000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x808515_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_2B068FAF-CBB7-4250-B6D9-5E0D6FC9DE1E_3001_1">5000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <us-gaap:DeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x809852_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_2002_6">2900000</us-gaap:DeferredRevenue>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x810995_759964x766452" unitRef="iso4217_USD" decimals="-5" id="id_3156006_20230DF7-3D01-4BFE-9213-83269643F824_4001_1">33000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x810995_759964x778268_853143x832174" unitRef="iso4217_USD" decimals="-5" id="id_3156006_9FD38356-75C7-4EE9-A433-48564CF19D1F_6001_2">29000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x810995_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F21F6296-A875-4611-8199-443F8AC4EAAF_6001_2">87000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x810995_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_02AF28BD-BB45-4A2F-B872-6197C178E5C9_4001_2">123000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x814120_759964x827281" unitRef="iso4217_USD" decimals="-5" id="id_3156006_71B7B13A-7970-47B6-BFBA-CFA86B919432_3002_2">500000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x827588_759964x778268_853143x832174" unitRef="iso4217_USD" decimals="-5" id="id_3156006_59009F41-CD00-4956-8D40-E6104E1CDF96_3001_3">20000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x827588_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_2B068FAF-CBB7-4250-B6D9-5E0D6FC9DE1E_4001_4">20000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x837394_759964x778268_853143x832174" unitRef="iso4217_USD" decimals="-5" id="id_3156006_59009F41-CD00-4956-8D40-E6104E1CDF96_4001_2">5000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x837394_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_2B068FAF-CBB7-4250-B6D9-5E0D6FC9DE1E_5001_3">5000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x879640_759964x766452" unitRef="iso4217_USD" decimals="-5" id="id_3156006_20230DF7-3D01-4BFE-9213-83269643F824_5001_2">165000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_713115x708980" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FD9FA894-3F05-4F74-A5C2-DAB245AF51AF_6001_4">1600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_713115x736920" unitRef="shares" decimals="INF" id="id_3156006_6242B8B7-E589-4FE5-A6F6-06196DA16714_1001_0">710534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_713115x818265" unitRef="shares" decimals="INF" id="id_3156006_AF0FEC6E-C215-402E-9F7C-DF715B62A90E_3002_4">460283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_714938x711305" unitRef="iso4217_USD" decimals="-3" id="id_3156006_36C95308-8BC8-4267-B4A9-F19F4F271C19_1001_0">960000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_714938x766191" unitRef="iso4217_USD" decimals="-3" id="id_3156006_36C95308-8BC8-4267-B4A9-F19F4F271C19_2001_1">404000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715757x707740" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_2_6">17170000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715757x707855" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_3_6">96198000</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715757x715798" unitRef="iso4217_USD" decimals="-3" id="id_3156006_83B2BA16-5767-4BC7-A15A-DFB8CB5B8F67_2001_2">11279000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisObligations>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715757x715798_716819x708807" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_6004_8">11279000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x710442" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_1001_2">119000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x710555" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_2001_4">119000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x716297" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_3001_3">1805000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x761833" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_4001_1">114000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x833191" unitRef="iso4217_USD" decimals="-3" id="id_3156006_CF8A4051-308F-4EE4-BFE4-EA662B42F8B6_5001_0">5342000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_716819x708807" unitRef="iso4217_USD" decimals="-3" id="id_3156006_9429A2BB-B702-49CD-A9CF-EFF5B71C1605_6001_8">11279000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x778268_853143x832174" unitRef="iso4217_USD" decimals="-5" id="id_3156006_9FD38356-75C7-4EE9-A433-48564CF19D1F_7001_0">144500000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x778268_853143x836413" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F21F6296-A875-4611-8199-443F8AC4EAAF_7001_0">432500000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <us-gaap:DeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_3002_5">2000000</us-gaap:DeferredRevenue>
  <us-gaap:CommonStockValue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_3002_0">25000000</us-gaap:CommonStockValue>
  <rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_02AF28BD-BB45-4A2F-B872-6197C178E5C9_5001_0">498000000</rgls:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
  <us-gaap:DeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x827281" unitRef="iso4217_USD" decimals="-5" id="id_3156006_71B7B13A-7970-47B6-BFBA-CFA86B919432_5002_3">300000</us-gaap:DeferredRevenue>
  <rgls:RevenueRecognitionPeriod contextRef="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x827281" id="id_3156006_BAAAD986-79F4-4F22-8F7A-EECB8B4262F4_3001_3">P2Y</rgls:RevenueRecognitionPeriod>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE841390--1310-K0016_STD_2_20120907_0" unitRef="pure" decimals="INF" id="id_3156006_34404F3D-1BC0-4F32-894F-2D35103A70D5_1_0">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE841390--1310-K0016_STD_21_20140228_0_710720x714667_711298x770834_759964x766452" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FBB17B85-588B-4C14-AB76-2955B8B8181E_1001_1">2500000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="eol_PE841390--1310-K0016_STD_21_20140228_0_710720x714667_714777x709629_759964x766452" unitRef="shares" decimals="INF" id="id_3156006_FC95A15C-3F18-406B-874E-79169FB9D11B_1001_0">1303780</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="eol_PE841390--1310-K0016_STD_21_20140228_0_710720x714667_714777x709629_759964x766452" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FC95A15C-3F18-406B-874E-79169FB9D11B_1001_2">10000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
  <rgls:NetProceedsFromIssuanceOfConvertibleNotesPayable contextRef="eol_PE841390--1310-K0016_STD_28_20100228_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_AF592521-9102-439F-B3DC-C304702F3974_2_1">5000000</rgls:NetProceedsFromIssuanceOfConvertibleNotesPayable>
  <rgls:NetProceedsFromIssuanceOfConvertibleNotesPayable contextRef="eol_PE841390--1310-K0016_STD_30_20080430_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_AF592521-9102-439F-B3DC-C304702F3974_1_1">5000000</rgls:NetProceedsFromIssuanceOfConvertibleNotesPayable>
  <rgls:TermOfDebtInstrument contextRef="eol_PE841390--1310-K0016_STD_30_20080430_0" id="id_3156006_AF592521-9102-439F-B3DC-C304702F3974_1_0">P3Y</rgls:TermOfDebtInstrument>
  <us-gaap:AdjustmentForAmortization contextRef="eol_PE841390--1310-K0016_STD_30_20130630_0_759964x778268" unitRef="iso4217_USD" decimals="-5" id="id_3156006_D6467DE7-93FF-4F2B-BED8-6EE904475847_1001_0">1100000</us-gaap:AdjustmentForAmortization>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE841390--1310-K0016_STD_31_20120731_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_BB1A1A43-BBB4-478D-B272-BF32F1933797_3_0">-1700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE841390--1310-K0016_STD_31_20130731_0" unitRef="shares" decimals="INF" id="id_3156006_BA4437E4-CDB6-46D8-9A9E-1C0E42162B41_1_0">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE841390--1310-K0016_STD_31_20130731_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BA4437E4-CDB6-46D8-9A9E-1C0E42162B41_1_1">9.50</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE841390--1310-K0016_STD_31_20130731_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_BA4437E4-CDB6-46D8-9A9E-1C0E42162B41_1_2">45800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE841390--1310-K0016_STD_31_20130731_0_711298x726565_759964x766452" unitRef="iso4217_USD" decimals="-5" id="id_3156006_9CD6A2C0-447F-4EEB-BDE6-0BB1E8B4D9B9_1002_4">25000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_31_20130731_0_711298x770834_759964x766452" unitRef="iso4217_USD" decimals="-4" id="id_3156006_9CD6A2C0-447F-4EEB-BDE6-0BB1E8B4D9B9_2002_2">1250000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE841390--1310-K0016_STD_31_20130731_0_711298x770834_759964x766452" unitRef="iso4217_USD" decimals="-5" id="id_3156006_9CD6A2C0-447F-4EEB-BDE6-0BB1E8B4D9B9_2002_0">2500000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE841390--1310-K0016_STD_31_20120831_0" unitRef="shares" decimals="INF" id="id_3156006_72A3246B-2577-4FF6-B664-6C775BF81CFE_1_1">1256232</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE841390--1310-K0016_STD_31_20120831_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_72A3246B-2577-4FF6-B664-6C775BF81CFE_1_0">5000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_1_14">70000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_708873x784846_713115x818265" unitRef="pure" decimals="2" id="id_3156006_AF0FEC6E-C215-402E-9F7C-DF715B62A90E_1001_1">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_708873x825279_713115x818265" unitRef="pure" decimals="2" id="id_3156006_AF0FEC6E-C215-402E-9F7C-DF715B62A90E_2001_2">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_710552x708807_714777x711552" unitRef="shares" decimals="INF" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_1001_9">2703269</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_710552x710593_714777x711552" unitRef="shares" decimals="INF" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_2001_10">13699999</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_711196x713713_714378x823469" unitRef="shares" decimals="INF" id="id_3156006_A8E837E7-7A55-4CB6-BB2A-6F9673EDF292_1002_3">1447037</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:NotesIssued1 contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_711461x714242_714378x757334_759964x778268" unitRef="iso4217_USD" decimals="-5" id="id_3156006_A721273B-877F-4A34-A65B-B8CF6C8E5091_1001_0">5400000</us-gaap:NotesIssued1>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_713115x818265" unitRef="shares" decimals="INF" id="id_3156006_AF0FEC6E-C215-402E-9F7C-DF715B62A90E_3001_3">48035</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714378x757334" id="id_3156006_A721273B-877F-4A34-A65B-B8CF6C8E5091_2001_3">P3Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714378x757334" unitRef="iso4217_USD" decimals="-5" id="id_3156006_A721273B-877F-4A34-A65B-B8CF6C8E5091_2001_2">400000</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <rgls:DebtInstrumentsMaturityDateMonthAndYear contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714378x757334" id="id_3156006_A721273B-877F-4A34-A65B-B8CF6C8E5091_2001_4">2015-10</rgls:DebtInstrumentsMaturityDateMonthAndYear>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x711552" unitRef="shares" decimals="INF" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_3001_0">11250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x711552" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_3001_1">4.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x711552" unitRef="iso4217_USD" decimals="-5" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_3001_2">39500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x783665" unitRef="shares" decimals="INF" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_4001_11">1480982</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x783665" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_4001_12">4.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x783665" unitRef="iso4217_USD" decimals="-5" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_4001_13">5500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x826261" unitRef="shares" decimals="INF" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_5001_3">6250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x826261" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_5001_4">4.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_60765CA8-658B-4F40-A3A5-344D840C748B_5001_5">25000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:EquityIssuancePerShareAmount contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_759964x826261" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_1001_2">4.00</us-gaap:EquityIssuancePerShareAmount>
  <rgls:FairValueInputsPeriod contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_759964x826261" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_1001_4">P1Y</rgls:FairValueInputsPeriod>
  <rgls:CommonStockTransactionRestrictionPeriod contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_759964x826261" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_1001_3">P365D</rgls:CommonStockTransactionRestrictionPeriod>
  <rgls:ResearchAndDevelopmentPlanExpectedTerm contextRef="eol_PE841390--1310-K0016_STD_31_20121031_0_759964x826261" id="id_3156006_02AF28BD-BB45-4A2F-B872-6197C178E5C9_1002_5">P4Y</rgls:ResearchAndDevelopmentPlanExpectedTerm>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="shares" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_21">88582000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_9C35609D-EB9B-45B3-BB71-960A2D47A60C_3_0">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_18">-15063000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_3_3">16038249</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_20">-85.82</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_22">467000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_18">-80000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_4006_900002">58000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:ProfitLoss contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_1">-7602000</us-gaap:ProfitLoss>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_20">50663000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_14">-7396000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:InterestPaid contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_35">65000</us-gaap:InterestPaid>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_3">13789000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_12">136000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_28">412000</us-gaap:RepaymentsOfOtherLongTermDebt>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_3_2">147000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_19">-7682000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:GainLossOnInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_7">1000</us-gaap:GainLossOnInvestments>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_8">-7137000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_23">131000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:InterestAndOtherIncome contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_10">129000</us-gaap:InterestAndOtherIncome>
  <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_3_2">683000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_16">-7602000</us-gaap:NetIncomeLoss>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_6">-551000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_4006_900003">825000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_3_9">211000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_17">452000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_14">-528000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_6">3637000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_30">-354000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_3_6">3058000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_8">825000</us-gaap:ShareBasedCompensation>
  <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_40">21000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FC99C631-3F5E-4A78-B72F-3D69E2A8898E_3_0">800000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_31">-12093000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_3_8">248000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_3_2">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_454CA124-542C-47EE-81A7-9DB05C9063BB_3_1">100000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_3_1">205000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_7">20926000</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_3_3">-7000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_15">206000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_16">-8219000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_3_7">333000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_454CA124-542C-47EE-81A7-9DB05C9063BB_3_0">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_15">29000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_11">388000</us-gaap:InterestExpense>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_3_1">-432000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_13">-1345000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_3_0">-2522000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_29">58000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_3">911000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8C20D543-4BE9-4D72-9105-57D953E540B5_3_0">100000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_3_3">206000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_3_2">825000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_43F3CC12-6573-40AE-A31F-2D49699BF00A_3_0">500000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_24">3324000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_3_5">17289000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_21">54585000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F800B7F8-8ECB-4CD9-B0E5-6E1DE063A201_3_3">100000</us-gaap:DefinedContributionPlanCostRecognized>
  <rgls:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_3_1">-29000</rgls:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
  <rgls:TenantImprovementAllowance contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_3_39">586000</rgls:TenantImprovementAllowance>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_708873x801067" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1003_2">22000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_708873x816429" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2003_1">13767000</us-gaap:Revenues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_4003_600002">58000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_4003_600003">825000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_4001_400002">153184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_4005_800005">-7602000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x716406" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_4004_700004">-80000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <rgls:RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_711672x809276" unitRef="iso4217_USD" decimals="-3" id="id_3156006_C77CE24D-02CF-400F-AF68-86C5212F8401_1003_0">8000</rgls:RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_1003_1">268000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_2003_0">557000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_712375x816429" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_1003_4">13767000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_712375x816429_759964x775748" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_2003_0">10033000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_712375x816429_759964x778268" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_3003_1">3734000</us-gaap:Revenues>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_712382x708980" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_2003_1">2338250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_712382x710593" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_3003_0">13699999</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_3_1">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_3_3">0.729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_713115x708980" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_3_4">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE841390--1310-K0016_STD_365_20111231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_3_2">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <dei:TradingSymbol contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_1_400000">RGLS</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_1_400001">REGULUS THERAPEUTICS INC.</dei:EntityRegistrantName>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_1_400005">Yes</dei:EntityCurrentReportingStatus>
  <dei:AmendmentFlag contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_7CEA0BFF-C7E8-42C1-864E-7B4021549712_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_1_400007">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_7CEA0BFF-C7E8-42C1-864E-7B4021549712_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_7CEA0BFF-C7E8-42C1-864E-7B4021549712_1_0">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_7CEA0BFF-C7E8-42C1-864E-7B4021549712_1_2">2013-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_1_400002">0001505512</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_1_400004">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_7CEA0BFF-C7E8-42C1-864E-7B4021549712_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityVoluntaryFilers contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_89D17856-8627-48A4-BCD9-A9CFF1700D96_1_400006">No</dei:EntityVoluntaryFilers>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_9C225524-E437-48E3-B103-ACF47F3A8F1A_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Intangibles&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We capitalize costs which consist principally of outside legal
 costs and filing fees related to obtaining patents. We review our
 capitalized patent costs periodically to determine that they
 include costs for patent applications that have future value and an
 alternative future use. We evaluate costs related to patents that
 we are not actively pursuing and write off these costs. We amortize
 patent costs over their patent lives, beginning with the date the
 patents are issued. The weighted average remaining life of the
 issued patents was 12 years at December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We obtain licenses from third parties and capitalize the costs
 related to exclusive licenses that have alternative future use
 within multiple potential programs. We amortize capitalized
 licenses over their estimated useful life or term of the agreement,
 which for current licenses is 10 years.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_FDB05EE7-2C40-48AF-9031-813AD76A82FD_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes our major classes of property and
 equipment (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,342&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,583&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;119&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;93&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,805&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;751&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;119&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;211&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,499&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,752&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,731&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,442&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,768&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,310&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_0EFCAD41-97AD-49AD-8115-4088C7B6B810_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Potentially dilutive securities not included in the calculation of
 diluted net loss per share because to do so would be anti-dilutive
 are as follows (in common equivalent shares):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Years ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Convertible preferred stock outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,699,999&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,639,270&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,883,311&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,338,250&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Convertible note payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,411,659&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,366,787&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,050,929&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,250,098&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,038,249&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_469C0873-D1D3-44BF-9ED2-1F415736BCDF_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;6. Property and Equipment, net&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes our major classes of property and
 equipment (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,342&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,583&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;119&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;93&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,805&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;751&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;119&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;211&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,499&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,752&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,731&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,442&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,768&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,310&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Depreciation and amortization of property and equipment of $1.3
 million, $0.9&amp;#xA0;million and $0.8 million was recorded for the
 years ended December&amp;#xA0;31, 2013, 2012 and 2011,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_B6837E5D-2D11-45BB-A364-FB52FEC2C690_1_1">P7Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_FDC25CE9-E108-4DD9-98CA-89162C7CBCBB_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;9. Convertible Notes Payable&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As part of our strategic alliance with GSK established in
 April&amp;#xA0;2008, we issued a three-year convertible note in
 exchange for $5.0&amp;#xA0;million (&amp;#x201C;2008 GSK Note&amp;#x201D;). In
 February 2010 and in connection with the subsequent expansion of
 that strategic alliance, we issued a convertible promissory note in
 exchange for $5.0 million (&amp;#x201C;2010&amp;#xA0;GSK Note&amp;#x201D;).&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;2012 Amendment of the 2008 GSK Note&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2012, we amended and restated the 2008 GSK Note. We
 accounted for the amended and restated note as a debt modification.
 The amended and restated note provided that the principal amount
 plus interest under the note will, upon completion of our initial
 public offering in which we receive a minimum level of proceeds
 from new investors or that results in certain of our current
 stockholders together owning less than 50% of our voting
 securities, automatically convert into shares of our common stock
 at the initial public offering price. The $5.0 million note plus
 accrued interest converted into 1,447,037 shares of our common
 stock upon the closing of our initial public offering in October
 2012 at a conversion price of $4.00 per share.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;2012 Amendment of the 2010 GSK Note&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2012, we amended and restated our 2010 GSK Note. The
 amended and restated 2010 GSK Note provided for a rollover into a
 new promissory note, effective as of the closing date of a
 qualifying initial public offering (the &amp;#x201C;Post-IPO GSK
 Note&amp;#x201D;). The Post-IPO GSK Note would be equivalent to the
 aggregate amount of principal and accrued but unpaid interest as of
 the initial public offering date. The 2010 GSK Note would then be
 simultaneously cancelled and obligations thereto would be
 terminated.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In October 2012, in conjunction with our initial public offering,
 the Post-IPO GSK Note was established in the principal amount of
 $5.4 million, which was equivalent to the original principal amount
 of $5.0 million plus accrued but unpaid interest of approximately
 $0.4 million. The Post-IPO GSK Note has a maturity date of three
 years from the anniversary date of the agreement, or October 2015.
 At GSK&amp;#x2019;s option, the Post-IPO GSK Note shall be convertible
 into shares of common stock of Regulus at any time prior to the
 maturity date with a conversion equal to the quotient of all
 outstanding principal and interest divided by the initial public
 offering price of $4.00 per share. Concurrently with our initial
 public offering, we accounted cancellation of the 2010 GSK Note as
 a debt extinguishment and recorded a loss on the extinguishment of
 debt of $1.7 million and elected the fair value option for the
 Post-IPO GSK Note. As of December&amp;#xA0;31, 2013, the fair value of
 the Post-IPO GSK Note was $11.3 million, and is classified as
 &amp;#x201C;Convertible notes payable, at fair value&amp;#x201D; on the
 balance sheet (see&amp;#xA0;Note 4).&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Note payable to Biogen Idec&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In August 2012, we entered into a note purchase agreement with
 Biogen Idec, pursuant to which we issued Biogen Idec a convertible
 promissory note in the principal amount of $5.0 million. The $5.0
 million note plus accrued interest converted into 1,256,232 shares
 of our common stock upon the closing of our initial public offering
 in October 2012 at a conversion price of $4.00 per share.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:InvestmentPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_8EE33E71-4723-4E2D-9833-954DD5B094D2_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Short-Term Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We carry short-term investments classified as available-for-sale at
 fair value as determined by prices for identical or similar
 securities at the balance sheet date. Our short-term investments
 consist of both Level 1 and Level 2 financial instruments in the
 fair value hierarchy. We record unrealized gains and losses as a
 component of other comprehensive loss within the statements of
 operations and comprehensive loss and as a separate component of
 stockholders&amp;#x2019; equity (deficit). We determine the realized
 gains or losses of available-for-sale securities using the specific
 identification method and include net realized gains and losses in
 interest income.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At each balance sheet date, we assess available-for-sale securities
 in an unrealized loss position to determine whether the unrealized
 loss is other-than-temporary. We consider factors including: the
 significance of the decline in value compared to the cost basis,
 underlying factors contributing to a decline in the prices of
 securities in a single asset class, the length of time the market
 value of the security has been less than its cost basis, the
 security&amp;#x2019;s relative performance versus its peers, sector or
 asset class, expected market volatility and the market and economy
 in general. When we determine that a decline in the fair value
 below its cost basis is other-than-temporary, we recognize an
 impairment loss in the year in which the other-than-temporary
 decline occurred. We determined that there were no
 other-than-temporary declines in the value of short-term
 investments as of December&amp;#xA0;31, 2013 and 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_87AC764C-70A9-4126-82AD-214BFE68CA3B_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As of December&amp;#xA0;31, 2013, future annual minimum lease payments
 for our operating leases are as follows (in&amp;#xA0;thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,066&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,138&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,211&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;624&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,039&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="shares" decimals="-3" id="id_3156006_09612DD9-C5AA-4193-9C75-5DDB5A4DCA35_1_2">1864000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3156006_F800B7F8-8ECB-4CD9-B0E5-6E1DE063A201_1_2">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_88E0A291-D444-401D-8870-ED9DAA2A53E3_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Our revenues generally consist of upfront payments for licenses or
 options to obtain licenses in the future, research and development
 funding and milestone payments under strategic alliance agreements,
 as well as funding received under government grants. We recognize
 revenues when all four of the following criteria are met:
 (1)&amp;#xA0;persuasive evidence that an arrangement exists;
 (2)&amp;#xA0;delivery of the products and/or services has occurred;
 (3)&amp;#xA0;the selling price is fixed or determinable; and
 (4)&amp;#xA0;collectability is reasonably assured.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Multiple element arrangements, such as our strategic alliance
 agreements with Sanofi, AstraZeneca AB (&amp;#x201C;AstraZeneca&amp;#x201D;)
 and GlaxoSmithKline plc (&amp;#x201C;GSK&amp;#x201D;), are analyzed to
 determine whether the deliverables within the agreement can be
 separated or whether they must be accounted for as a single unit of
 accounting. Deliverables under the agreement will be accounted for
 as separate units of accounting provided that (i)&amp;#xA0;a delivered
 item has value to the customer on a stand-alone basis; and
 (ii)&amp;#xA0;if the agreement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially in the
 control of the vendor. The allocation of consideration amongst the
 deliverables under the agreement is derived using a &amp;#x201C;best
 estimate of selling price&amp;#x201D; if vendor specific objective
 evidence and third-party evidence of fair value is not available.
 If the delivered element does not have stand-alone value, the
 arrangement is then accounted for as a single unit of accounting,
 and we recognize the consideration received under the arrangement
 as revenue on a straight-line basis over our estimated period of
 performance, which for us is often the expected term of the
 research and development plan.&lt;/p&gt;
 &lt;p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Milestones&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We recognize revenue from milestone payments when earned, provided
 that (i)&amp;#xA0;the milestone event is substantive in that it can
 only be achieved based in whole or in part on either our
 performance or on the occurrence of a specific outcome resulting
 from our performance and its achievability was not reasonably
 assured at the inception of the agreement, (ii)&amp;#xA0;we do not have
 ongoing performance obligations related to the achievement of the
 milestone and (iii)&amp;#xA0;it would result in the receipt of
 additional payments. A milestone payment is considered substantive
 if all of the following conditions are met: (i)&amp;#xA0;the milestone
 payment is non-refundable; (ii)&amp;#xA0;achievement of the milestone
 was not reasonably assured at the inception of the arrangement;
 (iii)&amp;#xA0;substantive effort is involved to achieve the milestone;
 and (iv)&amp;#xA0;the amount of the milestone payments appears
 reasonable in relation to the effort expended, the other milestones
 in the arrangement and the related risk associated with the
 achievement of the milestone. Any amounts received under the
 agreements in advance of performance, if deemed substantive, are
 recorded as deferred revenue and recognized as revenue as we
 complete our performance obligations.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Generally, the milestone events contained in our strategic alliance
 agreements coincide with the progression of our product candidates
 from target selection, to clinical candidate selection, to clinical
 trial, to regulatory approval and then to commercialization. The
 process of successfully discovering a new development candidate,
 having it approved and ultimately sold for a profit is highly
 uncertain. As such, the milestone payments we may earn from our
 partners involve a significant degree of risk to achieve.
 Therefore, as a product candidate progresses through the stages of
 its life-cycle, the value of the product candidate generally
 increases.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We recognize revenue from government and private agency grants as
 the related research expenses are incurred and to the extent that
 funding is approved. Any amounts received in advance of performance
 are recorded as deferred revenue until earned.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Deferred Revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Amounts received prior to satisfying the above revenue recognition
 criteria are recorded as deferred revenue in the accompanying
 balance sheets. Amounts not expected to be recognized within the
 next 12 months are classified as non-current deferred revenue.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_4F3C32BD-735F-45DE-84F7-4E6E801CA56D_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;5. Strategic Alliances and Collaborations&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes the amounts included in our revenues
 which resulted from our strategic alliances and collaboration (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Year ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Sanofi-Aventis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,336&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,030&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,033&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 GSK&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,778&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,996&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,734&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 AstraZeneca&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,859&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;559&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Biogen Idec&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;596&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,569&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,700&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,767&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Sanofi&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2012, we amended and restated our collaboration and license
 agreement with Sanofi to expand the potential therapeutic
 applications of the &lt;i&gt;micro&lt;/i&gt;RNA alliance targets to be
 developed under such agreement. The modification made to the
 agreement was considered a material modification, which required
 the application of the new authoritative guidance adopted by us in
 January 2011 for multiple element arrangements. We determined that
 the elements within the strategic alliance agreement with Sanofi
 should be treated as a single unit of accounting because the
 delivered elements did not have stand-alone value to Sanofi. The
 following elements were delivered as part of the strategic alliance
 with Sanofi: (1)&amp;#xA0;a license for up to four &lt;i&gt;micro&lt;/i&gt;RNA
 targets; and (2)&amp;#xA0;a research license under our technology
 alliance.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In June 2013, the original research term expired, upon which we and
 Sanofi entered into an option agreement pursuant to which we
 granted Sanofi an exclusive right to negotiate the co-development
 and commercialization of certain of our unencumbered
 &lt;i&gt;micro&lt;/i&gt;RNA programs and we were granted the exclusive right to
 negotiate with Sanofi for co-development and commercialization of
 certain miR-21 anti-miRs in oncology and Alport&amp;#x2019;s Syndrome.
 In July 2013, we received an upfront payment of $2.5 million, of
 which $1.25 million is creditable against future amounts payable by
 Sanofi to us under any future co-development and commercialization
 agreement we enter pursuant to the option agreement. The
 non-creditable portion of this payment, $1.25 million, is being
 recognized as revenue over the option period from the effective
 date of the option agreement in June 2013 through the expiration of
 the option period. Revenue associated with the creditable portion
 of this option payment will be deferred until its application to a
 creditable transaction. In addition, we agreed to continue
 specified research on the miR-21 programs during the option period.
 As a result of the expiration of the original research term and
 subsequent option agreement, we re-evaluated our estimated period
 of performance and are now amortizing the remaining deferred
 revenue associated with the initial upfront payment of $25.0
 million ratably from June 2013 through the expiration of the option
 period. Deferred revenue at December&amp;#xA0;31, 2013 was $2.2
 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We have evaluated the remaining contingent event-based payments
 under our strategic alliance agreement with Sanofi and determined
 that the preclinical payments meet the definition of a substantive
 milestone. Accordingly, revenue for these achievements will be
 recognized in its entirety in the period when the milestone is
 achieved and collectability is reasonably assured. Other contingent
 event-based payments under the strategic alliance agreement for
 which payment is contingent upon the results of Sanofi&amp;#x2019;s
 performance will not be accounted for using the milestone method.
 Such payments will be recognized as revenue over our remaining
 estimated period of performance, if any, and when collectability is
 reasonably assured. As of the expiration of the research term in
 June 2013, Sanofi no longer had rights to select additional
 &lt;i&gt;micro&lt;/i&gt;RNA targets. We can earn a preclinical milestone of
 $15.0&amp;#xA0;million upon the filing of an Investigational New Drug
 application (&amp;#x201C;IND&amp;#x201D;) for the selected &lt;i&gt;micro&lt;/i&gt;RNA
 target. We can also receive milestone payments of up to $33.0
 million for clinical milestones and up to $165.0 million for
 regulatory and commercial milestones. In addition, we are entitled
 to receive royalties based on a percentage of net sales which will
 range from 8 to 12%, depending upon the volume of sales.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;GSK&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In April 2008, we entered into a strategic alliance with GSK to
 discover, develop and commercialize novel &lt;i&gt;micro&lt;/i&gt;RNA-targeted
 therapeutics to treat inflammatory diseases (the
 &amp;#x201C;immuno-inflammatory alliance&amp;#x201D;). In February 2010, we
 and GSK expanded the strategic alliance to include hepatitis C
 virus infection (&amp;#x201C;HCV&amp;#x201D;) to discover, develop and
 commercialize &lt;i&gt;micro&lt;/i&gt;RNA therapeutics targeting miR-122 for
 the treatment of HCV (the &amp;#x201C;HCV alliance&amp;#x201D;). In June
 2012, we amended our immuno-inflammatory alliance to extend the
 target selection period for the fourth collaboration target. The
 modification made to the agreement was considered a material
 modification, which required the application of the new
 authoritative guidance adopted by us in January 2011 for multiple
 element arrangements. We determined that the elements within the
 immuno-inflammatory alliance should be treated as a single unit of
 accounting because the delivered elements, the opt-in licenses for
 &lt;i&gt;micro&lt;/i&gt;RNA product candidates, did not have stand-alone value
 to GSK. As a result of the extension of the target selection
 period, we extended the amortization period for the remaining
 deferred revenue to approximately eight years, which represented
 our new estimated period of performance. As of December&amp;#xA0;31,
 2013, deferred revenue associated with the immuno-inflammatory
 alliance was $3.5 million, which we are expecting to recognize over
 the remaining estimated period of performance of approximately 6
 years.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In June 2013, the HCV alliance was amended to state that RG-101,
 and other formulations thereof, will be developed by us
 independently of our alliance for the treatment of chronic HCV
 infection.&amp;#xA0;This amendment removed any further milestone or
 royalty obligations owed by GSK to us as it relates only to RG-101.
 Concurrent with the amendment, we recorded the remaining $1.1
 million in deferred revenue associated with the upfront payment
 from the HCV alliance, as our estimated period of performance was
 complete.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Immuno-Inflammatory Alliance&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The immuno-inflammatory alliance includes contractual milestones.
 If all the product candidates are successfully developed and
 commercialized through pre-agreed sales targets we could receive
 milestone payments up to $432.5&amp;#xA0;million, including up to $15.5
 million for preclinical milestones, up to $87.0&amp;#xA0;million for
 clinical milestones, up to $150.0&amp;#xA0;million for regulatory
 milestones and up to $180.0&amp;#xA0;million for commercialization
 milestones. We are also entitled to receive tiered royalties as a
 percentage of annual sales which can increase up to the low end of
 the 10 to 20% range.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We have evaluated the remaining contingent event-based payments
 under our immuno-inflammatory alliance and determined that the
 preclinical and clinical payments meet the definition of a
 substantive milestone. Accordingly, revenue for these achievements
 will be recognized in its entirety in the period when the milestone
 is achieved and collectability is reasonably assured. Other
 contingent event-based payments under the strategic alliance
 agreement for which payment is contingent upon the results of
 GSK&amp;#x2019;s performance will not be accounted for using the
 milestone method. Such payments will be recognized as revenue over
 the remaining estimated period of performance, if any, and when
 collectability is reasonably assured. We can earn the following
 preclinical milestones: $0.5 million upon the selection of a fourth
 &lt;i&gt;micro&lt;/i&gt;RNA target and $5.0 million upon the selection of a
 development candidate for each of the selected three targets. We
 can also earn the following clinical milestones for each of the
 selected three targets: $4.0 million for the initiation of a Phase
 1 clinical trial; $5.0 million for the initiation of a Phase 2
 clinical trial; and $20.0 million if GSK chooses to opt-in to the
 program following the completion of a proof-of-concept trial.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;HCV Alliance&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Notwithstanding the foregoing, GSK has retained its interest in the
 miR-122 program in HCV, and &lt;font style="white-space:nowrap"&gt;miR-122&amp;#xA0;remains&lt;/font&gt; a collaboration
 target under the alliance. If the HCV program is successful, we
 could receive contractual milestone payments up to
 $144.5&amp;#xA0;million, including up to $5.5&amp;#xA0;million for
 preclinical milestones, up to $29.0&amp;#xA0;million for clinical
 milestones, up to $50.0&amp;#xA0;million for regulatory milestones and
 up to $60.0&amp;#xA0;million for commercialization milestones. In
 addition, we will receive tiered royalties which can increase up to
 the low end of the 10 to 20% range on sales from any product that
 GSK successfully commercializes under this alliance.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We have evaluated the remaining contingent event-based payments
 under the HCV alliance and determined that the preclinical and
 clinical payments meet the definition of a substantive milestone.
 Accordingly, revenue for these achievements will be recognized in
 its entirety in the period when the milestone is achieved and
 collectability is reasonably assured. Other contingent event-based
 payments under the strategic alliance agreement for which payment
 is contingent upon the results of GSK&amp;#x2019;s performance will not
 be accounted for using the milestone method. Such payments will be
 recognized as revenue over the remaining estimated period of
 performance, if any, and when collectability is reasonably assured.
 We can earn a preclinical milestone of $5.5&amp;#xA0;million upon the
 selection of a development candidate. We can also earn the
 following clinical milestones: $4.0&amp;#xA0;million for initiation of
 a Phase&amp;#xA0;1 clinical trial; $5.0&amp;#xA0;million for the initiation
 of a Phase&amp;#xA0;2 clinical trial; and $20.0&amp;#xA0;million if GSK
 chooses to opt-in to the program following the completion of a
 proof-of-concept trial. We have no obligation to perform any
 research or development activities unless mutually agreed upon by
 the parties.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;AstraZeneca&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In August 2012, we entered into a collaboration and license
 agreement with AstraZeneca. Under the terms of the agreement, we
 have agreed to collaborate with AstraZeneca to identify, research
 and develop compounds targeting three &lt;i&gt;micro&lt;/i&gt;RNA alliance
 targets primarily in the fields of cardiovascular diseases,
 metabolic diseases and oncology. Pursuant to the agreement, we
 granted AstraZeneca an exclusive, worldwide license to thereafter
 develop, manufacture and commercialize lead compounds designated by
 AstraZeneca in the course of the collaboration activities against
 the alliance targets for all human therapeutic uses. Under the
 terms of the agreement we are required to use commercially
 reasonable efforts to perform all research, development and
 manufacturing activities described in the research plan, at our
 cost, until the acceptance of an IND or the end of the research
 term, which extends until the fourth anniversary of the date of the
 agreement, and may be extended only by mutual written agreement of
 us and AstraZeneca. Following the earlier to occur of the
 acceptance of an IND in a major market or the end of the research
 term, AstraZeneca will assume all costs, responsibilities and
 obligations for further development, manufacture and
 commercialization of alliance product candidates.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Under the terms of the agreement, we received an upfront payment of
 $3.0 million in October 2012. We determined the elements within the
 strategic alliance agreement should be treated as a single unit of
 accounting because the delivered element, the license, does not
 have stand-alone value. As a result, we are recognizing revenue
 related to the upfront payment on a straight-line basis over our
 estimated period of performance, which is four years based on the
 expected term of the research and development plan. If all three
 targets are successfully developed and commercialized through
 pre-agreed sales targets, we could receive milestone payments up to
 $498.0&amp;#xA0;million, including preclinical milestones of up to
 $5.0&amp;#xA0;million upon lead compound identification, up to $123.0
 million for clinical milestones, and up to $370.0&amp;#xA0;million for
 commercialization milestones. In addition, we are entitled to
 receive royalties based on a percentage of net sales which will
 range from the mid-single digits to the low end of 10 to 20%,
 depending upon the product and the volume of sales, which royalties
 may be reduced in certain, limited circumstances.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We have evaluated the contingent event-based payments under our
 strategic alliance agreement with AstraZeneca and determined that
 the preclinical payments meet the definition of substantive
 milestones. Accordingly, revenue for these achievements will be
 recognized in its entirety in the period when the milestone is
 achieved and collectability is reasonably assured. Other contingent
 event-based payments under the strategic alliance agreement for
 which payment is contingent upon the results of AstraZeneca&amp;#x2019;s
 performance will not be accounted for using the milestone method.
 Such payments will be recognized as revenue over the remaining
 estimated period of performance, if any, and when collectability is
 reasonably assured.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Concurrently with the collaboration and license agreement, we
 entered into a Common Stock Purchase Agreement (&amp;#x201C;CSPA&amp;#x201D;)
 with AstraZeneca, pursuant to which we agreed to sell to
 AstraZeneca an aggregate of $25.0&amp;#xA0;million of our common stock
 in a private placement concurrently with our initial public
 offering, at a price per share equal to the initial public offering
 price. In October 2012, in accordance with the CSPA, we sold
 AstraZeneca 6,250,000 shares of our common stock at a price per
 share of $4.00. Further, the CSPA stipulated that AstraZeneca could
 not sell, transfer, make any short sale of, or grant any option for
 the sale of any common stock for a 365-day period following the
 effective date of our initial public offering. Accounting guidance
 for multiple element arrangements contains a presumption that
 separate contracts negotiated and/or entered into at or near the
 same time with the same entity were negotiated as a package and
 should be evaluated as a single agreement. We valued the discount
 applied to the shares of common stock due to the one-year
 restriction. Based upon restricted stock studies of similar
 duration and a Black-Scholes valuation to measure the lack of
 marketability discount, $4.3 million was attributed to the
 collaboration and license agreement. We continue to recognize the
 $4.3 million into revenue ratably over the estimated period of
 performance of the collaboration. As of December&amp;#xA0;31, 2013,
 deferred revenue associated with the collaboration and license
 agreement and CSPA was $2.0 million and $2.9 million, respectively,
 which we are expecting to recognize over the remaining contractual
 term and corresponding estimated period of performance of
 approximately 2.5 years.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Biogen Idec&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In August 2012, we entered into a collaboration and license
 agreement with Biogen Idec pursuant to which we and Biogen Idec
 have agreed to collaborate on &lt;i&gt;micro&lt;/i&gt;RNA biomarkers for
 multiple sclerosis (&amp;#x201C;MS&amp;#x201D;). Under the terms of the
 agreement, we granted Biogen Idec an exclusive, royalty free,
 worldwide license to our interest in the collaboration intellectual
 property for the purpose of commercializing non-&lt;i&gt;micro&lt;/i&gt;RNA
 products for the treatment, diagnosis and prevention of MS and
 non-MS diseases and disorders. We also granted Biogen Idec an
 exclusive, royalty-free, worldwide license, with the right to
 sublicense, to our interest in the collaboration intellectual
 property (and a non-exclusive license to our background
 intellectual property) for the purpose of commercializing products
 for the diagnosis of MS. We also granted Biogen Idec a right of
 first negotiation on certain commercial transactions relating to
 &lt;i&gt;micro&lt;/i&gt;RNA products which utilize intellectual property
 developed during the collaboration. Pursuant to the terms of the
 agreement, in August 2012 we received an upfront payment of $0.8
 million. We are also eligible to receive research milestone
 payments up to an aggregate of $1.3&amp;#xA0;million. We considered the
 elements within the collaboration and license agreement as a single
 unit of accounting because the delivered element, the license, does
 not have stand-alone value. As a result, we are recognizing revenue
 relating to the upfront payment of $0.8 million on a straight-line
 basis over our estimated period of performance, which is
 approximately two years based on the expected term of the research
 and development plan.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In June 2013, we amended the collaboration and license agreement to
 provide for revised terms with respect to Phase 1 of the research
 plan and related milestone payment provisions. The Biogen Idec
 amendment does not modify the maximum dollar amount we were
 originally eligible to receive in connection with Phase 1
 milestones under the Biogen Idec agreement, or our estimated period
 of performance.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We have evaluated the contingent event-based payments under our
 collaboration and license agreement with Biogen Idec and determined
 that the research payments meet the definition of substantive
 milestones. Accordingly, revenue for these achievements will be
 recognized in its entirety in the period when the milestone is
 achieved and collectability is reasonably assured. In October 2013
 and November 2013, we received research milestone payments totaling
 $0.3 million. In addition, we can earn the following research
 milestones: $0.5&amp;#xA0;million for validation of the &lt;i&gt;micro&lt;/i&gt;RNA
 biomarker in a second independent sample set; and $0.5 million upon
 the refinement of the &lt;i&gt;micro&lt;/i&gt;RNA biomarker signature from a
 longitudinal study of patient samples on MS therapy. As of
 December&amp;#xA0;31, 2013, deferred revenue associated with the
 collaboration and license agreement was $0.3 million, which we are
 expecting to recognize over the remaining contractual term and
 corresponding estimated period of performance of 10 months.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Concurrently with the collaboration and license agreement, we
 entered into a note purchase agreement with Biogen Idec, pursuant
 to which we issued a convertible promissory note in the principal
 amount of $5.0 million. The $5.0 million note plus accrued interest
 converted into 1,256,232 shares of our common stock upon the
 closing of our initial public offering in October 2012 at a
 conversion price of $4.00 per share.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_65FCE1FC-99B4-47B6-A3C7-E0D0452FABCB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes our stock option activity under the
 2012 Plan for the year ended December&amp;#xA0;31, 2013 (in thousands,
 except per share and contractual term data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
 options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 average&lt;br /&gt;
 exercise&lt;br /&gt;
 price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 average&lt;br /&gt;
 remaining&lt;br /&gt;
 contractual&lt;br /&gt;
 term&lt;br /&gt;
 (in&amp;#xA0;years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 intrinsic&lt;br /&gt;
 value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,720&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,864&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(732&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Canceled/forfeited/expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested or expected to vest at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,800&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,244&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,842&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_DD9843D8-9325-4BF7-AEEE-EA5BBF2DB83E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The following table presents our fair value hierarchy for assets
 and liabilities measured at fair value on a recurring basis at
 December&amp;#xA0;31, 2013 and 2012 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair value as of December&amp;#xA0;31,
 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,416&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,416&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Debt securities of U.S. government-sponsored agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,001&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,001&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113,368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,198&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Convertible notes payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair value as of December&amp;#xA0;31,
 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,911&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Convertible notes payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,134&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,134&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_CD14D707-67D3-485C-87E8-68254AD5E977_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Comprehensive loss is defined as the change in equity during a
 period from transactions and other events and/or circumstances from
 non-owner sources. Our only component of other comprehensive loss
 is unrealized gains (losses) on available-for-sale securities.
 Comprehensive gains (losses) have been reflected in the statements
 of operations and comprehensive loss and as a separate component of
 the statements of convertible preferred stock and
 stockholders&amp;#x2019; equity (deficit) for all periods presented.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_C0B9FCE4-9F94-4676-8F7E-7DC0434704D7_1_2">6.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3156006_F800B7F8-8ECB-4CD9-B0E5-6E1DE063A201_1_1">0.25</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_DC6C87FC-1DF4-4C78-AA84-D08B09E1BFE3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents a reconciliation of the liabilities
 measured at fair value on a quarterly basis using significant
 unobservable inputs (Level 3) from December&amp;#xA0;31, 2012 to
 December&amp;#xA0;31, 2013 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="21%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;br /&gt;
 Using Significant&lt;br /&gt;
 Unobservable Inputs&lt;br /&gt;
 (Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,134&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in estimated fair value of convertible notes payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_95399ADF-1F96-4ECF-8BE9-9EC7C49C004F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Summarized quarterly data for 2013 and 2012 are as follows (in
 thousands, except per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;For the quarters ending&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;March&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;June&amp;#xA0;30&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;December&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2013:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,759&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,454&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,788&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,023&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,229&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,348&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,164&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic net loss per share&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.05&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.05&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted net loss per share&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;(1)(2)&lt;/sup&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2012:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,809&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,525&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,867&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,341&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,541&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,876&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic and diluted net loss per share&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13.06&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10.78&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15.98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Net loss per share is computed
 independently for each of the quarters presented. Therefore, the
 sum of the quarterly per-share calculations will not necessarily
 equal the annual per share calculation.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(2)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Applicable accounting guidance
 provides that a contract (such as the 2010 GSK Note) that is
 reported as an asset or liability for accounting purposes may
 require an adjustment to the numerator of the diluted earnings per
 share calculation for any changes in income or loss that would
 result if the contract had been reported as an equity instrument
 during the period. For these periods, adjustments were made to the
 numerator of the diluted earnings per share calculation to adjust
 net loss to remove the gain from the change in value of the
 convertible note payable. Adjustments to the denominator were made
 to add the number of shares to be issued upon conversion of the
 convertible note payable.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_ABACAE04-1783-46A4-B059-36D2963437EC_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes the amounts included in our
 operating expenses as a result of costs incurred from services
 provided under the Services Agreement (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Years&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Services performed or out-of-pocket expenses paid to Alnylam&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;550&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_B7AD6583-3AC0-4357-AA6D-9724A47D0608_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the components of our income tax
 (benefit) expense (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;b&gt;Year ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Income tax (benefit) expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_5A9BEA0F-904F-42E5-B2DE-0FAEB7B0E38C_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The accounting guidance for accounting for uncertainty in income
 taxes prescribes a recognition threshold and measurement attribute
 criteria for the financial statement recognition and measurement of
 tax positions taken or expected to be taken in a tax return. For
 those benefits to be recognized, a tax position must be more likely
 than not to be sustained upon examination by taxing
 authorities.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We use the liability method of accounting for income taxes. Under
 this method, deferred tax assets and liabilities are determined
 based on the difference between the financial reporting and the tax
 reporting basis of assets and liabilities and are measured using
 the enacted tax rates and laws that are expected to be in effect
 when the differences are expected to reverse. We provide a
 valuation allowance against net deferred tax assets unless, based
 upon the available evidence, it is more likely than not that the
 deferred tax assets will be realized.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_84B47805-655C-4601-B056-E7D41DC55097_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We have certain financial assets and liabilities recorded at fair
 value which have been classified as Level 1, 2 or 3 within the fair
 value hierarchy as described in the accounting standards for fair
 value measurements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Applicable accounting guidance defines fair value as the exchange
 price that would be received for an asset or paid to transfer a
 liability (an exit price) in the principal or most advantageous
 market for the asset or liability in an orderly transaction between
 market participants as of the measurement date. Market participants
 are buyers and sellers in the principal market that are
 (i)&amp;#xA0;independent, (ii)&amp;#xA0;knowledgeable, (iii)&amp;#xA0;able to
 transact, and (iv)&amp;#xA0;willing to transact. The guidance provides
 an established hierarchy for inputs used in measuring fair value
 that maximizes the use of observable inputs and minimizes the use
 of unobservable inputs by requiring that the most observable inputs
 be used when available. Observable inputs are inputs that market
 participants would use in valuing the asset or liability and are
 developed based on market data obtained from independent sources.
 Unobservable inputs are inputs that reflect our assumptions about
 the factors that market participants would use in valuing the asset
 or liability. The guidance prioritizes the inputs used in measuring
 the fair value into the following hierarchy:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1 includes financial
 instruments for which quoted market prices for identical
 instruments are available in active markets.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 2 includes financial
 instruments for which there are inputs other than quoted prices
 included within Level 1 that are observable for the instrument such
 as quoted prices for similar instruments in active markets, quoted
 prices for identical or similar instruments in markets with
 insufficient volume or infrequent transactions (less active
 markets) or model-driven valuations in which significant inputs are
 observable or can be derived principally from, or corroborated by,
 observable market data.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3 includes financial
 instruments for which fair value is derived from valuation
 techniques in which one or more significant inputs are
 unobservable, including management&amp;#x2019;s own assumptions.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The following table presents our fair value hierarchy for assets
 and liabilities measured at fair value on a recurring basis at
 December&amp;#xA0;31, 2013 and 2012 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair value as of December&amp;#xA0;31,
 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,416&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,416&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Debt securities of U.S. government-sponsored agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,001&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,001&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,071&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113,368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,198&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Convertible notes payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair value as of December&amp;#xA0;31,
 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,911&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Convertible notes payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,134&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,134&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents a reconciliation of the liabilities
 measured at fair value on a quarterly basis using significant
 unobservable inputs (Level 3) from December&amp;#xA0;31, 2012 to
 December&amp;#xA0;31, 2013 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="21%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Fair&amp;#xA0;Value&amp;#xA0;Measurements&lt;br /&gt;
 Using Significant&lt;br /&gt;
 Unobservable Inputs&lt;br /&gt;
 (Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,134&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in estimated fair value of convertible notes payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Balance at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We obtain pricing information from quoted market prices or quotes
 from brokers/dealers. We generally determine the fair value of our
 investment securities using standard observable inputs, including
 reported trades, broker/dealer quotes, bids and/or offers.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In July&amp;#xA0;2012, we amended and restated the 2010 GSK Note, which
 resulted in a debt extinguishment for accounting purposes.
 Concurrently with the debt extinguishment, we elected the fair
 value option for the 2010 GSK Note. The amended and restated 2010
 GSK Note provided for a rollover into a new promissory note,
 effective as of the closing date of a qualifying initial public
 offering (the &amp;#x201C;Post-IPO GSK Note&amp;#x201D;). In October 2012,
 upon our initial public offering, the Post-IPO GSK Note was
 established, and the 2010 GSK Note was simultaneously cancelled and
 obligations thereto were terminated. We valued the 2010 GSK Note at
 July 2012,&amp;#xA0;September 2012 and at the extinguishment date. We
 valued the Post-IPO GSK Note each quarter since that date. We
 recorded a $1.7 million loss on extinguishment of debt (the
 difference between the original $5.0 million carrying value and the
 then fair value) in July 2012. In subsequent periods, changes in
 fair value have been recorded on a quarterly basis in non-operating
 earnings. We recorded a loss from change in value of the
 convertible note payable of $1.1 million and $3.0 million on the
 statements of operations and comprehensive loss for the years ended
 December&amp;#xA0;31, 2013 and 2012.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We used an income approach in the form of a convertible bond
 valuation model to value the note. The convertible bond model
 considered the debt and option characteristics of the note. The key
 inputs to the model as of December&amp;#xA0;31, 2013 and 2012 was
 volatility (66% and 75%, respectively), risk-free rate (0.325% and
 0.421%, respectively), and credit spread (7.4% and 9.5%,
 respectively). The volatility inputs were based on historical and
 implied volatility of peer companies. Peer companies were
 consistent with those used previously for purposes of determining
 volatility for stock-based compensation. The risk-free rate inputs
 were based on the yield of US Treasury Strips as of each date. The
 credit spread inputs were based on a creditworthiness analysis of
 the Company and market rates for comparable straight debt
 instruments.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_6314A5B0-5C59-47B4-ADF0-83566DA623A9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the changes in the amount of our
 unrecognized tax benefits (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning balance of unrecognized tax benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;569&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Increase (decrease) for prior year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Increase for current year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;147&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,092&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;569&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_0F377BAC-D754-4DCA-A025-995D6A125254_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;14. Selected Quarterly Financial Data (Unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following financial information reflects all normal recurring
 adjustments, which are, in the opinion of management, necessary for
 a fair statement of the results of the interim periods. Summarized
 quarterly data for 2013 and 2012 are as follows (in thousands,
 except per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;For the quarters ending&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;March&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;June&amp;#xA0;30&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;December&amp;#xA0;31&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2013:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,759&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,454&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,788&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,445&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,023&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,229&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,348&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,164&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic net loss per share&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.05&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.05&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Diluted net loss per share&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;(1)(2)&lt;/sup&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;2012:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Revenues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,809&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,525&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,867&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,341&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,541&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,876&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Basic and diluted net loss per share&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13.06&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10.78&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15.98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Net loss per share is computed
 independently for each of the quarters presented. Therefore, the
 sum of the quarterly per-share calculations will not necessarily
 equal the annual per share calculation.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(2)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Applicable accounting guidance
 provides that a contract (such as the 2010 GSK Note) that is
 reported as an asset or liability for accounting purposes may
 require an adjustment to the numerator of the diluted earnings per
 share calculation for any changes in income or loss that would
 result if the contract had been reported as an equity instrument
 during the period. For these periods, adjustments were made to the
 numerator of the diluted earnings per share calculation to adjust
 net loss to remove the gain from the change in value of the
 convertible note payable. Adjustments to the denominator were made
 to add the number of shares to be issued upon conversion of the
 convertible note payable.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="shares" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_21">38479447000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_D430F2D9-4E5B-497E-9940-FBAB3213B552_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;10. Convertible Preferred Stock, Common Stock and
 Stockholders&amp;#x2019; Deficit&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Reverse stock split&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On September&amp;#xA0;7, 2012, our board of directors approved a
 one-for-two reverse stock split of our common stock. The
 accompanying financial statements and notes to the financial
 statements give retroactive effect to the reverse split of our
 common stock for all periods presented.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Prior to the conversion in the initial public offering in October
 2012, our convertible preferred stock was classified as temporary
 equity on the accompanying balance sheets instead of in
 stockholders&amp;#x2019; equity (deficit) in accordance with
 authoritative guidance for the classification and measurement of
 redeemable securities. Upon certain change in control events that
 were outside of our control, including liquidation, sale or
 transfer of control of the Company, holders of the convertible
 preferred stock could cause its redemption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2012, all Series A Preferred Stock and
 Series B Preferred Stock had converted to common stock in
 conjunction with the initial public offering. Following our initial
 public offering, we filed an amended and restated certificate of
 incorporation to authorize 10,000,000 shares of undesignated
 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Public Offerings&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October 2012, we completed our initial public offering whereby
 we issued and sold 11,250,000 shares of common stock at a public
 offering price of $4.00 per share, resulting in net proceeds to the
 Company of $39.5&amp;#xA0;million. Concurrently with the completion of
 our initial public offering, we sold 6,250,000 shares of common
 stock in a private placement to AstraZeneca at the initial public
 offering price of $4.00 per share, resulting in net proceeds to the
 Company of $25.0 million. In addition, $5.0 million of outstanding
 principal plus accrued interest of $0.8 million underlying a
 convertible note that we issued to GSK in April 2008, which was
 amended and restated in July 2012, together with $5.0&amp;#xA0;million
 of outstanding principal plus accrued interest underlying a
 convertible note that we issued to Biogen Idec in August 2012, was
 automatically converted upon the closing of our initial public
 offering into an aggregate of 2,703,269 shares of our common stock.
 Upon the closing of the initial public offering, all shares of the
 Company&amp;#x2019;s then-outstanding convertible preferred stock
 automatically converted into an aggregate of 13,699,999 shares of
 common stock. Underwriters for our initial public offering
 exercised an over-allotment option to purchase 1,480,982 additional
 shares of our common stock at $4.00 per share, resulting in net
 proceeds of $5.5 million. Inclusive of the initial public offering,
 underwriters&amp;#x2019; exercise of their over-allotment option and
 concurrent private placement, we raised a total of $70.0 million in
 net proceeds after deducting underwriter discounts, commissions and
 other offering expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In July&amp;#xA0;2013, we completed a public offering whereby we sold
 5,175,000 shares of common stock at $9.50&amp;#xA0;per share and
 received net proceeds of $45.8 million, after deducting
 underwriting discounts, commissions and other offering
 expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2013, there were 41,787,326 shares of
 common stock outstanding. Each share of common stock is entitled to
 one vote. The holders of the common stock are also entitled to
 receive dividends whenever funds are legally available and when
 declared by our Board of Directors. Following our initial public
 offering, we filed an amended and restated certificate of
 incorporation to authorize 200,000,000 shares of common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Shares Reserved for Future Issuance&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following shares of common stock are reserved for future
 issuance at December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock options outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,598,207&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock options available for future grant&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710,534&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employee Stock Purchase Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;460,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Convertible note payable (Post-IPO GSK Note)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,411,659&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total common shares reserved for future issuance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,180,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The combined total number of shares reserved for issuance under the
 2012 Plan is 710,534 shares as of December&amp;#xA0;31, 2013. The
 following table summarizes our stock option activity under the 2012
 Plan for the year ended December&amp;#xA0;31, 2013 (in thousands,
 except per share and contractual term data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
 options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 average&lt;br /&gt;
 exercise&lt;br /&gt;
 price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 average&lt;br /&gt;
 remaining&lt;br /&gt;
 contractual&lt;br /&gt;
 term&lt;br /&gt;
 (in&amp;#xA0;years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 intrinsic&lt;br /&gt;
 value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,720&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,864&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(732&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Canceled/forfeited/expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.98&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Vested or expected to vest at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,800&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,244&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,842&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The weighted average grant date fair value per share of employee
 stock options granted during the years ended December&amp;#xA0;31,
 2013, 2012 and 2011 was $4.14, $2.97 and $1.14, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The total intrinsic value of stock options exercised was $5.7
 million, $0.8 million and $0.2 million during the years ended
 December&amp;#xA0;31, 2013, 2012 and 2011, respectively. Cash received
 from the exercise of stock options was approximately $0.6 million,
 $0.1 million and $0.1 million for the years ended December&amp;#xA0;31,
 2013, 2012 and 2011, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The assumptions used to estimate the fair value of stock options
 using the Black-Scholes option pricing model were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;&amp;#xA0;2013&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;&amp;#xA0;2012&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;b&gt;&amp;#xA0;2011&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employee Stock Options:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;i&gt;Risk-free interest rate&lt;/i&gt;&amp;#x2014;The risk-free interest rate
 assumption is based on observed interest rates appropriate for the
 expected term of the stock option grants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;i&gt;Expected dividend yield&lt;/i&gt;&amp;#x2014;The expected dividend yield
 assumption is based on the fact that we have never paid cash
 dividends and have no present intention to pay cash dividends.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;i&gt;Expected volatility&lt;/i&gt;&amp;#x2014;The expected volatility assumption
 is based on volatilities of a peer group of similar companies whose
 share prices are publicly available. The peer group was developed
 based on companies in the biotechnology industry.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;i&gt;Expected term&lt;/i&gt;&amp;#x2014;The expected term represents the period
 of time that options are expected to be outstanding. Because we do
 not have historic exercise behavior, we determine the expected life
 assumption using the simplified method, which is an average of the
 contractual term of the option and its ordinary vesting period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;i&gt;Forfeitures&lt;/i&gt;&amp;#x2014;We reduce stock-based compensation expense
 for estimated forfeitures. Forfeitures are estimated at the time of
 grant and revised, if necessary, in subsequent periods if actual
 forfeitures differ from those estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Stock-based compensation is reflected in the statement of
 operations and comprehensive loss as follows
 (in&amp;#xA0;thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,246&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;912&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;557&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,176&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;268&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,422&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,550&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;825&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The total compensation cost related to non-vested awards not yet
 recognized was $7.8 million as of December&amp;#xA0;31, 2013. The
 weighted-average period over which this expense is expected to be
 recognized is approximately 2.3 years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In October 2012, we adopted the 2012 Employee Stock Purchase Plan
 (&amp;#x201C;2012 Purchase Plan&amp;#x201D;), which enables participants to
 contribute up to 15% of such participant&amp;#x2019;s eligible
 compensation during a defined rolling six-month periods to purchase
 our common stock. The purchase price of common stock under the 2012
 Purchase Plan will be the lesser of: (i)&amp;#xA0;85% of the fair
 market value of our common stock at the inception of the enrollment
 period or (ii)&amp;#xA0;85% of the fair market value of our common
 stock at the applicable purchase date. We issued 48,035 shares of
 common stock under the 2012 Purchase Plan for the year ended
 December&amp;#xA0;31, 2013. As of December&amp;#xA0;31, 2013 460,283 shares
 of our common stock were reserved for future issuance and have been
 authorized for purchase under the 2012 Purchase Plan.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3156006_BA8464D9-B7BA-438E-8ED3-EA04EA131E95_1_0">0.66</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:FairValueInputsEntityCreditRisk contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_3156006_BA8464D9-B7BA-438E-8ED3-EA04EA131E95_1_2">0.074</us-gaap:FairValueInputsEntityCreditRisk>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_9C35609D-EB9B-45B3-BB71-960A2D47A60C_1_0">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_99E2A55B-D71A-4715-9CD3-48F48FB0A798_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following tables summarize our short-term investments (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Maturity&lt;br /&gt;
 (in&amp;#xA0;years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 fair&amp;#xA0;value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;As of December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&amp;#xA0;or&amp;#xA0;less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,402&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,416&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,710&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,710&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,069&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,071&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Debt securities of U.S. government-sponsored agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,001&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,181&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,198&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Maturity&lt;br /&gt;
 (in&amp;#xA0;years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 fair&amp;#xA0;value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;As of December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,898&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(49&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,856&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&amp;#xA0;or&amp;#xA0;less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,200&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,200&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,492&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,492&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,590&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(49&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,548&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="pure" decimals="5" id="id_3156006_BA8464D9-B7BA-438E-8ED3-EA04EA131E95_1_1">0.00325</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_53F72581-87B2-4228-812E-E7A8BF62798C_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We carry our property and equipment at cost, which consists of lab
 equipment, computer equipment and software, furniture and fixtures
 and leasehold improvements. Property and equipment is depreciated
 using the straight-line method over the estimated useful lives
 (generally three to five years). Leasehold improvements are
 amortized over the lesser of their useful life or the remaining
 lease term, including any renewal periods that are deemed to be
 reasonably assured. Repair and maintenance costs that do not
 improve service potential or extend economic life are expensed as
 incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_9BAD38A2-5842-4F6C-8669-36D5608D232C_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We classify time deposits and other investments that are highly
 liquid and have maturities of 90 days or less at the date of
 purchase as cash equivalents. The carrying amounts approximate fair
 value due to the short maturities of these instruments.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_18">-28330000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_B6837E5D-2D11-45BB-A364-FB52FEC2C690_1_2">P7Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_3156006_DEC4D083-6413-4986-BA96-8BE22D4152A6_1_1">1256232</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_5ED9C6F7-5CD3-459B-8834-42338B6FDB36_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2. Net Loss Per Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Basic net loss per share is calculated by dividing the net loss by
 the weighted average number of common shares outstanding for the
 period, without consideration for common stock equivalents. Diluted
 net loss per share is calculated by dividing the net loss by the
 weighted-average number of common share equivalents outstanding for
 the period determined using the treasury-stock method. Dilutive
 common stock equivalents are comprised of convertible preferred
 stock and options outstanding under our stock option plan. For all
 periods presented, there is no difference in the number of shares
 used to calculate basic and diluted shares outstanding due to our
 net loss position.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Potentially dilutive securities not included in the calculation of
 diluted net loss per share because to do so would be anti-dilutive
 are as follows (in common equivalent shares):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Years ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Convertible preferred stock outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,699,999&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,639,270&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,883,311&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,338,250&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Convertible note payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,411,659&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,366,787&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,050,929&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,250,098&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,038,249&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In October 2012, all convertible preferred stock converted in
 conjunction with our initial public offering. For the year ended
 December&amp;#xA0;31, 2011 we had convertible notes payable outstanding
 of $10.0 million that were convertible into convertible preferred
 stock upon the occurrence of various future preferred stock
 financing events at prices that were not determinable until the
 occurrence of the future events. As such, we have excluded those
 convertible notes payable from the table above. For the years ended
 December&amp;#xA0;31, 2013 and 2012 we had a convertible note payable
 outstanding with a principal balance of $5.4 million that was
 convertible into common shares at $4.00 per share, at the option of
 the note holder. Those shares are included for the years ended
 December&amp;#xA0;31, 2013 and 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="shares" decimals="-3" id="id_3156006_09612DD9-C5AA-4193-9C75-5DDB5A4DCA35_1_3">732000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_DF65FD00-85C9-4F8E-B370-404883FB5DFD_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Financial instruments that potentially subject us to significant
 concentrations of credit risk consist primarily of cash, cash
 equivalents and short-term investments. We maintain deposits in
 federally insured financial institutions in excess of federally
 insured limits. We have not experienced any losses in such accounts
 and believe we are not exposed to significant risk. We maintain our
 cash equivalents and short-term investments with three financial
 institutions. We invest our excess cash primarily in commercial
 paper and debt instruments of financial institutions, corporations,
 U.S. government-sponsored agencies and the U.S. Treasury.
 Additionally, we established guidelines regarding approved
 investments and maturities of investments, which are designed to
 maintain safety and liquidity.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_76AC465B-11E1-4020-B3AD-CE995FD916EE_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;7. Intangible Assets, net&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes our major classes of intangible
 assets (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Patents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;960&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;913&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Licenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,364&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,317&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(236&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(163&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Intangibles, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,128&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,154&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Intangible asset amortization of $0.1 million, $0.1 million and
 $0.1 million was recorded for the years ended December&amp;#xA0;31,
 2013, 2012 and 2011, respectively. Amortization of these intangible
 assets over the next five years is expected to be approximately
 $0.1 million per year.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_18B6D647-CCD4-495F-BAFD-72440CC24274_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;13. Related-Party Transactions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We have entered into several agreements with related parties in the
 ordinary course of business to license intellectual property and to
 procure administrative and research and development support
 services.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In August 2013, we entered into an amendment to the Amended and
 Restated License and Collaboration Agreement with Isis and Alnylam
 dated January&amp;#xA0;1, 2009, as amended in June 2010 and October
 2011 (as&amp;#xA0;amended, the &amp;#x201C;Amendment&amp;#x201D;). Under the
 terms of the Amendment, the parties agreed to our use of certain
 Alnylam-controlled intellectual property concerning the use and
 manufacture of GalNAc conjugates (&amp;#x201C;GalNAc&amp;#xA0;Process
 Technology&amp;#x201D;) on a non-exclusive basis. We will generally not
 be permitted to sublicense or otherwise transfer the GalNAc Process
 Technology and other Alnylam licensed intellectual property rights
 relating to GalNAc conjugate technology without the prior written
 consent of Alnylam, subject to certain limited exceptions for
 sublicenses to third party collaboration partners. There were no
 financial terms related to this Amendment.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes the amounts included in our
 operating expenses as a result of costs incurred from services
 provided under the Services Agreement (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Years&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Services performed or out-of-pocket expenses paid to Alnylam&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;550&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_C56E05FA-D07B-4CA1-90FF-9528085BCD3A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following is a reconciliation of the expected statutory federal
 income tax provision to our actual income tax provision (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected income tax benefit at federal statutory tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,923&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,522&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State income taxes, net of federal benefit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,090&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,016&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(432&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Tax credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(423&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government grant&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in fair value of convertible note payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;456&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loss on debt extinguishment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,058&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prior year true-up&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(235&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;333&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;211&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Income tax (benefit) expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_A736F2C7-264D-4845-B271-6CC690AE5B1D_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Certain current and non-current liabilities in prior period
 financial statements have been reclassified or consolidated to
 conform to the current period presentation. These reclassifications
 had no impact on our statements of operations, statements of
 preferred stock and stockholders&amp;#x2019; equity (deficit) or
 statements of cash flows.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_82A99CA3-C19B-4ACD-889D-9AC0D4D58E96_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Operating segments are identified as components of an enterprise
 about which separate discrete financial information is available
 for evaluation by the chief operating decision-maker in making
 decisions regarding resource allocation and assessing performance.
 To date, we have viewed our operations and managed our business as
 one segment operating primarily in the United States.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_466F614A-46E3-4036-B274-DDB39BE93CF3_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes our major classes of intangible
 assets (in thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Patents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;960&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;913&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Licenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,364&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,317&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(236&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(163&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Intangibles, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,128&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,154&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_C0B9FCE4-9F94-4676-8F7E-7DC0434704D7_1_4">3.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_B87B1B31-0783-4D3C-BB2B-FDDA16EA5C66_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the significant components of our
 deferred tax assets and liabilities (in&amp;#xA0;thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net operating loss carryovers&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,460&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,528&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development and other tax credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,727&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,983&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,999&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Intangibles and property and equipment basis difference&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,213&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,297&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,505&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred tax liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(973&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_1_3">5050929</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_22538132-85E2-459A-AD62-B8A9C0F3B427_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We regularly review the carrying amount of our property, equipment
 and intangible assets to determine whether indicators of impairment
 may exist which warrant adjustments to carrying values or estimated
 useful lives. If indications of impairment exist, projected future
 undiscounted cash flows associated with the asset are compared to
 the carrying amount to determine whether the asset&amp;#x2019;s value is
 recoverable. If the carrying value of the asset exceeds such
 projected undiscounted cash flows, the asset will be written down
 to its estimated fair value. No impairment charges were recorded
 during the years ended December&amp;#xA0;31, 2013, 2012 and 2011.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_F2CAE057-ACD2-4A97-BB17-B13E5064C096_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Stock-based compensation is reflected in the statement of
 operations and comprehensive loss as follows
 (in&amp;#xA0;thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,246&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;912&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;557&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,176&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;638&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;268&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,422&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,550&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;825&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_BDEA2D90-8DC5-4851-8B04-A02C7716D96B_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Our financial statements are prepared in accordance with U.S.
 generally accepted accounting principles. The preparation of our
 financial statements requires us to make estimates and assumptions
 that affect the reported amounts of assets, liabilities, revenues
 and expenses and the disclosure of contingent assets and
 liabilities in our financial statements and accompanying notes.
 Although these estimates are based on our knowledge of current
 events and actions we may undertake in the future, actual results
 may ultimately differ from these estimates and assumptions.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_1180E7AE-BB40-4749-B941-746EED09FD91_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;1. The Business, Basis of Presentation and Summary of
 Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Regulus Therapeutics Inc. was originally formed as a Delaware
 limited liability company under the name Regulus Therapeutics LLC
 on September&amp;#xA0;6, 2007, when Alnylam Pharmaceuticals, Inc.
 (&amp;#x201C;Alnylam&amp;#x201D;) and Isis Pharmaceuticals, Inc.
 (&amp;#x201C;Isis&amp;#x201D;) contributed significant intellectual property,
 know-how and financial and human capital to pursue the development
 of drugs targeting &lt;i&gt;micro&lt;/i&gt;RNAs pursuant to a license and
 collaboration agreement. Regulus Therapeutics Inc. was converted to
 a Delaware corporation on January&amp;#xA0;2, 2009. As used in this
 report, unless the context suggests otherwise, &amp;#x201C;the
 Company,&amp;#x201D; &amp;#x201C;our,&amp;#x201D; &amp;#x201C;us&amp;#x201D; and
 &amp;#x201C;we&amp;#x201D; means Regulus Therapeutics Inc.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We are a biopharmaceutical company focused on discovering and
 developing first-in-class drugs that target &lt;i&gt;micro&lt;/i&gt;RNAs to
 treat a broad range of diseases. We believe we have assembled the
 leading position in the &lt;i&gt;micro&lt;/i&gt;RNA field, including expertise
 in &lt;i&gt;micro&lt;/i&gt;RNA biology and oligonucleotide chemistry, a broad
 intellectual property estate, key opinion leaders and disciplined
 drug discovery and development processes. We refer to these assets
 as our &lt;i&gt;micro&lt;/i&gt;RNA product platform. We are using our
 &lt;i&gt;micro&lt;/i&gt;RNA product platform to develop chemically modified,
 single-stranded oligonucleotides that we call anti-miRs. We use
 these anti-miRs to modulate &lt;i&gt;micro&lt;/i&gt;RNAs and by doing so return
 diseased cells to their healthy state. We are pursuing several
 &lt;i&gt;micro&lt;/i&gt;RNA targets and are focusing our proprietary efforts in
 oncology and orphan diseases. We believe &lt;i&gt;micro&lt;/i&gt;RNAs may be
 transformative in the field of drug discovery and that anti-miRs
 may become a new and major class of drugs with broad therapeutic
 application much like small molecules, biologics and monoclonal
 antibodies.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Our financial statements are prepared in accordance with U.S.
 generally accepted accounting principles. The preparation of our
 financial statements requires us to make estimates and assumptions
 that affect the reported amounts of assets, liabilities, revenues
 and expenses and the disclosure of contingent assets and
 liabilities in our financial statements and accompanying notes.
 Although these estimates are based on our knowledge of current
 events and actions we may undertake in the future, actual results
 may ultimately differ from these estimates and assumptions.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Our revenues generally consist of upfront payments for licenses or
 options to obtain licenses in the future, research and development
 funding and milestone payments under strategic alliance agreements,
 as well as funding received under government grants. We recognize
 revenues when all four of the following criteria are met:
 (1)&amp;#xA0;persuasive evidence that an arrangement exists;
 (2)&amp;#xA0;delivery of the products and/or services has occurred;
 (3)&amp;#xA0;the selling price is fixed or determinable; and
 (4)&amp;#xA0;collectability is reasonably assured.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Multiple element arrangements, such as our strategic alliance
 agreements with Sanofi, AstraZeneca AB (&amp;#x201C;AstraZeneca&amp;#x201D;)
 and GlaxoSmithKline plc (&amp;#x201C;GSK&amp;#x201D;), are analyzed to
 determine whether the deliverables within the agreement can be
 separated or whether they must be accounted for as a single unit of
 accounting. Deliverables under the agreement will be accounted for
 as separate units of accounting provided that (i)&amp;#xA0;a delivered
 item has value to the customer on a stand-alone basis; and
 (ii)&amp;#xA0;if the agreement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially in the
 control of the vendor. The allocation of consideration amongst the
 deliverables under the agreement is derived using a &amp;#x201C;best
 estimate of selling price&amp;#x201D; if vendor specific objective
 evidence and third-party evidence of fair value is not available.
 If the delivered element does not have stand-alone value, the
 arrangement is then accounted for as a single unit of accounting,
 and we recognize the consideration received under the arrangement
 as revenue on a straight-line basis over our estimated period of
 performance, which for us is often the expected term of the
 research and development plan.&lt;/p&gt;
 &lt;p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Milestones&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We recognize revenue from milestone payments when earned, provided
 that (i)&amp;#xA0;the milestone event is substantive in that it can
 only be achieved based in whole or in part on either our
 performance or on the occurrence of a specific outcome resulting
 from our performance and its achievability was not reasonably
 assured at the inception of the agreement, (ii)&amp;#xA0;we do not have
 ongoing performance obligations related to the achievement of the
 milestone and (iii)&amp;#xA0;it would result in the receipt of
 additional payments. A milestone payment is considered substantive
 if all of the following conditions are met: (i)&amp;#xA0;the milestone
 payment is non-refundable; (ii)&amp;#xA0;achievement of the milestone
 was not reasonably assured at the inception of the arrangement;
 (iii)&amp;#xA0;substantive effort is involved to achieve the milestone;
 and (iv)&amp;#xA0;the amount of the milestone payments appears
 reasonable in relation to the effort expended, the other milestones
 in the arrangement and the related risk associated with the
 achievement of the milestone. Any amounts received under the
 agreements in advance of performance, if deemed substantive, are
 recorded as deferred revenue and recognized as revenue as we
 complete our performance obligations.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Generally, the milestone events contained in our strategic alliance
 agreements coincide with the progression of our product candidates
 from target selection, to clinical candidate selection, to clinical
 trial, to regulatory approval and then to commercialization. The
 process of successfully discovering a new development candidate,
 having it approved and ultimately sold for a profit is highly
 uncertain. As such, the milestone payments we may earn from our
 partners involve a significant degree of risk to achieve.
 Therefore, as a product candidate progresses through the stages of
 its life-cycle, the value of the product candidate generally
 increases.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We recognize revenue from government and private agency grants as
 the related research expenses are incurred and to the extent that
 funding is approved. Any amounts received in advance of performance
 are recorded as deferred revenue until earned.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Deferred Revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Amounts received prior to satisfying the above revenue recognition
 criteria are recorded as deferred revenue in the accompanying
 balance sheets. Amounts not expected to be recognized within the
 next 12 months are classified as non-current deferred revenue.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We account for stock-based compensation expense related to stock
 options granted to employees and members of our board of directors
 by estimating the fair value of each stock option on the date of
 grant using the black-scholes model. We recognize stock-based
 compensation expense using the accelerated multiple-option
 approach. Under the accelerated multiple-option approach (also
 known as the graded-vesting method), we recognize compensation
 expense over the requisite service period for each separately
 vesting tranche of the award as though the award was in substance
 multiple awards, resulting in accelerated expense recognition over
 the vesting period.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We account for stock options granted to non-employees, which
 primarily consist of members of our scientific advisory board,
 using the fair value approach. Stock options granted to
 non-employees are subject to periodic revaluation over their
 vesting terms.&lt;/p&gt;
 &lt;p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Research and development costs are expensed as incurred and include
 compensation and related benefits, non-cash stock-based
 compensation, license fees, laboratory supplies and associated
 overhead and facilities costs. In certain circumstances, we make
 non-refundable advance payments to purchase goods and services for
 future use in research and development activities pursuant to
 contractual arrangements. In those instances, we capitalize these
 amounts and record expense in the period that we receive the goods
 or when services are performed.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The accounting guidance for accounting for uncertainty in income
 taxes prescribes a recognition threshold and measurement attribute
 criteria for the financial statement recognition and measurement of
 tax positions taken or expected to be taken in a tax return. For
 those benefits to be recognized, a tax position must be more likely
 than not to be sustained upon examination by taxing
 authorities.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We use the liability method of accounting for income taxes. Under
 this method, deferred tax assets and liabilities are determined
 based on the difference between the financial reporting and the tax
 reporting basis of assets and liabilities and are measured using
 the enacted tax rates and laws that are expected to be in effect
 when the differences are expected to reverse. We provide a
 valuation allowance against net deferred tax assets unless, based
 upon the available evidence, it is more likely than not that the
 deferred tax assets will be realized.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Option&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Applicable accounting policies permit entities to choose, at
 specified election dates, to measure specified items at fair value
 if the decision about the election is: 1) applied instrument by
 instrument, 2) irrevocable, and 3) applied to an entire
 instrument.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2012, we amended and restated our $5.0 million convertible
 promissory note originally issued in February 2010 to GSK
 (&amp;#x201C;2010 GSK note&amp;#x201D;), which was accounted for as a debt
 extinguishment of the original note. We elected to measure the
 amended note under the fair value option. The difference between
 the carrying value of the original note and the fair value of the
 amended note was recorded as a loss on extinguishment of debt to
 non-operating earnings. Thereafter, any change to the fair value of
 the amended note is recorded as gain (loss) from valuation of
 convertible note payable to non-operating earnings.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We classify time deposits and other investments that are highly
 liquid and have maturities of 90 days or less at the date of
 purchase as cash equivalents. The carrying amounts approximate fair
 value due to the short maturities of these instruments.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Short-Term Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We carry short-term investments classified as available-for-sale at
 fair value as determined by prices for identical or similar
 securities at the balance sheet date. Our short-term investments
 consist of both Level 1 and Level 2 financial instruments in the
 fair value hierarchy. We record unrealized gains and losses as a
 component of other comprehensive loss within the statements of
 operations and comprehensive loss and as a separate component of
 stockholders&amp;#x2019; equity (deficit). We determine the realized
 gains or losses of available-for-sale securities using the specific
 identification method and include net realized gains and losses in
 interest income.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 At each balance sheet date, we assess available-for-sale securities
 in an unrealized loss position to determine whether the unrealized
 loss is other-than-temporary. We consider factors including: the
 significance of the decline in value compared to the cost basis,
 underlying factors contributing to a decline in the prices of
 securities in a single asset class, the length of time the market
 value of the security has been less than its cost basis, the
 security&amp;#x2019;s relative performance versus its peers, sector or
 asset class, expected market volatility and the market and economy
 in general. When we determine that a decline in the fair value
 below its cost basis is other-than-temporary, we recognize an
 impairment loss in the year in which the other-than-temporary
 decline occurred. We determined that there were no
 other-than-temporary declines in the value of short-term
 investments as of December&amp;#xA0;31, 2013 and 2012.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Financial instruments that potentially subject us to significant
 concentrations of credit risk consist primarily of cash, cash
 equivalents and short-term investments. We maintain deposits in
 federally insured financial institutions in excess of federally
 insured limits. We have not experienced any losses in such accounts
 and believe we are not exposed to significant risk. We maintain our
 cash equivalents and short-term investments with three financial
 institutions. We invest our excess cash primarily in commercial
 paper and debt instruments of financial institutions, corporations,
 U.S. government-sponsored agencies and the U.S. Treasury.
 Additionally, we established guidelines regarding approved
 investments and maturities of investments, which are designed to
 maintain safety and liquidity.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We carry our property and equipment at cost, which consists of lab
 equipment, computer equipment and software, furniture and fixtures
 and leasehold improvements. Property and equipment is depreciated
 using the straight-line method over the estimated useful lives
 (generally three to five years). Leasehold improvements are
 amortized over the lesser of their useful life or the remaining
 lease term, including any renewal periods that are deemed to be
 reasonably assured. Repair and maintenance costs that do not
 improve service potential or extend economic life are expensed as
 incurred.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Intangibles&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We capitalize costs which consist principally of outside legal
 costs and filing fees related to obtaining patents. We review our
 capitalized patent costs periodically to determine that they
 include costs for patent applications that have future value and an
 alternative future use. We evaluate costs related to patents that
 we are not actively pursuing and write off these costs. We amortize
 patent costs over their patent lives, beginning with the date the
 patents are issued. The weighted average remaining life of the
 issued patents was 12 years at December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We obtain licenses from third parties and capitalize the costs
 related to exclusive licenses that have alternative future use
 within multiple potential programs. We amortize capitalized
 licenses over their estimated useful life or term of the agreement,
 which for current licenses is 10 years.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We regularly review the carrying amount of our property, equipment
 and intangible assets to determine whether indicators of impairment
 may exist which warrant adjustments to carrying values or estimated
 useful lives. If indications of impairment exist, projected future
 undiscounted cash flows associated with the asset are compared to
 the carrying amount to determine whether the asset&amp;#x2019;s value is
 recoverable. If the carrying value of the asset exceeds such
 projected undiscounted cash flows, the asset will be written down
 to its estimated fair value. No impairment charges were recorded
 during the years ended December&amp;#xA0;31, 2013, 2012 and 2011.&lt;/p&gt;
 &lt;p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Clinical Trial and Pre-Clinical Study Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We make estimates of our accrued expenses as of each balance sheet
 date in our financial statements based on the facts and
 circumstances known to us at that time. Our accrued expenses for
 clinical trials are based on estimates of the fees associated with
 services provided by clinical trial investigational sites and CROs.
 Payments under some of the contracts we have with such parties
 depend on factors such as successful enrollment of patients, site
 initiation and the completion of clinical trial milestones. In
 accruing service fees, we estimate the time period over which
 services will be performed and the level of effort to be expended
 in each period. If possible, we obtain information regarding
 unbilled services directly from these service providers. However,
 we may be required to estimate these services based on other
 information available to us. If we underestimate or overestimate
 the activity or fees associated with a study or service at a given
 point in time, adjustments to research and development expenses may
 be necessary in future periods. Historically, our estimated accrued
 liabilities have approximated actual expense incurred. Subsequent
 changes in estimates may result in a material change in our
 accruals.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Operating segments are identified as components of an enterprise
 about which separate discrete financial information is available
 for evaluation by the chief operating decision-maker in making
 decisions regarding resource allocation and assessing performance.
 To date, we have viewed our operations and managed our business as
 one segment operating primarily in the United States.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Comprehensive loss is defined as the change in equity during a
 period from transactions and other events and/or circumstances from
 non-owner sources. Our only component of other comprehensive loss
 is unrealized gains (losses) on available-for-sale securities.
 Comprehensive gains (losses) have been reflected in the statements
 of operations and comprehensive loss and as a separate component of
 the statements of convertible preferred stock and
 stockholders&amp;#x2019; equity (deficit) for all periods presented.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Certain current and non-current liabilities in prior period
 financial statements have been reclassified or consolidated to
 conform to the current period presentation. These reclassifications
 had no impact on our statements of operations, statements of
 preferred stock and stockholders&amp;#x2019; equity (deficit) or
 statements of cash flows.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2013, the FASB issued Accounting Standards Update
 No.&amp;#xA0;2013-11, &lt;i&gt;Presentation of an Unrecognized Tax Benefit
 When a Net Operating Loss Carryforward, a Similar Tax Loss, or a
 Tax Credit Carryforward Exists&lt;/i&gt; (&amp;#x201C;ASU 2013-11&amp;#x201D;).
 This update provides explicit guidance on the financial statement
 presentation of an unrecognized tax benefit when a net operating
 loss carryforward, a similar tax loss, or a tax credit carryforward
 exists. This guidance is effective prospectively for fiscal years,
 and interim periods within those years, beginning after
 December&amp;#xA0;15, 2013, with an option for early adoption. We
 intend to adopt this guidance in 2014, and do not believe the
 adoption of this standard will have a material impact on our
 financial condition, results of operations or related financial
 statement disclosures.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_E407D171-3520-446F-A4E5-ED96DC23896D_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The assumptions used to estimate the fair value of stock options
 using the Black-Scholes option pricing model were as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;Year&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;&amp;#xA0;2013&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;&amp;#xA0;2012&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;&amp;#xA0;2011&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Employee Stock Options:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.9&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.3&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72.4&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73.4&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72.9&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.1&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.1&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.1&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_25A53C52-E9C7-4E4A-A361-08F8EEB5DA51_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;3. Investments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We invest our excess cash in commercial paper and debt instruments
 of financial institutions, corporations and U.S.
 government-sponsored agencies. As of December&amp;#xA0;31, 2013, our
 short-term investments had a weighted average maturity of less than
 two years.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following tables summarize our short-term investments (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Maturity&lt;br /&gt;
 (in&amp;#xA0;years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 fair&amp;#xA0;value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;As of December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&amp;#xA0;or&amp;#xA0;less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,402&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71,416&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,710&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,710&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,069&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,071&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Debt securities of U.S. government-sponsored agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,001&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,181&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(25&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96,198&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Maturity&lt;br /&gt;
 (in&amp;#xA0;years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Amortized&lt;br /&gt;
 cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 fair&amp;#xA0;value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;As of December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Corporate debt securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,898&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(49&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,856&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Certificates of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&amp;#xA0;or&amp;#xA0;less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,200&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,200&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2 or less&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,492&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,492&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,590&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(49&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,548&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_20">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_C0B9FCE4-9F94-4676-8F7E-7DC0434704D7_1_3">0.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_B0AC2231-2DB8-4A1F-9AC9-9F91AEF705CD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;15. Subsequent Events&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In February 2014, we and Sanofi entered into a second amended and
 restated collaboration and license agreement to extend our
 strategic alliance. Under the terms of our extended alliance,
 Sanofi will have opt-in rights to our miR-21 pre-clinical fibrosis
 program targeting miR-21 for the treatment of Alport Syndrome, our
 preclinical program targeting miR-21 for oncology indications, and
 our preclinical programs targeting &lt;font style="WHITE-SPACE: nowrap"&gt;miR-221/222&lt;/font&gt; for oncology indications,
 each of which is to be led by us. If Sanofi chooses to exercise its
 option on any of these programs, Sanofi will reimburse us for a
 significant portion of our preclinical and clinical development
 costs and will also pay us an option exercise fee for any such
 program, provided that $1.25 million of the $2.5 million upfront
 option fee paid to us by Sanofi in connection with the June 2013
 option agreement will be creditable against such option exercise
 fee. In addition, we will be eligible to receive clinical and
 regulatory milestone payments under these programs and potentially
 commercial milestone payments. We also continue to be eligible to
 receive royalties on &lt;i&gt;micro&lt;/i&gt;RNA therapeutic products
 commercialized by Sanofi and will have the right to co-promote
 these products.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In connection with our entry into the second amended and restated
 collaboration and license agreement with Sanofi, we sold and issued
 1,303,780 shares of our common stock to Aventis, an entity
 affiliated with Sanofi, in a private placement at a price per share
 of $7.67 for an aggregate purchase price of $10.0 million.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_8B1B8DA5-8B15-4A23-9B4A-5F5BAF54F224_2_1">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_8B9BAE8E-5D6D-4FB6-9405-E9F1D089DE41_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;12. Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the components of our income tax
 (benefit) expense (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"&gt;&lt;b&gt;Year ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Federal&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 State&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;(11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Income tax (benefit) expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following is a reconciliation of the expected statutory federal
 income tax provision to our actual income tax provision (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected income tax benefit at federal statutory tax rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,923&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,522&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 State income taxes, net of federal benefit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,090&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,016&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(432&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Tax credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(423&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Government grant&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in fair value of convertible note payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;456&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loss on debt extinguishment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,058&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prior year true-up&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(235&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(368&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;333&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Stock compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;211&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Income tax (benefit) expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the significant components of our
 deferred tax assets and liabilities (in&amp;#xA0;thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Deferred tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Net operating loss carryovers&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,460&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,528&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Research and development and other tax credits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,727&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,983&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,999&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Intangibles and property and equipment basis difference&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,213&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,297&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,505&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total deferred tax liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(973&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(28,306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,279&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net deferred tax asset&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 For all periods presented, we have determined that it is more
 likely than not that our deferred tax asset will not be realized.
 Accordingly, we have recorded a valuation allowance to fully offset
 the net deferred tax asset of $28.3&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of December&amp;#xA0;31, 2013, we had federal and California tax net
 operating loss carryforwards of $44.2&amp;#xA0;million and $52.6
 million, respectively, which begin to expire in 2030 and 2031. At
 December&amp;#xA0;31, 2013, approximately $1.6 million of the net
 operating loss carryforwards relate to stock option exercises,
 which will result in an increase to additional paid-in capital and
 a decrease in income taxes payable at the time when the tax loss
 carryforwards are utilized. As of December&amp;#xA0;31, 2013, we also
 had federal and California research and development tax credit
 carryforwards of $3.6&amp;#xA0;million and $2.8&amp;#xA0;million,
 respectively. The federal research and development tax credit
 carryforwards will begin to expire in 2029. The California research
 and development tax credit carryforwards are available
 indefinitely. As of December 31, 2013, we also had $0.2 million of
 Federal Alternative Minimum Tax Credit carryforwards that are
 available indefinitely.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The future utilization of our research and development credit
 carryforwards and net operating loss carryforwards to offset future
 taxable income may be subject to an annual limitation as a result
 of ownership changes that may have occurred previously or may occur
 in the future. The Tax Reform Act of 1986 (the Act) limits a
 company&amp;#x2019;s ability to utilize certain tax credit carryforwards
 and net operating loss carryforwards in the event of a cumulative
 change in ownerships in excess of 50% as defined in the Act.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the changes in the amount of our
 unrecognized tax benefits (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Year Ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning balance of unrecognized tax benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;569&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;288&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Increase (decrease) for prior year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;137&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Increase for current year tax positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;147&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,092&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;569&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;406&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Included in the balance of unrecognized tax benefits at
 December&amp;#xA0;31, 2013, is $1.1 million that, if recognized, would
 not impact our income tax benefit or effective tax rate as long as
 our deferred tax asset remains subject to a full valuation
 allowance. We do not expect any significant increases or decreases
 to our unrecognized tax benefits within the next 12 months.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We are subject to taxation in the United States and California. We
 are subject to income tax examination by tax authorities in those
 jurisdictions for 2009 and forward.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 It is our practice to recognize interest and/or penalties related
 to income tax matters in income tax expense. For the years ended
 December&amp;#xA0;31, 2013, 2012 and 2011, we have not recognized any
 interest or penalties related to income taxes.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="shares" decimals="-3" id="id_3156006_09612DD9-C5AA-4193-9C75-5DDB5A4DCA35_1_4">254000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_B514ADE9-FD69-4D92-9C78-0EFFBAF08DD0_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Research and development costs are expensed as incurred and include
 compensation and related benefits, non-cash stock-based
 compensation, license fees, laboratory supplies and associated
 overhead and facilities costs. In certain circumstances, we make
 non-refundable advance payments to purchase goods and services for
 future use in research and development activities pursuant to
 contractual arrangements. In those instances, we capitalize these
 amounts and record expense in the period that we receive the goods
 or when services are performed.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_B6837E5D-2D11-45BB-A364-FB52FEC2C690_1_3">P6Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_709D5146-8333-4DD1-8EB2-CE8BE168A823_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2013, the FASB issued Accounting Standards Update
 No.&amp;#xA0;2013-11, &lt;i&gt;Presentation of an Unrecognized Tax Benefit
 When a Net Operating Loss Carryforward, a Similar Tax Loss, or a
 Tax Credit Carryforward Exists&lt;/i&gt; (&amp;#x201C;ASU 2013-11&amp;#x201D;).
 This update provides explicit guidance on the financial statement
 presentation of an unrecognized tax benefit when a net operating
 loss carryforward, a similar tax loss, or a tax credit carryforward
 exists. This guidance is effective prospectively for fiscal years,
 and interim periods within those years, beginning after
 December&amp;#xA0;15, 2013, with an option for early adoption. We
 intend to adopt this guidance in 2014, and do not believe the
 adoption of this standard will have a material impact on our
 financial condition, results of operations or related financial
 statement disclosures.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="Segment" decimals="INF" id="id_3156006_65693A97-2DC1-4DAA-B7A2-B6394B591C60_1_0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_43327C20-D589-4E1E-A68B-14D29B272624_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We account for stock-based compensation expense related to stock
 options granted to employees and members of our board of directors
 by estimating the fair value of each stock option on the date of
 grant using the black-scholes model. We recognize stock-based
 compensation expense using the accelerated multiple-option
 approach. Under the accelerated multiple-option approach (also
 known as the graded-vesting method), we recognize compensation
 expense over the requisite service period for each separately
 vesting tranche of the award as though the award was in substance
 multiple awards, resulting in accelerated expense recognition over
 the vesting period.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We account for stock options granted to non-employees, which
 primarily consist of members of our scientific advisory board,
 using the fair value approach. Stock options granted to
 non-employees are subject to periodic revaluation over their
 vesting terms.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_14588D42-D6F7-4D1A-999F-5B54B8CE2239_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;8. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We lease office and laboratory space located at 3545 John Hopkins
 Court, La Jolla, California (the &amp;#x201C;Facility&amp;#x201D;) for our
 corporate headquarters and research facility under an operating
 lease agreement (the &amp;#x201C;Lease&amp;#x201D;). The Lease commenced in
 July 2010 and provided for approximately 22,000 square feet of
 office and laboratory space, expiring in June 2017. In November
 2012, we amended the Lease to expand our laboratory and office
 space by approximately 7,000 square feet, including the addition of
 an approximately 3,000 square foot dedicated research and
 development laboratory. Lease payments for this additional space
 began October 2013. We have an option to terminate and cancel the
 lease in June&amp;#xA0;2015 upon six months&amp;#x2019; written notice to
 our landlord. We also have two options to extend the lease for
 successive three-year periods.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In connection with the inception of the Lease, we were provided
 tenant incentives of $0.1 million which was used to construct a
 leasehold improvement. In addition, we were provided and fully
 utilized a tenant improvement allowance of approximately $0.6
 million, which was used to fund additional leasehold improvements.
 In January 2011, the Lease was amended to memorialize the payback
 of the allowance into our base rent. In conjunction with the
 amendment of the Lease in November 2012, we were provided an
 additional tenant improvement allowance of approximately $0.7
 million, which was utilized in 2013 to fund leasehold improvements
 in the newly occupied space. We are obligated to repay our landlord
 the tenant improvement allowance, plus interest at a fixed rate of
 8%, on a monthly basis over the remaining term of the Lease. The
 future minimum payment summary below includes our amended base
 rents over the remaining period of the lease agreement.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Cumulative rent to be paid over the lease term is being amortized
 on a straight-line basis over the term of the Lease. Rent expense
 for the years ended December&amp;#xA0;31, 2013, 2012 and 2011 was
 approximately $0.7 million, $0.6 million and $0.5 million,
 respectively. We account for the difference between the minimum
 lease payments and the straight-line amount as deferred rent.
 Deferred rent at December&amp;#xA0;31, 2013 and 2012 was approximately
 $0.9 million and $0.5 million, respectively. We also pay property
 taxes, maintenance and insurance, which are expensed as
 incurred.&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As of December&amp;#xA0;31, 2013, future annual minimum lease payments
 for our operating leases are as follows (in&amp;#xA0;thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,066&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,138&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,211&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;624&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,039&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We have license agreements with third parties that require us to
 make annual license maintenance payments and future payments upon
 the success of licensed products that include milestones and/or
 royalties. Minimum future payments over the next five years are not
 material.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_E03826EE-AFED-47D5-AB4E-B45997116DF4_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Option&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Applicable accounting policies permit entities to choose, at
 specified election dates, to measure specified items at fair value
 if the decision about the election is: 1) applied instrument by
 instrument, 2) irrevocable, and 3) applied to an entire
 instrument.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2012, we amended and restated our $5.0 million convertible
 promissory note originally issued in February 2010 to GSK
 (&amp;#x201C;2010 GSK note&amp;#x201D;), which was accounted for as a debt
 extinguishment of the original note. We elected to measure the
 amended note under the fair value option. The difference between
 the carrying value of the original note and the fair value of the
 amended note was recorded as a loss on extinguishment of debt to
 non-operating earnings. Thereafter, any change to the fair value of
 the amended note is recorded as gain (loss) from valuation of
 convertible note payable to non-operating earnings.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11006_900021">45779000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_22">800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NonoperatingGainsLosses contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_13">-1145000</us-gaap:NonoperatingGainsLosses>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_18">36000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11006_900018">594000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_36">1000</us-gaap:IncomeTaxesPaid>
  <us-gaap:ProfitLoss contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_1">-18668000</us-gaap:ProfitLoss>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_20">72005000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_14">-18691000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:UnrealizedGainOnSecurities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_5_3">42000</us-gaap:UnrealizedGainOnSecurities>
  <us-gaap:InterestPaid contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_35">37000</us-gaap:InterestPaid>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_3">19569000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_12">2283000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_28">100000</us-gaap:RepaymentsOfOtherLongTermDebt>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_1_2">386000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_19">-18632000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:GainLossOnInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_7">25000</us-gaap:GainLossOnInvestments>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_8">-17802000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_23">35000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_11">79000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
  <us-gaap:InterestAndOtherIncome contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_10">292000</us-gaap:InterestAndOtherIncome>
  <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_1_2">2406000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_16">-18668000</us-gaap:NetIncomeLoss>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_6">-1464000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11006_900020">201000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11006_900019">3422000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_1_7">-24000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_1_9">-86000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_17">-11000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_14">-51000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_6">7429000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_30">46474000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_1_6">9026000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_8">3422000</us-gaap:ShareBasedCompensation>
  <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_40">11000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FC99C631-3F5E-4A78-B72F-3D69E2A8898E_1_0">1300000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_31">-22745000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_1_8">667000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_1_2">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_454CA124-542C-47EE-81A7-9DB05C9063BB_1_1">600000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:UnrealizedLossOnSecurities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_5_4">25000</us-gaap:UnrealizedLossOnSecurities>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_7">37371000</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_DEC4D083-6413-4986-BA96-8BE22D4152A6_1_0">5000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_15">-23000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_16">-16819000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_1_7">-235000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_454CA124-542C-47EE-81A7-9DB05C9063BB_1_0">5700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_15">1355000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_11">36000</us-gaap:InterestExpense>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_1_1">-1090000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_13">860000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_27">45980000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_1_0">-6355000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_1_5">-20000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_29">594000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_1_6">-4000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_3">1360000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8C20D543-4BE9-4D72-9105-57D953E540B5_1_0">100000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_1_3">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_1_2">3422000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_43F3CC12-6573-40AE-A31F-2D49699BF00A_1_0">700000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_24">-40889000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_1_5">29942000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_21">31951000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F800B7F8-8ECB-4CD9-B0E5-6E1DE063A201_1_3">100000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11006_900022">434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <rgls:LeaseExpirationMonthAndYear contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_E6FAD7EB-C5DA-4AA5-88B1-E9744521041B_1_0">2017-06</rgls:LeaseExpirationMonthAndYear>
  <rgls:OperatingLossCarryforwardExpirationYear contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_FD9FA894-3F05-4F74-A5C2-DAB245AF51AF_2_2">2030</rgls:OperatingLossCarryforwardExpirationYear>
  <rgls:DebtInstrumentsAmendmentDate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_A8E837E7-7A55-4CB6-BB2A-6F9673EDF292_1_0">2012-07</rgls:DebtInstrumentsAmendmentDate>
  <rgls:TenantImprovementAllowanceInterestRatePercentage contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3156006_F02DAB0A-6862-4DBE-A39B-986A6C4FA171_1_3">0.08</rgls:TenantImprovementAllowanceInterestRatePercentage>
  <rgls:ExtensionPeriodOfOperatingLease contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_E6FAD7EB-C5DA-4AA5-88B1-E9744521041B_1_4">P3Y</rgls:ExtensionPeriodOfOperatingLease>
  <rgls:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_0472AA44-134B-46E3-A303-6244E416497B_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The following shares of common stock are reserved for future
 issuance at December&amp;#xA0;31, 2013:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Common stock options outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,598,207&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Common stock options available for future grant&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710,534&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Employee Stock Purchase Plan&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;460,283&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Convertible note payable (Post-IPO GSK Note)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,411,659&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total common shares reserved for future issuance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,180,683&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</rgls:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock>
  <rgls:RevenueFromStrategicAlliancesTableTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_4F880116-3C4D-4257-BF07-8831C2C3862B_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes the amounts included in our revenues
 which resulted from our strategic alliances and collaboration (in
 thousands):&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Year ended
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Sanofi-Aventis&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,336&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,030&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,033&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 GSK&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,778&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,996&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,734&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 AstraZeneca&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,859&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;559&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Biogen Idec&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;596&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,569&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,700&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,767&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</rgls:RevenueFromStrategicAlliancesTableTextBlock>
  <rgls:DefinedContributionPlansTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_E7B049DF-A844-4559-B790-F84B850B5A1D_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;11. Defined Contribution Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In 2009, we established an employee 401(k) salary deferral plan
 (&amp;#x201C;401(k) Plan&amp;#x201D;) covering all eligible employees. Active
 employees who are at least 18 years old and are not otherwise
 disqualified under the terms of the 401(k) Plan are eligible to
 participate. Employees may contribute up to 50% of their
 compensation per year (subject to a maximum limit prescribed by
 federal tax law). Under the 401(k) Plan, we may elect to match a
 discretionary percentage of employee contributions. We have elected
 to match 25% of employees&amp;#x2019; contributions up to 6% of the
 employees&amp;#x2019; eligible salary. We made $0.1 million, $0.1
 million and $0.1 million in matching contributions for the years
 ended December&amp;#xA0;31, 2013, 2012 and 2011, respectively.&lt;/p&gt;
 &lt;/div&gt;</rgls:DefinedContributionPlansTextBlock>
  <rgls:OptionalLeaseTerminationDateMonthAndYear contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_E6FAD7EB-C5DA-4AA5-88B1-E9744521041B_1_1">2015-06</rgls:OptionalLeaseTerminationDateMonthAndYear>
  <rgls:AccruedExpensePolicyTextBlock contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" id="id_3156006_6F4BB106-96F0-457E-B9CA-C16ADEE25381_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Clinical Trial and Pre-Clinical Study Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 We make estimates of our accrued expenses as of each balance sheet
 date in our financial statements based on the facts and
 circumstances known to us at that time. Our accrued expenses for
 clinical trials are based on estimates of the fees associated with
 services provided by clinical trial investigational sites and CROs.
 Payments under some of the contracts we have with such parties
 depend on factors such as successful enrollment of patients, site
 initiation and the completion of clinical trial milestones. In
 accruing service fees, we estimate the time period over which
 services will be performed and the level of effort to be expended
 in each period. If possible, we obtain information regarding
 unbilled services directly from these service providers. However,
 we may be required to estimate these services based on other
 information available to us. If we underestimate or overestimate
 the activity or fees associated with a study or service at a given
 point in time, adjustments to research and development expenses may
 be necessary in future periods. Historically, our estimated accrued
 liabilities have approximated actual expense incurred. Subsequent
 changes in estimates may result in a material change in our
 accruals.&lt;/p&gt;
 &lt;/div&gt;</rgls:AccruedExpensePolicyTextBlock>
  <rgls:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_1_4">456000</rgls:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes>
  <rgls:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_1_1">137000</rgls:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
  <rgls:NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3156006_DC3E81CD-F270-4FFE-96D4-BC8403AB2EE9_1_0">0.50</rgls:NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum>
  <rgls:DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="pure" decimals="2" id="id_3156006_F800B7F8-8ECB-4CD9-B0E5-6E1DE063A201_1_0">0.50</rgls:DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation>
  <rgls:NumberOfLeaseExtensionOptions contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="Leases" decimals="0" id="id_3156006_E6FAD7EB-C5DA-4AA5-88B1-E9744521041B_1_3">2</rgls:NumberOfLeaseExtensionOptions>
  <rgls:AdditionalTenantImprovementAllowance contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F02DAB0A-6862-4DBE-A39B-986A6C4FA171_1_2">700000</rgls:AdditionalTenantImprovementAllowance>
  <rgls:TenantImprovementAllowance contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_1_39">653000</rgls:TenantImprovementAllowance>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_708873x816429" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2001_1">19569000</us-gaap:Revenues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11003_600021">45774000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11003_600018">593000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11003_600020">201000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11003_600019">3422000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11001_400021">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11001_400018">732483</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11001_400020">48035</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11001_500021">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11001_500018">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11005_800024">-18668000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x716406" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_11004_700023">36000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <rgls:MaturityPeriodOfShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x709312" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_2_1">2 or less</rgls:MaturityPeriodOfShortTermInvestments>
  <us-gaap:UnrealizedGainOnSecurities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x712703" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_3_3">2000</us-gaap:UnrealizedGainOnSecurities>
  <rgls:MaturityPeriodOfShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x712703" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_3_1">1 or less</rgls:MaturityPeriodOfShortTermInvestments>
  <us-gaap:UnrealizedGainOnSecurities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_1_3">39000</us-gaap:UnrealizedGainOnSecurities>
  <us-gaap:UnrealizedLossOnSecurities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_1_4">25000</us-gaap:UnrealizedLossOnSecurities>
  <rgls:MaturityPeriodOfShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x712929" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_1_1">2 or less</rgls:MaturityPeriodOfShortTermInvestments>
  <us-gaap:UnrealizedGainOnSecurities contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x717071" unitRef="iso4217_USD" decimals="-3" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_4_3">1000</us-gaap:UnrealizedGainOnSecurities>
  <rgls:MaturityPeriodOfShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x717071" id="id_3156006_973C043F-FD0B-4B3E-B249-4DF80E669DAF_4_1">1 or less</rgls:MaturityPeriodOfShortTermInvestments>
  <rgls:OperatingLossCarryforwardExpirationYear contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_710844x707112" id="id_3156006_FD9FA894-3F05-4F74-A5C2-DAB245AF51AF_1002_3">2031</rgls:OperatingLossCarryforwardExpirationYear>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169" id="id_3156006_98CF92D1-5B3B-465C-94FA-717B6E2C6D94_1001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <rgls:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169_759964x766452" unitRef="pure" decimals="2" id="id_3156006_20230DF7-3D01-4BFE-9213-83269643F824_1001_3">0.08</rgls:RoyaltyPercentageBasedOnNetSales>
  <rgls:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169_759964x778268_853143x832174" unitRef="pure" decimals="2" id="id_3156006_9FD38356-75C7-4EE9-A433-48564CF19D1F_1001_5">0.10</rgls:RoyaltyPercentageBasedOnNetSales>
  <rgls:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169_759964x778268_853143x836413" unitRef="pure" decimals="2" id="id_3156006_F21F6296-A875-4611-8199-443F8AC4EAAF_1001_5">0.10</rgls:RoyaltyPercentageBasedOnNetSales>
  <rgls:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169_759964x826261" unitRef="pure" decimals="2" id="id_3156006_02AF28BD-BB45-4A2F-B872-6197C178E5C9_1003_6">0.10</rgls:RoyaltyPercentageBasedOnNetSales>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112" id="id_3156006_98CF92D1-5B3B-465C-94FA-717B6E2C6D94_2001_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <rgls:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112_759964x766452" unitRef="pure" decimals="2" id="id_3156006_20230DF7-3D01-4BFE-9213-83269643F824_2001_4">0.12</rgls:RoyaltyPercentageBasedOnNetSales>
  <rgls:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112_759964x778268_853143x832174" unitRef="pure" decimals="2" id="id_3156006_9FD38356-75C7-4EE9-A433-48564CF19D1F_2001_6">0.20</rgls:RoyaltyPercentageBasedOnNetSales>
  <rgls:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112_759964x778268_853143x836413" unitRef="pure" decimals="2" id="id_3156006_F21F6296-A875-4611-8199-443F8AC4EAAF_2001_6">0.20</rgls:RoyaltyPercentageBasedOnNetSales>
  <rgls:RoyaltyPercentageBasedOnNetSales contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112_759964x826261" unitRef="pure" decimals="2" id="id_3156006_02AF28BD-BB45-4A2F-B872-6197C178E5C9_1004_6">0.20</rgls:RoyaltyPercentageBasedOnNetSales>
  <rgls:RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_711672x809276" unitRef="iso4217_USD" decimals="-3" id="id_3156006_C77CE24D-02CF-400F-AF68-86C5212F8401_1001_0">550000</rgls:RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_1001_1">1176000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_2001_0">2246000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_1001_4">19569000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429_759964x775748" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_2001_0">15336000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429_759964x778268" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_3001_1">1778000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429_759964x826261" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_4001_2">1859000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429_759964x827281" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_5001_3">596000</us-gaap:Revenues>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712382x708807" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_1001_2">1411659</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_712382x708980" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_2001_1">3639270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_1_1">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_1_3">0.724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_713115x708980" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_1_4">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_1_2">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <rgls:MinorityInterestOwnershipByNoncontrollingOwnersPercentage contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_714378x823469" unitRef="pure" decimals="2" id="id_3156006_A8E837E7-7A55-4CB6-BB2A-6F9673EDF292_2001_1">0.50</rgls:MinorityInterestOwnershipByNoncontrollingOwnersPercentage>
  <rgls:FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_714938x711305" id="id_3156006_0B5F61D5-BE08-445A-A3A8-BAF2E664C4A4_1001_0">P12Y</rgls:FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_714938x766191" id="id_3156006_2741F702-D4DC-4257-84FD-E01C398F95E7_1001_0">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:NonoperatingGainsLosses contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_715757x715798" unitRef="iso4217_USD" decimals="-3" id="id_3156006_83B2BA16-5767-4BC7-A15A-DFB8CB5B8F67_1001_1">1145000</us-gaap:NonoperatingGainsLosses>
  <rgls:DeferredRevenueRecognitionPeriod contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x778268" id="id_3156006_E464BB75-E831-4CC1-8441-CEDD9804A7CA_1001_0">P8Y</rgls:DeferredRevenueRecognitionPeriod>
  <rgls:DeferredRevenueRemainingRecognitionPeriod contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x778268" id="id_3156006_E464BB75-E831-4CC1-8441-CEDD9804A7CA_1001_2">P6Y</rgls:DeferredRevenueRemainingRecognitionPeriod>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x826261" unitRef="iso4217_USD" decimals="-5" id="id_3156006_02AF28BD-BB45-4A2F-B872-6197C178E5C9_1001_4">3000000</us-gaap:ProceedsFromCollaborators>
  <rgls:CollaborativeAreasGranted contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x826261" unitRef="Agreement" decimals="0" id="id_3156006_FA6F4A18-CAD0-49AE-BE95-77B8E86D41BC_1001_0">3</rgls:CollaborativeAreasGranted>
  <rgls:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x826261" id="id_3156006_FA6F4A18-CAD0-49AE-BE95-77B8E86D41BC_1001_1">August 2012</rgls:CollaborationAndLicenseAgreementEnteredDate>
  <rgls:DeferredRevenueRemainingRecognitionPeriod contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x826261" id="id_3156006_3E6A694D-9CCD-4875-BAF4-A6DA62CAA030_1002_7">P2Y6M</rgls:DeferredRevenueRemainingRecognitionPeriod>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x827281" unitRef="iso4217_USD" decimals="-5" id="id_3156006_BAAAD986-79F4-4F22-8F7A-EECB8B4262F4_1001_1">800000</us-gaap:ProceedsFromCollaborators>
  <rgls:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x827281" id="id_3156006_BAAAD986-79F4-4F22-8F7A-EECB8B4262F4_1001_0">August 2012</rgls:CollaborationAndLicenseAgreementEnteredDate>
  <rgls:DeferredRevenueRemainingRecognitionPeriod contextRef="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x827281" id="id_3156006_71B7B13A-7970-47B6-BFBA-CFA86B919432_1002_4">P10M</rgls:DeferredRevenueRemainingRecognitionPeriod>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="shares" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_21">8212538000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="pure" decimals="2" id="id_3156006_BA8464D9-B7BA-438E-8ED3-EA04EA131E95_2_0">0.75</us-gaap:FairValueAssumptionsWeightedAverageVolatilityRate>
  <us-gaap:FairValueInputsEntityCreditRisk contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="pure" decimals="3" id="id_3156006_BA8464D9-B7BA-438E-8ED3-EA04EA131E95_2_2">0.095</us-gaap:FairValueInputsEntityCreditRisk>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_9C35609D-EB9B-45B3-BB71-960A2D47A60C_2_0">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="pure" decimals="5" id="id_3156006_BA8464D9-B7BA-438E-8ED3-EA04EA131E95_2_1">0.00421</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_18">-8721000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_2_3">3250098</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_20">-2.12</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_22">1151000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NonoperatingGainsLosses contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_13">-2969000</us-gaap:NonoperatingGainsLosses>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_18">15000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6006_900007">138000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_36">208000</us-gaap:IncomeTaxesPaid>
  <us-gaap:ProfitLoss contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_1">-17408000</us-gaap:ProfitLoss>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_20">62041000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_14">-17418000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_12">-1738000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:UnrealizedGainOnSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_4_3">7000</us-gaap:UnrealizedGainOnSecurities>
  <us-gaap:InterestPaid contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_35">8000</us-gaap:InterestPaid>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_3">12700000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_12">308000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_28">445000</us-gaap:RepaymentsOfOtherLongTermDebt>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_2_2">113000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_19">-17393000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:GainLossOnInvestments contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_7">28000</us-gaap:GainLossOnInvestments>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_8">-12574000</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_23">275000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:InterestAndOtherIncome contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_10">110000</us-gaap:InterestAndOtherIncome>
  <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_2">423000</us-gaap:IncomeTaxReconciliationTaxCredits>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_9">-36000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6006_900014">10813000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_16">-17408000</us-gaap:NetIncomeLoss>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_6">-422000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6006_900010">42691000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_38">10813000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6006_900008">1550000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_2_7">-11000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_9">-4000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_17">337000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_14">677000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_6">4932000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_30">70482000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_6">5386000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_8">1550000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_FC99C631-3F5E-4A78-B72F-3D69E2A8898E_2_0">900000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_31">31377000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_8">463000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_2_2">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_454CA124-542C-47EE-81A7-9DB05C9063BB_2_1">100000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
  <us-gaap:UnrealizedLossOnSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_4_4">49000</us-gaap:UnrealizedLossOnSecurities>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_7">25274000</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_15">-10000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_16">486000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_7">-368000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_454CA124-542C-47EE-81A7-9DB05C9063BB_2_0">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_15">-20000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_11">247000</us-gaap:InterestExpense>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_1">-1016000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_13">-189000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_27">65788000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_0">-5923000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_2_5">-9000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_26">5000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_29">139000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_2_6">-2000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_3">1017000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_8C20D543-4BE9-4D72-9105-57D953E540B5_2_0">100000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A0660148-4A96-430E-A3D4-D921ED8F4CB6_2_3">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_2_2">1550000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LeaseAndRentalExpense contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_43F3CC12-6573-40AE-A31F-2D49699BF00A_2_0">600000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_24">-30384000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2_5">20342000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_A5C45F48-9B38-4BFB-95CE-9EC7536CB326_2_21">33083000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
  <us-gaap:DefinedContributionPlanCostRecognized contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-5" id="id_3156006_F800B7F8-8ECB-4CD9-B0E5-6E1DE063A201_2_3">100000</us-gaap:DefinedContributionPlanCostRecognized>
  <rgls:IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_5">692000</rgls:IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt>
  <rgls:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_8987A700-041D-4348-8317-072E55F74BAE_2_4">1183000</rgls:IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes>
  <rgls:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5098CB39-7E3B-4AC5-B4D6-9329646B0BCA_2_1">50000</rgls:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_708873x816429" unitRef="iso4217_USD" decimals="-3" id="id_3156006_51173CF3-EEEA-4216-A853-4FF4CFEA1FD0_2002_1">12700000</us-gaap:Revenues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6003_600007">138000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6003_600014">10810000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6003_600010">42677000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6003_600008">1550000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802_714777x709629" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_7003_600013">20744000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802_714777x711552" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_8003_600011">45025000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6001_400010">13699999</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6001_400014">2703269</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6001_400007">294374</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6001_500014">3000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6001_500010">14000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713_714777x709629" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_7001_400013">6250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713_714777x709629" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_7001_500013">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713_714777x711552" unitRef="shares" decimals="INF" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_8001_400011">12730982</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713_714777x711552" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_8001_500011">13000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x715280" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6005_800016">-17408000</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x716406" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_6004_700015">15000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <rgls:MaturityPeriodOfShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_710256x709312" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_2_1">1 or less</rgls:MaturityPeriodOfShortTermInvestments>
  <rgls:MaturityPeriodOfShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_710256x712703" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_3_1">2 or less</rgls:MaturityPeriodOfShortTermInvestments>
  <us-gaap:UnrealizedGainOnSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_1_3">7000</us-gaap:UnrealizedGainOnSecurities>
  <us-gaap:UnrealizedLossOnSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_710256x712929" unitRef="iso4217_USD" decimals="-3" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_1_4">49000</us-gaap:UnrealizedLossOnSecurities>
  <rgls:MaturityPeriodOfShortTermInvestments contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_710256x712929" id="id_3156006_20D2B3D3-9491-43D3-9E2D-164482BBC47F_1_1">2 or less</rgls:MaturityPeriodOfShortTermInvestments>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_711196x710990" unitRef="shares" decimals="INF" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_6003_600006">-1249999</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesStockSplits contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_711196x710990" unitRef="shares" decimals="INF" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_6003_600005">-1250000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_711196x710990" unitRef="iso4217_USD" decimals="-3" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_6003_700006">-10000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_711196x713505" unitRef="shares" decimals="INF" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_6001_400006">-12450000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesStockSplits contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_711196x713505" unitRef="shares" decimals="INF" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_6001_400005">-12450000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_711196x713505" unitRef="iso4217_USD" decimals="-3" id="id_3156006_16BD7E7A-7561-4F73-BDD3-F8A35EB784EF_6001_500006">-32691000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <rgls:RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_711672x809276" unitRef="iso4217_USD" decimals="-3" id="id_3156006_C77CE24D-02CF-400F-AF68-86C5212F8401_1002_0">2000</rgls:RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712080x707836" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_1002_1">638000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712080x713040" unitRef="iso4217_USD" decimals="-3" id="id_3156006_360A27F4-48A8-44EF-8DFE-71904385ABD5_2002_0">912000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_1002_4">12700000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429_759964x775748" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_2002_0">10030000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429_759964x778268" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_3002_1">1996000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429_759964x826261" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_4002_2">559000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429_759964x827281" unitRef="iso4217_USD" decimals="-3" id="id_3156006_7C744418-C48C-4802-9552-26F89284D1D0_5002_3">115000</us-gaap:Revenues>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712382x708807" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_1002_2">1366787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_712382x708980" unitRef="shares" decimals="INF" id="id_3156006_B0B8368A-FA31-4FBE-95CE-76EF567EBE2C_2002_1">1883311</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_2_1">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_2_3">0.734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_713115x708980" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_2_4">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_713115x708980" unitRef="pure" decimals="3" id="id_3156006_6F8F6A42-D641-447A-BD1C-BAEC8485140F_2_2">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_714777x709629" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_7006_900013">20750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_714777x711552" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_8006_900011">45038000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE841390--1310-K0016_STD_366_20121231_0_714777x711552" unitRef="iso4217_USD" decimals="-3" id="id_3156006_B7574302-AE84-4BD1-88CE-90EA65BC754E_8006_900012">5886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE841390--1310-K0016_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_3">-0.20</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE841390--1310-K0016_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_4">-0.20</us-gaap:EarningsPerShareDiluted>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_0">3238000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_2">-7229000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_1">8788000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_91_20120331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_1_3">-13.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_1_0">3344000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_1_2">-2248000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_91_20120331_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_1_1">5525000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_91_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_2_3">-10.78</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_2_0">3309000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_2_2">-2599000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_2_1">5867000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE841390--1310-K0016_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_3">-0.20</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE841390--1310-K0016_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_4">-0.20</us-gaap:EarningsPerShareDiluted>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_0">4759000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_2">-7348000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_1">9445000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_3_3">-15.98</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_3_0">2809000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_3_2">-5685000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_92_20120930_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_3_1">6341000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE841390--1310-K0016_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_3">-0.05</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE841390--1310-K0016_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_4">-0.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_0">6118000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_2">-2164000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_1">9023000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE841390--1310-K0016_STD_92_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_4_3">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_92_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_4_0">3238000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_92_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_4_2">-6876000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_92_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_4_1">7541000</us-gaap:OperatingExpenses>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE841390--1310-K0016_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_3">-0.05</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE841390--1310-K0016_STD_92_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_4">-0.11</us-gaap:EarningsPerShareDiluted>
  <us-gaap:Revenues contextRef="eol_PE841390--1310-K0016_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_0">5454000</us-gaap:Revenues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE841390--1310-K0016_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_2">-1927000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE841390--1310-K0016_STD_92_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_1">10116000</us-gaap:OperatingExpenses>
  <context id="eol_PE841390--1310-K0016_STD_92_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_92_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_91_20120630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-04-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_91_20120331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_90_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_714777x711552">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_714777x709629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712382x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712382x708807">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429_759964x778268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429_759964x775748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712375x816429">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_711672x809276">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rgls:AlnylamMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_711196x713505">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_711196x710990">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_710256x712929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_710256x712703">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_710256x709312">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x716406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713_714777x711552">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713_714777x709629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802_714777x711552">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802_714777x709629">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0_708873x816429">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_759964x778268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_714938x766191">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rgls:LicensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_714938x711305">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_714378x823469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rgls:AprilTwoThousandEightMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712382x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712382x708807">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429_759964x778268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429_759964x775748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712375x816429">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711672x809276">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rgls:AlnylamMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x716112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_711502x711169">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_710844x707112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x717071">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x712929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x712703">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_710256x709312">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x716406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0_708873x816429">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_712382x710593">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_712382x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_712375x816429_759964x778268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_712375x816429_759964x775748">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiAventisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_712375x816429">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_712080x713040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_712080x707836">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_711672x809276">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rgls:AlnylamMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x716406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_708873x816429">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">rgls:ReferralAndStrategicAllianceAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0_708873x801067">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">rgls:GovernmentGrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_365_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x783665">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rgls:UnderwriterMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_714777x711552">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_714378x757334">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rgls:OctoberTwoThousandAndTwelveMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_713115x818265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rgls:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_711461x714242_714378x757334_759964x778268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rgls:OctoberTwoThousandAndTwelveMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_711196x713713_714378x823469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rgls:AprilTwoThousandEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_710552x710593_714777x711552">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_710552x708807_714777x711552">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_708873x825279_713115x818265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rgls:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">rgls:ScenarioTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0_708873x784846_713115x818265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rgls:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">rgls:ScenarioOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20121031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-10-01</startDate>
      <endDate>2012-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20120831_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-08-01</startDate>
      <endDate>2012-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20130731_0_711298x770834_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20130731_0_711298x726565_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:ResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20130731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_31_20120731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_30_20130630_0_759964x778268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-06-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_30_20080430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2008-04-01</startDate>
      <endDate>2008-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_28_20100228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2010-02-01</startDate>
      <endDate>2010-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_21_20140228_0_710720x714667_714777x709629_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-08</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_21_20140228_0_710720x714667_711298x770834_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-02-08</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_2_20120907_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <startDate>2012-09-06</startDate>
      <endDate>2012-09-07</endDate>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_716819x708807">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x833191">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rgls:LaboratoryEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x761833">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rgls:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x716297">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x710555">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715832x710442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715757x715798_716819x708807">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_714938x766191">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rgls:LicensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_714938x711305">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_713115x818265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rgls:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_713115x736920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rgls:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_713115x708980">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x879640_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:RegulatoryAndCommercializationMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x837394_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:PhaseTwoClinicalTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x837394_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:PhaseTwoClinicalTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x827588_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ProofofConceptTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x827588_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ProofofConceptTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x814120_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:LongitudinalStudyOfPatientSamplesOnMsTherapyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x810995_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ClinicalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x810995_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ClinicalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x810995_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ClinicalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x810995_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ClinicalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x809852_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:CommonStockPurchaseAgreementsCspaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x808515_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:DevelopmentCandidateMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x795445_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:CommercializationMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x790602_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:PreclinicalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x790602_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:PreclinicalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x790602_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:PreclinicalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x790602_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:PreclinicalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x788356_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:FourthMicroRnaTargetMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x784252_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:PhaseOneClinicalTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x784252_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:PhaseOneClinicalTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x772189_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:ValidationOfMicroRnaBiomarkerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x754265_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:RegulatoryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x754265_759964x778268_853143x832174">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:HCVAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:RegulatoryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x742023_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:CommercializationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x742023_759964x778268_853143x836413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:AgreementAxis">rgls:ImmunoInflammatoryAllianceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:CommercializationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712375x714598_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ResearchMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x717071_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x717071">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x712929_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x712929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x712703_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x712703">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x711008_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x711008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x709312_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_712021x709312">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_711298x726565_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:ResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_711196x715677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_711196x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_711196x708807">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_710844x707398">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_710844x707112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x717071">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x712929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x712703">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_710256x709312">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x716406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_707402x714598_710844x745434">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">rgls:FederalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0_707402x714598_710844x707112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_716819x708807">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x833191">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rgls:LaboratoryEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x761833">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rgls:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x716297">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x710555">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715832x710442">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715757x715798_716819x708807">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715757x715798">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_714938x766191">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rgls:LicensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_714938x711305">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x712929_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x712929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x712703_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x712703">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x711008_715757x707740">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x711008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x709312_715757x707855">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_712021x709312">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x712929">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x712703">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_710256x709312">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x716406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20111231_0_711196x713505">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20111231_0_711196x710990">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20111231_0_709650x716406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20111231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20111231_0_709650x713713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20111231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20101231_0_711196x713505">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20101231_0_711196x710990">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20101231_0_709650x716406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20101231_0_709650x715280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20101231_0_709650x710802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20130930_0_711298x770834_759964x778268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121031_0_759964x826261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:AstraZenecaMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-10-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121031_0_714378x823469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rgls:AprilTwoThousandEightMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-10-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121031_0_714378x757334">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rgls:OctoberTwoThousandAndTwelveMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-10-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121031_0_713115x818265">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rgls:EmployeeStockPurchasePlanTwentyTwelveMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-10-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121031_0_710552x734047_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">rgls:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-10-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121031_0_710552x734047_759964x778268">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">rgls:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-10-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20120831_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <instant>2012-08-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20130731_0_711298x770834_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-07-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20130628_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <instant>2013-06-28</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20120731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <instant>2012-07-31</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20131130_0_712375x879645_759964x827281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:BiogenIdecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rgls:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-11-30</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20140228_0_710720x714667_714777x709629_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20140228_0_710720x714667_711298x770834_759964x766452">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:StrategicAlliancesAxis">rgls:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rgls:DevelopmentCommercializationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-02-28</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20140207_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
    </entity>
    <period>
      <instant>2014-02-07</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121130_0_843826x823826">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:TypesOfFacilitiesAxis">rgls:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-11-30</instant>
    </period>
  </context>
  <context id="eol_PE841390--1310-K0016_STD_0_20121130_0_843826x726565">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001505512</identifier>
      <segment><xbrldi:explicitMember dimension="rgls:TypesOfFacilitiesAxis">rgls:ResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-11-30</instant>
    </period>
  </context>
  <unit id="sqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Vote">
    <measure>rgls:Vote</measure>
  </unit>
  <unit id="Segment">
    <measure>rgls:Segment</measure>
  </unit>
  <unit id="Leases">
    <measure>rgls:Leases</measure>
  </unit>
  <unit id="Agreement">
    <measure>rgls:Agreement</measure>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_1_3" xlink:label="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_1_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_2_3" xlink:label="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_2_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_3_3" xlink:label="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_3_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_4_3" xlink:label="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_4_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_3" xlink:label="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_4" xlink:label="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_3" xlink:label="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_4" xlink:label="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_3" xlink:label="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_4" xlink:label="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_3" xlink:label="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_4" xlink:label="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_4" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_230950166" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation.</xbrll:footnote>
    <xbrll:footnote xlink:label="footnote_230950171" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Applicable accounting guidance provides that a contract (such as the 2010 GSK Note) that is reported as an asset or liability for accounting purposes may require an adjustment to the numerator of the diluted earnings per share calculation for any changes in income or loss that would result if the contract had been reported as an equity instrument during the period. For these periods, adjustments were made to the numerator of the diluted earnings per share calculation to adjust net loss to remove the gain from the change in value of the convertible note payable. Adjustments to the denominator were made to add the number of shares to be issued upon conversion of the convertible note payable.</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_1_3" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_2_3" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_3_3" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_5CB0EF53-3323-4843-8222-CE6814077C5B_4_3" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_3" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_4" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_1_4" xlink:to="footnote_230950171" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_3" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_4" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_2_4" xlink:to="footnote_230950171" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_3" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_4" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_3_4" xlink:to="footnote_230950171" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_3" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_4" xlink:to="footnote_230950166" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_3156006_BBCD0C46-D140-460D-A01A-AA00BA92F629_4_4" xlink:to="footnote_230950171" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>rgls-20131231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-02-27T18:35:01Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
  xmlns:us-types="http://fasb.org/us-types/2013-01-31"
  xmlns:rgls="http://www.regulusrx.com/20131231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.regulusrx.com/20131231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen">
        <link:definition>107 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>109 - Disclosure - The Business, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>110 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
        <link:definition>111 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock">
        <link:definition>112 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>113 - Disclosure - Strategic Alliances and Collaborations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>114 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
        <link:definition>115 - Disclosure - Intangible Assets, net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>116 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>117 - Disclosure - Convertible Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>118 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDefinedContributionPlansTextBlock" id="Role_NotesToFinancialStatementsDefinedContributionPlansTextBlock">
        <link:definition>119 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>120 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>121 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
        <link:definition>122 - Disclosure - Selected Quarterly Financial Data</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>123 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies">
        <link:definition>124 - Disclosure - The Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables">
        <link:definition>125 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
        <link:definition>126 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
        <link:definition>127 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
        <link:definition>128 - Disclosure - Strategic Alliances and Collaborations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
        <link:definition>129 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
        <link:definition>130 - Disclosure - Intangible Assets, net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>131 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
        <link:definition>132 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>133 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
        <link:definition>134 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" id="Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
        <link:definition>135 - Disclosure - Selected Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>136 - Disclosure - The Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare" id="DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare">
        <link:definition>137 - Disclosure - Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation" id="DisclosureNetLossPerShareAdditionalInformation">
        <link:definition>138 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments" id="DisclosureSummaryOfShortTermInvestments">
        <link:definition>139 - Disclosure - Summary of Short-Term Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" id="DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
        <link:definition>140 - Disclosure - Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis" id="DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis">
        <link:definition>141 - Disclosure - Reconciliation of Liabilities Measured at Fair Value on Quarterly Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation" id="DisclosureFairValueMeasurementsAdditionalInformation">
        <link:definition>142 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliances" id="DisclosureRevenueFromStrategicAlliances">
        <link:definition>143 - Disclosure - Revenue from Strategic Alliances (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation" id="DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation">
        <link:definition>144 - Disclosure - Strategic Alliances and Collaborations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfPropertyAndEquipment" id="DisclosureSummaryOfPropertyAndEquipment">
        <link:definition>145 - Disclosure - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation" id="DisclosurePropertyAndEquipmentNetAdditionalInformation">
        <link:definition>146 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfIntangibleAssets" id="DisclosureSummaryOfIntangibleAssets">
        <link:definition>147 - Disclosure - Summary of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformation" id="DisclosureIntangibleAssetsNetAdditionalInformation">
        <link:definition>148 - Disclosure - Intangible Assets, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>149 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases" id="DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases">
        <link:definition>150 - Disclosure - Summary of Future Annual Minimum Lease Payments for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation" id="DisclosureConvertibleNotesPayableAdditionalInformation">
        <link:definition>151 - Disclosure - Convertible Notes Payable - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation" id="DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation">
        <link:definition>152 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance" id="DisclosureCommonStockReservedForFutureIssuance">
        <link:definition>153 - Disclosure - Common Stock Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity" id="DisclosureStockOptionActivity">
        <link:definition>154 - Disclosure - Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel" id="DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel">
        <link:definition>155 - Disclosure - Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>156 - Disclosure - Stock-Based Compensation (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformation" id="DisclosureDefinedContributionPlanAdditionalInformation">
        <link:definition>157 - Disclosure - Defined Contribution Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsIncomeTaxBenefitExpense" id="DisclosureComponentsIncomeTaxBenefitExpense">
        <link:definition>158 - Disclosure - Components Income Tax (Benefit) Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision" id="DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision">
        <link:definition>159 - Disclosure - Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsOfDeferredTaxAssetsAndLiabilities" id="DisclosureComponentsOfDeferredTaxAssetsAndLiabilities">
        <link:definition>160 - Disclosure - Components of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>161 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureChangesInAmountOfUnrecognizedTaxBenefits" id="DisclosureChangesInAmountOfUnrecognizedTaxBenefits">
        <link:definition>162 - Disclosure - Changes in Amount of Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities" id="DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities">
        <link:definition>163 - Disclosure - Summary of Operating Expenses From Related Party Activities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData" id="DisclosureSelectedQuarterlyFinancialData">
        <link:definition>164 - Disclosure - Selected Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>165 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="rgls-20131231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="rgls-20131231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="rgls-20131231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="rgls-20131231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedExpensePolicyTextBlock" id="rgls_AccruedExpensePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalTenantImprovementAllowance" id="rgls_AdditionalTenantImprovementAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgreementAxis" id="rgls_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="AgreementDomain" id="rgls_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AlnylamMember" id="rgls_AlnylamMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmendedCollaborationAndLicenseAgreementMember" id="rgls_AmendedCollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AprilTwoThousandEightMember" id="rgls_AprilTwoThousandEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AstraZenecaMember" id="rgls_AstraZenecaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BiogenIdecMember" id="rgls_BiogenIdecMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalMember" id="rgls_ClinicalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementEnteredDate" id="rgls_CollaborationAndLicenseAgreementEnteredDate" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborativeAreasGranted" id="rgls_CollaborativeAreasGranted" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommercializationMember" id="rgls_CommercializationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommercializationMilestonesMember" id="rgls_CommercializationMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesDisclosureLineItems" id="rgls_CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesDisclosureTable" id="rgls_CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CommonStockPurchaseAgreementsCspaMember" id="rgls_CommonStockPurchaseAgreementsCspaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockTransactionRestrictionPeriod" id="rgls_CommonStockTransactionRestrictionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommonStockVotesPerShare" id="rgls_CommonStockVotesPerShare" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ComponentsOfIncomeTaxExpenseBenefitLineItems" id="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ComponentsOfIncomeTaxExpenseBenefitTable" id="rgls_ComponentsOfIncomeTaxExpenseBenefitTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ComputerHardwareAndSoftwareMember" id="rgls_ComputerHardwareAndSoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertibleNotesMember" id="rgls_ConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentsAmendmentDate" id="rgls_DebtInstrumentsAmendmentDate" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentsMaturityDateMonthAndYear" id="rgls_DebtInstrumentsMaturityDateMonthAndYear" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRevenueRecognitionPeriod" id="rgls_DeferredRevenueRecognitionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRevenueRemainingRecognitionPeriod" id="rgls_DeferredRevenueRemainingRecognitionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" id="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation" id="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DefinedContributionPlansTextBlock" id="rgls_DefinedContributionPlansTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentCandidateMember" id="rgls_DevelopmentCandidateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentCommercializationAndLicenseAgreementMember" id="rgls_DevelopmentCommercializationAndLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="rgls_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeStockPurchasePlanTwentyTwelveMember" id="rgls_EmployeeStockPurchasePlanTwentyTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityLineItems" id="rgls_EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityTable" id="rgls_EquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ExtensionPeriodOfOperatingLease" id="rgls_ExtensionPeriodOfOperatingLease" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueInputsPeriod" id="rgls_FairValueInputsPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FederalMember" id="rgls_FederalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FinitelivedIntangibleAssetsAndLiabilitiesLineItems" id="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife" id="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FourthMicroRnaTargetMember" id="rgls_FourthMicroRnaTargetMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GovernmentGrantMember" id="rgls_GovernmentGrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GskMember" id="rgls_GskMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="HCVAllianceMember" id="rgls_HCVAllianceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ImmunoInflammatoryAllianceMember" id="rgls_ImmunoInflammatoryAllianceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxRateReconciliationLineItems" id="rgls_IncomeTaxRateReconciliationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxRateReconciliationTable" id="rgls_IncomeTaxRateReconciliationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" id="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" id="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LaboratoryEquipmentMember" id="rgls_LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseExpirationMonthAndYear" id="rgls_LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeasesFutureMinimumPaymentsLineItems" id="rgls_LeasesFutureMinimumPaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeasesFutureMinimumPaymentsTable" id="rgls_LeasesFutureMinimumPaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LeaseTerminationNoticePeriod" id="rgls_LeaseTerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicensesMember" id="rgls_LicensesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LongitudinalStudyOfPatientSamplesOnMsTherapyMember" id="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaturityPeriodOfShortTermInvestments" id="rgls_MaturityPeriodOfShortTermInvestments" type="us-types:durationStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinorityInterestOwnershipByNoncontrollingOwnersPercentage" id="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum" id="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetProceedsFromIssuanceOfConvertibleNotesPayable" id="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfLeaseExtensionOptions" id="rgls_NumberOfLeaseExtensionOptions" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OctoberTwoThousandAndTwelveMember" id="rgls_OctoberTwoThousandAndTwelveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OfficeAndLaboratorySpaceMember" id="rgls_OfficeAndLaboratorySpaceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardExpirationYear" id="rgls_OperatingLossCarryforwardExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OptionalLeaseTerminationDateMonthAndYear" id="rgls_OptionalLeaseTerminationDateMonthAndYear" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" id="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PhaseOneClinicalTrialMember" id="rgls_PhaseOneClinicalTrialMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PhaseTwoClinicalTrialMember" id="rgls_PhaseTwoClinicalTrialMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreclinicalMember" id="rgls_PreclinicalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProofofConceptTrialMember" id="rgls_ProofofConceptTrialMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReferralAndStrategicAllianceAgreementMember" id="rgls_ReferralAndStrategicAllianceAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulatoryAndCommercializationMilestonesMember" id="rgls_RegulatoryAndCommercializationMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RegulatoryMember" id="rgls_RegulatoryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty" id="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentMember" id="rgls_ResearchAndDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentPlanExpectedTerm" id="rgls_ResearchAndDevelopmentPlanExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueFromStrategicAlliancesTableTextBlock" id="rgls_RevenueFromStrategicAlliancesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" id="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognitionPeriod" id="rgls_RevenueRecognitionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyPercentageBasedOnNetSales" id="rgls_RoyaltyPercentageBasedOnNetSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SanofiAventisMember" id="rgls_SanofiAventisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SanofiMember" id="rgls_SanofiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScenarioOneMember" id="rgls_ScenarioOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScenarioTwoMember" id="rgls_ScenarioTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" id="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" id="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ScheduleOfEarningsPerShareBasicAndDilutedLineItems" id="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfEarningsPerShareBasicAndDilutedTable" id="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ScheduleOfIncomeTaxesLineItems" id="rgls_ScheduleOfIncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfIncomeTaxesTable" id="rgls_ScheduleOfIncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" id="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" id="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SelectedQuarterlyFinancialDataLineItems" id="rgls_SelectedQuarterlyFinancialDataLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SelectedQuarterlyFinancialDataTable" id="rgls_SelectedQuarterlyFinancialDataTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" id="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" id="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" id="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" id="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShortTermInvestmentsAmortizedCost" id="rgls_ShortTermInvestmentsAmortizedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StrategicAlliancesAxis" id="rgls_StrategicAlliancesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="StrategicAlliancesDomain" id="rgls_StrategicAlliancesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TenantImprovementAllowance" id="rgls_TenantImprovementAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TenantImprovementAllowanceInterestRatePercentage" id="rgls_TenantImprovementAllowanceInterestRatePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TermOfDebtInstrument" id="rgls_TermOfDebtInstrument" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandTwelveEquityIncentivePlanMember" id="rgls_TwoThousandTwelveEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TypesOfFacilitiesAxis" id="rgls_TypesOfFacilitiesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="TypesOfFacilitiesDomain" id="rgls_TypesOfFacilitiesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UncategorizedAbstract" id="rgls_UncategorizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnderwriterMember" id="rgls_UnderwriterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" id="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" id="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ValidationOfMicroRnaBiomarkerMember" id="rgls_ValidationOfMicroRnaBiomarkerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>rgls-20131231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-02-27T18:35:01Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DocumentandEntityInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureNetLossPerShareAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfShortTermInvestments" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureRevenueFromStrategicAlliances" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliances"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfPropertyAndEquipment" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfIntangibleAssets" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfIntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureIntangibleAssetsNetAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureConvertibleNotesPayableAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureCommonStockReservedForFutureIssuance" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStockOptionActivity" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureDefinedContributionPlanAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureComponentsIncomeTaxBenefitExpense" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsIncomeTaxBenefitExpense"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureChangesInAmountOfUnrecognizedTaxBenefits" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureChangesInAmountOfUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSelectedQuarterlyFinancialData" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsDefinedContributionPlansTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDefinedContributionPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndOtherIncome" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0500" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt" order="1.2400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.2000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnInvestments" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.1500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliances">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfIntangibleAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsIncomeTaxBenefitExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:label="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" xlink:label="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="1.1000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0900" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureChangesInAmountOfUnrecognizedTaxBenefits">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDefinedContributionPlansTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>rgls-20131231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-02-27T18:35:01Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DocumentandEntityInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureNetLossPerShareAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfShortTermInvestments" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureRevenueFromStrategicAlliances" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliances"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfPropertyAndEquipment" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfIntangibleAssets" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfIntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureIntangibleAssetsNetAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureConvertibleNotesPayableAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureCommonStockReservedForFutureIssuance" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStockOptionActivity" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureDefinedContributionPlanAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureComponentsIncomeTaxBenefitExpense" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsIncomeTaxBenefitExpense"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureChangesInAmountOfUnrecognizedTaxBenefits" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureChangesInAmountOfUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSelectedQuarterlyFinancialData" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsDefinedContributionPlansTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDefinedContributionPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GovernmentGrantMember" xlink:label="rgls_GovernmentGrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ReferralAndStrategicAllianceAgreementMember" xlink:label="rgls_ReferralAndStrategicAllianceAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="rgls_ReferralAndStrategicAllianceAgreementMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="rgls_GovernmentGrantMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TenantImprovementAllowance" xlink:label="rgls_TenantImprovementAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rgls_TenantImprovementAllowance" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife" xlink:label="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LicensesMember" xlink:label="rgls_LicensesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="rgls_LicensesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="invest_InvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="invest_InvestmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_MaturityPeriodOfShortTermInvestments" xlink:label="rgls_MaturityPeriodOfShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShortTermInvestmentsAmortizedCost" xlink:label="rgls_ShortTermInvestmentsAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainOnSecurities" xlink:label="us-gaap_UnrealizedGainOnSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedLossOnSecurities" xlink:label="us-gaap_UnrealizedLossOnSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="invest_InvestmentLineItems" xlink:to="invest_InvestmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="rgls_MaturityPeriodOfShortTermInvestments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="rgls_ShortTermInvestmentsAmortizedCost" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="us-gaap_UnrealizedGainOnSecurities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="us-gaap_UnrealizedLossOnSecurities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="invest_InvestmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="invest_InvestmentTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.1200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsEntityCreditRisk" xlink:label="us-gaap_FairValueInputsEntityCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueInputsEntityCreditRisk" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliances">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AstraZenecaMember" xlink:label="rgls_AstraZenecaMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_BiogenIdecMember" xlink:label="rgls_BiogenIdecMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ReferralAndStrategicAllianceAgreementMember" xlink:label="rgls_ReferralAndStrategicAllianceAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SanofiAventisMember" xlink:label="rgls_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_ReferralAndStrategicAllianceAgreementMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="rgls_StrategicAlliancesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_SanofiAventisMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_GskMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_AstraZenecaMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_BiogenIdecMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AgreementAxis" xlink:label="rgls_AgreementAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AgreementDomain" xlink:label="rgls_AgreementDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AgreementDomain" xlink:label="rgls_AgreementDomain_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AmendedCollaborationAndLicenseAgreementMember" xlink:label="rgls_AmendedCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AstraZenecaMember" xlink:label="rgls_AstraZenecaMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_BiogenIdecMember" xlink:label="rgls_BiogenIdecMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ClinicalMember" xlink:label="rgls_ClinicalMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CollaborationAndLicenseAgreementEnteredDate" xlink:label="rgls_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CollaborativeAreasGranted" xlink:label="rgls_CollaborativeAreasGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommercializationMember" xlink:label="rgls_CommercializationMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommercializationMilestonesMember" xlink:label="rgls_CommercializationMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockPurchaseAgreementsCspaMember" xlink:label="rgls_CommonStockPurchaseAgreementsCspaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockTransactionRestrictionPeriod" xlink:label="rgls_CommonStockTransactionRestrictionPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerAdvancesCurrent" xlink:label="us-gaap_CustomerAdvancesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredRevenueRecognitionPeriod" xlink:label="rgls_DeferredRevenueRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredRevenueRemainingRecognitionPeriod" xlink:label="rgls_DeferredRevenueRemainingRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DevelopmentCandidateMember" xlink:label="rgls_DevelopmentCandidateMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:label="rgls_DevelopmentCommercializationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FairValueInputsPeriod" xlink:label="rgls_FairValueInputsPeriod"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FourthMicroRnaTargetMember" xlink:label="rgls_FourthMicroRnaTargetMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_HCVAllianceMember" xlink:label="rgls_HCVAllianceMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ImmunoInflammatoryAllianceMember" xlink:label="rgls_ImmunoInflammatoryAllianceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember" xlink:label="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PhaseOneClinicalTrialMember" xlink:label="rgls_PhaseOneClinicalTrialMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PhaseTwoClinicalTrialMember" xlink:label="rgls_PhaseTwoClinicalTrialMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PreclinicalMember" xlink:label="rgls_PreclinicalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ProofofConceptTrialMember" xlink:label="rgls_ProofofConceptTrialMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="us-gaap_RecognitionOfDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RegulatoryAndCommercializationMilestonesMember" xlink:label="rgls_RegulatoryAndCommercializationMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RegulatoryMember" xlink:label="rgls_RegulatoryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ResearchAndDevelopmentMember" xlink:label="rgls_ResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ResearchAndDevelopmentPlanExpectedTerm" xlink:label="rgls_ResearchAndDevelopmentPlanExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueRecognitionPeriod" xlink:label="rgls_RevenueRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RoyaltyPercentageBasedOnNetSales" xlink:label="rgls_RoyaltyPercentageBasedOnNetSales"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SanofiMember" xlink:label="rgls_SanofiMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ValidationOfMicroRnaBiomarkerMember" xlink:label="rgls_ValidationOfMicroRnaBiomarkerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="rgls_AgreementAxis" xlink:to="rgls_AgreementDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="rgls_AgreementAxis" xlink:to="rgls_AgreementDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_AgreementDomain" xlink:to="rgls_HCVAllianceMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_AgreementDomain" xlink:to="rgls_ImmunoInflammatoryAllianceMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_PreclinicalMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_ClinicalMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_RegulatoryMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_CommercializationMilestonesMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ResearchMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_RegulatoryAndCommercializationMilestonesMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_CommercializationMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_FourthMicroRnaTargetMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_DevelopmentCandidateMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_PhaseOneClinicalTrialMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_PhaseTwoClinicalTrialMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_ProofofConceptTrialMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_CommonStockPurchaseAgreementsCspaMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_AmendedCollaborationAndLicenseAgreementMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_ValidationOfMicroRnaBiomarkerMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CustomerAdvancesCurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RecognitionOfDeferredRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_RoyaltyPercentageBasedOnNetSales" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_DeferredRevenueRecognitionPeriod" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_DeferredRevenueRemainingRecognitionPeriod" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdjustmentForAmortization" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_CollaborativeAreasGranted" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_CollaborationAndLicenseAgreementEnteredDate" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_ResearchAndDevelopmentPlanExpectedTerm" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockValue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_CommonStockTransactionRestrictionPeriod" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_FairValueInputsPeriod" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_RevenueRecognitionPeriod" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rgls_DevelopmentCommercializationAndLicenseAgreementMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rgls_ResearchAndDevelopmentMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="rgls_StrategicAlliancesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="rgls_AgreementAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_GskMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_AstraZenecaMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_BiogenIdecMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_SanofiMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComputerHardwareAndSoftwareMember" xlink:label="rgls_ComputerHardwareAndSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LaboratoryEquipmentMember" xlink:label="rgls_LaboratoryEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rgls_LaboratoryEquipmentMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rgls_ComputerHardwareAndSoftwareMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfIntangibleAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LicensesMember" xlink:label="rgls_LicensesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="rgls_LicensesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:label="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AdditionalTenantImprovementAllowance" xlink:label="rgls_AdditionalTenantImprovementAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="rgls_CommitmentsAndContingenciesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommitmentsAndContingenciesDisclosureTable" xlink:label="rgls_CommitmentsAndContingenciesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ExtensionPeriodOfOperatingLease" xlink:label="rgls_ExtensionPeriodOfOperatingLease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeaseExpirationMonthAndYear" xlink:label="rgls_LeaseExpirationMonthAndYear"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeaseTerminationNoticePeriod" xlink:label="rgls_LeaseTerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NumberOfLeaseExtensionOptions" xlink:label="rgls_NumberOfLeaseExtensionOptions"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OfficeAndLaboratorySpaceMember" xlink:label="rgls_OfficeAndLaboratorySpaceMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OptionalLeaseTerminationDateMonthAndYear" xlink:label="rgls_OptionalLeaseTerminationDateMonthAndYear"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ResearchAndDevelopmentMember" xlink:label="rgls_ResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TenantImprovementAllowance" xlink:label="rgls_TenantImprovementAllowance"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TenantImprovementAllowanceInterestRatePercentage" xlink:label="rgls_TenantImprovementAllowanceInterestRatePercentage"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TypesOfFacilitiesAxis" xlink:label="rgls_TypesOfFacilitiesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TypesOfFacilitiesDomain" xlink:label="rgls_TypesOfFacilitiesDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TypesOfFacilitiesDomain" xlink:label="rgls_TypesOfFacilitiesDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_CommitmentsAndContingenciesDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_LeaseExpirationMonthAndYear" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_OptionalLeaseTerminationDateMonthAndYear" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_LeaseTerminationNoticePeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_NumberOfLeaseExtensionOptions" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_ExtensionPeriodOfOperatingLease" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_IncentiveFromLessor" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_TenantImprovementAllowance" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_AdditionalTenantImprovementAllowance" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_TenantImprovementAllowanceInterestRatePercentage" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_CommitmentsAndContingenciesDisclosureTable" xlink:to="rgls_TypesOfFacilitiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="rgls_TypesOfFacilitiesAxis" xlink:to="rgls_TypesOfFacilitiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="rgls_TypesOfFacilitiesAxis" xlink:to="rgls_TypesOfFacilitiesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_TypesOfFacilitiesDomain" xlink:to="rgls_OfficeAndLaboratorySpaceMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_TypesOfFacilitiesDomain" xlink:to="rgls_ResearchAndDevelopmentMember" order="1.1500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeasesFutureMinimumPaymentsLineItems" xlink:label="rgls_LeasesFutureMinimumPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeasesFutureMinimumPaymentsTable" xlink:label="rgls_LeasesFutureMinimumPaymentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="rgls_LeasesFutureMinimumPaymentsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_LeasesFutureMinimumPaymentsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AprilTwoThousandEightMember" xlink:label="rgls_AprilTwoThousandEightMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DebtInstrumentsAmendmentDate" xlink:label="rgls_DebtInstrumentsAmendmentDate"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DebtInstrumentsMaturityDateMonthAndYear" xlink:label="rgls_DebtInstrumentsMaturityDateMonthAndYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage" xlink:label="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OctoberTwoThousandAndTwelveMember" xlink:label="rgls_OctoberTwoThousandAndTwelveMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TermOfDebtInstrument" xlink:label="rgls_TermOfDebtInstrument"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_TermOfDebtInstrument" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_DebtInstrumentsAmendmentDate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesIssued1" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_DebtInstrumentsMaturityDateMonthAndYear" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="rgls_StrategicAlliancesAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rgls_AprilTwoThousandEightMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rgls_OctoberTwoThousandAndTwelveMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_GskMember" order="1.2000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AstraZenecaMember" xlink:label="rgls_AstraZenecaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_BiogenIdecMember" xlink:label="rgls_BiogenIdecMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockVotesPerShare" xlink:label="rgls_CommonStockVotesPerShare"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ConvertibleNotesMember" xlink:label="rgls_ConvertibleNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:label="rgls_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScenarioOneMember" xlink:label="rgls_ScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScenarioTwoMember" xlink:label="rgls_ScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="rgls_TwoThousandTwelveEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnderwriterMember" xlink:label="rgls_UnderwriterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rgls_CommonStockVotesPerShare" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="rgls_ConvertibleNotesMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rgls_AstraZenecaMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rgls_UnderwriterMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="rgls_ScenarioOneMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="rgls_ScenarioTwoMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="rgls_StrategicAlliancesAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ShareholdersEquityClassAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rgls_TwoThousandTwelveEquityIncentivePlanMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rgls_EmployeeStockPurchasePlanTwentyTwelveMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_GskMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_BiogenIdecMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EquityLineItems" xlink:label="rgls_EquityLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EquityTable" xlink:label="rgls_EquityTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_EquityLineItems" xlink:to="rgls_EquityTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_EquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_EquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_EquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_EquityTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_EquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation" xlink:label="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsIncomeTaxBenefitExpense">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComponentsOfIncomeTaxExpenseBenefitTable" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="rgls_ComponentsOfIncomeTaxExpenseBenefitTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxRateReconciliationLineItems" xlink:label="rgls_IncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxRateReconciliationTable" xlink:label="rgls_IncomeTaxRateReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:label="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" xlink:label="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="rgls_IncomeTaxRateReconciliationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_IncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FederalMember" xlink:label="rgls_FederalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum" xlink:label="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OperatingLossCarryforwardExpirationYear" xlink:label="rgls_OperatingLossCarryforwardExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfIncomeTaxesLineItems" xlink:label="rgls_ScheduleOfIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfIncomeTaxesTable" xlink:label="rgls_ScheduleOfIncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:label="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="rgls_FederalMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="rgls_ScheduleOfIncomeTaxesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="rgls_OperatingLossCarryforwardExpirationYear" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="1.1200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureChangesInAmountOfUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AlnylamMember" xlink:label="rgls_AlnylamMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty" xlink:label="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rgls_AlnylamMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SelectedQuarterlyFinancialDataLineItems" xlink:label="rgls_SelectedQuarterlyFinancialDataLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SelectedQuarterlyFinancialDataTable" xlink:label="rgls_SelectedQuarterlyFinancialDataTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="rgls_SelectedQuarterlyFinancialDataTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_Revenues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_OperatingExpenses" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rgls_SelectedQuarterlyFinancialDataTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerAdvancesCurrent" xlink:label="us-gaap_CustomerAdvancesCurrent"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:label="rgls_DevelopmentCommercializationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SanofiMember" xlink:label="rgls_SanofiMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rgls_DevelopmentCommercializationAndLicenseAgreementMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_SanofiMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CustomerAdvancesCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="rgls_StrategicAlliancesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AccruedExpensePolicyTextBlock" xlink:label="rgls_AccruedExpensePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rgls_AccruedExpensePolicyTextBlock" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueFromStrategicAlliancesTableTextBlock" xlink:label="rgls_RevenueFromStrategicAlliancesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rgls_RevenueFromStrategicAlliancesTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:label="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDefinedContributionPlansTextBlock">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DefinedContributionPlansTextBlock" xlink:label="rgls_DefinedContributionPlansTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rgls_DefinedContributionPlansTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>rgls-20131231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-02-27T18:35:01Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_3156006_713053_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_3156006_713053_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" id="id_3156006_721418_1_1">Accounts And Other Receivables Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" id="id_3156006_721418_2_1">Contracts and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_3156006_718248_1_1">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_3156006_718248_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" id="id_3156006_720531_1_1">Accretion Amortization Of Discounts And Premiums Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" id="id_3156006_720531_14_1">Amortization of premium on investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AccruedExpensePolicyTextBlock" xlink:label="rgls_AccruedExpensePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_AccruedExpensePolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_812879_3_1">Accrued Expense [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_AccruedExpensePolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_812879_1_1">Accrued Expense Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_AccruedExpensePolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_812879_2_1">Clinical Trial and Pre-Clinical Study Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_AccruedExpensePolicyTextBlock" xlink:to="rgls_AccruedExpensePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3156006_719377_1_1">Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3156006_719377_2_1">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3156006_717952_1_1">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3156006_717952_14_1">Less accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_3156006_717591_1_1">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_3156006_717591_2_1">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_3156006_716406_1_1">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_3156006_716406_2_1">Accumulated other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_3156006_718196_1_1">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_3156006_718196_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_3156006_710802_1_1">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_3156006_710802_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AdditionalTenantImprovementAllowance" xlink:label="rgls_AdditionalTenantImprovementAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_AdditionalTenantImprovementAllowance_lbl" xml:lang="en-US" id="id_3156006_847238_3_1">Additional Tenant Improvement Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_AdditionalTenantImprovementAllowance_lbl" xml:lang="en-US" id="id_3156006_847238_1_1">Additional Tenant Improvement Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_AdditionalTenantImprovementAllowance_lbl" xml:lang="en-US" id="id_3156006_847238_2_1">Additional Tenant Improvement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_AdditionalTenantImprovementAllowance" xlink:to="rgls_AdditionalTenantImprovementAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US" id="id_3156006_722798_1_1">Adjustment For Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US" id="id_3156006_722798_2_1">Acceleration of remaining amortization of upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_3156006_720768_1_1">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_3156006_720768_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" id="id_3156006_724847_1_1">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" id="id_3156006_724847_2_1">Issuance of common stock,offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3156006_715215_1_1">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3156006_715215_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AgreementAxis" xlink:label="rgls_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_AgreementAxis_lbl" xml:lang="en-US" id="id_3156006_853143_3_1">Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_AgreementAxis_lbl" xml:lang="en-US" id="id_3156006_853143_1_1">Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_AgreementAxis_lbl" xml:lang="en-US" id="id_3156006_853143_2_1">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_AgreementAxis" xlink:to="rgls_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AgreementDomain" xlink:label="rgls_AgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_AgreementDomain_lbl" xml:lang="en-US" id="id_3156006_853188_3_1">Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_AgreementDomain_lbl" xml:lang="en-US" id="id_3156006_853188_1_1">Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_AgreementDomain_lbl" xml:lang="en-US" id="id_3156006_853188_2_1">Agreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_AgreementDomain" xlink:to="rgls_AgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_3156006_723905_1_1">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_3156006_723905_2_1">Stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AlnylamMember" xlink:label="rgls_AlnylamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_AlnylamMember_lbl" xml:lang="en-US" id="id_3156006_809276_3_1">Alnylam [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_AlnylamMember_lbl" xml:lang="en-US" id="id_3156006_809276_1_1">Alnylam [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_AlnylamMember_lbl" xml:lang="en-US" id="id_3156006_809276_2_1">Alnylam</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_AlnylamMember" xlink:to="rgls_AlnylamMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AmendedCollaborationAndLicenseAgreementMember" xlink:label="rgls_AmendedCollaborationAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_AmendedCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_3156006_879645_3_1">Amended Collaboration and License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_AmendedCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_3156006_879645_1_1">Amended Collaboration And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_AmendedCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_3156006_879645_2_1">Amended Collaboration and License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_AmendedCollaborationAndLicenseAgreementMember" xlink:to="rgls_AmendedCollaborationAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_3156006_705992_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_3156006_705992_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="id_3156006_723715_1_1">Amortization Of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="id_3156006_723715_2_1">Amortization of intangible asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_3156006_714738_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_3156006_714738_2_1">Potentially dilutive securities not included in calculation of diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_3156006_712382_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_3156006_712382_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_3156006_716454_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_3156006_716454_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_3156006_709542_1_1">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_3156006_709542_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AprilTwoThousandEightMember" xlink:label="rgls_AprilTwoThousandEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_AprilTwoThousandEightMember_lbl" xml:lang="en-US" id="id_3156006_823469_3_1">April Two Thousand Eight</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_AprilTwoThousandEightMember_lbl" xml:lang="en-US" id="id_3156006_823469_1_1">April Two Thousand Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_AprilTwoThousandEightMember_lbl" xml:lang="en-US" id="id_3156006_823469_2_1">April 2008</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_AprilTwoThousandEightMember" xlink:to="rgls_AprilTwoThousandEightMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" id="id_3156006_713392_1_1">Area Of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" id="id_3156006_713392_2_1">Area of facility under operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_3156006_713740_1_1">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_3156006_713740_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_3156006_722688_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_3156006_722688_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_3156006_712527_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_3156006_712527_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_3156006_724901_1_1">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_3156006_724901_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_3156006_708149_1_1">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_3156006_708149_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_3156006_722101_1_1">Assets Fair Value Disclosure Recurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_3156006_722101_2_1">Assets measured at fair value on a recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureRecurring" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AstraZenecaMember" xlink:label="rgls_AstraZenecaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_AstraZenecaMember_lbl" xml:lang="en-US" id="id_3156006_826261_3_1">Astra Zeneca</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_AstraZenecaMember_lbl" xml:lang="en-US" id="id_3156006_826261_1_1">Astra Zeneca [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_AstraZenecaMember_lbl" xml:lang="en-US" id="id_3156006_826261_2_1">Astra Zeneca</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_AstraZenecaMember" xlink:to="rgls_AstraZenecaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_3156006_713115_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_3156006_713115_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_BiogenIdecMember" xlink:label="rgls_BiogenIdecMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_BiogenIdecMember_lbl" xml:lang="en-US" id="id_3156006_827281_3_1">Biogen Idec</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_BiogenIdecMember_lbl" xml:lang="en-US" id="id_3156006_827281_1_1">Biogen Idec [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_BiogenIdecMember_lbl" xml:lang="en-US" id="id_3156006_827281_2_1">Biogen Idec</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_BiogenIdecMember" xlink:to="rgls_BiogenIdecMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US" id="id_3156006_707112_1_1">C A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_CA_lbl" xml:lang="en-US" id="id_3156006_707112_2_1">California</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3156006_722785_1_1">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3156006_722785_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3156006_722785_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_3156006_722785_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3156006_721794_1_1">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_3156006_721794_6_1">Net (decrease) increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_712759_1_1">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_712759_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" id="id_3156006_711008_1_1">Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" id="id_3156006_711008_2_1">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" id="id_3156006_709312_1_1">Certificates Of Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" id="id_3156006_709312_2_1">Certificates of Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_3156006_710800_1_1">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_3156006_710800_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_3156006_707608_1_1">Class Of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_3156006_707608_2_1">Class of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ClinicalMember" xlink:label="rgls_ClinicalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ClinicalMember_lbl" xml:lang="en-US" id="id_3156006_810995_3_1">Clinical</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ClinicalMember_lbl" xml:lang="en-US" id="id_3156006_810995_1_1">Clinical [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ClinicalMember_lbl" xml:lang="en-US" id="id_3156006_810995_2_1">Clinical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ClinicalMember" xlink:to="rgls_ClinicalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CollaborationAndLicenseAgreementEnteredDate" xlink:label="rgls_CollaborationAndLicenseAgreementEnteredDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_3156006_813800_3_1">Collaboration and License Agreement Entered Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_3156006_813800_1_1">Collaboration And License Agreement Entered Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_3156006_813800_2_1">Collaboration and license agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CollaborationAndLicenseAgreementEnteredDate" xlink:to="rgls_CollaborationAndLicenseAgreementEnteredDate_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CollaborativeAreasGranted" xlink:label="rgls_CollaborativeAreasGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CollaborativeAreasGranted_lbl" xml:lang="en-US" id="id_3156006_748954_3_1">Collaborative Areas Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CollaborativeAreasGranted_lbl" xml:lang="en-US" id="id_3156006_748954_1_1">Collaborative Areas Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CollaborativeAreasGranted_lbl" xml:lang="en-US" id="id_3156006_748954_2_1">Number of collaborative areas granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CollaborativeAreasGranted" xlink:to="rgls_CollaborativeAreasGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_708343_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_708343_2_1">Strategic Alliances and Collaborations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_3156006_716948_1_1">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_3156006_716948_2_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommercializationMember" xlink:label="rgls_CommercializationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CommercializationMember_lbl" xml:lang="en-US" id="id_3156006_742023_3_1">Commercialization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CommercializationMember_lbl" xml:lang="en-US" id="id_3156006_742023_1_1">Commercialization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CommercializationMember_lbl" xml:lang="en-US" id="id_3156006_742023_2_1">Commercialization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CommercializationMember" xlink:to="rgls_CommercializationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommercializationMilestonesMember" xlink:label="rgls_CommercializationMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CommercializationMilestonesMember_lbl" xml:lang="en-US" id="id_3156006_795445_3_1">Commercialization Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CommercializationMilestonesMember_lbl" xml:lang="en-US" id="id_3156006_795445_1_1">Commercialization Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CommercializationMilestonesMember_lbl" xml:lang="en-US" id="id_3156006_795445_2_1">Commercialization Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CommercializationMilestonesMember" xlink:to="rgls_CommercializationMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" id="id_3156006_712703_1_1">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" id="id_3156006_712703_2_1">Commercial Paper</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_716008_1_1">Commitments And Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_716008_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="rgls_CommitmentsAndContingenciesDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US" id="id_3156006_806031_3_1">Commitments and Contingencies Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US" id="id_3156006_806031_1_1">Commitments And Contingencies Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US" id="id_3156006_806031_2_1">Commitments and Contingencies Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommitmentsAndContingenciesDisclosureTable" xlink:label="rgls_CommitmentsAndContingenciesDisclosureTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CommitmentsAndContingenciesDisclosureTable_lbl" xml:lang="en-US" id="id_3156006_785276_3_1">Commitments and Contingencies Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CommitmentsAndContingenciesDisclosureTable_lbl" xml:lang="en-US" id="id_3156006_785276_1_1">Commitments And Contingencies Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CommitmentsAndContingenciesDisclosureTable_lbl" xml:lang="en-US" id="id_3156006_785276_2_1">Commitments and Contingencies Disclosure [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CommitmentsAndContingenciesDisclosureTable" xlink:to="rgls_CommitmentsAndContingenciesDisclosureTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_716962_1_1">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_716962_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_3156006_707883_1_1">Common Stock Capital Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_3156006_707883_2_1">Total common shares reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_3156006_713713_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_3156006_713713_2_1">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_3156006_714811_1_1">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_3156006_714811_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockPurchaseAgreementsCspaMember" xlink:label="rgls_CommonStockPurchaseAgreementsCspaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CommonStockPurchaseAgreementsCspaMember_lbl" xml:lang="en-US" id="id_3156006_809852_3_1">Common Stock Purchase Agreements Cspa [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CommonStockPurchaseAgreementsCspaMember_lbl" xml:lang="en-US" id="id_3156006_809852_1_1">Common Stock Purchase Agreements Cspa [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CommonStockPurchaseAgreementsCspaMember_lbl" xml:lang="en-US" id="id_3156006_809852_2_1">Common Stock Purchase Agreements Cspa</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CommonStockPurchaseAgreementsCspaMember" xlink:to="rgls_CommonStockPurchaseAgreementsCspaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3156006_713746_1_1">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3156006_713746_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_3156006_707767_1_1">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_3156006_707767_2_1">Common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_3156006_707767_12_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_716560_1_1">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_716560_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockTransactionRestrictionPeriod" xlink:label="rgls_CommonStockTransactionRestrictionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CommonStockTransactionRestrictionPeriod_lbl" xml:lang="en-US" id="id_3156006_775560_3_1">Common Stock Transaction Restriction Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CommonStockTransactionRestrictionPeriod_lbl" xml:lang="en-US" id="id_3156006_775560_1_1">Common Stock Transaction Restriction Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CommonStockTransactionRestrictionPeriod_lbl" xml:lang="en-US" id="id_3156006_775560_2_1">Number of days during which AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CommonStockTransactionRestrictionPeriod" xlink:to="rgls_CommonStockTransactionRestrictionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_3156006_720509_1_1">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_3156006_720509_2_1">Common stock issue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_3156006_720509_12_1">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2013 and 2012, 41,787,326 and 35,831,808 shares issued and outstanding at December 31, 2013 and 2012, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockVotesPerShare" xlink:label="rgls_CommonStockVotesPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_CommonStockVotesPerShare_lbl" xml:lang="en-US" id="id_3156006_776259_3_1">Common Stock, Votes per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_CommonStockVotesPerShare_lbl" xml:lang="en-US" id="id_3156006_776259_1_1">Common Stock Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_CommonStockVotesPerShare_lbl" xml:lang="en-US" id="id_3156006_776259_2_1">Number of votes of each share of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_CommonStockVotesPerShare" xlink:to="rgls_CommonStockVotesPerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems_lbl" xml:lang="en-US" id="id_3156006_767750_3_1">Components Of Income Tax Expense Benefit [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems_lbl" xml:lang="en-US" id="id_3156006_767750_1_1">Components Of Income Tax Expense Benefit [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems_lbl" xml:lang="en-US" id="id_3156006_767750_2_1">Components Of Income Tax Expense Benefit [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComponentsOfIncomeTaxExpenseBenefitTable" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitTable_lbl" xml:lang="en-US" id="id_3156006_740774_3_1">Components Of Income Tax Expense Benefit [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitTable_lbl" xml:lang="en-US" id="id_3156006_740774_1_1">Components Of Income Tax Expense Benefit [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitTable_lbl" xml:lang="en-US" id="id_3156006_740774_2_1">Components Of Income Tax Expense Benefit [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitTable" xlink:to="rgls_ComponentsOfIncomeTaxExpenseBenefitTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_3156006_719607_1_1">Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_3156006_719607_6_1">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_709116_1_1">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_709116_2_1">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComputerHardwareAndSoftwareMember" xlink:label="rgls_ComputerHardwareAndSoftwareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" id="id_3156006_761833_3_1">Computer Hardware And Software</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" id="id_3156006_761833_1_1">Computer Hardware And Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" id="id_3156006_761833_2_1">Computer Equipment and Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ComputerHardwareAndSoftwareMember" xlink:to="rgls_ComputerHardwareAndSoftwareMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_3156006_713809_1_1">Concentration Risk Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_3156006_713809_2_1">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" id="id_3156006_710555_1_1">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" id="id_3156006_710555_2_1">Construction in Progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" id="id_3156006_720537_1_1">Convertible Debt Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" id="id_3156006_720537_2_1">Convertible note payable, at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US" id="id_3156006_720537_12_1">Convertible notes payable, at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" id="id_3156006_714242_1_1">Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" id="id_3156006_714242_2_1">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" id="id_3156006_719862_1_1">Convertible Long Term Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" id="id_3156006_719862_2_1">Convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US" id="id_3156006_719862_12_1">Convertible notes payable outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ConvertibleNotesMember" xlink:label="rgls_ConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ConvertibleNotesMember_lbl" xml:lang="en-US" id="id_3156006_734047_3_1">Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ConvertibleNotesMember_lbl" xml:lang="en-US" id="id_3156006_734047_1_1">Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ConvertibleNotesMember_lbl" xml:lang="en-US" id="id_3156006_734047_2_1">Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ConvertibleNotesMember" xlink:to="rgls_ConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" id="id_3156006_717089_1_1">Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US" id="id_3156006_717089_2_1">Outstanding principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" id="id_3156006_708807_1_1">Convertible Notes Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" id="id_3156006_708807_2_1">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_3156006_710593_1_1">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_3156006_710593_2_1">Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_3156006_712929_1_1">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_3156006_712929_2_1">Corporate Debt Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_722204_1_1">Current Federal Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_722204_2_1">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_3156006_706049_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_3156006_706049_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_723757_1_1">Current Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_723757_6_1">Current Income Tax Expense (Benefit), Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_3156006_715518_1_1">Current Income Tax Expense Benefit Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_3156006_715518_2_1">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_721948_1_1">Current State And Local Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_721948_2_1">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerAdvancesCurrent" xlink:label="us-gaap_CustomerAdvancesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerAdvancesCurrent_lbl" xml:lang="en-US" id="id_3156006_720508_1_1">Customer Advances Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerAdvancesCurrent_lbl" xml:lang="en-US" id="id_3156006_720508_2_1">Upfront payment creditable against future accounts receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerAdvancesCurrent" xlink:to="us-gaap_CustomerAdvancesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="id_3156006_720735_1_1">Debt Conversion Converted Instrument Amount 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="id_3156006_720735_2_1">Conversion of notes payable to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_3156006_713516_1_1">Debt Conversion Converted Instrument Shares Issued 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_3156006_713516_2_1">Conversion of convertible notes, converted number of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="id_3156006_713516_12_1">Conversion to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_712818_1_1">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_712818_2_1">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_707944_1_1">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_707944_2_1">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_3156006_711461_1_1">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="id_3156006_711461_2_1">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="id_3156006_719645_1_1">Debt Instrument Carrying Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="id_3156006_719645_2_1">Convertible notes payable, carrying value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_3156006_707441_1_1">Debt Instrument Convertible Conversion Price 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_3156006_707441_32_1">Conversion rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_3156006_707441_2_1">Conversion price per share of convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="id_3156006_707441_12_1">Conversion price per shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_3156006_709003_1_1">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_3156006_709003_2_1">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_3156006_714290_1_1">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="id_3156006_714290_2_1">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DebtInstrumentsAmendmentDate" xlink:label="rgls_DebtInstrumentsAmendmentDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DebtInstrumentsAmendmentDate_lbl" xml:lang="en-US" id="id_3156006_744739_3_1">Debt Instruments, Amendment Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DebtInstrumentsAmendmentDate_lbl" xml:lang="en-US" id="id_3156006_744739_1_1">Debt Instruments Amendment Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DebtInstrumentsAmendmentDate_lbl" xml:lang="en-US" id="id_3156006_744739_2_1">Convertible notes amendment date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DebtInstrumentsAmendmentDate" xlink:to="rgls_DebtInstrumentsAmendmentDate_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DebtInstrumentsMaturityDateMonthAndYear" xlink:label="rgls_DebtInstrumentsMaturityDateMonthAndYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DebtInstrumentsMaturityDateMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_726078_3_1">Debt Instruments Maturity Date Month and Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DebtInstrumentsMaturityDateMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_726078_1_1">Debt Instruments Maturity Date Month And Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DebtInstrumentsMaturityDateMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_726078_2_1">Conversion date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DebtInstrumentsMaturityDateMonthAndYear" xlink:to="rgls_DebtInstrumentsMaturityDateMonthAndYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_3156006_708225_1_1">Debt Instrument [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_3156006_708225_2_1">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="id_3156006_708071_1_1">Debt Instrument Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="id_3156006_708071_2_1">Maturity period of note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_723119_1_1">Deferred Federal Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_723119_2_1">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_721154_1_1">Deferred Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_721154_6_1">Deferred Income Tax Expense (Benefit), Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_3156006_709766_1_1">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_3156006_709766_2_1">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_3156006_720491_1_1">Deferred Rent Credit Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_3156006_720491_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_3156006_718953_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_3156006_718953_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_3156006_719153_1_1">Deferred Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_3156006_719153_2_1">Current portion of deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_3156006_717092_1_1">Deferred Revenue Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_3156006_717092_2_1">Deferred revenue, less current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredRevenueRecognitionPeriod" xlink:label="rgls_DeferredRevenueRecognitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DeferredRevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_835234_3_1">Deferred Revenue Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DeferredRevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_835234_1_1">Deferred Revenue Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DeferredRevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_835234_2_1">Deferred revenue recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DeferredRevenueRecognitionPeriod" xlink:to="rgls_DeferredRevenueRecognitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredRevenueRemainingRecognitionPeriod" xlink:label="rgls_DeferredRevenueRemainingRecognitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DeferredRevenueRemainingRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_883747_3_1">Deferred Revenue, Remaining Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DeferredRevenueRemainingRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_883747_1_1">Deferred Revenue Remaining Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DeferredRevenueRemainingRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_883747_2_1">Deferred revenue remaining recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DeferredRevenueRemainingRecognitionPeriod" xlink:to="rgls_DeferredRevenueRemainingRecognitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_723413_1_1">Deferred State And Local Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_723413_2_1">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_3156006_724080_1_1">Deferred Tax Assets Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="id_3156006_724080_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_3156006_721201_1_1">Deferred Tax Assets Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_3156006_721201_6_1">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" id="id_3156006_709171_1_1">Deferred Tax Assets Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" id="id_3156006_709171_2_1">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_3156006_722921_1_1">Deferred Tax Assets Liabilities Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_3156006_722921_2_1">Net deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_3156006_722921_6_1">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_3156006_722045_1_1">Deferred Tax Assets Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_3156006_722045_6_1">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_3156006_720945_1_1">Deferred Tax Assets Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_3156006_720945_2_1">Net operating loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_3156006_720945_12_1">Net operating loss carryovers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_3156006_722250_1_1">Deferred Tax Assets Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_3156006_722250_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" id="id_3156006_800366_3_1">Deferred Tax Assets Property Plant And Equipment And Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" id="id_3156006_800366_1_1">Deferred Tax Assets Property Plant And Equipment And Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_lbl" xml:lang="en-US" id="id_3156006_800366_2_1">Intangibles and property and equipment basis difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:to="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl" xml:lang="en-US" id="id_3156006_722530_1_1">Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl" xml:lang="en-US" id="id_3156006_722530_2_1">Alternative minimum tax ccredit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_3156006_723077_1_1">Deferred Tax Assets Tax Credit Carryforwards Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="id_3156006_723077_2_1">Research and development and other tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_3156006_718566_1_1">Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_3156006_718566_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="id_3156006_719233_1_1">Deferred Tax Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="id_3156006_719233_14_1">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" id="id_3156006_715127_1_1">Defined Benefit Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" id="id_3156006_715127_2_1">Defined Benefit Plan Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" id="id_3156006_724832_1_1">Defined Contribution Plan Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" id="id_3156006_724832_2_1">Employer contribution to 401 (K) plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation" xlink:label="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation_lbl" xml:lang="en-US" id="id_3156006_839291_3_1">Defined Contribution Plan, Employee Contributions, Percentage of Eligible Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation_lbl" xml:lang="en-US" id="id_3156006_839291_1_1">Defined Contribution Plan Employee Contributions Percentage Of Eligible Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation_lbl" xml:lang="en-US" id="id_3156006_839291_2_1">Maximum 401 (K) plan contribution rates as percentage of employees compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation" xlink:to="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" id="id_3156006_709960_1_1">Defined Contribution Plan Employer Matching Contribution Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" id="id_3156006_709960_2_1">Rate of contribution to 401(K) plan as a percentage of employees contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_3156006_708181_1_1">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_3156006_708181_2_1">Percentage of employee's earnings the company may contribute to the 401(K) plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DefinedContributionPlansTextBlock" xlink:label="rgls_DefinedContributionPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DefinedContributionPlansTextBlock_lbl" xml:lang="en-US" id="id_3156006_792197_3_1">Disclosure of the description of the plan, the basis for determining contributions, and the amounts of contributions under the Company's defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DefinedContributionPlansTextBlock_lbl" xml:lang="en-US" id="id_3156006_792197_1_1">Defined Contribution Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DefinedContributionPlansTextBlock_lbl" xml:lang="en-US" id="id_3156006_792197_2_1">Defined Contribution Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DefinedContributionPlansTextBlock" xlink:to="rgls_DefinedContributionPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="id_3156006_721752_1_1">Depreciation And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="id_3156006_721752_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_3156006_723416_1_1">Depreciation Depletion And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_3156006_723416_2_1">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DevelopmentCandidateMember" xlink:label="rgls_DevelopmentCandidateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DevelopmentCandidateMember_lbl" xml:lang="en-US" id="id_3156006_808515_3_1">Development Candidate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DevelopmentCandidateMember_lbl" xml:lang="en-US" id="id_3156006_808515_1_1">Development Candidate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DevelopmentCandidateMember_lbl" xml:lang="en-US" id="id_3156006_808515_2_1">Development Candidate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DevelopmentCandidateMember" xlink:to="rgls_DevelopmentCandidateMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:label="rgls_DevelopmentCommercializationAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DevelopmentCommercializationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_3156006_770834_3_1">Development Commercialization And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DevelopmentCommercializationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_3156006_770834_1_1">Development Commercialization And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DevelopmentCommercializationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_3156006_770834_2_1">Development Commercialization And License Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:to="rgls_DevelopmentCommercializationAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_3156006_713687_1_1">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_3156006_713687_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DocumentAndEntityInformationAbstract" xlink:label="rgls_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3156006_739630_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3156006_739630_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_3156006_739630_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_DocumentAndEntityInformationAbstract" xlink:to="rgls_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_3156006_706064_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_3156006_706064_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_3156006_706019_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_3156006_706019_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" id="id_3156006_705969_1_1">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" id="id_3156006_705969_2_1">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_3156006_706034_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_3156006_706034_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_3156006_706029_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_3156006_706029_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_3156006_715782_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_3156006_715782_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_3156006_707625_1_1">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_3156006_707625_2_1">Basic net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_3156006_715198_1_1">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_3156006_715198_2_1">Basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_3156006_715198_12_1">Net loss per share, basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_3156006_708479_1_1">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_3156006_708479_2_1">Diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_3156006_713711_1_1">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_3156006_713711_2_1">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3156006_717843_1_1">Employee Related Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3156006_717843_2_1">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_3156006_711192_1_1">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_3156006_711192_2_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl" xml:lang="en-US" id="id_3156006_722134_1_1">Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl" xml:lang="en-US" id="id_3156006_722134_2_1">Cash received from exercise of common stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_3156006_723785_1_1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_3156006_723785_2_1">Compensation cost related to non-vested awards not yet recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_3156006_715534_1_1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_3156006_715534_2_1">Weighted-average recognition period of compensation cost related to non-vested awards not yet recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="id_3156006_715677_1_1">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="id_3156006_715677_2_1">Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_3156006_708980_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_3156006_708980_2_1">Common stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:label="rgls_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_EmployeeStockPurchasePlanTwentyTwelveMember_lbl" xml:lang="en-US" id="id_3156006_818265_3_1">Employee Stock Purchase Plan Twenty Twelve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_EmployeeStockPurchasePlanTwentyTwelveMember_lbl" xml:lang="en-US" id="id_3156006_818265_1_1">Employee Stock Purchase Plan Twenty Twelve [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_EmployeeStockPurchasePlanTwentyTwelveMember_lbl" xml:lang="en-US" id="id_3156006_818265_2_1">2012 Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:to="rgls_EmployeeStockPurchasePlanTwentyTwelveMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US" id="id_3156006_705990_1_1">Entities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US" id="id_3156006_705990_2_1">Entities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_3156006_706042_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_3156006_706042_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_706087_1_1">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_706087_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_3156006_705987_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_3156006_705987_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_3156006_706015_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_3156006_706015_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_3156006_706000_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_3156006_706000_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_3156006_706038_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_3156006_706038_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_3156006_705982_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_3156006_705982_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_3156006_706072_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_3156006_706072_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_3156006_706048_1_1">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_3156006_706048_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xml:lang="en-US" id="id_3156006_709196_1_1">Entity Wide Information Revenue From External Customer [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xml:lang="en-US" id="id_3156006_709196_2_1">Revenue from External Customer [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_3156006_710583_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_3156006_710583_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_3156006_709383_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_3156006_709383_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xml:lang="en-US" id="id_3156006_714918_1_1">Equity Issuance Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xml:lang="en-US" id="id_3156006_714918_2_1">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuancePerShareAmount" xlink:to="us-gaap_EquityIssuancePerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EquityLineItems" xlink:label="rgls_EquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_EquityLineItems_lbl" xml:lang="en-US" id="id_3156006_768435_3_1">Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_EquityLineItems_lbl" xml:lang="en-US" id="id_3156006_768435_1_1">Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_EquityLineItems_lbl" xml:lang="en-US" id="id_3156006_768435_2_1">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_EquityLineItems" xlink:to="rgls_EquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EquityTable" xlink:label="rgls_EquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_EquityTable_lbl" xml:lang="en-US" id="id_3156006_799979_3_1">Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_EquityTable_lbl" xml:lang="en-US" id="id_3156006_799979_1_1">Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_EquityTable_lbl" xml:lang="en-US" id="id_3156006_799979_2_1">Equity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_EquityTable" xlink:to="rgls_EquityTable_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ExtensionPeriodOfOperatingLease" xlink:label="rgls_ExtensionPeriodOfOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ExtensionPeriodOfOperatingLease_lbl" xml:lang="en-US" id="id_3156006_765604_3_1">Extension Period Of Operating Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ExtensionPeriodOfOperatingLease_lbl" xml:lang="en-US" id="id_3156006_765604_1_1">Extension Period Of Operating Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ExtensionPeriodOfOperatingLease_lbl" xml:lang="en-US" id="id_3156006_765604_2_1">Operating lease optional extension period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ExtensionPeriodOfOperatingLease" xlink:to="rgls_ExtensionPeriodOfOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" id="id_3156006_711346_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" id="id_3156006_711346_2_1">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" id="id_3156006_713724_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" id="id_3156006_713724_2_1">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_3156006_710968_1_1">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_3156006_710968_2_1">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_3156006_712618_1_1">Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_3156006_712618_2_1">Fair value assumption, risk free rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" id="id_3156006_712251_1_1">Fair Value Assumptions Weighted Average Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" id="id_3156006_712251_2_1">Fair value assumption, volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" id="id_3156006_707858_1_1">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" id="id_3156006_707858_2_1">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_3156006_712021_1_1">Fair Value By Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_3156006_712021_2_1">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" id="id_3156006_711033_1_1">Fair Value By Balance Sheet Grouping [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" id="id_3156006_711033_2_1">Fair Value, by Balance Sheet Grouping [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_3156006_715757_1_1">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_3156006_715757_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_lbl" xml:lang="en-US" id="id_3156006_710273_1_1">Fair Value By Shareholders Equity Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain_lbl" xml:lang="en-US" id="id_3156006_710273_2_1">Fair Value by Shareholders' Equity Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_3156006_713878_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_3156006_713878_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_3156006_711336_1_1">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_3156006_711336_2_1">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsEntityCreditRisk" xlink:label="us-gaap_FairValueInputsEntityCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsEntityCreditRisk_lbl" xml:lang="en-US" id="id_3156006_712292_1_1">Fair Value Inputs Entity Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsEntityCreditRisk_lbl" xml:lang="en-US" id="id_3156006_712292_2_1">Fair value assumption, credit spread</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsEntityCreditRisk" xlink:to="us-gaap_FairValueInputsEntityCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_3156006_707740_1_1">Fair Value Inputs Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_3156006_707740_2_1">Fair Value, Inputs, Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_3156006_707855_1_1">Fair Value Inputs Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_3156006_707855_2_1">Fair Value, Inputs, Level 2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_3156006_715798_1_1">Fair Value Inputs Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_3156006_715798_2_1">Fair Value, Inputs, Level 3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FairValueInputsPeriod" xlink:label="rgls_FairValueInputsPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_FairValueInputsPeriod_lbl" xml:lang="en-US" id="id_3156006_762201_3_1">Fair Value Inputs Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_FairValueInputsPeriod_lbl" xml:lang="en-US" id="id_3156006_762201_1_1">Fair Value Inputs Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_FairValueInputsPeriod_lbl" xml:lang="en-US" id="id_3156006_762201_2_1">Restricting common stock valuation measurement period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_FairValueInputsPeriod" xlink:to="rgls_FairValueInputsPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_lbl" xml:lang="en-US" id="id_3156006_719760_1_1">Fair Value Liabilities Measured On Recurring Basis Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_lbl" xml:lang="en-US" id="id_3156006_719760_4_1">Balance at December 31, 2013</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_lbl" xml:lang="en-US" id="id_3156006_719760_5_1">Balance at December 31, 2012</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_3156006_707199_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_3156006_707199_2_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_3156006_709987_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_3156006_709987_2_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_3156006_710050_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_3156006_710050_2_1">Reconciliation of Liabilities Measured at Fair Value on Quarterly Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_717025_1_1">Fair Value Measurement Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_717025_2_1">Fair Value Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_3156006_713468_1_1">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_3156006_713468_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FederalMember" xlink:label="rgls_FederalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_FederalMember_lbl" xml:lang="en-US" id="id_3156006_745434_3_1">Federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_FederalMember_lbl" xml:lang="en-US" id="id_3156006_745434_1_1">Federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_FederalMember_lbl" xml:lang="en-US" id="id_3156006_745434_2_1">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_FederalMember" xlink:to="rgls_FederalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="id_3156006_720467_1_1">Finite Lived Intangible Assets Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="id_3156006_720467_14_1">Accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" id="id_3156006_720963_1_1">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" id="id_3156006_720963_2_1">Intangible assets, amortization expense, next twelve months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" id="id_3156006_722539_1_1">Finite Lived Intangible Assets Amortization Expense Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" id="id_3156006_722539_2_1">Intangible assets, amortization expense, year five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="id_3156006_722076_1_1">Finite Lived Intangible Assets Amortization Expense Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="id_3156006_722076_2_1">Intangible assets, amortization expense, year four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="id_3156006_723754_1_1">Finite Lived Intangible Assets Amortization Expense Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="id_3156006_723754_2_1">Intangible assets, amortization expense, year three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="id_3156006_721980_1_1">Finite Lived Intangible Assets Amortization Expense Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="id_3156006_721980_2_1">Intangible assets, amortization expense, year two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:label="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_3156006_778053_3_1">Finite-Lived Intangible Assets And Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_3156006_778053_1_1">Finitelived Intangible Assets And Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_3156006_778053_2_1">Finite-Lived Intangible Assets And Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_3156006_714938_1_1">Finite Lived Intangible Assets By Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_3156006_714938_2_1">Finite-Lived Intangible Assets by Major Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="id_3156006_724357_1_1">Finite Lived Intangible Assets Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="id_3156006_724357_2_1">Finite lived intangible assets, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_3156006_716482_1_1">Finite Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_3156006_716482_2_1">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_3156006_708822_1_1">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_3156006_708822_2_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife" xlink:label="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife_lbl" xml:lang="en-US" id="id_3156006_757647_3_1">Finite Lived Intangible Assets Weighted Average Remaining Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife_lbl" xml:lang="en-US" id="id_3156006_757647_1_1">Finite Lived Intangible Assets Weighted Average Remaining Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife_lbl" xml:lang="en-US" id="id_3156006_757647_2_1">Finite lived intangible assets, weighted average remaining useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife" xlink:to="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" id="id_3156006_711145_1_1">Finite Lived Intangible Asset Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" id="id_3156006_711145_2_1">Finite lived intangible asset, estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FourthMicroRnaTargetMember" xlink:label="rgls_FourthMicroRnaTargetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_FourthMicroRnaTargetMember_lbl" xml:lang="en-US" id="id_3156006_788356_3_1">Fourth Micro Rna Target</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_FourthMicroRnaTargetMember_lbl" xml:lang="en-US" id="id_3156006_788356_1_1">Fourth Micro Rna Target [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_FourthMicroRnaTargetMember_lbl" xml:lang="en-US" id="id_3156006_788356_2_1">Fourth Micro RNA Targets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_FourthMicroRnaTargetMember" xlink:to="rgls_FourthMicroRnaTargetMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_3156006_710442_1_1">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_3156006_710442_2_1">Furniture and Fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" id="id_3156006_720042_1_1">Gain Loss On Disposition Of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" id="id_3156006_720042_14_1">Loss on disposal of long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US" id="id_3156006_719619_1_1">Gain Loss On Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US" id="id_3156006_719619_14_1">Gain on investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_3156006_718819_1_1">Gains Losses On Extinguishment Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_3156006_718819_2_1">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_3156006_718819_14_1">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_3156006_721462_1_1">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_3156006_721462_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_3156006_707836_1_1">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_3156006_707836_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_710175_1_1">Goodwill And Intangible Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_710175_2_1">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GovernmentGrantMember" xlink:label="rgls_GovernmentGrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_GovernmentGrantMember_lbl" xml:lang="en-US" id="id_3156006_801067_3_1">Government Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_GovernmentGrantMember_lbl" xml:lang="en-US" id="id_3156006_801067_1_1">Government Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_GovernmentGrantMember_lbl" xml:lang="en-US" id="id_3156006_801067_2_1">Government Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_GovernmentGrantMember" xlink:to="rgls_GovernmentGrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_GskMember_lbl" xml:lang="en-US" id="id_3156006_778268_3_1">Gsk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_GskMember_lbl" xml:lang="en-US" id="id_3156006_778268_1_1">Gsk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_GskMember_lbl" xml:lang="en-US" id="id_3156006_778268_2_1">GSK</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_GskMember" xlink:to="rgls_GskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_HCVAllianceMember" xlink:label="rgls_HCVAllianceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_HCVAllianceMember_lbl" xml:lang="en-US" id="id_3156006_832174_3_1">HCV Alliance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_HCVAllianceMember_lbl" xml:lang="en-US" id="id_3156006_832174_1_1">H C V Alliance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_HCVAllianceMember_lbl" xml:lang="en-US" id="id_3156006_832174_2_1">HCV Alliance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_HCVAllianceMember" xlink:to="rgls_HCVAllianceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ImmunoInflammatoryAllianceMember" xlink:label="rgls_ImmunoInflammatoryAllianceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ImmunoInflammatoryAllianceMember_lbl" xml:lang="en-US" id="id_3156006_836413_3_1">Immuno-Inflammatory Alliance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ImmunoInflammatoryAllianceMember_lbl" xml:lang="en-US" id="id_3156006_836413_1_1">Immuno Inflammatory Alliance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ImmunoInflammatoryAllianceMember_lbl" xml:lang="en-US" id="id_3156006_836413_2_1">Immuno-Inflammatory Alliance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ImmunoInflammatoryAllianceMember" xlink:to="rgls_ImmunoInflammatoryAllianceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_714822_1_1">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_714822_2_1">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncentiveFromLessor_lbl" xml:lang="en-US" id="id_3156006_720388_1_1">Incentive From Lessor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncentiveFromLessor_lbl" xml:lang="en-US" id="id_3156006_720388_2_1">Tenant incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveFromLessor" xlink:to="us-gaap_IncentiveFromLessor_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_3156006_718011_1_1">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_3156006_718011_6_1">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_3156006_709908_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_3156006_709908_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_3156006_712080_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_3156006_712080_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_3156006_714971_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_3156006_714971_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_3156006_710844_1_1">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_3156006_710844_2_1">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_3156006_713110_1_1">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_3156006_713110_2_1">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US" id="id_3156006_709928_1_1">Income Tax Contingency [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US" id="id_3156006_709928_2_1">Income Tax Contingency [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xml:lang="en-US" id="id_3156006_712876_1_1">Income Tax Contingency [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xml:lang="en-US" id="id_3156006_712876_2_1">Income Tax Contingency [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_710538_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_710538_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_715742_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_715742_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" id="id_3156006_717783_1_1">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" id="id_3156006_717783_2_1">Income taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_722444_1_1">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_722444_2_1">Income tax (benefit) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_3156006_722444_6_1">Income tax (benefit) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_710792_1_1">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_710792_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxRateReconciliationLineItems" xlink:label="rgls_IncomeTaxRateReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_IncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" id="id_3156006_759636_3_1">Income Tax Rate Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_IncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" id="id_3156006_759636_1_1">Income Tax Rate Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_IncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" id="id_3156006_759636_2_1">Income Tax Rate Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="rgls_IncomeTaxRateReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxRateReconciliationTable" xlink:label="rgls_IncomeTaxRateReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_IncomeTaxRateReconciliationTable_lbl" xml:lang="en-US" id="id_3156006_729988_3_1">Income Tax Rate Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_IncomeTaxRateReconciliationTable_lbl" xml:lang="en-US" id="id_3156006_729988_1_1">Income Tax Rate Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_IncomeTaxRateReconciliationTable_lbl" xml:lang="en-US" id="id_3156006_729988_2_1">Income Tax Rate Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_IncomeTaxRateReconciliationTable" xlink:to="rgls_IncomeTaxRateReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_3156006_721578_1_1">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_3156006_721578_2_1">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:label="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_lbl" xml:lang="en-US" id="id_3156006_822398_3_1">Income Tax Reconciliation Change in Fair Value of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_lbl" xml:lang="en-US" id="id_3156006_822398_1_1">Income Tax Reconciliation Change In Fair Value Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_lbl" xml:lang="en-US" id="id_3156006_822398_2_1">Change in fair value of convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:to="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" xlink:label="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_3156006_764055_3_1">Income Tax Reconciliation Gain Loss on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_3156006_764055_1_1">Income Tax Reconciliation Gain Loss On Extinguishment Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="id_3156006_764055_2_1">Loss on debt extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" xlink:to="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_3156006_723096_1_1">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_3156006_723096_2_1">Expected income tax benefit at federal statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_3156006_721871_1_1">Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="id_3156006_721871_2_1">Stock compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_3156006_722415_1_1">Income Tax Reconciliation Other Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_3156006_722415_2_1">Government grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" id="id_3156006_721225_1_1">Income Tax Reconciliation Other Reconciling Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US" id="id_3156006_721225_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" id="id_3156006_722746_1_1">Income Tax Reconciliation Prior Year Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" id="id_3156006_722746_2_1">Prior year true-up</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_3156006_723046_1_1">Income Tax Reconciliation State And Local Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="id_3156006_723046_2_1">State income taxes, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_3156006_719846_1_1">Income Tax Reconciliation Tax Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" id="id_3156006_719846_14_1">Tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" id="id_3156006_719713_1_1">Increase Decrease In Accounts And Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" id="id_3156006_719713_14_1">Contracts and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_3156006_723051_1_1">Increase Decrease In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_3156006_723051_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_3156006_722985_1_1">Increase Decrease In Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_3156006_722985_2_1">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" id="id_3156006_721245_1_1">Increase Decrease In Deferred Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" id="id_3156006_721245_2_1">Deferred rent and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_3156006_722619_1_1">Increase Decrease In Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_3156006_722619_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="id_3156006_721442_1_1">Increase Decrease In Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="id_3156006_721442_2_1">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_3156006_708625_1_1">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_3156006_708625_2_1">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_3156006_719480_1_1">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_3156006_719480_14_1">Prepaid and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_713813_1_1">Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_713813_2_1">Intangible Assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" id="id_3156006_707362_1_1">Intangible Assets Finite Lived Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" id="id_3156006_707362_2_1">Intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="id_3156006_721609_1_1">Intangible Assets Net Excluding Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="id_3156006_721609_2_1">Intangible assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="id_3156006_721609_6_1">Intangibles, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" id="id_3156006_719835_1_1">Interest And Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US" id="id_3156006_719835_2_1">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_3156006_722986_1_1">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_3156006_722986_14_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xml:lang="en-US" id="id_3156006_720075_1_1">Interest On Convertible Debt Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xml:lang="en-US" id="id_3156006_720075_2_1">Accrued interest on convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_3156006_718952_1_1">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_3156006_718952_2_1">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" id="id_3156006_720329_1_1">Interest Payable Current And Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" id="id_3156006_720329_2_1">Accrued interest on convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" id="id_3156006_707398_1_1">Internal Revenue Service I R S [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" id="id_3156006_707398_2_1">Internal Revenue Service (IRS)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="invest_InvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentLineItems_lbl" xml:lang="en-US" id="id_3156006_707063_1_1">Investment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentLineItems_lbl" xml:lang="en-US" id="id_3156006_707063_2_1">Investment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentLineItems" xlink:to="invest_InvestmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_707996_1_1">Investment Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_707996_2_1">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" id="id_3156006_714766_1_1">Investments Debt And Equity Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" id="id_3156006_714766_2_1">Investments, Debt and Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_715055_1_1">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_715055_2_1">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="invest_InvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentTable_lbl" xml:lang="en-US" id="id_3156006_707097_1_1">Investment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentTable_lbl" xml:lang="en-US" id="id_3156006_707097_2_1">Investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentTable" xlink:to="invest_InvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_3156006_710256_1_1">Investment Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_3156006_710256_2_1">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_3156006_710825_1_1">Investment Type Categorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_3156006_710825_2_1">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_3156006_711552_1_1">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_3156006_711552_2_1">Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LaboratoryEquipmentMember" xlink:label="rgls_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_LaboratoryEquipmentMember_lbl" xml:lang="en-US" id="id_3156006_833191_3_1">Laboratory Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_LaboratoryEquipmentMember_lbl" xml:lang="en-US" id="id_3156006_833191_1_1">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_LaboratoryEquipmentMember_lbl" xml:lang="en-US" id="id_3156006_833191_2_1">Laboratory Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_LaboratoryEquipmentMember" xlink:to="rgls_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" id="id_3156006_723960_1_1">Lease And Rental Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" id="id_3156006_723960_2_1">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeaseExpirationMonthAndYear" xlink:label="rgls_LeaseExpirationMonthAndYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_LeaseExpirationMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_735314_3_1">Lease Expiration, Month and Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_LeaseExpirationMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_735314_1_1">Lease Expiration Month And Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_LeaseExpirationMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_735314_2_1">Operating lease expiration date, year and month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_LeaseExpirationMonthAndYear" xlink:to="rgls_LeaseExpirationMonthAndYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_3156006_716297_1_1">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_3156006_716297_2_1">Leasehold Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeasesFutureMinimumPaymentsLineItems" xlink:label="rgls_LeasesFutureMinimumPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_LeasesFutureMinimumPaymentsLineItems_lbl" xml:lang="en-US" id="id_3156006_726990_3_1">Leases Future Minimum Payments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_LeasesFutureMinimumPaymentsLineItems_lbl" xml:lang="en-US" id="id_3156006_726990_1_1">Leases Future Minimum Payments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_LeasesFutureMinimumPaymentsLineItems_lbl" xml:lang="en-US" id="id_3156006_726990_2_1">Leases Future Minimum Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="rgls_LeasesFutureMinimumPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeasesFutureMinimumPaymentsTable" xlink:label="rgls_LeasesFutureMinimumPaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_LeasesFutureMinimumPaymentsTable_lbl" xml:lang="en-US" id="id_3156006_790862_3_1">Leases Future Minimum Payments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_LeasesFutureMinimumPaymentsTable_lbl" xml:lang="en-US" id="id_3156006_790862_1_1">Leases Future Minimum Payments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_LeasesFutureMinimumPaymentsTable_lbl" xml:lang="en-US" id="id_3156006_790862_2_1">Leases Future Minimum Payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_LeasesFutureMinimumPaymentsTable" xlink:to="rgls_LeasesFutureMinimumPaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeaseTerminationNoticePeriod" xlink:label="rgls_LeaseTerminationNoticePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_LeaseTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_3156006_738374_3_1">Lease Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_LeaseTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_3156006_738374_1_1">Lease Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_LeaseTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_3156006_738374_2_1">Operating lease optional termination notice period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_LeaseTerminationNoticePeriod" xlink:to="rgls_LeaseTerminationNoticePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_3156006_705999_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_3156006_705999_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_3156006_720217_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_3156006_720217_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_3156006_720602_1_1">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_3156006_720602_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3156006_708470_1_1">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3156006_708470_2_1">Liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3156006_717569_1_1">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_3156006_717569_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_3156006_715754_1_1">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_3156006_715754_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_3156006_719596_1_1">Liabilities Fair Value Disclosure Recurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_3156006_719596_2_1">Liabilities measured at fair value on a recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LicensesMember" xlink:label="rgls_LicensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_LicensesMember_lbl" xml:lang="en-US" id="id_3156006_766191_3_1">Licenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_LicensesMember_lbl" xml:lang="en-US" id="id_3156006_766191_1_1">Licenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_LicensesMember_lbl" xml:lang="en-US" id="id_3156006_766191_2_1">Licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_LicensesMember" xlink:to="rgls_LicensesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember" xlink:label="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember_lbl" xml:lang="en-US" id="id_3156006_814120_3_1">Longitudinal Study Of Patient Samples On Ms Therapy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember_lbl" xml:lang="en-US" id="id_3156006_814120_1_1">Longitudinal Study Of Patient Samples On Ms Therapy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember_lbl" xml:lang="en-US" id="id_3156006_814120_2_1">Longitudinal Study Of Patient Samples On Ms Therapy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember" xlink:to="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_3156006_714378_1_1">Longterm Debt Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_3156006_714378_2_1">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_3156006_707980_1_1">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_3156006_707980_2_1">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_MaturityPeriodOfShortTermInvestments" xlink:label="rgls_MaturityPeriodOfShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_MaturityPeriodOfShortTermInvestments_lbl" xml:lang="en-US" id="id_3156006_819418_3_1">Maturity Period Of Short Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_MaturityPeriodOfShortTermInvestments_lbl" xml:lang="en-US" id="id_3156006_819418_1_1">Maturity Period Of Short Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_MaturityPeriodOfShortTermInvestments_lbl" xml:lang="en-US" id="id_3156006_819418_2_1">Maturity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_MaturityPeriodOfShortTermInvestments" xlink:to="rgls_MaturityPeriodOfShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_3156006_716112_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_3156006_716112_2_1">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_3156006_711169_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_3156006_711169_2_1">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage" xlink:label="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage_lbl" xml:lang="en-US" id="id_3156006_806553_3_1">Minority Interest Ownership By Noncontrolling Owners Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage_lbl" xml:lang="en-US" id="id_3156006_806553_1_1">Minority Interest Ownership By Noncontrolling Owners Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage_lbl" xml:lang="en-US" id="id_3156006_806553_2_1">Voting securities percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage" xlink:to="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_3156006_721507_1_1">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_3156006_721507_6_1">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3156006_708682_1_1">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3156006_708682_2_1">Financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_3156006_724159_1_1">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_3156006_724159_6_1">Net cash (used in) provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3156006_708507_1_1">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3156006_708507_2_1">Investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_3156006_712906_1_1">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_3156006_712906_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3156006_713979_1_1">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_3156006_713979_2_1">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3156006_720460_1_1">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3156006_720460_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_3156006_720460_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum" xlink:label="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum_lbl" xml:lang="en-US" id="id_3156006_834650_3_1">Net Operating Loss Carryforward Limitation On Use Percentage Ownership Change Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum_lbl" xml:lang="en-US" id="id_3156006_834650_1_1">Net Operating Loss Carryforward Limitation On Use Percentage Ownership Change Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum_lbl" xml:lang="en-US" id="id_3156006_834650_2_1">Limitation of company's ability to utilize certain tax credit carryforwards and net operating loss carryforwards, minimum percentage of ownership change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum" xlink:to="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US" id="id_3156006_791335_3_1">Net Proceeds From Issuance Of Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US" id="id_3156006_791335_1_1">Net Proceeds From Issuance Of Convertible Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl" xml:lang="en-US" id="id_3156006_791335_2_1">Proceeds from issuance of convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:to="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_716494_1_1">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_716494_2_1">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_3156006_710578_1_1">Noncash Investing And Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_3156006_710578_2_1">Supplemental disclosures of non-cash investing and financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xml:lang="en-US" id="id_3156006_721743_1_1">Noncash Or Part Noncash Acquisition Intangible Assets Acquired 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xml:lang="en-US" id="id_3156006_721743_2_1">Amounts accrued for patent expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US" id="id_3156006_717260_1_1">Nonoperating Gains Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US" id="id_3156006_717260_32_1">Loss from valuation of convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US" id="id_3156006_717260_2_1">Change in estimated fair value of convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US" id="id_3156006_717260_12_1">Loss from change in value of convertible note payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US" id="id_3156006_717260_14_1">Loss from change in value of convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingGainsLosses" xlink:to="us-gaap_NonoperatingGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_3156006_709554_1_1">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_3156006_709554_2_1">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US" id="id_3156006_720188_1_1">Notes Issued 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US" id="id_3156006_720188_2_1">Convertible notes issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NumberOfLeaseExtensionOptions" xlink:label="rgls_NumberOfLeaseExtensionOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_NumberOfLeaseExtensionOptions_lbl" xml:lang="en-US" id="id_3156006_839692_3_1">Number Of Lease Extension Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_NumberOfLeaseExtensionOptions_lbl" xml:lang="en-US" id="id_3156006_839692_1_1">Number Of Lease Extension Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_NumberOfLeaseExtensionOptions_lbl" xml:lang="en-US" id="id_3156006_839692_2_1">Number of options to extend operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_NumberOfLeaseExtensionOptions" xlink:to="rgls_NumberOfLeaseExtensionOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_3156006_716651_1_1">Number Of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_3156006_716651_2_1">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OctoberTwoThousandAndTwelveMember" xlink:label="rgls_OctoberTwoThousandAndTwelveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_OctoberTwoThousandAndTwelveMember_lbl" xml:lang="en-US" id="id_3156006_757334_3_1">October Two Thousand And Twelve [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_OctoberTwoThousandAndTwelveMember_lbl" xml:lang="en-US" id="id_3156006_757334_1_1">October Two Thousand And Twelve [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_OctoberTwoThousandAndTwelveMember_lbl" xml:lang="en-US" id="id_3156006_757334_2_1">October 2012</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_OctoberTwoThousandAndTwelveMember" xlink:to="rgls_OctoberTwoThousandAndTwelveMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OfficeAndLaboratorySpaceMember" xlink:label="rgls_OfficeAndLaboratorySpaceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_3156006_823826_3_1">Office and Laboratory Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_3156006_823826_1_1">Office And Laboratory Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" id="id_3156006_823826_2_1">Office and Laboratory Space</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_OfficeAndLaboratorySpaceMember" xlink:to="rgls_OfficeAndLaboratorySpaceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_3156006_722298_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_3156006_722298_2_1">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_3156006_722298_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_3156006_709967_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_3156006_709967_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_3156006_719696_1_1">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_3156006_719696_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_3156006_718205_1_1">Operating Leases Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_3156006_718205_6_1">Operating Leases, Future Minimum Payments Due, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_3156006_717427_1_1">Operating Leases Future Minimum Payments Due Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_3156006_717427_2_1">2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_3156006_718550_1_1">Operating Leases Future Minimum Payments Due In Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_3156006_718550_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_3156006_720249_1_1">Operating Leases Future Minimum Payments Due In Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_3156006_720249_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_3156006_719514_1_1">Operating Leases Future Minimum Payments Due In Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_3156006_719514_2_1">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_3156006_717603_1_1">Operating Leases Future Minimum Payments Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_3156006_717603_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OperatingLossCarryforwardExpirationYear" xlink:label="rgls_OperatingLossCarryforwardExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_OperatingLossCarryforwardExpirationYear_lbl" xml:lang="en-US" id="id_3156006_741121_3_1">Operating Loss Carryforward, Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_OperatingLossCarryforwardExpirationYear_lbl" xml:lang="en-US" id="id_3156006_741121_1_1">Operating Loss Carryforward Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_OperatingLossCarryforwardExpirationYear_lbl" xml:lang="en-US" id="id_3156006_741121_2_1">Operating loss carryforward expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_OperatingLossCarryforwardExpirationYear" xlink:to="rgls_OperatingLossCarryforwardExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_3156006_723252_1_1">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_3156006_723252_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OptionalLeaseTerminationDateMonthAndYear" xlink:label="rgls_OptionalLeaseTerminationDateMonthAndYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_OptionalLeaseTerminationDateMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_806629_3_1">Optional Lease Termination Date, Month and Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_OptionalLeaseTerminationDateMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_806629_1_1">Optional Lease Termination Date Month And Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_OptionalLeaseTerminationDateMonthAndYear_lbl" xml:lang="en-US" id="id_3156006_806629_2_1">Operating lease optional termination, date, year and month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_OptionalLeaseTerminationDateMonthAndYear" xlink:to="rgls_OptionalLeaseTerminationDateMonthAndYear_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_3156006_795348_3_1">Organization And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_3156006_795348_1_1">Organization And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_3156006_795348_2_1">Organization And Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_3156006_709883_1_1">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_3156006_709883_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_714928_1_1">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_714928_2_1">The Business, Basis of Presentation and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_3156006_720829_1_1">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_3156006_720829_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_3156006_709305_1_1">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="id_3156006_709305_2_1">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_3156006_717486_1_1">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_3156006_717486_2_1">Unrealized gain (loss) on short-term investments, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="id_3156006_717486_12_1">Unrealized loss on short-term investments, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3156006_718646_1_1">Other Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_3156006_718646_2_1">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US" id="id_3156006_711305_1_1">Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US" id="id_3156006_711305_2_1">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" id="id_3156006_719708_1_1">Payments To Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" id="id_3156006_719708_14_1">Acquisition of intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3156006_717252_1_1">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_3156006_717252_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" id="id_3156006_717953_1_1">Payments To Acquire Short Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" id="id_3156006_717953_14_1">Purchases of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PhaseOneClinicalTrialMember" xlink:label="rgls_PhaseOneClinicalTrialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US" id="id_3156006_784252_3_1">Phase One Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US" id="id_3156006_784252_1_1">Phase One Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US" id="id_3156006_784252_2_1">Phase One Clinical Trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_PhaseOneClinicalTrialMember" xlink:to="rgls_PhaseOneClinicalTrialMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PhaseTwoClinicalTrialMember" xlink:label="rgls_PhaseTwoClinicalTrialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US" id="id_3156006_837394_3_1">Phase Two Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US" id="id_3156006_837394_1_1">Phase Two Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US" id="id_3156006_837394_2_1">Phase Two Clinical Trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_PhaseTwoClinicalTrialMember" xlink:to="rgls_PhaseTwoClinicalTrialMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PreclinicalMember" xlink:label="rgls_PreclinicalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_PreclinicalMember_lbl" xml:lang="en-US" id="id_3156006_790602_3_1">Preclinical</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_PreclinicalMember_lbl" xml:lang="en-US" id="id_3156006_790602_1_1">Preclinical [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_PreclinicalMember_lbl" xml:lang="en-US" id="id_3156006_790602_2_1">Preclinical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_PreclinicalMember" xlink:to="rgls_PreclinicalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3156006_715507_1_1">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_3156006_715507_2_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_3156006_724462_1_1">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_3156006_724462_2_1">Prepaid and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="id_3156006_713867_1_1">Prior Period Reclassification Adjustment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="id_3156006_713867_2_1">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="id_3156006_709629_1_1">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="id_3156006_709629_2_1">Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US" id="id_3156006_722617_1_1">Proceeds From Collaborators</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xml:lang="en-US" id="id_3156006_722617_2_1">Initial upfront option payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_3156006_722440_1_1">Proceeds From Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_3156006_722440_2_1">Issued promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_3156006_723060_1_1">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_3156006_723060_2_1">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_3156006_723060_12_1">Proceeds from issuance of common stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" id="id_3156006_723194_1_1">Proceeds From Issuance Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" id="id_3156006_723194_2_1">Proceeds from issuance of convertible notes payable and other long-term obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" id="id_3156006_724507_1_1">Proceeds From Sale Maturity And Collection Of Shortterm Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US" id="id_3156006_724507_2_1">Maturities and sales of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_3156006_723323_1_1">Proceeds From Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_3156006_723323_2_1">Proceeds from exercise of common stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" id="id_3156006_717859_1_1">Profit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" id="id_3156006_717859_2_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ProofofConceptTrialMember" xlink:label="rgls_ProofofConceptTrialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ProofofConceptTrialMember_lbl" xml:lang="en-US" id="id_3156006_827588_3_1">Proof-of-Concept Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ProofofConceptTrialMember_lbl" xml:lang="en-US" id="id_3156006_827588_1_1">Proofof Concept Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ProofofConceptTrialMember_lbl" xml:lang="en-US" id="id_3156006_827588_2_1">Proof-of-Concept Trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ProofofConceptTrialMember" xlink:to="rgls_ProofofConceptTrialMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_3156006_712938_1_1">Property Plant And Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_3156006_712938_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_3156006_715832_1_1">Property Plant And Equipment By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_3156006_715832_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_707729_1_1">Property Plant And Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_707729_2_1">Property and Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_3156006_722049_1_1">Property Plant And Equipment Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_3156006_722049_2_1">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_3156006_707383_1_1">Property Plant And Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_3156006_707383_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3156006_722476_1_1">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3156006_722476_2_1">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_3156006_722476_6_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_712697_1_1">Property Plant And Equipment Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_712697_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_3156006_707471_1_1">Property Plant And Equipment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_3156006_707471_2_1">Summary of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_3156006_713515_1_1">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_3156006_713515_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_3156006_712541_1_1">Property Plant And Equipment Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_3156006_712541_2_1">Property and equipment, estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_713042_1_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="id_3156006_713042_2_1">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_3156006_711950_1_1">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="id_3156006_711950_2_1">Selected Quarterly Financial Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_3156006_711502_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_3156006_711502_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_3156006_713888_1_1">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_3156006_713888_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="us-gaap_RecognitionOfDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US" id="id_3156006_719912_1_1">Recognition Of Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RecognitionOfDeferredRevenue_lbl" xml:lang="en-US" id="id_3156006_719912_2_1">Upfront payment non-creditable portion recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecognitionOfDeferredRevenue" xlink:to="us-gaap_RecognitionOfDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ReferralAndStrategicAllianceAgreementMember" xlink:label="rgls_ReferralAndStrategicAllianceAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ReferralAndStrategicAllianceAgreementMember_lbl" xml:lang="en-US" id="id_3156006_816429_3_1">Referral And Strategic Alliance Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ReferralAndStrategicAllianceAgreementMember_lbl" xml:lang="en-US" id="id_3156006_816429_1_1">Referral And Strategic Alliance Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ReferralAndStrategicAllianceAgreementMember_lbl" xml:lang="en-US" id="id_3156006_816429_2_1">Strategic Alliances and Collaborations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ReferralAndStrategicAllianceAgreementMember" xlink:to="rgls_ReferralAndStrategicAllianceAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RegulatoryAndCommercializationMilestonesMember" xlink:label="rgls_RegulatoryAndCommercializationMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_RegulatoryAndCommercializationMilestonesMember_lbl" xml:lang="en-US" id="id_3156006_879640_3_1">Regulatory and Commercialization Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_RegulatoryAndCommercializationMilestonesMember_lbl" xml:lang="en-US" id="id_3156006_879640_1_1">Regulatory And Commercialization Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_RegulatoryAndCommercializationMilestonesMember_lbl" xml:lang="en-US" id="id_3156006_879640_2_1">Regulatory and Commercialization Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_RegulatoryAndCommercializationMilestonesMember" xlink:to="rgls_RegulatoryAndCommercializationMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RegulatoryMember" xlink:label="rgls_RegulatoryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_RegulatoryMember_lbl" xml:lang="en-US" id="id_3156006_754265_3_1">Regulatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_RegulatoryMember_lbl" xml:lang="en-US" id="id_3156006_754265_1_1">Regulatory [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_RegulatoryMember_lbl" xml:lang="en-US" id="id_3156006_754265_2_1">Regulatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_RegulatoryMember" xlink:to="rgls_RegulatoryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_3156006_710338_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_3156006_710338_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty" xlink:label="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="id_3156006_801144_3_1">Related Party Transaction Direct Operating Expenses From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="id_3156006_801144_1_1">Related Party Transaction Direct Operating Expenses From Transactions With Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="id_3156006_801144_2_1">Services performed or out-of-pocket expenses paid to Alnylam</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty" xlink:to="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_3156006_710001_1_1">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_3156006_710001_2_1">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_3156006_712837_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_3156006_712837_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_3156006_711672_1_1">Related Party Transactions By Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_3156006_711672_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_713821_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_713821_2_1">Related-Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xml:lang="en-US" id="id_3156006_719559_1_1">Repayments Of Other Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xml:lang="en-US" id="id_3156006_719559_14_1">Principal payments on other long-term obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_3156006_711298_1_1">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_3156006_711298_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_3156006_708351_1_1">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_3156006_708351_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_3156006_724274_1_1">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_3156006_724274_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_3156006_713040_1_1">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_3156006_713040_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_3156006_715843_1_1">Research And Development Expense Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_3156006_715843_2_1">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ResearchAndDevelopmentMember" xlink:label="rgls_ResearchAndDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ResearchAndDevelopmentMember_lbl" xml:lang="en-US" id="id_3156006_726565_3_1">Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ResearchAndDevelopmentMember_lbl" xml:lang="en-US" id="id_3156006_726565_1_1">Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ResearchAndDevelopmentMember_lbl" xml:lang="en-US" id="id_3156006_726565_2_1">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ResearchAndDevelopmentMember" xlink:to="rgls_ResearchAndDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ResearchAndDevelopmentPlanExpectedTerm" xlink:label="rgls_ResearchAndDevelopmentPlanExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ResearchAndDevelopmentPlanExpectedTerm_lbl" xml:lang="en-US" id="id_3156006_818981_3_1">Research and Development Plan, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ResearchAndDevelopmentPlanExpectedTerm_lbl" xml:lang="en-US" id="id_3156006_818981_1_1">Research And Development Plan Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ResearchAndDevelopmentPlanExpectedTerm_lbl" xml:lang="en-US" id="id_3156006_818981_2_1">Expected term of research and development plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ResearchAndDevelopmentPlanExpectedTerm" xlink:to="rgls_ResearchAndDevelopmentPlanExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" id="id_3156006_714598_1_1">Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" id="id_3156006_714598_2_1">Research Tax Credit Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_3156006_719144_1_1">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_3156006_719144_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_3156006_715280_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_3156006_715280_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueFromStrategicAlliancesTableTextBlock" xlink:label="rgls_RevenueFromStrategicAlliancesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_RevenueFromStrategicAlliancesTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_786494_3_1">Revenue from Strategic Alliances Table</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_RevenueFromStrategicAlliancesTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_786494_1_1">Revenue From Strategic Alliances Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_RevenueFromStrategicAlliancesTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_786494_2_1">Revenue from Strategic Alliances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_RevenueFromStrategicAlliancesTableTextBlock" xlink:to="rgls_RevenueFromStrategicAlliancesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xml:lang="en-US" id="id_3156006_868516_3_1">Revenue Recognition, Milestone Method, Expected Milestone Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xml:lang="en-US" id="id_3156006_868516_1_1">Revenue Recognition Milestone Method Expected Milestone Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xml:lang="en-US" id="id_3156006_868516_2_1">Revenue through milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:to="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueRecognitionPeriod" xlink:label="rgls_RevenueRecognitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_RevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_754996_3_1">Revenue Recognition, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_RevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_754996_1_1">Revenue Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_RevenueRecognitionPeriod_lbl" xml:lang="en-US" id="id_3156006_754996_2_1">Revenue recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_RevenueRecognitionPeriod" xlink:to="rgls_RevenueRecognitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_708341_1_1">Revenue Recognition Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_708341_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_3156006_719383_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_3156006_719383_2_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_3156006_719383_12_1">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_3156006_715210_1_1">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_3156006_715210_2_1">Revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RoyaltyPercentageBasedOnNetSales" xlink:label="rgls_RoyaltyPercentageBasedOnNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_RoyaltyPercentageBasedOnNetSales_lbl" xml:lang="en-US" id="id_3156006_797745_3_1">Royalty Percentage Based On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_RoyaltyPercentageBasedOnNetSales_lbl" xml:lang="en-US" id="id_3156006_797745_1_1">Royalty Percentage Based On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_RoyaltyPercentageBasedOnNetSales_lbl" xml:lang="en-US" id="id_3156006_797745_2_1">Royalties based on percentage of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_RoyaltyPercentageBasedOnNetSales" xlink:to="rgls_RoyaltyPercentageBasedOnNetSales_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US" id="id_3156006_721372_1_1">Sale Of Stock Consideration Received Per Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US" id="id_3156006_721372_2_1">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_3156006_714660_1_1">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_3156006_714660_2_1">Sale of Stock, Name of Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="id_3156006_715000_1_1">Sale Of Stock Number Of Shares Issued In Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="id_3156006_715000_2_1">Sale and issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_3156006_715089_1_1">Sale Of Stock Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_3156006_715089_2_1">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SanofiAventisMember" xlink:label="rgls_SanofiAventisMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_SanofiAventisMember_lbl" xml:lang="en-US" id="id_3156006_775748_3_1">Sanofi Aventis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_SanofiAventisMember_lbl" xml:lang="en-US" id="id_3156006_775748_1_1">Sanofi Aventis [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_SanofiAventisMember_lbl" xml:lang="en-US" id="id_3156006_775748_2_1">Sanofi - Aventis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_SanofiAventisMember" xlink:to="rgls_SanofiAventisMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SanofiMember" xlink:label="rgls_SanofiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_SanofiMember_lbl" xml:lang="en-US" id="id_3156006_766452_3_1">Sanofi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_SanofiMember_lbl" xml:lang="en-US" id="id_3156006_766452_1_1">Sanofi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_SanofiMember_lbl" xml:lang="en-US" id="id_3156006_766452_2_1">Sanofi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_SanofiMember" xlink:to="rgls_SanofiMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScenarioOneMember" xlink:label="rgls_ScenarioOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScenarioOneMember_lbl" xml:lang="en-US" id="id_3156006_784846_3_1">Scenario 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScenarioOneMember_lbl" xml:lang="en-US" id="id_3156006_784846_1_1">Scenario One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScenarioOneMember_lbl" xml:lang="en-US" id="id_3156006_784846_2_1">At inception of the enrollment period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScenarioOneMember" xlink:to="rgls_ScenarioOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScenarioTwoMember" xlink:label="rgls_ScenarioTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_3156006_825279_3_1">Scenario 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_3156006_825279_1_1">Scenario Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScenarioTwoMember_lbl" xml:lang="en-US" id="id_3156006_825279_2_1">At applicable purchase date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScenarioTwoMember" xlink:to="rgls_ScenarioTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_3156006_713961_1_1">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_3156006_713961_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_3156006_712295_1_1">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_3156006_712295_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_3156006_707705_1_1">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_3156006_707705_2_1">Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_712616_1_1">Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_712616_2_1">Summary of Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_3156006_714157_1_1">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_3156006_714157_2_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_710572_1_1">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_710572_2_1">Components Income Tax (Benefit) Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_3156006_740132_3_1">Schedule of Deferred Tax Assets and Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_3156006_740132_1_1">Schedule Of Deferred Tax Assets And Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_3156006_740132_2_1">Schedule of Deferred Tax Assets and Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable_lbl" xml:lang="en-US" id="id_3156006_745055_3_1">Schedule of Deferred Tax Assets and Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable_lbl" xml:lang="en-US" id="id_3156006_745055_1_1">Schedule Of Deferred Tax Assets And Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable_lbl" xml:lang="en-US" id="id_3156006_745055_2_1">Schedule of Deferred Tax Assets and Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" xlink:to="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_714474_1_1">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_714474_2_1">Components of Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" id="id_3156006_713206_1_1">Schedule Of Defined Benefit Plans Disclosures [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" id="id_3156006_713206_2_1">Schedule of Defined Benefit Plans Disclosures [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" id="id_3156006_772321_3_1">Schedule Of Earnings Per Share Basic And Diluted [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" id="id_3156006_772321_1_1">Schedule Of Earnings Per Share Basic And Diluted [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" id="id_3156006_772321_2_1">Schedule Of Earnings Per Share Basic And Diluted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xml:lang="en-US" id="id_3156006_785415_3_1">Schedule Of Earnings Per Share Basic And Diluted [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xml:lang="en-US" id="id_3156006_785415_1_1">Schedule Of Earnings Per Share Basic And Diluted [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xml:lang="en-US" id="id_3156006_785415_2_1">Schedule Of Earnings Per Share Basic And Diluted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_713839_1_1">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_713839_2_1">Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_3156006_707606_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_3156006_707606_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_3156006_714886_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_3156006_714886_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xml:lang="en-US" id="id_3156006_711899_1_1">Schedule Of Entity Wide Information Revenue From External Customers By Products And Services [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xml:lang="en-US" id="id_3156006_711899_2_1">Revenue from External Customers by Products and Services [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_709069_1_1">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_709069_2_1">Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_3156006_713098_1_1">Schedule Of Finite Lived Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_3156006_713098_2_1">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_713970_1_1">Schedule Of Finite Lived Intangible Assets Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_713970_2_1">Summary of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_708106_1_1">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_708106_2_1">Summary of Future Annual Minimum Lease Payments for Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfIncomeTaxesLineItems" xlink:label="rgls_ScheduleOfIncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScheduleOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_3156006_768756_3_1">Schedule Of Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScheduleOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_3156006_768756_1_1">Schedule Of Income Taxes [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScheduleOfIncomeTaxesLineItems_lbl" xml:lang="en-US" id="id_3156006_768756_2_1">Schedule Of Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="rgls_ScheduleOfIncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfIncomeTaxesTable" xlink:label="rgls_ScheduleOfIncomeTaxesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScheduleOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_3156006_819878_3_1">Schedule Of Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScheduleOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_3156006_819878_1_1">Schedule Of Income Taxes [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScheduleOfIncomeTaxesTable_lbl" xml:lang="en-US" id="id_3156006_819878_2_1">Schedule Of Income Taxes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="rgls_ScheduleOfIncomeTaxesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_3156006_832176_3_1">Schedule Of Organization And Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_3156006_832176_1_1">Schedule Of Organization And Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_3156006_832176_2_1">Schedule Of Organization And Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_3156006_714210_1_1">Schedule Of Property Plant And Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_3156006_714210_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_710070_1_1">Schedule Of Quarterly Financial Information Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_710070_2_1">Selected Quarterly Financial Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_3156006_710840_1_1">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_3156006_710840_2_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_710394_1_1">Schedule Of Related Party Transactions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_710394_2_1">Summary of Operating Expenses from Related Party Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_3156006_713648_1_1">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_3156006_713648_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_708925_1_1">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_708925_2_1">Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_714968_1_1">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_714968_2_1">Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:label="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_772864_3_1">Schedule Of Shares Reserved For Future Issuance Table</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_772864_1_1">Schedule Of Shares Reserved For Future Issuance Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_3156006_772864_2_1">Common Stock Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:to="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_3156006_715865_1_1">Schedule Of Stock By Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_3156006_715865_2_1">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_713945_1_1">Segment Reporting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_3156006_713945_2_1">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SelectedQuarterlyFinancialDataLineItems" xlink:label="rgls_SelectedQuarterlyFinancialDataLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_SelectedQuarterlyFinancialDataLineItems_lbl" xml:lang="en-US" id="id_3156006_759689_3_1">Selected Quarterly Financial Data [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_SelectedQuarterlyFinancialDataLineItems_lbl" xml:lang="en-US" id="id_3156006_759689_1_1">Selected Quarterly Financial Data [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_SelectedQuarterlyFinancialDataLineItems_lbl" xml:lang="en-US" id="id_3156006_759689_2_1">Selected Quarterly Financial Data [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="rgls_SelectedQuarterlyFinancialDataLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SelectedQuarterlyFinancialDataTable" xlink:label="rgls_SelectedQuarterlyFinancialDataTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_SelectedQuarterlyFinancialDataTable_lbl" xml:lang="en-US" id="id_3156006_792226_3_1">Selected Quarterly Financial Data [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_SelectedQuarterlyFinancialDataTable_lbl" xml:lang="en-US" id="id_3156006_792226_1_1">Selected Quarterly Financial Data [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_SelectedQuarterlyFinancialDataTable_lbl" xml:lang="en-US" id="id_3156006_792226_2_1">Selected Quarterly Financial Data [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_SelectedQuarterlyFinancialDataTable" xlink:to="rgls_SelectedQuarterlyFinancialDataTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_3156006_713505_1_1">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_3156006_713505_2_1">Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_3156006_710990_1_1">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_3156006_710990_2_1">Series B Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_3156006_721665_1_1">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_3156006_721665_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="id_3156006_711846_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="id_3156006_711846_2_1">Employee Stock Options:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_3156006_712725_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_3156006_712725_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_3156006_711443_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_3156006_711443_2_1">Expected term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_3156006_709143_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_3156006_709143_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_lbl" xml:lang="en-US" id="id_3156006_725572_3_1">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_lbl" xml:lang="en-US" id="id_3156006_725572_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_lbl" xml:lang="en-US" id="id_3156006_725572_2_1">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_lbl" xml:lang="en-US" id="id_3156006_800356_3_1">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_lbl" xml:lang="en-US" id="id_3156006_800356_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_lbl" xml:lang="en-US" id="id_3156006_800356_2_1">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_3156006_708259_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_3156006_708259_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_3156006_711563_1_1">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_3156006_711563_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US" id="id_3156006_710725_1_1">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US" id="id_3156006_710725_2_1">Percentage of participants eligible compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_3156006_715297_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_3156006_715297_2_1">Common stock shares reserved for future issuance and authorized for purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_3156006_710236_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_3156006_710236_2_1">Common stock shares available for future grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" id="id_3156006_751128_3_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" id="id_3156006_751128_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US" id="id_3156006_751128_2_1">Aggregate intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_3156006_723111_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_3156006_723111_2_1">Exercisable at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_3156006_708419_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_3156006_708419_2_1">Exercisable at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_713325_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_713325_2_1">Exercisable at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_3156006_716095_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_3156006_716095_2_1">Exercisable at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_3156006_722911_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_3156006_722911_2_1">The total intrinsic value of stock options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="id_3156006_715814_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="id_3156006_715814_14_1">Canceled/forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_714444_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_714444_2_1">Canceled/forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_3156006_708168_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_3156006_708168_2_1">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_3156006_712434_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_3156006_712434_2_1">Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_3156006_723332_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_3156006_723332_2_1">Options outstanding at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_3156006_710185_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_3156006_710185_4_1">Options outstanding at December 31, 2013</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_3156006_710185_5_1">Options outstanding at December 31, 2012</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_3156006_710185_2_1">Common stock options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_3156006_711304_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="id_3156006_711304_2_1">Number of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_709772_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_709772_4_1">Options outstanding at December 31, 2013</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_709772_5_1">Options outstanding at December 31, 2012</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_3156006_708379_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="id_3156006_708379_2_1">Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_3156006_707840_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_3156006_707840_2_1">Options outstanding at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3156006_722773_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_3156006_722773_2_1">Vested or expected to vest at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_3156006_715855_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_3156006_715855_2_1">Vested or expected to vest at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_712289_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_712289_2_1">Vested or expected to vest at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_3156006_713422_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_3156006_713422_2_1">Vested or expected to vest at December 31, 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" id="id_3156006_755232_3_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" id="id_3156006_755232_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" id="id_3156006_755232_2_1">Weighted average remaining contactual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="id_3156006_709363_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="id_3156006_709363_2_1">Percentage of fair market value of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_3156006_712670_1_1">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_3156006_712670_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_715423_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_715423_2_1">Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_709341_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_3156006_709341_2_1">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_3156006_716915_1_1">Share Based Compensation Option And Incentive Plans Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_3156006_716915_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityClassAxis_lbl" xml:lang="en-US" id="id_3156006_710552_1_1">Shareholders Equity Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityClassAxis_lbl" xml:lang="en-US" id="id_3156006_710552_2_1">Shareholders' Equity Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_ShareholdersEquityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_716698_1_1">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_716698_4_1">Ending Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" id="id_3156006_716819_1_1">Short Term Debt Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" id="id_3156006_716819_2_1">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" id="id_3156006_716849_1_1">Short Term Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" id="id_3156006_716849_2_1">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" id="id_3156006_722884_1_1">Short Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" id="id_3156006_722884_2_1">Estimated fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" id="id_3156006_722884_12_1">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShortTermInvestmentsAmortizedCost" xlink:label="rgls_ShortTermInvestmentsAmortizedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ShortTermInvestmentsAmortizedCost_lbl" xml:lang="en-US" id="id_3156006_823943_3_1">This item represents the cost of Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ShortTermInvestmentsAmortizedCost_lbl" xml:lang="en-US" id="id_3156006_823943_1_1">Short Term Investments Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ShortTermInvestmentsAmortizedCost_lbl" xml:lang="en-US" id="id_3156006_823943_2_1">Amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ShortTermInvestmentsAmortizedCost" xlink:to="rgls_ShortTermInvestmentsAmortizedCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_3156006_711196_1_1">Statement Class Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_3156006_711196_2_1">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_3156006_709650_1_1">Statement Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_3156006_709650_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_3156006_711635_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_3156006_711635_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_3156006_710972_1_1">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_3156006_710972_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_3156006_708775_1_1">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_3156006_708775_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3156006_711354_1_1">Statement Of Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3156006_711354_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_3156006_708873_1_1">Statement Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_3156006_708873_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_3156006_711836_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_3156006_711836_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_3156006_718765_1_1">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_3156006_718765_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_3156006_718765_5_1">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_3156006_718765_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3156006_707190_1_1">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_3156006_707190_2_1">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_712192_1_1">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_3156006_712192_2_1">Convertible Preferred Stock, Common Stock and Stockholders' Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_3156006_714795_1_1">Stockholders Equity Note Stock Split Conversion Ratio 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_3156006_714795_2_1">Reverse stock split of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_3156006_711303_1_1">Stock Issued During Period Shares Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_3156006_711303_2_1">Common stock issued upon conversion of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_3156006_711303_12_1">Conversion of shares of preferred stock to common stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_3156006_715369_1_1">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_3156006_715369_2_1">Common stock shares issued under purchase plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="id_3156006_715369_12_1">Issuance of common stock under Employee Stock Purchase Plan (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_3156006_711089_1_1">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_3156006_711089_2_1">Common stock shares, issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_3156006_711089_12_1">Issuance of common stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" id="id_3156006_712286_1_1">Stock Issued During Period Shares Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" id="id_3156006_712286_2_1">Conversion of notes payable to common stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_3156006_713738_1_1">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_3156006_713738_2_1">Issuance of common stock upon exercise of options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_3156006_713738_14_1">Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US" id="id_3156006_716327_1_1">Stock Issued During Period Shares Stock Splits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US" id="id_3156006_716327_2_1">Effect of 2-for-1 split on shares of preferred stock (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_3156006_720661_1_1">Stock Issued During Period Value Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_3156006_720661_2_1">Conversion of shares of preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_3156006_720676_1_1">Stock Issued During Period Value Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="id_3156006_720676_2_1">Issuance of common stock under Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_3156006_717250_1_1">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_3156006_717250_2_1">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US" id="id_3156006_720417_1_1">Stock Issued During Period Value Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US" id="id_3156006_720417_2_1">Conversion of notes payable to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_3156006_717723_1_1">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_3156006_717723_2_1">Issuance of common stock upon exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_StrategicAlliancesAxis_lbl" xml:lang="en-US" id="id_3156006_759964_3_1">Strategic Alliances [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_StrategicAlliancesAxis_lbl" xml:lang="en-US" id="id_3156006_759964_1_1">Strategic Alliances [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_StrategicAlliancesAxis_lbl" xml:lang="en-US" id="id_3156006_759964_2_1">Strategic Alliances [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_StrategicAlliancesDomain_lbl" xml:lang="en-US" id="id_3156006_737976_3_1">Strategic Alliances [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_StrategicAlliancesDomain_lbl" xml:lang="en-US" id="id_3156006_737976_1_1">Strategic Alliances [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_StrategicAlliancesDomain_lbl" xml:lang="en-US" id="id_3156006_737976_2_1">Strategic Alliances [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_StrategicAlliancesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_3156006_717050_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_3156006_717050_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_3156006_714667_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_3156006_714667_2_1">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_3156006_707774_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_3156006_707774_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_3156006_715486_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_3156006_715486_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_3156006_713783_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_3156006_713783_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_3156006_710720_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_3156006_710720_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_3156006_715840_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_3156006_715840_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_3156006_714777_1_1">Subsidiary Sale Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_3156006_714777_2_1">Subsidiary, Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xml:lang="en-US" id="id_3156006_711584_1_1">Summary Of Income Tax Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xml:lang="en-US" id="id_3156006_711584_2_1">Changes in Amount of Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_3156006_713511_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_3156006_713511_2_1">Supplemental disclosure of cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="id_3156006_722458_1_1">Tax Credit Carryforward Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="id_3156006_722458_2_1">Research and development tax credit carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" id="id_3156006_707402_1_1">Tax Credit Carryforward [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" id="id_3156006_707402_2_1">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" id="id_3156006_713011_1_1">Tax Credit Carryforward Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" id="id_3156006_713011_2_1">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_3156006_718866_1_1">Temporary Equity Carrying Amount Attributable To Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_3156006_718866_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_3156006_718866_5_1">Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_707526_1_1">Temporary Equity Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_707526_4_1">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_3156006_707526_5_1">Beginning Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TenantImprovementAllowance" xlink:label="rgls_TenantImprovementAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_TenantImprovementAllowance_lbl" xml:lang="en-US" id="id_3156006_847615_3_1">Tenant Improvement Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_TenantImprovementAllowance_lbl" xml:lang="en-US" id="id_3156006_847615_1_1">Tenant Improvement Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_TenantImprovementAllowance_lbl" xml:lang="en-US" id="id_3156006_847615_2_1">Allowance for tenant improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rgls_TenantImprovementAllowance_lbl" xml:lang="en-US" id="id_3156006_847615_12_1">Tenant improvement allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_TenantImprovementAllowance" xlink:to="rgls_TenantImprovementAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TenantImprovementAllowanceInterestRatePercentage" xlink:label="rgls_TenantImprovementAllowanceInterestRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_TenantImprovementAllowanceInterestRatePercentage_lbl" xml:lang="en-US" id="id_3156006_758040_3_1">Tenant Improvement Allowance, Interest Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_TenantImprovementAllowanceInterestRatePercentage_lbl" xml:lang="en-US" id="id_3156006_758040_1_1">Tenant Improvement Allowance Interest Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_TenantImprovementAllowanceInterestRatePercentage_lbl" xml:lang="en-US" id="id_3156006_758040_2_1">Tenant improvement allowance, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_TenantImprovementAllowanceInterestRatePercentage" xlink:to="rgls_TenantImprovementAllowanceInterestRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TermOfDebtInstrument" xlink:label="rgls_TermOfDebtInstrument"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_TermOfDebtInstrument_lbl" xml:lang="en-US" id="id_3156006_830951_3_1">Term Of Debt Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_TermOfDebtInstrument_lbl" xml:lang="en-US" id="id_3156006_830951_1_1">Term Of Debt Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_TermOfDebtInstrument_lbl" xml:lang="en-US" id="id_3156006_830951_2_1">Term of convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_TermOfDebtInstrument" xlink:to="rgls_TermOfDebtInstrument_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_3156006_714272_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_3156006_714272_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_3156006_705972_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_3156006_705972_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="rgls_TwoThousandTwelveEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_TwoThousandTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_3156006_736920_3_1">Two Thousand Twelve Equity Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_TwoThousandTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_3156006_736920_1_1">Two Thousand Twelve Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_TwoThousandTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_3156006_736920_2_1">2012 Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_TwoThousandTwelveEquityIncentivePlanMember" xlink:to="rgls_TwoThousandTwelveEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_3156006_712375_1_1">Type Of Arrangement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_3156006_712375_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TypesOfFacilitiesAxis" xlink:label="rgls_TypesOfFacilitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_TypesOfFacilitiesAxis_lbl" xml:lang="en-US" id="id_3156006_843826_3_1">Types Of Facilities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_TypesOfFacilitiesAxis_lbl" xml:lang="en-US" id="id_3156006_843826_1_1">Types Of Facilities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_TypesOfFacilitiesAxis_lbl" xml:lang="en-US" id="id_3156006_843826_2_1">Types Of Facilities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_TypesOfFacilitiesAxis" xlink:to="rgls_TypesOfFacilitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TypesOfFacilitiesDomain" xlink:label="rgls_TypesOfFacilitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_TypesOfFacilitiesDomain_lbl" xml:lang="en-US" id="id_3156006_760588_3_1">Types Of Facilities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_TypesOfFacilitiesDomain_lbl" xml:lang="en-US" id="id_3156006_760588_1_1">Types Of Facilities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_TypesOfFacilitiesDomain_lbl" xml:lang="en-US" id="id_3156006_760588_2_1">Types Of Facilities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_TypesOfFacilitiesDomain" xlink:to="rgls_TypesOfFacilitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UncategorizedAbstract" xlink:label="rgls_UncategorizedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_3156006_725442_3_1">Uncategorized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_3156006_725442_1_1">Uncategorized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_UncategorizedAbstract_lbl" xml:lang="en-US" id="id_3156006_725442_2_1">Uncategorized [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_UncategorizedAbstract" xlink:to="rgls_UncategorizedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnderwriterMember" xlink:label="rgls_UnderwriterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_UnderwriterMember_lbl" xml:lang="en-US" id="id_3156006_783665_3_1">Underwriter [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_UnderwriterMember_lbl" xml:lang="en-US" id="id_3156006_783665_1_1">Underwriter [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_UnderwriterMember_lbl" xml:lang="en-US" id="id_3156006_783665_2_1">Underwriter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_UnderwriterMember" xlink:to="rgls_UnderwriterMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainOnSecurities" xlink:label="us-gaap_UnrealizedGainOnSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainOnSecurities_lbl" xml:lang="en-US" id="id_3156006_718949_1_1">Unrealized Gain On Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrealizedGainOnSecurities_lbl" xml:lang="en-US" id="id_3156006_718949_2_1">Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainOnSecurities" xlink:to="us-gaap_UnrealizedGainOnSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedLossOnSecurities" xlink:label="us-gaap_UnrealizedLossOnSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedLossOnSecurities_lbl" xml:lang="en-US" id="id_3156006_722165_1_1">Unrealized Loss On Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedLossOnSecurities_lbl" xml:lang="en-US" id="id_3156006_722165_14_1">Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedLossOnSecurities" xlink:to="us-gaap_UnrealizedLossOnSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_3156006_717835_1_1">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_3156006_717835_4_1">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_3156006_717835_5_1">Beginning balance of unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3156006_822846_3_1">Unrecognized Tax Benefits, Increases (Decreases) Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3156006_822846_1_1">Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3156006_822846_2_1">Increase (decrease) for prior year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3156006_719573_1_1">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_3156006_719573_2_1">Increase for current year tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:label="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_3156006_826813_3_1">Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_3156006_826813_1_1">Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="id_3156006_826813_2_1">Unrecognized tax benefits that, if recognized, would not impact income tax benefit or effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:to="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_3156006_714925_1_1">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_3156006_714925_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_3156006_717071_1_1">U S Government Sponsored Enterprises Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_3156006_717071_2_1">Debt securities of U.S. government-sponsored agencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ValidationOfMicroRnaBiomarkerMember" xlink:label="rgls_ValidationOfMicroRnaBiomarkerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rgls_ValidationOfMicroRnaBiomarkerMember_lbl" xml:lang="en-US" id="id_3156006_772189_3_1">Validation Of Micro Rna Biomarker</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rgls_ValidationOfMicroRnaBiomarkerMember_lbl" xml:lang="en-US" id="id_3156006_772189_1_1">Validation Of Micro Rna Biomarker [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rgls_ValidationOfMicroRnaBiomarkerMember_lbl" xml:lang="en-US" id="id_3156006_772189_2_1">Validation Of Micro Rna Biomarker</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rgls_ValidationOfMicroRnaBiomarkerMember" xlink:to="rgls_ValidationOfMicroRnaBiomarkerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_3156006_712169_1_1">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_3156006_712169_2_1">Shares used to compute basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>rgls-20131231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-02-27T18:35:01Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DocumentandEntityInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureNetLossPerShareAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfShortTermInvestments" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureFairValueMeasurementsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureRevenueFromStrategicAlliances" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliances"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfPropertyAndEquipment" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfIntangibleAssets" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfIntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureIntangibleAssetsNetAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureConvertibleNotesPayableAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureCommonStockReservedForFutureIssuance" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStockOptionActivity" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureDefinedContributionPlanAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureComponentsIncomeTaxBenefitExpense" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsIncomeTaxBenefitExpense"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureChangesInAmountOfUnrecognizedTaxBenefits" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureChangesInAmountOfUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSelectedQuarterlyFinancialData" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsDefinedContributionPlansTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDefinedContributionPlansTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="rgls-20131231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DocumentAndEntityInformationAbstract" xlink:label="rgls_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_DocumentAndEntityInformationAbstract" xlink:to="dei_EntitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GovernmentGrantMember" xlink:label="rgls_GovernmentGrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ReferralAndStrategicAllianceAgreementMember" xlink:label="rgls_ReferralAndStrategicAllianceAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="rgls_ReferralAndStrategicAllianceAgreementMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="rgls_GovernmentGrantMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TenantImprovementAllowance" xlink:label="rgls_TenantImprovementAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="1.1200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="1.2800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt" order="1.3700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.2300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1.2600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rgls_TenantImprovementAllowance" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife" xlink:label="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LicensesMember" xlink:label="rgls_LicensesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UncategorizedAbstract" xlink:label="rgls_UncategorizedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="rgls_LicensesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_UncategorizedAbstract" xlink:to="rgls_ScheduleOfOrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="invest_InvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="invest_InvestmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_MaturityPeriodOfShortTermInvestments" xlink:label="rgls_MaturityPeriodOfShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShortTermInvestmentsAmortizedCost" xlink:label="rgls_ShortTermInvestmentsAmortizedCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedGainOnSecurities" xlink:label="us-gaap_UnrealizedGainOnSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrealizedLossOnSecurities" xlink:label="us-gaap_UnrealizedLossOnSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="rgls_MaturityPeriodOfShortTermInvestments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="rgls_ShortTermInvestmentsAmortizedCost" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="us-gaap_UnrealizedGainOnSecurities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="us-gaap_UnrealizedLossOnSecurities" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="invest_InvestmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentTable" xlink:to="invest_InvestmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsEntityCreditRisk" xlink:label="us-gaap_FairValueInputsEntityCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_NonoperatingGainsLosses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueInputsEntityCreditRisk" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliances">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AstraZenecaMember" xlink:label="rgls_AstraZenecaMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_BiogenIdecMember" xlink:label="rgls_BiogenIdecMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ReferralAndStrategicAllianceAgreementMember" xlink:label="rgls_ReferralAndStrategicAllianceAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SanofiAventisMember" xlink:label="rgls_SanofiAventisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_ReferralAndStrategicAllianceAgreementMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="rgls_StrategicAlliancesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_SanofiAventisMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_GskMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_AstraZenecaMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_BiogenIdecMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AgreementAxis" xlink:label="rgls_AgreementAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AgreementDomain" xlink:label="rgls_AgreementDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AmendedCollaborationAndLicenseAgreementMember" xlink:label="rgls_AmendedCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AstraZenecaMember" xlink:label="rgls_AstraZenecaMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_BiogenIdecMember" xlink:label="rgls_BiogenIdecMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ClinicalMember" xlink:label="rgls_ClinicalMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CollaborationAndLicenseAgreementEnteredDate" xlink:label="rgls_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CollaborativeAreasGranted" xlink:label="rgls_CollaborativeAreasGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommercializationMember" xlink:label="rgls_CommercializationMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommercializationMilestonesMember" xlink:label="rgls_CommercializationMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockPurchaseAgreementsCspaMember" xlink:label="rgls_CommonStockPurchaseAgreementsCspaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockTransactionRestrictionPeriod" xlink:label="rgls_CommonStockTransactionRestrictionPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerAdvancesCurrent" xlink:label="us-gaap_CustomerAdvancesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredRevenueRecognitionPeriod" xlink:label="rgls_DeferredRevenueRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredRevenueRemainingRecognitionPeriod" xlink:label="rgls_DeferredRevenueRemainingRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DevelopmentCandidateMember" xlink:label="rgls_DevelopmentCandidateMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:label="rgls_DevelopmentCommercializationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FairValueInputsPeriod" xlink:label="rgls_FairValueInputsPeriod"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FourthMicroRnaTargetMember" xlink:label="rgls_FourthMicroRnaTargetMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_HCVAllianceMember" xlink:label="rgls_HCVAllianceMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ImmunoInflammatoryAllianceMember" xlink:label="rgls_ImmunoInflammatoryAllianceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember" xlink:label="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PhaseOneClinicalTrialMember" xlink:label="rgls_PhaseOneClinicalTrialMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PhaseTwoClinicalTrialMember" xlink:label="rgls_PhaseTwoClinicalTrialMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_PreclinicalMember" xlink:label="rgls_PreclinicalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ProofofConceptTrialMember" xlink:label="rgls_ProofofConceptTrialMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="us-gaap_RecognitionOfDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RegulatoryAndCommercializationMilestonesMember" xlink:label="rgls_RegulatoryAndCommercializationMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RegulatoryMember" xlink:label="rgls_RegulatoryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ResearchAndDevelopmentMember" xlink:label="rgls_ResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ResearchAndDevelopmentPlanExpectedTerm" xlink:label="rgls_ResearchAndDevelopmentPlanExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueRecognitionPeriod" xlink:label="rgls_RevenueRecognitionPeriod"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RoyaltyPercentageBasedOnNetSales" xlink:label="rgls_RoyaltyPercentageBasedOnNetSales"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SanofiMember" xlink:label="rgls_SanofiMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ValidationOfMicroRnaBiomarkerMember" xlink:label="rgls_ValidationOfMicroRnaBiomarkerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_AgreementAxis" xlink:to="rgls_AgreementDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_AgreementDomain" xlink:to="rgls_HCVAllianceMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_AgreementDomain" xlink:to="rgls_ImmunoInflammatoryAllianceMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_PreclinicalMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_ClinicalMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_RegulatoryMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_CommercializationMilestonesMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ResearchMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_RegulatoryAndCommercializationMilestonesMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_CommercializationMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_FourthMicroRnaTargetMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_DevelopmentCandidateMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_PhaseOneClinicalTrialMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_PhaseTwoClinicalTrialMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_ProofofConceptTrialMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_CommonStockPurchaseAgreementsCspaMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_AmendedCollaborationAndLicenseAgreementMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_ValidationOfMicroRnaBiomarkerMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rgls_LongitudinalStudyOfPatientSamplesOnMsTherapyMember" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CustomerAdvancesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RecognitionOfDeferredRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_RoyaltyPercentageBasedOnNetSales" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_DeferredRevenueRecognitionPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_DeferredRevenueRemainingRecognitionPeriod" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdjustmentForAmortization" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_CollaborativeAreasGranted" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_CollaborationAndLicenseAgreementEnteredDate" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_ResearchAndDevelopmentPlanExpectedTerm" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_CommonStockTransactionRestrictionPeriod" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_FairValueInputsPeriod" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rgls_RevenueRecognitionPeriod" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rgls_DevelopmentCommercializationAndLicenseAgreementMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rgls_ResearchAndDevelopmentMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="rgls_StrategicAlliancesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="rgls_AgreementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_GskMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_AstraZenecaMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_BiogenIdecMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_SanofiMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComputerHardwareAndSoftwareMember" xlink:label="rgls_ComputerHardwareAndSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LaboratoryEquipmentMember" xlink:label="rgls_LaboratoryEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rgls_LaboratoryEquipmentMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rgls_ComputerHardwareAndSoftwareMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfIntangibleAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LicensesMember" xlink:label="rgls_LicensesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="rgls_LicensesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:label="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AdditionalTenantImprovementAllowance" xlink:label="rgls_AdditionalTenantImprovementAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="rgls_CommitmentsAndContingenciesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommitmentsAndContingenciesDisclosureTable" xlink:label="rgls_CommitmentsAndContingenciesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ExtensionPeriodOfOperatingLease" xlink:label="rgls_ExtensionPeriodOfOperatingLease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeaseExpirationMonthAndYear" xlink:label="rgls_LeaseExpirationMonthAndYear"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeaseTerminationNoticePeriod" xlink:label="rgls_LeaseTerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NumberOfLeaseExtensionOptions" xlink:label="rgls_NumberOfLeaseExtensionOptions"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OfficeAndLaboratorySpaceMember" xlink:label="rgls_OfficeAndLaboratorySpaceMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OptionalLeaseTerminationDateMonthAndYear" xlink:label="rgls_OptionalLeaseTerminationDateMonthAndYear"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ResearchAndDevelopmentMember" xlink:label="rgls_ResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TenantImprovementAllowance" xlink:label="rgls_TenantImprovementAllowance"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TenantImprovementAllowanceInterestRatePercentage" xlink:label="rgls_TenantImprovementAllowanceInterestRatePercentage"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TypesOfFacilitiesAxis" xlink:label="rgls_TypesOfFacilitiesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TypesOfFacilitiesDomain" xlink:label="rgls_TypesOfFacilitiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rgls_CommitmentsAndContingenciesDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_LeaseExpirationMonthAndYear" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_OptionalLeaseTerminationDateMonthAndYear" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_LeaseTerminationNoticePeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_NumberOfLeaseExtensionOptions" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_ExtensionPeriodOfOperatingLease" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_IncentiveFromLessor" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_TenantImprovementAllowance" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_AdditionalTenantImprovementAllowance" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rgls_TenantImprovementAllowanceInterestRatePercentage" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureTable" xlink:to="rgls_TypesOfFacilitiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_CommitmentsAndContingenciesDisclosureTable" xlink:to="rgls_CommitmentsAndContingenciesDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_TypesOfFacilitiesAxis" xlink:to="rgls_TypesOfFacilitiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_TypesOfFacilitiesDomain" xlink:to="rgls_OfficeAndLaboratorySpaceMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_TypesOfFacilitiesDomain" xlink:to="rgls_ResearchAndDevelopmentMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeasesFutureMinimumPaymentsLineItems" xlink:label="rgls_LeasesFutureMinimumPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_LeasesFutureMinimumPaymentsTable" xlink:label="rgls_LeasesFutureMinimumPaymentsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rgls_LeasesFutureMinimumPaymentsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_LeasesFutureMinimumPaymentsLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_LeasesFutureMinimumPaymentsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_LeasesFutureMinimumPaymentsTable" xlink:to="rgls_LeasesFutureMinimumPaymentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AprilTwoThousandEightMember" xlink:label="rgls_AprilTwoThousandEightMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DebtInstrumentsAmendmentDate" xlink:label="rgls_DebtInstrumentsAmendmentDate"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DebtInstrumentsMaturityDateMonthAndYear" xlink:label="rgls_DebtInstrumentsMaturityDateMonthAndYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage" xlink:label="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable" xlink:label="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OctoberTwoThousandAndTwelveMember" xlink:label="rgls_OctoberTwoThousandAndTwelveMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TermOfDebtInstrument" xlink:label="rgls_TermOfDebtInstrument"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_TermOfDebtInstrument" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_DebtInstrumentsAmendmentDate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesIssued1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="rgls_DebtInstrumentsMaturityDateMonthAndYear" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="rgls_StrategicAlliancesAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rgls_AprilTwoThousandEightMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="rgls_OctoberTwoThousandAndTwelveMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_GskMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AstraZenecaMember" xlink:label="rgls_AstraZenecaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_BiogenIdecMember" xlink:label="rgls_BiogenIdecMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_CommonStockVotesPerShare" xlink:label="rgls_CommonStockVotesPerShare"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ConvertibleNotesMember" xlink:label="rgls_ConvertibleNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EmployeeStockPurchasePlanTwentyTwelveMember" xlink:label="rgls_EmployeeStockPurchasePlanTwentyTwelveMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="us-gaap_FairValueByShareholdersEquityClassDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_GskMember" xlink:label="rgls_GskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScenarioOneMember" xlink:label="rgls_ScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScenarioTwoMember" xlink:label="rgls_ScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="us-gaap_ShareholdersEquityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="rgls_TwoThousandTwelveEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UncategorizedAbstract" xlink:label="rgls_UncategorizedAbstract"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnderwriterMember" xlink:label="rgls_UnderwriterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityIssuancePerShareAmount" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rgls_CommonStockVotesPerShare" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="rgls_ConvertibleNotesMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByShareholdersEquityClassDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rgls_AstraZenecaMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rgls_UnderwriterMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="rgls_ScenarioOneMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="rgls_ScenarioTwoMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="rgls_StrategicAlliancesAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ShareholdersEquityClassAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rgls_TwoThousandTwelveEquityIncentivePlanMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rgls_EmployeeStockPurchasePlanTwentyTwelveMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareholdersEquityClassAxis" xlink:to="us-gaap_FairValueByShareholdersEquityClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_GskMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_BiogenIdecMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_UncategorizedAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EquityLineItems" xlink:label="rgls_EquityLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_EquityTable" xlink:label="rgls_EquityTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UncategorizedAbstract" xlink:label="rgls_UncategorizedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_EmployeeStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_EquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_EquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_EquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_EquityTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_EquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_EquityTable" xlink:to="rgls_EquityLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_UncategorizedAbstract" xlink:to="rgls_EquityTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:label="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTable" xlink:to="rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation" xlink:label="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsIncomeTaxBenefitExpense">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ComponentsOfIncomeTaxExpenseBenefitTable" xlink:label="rgls_ComponentsOfIncomeTaxExpenseBenefitTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ComponentsOfIncomeTaxExpenseBenefitTable" xlink:to="rgls_ComponentsOfIncomeTaxExpenseBenefitLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rgls_ComponentsOfIncomeTaxExpenseBenefitTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxRateReconciliationLineItems" xlink:label="rgls_IncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxRateReconciliationTable" xlink:label="rgls_IncomeTaxRateReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" xlink:label="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" xlink:label="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rgls_IncomeTaxRateReconciliationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_IncomeTaxRateReconciliationTable" xlink:to="rgls_IncomeTaxRateReconciliationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureComponentsOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" xlink:label="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" xlink:label="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesTable" xlink:to="rgls_ScheduleOfDeferredTaxAssetsAndLiabilitiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_FederalMember" xlink:label="rgls_FederalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum" xlink:label="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_OperatingLossCarryforwardExpirationYear" xlink:label="rgls_OperatingLossCarryforwardExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfIncomeTaxesLineItems" xlink:label="rgls_ScheduleOfIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfIncomeTaxesTable" xlink:label="rgls_ScheduleOfIncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:label="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="rgls_FederalMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rgls_ScheduleOfIncomeTaxesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="rgls_OperatingLossCarryforwardExpirationYear" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesLineItems" xlink:to="rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="us-gaap_AwardTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_ScheduleOfIncomeTaxesTable" xlink:to="rgls_ScheduleOfIncomeTaxesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureChangesInAmountOfUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AlnylamMember" xlink:label="rgls_AlnylamMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty" xlink:label="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rgls_AlnylamMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SelectedQuarterlyFinancialDataLineItems" xlink:label="rgls_SelectedQuarterlyFinancialDataLineItems"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SelectedQuarterlyFinancialDataTable" xlink:label="rgls_SelectedQuarterlyFinancialDataTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="rgls_SelectedQuarterlyFinancialDataTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_Revenues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_OperatingExpenses" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_SelectedQuarterlyFinancialDataLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_SelectedQuarterlyFinancialDataTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_SelectedQuarterlyFinancialDataTable" xlink:to="rgls_SelectedQuarterlyFinancialDataLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerAdvancesCurrent" xlink:label="us-gaap_CustomerAdvancesCurrent"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DevelopmentCommercializationAndLicenseAgreementMember" xlink:label="rgls_DevelopmentCommercializationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_SanofiMember" xlink:label="rgls_SanofiMember"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesAxis" xlink:label="rgls_StrategicAlliancesAxis"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_StrategicAlliancesDomain" xlink:label="rgls_StrategicAlliancesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rgls_DevelopmentCommercializationAndLicenseAgreementMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesAxis" xlink:to="rgls_StrategicAlliancesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rgls_StrategicAlliancesDomain" xlink:to="rgls_SanofiMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CustomerAdvancesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="rgls_StrategicAlliancesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_AccruedExpensePolicyTextBlock" xlink:label="rgls_AccruedExpensePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rgls_AccruedExpensePolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_RevenueFromStrategicAlliancesTableTextBlock" xlink:label="rgls_RevenueFromStrategicAlliancesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rgls_RevenueFromStrategicAlliancesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:label="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDefinedContributionPlansTextBlock">
    <loc xlink:type="locator" xlink:href="rgls-20131231.xsd#rgls_DefinedContributionPlansTextBlock" xlink:label="rgls_DefinedContributionPlansTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rgls_DefinedContributionPlansTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g652681ex10_52pg133.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g652681ex10_52pg133.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.@#Z`P$1``(1`0,1`?_$`.4```("`P`#`0``````
M``````D*!P@`!08!`P0"`0``!P$!`0$``````````````@,$!08(`0D'"A``
M``8!`@,"!P8."PL-`````0(#!`4&!P`($1()(1,Q%!4V-S@*02*3-&0U46%Q
ML3)2,U.S%F87=SE"TB-C5&5VEK:7MX%B576UU2965V<ZH='AHD.#=-;7&'BX
M&1$``0(#!`4&"`H'!0D!`````0(#`!$$(3$2!4$R$P8'46%Q@;$(D<'1(G(S
M%#6A0E*"0S05=94W\/&RPB,DM.%S1!8VDJ*#TU241548%__:``P#`0`"$0,1
M`#\`8KW[;P=P^&-PK^CXWOQ:]6$*?591*-&N5F3$KZ23?&>+>-2D2\=CWPHE
M]Z)^4O#L`->?/>.XW<3=P^)KN[^ZN8BFRE-#3N!&P8<\]87B.)QM2K9"R<AH
MCTG[K_`/A1Q#X4-;R[WY6:O.E9A4MESVBH;\QLHP#"VZE-DS;*9TQ3#_`/1?
M>)_M9+_,RD?^7]?"/_J#CA_[D?\`:TO_`"8T-_\`)G`'_P!$?^[K/^?$EXVW
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M%)4FLJU)4DVA25!\A23H()!T08KISYPR?G7$MRLV4K(%EFHK(3F#8/`BHF*[
MB,3KT"^(V[B(9,D%.#IZH;G,43^^X<>``&MQ]UW?_>SB)N779MO?5>UU[.9J
M:0K9MMR;#+*PF3:4@^<M1F1.V^//_O;<.-S>&>_679/N32>QY<_E*7EHVCKL
MW"^^@JFZM:AYJ$B0(%DY3)BCF]K>?N1Q)N3OE!Q_D(L%5(9I5%8V+&LU>1%N
M>2K$7(/1\;DHAT\5[YXX.?WQQY>/`.```:SYQ\X[<4]R^*F8[N;M9F*?)F$4
MY0WL*=>$K8;6KSEMJ49J)-I,IR%D:4[N7=ZX1;]\'\KWHWIRHU.>5"ZD..>T
M5+>(-U#B$>:VZE`DE(%@$Y3-L1_MZW=[Z\SY5I]6@+7)VZ++9:^M<TX^D4Y)
ME&U3RJU\MN9:6+!MT(I`T:"H%,95-4YNQ+B?@&JWPSXU]X;?O?&AR?+:QVMH
M_:V35!%+3!#=/M$[53CFR`;&SQ2)4%$V(FJ46GBMP'[L_#S<C,,[S6A9H*WV
M-\4A76516Y4[)6Q2TUME*=4',)("5)`M7),S#%0G'B/`>SCV=@:]/H\F(7#]
MH?ZE.['ITU':9)[5IZDP<MF.\9+KEM&Z4EA<D7;>NPM2=0*;$CYVT+&G(]F5
M>\.`CSE,''@!=2^4T;%8IP/@R2!*1E?.(/.Z^IH4MFG(!62#,3NE%6TK3[76
M#5.21H^T*31%`CQ)F1QA<%'B1DP6(B4!NC'WZI1``#OD^T?L@\.E\.0SE-P>
M&&V+>6^31_V?+%J.DAUJ,L;HMP.1-@F_'#\7@7>MC9&=<,FL"SD8FN7PE331
M7M4&O7I22G%Z[<(6,73DT1;OWL9,11CNFIR%3Y5$*_+D,M"JI5%5,?@G=;I'
M88<Y;FKE0^JBK$A%6F=UQE?9;;IOD1:(O-UH=V>9MDO3TS!N+P')P$3D^FSN
M,6$&^L]>;VB&2;6C(E<K<N5S"NEFZ+DZD5)JE3$3AW9Q`P<>'#37+F&ZFK2R
M[/`9W6:(=YK4NTE$I]B0<!$IB=Y`@!VWW<U[5+NAPQCS<!AF`VJ6#%V4X!.S
MTJ9DX_#]=?R$,JZ<LR+NH26MB$C'*BNT.'=JD*<``!]W4JZSDC+A:<*PM)D;
MS$,S4;Q5#27F@V6U"8U1XX(%LPF?:47&Z#$2.]2J;;H_:VI,S`9?>4MQB8]H
M0A0JD^:&-$%@+.^F!6-;`CRG[A(YNZ$_$.7B(-:@9/L5>S%>WE9.<K_)#VE.
M>FH3[6&_9YVRPSNYCRP>?.F=<6;:L2WK.6;;E&4+%^.(->?MEGEA.*#)FB8B
M2+=JU035>2<M)O%4VS-FW34<NW2J:*1#'.4HQ;32WG`TV)K4;!$R\\VPV7G3
M)M(M,*.O.MKU;>IED>UTOH];3F-3Q+4I$\8^S3E2'@)>6`RA3':.+)/W&9C,
M1461?-2=^E")EGI0B1@,8P^`)[[-H*-`5F#DUG0)_`!:>FP16OM;,J]91EC<
MFQ\8^.?FCHM,;U>N^U\8];K6E.XX0RF#9,SMQ3D3[:Y%RNF0.].U;M%JU1!6
M5$/>@5"1*H;P%-QX#KD\@7YLE)Y_.\ICN'>9'G30KF\WR#M@Y'21W2[X]T^!
M[S8=^&VYGMRRICS)TCC-LT0CK%5U[ZG!0\6]E[2:CV4TBXK[%%_)E;(.&TD_
M82)DU%&YB$(`#&5[%,PZ!2KQME,^67-/^R)?+:BKJ&2:QO`XE4M(GSR/EMB@
MW69ZF^[+95O;Z>>#<"V"D1./MQ=@B([*#.S49C9Y1\U>9AH],7+#2KIVW5A3
MC!3K@@&(4W!02G\)>&G6743%33.NN@XT"RV6@F&>:5]1253#+)&!PVS$]($,
MH"8W$>WW1]P-0\3L49ZF&>LC;8-@^ZK<#B5[%1^2L38CG;A3'LY$HSL0VFV"
MK0K960B%U$49!N!5C<4S&`!TYHVD/53;2]12@##2O>73T;C[>NE,Q%<^B%O#
MSAOHZ?M#W#[A)2NR^39^_95K\D^JU;;56'/&U.YOX6&(E#-5W"**R;!N4%#@
M814-Q,/#2V94[=-5%IJ>``7VWB$,IJG:RB2^]+:$D667&44AWT]3?=E@7K<;
M'=C6.K!2&>WS.S/#BV0X>5HS&6M+Q2Z7K(,#.C%6I5VFZB@5CJZV*D!$S=T<
MIC!QYA#3FEHF'<M=J5@[5.*5ME@&CKAI5U]0SFK5(@C8KPSLMM)G;#*`F-Q'
MM]T?<#4/$['-W&5>0M0M<PP.0CZ)K4])LC*IE53*[813MVV,HD/`%"%62*(E
M'PAV:,D`J`-TX*HR22+Y0OE[.YU)]U/4=QEN?M&Z.>I<[+XLR/1*U4%*;26-
M+0;Q4_59.6DDWR#)TZ*_6.\:D$AS"`D*`@'AU*YM1L4:T)9!`4#.9GIB&R6N
MJ*YMQ5002E0`D)0QASF^C_R!_P`VHB)N%MMXW4TW888ZZ&S;8;1+!26NW7-,
M%B]_?(:2H[&3M;MS:93*#68-&VQ5VF[C"*HU5F"92IF[L2F$/LAU,T]$PYEC
ME4H';)G*VRR6CKB"J:^H:S=JC21L%@3LMMGIZH-QN]W3XTV5[<<K[F\O.7A*
M-BFN'F7C"+*@I-V*5=.F\57*I`(.%$45YRSS[YLR;`<Q4RJ+`=0Q4RF,$93L
M+J7DLMZRCX.4]42U34-TC"JAW42/#R`=,*38VWU^TC=4IC-9JV14#%NV_;@>
M;D(ZEOI1ECMNE,DBW*S-9LUN>7&-CF[Z\9+I&1?/HN(81!7A#I$Y3)F*$\NF
MR>A(;J2I;TK;^P7=9G%;;K,]S$%VD2EMB=EW:9SZ0`(L%MVWG>T:;<=TF!\#
M;V-K59S_`(YS;?X2A%R-7H>K1C"LMGJJCJ8LR^5\-#(4V#_%R`9NI!5I885!
M1XBV,FB<B@E$$GJ?*'F5NTRRA:1.5MO-(V^`PLQ59XQ4(9JVPM"U2F)6<\TV
M6"VT0W5Q'[;]EP\`>#Z.H"++"S_5'];*5_1_1_P,GKRC[WGYS/?=M)V.1[$]
MRO\`(MC[UK.UN!V:S#&L8,CTT=S&WW%->EL:W-96BWNWV/RDYO$ZHC^*UB(1
M,&D)#GE2@0*YY+0,8"$=@#=1990X+`8_=AN;NI<5^&FYN6O;J9ZHY=O%6U6-
M56\1[.]9A::+EFPV8F`')(4I2E!<U81Y]]\3@[Q5WXS5C?#=Y(S/=F@I-FFC
M9!]I8).)YT-6^T;14BHM36E*4)+<DXB1K<;LLPMN99&F9)F2KWI5J0\7DBJ(
MM2R#DAB<S;RXV()&-JCA(8!+WP]\!.'=+$#6H^*/`7</BQ3^W538I-X2B;==
M3A.-0EYNU2)(J$2E+%YTM1Q,9(X2=XGB)P<J1E](X:W=E*R',OJ2K9I,Y*V*
MC-=,Y,6X/,)UVU11_;IF3%/3Z3RA@+-5O/+6QO?@LC9]1(*4L$6M"RE9@4F'
MCQDB`>(F>#0PKLE.8Z`&(/,<I@'6?N%^_.YW=I1F_#??VN+V<IS+;I72-./-
MEIQAD(QR$VW?-)6TJ93,&9!!C27%KA]OOWJ59+Q1X=4`8R-65^SJ16O-,.!Y
MNH?*\`)DZSYP"'DR"R%#"DI(C1Q.W*B=0C<%D;/\??5F.&$9&KP*D*R;'C\A
MR\E#52%0>M7C)\F<M6B5S$-W+HY5E7)0$4B%X"<L=1<+MW>\OQ+S3B339B6]
MQ$NT[):0DHK7%M4[06E25@^SMFW"X0I2Q/`D2Q"2KN+>\W=4X5Y1PMJ\K2[Q
M#4S4O!Y:@Y0--NU+RD*2M!_F719C;!0ELD8U*F$DK=?@L)[:J;#UR&1J>,JL
MO)QT+&(JK(,G$_8)1RBP8HG<N#GD['/R+E<I>8YEW!^/;[T.S9&6Y=N!PIR)
MC*Z%-%E.4*=0TV"0E3SSB@A`*E$N/O+40)DK6>@68=S7,^(W&'>&HS?,%5V<
MYVEEQYP@%:6&&TE:R$I`;IV&T@F0"$#I-LRZO<?/H37]K[\S.G?^F'+G^1<<
MZL.0:SOHI[3%7WEN8])7BAPZ.<-XZMQSR0<(,6C.$8K.W3Q9)JW:HHL4C+*N
M5US$3022*41,8P@!0#MU7S:9#EBSBQ,S=*$CL>6"#WL>U<K9=VRRB-LQ?@^*
M(\R+DJJB#ZKOVF-\&.L7V-Z2:8"HQD(V;O4XW@&C@JADGWBYCHF.D7FU9%`T
MV1[-ZQ:K@;[53[+8J:%"KWCVE/:V@6D76)D?AL@T_M*WZH#<5_*G"']L5,U'
M9/[P1U]AB4S[W8OI3^T(Z#HH[BMO=0Z5&Q^M6W/&&*O8XC"[)K+0%BRC2(6;
MBW06"?.+:1BI*<;/F3@"'`1(JF4P`/@T7,F755SI2E1&+D,&RI]A.7-)4M`4
M$7$B#"T?*^+,G>4OS:9,Q]D3R+XKY8_$6YURV^2?'N_\1\I^0)&0\0\<\55[
MKO>7O.[-R\>4>#!3:T:X(Z1*)1#K;GJU)5+D(/9"=_M065,E9\W.[$>EYC26
M.R:Y6G:K?+,R16.#>6NF1+ZOBK&!II$!`CAE3VS.8D@2-Q**C@B@^^3((3^2
MH0TP[6KO38.@"9\-@BL;P../5#.7MW*()Z29#P6F&S]K>V7$VSS`V.-NN$ZZ
MUKM!QO7V<.S*FBD21GY0J)!F[=9'290/*6BT2?>/'[I01,JNJ/#@0"E+!/O.
M5#I><,UJ/Z#H$62GIVZ5E+#0DA(\/.><Q8#24+1G'CX="!"6/M)7ZSKI`?RN
MKW_V+Q=JQ9/]2J.C]TQ5<]^OTOI#]H0Z>/A'ZH_7U78M4"VZV?ZIS?I_\?+5
M^'C]/<M^O->F(CLV]VO>@8IO[,%^J.Q3^EG/7]I,MIQG/U]7HI[(;;O^[4^D
MKM@8'5._XG;I=_XOVX_VI9=T^H?<K_SNQ,1^8^_J?YO:8=0'PC]4?KZKD6J.
M+R/Z/+[_`"*M7^0G^C(UQTB"KU#T&%#_`&/#T(;Y/TS8J_H'-ZG]X/6M^B>V
M*UNSZI[TQV0Y'JO19X2ZZCG_`!3'3>_DM@W_`"YG+5DH_<;WSOW8JM;_`*A8
MZ$_O0<7KM[3,H[S.FMF[%&%X]U8,F0<C3,J5BG,>`O[TIC:PMK!)T^-3$Y`<
M3,M#)N!8(]HN'Z:*0=IP$(O*WT4]8E;EB#,3Y)B^)?.*9RJH%MM6N"1`Y9&<
MO)SP);H"]:;:U';=L/\`3\W&S+#;AFW"+-UC*HR-^$*U0\EMFLX^.P8J3LDF
MS:4K)359Z9H_B9<6QG3I$5&ZJBBIFZ3_`#7+GR\JJ9&-M5IE:1Y1SB(W)LUI
MPPFB?(;=18)V`]>@\H,-SIJ$43(JD<JB2I"J)J)F`Z:J9R@8AR'*(E.0Y1X@
M("("`Z@(LL?K0@0M'U1_6RE?T?T?\#)Z\H^]Y^<SWW;2=CD>Q/<K_(MC[UK.
MUN!V:S#&L8\#PX#QX<.`\>/@X>[QX]G#AKAE*VZ.B<[+X+IT]9/>^HB9OCA%
MM(863:OB)*9:4DTZ:U>D;K^*IT5ZD12=,L5YR\Z+(#QH<1[WD,(&UM7NS5?>
M`6WLMUDH=W""%@',2X*9*L)PBD4`7IXI32U-CY>$VQ@[O6T?=N0X'=[E+:XB
ME:"1E@;-6I!4,1K4$AF6"<EO2J+L&(60+B^JV]>\W);()GYKXI:)PUR&3`0D
M/QE\HN`F"NBCV%.1Z!@``]Z!``"^]X:R)O&O.W-X:Y>\NT_S$:MWVK::^WQG
M:XN<*F!HE*5DHVINPC(&]VLO;W5V0W8%$S[)L]3V?9IV6'E!1(DFTF<[9Q>G
MIPO-P2.1LC-\%)5IR"N/'J]B;WE:41IP22+@I:>LY/%D.N$X,@HN1L`<`,W,
MXYS%(`B&ANZV_P`2F]Z,T:X>)I5SRQ9>%67!3;0'^6*BW,[7&5A%P*"YB(2)
MC-'>YI^%;FZ.4.\3%5B,.;(#"J,-FKV93_-!(<(&QP!!<-LEAK""HR,?W)[N
M,=[L<7$W,&M!+JEE.C>(M9PI4H%!@:X18<:4BQ_T>"$,(=AV'$I_^T,)^.JU
MGK_%![C+E`XK^UC/QF])@2Z),A'M+?U4(_@[+D+,P?C$JG%JW>I^$K'`W.E<
M'/8CNZK)*S&IDS>4OV5SZV5_Q]L-(>D1\0!,H:;'PC]4?KZ]@(\3H3-]L(2[
M_'W3];\YD_&,IYI;]X7[-/OZYCY'O"=H>_3Y^(?3#5AW?UG?1':8JV\^HQZ2
MNP0.CJX=#;*VPW:]6MRV-MSN?MS6*F,U#Q^?*C>)F2B5:E5K&$>A`6)H2+F9
M9@XKJ\POY,D%'+=3Q$[QJL`'3!;E>4&9-U3Y96A*')>:1I/ETPQS+*'*.G%0
MVXMQJ?G`FX&X]&@PV)T2L/=/ZF[*,?Y9V!T8M<J>:XB/F,A3=CFE+;EAS>8$
MJT7.TW)5H=E3<'DZ%,^-,DV3=%G&I@(N&K<A'/.I!9DY5*J2W5&:DW2L$N4=
M/ABR92U1)I$NT8DE8MG:9\A/-X.2(@]I6_5`;B?Y4X0_MBIFCY/[P1U]AA'/
MO=B^E/[0@3730]G(Z=6[S8=MBW*Y;'/09)S#C9M;;?\`BODV,AJ_Y66EI5B?
MR7%K4Z049->Y9$X$%900'B/'MU(5N;U;%4MEO#@29"S^V(Z@R.AJ:-M]W'M%
M)F9&SLAA7IV])K:ATP#99-MC')HCFC\3?QR_.+<&=K`/Q%"QA!^2?%("$\1\
MZ'7?<W>=Y[SAR\O;$U=>_6X=MA\V<I"5_P"J)NARVFR_%[/B\^4YF=W5SPLY
M[0A)K[4^M+TX]ZEB9.UL<1T7B*:D7W<F%N13"6:I)_>V""@@)#.650N;-V!/
MLO?\>&IC*AM\N>IAKV_"+/A$0&=$TV:L5:O5C#_NJM^`P\-$RT7/Q49/0<@S
MEX2;CF4Q#RT<X2=Q\I%2;9)['R+%VB8Z+IF]:+$424((E.0P"`B`ZK9!!D;Q
M%M!"@%"T&/,JZ4914F]1`@K,XY\Z2!0!,056[559,#E`2B8G.0.(<0XAH"TR
M@$R!/-"__0)ZH.Y#J953=9-;B8O&$:\PMD&AUBH!C2LS-;16C;+$6A](FFB2
M]FLAGCHJT.EW9DQ1`I1,`E'B`A*YK1,T2D!G%)0,YF=W4(ALFS!^O2X7\/F*
M`$A*^?.8%Y[2BH1OU,^D(Y6'D02MD"8ZINP@`GN*Q<8_OAX%]Z40$>WL`=/<
MGMHJ@<W[IB/S[Z_2^D/VA#J8^$?JC]?5<BU0++K;J)I=)K?H90Y2%';_`&9,
M!,/`!.L[C4DB\1]TZAP*'T1'3[+?K[7IB([-O=KWH&*>^S!D.3I&XG$Q3%`^
M5\\G()@$.8@Y*F"@8O'PEYBB''Z6E\Z^OJ]%/9#;=_W:GTE=L"^ZIW_$[=+O
M_%^W'^U++NGU#[E?^=V)B/S'W]3_`#>TPZ@/A'ZH_7U7(M4<;D4ICX^OA2@)
MC&IEI*4I0$1,88)^```!VB(B.C(UQTB"KU#T&%"_8\#E_,KOG1Y@[U/,F)SJ
M)_LB$4HT^0AC!X0`QTC`'TRCJ?W@]:WZ)[8K.[/JGO3'9#DNJ]%HA+;J,*$5
M]J<Z<B28\ZB%7P8"Q2^^%,1E\Y+!S`'$0_<AYNWW.W5DH_<;WSOW8JM;_J%C
MH3^]#I0^$?JC]?5;BU0%GJ/=";9)U%?+=UG:VKA+<-)(B8N=\7L&+64G'A0$
M$C9+J"W<US([;@/`ZKD&\KR`4J;Y,I0+J1H\SJ:220<3/R3XCH[.:(JNRBDK
MIJ(P/_*'C%Q[>>`#;*MS>^_HC=1'$_3&WC7X^:]K>9YBIUS%-E?/Y2595>&R
M#.N*G0[_`(NEIQ1:>KU=:7!'R9/U9TJX:,![Q5GR\$U7,K4LTN94BJVG&%](
M,QRRM(/5:#X8AJ6HK,IK4T%4K%3K(`/).P$:0)V$>"'H.4?^MR_W=5F+="T/
M5'];*5_1_1_P,GKRC[WGYS/?=M)V.1[$]RO\BV/O6L[6X'9K,,:Q@OW3:VN8
M`S'#3.1;VLO>+=3[`6/<8XE$R-ZS"IJ)^-0LV_:)*'6M"4H0AA3!8Q&J:J*B
M9T5!*!QVWW5N$7#;?FA?WGWB4K,,[H:G`JB<`2PT",33JT@SJ`X`<.(AL*2I
M*FU2G&".]]QIXI</\PI]TMV$IRW(<PI<::]LE50\0<+S*%$`4Q;)&(H!<4E:
M%I<0#A@IV?-UN$MK\(BTM4H@K/D8D+7L;51)JO8'+=-("-"ECDCHLX"(*!2E
M!=R9!$"`()@<P<@[!XC\9-P.$=`EC-WDG,@V-C0TX27E`"2?,$DLMW`+<*$R
MU<1$HQ-POX'<1^-&8JJ,D94G*RZ=OF%25!A*B9J_B$%;[MY*&PM<[5E(.*!W
M83P/B3J)/<I[@\BPUBQ[,N;X6MMX''D^Q:QZL?%UN#6;24TK*P$B>1LCLKO@
MZ<I%;)*<A>"0"!C&S%N!PZW+[SS^<<3-YV*K+*Y68[!+-$\E*"AMADI<=+C*
MRM]6+^(M(0E4A)`,R=9<1^)^_?=-I\DX5;I5%)FV7HRLU"GJYA:G`XY4/!3;
M(;?;#=.G#-MM1<4G$J:R)`>BEY[Q;T\,[Y+V\J5&8DL9O9*K3JF02N4Y6_LG
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MCES,/#C_`(BQUJPY!K/>B/'%6WFU6/25XH;FGJ#3LJXCDL9Y"@&%JHE_Q^K3
M[A6Y1(%X^;KEA@`BY>-=)\0-W;IDY.7F*('((@8H@8`$($+4VYC09*!F#%E*
M$N-;-8FA29$<Q$)>;",CV_H&=5;(/3FSQ89%39?NJLL9/8*R%8%%2Q,-)V-V
MI#XONZCU<",VJDB*9:?<#%$B:<DR:/3B5`G,>Q52$YK0BK:'\RV/.`^$>,>"
M*M1N*R;,543Q_E7#-)//8#^ZKGD8-/[2N(!T@-Q0B(`'XTX/[?<[<Q4SAJ-R
M?W@CK[#$IGWNQ?2G]H0&/IQ>TI;*=GNQS;5MDR+BK<C.W?#6.F]0LDO3ZSC]
M[67\BC+2CXR\,ZE<B1$BNS,D])P%5LB?F`0Y>SB,E69/4U%2MY"D!*C.V<^R
M(RASVEI:1NG6EPK2F1D!+M@I>V3VFG9%NIW"X=VW4/$NY>'NF:[Q&4*LRMIK
M&/6E<CY:42<JH.9IS&Y'DWZ#`A6IN<R+=8X"(<"CIB]DU2PTIY2D84B9D3Y(
MD*?/J6H>2PA+@4LR$P)=L7]ZL736HW4\VM2F%IF4:4_)U4DC7?!N27+0[M"G
M9`:LG#(&TV@W(+QY3+7'KG82R"/[IW1R.$RF6;I!IK05BJ)_:"U!L4.4>4:(
M>9E0(S"G+1L<%J3R'R'3"KNU+JU;^.AH=ALKZDVV>^WS"5($\1BVYL'B:5@K
ME7;+F2:L\:Y$D"?B#EW'#<A1\GLEWK"2BTQ\7,L0B9&B4V_04N9_S-(L!PW_
M`-HO![?ABO4V95F4?RM>V2T+CR#F-Q')I$%)L_M9O3(/3GZD33]TLK/R$4[;
M(5LV.:3'*E=N6JB0(KS#K)AHDB0*'X=XF=;L[>4?!IDG(JW%:42Y9GR1(*WC
MH"BP.8B+I#RQ`7LA5:M$9B'?'9IFK66#@;CEC%#VK2\U!2D7&6)%I6KF,@>!
MD7S1NSFB1IWJ1%SM3JD2.H4#"`F#2N?J27&@")A)GX1".[25!IY1!"2H2Y[X
MNQ[1?TU\P[VL%8ES=MDCG4[N(VEV*=M4'4(@4DK-=Z5.^1)";94]18Q4G5VJ
MLY58^5BV9N`O>[<()\RZB)#M\HK&Z9Q33]C3@E/0#S\QG(P[SR@=JV4NT]K[
M9G+21S<XD"(K!M!]JFVV?F]BZ'U`J3E7"&XZD,DJ]?Y&`QU)6&I6J=B4_$WL
MR%=9&0N=#G))9$5'<2\C10:.#'*DX.3E`JU1D;V/%2E*FC=;(CQ$<\X;TN\3
M&#!6A2'TV&R8/5>.B44KZD_67N_6*A$.FWTM<&93N\7F"8AF^4[Y98%"$DY^
MN0TJRFD(5M&I/)!MCO'J<K'HO)N?G7+,XM&_BY$"%4.8[BCRY.7GVNM4D%(L
M'Z7GD`AK79JO,Q[#EZ%$*-I-DQXARDPV=TY-H378ALJP'M:)+-+!,8TJ)RW.
MQL$5$&4_?K+*/[5=Y-@18"K^3%++-.$V8J%*IXHFES@!N(!!5E1[54K?E(*-
M@YA8(L=#3"CI44\YE(M/*3:?AA1[KPYXJ>U[K[['-Q5[CYR7IV%,88.R)9HJ
ML(,G5CD(:`R;EM5VVA&TB^C&"\@H4X=V59P@F(^$X:GLK:4]E3K*)8E*4+><
M)BMYNZEC.&GUS*4)23*^PF"*C[7-T]1$1_,GNU_FAB__`-5M-/L&K^4WX3Y(
M??YDH_D.^`>6"X=-7JF8"ZJ%/RW:L'TK*%4B,2V2!J%G9Y4B*U&N))U:(5U+
MMCQ:5=L]G1<,BLVYB*BL9(W,/`"B';IA64+M"I*72DE0G9/1T@1)4&8,Y@E2
MF@H!)D9RT]9A5F%L.Y'V9'?OFR;LF(K/E_IT[H+&H^8V:KI@5)&(;2\S,TH6
M,\X*6%K^6<7M[&\BW41+*,VT]'F[YNL7]R51G"&<YI4@*":M`_7U&^8NBN@U
M&05BU*254+AO'P="A.4C>(+[<_:M^EW!4)Q9ZF7/MZMQF)U8W'">+QK$FI(B
MGQ08RUFGIE&H1K?O1`JKA!X]Y`XF3(KV`,>G(ZTJPJP!/+/Q7Q)JWCR\(Q)Q
ME7)*7PW10OI*X%W:=3SJ?O\`K/;J,>N,58?IR$B3`E:DF3U@A8W2%:DJ/0X2
MD(23=C)3%,Q[`RSM\^L*B"*,O.K<6Y3%%<J#JO=8HJ+[.9.)PZW-;,SYSR:!
M#/+6:G,,P^U*E.%L:HY=`ES`:=)AB7JP[GMV6T?:9+9@V<;?'&X7)T1;ZR6=
MA_);ZQQE-QTU<*RUSMTM4X"4CKA9&PQD<,>4D4599F=]XXH7N6QP&(H6&*A_
M9U"\")'FF=`G<.N)O,:BIIJ8NTJ,;DQSR&DRO/5TP&3%/M=6R62JJ7Y^L#[B
M,69(8MBI3M:IT93,AUT95%/E=)QDU)6RD33=`[@H\I'T:V52`>4W$0$PR+F0
MU(5_"4A2.4S'B/;$4WO+2%/\9"TN<@D1VCL@=-6NN8/:(>K]MRW!XYPG;,8[
M.=HDA1GDI=+2F10J5;HEW6R6LTFK#'E7K[O(N3+0@@Q:0L:X>>38Y(5UE!*1
M50SPI;RF@6TM054.3LYR)>`#3IADE;N=YFV\A!32M2M/(#/HF3H%PA^+F^E^
MRYO^C56BXPM#U1_6RE?T?T?\#)Z\H^]Y^<SWW;2=CD>Q/<K_`"+8^]:SM;@=
MFLPQK&)2Q3FK)F$92=FL7VAS5I2QUYS691VV1;N3'C7*R+@%$$W::R"$BS61
M`S9P!140,8PD$.8=6_<[?W>S<"KJ*_=&K71UE53*8<4D)5-"B%3`4"`M)$T+
MEB0297Q2M^.'>YO$>BI<NWTHD5M%1U::AM*BI(#B04R)202VL&3C<\*P!BN$
M1W)RDG-R+V8FI%_,2\FX4=R,K*/'$A(OW2H\RCAX]=**N7*QQ'M,<PCJL5=7
M5YA5.5U>ZX_6NJ*EN.**UK4;U*6HE2B>4F+9145'EM(WE^7,M4]`R@);:;2E
M#:$BY*$)`2D#D`$,"](KT#Y#_2P]_HG5]>E/<H_+K,_OI?\`3T\>6'?R_,W*
M?N)']54P-'J0^N)D_P#\!1OZ%PFLH]Z;\\,W_NZ3^E:C8G=$_(#)?[RL_JWH
MB#:YDR_8US7CM2C6J6KJ=DO-/@+$R9..,9/0\G8&#!XREXQ8%6#\AFS@X$.H
MF*B)AYDS%,`#JD\(=[-Y-U-_<L5N]6/4J:K,*9E]*#_#>;<>0A2'&S-"QA49
M$C$DVI(-L7[C3N;NOOAPZS9&\M"Q5JI,LJGF%K3_`!&76V%K0MIP26@XDB82
MH)6+%`BR&ZA\(_5'7M;'@W&DF*Y7;$5N6P0$).E9G.HT+,Q3"4*U44`H*';`
M^;K@@=0"`!A+P$>`<?!KH)%QE'"E*KP#&Y``````````````````X```'8``
M&N1V-%,56KV)1NM8*W`3JK0IR-%9F&CI11J10Q3J$;G?-ES(E.<A1$"B`"(`
M/N:Z%*%Q(@I2E6L`8^^2BHN:9*1LQ&1\M'+"F*K"39-G[)443E42%1J[260.
M*2A0,7B4>40`0T`2#,7QT@$2-T<O^;+&W^SVC?S1K_\`F_7<:^4^&"[-OY(\
M$?2RQ_0XUVW?QU(J#!\T5*LT>LJS"M7;58O'E6;N4&*:R"I>/88I@$-`K4;"
M3*.A"`9@"?1'7:+!HY^T5*J7B&=5RZUBNW"NO0`'L#:82-L,*[`O'@#J+EFS
MMBN`<P_9$'PZZE2DG$DD'F@JDI6,*P"GGMB#879IL_K<B68KNU+;;`RQ%@<$
ME(?!N,HV037*;G!5)XSK"+A-0#=H"4P#QTJ:BH(D7%D>D?+"0I:9)FEML'T1
MY(L:@@@U01;-D46S9NF1%!NW2(B@@D0`*1)%%(I4TTR%#@`````:1A>ZP1[=
M"!%<\M;/]J&>I,LYFS;3@C+$Z0J9"SV0<4TBUSH)I%`B:0S,S"NY,44RAP`@
MJ\H![FEFZA]H2;6I(YB1"#E-3/&;K:%'G`,=WBS!^%\&0RM>PKB3&F(X)P8A
MW41C6CUJD1[M1,!*FJ\;5R-CDG:Q"B(`=0#&X>[HBW7'3-Q2E'G)/;!VV6F1
MA:2E(Y@!V1*.B0I'.2].J,^Y*]GJK6IMX1$K<CN7@HN2=$;D,<Y$"N'K5=4J
M)#J&$"@/*`F'L[=="E"XD04I2JT@$QJ_S98V_P!GM&_FC7_\WZ[C7RGPQS9M
M_)'@C?0]<KU=372K\#"P23HY%7*<-%,8M-PHF42)J+D8H(%6.0@B`"8!$`'@
M&N$DWF<&"4IU0!'FP5ZOVR&D*Y:H*&LU>EVYFDK`V&+8S4+)M3\.=M(1<D@Y
M8O6Y^`<2*$,4?H:`)29I)!@*2E0PJ`*3RQ5:$Z>VPRMV,EO@-E^UJ'LR3CQM
M";C\#XS;OVSOF[P'315.M!XHY*H',!TP*8INT!XZ7-75$82XO#Z1\L-A14:5
M8@TV%>B/)%ODTTT4TT4DR)(HID2222(5-))),H$3333(`$(F0H``````!IO#
MJ/WH0(@.Y;4]KF1IQ2SY"VV8#O5E65!=:PW'#V/;+.++!X%%I69KSQ\L</HF
M4$=*I??0,*%K">8D0BJFIUG$MM!5RE(/BB8:[6JY3X9E7*E7X.K5Z,3[F-@:
MY$L(.&CT0'B"3*+C&[5BU3#[4A"AI,J*C-1),*I2E(PI`">:-WKD=A:/JC^M
ME*_H_H_X&3UY1][S\YGONVD['(]B>Y7^1;'WK6=K<#LUF&-8QFA`C-"!%FL)
M[OLY[>ZY)U3%\[!1<++S2E@?(RE8C)M=2359,X\ZA'+T!532%JP2`"![T!`1
M#M$=?6=P>-O$+AGE;N3;HU%.S0/U!>6'&$.DN%*4$A2K0,*$V77G28^.<1>`
MO#3BKF[.>;Z4M2_F-/3AA!;J'&0&PM;@!2BPG$M1Q7R(&@1%&5,I7+-%YE\C
M7]XR?VJ<2CD9%W'QS>):*)Q4>WC&0)L6@`@D)&;4@&$.TY@$P]HZIF^&]^>;
M][PO;T;R+;<SBH"`M2$);20V@-IDA-@DE(GRFTQ>-R=RMW^'F[3&Z6ZS;C61
MTRG"VE;BG5`NK4XN:U6F:U$CD%@L$?3A3TS8A_2CC_\`I9$Z6W"_UUDGWO1_
MU#<(\1/R^S[[EKOZ9V')!\(_5'Z^O<Z/S[153/N^+:'M8L$/5MQ>X?%^&K#/
MP8V:&B;[8T(-U(0`2"\4,NW!<O(++RDV40YQ,`=X40TNU35#X*F4*4`=$-WJ
MNFIR$OK2@D3M,=SA+<O@+<C3IG(6!\LTO*M)KLN\@9RST^5))Q$7,Q\<SEWL
M<\<E(0J3EM&2""YR^XFJ4?=T5QEUE00ZDI41<8,T^R^DK94%(!E,1^QW)X#+
MA%AN4'+E%#`<I%0LY'9<&=:_B,\B+%,,Z_!2+><YO%E&LK-R*#5`X#P.LJ4H
M=HZ&Q=VNQPG:\FF.[=G9;?$-B=.BVP1OLR9KQ+MYH$ME3.&0JMBW',$YBF<Q
M<[E)HQ$!'NIR2;0\.W<OE_W,BTE*/$D$2^$ZJA2AVCHK;3CR\#0*EG0(ZZZT
MP@N/*"4#2;HY+`>Z;;MNEC+'-;=\PT?,$54))G#V=_2)<DLWA)20:B^9,9`Y
M2$[APY:%%0A?=*''1G6'F"`\DI)NG!6:ABH!+"@H"^41RSZ@VQ][F!W@!'=5
M@XF:&5R>8[<8W>7Z$C[06_,'1V+JE)L7[AL#BTIO2"B#!,QW)U?>E()N`:/[
M)4[/:[-6SE.<K)<O1"8K:0N[':(VLY2F)SY.GFBXG`>/#W=-X=1%F(LWX?S[
M6I*Y83R53<IU2'M=BHTI8:/.L;#$L+A47ODZRUQT]8*JHI2T*\X$72$>8O,4
M>T#`(G6VXT<+@(5*=O)!&W&W1B;(*9Z(BO/&][:)M?LT!3=Q&XK%&&K1:(16
MRP,)D&UL*\]DJZ@_/%+SJ)7IR$)$H2)#(G<',5(AP$#&#2C5-4/@J90I2096
M"$GJNFIU!#ZTI41.TRLB99/+&,8?&#_-<A?ZBEB",ISG(3W)B4]'.Z0E16D8
M>:<6XEC9KN(MQ7DXE,7/C2:AT11#G`PAVZ3#:RO9`':3E+3/DA4N-AO:E0V8
M$YZ)<L^2(:P)O=VD;I)^9JVW?<'C/,-BKT&E99N(HU@2F'D;`+O48Y&7<IID
M*!&*KYRFD4X"("8X</#I1VF?8`4\A20>6$F:NFJ"4L+2I0$[#$VPF3,?62]7
MG&,#<(&6R%C)G4Y#(%.8OTEYZGLKVTD7]-=3S`H]ZP1LC*)<JM!/]V(@<0^Q
M'290L(#A!P*G(\LKX5#B%++:2"M,IC2)W3Z8T$+G;#EDH5URE`9)J4QCO'$C
M?XB]W&.E474%5)3%;V1C<C,)EZES$:.Z8_B'2,@0??(*('`>T!UTM.)4$%)"
MU2D.6=WA@H>:4@N!0V:9S.@2O\&F*NTWJF].K(5MKM#I&\;!=HN=MFX>MUNL
MP]Q;.YB7G;`Z290D6T9$3[T7<J[6*1`I@#O##V:650U:$E2FU!($[H03F%"M
M00AU!43("?+%OY')^/(C(M9Q%)W*`8Y.N=:LMQJE%<R"*=DL%6ISN&86F>BX
MT1[YU&0+RPL4W*I?>I'=)@/V0:;A"R@N`'`#(G1,W0Y+B`L-$C:$$@:2!?X)
MQQN==R>`ML=69W3<'E^@X@K4G(EAX>1O5B80@SLP9/O2Q%>8KJ^4;!*]R`G\
M69(KK`0!-R\H".CM,NOJPLI*E<T%>?9ITXWE)2GG/9RQ]>*=PF$<XXP#-.)\
MH4^[8I#R]W]]BI9$E<8#5E7"%F+*OGWBA8DU?5:*@]!R"0MN[,*G*`#KCC+K
M2]FXDASDTVW0&WV7F]JVH%NVW19?X(XG`&\K:SNI?VN,VZ9TQ]F)[2$HYS:$
MJ1+^521C*77?-8J2!P"*;9_%2;B,<$;NVQUFRQD3<AQX:.[3/L`%Y!2#=.",
MU5/4$AA:5$7RBS&D(<1FA`C-"!&:$",T($9H0(6EZHQ%#;L942IJ&#\W]'[2
MIG,'W&3]TI1#7E)WO$J/&9X@$C[-I-!Y'(]A^Y8I(X&,`D`_:M9I'*W`[>Z6
M^\K?`J_M-9BP+^2KP&-8XT?*3X1Y8SNEOO*WP*O[30P+^2KP&!C1\I/A'EC.
MZ6^\K?`J_M-#`OY*O`8&-'RD^$>6,[I;[RM\"K^TT,"_DJ\!@8T?*3X1Y8SN
MEOO*WP*O[30P+^2KP&!C1\I/A'EB3,*I*AF;$0BBL`!E"@<1%)0`#_2N)[1$
M2]@:MFX2%_YZR7S5>]Z/0?\`J&XI_$1:/_S[/O.3[EKM(_Z9WGAR$?"/U1^O
MKW,C\^\"MZV2+0>EUN_<KHMA41H5;`KA9)$3I%')5)["K*%$Q"B)OHAVCI]E
MOUUOI\1B.S:7V>[Z/C$$?G6[=M0K`5NW0;$-4950Q&Z*2!!,,&L`F$J12%X\
M`#^X&F8UQTP_.H>B$]D:?O+)[/?BBU/]P>!G.V@<3[>':>*VVWRR-<F!55L_
M8^1BH8V7SYL<01Y=I(G145?!6037(0Q`0()P4"PE5/\`:ZDX%;;$JW%9/"=&
M'QQ6<-5]BI45HV&%-F$SEB'QL4O@@W'73>+1^P5^^;V"O5-TTW+[-G+2U6U!
M)U5*R[0W08L4;6"S-%Y")1=UZ&7*5R]2,[:E4;)G**R0#SEC,LMJY2)\Q=@O
M/FF)3-S*CG,`[1%IN'GBT\PBWFR^]S]WIUP4M.Z7:[NIG8RV)IFM&UJN1E6K
M57C'44S48U^T1<=ES,!CSZSE)PY(NH^;=XW4*4J'O!4.WJ4A*AA0ML2^,9D]
M%@AU2K4M)QN-N*!O0)`<QM5;"T=VK62G-'W,VC*=GQZ;IV1O7.R$?<HPKF/C
MH;@\;M(O<!4GL+E)MEZ8FYJOQ&.8?*:$`2P%8P+&;90"[LR,B`=X&IE"D8D)
M0#[7[*,-OFGS39+EE.5LIZ(@5)64.*<(]B]K..0\X><+<5TIRG(3EIA@7JD[
MA;KA/:?.0.#V[^?W)[EIR+VW[9J_7%HO\8)7)F46C]%6PP9Y62BXI,U`HS*6
ML0N73A%DEY,)WZJ:9N8(JA92Z^"[8P@8E=`T=9D.N)K,'UM4Q2S:^X<*`+YG
M3U"9ZH'IL1EG&R[?!#[=#;9,O[4-MV[_``S48?$4'F"9Q!*)R>ZS;!1$8"WJ
M13G%&2<@1[:7R[@&&CI)^=\=NZDYBMN%B%5.JJ8'=4/::8O8TN/-J,Y3U5&R
M\"Y7@!AE1GV6K#&S4VPZD89X==`MN)UD@'G(B1MUL-N*L?6`J,!MH+MS/<I3
MI>WEE9/_`',0EULU*1I[S<[6FKEQ&5ZC.&;V8FB22J',V=K(LEVG>IF.4QBC
MHC!9&7DO8\.W&K(&>$\L'J$OJS,!C!B]G,\0)$L8Y([[,FUQGLJZ$FXS;$C;
M5[ZGBC9'N1CW]J&*1K:,S*3]6OUOG3P\`W</F];K[>7L"Z$8P(JL5BP311YS
M\G,)6WS4YHA^6'$ZFR_2!U\\'=IQ2Y.Y3SQ8656W:";M%]D25TPLC6FV4*MP
MEHWC[.MQH1^$,5N8*@;=:E$5F_8Y9MH2/9O5LAKL<WY0=3#<H+-67.,=$D3>
M)'$0XJ%2(G6H"5DAMQ'G&U1L/1YH\<*4"U*0`IUI?F"02)$=/G'L$<%0LOXL
MV]]6+J"M\[9$I6'$LR8#V:9#Q;*9-LT+1X.]U7&4+EJGY#?5N<LKV-BI->E3
MKUNG(MTEC+M4W*2IR@F<#:.I"W<O9V0*BE:P9"<B9$>'1":'&V,R?VR@G&A!
M$S*8`(,I\FF.VZ-!?*^SZUWUNW6/4<R[M=Y>7\=R#MJJV):,9Y"W&9!EZ7;&
MK9TFFL,/:X,R;UF<Q0!=FNFJ'$IP$2YC94!'QDMH!YB$B8ZH4RNVF*_BJ=6H
M<X*C(]<>_:PRC@ZI75=3(S8<S2J]/HZ12MFW,V,?$^4S`8@`3BB)Q+QXAPX\
M./N:#\_86.ESM$"G`^T*GH;[%1Z<R'('6;V-$$Q0.;9+O9,4@B'.)0O^VSF$
M"\>(@`B''0;]W._WB.Q4!WWHS_=.=J(A[*]MQ5A[K2U[(V[J6K%1H]MV6UZC
M[*LEY058QF,:SEB/R?;);<#3H*U3P)5BIY?ME9<UUPB=5=L^D8=J=N@H<"G1
M,HA+CF6E%/,J#A*P+R)#"9:0+>N$G%-M9J'*D@(+0"";L4SB`-P41+I$$BRJ
MCMQW/;7L[U61R?29/`.2,=Y5Q]E'(]!OM8"!@8.4KTI`Y"DE;S&/'<!#RM:9
M.%E':[E0Q6BB0^,%X%,73-O;,/H4$D.@@@$'JLA\YL*BG6DJ!94D@D$2E*1M
MNL@=73:S_D*O;@;MT]K!FG".\/'V"=MF.<AXJW2X1CH:&E(2DJ61S0*YA7<!
M$4Z2G,>MLFEAXU*3BW4,X:)R<6DJY59)'-QT[K&4EH582IM2ED%*N64R4SME
MHMN.F&-`\M+QHBM#J$-@A:>2<@E4K)Z1*\0;74;$M&:$",T($9H0(S0@1FA`
MCDIOX^;S*^Y)?/?Q_P``_9?O7VGTM068?6/\!JCUNO\`JY(L.6_5?_(ZQ]3J
M?KY8U']6>F/X5$A^,1G]6>A^%0/QB,_JST/PJ!^,1G]6>A^%0/QB,_JST/PJ
M!^,1[FWQAOZ.?NZ7Q;XQ]T+\7_?_`+3^^X:4:]:GW7K#5UK]'/R<\)/^I7[V
MU3K:MWQN;EYHD+X/5GBIQ$6>?1%=_0]\W-?3SZ(OG6/\]_XN^]?*NZTHUZP:
MWS;^J$GO5'5^=J]<2B[^;W/S?\16^-_-_P`7-\9^0_;_`+WQT33"FB*JCZH\
M-ZHGF[5/#ZH_G1%_,WY._P""OXT[C2_^(/K+SZ=WZ3YH;_X8>JN'H7]G)SQU
M>Z_T'VOU</C,#ZU_H/\`GEEYU_*?X!\M[O16/6C7^;K=4&J/5'4T:^KU^*(9
MV'^;.0_4*\XH?U#_`#9^:S^D/\HOX'\EXZ4JKQZV[X_BA*CU5>IO^CNZX[B8
M]"&X[U0O/'*/SQZ$/C2'K'?EC_K3^^\NBCUJ/67#TOF\W)!_HE^JO/H_.Y^6
M.^M'G5MS]`'SK+^='G5Z/I'U<_XU_A?Y/]]HB=5>M=HNO^-^E\'5K(U.N^[X
MOZ71L,M><.$_0AZ56?I:\X?-JQ>A/_>K]Y_BWQO7&[E:VKH\?-'7-9&IK:;[
MCJ\_BG'UJ^GYGZ&_0^_^Z^G[SR8?$_\`<_\`?_XY[K0^B^-K?-N[?%`^G^)J
M_.O_`&?'&_RSZ+\A>CKS-L7I9]%_S6Y](7Y&_P"$?DO/KC>N+[]%_5SP9SU:
MM6[3=U\T4#V,>D.[?JOO,Y+U&/2'\^-//;\COM?EW=Z=56H/7W_'NZN>&5)K
MGZO=]'?U\T=+U$O-?&'ZN/SN7_6)>:_W)KZ,/RN^W_O>37*/65ZZ[Z._KYH-
M7:J?47_2W=7/%^ZMYL5OS>^8(?S6\V/F]OYM_P`0?P/Y/R::*UC??IOZX>IU
M1==HNZHCZH^EW,GH=^)XU\T?2[\S2_ID^1_ZM?(O&-'5ZM.MIONZO'":?6JU
M=%VM\[Q1ZISTYX^]#'F%??GSTY_.56]'WY!?X?\`E/B.@/5'6O'H]?/R0#ZU
M.K<?2T7<W+U1&>];U?;5ZIGQJ.]=;U??LU?.KY5_!_I\VE*;UH]9\S6ZH3J_
M4GU7_$U>N.%VU>I>Z]1+S:R)ZM7J7^"5^-?DU_K%_P!_HSWUGZ6\:VO^OD@K
M'U7Z&XZNI^KEC3=._P!%=H_5\^=JOZN_T5_<!\Z/RM^V_>]=J_6#UMWTE_5S
I06A]6?47_17=?/!`O@]-(>QGP>A`C/@]"!&?!Z$",^#T($9\'H0(_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g652681g80f67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g652681g80f67.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0G(4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````U@```CL````&`&<`.``P
M`&8`-@`W`````0`````````````````````````!``````````````([````
MU@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!RP````!````<````"H`
M``%0```W(```!Q``&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``J`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T'+W,]/T_7:"QI_05->V??W<T_P!K_K2L8P#G6[P]T/`;ZM;6B/\`
M@H;[FH&75:_TRRFZP>FT37<VMLZ_FN<WW_RU8QF/:;=S+&`V`@V/#YUY8T.=
MZ:2FQZ57[C?N"7I5?N-^X*:22F'I5?N-^X)>E5^XW[@IIG.:QI<XAK6B7..@
M`'<I*8^E5^XW[@EZ57[C?N"%^T,&)=>QH_EN#9'9S=^W<QWYC_STS\VIXV8K
MV77$@`-.X#]Y[]GYM?TG?^I$E,[OLU-;K;&@,8)<0V?P:"Y3]*K]QOW!";CV
MFP.MM]1L:LVP-W&YNW\S:[^;L]5#^S9-+@['M-A>-K_6<2T:>RUK&[6^S_15
M^EZJ2FSZ57[C?N"7I5?N-^X()KZAIMOJ)/TMU9@>;0VT?]7_`.I'%SJ`&Y;V
MB>+OHM/D[=[:W?V_>DI+Z57[C?N"C;54*GG8WZ)[#P14'U:[L=[ZSN80Z'=C
MYM_>;_*24__0]`SV5^FPV#%'J,8UIR7%L[=[G#3]S=_U:-B@`Y'I"C?Z@_FW
M%QF?\/I[7JTVJNRJOU&-?#1&X`QIYH+'LI+<=SVV9#B'/]-@!@GVO?6TG:W\
MW<DIA9^U!=+-KF&8@C:-?;N8YK+?H_2>V[_K2=]74K&[;'5.8?I-9NK+A^[O
M/K;6_P!56G$L!<Y[6M`DDB`/G*A1?ZX<YA]H,!Q:0'"/I,=/O8DI",+3:2[T
MP996VQ[`R?<6AU>US_?]'?\`S?\`-UIG8F22T[VO#2"UEOO:"/SI#:GN?_QC
MD6_);0`'.W6.'LK:)>Z.=K-R,=P$EP`&I)';[TE--U'5WN(.534SMZ=)+X_K
MVW/9_P"`IVX>:VDL&:[=!#7>G6`/W89L_-1J,EN0YWI'<QL?I-IVN,N'Z-\^
M_;M2R,AN.T%[I<Z0QC6RYQYVL9/N24A9B=0WG?G.=7V`K8UVO[SX_-_,VUL_
MMIQ@.:_U!DW;^/I2(_XM^ZK_`*"M#>0#(^[_`&H-62VZUS*G;PP:O#263,%G
MJ3MWM24A_9-#OYU]MQ\7V6'_`*._TV_V6)-Z-AM!$W$'1H]>T!H_<J#;!Z;6
M_P`A6+KFT-W6O:-QAHC4G]UHGW.4F%[ZVN^B7`&'-@B?WF[DE-1O0ND!A8[&
M98#R;1ZKCIL]UE_J6.]O\M6?1JIQW5U-#&!IAK0&@:1]%H"9N2U]WHUNWEL[
MRT2&D?F/=N]KT2R?2?.OM/Y$E/\`_]'U!K2['#6N+"6`!PY&GFALKQ<%DN=M
M+S[K;#+G._E/*E7_`#;/I_1'Y%+_`+<24TLK*Z6^ZO[3E#:`',I+H8X[G;'G
M_2>ZKZ"N4Y.-;2;:;&NI9(+FGVC;]+_-3C^W\TC_`&TE-*C,Z-5OO;E,L>2"
M^USMSH<?T;?Y#-?39M2R,_I.1`LR1LKE[JP2`X-!=^DT]S6;-^S_`+<5W_/3
M_P">DIK,ZKTIH#&7U@`>UHT`$(-67T>DNR3DML>YQ:;GNDCE_I-TVLVM*O\`
M^>F[_G?+^*2F%C*LZAA9:[T7^[=4Z-[2"-A=]+8[=^8I"S%H86M+:V5@DM;I
M`'N=[6I_\]+_`+<24T:\OI`N.0_*;=8XDL>\R&-(-FVK\QC=K?IHF5U#I[P:
M7Y8I(,/VNVG3W%F[\W^4K?\`GI#^VDI'A.PW8X^QEII!+06^+3M=NGW;_P"L
MBV_S3_ZI_(H_YZC9_-O^G]$_D24__]DX0DE-!"$``````%4````!`0````\`
M00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@
M`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(
M``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#
M`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`U@([`P$1``(1`0,1`?_=``0`
M2/_$`*0``0`"`@,!`0$````````````'"`8)`P0%"@(!`0$!`0$`````````
M`````````0(#$```!@(!`0,'"@4"`P8'`0`"`P0%!@<``0@1$A,4(1475]<8
M"2*4E=46MG>7.%@Q(T>(R4$R)"4984)28E7647$S5I:8"B81`0`"`0(%!`(!
M!0$!```````!$0(24B$Q05&A87'1,H'!(I%"8@,34T/_V@`,`P$``A$#$0`_
M`/LZH2A*+>*+I=W=Z7J9U=G6IJY<G-S<JYAZYQ<G%=#V=4M7KUJIG-4K%JQ2
M:(PTTP0AF#%L0M[WO>\WEEEJGC/-F(BHX1R2BKX^\<$"52N74C22)$B3G*UB
MQ76T$3)4B5,6(Y0I4J#F4!)"<@D&QC&/>@A#K>][UK69U9;I73CVA7F$3/X:
M5D0^<V!!U_#B10FLO&#L24(F^I`LL)1HW!U:].\H7*49!3*P."ID5;0.)^P(
M7(DG9R0XXG83-M4[I71&UVC93\-1-6::Z%[SPE:JC5OXHD39CT?1[)!?M:`!
MXS(F;*';P3.GE)(4INS&XPX"TONA]HK79%T:IW2FF.6E^WZ2?#:C#!7DL?W'
MA>UQ6VQB#5\F4AI?[/6`66<G3'K(@]@+&V/[8E5+""CE:8TQ,2:H*`,P(C2]
M":IW2NB-J4)]6O$"JHD\3VRZXXZP*%,!1!KS*9;"*Y86)NTK5$($1:EQ<FI.
MF"H7N"HI.G*T+9JA0:`HL(C!A#MJRW2FF)_M1G('SX<D4K>+7#)3.'K'5<X4
M:20VPG-OJ))$90JT2X*3DS"^FI0H'10B3-*LU2`D8Q)2D:@9V@!(-V!JRW2:
M8VIS14!QN<D:1Q;J3I!>WKTQ"U`O15O`U2-:C5%`/2JTBHAF,(4IE)!@1EF`
M$(`P"UO6]ZWC5ENDTQVAVO=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'
MU'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]
MH/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBF
MOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5E
MNDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX
M]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'
MU'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]
MH/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBF
MOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5E
MNDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX
M]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'
MU'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]
MH/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBF
MOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5E
MNDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX
M]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'
MU'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]
MH/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBF
MOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5E
MNDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX
M]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'
MU'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]
MH/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBF
MOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5E
MNDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX
M]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H/=RX]^HBFOROA'
MU'C5ENDTX]H/=RX]^HBFOROA'U'C5ENDTX]H5-]"U.>F#S9Z)JS\V^]C]G/-
M_P!@XMX'[/>XO]KO,/A/-7<>9OM7_P`S\+V>X\X_\3V>^^7F[FN<\OVS47RZ
M_I__T/N3XY?I[HC\&JO^Y#'ER^V7NF/UCV?CD>PM<JX]7K%GV(R^?L4FIZRX
MZ^0:OCTR:>S%E>X:\MCO&(0>L/2I2I>^-RHQ,V[,-*!XTPOJ,.OE:C4<X:=.
M.UBMPD-@+)[$7OF%241?BWQSN+W5WV$79"'&/<X7.41UOF`FJ+Q-OM5AASD#
MTCKV2-1]$OBNVM4!2V'#4IB=19_HQR*,:8Q[E=EV1<7(EG@KES=77)"N7U7\
M>]10V9R9RX6IZ/4^?(7)X).T,&B3%&W)5%&Z8MD9+;I`M)&F,.`X[\<I+^.C
M+DEA25H)GMB<NZYLNPC;XX/KZ+J18JHJ0#E-HJ(E>W*<C[)R>`16(E@K2TN3
MM0S2M'U;'%:!H1@6I%)`2R0-AH"![=UF+,-<H75G!<JRFR62X/$JSZ&D7*8:
M*"RR0IT90^+]LP1JGI!B5C4$3%L@MW2>/2%Q4LNW`;,%NVJ4:)T0+821U5UK
M60QRK[Y2\I[$@DW:N,-B2'G1NJ%YE135T%#W.S9#QC<$D@<8$VQE=,&$KD>?
M5LS=F=6I;2C%8%ND^^P8\EDJ"]*ZMF'!V(26!<1>/D1EC`X1%X9*T8$X84[)
MPI'2",QQ0U<9@#DC"(8$+A!(TH2-!Q`1""08BV#6]Z#UW69YRM5A&#5A+%$]
MK2O)TL2$H%<T@T2EBI"F&,U.B42-@;W@](G,-_FF$IC5FP`$+Y6PAUO?ERS%
M3,)$W$2SG(I@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"FG];O[R_P#'MF^GX_;/
M7\_I_]'[D^.7Z>Z(_!JK_N0QY<OME[IC]8]DRY%<)"9.E`(I*02F+$<I4B+(
M*`2`2A8H-5JSQ`+"$.SE2L\9I@O]PS!B$+>][WO`YL!@,!@,!@0UQR_3W1'X
M-5?]R&/+E]LO=,?K'LF7(I@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"FG];O[R_
M\>V;Z?C]L]?S^G__TON3XY?I[HC\&JO^Y#'ER^V7NF/UCV=J_EKZW45<ZZ+3
MZ+53*4U56";%[.G"I&AAE=R743=M1^;RM8X&%(4T<BSOLE:M&<+1>DY`^UOI
MUR+#4;QK"N\V6+0T^M;D_P`59Y84A6[UJRN0*2Z8K*T#7S%?(E,=\>[JD,S<
MIG%K*G!3T"`K"BPQA8!P<43TU,YJK9:D^-3WJW@U5(K5EUI$</K)EW(2GH@Y
M<N9ALR$O?("922^&FHF/B6RV=`ZHWRQBEA.\[>&FQ9PF=I?LUMD@Y(V-;8:S
M*%YB?ONR7AS<-?/-C7<JOBMISR:NN)LW#^FK;<*BLV*V@^PEZG#['N5G,2H6
MBV+07QMQ9$UOG4M"N-L=;7)#(1.L<>E[FM6.2(1RD&BR<JX+IVC8,YM&E.`C
M.]R&4U3OEI855,5U.T$D3Q`Y:Q-#CQIM>^G>(1^8L:EHE4+4S.>UNW1<2YL5
MM[L00ZF!2GE*!`WE3NK378)E;E[E<.9?>E[)JDJU[YD*XO,(M<\[A=MVCJLW
MSC"WP9D?[EBS\TV-)4E`F<@'EJ6@4.:PU_6M[>:][4C3J"U47I=-B_"^?2NS
M^*U%SF<//VGE+Y`&KSO,/#)$?VZ,;!'LZ>P?"-Y1+8F^WZ-O+>>[2!"D!X[H
M1KNM`RI/.5G<(AKCE^GNB/P:J_[D,>7+[9>Z8_6/9,N13`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&"P:S8#98)(;`Y2U2@N(2=TAD
MD&UFC,TU25FV6%Q;#^\++[8B>]#L)I?;(-#OJ6,6O+EF)CFD3$\F=9%,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4T_K=_>7_`(]LWT_'[9Z_G]/_T_N3
MXY?I[HC\&JO^Y#'ER^V7NF/UCV2B^,;-)V1XC4C:6Y^CTA:W!C?F-X1)W%I>
MF9V2'('1I=&]66:D7MSBA4&$GDF@$6:4,01:WK>]9%59AG!/BQ!XC-H2W56W
MO#)80S`R@R8.\@F+TH;RIJXV&PLS;(9&Z.+Y'VF&R]QVX,I2!0FVVKR2EA0M
M+0>)V6Y>]OAMQK%7AU7[K%)N+J9HEL@]9]HYCJ=FV,B;2&-)8([4U(O2AN=$
M1Y,!K"\>>/..FH/@>^\)U)P7/=TY+PCXI2Z,5_"WVDHB=%:P8543A[$W[=F-
MO3Q!Q4(UCS#'TEB<VW[90N1."`E4ZL[SMP;7567H]60<=U'L7/=(LYX_4W9+
M3*V2:P-K>D$T41-:_:\0YMRW;G`]EBA3RS.C2N0.D7?HF82`QN7M9R-8D-`$
MPHT(]:%HEL`>^%O&"05S$:H<*E9RX3!%S^YQ5(TN\HC[XUN$O\X[FRS<T87U
MMFJY1/ANZH<A$I<#MOXU`QN'B1"WO"W*QC`PL<58F6+QEG;(]&XVTMS#'V!E
M0IFQF8V-G1DM[2SM+:C+)1M[8V($Y9)!!0`%E%`"$.M!UK6$>M@0UQR_3W1'
MX-5?]R&/+E]LO=,?K'LF7(I@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@5.YBV_+*HK!H;ZW\`*U+:G49J&N=K^\,*0R&9'')Q/HDQ':.
M-"R(2#30"[(RBU&RMF!&'?8'K&+GCR9RF8CAS4B9N-+%POY`\,%T/E$H7:L-
MXF5?V\8K=#P1^92E5!%`&)]"QB4#\">:\KE!H2Q#4ZUHHGY81A&([5ZL<F:T
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MJFL3C?'%UN>22^"TG4DMLBT'I^C5@)`0ES2-<@?4*)>4J4;5C$D7)$0I(JOE
M5R)L1(4AXVO?'"?N->\8X[R6LJ6O43L=)$;-'.I9:T6K^J:Y9MV&SO\`4CH]
M+*,E!3J\OITD-CJQ*2G4LQI@S-%"HZIZLKD?*7&J>,;[0Z&,@G',*4P2-58X
MV2W/#M%(>AE%0S6_GZ52R-L+U%'B2_9JJ:W>#B6HAV9QN#B$A/XQ/HS8]5*Y
MV@&/\I.4UDS%!QM@Z:A(QR+AKM?Y=QV!*HE8$HIXMEI=74I,/4PVO6FR(I+T
MSA=;?>L?7:+.DSB")%)G(I0)T.+2A4Q:CGT7AXYVV;>U&UC;2MB#%G::Q5"X
M2.+@7>=2(S+4NS&N7QU([Z(2!>4+')T"M*0MT44%824$[0`:'H.JDQ4IIPB&
MN.7Z>Z(_!JK_`+D,>7+[9>Z8_6/9,N13`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8'2<G%"SMS@[NBHE"V-2)4XN*U0+L$(T*$@Q2K5'C\
MO8)3IRA#%O\`T#K>!K>@$F!S3Y+Q*VX\A>`<<N.3:Y*((]NS8N90V5;LJ2%)
M53NB;W),B<!,D0:=:T6(P`1E+2@[\H5`P`Z3_'&O[I8C^65](9SS]%IDB?'Z
MQNNRBJPY54U*G-5Y>P4PF+W)F="C]]L.@)E(G(D(Q=-B_AK73KO>3#K'HN72
M?5>AR<F]F;E[N[+4S:U-2)4Y.3BM.+3(T#>A(,5+%JM0:()1"9*F*$,P8MZ"
M$`=[WOIK,-*K51SAXUW$MD"&+V$A;36%V1M).YCW4/%(]KVIS>4JZ,I'P]*X
MN2$:!E5#WL1)1H-$]1%ZT(O8]3AE'1F,HGJDJL^1U'7(]N<<JZRHY-GIG:2'
MQR0LAJDX:5K4J`I"U0C34Q2<>@*3`@,``8C"1##H80]H/63C,<X6)B>4ILR*
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%-/ZW?WE_X]LWT_'[9Z_G]/_5^Y/C
ME^GNB/P:J_[D,>7+[9>Z8_6/9F\_B6I[!IC!]R*51#[7QA]C.I9!7Q3&9K&!
M/;8I;@2&)2%'U4LLD9A*-*42H.A=RI+`+81:UL.XK6FX_#CGT[C,X)M/DL-U
MG$O`]1,3_%:EC#"PJJI>>0;A?LCADNCPW(]7+R;(>-I4KZF/7`:BVP:QN3)-
M)UJTQ7&K]%C6[CO?+!"HBPQ?E*".OL"?##(T)HHF!L]9FP<Z-ZC^J\D54QUS
M8D:YI:3PA7MBE`Y-2I"K*+!H1B7O4YU2XODBD_X?3HQ,ND=4\CYU7<CF5?3.
MM;YFAD0B$C>[79["M&R+GDDJ:4FRF5DKFQF^QKFEZMD7I4JQM:R)`>2)M4Z*
M3")%^B;K`XN'R:*PN.PNRW&NCJ4D-<ROCDJ0Q5C>$-2/%?P=]K@]$M;CC$"J
M=1B9P>4.32Z(E2M,=I`N-`E4IC.P<`6BE+P<EL9^S<\KSD6^1CD<E<[I7SJY
MW6N8Q)VFPR+]<88[3=L<JQ&X-+2W(HRMK.,AB797'#8TC&4G/$X%J%NE(OTX
M+@TY5D=I"JJ_J.)GNBV/UY%6>+('-^5%KI`]>:TA9*I_D*XE.D)7R%_6Z,6K
MSP%%!.5GF#T`.A=G1)XI*P(:XY?I[HC\&JO^Y#'ER^V7NF/UCV3+D4P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!KHFU^<I9+R$LB&\<(77TW
MA%!%0YOG[!)744>=YS()PT*G8QOCLK4F;:FQ5%R4V@#"/0`EF]OON][11>MQ
M&.F-7.6)G*YJ.$(^M"NN;E_QN73V</9G&-#7#.]RVJ:>KB4(95*I#.HZT'N#
M$NGD\8U'FI8V&N1'=DITP.SV#>HTY9A>C#;$XQPCB3&4\9X.:V.1TFM;AS24
M8A*4I[N3F-&B:S0"`J3-+:VN.FS35;L@6;)!U(:VD9:LD022]=SI1H?3H7W8
MT8UE/:"9O&*YRV05W"VVN(#"J_9^FVN$Q5@BJ$>BPE[.3L36E;0*3`AZZ[Y3
MI-WAF^N]B&+>][WO>]YB>,S+4141"OG.R%CGG$B\V0A.)2K10PV6(P%A&)1I
M3!EZ&9`VE[KH;X@0&(0=:#Y1Z%L/3>A;UNX<,H3+CC*I4:A_+KG%7J179LK9
MJ5X_SMP:SE<$01Q5JSY3"&7S*<68-X-,(TUM\]5)E!XA&"ZEE[!L)*A*;H(]
M?QPGAQR3^64<>25[\^&M2=X/B&1IG)^KMQ:(!'X`RIHL6B$S-R2,."3S0Y>;
MU``'*5B>-%&M/8$?W6R!E&=GO"=;'(SF(HG")8C<U;0OB+:/%2ZZVCS=%(.S
MN:?CK:P6M`0ETXPR:)"4L8DTH4("4HEZAB?F_:E6M4=X:I4B([6]BUK0K$SE
M&43SYDQ&,XS')M!SFVZ*]T;&HDU2YN*%N3D)SEAZA>K3HR24B8105"HTU086
M`M.G$H+T,>]Z"#8P]=ZZZP,546;6R1U<&)78,'2O;04`YU9U$L8275L),TG$
M6:X-YB\*M$48%45L(C`!UO1@.G^[76U/8N.Z/N0]VMU*4/8]P(C6EW,B;`>8
MQDFJ/$M;A)UZA.SQQO5B0J2CC4I[\X)PGA*,`;W6Q=D0=_*TQBYB$F:B98OQ
M7Y'H^0D(4&/37J&VW"U6X];%;JRU"%TBLD3B&4(\ML<#!N9+$[]T(U(,W8]A
MZ#)$,9A(Q;N6-3Z)C-QZK0YEIYZ1V:EZ`IU0N;>M:SM;V2Y)%J92@-T$T1`M
ME+"3!IS-!/#L&^@M]!ZWK^.!4>X^=O':G&U$M73-!+E:BPCJY7L\.7-[HYL3
MJUFDADZYZ($K)\&W1@I06)0+Y0QC-``H(]BWL.HPF69RB.JXP!A,"$8!!&`8
M=#`,&]"",(M:V$01:WO0@BUOKK>O)O69:?K`8#`8#`8#`8#`8#`8#`II_6[^
M\O\`Q[9OI^/VSU_/Z?_6^Y/CE^GNB/P:J_[D,>7+[9>Z8_6/9G4[F\6K.#S*
MQYP[IX_"J_BDAF\P?E831)62+11H6/T@=U(2"S3A)VUI0''#T`(A;"#?36]^
M3(JHD6Y[5P\1>82&4UG>E:N,8>6]D:8A-*Y4E22PG"1VX[TC#6J`A9USJT.T
MFD%B-@&X]I/5I%[,<J*,<2TR0050BT]8SG'6I4;VK'`;H])?I8(H\''P,(1"
MNLVS#X`5;6F0IHU(MPP;235)NY&8^>??,`&PL?5;WX=D8*>`\_$0HMNB\9E;
M/';EFR1TA4MLB9M<-K!X<I'3,%KV6.<!L-]MQ@6G-CC'%,*G3`Z-"MI2`<'U
M0M9W#2)$J+1J#"Q4K"6K?<%J>`L%@+RW^8I9J\Q>-5U':\:?M/*;'DLT#LV,
M,</;PJ$:)2<Y(BS5@U2I2D;T:!.<K5*"$Q)IH"4A%5SOJP48ACK'()=TXF\T
M=K/92J2B-<F+;CCBVDEJ1LN+[6QEQ=FII94U>NSHWI%!WG$PMR4.S>!KVOVO
M2=\6EJ*\GT2M6!PRS8$\%2"$V!&&.8Q-[)(5)0.D>D;:G=FE9M&N(2KT1IR)
M4#8R%!12@@?4LP`!A$'1&8X$-<<OT]T1^#57_<ACRY?;+W3'ZQ[)ER*8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`K'RPO151U8[41AM5R"T[!=2
M*[J"-($WBE+O8$A)/*:332Q:[K2!H[(E1W>;"`SNPD]H(C0[S6,7/HSE-1ZJ
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MHP"\_=IE$5AJL*QV>)!'FE.M=).D"H,6%KAC;$RD[?=&;3*U0`@+-+`<$0=S
MA>7">%6S&51QYW2-2ZEC_P`2^YI?;KP[6!'N.T#:(]7-=&-H=QI199R=6L?Y
MR<:E=F]2>G;$S\80289W81C[@D/D.)'HE>B(CJE:YOHLU7/PW.,D2AR&/S:'
MIK:D9+J[.[E/);M>FD#NH<C-`*(4B;',K_@&]`44440(9A6C`C/UK1IH][DY
MY3/"6HPQCHR-O^'7P[:Y"AD:*GDH#V]0G7$-1\JFRZ-C<$FNRF7*HZX2-4TJ
MS20;V'L&%"(%UWL18A;V+<UY=S1CV>AR&XBM-HO`K7J^1N-/<B6E(D"P65'%
MBM"E=QMJA(>C:YZU).VFDC280D\,+9I1@]$""`P*@DL*?:,JX3%P3C?&.:I4
M7XH<]74F65O+.5DBBT+A_>*(#.FX1;VZV6Z3`OQDEU)BQ/NI07'X_I6J2$)5
MZ@&BU!A9J8L9901ZU.6/.,>+.G+EJ>B9\-26(D(Z:C5]/C-Q;D!T0D4XA>B1
M*)BX3*-M@T[HH85BHA4UM#1*'E(D<U!8A&@+4E@UHD04Y7::XYU_(T=+_BGN
M-?#BXQ1J#/47+B)KG))%`'*"O%D.RHUPEA@W8*TQ9*4!2L9[$U232Q;W@%!"
M0(]%%%DCV,K0@CFO*_1K1C7)@5'\DE/'IW?.,G+J:PF.O=81^)"KBSE"X]J:
M[0@3CM:VM2I24Y`+VG?&("`I*J$'J`0RS>V(6R!J#TQJ_EC"1-<,I7VC%GUI
M-E@FZ&6'!I<X`1^<1H8Q+6!^6`;^T2#QPDS4X*SPH^VI+UWNP]CJ8'77Y6NN
M:F.<-7$\I9SD4P&`P&`P&`P&`P&`P*:?UN_O+_Q[9OI^/VSU_/Z?_]?[D^.7
MZ>Z(_!JK_N0QY<OME[IC]8]F06^R/LEJ>S8Y&&&&RJ1O\`F#,QQ:Q0+#(!)W
M5SC[@B0QR;Z;^JX,3?5!X4K@(D(S`)#3!!`/>NP**TU5%6_-.K8+9Q_'VB;F
MKI@7.KZR1FE[XMNL+5.C$H<^2[\ZKK8IA!,;EE;*PH8331JS29*XR!&V2>1'
M-Z\M!X4*E8XQJ:ZRF6)4S;M>;J>[HOQPN:0V'`+IGLINB,V7<-$RF][]0V=3
M:>MW&SF"4I+&:*:2R>**F&/(4;&K=8LT)(XW*DR$DG8491HN.+"H51_+JC5=
MO66QT&ALV;\OZRG#5)H.S657S<S\?;%=>1'*6Z*^23=VEDBC!3_7B2-<HQ-\
MK<8ON0NAKNP#-;VTY,I+$$7$UQ64FM/V[":]XG-4`KU=9:S@Q,:G?6EM*EL-
M9WB^(XBXUVCQRGB>+!DKQ'V%DEK`U6F<Z("G]Q9V]<O0EAVK*+%L65._'FAB
M&59R=J6V/>^)X]NT]DUJN?)DB=<=XQ8U3(9[6[79R_C[Z'%Q4GETVC=5.1R-
MFX\EZG!2%_7[(<'T)C3YR*0BTIB\.5K]<4ZND=+\=:CK69*&M3,XY$DHIGMA
M./41Y-,'M0ID,I;8XI5D)EBJ-M+^[*$K>:<44<:B)*$8`(]B#JI/&5@\(AKC
ME^GNB/P:J_[D,>7+[9>Z8_6/9,N13`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$1
M/5^4O'+$;ZF?K-A[38SFF"I21-<\)D[EL!I19Z8E3L8M)4*Y<G-"8F3'F%J%
M1>^V4`8?+EJ:NN"7%U?%+N13`8#`8#`8&OZX3RY_SQXLU\G/*4I*FAMGW/*4
M)0M&;*/=T!$0AYJS0=#\.<D=B^]*UOL[$`W>_+K8=YN.&&4]V9XY1#8#F&C`
M8#`8#`8#`8&MUIX4RD/-A^OMSDC.54*64`LN,PQ.)4I>'.QG2")8JZ+W8L25
M.B;D[6ZE'+B#`&G&&;$6#8=?S!:WJC35<6-,ZKZ-CQ111`.[)*+)+T(8^P4`
M)8.T8,1A@NR#6@]HPP>Q"W_'8M[WOR[S#;DP&`P&`P&!$LUH>FK(E35-9_6T
M2F<E9&5;'6QPDS20\@3LK@,\Q2A$WK]'MBDO8U1NRQ&DC&3LTSNQ![8^MB9C
MA$I43SA0OD!55>\.YM1/)RIX$T0R$0F5+X->"&*M_A]*X!9($S0GDKF``3#5
MNHF\Z`86'M=LP\X@OKH&OD[QF<HG&99F(QK*(X-HZ92F6IDZQ&H(5I%9!2E*
MJ3&EGIE*8\L)I"A.>4(91Q!Q0]"`,.]A$'>MZWTSFVY\!@,!@,!@,"/J^M:N
M;62ORVN9@S3!)&)"NBKZH9E&U!3>^MVBQ*D0QB`#1H.P:$19Q?;3GAWVBQCU
MUWEF)CG"1,3R2#D4P&!33^MW]Y?^/;-]/Q^V>OY_3__0^Y/CE^GNB/P:J_[D
M,>7+[9>Z8_6/9,8A!`$0QB"```[$(0MZ"$(0ZZB$(6^F@A#K77>]_P`,BL`K
MZV*OME$ZN-7V'"["0L3PX,#TJALE:)&2TO36N5MJYL<AM*M5I$K)6(#0Z"9V
M=CT#M`[0-Z%L.^Z6-7K)'R)8]3N&M$64K1MR:2NDH9&^/J'`LY4F,0$/*M<4
MW&K2U"$\L103-CT,D8=ZZ@%K0>:YV]4[*@B3J\VA7;2USYQ(9X*Y.<UC2!!-
M'=5OLIFN)+%3F4GD;BH%KH`A&(XT>_X!W@93(Y+'(<Q.DHES^R16,L:0Q>]2
M*1NJ%C8FA"5T[U:Z.[F>E;V](5UUVC#3``#U\N\#%7BX*ECL.:+$D%HUTQ5_
M(!MQ;#.GB;1ILASV8\%C-:"VB3K7,AD<ANA10A)M$GCV>$.]@[6M;P)#"((P
MA&`01@&'0@B#O0@B"+74(@BUUT((M;ZZWK^.!^L"&N.7Z>Z(_!JK_N0QY<OM
ME[IC]8]DRY%,!@,!@,!@,!@,!@,!@,!@,!@,!@8]*9=%(,RJI)-9/'H?'40T
MY:U_E+TVQ]E2&*U!:1(!4ZNRE(A3C5*C@%%Z&9K8S!Z#KKO>M8J9Y')KPM3X
MC$&52)?3/&K:.SKN=Y-$(9"7$XL+A53@XRDTSSB]ER-C<QFNC1#TQ7_&C#W!
M/>'`$48<46H$7N,)YY<F)SCE'-FM?\$(.OA%B)N22>.7+9EN3!TF<TFY348U
MJ&E8H(,0LS="%^Q`=F%"P(S!^'[G9.M;.$7L&R0`!I.<W&GA"QC%3?-`?'OF
M?'^/S<\<<N0H;,$Y4S8;Y6IEQK(^8_09/&#710*N#)=)4JTQS:U3DS[[M($2
M$9?@4Y8Q#UK0^Q9QOCBS&5<)Z)SD7/AM?7=R9N,=.SGE'N-(2G*8O\+,$P1!
MC(-T6:!N1/SDTKC)#)3$FQF%H$R;M';#H!0QCT=HF:-TTUJ[1;%Y5\2F!;9U
M4?@-;6JJO-XVTM5>U3.8([1A;)9&\K1-XDXU)1BP@M''3@"&NWLTK0^SH!0]
M[V,9:,)ZSP37'2.+]QSXEU="<(C#[`K2T8/82B3,D*M%N6Q\LN+5+(7ER"T)
MCI-)7)8W:TSKE(M*$Q@"!#&B[0Q:T(/8$T3TG@:XZQQ>^M^(7&E13^]P'C]R
M.M2O6)P>6X-GP2!)W.$NPH]L8GEQ;7(;L48)D2%$F"TJ-`4$0@=G80[WY&B>
MLQ$FOM$TQ9IOWEKR==&];QR@*2DJO):'IZ2V7=[(8Y$V&`3D!OC*=B9F_6U+
M62K)3'*#A!\5H)0M"T9TT5I1:QQ^TW)>67**A^55S\])LTF4RT\=PUO;03B&
MB5WVK=V]13[&TGGDEBFT'3+RE8I,O5(MF#"VEG+%#>9V-FE&;V(HM6$<;X%Y
M3PKBL[0/&=GI!RFDQ=)M+;5M2QC&S<ULB<'IS79>E9BAD-3.U)$X.Z96-$4+
M6@I@F&_["P]KNRB2R\SE=17!8QKW68S+1@,!@,!@,!@,!@,!@,!@,!@,!@8U
M,HA'I_%)%"98VD/$:E+0N8WMM4:_EJF]Q3C3G@"/709)X`C[11H-Z,*,"$8-
MZ$'6](FN)SX-8D.3_$2XT1K[!Q^M:^ONK:_*?V6%KSI0!JL13#V%86YQY2O*
M$Z%Z6FJHX:)J;V](D.4DJ$X=##LH!?B>G\,N,S4L1KCA5PSU)\4"CRU9C-):
M\OR)25E\8.P8\[UH8-?62!`!HT<_3(A*[&K$<?.4N^BRC2R#%.ME[V>G([PC
M1LT3W@UQVEL(C4D8YC'F.61AR3/,=DC2@?&-V2;'M,XM3HF+6(5A/>!+-"`]
M,<$79&$(P]>@M:WK>M8Y-O;P&`P.LL5I6](J7K3RDJ)$F/5JU1X]%DIDJ8H1
MR@\X8OD@*)*!L0M[\FM:P-55N_$SX]2JJKGC]8R-\42S51R$^,N;HQGQYM6R
M![6D0Q$RL_G<](\.,F;37TETV04D$3M``9FC>I1P"^D83$Q;$YQ4TR&%_#X,
MA\%KUXIRWY[QSMS<`AC19CE%P`?(K,79(Q@+?U3]!UZYN2&O.EZH_P`,HTH"
M%*+^9W0SMB,W)SN9N+@C#A%34MDD=;%C+'V)G<'I?)%[2S-C8ND3J!(6Z/RQ
M`B(2J7IR+0$)4):]T.*$><$DHLK1AF]`"$/36L-O9P&!33^MW]Y?^/;-]/Q^
MV>OY_3__T?N3XY?I[HC\&JO^Y#'ER^V7NF/UCV=;DPULK[QROUCDB>>*XX]T
MO:#-(4]6I3%UF#8G6$O:!X]'J$DY.H6S4#<H,$UDE#T<:MT6$OJ/8=;BQSAJ
ME^']JO[5D-O58!?0MXPYTA5@MCUR#XR-[W3;ZE9$/(^Q!QVI;-W7<V<&MI=G
M4A\62"-:9')N4MC08H3FHDQ1A*A?&I8XCA%4-/"G@'&[0NAIXQ5_7-HV4Y-$
MIGU=QF8P$IR01>_:]CD:ELJMWSA64%4FL,W5'-:J4)G`AR5I@D$%^<!)3RB\
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M(6))+'(CM-LR!QN2(7'JXM\ACT(&WHER93O:E,J(,*-WLP`M[K,\Y6RPB&N.
M7Z>Z(_!JK_N0QY<OME[IC]8]DRY%,!@,!@,!@,!@1I<5K16D:UEUHS-3W##$
MFHU>:4`8`*G):,0$S6RH-&;T$;B\N1Q28C6_D]X;K8MZ#K>]6(N:A)FHN6N1
MGY6<D*(-KVT>7J9@(I*[F]X6$I8M%'`N0T8_EH#GJ(19X`D3[7/.I2T%:"("
MD)RDE7WG:-)`F&$[>F)N,><,:IBIRY2N_P`?N3=;<D&Z0*825)V-YBBEO(DT
M-G#+J/2YD*>4HES&X+&PM8X)Q-KVC+&8E.*/,"8$&^O9WKIF)QG'FW$Q*?UB
MQ(WI%2]>J3H4*%.>L6K5AY29(C2)BA'*52I2<(!*=.G)`(8QC%H(`ZWO>]:U
MD571_P"8'&6/0EWL%1=5?N,;9E*IO-,8)$W/SDN=$HA`VUM#0UGJ7)U6J-Z[
M16B"Q@&3O1VA=SU,UK3E=5Q35%7:`7'XGO&1I;QG.(;/1/A2TLD^&+:]<D,M
M3M8VU8[;DQC>M4)T8XZ2A1"&8<!0,TL(@B$5H.^UET9,Z\5_V9X;)"T-3^RK
M2')F?&U"\-+BF%L29>V.24I:@6IQ;T'8B%24X`P;Z:ZA%K,-O1UO0M:$'>A!
M%K6PBUO6];UO776];UY-ZWK`_N!7WD/R"9J!CC`L''7B=36<21#$*[KN.;"%
M]F,B6C#L29.>,E04@1(4V]F'J3`"`7U`'IL1@-;N,7[),TJ2P4%;W*JS5MF\
MJ6F35W5<8E,5<:[XR+9)'I9%7L4<95Q*Q]G)+8:J;%_C'Y:(>BCDY9IR;9J<
MP(DXBQCU<8Q6//NS4Y3>7)=N/T#242=HZ^Q6J8%&76(J)$KC*R/1EJ91LBF6
M)RDDA.;RVU,F)(&YI"0E#Z!^25KL`[(?)F=4SU:J.R7<BO-7,S0YI5J)R:FU
MP1N6R]N*1<A2JTKALG102MK4YY1A2K96DY>@]YH79T`/3^&N@<;,PL<=2B0Q
M]E:6)$,\:D:-F;D;8E&I,`668H$G1$D$B/&62`.Q[UVMZ#K77IK6!VC6YO/6
MI'$]`C.<$`%!:%>:E(,6HBU80@5`2*A@V>F`I`#6C-`$'0]:UK?7I@1+?5(Q
M;D!54PJJ3F'-S?+D[?H;RWITHW-M<&=Q2.C4Y)=J`"`,Y(J1`UL(MZ[9(AE]
M=!'O+$U,2DQ<4S*NH#&ZM@L4KN'HM((U#F1"Q-*?Y.S1$(BM`&J5F!"#Q#@O
M/[9ZD[>NT<H,&,7RA;Q,W,R1%14,TR*8#`8#`8#`8#`8'X,,+)+,..,`444`
M1AII@@@+++`'8AF&#%O00``'6][WO>M:UK`PZ*617<[.7IX//87,E#4$D3H1
M%)2QR(YM"H&:!.)>4T+E@T83QD#T#9F@]K8!:UUZ;P,TP&`P*^6YRQXQ4*%]
M#<W("GZU71MD%(G=BEM@QAJE)#/X<Q24K3Q(YR^T[B)847OPQ29(<<J%T`2`
M8]Z#LM3/10QY^.W\+)L2!-;>3I,Q<U!P$K;&H15MR221NZPP(QEI4#<DK_0>
MV,)8OEG&$DZWT#L>A"#H4N%TY=F'F?',XWMH#I)*^-G/^#4TD4[2K^1<MXGR
M=#23<87LD*K:Y]1/+C)R/!;-WWH?-&S`]V+H'?4':6:9[Q;HN/QY.)$E$\:X
MRU+S%YFI&%K*5ODBXX\:)R[Q6,NB[:@EG8Y<NG0(*^L:AT6@)*`<!L4D;VI!
MV!&"T,(5FF>M.L7\;..0!VCK7RMX.\VN*38J>&QEG-H6%5J=UHNN3Y*<0DB*
MYZM!L<B"U;.^+QF)Q'EH`#3G%[ULL>M&"*6:>TMH\JY1\9X,<O2S/D-1\46-
M93<<XH9#:T%:%Z(MX:M/K/M0A7OI"LL3NR;TK2!V#M*4V]&%:$#>MY4J>S6X
M+X_'PPMI'I0ENJ7K5*$"<R-M)5)7"F=+("K=B&5-JNT[G"T!3^<:N5%]"C#$
MQW=BV9L/8+-V"7"Z,GGJOC;UR0V.$J2\`_BHNE;-OC5*FVD'#PT-<!8FXPP*
M^4#?%]@H529@1$E#-.,/3%'%%@%VBM"UV<6:?6'HIOC'_!N<ERA\'R.K1(^W
M,W1R-R9<JK2RD;P\MZY,:TM+583J57W_`"=`TI%AA"@UV/(2MQ.][.,**UH6
M6^7%-$\>"NL/^+!Q*^'?+)9Q&NRY6N=1&!.RA;6,^K`TFRU;9$Y(;I\20^<M
MT3,7GI'QD-<1ZWW.S3>AF@]P`D)8LUE.,\;XLXXY1PK@\V;?';M!X<5;+0GP
MVN9$G.D34A>*?=Y534S-,L9E4NX4>I8DBD>2Z$7$5J=(I`0J`["$$>RS1!%V
M3"-2-/6VIQRZ3#RX4Q?_`-`W+Y6MLQ1=L)^'G7LM.=E$5IMPINMYW*(DQ)@'
M#CQ$F6S&/.=@@D+D8`DM888-$'74PX*1/KLI,5WGB7$<(QM'$7,__HHI]]-I
MU%)X);J>1/IJMIM6V:V12%8QIUQA.EV]RV"NB2#-K$0=VSTJ=VWM264/NPEE
MZ"$D#3VSBDU1UPFWKNU[?'U4)+TXVRGB'6_(LYV9%,537!!WUFH1M94;\D7H
MG<#8Z3M]0QB6!=F8?:0G)0D#1=Z$2@??;[@I]9B>:_QRB8N8E_#^,WQ9>6J.
MI*Q<J'XU_#V@W'!+%HP@M:3S`R_[M>E8&\M&_P`VJ]/"5!E9O:<:%C:C=HI"
MF0'IW$&C4[CL>C"DS5EQ]33A%=:753?"@OH/<>-^+Q\191OM&!6^$L&/HN_3
MZ*!I(!)HUI6^"4%'%Z$:;OOMG!ZAZ`WO8MYKU75&V&WZ%QL<-AT3B!LCDTP,
MBL988V9+IHX)W:8RD;&UI6P<CECJD0MB1RDSV)+XE>H*3)RSE1HQA*+UO0=5
MEDV`P*:?UN_O+_Q[9OI^/VSU_/Z?_]+[D^.7Z>Z(_!JK_N0QY<OME[IC]8]D
MRY%=)`W-[40-,V($3<F-6N+B:G0)2$9!C@\."IW=UXRDX"RQK75U7'*E)N]=
ML]0<,P>Q#&(6P[N`P&`P&`P(:XY?I[HC\&JO^Y#'ER^V7NF/UCV3+D5`U\\B
M8+Q[9F!PE*"42A\ELA01B(P&OFI+(Y]*79PV9H!3%'3G)L&M*(T5OO!]Z'7;
M$`L/:-,++'8QF4F8A#$;^(AQ<=6%R=I5,U]4O+(MD;>_P"RV52TV&QJXNJ1H
MW),XQ=D'(E`59IRXO2=.6,Q2H$$TL!>S4Z@!6M&2:\>[/X7S5XI3YJ5/3#>]
M?)&Y$N(;3S9>["KP[2U46><F(*13\B,KE.SRDI@@"++&$6@"Z;\F\DXY1T(R
MQGJL4TR%@?\`Q_F)\:'KS6N,;'/S2Y(G+S<Y$@+,.;U_@SCO!KBBS0B$49V3
M`A%K>]=-ZS+3U\#J[7(=+@MFUB73D-*-<!OVH)TN&A*.+3F+`I.WWXDI9YP`
M",T'L:&+6M[Z[UK`[6!7CD-R*8:`:XB$Z-2"?3:PY(7%8!7D2"G,D4G<]%A.
M6G$:4C"6G;&LLTKQ)^]"T4(\K6]=!]=:QQN^R3-5W5!D9EW\M[5HN&6)QQF-
M/U16\V4VG98Y>Z,C^QRARCC<?]@F%$I0;3)GE(H<SS`KD^P&`[L_J,&PE?+U
MPQB9C*Y9F\IB)C@V?GIR%1)B=402I3FA[!I!Y8#B30[\O9,*,"(`P]=?PWK>
MLYMM>E^!143R]X_\A"Q$,\6MP#CQXMU>+NDB`Q6XIPN]9.[HI,V%,%26ZM^R
MCE1VPB*0(0@[78UO0=QQQG'\LSPRB6&R-^F'Q!)2]UY7[LHB?#R)/Q+58ECM
MIBA._P!Y.;?V%2Z'P<\:<)2:))E00`5J^H@G!V`S6S`""0*_3C/V3[\(^JW3
M+Q(XRQV2-LO9*-K=ND+-I!MJ<$\90?\`+SFQ.0F0+$J098T)+DE`F`(*K17B
M.^UWO;[W>Q[SJR[M:<>R2I15=<S-8Y.<FA<<=WEVA[S`%KZJ:41CZ9#7\LTM
MWCH'?9/G`IK6:.'L103-![0M[UKKO?67/<J.RC)WPSZY3:86>/W+?C-!2DVV
MJ;PD=@KUC;.HZG/2*FN/J!$>;D[(W(348`""0G'H9&M!!HHS7>YK7/:+9T1W
MFF-1NN.='$J.[8ZP5P7DE4D>-?6V)UV^*@1>>16+^/7.;$M+DZL#>4]'(B%/
M<*46SE/9**+*1%:UO7=V\<N?"2LL>7&'DQOXN=#+8NP+7R)V3]J#$C'N6-T<
MC9#DRM*@UM`KEJ]L<U;LC.7,L3/%H)^S2R3QA-+$6`T&Q#T_YS9_TA)U&1:T
MN1EOQ7ES;S(5`89$&23-W'>JE)!ADF2M<Q)+1KK#F:@P?=(W1]8P:`2F+#OJ
M6(`]=@)0#%4F8B)QCF1<SJEL2S#9@,!@8HNG<':SW=,YS**-RF/E-9S\G72)
MH2'LA+VM\W,IKN4H6%F-I3NX:[A*([0-*#OD%]H7DP*<7I\3W@-QJLA+4-V\
MG:]A%CJ%C(A4Q8S3^_JV`^1$IU309,5,69'MN@Z)2A5DJ1*7@Y"G)2&@/-&`
MD81[6L8S/&(1JT_&>^%T]/:B/H^9M4$KTPE83#W;4I8&06T1G='>'DK['&Z.
M*PC%Y2ME*QZ4!^45VP^7%P:<NR*U/Q]/A:(%BP#AR"D"1B2N"QJ(FH:,OAQA
MCJX(C323$S,]LU;N6G/O1)S=E&%E[*,`4(01;#TWN7"Z<NR+4OQ+?B!7VG]-
M7"OX<;G.N*,:\6Y&2"[)TDJZV^1,?TNTC)74#$3CQ>8TQ*((G$E8YIG<IU3=
M2$Y9:P.B3%^BZ8CA.7%GR3XE?.5]-VFC7P:N41JLDH2M7J6VG6<$0@0GGC`V
MB1N3XBVF7N)Q(.TI2`Z'(Q;Z"[8>@]K]$TQN>-(_B/?$DC28<E=O@O7&1!X^
MN0N<Q5Q_D56-A3K[$;-2(7=1#JVBK#M]E4Q2K5FQIVM*,X1R4C9HQ%%B,,3+
M]"HW,I4_'8X)*(5''6&FW99MOR>6G0-#Q*KZHGEWY5IY>B^4[,B^KG!8T)$Y
MK05UV8?IS&D4#`84E-4'E&E`6:9>0G^//PI85SLQ7G"N6O%J7L(D:AZ@W(#C
M)/V*7-+"XEB,02IS;(.7/RFZ/+@D']R8>:6>;X8W82MZ#K8EFF>E+?\`''XF
M/!KE8P261TWR)@[@CB#F2V2%%,CEM8OK?XS6QM3F./6.DBSV:QO16NJ1:`@2
M<T6AE=K1Q9I8+:3C,=$`79\;SX=M-R=]KAMMQ[O:Y&AX:XXWT[QU@<HM*6R^
M3NSNC928O#9$D0MU5/4D(6+.R:A^T9:@(RADZ")3H)(I:QC,^R._^IMS=LEQ
M=`<<?@X<K7N.DDHD+:^<G)M!>)3V.2*/EKBUL,FR20]J,MZ86C"W%,Z'A5&:
MV2("<7R]+]#3'7)B#)Q1^++;`G6X+?\`B6(^'=JR][4+&>@*DJ^"7)3=:5\%
MMTWD1\1<Z=V8V13,6M".4N@5"LE,I[0RC3MB!LA4R7C'"GOH?A-7`\`4V`=\
M7#GDX76\N*X+]8$6G+"R5FNCZA-X0F/-=*MY:R,L`D!("C"S4R_L%J>V<`D`
MQ`[I1JC;%.B/X)7$]0(Q+<7+'FW=,,4%"W/:ZM_EN\*8/.9.$@`02B7I&%%%
MW@3V2V]Z3T+7$E^''K79^3L0K1K]G:DOPH?A,/[@B/K;0^.LG8FM4T_:SCY>
MDHJYW7H#]$'%Z<70;ZX-,@-;U*0"@LTP!QFS0:V:(P.NSET3MEG_`*?Y0Q=Z
M^'@^05`>JXM?&2Y<P:5-HDSK"(Y='(*'7O6!,B+4A5:2OD4?&YO4ND9>/X&H
MQF'EZ.-&<(!^A=QMIR[2NO&>=,E7TI\9:RQ%1:YOB!\2^.]<(DR82F=<9:K=
M7BV9TVE*@&*E+H9;6VN/P!8<+99(5;(I,*!H?79(O*`R5*WA'1C3%\):7*G"
M1JP?&$YV+HA.5"!WN$F)VU&V:322;)5+CYN=V"<I@NA5=-8F<2)&-K3-YX5)
M2'01FB)[@A,TSZFN.T)TJKX5OPS*3:E8[!AL%Y"60J>E$OFMS\JWR.W!;DPD
M9ZD2TUWD#K(R0(@CV+LAT0D0IRS]`T(X)QXC#3$8S/1)S]:A>=LMKC(P'B6,
MCK!6=4E#M+I2TQD2%0$HSJ6(I.<B92C34XM%]-]WL0.G3KY-ZS6C+LQKQ[N]
MOE!3?39@']U-2!%O6UY<5DXD78`+81F][MJT+NB]ZWUWV>ODWY,NC+L:\74#
MR8I!&!6>V.BY02<<8K5*&N'R`HI6N&`L)@SC#6E)HQ88$``[&9TWOH'6Q=-8
MT9=C7BPNS;*X^7)`I94=V0B1KJVL1B6Q6:,<XA[ND95C,]$]QHI:J;S1+VTX
M_8]&)%B49:E(>6`\HTDTL!@6B?0C.(:R*I^%_P#"-IID>(DHI]QY/NJQY<W1
M5-K*;W"T)*SLZY,@2,T40/Z%#'VM/'8DR-J=*AT06-03H(Q#.$:,SI/^<]FI
M_P!OJV1)$[.YM%;-T,X6L[G#J8"TGU`5+V^!Q$VMC&9M`V,JRMV5Z:7(R-&H
M&<H!*=0V&E&!*Z`#O6OXW3C'/*+9U93RQE*7V_OI5H:A%1"1,FUUT60Z6,Q%
MKSNQUZB[LI/HLCM[UT#H>_\`MZ]-ZWBL=_@O+:AV85T.?1.9P>5<&*N=8K8*
M=V*G+.Y22MC4<I`\`T)T&Y:0,R94<[KS2@#"LV/ORU``&Z&$8`C"TX;_``:L
M]OE%G&CC1`.*\#-@/&[@A&H)'%3XN>U:V1SIF=I&L?5IVS#E;R]S(ITF;TC:
MM#\.AV:L&$I&4`!.@!^3C3A']Y.6<_VK:#F7(E%VM'TU&GOO2Q!)VSV"WM^D
MAWE[)BO3N7K:DK_R%]D7_FUBL-Q>>T$LY-O&^X(9JKB!6P?S5RYP>WY5K>_]
M49",.DW>AZ_P.#L&^F_+_IC^'>3^?H_7FCDUO6B=RZJ-`ZZ!M9IB?]J^QVM:
MV=W&Q>%V=L/E[/\`LZ^3K_KC^':2L^\'F_D^@'O2604V_EF!UL0WQKE368G'
MK>]=@@ME[8#0##TWL0Q=>ODUK_7;^':3^?>'Y^S7)%S#W2^R(%'"S=:+-/CD
M45.BDD&]?+,3Z>QE%[.ZBWK77IKR:WKIO%X=I*S[P_NJ6F.]=HR^K-V<;K0%
M0BS6XH@970.MZ2I]$B"B-Z!_^H$6]]=]?_CU:HV0:9W2GAN2"0-Z%"-6K<!H
MD:9()>O,`:N6B3$`)$K6FEEDEF*U.P=LP00!#L8M[UK6O)F&G<P&!33^MW]Y
M?^/;-]/Q^V>OY_3_T_N3XY?I[HC\&JO^Y#'ER^V7NF/UCV>A>JZ5MM)6^O@4
MKBT$G:6L)X;!IK.#TB:&1*9ZB[IJ*2.5GKQ`1%QQE?\`:=0MV;O1?ARQ]KR9
M%:SN$SU99Y]LU,HGO(JK+H=&FS']CC/)DZ+<AH8D/C/(*>QAZLVMII&)@2&4
M`;#W9"R2)C$XLJ<E84D5IF],0I"<LC4N.MI=;EJ4CP`JJ;W782-QNR7W'Z8[
M7B3O]A[`L$FI66SGY##F22-?_'0<<L>FQ*XGZ9SB%I;,QJ4:<PM.,XP`ZS-(
MK@$MNB\E=Y5K(N4-L0@CAY4EJ+(#:,9D#%&EUHRV.\I>7M-QRS;/4IFA.S6(
M"HXCQD:$3^VJ`#8'%U>5ISBE[T:;1`X<.'-<FS+-GUH4MP-;PR235"JY?3RK
MF2TY##%HHY*HFQ.7&RU.0;_&6%^/($NB;A+Y'6:2*A6D;(<DP7?>DAI2S9(P
MU.'%6ZOG&S[>N\/#B1\A+K:8%5+SRZ5H;+B4T)C%MVJFK-VXSHJZ9':QVYM`
MYO1-+$\B%[>\B+V,UX<FIN$\;/%I62JB]+IL/X;V)*[7XO4E/IRZ$O\`+WV#
MMX9#*$R-(W))DY-!REC/G*-`W@+;4:.<>;-.Q)277A`%K0Z(ZE:!O*D\)E9?
M"-0L>Y6WG6,?XY)6>G"76DTE25:PR(UX"M8IX]JP1IN)=)1"USHJ;HBH94"-
M.`:1.8<88O"+8MC(T/7<=M$3JX\;<M<Q7#@FAYYZ*U[3,2(!05I.,D0-3CJ)
M&NYU>Z9%SQH@S3:I?`-<^6.*!B"=T,.$6$PW9>NSK6A;WL&?^<QSF&M<3=,+
MX@5MQVC31&;DLR4QR3<GG@IPD4VG-@2,\IX99&]FJP.+,R(WYP*9T13*0K&C
M+5)"MB4EZ&:49L@P`0LM?*OXICIYS/%+TZJS@;,+`W/Y@W5@\3I4_,<T5OY#
M\H4!<'6*)O!-OG(32YC9E"8PH8=J6XP/<N8R@#4$GB+"(,C_`*5PB:6=%W-6
MSYTX_<3[ZE[E:SI"8%9,D<8W]D75S.,TZ$^`$$PLDY8T!4^$121.G%W:=R$0
M6YD$A!HHX&@`[,O+'AQA:QRXJ[3?X>5=5W"G:1<9)98%'VLPL"@QA?F:S'AN
M:)>[HSCG%K:;`T[*%2)8U."L?AA=CPY(`C#LP!A8=ECL9S,\>,)HB(X34J^2
MSC(\R&%3R[+%ON,M?-EV<&R<1DB+62A:HC$3(^-I5Q>O"FD]R4)W$A&D1&%%
M*!]L@E0H"+O#RP#./W$\8B,9TLS'"9G+^3W*_P"*'&TB%0]X<^0DKA_)H*(#
MI([JB%E/:-X+DKH6L4O344-T-$S#CI8W(U*/NP)35I1>A#,ULP8129SN?X_Q
M(C'=_)UD%0W+7:P+)&OB0)4E?&OZYD:D)YZ>=R5NKM6XG20Q>>X@"M2%S_SD
M:--X@8""O##WW:D!?91AO/\`^?$Y?W\&6T26O:+>0W!ROO&%3I^K&+/U:4P.
M-(UKP<O9E;@H6.%H243(B5E-<K>V51YN`2,!2@PCM:.!WP0C,DQ,Q6.)$Q=Y
M9-D#/>50/A6C4-B18H(M![('5R*83]]O_:'29\\W*=CZ_P"G8ZZ_US&G*.C>
MK'NC$SF7Q[+DR^(?;<HU]0FIRM(4J4U8H6^*"8).:B1I>^<#"#^Y,T6,1(`G
M=@6R^T'7:QHR-<(FN>PJJY!09[KV>4)R!ED.$X-;JC5,D<9T/GA6TNA`TJN/
M.)4U2+4G;(&9L>U(4FQ)!&@\A@@@W8QRQF[BTG+&>$Q-/9C_`"PH6MHHDC3%
M!I="HQ"6\MN/8B6.+M:*&Z2]K2IJ=@_:O29"N1*>WI4(1@^V?VQ;,&+>Q;:;
MXSE%^ZQEVQFO9FZ?E]`%J)"Y-\/L]Q;7-NT[MSBACC2H0KFW0=B,7(U09'W*
MM&3L`M".+V,GJ'?06]:ZXT?Y1_4U?XR_&^6+08$PQ%4=UN!>DASF0-'!52P*
MII2A'XMS3[;SENE*1*<'11AA.S2@'"T6(>C-A`)I_P`H-4[914;S^9]"4[34
M)R&6$?S=,YZ6F;?5ER(U.882I(CYC?6ZTB1J$QQ?9,+:AN!@-]>T'7DZM..^
M"\MKSV7XCU<JB5"F2UG<$'2%N)S(0HF5=SN$!6/Y198M,:/TDQ&!A6NPC#RP
M>&3;/4;$/6@EB'T#N:8GEG!>4?V2]&#7]4*>//44XW48ME3DA&_.;A$V5L0-
MK&WR1^."L=$DN>65++U$>$[*2@Z-&:B-'L)0``)'HL)8+.,SSSA+Z:980MDW
MQ39H0C71IEXW54@7`,\8TN]:2ZPGQJ,T;K98$4I>.0M3@5!`$/9$:HB!?>A%
MO82@>3>IIQW^&KG9/]6%$P_XOFEBE6;>M*C)*<%RA,UBX]10"(](>G(`F;QF
M%WT)Q-3(SRQC*'XE,>+9G9-$(.M;Q6._P7.SR]`QM^+Z>2CWNQ.-:104B-3J
MMH>.P@$JE1!`0I5YA*[E^Z&$GJ3==H\!9W<F#WT`%,#IC3CO\&J?_/RK[:'%
MGXO-MN6AOO.J60&*K_"$K8?0E<TS59B`K_A#%9K5-%4CED[0F&G(]"$,QT<!
M%]L8"P]T,8!-.._PNJ?_`#\HO,X&?%)=6]3'I%\0SENI1+FDUO5AC[E2L57;
M[Q.)M"L33%`<I=$!H&OL@$62/2L:OJLTH";OIC3C_P"G@US_`.?ERHO@7<66
MDN*K)AQ'#;CTU$N*J2R59R2LI/*+)<''0%*Y?;RI5*$*&2O1R\'B@;9TS:F"
MLZ;T#N==UMI_U[I/^G^SM"UO'[@GQ\H.M9]3]0<"6A?"+-<5JRPB+SD;/,U#
MXB-*3I444.<IX0_/+E$F!*A)*;4NSME$;!L_>A*##3QM.,?W).><]%B5_'!;
M*8BV0%;QAX9((`PMZ5L:X'+:[:I1&2&](F"E2M:%D2L)[*WMB9*`)>BP$A[.
M@:T'?9ZZRU_K]4O_`&>B76*K;J;V9N96^T(76[,TI"$#5$Z[J]C'&VE`1K02
M4+4!PVW&(4B4`=!++++"#0?)TQ>&TK/<];=06,OUL;YR`FQZC>Q"V-@9V6,)
M^N@[[KHD1;4`"$(M]1ZT+H/7D\GDWC5CTP@TSN?C5!K4FBE;5<EN(WKM"VL<
M54D"YI5O>]=G:,:E"8*8/4>];!\K>@=/^]OIO37_`(P:?\IMRZI.4[UWH[WM
M7:SKL>C`+T!:/O-"Z@ZM^DHB]EZUK6A`[79%Y?X:WTQJC;!IG=**".&#*GMA
M==)$M;TUFN[(GCCQ9R&LX2AMYP8D^R]@93+23I@R4+/T)+#M-O8BA`+"$6A!
M"'6FK'9%E9<M<TDLVG+./*,;SN0$D4,NR5"4I$JB;&J6F)%8.Z4DNCF<I$)W
MV83L0="-*UV.OR>GEZM6.PTSN4CO+X2M`W98;=:L\@-8W!-&YA*8@K[:8W<L
MQ8D2EED)$;JHAC@TE/B-(E!HE)M>F5'-I0=`3"#K?DEX3SQ6-<<LD^4WP_74
MK#&N`U8IJ*C(:TN:E[21.IZD8SD!;RM&+QCSYX?]%O9SV:2/9>EIHS%'=="]
MBV`(0ZMX1RQ2=<\\DT^@U_<O+)[OM1ST,SO#B&9U2Q=$=H/^PO:5"G4Z`7K>
M]]K01:UOR;UTWK6\:HZ8P:9ZY2[*/C)3"<CL*XH8]*QCV<J='EZ>U;DN4;%L
M0U"DXMP()[PS>_E:+++`+?EV'KUWC7EW-&/9R*N,E&K#A'G0-,`8NFMA2O<F
M0DZZ?^%.B>DZ<&_+_H'6->7<T8]G;3<<:32B+$5`&L6RB^[#XE6\+`[#Y/*8
M%8XGA.,\G^X>A"_[<FO+N:<>S,U%7ULK2D(5,`AIR1+H&DQ`XTS[`GT#>MAT
M3_P?4O6^G3?3>NUKKK?76]Y-67>5J.SH&4Y4QI!Z<5;0?1:CO=&"+C#.2>'O
MNO;[A42D`I2].OR>Z&#L?]WIC5ENDTX]H8PFXW4BE-T<5`&X0]*-*=:4N#XL
M*[S7_=V0K=#R=I_)_P#2V'NM_P#ARZ\NZ:,>SG6\=J57JBUA]?,Y9Q9?=!`B
M-<FU+L/7KU,0MRY*B-,Z[_WB+V/IY.O3&O+N:,>ST$%$T\VEEE)J[C`PE#[P
M`ER`+H=VNNA?+/<Q*SS`ZWK_`&B%L/\`V8U93U-./9((8['P;)$!C9P"3`[M
M.(+8B#L@O8=AV63O1&ME`V'?3H'IKIF;GNM1V>N$(0!"``0A`$.@A"'6@A"$
M.N@0A#KIK0=:UY-85_<#B.))4%&$*"BCR#0;`:2<6$THT`M=!`,+'H0!@%K^
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MM8T,`\09[7ENTA@UBJ8?+V);;D(E+R7M<[L\K,>FUV7F&J5A)YYQI@Q<I.GW
M'6GK.:)$R3***%J.2KH>[*3FN4S&+.[&]P``00N0P20120,C]6LDC00_\*Y1
MU2UKB][WOO>N][V+1X[\(.,SS`(=6QT">6Q@@3A+72,.T7M"VX98J9PL(U8H
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M:/\`+:Z%#.!J.UH3Q%T_VLDDH=D4<D"HLHY402K+,"806$@P@L/=XN=TKPVQ
M_1Y</^$:R5Y+]&0?F#RF9Z?+5;6I*>>5]56-MLWTWV65KLNTZUG$^2Q0O>M:
M`D$I,4@!U"%4'?00;&64<LB8QGGA%IM:_A^)P2'6Y/R/NZ75RE[)C?7JDJN8
M^,9AAAHEB9UET4A#*\Z;C0&]"O-`65>5L/:VK'O>^K7EW9TX]EHU_'&CW-$6
MW+JX8#D983P;*UI83M06I"4`TM<:0K+.<"]A)UV0GB,"#J+LZUVQ]J:LIZRL
M1$=(<2/C)QN;U;<X(N/]*IW%H3)$;6Y%U;"/.:!*@*"0B(2N.V/:TH"4D&@@
MZ&?)UKR8N>ZU#)6:F:J84SBC;H#&=)G8)Q3B4N;27?2M.H+[H]&8)WTN'X`T
MOR"3ZWHG?7?R?+OJN>\I4=H>0_<=N/TJC'V*E%%TY)(;VBA_9)^K&%/$8[9`
MNT2/S"X,BAJ[1(O*'?==0[_ABYGG*QPY(S5\&^)QC>2TL=)16NFLA/I*!NID
M]\HU"(H)^E`=G):<=X,0H.`9KH$PP(C-`WL&A=@6P[1,QRDY\X2W6%'U)3#9
MMJK"OXW$"35"M:N7($.CY`].*_N-.#M(Y0X"6263/*_24K1ZQP5J51P2B]#,
M%H`=:@E3`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8%-/ZW?WE_X]LWT_'[9Z_G]/__5^Y/CE^GNB/P:
MJ_[D,>7+[9>Z8_6/9,N15>.4]X'<=:5D%J$-K&MVV/D%CYKC+GL^,P.'I9Q.
M8["E=A6-(TK<[*6*O:_3/XWAY4@3B[M`C,[0R`;$H*+$7*AO_4*M.-\=*`LB
M7L/')1*KSL5GA<7FS3;[VNI211DWC[)KE>)NG,B4/FUA-3XVR6**(JHCA+6Y
MJ"7,8#PJ346S#B8M<92B^<OKQ?D;>GHB"T);SS$^-S!RAM%V9K;D:JOI!%)F
M^SUFKF$TK*44'$>^/EA@JJ2F)W=T2I$#>-M++.(-TIV8GJ5'5.5F\DW--5W'
M^3TG'6:83+E5)H1%J903)V6Q^,$:E];RFY7"3RU8TH'=T\V1.J(*\NQB1(5L
M]><C`D`:1WWB"Q7-`C1S!Y!3U]9Z,KVJ:G)Y,,CM>R.W$LNGLJ*J&+-=%K*V
M1)WA@>&>(J9<[>E_5RQA6S)ST2<QL0*EIBK9YJ`)*N+4<[X+J4);2.]J9K:W
MD;(KC'V]BK:^+XLO5D+UT4?!E[32**K7!*`M*X*XR_)U*$Q04$)1XT^Q@UH(
MM969X)=P(:XY?I[HC\&JO^Y#'ER^V7NF/UCV3+D4P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&!33^MW]Y?\`CVS?3\?MGK^?T__6^Y/CE^GNB/P:J_[D,>7+[9>Z
M8_6/9,N1486]$YY,8:-OK&P@5E.VY\C<BC\F6L)TKCQQS`]HG-;&YA%DSY&%
M<@B$M:R#VUP(3N2!6`A5LY.H)4%%#T(4(H7A3R!H>$-SM!;FIF(VX]R&)R2Q
MHPVT`-10<@+8:6CM1[0[CQ-B(+$(GI>V`IR5S!!(6\U]4%Z(6-O@]$$)XU,Q
M/1RIN!5M0)E5%TMR,8(G+K*K.85??\JD5/F/:60AFMP7#>([`J6.-=AL1%;2
M:%3CD#,@,#8O4R!D1MSJG(&29I#K:D7WA.T]XORM?$*NC]7V-'H.KXVR2MI7
MQH\\5\HD3;%%$&K*4T^_QRQ0I)DQK9M'I[7<W=FLP;:-@5MA:SO"QJ-E]@=2
MT2MG"^ZH4Z,=PUW?,'1\FW!SO)7:TQEU/.+[54Y;[Y<*[<5K4V5ZT65'9.P`
MJG=01=-%SCI&O-\WMRI.MV>-Q&>G%^G!<ZC*G:Z+I^N:A:'9QD*6`15KCYTE
M>0)"GF4NB<GO'R5O)2`E.@*>)0]&J'!4$@LL@*A2/180@UK6B3QFTKX$-<<O
MT]T1^#57_<ACRY?;+W3'ZQ[)ER*8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`II_
M6[^\O_'MF^GX_;/7\_I__]?[D^.7Z>Z(_!JK_N0QY<OME[IC]8]DRY%,!@,"
MH,JYM4U$;L)I%>CL1<O(>$44DT^9*\E#O5\)G+NKJ]*R0V5S)"@-0MSBNU<<
M=&H5!T8V-?G1,!>J3&&Z!HM=5OL(8#`AKCE^GNB/P:J_[D,>7+[9>Z8_6/9,
MN13`_(A!`$0QB"```[$(0MZ"$(0ZZB$(6^FM!UK77>]X'\+,+.++.),`:4:`
M)A1I8@C+,+&'0@&%C#O81@&'>MZWK>];UO`_>`P/P886268<<8`HHH`C#33!
M!`666`.Q#,,&+>@@``.M[WO>]:UK6!_0B",(1@$$8!AT((@[T((@BUU"((M=
M=;#O6^NMZP/U@,#B//)3$G*5)Q2=.G*,////,`42024#9AIQQIFP@+*+`'8A
M"%O6M:UUW@<N`P&!Q''DIBAGJ#BB""@]HPXXP!118?X=H9@]A``/7?\`'>\#
MEP&`P.(X\E.7LU0<405H0`[,.,`47H1@PE%AV,>PAT(PP>@AUU\HMZUKR[P.
M7`8#`XCCR4X-&'G%$`$:00$9Q@"P".4G%IDQ.A#V'6S5"@T)8`_Q&,6@ZZ[W
MK6!RX#`8'$<>2G!HP\XH@`C2"`C.,`6`1RDXM,F)T(>PZV:H4&A+`'^(QBT'
M77>]:P.7`8#`XC#R2=E:..**V>;H@G1A@`;..$$0PDE:%O7>&B``6]!UUWO6
MM[_TP.7`8#`XC#R2AD%FG%%C4F[(3`,,``:@X))RD1)`1;ULTT*=.89L(>N]
M``(7\-;WH.7`8#`XC#R2AD%FG%%C4F[(3`,,``:@X))RD1)`1;ULTT*=.89L
M(>N]``(7\-;WH.7`8#`XAGDEF$E&'%`-4"&$@L9@`F'B+!LTP)(!;T(P0"P[
M%O0=;Z!UU_A@<N`P&!Q;/)"<6F$<4%0:4<>41LP&CC"4XR"SSBRM[[8RB!J2
MPC%K6]!V8'6^G:UU#EP&`P.+9Y(3BTPCB@J#2CCRB-F`T<82G&06><65O?;&
M40-26$8M:WH.S`ZWT[6NH<N`P&!Q=^3H[2;9Q6E`BA'A([P'?;)`,)8CM%=>
MWLH(QZ#L73IK>]:_UP.7`8#`8#`8%-/ZW?WE_P"/;-]/Q^V>OY_3_]#[D^.7
MZ>Z(_!JK_N0QY<OME[IC]8]DRY%,!@,#3!=%57X5S6*F%)U#<-?3U]>?./IL
M@%EQD[C58D$`_P#%UN>G*^*NF]B'I4$C;X-'GQ@=RF2*ER=[(;F=2VKS/"Z-
M9HUPKFVIUS#9O$?M+]M+=DUK^>'D;BR?:.,U_'/LBV"[SLL#;]A(O&O.:,OM
MAZ'.'BE>^QKJ9OKOK64F8#`K=`Z'D$4@T,BYUT6DC.C<3CK`:C9'&$F,J0QG
M9T;<-,T#<J[$XC:R!)]A3[/WL[96@]OY77-3E$S,Z89B.$<66>B5[]>%R_/J
M]]G.2XVPM>LGHE>_7A<OSZO?9SBXVP5ZRZ3E3S^K;EZ4J[[?&8I1*DY8%*^`
M:3B&<0,L`3]E5UWNB1"%T%V?E=GKT\N+C;!7K+I1REI$TQYA:U-V6P2I;69K
M;U!3:O@@FXH]&A(3FEH-JZZ\5M$`PO>BMF?S.QK7:\O7+<;8*]9>UZ)7OUX7
M+\^KWV<Y+C;!7K)Z)7OUX7+\^KWV<XN-L%>LO%D=+2)VCS\UIKLM@Y2Y,SHW
MIRG)?!`MQIZQ">G*+7[25UXK2(9AFM&[+_F=C>^SY>F6XVP5ZR[K;3S^D;D"
M4V[[?`8F1)4Y@$R^`;3A&20`L82-FUUWNR0B#T#VOE=GIU\N2XVP5ZR[OHE>
M_7A<OSZO?9SBXVP5ZR>B5[]>%R_/J]]G.+C;!7K+&9K1TED,-EK`ANNTE"U\
MC+\T(T[TX0@+,>J<FI4B3DNPF^NO'A;#33M!/V1_.T5L78^5TRQE$3$Z828X
M<Y9-Z)7OUX7+\^KWV<Y+C;"UZR>B5[]>%R_/J]]G.+C;!7K)Z)7OUX7+\^KW
MV<XN-L%>LL9F5'25_B[TS(KJM)0J<$0DY!+RX0@+68,0P"T%:)!77C-$=`^7
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MA`3"4I+<Z)1G-?A:Z[(G,)BP&@:._D]V(?7Y79RW&V$F/5DWHE>_7A<OSZO?
M9SDN-L+7K)Z)7OUX7+\^KWV<XN-L%>LGHE>_7A<OSZO?9SBXVP5ZRQE^HZ2N
M3K"EJ>Z[2-*CTF5NZX:]PA&E2=*=#9:P`.9=)JZ[D3F):^$ECTH_D^#&?O7\
MW1>75''^,)7+C+)O1*]^O"Y?GU>^SG)<;86O63T2O?KPN7Y]7OLYQ<;8*]9/
M1*]^O"Y?GU>^SG%QM@KUEC+]1TE<G6%+4]UVD:5'I,K=UPU[A"-*DZ4Z&RU@
M`<RZ35UW(G,2U\)+'I1_)\&,_>OYNB\NJ./\82N7&63>B5[]>%R_/J]]G.2X
MVPM>LGHE>_7A<OSZO?9SBXVP5ZR>B5[]>%R_/J]]G.+C;!7K+&7BCI*N?HDY
MDW5:1B=C6NRA8:L<(1I>0!:RK&\D31HBNO#"/&>H"$[O_D]QL79^7TRW&V$K
MEQ9-Z)7OUX7+\^KWV<Y+C;"UZR>B5[]>%R_/J]]G.+C;!7K)Z)7OUX7+\^KW
MV<XN-L%>LL95T=)3IDPOX+KM(2)MC,M:%"@UPA'GDI4^.L*6HR4`05UX#;8>
M5'CQ*]F?SM&EIN[^3LW+JBJTPE<><LF]$KWZ\+E^?5[[.<EQMA:]9/1*]^O"
MY?GU>^SG%QM@KUD]$KWZ\+E^?5[[.<7&V"O66,JZ.DITR87\%UVD)$VQF6M"
MA0:X0CSR4J?'6%+49*`(*Z\!ML/*CQXE>S/YVC2TW=_)V;EU15:82N/.63>B
M5[]>%R_/J]]G.2XVPM>LGHE>_7A<OSZO?9SBXVP5ZR>B5[]>%R_/J]]G.+C;
M!7K+&3*.DHIDE?\`5U6EM$3&5[0-0)PA'GD*I2ZMJTLDH.JZ\!YL$4D$(S8O
MYW>Z!V?D]K+<5]82N/-DWHE>_7A<OSZO?9SDN-L+7K)Z)7OUX7+\^KWV<XN-
ML%>LGHE>_7A<OSZO?9SBXVP5ZREAM2#;VY`@-7+70Q$B2I#')R$G$XN(TQ`"
M1KEXD:9&D$M5B!WANRB2B]C%OL@#KH'45W<!@4T_K=_>7_CVS?3\?MGK^?T_
M_]'[D^.7Z>Z(_!JK_N0QY<OME[IC]8]DRY%,!@,!@,#\B$$`1#&((``#L0A"
MWH(0A#KJ(0A;Z:"$.M==[W_#`I=R6Y;.M&.$C;8=5A-H**YI1_Y(6F-PL1IK
ME*PTW&5RU&Y*H@H<F1_#-IXK"SKS4C:9IJ:0`2:\>[H-J4>E!8BUPF=T2OC0
MUO2+2@*)X;D+HD"K3'(U04K@F*5I]*4B@(#TJC11VNV6,.A@%U#O6MZWA'HX
M#`8#`8'X,-+)!LPTP!18>G:,,&$``]=Z#KJ(6]!UU%O6O_G@4?O/F0NJ&;2]
ME9ZI'-H=3R6H76]969.F^,/D69[JD[A%XGNN8.<PO"RSWE$:W"5+4YZQ@3#3
M[[E`J7N`#4)98B^J\>$,!@,!@,#\B$$`1#&((``#L0A"WH(0A#KJ(0A;Z:"$
M.M==[W_#`HURKYJIN-:F0%(:^3SI+75/JN05JKW2P&:NDK+5*61BBQ!$#.>6
MMT3V+:<C=TYY+2P=XUHU)Q91*ES1G+6\M46(M;:`6%!+6A['8-9S"-SZ#25.
M<J8);$7E`_Q]V)3*U#>L\$Z-IZA(<:A<49R907H7>)U))A1@0F`&'1.3,<!@
M,!@,#\;,+T8$G9@-&C`88`K8@Z,&64(L)I@0=>T(!8C@:%O6NFMCUU_CK`UV
M5C\16O9G;-=5[-VR*U2Q7_&Y5)N-L@DML1@<HL4F)S]HKH+!+J[4H6=PKN8S
MUV>-*(HV%K7H]V(0KTZCP#FB-;L+7!L6PA@,!@,!@>)(I"V1=D>7]W--`@86
M1VD*\"5.<N7;;&1():XFHVY(`U:N-*)#K6BR@#&,8@AUK8A!UL*-T#SYAMMV
MBUU!.VJ&U%.Y_6%>W52L847%$)C([#KNR&N3O;0C7,J!*T',5EM#'%3W%Q94
M`WU$6V&EJD[FJ+T=W)9CA:_^$,!@,!@,#`+2LF-5!6MDVI+-N!D:JJ`2NR94
MG9$0G5]^S4.8'61NNVMH*&`]P<#D#,>%,3K8=GG![`=]?X#FK'0O-"/6?;4O
MX]V0WP*JKZCK)%YDTUPT7/%;,52>%2^/[DJ0]`H;VZ-.&IC%FW0!R%J*0J4S
M>2J2*DRY>B5E*MEF.O1=O"&`P&`P&!#E[7(U496+_8RUH72@UM>X1$&F-M*E
M$D5.\ULR;1:N8(RJW->:6W1YN<9=-&X"UQ5;TG;$!IBPW6RBA=2Q%HLXT<MH
M=R`=[.KA>H@<8O:E)>]1"SZNBEHLEF%MWFD](07*HT])6V,/;W#52A;I"8J6
M,C2H1O"96@4)RST^^V)BO9;;"&`P&`P&!"-[70GIB&MC^CCQTUD<IG\'JN%Q
MA,ZI&-&ZSRPY$BC,>1OTF6$JT468R%BWO5JP9*@X!)>RTR96L,3I#RPP'BMR
MR@/*!@E930Y0MNL^LI5)(3;-;1>Q6&Q38:^1N6R6'EN25Y:2&M8ZPN5K(JK4
M,CFI;6TQ<F`+MIB3BCB2Q,4M9A#`8#`8#`II_6[^\O\`Q[9OI^/VSU_/Z?_2
M^Y/CE^GNB/P:J_[D,>7+[9>Z8_6/9,N13`8#`8&%3ZRJYJEAU*;1G\*K:,"<
M$;2&1SZ5,4.81.KB(8&]LT[R)>W-^W!<,L6B2>\[PW8=Z#K?3`UUS_E58<G:
M;@7.L486#BLDM":\5Y[9<'EVU5]TJJ6;20U'?CU$Y)"WFO5==G.<A2.`0:&K
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M<[6?`7EP3+W-I4GI6S<WC^EFM^;G`)>#AS;!*O@0ZUAC9%%$UG5B."8U<N=I
MK8\@,D,KD+PZK#W%S<%9H"430T)#5B@?AFQK2(&AM3Z`G1I2""P%ZK*0<!@,
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M)5K1&$2E:DC3&4K6Z3HD>CU1Q:8D`E2E6K&H5GU)XIKPA@,!@52Y"\L:ZIF'
MVB-@E5=3&V:U9HNZ.U5F6`RH7Z,H)K*&"),TRL5K;Q.\HA];LZF1E.+JZC;C
M`D-2<\XL)@@A#LL1_13R?1R];SM5,U2)T34US6XFQQ?;7'8F&RA4Y<9;[BTW
M<&QH?7&0@=(HBGHVER3L1T&E3.H.,'&//!+PDTJ.4-*HJ+PCV6$D=/V7RE9H
M,_RZ0>B"H)U'*8DMH<=)-4C.KN-HDU;2\%C)8@FN9NFJ=!'V8<@+(2.9(F%W
M4A`F&>SKVLU0,W*G)>S"&`P&`P*?WGRQB<+:%C'4DJJ>P;8)MNKZ4=XZLL!O
M,:JJEEK2M)$V)QN%-%A/<FBR(*]5HA*C-3)U#HZ')4(#"-J?$%%B%2I*U7?<
M]BN5L-)*Z`<[>#K44THJ+;9HE54!=566JN$_/9S2^KHHT/ZV*\FV*OPMC:O>
M.UN&RZ'E]$^AH%QSA%X1[2M`HI&<W7,Z_LB83HIBI<B3UA?T?HARIA!%+@B]
MBQB(M@&"/S>U$TU5DG,,>>0Z7*6H$>)>`+RQ(3'DYJT)`.I=+JX0P&`P&!3*
MY^6+&SK8A`*&E5-6):TNO1NH)X)=+`3+8O3<L6UY9-D%BMY)"A/4E85CPEK(
MYD:VXTM(H6OSJA)V,`!B%HL1W5,7@M^?3:4\LXBRRQHY@<6/"TC=_$=-*VQ\
MJRSZD("HG<@8JQ=#(O''"1K;<CLH02R#2)S"2:2\-B9D5D-VMOI&XO#ET7#]
MW^<3:YHA:=@V>TNU=0&?K+FJJLV^H44*GD?G3[5CW5?8LFS2)D[ES9IC<2ES
MD0A2)6)D6@&:46O6N)28LO=2^"WN$,!@,#\B$$`1#&((``#L0A"WH(0A#KJ(
M0A;Z:"$.M==[W_#`HO8/+5=*)C6%<\0GF@+BD5A,]VONI>_6F<?5Z5PHE16:
M)^JO<BK)KG"E-9LB.M`E222,H>VYK9G14:G/VG"0,M=U?ZX^VZF?)><=1-EI
M/Z^WY^U4US2XKRUQCR]TK!=!W-MJI&OKY"S-[<U!D?'&8-BI4N4]^H!+XD[+
MG$M2?HEC++B^BVU<\=IPT7&EN*V;78+'=(7'+1A%2MT3J=%5(8]$[>F<4FDR
M4V`K23&6`L.<KED%:2?."(B.->P$&G":MJSQJ-5+6TPA@,!@=)Q<6]G;U[N[
MKT34U-2)4XN;FXJB$+>W-Z$@:E:O7K5(RDR-$C3%",--,$$!8`[$+>M:WO`H
MQ/.6,OE<WAD*X>I*,O(<@JF<70FD#S;(T</L)D@4OC$,=H%6,NA+/,611*P.
MDF)TX.*H8D+&(]"$\@[2W9B4M=T.<=D<ECT[8^15-'6E8](\SYY+57(NOIP)
ME%->.E]-CH[1I++&]B0-S8TM+-7JV&>C:9-A03CTQS$U.6S%1Q#JI5Q9[3SA
M:6E>.\WA5A*+7MZU(]:<[;ZX(IV&JH94Z2FV%DKHJ0%R=7M\8$DRFX)%-WYW
M1I!K5Q![8SDZ2Z"VM#:$Y5I14M;+"&`P&`P&!33^MW]Y?^/;-]/Q^V>OY_3_
MT_N3XY?I[HC\&JO^Y#'ER^V7NF/UCV3+D4P&`P*U<BN237155SZQ&&)/%POM
M<S2IX6^UE!UB4,V4.=J3FNXLA0M2-46,"Q^+9K$3N:)#OL><Q!"F`:6,WO"R
MQ%J+VM-8L^RNUN4,2D)%ZQZ)<+;3Y!\:H@NTEED"EX9[74'8;$9TC,O;75Q9
MD47;JTAZXP"-,4Y`3V2[%;)-TX'ISHOIZO,H/A+%+2JQ,PZ)Y#TE3JVE*DX^
M3!.M>XA&GCG%6=:0)#7PY)>5,3>LY?(*D1/,6:RVE"N;':-SAQCZ@2->!O2H
MVTC0F6Y#*R8#`8#`J)R+YAP7CQ&:\G2YJ73:#22\'*G[!D475E'^B-LC$0M"
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MWO"1N%LL;B`T@@)A6U`3`EB+47L6:Q62/EY<FXI(2+Z:JTXF6+R(XW117I+*
MZ_E,9NZIH8S/T>+:7-M<WA`=&76A4SBH"B3Z7I6JR5:7NS`KS$8HOH\R@^$L
M4M*K$S#HGD/25.K:4J3CY,$ZU[B$:>.<59UI`D-?#DEY4Q-ZSE\@J1$\Q9K+
M:4*YL=HW.'&/J!(UX&]*C;2-"9;D,K)@,!@>-(Y$QQ"//TLD[HB8XU&&9TD4
MA>W$X*=O9V-E0GN3LZ+U`_D$(F]`F,.-'OR!`#>]_P`,"F-L\D&]TN"S.&PE
M+W4DOEM&+G.I;W&\!0QY18SQ')TXK(TC6)R0G1^806.1T$F2@.,,\[-J1R&4
M7V&M3VRUPM0%6@C(WGB@V-%$S*[3K,B',?D(M@H8RS>)F5G\G'L^,V!35QV"
M-M#%(K556,=P/C=*UTB4GJ5`VEC)**=7(LE*9%[\6RB@^)313<B8)PZ6/;%A
M/\6K-PJJO&"QY=&)LS4I7\F>(I))57T!EK=6L!GLU9EKO!F,K;O,53V_*$K&
MCT)05_-`.I,VM[A#`8#`\9_D3'%F[SO(G1$S-?G!F:]KW`X*=*%PD#P@C[,F
M&</H`L;@\N:=.7L6]![PT/7>M>7`H+;O*P]YF?(SCQ&&J20JUZA;6";TX_;>
M"T3+R`E%=QNJ+QE55Q]65I'M,X@3SF/,KTTG&C-<F>1#-(T:2!8%.6(Y2I>9
M65>&6-5-`0:EY)R3AC7\/R*U]`W0Q-J!Q2T8;R,LM-*9E;=XWFRQ\*");@8>
M/K([-:I*%RF+G)),O7HFXY8`2_47O/+BVHTAQK;Z:D4FFCI:]NW=.Y+%(97X
MIQ<[C`W&2-->U\LE#E%(:WGP"OJ[0K4B)UF;DK4N+DG7OSHI4]M<O4[+*[NI
M:R6$,!@,#QGZ1,<80D.4A=$3.@4O,<CJ=6O."00<^2^0M<3C#6`8O():^25Z
M2(DP/XF*%``:\HM8&N>UN8;>]N7)"MDI$IK.:\7I-#[+1J0O@TP;UI.".E=O
M5W#@IJ`*3QCRD:9$NC2AF&(]2D<7-D6;Z><4@0EKDJP\41$2;DC_`!48:7F5
MO-M;<.:&I>'RIGV54S%MI<[$+L!\Y+SR[XK'P,\0E,#E51LKA"PL*=PDXY6-
MW4(D($XE*XF+?"[ZMK-(\?T-,KYQ)'"R;*N2P;%-C1<KLJUS*_U*US+"FU4U
MPZ,E)*OK^L8:D9(X2Y+3"=EM(59ZE>H.4GGFF=K51/\`A#`8#`\9TD3&RKHX
MVNSHB;U\O>3X[&$BHX)1[X^)H\_2Q0UMP!>50M)C48<%H@:\NDZ,T?\``.\#
M4W97(.-\OZQF$"4.4RI(37<,IXT75$-/2,Q^>*CY!)K-X^5A;493J$X&"41E
MVFJMLD`3CDZA.W:CS\W*-CVB6;%&JIB::L&^Z>4W(2(LE/V+%'B+V]3#4R7-
M"!H:>9>-S%1%1F$PJRX1*W&&O\?L*Z)[Z67UM^SB!H=657!#$2"1&)$)I214
M.D-HU)4NS4C&GME0R>73Q^E\Q?+!GMA3T<8%,9U-'\M"D6O[Z3"(O"88B-):
M6E$@3IFIG;42=$B)+`3KL[$*LICP&`P&!XRF1,:)]:(PK=$2>0/S>\NC*TG'
M!+6N;?'36@E[4HBA=-G@;#'Y)WN@_*#H\.^G3KO0:D%%ZQ#GK5''"5JU,JJA
MAE%FP6#<@*3>7)K<U<.7/;Q5=Z56;+69:C,8)K&Y]*HE"F5M6F(34+M%;,,`
M(LOQIQ`8U56QVG:U%R$M"YU3775M5'(V_F1>5FJ.2$4/:*L/HJ30AM:>-4;C
M%+MTS@<QCM[.5O0&FFYVG:98RK(0,;\I"H6N*](E3!')M3I>H(_1\$)@S`[2
M&1[.D,QF4CELN/:%,KF4VL&5O$WFLMD9L?9HXP!='^3/RE0(EO;T"!,`02$J
M<A.664"I,VE?"&`P&`P&`P*:?UN_O+_Q[9OI^/VSU_/Z?__4^Y/CE^GNB/P:
MJ_[D,>7+[9>Z8_6/9,N13`8&N*]N433-HS6JVE+Z5UO6JWEC*N,5^WC#&6#.
MLGIJ7Q9%8,1;HZH0V_#9I"XX*1WRTQY@,<71B<"#$;VF,3:`4O3N))8CT0='
MV"T;HMVSJ%M^4O<8L-M#7$/F]X5&Q-*!,Y2'C=9$"Y2<7[1CC+(&661>*R&T
M8/8;ZWR!*O3*DB-YAQI*;O$IB#6XO"./1=_CUPMHCC"K=U=4LS\C-<Y#,),2
M;(),ZR5>VNECM=>);+&%^=33I*_ZL-\K%K>W03VM=#1/(1G$C)+V`DNI,VM?
MA#`8#`XCSBDQ)R@\82R2"C#CC!?[2RB@;&8,73KOL@`'>]X&M>YK\?+?J&&<
M@N/UY/T#XH'\=KEOQWOJK&&NY-*U\KA6H/NM*\4Q2UHK*CB$+P!PD)J]K2,H
MWA6ZL86L]0V"[2=QC41QJN*.HC60^1TQ>ZOLN?.D)G;251')6ZFND9.T$KHO
M>4UXUROCIR%H9>^HR'M;`FA="%[4YEG)#FR0F!D)BQO4DF!\7H<EYN.O%:F^
M+493Q&H&)6RLK>W*HXT$JUXE0VF%:G4[L*.P<@1124*]AA+U9#N6U'+@JW0M
M*J$`]8H%L0Q5)FUC,(8#`8#`K+R1+MA<77S-!IN\U+7;@\RU9>5QQ(->'3*N
MH1'J]E$@;%;,7:+%*HHWM[U)VY*D7N7FAV5HBAA"2G*[X;B@+"@-4%2#D@GB
M$`L&SG2*VQ>W'.@[WG[Q`4L.:[*KF7<>KNC,_IRQ93!W-ED$?A,POR$/;<(]
M&N:_!HC(FI3$D_RM`U%GA[+T\=^%U$<75SXOJ=F?D9ST[S![T9(9,Z2=8WK[
M'25KZ23@/3P:HD#ZHGL@JEK>G!2\JW16%U$I$F.3D*!I\J3,RM?A#`8#`8&G
M_F)S%<^,G*AV2V"\$SGC2[<=:U:Y[0#:CCAU@:63J2<G]OEW0W3BK9SU\3BS
M-6J)JF@'!<E96QF<278]6C"WG!61J(N/5[,<X%P+DO!6M7?DFMAQ-BK-':J+
MBY+PWL,?4V)Q=F$]@=?<F@)P,AXI9)I&Q!3O;6C=S7>+%!6Z-$WJ#1Z&6+KD
MVAQ2(Q^$-)K'&6\+:VJ'Z5R<].$Y0?HU^G$I>9M*G#M*33A%B=I1(%BO90-A
M()V=W9("R@@+#6628#`8#`8&B2=\AK:D3USHB]E)+8DT$JXFQZZOV&H7.H(;
M"Z.IJPI?*6RB[8J"/K*Z%;=KV$EH5F3SAT//E;<UF'O9Z-)M4K0)$;=&JC@M
M*S<+H+R?11*][R<+-0S9ZEM/<@2JP(=$;)$:6Y-5G#*]@<FE3"R'1[7VJ>#"
M:Q*9!"D(7AN+:Q*_-Q";SBJ.45+KDV)Q")1Z!16.PF)-H&:+1)F;H['&<H]4
MI3M#&T)2D+6UI3%IZE3I$W(B0$D@$,6BR@!`'H$.M:(R/`8#`8#`T$O]\<FW
MUSO6'W8@M937Q#.JIR^Q#9>/A$,XL7Q:=A1$GC#.*%^R2]%:UD5^R126HGU^
M->U3T\:)4LRTDE*>%Q;"HU4+C1+A-5?(!Q@7**U16;J;O4G@O(>&UN_N+:GC
M5$3=YA4(0V3%$$041W37)#9CJ/FM;TJD*=T7D(3!DM9S?O6CA5+GDV*QJ.M$
M0CD?B<?3&HV&+LC5'61(<M7N1R5H9$!#:VIC7%T4K7->:0C3`"(]2<:>;O7:
M,&(>]BV1[>`P&`P(1GMW1:.30%)LCXQG<@I754]LNJZ^?#3T!,S3PD3>VJ@E
M.)FTB`0$SZ^(0J2-*2U6DAAIX0]R0<846NO1J2473=AM14):;K:CSR0BULJ6
MZ:QU.[0F"1.U:9Y<4`Q/UX33CND9:RAL03_8VP(U4TU@9Z5Y3+9+''G1294X
M.'C=F$1>'%<N/_#:H#<T0VE*WFQ[%EZ?=KMC*XRB0$)4+-4]P+I6\+ZA8V!J
M:&I%&H\TN<L\Y$NZ`M%,#'9&0><["+#X;5I-4MB&$,!@,!@5BN"^/![O&F*0
M71^5<NX-QX671!ZF>!^$,>2)`.9QN`.(1.*IE:G=O53F)#1J2=.*0L@PU,!8
MI0%K2%.%KOR455SZ8U_8[V1/[Q=K<;:!Y.\>8_6<HLI%6,9G\QL"TZ\?&7D_
M5#"V5A$X(US=IK>E[:2S%`F0-BM8!R(4(-C-"V!TGB_A/=-?#4H2HWR*S-6\
M6+9-@QZMXA5CE,9U(TIZF11*LI)7<LJ!OVV,K4T-D0)J!\K)O/8@1TMHT,\U
M4H<O.*M28HW4F6PS"&`P&`P&`P&`P*:?UN_O+_Q[9OI^/VSU_/Z?_]7[D^.7
MZ>Z(_!JK_N0QY<OME[IC]8]DRY%,!@4J.X:09@M(3[7,<KR/4I9U=KJGY+\?
M5<.;-UM94::F-P35U*6B,HT8&-OFD:,4#9'#O2-I7F-+NZ4]HUL;NR6^'JL+
M4]+591D?71>IX4SPIF=7@V0.Y+9I2<K>GPUO;FC;N^.SBH6N[TXELS.C1%G*
MCSAE(D9"<&PDDE``3FE#`8#`8#`\M\8V:3LCQ&I&TMS]'I"UN#&_,;PB3N+2
M],SLD.0.C2Z-ZLLU(O;G%"H,)/)-`(LTH8@BUO6]ZP*9:X6QI.^7O"6U6D;.
M+W(V*'.$SI]C\;&%\#NP![4@/L2HGF/B1AB"28LB0I:Y)B>ZVCDK0G<TG\Y<
MX;V6^7=:2LZNKVFX<V0"KXDSPN(M`E1R5G9R!`"<N<%!BUU>718>,]Q?)"^.
M)QBIP<EIRA>X*S3#U)QIQ@QB)S9[@,!@,!@,#')A%&&>1*4P:4H0.D8F<<>X
MI(VPP0@EN+#(FQ4T.Z$P0-Z&$"MO6&%[WK>MZT+R8&#TO1E7\?8:5!JKC!+`
MTB4B<WEQ4*EKU*9A(#R2$ZV5SJ7/"A=))I+'$I,6$]Q<E*E4,!8"^WHLLL`2
MS-I;PA@,!@,!@8\?$8HI>UTE4QB/*)&YQXN(N3^>RMIKVX10E6M7DQA<ZF)A
M+E<>*7.2@\*(PP28)QY@]`[0Q;V'OA"$`0@`$(``#H(0AUH(0A#KH$(0ZZ:"
M$.M=-:U_#`_6`P&`P&`P(-L'C10=JS>-V18M3PV7SB)`;"621O+6`]>6F8WG
M4C843CV1`(?6]@D6O."!.O`I(0KA"4$!+-$(>RW/).6$,!@,!@,!@08_\:*(
ME-JMUV2&LX\ZV8V!8!$R)5I=LE6LB2LQ?#7IZ8`+`1F0R2$K3=FL;HO1J7%F
M,^4B/(WK6%N4YX0P&`P&`P*N\CN+\4O!F52!@`SU]R"CPHV^U-?;<P-JB:06
M90!3('*"#5N&R`+WZ$$J96[(G5C..\(XLSXYI-Z!XP8\+$U[/?B?&NGF>P4]
MZKJIKQ!?;DD"NE4WC;8H**.E[E&TD;DT@:"5@]`*='-J(VW"=!DA=E#7K2<\
MX1>Q`V+Z=%@\(8#`8#`8%2KZXOMD\<F>W*B!%:RY-0>7()U$;3\P)]?:A60R
MH(C(8#:Q[804\RJNY]`&\MC7%#,,/;PD(ER36E3<D[)8G^C-X3Q@I&OK:G]Y
M1V%)M6E8S@J7.\K=5B][5LA3FB9D[\TP<EU4JDL%9I4O9"7%X3M0$H79R_GJ
M^^$61HH7-4G["&`P&`P&`P&`P&!33^MW]Y?^/;-]/Q^V>OY_3__6^Y/CE^GN
MB/P:J_[D,>7+[9>Z8_6/9,N13`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`II_6[^\O_'MF^GX_;/7\_I__U_N3XY?I[HC\&JO^Y#'ER^V7NF/U
MCV3+D4P&`P&`P&!2!Y^(;QF87=T9')[GA+@SN"QL7%!JFQ!A`K0J#$R@(!ZC
MG08-&E;Z"UY!:\N:T9=F=</-_P"I%Q9_]?GOY3V+_P"W<NC+L:X]3_J1<6?_
M`%^>_E/8O_MW&C+L:X]4[4IR4JOD"9(2ZU6R-;N+@;1NPWN&RB,$@TZB6A2!
M3*'YK0$+#=^`,V,!8A#!KIO>NF^N9G&8YK$Q/)J!XM<[KE$R\1K"MZSKFET9
MN"@Y!;]\AMSC&T5#7$;:XMQK<KH?73CY8C!`H("Q7@N4HB"T+=I0]%.,5VN<
M`&`VC":;EN8CBMW"?B2%S]&)KCM)."VQ)*YU:V59%TUALJN+RA5:R.?NJ-JF
M5C)F,QF@,F@C'6CDMDB`DA[\,08DTW&N@U'8`LT^KTVKXC"!=!;PF"^F7]B<
M*+K2R)W)(NX3!C4KE#M5_)/D#QJD43+<F="Y-(![D?']8N*7%&*21IUY8-`W
MLO8QU*=2)<XGUA3W^DG$>-EZZK6OGW:[6M0JVY@+.@O%.ZP0:/P+PZ=I-#MQ
M<F1W3@TYF;,$$280C2S1F;%H5R2G4W-`-FWTMI-?5ZR![$TO+A'G"5S5A:)A
M(0Q]*TK%SXV5F_)6%ZD->NJ9V"-L?8ZI?P#!H(G!.VZ,!O8F*BUX\(8'DO[V
M@C3$]2-UVI"UL#2XO;D)$A6NBP*!J1G+EFTC:VD*G%Q4Z3D"[LA.48<</H``
M1"WK6PU""^/)\.L`A`',KG`,`MA$$7&N]`B"(.^@@B#N"ZWH6MZ\NLEM:9?G
M_KS?#I_^\[E__6R\_P#V-BS3)_UYOAT__>=R_P#ZV7G_`.QL6:99S8//=+R'
MX>2BW>",S6L<S]XKC%0$=EUMU#,6-A:Y%;_)*AZT>35\7F[&S+)"P:C-GF%G
MG(NII6Q#[HPI06`0153Q87,_B.O+(QWS,U.VN`*Z\XP5QKT933S;WE;<OYG=
MML4<IA\Q?@$$*ET>039H90B5@ZHE3`'3NE`),J"8,4[T-Y9W9<'&&M'2J9D3
M84YC]W6-27(:RJ<C]:2FP5K!537,RTMJ5!5<O>F6'O+A9>OL;(3491#D-I8I
M&9LEJ/V$.TXJ+E^ZXN'D#R!M:"U''>3[M!?,->\A'F;/L>H2/1*>.4AKJU*@
MCD.8[1K.^("[N,`EZ&%V.$YT);"T[<[#-)<V\1:!8F)*%1'1$]X?$@LVN*`K
M4TR95O'[V1VWRK:I6Z+6=(TQ*Y8)P;G\\A,H25VT/3L_!97SD;*F&.,:(K:L
MT30H?''N%&Q-H3=BH_"X>[=M#DM;<LC=$WDS4Q4M>4C1]O(9NGKZ-3Q\M(^^
MDDXD<8>-FS%:)B:JA9XS#"PF#1IRW%W6J5A93B@\!VCJG+FP6Q.55ON?P_&J
M[V(]7#[<47Y4]#/[M6<2:I:H<%8>>4.XG65**DALZ+D36YE6`R@<W&*)'`2_
M0"W)'H1YX@Z/'%KC2'6#GO-J@V[DWF[VX^-<*O-T:Q))O54)JN[WNLR."W(;
MD64*7PMN9"H8\,+U-:1<D<<<6!0QJ%;BBTF6FEDHUI:T5V6+GG,*Z&:8P.L2
MJ=C$%LTR\./#'84>E-A?:-F%2-^K[6:HY*XC)8M%E(%,K.=Z@>T:E"J2IBT*
ME`+8#E2<XE0,5'=AT$^*?!+"+2JX[6#X[H)\S1![HH;'*V1U53LJ>6A6M41)
MMGW:2(F>GWQ[=[:9G0E*I7.8QL0'!1K>U#<I1A6:77LOF_?=23F2/DWX_KFV
M$5?Q7L>][I@9<_A2D^+M%63QW32*<P27E->W"QM/T*:O$,36:F9=*PB%I=MM
M4AT6,5'=GTN^(@U5W)IDIGU/29AIB'6+>E3GVNEE4<>7!QFE`T-8W)&6C2UX
MET6ZDQ9;6M5/0$BTY8!4)X3!3"2!3FE+!U*8S:W.>9UW**\CEC0)91SLU3F)
M3&T&<;S'+,2O''Z45)RGE11C>\M2-.)OE[5(:!,TZ(B2=;2F%E`3+%A"C9F1
M:9NJYSR=L6,$(?./+VRW-9B2O'6E:^56/%5#/,VBQ_M@<F'+)RWHEB2`ND(;
M8,N4R).!$[%$@&G`UGNQIH@%"O7@\9I^(@2L9'12[TG(8Y*58IO&JYAR^8,J
MQ7/K6KCF2_\`"6:5R!X:V]:RM6V6T5,24#<R37!/INE8#1@+"D$(^I3-^4W*
M)^XX6G'%IK<MDU<M/#SF)>TKA+.4RIW^3R:E+$X<L<-):'MXVG+;3BVBWGTC
MNQJ"4AQBLL9^_P"26(`B+>$@YNSIRF2^E4G&YS'R):YJ^,"^NMVG%@P]-%8_
M6E=6JMF8K.\T]P+O&*TV=N*;@M8CQ/IPRMC"@+$Y8*ZWP5ZI_P"*%WL!H!!.
M(BNF4\D%7T)+[J=$KFQ1]]8UMX.1[8B#$*\96]T'-G2*)4_G9^2)3&\A*UF`
MV@-<%6Q)`2UT\USN-_*Y3R%G-JP0NLEL,<:'<#H1<"M=*$CPB8[?`_O"<J!Q
M<U(SI0R]I,@[>CD8WK6T1921\;THD_CM.*=NJ3%+AX0P&`P,&G%B1FNTJ!9)
MSG$A.XJ#4R8:!H<W76SB2]&B`=YN3*.XZ@WU#V^SVNF^G7IOI8B9Y),Q'-&_
MO-U-_P"H2'_\0DOU;FM&79-<>I[S=3?^H2'_`/$)+]6XT9=C7'J_NN353BWH
M(5\B$(6]:"'4/DN][WO?36M:TV]=[WO&C+L:X]56^1')NUZ4Y60;PYC<Y<8(
M]1VYWR#:!LI?VCB3%(+%!#B+M;'<)&W/S)51H4ZF1-YG9(!&CW%PUU4-Y1)^
M&XBX]51;L^)/.*OI6EW_`%8T';["7V%RCM>;$/3>PAW8''OB_?4N@RBH8<CT
M62D1V1:K6I:&QA5EAVI4";5YP-#,`::7+6(XRG[D!R5O6-RRP+#ATR6QZ@X=
M#81*JVFT3J)#>U*R<*Z'$3B5*N2KS`E,CO.KV#S<]H3=*VAG1)6F.F$O8E+B
M`TU&0(B/RQR:7?R2CE<\N>5T?OD;[$.-]MV60R4&HK>M72&3NMJW*8'`^*L\
MK:6ICL?[:R]H6GD,RX+TI*"ZG)MC2JBM[3F"HN(IDC-SX)=/B+JJ`!8T%-JL
M]TE7'=O@A>VL,U+ON'P&.W&=8IKGL7CP0QS1*9!!A)#MEA#)6$H)6A#5![QU
M*X7U>.P<B^28:`K'G,\6=&7"&V=(*K>#N*15;,[>%DJNWK0B-=-4;8IH%V.L
M)5?<,33M"8X&JC3VAS?B!M9;2W>)*4$"HN86<MJ:W%..3+#QJJVR4E*MC721
MUY3.=D0R/S:92/QL]U!XW#H>AF.E<5:FM$:VK53\M.0."G0%"`E/X41PC\J=
M+8&MYHR*N8[+2Y&P16\]\=J^66'RFMFGY2TLL-C$0:IK;\-<7*(15W6/3B_V
M!'2:2>U4HB_CR-,*M(>@*7+%0"R3!5L5>/B(34ATD2>/\6WQ]94;GR]0Q1]4
M6W"F8,G2<(K:<JLNIY6-IC>M6QUO7*4(11T`M*5;BN$,A42WI``<C8M>K)$'
MQ#FQ2N=94MIR3M7']DLV'U([7$JE,</<T4KG]=0>Q(NX#K-%I2]#B6R;`;FQ
M<K"LVL2N)VMEHU"31JHI9I]>+KO/Q`7^/10E[>^-LV0/DMKV'VW5K$1*&Z1I
M'>MI=(V.-J9#9;K#623+JQ'`%$H:SY(%.WR!*A3.!1B52NT6J\.*]4:RSGI8
MSP^52HJ..Q)6">J.).GYF?;)A\G@K8Q7+R9LJD)BLB4TJ^/3(R0R$P^'%DDF
M'+RDZ5(:$T]`D<DJIN/%<T[<<N>T1Y(6<"#QF&+44<D$9G$M@<S3R%'(!.31
M!).Q1M0&=,+<W`U73A+T\@+=(^08M7[6MR=1I5M"L*TC'4F*7YPA@,!@,!@,
M!@4T_K=_>7_CVS?3\?MGK^?T_]#[D^.7Z>Z(_!JK_N0QY<OME[IC]8]DRY%,
M!@,!@,!@,!@,!@08AXU4@W0ZBZ_3P-(.'<;&Y"STRQ+'>1.2:*L[=4LEHLAH
M7&N+NJ53)J-JN7N#4H3/ICF2KT<%2>$Q620>66YXH'FG!&L-5L_0^HTNXK('
M=XK1>7)9],[ML9U;6.JY`>^1*&0V:J+<:;6J%ABVW)?]FPP]_9B(NL6F*$2;
M83%"=0+8[7GPU^/S)4\2KFRT+W9#@RALW<D>44[N"#M$W(M:X)M>+]'IA'FJ
MT5RBP8C'Y[/ERAC32]?)E;:9OQ.E0UIAZHT7*79MP@XRV$C5()1`'8U(Y.=M
MN3V2R6;;$1U)RKW?`2:W8Y+QQ&<L9DP@<ZD!)2Q7''3:M@T>02(I&7LDKL"Y
M95$.*U%P.?ALN*Q)T;I(0K>7-K1'3ZQG6#1M\DJ=:FE,FAU7/$M7UE"I=+2G
M-5YW=VEH1.;L)6H&K/.$>:(8N5AL(8#`8#`8&&SNOHA9C(ACDW://;,VS*N;
M!1(_'N;;W,OJ:PHO:E?._B&A:@5&>8)[#&U?X<8Q)57ANX4EG)S#21A$2SB-
MQU776LY$GUHA!<3FZ09\=Y:C?)4W%OKU6D?F<6@KM((TWOJ:)/[C&V*>N))!
MRQ`>9L049H]B-;6T:0MS5='[FW$ZA[!=Y5(Y#$7=-*9A)V*;.LOB-AV77LR0
M3&.0<-:-LJB,P@$PC,F@,A,KT`618L8E3<H<FL`$RL9Y0`AT+EA#GP.XU.)D
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M%R]9OX?T"VM`F@J+R=8,<]A%EBDCU;-OR&P-RVMEVE\#.])C]/'*P_,,5V(U
M.C9O.GF8IO4J$7A?!J5!!HN7DI^$'&),GDZ,-<*U"*3H?-8$#A8%FNB""M89
M5'9X0V4NA<IDK24$W(IU#V=[3$0@$>*2O#0@6E!`J1IC2A<NT1PMXUD12:PP
M5>JUC+9-63ZF+!.=9[9+S(IM`+2<'5UL%)*ID[S!;,'V22MP>U)JJ0*5YDA$
M(S797!T`&@BY9>NXS4:Z&IS'6`(74">TYO=.DCHZ2!Q;5-D616DVIZ;O;BU+
M7<]L=$,AK>QGIK.:U)1K2$M=LTM*`\LDTL7+%H_PUXXQSS:--`ESPI:9"RR1
M"X32?V583L6HC4;G<0C#(<\3V821T606+QNSY`D;(T<<9'FXMV4;3(BA#[6A
M<HWF_!2L=UL]P^HD141?G-UK)41(IO*[FGKBUL%4R!0^1"%PR8^EADM*H6&*
M^<U_V;U$'YF)BZM88H1)]@&>G4"^/%A]3\`FRO#^+21[EC)+F'C)*[]MIMVI
MCDHW)'ZX^0,OG<L?UX'^1V)+%A-?1]98JX]&W.HGUW.<4+8M/=1J46S#A?-;
M*T>/U170JVLLN)?:12*M+'I[9GGZ3L_6N;;=ZZ?K"CO88'IJ+_\`]`[5-'S?
M%]/')/-_93'$@/4A.%L:F_%"B;"=Y!(I%$WDF32>7M<Z=I7%;%LR`RW4E:8&
M@J\I4TRJ!S&-R&.M[A7[82TN+>WJ4K>ZI-""M(4;&9L0N6.%\(N,*<$#3H:V
M.:6NN8Y#8BP1QDG=D,<1<XQ7+DH>:^8I_#6>8(HK:S9!7A6:K9BI2C>`MBHT
M9J;NS!;%L7+-ZMXT4C2KSN15A"0Q1[/BHH:ZN2:12Q>ID[0*8R*P1+)H)W?7
M#4YE0II,7ER\^O&ESYXEX7B\7T6JM&BYE.V$,!@,!@,!@,#`E]7P)UF:VP'2
M-I'*5.4"4U>XK5YRU8A7P)8ZC>U<;6L"A49'E214XF"&8,Q*(\8!;+$/96]@
MP(UH[BC0'&]O\U4Q7Q,/;=0UGKTI$.12Z3)DL+89984Y:XZB*ES^_A0-Y4JM
M1^5F:)[L2@2W0#1#+3I@$EN98`7P$XJ)VUF8D=>O[;&6B(1>`JX>TV]=+3")
MM#(4R$1F)1RVH2VV&EB=TMD?BR4EJ2@ER-[[IJ)+1ZWX8L!01<O14<'>-RR=
M.L_7QB=.2]\GI%HN\/=+VOMSIIQL)*L;W)'+55`+[-4T6:\(G1I2JR#-QWH2
ML3%'@T$X`1Z%RDH'':G2X,Q5P"(C#$HU9R6YV5'J22S3FDM!+:I]V"F(Y+Y]
M^TZQS<;,6*'%>$]882Y!5*$JL!R-0<G,%RAEV^'MQ)>)ZS64=6;HBE,;L`NU
M8N4RVA;;'$(G8PY,WRYVFD1K=IG2.N(G))6^MA1KVM;6E*H>];&!<,\(QZV+
MGNF2WN.]37FHC+C83(_"?X:%X*BDP@]@V+4T^CZ&1A;PR5F:[!J>60F;)(])
MP-"0+FVA7Z0.(4I.E))NBP=D1-,*6<+N,JQ)#&T%7)&EF@D;8(8U1Z,R6:1*
M,/4-BSHYOL=B%B1>+R1HC]M15H?WM<X$MLI3/*(+@O5*N[[]2>88+EDA?%ZB
MRBRRBX-V2RO>)[`?M-,-]GWL)PILB_\`RBD&Q;^WTT6&+?+O_E7:[EM\&1K1
M6A<H?J?@72]8V#+[#.3NDF6N=E$3^#1Y;);!*@T$*;JBA%/L9)]=K)X[UY,Y
MHQ1Z)G@2RMP:?/I*9PVF`:`)7;,$S+)TO!CC$A9')@101_1)5A,91M#DDMFX
MTTIKUKA2A>JA[#34U(GY<QHR,Q8UT4Z;FN&KF)O1@4&`*)``8@[%R]#7"OC6
M%`2@*K]P3=R"&[`ZH[#LY')A+X';\AOR/2$Z6I9F3*5,O'<,M='YQ>C%@G9Z
M6N"CSBI5%FC+V+EEU?<9:4JV;.=@PB)KFN2N">1(D>ELTG<BCD0;I@]HY+,&
MJLH3)9,\0JIF>72!M3+75'&&]H3.*I,28H`8,HO81:><(8#`8#`8#`8%-/ZW
M?WE_X]LWT_'[9Z_G]/_1^SJA+&F"&BZ71):$MEX3(ZFKE*G=VUXHLIN=2$\/
M9RBG)`4[W0U.Q:)<6#1I0525,HT`6M&%%C[0-;RB-4_RCGZLQ,U'">26?2A-
M_P!N5R_3G'OV[YFHW1Y^%N=L^#TH3?\`;E<OTYQ[]N^*C='GX+G;/@]*$W_;
ME<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ
M[]N^*C='GX+G;/@]*$W_`&Y7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OB
MHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^"
MYVSX/2A-_P!N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R_3G'OV[XJ-T>?@N=L^#
MTH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?\`
M;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTY
MQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_`&Y7+].<>_;O
MBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^
M"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-_P!N5R_3G'OV[XJ-T>?@N=L^
M#TH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?]
MN5R_3G'OV[XJ-T>?@N=L^#TH3?\`;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OT
MYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^
M*C='GX+G;/@]*$W_`&Y7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y
M^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX
M/2A-_P!N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?
M]N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?\`;E<O
MTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N
M^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_`&Y7+].<>_;OBHW1
MY^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVS
MX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-_P!N5R_3G'OV[XJ-T>?@N=L^#TH3
M?]N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R_
M3G'OV[XJ-T>?@N=L^#TH3?\`;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]
MN^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='
MGX+G;/@]*$W_`&Y7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YV
MSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-
M_P!N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?]N5R
M_3G'OV[XJ-T>?@N=L^#TH3?]N5R_3G'OV[XJ-T>?@N=L^#TH3?\`;E<OTYQ[
M]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_;E<OTYQ[]N^*C=
M'GX+G;/@]*$W_;E<OTYQ[]N^*C='GX+G;/@]*$W_`&Y7+].<>_;OBHW1Y^"Y
MVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A-_VY7+].<>_;OBHW1Y^"YVSX/2A
M-_VY7+].<>_;OBHW1Y^"YVSX/2A-_P!N5R_3G'OV[XJ-T>?@N=L^%3?MY*?3
M!XOT+69W_O8^=/-GG6G/'>.]Q?S+]G.\]+/FWSSYM_YOV_$>;O-WR/%>._X+
--U%<XY?MF^/+K^G_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2KAI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">$ 113,368<span></span></td>
        <td class="nump">$ 96,911<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Notes Payable</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Liabilities measured at fair value on a recurring basis</a></td>
        <td class="nump">11,279<span></span></td>
        <td class="nump">10,134<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cash Equivalents</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">17,170<span></span></td>
        <td class="nump">39,363<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Corporate Debt Securities</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">71,416<span></span></td>
        <td class="nump">44,856<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Certificates of Deposit</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">11,710<span></span></td>
        <td class="nump">6,200<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Debt securities of U.S. government-sponsored agencies</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">7,001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Commercial Paper</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">6,071<span></span></td>
        <td class="nump">6,492<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 1</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">17,170<span></span></td>
        <td class="nump">39,363<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 1 | Cash Equivalents</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">17,170<span></span></td>
        <td class="nump">39,363<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 2</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">96,198<span></span></td>
        <td class="nump">57,548<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 2 | Corporate Debt Securities</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">71,416<span></span></td>
        <td class="nump">44,856<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 2 | Certificates of Deposit</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">11,710<span></span></td>
        <td class="nump">6,200<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 2 | Debt securities of U.S. government-sponsored agencies</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">7,001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 2 | Commercial Paper</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets measured at fair value on a recurring basis</a></td>
        <td class="nump">6,071<span></span></td>
        <td class="nump">6,492<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 3 | Convertible Notes Payable</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Liabilities measured at fair value on a recurring basis</a></td>
        <td class="nump">$ 11,279<span></span></td>
        <td class="nump">$ 10,134<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureRecurring</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureRecurring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosureRecurring</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Detail) (Common stock options)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Employee Stock Options:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.90%<span></span></td>
        <td class="nump">0.90%<span></span></td>
        <td class="nump">2.30%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">72.40%<span></span></td>
        <td class="nump">73.40%<span></span></td>
        <td class="nump">72.90%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
        <td class="text">6 years 1 month 6 days<span></span></td>
        <td class="text">6 years 1 month 6 days<span></span></td>
        <td class="text">6 years 1 month 6 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="2"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Leases

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2012

</div>
          <div>Office and Laboratory Space

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2012

</div>
          <div>Research and Development

</div>
          <div>sqft</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_LeaseExpirationMonthAndYear', window );">Operating lease expiration date, year and month</a></td>
        <td class="text">2017-06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OptionalLeaseTerminationDateMonthAndYear', window );">Operating lease optional termination, date, year and month</a></td>
        <td class="text">2015-06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_LeaseTerminationNoticePeriod', window );">Operating lease optional termination notice period</a></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NumberOfLeaseExtensionOptions', window );">Number of options to extend operating lease</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ExtensionPeriodOfOperatingLease', window );">Operating lease optional extension period</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of facility under operating lease</a></td>
        <td class="nump">22,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,000<span></span></td>
        <td class="nump">3,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Tenant incentive</a></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_TenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
        <td class="nump">653,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">586,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_AdditionalTenantImprovementAllowance', window );">Additional Tenant Improvement</a></td>
        <td class="nump">700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_TenantImprovementAllowanceInterestRatePercentage', window );">Tenant improvement allowance, interest rate</a></td>
        <td class="nump">8.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
        <td class="nump">700,000<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
        <td class="nump">$ 900,000<span></span></td>
        <td class="nump">$ 500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_AdditionalTenantImprovementAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional Tenant Improvement Allowance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_AdditionalTenantImprovementAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_CommitmentsAndContingenciesDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_CommitmentsAndContingenciesDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ExtensionPeriodOfOperatingLease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Extension Period Of Operating Lease</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_ExtensionPeriodOfOperatingLease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_LeaseExpirationMonthAndYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease Expiration, Month and Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_LeaseExpirationMonthAndYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_LeaseTerminationNoticePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease Termination Notice Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_LeaseTerminationNoticePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NumberOfLeaseExtensionOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Of Lease Extension Options</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_NumberOfLeaseExtensionOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_OptionalLeaseTerminationDateMonthAndYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Optional Lease Termination Date, Month and Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_OptionalLeaseTerminationDateMonthAndYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_TenantImprovementAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tenant Improvement Allowance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_TenantImprovementAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_TenantImprovementAllowanceInterestRatePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tenant Improvement Allowance, Interest Rate, Percentage</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_TenantImprovementAllowanceInterestRatePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area of a real estate property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AreaOfRealEstateProperty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.26(c))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e40010-112707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Lease Incentive<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516590<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584307&amp;loc=d3e41620-112719<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncentiveFromLessor</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseAndRentalExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#JK5)2/0(``#\F```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VM]NVC`4!O#[27N'R+<3
M,;;CK)N`7NS/Y59IW0-XR8%$)'9DNQV\_9S05E7%J-"0]MT00>QS/JSH=Y.S
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M.21(#@62HP#)H4%RE"`YWH/DN`+)\0$DAYBC!$$15:"0*E!,%2BH"A15!0JK
M`L55@0*K0)%5HL@J4625*+)*%%DEBJP215:)(JM$D56BR"I19%4HLBH4616*
MK`I%5H4BJT*15:'(JE!D52BR*A19"Q19"Q19"Q19"Q19"Q19"Q19"Q19"Q19
M"Q19"Q19-8JL&D56C2*K1I%5H\BJ4635*+)J%%DUBJP:1=821=821=821=82
M1=;R?\D:TW@.\>GSWY^.J<PK\R$A[CL*%WZG>RCZ6N?&>*I_1)\&F2X>X'GM
M4SG2F,^-=T-(`T^>SC^%QXFF<?=L2(7(QY:>9IJ.S08]=4S#4N<W?#&<1.,X
M5DWUD=Y\&O]:_0$``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`
M"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````",DL].PS`,
MQN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][N
MYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7
M^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(
M!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1
MR?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X
M8<'%#U1?````__\#`%!+`P04``8`"````"$`C?RA+X,"``#>)0``&@`(`7AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````O)K-BMLP%(7WA;Z#T;Y1KOYFIHPSFU*8;3M]
M`!,K<9C$-I;ZD[>O2(LG`^V9C3F;@&4B'="YY[NR??_PZW2L?L0I'8:^5K):
MJRKVVZ$]]/M:?7OZ_.%652DW?=L<AS[6ZAR3>MB\?W?_)1Z;7/Z4NL.8JC)+
MGVK5Y3Q^U#IMNWAJTFH88U_N[(;IU.1R.>WUV&R?FWW49KT.>KJ>0VU>S5D]
MMK6:'EL35/5T'LO2;T\^[':';?PT;+^?8I__L8;^.4S/J8LQETF;:1]SK>:A
MI"]W3%@5S4K_1XZPY0B28QU9CG5(CC-D.<Y`.3=L.3=(CB_%1;6R7T,YGBW'
M(SG!DN4$B^2PK0.=PRXK6%7"3F3!B7Q']HVY0[X1-B`$`L*P`6$@("S;R19:
MV;*KW,(R=VQ`.`@(QP:$@X#P;$!X"`A?.F,NS6]1[H1%4SGE\[%T^G.3_.<:
MK<_V"K1*8(=P@"$L;$0)1A2;"0*98-A,,)`)ALT$`YE@V4RPD`F67><6%KIC
M,\%!)C@V$QQD@E^4"?.#DA<LS$-_GYUXV*D'=NX$F#OLO<);Q2:6A\1BEQ6L
M*F$#0B`@A`T(@8`P[$0V,)$MW3K0.Y9=Y1:6N6,GLH.)[-F-J8>-:5BTLE+7
M3+']FJ?R+N/Z*',]C$XTAMUY&=AY.38A'"2$9\/<0Y@'-B,"9@3YV0#<*G;F
MP,@1-JX$XLJP<64@K@P;5P;BRK*M8Z%W'!M7#N+*+XJK^2P%CE>P$10VKP3R
MRK)Y96$(.C:O'.259_/*0UX%MG<"]$Y8%!*Y?(T27ZKJ<JDOO]@Q9(9#O["3
M#P:?L*$I$)K"AJ9@:++WRLZ;I5]]E;7Y#0``__\#`%!+`P04``8`"````"$`
ML)I$GL@%``!-$P``#P```'AL+W=O<FMB;V]K+GAM;)286V_;.!"%WQ?8_V#X
M?6M+OB0NFA2YH@%Z\<9I^T@P-FT3E2B7I)+XW_=02IPCT3%VGQ+&X?',\)O#
MD3Y\?,JSSH.R3A?FI)N\ZW<[RLR+A3:KD^[WN^M_CKL=YZ59R*PPZJ2[5:[[
M\?3OOSX\%O;7?5'\ZD#`N)/NVOO-^U[/S=<JE^Y=L5$&GRP+FTN/I5WUW,8J
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M+LZR3`<D7<U!D67RGG52#B0"<VIA0Q:M4'7%[U)O0B;"*,\:S&42@7F#2IM5
MQ="9<VB+]G8&,HF(O"CR7-<%?$X!S6E6\%@-)WT%Z8@[+(F(9)2_%A[UF,JM
M!-@LP4PG$8PL$;I!6:L68N:+^2]QP19QQ$PF$927:@D@%]ACO-7W9;!>,85Q
M<"C,8Q(!>8,;)E?B3CXU:\`H)A&+M\'GU0+V@A.]L](X.:]\G[[XF,F$X[8,
M;J8R-8>&^+>$BK+95EQK`\"TS,0EZS"@:0QH>>_4[S+`=/403(NW,I-IQ.3A
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MJD'$\:V:%[!'W,*5SR.LSUK>8XWJ.,YKR!QC\78\/!.(ND@4SY`QQJ*E<ZO@
MMQ@LEK;(<7FUO(-UF.AA1'2TM3%B-`#B0@]CI%\/;(\#44`3-HQA1/2>S>%Z
M"5RA1J0S9*"Q:!6(`(I'%[[B\,!!P],P(CK>_1Q+!34'Q`0-(Z(/.R'W?-)O
MG'W$-*5V77J,E>+,F!+M]44;G5-$2;]Q^!'4;*J-::K"L2'$?C:*J&:A>*9B
MBI(^&]HHXCI4"7-4/8[=8L"W#QA30L.&5"FD$:>&1?OXJWGNVZ;JUC/,1P_A
M4?!2>:GY66S4R"N"&B91YI6&$]\=`O&%N')>XUE>B6N.II%5!'65#AY<JG$Q
MQRL!5]M('`]#/8J@?G/F;!_8B-T5BU9U4.4-7F.$I\S7^U"<*X.9UK.;C9AI
M+%HZL2M>/6WJR1*/H%P?-H]11#3%`V=%EO50CL$X^#3I).'=P.Z1:Q01_9H-
M?(PNGOH=``F-N>FQ:"5VL<;##B2T$6=Y4<*`$-=W8W$+K(QF'6[5<80SM>KS
ML[Q9B5`CXYK7QIAQQJ(5S^&!@1MLS$1CT19J3^R-*E%B29\1&E=(]ZII`J]<
M\$)CCG=!X4=XF5*5K_?R)NST#P```/__`P!02P,$%``&``@````A`"P;:B>3
M!0``%A@``!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R46-MNHT@0?5]I
M_P'Q;D,WF$L49S2`LCO2CK1:[>69X+:-8HP%Y/;W6TUAH(H$VR\SL?OTX=2M
M#^[[;^_%P7A559V7Q[4IEK9IJ&-6;O+C;FW^\_?C(C"-NDF/F_10'M7:_%"U
M^>WAUU_NW\KJN=XKU1C`<*S7YKYI3G>656=[5:3ULCRI(ZQLRZI(&_A8[:SZ
M5*ETTVXJ#I:T;<\JTOQH(L-==0U'N=WFF4K*[*50QP9)*G5(&]!?[_-3?68K
MLFOHBK1Z?CDMLK(X`<53?LB;CY;4-(KL[L?N6%;ITP'B?A=NFIVYVP\3^B+/
MJK(NM\T2Z"P4.HTYM$(+F![N-SE$H--N5&J[-K^+NT0&IO5PWR;HWUR]U:._
MC7I?OOU6Y9L_\J.";$.==`6>RO)90W]L]%>PV9KL?FPK\&=E;-0V?3DT?Y5O
MOZM\MV^@W"N(2`=VM_E(5)U!1H%F*5>:*2L/(`#^-8I<MP9D)'UO_W_+-\U^
M;3K><N7;C@"X\:3JYC'7E*:1O=1-6?R'(-%1(8GL2%Q0WZW+I0Q68N5=9K%0
M41M@DC;IPWU5OAG0-?#,^I3J'A1WP'R.#'7TL7X5*L2H2;YKEI8+HJBA/J\/
M7G!OO4)*LPX2(00FHH<(BHC/")T_S9J,OK!`;J\9,L$U.U#3SZMQEJ@W,8DA
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M]I"--I<10E#V0OB!S;(94X!<3803@"^^RK>`\_OZA+=H-ID3O]&,:W-N-#N:
M&4@R"R&I%]JMKFZ9%LV2SQHYZC!N-Y\\]619"'X@TN71E%#5VJZN5XWF-C[(
M`_;<2"`&52^<H5%Q.NFR=%G')73="8:R4MW:J*[7C;9&='/W%'/6UVE'2#\.
MSB"N!22S'%2_]JN1?OW>=?D=1NA=M&L"UA91ASF+%"X[/F,*D"&WVJ0#?#X6
M-`IM7:,HYH])_<;,U7,_[3!G]8$7LCK%#.&[8E(%?$['X3OAT(-4O?:OZ]6C
MVY$>8J=T)!#3];YDP<5T>3JQX]W2_DJU-K#K5:/=$=6L(2(QML2%"#S^[AXS
MA._:DYP3#M\;&07-N3:RZ]6C[<'8]:]7P9`6M"B!F,^[M9O;BY!DEH5&H!UM
M%,&5DXL^2.K`CKY((`:[9WIPCE<%JV%"]BY&AS+1+F]RV1;-3AM6]ZC##//*
MW[=BAH!Q9&.14(3OC8XTJOXFAY7XZY%DG#MLAPE;AUW82Y<!8@J02\%.VX0"
M@M7R2_$@Y/:VD7H7+4'(#;?#8`F<P/5#E[MJ3#"!A&N'B7=12+#Z,A!M@J/^
MGS_S)5KFN`K\1(\ZS-P$7X8DLQ#:1]I%KX]`H]F[)O.D2")F-H*+D&26A49P
MD^_JVR'61).?WQT&F^BSW]\4\,D/<`IP?&\XWJCVFUQ73ETW9#,8=9C9[)^M
M=3`2YB/)+`N-X"8'ENB,8P_CO_ZB#C,;`=+,0))9%AK!32X,-ZN7^^>BQ<8=
MS6P$R(*W0'*H,XK'ZUF\O2Q4M5.Q.AQJ(RM?]-6K@$.\_Q:OA2.X%F[O4*U^
M`6YE3^E._4RK77ZLC8/:PE9[Z<.(5'BOBQ^:\M1>%CZ5#=S'MG_NX?Y=P;6D
MO03PMBR;\P=]<]S?Z#_\#P``__\#`%!+`P04``8`"````"$`:_:EQQ,#```:
M"@``&0```'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6R<5EUOFS`4?9^T_X!X
M+X8DD!*%5"6HVZ1-FJ9]/#M@P"I@9#M-^^]WC0.-24FCOB3`/?=PSKTVU^N[
MY[JRG@@7E#61[3FN;9$F91EMBLC^\_OAYM:VA,1-ABO6D,A^(<*^VWS^M#XP
M_BA*0J0%#(V([%+*=H602$M28^&PEC00R1FOL81;7B#1<H*S+JFNT,QU`U1C
MVMB:8<6OX6!Y3E.2L'1?DT9J$DXJ+$&_*&DK>K8ZO8:NQOQQW]ZDK&Z!8D<K
M*E\Z4MNJT]6WHF$<[RKP_>PM<-IS=S=G]#5-.1,LEP[0(2WTW'.(0@1,FW5&
MP8$JN\5)'MGWWBH);;19=_7Y2\E!G%Q;HF2'+YQFWVE#H-C0)M6`'6./"OHM
M4X\@&9UE/W0-^,FMC.1X7\E?[/"5T**4T&T?#"E?J^PE(2*%@@*-,_,54\HJ
M$`"_5DW5RH""X.?N_T`S64;V/'#\I3OW`&[MB)`/5%':5KH7DM7_-,@[4FF2
MV9%D`>J/\9DSN_4]/WB?!6E%G<$$2[Q9<W:P8-'`.T6+U1+T5L#<.],Z!J]3
M5L&C(KE7+!T7N!#0GJ=-$'IK]`0U38^86&-@1PR8$6+;(U0!%6UR\@"!WD$T
ME.)4]-MMZ+4IL*G-]T=OCL\Q,U/]]APQ]TU(<@Y9N@/$T#\W]:NBSV%17O:A
MD@!W4K\@'*F,-0;Z.-0X&!1T)=V^BT@N(0P7\)KKNZ#`D0TE>E46SDUML<:$
MW?IQG5&/MA>CR5344`R;[53Q=75726/EBY%RC5E,*.^C)][-_.02PG`0?,2!
M2AH[&"W>6&.F'/31:0>7$(:#Y4<<J*2Q@]'*CC5FRD$?G79P"6$X4$-]],E\
M?_>JI+&#I;D*8HV9<M!'IQU<0A@.PH\X4$EC![<C!QHSM8-U%';JZS?`S(<9
MKM[Q-D([T#-:C[":\()L254)*V5[-7\]V('#4WTTB.%HT`U2-`1@-+>X(#\P
M+V@CK(KDD.HZ2]B%7`]W?2-9VPV.'9,PE+O+$LY@!$:3ZP`X9TSV-^KX,)SJ
M-O\!``#__P,`4$L#!!0`!@`(````(0`*=M=7T@0``#D5```9````>&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;)R878_B-A2&[ROU/T2YWR0&D@`"5I.O=J56
MJJK=]CH$`]$D,4K",//O>QP')CZA-NP-$.?Q:Y_7QQ]X]?6]+(PW6C<YJ]8F
ML1S3H%7&=GEU6)L_OB=?YJ;1M&FU2PM6T;7Y01OSZ^;77U875K\V1TI;`Q2J
M9FT>V_:TM.TF.](R;2QVHA6\V;.Z3%MXK`]V<ZIINNLJE84]<1S/+M.\,H7"
MLGY$@^WW>48CEIU+6K5"I*9%VD+_FV-^:JYJ9?:(7)G6K^?3EXR5)Y#8YD7>
M?G2BIE%FRV^'BM7IMH"XW\DLS:[:W<-(OLRSFC5LWUH@9XN.CF->V`L;E#:K
M70X1<-N-FN[7Y@M9)L0W[<VJ,^B?G%Z:P6^C.;++;W6^^R.O*+@-X\1'8,O8
M*T>_[7@15+9'M9-N!/ZJC1W=I^>B_9M=?J?YX=C"<+L0$0]LN?N(:).!HR!C
M35RNE+$".@"?1IGSU`!'TO?N^Y+OVN/:G'J6ZSM3`KBQI4V;Y%S2-+)ST[+R
M7P&17DJ(3'J1&?2^?S^Q)G.7N-X3*M!>UQ7X[E4FGD5FSC,:7J\!WU<-UYJ[
M[LR;^]IX;.%-9W64MNEF5;.+`?D+T3>GE,\&L@3EJ\?"D9OK_V<ZN,U%7KC*
MVH2)!WXVD"EO&V^Q6-EO,+I9SP1CALA$>"7X4'+9"!?$N"`9%-@0T2TL&+9A
M6/=3YMI[#O/>7]L-1`%HW\*9H*Y>JWP24U=&HC'B.S(2C]OQ'=12HF:DH*?/
M!,UA*6A1,`S:=U"'0UPIP@7Q/96I''8R9LC\LR4I))AVCX\CAZ601($<$DXZ
M7"G"!?$#*HF:D4*"N3H,B<^X*:R-ZA3EE8`;9*3OS&1;`\%`3VY9Z\E$J"4B
M+1%KB41%2$[`>O.\$[S2VH19<8O2=]#4"P0S=,)WL!=C!A&1EHBU1*(B)"_\
MG_&"5\)>^/*8!X*1O9C+3#AFL!=:(M82B8J0O.`'.+0GZ6<(KX2]P%N08"0O
MR.?"T^TYX9C!7FB)6$LD*D+R8O$S7O!*R`N"UKU`,+-NLT9[3GA]]SG'L`=:
M(M82B8J0/""P/#Z?$%TM[`**-.BA84JX+DJ;\`Z$_=`CL1Y)E(AL"3_X#.:(
M>O<@G,96H%TYZ"%/9`3\U\$SHP>&7HUL$`TID%AJ!DX8J)5$>C\=OI<-X.>B
MQPT0IRAIUR!X_R0"\CL#"+2,^Q;VA"*\2(_$>B11(K(/_##UN`_BZ"7[@'=/
M(B"1")XKC8%8(WM"Z<-0Q)U[(S-CO4BB1&0;H"]/V,!I/!]0+@=$0,(&GJCC
M=!`$?-[.(D@DZD442*Q'$B4B^\`/7X-T>.QTR?]5C_S`!XD><L66X5@./D7T
M@"+62(_$>B11(K(=_/PUL$.S3(K3FCP[4)0!$9`J+88$3WR<.)&DX=XAXIY0
M>)DH$=D%?O)ZW`5Q3I-=0%MB`/<^/&/$6KFX$T$H$?=BC'I"$6.L1_@-%._)
M?15A@[AA$M<>):T/-*1%T1@9._/;(Q?6^UOI[6;K9<:O`U!Y0)9P)S$NC_E-
MV)WR<+(,[^E$DR7\S00=^]8`7%R=T@/],ZT/>=48!=U#UQR+W^S4XNI+/+3L
MU%W:;%D+5U;=SR-<45*X+G$L@/>,M=<'WL#MTG/S'P```/__`P!02P,$%``&
M``@````A`#]ZC_G7`@``F0<``!D```!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&ULG%5=;YLP%'V?M/]@\5[`)H$D2E(UJ[I5VJ1IVL>S8PQ8!8QLIVG__:[M
MA$"Z?NTE";GGGG//O?9E>?G0U.B>*RUDNPIP&`>(MTSFHBU7P:^?-Q>S`&E#
MVYS6LN6KX)'KX'+]\<-R+]6=KC@W"!A:O0HJ8[I%%&E6\8;J4':\A4@A54,-
M/*HRTIWB-'=)31V1.$ZCAHHV\`P+]18.612"\6O)=@UOC2=1O*8&ZM>5Z/21
MK6%OH6NHNMMU%TPV'5!L12W,HR,-4,,6MV4K%=W6X/L!3R@[<KN')_2-8$IJ
M69@0Z")?Z%//\V@>`=-ZF0MP8-N.%"]6P15>;.9!M%ZZ_OP6?*\'OY&NY/ZS
M$OE7T7)H-HS)#F`KY9V%WN;V+TB.GF3?N`%\5RCG!=W5YH?<?^&BK`Q,>PJ&
MK*]%_GC--8.&`DU(II:)R1H*@$_4"'LRH"'TP7WO16ZJ59"DX32+$PQPM.7:
MW`A+&2"VTT8V?SP('Z@\"3F0P/>!!).0S*9XFK[.$OF*G,%K:NAZJ>0>P:$!
M3=U1>P3Q`IBML\FSSL"2S;FR22X5T!JF<;_.2+R,[J&%[(#9>`Q<@!Y#>D0$
MXGT%H'I>00(3^G=OCQ78I'$%R:2G=T5N/&3F!CO42_Y'SR;!U`9N,H+/!#UF
M,L"D/6+D&"!#QR\[M>!50%R728S/7?IPYL(X3I]1A(F^7=&"!XK3WH3OJP^G
M7A$GLSX\\IB^1]&"!XHG$U[1AP^*!)_Z/E+,WJ-HP0/%K#?A%7UXXCRFY-3S
MD:!=[H.K\_(8+=@*GJY#,FB=5_68X0'*R#.79C[6MM?V]4MCD\8U9"0Y<^XQ
M_CQ-XF3>A[UUOR+]!FFX*ODG7M<:,;FSZP]#P_I__6;>P&8F[@[V`=B,'2WY
M-ZI*T6I4\P)2XS"#@Z7\;O4/1G;NBF^E@9WH?E;P"N2P@>(0P(64YOA@MW?_
M4EW_!0``__\#`%!+`P04``8`"````"$`1$$0#X\'``"F+0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970U,"YX;6R4FMMSHD@4QM^W:O\'R_=109'$BMD:Y7ZI
MVMK:RS-13*A1L8!,9O[[/4V#V@W37YB'T9S\^&CZ.WWAI)_^^'$ZCKZG19GE
MY_58F\S&H_2\R_?9^74]_N=OY\O#>%16R7F?'/-SNA[_3,OQ'\^___;TD1??
MRK<TK4:D<"[7X[>JNJRFTW+WEIZ2<I)?TC/]YI`7IZ2B'XO7:7DITF1?7W0Z
M3O79;#D])=EYS!56Q6<T\L,AVZ56OGL_I>>*BQ3I,:FH_>5;=BE;M=/N,W*G
MI/CV?OFRRT\7DGC)CEGULQ8=CTZ[E?]ZSHODY4C/_4-;)+M6N_ZA(W_*=D5>
MYH=J0G)3WM#N,S].'Z>D]/RTS^@)6+>/BO2P'G_55K&NC:?/3W4'_9NE'^7=
M]U'YEG^X1;:/LG-*O4T^,0=>\OP;0_T]"]'%T\[53NW`G\5HGQZ2]V/U5_[A
MI=GK6T5V&_1$[,%6^Y]66NZH1TEFHAM,:9<?J0'T_^B4L=2@'DE^U)\?V;YZ
M6X_GRXEASN8:X:.7M*R<C$F.1[OWLLI/_W&H?J*KB-Z(T&<CHNF3A6Z8#T-4
MYHT*?;8JVG"51:-"GZV*/M$?#,U8#G@B>O:Z6^CSIJ(M9D,TEHT&#;6;QN"6
M/#8J]-FJ+(?WBD:)Q7UF&=9X2'9]TF#MFB;TI;U\,;Q;M393V)=69T`SVA31
M[G)D^>EF3'GNUT/)2JKD^:G(/T8T/]%#E9>$S7;:BDFW@XBG_'58_6I4T7!B
M*E^9S'I,=M.`*6DJ^/YLZHNGZ7<:OKN&V729Y<P0F6W+L-'*A"TY8,L!IPW<
M;JV)HFY+M*(>#_"!S.[BMX%?:@0MT6J$K>CMDL[31"W37A3?!:9DP-4%R@/!
MA?XIK.UL1K/.;F4W;>#6%L.4.F';PQASL:.L+F/JDD-V'[,4=9PNHXN$VR7F
MTHV\+F+.1!6?(]2IUZR3[A-TB>7\050)/\%$GV!B-2/X30-M@-^,%OR6`ULY
M8,D!6PXX<L"5`YX<\'G`,.KQ/7\TYH]B3P8("!$0"<!"TQZD%(T5@-##M`8.
MZ&%&"STL![9RP)(#MAQPY(`K!SPYX//`;6(*Y$#8!FXIK\VD81&U3#L_Q&W@
M=I&IFU?OA'ZC57]`OS%:Z#<YL)4#EARPY8`C!UPYX,D!GP?N^DT.A'(@D@-Q
M&[AU$FU8^CN)MC<#.HG1M+>\FZ5,79J#-IPAGZXSF32G;B%A0<*&A`,)%Q(>
M)'Q(!)`((1%!(E81PJ@P!QG.Z/68EH.KF:8N394;SJ@,AX0%";M+&(;4$J?+
M2*GG0L*#A`^)`!(A)")(Q"I"L)Q5">2-\9S>(-1;,W:59/U<FIXWG%%9#PF+
M$V:]$ANS^M]UJJHWSC8D''@7%Q(>)'Q(!)`((1%!(E81@O'TMBD8KS:<T;+A
MTM9[PQF5X9"P(&%#PND2YES:,+M=1IH-/$CXD`@@$4(B@D2L(@3+68E@@.<U
M+ILN;50W#:1R'2,61FR,.!AQ,>)AQ&\08U%/3+/);?]43TH!E@@Q$F$D5B*B
M]^R=_'ZB5X]W5@Z2!KR^E(;(IH&4WG,=!6)A%1LC3H,L^5*QZ%DJ7(QX`D)O
M'#TR/FY,(,CTKELA5HDP$BL1T7_VVG[O/ZN`X86>5?&D/##GG8H7AWC?4SUX
MJ<OS[;;14>8!5U$@-E9Q&D31%A>K>!CQ,1)@)&R0IKF+!97E;V^L]6028958
MB8AIP`H+]VD`I@%>AR!G;GM\N8*U8?54RA&^2Y-R8]O\4N&JA1$;(XZJ%:[J
MEQX6]S$2J&X1XNLCU?6Q\GK18.KI(08S7%[C._,\AQ0>;C6(6!BQ,>)@Q,6(
MAQ$?(P%&0HQ$&(D;I']Q$^UGY9T!XYM7@^['MV%(NYD-^V,CY8C2?HXT#>Q;
M-BVL8F/$P8B+$0\C/D8"C(08B1I$T76Q4D6TGY5Z!MC/*T/W]IOR^K/15.6C
M>HG:8L3"B(T1!R,N1CR,^!@),!)B)&H0;G_?MC56BHCNLZK/`/=YD4AT7Z[8
M:JI*4N,^1"RL8F/$P8B+$0\C/D8"C(08B7J03N4R[H%N*[28`*SZ,R`!>+%(
M3`"I;KK15!6E)@$@8F$5&R,.1ER,>!CQ,1)@),1(U(.8"ZF2&O=`OTH`5@L:
MD`"\="0DP$(NZVFJ^E*3`!"QL(J-$:=!^&RI:;KY2'L-L2+LBLQ,F[-9560\
M?"L?(P%&0HQ$&(F5B#`#Z,-*?#4N;O\?9/\;1K7]:Q!NRQ?-["F;6%C&QHB#
M$5=NS/RAZS^6\3$28"3$2(216(F(_@\K\^G=,M_2E/?_#:3X*\RV010Y8F'$
MQHB#V^)B%0\C/D8"C(08B3#"3I?^^@6,V\]/C_(C;Z>T>$VWZ?%8CG;Y.SL9
M2F7"YZ=KF!];]?05'3"@LQ-2G(ZS?NV+;[05'4KK\HZVHI-GW7A(QV+[XAM]
MM>G3W^HK.D71U;'T%1VFZ,9M?45G*KIQ1U_1T8INW-57=,*"XM/K`],IV4OR
MFL9)\9J=R]$Q/5!?S28FO<P6_)PM_Z'*+_4)PI>\HO.Q]=<W.@^=TI$ZJOV/
M1X<\K]H?V`VN)ZR?_P<``/__`P!02P,$%``&``@````A`*5$76.'"P``G5,`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-3$N>&ULG)Q;;^)*%H7?1YK_@'@_
M@.^`DAPUKMN1SDBCT5R>:>(DJ$.(@+[]^ZER%;1WF>QE3C^$CO-YN6JY;@M#
MW?W^8_<Z^M8<CMO]V_TXF<S&H^9MLW_<OCW?C__S;_7;?#PZGM9OC^O7_5MS
M/_[9',>_/_S];W??]X<OQY>F.8VLPMOQ?OQR.KTOI]/CYJ79K8^3_7OS9O_R
MM#_LUB?[Z^%Y>GP_-.O']J3=ZS2=S<KI;KU]&WN%Y6&(QO[I:;MIQ'[S==>\
MG;S(H7E=GVSYCR_;]^-9;;<9(K=;'[Y\??]ML]^]6XG/V]?MZ6<K.A[M-LL_
MGM_VA_7G5UOO'TF^WIRUVU]Z\KOMYK`_[I].$RLW]07MUWDQ74RMTL/=X];6
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MV)YO6\;1MOEO#U6>WDV_V7:Z"<S*,_9GA\DH4_=UREE!&7%F7--U%Y?G`[^$
M$WJ*.A/G4W1\P/@#;2.>6F<N]MBFTK7G>B<ZN^!@Y\+Y,JOS@5\EJ_*<EJWN
M,V5:4D9<8;(Y9:1G;#TN]D8W0/55LLA;W4>J&;V.Z2-%\>LV$O-LOQUNGH.)
M>?&!.CX@X@/2'^AZ4.51%55\DHX/F,X!4AT[@@ROCH/MT-FY'54>W=:59^S/
MRRV+B!H2`A(2$@H2&A*&(XB+=B@=[J*#[\>VR5T<JO**-LB59_)VU)E-HMM=
MG__Z2R'R6$!"0D)!0D/"<`1QT$XGPQUT<.Q@-'2L/&/OX,7ER*,:$@(2$A+*
M$V5[)Y.9_T=OMH8BAB.(C78V'FZC@V,;%[1L*\]P-GK"5[!(JL)6D6H(J"$A
MH2"A(6$X@KAHY_SA+CJ8NEB6<6/T#.>B)Q9M,UG$'5[`\R4D%"0T)`Q'$`<7
MU$&W`LOLJI]?:KB3J).V-=&VM/(,YZ0GJM;)O)BW/8Z*B"Y27>V3LHODQ:*5
MH2JJBY0V!3B&(MHC3&D-1Q!'$VO?\$;9TM3+HHBFD56`F.+5&!$8D1A1&-$8
M,0$)@Y&_LY=;0NUTB^-.1N!;9N*7TMTYNXRG[,"P;GH9!A%810;$5S)/JGF5
MQ8MK19BLF&?)?!8-2AI?RK`(]=,MH3M^#NOQB5]X=WVMBBCHK`+$N%9C1&!$
M7A"7]:)2J,L?/UQ0:(P8%J&&NA5[QU#00/WZOFMDV>ONGF%]A(A(("(#XANH
M?:<LZH=MP%5#((TO9EB$.FIK?H.CCJ8C:%5$Z7.5>(BU%"("J\B`^/5!/DFR
M1?=?-!0I0J>31?1W3?Z>Q&K1$M"PQ:,.N^5^I\T.'`1\2.BVW:J3OMOFLG+O
M]MG;P3H-$8%59$#"%.)7!Y<I)#1=?R&/7%M@:"+B>P#5,&Q)J*EN\7^[J3XR
M4%.CMVE6"9<KVKK6&!$8D0'QCI7M>$#]4(3P.8D2&A*&+0CUU$6!VSWU`8)Z
MVAMEN901/(6(2"`B`^(]K:XU0X55-$8,BU!;73Z(;,UM9P%SET\5U-8HK*\2
M+GH$6R$BL(J\@E1%-("J*U!48(T1PR+46!<3.L8"0WVHH(9&J[]5PB6/8"A$
M!%:1&%$8T1@Q+$+L3&_*4BV-WO8,$#<_841@1&)$841CQ+`(M?.F+)7VLU0_
MF@:(M1.'J:`2YO)KRU")+Z0PHC%B6(3::3ON\,Z>.CI:IV;1>+4*$&NGUV$0
M$50^7O=(?!V%$8T1PR+439=7!@^=J4\W=.B,%L2K`#%6U1@1&)$841C1&#$L
M0NVTM;[!3D?#H=-#K)T0$2E$)$841C1&#(M0.UV4&-XZ??#HMLXK0Z>'6#LA
M(MPS?'OGV*$3JJB@PI1%8\2P"+4SRDK\.BGM9Z1%O$P*#%.#&B,"(Q(C"B,:
M(X9%J)LNA`QOG#ZRV`'T\L2M_W0XA;FFQHC`B,2(PHC&B&$1:F>4CD#CO)**
M\MY,!"-/G4)$!,3W]<1^F,FME&CZEEA&841CQ+`(]?.F4)3V0U'_.5V`V-Z.
M0U%0"8^@8B/A^0J70F/$L`@QTCV9Z_;S86_;M6=%"\_>X[H`<89B1`3$-]!L
MT;;/N(%B&841C1'#(M37*!<-]+6?CZHRJNTJ@^&GQHC`B,2(PHC&B&$1:JM+
M*H.GI<SG&GY:"A#;3+T.@PBL(C&B,*(Q8EB$VAD%I(&M]$I0*J-G9JO,0XQG
M-49$0'SO3^V'=M,RF@<E5E$8T1@Q+$)MM;7NMM*!MKJSHD&UC)\Z91YB;86(
MP"H2(PHC&B.&1:BM+G0,[_P^HH#.#W-,G4%$8$1B1&%$8\2P"+4S"DP#6VD_
M.%7]SN\AMI5"1&0>"6O3K&P?>T9+JL`P5U(8T1@Q+$)]O2DZ93X5=7-]F45C
MW"I`3"UKC`B,2(PHC&B,&!:A=MX4G3(?>4"OA[FH#CJ,XP(C$B,*(QHCAD6H
MG3<EIZR?G*I>$@T0XU6-$1$0W]OM]TBN!%&LHC"B,6)8A-B91_F)#_8M3:?X
M?A`-$&<G1D1`K@=1?+["B,:(81%JY%\*3/F5P-0+H@%B#8692@25L!3U.32*
M9A)?26%$8\2P"/7UIL24^Z33G8VJ\M>W8=IGPZL`L7YZ'0816$5B1&%$8\2P
M"+73Q9K!:]#<AR!^-@H0XU6-$8$1B1&%$8T1PR+43EOK&^QT-!T^^[-1[B'6
M3HB(H!+6GOE\MIA'44SB"RF,:(P8%J%VWI20W,=S(CNOS$8P_M1!AW%<!.2#
MV0A>0N%+:(P8%J%&NNC1Z>;#LE'N`PL9/?NS$0P^==!A#?4JWM#BZKNB6$5A
M1&/$L`BU]:9HE/>C457&GV,,$.-5C1&!$8D1A1&-$<,BU,Z;HE$^)!H%B+43
MIB>!521&%$8T1@R+4#NC:.0ZO1LRP)K^2D3J??X^]Q!K*T0$5I$!\?-6E<R*
M+.HP"HMHC!@6(:X6-R6DEHZF^#+Z?.4J0)R;&!$8D1A1&-$8,2Q"[8QR$M\X
M"Y]K^`5H@%@[<3["*A(C"B,:(X9%J)TNJ$03/>[SA8\W9*+O]?D`L;9Z'081
M6$4&Q/?YO)RE\RBQ*2RB,6)8A+H:I:1ARZ?"IR7J:OQQQ@`QEM48$0$ISM^R
M3Z*/\DNLH3"B,6)8A)IJZQPW5?=`&HP`[JQX0(T_Z61]<!!K*D1$4`GM<#Z+
M=^.0^#(*(QHCAD6HJ2Y[1/U_@*D^L="6&K]I7\!84V-$8$1B1&%$8\2P"+4U
MRD^@C?HP`V8IG)L*B`B,2(PHC&B,&!:A=D:Y:>!X>B4_Q=O?K`H/L5T?(B*H
MV'[GOC\[F\Q[XRG44+@D&B.&1:BI47H::*I//Z3K5_&''PH8D6J,"(Q(C"B,
M:(P8%J&V1BD*='V?>D#7A]&H+B`B,"(QHC"B,6)8A-AIM];["Q-4>U8TZ_>Z
M?H"XKH\1$9"/NS[64!C1&'&[$'Z\BO&F^ET&_89QN^;PW-3-Z^MQM-E_=3L(
MNJ]87X[ZW0U-NK3[9]D-T*+C=M?#3]>.U\E2M+NN1;Q,EG:3MK[.*EVNKNJD
MR_K:<9$NQ;7C*EW:G<#Z^CI=V@W![/'II4!V<\3W]7/SC_7A>?MV'+TV3[;J
MLTEEERL'O[VB_^6T?V^WT_N\/]EM$=O_OMAM,!N[19W=EFH\>MKO3^=?W`4N
M&VL^_!\``/__`P!02P,$%``&``@````A`%$E5)!>`P``[`L``!D```!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&ULG)9=;YLP%(;O)^T_(.X+&`(D49*JH>I6
M:9.F:1_7#IC$*F"$W:;]]SOFT!2'B"2[(2%Y_/H]'QR\N'TM"^N%-9*+:FD3
MQ[,M5J4BX]5V:?_^]7`SM2VI:)710E1L:;\Q:=^N/G]:[$7S)'>,*0L4*KFT
M=TK5<]>5Z8Z55#JB9A7\DXNFI`INFZTKZX;1K%U4%J[O>9%;4E[9J#!O+M$0
M><Y3=B_2YY)5"D4:5E`%_N6.U_)=K4POD2MI\_1<WZ2BK$%BPPNNWEI1VRK3
M^>.V$@W=%!#W*YG0]%V[O1G(ESQMA!2Y<D#.1:/#F&?NS`6EU2+C$(%.N]6P
M?&G?D7E")K:[6K0)^L/97O:^6W(G]E\:GGWC%8-L0YUT!39"/&GT,=,_P6)W
ML/JAK<"/QLI83I\+]5/LOS*^W2DH=P@1Z<#FV=L]DRED%&0</]1*J2C``%RM
MDNO6@(S0U_9SSS.U6]I!Y(2Q%Q#`K0V3ZH%K2=M*GZ42Y5^$2">%(GXG$H#[
M[G_?\:<A":/S*BXZ:@.\IXJN%HW86]`UL*>LJ>Y!,@=E'5D`^3D=&82DU]SI
M1>U2H"64XV45Q_["?8$4IAVS'C)'1#(D@O`@XH*_@TD(O6]RW)R&(0C;ZID+
M#KIM`&MD)CTF,HEDC#"\P4:7>]/PT@;M@[<@FI@[KY&)VK2&X6SJ>9Y))'UB
M$L,LZ!&&-PBP[^VRXNI%QQZGIH,U,NAQ2J9>-#W*<(($7`^1?F38\`@/0-_C
M>&TU;'HCO=BQMLB<WKDEDC'"\!9=XTW#Y_H.F3%O8X3A+;[&FX;-O`W[#IF/
MOO.]V*QZ@L1I]X8W_=Z[>JCH1:;'.#Y^-I!!CS'QPN`(2!"XP.+,M#C>=AHV
MK0711SMCVR%S>F=LNS'"2!^!`=S/W[BYEC[7>!TT9F\4,?W]WTL#YWU_^`T+
M3!#""D\BSQ\,EHXX'8EI4\_P7AN>22-._+Z]8$+,)V!-$#J].59Y%#']7?7J
M(#CUX7J8J'%\-'77'33J#W5.(Z8_8/KYN^SU`>>PX<-R_/[H("PSF1`2A3,S
MU?H\IW7&?.)Y#8\S-=VR[[39\DI:!<LA1YX3PZ!O\+2&-TK4[;%E(Q2<LMJO
M.SA5,SC3>`[`N1#J_4:?!P_G]-4_````__\#`%!+`P04``8`"````"$`(MMY
M6TL#``"\"@``&0```'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R<5EUOFS`4
M?9^T_X#\7L"0D`^%5"U5MTF;-$W[>';`!*N`D>TT[;_?M9V2F'2TV4L2\+DG
MYYYK7]_5]5-3>X]42,;;%&$_1!YM<UZP=INB7S_OK^;(DXJT!:EY2U/T3"6Z
M7G_\L-IS\2`K2I4'#*U,4:54MPP"F5>T(=+G'6UAI>2B(0H>Q3:0G:"D,$%-
M'41AF`0-82VR#$OQ'@Y>EBRG=SS?-;15ED30FBC0+RO6R1>V)G\/74/$PZZ[
MRGG3`<6&U4P]&U+D-?GRR[;E@FQJR/L)3TC^PFT>SN@;E@LN>:E\H`NLT/.<
M%\$B`*;UJF"0@;;=$[1,T0U>9CA"P7IE#/K-Z%Z>_/9DQ?>?!"N^LI:"VU`G
M78$-YP\:^J70KR`X.(N^-Q7X+KR"EF17JQ]\_YFR;:6@W%/(2">V+)[OJ,S!
M4:#QHZEFRGD-`N#3:YC>&N`(>3+?>U:H*D5QXD]G88P![FVH5/=,4R(OWTG%
MFS\6A`]4EB0ZD,2@_K`>^=%\BJ?)VRR!5602O".*K%>"[SW8-?"?LB-Z#^(E
M,.O,8O#G]<P@)1USHX-,**`EE.-QG<SGJ^`1+,P/F%N+@1/08R(7D9TCXFD/
M"4!?+Q)2OURD#G)%QI.>WN1Q:R%S8[-.+#MYX0@`9RX7H(/`S1,'DOEBH,!B
M)J<8%Y&-(1R-0'*J<;R"&IPB2+>O3K((W7^^M9B9J2^.DX%YF;N,9WVTHPKV
M]_M5:;"K*HZ2GM?6S&(F1M55%`^6,V<9)W$?[:A*+E&EP4-5PSI:3&*]PM'@
M,&3N\O1HI:-J=HDJ#1ZJ.O):KRP&"G6L<N^'061C"$>;OLHN[A,ZZ*T38#%C
M&L<0CL:%JW'\!&BPZ]_Y";`8N]<6R>!\9,XJ_L=.P]!,3XT;%V70KJHX.C9%
M6]4#:,RR48CC&?Z_"\#V[O'>9JA3-*K3\KP.<77JUGRR`=_PT3;R\?X&$X/>
M`K;!3<+!X=$#Q>O+5I<=%NQ=VE"QI1FM:^GE?*<'@0@Z0?_6#BFW>`D7#@P'
M@_<9#"_F?=`OP.S0D2W]1L26M=*K:0F4H3^#YB;L]&$?%._,#;?A"J8&\[."
M*9'"51;Z`"XY5R\/>K[IY\[U7P```/__`P!02P,$%``&``@````A`('TZ'.5
M`@``4`8``!D```!X;"]W;W)K<VAE971S+W-H965T-#4N>&ULC%5;;]L@&'V?
MM/^`>*^QDSHWQ:F:6-TJ;=(T[?),,+91C;&`-.V_WP<D7IQL;5X28\YW..>[
MX.7=BVS0,]=&J#;#211CQ%NF"M%6&?[YX^%FAI&QM"UHHUJ>X5=N\-WJXX?E
M7NDG4W-N$3"T)L.UM=V"$,-J+JF)5,=;V"F5EM3"4E?$=)K3P@?)AHSB>$(D
M%2T.#`M]#8<J2\%XKMA.\M8&$LT;:D&_J45GCFR274,GJ7[:=3=,R0XHMJ(1
M]M638B39XK%JE:;;!GR_)+>4';G]XH)>"J:54:6-@(X$H9>>YV1.@&FU+`0X
M<&E'FI<9OD\6^2TFJZ7/SR_!]^;D&9E:[3]I47P1+8=D0YE<`;9*/3GH8^%>
M03"YB'[P!?BF4<%+NFOL=[7_S$556ZAV"H:<KT7QFG/#(*%`$XU2Q\14`P+@
M%TGA.@,20E_\_UX4ML[P>!*ETWB<`!QMN;$/PE%BQ';&*OD[@)(#52`9'4AN
M0?UA?Q2-9FF23MYG(4&1-YA32U=+K?8(F@;.-!UU+9@L@/GH+.CHO?[/*GAT
M)/>.Q7.!"P/E>5Y-9I,E>8:<L@-F'3`P$3TF&2(V1X1+H*/-3UX0T-N+AE2<
MBOYW&8[:''BH+4W/3EY?8D9GVBX1XW0(R2\AT[B'#/2/A_I=TL?0E&_[<$&`
M.\G?9#KO^7W"U@$#=>QS?%:%S;N(_"W$P`4<<WT5'#C#D**_RF;3,_4!,_?]
MDT3CX>[F=#>.SIS#]#O^$!M'LSXV*`Z3'1I?<EWQ#6\:@YC:N:E-X,3^;;A0
MUG"A^/$C_08,=$<K_I7J2K0&-;R$T#B:P@3K<"6$A56=;[>MLC#*_K&&FYM#
M0\<1@$NE[''A+IW^6[#Z`P``__\#`%!+`P04``8`"````"$`^;;HD2<$``!G
M$```&0```'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R<6%V/HD@4?9]D_P/A
MO<4"^="HDY%.[TXRFVPF,[//"*62!HI0V';_^[U5%X$JG5+WI5NH4\=S[RGN
MY;K\_%X6UAMM>,ZJE4TF4]NB5<JRO-JO[)\_7IXBV^)M4F5)P2JZLC\HMS^O
M__BT/+'FE1\H;2U@J/C*/K1MO7`<GAYHF?`)JVD%*SO6E$D+E\W>X75#DTQN
M*@O'G4X#ITSRRD:&17,/!]OM\I0^L_18TJI%DH8620OZ^2&O^9FM3.^A*Y/F
M]5@_I:RL@6*;%WG[(4EMJTP77_<5:Y)M`7&_DUF2GKGEQ05]F:<-XVS73H#.
M0:&7,<^=N0-,ZV660P0B[59#=RO["UG$+K&=]5(FZ%=.3WSTV>('=OJSR;-O
M>44AV^"3<&#+V*N`?LW$+=CL7.Q^D0[\TU@9W27'HOW.3G_1?']HP6X?(A*!
M+;*/9\I3R"C03%Q?,*6L``'PURIS<30@(\F[_'_*L_:PLKU@XH=3CP#<VE+>
MON2"TK;2(V]9^2^"9$0]B=N1>*"^6W<G;N03/[C-XJ`B&>!STB;K9<-.%IP:
M^$Y>)^(,D@4PB\@\R,_UR"`DL>>+V"2W`IJ#'6_K((R6SAND,.TP&\3`$]!C
M7!417R(\OX<XH*\7":$_+E)L4D5ZLYY>QK%!2"0=$X'%HQN*`,C,XP+$)LCF
M*`-!.-<4(&8VQJB(V(10-`+)6*/900%>V1!N[TX03=5OWB`FE/Z&L[DF/1XO
M^Z$_N*NH@O,]5G7?^1*;5'4>"35UB`FDNB<O](BZ'BOK[FSV&WV!JL^<-0%6
M=8UH\4@A!&5Y8:`]%;&R[)$AY4K2PD=$";`J*HBT9&P0`XX-=FOI,B$4;:*G
M/5PPQ*9;CP)B3!I-"$7C7-5H-E6`]?P-OJ"KB$%7?4\W/1XOS_S(ZW.KJ")0
M5\>I,\N2:%W7<(A15P<R)<T(4?7]OUZ`9=Q<Y@B"C#I-$%6GJ-*C(W@CCUC3
MS:6.(&@FJPDA6I^(?[NLZA*E^GY=6-A57</)Z?PU57\)B8D)HNJ#](_UW5>+
MB=AUZ]GM0$9_D><Z1-6I]8P;_EXVB\M6)E[6((BSOWHK4Y;G@PFJK(=:!;GL
M%4&DG:M-![J>D\Y>Y+D.4?5I7>-.>['PPR$:6L/%6PHQ=8=.IPFBZM0ZR`U[
ML>BKCXE>G@F"L#Z3:#J\1G;BSIU#O*J&_M`=56$/M0URK6]H7[SI0-?=Z[0A
MSW6(HL_5^L=]!LM=MY[?#G1=!.HT0E2=6A\Q&^QBW3<;W('P7900_?E5EEVB
M^XMS'8X])6WV-*9%P:V4'<7,YD+1[^_B/+DA"Y@-8([3[L=BSI238K\`8UZ=
M[.G?2;//*VX5=`>4TTD(!:?!01$O6E;+863+6ACPY,<##/04IH[I!,`[QMKS
MA1A%^Y\(UO\!``#__P,`4$L#!!0`!@`(````(0!ENK<+-08``.\@```9````
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;)Q:VX[:2!!]7VG_P?)[,.T;&`T3
M!:+L1MI(J]5>GCW&@!6,D>W))'^_U5T-N-H]U<Z\)`.<*D[7Z:KCGIZ']]_K
MD_>M;+NJ.:]],9O[7GDNFEUU/JS]?_[^]&[I>UV?GW?YJ3F7:_]'V?GO'W_]
MY>&E:;]VQ[+L/<AP[M;^L>\OJR#HBF-9Y]VLN91G^&3?M'7>P\OV$'27MLQW
M*J@^!>%\G@9U7IU]S+!JI^1H]ONJ*#\VQ7-=GGM,TI:GO`?^W;&Z=-=L=3$E
M79VW7Y\O[XJFOD"*I^I4]3]44M^KB]7GP[EI\Z<3K/N[B//BFEN]&*6OJZ)M
MNF;?SR!=@$3':\Z"+(!,CP^["E8@R^ZUY7[M?Q"K;9SZP>.#*M"_5?G2#7[V
MNF/S\EM;[?ZHSB54&W22"CPUS5<)_;R3;T%P,(K^I!3XL_5VY3Y_/O5_-2^_
ME]7AV(/<":Q(+FRU^_&Q[`JH**29A8G,5#0G(`#_>G4EMP94)/^N_G^I=OUQ
M[4?I+%G,(P%P[ZGL^D^53.E[Q7/7-_5_"!(Z%28)=9((V.O/PUFX3$22NK,$
MR$@M\&/>YX\/;?/BP:Z![^PNN=R#8@69Y<KB5U<&2Y(Q'V20"@5T!W)\>TR6
MZ4/P#4I8:,P&,=`!-TQ($=LQ(DIND`#XW4C"TDV2$8AH+_^5I`RB)*/XEEZM
M8X.0I2JS7-AV\`8A`)4Q";BK)(-`Z4$%DN7"8("8>(`QZKCE$(0C)#$YNHLD
M@]8^+/NF4K)<&AP1LU`Z"Q%%J0'8#@%9F@EQ2T`(PK8:$N35DV!*+(KO>5$^
MQ,"WW\B;Q>,0A%M*N4UK`QGD$A@Q'$<.03@NQAS=`LL@6L=DF=WTP3HB)M4"
MAPOC\RWY?"X&;43X2;<;C!)>7PDV>&5S@Q=BN-IQ",(MH]RFZ2N#7/HBAN/(
M(0A'`2-M6$!)TBVPBC(J.6IA#=(2+\3"*/66`*(L2J.;%I2CX1>\R`)'/!TO
M9A=K$%="%D+YR0D^V(33A!8X]_E1K4$L3\QCAU"><JP;/"=HC69`ZVE,XXU`
M$&J]$+$PAR(!Q/$RN0,H1UC'D*-#:XDV]^%]%^&D$0BR%TA!MBR$\C,,9:+6
MZ`D.K3GCT#PY".5I,9<)6J,O.+1&T'5T+\2HKX>`%(X-K[3UF[Q%C,TEC.^;
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MCHSFZQG93CGF)-<@E#)+168`M@20+)+X#J`<W^0VD<5M,O/781K$UA+SV"&4
MI^$YTV9ZA+;"][<&V4G@WF0AE">D,??F!,UEE#$O1_T=(0@UMYW$"(`YB45O
M\AT597#,S"<V#6)KB=9DA]!:6KS'/=,C]`R'YIRQ:,TY".5I\9X)FJ-G\#,]
M0I">Z6)\(B.`UT]DD<5V)I328CN9>2)3J>'7_,SO35D(+:5A/1/;'*W#(3GG
M+UIR#D)XQA8+<DNNHHP6&K6Y!NDV'Y_(].?V>E.2;_*?V.(_F7G1H$%V$EA,
M%D)Y6CS(O3EC]`Y>=`UB>4[VH!B^Z^=GNXIRBBY37Y_=+"<SG00W1?KJR2R&
MA;Z!H8PR&)H/%!N5FF]S%D(5MSC0!,71.1R*<_:B=R8'H3PM#C2AS=$YZ&0W
M;D$V<,$LBWZ]!QM?DU"`Y9X$[Y?Q^K4NVT.Y+4^GSBN:9WEW',+]R^U=O-?>
MB-4FE+>3QOM;N.]6[P>W#^"Z^9(?RB]Y>ZC.G7<J]Y!R/EM`Y5J\L,87?7-1
MEZ)/30\7S>K'(_QA00FWG_,9@/=-TU]?R"OQVY\J//X/``#__P,`4$L#!!0`
M!@`(````(0#EG@[["0,```0)```9````>&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;(R676^;,!2&[R?M/R#N"Q@2TD0A54/5K=(J3=,^KATP8!4PLIVF_?<[
MMA,:0TMZTX;X]<MS/NR3]<U+4SO/A`O*VL1%7N`ZI,U83MLR<?_\OK^Z=ATA
M<9OCFK4D<5^)<&\V7[^L#XP_B8H0Z8!#*Q*WDK);^;[(*M)@X;&.M+!2,-Y@
M"8^\]$7'"<[UIJ;VPR"(_0;3UC4.*_X9#U84-"-W+-LWI)7&A),:2^`7%>W$
MR:W)/F/78/ZT[ZXRUG1@L:,UE:_:U'6:;/50MHSC70UQOZ`9SD[>^F%DW]",
M,\$*Z8&=;T#',2_]I0].FW5.(0*5=H>3(G%OT2I=NOYFK?/SEY*#./OLB(H=
MOG&:_Z`M@61#F50!=HP]*>E#KKZ"S?YH][TNP$_NY*3`^UK^8H?OA):5A&K/
M(2`5URI_O2,B@X2"C1?.E5/&:@"`OTY#56=`0O"+_G^@N:P2-XJ]^2*($,B=
M'1'RGBI+U\GV0K+FGQ&AHY4Q"8\F$=`?UT,OO)ZC>7S9Q3=$.L`[+/%FS=G!
M@::!=XH.JQ9$*W`^168X^E@_"A5B5":WRD5[010"RO.\F2^7:_\9<IH=-5NC
M@1/1:Y"M2$\*50K`ZQDA\B%C!#5\/_LG)+7)1HIF]ONV8TEH*]*Q(IKW$HL1
M<C=DG'W8(2=&M0EZX2PE<1#T_CJU6Z.9G6ML13JEL!C!9,AX.8]J4^)"(OJR
MA8O8)M@:S4(7_@JAV5N.=`RIM1XNX[?6L/@@7^=\T_558ILK#@8-M34:>'O/
M/B!/IQ066VRSJ7-RN;YJTZ7Z&LT4XY3"8ES8C-/Y4^)A_@;MOS6:6-<5!6AX
M@%*S_CZ[1:;FX."6N=QY:I--..X\HSD2CAO/+'\"<&D#3J=.B6VP.(@&1\)H
MS)%`*%R\M;PY$F9]BLQ,(W-9-X27)"5U+9R,[=6D05"4_ELS!+<P!/7(\/L%
M&$(=+LDCYB5MA5.3`K8&W@+:GILQ9AXDZ_1=N6,2QH_^6,&O#0)W>^"!N&!,
MGA[4[=S_?MG\!P``__\#`%!+`P04``8`"````"$`2#'&*VL#``"M"@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R<5EMOFS`8?9^T_X!X#_=+B)),
M35BW29LT3;L\.^`$JX"1[33MO]]G'%+LK+1='@B7X\,YY[/QM_SPT-36/6:<
MT'9E^XYG6[@M:$G:P\K^]?-V-K<M+E!;HIJV>&4_8FY_6+]_MSQ1=L<KC(4%
M#"U?V940W<)U>5'A!G&'=KB%)WO*&B3@DAU<WC&,RGY04[N!YR5N@TAK*X8%
M>PT'W>])@7-:'!O<"D7"<(T$Z.<5Z?C`UA2OH6L0NSMVLX(V'5#L2$W$8T]J
M6TVQ^')H*4.[&GP_^!$J!N[^XHJ^(06CG.Z%`W2N$GKM.7,S%YC6RY*``QF[
MQ?!^9=_XBSRSW?6RS^<WP2<^.K=X14^?&"F_DA9#V%`F68`=I7<2^J64MV"P
M>S7ZMB_`=V:5>(^.M?A!3Y\Q.50"JAV#(>EK43[FF!<0*-`X02R9"EJ#`#A:
M#9$S`P)!#_W_B92B6MEAXL2I%_H`MW:8BULB*6VK.')!FS\*Y)^I%$EP)H'_
M,XD?.U$0I_.WL(1GENB))7"">>S'R<M:7.6KCRE'`JV7C)XLF'J@G'=(3F1_
M`<Q#/LK-);'G`H.D),F-9%G9L&8@"PY%OE\G7K1T[Z$RQ1FS41@XCC"QCME>
M\_@Z(A\0LNA@X>(#LAW[^'=]![D2+.7*>DO]&W5CK"V.0_W-VVM,H"/R:T3X
M9%!3"[4<JY6I1\_.RD&U'`3S3PLPT25L%`8*^12RCMB^B,BG$)H+>,W8Q73F
M$KRR(:*+LKE1VXV"I/W\F?FI)W^&>@6!XX7%2"`W2,+YF$23#X&/Y<LBA/"!
MF;8A!^DV$B_516X4)NE]Q+T+TX9"3-F80F@NDO]Q(0>9+N:&"X69T+A5B*%>
M?B2]ZB2Y!@FR)!M#-!^I[F.Z"A)LZL_T5V\49DJ_0L117RC/2<RI9#Q/GUG,
MLE48?4*GE4NPH=PW0MLHS)1RA3@K#YWPX\SX6N4:(G+\3/NEXP%:&;*WF)%@
MTXRYJ!5FRHQ"G,VD3J@IS9*/,_,[JPW(G/,24PO-\_SQ`.5-M0=JWVLP.^`M
MKFMN%?0HM_X`ZG^Y>^E*;@*Y/1CWM]"M]'N[>WD`W4*'#O@;8@?2<JO&>Z#T
MG!06,%/]AKH0M.MWVQT5T"?TIQ6TA1BV'\\!\)Y2,5S(S>W2:*[_`@``__\#
M`%!+`P04``8`"````"$`)5X,KV\&``",)P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6R<FEUSHD@4AN^W:O^#Y?V(0,1HQ4R-\@U;M;6U']=$4:E1
ML8!,)O]^3].(=./T:W(38I^G#]W]]CG"L9^^_CP>!C_2HLSRTV*HC\;#07I:
MYYOLM%L,__G;_?(X')15<MHDA_R4+H;O:3G\^OS[;T]O>?&]W*=I-2`/IW(Q
MW%?5>:YIY7J?'I-RE)_3$UFV>7%,*OI8[+3R7*3)INYT/&C&>&QIQR0[#;F'
M>7&/CWR[S=:IG:]?C^FIXDZ*])!4-/YRGYW+B[?C^AYWQZ3X_GK^LLZ/9W+Q
MDAVRZKUV.AP<U_-@=\J+Y.5`\_ZI/R3KB^_Z0\_],5L7>9EOJQ&YT_A`^W.>
M:3.-/#T_;3*:`5OV09%N%\-O^CS69T/M^:E>H'^S]*WL_#\H]_F;5V2;.#NE
MM-JD$U/@)<^_,S38L";JK/5ZN[4"?Q:#3;I-7@_57_F;GV:[?45R3VA&;&+S
MS;N=EFM:47(S,B;,TSH_T`#H[^"8L:U!*Y+\K*]OV:;:+X:F-9I,QZ9.^.`E
M+2LW8RZ'@_5K6>7'_SBD-ZZX$Z-Q8M+H&[LQ,AXG^L3Z@)>'Q@M=6R]W#X$&
M6\^#KFWG#\_#:IQ,NTX^/`\*K7HH=&V'<O<\9DUGNK:=/SP/G;815Y64N;JY
M=R8:WR/UEK.3*GE^*O*W`<4Q[8+RG+"LH,]U<GW9;'QKM-OO5[N/MAWS\HVY
MJ9W1QBHI9'X\6[KQI/V@;;YNF"5G:`D[C"DRJPO#=C5S;,L-CMS@R@V>W.#+
M#8'<$%X:KD/3Q8%%%^(RL+C3H-%:M@M*:]A;4)/$NQV]E_5CO<3U,Q_$$2S[
MB+3`JSYAZ9(7^Q8S$>_DW&(LD7'[C"FY\?J(I4]%-_XMYE%D@EO,3&3"/B,M
M3M0GY`''?60Z;N\CB$Q9\1,BLUZ4C+L!8%QO4._W)6<H7UZ#I!U"3:P@84/"
M@80+"0\2/B0"2(20B"`1JPA!5EIV059US#)Z,:1-TTHUE3;=DB/3.B%.'B92
M,*ZZ9DO7I8UO=\T/TXFTYYVNV31,J;>K-GM=L_$XEIS[7;-IRN9`-#]($PN[
M9GTVL23OD6`WIF,I"F+!;DX?K_T%O>C)X`-Z,5K4:R9E^25'Z.ZMI%+>6T'"
MAH0#"1<2'B1\2`20""$102)6$8*:]*@FJ,D>1?`W)^N%DBIG5+)"PH:$`PD7
M$AXD?$@$D`@A$4$B5A&"K/3D+<BJ3JJ,%H.TEU0YHE(3$C8D'$BXD/`@X4,B
M@$3(":O^DKF5;`7[C60KV,VI=7U&$W1DY07Y30&')^LEZFD9<M;EC$I02-B0
M<"#A0L*#A`^)`!(A)")(Q"I"D)7>2C\A*^N%LBYG5+)"PH:$`PD7$AXD?$@$
MD`@A$4$B5A&"K*Q>(.BJ3KLU+L9I+^\VC$I0C-@8<3#B8L3#B(^1`"-A@S0)
M>&*:TC-C)`+CL2D_[O:`:UE$%)45'3Z>@W5>J^B^J5B&_*K20$IUN1\%8F,O
M#D9<C'@8\3$28"3$2(216(F(&K,JQ"<TYL4+>M6]OKKTB@NLP$=I6R'@"B,V
M1AR,N!CQ,.)C),!(B)$(([$2$35F%8FNQB`Y\P)&-W[[R5E5Y."%(QTB-D8<
MC+@8\3#B8R3`2-@@37*>3J4J223:9S,I=\>"W9QVJK*BHA13@J+WO;SJK)OX
MM6L9U^3/2X(-I(Q:[D>!V-B+@Q$7(QY&?(P$&`DQ$F$D5B*BQJR2T8W:.S7F
M!1`*/E5F5E5)FO"%B,U^)53G=P<C+D8\C/@8"3`28B3"2*Q$1(U96:.K,<C,
MO`JBSLRJ2DDC+41L'2(.1ER,>!CQ,1)@)&R0)C,_RN7MJ'7!?DV<R.:X-7?"
MJOVE1-24%3BZFMX9M[PNTM76,J1"]U+GD"+QKC!B8\3!B(L1#R,^1@*,A!B)
M,!(K$5%C5N_XA,:\3`)RLZJ6T@0P1&P=(@Y&7(QX&/$Q$F`DQ$B$D5B)B!JS
MXD=78Y";>:VD&[_]IV95/:61%B(V'0:"7[L0<;$7#R,^1@*,A`W2_'`I/Q1'
M@EG7I1_^V>&H7Z\'EY0??N(G48YIL4M7Z>%0#M;Y*SO89%`MNVWEAZZ6^IR.
M;=#I"ZD]9(>QZN-4K8'.0IV37?I'4NRR4SDXI%MR.1Y-Z>&HX*>I^(<J/]='
M+E[RBDY!U?_NZ=1;2L=.QB."MWE>73[0C;7V'-WS_P```/__`P!02P,$%``&
M``@````A`!N4R.O+%@``"\H``!D```!X;"]W;W)K<VAE971S+W-H965T-#,N
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MA\.?`=K]$C3IDR\RSVX=NV#R>/9E__7FKQ_/L\.OSO[NV_=G[>^*OJ3@E5U_
M^;>Q?[K50ZIEWA4K0:7;PP_=`?W_V?U=,#;TD-S\<_SYZ^[+\_=/YZ7JN\KE
M^U)!\;,_]D_/K;N@Y/G9[5]/SX?[=0@5HE)AD6)41']&10J%=^5BY?+J-55*
M417]&5<IOKY*.:JB/^,JU==7T==^/"SZ,ZY2?%>\JA0JU5<<EVI417_&52JO
MWY?+J(K^C*N\X16I\<=7I#^C*F_HZ`]1D<+)T7W#<0D&:#CJ7HYO\>K5PZX0
M']_"RZ$IZA@TCMI"?$B"7Z)C4M2!;GUZ?#!*@;2A%L4/KQ\DI5C!X)>X@]\P
M3$JQA<$O<9WJ&_8G\?!DV+ZADTOQN`U^B??G\MU5I5*N7EUJQQN/<RGNIN"7
MJ,X;AFXIZ2[])=Z=-WA4UMX^CMW@EWAW[*.F'/=V\$O\]->_XY;CS@Y^B<N\
MH9/*<6<'O\1UWK`[R;ON25^_97?BOBZ_=-(;^KH2]U'EY2`7*^:A=Q%FY#%R
M&S?/-Y\_/AY^G>D'&:WV]/,F^%A4N`Y*QV$;1F,2O[]+7XW=H(H$93Z=ZTO5
M8'W2SPQ_?]90^7CQM\;\;<34/,Q[AZG'3)#J0>%&V*#_3PH7TF6;,1$_I14W
MO#REZFZGG66<LIV8B,MVW89>V'#ZFIT:_9B(:PS<AJ';,'(;QF[#Q&V8N@TS
MMV'N-BSBAI=#Y.SZ,B;B75^Y#6NW8>,V;-V&G=L@R;B)-R/)*$E:,F-"HD%Q
M=?S`=AQ^R2!X>4&9/I=H8.1TF$3CXJ1R-`Y.6J*!<-*2C(1DGS,]+YFNEZCO
M]9C\;FA+-!K"3Z;'%QH-AY.6S'B0S("09$3\?E.9,2+)($E>56902&942#(L
M7C:5[8G,4)%HK!Q?UX6^-27O3YH%J?<G_R0@?AL*Z.!M*-[E6MQPLC?%:OH-
MI)YE*I>.#HTL4TQ7:6:)DO/FU@J1TPZO%ARFG66<#76R1+503N],-\LX57I(
M])$8(#%$8H3$&(D)$E,D9DC,D5@@L41BA<0:B0T26R1V2(@P$NEW.N*=<2B1
M?7E()%\>$MEWBE1+5VDIQ..?NS>LGWC\<ZNP?L+^"0LH;*"P@L(.BD?":KGD
M'%_V4%A$81.%511V45A&81O%HV/531CQ&)F%<J5,9:+.:UZ1B0&=RD2WH>XV
M--R&IMO0"AM.?=,S2>GQT#8P'0/3-3`]`],W,`,#,S0P(P,S-C`3`S,U,#,#
M,S<P"P.S-#`K`[,V,!L#LS4P.P,C8H%J%B@R+E<?B2S,AR(S3Z%JZ4-:1/'8
MFH4\NF8ACZ]9R"-L%O(8FX4\RF8AC[-9R"OMI7.<O-:ZD%=;%_)ZZT)><5W(
M:Z[[R<:KK@MYW74AK[PNY+77A;SZNI#77Q?R"OP"I:)13]JEHC$XG16<S,Z?
M-@;/2D6DVU!W&QIN0]-M:(4-+S/UMMO0B1M.)Z=._W>S3/&#P_0,3-_`#`S,
MT,",#,S8P$P,S-3`S`S,W,<XL^J%@5D:F)6!61N8C8'9&IB=@1&Q0#4+%+ET
M&EG%#\ZAELBO?"AR[D4Q2:0[4:K\WGF;3T1\@2H5QRGQR%FINI4\=E:++^],
MX:EQCY[5HAO1'C^K[ODC\0A:+3MGJB0Q-#X')AX?JV5WSNH1LEIV>\5C9+7L
M?.P7CY+5LG/.33Q.9OO`(V6V#SQ69OO`HV6V#SQ>5LONN/"(62VZD,?,PI4[
M>#QJGD*I6--+BZE8RX^S@$[%F=M0=QL:;D/3;6B%#2^NM=V&CMO0=1MZ<4..
M>'T/XWHWR#*9+A_Z&,>ZD8<I.=TT]C&.<Q,?XP@V]3'.&929CW$<G,=,K/<B
M;L@YJ$L/XQ[459;)'-2UCW$.ZL;#N`=UZV.<]Y&=CW'?1L0'N3;6?)#3/1(I
M<1HXU9+3/Q)IDH:<#I)(G1=3)...9.21C#V2T4<2?^*^E\26I"5Q(VE)3$A:
MDG&?M"2C/&E)QG32DHS@I"49KTE+9G1*,CP3)AF,24LR])*69*`E+<FP2EJ2
M0:0MJ3=+O<<C]689S`'*.@;RWS2#9^E<X>1J7+7L1'DM9/1#3G+%SAF0=20:
M2#21:"'11J*#1!>)'A)])`9(#)$8(3%&8H+$%(D9$G,D%D@LD5@AL49B@\06
MB1T2(HRP=<+:"7LG+)ZP><+J";LG+)^P?<+Z"?LG+*"P@<(*"CLH+*&PA<(:
M"GLH+**PB<(J"KLHN3*FTE'O9DNE8WXJ!O2G<[W2^Y)X9><#7RUD\E(1B082
M321:2+21Z"#11:*'1!^)`1)#)$9(C)&8(#%%8H;$'(D%$DLD5DBLD=@@L45B
MAX0((VR=U+D*>R<LGD3F71[O^RR]/_[GGG/C?6'WA.43MD]8/V'_)!(P?-%7
MOM?,`@H;**R@L(/"$@I;**RAL(?"(DID8GAPBQ7?T8U43"'.N1O)E3&5BGI3
M:"H5;=>-@F<YZ5AQ]J$6,GGIB$0#B282+23:2'20Z"+10Z*/Q`")(1(C),9(
M3)"8(C%#8H[$`HDE$BLDUDALD-@BL4-"A!&V3NI<A;T3%D_8/&'UA-T3ED_8
M/F']A/T3%E#80&$%A1T4EE#80F$-A3T4%E'81(E4K!X_<.GW48-\=#YPL8N2
M*V,J'?6;2V](Q^!9;CHZ5TYJ(9.7CD@TD&@BT4*BC40'B2X2/23Z2`R0&"(Q
M0F*,Q`2)*1(S).9(+)!8(K%"8HW$!HDM$CLD1!AAZZ3.5=@[8?&$S1-63]@]
M8?F$[1/63]@_80&%#1164-A!80F%+1364-A#81&%391(Q=QTY.&=*V,J'0MZ
M?V$J'O-/J1[Q="X62LXUZUH$Y04C(PU&FHRT&&DSTHF0L%=*OBE]EZOT&.DS
M,F!DR,B(D3$C$T:FC,P8F3.R8&3)R(J1-2,;1K:,[!C1[R`'_NHM`J<7.9Q/
MTP8?I6ZH8S!28B5#4\KA^51G?V(G0T87*/+,``Q22FQEWFLW:"D&+\4@IGY+
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M,:)I&DJ8XY>F*3,&"75U+:YCT%##E.O$(OZN'W6"&A9)`*<C-41Y*[&%>4<O
M-C&/,=BHJWKQ_AA\U.DIUS$8*08E=7DPYR"_=[[XH)-3ARBX_1`;F7?\8BOS
M&(.9NL88'QN#FSHUS:N3SLY@68?3[(1SO.$J$%K^Y;[9BO-%H5HAA'*.1IV1
M!B--1EJ,M'U(Q?G25L<'I3^Q=1GI,=)G9,#(D)$1(V-&)HQ,&9DQ,F=DP<B2
MD14C:T8VC&P9V3&B"8JV:8(R8U!2$Y3K&*34!.4Z7BW3QFF(<AV#EGJ6E^L8
MQ-2)*-<QJ*D34:YCD%-/\W(=@YZ:HUS'(*B>YN4Z!D7U-"_7,4BJIWFY3KZF
MZ2S5Q$MEJ>UFVV"!]LSI7N?[E[4(RLW4L$X.TN`J349:C+1]B+L41<<'I0WO
M,M)CI,_(@)$A(R-&QHQ,&)DR,F-DSLB"D24C*T;6C&P8V3*R8T0S%5723&6F
M;F`,3NHI7MZ6U\J*.]_QBIEV3E.5MV804U.5ZQC4U%3E.EXY*\X7^C17N9)!
M4,U5KF-05'.5ZQ@DU5SE.@9--5>YCD%4S56NDZ]J.E>#=2Y.YZC&7`V7QTC-
M5=W%06K!GS?)OT>BSDB#D28CK0B)SM07CI=[TFZVN4J'D2XC/4;ZC`P8&3(R
M8F3,R(21*2,S1N:,+!A9,K)B9,W(AI$M(SM&-%71-4U59@Q"ZDR5ZQB4U)DJ
MUS%(J9G*=0Q::J9R'8.8FJE<QZ"F)BK7,<BIB<IU#'IJHG(=@Z":J%S'H*@F
M*M<Q2*J)RG7R-4TG:K`ZR6FB_N/]$W3Q7Y\(_GB7.T.M.E?\:A&DR?]R:CB=
M7G5&&HPT&6DQTF:DPTB7D1XC?48&C`P9&3$R9F3"R)21&2-S1A:,+!E9,;)F
M9,/(EI$=(YJDAM6%#(Q!2$U2WI9!24W2N$[P1[2<VRSTUJ/XT=^^>VB&,F,0
M4C.4ZQB4U`SE.@8I-4.YCD%+S5"N8Q!3,Y3K&-34#.4Z!CDU0[F.04_-4*Z3
M+V@Z0X.5/TXSU#@K#1<,2<]*G8O.M>"/9-*L%)$&5VDRTF*DS4B'D2XC/4;Z
MC`P8&3(R8F3,R(21*2,S1N:,+!A9,K)B9,W(AI$M(SM&-$M1))V5,E,W,`8C
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MJ.E,#1:%.,U4.-L;KB&1SM+,_4BXT$2]@$@C0L(KGN7@"XGI3U_-%%`*OAN9
M!EJ\D38C'4:ZC/08Z3,R8&3(R(B1,2,31J:,S!B9,[)@9,G(BI$U(QM&MHSL
M&-$<18DT1YDQR*@YRG5B(7.N\FB*AG5"JZ/O#SO>Z@E?WIA!2YV<<AV#F#HY
MY3H&-75RRG4,<NK4E.L8]-2OR7`=@Z#Z11FN8U!4#(YJC/*V#)9JC'*=?$]3
M,5H,UGNPQ^@1=U9QJ+K+(450CDYU1AH1$L5HX?+JLN3^J>9FBBE5KDKZ-[F<
MNP-;O*DV(QU&NHST&.DS,F!DR,B(D3$C$T:FC,P8F3.R8&3)R(J1-2,;1K:,
M[!@1,3`U`V-04F(G<\R6M)-5[W*G!B?%(*48K!2#EF+P4@QBBL%,,:@I!C?%
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MI7/'O\Y3N9)!2SW/RW4,8NIY7JYC4%//\W(=@YQZGI?K&/34\[Q<QR"H&`S5
M3.5M&1S53.4Z!DLU4[F.P5/-U+PZZ4S5Q$ME*LQ/`]R9GUXZ][77BB&4FZ6(
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M:I)R'8.>FJ1<QR"H)BG7,2BJ2<IU#))JDG*=?$W321HL!/&*)`W7C4@GJ?N%
MF"(N+E&/D&A]OV*E6BPYIX$:C#1Y0RU&VHQT&.DRTF.DS\B`D2$C(T;&C$P8
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M-U_VCP&@\-?#X3G^A_;IQ:_#XY_'0?'Y?P(```#__P,`4$L#!!0`!@`(````
M(0#.*=Q,$@0``/0/```9````>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;)Q7
M76^K.!!]7VG_`^*]@$T22!1R=:NJNU?:E:Y6^_%,P$E0`2/L-NV_W[&'`C9-
M2OK2A'(\Y\QXYCC>?GNM2N>%M:+@=>(2+W`=5F<\+^ICXO[S]^-=[#I"IG6>
MEKQFB?O&A/MM]^LOVS-OG\2),>E`A%HD[DG*9N/[(CNQ*A4>;U@-;PZ\K5()
MC^W1%TW+TEPOJDJ?!L'*K]*B=C'"IIT3@Q\.1<8>>/9<L5IBD):5J03]XE0T
MXCU:E<T)5Z7MTW-SE_&J@1#[HBSDFP[J.E6V^7&L>9ON2\C[E2S2[#VV?IB$
MKXJLY8(?I`?A?!0ZS7GMKWV(M-OF!62@RNZT[)"XW\GFGJY<?[?5!?JW8&<Q
M^NZ($S__UA;Y'T7-H-JP3VH']IP_*>B/7/T+%ON3U8]Z!WZV3LX.Z7,I_^+G
MWUEQ/$G8[B5DI!+;Y&\/3&1040CCT:6*E/$2!,!?IRI4:T!%TE?]>2YR>4K<
M<.4MHR`D`'?V3,C'0H5TG>Q92%[]AR#2A<(@M`L"GUT0NO`6=!G%,Z+XJ$@G
M^)#*=+=M^=F!K@%.T:2J!\D&(G^<$:2BL-\56"\!L0*VX6471<NM_P*ERSK,
M_11#>H0/I#TSL(V954U#V)GK"M0B4\%JW8?7(N^G$-HC#`&A*>`ZL0*#0-<9
MI;[JXR(S8A8CS(`PF`%R>^IJ4>)"=B,%D:4`,2N]-8N(!OUK@QYZ;DQ_/7$%
M-FG#..SC8N*(05H2KQ;]:X-V=0NM`MNT0URD1<Q"9WL7A1>V.;J%5H%MVF$3
MD18Q'2U=#JJ,;)7WCP9K7GNK129]%,5]-9$>,5CLY7(]O#;HUU^A5XML>GN\
M$-/1A_&%HA.8Y''ZUWM,HRWB>&A>S+L#(3.EBPMU)[<Y&MJ5,=?Q8%@=,X)F
M##;YDJGI55;ZD3W:'6BMNYUZ9!!I[#M1)C3JNT\*CY8U-I7I=.N0B8O,<&Y=
MVG++U3YAGMI9&`];VA4>0<@<>*.-,7.^R=#4P6UU>1C;,]Z!D#F\G+/E:?.F
MG$S-;3KF'>A=P>B8,W.W[&VF@JG/19$]Z01!O8+>ATP!EM%]LNT?.-QTTA&$
MQ,2CEQKN2QY'T,#,B1\8NL9#T(R)IY;1S:N_7F5/_.#D**(#C45$HZ/7V`5J
MN=Y,&6ALX_&?MH$.G;BFC&%231F6_UUO!JK05A4FS="!3/KA1Z=)?Y/Y430_
MLQ-L(^A`8_H!8I(#9NR\,[=`K;)J,#GR*8(B]'Y"5D._FA(L(YPI86J('W0!
M@KK3-XB#X7@V)5B.^$D'?."$TPY`$&9/X)2PL\=[&UYKFO3(_DS;8U$+IV0'
M^*T<>!%H;_'6A@^2-_H2L><2;EOZZPENUPSN.($'X`/G\OU!W0O[^_KN?P``
M`/__`P!02P,$%``&``@````A`$)X7)X:`P``?0D``!D```!X;"]W;W)K<VAE
M971S+W-H965T-30N>&ULE)9=;]HP%(;O)^T_1+XGGT`((E2%M%NE39JF?5R;
MQ"%6DSBR36G__8YC"'$8E.8"B/WX]7N.#SE9W+U6I?5"N*"LCI%GN\@B=<HR
M6F]C]/O7XVB&+"%QG>&2U21&;T2@N^7G3XL]X\^B($1:H%"+&!52-G/'$6E!
M*BQLUI`:9G+&*RSAEF\=T7""LW9153J^ZTZ="M,::84YOT6#Y3E-2<+2745J
MJ44X*;$$_Z*@C3BJ5>DM<A7FS[MFE+*J`8D-+:E\:T615:7SIVW-.-Z4$/>K
M-\;I4;N].9.O:,J98+FT0<[11L]CCIS(`:7E(J,0@4J[Q4D>HWMOGLR0LURT
M^?E#R5[T?ENB8/LOG&;?:$T@V7!,Z@`VC#TK]"E30[#8.5O]V![`#VYE),>[
M4OYD^Z^$;@L)ISV!@%1<\^PM(2*%A(*,[4^44LI*,`"?5D5594!"\&O[O:>9
M+&(43.U)Z`8>X-:&"/E(E22RTIV0K/JK(>\@I47\@\@8W.MYW[M5Q-&&VO@2
M+/%RP=G>@IJ!+46#505Z<Q!6@8W!DK;1A7HI4@A1B=PKE1A!L<-R`:?SL@QG
MX<)Y@92F!V9USG@FL3X2*G]*-ND-.."W,PV9Z)O^_RD<O2E8>3NJKO0`:'=F
M_8&1<R*8F$ARCH1NAQAF@X^857",0/SDS3_IMEE9:08.JV.FW<XML7Z72*X1
MAGO8YO94*QA*N^<LB&:FMY5FKKE_ETBN$89[J.3;W2O8S'T010/WFIF,VQKW
M[.AA-*P=@YC9D7D%#Z/`E$R,!;X-Q$G2"&;ZD6`4;`8S=@?_MY5F#L$,JFQ]
M;3*Y,&G8#3]B5\%#NZ<TZ+K7S-&N'?IP/+UK4&CK(1Z8^.!DDR'NSWK:4:^,
MC2!5?^\]/J\_B10\#')0#2O-]/\>X6P8V0T,-$.UUR4='8-N=[H=5(1OR9J4
MI;!2ME.MS(<:[T:[+GOOJP?I8'P%W;?M54XW`=VOP5OR'?,MK855DAPD73N$
M:N>Z?^H;R9JV"6V8A+[7_BS@-8?`X]^U`<X9D\<;V-CI7IR6_P```/__`P!0
M2P,$%``&``@````A`!U+BZQ*`P``RPH``!D```!X;"]W;W)K<VAE971S+W-H
M965T-34N>&ULE%9=;YLP%'V?M/^`>"]?"9!$(553U&W2)DW3/IX=,(E5P,AV
MFO;?[]I."(85LI<VX./#.?<>\%W?OU:E]8(9)[1.;-_Q;`O7&<U)O4_L7S^?
M[A:VQ06J<U32&B?V&^;V_>;CA_6)LF=^P%A8P%#SQ#X(T:Q<EV<'7"'NT`;7
ML%)05B$!EVSO\H9AE*M-5>D&GA>Y%2*UK1E6[!8.6A0DPRG-CA6NA29AN$0"
M]/,#:?B%K<INH:L0>SXV=QFM&J#8D9*(-T5J6U6V^K*O*4.[$GR_^G.47;C5
MQ8"^(AFCG!;"`3I7"QUZ7KI+%Y@VZYR``UEVB^$BL1_\5>I[MKM9JP+])OC$
M.[\M?J"G3XSD7TF-H=K0)]F!':7/$OHEE[=@LSO8_:0Z\)U9.2[0L10_Z.DS
M)ON#@':'X$@:6^5O*>895!1HG""43!DM00#\M2HBHP$50:_J_XGDXI#8L\@)
M8V_F`]S:82Z>B*2TK>S(!:W^:)!_IM(DP9ED#NK/ZX$3+$(_C*997*U(&4R1
M0)LUHR<+4@//Y`V2&?17P'QQIG6T7M^S"AXER8-D45S@@D-_7C;Q8KEV7Z"F
MV1FSU1AX)5J,;R(>+PA90$F;=FZXH+<5#:7HBYY!4__=CHM&N<G4.)N;`K9#
M2&`B'H>(66A"TB$D]EJ(86,VM#%_-U47&W(3Y*=3QGAYY5=UVVH,M+,M==0J
M4(C'240ZAC!<P&.ZS1AO@@0G-I2H518O>S'8:DRL8C2;!_T6=)?],.QY3[O+
MB^#:'$,S5/EVS1+<T]P/CH;`HUM;_8)/(M(QA"$^,L7+5W8Z-G+35&PT9LS%
M)"(=0Q@N8M/%>&PDN->"06PT)E*Q"8)YOP%Z>:Z6EWXO5&EW-0SC]FTQ),OC
MO/.M')<LP3W)US#JUU1#QNH]B4C'$(;XI2G^MM3(35.IT9@Q%Y.(=`QAN(!3
M_C]ZH-"])@QR<P;I[XWOQ_W@&.O1;-%FXWQ&246)K;<'T759Z]8SA3YR*\SV
M^!&7);<R>I3S@@]Q;._J668K9QDUC;0+,$HT:(^_(;8G-;=*7,!6SXGAB\'T
M,*(O!&W4`;>C`H8(]?,`0R.&H]1S`%Q0*BX7<MQIQ]#-7P```/__`P!02P,$
M%``&``@````A`%;[.1]1`P``]0H``!D```!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&ULE)9=;YLP%(;O)^T_(.[+9P(D2E(54+=*FS1-^[AVP`2K@)'M-.V_
MWS&&%).5-C=),*_?/.<#<S:WSW5E/&'&"6VVIFLYIH&;C.:D.6S-W[_N;R+3
MX`(U.:IH@[?F"^;F[>[SI\V)LD=>8BP,<&CXUBR%:->VS;,2UXA;M,4-W"DH
MJY&`2W:P><LPRKM-=65[CA/8-2*-J1S6[",>M"A(AE.:'6O<"&7"<(4$\/.2
MM'QPJ[./V-6(/1[;FXS6+5CL247$2V=J&G6V?C@TE*%]!7$_NPN4#=[=Q85]
M33)&.2V$!7:V`KV,>66O;'#:;7("$<BT&PP76_/.7:>N8]J[39>@/P2?^.BW
MP4MZ^L)(_HTT&+(-=9(5V%/Z**4/N5R"S?;%[ONN`C^8D>,"'2OQDYZ^8G(H
M!91["1')P-;Y2XIY!AD%&\M;2J>,5@``GT9-9&M`1M#SUO3@CTDNRJWI!]8R
M='P7Y,8><W%/I*5I9$<N:/U7B=S>2IGXO0E\]R9N:"V\91A=X[+H7>#[:A1;
MA=5E*44"[3:,G@QH/0#G+9*-[*[!>$B/"N:<L+?R!8F2)G?2I?."5'`H\M,N
M\MV-_02%R7I-K#3P7)TU@;/4-<F@D760QNEHP0;B,S:48XKM0V_\OZH#I=PT
MI?1T@OA2$WB!KDDN-9'OZYIT7J/%`EUQ?2QRDXQER%0\+(S2ZX4Z5'*IB?R%
MKDGG-1HX],OUX'*3!CY=2(:%UTA6JPGDI208!:M!PE,ZAISO$"F&)WS4HY$_
MZ=%8:8#@M8]UNN1=13JGT.@#G5X^GN_WN=S4G5BOA$M'9XR59M4]JRX<??KM
M1-V>"3)]TT#C#W7^^>Q+\81[,:E\K#2+CMNSIMC#W3=KDPX*>4:-]VO4\N4_
M.A3GJ:58IX[\R8D1*\U,.A.E"%0]?,</HTG%TCD/C7YU#;T4Z_1!$.G-$"O-
M'+U2J&X*K6!R[J1S!AHZ3`)79+Y3Z_"1/_GON!?-T?>24"5_FO=9`T6OI@_U
M7JTQ.^`$5Q4W,GJ4DX4+ON=5-?7$<NKIYI;S#1@Z6G3`WQ$[D(8;%2Y@JV.%
M<%0P-;:H"T';[AVVIP+&C>YG">,EAK>E8X&XH%0,%W(P.@^LNW\```#__P,`
M4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q
M+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]
M&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_
MW^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$CO
MVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=
MB%76JM5F)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T
M0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I
M@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L
M@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#U
MSG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<H
MB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<
M&M*\D/0%353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$N
MCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+
MKS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*
M'>"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX
M.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2
M[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-Z
MAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQ
MD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^0
M4PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!
MG$TP,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)
M9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]
MMX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#
MB1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@
MK,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)
MQW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*
MU0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)Q
MTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2
M(=4.EJ$-#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/BJZ*S
M"R/:=O8U+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46YS3I
MBI=B!F?',4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\/U-%
M[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@
MA_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/
MR"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR
M@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NM
MK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1
M?<DV'D@72#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQE
MY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!
MIRJ!H8<>F#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`+6LW>&H"P``
M%&8```T```!X;"]S='EL97,N>&ULU%W_;^+(%?^]4O\'R]M6=U(3P)@`N9#3
M0N)VI6UZNDW52KVJ,F`27_R%VF8WN5/_][XW_O8&L#V&@=DVZBT8YKW/^S+O
MR\S8W'S_ZGO:9R>*W3"8Z+W+KJXYP2)<NL'31/_;HW4QTK4XL8.E[86!,]'?
MG%C__O:WO[F)DS?/^?3L.(D&)()XHC\GR?JZTXD7SXYOQY?AV@G@DU48^78"
M;Z.G3KR.''L9XR#?ZQC=[E7'M]U`3RE<^PL1(KX=O6S6%XO07]N).W<]-WEC
MM'3-7UQ_>`K"R)Y[`/6U9]J+G#9[LT/>=Q=1&(>KY!+(=<+5RETXNRC'G7$'
M*-W>!!O?\I-86X2;()GH1G%)2S_YL)SH5[J6BCP+EP#B#__9A,EWOTO_>??'
M=^^Z__[VNW_^Z"S_]=,WNY_]]*W>R=D0FF"#>IJ7W5JR\'%*N9-)<'NS"H-2
MD#Y8G2GH^B4(OP06?@;.`.+AUVYOXE^TS[8'5WH(;Q%Z8:0E8&60CUT);-])
MOS&S/7<>N?BUE>V[WEMZV<`+S#&R[_DNF`DO=E(.Y^4S1S2Y3".$P<G4QRM4
M)A]$LO%BO4SVSWMDXG@-FGD=HS^.%Y.B7BYIO';]8D>'Q_`J;$7X1$_SB6Y9
M$$-ZW2ZJE1KL1,S&LR[P.QNSJ\'9).M;?6LH53+.%W?MA@S[EDQ5-C"TW@_O
MSJ9.^<RJI,O"\+EF`$XXN5IT8>K6S.^AA7_G\),S)[336(Q1Y8(^FWIE;'QT
M?2?6'IPOVH^A;P>H6)K4V+>YG,PYGGSRG/GEDT?T)V91..]N(;&E>TG%$2NF
MZFPLAT^C.$>YDGSJA1W0I^O4TQIW3IGEQSK*<A0_ONSOUHE;KM1:!FCQDO>>
M^Q2D!7F\64//MXC<=8+JRB4\78'/8DH,P<;UO**!ZIO88L"5VQOHY1(G"BQX
MHV6O']_6T&`$T'8BQ$[ZO89O/T7V6\]@ZA,;$(>>NT043S/6UF1EY>SJWIK=
M,[X$F2B*"J*6-1N>@.C]=#R3CW0V'LLF:ECP)YGH^P'^229JP?]FTG2:%1:F
M+)`%/2UQ<1FB>SD<C\>CWM5H-!J;_9YI,B7/,X]V@Z7SZN#*A#0U[2(8`()Q
M?S2^,@!(UQPQ5F=%T`<`P\%@-.B-#1/^SP+FZ1'(UNE`5VU5@D"150D"159E
MF;XC(?)G,P46!17/58)`D54)`D56'4J.P$/E5B4(%%F5(%!D5=9)2)RKL-BN
M>*X2!(JL2A`HLJJTXC.+P&/E5B4(%%F5(#BW5?.V:G9_;['5O-W*K+H^9IT<
M]([S,%I"UYIOO_6P>TROW=YXSBJ!+C%RGY[QWR1<PW_G89+`OM[MS=*UG\+`
M]N!E)Q^1_ULS$G8^89-SHB?/[N(%F'&]?XHW97$J#D4D,K'"-X=F=V@.C*NT
MB9+$VG>6[L;?E:[@O==70(VHVV;!B0Z#@DGF#N7B;@>MD)E/<`0S-;.TX`#P
MB=PE!$?(D+'<Z!"5D8P0DY$,$)21C!"5$:;.OLF5:W(9;F#3?=O`EC7J=M,U
M95$^]00)\#T>LQ\$&;.KS\8A>S3:.*:MK!!?=N;&U,`_5K'ND;1AQ*Z<#0/V
M2-DP0E1&WF]RZW+$B^4$#,][D&SIF_OZ83"`43HPQ[,5!+/XA'M=Z6Z7<+C;
M+VXC>2(U4&B7KG(9MM2T*X,,)FTDR8$UCJDS8I:O(?TO',_[A`GY'ZNB!H"E
MKMN;UQ4Y*P-'6?`P"1[%P9>PGIR]3/-]^@9T7#7(J!RDV>NU]_:P\>=.9+%3
M38P%NXKKUN6[*2M4RO=LX=UWV&*=GI+Y(0H39Y&P4U=LVZL*3[\"3R\C)(+G
M&/YF!7_0D[`^CN$/BT%[C0AZ4<H?G$N8OTQ_P/-EF5.#":A3U^&1B0!:_AP!
M&$$%`CP/E^D`W%,%`FBE<@3@H"4"@%/C%<?,@QZ)9N`#)4O@?RJ6$&-R*3F6
M)Y2R*OP"_QHI+2[\'J5F$F_!T4LUPYL:`$>QK`JQJD(,,3O,M%(%\*9&!19D
M73DIKU<5\Y4IA`1=P%!J!,)`G4;D>26)N<"S!%"OD:G$.H0X!88BU1``CA((
MQ!`]1?FW1S$HRL#4&Q2E8`J!R\%GG!/4$ER&5(0!\"B9%66=T.,RQAG50""H
MBI#$&PQ5(9)B4!4C2U,8JD(D@:`J0E)+J`J1%(.J&$E,H2I$$@B@$241DEI"
M58BD&%3%R-(4>-.9$E,0"*HB)+%$_\0ALD.73=-%5+)^.A@>M'ZJO:X:%U)[
M54T3V#T?GG9/:><(MF"]%&FE\0Y$&P\MX]JI]AQ&[B_09.*=B`NXX$0ZWKF:
MN`MZY4MDKQ^=5VA%TWVGUU7U6B\@R=<WMIV11UB)J>0/B^NZUH:Y=/T<@>5X
M131*SIKZQH7Y+<_@%[<;/:01!"[NJ,:`TT(U!K1WAD&Z&TJ:II`D<XC"WBG;
M7:B:(&&*Q0H+%(O!IR&:-?HJ98[*R!:\X3*7-?E`E3.OV>#"#JT=,8F2&*`7
M=<PAU:IC+NS%N0UEJIVL:HLYD$3FPH*?(LL:-8OK^Z>.1,GI5.MO]Z%UW"VV
M<MP80VBHQ4,BM![:J4<TO!$D#4T0'3IU==&I<1\:^P[2H6`H/(AV@Z]0^[`C
M.>PXSX[F25720O/[DQT?/`[PHQ1GNTI6=D:A>CO:KRNT6Q\&191;&:XH_`/4
M:<ANG-I,MTKF<&OH5G'.N]HTVVMJ#%IRT$`JKPN@IT%3LR]9!T;(4?*.MI5Z
MJ@#A#ET=(F'U4%<^!.'QN;^-/GK_7T5Z0_9H([FALL"#^ZWWU]7B;OA5)>FO
M)_D=D#UH!5&?X_CX+12D:HH8G.G9D@*MN4]15K6:&"KK_^J)`=/UJXC/)_66
MQM*M31\BQ9>/6")5JZFB>6//55/:O-&2H-'"7Q'N(VQOD/T:*7[8*H)A9&VU
M^">SKJA*[0"J+H`)99.LH&R*`M51M`'$,57NX:!.&-H;09U]@=,DNQFT^FY(
M^R+M]0%K%^+AJ&)OD!VR5KTYP\[WM=Z=$5%IFUEYY-:J<8Y6C.UMPVXVN3>(
MOS.HV/O6\`EX\,3>[N^U"^W]`B-/L9Z!?CO?N![<]8^;VG@N8;&)X>;6:7HQ
MVTFNHU6L1F`?1FE!]=F65A$_,.M06K#*UI86L$^C=!^D);3@MJG6M"`39+3@
M%:4%(:`M+AB2T>)U/Q#4O;G/CNS,';$CB"R"B](J[0B:(S+"`]E:TRKM"(:C
MM$#DMKA*.P)"0LL$)FUIE78$*U!:X&YM:15V-,%PA-9`4/=7>^W(^RH>D!'!
M16F5=N1]M2_HJY16:4?>5U'DMKA*.P)5HB\3/FA+J[0C'R=,P3A!92SMR.M^
M(*C[[8C*>SSF`A'I4BJE[>`5T1&6%.)42JOQ7MX7]/(42VDOWK]-0?].J926
M`GI$(A,^$)>HL%&?UZXIJ-VIO<RC+N\PF&=$8,#3+1<;#YZY'^(3^]D!,-P4
M(`+A<5\A2L_.XD6;P?V\!2%^/F`:%2%T_[KV[,!.PNA-PT-?!3G>Z`-!<G\*
MPT)'/`7<%A$!]&?X?0/XZ00-]))JB/=A/&S3ADPQ%WCU8(78A@R,3M'P_H=+
M&FW(P.B4#!]4L7X2(?,A6&\*"_&Q%%.W"(F/;O#B+'G/X36,:X\BE!Z<31+9
MA?_Q4\H05,P#W@5>T.!#1/HLX_R6]:S^?(";OG,EXH$X,G>P]1`!_M=-0M2(
MHP@1/%XC0N313>!A'?DDYD@@+"$2(1S$+$AL111!&G^WHP!G"S=UMWRT0J+R
M6"M4_\O7\HD`3.\)_@((>U9`T0^`HI;.RMYXR6/QX40O7_^%/08'G"G[U@_N
MYS!A)"9Z^?HC/E\(9C%TXA!N/L;PS!KX5]M$[D3_]7XZ'-_=6\;%J#L=79A]
M9W`Q'DSO+@;F;'IW9XV[1G?V7U`9_ES*-?S>QA$_1\)^-@4.MO;,Z]B#'RV)
M,F$S\)_*:Q.=O$GALU,(`!M.@>1"=.+BYUQN_P<``/__`P!02P,$%``&``@`
M```A`+D,63MN=P``Z)\!`!0```!X;"]S:&%R9613=')I;F=S+GAM;.R=W6X=
MQ[7G[P>8=V@("DP!)$52DJTXM@]HRG*8R)8@2@DR@[EH[MTD=[P_F-U[BV*N
M\A#G9H`90)A'T:/D2>;W7ZNJNOICD[3'.0/8!S@Y%G=W5U>M[_5?JZJ_^+?W
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M?V_GC]T?#Z'.V"CT?%J>=Z]^<E9.Z]Y`Z2VOJN5D(;J.BV?E:O-]SR?UJ)P6
M?ZG*9?$<CM2]]PP1,KTF/![>-CS`\[]TQWRS+"6+Q<GU['0Q[5[]Y/6W+TZZ
M/P8!>5V=3^K5LD1LOB]GO65]\OJ;;]^^>'M2O/G]-Z\/7WWS]LWQT4EQ_/W1
M[H;QCA#`)>L_1I;>%W^LKKOW?;*WM[?_9._)D_V#[J6C]7(I^<U)N(G>G^SL
M[!_L/-KOCA&6]>=J.MWY8;ZXFA<G55FCE./BN*[7U;+[P"??+[H_A3'B=%Y7
MEXOERLB[*E<##/U+U6-R&.)/B^EZOBJ7UZQIBOG8\":[6!PA5N>+99]BAZ-1
MQ=-<'OLX&X8Y6LQFZ/G):C'Z8;LXN2B755V\7*_,,C'_#8^]6I].)Z/B^711
MKKJW?%U.R_FH8C",4KW)A!S/BS<7BW6-X:FW,5#3JJZ+Q>JB6EY-ZJJH+ZO1
MY&QRLVW9*`UE7?/JS[LS.RKK"[-T(_VC^MMZ\JZ<5O-5C\8G%W!O9U4M9\5D
M_JZJ5[(`O;N.,('+<L0:93UM[L6R&E6,>LIRNF]_M:PNR\DXNWD4A->GV[W_
MS6*%4MQ\SZLE/F&)T=8,M*!+S72[F%<]MAPC5//S"3,K_'V#=[T4!\(-PQ,:
MGFP4_.FD/)U,)ZM)U2<_,BD/5!>7Y;4HU!V?Z\LU\IJ-L>F6T6*&+ZS+%4ZJ
M>T^<BFD@LKTX*\;5686=&,.>=]5\W7MSF]0WO!^6X])71L7Y8H6NA+5L%^6J
M."LGRP*1ZK_@66<"VX7)>V1NF&IW)<X,PH-SE\4;)N8KN.$&T_"+Q72,2?G$
M1&5UW5<0MP:U6X/[>[O87588%O4[_/G>-K98_RMJMQ7E>H6R3/X.<:$`GK^:
MG2)!T?N;8.*]#K:+Q_O;GSW];/O1P:?VXZ,GVT^YZ^G>TSC41,8VZ$=C@6X;
M%H.%K5A-WE73GAD\'(\1Q<4</9+J[4SFQ:B\G*!775(C>^O9>FKVTC59(K:L
M+I`RABZFB[JGT/DS2-AD-.DIG;/%Z-FA?7<"/08:D>[R9-?>OL*&$YM5JPE!
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M?3LG&9R:+3XG"2RV=->#`LK4@P'-8`305B6-L&F>!<+BMGN[."UKXD%%(>/)
M=$W4V7THA);K&@N_6D#GV26W]9]3Z&)4:$;O#4741=C+^PZG>#QBS6@$IM/R
M=!'L0O>I;Q=X[KD)QK?*7;K7V_8E=_2OEM%[G\@QVBKM7\FD?T/D11"VA9N7
M%]AH=`>-CU'&#$]W2J:3W1]/2"I9\&%QPQ0W//-UT5E*][[C.>X2<Q'"^Y=G
MA$T#2<"K)2$NS'LU+7'W.)ON.,A0RBJZUW*O.>1IH]DPV>T^_#5LG\]EGZ+7
M\Z`CP0U[MS^QA6:X(WL08HO-3RO_LV3&3(,MRCQFL;XT>U,M1\I6N+JX5*"!
MVVE&[T[E1P_6'<"$;@=50X>D0#$"WF10,GL@:MYB"+0*;%CWI633-]"[Y_,Z
MMV?DZ!*[]^BMS+W#$S_F?=\@WJ.5EGVP@R'?V2?K)'5Q,EDBS"5L;L@=G/'9
M"[J4<H44WJ<Q7<3TK^X0;OZD(/^J(;LSVRAY-ZQFTS/=L=NKGN=)43#T/V&E
M-P[3G4%'Y#H6H0<2=&[/2-"5T-ZCFV@"?D%>57PSNYPNKBN@#_,3K]9$:"BK
M["3.^*<8AEN'_7&T>'3+[=D<N[3H/?KS^LN[)2V;Z+^]")X*LUCW@9K.5`7^
M@%Q=;<P1F@`<=&?RSM",+N4.QW]=!UQ(8@[NLYB/`.R:^(5?%<L8UF1A#P+0
MQ-?-R+TP[EF%Q1A-++WQR'TF,/'O_L.&&/@PO\>-SFRR)DJ?YQ#68,3WK6+%
M]GW=U6[R/-W[7@0W,Y[4EXN:2(*9-/C%!N@H1>$9=0S`L\5GF$:/4J]ZD-KP
M*[KP2W?:V?50"_'()'MW]Q$%Z[>RMOO0L8&)<J<-^[OW1*N!NY83N0L0^1T0
M\]*DU"@&W0D0[_QTZX67@X!B=XZ'(P+>VJ`5O6>2H,7!7,'(M!54X`'N</%N
M0M6H.+T.HGDS09Y/YH1@-]\##CJJJG%=6&8Z:45M&Q`[(U5@<T+8%L#:YXXK
M=-=\TRN:P'!0P8B76<"EH5#7`<)`XRQ+;K3CSN^NWC=A)V%@XUY##-J=>1+5
MG/(-/\[N0%\-L36N1N27=?5`&:_]BW^X$BCQNPU4/]J$OLO5G*;`'GDBKZ1N
MUEW&C<]70N`W/7FROKR<6J(""S!-(Z+A-8D[#]BDSW`&+"65/;MO3OB#0,3^
M17A0*7(V-+A_PX:WFX;.%_,=FX*7&4S(6<E=6$+NN[BRW(1Y%ZL*)5D5$S`"
M\ER3L>Y$\1"&OI<!9M=CEZ1Q/&8^!:@4HO0T^,U%57R]KJFRUO4V:5<]L9EC
M>FL>;9S4R7HV4]4*HIY,SN<4;T::$>F>7JN5O5I0,R)W[4YL?Y=2T+_V)4N*
MW2JJ?UY?DK)^>0\'6U?+=]6]KRAFKJ?K6C-8EI?5&M2TIA))`?NJ9*'+"0EG
M.9U>%Y(.H=-@#<#<T_**#(%2Q6RB$EMT%->6EY7SZQ`1HN+%G!II,?B:%R^.
MY'=/@"`--?_XX5-5OE4<OP)X!MZ87T_+6?$*J'W&O#4Y"L[;/K^M?_[C?X4[
M_OF/_TTNB^`<BSN;;]=ENY=@9;6<G`JH*>J,6UARJJ!D16L9J^`+M@M517<N
M4!*](P@G-^BOB_6,X#:@ZHJ$+M=+8/Q"*\^`28G%>+D^KU&4Y3G8-/+@<@!K
M]'^O^'^3AS08_%U@'`T3>_?X:[282KAI?X!I^_IE^9RI^RUO)C-4[OOJJGB]
M8!*Z>E;.)O#*1]`/#VW@U5>SR6@9BK;9"_]%+WO]_2&%(=%!&@!-2@1D)"37
M2,:B&IRJ*,^7E2GL[K"0)%F$9ZH]P3$;,<G@:+&D?N2*B#3]H9ROT<./'RBY
M($N_W2V83(P_5Q?(!T$3445"N<4IR0/H:5&OS\]!9!%\?K5*[':!F.D6,)U+
M!'L;^=%/B_4R_G,MF;*5\?M5I3]F50D6,BCT6D_B?.HI@2D;%/3/$`U-*XO3
MR>*RI0A)U\[4,P%=6+VLNX"^:$F#".K/L\FR7E$"VAE-B1*C-%[@?%PD?['R
MN,'P24B1I!6>'`B^.%TN2@JDAHA+6<&U\/7U;@$#3JOIA")#<545%R7_590]
MHX*+*"(94SJ01&`B?@\)B0KT>^+R+TR_-](3$:NFXVV%1].UD42.E=0-Q8<F
MOSYZH++3Q;EW)^#\SQ?S]6A:+5:$_X5ZVE2-NJ9T'H1OT/L4V".B%)Q017!Q
M20D+-9?(4<@VHR.5GP#<J5]'+B;9`']O[H3P:!0+HE0;LF<J<$$T$)H>Y."Q
M;;]"9D&<\1H\])(JN((=TWR97@5_Y_])%".*Q"5(E$LP`1D!QXR^3G4K;1--
MS<^GU8[UQRG)[8@])E<>!T.J!Y'?U61G-GGM9A8G)L-I84+X7>]C<.M,^/7)
MI"LX.,%X(1&LA;.1I)B;EW<BZ21<=3=V4=%\<T']<W5QK<;:594$V$(Q&P`G
MIG+XK\\2>XCC])1.6\@4U5J!/D5%:SJLSM!]`D"#!!5^1_.])/A*A&^'!;]4
M<GYE@?RLO"8`(DXBI)5=)-(F!`HQCGG\F-QT/(]I>M+PPL<QL*`$&?9D:E;^
ME03'(]*4(EU-5A?!)6(.8EI:E*`8)("J,Q:S-<T?T\D/=$K.9$AF"[*V-;@?
MI7ASNDICE9^!#BW`.]0"I:F<8J@(ZA+'4@"^^NHM=H<I?%.O)JRQGZ:_Q"LV
MN9]IF&-9DB<2:GJ(4$CH`L"P6(X-FK"5O-T]V2W.O1,%6\EE);RDT@TT@/@)
M(6/^C@7X<"&GH;BZZ=5+]3R2R^.CS%*6$(1XP1=@ZR=47<]";=89XE4_!:B>
M"&DF`1IA^0X@TY_7-#)N<Z.U#3I%`P#O?V@8!2`9HD0JA6()5O&Q;!K9<*9:
MFQ8DEHDNEFM)/^<JJ)'#8=86Z_.+X!^R-4)\KP@C%:*3<G4B\W.'MT*'J>:/
M4OOH7JC&!4DBK7*U$MVB1*\%`Q&4.0@`<==3'K5[ITY9F(B[HRSJ<*N[K&Q*
M6D-#]B!LS>Z!T!95O*9F`E"DZ;@\-K=(UA+1&]$A307!H$)[1@$>J!<:TW_I
M4HAJPC3+LH7;I((\#G1QNE*)(UWMK%18T%`S57$&<<0#TR-J.Y1KV6N0WNA%
M/WEZ[T9!#ZT;I4GIT4;"R2M\E/X;A_,>8<3.!SAO&E/.U9CBME4%)8CS=TEI
M$#[#A*3L9^(S-)#PG0$F+*XTRQ$E`!+?TM+E6;7ZO-C:?_#Q`PD(.(0U,5;"
MW=6:'2P3=UJ^)P*"`4+9^G?%U@$/C4GX<)6&YNDM(38T"7H(<06>0>N:=!!B
MTSNI[EJ>?<2SNK]FR9H3>LWKP!S.)N]9,$^.*R9)(YH:@']GE-UZS$/"1("=
MO'F8NH!0"O7@<QL6`V%B_)X@?8=DRF@4M+K;&K+U0/I:-C*$\S=RJ3`S=5+.
M%V>3;>`2./K?,%>CLCC\NC"8K?G)X#,)Q+?3\OWB!/COXH_*/0B;1W;OMR=_
MU#UP'LTLL;O7ZHVUL-%73AI-<R9VW?@7*&T=XS:/()P)%B)0G,O_U#*P2)I1
M,1N!X'.-2G!'L*?<(5U@X66(1A$TM35@W)+%W16&*1;[BUT2Q;GFO5<31&UH
MV#@3&Q;VY^-*4KRZ8S*V-8&W)4RW=S$S1'1F0F-MTB*+7@I\LP)$1ZCQ'KXK
M:L>V15E_&$(I@F]---C$Q;Z9IB?;B&(9?4P!:'MAZPW1XA*XUIQV>%U[.MMQ
M>D@[B'BU-"<O-0DJ)N*TYH]TFB4B!65)K/A45+1)UNM3/",>`#U5><N7AZ%:
M+JP8JM6BSN/%TAT=MRV"2^=M<51W?'BE^3FLU3-A!INYQ9R8#AS%K%B^5@JE
M.\5F)8>H];044T@=]/3YQ"T7(\SE7U%%!3G)8(C^8(?+\0Y"2*=;NL"03=>[
MU!9_593OR@D(YY0(_-C9U1`PJNIX`<MTLP%*HMDXL-PD8]M6G>FSQH80'EU0
M4+B3E*.$3!Q/UUA3$S>Y$:CE9.Z88]V0OQ<]"A8X2N>RE'SMF-:K[Q$50)',
M^4)NBSV0"JMAB>291`G7GV"4I)]$+'KRC`*,K55AQ4C+DI6(HK?1-9&DS_OV
M,/JH7HGESSD)XG*L5@I>SJ1;?LW\#!X10&5[2)]%H>8Q"RVTE"3Z,3HFS\7L
MR'PMYBB#F9(+X8B4?BUY0SVNZ*%$T992%8F6:%QA4P,],]J93W=2!8<35!2#
MX9N%D-SURN)K#UKD@+Q3>=W6:PG%1.'02-.)/D?U'@EDW_&H0*E%8VJ(7$-_
ME\E)Q.ZW@W5"U,:T?42Q1G\M<6TMHRDQ\RH,DUCN9M#GXZX,P6G369/&!)H-
M!$!8K*?:SJ+@+)H9$V2ZV7FTS#<^>(!$#)EQ+00QXELT.LRCQ4)&P0&$>61A
MQH*@R$-(>3@/-#2K]G2S%ZC("=:&&95-($JP1=RXV)_"BR:6L5=H2OEZ/+'5
M@JFU+J:20L@>9M&F=?0W[\*J/#V(I&A$/T6"9&;H2Q:S6#3M;@>!#NP-,_!B
MJW1+%/,N@#2F)=XF6LURS(CIMR@NRTE-%W)=+]0DQ#HL?+&'3*"'!0C^4Y:,
MF<Z0T8O";',HQ^]BXVLFO6#;VDW%&UK"XL&.C.QRS!44B?TPK1U7M@;=8#&M
MW1+-$'>C-DIYIL2&9D:S-^*-4DM&S^"%[0U3,&0M/U$1_V3Y#J*MR)\I85X4
M--\<!HY0UI&PZ410?#M4J6-/IX8(H;#LVGC"=A'<F!F94$3"P<IY+N9,B39W
MG(1JMLW=\L!#-U".+:?VS%(5Z7+%KDYE_(13EKHCK?)^&I.6#S6`J-/?/)A'
M$MPI;%M22N"K?YZM%8,H.TT5,<,=<D0\K6);CE@6$Y/MKQ4CL3F*L84',%3-
M]C&/+44%MC)(FRYPAEQ;8QN7(K;5&Q5Z=WF2M`5N*YN4A\GL,\:?O2I).RUX
M;=H(QI6D4XLSX6\TUQ:/=6$C!E*H*+#'(/UB7(15JXME3*,59U+LU)AR!M/)
M6;4SNJ8^X1/W`#68O_Z835**S%@S3$15FBS6]AF0YEK^]D5G#_UFEYPEA&(`
M.91UVS/9^>BZ\!Q12VV9A)C#-N@$QIFI66;F%L2=#&5>I7L6GL>,%#9&GF\P
M$^C/L$4@5O+88J/F$ZQ-IL;M@10N==YMH-)A0&:2O8(:1`OP7YL_Z[-KB:R9
MOE.$'`MIM.:_"5IHY\4WVB@6:4/E^,MIV,UL1RP(B`D3DH]O0K:%HIO,O,F`
MA-'FJJMS8`+!O`Y,$+D,[K-Z@=AH/4`!I^F:S9[%\T9,NG#0SJ-L"\"`=(5D
MSQ26"&_TPPT[!Y)K$6&M>3GN9S!QXV5<J$)[,XM`+&?6LF+J([-XNBB78^G2
M&#QNA/6JU=\7XN'(I"Q5X,X*Y]MZFX(_,4!654/9NT,ZH]]/V6_RPPZG81`S
M@D@MR"H,XT^$]]%N6J?G1H'+6&+/J-GY:4#"CJ_:E8'9[19OK0/[KO<76[3G
M+`R"0U]<0UD$/G%'N\A%!N*EB\48>``KV,Q;WJ^[F\.S"KW:4$YJZP(!#'>)
MV87R"*=B``<PQ/%%PJNIL8J.-GWZE<SM-CABH1XFH@<FBJR&6(FT-U+#KP.D
M-.&TS$!VLD`P-G$A'AHK%](;XT1PYG3S]209^]>3T`3:95(G]4B2%Q,HK`#-
M9FKUL>C5(<&.1%(5QM"I#TVF:U++H9J4TOEB&;(FF4FD64!CNBG9K7,Q589J
M2I:E'KY.WH818@^X)Y>6&?(B;0P/$J#\KN\K7D<#+MUZAAG;L*.S=5_+DZOS
MW>84N&+<;GD`_J`OP6.M)&UZ7PPLPPY%6)X:$S=9#B'DWM)T5JGJ$#J:1.1:
M[9;:HZ:ALS!5M*!`YV'%64FW/'D$MUG//E`!;60>0A2CR9+MV`(%B&-,569"
MJ-N)1')(*;`0$^*>B_/%8NPS2%BEM.7,T&T$($3H&Y#?ICV[U<>E>%(G/J@[
M+L,(<`M,'L6R4?-IA[XXP;@(`9=C_.U45[P<-V])!R61+D;\T\O$V`@.E+#'
M"U\3J[`,/:U++B5$S`,>]MAWH+X9VIWZAO<UF&#!UEDOVXA2V>_Z,\5WH#_,
M%%'*NEXQ$*#/IV)YRQ80;56TL!,U:KTTA0G'=:1V%?H/&_>LMX@``S6FUJ#=
MH63@RO>I^PBKBZP0[F,:$Z1B_ME_9_*E/>#@X"XG[NB]XET4?VESRY\36;;>
MD2!7-EVH"?0'1<=P;&ZIOS]=KQ$$RSW"7D%:$^=N%'",S%C>()R>(#48,I`2
M4Y$D5H_`>LU]R*AW^),SI'%;!';^A$#.D)&)6&BESF81*>/8IK"L)@+T^/Q4
M5](<O.)CY8/3:G55!=BJX997TVQ5#*M']*;FUP"5,?,-+Y>U8`)!3"*.J8%H
M;G9H3`-:RF4S+]G"8WJBQSK,ALWDVS+-IBSM%;#RSA,*')>UMPP0[`O"AN>-
M'1=.Z]W6I;96XW"TMV>(IGZ4C>V(AH3&>[T\8:().R67M@1J6(:L+U%D'V!;
M1.9).VRW=T]TGNL@DC_I(!(.2I!7[H:'AUY*-M0ZU010(6RZY`!K0F$#LG,@
MF/Y&H@FZ4!$4@2;1>#:/ZBZ6ZUK$AJ'FOL"]["9!_A!\E?O:@.*SHX!M)`+]
M3X'N3&;2D)/Z\V+_@4(Q?(D2>'+WM=D.U*?YBR;7!\6$\M,[<'36PPR1HT?-
M@\P)O=128'GS7(]FQ[3.KE%C/ZR$Z(RV;8(_-UV8,764$.`2ZMY_LKLGK&&J
MF>,2D!P_$0;!H:7-`@W2`T*OIGM<6U)L%07GGRW7:I3G17NB&`4C*QS9W_I#
MSWH)R=%B!6A!VQG";#,_(!FG2D$45>9''DC8XHMM*`N1C:P\G7'(I#*LT:8+
M0!="MRPJ\HC8(88-)F"$*[0\K)4RM^9@3-$+\Y%#8)I/04M55!R321JGPXZR
M_D)M_:Q'44&S<TRH`A3!);\!1*Y*\/6E9()(T?>9\<0=)H+AS.>1'Z=@:$]C
M&3#%N0P8)8E()(NB]H;9?=%!`]+F%ON'SA/@#0CM$)(?TD><"`WPB('UW2(1
MR+VCB=F958U]##C-E),`PR%45GD!VEF'O6.LY+=[J/(U21VU=(%)`?B."5F*
MKF"3;5M1^T68J(M(DH44Z%RB%>\-0<J9/]86`>>$[7$#$<KG`8="+.4ZW_>.
M)[8S[HUJ);ZK3J9AD%J2S@T;Z3J9>++1MAV\A@$=L\6R<_=X+6Q&57#II$KK
MMC]#Q*O9%S+EW*2:IIRX,\_M6PM/,+NYRWEKW#FXTR]/;TYA;O%"F4&Q;\SV
M?Q]D`5-CWA*.G"D<Q8ZE^ARN4]),]+ENGQGB8B2E4S#'_S&#V27E(2`CY,/E
M2S^UCT;**]=F*8T;]@2^Q*(>'WG@4<FMO2G5E5NOM`0DG+3QSW_\SW!TE7:C
M^5D;MIC$%=/MZ!<+<]4FS+X@A4WO0FVRX7'&I"8Q3#4EYZMV,UEZ&P(P33JF
M4XH$.J_4Y4!$"Y8Q0G@0/4'4W',]A]AQ82%]V;#<1_&2=/'&F2NLG>?<-,.9
M6O+1M89&6?=`[PD,GS%Y1^$LQX[!?(3&1<9R;?D(DC=#>)P"F-O/C>[-3J)1
MPAUP\58H97[N'L1<HB]S13+$ROZ\S*\=*8P^-5\27V$IEW8J*;!D%?)[:40]
M'U00UF9\%#5B\X.%FZ[ICNQB5\]1)9XP`ZI!`!-^@(L^0UW@MS#<M;4KG"K>
M-9-H8;X`XWSB^?T(J9S'%'DA;PN)F=52%&*NT4P>OJSX-RTJ!I5)0ENS3+%L
MG-="HY$N4Q)`LK(9ZT_\Y7PQL[0LH-+HA(H%!#$-TSU0[E(O,P^G0`YL@VRM
M3`#_D#ATX"LDCYV'!)U2>W?9<$#3O,8?(_:A[JU?AH9+LXJM1&VEUHK=$Q'"
M7:%*>-4;QTG6+S%T@WG%[L#M9^'4NH\?>L?6]73UB&W^+#+:-)X^0I@)EE]3
ME.MZ]>>^M1:T(+?,MIA+@CS\A;6)1!`)V4#"&RVB>-Y[&[4&O<VJ(%RU=K@&
M#6,Z\LO;/>]L<C-,!*.U#@VV)KD43L"TLPIUM!DR?3)W@L_6@M@P*IMHU-9)
M:EY]ZC]ENR2)R(#\+.8@1K)TC9YCB*D(^SJSEMZVY5F).PTD,VX_4MX6'B<=
M,2.2TTMD::]'`7LW5+F!&+'TIV+3\&)M>(^P+!L("[=W-(R`>ABZ4*>CLP$S
M8&^UH#47!C@V_!YXV&SLPU1X%ZTP-#O$:H<#%N:D&B*?"D.6O@?;8+>^P27!
M-"QW<PJB"J48!24S5%4I:8P-\X&\[.[%9IV#!\O.QF(08BO4TIVY3$T[2LNN
M,JYUMH@_XTHL<>8DN:K+LRJ8+P]!,68]Y7J5GSZ@(/A2K^YJ%6)D8::7BO-'
M%([:(XK;9)_CM(*FF+:#5.9'I<H?L0\6M*AYF)76=.8`CY-/GK'AP+9&&P-I
M9%1_K`LFVY#JRO"M?./U+L=L*2$)RVW&Q9BB7N057K;/@@WL2=-3%#$>6&TV
M%`Z$IB+P((JZ0#9PI=AJ2I#"V2R>/I/+D<VM'^P2*P[-SJ`/HG.=*`*/(D!M
MSHT7(H]8:>"#]*XSY9,V$;`[S(0$Q!9NG4KY;C?I,6=/5E<8/-8/ZI_A,Z%K
M``-WJHI&K[FS>*WC<5U+3&JTHYTXPM!A=P!C;ZT)M,9YAF)(-*6:IY4WHT\$
MC%=9-Z$][,"U6).XQ>JB/0%DIW\X)'<XE;C4V:%"<WU6+O.9&?9C'D`1(*/.
MLA2,-$6M:`!P>![).L.10T+!YM`!Q^Z:XDW*NG+)3TT;\+L)6P7<BL6W4Q.V
M6\*@3FJU&0B%S`.]Z#85&T3H7U4"Y2MA",-7/+8-S#(3'7!R]Y_2?%P\6VLP
M/A[6-#BZV<-0\8ATR985%N,,Q/9$`VX(NV#3M#E';[E2#S/$,R$D`S2JV1NB
MQ,9Y.SVC]"(W83VF&Z!OZ3R)U,MA2:PBD#@E3<5Q&<]=KRKIH"0$S<.HPITD
M[Y(B5XWP2!I%D`7E75.Z`K/3#R9Z4H8!Z[:D>PN).BP9&-4,!J9=/PC\SJB+
M\^'P`BE]:FXWGAL/A_D54[54Y4N1"*$T?1(EQ2EYZD3P9@X"BV.#?3!.$'[`
M/`63D34RIG[=:)$E@J:$"ACCJ!A(,#$C98]HQTV`"2->Z,B6%RQ\3+^VL.P!
M)^&--.03,-*T2,SO`!2NJ-;58Q9[N^,&%!6U3LUN*UC,I";T`J%$JGHSN2P6
MMD87==8'_XA+48\_M:O6\5%I5J9P##)(5JR^==2&MUGHU7Z=-?%;TZ:JDA`G
MZBGSHPUH;7VS%JKHS!.<V%`3F>AI>MI+U2+0Y^#.,"E$9$MF+`]R`P)?A:9)
MK8#%4E=P>]51OSP34EBE`WTL&D0PPWK($(<6XHF=/QG1<=D2#"D-F5?D(@O+
M;!I9;1*?W>)[+C;2!4[("15J2L,^)!!P#(Z#;=;J7-4='.YKNWV[XL!B!1#=
M_9X<'\66L#?J^++[7BVKG?3SR6H]OM:Q*:#$TR&QME)H7(C)F[P#`+$=GAZ*
MOV*M"+H!5U!*IJ>:T#-#;5IE'^7A'NRTBK*AQP&RKKFZ<O.N=-K1K-YL3-WC
MRJW7C<>@;WI7:T&BLOG'KGRFFB<2D0Z1$AQ@378V;HA9PS%.4%B-$[Z"H]<O
M4:!7<<>0X]VUZIA0RHQ#J.]:1Z+94/,>+H/!+!/!P7JUJD2(PA,6$U7E0(K0
MJCG]_E/+AAD:AZ-6A%J[@W%OS);$S]`D^3Q_L74_JJ#`_9T%I;9&:3]N6)R6
M+,;XQPOP^-9(0QO2L`T/#3S(\V`E43"J";?`'#O:)DQF:ABCA,?V@DIW"-E,
ML,:8%$3'I,K'-F4&9JIU)KYE%\&U9><IH44QLUC/^3R`#HY(\_!^(8QT<($"
M?N/*`I>7+/SWBRN5Z.P-,JK,*&S^LR0P7WHS`#U(UBDELD)F(1%::Z!]Q-.T
MP+5;5HAH4I&&PQ#+;*6_Q2P+783%<'%02K6%14K,];@25(3]*?@KVMSI,A44
M:.@3I8FV)^!5A._:N`0W\OZ.I-AA]>Q/0MA42&*H8.:=):(6'H<"C(6$VZ;I
M<05$-\%2Y(5?CQ<:J%YW69=#>"OO"!%S<<(.%U(:Y#E45#S]#SF*;Q1D$:$O
MO53*2"J@"-CK+\PVV2L,7,\^GE3GIC>D`\I1^I\@><DJX:`I@-WJEB3BM,@6
MID^NRU!KLX*E%0"K)?DYPN'%QJ@.A%O,T-IDZ0AH9_V-L.#!$OYJX7/6XT,]
MTG08?%WG`,?9@5-:<7-'!MM`,/ZA:<<+><8-Q:#*B,DU&X(L[#;L5T\QKDV'
MG(APE2B?69LV&.\4W[!R43;,0+B,1N!D)&)9OW2JE-.P9,C"GK4ZT+J9=`O!
MT*K>8JQX^D3ESSZSCEJ5@!>8@6X<UK[#0&E+@_$\SBDG73R(7<DRFA6\+<V\
MED8&VT#D5$OYXM)<IS$+V%:M53L3VU[*;(J5X*YH+B:I%XW1CY>BDS:E)#F1
MW?7Q]%.GNL&,>W42.UR]\N/5DV@,%15VK5&S&=&+$NEQ8Y_!RW0QJYX.660<
MH'WFDS4[EZRX^(%INL`(^0[M@.WE]8<D<\6XQ>)U[#2PBHO)SFVU%R]&LTO$
MV02L+?.E(+.GUJ]![?'F=BR<<;`G*+'W*[3":C'B7),DI"_+B#X(*MR.XI%@
MR8QD.6'CNZ4'R(B0LZDU[YOSX&^IEOR`26.801@\K,F<AB6*F!#"PO9J`#8U
M78LC1RM%!U+%;#8M!A((2)\<5^,*KSBK[`,U/X+V\BZM49JX?HCZ,MB'3:_'
M*W9/DP_X^>T=K=U\&-=QTR3QR&/NYX<G7\>4.!O^A+1I#)I8%V\O9:F(L7<Y
MDHSOP>WL\V$X9WYV$MN_\.BW5RZ3[O0A-LY`!Z.GK2AO:"KZVC_-X&63DC/E
M5O$+(UA>F36^M$49&2DA@6/G3LD9AU[AU=.Z`2]+$%[HSU`0R)\HOK'=U;UE
M_VL.H!L^H,IW,I^\5>.)N*`6$\FSC)OS*(1;M6(]=0*MFHY`!%JJ,9`O1)W/
MZ2MCF>BK+K#06>>]6#K]`A5Q<P9]S2E8+IC1-U;0];1N"/35GZ$$DC_!C+5[
M/2PG]3&R-&\"$T+"ZIHO!9GE.B.5)#"Q?$X](C*\"E9FR9ZE/GZU!X;[&FC)
MFDLRP&?_B25_:(:E#0A:Z"=G7<3,0B+*<6RH`6+1VW@I9L=^AL),N)G\7)QZ
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M0![PPUFK6@BF&C+5SN%UJ!\FZ;$NA)'9@?`1&Q>Q]NQ"YY*FEX0KMEGT_.ZK
M6)I`]6U,42_K4YA3"0W0?(KZXGP"&!"GTKPLB?XI1U2P"AD0[`,;3WQ7,*FQ
M3B#822\4T$).Y'MX_1,E@8.-B(:E]K_2]/'#QP]=C?V+*DR`'&.8W$+`NC<>
MW1!@9BSO/O;/?_S[T&N/[G#8=?Y&J"NT?_!C@T0R+T>KA;Y5AY7EK%0)%0J]
M,1X.UU@Q`L4??R5X,@S';+W$P7$=1-,_CAF_21`[S$,SQ`#5-(-]%6851.9S
MT`((JD,W848PJ=;]?;[/E_I0#?8WR#(?``^C#:.;5Y7ZD]M[ZM^QN8:/<R9<
MH1.?!C^`C8W)UTH!.:D51A>H(_1HJ$':K8MU0ZX1RJE9Y?;+++#P?1D^7+:%
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MW;.]#V#RV,</)O0/NJPYC"T`W0NJK'9_4\+D>PVZ5[Z)S0G="RJP?/Q@]9_N
MI4,+,?LLZ-[W+=T&G=1T]95BR?[A=$>A5T;=)[3%-RZV.^;!QP\+YB5N=2_=
M[_ZP=?"D^Q,G0G1_.A*"8OVAF#]$*W10=6\[4"`]]%IY-=_/CZ5'X;L/[F]Z
M\%E[I7KW[0K0'7T#+WJ?/MIZ_-ONH_N;2?F\V8#RG862CG5T1WB,9;[;G1@2
M2VA&`25J,A$K^CG4F2/:2D!]%\$J[SMWU+>!AB*,@V?!+(?N:K(XT?Q1+)6;
M@](\39HY\8"07WW4>H1F)]OZEL(WX/7XP8.8D'G#A10BC)#MA(M)4W-JP/#>
MG)06JN]9W5K9<$Q#4\2\.L1NKIB?Y(GMG!@KEM@^0O<%9*9>*V65^J:%(5]"
M5T&A`#$B'?FB(7>26@?OSD8;AP$:3\<`,S7PVN$`.D]!44/H6E76JWFE5S7C
M,@XCBT%*BK55.0"[(`6^MRR,`3I/4SW?3C&(U_1+0V8$##WTWWD';_M^XM[3
M];5.E5!RK[.O]._>(L*[C&#RFW9J&45VJ_21OL73?=+1B@HM[$<=,F-Q!F%6
M7(4G[%L3G1ZC3-Q2T>:R_'359/D)<Q&E$9C8E]<(F<@XF=.CUASC[\O7P)D4
MV/1G["N<X4M<(I0<8!465&R6]E'R.)#(0=+7OW4][]],ZNRE-D^J0R!B;!^X
M6>=%HTVVZR[AXB#N_3E`Z;"N,'7KP6YQT,57RX!ITKZ8UP_(E-8D[H6B&7-(
MQ;_`8(#(,G3><-4BQ8S+377@[0`1/)XR+MAL`UAO/IO)I#-&FYULL3S\<RRN
M)S2`WQ21(Y\WBH=T)1,1"S7MMW1J9)*SWL>U_OF/_].UUW'W24A9,4()>,][
M6B6Q;FC_MB:#40W*63NT6R9_4$1.,B.66ZDUMN?W367<`7/G^;!VO:*1/"_Y
MP*)Y$>8:\IB4E0<(,"[=N*D!,M&/AJY9BK>M8)?;@^K&"&PV-YM%:J]T>^!!
M+W`*L-P\BA.:]@6=(,P;UF?:)"/HGR.OV#VI1ZF!2YWU8S195E';L@BV/8\'
M>L`.VM@9ZW!!5T*#>FW6H8C:^H*,Z4B'0HRB<^!.I9U^2&%R(=A_::+AN[AL
M#E/4QTRDO30K9T3.=+@75SMS'K$TZW*\72YSG9`/]SF919"5<2Q[58TNYFR7
MPY@BBKY454V-)$A`WG@>-%#+SDUHWAWKA5C5?*PS2EU)F>'HK4E>HI,K1*A=
M@)0VX:1X(BFQH7MF&_L14?"9&,E61`2R;YOV*7K)N&(S0="XI1^>FQ.U]/B6
M;.1Y,S-48##;VF!9AG_N!:/&;W9K=&\_M%;`GB4[TI?'&JBK%_B_:,YZ[C_;
M`0`2'--]]^V+WK2,WF=M/W[8`(#=*!-^]`((!&&6`5,07K8^1EWJ*;U)!OZV
M)M:R>,QEP.'@7,ASR48E3-&W@NX]<'_:DYH#Q9:]7Q\18]V8T(J:'S_\25O8
M/W[X[H84XJT=Y7+26*`N7UK._-@FW;TEK:%[X>N`XPRI0X^;1ZF_I>FUR704
M;G3!I(VR=--[>T)/:A1:KN2ZI,-YEY/9M$$WC!FSW[&6V%^=-T^;2OUP3*+/
M?ZT'N-EA$($\P.9V2*'PTK#/B`%EN7>H*,0T*+?F+CVY>?2#(K#[."62*EJX
M;4)A/F&J_#JAIDRHIUX/0UC[4<&Q%ZFMW`RP"X0XN)5?"\&:[=D&_.^)4[C5
M]K!04:![B9DH`,$Y]+?9RX]G>1XM[%0`U%=RQ'XM[Q[`K9D3UEL&AK!II4WY
M'9(ZQ!>CBM8</1`<7$_K/E4[O4'2YEJH'=&:Y2T$].\/<$M^7`&MSW9@ADH4
M;K8U=YUL+YFR(C[,+N$$2)`?O+8!\2ZV]"3'#[\B-=PY?O4RD=AKSC"HC;T;
M"GT#A.ZM!KW1[.BJ+&GRS*O'5[N-L`NFEG,EJ/"&:&2D=!!O2-J0G3$I^:8/
MC%J*(D7LH9W:0D.+>N(M_T="65V;VAB(YO"(CQ].XA?]=-N!O8([]%CG&`-1
MM3MR?YG6;AG,,U&'D&4+0]/3#=A!56#WLX0W6^43!]]Y*VPTD30V996RF'MK
MHNGXAO9I%[$#W"AA"]/-_$_ML#$>,9P@T<.:5MGB&+L&O8J*@CM:8<%5\ZS#
M/*$?*D`X%J)TW1/*N>%L!7$JHX@1P4Q<@$=XTJ</'33[KEEN"BXJLNSN)W)*
M5.X_RHHNH2LB%<,MV+F]3RMJ]AVK$;W0D/59CDU$C3"H?]DV[&D+.6O3DGB#
MG2'=+F"<4NJWI7M\8'&]W+-30\_-,8-N8G*BV'-^-S];R5MVFOM-C$R#W&9!
M89V/13P-+#Q*<$TSK#[B%2('028,X>-NBA--Q$R)M,^&)(:IVS[HK4\__8U=
M_.S);ZQS0:=G8[JFUYRMIVV@.V0YR(%ZC[;V=A\=//';]W8?'^SWG]`:0E])
M34F9.MS69[N/_9'?[O9>X33*IA/69$8CP0ZT<X0N7)LI'1AVE$WV&!*HG>"(
M(-T9<R(TVM-;?[L9,JK7VA46G8HJ/28#3/:=2G5*H_!*T14IZHX^6^8[>Z=N
ML[K^P#F)OJX.^0;7)M9=ZW-W>M/;DR)N-Z53=#FYQ$4;\\URN9EZPP-M"@^.
MB\3:#N<KFG\O0K.J/J*@K"3H*X`YQ/*M\"$K%)N)8UB94=*VF;!(WU7I4IKE
MVSV%>K*K:3/&.3TFAT!V\@Z>01WA.,%TN*@DN1L@:E%G"4OQDF.JYS@&YWME
M9.4L-[6H0JY.)T[-E5MV@@ZS5+I!TV]_6,1GI$]EI!G=%D>K4G^70OV)??QB
MYU"]M)/>,CF5J+OR["L9W4M?3Q8$CL7QN!IU+_EKVK_>J=OPACA.M&K31,H<
M]I2UOF<!)N(3D-&CQTWW28Z;'7#\-?2YI21Z/O/_F+[%_\A/U@YW#/+Y*[5%
M^$=MXA?$()W!.'9")6[`NW5\#TP\0=S-")8]M?L"`8Z)$]SDI\V`%IEE+B7;
M+9`_W`3F=%1IQ[N8EFU<C8;!/JJUIDP*-HJ^$L>FJHDUR_$D6/;:(H[PF5P%
M:/MF.-)^2*)RVX!@._7.O7!E,5JTIS:!&,_YS8ZX!>?;5]P-4DBQ6:?X0T[[
M""OC8C73N27]C[9P9VCX8?V]3VJ`8U')F<=O#UC6E7]20]1W\7?V-'8KK)A%
M*.9M!F8V0N,C>0?692F.#QH^-]1\ZEC6>'VIM]KWBGZIJJ./Q-%LHH]:QP_5
MZ`M*0F/"3IYHBIJ^MI60Q?!MO:!?P2?EO9.W&$:02(279E-I0PK7TUN5NLC(
M26$X68?=,,'37*$[&+Y@";'W,%U>"4814(9FNT9%;7^VMJQRW5T5`\3S><,@
M/&<-.K83V;^^P]WSZIQ/O2H`TPQ'BYU\.Y,%7*GR'4ZREZ3%"B__E&5?<_04
M9\'2I\4D?]$R1#INNZ^-.]#8E#$26A2\D<29)H8XZ,>1FX^0[ASH7+'XX5&,
M&6!&\P'(P^DE(9E!UR?7\S'8`9G"<6L_`),F[])QM4JKD3EB&02'_C4SJ'#T
M_L'NDYA.@>Z?!8DBRSI(OUM'+]S&AEL'E^V7`;+V#K$83L6F.`QZ$$(D#M/N
M2J;P,#QP)[EKQ)TUF$JTSOTU#?,,)]WI1M1VJ#23%8E"WZ8U<X>E;RN/;%8(
M[,7.Q$IQN?+4_B<Q#*G)7NHIL^-T)@D)J%%L'>US3W5AX1_0'S,3Z&#SY0,S
M"YX$PH/>B_0E>@M.5:#H?63$XW/C37>YL5,W,#QN,4UGF*ZM`U!'3.7>6X8G
M1/U>2V_:`4S"XL=L',I3C$$$8&V-[`+D','F/-)D_$)B'H0Z:5:VB3M.E525
MP\DY1(`Y./`7R3E`I'">9V/:S<C*E&7X1I<--FUV>,<S,LB8L&L-1AR8"R/X
M%TZ3.A$`CP95-8FO.<:C&"0OXE5S+$4B;$@F!OD50;I!=<R/,B7=@/Y>CONI
M@O,L;F1*,QJL)"F9QQ;P500_1O5'>;\_AUZ@AJ!MJA!0:GLH:NSMJ2'/#;H8
M3<1PBK4A4A,WAL*_2_0W[CY/X\\J-AUH2M:J0YD>:82[!';QXW!$IFE3-[)'
MQY"=NZ3CF2+=%#TQ!FD^L(Y.O_+-8E&E,KN!EDNC6"ZNGKV3_*V7![&R/@S]
MG5XHXQ/&=/13R1/@2?P.%I>'CN=YR2!*M.Y"6[UO(%I,MM,\E`<3@6IF])NQ
M4UNRJZ3E7V[FS0'EBF(44=1+&!TP>>R#!9\&7+?7'K<RG.C;D(EC`U1%0",K
MS!I+7!K%NT5[,?#P>PX[)3C&@KL1&3,4#'+?^B3C9D8GM^W;T06R\8%/_9[#
M)W626R`&",'6`*LTT*3E.WUH(?BE1E*;$]D0HELF-U+`JL\/Z6M!C08W*@(3
M[N]C&S]^"`;*`VC)4CB^20H-QF&MS\U9$]]S5M.SY=I.4"/L=Q>K+X@>?_],
MM0^32]..6/OYI3(B2XL2R>WC*-!;$6)FCY(:0E-/&.\_RE%VZ7*RLHE'&#%T
M*]R__VGNR/2`'_X#_.HX(;!@;+)M1AB(+O"X,J0K5890G#C9Y>*:TY1404_@
MKNU-UU&0.BF*F6M_3DWI-`)Z9E.(9+AJD-Y3C;=_`/3L?87RYLG,`<]:=PZ'
MF&J('^4.C^?%(97?*6'>WE.O*[9RNB%+;-F"SAIG3G:@#MM>-#$#=8RP#<'4
MF3['!OX*C<:.&PW)0@,,FD4UP`97>S8MZ=XW,8..]"G`_UC]G,QF=$SLM&Z*
M<%HJA+:.@_<(%[$6:_``2+B_>XB'L"Y@RL4%^_T16CSW4?%NLB0-XJ6JAQ!Y
MR/K\_NA/9GWNR.U?JDVZP3FTV&M@CO13^</^P4&RVL;UF,M"U,1J_;O'VIA[
MM;%K!1(W2894,AQB*$?A$A@\N/@9XKH0'S*U-862#@#N#_VZ4=@;:?PS(Z\!
M@[M<H>RQ\N#EJ%^J*IE[)Z\>K]E33C@5/H6)#[D5@\:V;<BW*7#&+VW>(/KN
MXO05PV@<P82`7?QCF%W]:&+V7K*,HEG=W+].0.)KV[OB-O]8EB-`]`W&EK:K
MQ'!+\&^+(R#H-[UE'^&)N<40P'*CY%KF_"A'T1(H*[@`IR&[+Z3`HA<'EYI3
M7AMRW+(*RU@OX7"BSJ>M36TY4+WZBA@D6KL`2.<6T<H\L6>)>5F_!"Z5&LKK
M;W?V]S@01+&<]V)CV"C%6.1L!=1EM3B#Y3K2@`PO:^X/E9RT2P,&0G69UVB)
MA^WV""",\^(*S3"Y20XGL9,P;)9FX:$408\R9$&)V%BRJA0Z%HHP+2;DI<T'
M:@L.*;,:4PBM<,3DD3JNV\YY);G3F4-0P)>=]XO%PCY)+*\?:PHFZ$KT;1^3
M-*+A7JLO!:/3$^XAP>HB0!:7:MR<6?"">4+%VP1$DJAJN[[:VZNH'WOL<YP'
M2(>AU.$VL=GP](89W"CS(<S1ZYKOKR5>U(3Q)&/(AY;2MTD&HU&?I*(?/XGK
M<:XQ5QNN8VI`I*M(SW%2]'['``O`/0OK0P()+L\C_O7MC9E,2$L>/P+O3CED
MWNT8\Y8GC2:;M/+6@51']1N)S?VGG^4YZ8;$*-V]_X0=XNGU-GZ6%C4$-.V+
M,WK:>R8GD&>TS:.6V\GP6&XWE#J1-:ETTV10B$TW=RKG<YH*6^F34G3X+B2*
M3A=;O=BK3Q2@'A$E\2\H'>S]AD8?,JV.&&XNH/U\$.*-@BNK=AMLJ'L2RU,J
M_)\8HKC]LV.(V.7_7P"BUM/8[UN,ZT\&$!'L!&[IC4V1?]BR?%[<W\M,4`(D
MTE?*+0Y@&,LR?M'1;,BTI(^MGM=--,FKV2D"_K_LG>MN7$>2YU^E,'!#-%"4
MR>)-VMD50%-2+W<EF2/2W9@=[`=>BA)MJHK+8ME68S[L0^P#Z%GT*/LD^_M'
M9.;)DWE.59&6W0WO`(8AGCHG+Y$1D7$/8[(6]88L8B@<#7VA1K\'"K1-8F:*
M;)]6X@@-JUUQ:$Z4TA$25:P_7=03W0O4^"*.WHNQ;C:LQXKG_G-[ZXL_'E4?
M&^Q&>5D2[."2A<ZM>Z!93G"/24OB-M..N:[E],[P5$^#6)$<)[PUO5SG/P2`
M<V*KB9>AHFB'E>SNF429/D'CS?1.AB^+C#$1V0B$*Y&*K.^&ME"@`I6&QIUR
MJQ`7P?U%AK/6S/O1)!`7SF.F=`$V_/;YD].Y[KEV8%I`,?=1:[0HJ9H(HP=:
M?AHZ+RELPF!;[NB4AAJG1KS0M[<7RR"((&T9H9M3)*EB]+04*CJ0-;W]`!%D
M]YX2R"%V_.#9,"BYY368F2OQP]6E!XD7*NOHLJ!)SM(,."M3@4V9$::W!,U<
M<L(P&,]=#KAVV$\C#'\9R22B4IS&)+S_D$3D'Y\CC9*.#H3^KM[,_Z\DD45N
MMA;[N===^Y!+U&_'-K_KO!H_?^J^&]N?BLYZ/E]P.S9C_*;78]9O*S-2Z.8-
M_G.S;22W,B:-7*2Q1'!\"L:W+#7\`Q%8,!0<:AZ#8X=%_)6`H#A1I2^T=?M^
M!0R>O3]_-^=>57*'L6V41],40X9:^^:49!'C*)LP`G-C99'H3>-K#.?$/R9O
M>OK$9O+2F%D@40RH)^A.B?/9B()6J"QNP1EU<7835JCX<H%TDQP'+NS]H<7E
M=+5$NP@^2+(QKL"/("I=*CW$CH!2K1=7TY].9RK3"9H%3]E0E25)9>!@TS.[
MJ6+@(=DP<UHFANA3X5G[(&-T9'Y@<NW'KCB<]O3V^N)G3C!ACPN>V!74&3AB
M/"LYG<Q5L8/KP9;0NKJIVV25^:@I;P=-?BH)QX3>F;$OGSUL'4'M%O$ZZ``%
M*BM/R0DK]A*WG06)(,82F[@/D`?OYZQ-1)8R$TC\P>CU/?9O+[#3C>HR5,DR
MD[=)X$OA:W"%<U0IT@?3L75[,!D]\0>FC_PAN8?-.BIZ;$`F83KC%U5-I#C&
M0#4\D94)*<?`J$)CR(FXV]UT1_0.LGTLG,>>"9J0H570&3-?@&8:3-OFA"UG
MUSUF$K'B:$%EQ;1$M,'M3(T2P@!YS&2&3[XEZRSAHW&Z9J^%Q3GKL_94^!T:
M+-20,O*RN@P+5&]0_>*CCH%^1^(7&Z%KY3GYP7$AG1L&@Y0&\0,;#\E-2T&0
M3>V&<HDYR@KD^*Q/EB?(*76/[AL!]030S'(M52^:N;-K8#%AN#40&"1F$.7A
MI!#'*Z'M+UB&N\:F0_!%;RQQ'B,"U/*48A,-6O(N*'3?5(TOZR1T'V&XPR"F
M*1?KI#=9H^4A,V@X*7NTL!`K>I!B;6;G:YA*BZ!KH9/L:$U_02_OD*+:EIJB
MG,)06BR/PY-64QB,$:<YG60[5\Y!2:8BC@RCC`=D)GME:<8K1'ML*5#A.X;6
M*`WG6LE2;V!KJ\S)FE*IR=M/GV1J;6ZJO^DTR1OENU&^CA-K71=1?@CA8$DS
MWASE"-QKR]?&@RJ_M?<K-6/!M\M&WQCGT[F6)OIEX4W"@P]7%^N*N:3NZL75
M.UE/`E)F5OMDL==]<@-;%RXGL3^R#VU:(Q9Q49';-^M-K8#0PL$2V$#('QER
MX7^PUB6MCB"%@'KWK%O?7BW,59?80A-U)4TZ+8A,K.*V60VTSQS'EOD`.J.(
MD0?^(XR8@&^X5'9V":^0&:C^8+)H=EG^H5T!;4WL[ME!9VF20C2%["HMR]AH
MH9P=($-B##NV\O#(Z.3](UGNQ_Q/"SH[.#[:MZBSD@KH3YA)]4WX0E+(5*A1
MK",[*O@_4A=OO`L)+U^-6FR72\=%2B^C;.LR20JMY"=]@N3IO4Z$'T6-%GT9
MLR2*XMTFK,I\07%KJ<U>7EG%I/!7!N[6\ZE_Q$W7%DUTM5B@^NV%B;H&'?$`
MP<M@/:.><VOON\/1SL9P@WK0L]"<H&.W"-7U.@&+%9)&(O40!I="-!6<Z^HF
M=$TP/I1#VV]-B2<Z"SY22@[%024._B@%Z2-+(>C&S*%<A5:]S;0Q^RVDP$3W
M@6RFNB_UF>YPF5'MA/3"Z6!K=V?]@I9N*;*M)3M7J4X+3LN9H'0`+I64^ZM9
M%F;W&LM0K6&#(*SB@^=Z&5BR7DH>?(#8%A,;32Q1):(V>=Q):YDH\U[G.B.@
M8V#=^-)1VR.[B*D2A-&C-:*MXO3\1\45Z[YHQ-`FX<5\Z.&J32J,";U9B1H+
M[`48GFPE\<Q]+@T2M0XC-#;0DJERMRXY3\H?KA8+)'T\^!8:ERS"\<7G_.TG
MJ89W,A5QRK'`(<E6KA]H$Z>#;R'`']>/\00I1EK+]%]95*A*9M#26QK%=9^8
MDQ*W0B+=]N.MY-Q2",KI'2L\FTL7#_M;@:>YZ=#R34@@XSN%V5@>GBVB-8G9
MHY*T'7*D3'H6J)9(S]J*7FNMR81[?GAPA%AK-$.2BFO;4Z/SD&O5N`1U'B1?
M/8U@=.U086,JGQ)EK&`]6#V@3/>NBK\89Y0BH'E4T7&L5O4FYZT`K'9$GM)%
M3>$HY+;?Q;"8U;'HN;'88/[2`KLB-/.'M@:>74V-8BFOW&*WLW.*R5%!C*AX
MXM!?'WO<^TKJ?S3NY1!&"LB,>S$"3Y5^0-LN4Y]?%@C<H%ZT2[:I1PY>RW\3
MWJ)_<`N11!>O+B05E783&>?:I^X7I?[^4<^T/U(^:&A^S.)L*28>A>[J]-W$
M#ENDCTYCU61`?:#W^MCX@8#&/Z,%V)[QAU4"1X=!&[-`LI7/WJH\=9P]CV3)
MUP)3/0(4IV1^@>4_%#6HB:[[3#M)N)BDYC#N&;?8.^((>;,3OYI$L`4(5H&Z
M@:\!=`FXPL9Y]?+J%NR/4HM%520].4-KE_)DQ\52R(VH(%SPG"W]4=$\CV*/
M>5MS%1@CY:GSW*(A"V$CRR5O,93:9R%UO\L3A1Z0^<!DKE]F\=QX_"1>VG[X
MB(X>>'F-O475$ER4L00[6!XB'&FNO4:O2J?:?+R5?)-11,K+O7694%N;-WKN
MD$4DTP9Q];YE;5QC283[9>VF`;_%)BK#*:I3!F]D8NWARQA2VT).ZA?3)!=J
M02YY2:Q=V:J:Z#3KOX?ZF87F2ZI3?+F&98Y5#@^4@A.IF*C=BG!U:^[F6&U<
M5A(>XJ.0+X:5P76,]T8<E./'D".:JRND]$F4_\$]<,+:6O=^C(EO[.96(,J=
MS];T8/Z!WW#DHE%^4`,.T9/I5K$T#MZN<0>90(5(KG33MM@XVT_<1%IC$[I3
M+"L:/$S_U86R1,)=68SE(C1ILE'Y_+A,M45S7%;98)6#M;VVH,QUU7*:A")7
MB9/\L4V34$KF0]HR='V#HF<-(KW44LZC$U02FC1.A;OI'45RN3QA(4E=-5-0
M*U*M)U2W'GGF<;J).1LEHD.KAW&(DA1^)/I'/[H]XG^_85O=?XSR=$GO,*L:
MUBIH63)7R@J2^844%7ZY^V<[T>YX9]IY8)$WUW9@77]46)K,TX#-`QD4]>`Q
MC59`XDK6'*IN<M_-+\QOKOQBL1V')M+,1!(].$=0PL??Q9YA9HR,FO[.=@K\
M6-@Q"28.++WMWSZH;,S.OF.@D6A6:D0E*K$K<]&AL)KJH-)($XKRR@#A1O9D
M[G,-)^/?/7;U*X(!&$RQR$W306[TO/:WJ$<KQ,X=6AB&2Q1BR(/A_6;.GX35
M72L*XOS\5C-)<H:%W<4)XTXV,6-CRMX:+3)C)Y=-+#S."A98?+7PC&E3:QMS
M9YC8<DG=<J]MM!LJ%C?QW;.CJ/KK7%Y0:/)&W&"(VE1UP]M%QE_][1/@VJ1A
M>%&SK$:L-N?A'M:+S&VH'(_;(;08=:ZPQ2PK]MJR)SK_:@*+7WG-6!7$2`.6
M[^#6H:D#7H[TAF'I;'IY1]_S<?DZ/H4)K$)*",N\O/I%_ZZ*Q[Y2"I=Z5)+D
MQ[Y"):-R+"@&X7KN4AB'RIL(5W63OE<\$Z;-+4D4U(+3HS:%EA=:1YX-7,ZR
MMC7<VZKZ;:R-AMO;53^'YXL&EDFCYY"$:RA245'#9+WQ^&ES<VN)+<5"C$WF
M9\ORC'8GC[)P0;UUK*'FHZ(F#>K\@_19()7J7U>8?4B-DHFKA_O6(*43J?<D
MGJSRXD/P&980ET!L$I4REZ'R$3X[6KZ5Y_<*-]R$Z+?R.;[OA!`+SW^TM5M^
MN[:YNU4^:R`QZP16\[M"RJG\DD\JW."$4]UXPX#TEYU:_K-E1W]1!!CLYPGQ
MK`;6C@VS/H3DQ9@0\08!4Y;'$0][;:-^6L'?MLK:6K_<HOJL0CS8"2$88J.0
M+&@/C<NB1$%/7$4ER)\H&_H>[W_'M&Z@,@93#H<"112.66YI@>4<*I3-%@N<
MW>`.1M:A1)/NQKO!UL[VSN"_3=^3SC.]^5&^P`,X,_S_U2F/N;>'@P/UO9C"
M\DY3W8^7IVJW<_?1_-RB77%S2)G"B'(ZOR=L-/0M<`A`IVZ3(=34Z]AC(@1\
M*,>A;0`Z@Z^[N>=C/1G;IQO018/V)Y,1S4E2E*Y=%'V47#C"AH%;S!:MW8NA
MM<]O-')WLA;'[:2"=:`)_53Z0$5S$)62E4IC\WA52>,9@UQ':M<Z`>_",C$-
M,("00!#*#L(>^;Q^)D1;MM>Z5RXU#\[2#%&ETA9D9;AAXZEJP5;KZRD>;2"B
M4"S@DDY#B\A#U)KU/0[K3YJO,VCH(\XJ*=F0Z8S8A)8PLF4F-'<*Z7Q-4P,0
MLIP@78,?FA<=\)S:2MJ('WR`K[6OV7%WZ^SJER!M$K*2HE`G5-<%B1G183JY
MN.82::S"-K.,2SZU16-EE65\-NTGA-R)_"UPW7V_T!>E,:-\VP@2A[7!1(M'
M<"1Z-U-&#3]-GC4S3,)&&+L"NO4^[("V026_C&6&N1?G\CBS0417EPX0[FS=
MI3Q1Z];M207IR[F2%X)]%Z+G('PEC5BB0-;ISRD$N85)\+S=YE(/82O9&B]E
M[<^PHG.=,UMH7GS<[9L&K+).Q@=*4"C14>9H@1@DE&-!\#*\3VN%LSL2*'P/
MM)[<V31`[8=6EWK["G9AY27B,#XU6%?3<0G#?'OW!EYJ2Y,T-P'/K>W&O61B
MT6$;(+NA)^:C35"&A:-4,/7-%1AB!)@LXB&LV3&'ME*$EN0$8@,L6CUZE-09
M@.IJC*D42+?B&*):P/^$,FYF$#8=D*4`>'A"ND^;1&\1>PO2KD*%XL3P`?H2
M?8B&(RA1O<`5@ZZ024CD>DXPO2T_FFW3$7=.YT0;)S0@-M'J]07M0I,(7T@C
MX)\)S:CAD[;B8]@VV*%7+0[2#@!9;!77474`X*WFDGR!*)<\K?>2>)U22O+,
M,"PG5F.S/-AIJ+<E+YO7T;LVI]7T=$6*Y^5`29>"N(OVVG8/`*4Y&P7+L^HL
M(LWG39%<_=Y9(5=#FI!O,2[E3E/LQDI[NYYAPE>`5=0J[TY_48>U#\0\&2%P
MBV@^-0PET.M<SG3+JK!X83\G6)M(PB+G+BI$VC<FWJ6HQ++=7N&C!WY1<BID
M("Y9Z9;R-8O5F=+P^1/]'>8SECO[NFK6>((]RA-[2G$P*`Y-B&(E?T:+>V62
M\=X.G._5+4YMSW/C+XXM9-8H`P3*"9%Q5LDD#I)#N(4M`2SI63)[A+M8%!P&
MD2?=DHR91;,&KM"X]4RT5!1:"HM^/'@=&$LY3R+K4N(7I!$HV`4$VR37-]<^
MPCMY-'?F97R#16HV.#K]J'K=):B?2I!?\5WP1A#5;L6B13_MEC=NY%)B-08E
M9KN:O8?K<`M8R4O)2*'F9;)R91(,]U]:,GN3C`+;P8QF13D!F`Q9C6:N"!6-
M5W>K:Q5I#*0BF:3E-3(&T+0Y,W&W*6?&P=6[,^DHK3Q?+D=>VN>JE4=V9J$U
MDOH_?Q*@=#BF)90'8^QDO[S^6SLN/SEL=(JV9"]V`1.]X[B<];6&\:O862J_
MN\P,)6MN_FY];`<#C8=.BWG?%[\J^[\"2*[@&%T(_I7]LGV3N[*E%VU6%0I0
M.@:7&&K4#86L@O@J7.R+Z@6'4LAR\->S]H:QJ5`JZ,S:SBE4#^_B)"6O,*!:
M9$Z)D`+S`O_PJ'2&++I>A`!E4&9Z_J-D73+8X#'T&%':.JV#I8A94BX#308[
M&W^*)/032@&_X0B9JT.XV/SI_([@+'0%A%L%X!I1L!QX5A,*JBU+EP06'M$)
MP@I0?6`PN^JO-`=O;Z/;;>TM6D7BB[^W.;B/6-"M(Y$]C%@$:!%K&F8!EK?>
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M?_=0^_:^+."BY9WB/,#V\+*Z,9N358!D+=/Y72I5E!VR">J@'ZA`'*5S!(QF
MBXC!F+5NB-())DDMW#5<#;:^A8B)<Q(,D%K#->Z6J^M6!$*;V)IK';L3U](<
M\0T90-"2^!!\'IATICAUN'FTA^)-%FU-1K7XO+6M1FA*:Z%&INZST=(6I8X*
MYQ:YJ[6"?"BWM%1#F/[YU6;+S:,5H2&;%X^^=Y)S9FJ"#(A;4FCJ^FVY1<UD
MR&P1!F>A[SC"+I;9M=F8)NAO),!N?UVI7O8</4*BN#`I<PAW7%!9P*$)GQP&
MF"2)FD^_E*LY6P)CYO3$%5:*M8)XAMVN,^NTLXK^SCSR)W\8MW..'4=$H8S)
MEZ`YF^0^/`XND-E?1C/VKR`//I(=@8;OE7MZ<Z.M@=UO6%F8>P9^2T"WREJX
M@#B[P?-1HMAW)`7&YM>?/^T-S8:!K0RAYVQ*%1`QH0OZU)R;(&S7A179!?/'
MZU#LNNS5"APOYHGB;<Z!'2O$CZP?K,1>@GBP7Z"^LD8$`/$:TXX-74Q+-P+O
M>NN=6\'N;J=6R0)&9)EGD3FG-6G77:LQ+4=L.]C-06J</6*4%<DN./,2GD?Y
M;>*49#HE*H-VTB>=\W-V#:*ZZ0#:A!A1S0]3PD&;<P$]>;$P1DIHX&H._+D%
M[Q:CDGV()L542N&068&-')!56!7&6<,:)K2U+N$:+4^$1%?I:M\9>7E<8NBL
M(I8;DL?L6F%>J&<\_F#,L-&!*)9RP_*CDA4L`"P1D'#@UQY-&>PK'C3*W:N(
M5T8,H--[N>?I^@JP((6@,@Y#&B37?LB3U'=Q;/ZIHX*6;Q`2AH.HSH7GBT[%
MTS"]YZ?2Z;4YSTVL<&J_VP+'T0LGC['I8+'9)VXEGONQ96`*@N'';ZL?U40H
M+`^>Q`614Y].F!_;4NT"G,R+HBR3,>BQH^L37UZ7Q4#'Z(UE[7S0&8+#5=J[
MKC''(9PFFY8U6V3.R@B0RO=`I('E&K968#VRG)'!=_`".3\KJ^%A26A(2.)'
M*HH-'4!U?21*5ZC;,7(;'T0+$&<Q4YP,$1UUPF\+]BCG)/OZVO#:VMITBV+(
M!:T**<_"0TA_%X/DT%3)(5DG`%>&G/;Q%OW.DU',;I)"0M0'88_+[24F9=BN
MNK*86YMB;9;!7.1KL\0\-7D5N\2O!X*RRZ,"5?@66V((T.X6TUO:4M);=3AY
M4H$9I*X_ZF3:@M)$TIX9B1K\`!`R/0`F,WYRM9KMTRSUYB7H(A;>CE$!\()D
M0C)17SM))RV8W6<K]UUZ+A1J"ZWJ;U(4NJQ4T-#]+4!B`:!27BU@--S;V!J.
M=I\NL#6%2\*P&X5$9P)(%G`T9ZV-"2TC)-,W^7NRGH-T$:OOV[X+YL5VZ/J[
M^_3I\.G3?#\Y+87J8#^C4\MRJ.MS$2\:_S*^/;>L#@`G%P%]HZ^G%KD3M2F`
MFD)0-X?;3S:&3Y\0@=9TE&O@X!=FVY1X#Y8D&LG*XHOZ<(-::^%EYV$X&39M
M$D?85SC(*Z#0N3G=@AQ.M+K"2-L\R)@8)904C4#8@(+[C<6H'D_D$A5KC07F
M5!]6R)0M3OF/ID7/AN*D4HG@I"ZI>A>,Q-2#F[0S#$.$;6$B6[;`P)-MC>7=
MD-TVQHQWAIM[.\7%F".0O))?<1'`'Y!GG6I,`PDF;QJ-Y]>(SFQ[I\E.@S1"
M>;UJ]P+%%]A^C[P#)"`[?%DFQ6UO#O>>[`VW1KL9W;>VF9'GX\$+VF*&K;*A
MUGLH]LCRJ2\<V@JUB:*%L9+H<MQG+9ZBEWT>_09NOE'I2/6(E-9CP0\@`E]=
M$T]DU39_.KTB(`GM7FAJS20O:!+!*U9]4-3V;52MGD?5ZN\A;7$?":,68%4E
M7AU[/9.W:$JWT@/%J%YZH^=#PM;EBRXUHA.DCR:<NN$ZK>,2_*1^I4&#'U22
MED7W@-ZUM[KR)Q_D#I$8196A3+FVSO=/T_EI=V$AEN!<?OX"N7'ZD7IH+IL?
MQ9#_(Y+GRG</"JN2'/R&)&N5L>KK\ML38V`18'X$BZ!5?>\"X)G7L++!)M:B
M74PQG$AKO`1VXX%VIV(H'`VT,=G,]A#4=[:VX[=(`PQ4GX\K_,WA=\;2FQP?
M;ZU0E)*H+PNSU`W=3!R52EF9H6YY)NLYVX'*"H-4F%M6"BC<'>W2%^B%IW5X
MPAL#TN=/T\L2H@&WRL=_M8Y4XXOR^2F<@O(PY>-XC9?/33$H'Z80I?('+L*X
MF?(G.3W*9_M1SBI_0')!99I=G9<_6(F:\N%W%CO(P6=&[RXBK<+T_XS*C:Y5
MCO<BBC3E#VM[6]48!^()J)S?@!*78U6-^X9[%UY:#;LVVMDN1UQUZ5OEAW_!
MA`_2P15TRY_KWXA9\A)W!P65WX<]^MW0Q=#*#\0[?PXX-0A(-#!6Y(Z7QAB=
M(3BDB-'!&5-.7#/_DD5GJ?#WC^)",MS<)D2>@C1[=L.IM14/8"#]*0W:B(MA
M"<NLI)"IO^U%1J+@ZH2O(%FVH\120KW/O='T)'_PMHJU$S<^>\]VK%D45YSB
M`<2(XL*,:9HQ)MXPILS=H*.G*.8\G&U9.D'.UB2U7'3R-;?,VJ;AB,M22`1O
M*RH;J#3&Y8*J%'TV5;7TF[1/`?D=N4_;;M>!\BV;Z4(O$/U!^(3);AQ6"/NJ
MKN5_A6%__F0[^_RIQ;)+A'?I^/.GSN>CGN>;]?/B9@X47RWL[=7L1ZM(@C(0
M/'0*:"IG_U/'!)$!1)%P\%'5L\LO7\37?IK*[Z;4@]Y7Q*P':T:0A02@ZDG/
M%JY5^<,AA7CV-U'6?_FGS8U_^N;9?R:O'';%.7X8\TA/;E]R7_@K)U<?,#*J
M!_9;`DXF^O7RE.SHCV$$/?C&\I+OGOW?__U_A%2WW1#+D$WR@6)>X9/HIF=!
MIFO!%WE9U,(U)U2,^-_PU"P$-\=*YU]1L\H3.`U`"=9=1_*[`2CMHKV*/@")
MPE3&G"/B]L1V9$D`KEI8",6YF%$<RS5.?T55'LQA8;B+LN+&5,1*'+WY-T&(
M[X=7B9N_/ZR:%?3!*;T1BM9A>!RC?:EFSXTQ9(K'JI8$0O+-Z40O_?Q>=:!,
MNC5VQ2-I&:YH@^))S'<I-1M.[+PI9)QPN1D:<YC.[>P*C?+\_002>Z<B^A=S
M(@8_+@5W(Y3]_H`V'D.(O6..'"A`!&OTU'Q`%@]AB!AO-D$L832RSAD7=B/P
M/1Y\.W9G!XA[,;5X5$/.]U?0+=;MYLX\&_,#@19F^$@U*VS^-#[96OFM19AN
MO(,(^\&-9SYZ.A"\GUXPC)E1X34R';IX+3S0AC*!N!7-'NXN*0!RSN#'PJ^(
MOTP"G&9R0/2=WTL7->>`SEGX[W)Z?Y5>K%K)[IU;=VP4*A*,[Y$<@E\,S(_W
MNVGFDHRU7-D63$S6'T8$S6LP'8',3A[PN6PI"(6R,7C0+C$=J1<GH++0*-4S
MQC6(>25`##\B`3!>2!!F'J>%:\G3$04H46.<MXN'WST[EE#5M4-.&;?/M4O<
M@?B2OUBG'N+0HTE.X+D=8Z$Q(Z0%JS32B13$SY\6!*5+6AF\J,6P\N(^$=RB
M9MX<APKXLURN>U</5'=,&,9?IR1E8SN:$+;]$6L<(J;7L`RB[EYCCX,-:E\M
M64F:\)8SJZ@3K$?,CS0LBY13!N'O"),!-<(_H\8"%6=SBX9T'2?A=40RM(DA
M@12:F/+##N_9Z05TI:T"#M/5"]FK916)H<^8$G)CB<*?(TF3XX7MS./,<3O#
MS:%56(]1M14.Q<6@!YL[?S+./\<(J*#T\+*9\E/AH!:E!+U'D<NJ'@*2DZ<@
MRB=?;]TR@Q)&,WXRGY?V\7!AQ`V8MJZ5,%<3CCLO#!CQ;3.AQ.[(@IFB@CFU
MZ>5_`C.__OSIB6]+/YEZ%YI*F!*N6<K52/74R[A5V_E\XXFV9W[VB!ZW3/%K
MY@!/2'(P_35!1X%]%C\NHQ$PW7Y"C/!.-`W="RQ1$A3R#?H4H?YHL,'V[L9P
M]&0KF[L"EJDJNOWZ+8TP/[O$SL;J'!)]TV[K3+M>=+P5V2@\1^B&#=!KWTI6
MZS(2$J`&S:_X,L2(!?>IW:CP%T[%DRVX$)/^O[VQN?;CUPIWT$4'VA.NA"_D
M1G8\I4^$W[46T2`H#`<112@((1%1'(Z;9!_?"-EGZ8G$++M2P$(E6=T--I^$
MG'1YQG632(80RS-'R<_X9.1.4!RE7^@-)"6<&-L3.F<K\RLK*P66J%V8%]G-
MC*!4BY8/Y84#EPBA]@R)-ZG%#2`*6RGQ>O.S'[A<Q%04V@HC),7/VA&8C'U.
MO6).#]__)?$<@A_Y6(/KTY^_SIOZ9`NV(]%J+.!1PZ)SPZ5@//B1:%?)^>L\
M6(%R:E4X&CJ),&TXG7Q,1EJ&CREZ,@XW<DX1OYO)@Y:XI+X-(-@U/BF@MEY-
MQ^O881-].+T8WZL6`K>Q[4TXTYX[)^8O9=;8')EW<4J![A.EQ'5=R9>6>Z;U
M5.9F@4`H@#=(ETI@IHI'4<5OSG3M#*_.I4*=XLV)L`!W[4U@.Y@3_C>YJPP+
M+QU1RO4=*\BM?`C!6Q!A-<C::*-\=^UI]:0R;ZY5YM*U4?W29D=5E<K@N;99
MK>`$&#8@ENQ@L@1!?->AI@M@-5R+I@]):L0*@.^1?#*((W=0GE#\$"H1MPYR
M9.<K2P[C19PQ^S@<J"[).'NS'AUYE[UG;7>XM;-307IG^'14@V@TW!E5$+>#
MUI4<,$MI/7+``INXC+"R:I;-X<;3"NIK/-VL*Z'0K[[\'KH8P&(NT'#*GU0V
M9Z-CD(Y-[3ZI-OIG70T3$R<ZG6%K>^5\!YZX!P5E=FH@`)]@*,],G"AN)KC"
MRN]?A2ASBR=OAYF7KS9324YRO4@A$58:H'SYR&(T3<B@@M%X?7Y3OK$VVJJ/
M?VOW2?F>:2S&4J(V5KYA?4O+AVM/JE-HDU4GYU(,G(71H7C57,SO=JXI(76H
MV:/;%ZI,/<26:3Z1$V5C5$SIC;"8BPL8PV)-MZ);X.U'84>%<6\1M*RDK5:2
M%^S0WQXXH>7VX.MA*D(D+=_2:IF8R%;]H>!4+[*%2@P;:A+`2VB[][0#/BN\
MF$&O?'OMZ5Y%(VNC476R`E@]>3G:7Y:C[=KHR7"K@WXWGPY'>]6]@,IO0AP0
M4U60:"P<RW02K(S)#"/E#09)G#2`I(0%2LG5C[06T&/B#Y'=W"@$>ZYW0A8*
MLJ)>,K72JE]0U&3?`H7!$>M0$&:4UFEELT[-^U/0J:X`K_E!-(V*-.D:$=?L
MF!0V\M7H25[^N(3H?H\&'?://!^$.6%35BI("&FLN@/)D6E<A=?TV]N/\4A@
M=K2^[1KEJYU17G($-2-YQ)C5#%84G9%$8=5U\%=R12#$;WG]'_Z!_+_?Y1@D
M/J>EHN-SVTV!3"PF0JJ+,M.BW2BAR5M6]>C7XHH*B;(Z4!9/"*K6!PIPD:GQ
MI.P=>0B9#-3KO'%^>G.E$"O!0,IU>)E?\ALPLOFHL)K-R<)CM'J!O>$F:<U2
M'F+-D7[-S\[4HG84`MUSL-+Z.IE1PX+8":PL3:Y3WGJ\6QSRZ/&3]*1T'1H;
M#WAU__F"6:`#0^CA;C66,SR]__""9;)Z<S20E8*=(?02LH,M'(PR-[4!BU=S
ME&/=R[#3_6M4-PHD23.,A0Q..,\#DT,*H!HK6;"4DHX-I!YBY(C@7(.SD;C8
M"P6_4XJYA:!+:1L<#_PGQ/Z`'V;R",@<6MCE2J.()-21H(!:8&LN&AL5:;$_
M3[@@WU_=#,Y-+`K)"QK,M#MK-`J\Q*@QE,]GL%]8N'[W'J10D^C$U^38(!B_
M'8.N'Z272[C<?/IDUXN=\>!KUV&U#LD+)#.8;<SE`9C[-%)62K3HI825`!=6
M:%TDM!BF;>K5^*[%3Q(DE'^"HB7;LEZ7IFZ>%[=_A-'81V5/,918HN8%((=1
MFIQE(<U\DID_M><@BR^M<OBMN+?E\L=$&M;=.UJ)R8>1BY)1XRS2VTI@0.2D
M71YE,3?$,LM"4$E3:Z/JED]#@@1`VY31%4;B,Q4JP@_B2+7*;KI#7/`($*1!
M!$CB"Z)O\QHT,(:+6!JVA`0\.:AX1KN!GK(#L-`:2^,2*]$/4L^$%==3&:7`
MDVX9Q(.C9M1CRBPYDB6ZY`RS=%RXNTIZ/LM1-G`N7[,TN_"84#)/_$.L82'^
M*$P_P-0*MA`S9W;EZ/!H3.E_95OPXVS!;-<Y1QC@>_%FI18"`A>`&^YO6RB^
MS\`Y_@4WOA@R>C5F*P$R&#)58<)/7?Z8'^;X\ZFN9^AFCGA9%.T>#Y=@17N'
M)B0*"C=J'A4*VJ6S9FSN`LR1&D0U;G",G)+*PJR93R1;*M8C/K`U94^#^<4\
M5\;VS!_1:Q.N@F.BB"N,2VM#..&8TP*7+P[764G#;]VQLWZ$P^'CX$3I8X)"
M![7*5[/ZVZ"#&_D,?"),<&VF"&/)5536#;F1E@<2(6EVT'B>V!"C0Y-0=:5C
MPIO.Y$,5?V6T6.-(`*@;*(G#\Q+V&-@(N'D!`N'%E9X'*>K7WJMV-K^YL=Z"
M&-7!AQIHAY,L?<1E"HQFH$G8)Q*F)8Z9<8%%Z)[;SY)CWLJ\+5IXQ?!R=6HY
M!UP`7B)96+X?0>1)\8=2"?76_O7DX_4IK2;L^U#'[_,G$V]D.X>EQ)PUR"XV
MWG!Y/,O(W!RLG<X^?PJO6LRZ4L5MD5JUU>_IZ_">WO+OXJG9J1K0C:?X@9VC
MX%+E*ZY[W6RJ[-1!U7%NO,`W=B<);/,`G:;7N^'!GT^OW^R?R_+RPUP=.;V]
MES_]_.E(M6]`DI,4S6#.`,!:MDTR7=N8C\FJE(85@B*JB-#.+)8``<C<@:!O
MZM\D+MJ8_T$J:TYIYQQ65B_!CL]M!/$04X&M;A2VQE&!SYC]E_RK8M_$`Z2`
M#9$2P0RV"K^"E8E"?36!29G`(J`P-1FCS<T2SR@V+/808_$`8Z'-MHWLFCID
M\D[D."M$D%!HPAPT9[ZI"3IP2G>&1O"(1'(WR@"O$SY5W&D%P<@E(?';1@00
M_C6:8^"]$`;_B>JE!P(*ZTRO[R1FH&4I+E)^-)&\^(97MFC<.<?QMX8VEQAP
M_Q7]#"HSS]^20,$T.%JZ!&`6)!R;WZU/+]=OB"/`;)`V8H%40"\<9LG3CZ-G
MY5_FG,CX%G1^F8[@.9'AY0>;VX])P@WQ"'T?#=:^GYS2E@%B*,+Y[IZUSZDY
M[ZN)]N+W=HAXX`S,O,)C*>4"OG#[].*'^<Q+-4>U'7'`XC/$!J8W<&_HEV.#
M$^!@$I.2"5IT+M>3Y,53M\L:;S76R]OZV(_<9'+]:1?F%34OW9+$UJWHI;5T
MQXT7(`:#93Q&E=IHM&O!`))1P"/W&!3R=4=POD:IX_!?,JQ6$F8S;Q)`*(_E
MM;3[SY_J>O%BZSROK.I9Y8/ZQ^?`2IUDN@9\*QUG7ON?ODLVHXA[Y1K7]H:C
M6HSGZ=9V95W&7K^YV^&YP0U1V-H)1;I[]BUVT'-3;\V.PE+<$>Y+Z(A6>OIX
M:^>+QHBN;09,9[*LH]4:9H,*]CS<*&SLMHOG5]?6&U9J^M]Q'VNCOJUL%+"_
M>\96NKQIPU'GD>X\K;2XM9WA[I,"&`R[.WRR5YB3LX.6='/QCP&LA&'YH2/_
M=AFK-Q[OU8B^N?/X:?T4M*G<6V\JM)`"*O.&84W62`@N+G8T5HY@8&R)?]Q(
MED4"Q4Y]HNQ#7H1WBL50T+=XFW$@I?69TJXP)UV?JP>W7?;)\!W9JB*G\4O`
MJ#54,`DE.LP_KF[N_2:R1B4VYL3SPN532^QPO0:CD:6>6\Z/8A<46*`?+/RJ
M*5/W-8]DU)?\(/&<&U(7.C*=-4``--&Y$6Z#9EJB7#!"<*O+^A2+INK+=.E(
M5=",I)')%<1@`<01([G))9,B&$0VE&_?KQ]U%V_,-$'[T[KD][/%N]D@B"`$
M&6I*DXAE0I"IUV)TBOV%LB6J;7++\I#CLGP7EH,[).F52,O^9(8JD'9'\#!(
MP>X)AOB5&^5S'[=AS#S"7(&_S+;S3M)^RC%IK&0IWBOLN=-CBMTV6W18ZL5X
M0M$FM']`V=H'R=_QT+C7=&*&U":EGJ6J%I:_#Y#ESPLBQ,(EE#?<<1,>^D+]
M9"LS%L2.")%B2+M>$IOK;FF+*ID7=]UV`S6L\/AT,KV\PD*0ZY4JJZG^8D%O
M,[$$;+HS9;`MC(N=1@TYZ=LZ_5"!7S)R71`V#P!R81VHZE7_2C2'>TC9:L.X
M0N,:;O*]N5OG\(/:PE3Z\,/5V_71IJS`Z^?$)JH(*`K!F?=DA@W@>R<=Z?26
MTJ+B$.%U<3J=4FKNJ]/=OQ;=#XX_3BZ0U5F!QF?@-.["X=`K4V"[^B^(Y4$D
M@*EG&/"HO:S1YC>CT<AHO7NPR)M3+#<P`!&E[&*UFJ,8'5Y&L-&'WEB2G0AQ
M4XHCLRANRW!2KHF,.\Z%1-4.*58<$,/`?CN^^G!FMI&YZVKJ<MIXU06N@/+E
M'K7O!+?<D^U:D7ZV&<P)I1P,)H!CAI#SZ&+#-:7H&41OV1LM<-7720G[J$`9
MX\.B.DKESR-O)>6N>1;;GX89-'!4<Y@:\(5]@V"00%7X.%HZMN(2&YRW?7`,
M[D$QS\>IN!0V/5MRQYZ*BBM8W^(@*<B,<P/SK-%M@J.@=JN2C.)5'V5!AC:5
MJ@\`Q;BS-I[9D1H.WA`WPAUIM@=N?VXAJR)6#^&64E54U\5QA=0NHF9[72M+
M!;F%3TFJ@1O]D9HS6D-!F`6=`,=XU,Z%>JKZ8&)4`*0I=PT2)?0VOB5&DYIT
MGT_7^?Z#PGAX[L=DHP41!^!E4B'LN\1&41I'R?F;S5.#_UJN;492QW^['V8Q
M%#6$*&\21T%CL2<;\0(,3%N(Q,&[=QPLV;=^Z,;UM$0553NE]0T,7=)4:Q;(
MK*L6$@*8/3XW.<.G$SE_M?=X=R]P@JSR30HOQA[%)WJ1XH"I9$DE-9X`K&^#
MB7<XD`)H6ON1B[=N1]#9N<9N[/$XXW>*T9B[I'DTY?*3E9YR!/ZORF@AT?N5
M1+.C\>W@V,3AM1.QAUGUZE%&G:;0R89\G$I<J^2Y5XFY`(Z`#L=&%*NUZ:@#
MIADE1-J,I;!QB)@2S""#OL7DFZ=6W=WZB?(+LR_+05^J-*D"<O!F$_6`.=R9
M4=\$V?O_]0JRP@KA(O6^MT[3";S*PK#"H,@&=X/L6S#O;;+OV%F6"^-G+M(\
MT'*U8?\E66DZASV6E1_/YCD2@PLKNKL*"SN8T7/8P1CB0FS'6.4NCF)7"\WQ
M(H9Q>7QDWQS9&79_7DYRF&+'*$:F!G8KCU]]60Y]`)?H[9+6"Z5L!R\]FF'?
M0P9>(^0IWOR5!=@<Q9M/4D)C3K(?*TGZ(`NDA.8O+8S8BY&L6HNT=[W:)1CI
M$8YO8>PI82(L_["GWHM_\9V+9?M*%^A(>A;C:J*(JW!'W0G.A8.P(1^;QOG'
MJ`L"1LV]K.-L\'WH>/5B1CP39-2B:*17*Q3@T-#+DMG;&?4!4D=P?/WX6AGU
M)<H=>B#QB6+>%YU8C&QOWA^L?1M#VE]X,E@Y=LU4]**EBLGU[)';,=(G&Q@Z
M;"*W.6>9/;I^+N<#L>(RQ>HCUK*W0*G&>S+&5@W0V`SV4_7A[_.0#HT5MEW1
M3+]+MA>P&>DV%!F@B1HA/T@8E18K<@L'K.<Z+=>^@M>@A\OZ(GY'H_MO(%NL
M8Z[`(8**9;@"BPN^CK7G8[R>UU_C,SE^/OBJDB<0&U][G"5\?#Y1RESF3U24
MI>42U=!^IYN[?$P9ML<QPJTR,'YW2U?`J[^Y[+2?R4[?0<Q+9*=_>X6S?7!(
M)=[9_RPG_:Y)FT;@OHI]$PR!RW>][I`DH<8K-QO;7BJ,"M='.43KEDRQTGA<
M`INB3N-L3(`,-@\DJ/+K1R$!M'S^VG.CRL>/=CSEJWR.%PWWETUAGOY62]F5
MUT+K#8O^N-?HX$E,DDWIX:F"4K/WRW$YZB-"=CJG^\UDVD'$_G(I^XCF9D\M
MI.<7OP37K;$>\=,YC#H8+EY$PVLCI2]"RWQ7::ZF$+/Y]4'6%"V6&<"%G_8)
M,GR?MZ:)=TJR?+.N+\,.0H&O9ECY$._#):ALVL\.CL_I7S6GEA_DWP%:][F)
M342=91&P<WEM@HJ$=3P4@<N**I18X!^9*=:U0BE#9KC5`:`0M"S#:<ARF.P2
M.^[4@A(:]C/AJ&L-%FV2.QDKVM]`"IG&RF7HGO84`6(SL"DM^%VZ9LV:HIQ%
M`$+J(%$.<I`:^CX?GV$`38IG^>*CT0`Q6]=)^<M!4[/:5&J:BRLLLWSMT6;O
M`(U1Z@A#RVWY9:;X?5FE<>DY-C/+9$#F+Y:&8VM<\6=54T$('6;Q#Y(!3?]%
M20_%I!:>OJN\H<B[J;C-.9F55F;`$,1P)H-%"9A,\HNUXA\RC!7QDG:)(P49
MH)HFA\+A!`[*C?$*M_[UH$J,7/#JX-^]6MB#)JIDC_Z)1IIH5:Q>,LQJF+UX
M$*.K[)J`$WW_^/CQX%U*$ER?(>7/\*MR>#T=Q!=/(04T6'67$-`0O2,_P"T#
M5L,7WQBK1;.6L:I$MUK]R1&PWU13V%3N176=,]3FGR$!A5Y`RXSPMDF9B'(;
MT"):[(?O5@F%R`>P2,6XEUX)><&[U;C-$MJFM`=?_9LHR).[]S,OT%)NHV>Z
M8698D]'IS53:HC.AH5GZ7'RR^$?:1'`Q+X)K[S5.<6CE#TF-A^O,*UPSZZD)
M;?HYB6PKW^&V/1M93OQ@@AA2V%@1":HMUYG-W/.5*KFAO.(WDO6O$Y+U5.X3
MHG\SM_A%^<TR0^!2&ME:>+A$:R&G;7AB4CDW_JS^'PD,2Q)>A:+YL!5'SH>M
M?LR'K7YL`>/%+SB'I?0>S#%KP=86XE>'#;7+'OOOT<4',;FCH@3*R@/1IN#!
MW^[/,!\/_@=6IO,J4'+E!7Q[1:_,R>#P8GS^P(4\F*/DUH`*.9Y+(IAZGG%S
M(>7F@5<A)#T%N9;KQS`;'9[E3P?!P5\^MS9UYA,M?ZG7@%T$G1ZGZ:Q\]XA6
M?>@M6"3B/.0KX#'M?N^$/DY+WKN=$EO+?_`_E1KJ'JU:83G=2XR[=^^QYYS?
M3@=OW^P/3BQJH%I^"_1P;?7NJ=@4(?J)LBL27(29O<>E]2>[]]$<7XZ@F%Z?
M#0YH7E_N2?9Q2RV5Y?$`F8=4ZH,LE;1\_\WTIWYN9>'=B$T'K6!QW5M+<>TO
MJ%:`2:8`]-4`XLFI>LQ].+W]L=9"7I%619&X"\*%:#K$/S[JPR.&0&:&OZ@Q
MS@P<&KPF.\!<QA_+O33(&IA4%-LBE?1C:+9#_(/[E":BT;/[VL(U3?Y#BIAO
MO]+*O5G(3@\Q0JG#6!$Q$6(,RNU\?\,%S=[#SUU1$"$M-,3I*;Y.<0WF"5TV
MFHK!97$5,>"$$4(EN'*`>(W07W,Z?_>^(T:B^F+Z,21<H5Z!1N`"ZF=69TBV
MFAE*40?%!0_2+5Q/@1)A689/C$'@7#G9HU#LJ7R>S/K-4&JM+LEHA4%WNRUP
M:.N>!D;JNPF!Y:R/,!5V_X*GFWA])3,!#I25QA1XZN:*]$O$DA[T:$RS;<P\
M5;I@++!=KBO#<Z87:N-B]T2FE+;4Q=T>94UWRC&3DT9A9[ZEGO1V%?LJOWZT
MW0WBP/W<]V;1$N67]1L54LB5E<4[E",T(+PX_4CA#G(000N/`3.6[;($YJ,Y
M%<0FA`K,R'LB/#>D#0T)S/Q1X;6$4,F2%9JY71+?IH*PU`NTWX+G,$;&">,%
M)GUV[CS>=EFN[M'6[@[98A\KZH#'4UD,/R2+S0?(,DR#U4,<+(255J-O&MS+
MQY'*5Z"-'NNTO+$0^PW.*(Y-T50`KKHN77.)Y9;R790KRM[L4@\R:V++TY#<
M^4ME_?C9T`KAZ<BR8("%_#Q^:9]DK@UJ`==VO%>>(BB`I+75>[7H<8I^QF`$
M&_IX>GE'M8\*B"_GA#:KL*J]]?+J%_V[0A?SV*O1S."08J281>Q>JZ>V*&6P
M"L9`(`Q[@R/4VVCM.2US2.WNN\&#)5]LFB!<J-HE^.>\L%QI=N)5A,32PW9'
MT/HK'!G`HPS-6'C:"WU(V.PZ3[V:XE=":LGZ]TTV:^HL+3(>[!?WS54##73Z
M<65ASK9BO[/E_)ABDIO"6WXAE_'G\35R4O<EN/)0NF49:EKBP#T'>(]QX=<-
M<8FN\"M'`.7*$72%]0?P/)B<NF-T9O_KLCK37/ROM);OB##D^A0]9LSKF*H)
M]]S(<VI-DDHA1K4((9N0AFN+0!JKD8J+0Y))AG9AV7(,JTI@/B+-;V^]SO0I
MA_7K&#%<\HJR$^!X0TO+7F6&G0?.H%LP""-=TFN?(-F(*+YL2Y&(B0!(PJP>
M*<#@5<*C=]_VN;OQ.D7I?21("2B7IXKP2Z%.301`YW0GE%=`VL!%B]#1@>OQ
M]^8.4D9"=UV\+#@C?)9=7>4^%PVL-%2.&8&IT[;X5O(1:"8)N+HW,\VACMS(
M+J$'!]$MO:R<CF-;LQB>A_O`-=-%M/3H\Z>Z54B#$3XRWC4/`*R&?CZ'W*Q<
M70EM%\>\9.*;W)WQ\-N?-)K'`TK**6&WRLZD86DT4&Q4B7GY8N0(*A=KSJ'#
M)OUJ$<1.@O9R7OBQHV>\'!M!Z'P\IIZ=F=&EH9C_$KHI1^CUA.?+GQ@L+3W(
MI/9.+4R)S.MUVN=?8"UP@<P+UNC9Y;)]SIA/52U5727-7X5X-$F=V5:4SXNH
M@(JBZOV:8E>I;>C(5,.T0!VG7432:J7EQEX3(7@K;N7V`3$PP;1\S==@^^\#
M\<YZC8;ETB-6(`/=+?3_-\Z_HP?&Q3Y8#-@8O%[@H3)OP\:>%ZPIH01&U9"[
M1NP36(\MDG01+4F+5-T7U]YG-Z'Q_2(T:J!C'U'FPKL+-F7/RS5*>`(QPASV
MMFI`2?LL7UU$J\T@Y5?-W:N&G;9URQ/+0E[Z/XX-^%+,E]L#A',+\$6ACO?M
M3E8NNZ-I6,KZ,N[4+#JD7'40:M;5XR%M),HU16BD-A&U?4&8!8+H+G:9[TO,
MFPQU6T$345'X+IN*VF,KL*$AUS<Z\W(?F7=HE=>CP;?H!=_U*:;NSJB`%I8[
M=F,_3@RQEY&7*U]M*0T5&I&7@WRO5A+>);G\R6ILJ'I_^4-K`X&H$<B:*/Y@
MQ$XWJ.G_W<T.RK%]TN@:Z9K]J&5PMH)'L9-'2KO+L:Z<H6OU\12LKT:3*-6Q
M]WI]'/V^"\DA6S24*"\[9)3K:._C4@%GYD>Q_FD8R`O"+C_O6TA?&XWR^P`&
M0PI"&++3"Q+D891_^D)(92KB<EYT:W3!NJD2*O-I0)7.JM^^MI##$+,]EHK8
M#8\/^E6Y<Q\0YI]%3:\2F[+B=UOE?']!5T'T8;/22V*?',4[YF4/8TA,]?D+
M;UYJ83H=RZS>CXPY75/IJC!AKEQ=]7KCOD!`NR,YQFI.($J77S[:"RZ330HT
MNE@RVNIDQ1UO;NK%:L3@G!F$`0>;W>.E-K/2!;'PJS:-Q9.4`^Z#P[]I,DV&
MC2U<#ZA7)1L\*G>XVPDPP_QU`H#!&\9M;M!(BWUQM"]B<]9C+Y#EF8VA[U4^
MTE#Y>%-/O1>K>9N\A$K!Q)[!O#/2=A=1MZ_2/8'G^2H7Z-_=O6H>KFFBTMN0
M(27'NTBO:)T*&0=J!S-8^^]?>^<:(3T]64A>YD:6>X)\1=2]UJ4S#E#VXC!1
MO"F1[ZT$0^/BV8AD_JJ92YQ-55,6#-Y\6`[>OCWB@AY1OBK&Z-\A>.I4Y)12
MK96T,4M2UZ_90LKA`QZIJTVS!B6WY[`J/Q)^A?8G6;)6E226T4QW1LX!T7,R
MXV2#O'"+3I-QUF/+2!:>!WPK$FAGP&K6+Y>LMG3?V9H-=XH%+2+%#/1@7()"
M?^+;/18#!3Q88<U3')KM,>*BS31&+4S,T%@6[*(K-%J0Y4DH41"+<5UM38ZL
MS-19CEFI!*_H]WGG&HL+8:(A2.NW*FZ-TYGP!>7IMME,*F8=2AF5FVWE)=X1
M'73FZ9A>X&AYG>2KU$(F?FE"2E4CN9P75XU''$;7<KQLU@[?'E=77E[`/>Y3
MB\4BI%BF<G#2]:\0#"=752"4SK:*GV]>1PZ7&'N?4*GTOA24O/"*K<]#K7+L
M*]<:,U?O/_/!O?),[T&L4GAE.AQ/SA>+YIFYNZ&WP&9G@Y>+$D^SY:02IMV<
MO*<H9CNC]42Q%\B9NG`7L845\EN7I'HN'V'1_(AC"VH@-MEH_[99)6CZIX9E
M2ZKJ-</$I"^%5!D?A#FX":U$0R8<_MNHFK3C454::Q7.'HN==!]Q*WTVY,L=
M6P$/#&/WRI7+G0;;Y1[+E2_[?3$F*5Y'IY$L%,[GD_&Q'+U1.!KC@`*1FO>^
MF<WNGOT_`0```/__`P!02P,$%``&``@````A`&O\X=ML`@``,P8``!@```!X
M;"]W;W)K<VAE971S+W-H965T,RYX;6R4E%UOVR`4AN\G[3]8W-?X(TY<*W;5
M)LM6J9.F:1_7!.,8U1@+2-/^^QT@=9MD[;)<.,:\O#SG'`[SJT?1!0],:2[[
M$L5AA`+64UGS?E.BGS]6%SD*M"%]33K9LQ(],8VNJH\?YCNI[G7+F`G`H=<E
M:HT9"HPU;9D@.I0#ZV&FD4H0`T.UP7I0C-1ND>AP$D53+`COD7<HU#D>LFDX
M94M)MX+UQILHUA$#_+KE@WYV$_0<.T'4_7:XH%(,8+'F'3=/SA0%@A:WFUXJ
MLNX@[L=X0NBSMQN<V`M.E=2R,2'880]Z&O,EOL3@5,UK#A'8M`>*-26ZCHM%
MAG`U=_GYQ=E.OWH/="MWGQ6O[WC/(-E0)EN`M93W5GI;VT^P&)^L7KD"?%-!
MS1JR[<QWN?O"^*8U4.T,`K)Q%?73DFD*"06;,'$85'8``,]`<'LR("'DT?WO
M>&W:$J59F&?99)K/P&;-M%EQZXD"NM5&BM]>%5NJT279NZ2`OY]/PB3/XFP*
MN_[#!7LD%^&2&%+-E=P%<&I@3ST0>P;C`IS_'A)06.VU%;LE`*NA#`_5-)WC
M!T@=W4MN3B7)H6)QJDBS48(!:V2#B,]GL^(2P?.%;3+:.OP;+[ETX/&GBR/T
MQ9O3!U"0I/.AK/@(ZB56#^4E4P<%;>U_A^"+]S4'>)/_P;/B([SIX=8W7N+Q
M)O$LGZ7)D63Q6I)F>1KG43ZZ',#!,3T_=U9\!#<;;7WNO.1=N->2-^!\W_NN
M&,B&?25JPWL==*QQ/6U[5/FNCT([,')P7;"6!IK5O;9P.3-HD2B$^49*\SRP
M]\IXW5=_````__\#`%!+`P04``8`"````"$`P23A64$%``#@%```&````'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;)18VVZC2!!]7VG_`?$>0S<W8]D>#439
M'6E'6JWV\DQPVT8!V@(29_Y^JZFV^T+B,2].[#H<3E=5GX)>?WEO:N>-=7W%
MVXU+%K[KL+;DNZH];-Q__GYZ6+I./Q3MKJAYRS;N#]:[7[:__K(^\^ZE/S(V
M.,#0]AOW.`RGE>?UY9$U1;_@)]9"9,^[IAC@:W?P^E/'BMUX45-[U/=CKRFJ
MUD6&57</!]_OJY(]\O*U8>V`)!VKBP'T]\?JU%_8FO(>NJ;H7EY/#R5O3D#Q
M7-75\&,D=9VF7'T[M+PKGFM8]SL)B_+"/7Z9T#=5V?&>[X<%T'DH=+KFU$L]
M8-JN=Q6L0*3=Z=A^XWXEJYRFKK==CPGZMV+G7OO?Z8_\_%M7[?ZH6@;9ACJ)
M"CQS_B*@WW;B)[C8FUS]-%;@S\[9L7WQ6@]_\?/OK#H<!RAW!"L2"UOM?CRR
MOH2,`LV"1H*IY#4(@$^GJ41K0$:*]_'ON=H-QXT;Q(LH\0,"<.>9]<-3)2A=
MIWSM!][\AR`BJ9"$2I(`U,LX7=!E1*+XYRP>*AH7^%@,Q7;=\;,#70/W[$^%
MZ$&R`N:/5P1+$=BO`CQ>`F)[*,/;-@C6WAMDKI20#"'0^%<(-1'Y%!%$5X@'
MLJ[:8,6Z-I'U`&IW6Z.XR-(87NG'960(68[9%>O*M1\,`9`07<#M&PLP"-16
M'L36C1$2:A`+D=]"&-*`Y'YI`KQQ8977H@2))0TAR5A4DBQ]*Y[K\="/(E55
M0Q:T\_VR!-B2M;1D(20>9:4Q2:UXKL>C)`I5W)`5SY$EP):LU)*%D'"4E5C!
M_!)4V595-E0E<U0)L*DJ]"U5",%D!?XD5QA&T4NJ5!N:Q,BZVP\$V-)$+$T(
M04V$)&2I&F?<C+D.2)?I9[K2.;H$V-)EW39#B,Q5$JN^055&."`JTT:R"+C1
M_=D:T9:LB7T*QHU[R1>U=4F.2SQ2UF8*FV?K:,FZ/X2*&#V3(`:[)UW:]F"$
M8:I=N\"4)8SV[NXB:,N&+$4L92%&YH,&?FPA<LDB$7X0$9534YSPWOO%H5/#
MY]530[7-I;A;;HY]1FY!3'FS')],+3^T:I9)S*67$FN+Y#*.)0^(VMFFKEF6
M+YZ:[*VIZB'3IIMZX!-KC^22`W7%D;K<U#7+\\G4]$/ED%(78BZ]EEKYS"6'
MC`>?S2(RR_9'M&D:D7(C*4PW_G"Y5!F13:;'B1]&GY5REOF3J?MKQ%*9[N[$
M#Q)+>BY)+CG5C=BLYBS_)],!H#VP2&FZQ1-")V-<DDAIT(;*$@UI=-80&-%6
M/:T&SR0&[QQ'OITT(TZ2)%+&8RJ;-07H=`IHXP63)C$R)V%D;9%<QG%K)K':
M(::N66.`3L=`9)E\)C&HBZ:Q;V\!`Q"2\+,)184?WST$1K3YS*_50J;LEL./
MD%S2@&5?9\EG%;6&@'@E2G_^2C0=!I$JC92)&*Q<:(\"JD>UUQJSK+,F@7AG
MM2:!9N52E#X)2$+UV2U39R`HC;0G)E.<-0[N?)F<C@6[YS.*&,S<`U&5DPJ-
ML&9#IKQ90X&BH>M/1K%E$IG$X)9X2%)_\LQF(F(_)&H[F^)FS04ZG0NQ&CBR
ML/I<2(/0;L=<DD@+I'ZJ/-*49LV%.\LZG0^QU?(9G">)_I1OQ!\]69J(CYXL
M\4`)SUL:UAU8SNJZ=TK^*@Z+*+P^7G_%@ZR,K#(JSB6LWW-QP"5^]ZX!.%\Z
M%0?VO>@.5=L[-=L#I;](8$-T>$*%7P9^&H]#GOD`)TOCOT<X261P[N$O`+SG
M?+A\$3>XGDUN_P<``/__`P!02P,$%``&``@````A`,"-5(?0!P``(",``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-C,N>&ULK%K9<N(X%'V?JOD'BO>`)>,%
M*LG4L._[S#P[X"2N!DS93J?[[^?*XMK6U9A`U_1#FQR=<[7<(UE(//[QXWBH
M?/>C.`A/3U56,ZH5_[0+]\'I[:GZU[;_X%8K<>*=]MXA//E/U9]^7/WC^???
M'C_#Z%O\[OM)!2*<XJ?J>Y*<6_5ZO'OWCUY<"\_^"4I>P^CH)?!G]%:/SY'O
M[5/1\5#GAF'7CUYPJLH(K>B6&.'K:[#SN^'NX^B?$ADD\@]>`NV/WX-SC-&.
MNUO"';WHV\?Y81<>SQ#B)3@$R<\T:+5RW+5&;Z<P\EX.T.\?K.'M,';ZAQ;^
M&.RB,`Y?DQJ$J\N&ZGUNUIMUB/3\N`^@!V+8*Y'_^E3]D[6VC%?KSX_I`/T=
M^)]QX7,E?@\_!U&PGP8G'T8;\B0R\!*&WP1UM!<0B.N:NI]F8!E5]OZK]W%(
MUN'GT`_>WA-(MP4]$AUK[7]V_7@'(PIA:MP2D7;A`1H`_U>.@;`&C(CW(WU^
M!OOD_:EJVC7+,4P&],J+'R?]0(2L5G8?<1(>_Y$D=@DE@_!+$'AB$*C.M9AE
MBRA7E.9%"<^+DCFW*1L7)3SOK!-:E'89GG?6:5^4\+RS3N>BA.>==<)$35L+
MSSOK;%Z4\+RS3@8VE*X0?KS8HE%SF-$TG>L)99FAX`-6:]0:W'+<U%)7S`#S
MY%)MP4@W5HM&8@4GW5HM6HD5O&3FD^!:B]%+8LK=VUMT$RO8R:JQAO'5I&'H
M)O$!:V6W31N&?N*%U!9FO-[9NEPQT@6HZR7>\V,4?E9@58<$QV=/O"-82T3#
MI4>&R!:CLK4(%B$1Y4\1)@T&RTP,"^CW9Y>;C_7OL.CM+IRVY$#3,X[-"*>#
M'+'&B<!="O0HT*?`@`)#"HPH,*;`A`)3"LPH,*?`@@)+"JPHL$8@'R*F#N(&
M&3A`VP)0AYQFB879IR76A`3_]SL%\RA4:A[MIMJ"MJ04T\A51@<9V,8N`GFW
M;-9013WDH*B/0%%DJ:(!<E`T1*`HLE71"#DH&B.0BTQ2T00IJ)DBD&MLYJ@5
MS9"#HCD"19&KBA;(0=$2@:*(Y&2%'!2M)0#>R.8:2=)&9]!.;W6*8V2M5<P&
MZ_4OF$VH8*M2:*3+B2W:D@-K>M81DLX.,K#O701*)3UDH*2/0*ED@`R4#!$H
ME8R0@9(Q`J62"3)0,D6@5#)#!DKF")1*%LA`R1*!4LD*&2A9(U`JV7S)V%YC
M*/:"]"OVNKZ&"?93%<R;6:;1).^9MN0XZ9O*:EC$=1U9W$CWQ^EKJ,BW&2.3
MMD?Y_2*_X5ADO@XH?UCDF]PD\4>4/[[.GU#^M,CGKD':,Z/\>9%OFI2_H/RE
MRF^0\5Q1_KK(9TV+OF0V2CEWC'S=2;<%6Z7<=-R\0XIQ8$-WAW$$FQJ']*0M
M.79J'&8P1E<C65YP3E'0-.BFJ$?Y?87?:)`7T8#RAT6^Z[C4.90_+O(=JT'V
M%Q/*GQ;YMDGY,\J?%_F6:Y-WXH+REPK?XJ2_*\I?%_FF8SJD`YMB.;>X0Q*X
M5<J-)L\3J#@'MO-W.$>P5>>XI"-M29$KS@-K<C(P'5E>,(XBX,PF'>E105\1
M.&:#6&%`!4-5P'D^B=))-J*"L2*P72<?NU0PH8*I(K!L.B@S*I@K`FXU29,6
M5+!4!9QV>D4%:T7`7-LFP[11"4[#((2M0G!L(]]9*0Z"KW6*@])O5G`N`@:\
M_OX20F(F.BW:DM-,EZ$'HV80MW5DN05-S5Z";L'J\KO5%T%ZMP3IDR#Y8*1U
M#&Z),;P>8W1+C+$DP7LAZS!U)S)P#S-%H%0R0P9*Y@B42A;(0,D2@5+)"ADH
M62-0*ME\R=A>8R@^A6]RO^93(:0^):M:6W*N9*6##.Q\%X'2SO>0@9(^`J62
M`3)0,D2@5#)"!DK&$LCF'"=6G\CRZW-NJ@1A5JU)5I?9+5'F:A2CYI`HBUNB
M+-4H9LT@,V9U2Y2U$@5.Z\B2O5'*>8V18=LJY:Y5<W."XE,X`?TUGPHA]2D9
MK[;D9+EE9%?1D>4DMZ2G726(4S/4?T[O(>]9NCCV;HG:5Z+"B7SV#5PNL+?$
M&%Z/,;HEQEB2KDSE"3)PQDP1*)UD,V2@9(Y`J62!#)0L$2B5K)"!DC4"I9+-
MEXSM-89B7'$0KSCW^NL_I<.QB+R=$=\^VSK4T:&N#O5TJ*]#`QT:ZM!(A\8Z
M--&AJ0[-=&BN0PL=6NK02H?6.K31H:T"J1D3AZK_QZFX/)PM'D5HN["VN&R!
M]4E<`V1;%XL>CW9R%IJXJT,]'>KKT$"'ACHTTJ&Q#DUT:*I#,QV:Z]!"AY8Z
MM-*AM0YM=&BK0&J^Q4DGS;<X++_W%D2>F"KY-LG115M<D.GYIAOXG)7G.Q,B
MU--9?1T:Z-!0AT8Z--:AB0Y-=6BF0W,=6NC04H=6.K36H8T.B1O[RT##>,E\
MRQMX>0%V]*,WO^,?#G%E%WZ(VW6X=GQ^S&"\^C?@[C^]OB<E,'&A)%VEM1*.
MOQ?02EJK_U*L12AQVDCYO`6W*3K>Y2VX,-'Q/F_!G8B.#WD+KCUT?,Q;<+6A
MXU/>@ML+'9_S%EQ0Z/B2MU8I7L\Z`+]/.'MO_LR+WH)37#GXKS#"L%.%K[^1
M_(6#_",)S^F%TTN8P"\3TH_O\$L4']Y[1@W(KV&8X!]0<3W[;<OSOP```/__
M`P!02P,$%``&``@````A`*^!+%.P`@``$0<``!D```!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&ULC%5=;YLP%'V?M/^`_%X,)"0T"JF:H&Z3-FF:]O'L&`-6
M,4:VT[3_?M=V0T.R)7U),#[W^)Q[KR_+NV?1!D],:2Z[',5AA`+645GRKL[1
MKY\/-QD*M"%=25K9L1R],(WN5A\_+/=2/>J&,1,`0Z=SU!C3+S#6M&&"Z%#V
MK(.=2BI!#"Q5C76O&"E=D&AQ$D4S+`COD&=8J/=PR*KBE!62[@3KC"=1K"4&
M].N&]_K`)NA[Z`11C[O^ADK1`\66M]R\.%(4"+KX4G=2D6T+OI_C*:$';K<X
MHQ><*JEE94*@PU[HN>=;?(N!:;4L.3BP:0\4JW)T'R^*%.'5TN7G-V=[??0<
MZ$;N/RE>?N4=@V1#F6P!ME(^6NB7TKZ"8'P6_>`*\%T%):O(KC4_Y/XSXW5C
MH-HI&+*^%N5+P32%A`)-F#@95+8@`'X#P6UG0$+(L_O?\](T.9K,PG0>36*`
M!UNFS0.WE"B@.VVD^.-!L14UD"2O)%-0_[J?A$F6QNGL.@OVBIS!@ABR6BJY
M#Z!IX$S=$]N"\0*8#\Z\CL'K_ZR"/$MR;UD<%[C04)ZG599$2_P$.:6OF+7'
MP(T8,/$8L3D@K&M+6QR]P*!W$`VI.!4]@:+^NQP'C39HK'$R'0M8GT.2,6)S
MCIBD8TAQ#IF_I6)D8S*V<5F^!><(R(?T9<E)`M<>`V4<,+.QN,U51'$),5(/
MQQP7X;)Z"X:N/U*6)2>Y77O,)?57$<4EQ$@]W+MC];;OK[>0#1K78)J=]I#'
MS-TE2-.WRKN.WASOGOB'`6;9?60VU,VK]J/)WUS!5,TVK&UU0.7.CIT83AO>
M^HFXAHGHY@<>-F`B]:1FWXBJ>:>#EE40&H5S.%?YF>871O;NGFRE@5GD'AOX
M]#"XD5$(X$I*<UC8J3E\S%9_`0``__\#`%!+`P04``8`"````"$`CFCF3_T"
M``!T"```&0```'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6R45MN.FS`0?:_4
M?T"\+V`N(8E"5DO0MI5:J:IZ>7;`@+6`D>UL=O^^8YP03-J]O"2!.7,X9V88
M9W/[U#;6(^&"LBZQD>/9%NER5M"N2NQ?/^]OEK8E).X*W+".)/8S$?;M]N.'
MS9'Q!U$3(BU@Z$1BUU+V:]<5>4U:+!S6DPXB)>,MEG#)*U?TG.!B2&H;U_>\
MA=MBVMF:8<W?PL'*DN8D8_FA)9W4))PT6()^4=->G-G:_"UT+>8/A_XF9VT/
M%'O:4/D\D-I6FZ^_5!WC>-^`[R<4XOS,/5Q<T;<TYTRP4CI`YVJAUYY7[LH%
MINVFH.!`E=WBI$SL.[3.8MO=;H;Z_*;D*":_+5&SXR=.BZ^T(U!L:)-JP)ZQ
M!P7]4JA;D.Q>9=\/#?C.K8*4^-#('^SXF="JEM#M"`PI7^OB.2,BAX("C>-'
MBBEG#0B`3ZNE:C*@(/AI^#[20M:)'2R<*/8"!'!K3X2\IXK2MO*#D*S]HT'H
M1*5)_!-)".I/<=_QEQ&*%J^SN%K18###$F\WG!TM&!IXINBQ&D&T!N:S,ZUC
M]/H_J^!1D=PIEH$+7`AHS^-VB98;]Q%JFI\PJ<;`&S%BD(G8G1&J@(HVF]QP
M0>\H&DHQ%QU`4__=CK-&E61J#$)30'H-\4W$[AH11"8DNX;$W@@Q;`2FC9?E
M*S#,S:1\2[0:>8=ZI1H#;1Q+O#`1NU<1V4L(0ST\YOU-4$F)#24:%8;Q;`Q2
MC8F',8H6,X^[:33T9OZR:=1?7D;04`[OW/N5JZ2Y\METI!H3#LI1$,]J/XU&
MEY'0HSX-WO@7TX;PA2G\Y8%1X+G@^<!KC!8<+&?%W$VC"`6FG<R(AA>SAN+X
M/8H5V%2\FKU<J8;HV4#>:M:`W31\-3IP0BA^G3P=':U8;W^]'%O"*[(C32.L
MG!W49D?0U/&N/G12.'2&%>V.`5CZ/:[(-\PKV@FK(26D>DX,W>7ZV-`7DO7#
M*MHS">M^^%G#Z4Y@Z7D.@$O&Y/E"'4SC_X7M7P```/__`P!02P,$%``&``@`
M```A`$O2;F?Q`@``FP@``!D```!X;"]W;W)K<VAE971S+W-H965T-38N>&UL
MC%9=;YLP%'V?M/]@^;U\)80F"JD:4+=*FS1-^WAVP(`5P,AVFO;?[QH'%&`E
M?2&!>^[AG'MM7[8/KU6)7JB0C-<A=BT'(UHG/&5U'N+?OY[N[C&2BM0I*7E-
M0_Q&)7[8??ZT/7-QE`6E"@%#+4-<*-5L;%LF!:V(M'A#:XAD7%1$P:W(;=D(
M2M(VJ2IMSW%6=D58C0W#1GR$@V<92VC,DU-%:V5(!"V)`OVR8(WLV*KD(W05
M$<=3<Y?PJ@&*`RN9>FM),:J2S7-><T$.)?A^=9<DZ;C;FPE]Q1+!)<^4!72V
M$3KUO+;7-C#MMBD#![KL2-`LQ(_N)@ZPO=NV]?G#Z%E>_4>RX.<O@J7?6$VA
MV-`FW8`#YT<-?4[U(TBV)]E/;0-^")32C)Q*]9.?OU*6%PJZ[8,A[6N3OL54
M)E!0H+$\7S,EO`0!<$45TRL#"D)>V]\S2U41XL7*\@-GX0(<':A43TQ38I2<
MI.+57P-R+U2&Q+N0+$'])>Y9WKWO^JO;++91U!J,B2*[K>!G!(L&WBD;HI>@
MNP'FSIG1T7M]SRIXU"2/FJ7E`A<2VO.R"];>UGZ!FB87S-Y@8$?T&'>(B#J$
M+J"FC:\>V*"W%PVEN!;]_S9TVC1XJ,WW1V_>3S$C]=$4L?"'\N,I)'!ZR$#_
M8JA?%WT!BW+>ATX"W%7]@O6BYV\+MC<8Z&-?X]40$=U$Q'.(@0MXS747M(OE
MNYNBZX9."C&4JE<8K)=#C7N#\9?M0G*L49TC$X9K3S$R&<\A!A9`[MC"[4;H
MI+&%D<:]P?06O%$\,O$Y#W.(@8?5U,/M-NBDL8=1%?<&TWMP1O'(Q.<\S"$&
M'H*AA_F-H,%C[<%H"1G,^K*"1ML]FHW"(-'\TURCV`P)<X965.0THF4I4<)/
M>@"X\,;^J9E->YA-[4EN]P&8#0W)Z7<B<E9+5-(,4ATK@)X+,UW,C>)->W(=
MN(*IT/XMX".`PMD(VP*CC'/5W>CYU7]6[/X!``#__P,`4$L#!!0`!@`(````
M(0`#<+8N80,``%H+```9````>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;)16
MRV[;,!"\%^@_"+I;+[\-VT%D(6V`%BB*/LZT1%E$)%$@Z3CY^RY)2S9I1W8O
MB:4=#F=GE]0N']ZJTGG%C!-:K]S0"UP'URG-2+U;N;]_/0UFKL,%JC-4TAJO
MW'?,W8?UYT_+`V4OO,!8.,!0\Y5;"-$L?)^G!:X0]VB#:XCDE%5(P"/;^;QA
M&&5J457Z41!,_`J1VM4,"W8/!\USDN*$IOL*UT*3,%PB`?IY01K>LE7I/705
M8B_[9I#2J@&*+2F)>%>DKE.EB^==31G:EI#W6SA":<NM'B[H*Y(RRFDN/*#S
MM=#+G.?^W`>F]3(CD(&TW6$X7[F/X2()0]=?+Y5!?P@^\+/?#B_HX0LCV3=2
M8W`;ZB0KL*7T14*?,_D*%OL7JY]4!7XP)\,YVI?B)SU\Q617""CW&#*2B2VR
M]P3S%!P%&B\:2Z:4EB``_CH5D:T!CJ`W]?]`,E&LW.'$&T^#80AP9XNY>"*2
MTG72/1>T^JM!*J..)#J2C$#],1YYT6P<CB>W67RM2"68(('62T8/#G0-[,D;
M)'LP7`!SFYG6T>7Z4:J0HR1YE"R*"[+@4)_7]70^6_JOX&EZQ,0:`T>BPX0F
M8M,BI(&2-CE[X8/>3C1888L>0E&OEZ/5*!>9&H<C4T!\"8E,Q.82,1R;D.02
M,@TZB)'&T$RC7[X$0]^<V3<*;8LU!LK863SI=E:.;FXBDCZ$H1ZV.2]"OWH)
M7KE@3:=L%,Y-;;'&]*F_B4@T8JI:,`I.I3&4PYF[7[D$6\JC4SV5J['&C-2N
M=E/WQ)+K,4/KQ-0JS^?M5I>+3,W3N>VVQES7W!-+SF-1<.HO0_745-W?&Q)L
M=79DN1AK3%]OW$0D?0A#O?QLG]V)_>HEV/3ZLK,U1GL]L+MG8T2M,B5M\'1P
M/K!\_C^B)=@2;<N*->8HVKHI-T;0NB23-GA3<PB7]KG3]W6W6F6JGP7VD3R"
M6L]M_68XM-HMZ<*W4Y#?J+N;!884V_B9)2T^8O0=-HB&YBVY,<.AE;<<@^0.
M[0UH-XL><?0$4&&VPQM<EMQ)Z5Z.+R'<8-U;/5K%<K12PU$7@,FF03O\';$=
MJ;E3XAR6!MX4;C.F9R/](&BCOK=;*F"F43\+F&$Q?-D##\`YI:)]D--7-Q6O
M_P$``/__`P!02P,$%``&``@````A`.L>EV;_`P``HPT``!D```!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&ULG%?;CN,V#'TOT'\P_#ZQY5LN2+)8VYAV@18H
MBN[VV;&5Q!C;"BQE,O/WI43?I,PFF;[,Q.$A?7A(B<SZRUM=6:^TY25K-C:9
MN;9%FYP597/8V-__>7Y:V!8765-D%6OHQGZGW/ZR_?67]86U+_Q(J;`@0L,W
M]E&(T\IQ>'ZD=<9G[$0;L.Q96V<"'MN#PT\MS0KE5%>.Y[J14V=E8V.$5?M(
M#+;?ESE-67ZN:2,P2$NK3`!_?BQ/O(]6YX^$J[/VY7QZREE]@A"[LBK%NPIJ
M6W6^^G9H6)OM*LC[C019WL=6#U?AZS)O&6=[,8-P#A*]SGGI+!V(M%T7)60@
M9;=:NM_87\DJ)8'M;-=*H!\EO?#)9XL?V>6WMBS^*!L*:D.=9`5VC+U(Z+="
M?@7.SI7WLZK`7ZU5T'UVKL3?[/([+0]'`>4.(2.9V*IX3RG/05$(,_-"&2EG
M%1"`OU9=RM8`1;(W]?]2%N*XL?UH%LY=GP#<VE$NGDL9TK;R,Q>L_A=!I`N%
M0;PN2`#L.[LW\Q8A":/[41QDI!),,Y%MURV[6-`U\$Y^RF0/DA5$[C-#'D.N
M/TL5<I1!OLHH*A9DP:$^K]N%2];.*VB:=Y@8,7`D!HR!2'J$%%"&32=?.,!W
M(`U2F*1]*.K'Y>@Y2B>=HQ\8%*\AGHY(KA%^J$/2:\C<'2!:&O[_24,Z0?],
M9%RX!LL8,5#.0>IH8*"43>XBTEL(+0MXS>>+(9TV-D@U,`Q\HQUBQ,Q5.SU%
M?F@(G6CV<.GY>HZI9O=";U1)XP\G\//\I9/)W^`7(R9"_L1=CEV`-3#LQ*A1
MBO8`_0/_)_0CG?[M,R#!)NVE+EN,F(ZV%[@&K03M/:TKU35SM!B+HHD^_PQK
M"398!V-<)6:,&"CYT%`F[[N(M$?(^^MI/LBB$9<CW;@O[U\]TLE,P.P6Q*"L
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MHGMP=6=S&'PM+MGX(-A)+6X[)F`Y5A^/\&.(PHKHS@"\9TST#W*-'WY>;?\#
M``#__P,`4$L#!!0`!@`(````(0!PR'WDD0,``$P+```9````>&PO=V]R:W-H
M965T<R]S:&5E=#4Y+GAM;)16VXZ;,!!]K]1_0+QOP%Q"B))4#:MM*[525?7R
M[("36`L886>S^_<=>UC`I$W3E]W`'!^?.6,/LWKW7)7.$VLE%_7:)3/?=5B=
MBX+7A[7[X_O#W<)UI*)U04M1L[7[PJ3[;O/VS>HLVD=Y9$PYP%#+M7M4JEEZ
MGLR/K*)R)AI60V0OVHHJ>&P/GFQ:1@NSJ"J]P/?G7D5Y[2+#LKV%0^SW/&?W
M(C]5K%9(TK*2*M`OC[R1KVQ5?@M=1=O'4W.7BZH!BATON7HQI*Y3Y<M/AUJT
M=%="WL\DHODKMWFXH*]XW@HI]FH&=!X*O<PY]5(/F#:K@D,&VG:G9?NU^YXL
M,Q*ZWF9E#/K)V5F.?COR*,X?6EY\YC4#MZ%.N@([(1XU]%.A7\%B[V+U@ZG`
MU]8IV)Z>2O5-G#\R?C@J*'<,&>G$EL7+/9,Y.`HTLR#63+DH00#\=2JNCP8X
M0I_-_S,OU''MAO-9G/@A`;BS8U(]<$WI.OE)*E']0A#IJ)`DZ$A"4-_%@UFP
MB$D\_S>+AXI,@O=4T<VJ%6<'3@WL*1NJSR!9`K/.+`1__IP9I*37O->+S%)`
M2RC'TV;AAROO"2S,.\P6,7`#>DQ@([)+1!CW$`_T]2(A]?\7J1?9(L.HIS=Y
M;!&R,#;KQ++1"TL`.#,6<-T=#0871YE'\9`8[HR8:(29V]JR:PA+&Y#<KDV#
MURZDV5<EBB<[;Q&3F+J2))K[$V7C^"(.%GW8D@4'>RSKMH.E%TWE)3T_6H>8
MN9$7)<$DG(W#)%T,Q])2-[?572^H!MNJ2#C9=HL85!6F:6J+SL;A)`R&JV"I
M2FQ5MWFF%]GJHGBH"7J&&%1'DG12\<P*!^0OGNFOV:A57/=,@Z>JAJQ1%6(Z
M54$ZL33#<(2%C@='+<O2_Q&EP5-1`R^*0@R*"M(@F<2S<9RDL3_<;$L7@29Z
MNUL&/5$VO7?;#H2&W*7)4":C/+/C03!4V58V:?G7ZTBP2UL=8S[9>=N!.M,6
MH3]LW4E#EJ[4EJNV-MV`;SYC!-NUK6W:XSL0;GT7_$D<TG0(<D6=[LFWJ\,.
M;JN[<.ZRS2>C[M"Y=QV$#N+P@M_VBK4'EK&RE$XN3GHP">`6]6]Q:-J2)7P`
M85B9O,]@F#+OO3X`LTQ##^P+;0^\ED[)]D#ISQ+HM2U.0_B@1&.^N#NA8(HQ
M/X\PM3+XM/HS`.^%4*\/>M[JY^#-;P```/__`P!02P,$%``&``@````A`!:,
M"*FG!```81,``!D```!X;"]W;W)K<VAE971S+W-H965T-C`N>&ULE)A=;^HX
M$(;O5]K_$.7^D#@$"`@X:JBZ>Z0]TFJU']<A&(B:Q"A)2_OO=\83@FU2$V[X
M?#U^9L:><;S\_E'DSCNOZDR4*Y>-?-?A92IV67E8N?_\_?(M<IVZ2<I=DHN2
MK]Q/7KO?U[_^LCR+ZK4^<MXX8*&L5^ZQ:4X+SZO3(R^2>B1.O(1_]J(JD@:^
M5@>O/E4\V<E!1>X%OC_UBB0K7;*PJ(;8$/M]EO)GD;X5O&S(2,7SI`'^^IB=
MZHNU(AUBKDBJU[?3MU04)S"QS?*L^91&7:=(%S\.I:B2;0Y^?[`P22^VY9<;
M\T665J(6^V8$YCP"O?5Y[LT]L+1>[C+P`,/N5'R_<I_88A-,7&^]E`'Z-^/G
M6OGLU$=Q_JW*=G]D)8=H0YXP`ULA7E'Z8X<_P6#O9O2+S,"?E;/C^^0M;_X2
MY]]Y=C@VD.X)>(2.+7:?S[Q.(:)@9D08J<@!`%Z=(L.E`1%)/N3[.=LUQY4[
MGHXF,W_,0.YL>=V\9&C2==*WNA'%?R1B"-49"5HC\-X:8=-1&$QFT2-6QJT5
M>+]8"49!-&&3Z7T6C_R287I.FF2]K,39@;4'Y/4IP97,%F#Y$A_RIHO85P$#
M)]'($UI9N;!I(!8U9/E]'?GATGN'S*2M)B8-O'8:IBLV%P4F%/`Z1HB;RMB?
MNPL*BA$%$X!L,?V@SAL8\]XJQI-.HI%`A(:3H!C6B^)PY%_M$AQI0D4S[6:6
MBHU-H;&!D>%L*%ZYX'B7C'`ZUF>.23.3Z0RBL3_U?5^7;%0)FP>SN2K1Z&"W
MJ'2XSL:PF^VYQ$$Z9>0;\8E)`R"=)Y$_,S!O-5<K&N54I[33H=BDB_298]),
M90S9+,00FC%4)=$DB%2%!C?3X3"$,_#,#HF#3,BY`4F:22@I_9&Q1C?TMQKA
M+Z*'3=.H)>%=0!QD`#(C1#%IVB@RC*&AV)!B`.-<9[0'#\4Z6Q`8,\>DZ9^9
M=K!-H268P890`VB'D^I[]:45V?"L$IT/"[22X#M\5,[5&A/YYOY@)&I3*[>'
M$>!-*^EW0>?#0CZ<C\J^QL>,EA0S$O5/3NFU2G0^K.7#^:CRPZM2V8R]&3-;
M>VCY;!*=#]Q\@`_5^N[HR2^)*+]A"*??V[W+2`.OG:-?%!@\N3T`2&5?3[#1
M^V-I<N428#\>F1F"]U#[8#W]@YD]N!7U3][FE^ST2_3\&AWDSOZENG]G_=F:
M0\MGD^A\1@.YP]?3.6[KB]HZ)D%_@1G</)C1/8:=8N0H<Z-<5[B,4MR*U"Q&
MS#A";WI$5SM:*`.CE0PCE:,,4F:6G%:DDEXA*.56B<[Y4$L)J%O8EV0KLO*1
MG7Z)SH?U7RG9`^-(74.O/$:0XH!$;>7!8]_-J::5#.'$(O\X)[4&G=,X/,<!
MB?HAVGS;)'H\P8S*:=_B`:KO'7%:D96/[/1+=#ZCPPS,=U^GN<DWB>AY:MQ;
MB?`Y'ORU<=)-!SW"%[PZ\`W/\]I)Q1O>8C`XPG>_=C<L3X&\(^G^@`N.4W+@
M/Y/JD)6UD_,]#/5'^#!1T14)?6G$25X0;$4#5QORXQ&NLC@\5<-3@NOLA6@N
M7_"9O;L<6_\/``#__P,`4$L#!!0`!@`(````(0!P&+V!8`0``)`1```8````
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULE%C;CJ,X$'U?:?\!\3X!0^?249)1
M`^K=D7:ET>S.S#,A3H(:<!8[G>Z_WRI,P)<,3?*0<#D<GU/E<N&L/K^5A?-*
M:YZS:NV2B>\ZM,K8+J\.:_?[O\^?%J[#15KMTH)5=.V^4^Y^WOS^V^K"ZA=^
MI%0XP%#QM7L4XK3T/)X=:9GR"3O1"N[L65VF`D[K@\=/-4UWS4-EX06^/_/*
M-*]<R;"LQW"P_3[/:,*R<TDK(4EJ6J0"]/-C?N)7MC(;0U>F]<OY]"ECY0DH
MMGF1B_>&U'7*;/GE4+$ZW1;@^XT\I-F5NSFQZ,L\JQEG>S$!.D\*M3T_>H\>
M,&U6NQP<8-B=FN[7[A-9)F3A>IM5$Z`?.;UPY=CA1W;YH\YW?^45A6A#GD2Z
M_8<6-!-T!YES'<S(EK$7?/0+7/)A$-X`<!#^WW68IP!'\;IAU./KD,]-VK[6
MSH[NTW,AOK'+GS0_'`6,-(4P8#26N_>$\@S2`&--@BFR9JP`"OAVRASG$X0Q
M?9/J\ITXKMUP-IG._9``W-E2+IYSI'2=[,P%*W]*$&FI)$G0DL#O1=X/YI-@
M,273V1TL8<L"ORT+">YG>6A9X+=G&6G(D\%IXIZD(MVL:G9Q8-:#?7Y*L8;(
M$HBO098AZ<+^JZA#N)'D"5G6+I0K!)1#ZE\W_LI[A>1F+2*2"/CN$$1'Q%<$
M9A))$^6"!VH[R9`+5?+M^7!5AF!4=F6-Y`552&`(L1&ACDALQ$.'T*1"PL=+
M13!,4B5$TXZUB4@D$9"F+H@S'1%_B$B&$)IV&&:\=@2O78A+IVRN*XLD0M6^
MT!&QC3#<)4,(33L4^'CM"-:U/^K*(HE0M1-C?L<VQ!0_A-#$S^X1CV!=/#$*
M*Y*0:5.6#V06&NYB>5]U9TH?0FC2Y_=(1[`AW2C%2$)4:<2HQ=B&F.J'$)IZ
M?-U0UL+AA07!AOI^$9#E*B&:>J.B8QMBJA]":.H?[U&/8$.],7`D(9IZHZ9C
M&V*0)$,(33V!EXKQP6_0AGYC.8E:C&;`G/HW,*:#08AN`1O6Z/E#9'M3E\S`
M6%2B%J-:"(SJCF]@+`MR*)6FA^@6L+.-MR#[H&;!K&`B,>K8@5G"-S"]OO9=
MP*;I(;H%;'#C+<AVJ%DPRYC8+3,PZ_@&IM?76K!I>HAN`:)UAP5$Z[40],1R
M)2(2HV7!+.8;&(,F&83H%K#;C<^"[(U:%JQRMONGG04;8UD8@N@6L.N-MR![
MI&;!6&TB8O?1T"CY^`;&LF#3]!#=`K8^Q0*^W8>PT`YW-B(;IFHE-%:=J,6H
M$ZK7T,RYN(7,Y'M'2&8+/S1**QFDT:U@'U2L?&!!=DW-@K4R#776UL*'$-PV
M8_7-&Y>PLR0^?KKW1^E![G?EOJND]8'&M"BXD[$S[E\)/-M=[3;D[4ZYNP%;
MVU-ZH'^G]2&ON%/0/3SJ3^8PGVNY.98G@IV:7=V6"=C4-H='^.>#PH[*GP!X
MSYBXGN!6O/LO9?,_````__\#`%!+`P04``8`"````"$`F#[^`20%``!H%@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R46-MNJS@4?1]I_@'QWA`3
M+DF4Y.B$JC-'FB.-1G-YIL1)4`%'0)OV[V?;VV!L"`DO;1(O;Z]]7>#-M\\\
MLSYH6:6LV-ID-K<M6B3LD!:GK?W/WR]/2]NJZK@XQ!DKZ-;^HI7];??K+YLK
M*]^J,Z6U!1:*:FN?Z_JR=IPJ.=,\KF;L0@M8.;(RCVOX6IZ<ZE+2^"`VY9GC
MSN>!D\=I8:.%=?F(#78\I@E]9LE[3HL:C90TBVO@7YW32]58RY-'S.5Q^?9^
M>4I8?@$3KVF6UE_"J&WER?K'J6!E_)J!WY_$BY/&MOC2,Y^G2<DJ=JQG8,Y!
MHGV?5\[*`4N[S2$%#WC8K9(>M_9WLHX6Q'9V&Q&@?U-ZK3J?K>K,KK^5Z>&/
MM*`0;<@3S\`K8V\<^N/`?X+-3F_WB\C`GZ5UH,?X/:O_8M??:7HZUY!N'SSB
MCJT/7\^T2B"B8&;F^MQ2PC(@`'^M/.6E`1&)/\7_:WJHSUM[$<S\<+X@`+=>
M:56_I-RD;27O5<WR_Q`D/&J-N-+(`MC+=7?F+GWB!_>M.,A(./@<U_%N4[*K
M!54#9U:7F-<@68/EQC/DT?IZRU7PD1OYSJT(6^!%!?GYV/FAOW$^(*:)Q.P1
M`RW18HB.B!H$3P70:SF"YR;'!>1P./H-);Y)I[3P]//V?8BK(Z(^8J'<TCA"
M[+H<Q[EQ,-1`)Q1^&.A'[Q'C=3`&(AI#:-S`R./<.'AK@^-MFOPP-+@A)A2)
M7@5D:2:RNPZ%L)JW^S5>4/N/\^)@D]>RM2O*<(\83_#RS%QV%Y5#&J%@"B$.
M-@FM#$*(04)/KBH=03?25CVU5^,43N'$P0:GI0H^!@DQ09.\E1'$J+L.R?/4
MNL:+:UMG<(P7/`>;O(RBV2,&2J<M/+/@QQ`:M]44;AQ\KQD1,\9M#*%Q(S"Y
M'@^<0.N1<UU5O9A1">K2\Y=F^=\!Z1P-51A/+L&Y/3XR)`C++B3>O,</K2#`
M\Y:=NM2Y\9G\<.$1G.`Z-U71,GX(PC9=J#[$+I4F<%6%7B?%9_'CI'!RZZ2,
M8_>D&>]<3?NS0U^^-3P(G\2/\^)HO=C\WO@0)K=VFTAB=JD&@$3Z"J#';-+X
MYX];/6X+8]Q*4+<1U.$RFXT,#(T9G=\D-2`XS"%I[?CJ:[H$C?)K1$'942[H
M_"8I`^E+P\`@05"7W\`@&0*I1RN=XR25(`,RT7OVD""L/T)"8NA;I`$">%-J
MBT2G-DDD",YWK67[K8&@$6I=P&UJ[B2)$&BS:XU'C;T$=3.KR@H[8Q2BA<Z=
M)`\"?4]@)6B4'PK$,$3GQ^?YPU//Q>G?36V_,R2H>[B_5$4O(XB6=)#2.9WC
M),5PAQ1#:9$X?B]!6'[!/#`4)=+7O=4M9L!_0O0XVJB^T!18%T$HH>I8&;5F
M\>[$XZ^Y$Y@-*88:!C)F"&IB%AH/I9$XLE&[X';,#*W@K]$/O*+BK-<JSS/:
M<N^."8*,X!A$K[I)FN'BI!_7-`F")+;"9[@0C4)T?I/TPNWKQ4#G(JC+;Z!S
M^R#EA,YPDFRX`[+14S0)PAH,YQW!DNE%(UT/;I#C)?=X@PCTO=:5(&Q=LSO:
MQ:'<:V&#V[DIS'#4=QNC_R`J3&YMO(6`L/7(W=<+O/##^["<EB<:T2RKK(2]
M\\L\`J_([:]XT;B'BT9Q*^>T"W#/=XE/]&=<GM*BLC)ZA*WS60B#I<2;0OQ2
MLXNXCGIE-=SPB8]GN-&E<'TVGP'XR%C=?.$78.T=\>Y_````__\#`%!+`P04
M``8`"````"$`C0I;\;D#``!>#0``&0```'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6R<5UV/ZC80?:_4_Q#E_9(X)N%#P-5"M.V5>J6JZL>S20Q8F\21;9;=
M?]^9&+)QV)O0\@#$.3XY9V;P#*NO;V7AO7*EA:S6/IF$OL>K3.:B.J[]O_Y\
M_C+W/6U8E;-"5GSMOW/M?]W\_-/J(M6+/G%N/&"H]-H_&5,O@T!G)UXR/9$U
MK^#.0:J2&;A4QT#7BK.\V506012&25`R4?F68:D>X9"'@\AX*K-SR2MC210O
MF`']^B1J?6,KLT?H2J9>SO673)8U4.Q%(<Q[0^I[9;;\=JRD8OL"?+^1*<MN
MW,W%'7TI,B6U/)@)T`56Z+WG1;`(@&FSR@4XP+![BA_6_A-9IH3ZP6;5!.AO
MP2^Z\]W3)WGY18G\-U%QB#;D"3.PE_(%H=]R7(+-P=WNYR8#ORLOYP=V+LP?
M\O(K%\>3@73'X`B-+?/WE.L,(@HTDRA&IDP6(`#>O5)@:4!$V%OS>1&Y.:U]
MFDSB64@)P+T]U^99(*7O96=M9/F/!9$KE26)KB134'^]'TVB>4SB9)PEL(H:
M@RDS;+-2\N)!U<`S=<VP!LD2F-$9A?A8':W7'UD%CTCRA"QK'\H=MFO(S^LF
M3I)5\`HQS:Z8[3V&N(C=#8$!1-JTLQ"`WE8TA*(K^O,TW+0A&+7=6+=V`;A;
ML5%/R#V"QBXDO8?,PA;BB*6N6(SP](>U<Q.-FR`3'8UQ,FOYF^AL+0:2UOKH
MA7PWBDB'$(X+>$PWY(^YP$UK'T+5*HR3><^%Q22V:,(X7$0+%['K(F@4A^&B
MQY%V$20)Z3R:?I`X-B#P71O#E8-@5SZ->W6PM1@0T%KL)V$4D0XA'/6)J_ZQ
M)."FL5*RF"$7HXAT".&XF/T?%[C)S<5]*5G,D(M11&H1MAP)31;X:NO1L8'-
MO7-R#I<2@EWY4?1Q7MC?L\4,R1]%I$,(1_W"5?]8*>&FL5*RF"$7HXAT".&X
M(-"JNDEXS$:SR\W&?3%=0;82:$(74>>`;Q*V<R!D/J>4]%I:ZD`B"B=3_)%V
MUPHVNX?KB=C6V#U:Z;3W\.T5-)2+<4@Z"'$M8%/L6'@P&[:5#O<Z8D&#5D8A
MZ2"+:P4;XW^W8MLI"&F[P2>%94'7(V9*2!)_G##7PG(@-$EF\U[SQW$7?XN?
M!\1:L>.LG?9*KHY\QXM">YD\XZ@:0<=M5]LQ^BG".:FWOL7Q&M>#]@9,MS4[
M\N],'46EO8(?@#*<S*"5*3L?VPLCZV;&W$L#<VWS]03_8SA,=^$$P`<IS>T"
M']#^,]K\"P``__\#`%!+`P04``8`"````"$`OJ6>BE\'```@'P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6RL6=N.XD80?8^4?[#\OH`OP(`&5@.^
M*Y&B:),\>XP9K`&,;,_,[M^G^N[NXC(D^[)>SE2=ZCI=U=UV/W[]?MA;[V73
M5O5Q83N#D6V5QZ+>5,>7A?W7M^C+@VVU77[<Y/OZ6"[L'V5K?UW^^LOC1]V\
MMKNR["Q@.+8+>]=UI_EPV!:[\I"W@_I4'N$OV[HYY!W\;%Z&[:DI\PUU.NR'
M[F@T&1[RZF@SAGGS&8YZNZV*,JB+MT-Y[!A)4^[S#L;?[JI3*]@.Q6?H#GGS
M^G;Z4M2'$U`\5_NJ^T%);>M0S-.78]WDSWO(^[OCYX7@IC\0_:$JFKJMM]T`
MZ(9LH#CGV7`V!*;EXZ:"#(CL5E-N%_:3,\]<QQXN'ZE`?U?E1]O[O]7NZH^X
MJ3:_5<<2U(9Y(C/P7->OQ#3=$`B<A\@[HC/P1V-MRFW^MN_^K#^2LGK9=3#=
M8\B()#;?_`C*M@!%@6;@C@E34>]A`/"O=:A(:8`B^7?Z_*@VW6YAN].!XX\F
M8&T]EVT75831MHJWMJL/_S`;FI#D<#D'/#F'-QF,IR//N8/$XR2^)/'E.*[$
MAE'2\<.3QW;<@>^.IP\T^!7/"?>$)_?T/^<XY8[PY([N:#!U1C-O"J.X$A%Z
MCHX5GC*BD/J*VXR[P?/.%!TH)S:[I*[8U%U/<LC*@U9;D'?Y\K&I/RQH8:B`
M]I23!<&9$UI19VS<LO(N%1Y4'&%Y(C0+&P2`HFJA6]Z7WNCA<?@.%5YPFQ6V
M<72+M;`@Y4QH`Q,(32`R@=@$$A-(32#K`4.016H#=?\SM"$T1!N1U4H`2BS7
M$$)8")?`!$(3B$P@-H'$!%(3R'J`)@3T\,\0@M!`G4%_7:D29N3!G$BCB:&.
M-)'R("1$2(20&"$)0E*$9'U$4PE6.$VE\TNUZ!AB3<402:P8XL$DR,R]T<S(
M71H)MP`A(4(BA,0(21"2(B3K(UKNL$#>D3NQUG-GB`?:JMR=D9&[-)*Y(R1$
M2(20&"$)0E*$9'U$RQTV&BUWMH0.R*9QO02(HRX#0SQ?KA5KA`0("1$2(21&
M2(*0%"%9']%RAA[6<KZ>*+'6$^6(JQ)%2("0$"$10F*$)`A)$9+U$2U1<I[&
M^R.=W&Y7%:^K&@H6%JLS`GBP#[+=D9#H^7-$;0IKB:@.<!UCY0N8D0?[=*]-
MC%TTE$:B32*$Q`A)$)(B)&.(0T>MJ01'F/^O$B'15>)(3R6)*`&P2LS(=^@Y
MQ!TYGKZ.A/+O4B!)*Y`8(8GT(J<;8#7V[%3^77!D?0Y-+G+0TO0Z4SUPQ!;E
M0\UU900$(7J58`QIS:W<?KU@N<Y:><;&$PHK4M7OR['G&\$B8=#?N5&P6%C1
MMQ_:'8F"5"ZN&3\55BR^/WXP9C43!I?BZS,`5O?,`#$W9H!!+FR)O1DP!K5V
MN&-_4T>B!,I*U$[((6]*Y78<7Z_A2+@`OPR/B&-AI=;9!$/IC5B9<+D42U>6
M'"+[*^:-VF9G3C@4BM17#H?TVC8$6'.K6[7-N,!*T(?<T9MP98U"CP3QI6QI
MT<;"2A$G&$KU6#.C.C+A<2F4+BPY>-XA+#NG:L(RR"C9L5Y9:X<[@G*7*RM0
M5DI83D\6KO>E\S`RF"/A<RE=KJR,+Y@3X:C*..40[X_IV-@$,^%R*98N+3G7
M]J7M'>$^O\L[['2L*<XAO92-77W-'6^5,N/22IE!ETN9NUP2@0N.B!,U(C$'
M*8=X+-=!@M^(I0M.#M-]P6\L$NSLK2G+('<B&WM-/H_!(@W0U<+E5FK!"86C
M@B(!*?H80XF`E&.*H4Q`E$N7@9RO[Y"!'<<U&1CD>ST9N!4<UJ[U+[=2+14Z
M#*('C_?EU)^AE9'[W"@G&5_43L*98;D34*H'&T_'QG$B$SZ7@NE"DO-[7TC2
MP.Z$?!JU[FA@_A:@IG,%6M.-7V_@J;ED,BNO;X4VXX!S:0W,'4$R.5>>8WPX
MBX2C)H5O-&#,K6`00N1$.*I-*A56>D1CIC/A>"FB+CYY+>B+?Z.9^5M$7V4&
M:<TL(:7,&4FYE>(*X>V$K@(*B@34;V9)K\1"CJEP5%R9@,XT,\R^)L-_VT0(
MBW'29)"V;9NG[[7#_2`)64EG].)6VMYN'K5#SL47`F\Z007):;3R,%]68S4D
MI?%GXJ=&?,_\$)0)YDOQM?(DV^K5>?E6GT#PLZ_PO9<P2J-/#(?Z9:N@:],@
MK-2+;8BA2$"]LL50(B#%E6(H$Q`N6Q<R1_*XXP&LG'?>`5`F0R%"OK#U[WJN
M^5V/.X*5*)0`0R&&(@S%&$HPE&*(7.;QH<(@6`&QRSEV77(HFY=R7>[WK574
M;^3B#7:SY:.$V:W@:C*';V9`8.*NO"XT_A(\S.%#"_8(9G/X3H'Q9#:'+PT8
MA_O()[J]&OPK"$QO]4S<A?O+<SP>\)QU\.;PZ1L'7OES^"Q\!A_/X9,IX$,9
M&>XG3_E+^7O>O%3'UMJ76Y`1KMB@U!IVP\E^=+PAG^L.KB9I;^[@)KJ$&Z$1
MJ<MM77?B!PD@[[:7_P(``/__`P!02P,$%``&``@````A`$J%`RN/!@``]QH`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,30N>&ULK)G;CJ,X$(;O5]IW0-Q/
M")`C2C+JA+-VI=5J=O>:)B1!'4($=/?,VT\9VQB[2/JP<S-,?ZDJ4[^K;`.K
MK]^+L_:2575>7M:Z.1KK6G9)RWU^.:[U?[[Y7Q:Z5C?)99^<RTNVUG]DM?YU
M\_MOJ]>R>JI/6=9H$.%2K_53TUP=PZC34U8D]:B\9A?XY5!61=+`G]71J*]5
MENQ;I^)L6./QS"B2_*+3"$[UGACEX9"GF5NFST5V:6B0*CLG#=Q_?<JO-8]6
MI.\)5R35T_/U2UH65PCQF)_SYD<;5->*U(F.E[)*'L^0]W=SDJ0\=OL'"E_D
M:576Y:$903B#WBC.>6DL#8BT6>USR(#(KE798:T_F$YL+G1CLVH%^C?/7NO>
M_[7Z5+X&5;[_([]DH#;,$YF!Q[)\(J;1GB!P-I"WW\[`7Y6VSP[)\[GYNWP-
ML_QX:F"ZIY`12<S9_W"S.@5%(<S(FI)(:7F&&X!_M2(GI0&*)-_;ZVN^;TYK
MW1J/)M9TOC#!7GO,ZL;/24Q=2Y_KIBS^HU8FBT6C6"P*7%D4>S::SL=V&^2.
MH\T<)YWC_%U^<&OM;<-5W+:UF)K3&;GM.R/.F"=<F2>TPAW[.;.'Z\=2@[#M
M+<*5.;XOM27S@^L'4S.A>NADDC*B\S28G$&+H*TI-VF2S:HJ7S5H5)CE^IJ0
MMC<=$HU7$]6GJZ];Y05U1:(\D#!K'8:&PJFA)UXVMF6NC!>HXY39;+&-8K'C
M%J1H25A7!9X*?!4$*@A5$*D@[@$#9.FT@=K^%=J0,$0;GM66`R&6)4NUXQ;<
MQ56!IP)?!8$*0A5$*HA[0!(">O97"$'"0)U!7]VI$FIDPYQT1C-%G<ZDDP<1
M#Q$?D0"1$)$(D;A/))5@19-4&EZ0><<0ZU8,GL26$ALFH<O<MM3*Z(RXFXN(
MAXB/2(!(B$B$2-PG4NZP`G\@=V(MYTZ)#=KV<K>5>>^,NMP1\1#Q$0D0"1&)
M$(G[1,H=]A4I=[J$CN;@<+\$B*,L`R7VI%LK=HBXB'B(^(@$B(2(1(C$?2+E
M##TLY7P_46(M)\J()1)%Q$7$0\1')$`D1"1").X3*5'8TJ1$>Y/;G/+T:5M"
MP<)B-2"`#?L@W1U)$#E_1L2FL.N(Z`#+5%8^EQK9L$^+-C&57=3KC'B;^(@$
MB(2(1(C$E-##K:02G%S^OTHDB*P2(SV5.B($P"I1HXG9GD.LL:FL(U[W>R=0
M%Y:3`)&P\R*G&XBJK,Q1]SN/$?=C2'*1@Y:DUT#UP*&6ET]K+BO#$0PA*L&:
M*`LFL[+Z]8+E&K2REW(LCUG9LU;5Y6PL_^[S*/V-&XT5<*OV$:=MCE`@D8JE
M#A\IPZMS&O,HMX:7]0<K2?]/=;5)HBC30I$%^V1O6J:R5#ONV-_ID52NL.(%
MY3%DS]LYF(R5^?:YRRT16L$#;B46WQ"CZ(VQ8NYR:RQ9<'*R[#]FO%'P]"`*
M)T6>^M:DR)IU:">0$'M`1N8H8GG<42"?(Q$^P"CD2#A&&,4<M;%D&<C9\0,R
MT*.F)`-%$W&?.Y,BN[\4#,A`K6`IX))ZS-$B^]3+QK1GJ)R8SZTI9N74C<\C
MASRR&"SBB`]FSN6FB+G!K<%D(<E!M"_DYQJ8'F<E?2E2&EC9AG<F<X3]L&OS
M`<F9E>@SCSE"`PM'VU*D\'EX28J)LLT'W$KLCB%'8L1H>,2%*CZ[U5LCRN*3
MDW!?_#>:F1Z<)94IDIJY0T*9`4F9E6A`C[SZ@E78$LCG2#1)@%'(D7",,(HY
M&FAF<CCNR_"Y&J1';$D=AOH-;5O*?KPSV=F\;S4@&+623P#JYNJQ6'PE,"VE
M/GQN(-6'>CH-Q"V)E>`]XT<\/%L<S*FR$L7<X-;X<GV2P_R]B?E67F';'CRS
M]T]=[)E`U,<69JFM-5%8.X'NUBUS%+WJ<4>!?(Y$^`"CD"/A&&$4<S10M^04
MK\IC34?01Q]]Z<>>!_H*420_R-O*67$'3Q!$1[#BA>)BY&'D8Q1@%&(4843>
MT8N;H`5$W[G3]Z-%5AVS778^UUI:/I/WZ;"O;U8=IB_[MS,''I(A"Y6;"_X5
M0/G%73CP9(4]W*4##R:8ATL''BTPA\\,#^TZK\3?DL\/`_9;RX'W>P-Q;.<!
MI,`_;&T'WG4-\(D#[X$&^-2!=R3`C>Z.X+/#-3EF?R;5,;_4VCD[@(SC]LU(
M13]<T#\:UI"/90/?&]K>/,$'I@Q>`8])71[*LN%_D`&Z3U:;GP```/__`P!0
M2P,$%``&``@````A`$\LTUS!!0``"Q<``!D```!X;"]W;W)K<VAE971S+W-H
M965T,34N>&ULK%C;CMM&#'TOT'\0]![+DGQ9"[:#M26U`5*@*-+V62N/;6$M
MCR%IU[M_7W)NGHOB58.\9.,CDL-##LF967Y^JT_>*VG:BIY7?C@:^QXYEW17
MG0\K_^]O^:<'WVN[XKPK3O1,5OX[:?W/ZU]_65YI\]P>">D\L'!N5_ZQZRY)
M$+3ED=1%.Z(7<H8O>]K410<_FT/07AI2[)A2?0JB\7@6U$5U]KF%I!EB@^[W
M54E26K[4Y-QQ(PTY%1WXWQZK2RNMU>40<W71/+]</I6TOH")I^I4=>_,J._5
M9?+E<*9-\70"WF_AI"BE;?;#,5]794-;NN]&8"[@CKJ<%\$B`$OKY:X"!AAV
MKR'[E?\8)GD4^<%ZR0+T3T6NK?9_KSW2ZV]-M?M:G0E$&_*$&7BB]!E%O^P0
M`N7`T<Y9!OYLO!W9%R^G[B]Z_9U4AV,'Z9X"(R26[-Y3TI8043`SBJ9HJ:0G
M<`#^]>H*MP9$I'AC?Z_5KCNN_!B@)])V>86F?*]\:3M:_\L_AL($5XZ$,OR5
MRK/1=#Z.0UCKGF(L%"=*,8Q'\W"\B.?W%>$K<Q?^JA7OKC03"O!7*-Q?*>#Q
M8>%.BZY8+QMZ]6`/0R3:2X$5$29@3,:91T=%_GN!AXBCD4>TLO*A^""V+>R6
MUW4<A\O@%3)<"IF-*V-);*4$IA/-IC:0V4"N`0$P4K0@=3^!%EI!6M*AC01N
M/".3Y59*2)74!C(;R#7`X`"[Z2=P0"N0W/G=W'`A+!&5P)E%3(DH9@Z2.4BN
M(P8Y*!&=7']=R^V%PHR#7'O#D1A"IQR.8SL72DBJI0Z2.4BN(X;+4)S#749A
MTV6.6"['5I25D'+903('R77$<!DJ6G<9JWL.K4RVEL'UC79,-AR)(;]:`B86
M&R6DV#A(YB"YCAAL8`_;;!X6V/]%3QY,!PV9=#ABT9E:=)20HN,@F8/D.F+0
MP;.*U7JG4('_L_6B%9,+1RPN=CDK(<7%03('R77$X+)PN833$4Z]^Y6->J;W
M'(DGJNEN'21UD,Q!<ATQ7`WA,*+'_;Z#3-KT4$!6@.?69KE)J0B[4.9"N0&9
MGN.TLW;,H"B'?$S"$)"^;`2DQ]F%4A?*7"@W(--CG&V:QQ_$FD]"PTT!L:,F
M.Q1L0P=*72ASH=R`3#=Q3`UWDP\UPTT!+=C9)QJ'=B<,N4`,NU+URRBTBC(5
M4A$[&S.VF81B9CD<SRR=7`KHLUNW;!+%X3:<*!^%!E$.11-)U.Z1H="!3G&/
MJ)"ZI343BM#-\?@8AO&#65"YM#R,*([$X411VBIR`:F,6G'?XFT$=#[**)<R
M,BH@D=$HM([!N;`<#2.*TW(X43Y;C8QRZ)91IY$)G0\R*J3TC'(HGK.,SB*K
M)O)0J`SCB6-4X\DO*FS"=,>J?-Y0V&Y@J:?#8*#%-87/8H.^@/3"C.V]MP6-
M(<GF4I`XV68SH0A79;T<%O;6UA7-@L6)J]'NH<<J1O#C\]G@QZ%HIGS:A@K2
M?;+V=RJE;C,C<Z%<0LR\Z3D.8,WS'TL8G^(&(0Y-8HV0D`)>]WJ.D#)2$5NI
MR$(N)=K09&P+Y$(`9U[O8D80H.[O!N$;O7QOUVII95;,]B0@/:TWJ-\QMD52
M*76[U&8NE$O(32MV)3VM]S<DD[8\1P/0-_4TQ':4MT(1I&0II2Z4N5!N0&8N
M\-Q@;<AH^@.7(2QF:UH(R#P23L9FF6]O4C=2W!8H2BASI?"EC<6,27%2_.6,
M/^74I#F0+3F=6J^D+_@J!B-DO50P?[+;+!(X%,,R-AZ.$SQT]GV!5S[8Z#U?
M(GS_Z_\2R9=!:QUX,GQDZ;3P#2[2NP88ZL$?8[#3]V$3)_#>T./L)(%+?0\^
M3>#FW(//$KB#]N#S!"YS/?A#`A<CP`/%#)XB+\6!_%$TA^K<>B>RAZ2,V;1J
M^&,F_]&)^G^B'3Q&LE9PA$=G`H]?8]R9>TH[^0,74,_8Z_\```#__P,`4$L#
M!!0`!@`(````(0#E/QF.\0(``-<(```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;)16VVZ;0!!]K]1_0+R'JR^Q91PYC=)&:J6JZN5Y#0NL`BS:7<?)
MWW=F%Q/6EYJ^8!AFSIDS.\QX=?=:5\X+%9+Q)G%#+W`=VJ0\8TV1N+]^/M[<
MNHY4I,E(Q1N:N&]4NG?KCQ]6>RZ>94FI<@"AD8E;*M4N?5^F):V)]'A+&WB3
M<U$3!8^B\&4K*,ET4%WY41#,_)JPQC4(2S$&@^<Y2^D#3W<U;90!$;0B"O*7
M)6OE`:U.Q\#51#SOVIN4URU`;%G%U)L&=9TZ73X5#1=D6X'NUW!"T@.V?CB!
MKUDJN.2Y\@#.-XF>:E[X"Q^0UJN,@0(LNR-HGKB;<'D?1JZ_7ND"_69T+P?W
MCBSY_K-@V5?64*@VG!.>P);S9W1]RM`$P?Y)]*,^@>_"R6A.=I7ZP?=?*"M*
M!<<]!44H;)F]/5"90D4!QHNFB)3R"A*`JU,S;`VH"'G5OWN6J3)QP<W94JD>
M&4*Y3KJ3BM=_S,NP@S#!41<,OUUP//.F\R`.KX/X)A&MZX$HLEX)OG>@68!2
MM@1;+UP"\'DAH`!]-^B<N-#,D*N$ZK^LXTFX\E^@8FGG<V]\X-K[O'OX0-HS
M`]MX9G1&9BPIIG)O#$.:J$_$HHG_AP:=H1+S0?:G"HW39.`S.T\-+N,5HK.F
M[B5V%FC2OI3QY()*Z*(AE>[+(/+F%WOS<*08:--V%BCP@#8^KW!FT_Z[>]#9
MINHLP#B@FIRG@C,Y5AC%^C.[TK08:--V%EOA]#PM3N[1WP<ZVU2=Q59XH5T6
M-I69+?&(,\1`F[:SV`KGYQ6&T&!#B<@;QQ$.L"N5U9$V\<%D,]]>8,99,;JX
M83=9YN]#X&"RR[NXP`8Y#=ET?<.I=UTF!A[)[$R6S&EP1&S6B!FW-14%_42K
M2CHIW^&*B&"`]M9^?6WT]CJVQ\N-66M^_P;62DL*^HV(@C72J6@.F('N%F$6
MDWE0O(7<8<EP!8M%WY;P!X+"$`U0>\ZY.CS@ZNO_DJS_`@``__\#`%!+`P04
M``8`"````"$`[U/^J7\8``!LC```&0```'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6RLG5M3'#FRQ]]/Q/D.!.\+]!TZ;&^8KON]*O;L/C.X;1,#M`.8\<RW
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M(4GWC51_X3*/J^R$Q9E8=8[KV`DKHOYB"IW>7$RO%Y/%(5$FI**NL"/GD15F
M02>.,$?U[X2%47_A'G8&XHBD$])2U_=(42_U%-C/J.#N[>[3AY?=SS-:IJB[
M7W_<J45OLE9>>2[IPOO9]=[DHEFEO'Q6;CZ>4WZ:-Z^T(OS^:;:8?+C\G6;Q
MO;&Y11MAL6$+-665VT""4()(@EB"1()4@DR"7()"@E*"2H):@D:"5H+.`9<D
M3Z\1S83_AD;*C=*(>_>6@15MZDNV80O.$D@02A!)$$N02)!*D$F02U!(4$I0
M25!+T$C02M`YP!.$%IC_AB#*#<T[FOTCLT8;S6AL]$9+H5)OTLL$)`02`8F!
M)$!2(!F0'$@!I`12`:F!-$!:()U+/-5H:?=4&]XN\(JFK/?B<*?>:C*C0=$K
M,5O(&=,;<;8`2`@D`A(#28"D0#(@.9`"2`FD`E(#:8"T0#J7>%K00_,$+92U
MKX4F0HN9F!>]4:\%D!!(!"0&D@!)@61`<B`%D!)(!:0&T@!I@70N\;2@?<L)
M6BAK7PM-9C3OG'DQ%UKT1KT60$(@$9`82`(D!9(!R8$40$H@%9`:2`.D!=*Y
MQ-."G@4G:*&L?2TT$?-B(;3HC7HM@(1`(B`QD`1("B0#D@,I@)1`*B`UD`9(
M"Z1SB:<%[68]+=36>+JXH'ETXN98.?)ETD1,&?E8[XUZF8"$0"(@,9`$2`HD
M`Y(#*8"40"H@-9`&2`ND<XDG$QU//9G&'^O*VM="$Z'%2DR9WJC7`D@()`(2
M`TF`I$`R(#F0`D@)I`)2`VF`M$`ZEWA:J//^"6+LS7TU#!(KV+60PUKU>B`*
M$46(8D0)HA11ABA'5"`J$56(:D0-HA91YR%?'G7"E*?]!<$3%S05I!&SR"`Q
MC6ZD;CHC65G=`(76%UM%B&)$":(4488H1U0@*A%5B&I$#:(64><A7S=U$'5U
M&U_C5.A,RJ.1+\_R2LK36W''!\:7HUB(*$(4(TH0I8@R1#FB`E&)J$)4(VH0
MM8@Z#_GRJ".G*\]^IS!3P>>AF/1L00$R$S;3AU4*`7"'WZKH)8FWF/9H@RA`
M%"**$,6($D0IH@Q1CJA`5"*J$-6(&D0MHLY#OBSJ].G*<F#6Z,.JIT5_?K5'
MF\D5S)K>BD4,5#R91*2G&*,0480H1I0@2A%EB')$!:(2486H1M0@:A%U'O+E
M40?2$^31YU=/'HW$H@9!Y=Z*M0C4RR(ECWT,A8@B1#&B!%&**$.4(RH0E8@J
M1#6B!E&+J/.0+X\ZHYX@CS[2>O*84RX]5&Q@8"D#9NJUB3]5`D0AH@A1C"A!
ME"+*$.6("D0EH@I1C:A!U"+J/.3+HXZM)\BC3[F>/.;@Z\5MEC*&1CG$5`D0
MA8@B1#&B!%&**$.4(RH0E8@J1#6B!E&+J/.0+X\ZKKKRZ/=J%^K%Z8''D#[H
MDFM>KF[5>SDU1>8]VB`*$(6((D0QH@11BBA#E",J$)6(*D0UH@91BZCSD"^+
M.KFZLAS00A]T/2T,LD_VS010@"A$%'G(J^?TM'/TWMP_1S.BNCF+KXS*&JN9
M:S6=B$!48*SH#QZ2(:/9_EWO8G%S/;T2,9.(;>B`UU?!=>ZW6!T#765LM&U<
MHZD^/[H:&32E35A?\&PIHZ"<D297;^563[^!9BNK=\CNU3;^]T^KR=5B)OHU
MXES'-5V=NMRF'VBP/J1Y#3;(E7&V%#)NIMKJD-C:RA/;("WV?'DUO1:/B<CX
M5NT>[$Q?Z\'STG)_7GK[_G#_Z^V.G)"K@8Y0==!GIRF>G0P2PHMQN>&,!X0W
M[EWA-:)CG1)^,I],E@L1X8C8^7$=H8X))RBO3Q6>\AI-E_W4W*C6T]."T+`4
M9EP;*_N8"3FC11&CO7M?0[6%=JN^GZ\G:Z@WXEZ+#/+'L@P`JJ.U>B2Z5@.3
M5UMY8]D@/9:O)]=72QS,QN8X#=7^57;$9+%_TN\'\[]V/]X;S/N19$:SW@9[
M/:&1IVV/1K4U5O93CU"-!C4H+(H8#6A[VMYRBGM+@\3)3,R5C;7BYTJ`*$04
M(8H1)8A21!FB'%&!J$14(:H1-8A:1)V'_*FGMH/OC+B!%=,=9'HCZ0TRC=R]
M)0T2L=T,$(6((D0QH@11BBA#E",J$)6(*D0UH@91BZCSD"\+K46>+`>T4.9B
MSV:0?>1LIH`"1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J$'4(NH\Y&DQ.VW_O#?W
MM3!H;O>\&XO&%E^V(N'ZG=!L)6*&H;7BI2]B9$N,$26,?/<BJ)):*W:?,;+N
M<XML5>$A6K#5:(FEM>(2*T:VQ-JBD1(;MO)+%$^/UEIQB1VC?8G^@*!G^0F3
M4WUN)R:G0=Z`T%8."MC*K[H(28;6BJL>,;*=%2-*&/GNQ68\M5;L/F-DW>>(
M"D:C[DMKQ>XK1M9]C:AAY+F_%E.CM5;LOF,TH*LZFKC/PO%%5[U6EKIJY(BX
M,58."AC=]/OL$%'$R'9#C"AAY'7#2APA4VO%W9`QLNYS1`4CW[TX#);6BMU7
MC*S[&E'#R'-_+49X:ZW8?<=H0$1Y'CP@(A[\U$:3='44VR`*&+DBFHP616QE
MNR%&E##RNF$E8@RIM>)NR!A9]SFB@I'O7IQD2VO%[BM&UGV-J&%DF]TBZA@-
M**9.CR=,.WW8=/>=M.$$Q0`%;&7K&2**&-DVQX@21M97BBAC9'WEB`I&OCSB
MD%I:*RL/M+%F*UMBP\A6M474,1J01QU@77F<Z//Q`19Z3PV+I4;>/`,4F(P+
MVZ(04620XRM&E&#&%%&&&7-$A<WH[#ZFH)IND%/["GW5B!KKGN5N$75>1G^/
MHL[HKFH'ED%]I/<FE4'>L+P6F\/-S,0":(_<[U!AVQ=8*VY-R,C$`5=3\>B.
MV."]P,D^U!&SE1T>B45.E69BQY<:*_I#Q=_H9ZS$4R=C-Z/EYVPUVO["6G'[
M2T05HMHBIRTRIMY8*W;?(NH\Y`^6TV(T,XS1&#2G%:D?!C,9"]MP1MHE]58#
M@\6XMR?7T&3D8.GU4FQP(O8\*E;,5M9S8I%3)1PLNDIDK`8+_5B=F`89NQDM
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M#PL!9]1/E-G%4NQH,W8S6G[.;D;;7[`O^]PK.:,N?W4AVU]QGM'R:W8S6G[#
MOD:[I&4K+<F47J&+?5G'%N_5R1^9M!*/CLSCWK[.E1LQ-#7REIT>C8Y#8V5?
MM8;&/;T[X@$4,7*7G=X]6R5HE2+*$.46C52UL%9<8HFH0E1;-.*^L5;LOD74
M><@75\8%_](W!G,,%QKD?R=R+2;GAC/2MG!LV3'N[0$E9/?Z.Y'%3)[`(_;\
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M[TVQ??DYNW%["39[!?MR-SNFXKK\Y<5$E%]QGM'RZZ/*;]C7:)>T;*4EF5#`
M1-2I8XOWZN2/3!6X'1N91RX[)DILST6W<Q,2MNO"QJ*1R1:PE;OL&%\616QE
MW<>($D0IH@Q1;M%(50MKQ0.[1%0AJBT:<=]8*W;?(NH\Y(NK8GRNN`<.RB8D
MZ(JHD7IKUV\.9C<B/+:9]U9<SP!1B"A"%"-*$*6(,D0YH@)1B:A"5"-J$+6(
M.@_Y\JC@X`GR*'-QH-!(R",6A,V\M[+R``K1*D(4(TH0I8@R1#FB`E&)J$)4
M(VH0M8@Z#_GRT./"D\?9D1V82"JG4$HC>K_*&FSF@`)$(:((48PH090BRA#E
MB`I$):(*48VH0=0BZCSDR4(O47U9QK78F_M:&"1FC?CB:6.M6+$`48@H0A0C
M2A"EB#)$.:("48FH0E0C:A"UB#H/^?+0MN.OS1IU:828-0:YLP91@"A$%"&*
M$26(4D09HAQ1@:A$5"&J$36(6D2=AWQ95"#H^&<-714`6AAD3^4;MK(H0!0B
MBA#%B!)$*:(,48ZH0%0BJCSD]Y^*?[C]YSP,CO_\96$".\X.BY'=VFXLLILN
M.*X$QDK-1&=K)@YHH;7B52Q"%"-*$*6(,D0YH@)1B:@RB'[2DJKJ=[Z*)_S]
MSM=1"3<TLC#([?P>V6X=Z'QMI>:;T_GBY7)HW).5[?S>/:,8*Y'8C*Y[$7-+
MK17[RM!7CJBP&5WWXHUF::W8?>7Y\B52)V57H@-/97VP]K0PB'9%3I>*MRN;
MA;8Z\#F`M>*JAX@B1#&B!%&**$.4(RH0E8@J#_F]+$_K!WH93^4+C52HRNEE
M&:8V5@?>E5LKV\O:O8G33BZ$XXBSN/-F+@.G,5O9YTJ"*#7(E'4ER\HXRVA9
M.5O9L@I$I5_6]&)ZX_TG1FG%'MXKVA?UM%/Z`D_I!JG`3R_J_$J>THW5H:FC
MW;M10).1/V(1[SO9[7MMU2%`MK+!M011.EI2QAE&2\K9RI94("I'2ZHXPWLE
M^?JIL_0)2Y\^>GM+GT;>I)Q?R6/\PF3T7DM`T-Y:V4FI,_++D^D%S3CG/_%8
MB=C#>XTW@O:UX7(2SFBG4FH0%ST;+SIC#Z-%YVQERRD0E:+HZ<6-TV;ZY1K^
M,*[8PWM%^Y*KH_L)DNN3OB>Y1F+*PAE46QV:LKT52Q$N-#)3E@+7?FLCDWX@
M;L]6=BHEB-(#966<Q>U9V%'E;&7+*A"5!\JJ.,M[97DJ+D^+).S-_4B"02J&
MY"R\8@^^L5:L3X`H1!0ABA$EB%)$&:(<48&H1%0AJA$UB%I$G8=\>4C$$R;9
M4ID+>302\HA=^L9D)"LK3Y^148A6$:(848(H190ARA$5B$I$%:(:48.H1=1Y
MR)?GM(C"$B,*!@EYQ,*\L5:L18`H1!0ABA$EB%)$&:(<48&H1%0AJA$UB%I$
MG8=\>63`8ORHL,3(A$%"'G%*W%@K*X_VY4RH$*TB1#&B!%&**$.4(RH0E8@J
M1#6B!E&+J/.0+X^*`QR_@UB:L($3.#)(R"-.(AMK9>71OCQY`$68,4:4($H1
M98AR1`6B$E&%J$;4(&H1=1[RY5%AAA/D,;$+5QZ-O)<,\RMQ'MXL>RLK#Z`0
MK2)$,:($48HH0Y0C*A"5B"I$-:(&48NH\Y`OCXR#.-'8`^L<AD26)F;AO)I#
M%"`*$46(8D0)HA11ABA'5"`J$56(:D0-HA91YR%?EM,B&4N,9#"R1[L-H@!1
MB"A"%"-*$*6(,D0YH@)1B:CRD-]_ZDSMKCK.L#[^)</2G,S=Q<@@N\7=L)5[
M=(%366"LU"48]H`S$=^7A=:*5[$(48PH090BRA#EB`I$):+*H(&7#$MU9/[[
MG:\/WNY1?^^8#B9NYQNK`YVOK>CC]?W/IEY-1'@@-)[)P/9[[YE1;,NW&H+2
MB?5E"A/AI]0:L.?,>F:46S126&%]F<)$?**T!NRYLIX)>=-F==HY?F_N'Q09
M4>?UPUS>GK$Q1@>",8-6\G/JD*WZ#RO%J2=B`SJ(]C4"T6*V<J<G6"6#5K)*
MJ;$R(:,;^:ECQEY&:Y2SU6B-BD$K6:/2K]%B(8X>%7MYKT;^(%%'^K\]O5?*
MBQ@[&GD?_LM+.S:<;SQV:ZUXU(<&\8\\3U8P4$R-Z(^Q@6*L1LM/L/S4(!/`
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MUE>**&-DW><6C;@OV,JZ+Q%5C`9FLPI0G+",ZGB&NR-6-];3RNK'1N3-*QMK
MQ8^#`%&(*$(4(TH0I8@R1#FB`E&)J$)4(VH0M8@Z#_GS1<9&#CSE,""R,@$1
M]VF-5W];*RM/GY%1B%81HAA1@BA%E"'*$16(2D05HAI1@ZA%U'G(ET?&2-1R
M]I=^!>0*PR<&B8DE3G(;:\4R!8A"1!&B&%&"*$64(<H1%8A*1!6B&E&#J$74
M>4@K=^G\BONG[<NW[6;[^/AZ=K_[[9FT6UW3\;S'9R_;KQ_/;U?+M1H#U+^0
MLJ*4_49*IBRG:_4^9R#/<D8I^U\L!'GFE+(/7$+*@E(6@]ZH;A3#&RAG17EH
M81E(F5ROU:_`&$B94GOH7NFA%,JC?SQ=UFU.>>C'8@;RS"F/?C$!>6XH9?\#
MA#)E0OU&7ZH->)M0O]'O\AI*H7ZC7R,UE$)]0+_!:"B%^HU^><Y0"K5'/]]D
MW517#^50@V"(4_,'>YD:/]SV*RIY_\F$+'DRH91]8$BD!,N;M8H<83LH!K16
M81Y,H8#-6L5D,.7S9/UYN.^I^`'[6Q)KR/[S;/UY>%J0AH,2DH*#`I)^0_+1
M1;[D:"B%OJ1>J^^1L7'!8KY6'_%B"GVANU;?WV(*?5Q+WH92*)A*G3@H[X+J
M1A]RH[?;!<FHOQ\6,MXN*0]]/#&09TEYZ+T]IM#UR6MU\2"FT"W*:W7_(*;0
MS<EK=2_R4,J$4H;*H0M=*65(9KHEE%*&^IHNJ*24H7ZC2Q`I9:AN=`'U6MW3
MB'6C>ZC7ZKI&3*&[I]?J9NFAE`FE#+6'[K^EE*'VT*6JE#+4'KK/DU*&VD-W
M1E+*4-WHONZUNL,2ZT;7=J_559:80K=WK]7=W$,I$TH9:@]=%TPI0^VA.V@I
M9:@]=-<II0RUA^[3I)2ANMU2W6X'4^CB\_5F,"6@%'65.;:'+L*FE*'VT%7*
ME#+4'KJ?EU*&VD/WP%+*4'OHKE%*V;?GLI]TKY\^_+C[MBWO7KX]/+^>/6Z_
MTJ/_:O\;.5X>OJD]G/['F_G-'+_LWMYV3Q0].C_[OKW[LGU1!G3L^;K;O?$_
MJ(F7/W<OO^ZW%Y_^7P````#__P,`4$L#!!0`!@`(````(0`=MG3Z80(``+@%
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)14V8Z;,!1]K]1_L/P^
M.$"6#@J,DD9I1VJEJNKR[)@+6,$8V<[V][V&!*632$U?`)OC<\[=/'\YJIKL
MP5BIFY2&P8@2:(3.95.F].>/]=,'2JSC3<YKW4!*3V#I2_;^W?R@S=96`(X@
M0V-36CG7)HQ948'B-M`M-/BGT$9QATM3,ML:X'EW2-4L&HVF3''9T)XA,8]P
MZ**0`E9:[!0TKB<Q4'.'_FTE6WMA4^(1.L7-=M<^":U:I-C(6KI31TJ)$LEK
MV6C#-S7&?0S'7%RXN\4-O9+":*L+%R`=ZXW>QOS,GADR9?-<8@0^[<1`D=)%
MF"PGE&7S+C^_)!SLU3>QE3Y\,C+_(AO`9&.9?`$V6F\]]#7W6WB8W9Q>=P7X
M9D@.!=_5[KL^?`995@ZK/<&`?%Q)?EJ!%9A0I`FBSH;0-1K`)U'2=P8FA!^[
M]T'FKDII-`XFLU$<(IQLP+JU])24B)UU6OWN0:$W-9!$9Q)\GTGBZ:,DK#?4
MQ;?BCF=SHP\$>P8E;<M]!X8)$M\/"$UX[,*#4XH]C5XM%F&?C<-XSO:8.7'&
M+'L,/@=,."`8B@[*J/:XL@=[99\/;V79;US+1/=EXO^1\6#,Q.S*_6V$/6A\
MA9G>ET;(XQ%Z<"<]A'C>P68=4CD.Q_>EL(NNI7Q_1G'7C/\HJ3_XM^QY!Q-\
M)3MY(]M/2M])"DP)'Z&N+1%ZYZ<@PMX8=H<!742^?&_WXV3130P;?N#@M+R$
MK]R4LK&DA@(I1\$,C9E^]/J%TRTZQ_'1#D>F^ZSPA@1LCU&`X$)K=UF@,!ON
MW.P/````__\#`%!+`P04``8`"````"$`W@.I(W<,``"+1```&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6RLG-E2XTH2AN\G8M[!X?N#+0D#)H`3C:U]
MB8F),S/7;B/`T1@3MGM[^\F2:E'FKQ;+Z9NF^2HS2_XKJU19DKGZ\\?V:?2M
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M0N0\`>^H&8%_[4=W]?WJZ]/QW[OO2;UY>#S2<,_H$ZD/=GGW<UD?UJ0HA3GQ
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M!%4',#%IHOP.,5482O?SH61M;0(:5IO09T)@:V(5!A("B8#$0!(@*9`,2`ZD
M`%("J;J$B4UK`1.[_WYCYK^R;C0U8MRV)*"QM`KZ%W+&6R/CM@02`HF`Q$`2
M("F0#$@.I`!2`JFZA&E(][!W:*BLN88M"6B,.AK*B6Z-K(9`0B`1D!A(`B0%
MD@')@11`2B!5ES`-Z;;.-&QO4"=J%S&<DLJ1R]F2X-0NHPL@2R`AD`A(#"0!
MD@+)@.1`"B`ED*I+F':TQ#'MA@53UEPP37PG&)`ED!!(!"0&D@!)@61`<B`%
MD!)(U25,,%4TX6ZH2;;CXV;]Y79'$Y%N"CU"!K3K:?="*@C741-W_UY8TIG9
MGKC#+%NC@#:9G>D?\-M0:(W,](^`Q$`2("F0#$@.I`!2`JE:XC6?GJE-^^V_
MK[8*PM76I*.V)1TA0>W6B$HYM7OUIYX4VK9;H6U80V)+!CI*;"#=D5C04]MN
MPF8VK"&Y)0,=%3:0[DC<?4O;;L)6-BP1-E2JTF%CU3,#J"0T4Z`QYZ-B$'71
MR>93GLT+;>6SG(>AZK4*YCQ6:*S4S/QVX\V"0$RPR%ATMWF^["TV5H/7E/1:
MR6M*C96^INDTF/*KSHS%X#7EQFKPFHI>*WE-I;%RUR12OS(6O[HFGBID]9Y4
M4>8B55KDT[ZJDRHS+M3"TXYLARD';^FL3)*'&C7I2GEQ?G[!(T?&ASIP_<O(
ML;$:[#]Q5J;_5/0_GXNTS(S/8/^YL1KLOW!6IO^2]Q^<!V(25L;G5_WSX:;^
MWS/<REP,MT9\91"B++S6ZK65P5J9CQL:1YW>%S.Q3D3&X%<?M[FKQ\9J<,8E
MSLKTGVH4G#7+T$QVGQF7]N1-G7OD!@WV51@KYU@:1"IT,E=\X,I8-8Y\,%4Y
M^+<W0.I$2XYQB\24/N<3;V$<^>6+3%@Z*Z-QJ%%PWFHL9U1D7%X98GW=@]TG
M)I;;%:>\>\\32U5F7-Q(Y08-]E48*^=8FKYH5S4TQ/JC]`RQJE:[0_S*G;PM
M;NFTQ(A]JXX):7C],XL6#G4O"@9..[I8H7%T*#+(A8\=&@B?&"L7*T64&>3"
MYPX-A"^,E0M?(JH,:L+SN:5*W*[PG4KV[<6%.OJ7<TNC[OHY%RFXT'Y!UPBV
M.DMMQ1=9N6$(C95>4>>S,['"1,;BE?G67OCP-24F%EL,Y36EQDI?DW\^A8U5
MVYL_>$VYCC-\387I;?":2F.EKRDX/Q,+7F4L?G5-/(%4G3^40'_M7NC.VEN=
M=O?F[7$!F]$M8C/:HH$YL?2TE:NU0D2106[*Q0X-A$^,E0N?(LH,<N%SAP;"
M%\;*A2\150;US&AUCM`=D%>64GWLX!:06W4(3;-9G)**_>C"69DU>(DH1!0A
MBA$EB%)$&:(<48&H1%0QQ'-<'19T)56+9'"A'FWJQXUO?R2ESQVZ<K=('*B*
MQ6M!)Q7-H`3V_K9$%"**$,6($D0IH@Q1CJA`5"*J&.)RT^T`Y#X+F@.O]SX!
M5*'$QKY%7.ZY6)<7GK5RV0TH1*L(48PH090BRA#EB`I$):**(2:WNJ^"W#-:
ML=^I=1.':ZV1T%J<^"R<E=4:48@H0A0C2A"EB#)$.:("48FH8HAK3;(RK8<7
M9[4M$.FKD5B<Y<;*63E)VUCD:%"(5A&B&%&"*$64(<H1%8A*1!5#7%(J5IBD
M:G'^V&KAJU`B@ULD,E@<CBZT(UD9;9>(0D01HAA1@BA%E"'*$16(2D050UQN
M5</)>Z$_.WG_K=#7U6#G5JB14%L<_"V<E5.[C=49@!"M(D0QH@11BBA#E",J
M$)6(*H:XVN^KB]5)ADS@%IW2]L%5YG-QN+;0CF3E)+6.!H5H%2&*$26(4D09
MHAQ1@:A$5#'$)545U^])X+9VHWVC4>A6[0AI`$0"P^ILK8SCTCD:%"**$,6(
M$D0IH@Q1CJA`5"*J&.)JJUI,JNW-WO"DG.H^R.46=9^5:ZL.6B(*$46(8D0)
MHA11ABA'5"`J$54,<2EE8:=N=!_9IV'%Y^N*CU;1SB(A3LH6SLKDZ!)1B"A"
M%"-*$*6(,D0YH@)1B:ABB&NMJJUNVKZR3VN+,[82M$BLN^*H9>%;*R<IH!"M
M(D0QH@11BBA#E",J$)6(*H:XI*I\ZDJJTO=C&X>V$&-JV]JLF\#RR,*W5DYM
M0"%:18AB1`FB%%&&*$=4("H150PQM=7[&:#V!Q:+)@[?$FLD[G'RO,)96:T1
MA8@B1#&B!%&**$.4(RH0E8@JAKC6[ROJU/N;8I.FD2CJY/KKK)RD6-2A580H
M1I0@2A%EB')$!:(24<40E[2OJ/M(^F)%IT266[1`GLLOG)73VCH:%*)5A"A&
ME"!*$66(<D0%HA)1Q1#7NJ^B>],632T!,I-U(=9YG5%;=;=HB$)$$:(848(H
M190ARA$5B$I$%4-<2EFN?7"+1EJ!L"U2?=LM6C"51VG:D:Q,CBX1A8@B1#&B
M!%&**$.4(RH0E8@JAKC6?77<QP[EU7>/9![;$JTKMSSWT8Y,;NMH1B!$JPA1
MC"A!E"+*$.6("D0EHHHA+G=?(?>Q8S9ZZ03DUI4=SVYY\*,=F=S6T<D-*$+'
M&%&"*$64(<H1%8A*1!5#7&Y9[`T7(/2."4BJ:SJZ:]D%P[^0!8AVI+N#T6^)
M*$04(8H1)8A21!FB'%&!J$14,<0E5865+$`^F,%MC=:M0((6B?59GK,Y*R>W
M=30H1*L(48PH090BRA#EB`I$):**(2ZWJJRDW!^J]]1K#W)YMF6;2^Y@*L_9
MM"-;+ZRC4QM0A(XQH@11BBA#E",J$)6(*H:8VJ=]]=['[H9-*%[R:2226]8G
MSLIHNT04(HH0Q8@21"FB#%&.J$!4(JH8XG++DN_#AQGT:K],;HV$VG+E=E9.
M;5T-NMU?B%81HAA1@BA%E"'*$16(2D3J^^I*B7:VMFJWWS]OOQJ\K?</]:)^
M>CJ,UKNOZKOEM-3?7%G<?O']-IA?JFE"FLB6TRE])[[Y6CNTV&_+RY8@H&B-
MG-!R2BU-E0,M,VIIOO0.+6?4TKRQ`RWGU-(\1X"6"VII'LO(%I]\Z`2SYY/Z
MY$,'<7TMI`X=&O6T!*0.'7'TM9`Z5*GWM?C4TNP<X-K(AQ[9]OCXY$-/%_M:
M2&MZ$M;70EK3`YV^%M*:'C[TM9#6=);>TT(NO1[DT&OOD<[MG5Y^2H]TIM=8
M>OKP2&=ZXZ*GQ2>=Z?T`;%E>7-+7E'KX_#+LBY3,+^E+.6A?S"_I.S3(Z4]"
M?.K5G8:J?Z3H0OOB!)>?:*IB![=JKO1Q&KUF\"96/_I3$"^KA[I<[1\VSX?1
M4WU/TWG:/!3:MW],HOWEJ-\=_+P[TA^#H'L2_2D`^J,?-;V./E5/G.]WNZ/Y
MA2YH8O^,R,W_`0``__\#`%!+`P04``8`"````"$`38",FHP2``"B9P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RLG5USVSBRAN]/U?D/+M]O;'TZ
M5B7>BB52_/ZJ/;O7CJTDKK&ME.4D,__^-`2T&L!+05)V;L:3AR\:S>XF"(`2
M]>&??SX_G?U<O6X>UR\?SP?O+L_/5B_WZX?'EZ\?S__O7_$_WI^?;=[N7A[N
MGM8OJX_G?ZTVY_^\^=__^?!K_?K'YMMJ]79&%EXV'\^_O;U]GUU<;.Z_K9[O
M-N_6WU<O=.3+^O7Y[HW^^?KU8O/]=77WL&WT_'0QO+R<7CS?/;Z<:PNSUV-L
MK+]\>;Q?+=;W/YY7+V_:R.OJZ>Z-_-]\>_R^86O/]\>8>[Y[_>/']W_<KY^_
MDXG/CT^/;W]MC9Z?/=_/TJ\OZ]>[ST]TWG\.QG?W;'O[#S#__'C_NMZLO[R]
M(W,7VE$\Y^N+ZPNR=//AX9'.0(7]['7UY>/YI\&LFTS.+VX^;`/T[\?5KXWU
M_V>;;^M?R]?'A^+Q9471ICRI#'Q>K_]0TO1!(6I\`:WC;0::U[.'U9>['T]O
MW?I7LGK\^NV-TCVA,U(G-GOX:[':W%-$R<R[X=:-^_43.4#_/7M^5*5!$;G[
M<_OWU^/#V[>/Y\/QN\'X<DKJL\^KS5O\J"R>G]W_V+RMG_^C-0/ET\[&T-B@
MO\;&:/IN<G4Y&IQ@9&2,C'=&!@,Q$NB=_-R>`?W]_=ZGQ@A=%L;(D;U?FX;T
M5WKG^`6\'E"F=>`E:D=V.>!0J?\YK5,*KNZ4SO>T\QQ<<5/ZG],ZI9CJ3H\-
M[H6NT6W)+^[>[FX^O*Y_G=$X0F6X^7ZG1J7!;$#6N-AUG'?EOZ_ZJ625E4_*
MS,=S:D^5O:%+]N?-<'+YX>(G76;W1G.+FH&KF+-"70G*[,('D0]B'RQ]D/@@
M]4'F@]P'A0]*'U0^J'W0^*#U06>!"TK/+D=4SG]'CI09E2..[BT#*VE>0EC!
M318^B'P0^V#I@\0'J0\R'^0^*'Q0^J#R0>V#Q@>M#SH+.`FA0>+O2(@R0]<=
M7?V!JT:+1E0;.]'4R]).LDL3D`A(#&0))`&2`LF`Y$`*("60"D@-I`'2`NEL
MXF2-1FHG:_WW<Q[1E'J;'`[JK28C*HI=)H83?PC;B;C9`D@$)`:R!)(`28%D
M0'(@!9`22`6D!M(`:8%T-G%R03.+$W*AU&XN-!E1KJU<#+WK8B?:Y0)(!"0&
ML@22`$F!9$!R(`60$D@%I`;2`&F!=#9Q<D$3%R<7:@HP>J_FMF:&>O0L0%ER
M\Z2)EZ>1EZ>=:)<G(!&0&,@22`(D!9(!R8$40$H@%9`:2`.D!=+9Q,D3W2><
M/(7'+Z5V<Z')^&HW`9@#60")@,1`ED`2("F0#$@.I`!2`JF`U$`:("V0SB9.
MX&E:ZP3>ND#".5`-W1P8,I0<:#)V[RIC]PI9&-%HURSJ;3;9-7/\IX64XW_8
M::5VG=;$+AP@"R`1D!C($D@")`62`<F!%$!*(!60&D@#I`72V<0)O%J1.I'7
MJRNZ:X53L&WGYH"153D&'2@=5EFUP\BM.9E5NN>@5B7V"O&`ZWH10Y-:'LQO
M!QK9]8-H@2A"%"-:(DH0I8@R1#FB`E&)J$)4(VH0M8@Z![FY4`L2.Q>JGJ:C
M=U=TJSZ0%M72JRB#[(K2Z%!%&95=4;T-K_J'([7'`F<QF!QS%GIN[Q271J/Q
MKM[F6_LTA1&T0!0ABA$M$26(4D09HAQ1@:A$5"&J$36(6D2=@]SB4I-UN[@.
M5)2>VSNY,--]2HDU*W^_JX+MGLY\L%/Q"+%`%"&*$2T1)8A21!FB'%&!J$14
M(:H1-8A:1)V#W/2H^;N='GTO.>:JT3-_)U,:69?(7.UPTPAAH06B"%&,:(DH
M090BRA#EB`I$):(*48VH0=0BZASDID5-U^VT'+AJ].S>R85!]C@,:#$`%"&*
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M04ZJ5>Q/2/56[JZ`#!K3A-1*M;?W,N>&M,01E9^+1:]JY(_T1K6MP)\W@ZO!
ME7=%QVS''FA@=%BR*NA3TJOR?4H/^I2QG:!/.:N"/A6L<FSY/I5&-:)1UXJY
M%\VJUY:?F9I50;\:5@7]:H_RJ^NU9?GEEC'U>$H9*[E7QAJ-:0(OP1K)XELO
MNX9:I7P3E>64GK"(BB_*B)&:(?V\N1J,_48Q*ZB'_::7K`HZD+!*[J$I(S>!
M7C%DK`HZD;,JZ$0A*HY"R6AO%"I6!!VH615TH&&51*%E%(Q"QZI]3KBE1[9.
M*3TE]TI/(W<$'7MW\/G0-*0_^^MC(2H.>F00#Y<T7L)P:4SO.]]M52_%=,"!
MA%42]-2@\#B42<.`^9Q5P2@4HN(HE`;MCT+%C8)1J%D5=*!AE42A-2@<A4X:
M]D?!+;V^/<#AY!V-8>$9VQ"W``URQ[^QMQ2;&]6A\4^;)Q6'/^*&YLJ_O/2F
MQ#$+@M%?LBIXX2>LDNBGC-RTP?!G'`\ZD;.MH!.%J#@():-]0:A8$.R_9E6P
M_X95$H2643`(':OV.>&6H-J'M)<*O[5;,-2[F?8*PB!O4(1II6GHGI%7M0LV
M+YM#D4%F.)A>7D$]&LO[HF#&Q&/Z3[A_245J4'@TR*1A_VBP=2)G53`(A:BD
M'K7W>X-0<9M@$&I6!?MO6"5!:`T*!Z&3AOU!<.M1;<#:]7A@(-3[M4[A:32<
M[@:O.05(W;,)]7M@9GU&)3LE$3<4%#,2\TM!`?,)J\16BBAC).9S00'S!:O$
M?(FH8B3F:T$!\PVKQ'R+J&.T->_F5>W<GI!7L]$KW=VJ[%$2Q^+ZW*"1LTOA
M3\P71N7>\_S%5L0J/;8/!J/1U'MF$[,D>#4MCW(J85O./<!W*F65<0I7RADK
M@C[E1_E4L*V@3R6KM$_7T\&U%Z>*%4&?ZJ-\:GIM^7%J6>6.8-[LH&/5/K_<
M@E6;UB<4K-D)MPM6(S7\R81_ZFV7SH>FH;O(ASN@4=EW0$`QVQ+5DE'0?,(J
M:9@BRA#EC(+F"U:)^1)1A:AF%#3?L$K,MX@Z![FI)O.GI%K)O16@1N[D>^HE
M<3[4JD/#E58=&JZ,BH>KX957[;'I3:V%I?S\P7%YE$])KRW_*DQ9%;P*,U8%
M_<J/\JOHM>7[5;(JZ%?%JJ!?]5%^-6PK.)*VK-J;PXX5^WQRRUCMQI\P8NG-
M>V?J9)!<2/.A1O3959YU+A!%B&)$2T0)HA11ABA'5"`J$56(:D0-HA91YR`G
M%^I9IY.+WUI6;:VX(PTCZ]F=H,"%OC`J]4>&@ZFW/QJ)BM,=(UHB2A"EB#)$
M.:("48FH0E0C:A"UB#J#Z(D:G;:;2+KT_H9$*BM>(@VR$[E#5HK\$7NAO@2C
MYL'T9Y=(>`@K(LGCSCJCI5&I!XD[4_"8)1%;ELJ?'*>B8O.9F&>4"[)L^:=8
MB"U+!0]A1<7F*S'/J!9DV?)[;,26I8*'L*)B\YV8)^16#MUNG,H)KV35-VK\
M$C&(AF!)S]3?0C$-W?F"?X*+7I5_IXQ8I>](H^N1_\@W9H5=?5`R2U8Y@XWO
M4]*K\GU*6;77IXP509]R5@5]*ECEV/)]*ED5GE&PRK'E1Z%F5="OAE6.+=^O
MEE6.7U-O9MBQRK%E^>66L;]'?:",<6=:?>^%*MM=!\&3.:,:.*Y;3ND]&E'Q
M%1BQ>?5YAI\WX_'[B3?OCKG1OO/56X&L"CJ0L$IVP5*#PKM@F32T+F;__')6
M!9TH1,51*`VB#9@]4:BX43`*-:N"#C2LDBBT!H6CT$G#_BBXI:>V-X^?T-*'
M-F$$-<@90>')G&EX:`35MDC%08^XH1Z:IO2&"O<S;3$+@C%?LBHX`B2LDIBG
MC-QD>9=[QJJ@$SFK@DX4HN(@E(SV!:%B0;#_FE7!_AM621!:1L$@=*S:YX1;
M>&HGV"Z\WYN]Z_UD>X$U,EO,5$IR1Q_#'=TT=,_(&]46QA8-F)R*B,WK06`Z
MOO:>0<?<9E\4S$AX3/^)V.+^4X/"8T`F#:T@X$AXC!,%VY(@E`:9D1"#4'&;
M8!!J5@63T+#*KD?M>#@(G33L#X);CZ=MGH]P\]P@V@'E9,T%]7M@;KC:%FV>
M<<.(&PJ*&8GYI:"`^8158BM%E#$2\[F@@/F"56*^1%0Q$O.UH(#YAE5BOD74
M,=J:=_.JMG#_^W'&;`2+%[<CC>QG)08=V'PT*O=6Z$\S(U;I(?]Z>CWPG[ZR
M(GB-+8_R*6%;SIW!]REE56"9H(,2WA#-C_*IX-Z"/I6LTCY-KB9C_U$)*X)Q
MJH_RJ>FUY<>I994[KGESAHY5^_QRRUCM18?*^%_K[[3Y<>A#+6K$]%?`9I=;
MKLRY4:EG.7(+]>\>"U;)[DJ$*&8DYI>"`N835HGY%%'&2,SG@@+F"U:)^1)1
MQ4C,UX("YAM6B?D64<=H:][-M]H3MO-]8$FHMY"=>9!&[I(0'HVIL4H51'![
M:L$JF0)$!M%B@V]:,:(EH@11BB@SR)IYY8R"KA:L$E=+-%\AJA$UB%I$G4':
M52>)8QJZ3DCB5N[N8!ITX*&742E'`M>K41VX[[!*CZ>#R\'(FSK'K-@W;ND)
M[E$^);VV_/$T955P/,U8%?0K/\JOHM>6[U?)JJ!?%:N"?M5'^=6PK>`]L675
MWAQVK-CGDUO&I#JEC)7<*V.-U,Z$%*C_C82YVFZGAM:0LD`4(8H1+1$EB%)$
M&:(<48&H1%0AJA$UB%I$G8/<]%#Y.>FQ5M+ANX;Z^KV?*8UH*<_#^MRH++1`
M%"&*$2T1)8A21!FB'%&!J$14(:H1-8A:1)V#W+2<MJD[QDU=1G(KFR-:((H0
MQ0YR_51[;L?/--2'3?V:T8C&%*F9';(N>)A!&EOJ$:\U+'CKG$A4;#XV2/?H
MGHW:&3CA;,P.B+6N4_=:.D'G;``MC,ISW=L+BD0EKMNV7-=/VX&@A2<D0B/'
M=4`+T]!SW?O>820J<=VVY;K^MRRRZ;TM<$9FD6V7%J"%::B>,%MUY,U;(E')
M&=FVW#-2JZ(3ZD@OHNSY]]@@M[C]CZ89E3LIPPM%VW)5_G0D8EM[;_LQ*[9;
M:>[YJG6`?;[J)C*<;M_-=OPWVL?*BG?KU\A=AEQY&ZUS;NC.I#S50E2<P<@@
MLQ,Y&(R]`,?<AN864AM6@)TH3$Z;L&_E[ND:9&\""NKW0&\"LDI&H@A1S`@7
MC!,U>?(3:-YU<WP"MU:\,]*S,O7U6`G@E?>AEKEI>&`)8E0'ZIA5IHX'^+D[
M5AR7U,#\:!N9X[9.)CA9,LA)ME8=V#KAAK([$"&*&?4D^[2YQ03G%@9Y,W)O
MZVPN*K[@%H@B1#&B):($48HH0Y0C*A"5B"I$-:(&48NH<Y`[C/A3*C68_MZ+
M+B<XW3+(2YVWNS@7E:1.V[+65Q&J8D1+1`FB%%&&*$=4("H158AJ1`VB%E'G
M(#=U:GKF#Z/ZZX(GOJB<?CC`OQ<:Y&;NO?=`>RXJR9RVY60.4(P-EX@21"FB
M#%&.J$!4(JH0U8@:1"TB]7,,*JHZ$CIS^N<5]+OFGU>O7U?SU=/3YNQ^_4/]
M=`+=D6X^[+#^78?;\7"F5FX47__(9$0_^;#=TX0C8SJR71;#D0G_3(1_Y'K6
M7??U,J`?EJ"7[_7T/Z#^Z<UI?4>H?WII5]\1ZI_>&]5S9$S]T,8!'J$5U"S6
M[TGT?*;?O/C4&QGE<H^E6PIEG_[3:/:)DH5=W](9]IX@G5_OZ:GH]MF9SKKM
MG=$[@=NK6;>=1/F<3OFV]Y3G=&3>>V1!1]3Z$\^"%H!TI,\O6E_1D3[/:)U"
M1_I\HT\.S]1G9GOZ&0UF$7T`$H_09T9GZA.A>(0^VSDK>X_09S"IG[XVM)]/
MUOJ*E;;/J4W?D<7@:J9>MX0>+`;O9^HE17B$7C<T4R\3PB/T6J"9>ND/'J'7
M]U`_?4?HH_-4?5O?+G;IIE](^7[W=57>O7Y]?-F</:V^T#!PN7U]W:O^C17]
MCS?SQ.SS^HU^'(4FO?2;%/1;."OZ.8A+]?7P+^OU&_^#G+K8_;K.S?\+````
M__\#`%!+`P04``8`"````"$`E<6,RV\.```A2@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6RLG%MS&KD2Q]]/U?D.E-_7-A?;@4J\%7.'X0YSG@G&
M-A7;N(`DN]]^6S/J::G_@XSWY"4XO_FKU:-N749B^/SG7R_/A9_KW7ZS??UR
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MJ/`%E&XE$1CO"O?KA^6/Y\-T^ZNSWCP^'2C<5W1'YL9J]W\WUOL5M2B9.2]=
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M+W[2`+.RFCO4%'U%G15F-#%F&QHT-6AIT-:@HT%7@YX&?0TB#08:##48:3#6
M8*+!5(.9!G,-%AK$#KB@$&=QIM#^CC@;,R;.'*$[!D[@55!9P44:&C0U:&G0
MUJ"C05>#G@9]#2(-!AH,-1AI,-9@HL%4@YD&<PT6&L0.\()*8_'O"*HQ0_V?
MAME`[TU%9<JO3'2M(IU)LE`#:0)I`6D#Z0#I`ND!Z0.)@`R`#(&,@(R!3(!,
M@<R`S($L@,0N\:)/,ZL7_?R5&8_01IT$F8-SEY(R)5<6T5*IHF*:B;A8`T@3
M2`M(&T@'2!=(#T@?2`1D`&0(9`1D#&0"9`ID!F0.9`$D=HD74UHH>C$UTW'I
MZCQ;/YX\(1M#?KA34J9T<L)]I<*=B;)P`VD":0%I`^D`Z0+I`>D#B8`,@`R!
MC(",@4R`3(',@,R!+(#$+O'"36MB+]SA+FS4?DQ3HF*JA^5,E,442!-("T@;
M2`=(%T@/2!](!&0`9`AD!&0,9`)D"F0&9`YD`21VB1=3FD:]F*8KZG/SY!$.
MKRGHAS<EY4JVW*H#:0!I`FD!:0/I`.D"Z0'I`XF`#(`,@8R`C(%,@$R!S(#,
M@2R`Q"[Q8DD/-%XLPP$T:C^`EI0D@$`:0)I`6D#:0#I`ND!Z0/I`(B`#($,@
M(R!C(!,@4R`S(',@"R"Q2[P`TF.\%T"G,QZ>-JOO=UN:#&E-FQ/8,CW&I@^W
MQH@?5TOD.:B>$6=V+:J1N)&*2O3A3,$W_A3<S$0\7+=24DGVZQ*/VBDITFV+
M(5U;)S/DB$I5O[9N)N+:>E!;_Y3:HE14ILT/<:FL'O`'F8AK&P(9`1D#F0"9
MIH1:A"W/@,Q3XC=_N>0WR"(3L:$X)6GS>\EEMM/^_^Q*K/CI95&9I@RG,?72
MG`L&LZ#!MKS`E#[Y=]T4%=]VRR(W[4ZJL2.V7.\O_1J[HN(:>UAC_Z0:(R[H
M/IR6RFIM.Q`5US@4\XQ&@ASO==\:BRU'55;]?2(J-C\5\XQFB.86J=ZD-M06
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M?(]=BY*AX^=ML4@'9?Y(W^-"00?ZK`HZ$+&JF#7RP**R/PVJ7CR4@DY;Z48>
ML2KHQ)A5XL3D)">F6'#&2,(Z1[2PZ'@CQUSH6"/[F6WV%#^0V>D6I)?9%GES
M0056**GJO;D@4W%2-<TI(W4<?RZHJ`F]956E8_=L,SLS'XA\AVW)H--EE`XG
MUY?7*J=Z+`C6WV=5<)B-1,6-,+#(#O)JU!AR`4G"$:-@36-62<$)(S_MU>U.
M624%9XRDU>:(%HRX(6_4B!^SX%A#^LEK-D_=Y$WV2*_-MQ`*IS_3F7-IO;Y)
MD1JMU9JNS@7]ME*JAJ@XG$V+U&@-.6W].M84-J>M*NA$!YWH6F0'DIO+2QBL
M3ZF_+Y8#?2H2%3?"P")J!+-P47DPY`+!FQ^Q*GCS8U9)MDZX\N!,,96"@7N;
ML<H=M[.@\.TNK$J:6]UQS&:.W;&?^68?V<W\=Y;P1JZ6\"DJ76?39]U\I\>L
M4;QEMYX8&Z+B>VLB:B%J"PJT9H=5LG;J(NHQ$N_[@@+F(U:)^0&B(2,Q/Q(4
M,#]FE9B?()HR$O,S1'-&8FN!*&:4V/)SQ.Q+NSGRKW:\S)=U=.I8Y,[X535Z
MU6VYLBLJ83*EIFA9(,D$J&5M.:KV2>8[4M`)FGY8Z+(JG92JU\5/JF_V6'&L
M;R9#<?\DGR*VY4W-VJ<!VTH?Z_2#PI"-!!T:L9%@#,9L*^C0A&U1=)PG##5G
M3-F6YQ<^UJ4AIMS@J,^Y8-")!:NR2%75ID#,"L\!)^W\'F)V^T,]9+Y]HU$S
M=T\X&<B3N'\U7Y?0721%WNB:(:<!'<\26PUKRRG81-1"U!84,-]AE6R.=A'U
M&,GXU!<4,!^Q2LP/$`T9B?F1H(#Y,:O$_`31E)&8GR&:,Q);"T0QHYS1E98.
MQW+GG<G8E%23<8K<XSVSHT\J!S40-1&U$+41=1!U$?40]1%%B`:(AHA&B,:(
M)HBFB&:(YH@6B&(/^<,#C9M>B-^)JY&KN%HD2\.Z^3JI40EJ(&HB:B%J(^H@
MZB+J(>HCBA`-$`T1C1"-$4T031'-$,T1+1#%'O+B:C8AO+C^JX518L4/-R,9
M4^J"`@-;PZK\\ZB2VD]OBHJGS99%[LG,235VQ);C%QP)BHIK[&&-_9-JC*Q*
M'62HE=9`5%SC$-$(T1C1!-'4(NKS;'Z&:&Z1'PXX'A05VXHMRCES,3M3OR'G
MC!65<RGR#P@K*G7J2?54D"856;W!XL.J_!#!`:&H^+Y;%GEI:%T-UM@16XY?
M9;6J[(J*:^QAC7V+PO<8<4%R3UH"#@A%Q34.Q3RCD2#'EF[5L=AR5'!`*"HV
M/Q7SC&:(YA;Y02NKK?^%J-A6;%%>LM)^BI>LX8G/O"R@L](BFNR<5H:L3%6F
MUXA*MU_#FB<5N]ZT2&T*JWMN<4$OU-I\FU5!)SJY*OW4UF55^GQ2J7S2SR<]
M5@1]ZK,JZ%.4J](^#:S*[AVK$`S91M"?$:N"_HQS5=J?B?CC!+VBGN.F;,OS
M"QXD626I,1?DF-=.+%B5!>I*;=O&K/`<<)+'7U&8@P7W0?*=#I.>0]##!6?T
M7<D>3=#&H70%_=A?MRISPB,JQZGT&5)4;+YID=IQ5MOZ+2YX[)X3\VU6!9WH
MB(J=Z%IDMT"OZ2U.=3S(98+U]UD5K#]BE6SZ#BQZYW@0"XX8!6L<LTIJG)Q4
MXQ0+SAC)4\(<T<*BHPT:<YEC#>HGL=FT=I/XWRV+[=:WF]L6>9,!G!":PQ::
M1=Z;##(5IU73%GQO,K`%CS6%S>W,?*"#=<15=J++*!U0KBM5=4C78T&P_CZK
M@@-MQ"K)M`$C/T55!Q^R2@J.&`5K'+-*"DX8!6N<LBIXVS-6N>-X%@ENXP6K
MCK5QS()CE?GI_K$C%.IDL,C)SDO8Q;I5O7.$(BHNV$340M06%$Q/ZY=TP2X7
M%-1C)-MD?4$!\Q&KQ-8`T9"1F!\)"I@?LTK,3Q!-&8GY&:(Y([&U0!0SPDT^
M$\??,"2FV]W>=)\BD[#91`Y'*$GM[S^T6>LR532YH*`6HC:C=Y[0,O/B:4FO
MI[K6%K6D.<R]NKFJPMQN[1SKF\GXVS_)IXA5WM"C?1I8E3U@AH7O*?Z,N*9@
M&XU9%?1G(OXX+8D+WSR_<.%K5;*/,3_)B8552:"T`S';.18H?Q#]/2<H].L5
M,+AFQR4\1M:MRCB8=1H\4A05%VPB:B%J"PJ8[[!*6KZ+J,=(AJ>^H(#YB%5B
M?H!HR$C,CP0%S(]9)>8GB*:,Q/P,T9R1V%H@,C],DBSKG,$U_:&1]+<'7M:[
MQW5]_?R\+ZRV/\R/B-")Q^WG#&>_</(U&<P4OZ-?/DF6))J7Z!=1S,.5XE_+
MM:_D$%ZX*]?H[=H<7JG1&YHY_*I&K_+E\.L:O0Z6PV]J]&I1#B]^HCM(6E"Y
M2ONE-;.#B65H>[*V.'*E2%?R&H1V)JE%\J[0AEAMD'N%-J[(@[PRM%]=,[O1
MZ%N#RC1SR]!6=<WL$V(9VHNN=7.MT?8@7<DK0]O0-;,'B-:B:FV2G"NK]IQ7
M:_1"!^KI"_8U\_5YO!)7*31Y%^@E@YIYA0"+T,L`-?-5?[S2J-;H=9X<3B7,
M*Q=XI56MF1<O\$*G6J-W=7(XF3+O4N"57K5FWJB@"Q=9J]`/]+PM']>#Y>YQ
M\[HO/*\?J.]=)N\F[M*?^$G_<[!'X-^V!_J)'EJ-T`^#T$\QK>DW.2[-R\@/
MV^V!_V,JR'[<Z?8?````__\#`%!+`P04``8`"````"$`*F@;O)P,``#?6```
M&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;)S<6W.;NA8'\/<S<[Z#Q^^)
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MJA-_@,QT$@R0N4["`;+0231`ECJ)^X19EFX2:?C_W2[U3'J%R?KKFI(MSOMA
M*"DP*?LK8A;3=ZKJF]G'?D]XVG2YPT\'+7>&>^LV180F*>+JJ_8D632]LD@K
MGTX(Z(203HCHA)A.2.0$OIO=45N2UDX'",F/C(;-!Y8A88L!0L*6-&QU-D%K
M?-Z)?*+QA7X8\UC=/C/+)JTO#>\#.D-./E^*>7-^._9L25(G.)_/SP1ZOH1P
M#1$4,10)%"D4&10Y%`44)12526CIP`_;)])!:)0.TLR:@WWGN+,E[:TEX/]?
MRI<`BA"*"(H8B@2*%(JL%>+:-J>=9M[.O=@6!11E*\0:&+EZ5G)F>S2FKO71
M<6AYP,<C6AZ(Z[G#!S#FOEDL1?.!;($G#=^.2X?;ET)NH^TN10?P<>5HQ@D!
M(4O^3^^%0KB:"(H8B@2*%(H,BAR*`HH2BLHDM-S@P_H;<D,L17.#7KBE,>4&
M%`$4(101%+$4,D?9U&$+LBL)#)%"D4&10U%`44)1F826&?Q6[8;,$$O1S"`7
M"4\:M[F*T!&KW\Z\V*4$4(101%#$4"10I%!DK1#].VV*O)UYL2D**$HH*I/0
M$H+?IFD)8;Y\"$T3@8P=/6ED(BQLDB9^._?B[@=0A%!$4,10)%"D4&2M$)G0
M:XN\G7NQ+0HH2B@JD]!2@=<6M%2X;D0AEJ(I06[4/6ED2MPMR%#!;^=>;(8`
MBA"*"(H8B@2*%(H,BAR*`HJR%2+Q>BU>M7.'6EQ+"5$1TW+"W#TT7$^&!>D`
M/&74`'<^HW>GO@*&,4:`28A)A$F,28))BDF&28Y)@4F)2:7(T!'2DT,4D,Y+
MBB`Y9+U)+TV0PHG')%+K=IF[),,V7PEC>L@@!A+B*!$F,28))BDFF2+M:):.
M97,<HL"D[$C3:\Q(+UYI&W'G.A;[*`OIB2%*6>>)<=V5A,D*F)X@Y*[14\AP
M;'U,`DQ"3"),8D7:`S=P&X*#I)ADF.28%)B4F%1&HB>*J'J=)PKH06213$L0
M1D83GGCHP@<DQ@211!Z4H?*FBJ&.6K^Z$>*51)C$F"28I)ADF.28%)B4F%1&
MHF<'/X9:=ES9C8C%]$$(.^NIFO*4)YZ`H2R11";!A2J7"M.9@3(77E.$28Q)
M@DF*289)CDF!28E)921ZJHC2V'E'<F6JR(J:WJ'0IR7BZPDH5221:7#';'?:
M[S,"%:=#`R;$ZXHPB3%),$DQR3#),2DP*3&IC$1/%E$MNR%99)%-2Q:+C$X]
M9JK$-5V/CTF`28A)A$FLB.J_EJXS)SN4X"`I)ADF.28%)B4FE9'HB2*J:#<D
MBBR^Z8G2NPUN*W1BK,T<<A_DLW;VT"VZ?,*"28A)A$F,28))BDG6D<$VR;O9
M%]NDP*3$I#(2/4-$<>T\0\``5M;B],R@]5,FD3PGV71*!KB^FL]')Y>>SP68
MA)A$F,28))BDF&2*7&J4'(<H,"DQJ8Q$SPU193O/C2O')+(XI^4(?4CL,5,%
M3UUF).F&&\-C$HJ&!K!P71'>G%@1=0"=F5@1N;=/<)@4DPR3'),"DQ*3RDBT
M;+%II?6Z;&D6HS<[Y!KN*23;WNU_G<?7P-W0';$NAK[RHX2A6XHPB3O27`+(
MCB3=W(M=7XI)IDC7''-2Z,IQC`*3$I/*2/3T^%RMU1ZHM3(Z!%'(<,1\3`),
M0DPB3&),$D54)V//'6NY(+=SJ6;X]Y3[=VH97E..28%)B4EE)'J*\$N&=KTQ
MCT5LP6G/0<<B"AE31,8QD`!'"151Y^34H@/B2`.V-:?#HABO).F('%_JWT=*
MM;FD(;)NYL6>)U>DVP7ZZ+O0`-\%EW1O)5Y)921Z.M#:ZI47E($:JT4Z2,]N
M:ZQ-0Y)^Q>_F7FRK`),0DPB3&),$DQ23#),<DP*3LB-#;5]U<X?:7L\/?L9^
MIKL07.\N>H]V;6GD&7#'YJY%;VN5,'86,HB!A#A*A$F,28))BDF&28Y)@4F)
M2:7(X"'2T^.VBJKX&R22)HSUN@]<455Q#%D08!)B$F$2*R+;S.9_:\9'T/JU
M(\%14DPR3'),"DQ*3"HCT3/EMG*J/5!.9:2_\!223<^L!;T1]A4PY@DLR88X
M2H1)W!'1,Y,O52?=S*&.N;EC3S')%/EH#U(<RG&,`I,2D\I(]/R@550P+AVH
MGC)ROGFV1+(=9C;_^SS]A/05,.8%++&&.$J$2=R1)B_(R#+IYAH2`VYIIJ*H
MQ+#MJ4U.I1ROI\"D[(C8E[LIN;FJM,VXFUGNV9'3DX(63J\<G0X44&UR#GBV
M1(9C[V,28!)B$F$2*R(/G3-=\.^(T'%3@L.DF&28Y)@4F)285$:BIXJH/WZ^
MCFK+LJ561^T]KE-(MOW<X2\#(,GD*V%(I@"3$),(DUB1;FO=!>GV$APDQ23#
M),>DP*3$I#(2+4_$'S_=D"?-8OJ-#;/(+:VGD/KKAMYW$KO9%_OP`),0DPB3
MN"/-_:%^64RZF1<W-,4DZXA8Q91>>_-N]L65%)B4F%1&HN?&Y\JGSD#YU"(7
M;D\AU6^[-KD6^FJ^J>?`),0DPB3&),$DQ213Y%*CY#A$@4F)264D>F[0NJD8
MBKC\%M4\3G4&ZJ?VQQ=BFR&]IY`A!WQ,`DQ"3"),8D7DT7,7ED/ZP03'2#')
M,,DQ*3`I,:F,1,^3VPJJSD!!E?85GD+R^F+3/SKVN]D7>]0`DQ"3"),8DP23
M%).L(^(JTVN3O)M]L4T*3$I,*B/1,X2?Y]H(!/0@@I.11^\AG2.1L0>!),!1
M0DPB3&)%9`\R9?PQ#1U1)SA*BDF&28Y)@4F)264D>H;0JBK(D*%J:F\<(I'J
MM*?S.2F6^(X$AA0*,`DQB3").](,'>GH%&YHVBU_\:S/%/EH#_*8+<<Q"DQ*
M3"HCT?/BMAJJ,U!#[3VL4TA>6QR2/7XW]V*#!IB$F$28Q)@DF*289)CDF!28
ME!T1Z4[;ONKF#K6]GA^B`GA>`P']ABP8GM<^>@_K'&GD:7+'%K,9J1CZ2AC[
M#5B9#'&4"),8DP23%),,DQR3`I,2DTJ1P4.DIP>MIH+T&*JBDE*2YT@DWP&U
M=-PI>8KG*V!,#UB)#7&4")-8VUB7W(DG.$"*2::M@\WM*7U:E>,@!2:EMIX[
M1CKL2I\]7UJ+CP.C)\5M=5/^]L_>J-0FEU!/(<.Q]S$),`DQB3")%5%#`C9?
M\%(O:=<$ATDQR3#),2DP*3$1[W$51W+X(,E4D>]IE>^)W-6'Y]JO7U^/H\W^
MAW@'ZY*_S*6;*M\/F[$5?R$>?R\KF5ZR%7^C77]ZQ=\G.S3=8RMO:+K/5O[0
M]("M^"L!^_%#MN)O!NQ/C]B*OR"P/SUF*_Z>0#Y]TNT`?[WL^_JY+M>'Y^W;
M<?1:/_%=M^[%"S\/\@6U\I?3_KUYJ^&W_8F_6+;Y\86_2+CFKR^T[CE^VN]/
M[2]B!=VKB;_^#0``__\#`%!+`P04``8`"````"$`2K>!9I4"```=!@``&```
M`'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)24RV[;,!!%]P7Z#P3WT<N/.(+E
M(':0-D`#%$4?:YH:281%42#I./G[#D5+CIRT33>620V/[MR9X?+Z2=;D$;01
MJLEH'$240,-5+IHRHS^^WUTL*#&6-3FK50,9?09#KU<?/RP/2N],!6`)$AJ3
MT<K:-@U#PRN0S`2JA0;?%$I+9G&IR]"T&EC>'9)UF$31/)1,--034OT>ABH*
MP>%6\;V$QGJ(AII9U&\JT9J>)OE[<)+IW;Z]X$JVB-B*6MCG#DJ)Y.E]V2C-
MMC7F_11/&>_9W>(57@JNE5&%#1`7>J&O<[X*KT(DK9:YP`R<[41#D=&;.-U,
M:;A:=O[\%'`P+_X34ZG#)RWR+Z(!-!O+Y`JP56KG0N]SMX6'PU>G[[H"?-4D
MAX+M:_M-'3Z#*"N+U9YA0BZO-'^^!</14,0$R<R1N*I1`/X2*5QGH"'LJ7L>
M1&ZKC$[FP>PRFL083K9@[)UP2$KXWE@E?_F@^(CRD.0(P><1$B=!LIC%L_E_
M4"9'"CZ/E"0*XFGT#D;HL^I,NF66K99:'0@V'NHV+7-M'*?([=WQN0Q^_<DN
M],E!;ARE8Z$3!DO\N$)WEN$CUH4?8]8^!J?J%#..V/01KIPH;]"(KIUKG&`?
MO%W!7I([-)8TF8Z_M_8A+Q4EXXC-&Y!36B.-Z-U+C7_7YH*=-M=MSK^UWU@,
M&YL^XF36U6+0-OKP=/QA5\!_F^,.912S.]4BF0]\K\G'7';5G)Y[AQ/K"/[M
M;+$X'?;B_#CZ3I.@2]A`71O"U=Z-6H+08=??`FN\!3I#SO>3%-UQ'3&\P.EL
M60D/3)>B,:2&`I%1<(GCJ/U\^X55;=<`6V5Q+KN_%5[#@(9'`0872ME^X3XP
M7.RKWP```/__`P!02P,$%``&``@````A`"W_W'K"!P``A",``!@```!X;"]W
M;W)K<VAE971S+W-H965T-RYX;6R<6MMNHT@0?5]I_\'RNV.ZFYNC)*.!UNRN
MM"NM5GMY)C9.T-C&`C*9^?NMIMK051!,\I+$J=/%J4O7:3!WG[X?#XMO>547
MY>E^*6Z\Y2(_;<M=<7JZ7_[S]Y=5O%S437;:98?RE-\O?^3U\M/#SS_=O9;5
MU_HYSYL%>#C5]\OGICG?KM?U]CD_9O5-><Y/8-F7U3%KX&/UM*[/59[MVD7'
MPUIZ7K@^9L5IB1YNJSD^ROV^V.:ZW+X<\U.#3JK\D#7`OWXNSO7%VW$[Q]TQ
MJ[Z^G%?;\G@&%X_%H6A^M$Z7B^/V]K>G4UEECP>(^[OPL^W%=_MAX/Y8;*NR
M+O?-#;A;(]%AS)OU9@V>'NYV!41@TKZH\OW]\K.XU;Y:KA_NV@3]6^2OM?/W
MHGXN7W^IBMWOQ2F';$.=3`4>R_*K@?ZV,_^"Q>O!ZB]M!?ZL%KM\G[T<FK_*
MUU_SXNFY@7('$)$)[';W0^?U%C(*;FYD8#QMRP,0@)^+8V%:`S*2?6]_OQ:[
MYOE^J<*;(/*4`/CB,:^;+X5QN5QL7^JF//Z'(&%=H1-IG?C`WMKEC8P#$837
MO:R141N@SIKLX:XJ7Q?0-7#-^IR9'A2WX/D2&?+H8GTK5(C1./ELO+2^((H:
MZO/M0<CH;OT-<KJUF`0QL"5Z#$6D%X1)H'&KG7^L@6]'&E+!22LHZG@Y+AS-
M(LI1^91`,H1(BDB'"!50B!Y"(J^#D#`4#6.:O@%#W[CIDW'GM\U7@A@H8Y?B
MD"+2JP@]A2#LX3)N$:;9&_#]$E+3,8M9WA*$1&WWK$0<ABRZE`(BWV,`30!1
MZ/7%(\1AR[G$3<M?[QZSB*=_0Y.;(`98=$'R]%]%Z"D$B2+\2!1F$2V#4'US
M8A,A)L1=K$)F3HG9$VR7:S3[[>J-$%V&"/?H(]S-(LH][@N,U!%BJ0N?=5CJ
MFN4F9.73:!XO'Z%O9-V9F=.=;\",=I\5I(V0\0NWB!01-K!(\<:?<D"8;RCS
M>:UO%M$(A.(A(,82]$,V6%,T8U?XDI5-N]8@Z%T3Z@(&_/RLMVA.FETWL2"D
MM9*\79B9)YV:WV)M)&QVKP@4/'=,"J6Z/83=8D&8:S7(9DKL(@C8!M;6CE''
M3M0TW4;&YA-'T:/$61,D`D%3?=Y!S!%"L>FI.^O8@*7LC8HY[.<UND#M@Y_=
M`!=<WA,+FHQB2D/;(NI)+S04N)(;RO2T$09-^UZQ.9=8C&W[B)G3SMQG85`(
MO,IX#BA[HV=.(:ZP1_6C;<0NGIB#-X2(_;^2,F8;)+4`&Y\:'!.H73AM1JD;
M*9M/'87/I>XS;4R$*X[Q0%F)&4Y`K##:VFW@0CGZ1HD;(9M/'&6/$&=73L1%
M&LVV7#D3&M6)F,.(A:V)>14XIU9*VZC8?-JH>80VF]")(+*I@L&`O^AF&Y8<
M#$K7+/N<4-9&O.:S1JES60O%\I4(!%WJ',:BO[9-N*N8?LQVB*8.8NFL)]SE
MNR2U1=/1(OA))+$@N_><\Q\2)V;%(]?$[`>]7E/:[])4.::I+*&)!5UF2JSX
MJ3BEB#B2O>#C1*<`$7AA/Y<H?:C^_(Z1!LUN/'S6J8D%C<]CFWGT,P'1DUYH
M"$Q>IZ>Z1#DD3>^S]"469"L0P0,NOELI(I0>]Z$I`BKP9@F,?CF;=M[Q0)I5
M;`/X?8^V>4XL".-08C,8EA0`ZM2WB6TDO`QZ"/S`N5&F17B7M)I'1`/R[-*)
M!=G=&WNLSU)KMT42@@>GJ0,_[$<;I?XN:95#:14^/UQ:T$7T!\WC2N]*1LRN
MZ7+W_H829](ZLW&&$CNX.4TD@FQNX>$&U_^4(I2G8I8$31!*R=Y.HS#"YK3_
ME>V+,DA.Q3Z3G$1>M/+-0V-Z':(G(30$)KNF$#ZT^)501N1W<$J3%W&="`4A
M=HMZ?)_H21<D#O/@R2W%O(9J5_%)Q$\_%H0D_6`3\]U,`&$0Q<R#MH!QS:!A
M,$F>&<:(-/M<FA6"+B<*GNN4VGWG4(SCE-E%/[!I!$R59T:`JDJDC=]P)PI!
M&$&PZ3<E*C,Q"WZWIHDYZ$M$V3-!GLE^1)CY2$\4@FP;A7XTX.\"(L_G3^6T
M]="-YMX!C>%#HJQ&1-DY.*(H6Y"=K5)&O$M2@E!P)N^5R[:1J\HK(;U-+YXT
M#";+,TLQ(L]!?P4;!H)L*;R`QYDJ%[`1`Y4C=BFD\XB=QL#T>68,(SH=],6V
M,2`(8Q!1[+%$I\H%^,,@-0&0(&D,'Y)JA2H,+=T_`N+WC8D%C<_%-LST.D1/
M0F@H[])KA5),9Q+7:PO"/<GOPU)B[4>.W0D7J3=WS6%_D**4F3Y/Z[(:T>6`
M-49B04B9W3ZDQ"@'CWPZ<U_6/B.$N/\A06Y7L;LT9U9CZUO05-M<A^A)"`WE
M0Z+LCXBR8#V06-!D*.C';G0O%FR:Z4D?-!`CH+//JS[*+>U_?JJP(&RFD$_:
MM#./]0MN@PYBMD'@/(.AU(TX.M3G35)XEV%PL\8?%R86A%^8#IZT6.M$A<P;
M$^8JZ,!YGH$!X,L0^*[`,:^>\C0_'.K%MGPQ+SH(^(*O^R^^A)'`2QCM&POK
MS@#O0)RSI_R/K'HJ3O7BD.]AJ7<3@4Q5^!8%?FC*<_O-_&/9P-L/[9_/\+9+
M#N\`>#<`WI=E<_E@WM/HWI]Y^!\``/__`P!02P,$%``&``@````A`,T_?WD2
M!@```1T``!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6R<F5MOJT80Q]\K
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MIA=&^*HLFKJMM]T,P@7]1LV<LR`+(-+MS::$#+#L7B.W:_\N7-TGJ1_<WE"!
M_BGE6SOXWVOW]=NO3;GYO3Q*J#;T"3OP5-?/:/IM@TO@'!C>C]2!/QIO([?Y
MRZ'[LW[[39:[?0?M3B`C3&RU^?$@VP(J"F%F(L%(17V`#<!?KRIQ-*`B^?O:
M%R!<;KK]VH\6LR2=1R&8>T^R[1Y+#.E[Q4O;U=6_O5%(F^ICT=8>\BZ_O6GJ
M-P_Z#=;M*<?I"5<0&/<4069]A,LN79N$W6&0.XRR]F%0P;V%RK[>AHOP)GB%
M:A3*YKZW@;\?-A>+`'9SV1)L8[@E>WG.RFB,RE@NW,I]OS"4$7:9Z#,R:`PE
M2H>[-S+LC>*!S<(N#2;##+'H8H%-=\S".5GTHUU<LE4KT+&/JBX<"4-X0S5,
M9Z.JZ*>KJA4H]4`ULN>Z,%6C2$Q(%AUU6;6BR\9V6>C4,-GK0X3&NI1:@8X.
M,DSL4LAG]@B%:38A0W349=6*GJ%CB#)=]GJ&:*Q+J14]P]2>80CS9:2X`/B,
M#2PYZKKG)3W'I4,8H<%J&V4P!]>S#15K".8]%LY+NFSFD`4K+BLB5T>C!(BG
M.(B.+%^U%!.&AYP+D1>#Y$9RZND""+H\_!0`U*`-'U.:SATY6:`3I?,)/32I
M$ZHEK9CI!_`UG./VAFD2[>;Q+!V?'O1DU51+NK(#>"%CSTB!3>!0`*/`#M#A
MAP//,TU=0P.POPR-B1^*!<)ZF@[4A0Q`(VF:U*$`1IH.VH6,.]C.#/@PHFH"
MB`(9.3I@)QB!KJN1-80>/"OG)8UWJ8-WPH(=,6EDR9,I*QCIO70`3X#5_QHB
M<F3"&,LHL`-Y@L&(GM(IR"-')JQ092)/,`B-M-$D#P4`-:V-2P?R\$#%BSGM
MDYD\65(V\BP=S!.?(@]9,S4%(SU/!^>$A3RA6$Y`#WDR944C;5R7#N8)AAZ<
MFG#*P8`<F;#M\+-T,$\P"HT,DDD?"@`;T`OL8!Y^(^*#-`GMY*BG>5[2Z^O`
M7F0!49B!Z_5\R8W)VBBT=/`O0G),/IF0-5/#`$9U'<R+$!<#-1RB:=5%1R:L
MEO3J.I@7?8I&9,W4%*"T(<H<-()CHI'FM`\5\F3*-AIE#AI%C$;TE"83#F#D
MR(05F!;&<3:R4$@LPPD4(D\F8Z-0YN!?Q"@T\G"8!R`*`!O0^^A@7L300Y^4
M,;B.R)H,HD@@JPUKYB!>S!AT78VL]9*>E_0D'<2+;>"9]*66/)FRC3V9`WGQ
MI]A#UDS-QI[,03KL&V?/M",">3)E#`9+>C\=U(L9?'",QL_1Y,54%81T50?R
M8@:AD2E2E!F<HRD`;&`X1?`[LOT[9VP!SS3DD2?+4Y%GF*>8.Y`7VV`TY3A+
MCDQ8L<@\SL8,/(0"L!ZIJ@D@"F14U8&[V`*@:.E,;O!-DSQ9<@I+>E4=Z$L^
MQ2"RUM7.2_KT.(B7V!@TZ5A+GDS9PB`Q=]`O@6H,J7"]GV3-U#``+.EY.HB7
M(#;8^2=,H@F?S^3)E#$8+.G]=-`O80P:R5.!9D`#"F#DZ2!>PMA#QY"YF)*G
MR2$*9N3IH%[".#22IP+-,$^UI/4S=%`/[I",?HKQ`P*YL68J\FC-##GR^@NG
M_E:GDLU._B(/A]8KZA>\3!+P.]-E]7+1=2?P_,;7H]5=?P$67-Z!"ZA3OI/?
M\V97'EOO(+<0<TX]:_HKK/Y%5Y]@[W`-57=P]43_[N&J4<*5#/W&N*WK[OP"
ME(/+Y>7M?P```/__`P!02P,$%``&``@````A`#E%=V"!!P``QR```!@```!X
M;"]W;W)K<VAE971S+W-H965T.2YX;6RLFMMNVS@0AN\7V'<P?%];!Q^%)$5L
M2]89BT5W]UJQE5B(;1F2TK1OOT-1(XH<1W6+]J*R/\\,R9\<BH?<??YV.@Z^
MID69Y>?[H3[2AH/TO,OWV?GE?OC/%^?38C@HJ^2\3X[Y.;T??D_+X>>'/_^X
M>\^+U_*0IM4`(IS+^^&AJB[6>%SN#NDI*4?Y)3W#+\]Y<4HJ^%J\C,M+D2;[
MVNET'!N:-AN?DNP\Y!&LXI88^?-SMDLW^>[ME)XK'J1(CTD%]2\/V:7$:*?=
M+>%.2?'Z=OFTRT\7"/&4';/J>QUT.#CM+._EG!?)TQ':_4V?)#N,77\AX4_9
MKLC+_+D:0;@QKRAM\W*\'$.DA[M]!BU@L@^*]/E^^*A;L3X?CA_N:H'^S=+W
MLO-Y4![R]VV1[</LG(+:T$^L!Y[R_)69>GN&P'E,O)VZ!_XJ!OOT.7D[5G_G
M[VZ:O1PJZ.XIM(@US-I_WZ3E#A2%,"-CRB+M\B-4`/X?G#(V-$"1Y%O]?,_V
MU0$^S4?3N6;J8#YX2LO*R5C(X6#W5E;YZ;_&J`G%@QA-$'@V0<R9"-+C:#:.
M\&P<YR-C,=6G,U9ZC^.D<80GEC@=+:;3R6PQ[_>$7^L&PQ,]M=L\9XWGO/6\
ML;*0:W61\,0B;ZSLLO&$)WK>6%D=1A+O6.BZQO?&ZNK8G>P#%GMCA77L4?8!
M?2<C?:+]J$=U[%+VX:8*C_E0KC-CDU3)PUV1OP]@NH$6EY>$35ZZQ:)A3O#Q
MU&;)1TD"V<&B/+(P]T/H-!C_)63VUP=#-^[&7R$;=XW-BMKHLL4:+5CJL;`;
M%=@J<%2P58&K`D\%O@H"%80JB%00=\`8I&WUA6'Q._1E89B^J,P*04=P14RT
M0)>-"FP5."K8JL!5@:<"7P6!"D(51"J(.T`2$_+D=XC)PK"YNW>T<B,3^K4=
MTC-%X=:DE9@0FQ"'D"TA+B$>(3XA`2$A(1$A<9=(:L-L(*E]_36),P"SKD5%
M,5:<F-"9K8*&;BH:MD;HMB'$)L0A9$N(2XA'B$](0$A(2$1(W"62AO#FE#1D
MTZLQ';6OW9LG6!9(EI<3$[JO(^]$D;<U:N4EQ";$(61+B$N(1XA/2$!(2$A$
M2-PEDKRPS)#D[1^BS%K6D!-%PZFB86O4:DB(38A#R)80EQ"/$)^0@)"0D(B0
MN$LD#6$:E#3D*X`16QKVR\D<93DY,2?M:VI-R(80FQ"'D"TA+B$>(3XA`2$A
M(1$A<9=(VK&=87?UU"\8LY8%:X@A!"-D0XA-B$/(EA"7$(\0GY"`D)"0B)"X
M2R3!8''^$X(Q:UFPAHB%T+HEW6E0>5-ON)$!C\Y<.9?SW&Z-,,\=0K:$N(1X
MA/B$!(2$A$2$Q)SH=>LE6=D.1M*UD\35(=N]KG)H.*QEK@Q0$Y;KS2*>19'U
MK@,#Z@@N4%=,5?'&RM3X9D!37_RV,&CE%I$1;07J*<P5L>J=AZ9N/3QA@)%]
M$1E1(%!/8:&(U12F[&(B88"18Q$9D-QS;.-P^Q2B\WT&/R6I>VV%"`9'9W`O
MY,&];JP,Z.*.%>DU'M[0VPG)1D=Y&;>4PSMH)1RWB'I+=-%*.'J(>DOTT4HX
M!HAZ2PR%%79/A(BEPM<'W9PMV3^YB3$:@417%92[E6UA?J);F;F2>1P9L+04
MQ1F:7*DU.W9@CO`05CKIUM8*FVPWCG!TQ)ILSLRE,5>".QC\HQ;7XV^+5KU5
M<(455L&3JZ`O%J:I*[GDHUMO%0*TZJU"**RP"I%<!<,T%\9442%&MX^J(/<[
MVTUU^_W7)F*^)Y.RO$%2EAN*7&MVD@3#X4=9WEJA$#8Z-ADPT?795$D`!VT^
M$J(9#FWPGA'I8JSZP+9V]!"U23B;+Y17M(\VO54(T.H'\T!343&!1.@HCR-%
MAQBM/JJ$/"#8UK`[(*Z\@>LDK$5X9$=PZD3`D3%KY^1U8P6H1^,-6M4GZG5X
MFR('D0B_%:@GO(M6(KQ'D8](A`\$Z@D?HI4('U$4(ZK#R\*S36-7^%_+1+[U
ME#*1(VEB7JI[1G:MP/H1%L)]\W)C)=;_=N/8S,M3;:HM#64`.AC\HP'8).(M
M57`QEJB")U?!A!E16RK+"1_=>JL0H%6O"B%:B2I$<A7TF083\T21(4:_C^H@
M#P>V_^T;#E_R"_37U15R-S_Y-EH:#QQ)^=FBWMYOK,3:VM8)<A")!-H*U!/>
M12L1WJ/(1R3"!P+UA`_12H2/*(H17<E/MJE6.\1<L)NWYC+KYK,QZ`TR:39;
M=ICC1?X9RHW$NG&$\Q]\$6XHLBER*-I2Y%+D4>13%%`44A11Q&Y/F1*\07S\
M\]M0?N=S2HN7=)T>C^5@E[^QFTZ8/Q_N6LRO85=3"T[<0!&5SRPX1;K"YQ:<
MD%SA.OP`-:*_;)86[&ZO<%VSV,:0_@);/(OMXN@OL!^SV):+_@+7R8_UG**V
M@UTS7[%?&1;</%R)8UJ/5YNQ,BTX/:<.JXD%)\+`QVW)<(U\25[2*"E>LG,Y
M.*;/(+Y6'[(5_"*:?ZF:6>@IK^`"N9Z0#O`'`RE<AFGLU/@YSRO\P@IH_P3A
MX7\```#__P,`4$L#!!0`!@`(````(0#JS,<;[0(``%@(```9````>&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;)1676^;,!1]G[3_@'@O!A)"@I)4#:1;I4V:
MIGT\.V#`*F!D.TW[[W=MIS1`ER8O$*[//=QSKJ_)\O:YKJPGP@5ES<KV'->V
M2).RC#;%RO[]Z_YF;EM"XB;#%6O(RGXAPKY=?_ZT/##^*$I"I`4,C5C9I91M
MA)!(2U)CX;"6-+"2,UYC"8^\0*+E!&<ZJ:Z0[[HS5&/:V(8AXI=PL#RG*4E8
MNJ])(PT))Q664+\H:2M>V>KT$KH:\\=]>Y.RN@6*':VH?-&DME6GT4/1,(YW
M%>A^]J8X?>76#R/ZFJ:<"99+!^B0*72L>8$6")C6RXR"`F6[Q4F^LN^\:!O8
M:+W4_ORAY"!.?ENB9(<OG&;?:$/`;&B3:L".L4<%?<A4")+1*/M>-^`'MS*2
MXWTE?[+#5T*+4D*W`Q"D=$792T)$"H8"C>/K,E)600%PM6JJ=@88@I_U_4`S
M6:[LR<P)0G?B`=S:$2'OJ:*TK70O)*O_&I"GBNI(_"/)!*H_KON./P^\8'8%
MR_3(`O<WEJD?A/-K:H&JM2"XO[%<6@LR[FBS$RSQ>LG9P8(-#/I%B]4X>!$P
M*Y<GT*OW709G5,Z=2M*I@!:P,Y[6P6RQ1$_0SO2(V1@,#&.'\?N(>(R8!'U(
M,H8$H=?';,>8T.T@"&1V6J&;UVM520.M)_S:CXW!S/7640;%PT`R#&Q/`KT:
M8:==7Z-*@KZ=>!V$`[<W!@-;L.O'K'-)JX@_1"0?(K;G$#V=4,BISO/[38%7
M-EC6U1Z$DW[U&X-9F-WH3/NK\=G5Q*S"M>,?>+,UB%"S>__97C`^IY(N&R65
M-)0V*'YC,.;E@[7XS%IR9@U.;O7>]R6;1IF3V1P6->$%B4E5"2ME>W7J3L&*
M+FH^"!LO@DF`XW,0C[T(!F(<3[P(YF(<W\*'1<=11P0'>XL+\AWS@C;"JD@.
M);A.""JX^328!\E:/:L[)N%(US]+^((3F$G7`7#.F'Q]@!>C[C_!^A\```#_
M_P,`4$L#!!0`!@`(````(0`.O#/UG!<``!2!```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;*R=6W,;MY+'W[=JOX-*[\<2R2$IL6R?BH9SO]36UMG=
M9T6F;54DT24IQ\FW7V"`1J/[/QQ22EZB^#=]P330`!I#<C[^\X_'A[-_[YY?
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MQVA>N`$XC.?M[>OMYX_/^Y]G9I(P[7[Y<6NGG-EF9JS12'8FPM@^-+3-F+96
M?K%F/IV;+C+#]L7DX[\_SZ[F'R_^;7+HSLO<C,A(B90D;,)8LUL-,@UR#0H-
M2@TJ#6H-&@U:#3H-^@A<F-"&^)KA\'?$UYJQ\:7(W!#@@*MPIR1!*EL-,@UR
M#0H-2@TJ#6H-&@U:#3H-^@B(8)I$^3N":<V8\6XFEHG1ZH06IE^#T$H-UR`2
M0@PD`Y(#*8"40"H@-9`&2`ND`]+'1$3;S`8BVN.+&\T`5GH(*@7CQI&%Z<P0
MP62F8QB$2&T+)`.2`RF`E$`J(#60!D@+I`/2QT3$T"R3;XBAE98Q=&1A^BB*
MX5J-PR`48@@D`Y(#*8"40"H@-9`&2`ND`]+'1,30[!A$#-T2]6%M%*:'I%64
MX71DD81Y-`6R!9(!R8$40$H@%9`:2`.D!=(!Z6,B8F?F.!&[Z8!9:1DP3^8<
M,"!;(!F0'$@!I`12`:F!-$!:(!V0/B8B8+9"P_W0,-A>O]_?_7:S-XEH%H61
M0"[,OL?MAJP1&4=/>`%/`^',GNO9<>N$EF8[&M)_?K60Z9\%(4K_'$@!I`12
M`:F!-$!:(!V0WI'9</<BVF:+_M>C;8W(:'L213N0*)`0;2>TG`W[U_GE3`<Z
M7`^!#F:)%$#*H&5WQ<:JVJ=5X3K9J,%&`Z0-6M[J3`Z*+EPGJWUL0W2"+7M$
M+XR,;5-2TN`>Q&6\"1D789PFLRO9I-1+S<5HADY@*6IYABA'5"`J$56(:D0-
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M2A91I+V4G-E4<;JU!V)V:\%#*//(3(G#(9=.BZ`PT8$%F>7]24F(/563GFI6
MF/#4D!1[:@FQITYZFE^J,/2L,NY+]J*MX^)>/)(8KNP3W>602(R`QEO@3PN]
M%`_`S![*VXQBE!/BP5P@*@FQ8H6H)L2V&D0M(;;5(>H)C22&+>_>$%)7#8J0
M>B0V:'.U9TQG3FH12XU,/T[*K"BT,\F\8H1R1`6;)\42I2I$-:(&;;4HU2'J
M!9(#U]:$;XBR+R&Y4V],Q$_9H'G%(U./E^(TS;QYL1M+YJJ<R+V4W9"$;<$\
M45U=D!1/#"4A]EB->U1E4<V*$QX;DF*/+2'VV(UYG.L=9\^*D<=H]R'[U5:?
M<;^^;UFQ5E35X]"Q#9B3.I943DILP#PR6[/0D<D\T2M.4&2ID>X.C>#4"XJ$
M*E.@#Y.E]*BVNC5)30ZPQDN9VR;S+2L2Z@C%'D>Z.S0UNL>#W6WKW+B[CZP_
M5ESUJT-B_0EHO`5^_?%2/"5D,T`Y(5XS"D0E(;95(:H)L:T&44N(;76(>D*X
M_MCB083T71DT6)&1]BC>F)&4Z?(PZG$-(BF>.3*/U.RHMC(Y*T;F878D*9ZK
M2D+LL1KWJ`[G:U:<\-B0%'ML";'';LPCI@LK1AX/I8N9<63?3J?+(*XZT5H8
MBA9*Z]1+':EC2(J'988H)\1#O$!4$F);%:*:$-MJ$+6$V%:'J"<TDBZVF(YG
MH/>EB[6B(NV1F5-";ERI!2&=.Z$CZXV7LD,EF,+S'[)E=GQ!*IFK<[V<;$TN
M"`79X@6A),7)1E2D*!NA#J%JLC79B(9L<2-:4IQL1$>**W\VK.:5GJP(]P=S
MSA;P4P/D7_L?IN=''S)$![%S=PY@-D.4>#<>Q4L7(^[#D0G5GRGP_).1(J.<
M$.=/@:@DQ(H5HIH0VVH0M8385H>H)S22B[8@CT-]9'KS]7L<4H?D(]B%/F:;
M!RGJBRVB#%&.J$!4(JH0U8@:1"VB#E$OD-A/VT^7B9!&T]N1Z+IB7`Q8A^(G
MLH/]3^<1VB+*$.6("D0EH@I1C:A!U"+J$/4"R5#:4OH-H]-5WB)^'O&!=FI7
M7;MP,-HBRA#EB`I$):(*48VH0=0BZA#U`LGXV2(YCE\T%$\_6S>'0[#2AAJ=
MTCDEJ2,;4Z>X$*L)/+'UMHP4F<\1%8A*1!6B&E&#J$74(>H],H6:::H,OJW*
M_GKP76TGQK1'/.>G\X`F%S$GE1Q\@.O-&`&.>[!,J&!GA$I6//`0EP5(IT8S
M#:*6%0\\R&4!LMP+,[)/;+FI^V2^_&!FV2-3LZM313=X%.\VDX4Z2$KG3DIN
M)*.-CZN,1Z7@<:.76I@)C+>;"WW`1;;$5@M+N-`N"EM)BB(W=2.J\4;H,R^R
M-=F(AJ0XSUM&?(^P\>[&&Z&V^CW9.M0(,33LE"2&QO2`&,1E^>&1W1E$W:..
MAU)2-&5(D,+])DM1]V0>+<P,&A23A=IHYZ1XZ)Z'\5:0%*^!):)JW*,NX$EQ
MTF-#4NRQ1=2->U0%54^*ASS*?C52;^E7*Z[ZU2.9Z*K`2NTG86V9+[('$IVE
MN%^=HLSJ1&V@<U(TPJ'W\1R3I#BA2D251\JCFKEJ4ISTV)`4>VP1=>,>U<S5
MD^(AC[)?;1T?3^5'\M6?#425B_WDK>TQD:^)FLE2+V4??G/@L5^]>5XY,Z\H
M#MS@,"HG\^*>M?F"I#A[2D+LL3K)8\V*$S?4D!1[;!%UY%',28F>ATE1W&.T
M(LE^'2O^3UFB;06J,]<CD;D)S,B^MC^2N4&*,]<ADT=V;Y(L82[V*N*^L6_!
M<.EOQ<PEY*LB9#]$:;X\,M-[YIH$)ITU),666T(\D#I"<LRK&:\GJ4,>9;?:
M`X`WI*L[+XCW6Z;@'4E7%?/42QU+5V^>[SGSBL?2-2A.)$_!C:#^*Q%5Y'$]
M=.GJ6DV'-:D<BN^PE#<D%2=J:"2Y[\B7V<U'LQCT:%",I3C$LD?U.<>1"1@/
M-Q8>R?14^XO42QU;6)VM*&4R4G0I<WTYYQL90I>3P&2`"Y+BE"D1582<L^7B
M2CFK26#264-2[*Q%U!%RSA:72]@A^6@<<B8[TAZ(O"$U_?E)O)(ZI%92U:C4
M[C?L!"UG%16G+4O1X,T\DCO?1`W>G!3%/4>KC-_YAD:0^9(4.8.J48]+M2>K
M27'28T-2;+Y%U+%'.[\O%FH;TI/*,&/)[K-'*F_H/G<"(V96CT0>+M5^,+7A
M/V&#&Z0HOIE7-'=@;VVU4@F>DV$11EPFP7!)BIPLE?25K%08:U*9]-60%!MN
M$772USQ1X[TGE4.^9"_:<Y:X%]]U5&=7+[T'<DCFYE*M-2DI'LE-;YZ'<N85
M[;V&A259JK#G9%Z$`G,3S)>DR!ZK48_Z<Q\U*4YZ;$B*S;>(.O9H!_!\IC*C
M)Q7A*QK`LJ--EHF./K)L6G%5CSIDCGTIQ5+[--/FIIG<0B^,'"IX*9ZY,U)D
ME!-B\P6BDA`K5HAJ0FRK0=028EL=HIX0/L1*]-'-NW)GL"(C3<C$+805'BA[
M(=N\((2Q]U)R%Z,/US*R%?<C/E`F6V*\03:1+7Z66Y*BJ'1T(RI2E(U0RVU-
MMB8;T9`M;D1+BI.-Z$CQT`-ELB+<'\HY<Z`M<TX/D-,>*`]FU`BQEN6'.[S4
MD5PD*3[$SQ#EA#A_"D0E(;95(:H)L:T&44N(;76(>D(CN6@/0@ZL8],S76(U
M570=,L5+F.F\5(2VB#)$.:("48FH0E0C:A"UB#I$O4!BI3`?^Y*A/!(_=XX0
M;^P&"^91L;D2IJ9DJ8YG4I:B*&\198AR1`6B$E&%J$;4(&H1=8AZ@61(;8'[
MOM'I2V->HV[L%\W,@(V&8HIHBRA#E",J$)6(*D0UH@91BZA#U`LD0VE+S#B4
M1T:GK_7C^'G$FZ_4?E;8S@&,MH@R1#FB`E&)J$)4"R3OV1:/\3WK=>2D;S\G
MUHJ:Z#SB63<E*;,G#KD[LJUPBO:)2)!:Z`UJYFT9*<KP'%&!J$14(:H]&GD&
MGMBB[:\'S)5^8F;S*`Y80!R*D8`Y*;.`#7MY_!+ST&3S+5(^&LP]<O?GCA$0
ME:SH+:L:JV(!ZH5:F)%#S=9"<>2.I)<OG>+T\BC>ER9+??B=."FY+XWV4</M
M;EF*FIXARA$5B$I$%:):(!D96\6\(3)67&6;0W9N"TD#I_=IXA6G2^)1*;VE
MSKR4^:23'1NS=;)29TDYV3FTG_7#+K2)^J$D1=%,W8!*-N!JJ3^D6I.90_Y%
M%]@?7!!=8.?!4Y[1#(JR,SRRDV[4&>J,*/521X8I2U%X,D+NJ#19SY7EG`0.
MW;@+/$GQ#%HBJ@@Y9[-K>$A#`H><R2@;*1'EZ2G`_"Z#'N@>B8$^6Z@(I*0H
M1A!,`2S%L74>_:A>7%^K&C$GG4.WZV/K&\Z+?DF*C"J/O+/U0G^QJR:=0\YD
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M8QI`IDM29&\5(5J7EI=J&UB3Q"%O<I#]+670$LL@C^2S"KU52DG1[%Q#UXRD
MM3?/F99Y1?FL8J5.\W,R+T(!IZLDQ05(28@]5N,>56%0D^(ACS+XMH!YP]#V
M55$\M!T2&1[09$B]%-O*EH!R0G&&!_,\2D&Q(D4V7Q,:R7!;M[PA#+X88MLW
M2X]$ANL'AJF7.I;ASI;(<(]\AE\M],]&Y-ZT_:+<X7%<<`,X=N"M(EN4X3"?
MU"1QR)L<9+;.B*/[OH7;5RMQT!U2&:Y/))=>T=SGX<AL28KS+?-(9;B:[')2
M%*'`#`^-X,![Q!ZK<8]JBU8?\RB"O]+5U?3B-8C+':E'<88SF@HI27&/98AR
M0E&&(RH)L:T*44T(,WQENN>OC\'!BHJ.-:R7=DA\KW@D\;V4S&%=?6<D)3>B
M>L4G*3YY*K@180RB5$5HTGQ-4F+41V6>'(.V6IB:`$Y[8K:R9E3T'1)C,Z#)
ML>FE>,7-O'GS?0\*3TXH'IO!/$F5),6*%:*:T,C8U(7-D13%"F;ED'PTHS\:
MD[(4-7V+*$.4(RH0E8@J1#6B!E&+J$/4"R1'G*Y<[)*SN++O!_"_MW_RCZVO
ML*KQ2(5;U^@LQ>%VMHPBH0RE<D0%HA)1A:A&U"!J$76(>H%DN&WAH!/<'>&]
M\:?M5ZX$B4_G/5+15O-=RE(4VBVB#%&.J$!4(JH0U8@:1"VB#E$OD(RVKIB.
MS!=8&JT<DB%=JU/DE*4XI$&14(92.:("48FH0E0C:A"UB#I$O4`RI+:`T`-X
MMCSE9Z]=Z2$&K$/QH]P5H"VB#%&.J$!4(JH0U8@:1"VB#E$OD`REK2?B4!X9
MG:[\$/'SB#?&Z0K0%E&&*$=4("H158AJ1`VB%E&'J!=(QL^6!7'\WE4MK7QQ
MP?OE&T*\34D93>Z5G"WQ6#B9J=DB\[;BQ\*("D0EH@I1C:A!U"+J$/4>C3QB
M7NMJZ5W!'ZS(C2JA*/B,IH+OI0X_8F8!FI)SMDRH8#3AK&1;!YXZLP!9KMDR
MH8;1A+.6;7EGZNRL8P&RW+-E@T3:K,<*O%.>(@Z*JK/&:KJU:E[J%8\\@QF5
M@IK.2_E/M2]7:G>3DY5#Y98[OR6I^/,;<)99CDKI%E6R1>9E6?*G\&JR,MFB
MAJ0F6]2.2ND6=;)%\RNUW^[)RJ$6R>%BRS@]RYXT7%S]%Z]7:U\2FLU].&`R
MSX9EP%(O=>0+*RQ%8S[SR#_2@2>N.:D<NF\_-GR[S9_0R)&Q$:3(?27=P]=6
M3O+>D-2D]Y:ER'O'WKG9R5I](Z`G11&"Z`Q.=KTNM]\WQV,5OO;(+)<AQ,E:
M'T=ZJ6/3AK,5GP%[13]'P'?"<C(L@A`=R?AQ$`QS(T?&09"BGJBD^QD\RSW)
M?4-21R8$<-\I]XEZB-J3X4-W+X>`/AZ8WJ.N\0C`H_C@B=%$9+<DQ1NS#%%.
M*#IX8C1AOB0I-E\AJ@FQ^8;1A/F6I-A\AZ@GA$==]C5",.WZ.NOTWQ`:K*@E
MVYT;B$<!U^JH/B4]4TR$!(6QOR4I,5?IU2CS4O14_U)_X38G,X<&I$]'?]XQ
MV:22;$TVJ?)2?J&`341-5B9;U)#49(M:DIIL42=;!)N(GJP<:I%,6GWLH>?M
MTTZ1UW@<XI%(9B=ET.10\5*\J\_(%J.<$&=;P6C"?$E2;*M"5!-B\PVC"?,M
M2;'Y#E%/:"29WWUHLL9#$X_B0Q-$6T09HAQ1@:A$5"&J$36(6D0=HEX@.;;M
M^<;X=O2-!ZAK:TG-C0ZITSZ8'(,4+?E;;RL^KD:4(RH0E8@J1#6B!E&+J$/4
M"R2CK8]8CBS_>):R]D<B9I\25I)DK6JDE*4XI$&14(92.:("48FH0E0C:A"U
MB#I$O4`BI.;]SW(`3X=T$)>CU",U2M4V+V4IBM\6488H1U0@*A%5B&I$#:(6
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MK_O]*_W#-/?BY_[YM^%=XY__7P````#__P,`4$L#!!0`!@`(````(0"$F5@V
ME@H``*,T```9````>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*R;6W/B3`Z&
M[[=J_P/%_01L(`$JR5<33C;88+OV<,T0)Z$FX!0PIW^_:MMRN_4:!VJ_N1C(
M@UI2M]3J`_C^K]^[]\;/^'#<)ON'IG73;C;B_29YWNY?'YK__M?T2[_9.)[6
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MDXK`MR3YKD3=9X6H<0M:3],(!(?&<_RR_O%^BI)?3KQ]?3M1N'O4(]6QX?.?
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M>]C*)GI:-\;KT_KQ_I#\:E`QI@`>/]:JM%M#I8TK1C;/BQIRKH10[5!:OBHU
M#TUJ3U7B2'7OYV.WW[MO_:1:M<EEGE#&,B5&+*$*DU([EF`BP52"F02.!*X$
M<PD6$G@2^!(L)5A)$$@02A"50(O"4\2(ILK?$2.E1L6(1_>)@0Z:+0+"$MQD
M+,%$@JD$,PD<"5P)YA(L)/`D\"582K"2()`@E"`J`2,@5(G^CH`H-33O:/K7
MS)I,2"W#A="MB%(A4H0)R`3(%,@,B`/$!3('L@#B`?&!+(&L@`1`0B!1F1A1
MH]7`B%KUIH@KFI).@\.#^I21#B5%$8EN7\:B$.)F8R`3(%,@,R`.$!?(',@"
MB`?$![($L@(2``F!1&5BQ(*65R,6:MFQ>S>$KUQXE"(S3!GI4!J4PG0GIDPA
M5(0)R`3(%,@,B`/$!3('L@#B`?&!+(&L@`1`0B!1F1AAHKT,A(EVKW?4H'[V
MJ(9F6#+220\_Z>(^`C(&,@$R!3(#X@!Q@<R!+(!X0'P@2R`K(`&0$$A4)D8,
M:'DP8E`_\$K:'/B<V,6Z/P(R!C(!,@4R`^(`<8',@2R`>$!\($L@*R`!D!!(
M5";&P--NUACX;&N<)O_I;;OY_I10@:%UN2(@'=H"9QMCI<2,1T[T/FQ4$%VQ
M;$LL+.-,J$-GM5)9ZYME;5((<5F;`ID!<8"X0.9`%D`\(#Z0)9`5D`!(""3*
M")U8J*=&U.CX^_]'32DQHY:34M0*H@."4<N$>N7=6[<_$%$KA(JH%;J9S(`X
M12MMOSMHFZK=0H@5S4'1`HA7M"JK%H<UOQ!BU4M0M`(2%*W*JL6Q(RR$6'54
M5F2$6]UB&/&NF(UT0</3,14W(YNCGIJS/Q_[G9O^G3BYCG(1NSSY,-9:BMV>
M()HBFB%R$+F(YH@6B#Q$/J(EHA6B`%&(*#*0&2YUQBW?-WP2+B4NPI4AND4M
M9U#'S/N1NJ%2#<N;]8J(54EUY/3,=:59]/.Q8W=$U9VR,=)6U&8P-F,IO1`[
M&I4:2ONN:;][UQ,.SEE-K?T%2VG[GD8U]GW3_JUEB?XO64VM_15+:?N!1C7V
M0]-^K]OKFL&.6,TY^V8&JD/]%1F8W0'0(9TG]9-**I5;5).*<'<'PJE1+O59
MS<ATD12KGW##O![=]<5P3UG@7'?3C<>,I;1F!Y'+*#,VZ'9%Z9NS0*VQ!4MI
M8QXBGU%NK&V+6;MD@5IC*Y;2Q@)$(:/,F-6VY(XJ8HESULRT4=<*5Z1-=@MA
MI$V&C,(E[TA'ZI+[@KI52.FLR5"'=K.EI!31G+)ZH\M=L;+/6$K/5`>1FR-A
M46Q;Y]RPUN*"I;1%#Y%?;5$<[9?<L-;BBJ6TQ0!16&U13,B(&YZS:":2NA.Y
M(I&R*Q0CD7)DUA^Q*(S4EQ^429_5GRHIN0)-<ET=.J,6R=5KB[WFE"V>&X:\
M+A46.7<=;FALKZ03[D5.S%E7K1,+EM(EQ--(]]&63OC53H@)M&1=M4ZL6$H[
M$6A4XT1XD1,1ZSKGA)F5Z@KHBJS,;HR,K,R04=YZ;;&S'ZGOU2ZH;U52,A:3
M7)=1@"JR,M=U;ACRK"PLZJPL4$TLW(N<F'.W:YU8L)2N29Y&-4[XU4[`ZGK)
M2*RT11Z)0*,:)\)J)\2V*&)=YT;"S$IU*79%5F9W:$96YD@/Z4A]04LI2!?$
MW,$QH@FB*:(9(@>1BVB.:('(0^0C6B):(0H0A8@B`YFQ4/=D5\0BOU8K[YLS
M5#IH=TK_;%C`,O'/%K!"BJ,YH?CG*Q^C*:(9(@>1BVB.:('(0^0C6B):(0H0
MA8@B`YFA4Y=E5X0NOULKARY#1G'O#D2!&:G?#UQ0W*NDL+CG%M75#1VZ.UU1
M2*9LS"@D<H\_8RD]_QV-:JJ9FTOQH;_3%NDY9S6U]A<LI>U[&M78]TW[=E_:
M7[*:6OLKEM+V`XUJ[(>F?;STB%C-.?MF!JK[NRLR,+_N*V=@CLQ-KTB*D3J3
M7[#I+:2X0$RX879:[/5L.#GE;<YU-]]&@&:'->M=GLLH-]:_%4>8.0O4&ENP
ME-;L(?(99<9N._*TMV2!6F,KEM+&`D0AH\S874\:BUC@G#$C:U3IOR)K4G'S
MLC!'1MV",S>WHZN8XG0#UW=C+54D38[$!E1F#C<TNBP'9L92>J(ZB-QJB_+,
MS0UK+2Y82EOT$/G5%D7"+KEAK<452VF+`:*PVJ(\<W/#<Q;-1"*I:Q))B8M$
MRA'-[R)'>K(FC^Q,2OE62%5D4I44+("Y+O/,;<DS-ULDE=HB)E=AD7/7X8:&
MJ]()M]H)<=R=LZY:)Q8LI2N(IU')>^F$7^V$.%DN65>M$RN6TDX$&M4X$58[
M(79`$>LZYX29E>KNM[PHEKY@KO]:Q,YOH$OK8X[*OZ]`-$8T031%-$/D('(1
MS1$M$'F(?$1+1"M$`:(0460@,RSJ)E6&Y8Y^R5[Y37_INT4[OY4M1R5#73O=
MQ7X1$V>4MZ"/=>KU++VI,?U2%V?2+ZHN%_P:1ZU_LJ!EB#T3LVF4MQ">Z:4M
M\RQ[#B'[/?$N/KS&H_C]_=C8)#_4,P:T0WR\+W#Q`,37M/P+_D0/1J1/$TAN
MTP,3ZJ`N^-?.\"OYB!\\=8;T"\`*WAU&E?*]890^"2$,/-T.Z2<Y%7ILY5&5
M2^/^,$Q_'B`TC0?#R:!"DS,8TM?S:,$;#.F[=>3!8!A6<;K0&*J["6Q!UQ-#
M==.`G]!EPU#=&^`G='5`D4@_:14=H4=$/M:OL;\^O&[WQ\9[_$+A;:>)=\@>
M,LG^."4?%'9Z8"0YT4,BZ=LW>A@HII]RM]7\>4F2$_]!IEO%XT6/_P,``/__
M`P!02P,$%``&``@````A`#J</(R=!```.1```!D```!X;"]W;W)K<VAE971S
M+W-H965T,S`N>&ULK%?9CJ-&%'V/E']`O(^A6.PVLCVR69*1)E(436:>,2[;
MJ(&R@&YW_WUNK:8*CQM%\]*T#_<>[KE++:O/;W5EO>*V*TFSMM',M2W<%.10
M-J>U_>^W[-.3;75]WASRBC1X;;_CSOZ\^?VWU96TS]T9X]X"AJ9;V^>^OT2.
MTQ5G7.?=C%QP`V^.I*WS'GZV)Z>[M#@_,*>Z<CS7G3MU7C8V9XC:*1SD>"P+
MG)#BI<9-STE:7.4]Q-^=RTLGV>IB"EV=M\\OET\%J2]`L2^KLG]GI+95%]&7
M4T/:?%^![C<4Y(7D9C]&]'59M*0CQWX&=`X/=*QYZ2P=8-JL#B4HH&FW6GQ<
MVUL492BPG<V*)>A[B:_=X'^K.Y/K'VUY^%HV&+(-=:(5V!/R3$V_'"@$SL[(
M.V,5^+NU#OB8OU3]/^3Z)RY/YQ[*'8(B*BPZO">X*R"C0#/S0LI4D`H"@+]6
M7=+6@(SD;^QY+0_]>6W[\UFX<'T$YM8>=WU64DK;*EZZGM0_N!$25)S$$R3P
MO$/RP-$7CH%R?)H%7KAX8E]_X`BQL;#A*;[H>3,4N',:]0._N?"#I_![_$&'
MIXME/\G[?+-JR=6"EH:$=)><#@B*@$RFG7]:%>)G=8`"4)(M95G;,(N0X@Z:
MYW43^L'*>86"%\)F-[9!ND4L+6AU*6UB`JD)9`/``45*%E3P%\BB+%26#&@G
M@9M.S]`@+:1+8@*I"60#0-,`3?4+-%`6*.Y"JTVH1[WC1CYD4Q5PKIO$RD0I
M&R'I",F&B"8.)L44YX4SU?23.X_R,'DRK!U'?/BRTN+["T.-,I)NR0A)1T@V
M1#0U$+>I!H6S!<#WUR\Y-]1/CYXC/EMIV1#$(R09(>D(R8:(%BH,^3#4Q_%1
M8ST^@7AJ)N(1DHR0=(1D0T2+#QIU>GS46(]/($NV"'DN,E:AF+_WEX/N\)#1
MZPDW\MB.Q8J0"L1GM,B=&QZ9>#\<H"&MII`>609+[N,*4&-=(4>\0"HT9CD6
M'O!0_3\,A:^LPNA6QE30AEPA\I_TB<F$QR2%D-WI"JFQKE`@JH9&LF/^_H,:
M<J-A#04B:N@A8_O)Q/M)"A$<<*9+9-:Z1@'=RFBN4-+G<1VEU:"0`O(7K))S
MSYB`3+I,TPE60YW\?,!6MOY<%L\[`DT&-G>:F.:9-=L641)#OH`@YZI+?;/G
M8N'X0:6%E<?/<O3@D$H(ME9%[Z&ET=+2BCEJ(XKHGCQY1IFUH8]OZM[\MDX*
M*X"&,1F]G4BKA7),QU`F(4:O1TYWW$'D_Z]@?-N&0X/<'G>(0X&OH%A`Z(,.
M%5Q:*7RC%*G@@E,O/3P&KFF0R8]!WPPJ>LN>G@2Z43](PC=R^5G7L@A$V_+M
M7LL"A[2R*NA^8'R]A:L3'0'O=I9,QQ"]8#&K05GYA8D?V6O<GG",JZJS"O)"
M+T-TQA6J+FI;MAH8^(Y>X&CQ3-R+X`0ZQK=^M.47/M/!C^!8-W;8!1$<D.[@
M802G$<`=1007MTM^PG_E[:EL.JO"1]#BLE6EY5<__J,7==J3'JYLK&1GN*)C
M&'&7GA6/A/3R!_V`NO1O_@,``/__`P!02P,$%``&``@````A`!S1Q;\:%```
M$VD``!D```!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK)U;<]LXLL??3]7Y
M#BZ_KRR2DFRIDFS9$BG>=:D]N\^.HR2NL:V4Y9G,?/O3(-!L`'^*DF<S#^/D
MAT;CT@VPT63@#__\\_GIXH_=Z^%Q__+Q,A@,+R]V+P_[+X\OWSY>_M^_DG_<
M7%X<WNY?OMP_[5]V'R__VATN__GI?__GP\_]ZV^'[[O=VP5I>#E\O/S^]O9C
M=G5U>/B^>[X_#/8_=B]4\G7_^GS_1G]]_79U^/&ZN__25'I^N@J'P\G5\_WC
MRZ76,'L]1\?^Z]?'A]UB__#[\^[E32MYW3W=OU'_#]\??QQ8V_/#.>J>[U]_
M^_W'/Q[VSS](Q>?'I\>WOQJEEQ?/#[/LV\O^]?[S$XW[SV!T_\"ZF[^`^N?'
MA]?]8?_U;4#JKG1'<<S3J^D5:?KTX<LCC4!-^\7K[NO'R]M@MAU/+J\^?6@F
MZ-^/NY\'Z\\7A^_[G\O7QR_EX\N.9IOLI"SP>;__38EF7Q2BRE=0.VDLL'Z]
M^++[>O_[T]MV_S/=/7[[_D;F'M.(U,!F7_Y:[`X/-*.D9A".E::'_1-U@/Y_
M\?RH7(-FY/[/CY<A-?SXY>W[Q\MH,AA?#Z.`Q"\^[PYOR:-2>7GQ\/OA;?_\
M'RT4&%5:2624C%HEX>!F/!Y-;JY)24]%*FU:IY^F]2"4UGLJ3DQ%^FDJC@;7
MP7`:G6CPVM0C]S?USNSIU%2DGZ;B]5D-!F319HCJ#^_J:L"F"<0V9W8V8(.H
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MNJ/%;ZV::]<$=UHH(M]HA;R%-6]%6C,!B8$D0)9`4B`9D!Q(`:0$4@&I@:R`
MK(%L@&QMXEB-=G;':MTA`N]H2KHQ#D_JG281Z6\M$4TBUUSS5HBK+8#$0!(@
M2R`ID`Q(#J0`4@*I@-1`5D#60#9`MC9Q;$'/-\<6^K$S4-%+OUE41=<LFD2C
M=E^;`UD`B8$D0)9`4B`9D!Q(`:0$4@&I@:R`K(%L@&QMXMB`XA7'!OT3KZ3=
MB3<DE(D'L@`2`TELXG20-L9W=%!)NQTTA$)6:\&.O`6KA2);*`R\'7:AA<+F
M*-)$)K$AD8YUQM.;<.CMW(D1L7=N6[,S5(J<G*&J]1".!V2[?JNH>NZ@-0EI
MY5F#'GN#-M7H1RMD=TT'7T9([!L;W>-FT'3<&$?>;":FSEECIBEWQMP_4B7M
MCM00VW+1Q+/<7`N=,*\6LLUKB#;O:#(,;[R-/C$29XU4G7V<H3;FG:@3Z<7;
M]\>'W^[V9`=2U3$%J@LFQE9:W"EH%).GN-;V''%NI%1XWV-NEK+LS>JUP8-1
M$$S&4]>5$JYVWD20E#,1'0.F26E'K,2]$6L4-BF%9E[FZJ!(4H1ZAV>DKMOM
M*N:*@A)&C7IGA:I3J-/UOV=#'5)2S,?QP5VCF`9)#M5:)YK<N-,\-U(G'-E(
MV9[,2+OR37`SG(`OLPQ-4=L%>S]P)T(%6'AD;)[=C3/_:__CF#/;MM5QFC,3
M&CFV;5%WS_1.I8[YR@/D;!,C2AAUV%;%*3@D/H.??PK6\8X7T7NFO%.Y!NIM
M;T@O,NPG"T0QH@31$E&**$.4(RH0E8@J1#6B%:(UH@VBK8-<WU3!CF](_1Q]
M;T)#ATV.>VKD'`#&D;<?SE4^2%DW:E?X`E&,*$&T1)0BRA#EB`I$):(*48UH
MA6B-:(-HZR#7<BH*]"T7C,\X$00F?K2W5(WL,X&1LM`"48PH0;1$E"+*$.6(
M"D0EH@I1C6B%:(UH@VCK(-<L*HBUS7+B@:UC7F?5&"1AQ5SMC[1$Z*DCFQN@
M&*421$M$*:(,48ZH0%0BJA#5B%:(UH@VB+8.<FVA@NMWV,+$XO:ZT&@DYYBY
M"@K)%H1Z'[!&RHE1KH=NC!*SKFEKUX21M+A$E#)RU7O)R$RDV&UR1J*^$-0S
MH)*E>ENL1(I;K!E)BRM!/2VN6<IMT7MZ;$2*6]PR:EIT'8)TO<<AE+@736OD
M.`2@A0I-E8_0CS8\C*Z]Y'TL4MSUA)%,UA)1RLA5[YVW,I%B]3DC45\@*AGU
MJJ]$BM77C$3]"M&:D:/^QEL:&Y%B]5M&:%<*W]]CUT;<M:M!MET1+1C)>HT1
M)8QD&I:(4D;.-%Q[Z8%,I'@:<D:BOD!4,G+5>X?]2J18?<U(U*\0K1DYZF\\
M#]^(%*O?,NHPHCIOGK];A_IX2KL_Z[XSR#&BEK+0@J5L(QHI00E+R30L$:6,
MG&FX]I)'F4AQ5W-&HKY`5#)RU7O9BDJD6'W-2-2O$*T9R;`WB+:,.BSFG_#[
M8YT0C_(&6>:9(UHPDG[&B!)&,N8EHI21Z,H0Y8Q$5X&H9.2:QSN]5B(EYM$S
M80U[Q5+2XIJ1='6#:,NHPSSJD&\O*.N=P?E)M%"G"IQUII'5_;F1LM#"H+&,
M*$:48,4EHA0K9HARK%@@*J6B/)S#$*RFQVCUOD9=*T1K4<_FWB#:.A6=&$6E
M)AVKG5A4;0:%F[MK--#CS7'+&R\XG!LIM1^W,8J=PM*)(I%B]3$CD^J]#KU'
M=\("M*D>U[QD*7&/5)!5T<\79$8JFC1)]7`0>$^=G-7TME^P5._X2Y'B\5>(
M:D0K0=98_-<D:Y%B]1M$6P>YSN*G;TXX"^9H5$9=A:KD1JVQ(C_?.3=2*NW9
M2G4XBU$OQ]385&S2F']\"FXF7H"3L.9>8RU92C2G@JPNH;/H+D77C;/0AVK>
M,LA936_[!4OUCK\4*;9FA:A&M!)DC06=!:9W(Q6YQ:V#7&?Q,T8GG`731.J-
M@7(6ZDCK!M&-9]*YD3JULVA=),5=CTU%6MFV>B^:2EB]8[&1MPDL64K4IX)$
M?8@>H_MEMI?AP`]J<U;CM.\;JV"I$]L+3$(E%7E>:D0K0=98_$ZL18IU;1!M
M'>1ZC$HR_?<1A$E5V9&Z1MZNXYU.YF&;X^H9Y$*D>)"Q0;3JI6)TX\7-"5=T
M#(F.U':"U:=<T=D-T)%T1;/U1!U;C]'LM._;L.ALS)<J18I[62&J$:T$R53!
MSKX6*5:_0;1UD.M(*AUF.]*)K4=GSYR84R/R5>[!G-Y>J=U(N6^[&T'7%RPE
MWA<C2AB)^B6B%%&&*$=4".KI:BE2/,8*48UH):A'_5JD6/T&T=9!KA$IH'2,
M^/?.$TJ+EWPQR`U8O8A\'FJI$R]TC93S6-$5*>1N/K.E3T_<-&S"=7H7XE+:
MY^E+N:*SR>-&8#JN`]9H,/%RF#FKZ6V_D/9[C%RR+GGN55Q1MW\]\,=?<YW>
M]E>LQK82++<UZ^J=D@U+:9.$])F$%Y=M6>)8GQS/C*BU7L\\[PU[H\9U38/L
M;4=0CQT6+&6]84>4,+*V'40IH@Q1CJ@0U-/54J38L2M$-:*5H![U:Y%B]1M$
M6P>YQB47`..&[_T62'T\X&T[!JG35?O\B&Z\Q3GGBO2P::7`[1<L)0>4F-7K
M;X'&D7\"3[C.,1=O3N!+EA)'2AGUQQ]&JHT_O.@J9RV]S1<LU3O\DJ5D^)7;
M/.TZW@JON4YO^RN6ZFU_S5*],[(Q4G1"4@^"<'@S]%(76]9SK$^N8U)KX)CF
M#?P[ONN)E!IOU]'(V75:U.N&1DJ<)3;JZ;'.RR]A9.\ZK7J62E$J0Y0C*@3U
M=+44*6ZQ0E0C6@GJ4;\6*5:_0;1UD&O<7Y(\59^^^+8UR'Z,1E//$>>FXHE@
MQTC9P0XC\V0-1][I/&&!8RYN=AW=2VJ?IR_EBKU/]LQ(F>-S,`B]99^SFM[V
M"U9CSQ+LNB7KLH(=KJB#G<D@\-JON4YO^RM6T]O^FG7U3LF&I;1)`DJ8>'W:
MLL2Q/KF>Z2>(_3#\S&`'$\?TK8_R5F?;:5'/8EMP1=EC8D0)(WO;:=6+FP'*
ML&*.J!#4T]52I+C%"E&-:"6H1_U:I%C]!M'60:YQ58[//BAKX[[[P\K(Y`KM
M#,AXY.TR=T9*/?7:V,8+$^8BPR-:((H1)8B6B%)$&:(<48&H1%0AJA&M$*T1
M;1!M'>0:4F7V;$/V9SQ4SM-_4&BD]H;6.-'4^\IC;BJ2E)BGK<@H1JD$T1)1
MBBA#E",J$)6(*D0UHA6B-:(-HJV#7/.HW)MM'FL3/6$ID[63?-*=RC.2\6A5
M\X3/$2T0Q8@21$M$*:(,48ZH0%0BJA#5B%:(UH@VB+8.<LVB4GJV64[80HE[
MH;-!<A*91X`6B&)$":(EHA11ABA'5"`J$56(:@>Y\T?QBC-_EEN?_\I?19W^
MM!HD3_@Y2]'LMOL3A&@+(T7OT44JFGI!:2Q2O((21$M$*:(,48ZH0%0BJA#5
M!M%'AM159_+IXX=?,/F-%M>G&5F3+TBF%2??2(WMYWLT]5ZHQ2+53KZH9[1$
ME$I%Z40T]0*(3*185XZZ"D2E5+35>V]Q*I%B];6CRS41S82S/OKWEY$2]VQA
MD'TPB/R,ZMQ4//$*5*2XZS&B!-$248HH0Y0C*A"5B"I$M8/<65;)A/-W\9'.
M/=AO>PQRWP]._=0<5Z3Z/3N02,DLZQ;I.:020<'`4YQP%7O=C/QDT9*EY%&3
M(LH,,FT-_;9RKM+;5L%2TE:)J'+;"@?AU/G/>^]1LX9C3;M&51F!=QC5I#FL
M,&FDD?/UP&CHO;B?&ZE32T?KLC,?IB+%?,JHWE$G8;7'QJK3'BPE"8444=;;
M4LX5>ELJ6$I:*A%5O2W57.%82Z[]U+GZ'?;3QW!G46KD+,K1T,MES%6QVC-/
M+,I62A:E1F:A7(<#6G'6?]YC)>%VC@W>&!3:2;FB+*7,(&XZZF\Z9PV]31<L
M)>V4B"JOZ7`PM<9,-Z.YKRIKUG"L:=?D?C+AQ-.NS1FP3>[46B5C>DO6/X,:
MJ5-+5NMREJQ&9LE2LLX=;<**[=%"E+-D*5E**:+,H&-MY5REMZV"I:2M$E%U
MHJV:JQQKR[6BGTGXFRFA49MBD*=E<.V%4W=&JC<E)#+L*`M$,:($T1)1BBA#
ME",J$)6(*D0UHA6B-:(-HJV#7$/Z.8<3RQ$3#2.3:*"'7QOPC(9>]#(7*3%/
M6Y%1C%()HB6B%%&&*$=4("H158AJ1"M$:T0;1%L'N>91:0+[`6F=G4]8RB08
M[%A'(SLE-`*T0!0C2A`M$:6(,D0YH@)1B:A"5"-:(5HCVB#:.L@UBY/2H,?Y
M"5M@[D+],SP=D;#SSQ$M$,6($D1+1"FB#%&.J$!4(JH0U0YRYD]E7L2M:?XL
MMSX_)=1H<4_"C*RLA"#9G^!YO3!2ZHL/V<4"+V"/18JMEB!:(DH198AR1`6B
M$E&%J#:H(R6D,B^_8/*5%F_R#;(GOT4RK1V3KZ7H\*Z_@0B\8"YNNDPAG[ZP
M55TJF1BDQZ?C:D$]C:6BRS3F'18R$6`CYZ*942&HI[%2=)G&O&BR$@'67(MF
M0NZR42F"]FEP<ML9ZXR"?5QB9&>*_'_?.3=")T+G3BG_.\.8I=I7_][A(6$!
M<H%VX8&'+%G*7IX@E79*^5W*C)0)NJ?^R_B<M?3VJ&"IWAZ5G5)^CRJW1^.Q
M%__6K.58CUPG45D(VTG^WMZJ<QF.[YCT!OE=:RG_GY7.QZ9>_TE;I-CK8X/,
M=U!!<`V.8C0?FP2S!YS3?HKM9P:9X_8D\O)2.5?I;;Y@J=[AER+%PZ_<YD/_
MYJB:JQQKWG4!,I'C`OWAR5B)>UNY1O97%T:*D)@?EN""I23LC!$EC*RO+@3U
MJ$]92M1GB')&HKX0U*.^9"E17R&J&37JW8E7N8/_?NWI#(2S]@RR]VW_G<E\
M;#(7ME"'A;24N[O[6U)L=)GOTZ.1_\E4P@+''-(LQW.ZE+(N9R_UNY2QE/ED
M:3SVHK.<!7J[5!@I]<JLW<9@EDK6U=NEBG7I].Y-Z+W%JEG+L1ZYSN/D5&@!
M^AOW>=]0T3W]L)HU<E9SBWIF86%T6=]IQH@21K+<EH)ZU*<L)0%CABAG).H+
M03WJ2Y82]16BFI&UFO7O*=`WK#_O7K_MYKNGI\/%P_YW]3L()D,*4UML?D'"
M:#*[)4VTGWLEE+R:J?Q+5\DUE31;#=2YH9*FVU[);3":W>H#O%="%]+-U)UJ
M'>T$8RII?FT"U*&^T;516.<V&L]N*2.()?1]UDQ]8M150MHHJNHJH9'2DQ5+
M%N-@IJ)[+*$X?:9"<2RAH'JFXF8LH5]3<=MDMF&<-,P.^;MPMNV2OXUFMW3/
M(#9P%]$XNCC-?>?4TUQU315=!T0M=VFB;Q-FZ@T_MKT8#6?JM3B6T#OOF7JC
MC27TNGJF7D9C"1UX:1*[2NARI)FZ5@#KT!U),W6[`);0O4@S=>M15\F42KK&
M0]>US-1E+!UUPH!*N@Q&UT]029?)Z(H#*NGJ&UTO-5.W,&`[=,O43%W&@"5T
ML]1,W1O554+VZ1P/W6XS4W?7=-2A\:@+4;I*0BKI&@_="$$E77VCV[AFZH8*
MU$:7<LW411580G=SS=3-6UTE4RKIL@]=!C135_UTU*'Q9)WCH9M,J*1K/'1;
M!I5T]>V.^G;764+7FLW4)1[8@P65J(O*NDJF5-(U'KHH::9N1NJH0^.).\=#
MM[Q02==XZ"81*FGZ=M7N-O0K:7[<?]M5]Z_?'E\.%T^[K_2X&#:W'[[J7VJC
M__)F[E;]O'^C7T9#D3<]Z^F7#^THKS%4MT5_W>_?^"_4W:OVUQE]^G\!````
M__\#`%!+`P04``8`"````"$`^HSI3886``#F>```&0```'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6RLG5MS&[>2Q]^W:K^#2N_'$LDA*:ELG[+(N5]J:^OL
M[K,BT[8JENB2E)/DVV]C@)Y&]W\XI)R\Q/&/?<$TT``:&)/O__G'X_>S?^^>
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M)L*#R!!B("F0#$@.I`!2`JF`U$`:("V0+B8JVC0;J&B/KTH\`SCI/J@<C%M/
M%F1_B&`R6YL8#D*LM@62`LF`Y$`*("60"D@-I`'2`NEBHF)(:Z.*H9]>W[F5
M=3J<3E&'TY-%OQWI9\<-D"V0%$@&)`=2`"F!5$!J(`V0%D@7$Q4[VAZHV$T'
MS$GK@`4R'R;-#9`MD!1(!B0'4@`I@51`:B`-D!9(%Q,5,)K05,"BP?;Z[>'^
MU]L])2)-:".!7-":[5=R9T3',1!9?#8#D<R>S\SLN/5"2]I`#>D_OUKH]$\'
M(4[_#$@.I`!2`JF`U$`:("V0SI-9__0JVJX(PYU3G]JG1]L9T=$.)(KV0*)`
M0K2]T'+6[[WFES,;Z.'S(="#628YD&+0<CLZLFH6R7+XG&U48*,&T@Q:P:K9
M!K;#YVRUBVVH3J"=O>J$D:%-I1"/;2>MHQT(_3$,TF1VI0?IQ@O-U4B&#AB$
MN-$ID`Q(#J0`4@*I@-1`&B`MD"XF*JRN['E#7'MQ'=B`$EH9H\A>F\BR(FWX
M!BF<25@JWHO-%\96&J06-%8B6T8J&[5E.S-G*5D["D:3C2A/:D0U:LLVHF8I
M:43#:+(1K33")]A21[T3*S16=;^38=7O/[6$N%K8Y%E`"2WV0^<D\TO=L$V0
M.I)I+.6/,5R=F#*:]].?F4\R_E1%S88[9ZG^R*9?"PM&XJED-.JIXD\G/=4L
M)9X:1N*I933JJ>-/#WG2W>H*JGBMFIXFW1&&[3^/YBO93`4I0M*E([D;%->#
M8LJ*@C)&8CY'5#`2Q1)1Q4ALU8@:1F*K1=0QZFWID+JR*0[ISV6*+[ZH%.55
MX]8=`E'PD\6`-@'1'F0RTL&6#*$T*-*4Z"8"2(M!8<)L+LZYB04C\51.>JI$
M8<)3S5*R]6D8B:=6>YI?FFUG)RKCOG0ONL(M[L4CB>'K/-5='JG$&-!X"\+1
M5I"2KD_=^1MU_5Q0QD@&<XZH8"2*):**D=BJ$36,Q%:+J&,TDABNGGM#2'WY
MIT(:$.U.HK7"C-Z-.R>G8"UBJ9'IQTO1BL*C-PV*$<H0Y6*>%0N4*A%5B&JT
MU:!4BZA32`]<5P2^(<JA9I1.O9UY=&R#%A2/3#U!2M(T#>;5;BR9F_HA"U)N
M,1NZ>FX/CG.6DHFA8"0>RW&/I@ZJ1''"8\U2XK%A)![;,8_SF=EQ=J(8>8QV
M'[I?7;D9]^O/+2NA:(V[VZ-C&S`O=2RIO-1<0I&ZPU0W==%J/W1D,D_T_BYC
MJ2/=/31"4@\\EFQ+>S1;W8JE)CW608H>FSTVHLBH911['.GNH:D2B7A>TMWM
M"MNXNX^L/T[<U%D>J?5G0.,M".M/D)(QDKH-AEU_!EL<AIRE9!DI&(FM$E'%
M2!1K1`TCL=4BZAB-K#^NJ(U#^G,9Y$MCZG)^[MN91VIC%J0H2,.HC_LZ1#I(
MQ>GBD9D=S58F"QZ/S8Y#([BIA2@R*@,R'LUI?"6*T0/9^;AFJ7AVA&=LQSR.
MI,N@&'D\-#NZPE#U[72Z].(Z70**TT70>`M\)[*4#(@44<9(AGB.J&`DMDI$
M%2.Q52-J&(FM%E''"-.%)G$=TI]*E]Z*B;0S3(CZ=\B-*[,@;(+>D?4F2+F'
M&$SA^0_;HKW(()7,S5E>QK8F%X2<;<F"4+#B9"-*5M2-,%N"BFU--J)F6]*(
MAA4G&]&RXBH<!IMYI6,KROW!G',%_-1\^J_]#^KFT5N%Z.C5[0S,TA60RD4O
M14CZ$"=45I3Y)T64,9+\R1$5C,16B:AB)+9J1`TCL=4BZAB-Y*(KR#'4_#['
MR2]CS$-A3SN1(1.6B=D)WP:IR1MND>&%9(LH190ARA$5B$I$%:(:48.H1=0I
MI+9B<U=\V^#/E^^H@'SCNS"])3,9^LI>WX4O[/%G4"0IB?:@R"A%J0Q1CJA`
M5"*J$-6(&D0MHDXA'6U7E]MHSY8G7(R[-]OL1.)1?#4>I"*T190BRA#EB`I$
M):(*48VH0=0BZA32H73%=QS*(YLB)VY&9T!RT;!Q,["3$K1%E"+*$.6("D0E
MH@I1C:A!U"+J%-+Q<P5;'+^?VP'YLB\N&.@<KX^A+`<;03(SCZQO7G&A5GFX
M.@^V2(JGA@Q1CJA`5"*J$-6(&D0MHBX@*MJHJ3KXKK[\Z\'W5:H*?D!Q\`<T
M&7POE1R\29\/`A+WP3*C/$CY1^Y+B$(4#]RFBP";J=!,C:@1Q0,WZB+`ECME
M1O>)*\ELG_B5\,C4$FHYJ45NYP'%54"RL&>Y04IO\*,-:2C!O"TM!=?`P=:"
M)K!A\Y,L[,$C>U1;8%OHYBPE*58($O-0BY3CC3`[L(IM33:B9BEI1"-HHA'M
M>"-,"=:QK4.-4$/#34EJ:$P/B%Y<KS4!N9U!U#WFV&[#BOJHS=0Q6Y'B49T&
MM*`9-#)O%#-6//3,_7C+64K6P`)1.>[1'JRPXJ3'FJ7$8X.H'?=H"MV.%0]Y
MU/U*4F_I5R=N^C4@G>BF\-VX8H,4=0I#HHN4]*M7U%F=F`UTQHHD//0^7B>P
ME"14@:@,R'@T,U?%BI,>:Y82CPVB=MRCF;DZ5CSD4?>K+=Z/Y"L6Z8M0D:M\
MM;7D)DBYZW()//9K,!\=A`9%=2P)AX09FU?/;,WG+"794S`2C^5)'BM1G'B@
MFJ7$8X.H98]J3DKL/,R*ZAFC%4GWZ]A)P2E+M*M`;>8&I#(W@1G92QW+W$%*
M,M<CRB.W-TF6,!<'%?7<V+=@N`B/0BUB7R4C]S8KO>\PLWOFB@4FG=4L)98;
M1C*06D9ZS)L9KV.I0QYUM[IJ/]YY'4E7?S@0;WNIX.TG6)VN)N:;('4L78-Y
M>>8T*!Y+UT%Q(GER:03W7X&H9(_KODM7UV8ZK%CE4'S[I;QFJ3A1AT:R^Y9]
MT6X^FL6@1P?%6$I"K'O4GG,<Z5$\W%@$I-/3["\V0>I8>GI;4<JDK.A3YOIR
M+@_2ARYC@<D`YRPE*5,@*AEY9\O%E7%6L<"DLYJEQ%F#J&7DG2TNE[!#"M$X
MY$QWI#L0>4-JAO.3J!1R.PFW]Z'A,XRN)#&-V@2I8ZD9S,MX3H.BWODF9O!F
M;%X]<[3*A)TOF"]843R6HQZ79D]6L>*DQYJEQ'R#J!6/;GY?+$Q!U;%*/V/I
M[G-'*F_H/G\"HV;6@%0>+LU^<./"?\(&=Y#BN2<-BO0$[M%6*Y/@&1M68<1E
M$@P7K"C)4FI?R<J$L6*525\U2XGA!E&K?<WM>.]8Y9`OW8ONG"7NQ9\ZJG.K
ME]T#>:1S<VG6F@TKZA7?S&%;D9+.]>;=LTKJ+TW8,U94H<#<#*V73"E845`9
MD/9HW\>I6''28\U28KY!U(I'-X#G,Y,9':LH7]$`UAU-6:8Z^LBRZ<1-/>H1
M'?MR+VS<+;/+39K<AE[`PU>6DID[190Q$O,YHH*1V"H158S$5HVH822V6D0=
M([Q<3.S1S4_E3F]%1YH117<(*UST!R'7O$$(8Q^D]"X&3OC85MR/>-'/MM1X
M@VQB6W+'7K"B.GVWC2A943?"++<5VYIL1,VVI!$-*TXVHF7%0Q?];$6Y/Y1S
M=.*M<\X.D-,N^GLS9H0XRWWB#;D8I([D(DO)(7Z**&,D^9,C*AB)K1)1Q4AL
MU8@:1F*K1=0Q&LE%=Q""Z]B;;YJ3<*`2KRM+>[)P&Z3<P=&0>V;1VH@,=]$6
M48HH0Y0C*A"5B"I$-:(&48NH4TBM+?0"GP[^]-K2BYOQ'(XTZ(\AH,G2'.AL
M@B(=`$A(!T5&*4IEB')$!:(2486H1M0@:A%U"NF0NI(8Q_,)M_GN]7.S<@=$
MQ3@':8-HBRA%E"'*$16(2D05HAI1@ZA%U"FD0^F*TCB41T9G.!V07<&M>\7;
MA52V:QM$6T0IH@Q1CJA`5"*J%-+/[,K-^)GMRG/2/UQ/G!63J`')/+UA*=I%
M#[D[LA'QBNX.99!:V"UM&FR1%(_4#%&.J$!4(JH"&KDU3UR9]]<#YHO%N,CM
M#5,,XX`%J2,!\U*TY/6[?_SWY\$R"4BL!LN,<O1?B&*P;*JR4@383*7,Z*'F
MJJ<X<D?2*Q1;<7H%%.]DDZ4]+D^\E-[)1CNO_IQE*U+<]!11ABA'5"`J$54*
MZ<BXZN@-D7'B)ML\<G/;D#1PWK])@N)T$3TJ93?A:9"B=Z/<V)BMDY4Y?<K8
M3KSW@73/64JFS$*0/`S>\^L&7"WMZ\85FSGD7W6!^ZX,U05N'CSE5J=7U)T1
MD)MTH\XPITJ;('5DF(K4,$P9^</59#TWEC,6./3@_J"1I60&+1"5C+RSV35<
MZ[#`(6<ZRB2EHCP]!=!7:MB!'I`:Z+.%B<"&%:<'NDA);+W',*H7U]>FJLQ8
MY]#CAMB&AD>#FA4%E0$%9^N%_2=Z%>L<<J9C.U;8G#2"ATJ&PW"[],B,8'M>
M'J2.C6!OBZ38?,J*85"MKTU)E+'`H0</40;+!2N*LY)1<#:W7\]2L<`A9SK*
MMH+YJ?W2TA<C\?(?D!K8"1R#LB(]^3"UP)RZ%2D)N??(T_7\VJ1,QCJ'HA!"
M'AHNH[A@14%E0'0"ZM:&9&F2J&*50[YTQ&V!<V3.P*IFZ5%\'BEH,HY!4;8@
M*2L*RAC)N46.J&`DBB6BBA&>6RS?5ISTXF99"L4);0*&L0-]LPF*1TX+@Y1*
M:F^>WO+O-XO7\[7I]HR5#G5[&&+>#C6`!V_!BG%6*V^SZ^6EV096K'3(FQYD
M?TL9M,0R*"!]NV&W2AM6I)WKT#4C:1W,2Z:E05'?-:S,^7_&YE4HX#R6I:0`
M*1B)QW+<HRD,*E8\Y%$'WQ4CIV]_EZ%VD4RZ#4AEN)<Z<LK)BF(K190QBC-\
M,"^C-""Q5;*BH(K12(:[NN4-80C%D-B^70:D,MQ>,6Z"U+$,][94A@<4,OQJ
M8;\`)`NFW3]R.SR.<VF`Q`Z\E6PKK-LXGU0L<<B;'F2N]HFC^W,+=ZB@XJ![
M9#+<GD@N@R(]Y^'(;%E*\BT-R&2XF>PR5E2AP`P?&B&!#T@\EN,>S1:M.N91
M!7]EJZOI-;P7UXM70'&&"YH**4M)CZ6(,D91AB,J&(FM$E'%"#-\1=WSU\=@
M;\5$QQDF1)TYC"YXMV`3%(\D?I#2.0SE/TOIC:A=\5E*3IYR:<0P!E&J9#1I
MOF(I->JCDQX]!EVU,#4!G';'MG)F3/0]4F-S0-(AN*`'6_3/03@6*:*,43PV
M!_.L6+"4V"H158Q&QN9X8?/F>['54-K(DR_M*ZVW06KR7DQD^"&WB%)$&:(<
M48&H1%0AJA$UB%I$G4)Z;+ZMQEEAC1.0>^559H"U.9+;B)2$U-N*KLI2E,H0
MY8@*1"6B"E&-J$'4(NH4TB%U!<*!=#^R^OC2(B[.5Z$FB>[%$&T1I8@R1#FB
M`E&)J$)4(VH0M8@ZA70H;7%T)'Y8!:V@<MD@VB)*$66(<D0%HA)1A:A&U"!J
M$74*Z?BYPN#`4#S]ZXI7OKQ0PS(@F?,W+#6]SPQ2ZHXMF9G9(A4IGBTR1#FB
M`E&)J$)4(VH0M8BZ@$;NZU:NLOCKP??UB0I^0''P!R23\,BJ[Z4.W]?U3::O
MH91=4Q90=#F8"YIP5HBM`U=X(L"=7(EE1K6@"6>-V`K.S$%$*P)LN1/+A'3:
MN-+$]MPI!]JK4-/(-OV6D=H@KTWS-D'JR('VJ!1ND'TCPDO%RQ5LC?WG>IL=
M[5W]8=BH+RM5C$K9%I5!*K0HL<5[Q58.[:;[%M4L%5_/PQAO1J5LBUK=HOF5
MN6#HV,JA%JGALK8UYJDW>+VBWM$'I&OZM3GDVK`B;<:'/1>$8BM2/.;3@,+Y
M.%Q?9:QRZ+G]V&"I2?>%2+'[4KN'?S7`&I/>:Y::]-Z(%'MOQ;M$+5F;%[([
M5E2-B`XT=->3%,P4X1M-3E]@U\Z*&0<!Z6G#GNT$Q2/3ADAQ*-*`0D;"/\G)
M6$4%P69_SE*3&5F(%+LOM?L97(RQRJ3[FJ4FW3<BQ>Y;XSXQ-U(=JQQRKX>`
MJXCCQ6)ZC[IVXJ:O/8JK^"!UY`R9I62Y21%EC*(J7I!D`LP?!4N)^1)1Q4C,
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M-Y_H>!0_H9?X;]P[[6.?4`OHU>RQ3Z@%]"X'?D*_:_IIU!;]WFE?\,%34H/'
M[%!8Z.L,T<$MM6F\2=2B,7F*R%A`MLGJQKT:BQZVR?HFI?<\\1-Z8Y1TQC[9
MKM8WKG!'G>WJZB:E*A`_H>+UIAS]A"I-LC:FLR4WHU[(R9A\02[&>$,.QOAV
M3@[H.[6PM=LYN?"3A.E"^O:IFW+T$_KV*++6^[D8E.A79G_<?=VU=\]?'YY>
MSK[OOE`*7O8+ZK/_G5K_E]?PY9^_[%_I]V5I\:1?$*7?$][1C[)<NJ]._++?
MO_)?J+D7PR\4?_Q_`0```/__`P!02P,$%``&``@````A`)U;H0O1!```31(`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULK)A=CZ)(%(;O-]G_0+@?
M$=!6B3II/Q`4S6:SLWM-8ZFD@3)`?_W[/45!2=5AC)/,3=L^G'H/O.=44>7T
M^V>::.\D+V*:S72SU]<UDD7T&&?GF?[C'_?;6->*,LR.84(S,M._2*%_G__Y
MQ_2#YJ_%A9!2`X6LF.F7LKPZAE%$%Y*&18]>20973C1/PQ*^YF>CN.8D/%:#
MTL2P^OTG(PWC3.<*3OZ(!CV=XHBL:/26DJSD(CE)PA+NO[C$UZ)12Z-'Y-(P
M?WV[?HMH>@6)ESB)RZ]*5-?2R/'/&<W#EP2>^],<A%&C77U!\FD<Y;2@I[('
M<@:_4?S,$V-B@-)\>HSA"9CM6DY.,_W9=`X3W9A/*W_^C<E'T?I?*R[T8Y/'
MQR#.")@-96(%>*'TE87Z1X9@L(%&NU4!_LJU(SF%;TGY-_WP2'R^E%#M(3P0
M>R[G^+4B102&@DS/&C*EB"9P`_!72V/6&6!(^#G3+4@<'\O+3+>?>L-1WS8A
M7'LA1>G&3%+7HK>BI.E_/,BLI;B(78L,;B*]@34<C2N1.P,A194=/NOLK>1W
MQCW5X^"S'F>.[MXA7*T23<0`^[$[-*$BU4CVSV.YS,93\U$_#%Z4JL:KL`SG
MTYQ^:#!O0*FXAFP6F@Y3:ZK+K1'U_EFYH<Y,Y9G)S'28\5#)`EKT?3X</$V-
M=^BKJ(Y9X!A3CE@V$:R)F.Q*!6L5N"K8J,!3@:^"K0IV*@A4L%?!H04,L%;X
M"UW_._QE,LS?QIE%`VZ&6XJ9340S9*6"M0I<%6Q4X*G`5\%6!3L5!"K8J^#0
M`I*9L`K\#C.9#/0[S-A6MXYD^Q8\R(:ZBB"EH9<B1%B,R!H1%Y$-(AXB/B);
M1':(!(CL$3FTB>0VK`;(;6O8@Y7T%Q<')E3YW?BTX,2&U,+<P5AM8!'4#%LA
MLD;$162#B(>(C\@6D1TB`2)[1`YM(MD+/B)[S6%O!+S[U=JLM6R@;"<G]D`L
M#TM$5HBL$7$1V2#B(>(CLD5DATB`R!Z10YM(WL%;6?+NOF$L6C:L)K?U=(G(
M"I$U(BXB&T0\1'Q$MHCL$`D0V2-R:!/),%CK),/X:[YJMO(21Z\+"A,1UKH.
M(VUXG?.7/!.1?:Q)RT=!;C/;,I6%<\6#AK#?:4U_6UZ`UR*HF?XN(AM$/$1\
M1+:([!`)$-DC<N#$K)Y><IN=?/"FZA?=9B*RVS5IN2W(S4CL-@\:F-6VS.J;
MJM'BNC!:R#9D(\B=1)X08OL_2*0LZ+ZXWLANA6Q#=H+<210(H3J1LH_<B^N-
M[$'(`I%*!=MU5"K^DNN8"G!@:>8"&R=7IR;PT6KJ@=S42QYDM3L?%ZPKR)[(
M2FL>9#_QS?:P+U]V:PU^BF)[Z4V7JCHSO:X@-;4OI5:*O$6)=UV::N*@*TA-
MO)<2C^4GAB,PJXC5WK"UK>55YZ=<?@)*27XF2Y(DA1;1-W:"A7/5?"HP/UTO
MA@Z\AZ!M%+X:.;`D=/"QLZYFJ!+OC1V8`#@^&#O0KYC#J?[9ZN`+..U7557T
M%Y8#^^8.'=MYKGX=4.-M![9^.'XQ<&#/`MP0`^`T?PW/9!_FYS@KM(2<P*M^
MM9SE_/<`_J6D5_`0SO2TA'-\]>\%?K8AT'U]MFT\45HV7U@"\4/0_'\```#_
M_P,`4$L#!!0`!@`(````(0!-N`/J5@H``)`R```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;*R;6W/B2@Z`W[=J_P/%^P#&=B!4DE,)-QMLL%U[>6:(
MDU`#.`4DF?GWJW:WW&[).%![YF$@'VI)W5*K+YB[OW[OMHW/]'#<9/O[IM7J
M-!OI?IT];_:O]\U__VORH]]L'$^K_?-JF^W3^^:?]-C\Z^&?_[C[R@Z_CF]I
M>FJ`AOWQOOEV.KT/VNWC^BW=K8ZM[#W=PR<OV6&W.L&?A]?V\?V0KI[S1KMM
MN]OIW+1WJ\V^*34,#I?HR%Y>-NMTE*T_=NG^))4<TNWJ!/X?WS;O1]2V6U^B
M;K<Z_/IX_['.=N^@XN=FNSG]R94V&[OUP'_=9X?5SRWT^[?EK-:H._^#J=]M
MUH?LF+V<6J"N+1WE?;YMW[9!T\/=\P9Z((:]<4A?[IN/UB#IVLWVPUT^0/_9
MI%_'TOO&\2W[FAXVS\%FG\)H0YQ$!'YFV2\AZC\+!(W;K/4DCT!T:#RG+ZN/
M[2G)OKQT\_IV@G"[T"/1L<'SGU%Z7,.(@II6UQ6:UMD6'(#_&[N-2`T8D=7O
M_/5K\WQZNV_:-RVWU[$M$&_\3(^GR4:H;#;6'\=3MONO%+*4*JFDJY3`*RJ!
MMQ<VME5C>,7&UWO@*"7PJI18K;[K.C?]'G2CQG7X-.\_O*J&;JMG=6[M;]K=
MJ';PJMI=WF.8>[E->*UP]L)ANU5*X+5PW.FZO?XU@;,@WV3X1>+)T%[>#PM$
M96MX@ZTO&CT+@R[>J);]EN5T;D36U83+PD"+-VCRXE2S,&KB#;9NZ5&K,]S#
MOL(;U;1W68I9&&_Q!JU^YW-;SM-\VH]6I]7#W2'[:D`MA9EX?%^)RFP-A$*<
M\-+WH@2<JP`P]8661Z'FO@GM87(?H6Q]/KA._Z[]":5FK62>N(QE2@Q10M05
MH79$P9B""053"CP*?`IF%,PI""@(*5A0L*0@HB"F("F!-H2GB!%,A[\C1D*-
MB!&.[A,"';0N"0A*8),1!6,*)A1,*?`H\"F843"G(*`@I&!!P9*"B(*8@J0$
MC(!`E?D[`B+4P+R#"E#,&J?OFB%XDD(VY$8A=&.*#`N1(DR,C!F9,#)EQ&/$
M9V3&R)R1@)&0D04C2T8B1F)&DC(QH@8EWHA:]9X&*YJ0SH.#@_HDB0WZBTBX
MSBV)12&$S4:,C!F9,#)EQ&/$9V3&R)R1@)&0D04C2T8B1F)&DC(Q8@'+LA$+
MN>RTQ"ZI/BRBH1D626RGJ&M#1D:,C!F9,#)EQ&/$9V3&R)R1@)&0D04C2T8B
M1F)&DC(Q8@";%B,&]0,OI,V!5Z2K!YZ1$2-C1B:,3!GQ&/$9F3$R9R1@)&1D
MP<B2D8B1F)&D3(R!AX)O#'PI^4]OF_6OIPP*#!3\BH#8L+>2.RZAQ(R'(GJ!
M'Q9$5ZRN15:/D12R8<=>E#6G3_9NXT((R]J$D2DC'B,^(S-&YHP$C(2,+!A9
M,A(Q$C.22`);8>BI$378W/[_41-*S*@I4HI:071`>-2DD%O>%CA]LAB-"Z$B
M:H5N)%-&O**5MN_<=LQUSB^$4-&,*9HS$A2MRJK)*2`LA%#U@BE:,A(5K<JJ
MR7XV+H10=5)69(0;#L)&N"LF(QPN<38*:3.NDKABPGX^].T6W!R80SB4$MWR
MQ.-Q+H30XS$C$T:FC'B,^(S,&)DS$C`2,K)@9,E(Q$C,2%(F1FS$/<,5P<G%
MS>@HU(4-BJYZMS:)$#:$<T`AQ4-4*673N8@61<Y\/MA=FY38":HI3VEF;(I2
M>M7U-"IY2>W[IGVGYQ('9ZBFUOX<I;3]0*,:^Z%I_\:R2/\7J*;6_A*EM/U(
MHQK[L6G?=5S'#':":L[9-S,0I*[)0"%.,E`A2/(BMYQ;XM30DE+?%`DM550)
M1*K^].B*/D$!,%#8KTBWPCYJ]K!A?I&<[T5\1-+8K>.04C=#@5IC<Y32F@..
M0D3*6*=+9NT"!6J-+5%*&XLXBA%)8U;'HMNG!"7.63/31MPHE*_;ZE<5<2-*
MTT8BHW#1.X,AMONF;BGM>BJ-54,;-D%%4CBW))H35&]TV2'+^!2EM'J/([_:
M(MFCSK!AK<4Y2FF+`4=AM<6>60T6V+#6XA*EM,6(H[C:(JE_"38\9]%,)''+
M<44BR4L1N&K":?PDKLI%;IGUARP*0R7U7?V1NDPIN@*-E2X;SD5%<KD=LK&<
MH,5SPY!7G"E*Z=GK::35=ZD3_D5.S%!7K1-SE-).!!K5.!%6.T$FT`)UU3JQ
M1"GM1*11C1/Q14XDJ.N<$V96BON>*[)27@\962F14=[<#MG&#\6W-2)WOZEO
M55(T(<9*EU'R*K)2Z3HW#"HK"XLXS;Q*5ZD3_D5.S%!7K1-SE-(U*="H)B'"
M:B?8ZGK)2"RU11R)2*,:)^)J)\BV*$%=YT;"S$IQ`W9%5LH+,R,K%=)#.A1?
MBD,*PFTP=G#$T9BC"4=3CCR.?(YF',TY"C@*.5IPM.0HXBCF*#&0&0MQ*79%
M+-0=6GG=DJATL+9+_[IL`9/BYM)$-W$C\04N1!.D,)ICCB8<33GR./(YFG$T
MYRC@*.1HP=&2HXBCF*/$0&;HQ,W8%:%3%VGET$ED%'>''[I5PV^*>Y44K:MC
MF,1Y7-6AVW9((9DH`;&)+_8D%:>@PABFAX<-#2^I?9_:[Y#TG*&:6OMSE-+U
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M:@=^BE)Z\GH:E5RE3OC53I#C[@QUU3HQ1RGM1*!1C1-AM1/D9+E`7;5.+%%*
M.Q%I5.-$7.T$.6(EJ.N<$V96@I21E:5OD^MO%[NB)4E0B<H/4RBI$AIQ-.9H
MPM&4(X\CGZ,91W..`HY"CA8<+3F*.(HY2@QDA@76`1:6'CR)7/FU?NF;Q*YH
M2*(BD=/-OSKZ02;.4+6`CW7JN9;>U)A^T8M#D2Y072YX]`:>.V>>282>D=DT
M5"V(9WIIDY[)A]'E4ZF[]/":#M/M]MA89Q_B07/8(3[<%;AX"OXQ+_^$/\'3
M\?FCY)1WX:EY<;0C_-$>/(*/_(,G>P#/D55P9Y#D#QH114_N`)ZSJ9#OBN?U
MJUP:]09QOC$EFD;]`7QMSS5Y_0%\Y\YYT!_`%^:<1_U!7,7AXF(@[B!X"[B&
M&(@;!?X)7"H,Q/T`_P2N"&#$\T_:14?@]P#OJ]<T7!U>-_MC8YN^0!@[>8(=
MY"\*Y!^G[!W""T\N9R?X)4#^]@U^^9'"@[\=,4]>LNR$?X#I=O%;DH?_`0``
M__\#`%!+`P04``8`"````"$`?B*21MP#``#A#@``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6R45UV/FS`0?*_4_X!X;XB30.ZB)%7#Z=I*K515_7AV
MP$FL`XQLYW+W[[N+"<$F)=Q+"#`['L^NO7CY\27/O&<F%1?%RB>CL>^Q(A$I
M+_8K__>OQP]WOJ<T+5*:B8*M_%>F_(_K]^^6)R&?U($Q[0%#H5;^0>MR$00J
M.;"<JI$H60%O=D+F5,.MW`>JE(RF55">!9/Q.`IRR@O?,"SD$`ZQV_&$/8CD
MF+-"&Q+),JI!OSKP4IW9\F0(74[ET['\D(B\!(HMS[A^K4A]+T\67_>%D'2;
MP;Q?R(PF9^[JID.?\T0*)79Z!'2!$=J=\WUP'P#3>IERF`':[DFV6_F?R"(F
M=WZP7E8&_>'LI%K_/740I\^2I]]XP<!MR!-F8"O$$T*_IO@(@H-.]&.5@1_2
M2]F.'C/]4YR^,+X_:$AW"#/"B2W2UP>F$G`4:$:3$)D2D8$`^/5RCJ4!CM"7
MZGKBJ3ZL_&DT"N?C*0&XMV5*/W*D]+WDJ+3(_QH0J:D,R:0F@6M-0J+1;!+.
M[][",JU9X'IF(8-9`C.ORJ8'JNEZ*<7)@]H#Y:JD6,ED`<SH3P0N7_<'C,&8
M3QA4A0):05*?UV$X7@;/D(BDQFRZ&&(CXC,"\P=J&DE@4UM2OQ0$NU*<@39=
MS,218A"PZ%L3FC882QV8-%P=@E$=%A8ZMSD_:`_DBC&8:E%8(\_LD3%5L_^6
M\CE5&`1%:\ULULS,B#(8^&UF']F(N`]A:00]P]U!\,H'[YMQPS"T1]X83)\V
M@YB;,FRB+5716U0AV%7E^+$QF%DUIE-M\?G=95:7:$O5_"VJ$.RJFC>S-7DT
MF#ZO^A"6-NQ_SK9PN]8PZ%:M&4R?QCZ$I?&^JW%Z<^O"(-?'.\='@VEK#,-[
M&Q-W,?_),@%);2O[M[,*[>B+.ELK4L+B;RV<R^!5*<0USW6(Y2*YT@%NI[J*
MNI7K&G1=1*W3-('K$%LG[M%.2=Y.-S$[N[W'N/FN06T18>0NZRN@B^FV4MS`
M6TIO9-QL]VV%TXF["Q(#:BN\#%X[V0>Q]0%-6]^P1D(PZF;&#:A79Q_$UNDT
M$]0Y(.-7NDKDM-@-?@(Z*RB,+@V_=K0+NIAN*WU3@R'=#C.=N#VY!O4Z.;C3
M$*?5#,RXZ1905ZW^W-'9UU)J'_L@MH]7VLZ`C)N.T5Y!8=31V6TK8>0L,SR)
MN&7A9MR<-,PG=,[DGL4LRY27B".>(@A\$31/S0DGGBSB:75&:5[``:.D>_:=
MRCTOE)>Q'82.1W.H-VF.*.9&B[+ZM-T*#4>+ZN\!CI(,/B3'(P#OA-#G&_R(
M;@ZGZW\```#__P,`4$L#!!0`!@`(````(0"/S`?$C04``.L6```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;*R866^C2!#'WU?:[X!X'V/`5Y#M41R;
MPX"U6NWQ3'#;1C%N"\@D^?9;37-U%\,FTKS$X4=U5?.OZG/Y_3V]*C](EB?T
MME+UT5A5R"VFQ^1V7JE__V5_6ZA*7D2W8W2E-[)2/TBN?E___MORC68O^860
M0@$/MWRE7HKB;FE:'E](&N4C>B<W>'.B61H5\)B=M?R>D>A8-DJOFC$>S[0T
M2FXJ]V!EG_%!3Z<D)EL:OZ;D5G`G&;E&!?0_OR3WO/:6QI]QET;9R^O]6TS3
M.[AX3JY)\5$Z594TMKSSC6;1\Q6^^UV?1''MNWQ`[M,DSFA.3\4(W&F\H_B;
M'[0'#3RME\<$OH#)KF3DM%(?=>N@&ZJV7I8"_9.0M[SSOY)?Z)N3)<<@N1%0
M&_+$,O!,Z0LS]8X,06,-M;;+#/R1*4=RBEZOQ9_TS27)^5)`NJ?P1>S#K./'
MEN0Q*`IN1L:4>8KI%3H`?Y4T8:4!BD3OY>];<BPN*Q7,E&>2%W;"7*E*_)H7
M-/V7O]0K%[RQ436&WZJQ.1M-YV-3_X(3LW(R:9SH^F@QG4YFBSET92`\O"W[
M#K]UWXW1Q)C.%V7\@9:SJB7\]G1\H.&\:OC0-/QL9W5(+5>:Y9BKV55K(*C>
M).G3&FD\S675;*,B6B\S^J;`4`17^3UB`UNW='!7UPL/WU30SPH(*H=Y>61N
M5BI,(E`C.53]C_5DOEAJ/Z!2X\IF@VUTT>*IMF!ER=QN9;"3@2T#1P:N##P9
M[&7@RR"002B#0P=H(&VC+PR%7Z$O<\/TK979U*`5W)#$K"WJ)EL9[&1@R\"1
M@2L#3P9[&?@R"&00RN#0`8*8,#7\"C&9&ZAW&+L#U<J-3,AK8S23%&Y,&HD1
MV2%B(^(@XB+B(;)'Q$<D0"1$Y-`E@MHP&PAJ]R\A]0S`K$M1:S$VG)B0S$;!
MR?Q!TK`QJIMM$=DA8B/B(.(BXB&R1\1')$`D1.30)8*&L!1]04-F+6K(B0DY
M:C5<C"4-&Z-&0T1VB-B(.(BXB'B([!'Q$0D0"1$Y=(F@(2S*@H9LB3(7;/M2
M;08^O4HQ3Z*^G$CZRLM28]3HB\@.$1L1!Q$7$0^1/2(^(@$B(2*'+A'TA7E0
MT'=XG#-K44-.)`WEU:@Q:C1$9(>(C8B#B(N(A\@>$1^1`)$0D4.7"!JRXQ/>
M1HW8AG583M90E),3<]*L]4^(;!'9(6(CXB#B(N(ALD?$1R1`)$3DT"6"=K!W
M%K0;%HQ9BX)5I-T</2&R162'B(V(@XB+B(?('A$?D0"1$)%#EPB"L:.#H!C?
MM)?55ER2^&5#88J$G4N/DB9LSJLM._,B*EDZ!M21LD7M"F3HTDYH6UE-P65G
MG3+%=6K76M63@(V1@Y&+D8?1'B,?HP"C$*-#A;@2HOALI_^3H?X%\?EY`?:@
MM10;=JIC^>B*WZ!6UA[QN=5$+\]=QEA'NC<&=3`;!W-:-!#,K:S:8-)$[[4&
M=;!]Z[E&?HL&@@6M+W:BA"^35N:P-:@]'UK/@,3,L6.%G#EC.OK?.1KN:]!(
MJ1",T4[!3\2"?ZH:&MUAT9,_[DNT,J6-\J[R9<[*+$^GTB;0KF/Q&QEV>G9J
M-!C>[;62PWMB>"GI^]I'&]ROT6#PH-=*#AZ*P:5[!7:=QM)C0)4WN>BJS(N`
MWYCQNX^49&?R1*[77(GI*[L-@ZN/];+!_*IN,[5@4PI5)/.9!9NI'CZW8(/0
MPQ<6+'Z8PZQIL;FG[XUN[:"0\1L8?Q8;8O@-#!;PUO<&KAP?RQM'^3O8562/
MIXUAP0D<1W@TK4?0&K_8F!:<(GOXQ(*3$7"MB0Q7C??H3,(H.R>W7+F2$X@_
M+E>NC%]6\H>"WB$I</%("[AL+/^]P*4R@;(>LP%[HK2H'UB`YIIZ_1\```#_
M_P,`4$L#!!0`!@`(````(0"S<59E-`8``*48```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;*Q9VXZC.!!]7VG_`?$^(4"N*,FHDW#5KK1:S>X^TX0D
MJ$.(@+[]_93Q#;N2=&]K7H;)H>K8=5SE,N[%][?R9+SD=5-4YZ5I#X:FD9^S
M:E><#TOSGQ_!MYEI-&UZWJ6GZIPOS?>\,;^O?O]M\5K53\TQSUL#&,[-TCRV
M[<6SK"8[YF7:#*I+?H8W^ZHNTQ9^U@>KN=1YNNN<RI/E#(<3JTR+LTD9O/HS
M'-5^7V3YMLJ>R_S<4I(Z/Z4MS+\Y%I>&LY799^C*M'YZOGS+JO("%(_%J6C?
M.U+3*#,O/IRK.GT\0=QO]BC-.'?W`]&715973;5O!T!GT8GBF.?6W`*FU6)7
M0`1$=J/.]TOSP?82>V):JT4GT+]%_MKT_F\TQ^HUK(O='\4Y![5AG<@*/%;5
M$S&-=P0"9PMY!]T*_%4;NWR?/I_:OZO7*"\.QQ:6>PP1D<"\W?LV;S)0%&@&
MSI@P9=4))@#_&F5!4@,42=^ZYVNQ:X]+TYD-G-G8'D_`WGC,FS8H"*=I9,]-
M6Y7_42N;<5$6A['`D[/,![/Q>#2938'ECJ?+/$?2<S!RQM.938:_XPAONXG#
MDPTY^9SCA#G"D\]U,)X.W8\&G#(_>#(_&\*],T,HL6Z&\!0#?2JT.7.$Y_\+
MS8;TH:M)\H@MY[W@+)H-77)MTS9=+>KJU8"*A>5N+BFI?]LCK#RM:+@BT6[E
M&20887D@-$L3!(`,:J`X7E9CUUE8+Y#0&;-98QM;M=AP"Y*]A':K`[X.!#H0
MZD"D`[$.)#W``EF$-K#JOT(;0D.TX5&M.2#%TJ3:<`ONLM4!7P<"'0AU(-*!
M6`>2'J`(`;7[*X0@-)!G4%>]+''5'%A3(Q?61!A-5).-,!'R(,1'2("0$"$1
M0F*$)'U$40EV-D6EZSLSKQABW8G!@UA3Q`5^$;GK:/)LA!%WVR+$1TB`D!`A
M$4)BA"1]1(D=-F<E=KJ-#$A/N"\#<51EH(@[$O6R0<@6(3Y"`H2$"(D0$B,D
MZ2-*S-!7E)CO!TJLU4`9XLA`$;)%B(^0`"$A0B*$Q`A)^H@2*!2L$FAO<=MC
MD3VM*TA8*-@K`KC0"VB'("1J_`R1&^-&(+("'%NK_BTU<J%7R3*QM4[B"R->
M)@%"0H1$"(D1DE#$[F:MJ$0.VKB3=B7P>94(B:H20WHJ"40*@%6B1B.[Z\7.
MT-;V$5^\%P()6HZ$"(F$%^GPP*KUK5B\YQQ)GT.1"\X\BEQ7D@<.ACQ[B+6J
M"T/@(=/`&6F=@AHY_5S!4ETS<N<JDT^-W$FGYWPR5%\'C*/?M=!`H1B(JQ,)
M1`;AZ$/'ZM#Z2B8?#*V(3DYXBNI?*N6.15T-!CG0('K+,595VG!'.&<(*R33
M5EIQG7P&N=-._M%06^>`N]S7GUO)'3?"4/S!6`EWN366*CA8*8+?3W.;F&O*
M4LCI/BV[K73#K`"Z*R-SG(K^XG-'"04<DO0AAB(.2<<80PF'.BY5!G*R[&^.
M'\A`#Z)P4N09L":?8*#,2,YSPR`7"N!>-E%'V`,XE\\<'=*<7E:V.T'IQ'Q`
MP=O,H1R?,T><60X6<X@/9D_5HDBXP:W!5"')Z;,OY-<*F)YA%7TII!6PUGLW
M-G.$7?VV,%MN)>O,9Q`4L'1T'4V*@#LJ4HRTWAYR*]D2(P[)$>/K(\YT\5E`
MMT94Q2?'W[[X'V0Q/2TK*E-(*68!266N[(G,2E:$;R,HX)`LDA!#$8<D5XRA
MA$-7BIF<B/LR?"T'Z;E:48=!_8)V':T3;\BE%^P$'Y4]M5);O]Y:?<;%=P+;
MT?(CX`9*?NA'TE!.2>X$GQD_YO1L<[#'VDZ4<(-;XZOY24[P]Q;F1W6!YG+U
MH-X[:\$M)FI"%%+R5D!W\Y99R5KU&;TCH8!#_;P5]%)2Q!5S1\E%[F#)[.E4
MJ3ST3I5>>Y5Y?<@W^>G4&%GU3.Y+H9^O%@*FE[G;J0='?QA9QV<>G)PQ'LT\
M./MB'"Z%'[H]2>-9D\OB*_9KQX-+F"L\KO<`@>$7:]>#"XDK^,B#C_4K^-B#
M#UK`+3$CN"2^I(?\S[0^%.?&..5[$&78?;?4])J9_FA9\CQ6+=P.=WETA#\'
MY'!/-QQ`MN^KJN4_R`#B#PRKGP```/__`P!02P,$%``&``@````A`!!R,8+F
M!@``R1T``!D```!X;"]W;W)K<VAE971S+W-H965T,C<N>&ULK)E=<ZI($(;O
MMVK_@^7]40&_*_%4_$!0L+:VSNY>$\5(1<4"\G'^_?8P-,-T&V).G9L8']_I
M'M[I&6;@[OO[Z=AX#9,TBL_W3:/5:3;"\S;>1>>G^^8_/^QOPV8CS8+S+CC&
MY_"^^3-,F]\G?_YQ]Q8GS^DA#+,&1#BG]\U#EEW&[7:Z/82G(&W%E_`,O^SC
MY!1D\#5Y:J>7)`QV>:/3L6UV.OWV*8C.31EAG-P2(][OHVTXC[<OI_"<R2!)
M>`PRZ']ZB"XI1CMM;PEW"I+GE\NW;7RZ0(C'Z!AE/_.@S<9I.W:?SG$2/![A
MNM^-;K#%V/D7%OX4;9,XC?=9"\*U94?Y-8_:HS9$FMSM(K@"87LC"??WS0=C
MO#%ZS?;D+C?HWRA\2RO_-])#_+9,HIT7G4-P&\9)C,!C'#\+J;L3"!JW66L[
M'X&_DL8NW`<OQ^SO^,T)HZ=#!L/=@RL2%S;>_9R'Z18<A3`M,^_&-CY"!^!O
MXQ2)T@!'@O?\\RW:98?[IM5O]08=RP!YXS%,,SL2(9N-[4N:Q:?_I,@0G2J#
MF$40^,0@5FM@=$;6`(+4-+2*AMVR8;?5-7N#89Z]IB&$S;L-GT5&X[:,_:(A
MU'_1\,:,HZ(A?'XMHP%C*BU6]MR8TT!_Q#]?S`J6RJRW>MN6E9$7VCS(@LE=
M$K\U8/;"V*>70*P%QMB`:%AB<GC*HONHYJ!.1)0'$>:^";Y#.:4P45XG/7-X
MUWZ%XMX6FBG7&+IBA@I1?B+LG((%!38%2PH<"EP*5A2L*?`H\"G85$`;K"W]
MA;+X'?Z*,,)?=&:*0!EN$C-1@4WF%"PHL"E84N!0X%*PHF!-@4>!3\&F`C0S
M8:+\#C-%&*CW@5:M(]V^J119,*YE2?=UR:R4E!8SLF#$9F3)B,.(R\B*D34C
M'B,^(YLJT=R&U4!S^_I=!U<`H<Y-13.FDE@0OW30'-(J+478;,[(@A&;D24C
M#B,N(RM&UHQXC/B,;*I$\Q!N89J'<GEMB3MGO9VBH6ZG)%:W7`-FC,P963!B
M,[)DQ&'$963%R)H1CQ&?D4V5:-[!W5SSKMXPH=8-*XBI#&-DSLB"$9N1)2,.
M(RXC*T;6C'B,^(QLJD0S#!8TS;!*L66':/L\C>5F[XJ1%MRSY9U<!-%]+(BZ
M^<Q*4IG9!ED=YU)DP0:I,OTM?0E=E"*<_C8C2T8<1EQ&5HRL&?$8\1G92&+D
M5Z^Y+0Y9?.>43^W;W19!=+<+4G&[)!4CF=M2U#7RO9?9,:C1Y>^ET658),N2
MU"1RRD!BDP>)R(+NEK]CV%49%LFZ)#6)O#)0D8AL%OWR=PR[*<,"T88*MO7:
M4%V9`'`@PAD@U/J8%`0^*J7<U4MY)D6F5N]LF*Z)+++U6!0B,2=?)T;/LLC4
ML@M!=6]BTE3+:ZFHR+DFHOUQ]?YT.E9'O_35+?U97TM%^^-=$]'^^*P_I-@W
MG_1'JPUQ@OM"<>1RO3H*9,(FH%(>/=VC&3:$O:U2T>N?*Q56]0+#BP*%<A@,
MR+G*QC;UY8"JVOR.4F%^E^0?C4@UKK!-;?XUJFKS>TJ%^7T]OS6PR,3;8)N/
M\NO##:JO#+>0D^$N$!29&L@A,65F2-4GRX%2X>4N$!6S?]@CJX.-`DB@\M-"
M6J*J=CERE`KSNP6R^GFY]6CZ%3:1#XG$*7V-J#:7ARK5T$>DUP2YX`VJ\H;Z
M8$)#;3!_:<=CB"ADC"4B4WI`IW31$#X^'HDYAE?[T$6!K('TF,XH&YM\,L2W
MI'<PEDKOZND-@RQ5*VRB1FJ-J/92/52IAC[F@GMSQ2,VQ,6E7!EB<3RM;K/J
M[]WB61H=2XG,OCH'%"I`U4Z1*3Q'U:!LN.#(1J3"+Q6J">^@2H5W.5HA4N'7
M"M6$]U"EPOL<;1#EX?6Y)<ZT5>-_;6[)DS$\:\$%9BJ>,HHAJJZ?(U*"LT)D
M545LBS,O5/HB2[<+"U05*^JHUR?E9Z/BD_DF.U[?)P=C:8LA[9.+JJ)/YJ!#
M]U2HJ.W3NE#5]\G#6+5]\E%5],D:],F"MT'%1WW2"T@<[.L*Z$=\@3+X[$&(
M>-]!9[1$VHPN4<V<F!>Q3'6X6G!D(U)3;JE037@'52J\R]$*D0J_5J@FO(<J
M%=[G2+R/$GY)<^2`R/=+\K'_*4R>PEEX/*:-;?PBWAW![75R5V+Y8FO:&\-S
M&9BRA,\'8S@B7^'#\2+O%M$[PS$<"+G>&X[A_,8YO%![R&]4),Y4O&B[HI^:
M8WA8?"6.-7X`(_@/4VL,#SRO\.X8'N(!;Y>9X47:)7@*_2!YBLYIXQCNP:Q.
M?KY/Y*LX^24KRO@QSN`56E[1!WAE&L+.J-."P=C'<89?1(+R)>SD?P```/__
M`P!02P,$%``&``@````A`)9:LMM]`@``+@8``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C(N>&ULE%3;CILP$'VOU'^P_+X8R.:&DJRRC=*NU$I5U<NS8P:P
M@C&RG<O^?<=`:+))U?0%\'!\SISQC&=/1U62/1@K=36G41!2`I70J:SR.?WQ
M??TPH<0Z7J6\U!7,Z2M8^K1X_VYVT&9K"P!'D*&R<UHX5R>,65&`XC;0-53X
M)]-&<8=+DS-;&^!ILTF5+`[#$5-<5K1E2,P]'#K+I("5%CL%E6M)#)3<8?ZV
MD+4]L2EQ#YWB9KNK'X16-5)L9"G=:T-*B1+)2UYIPS<E^CY&CUR<N)O%%;V2
MPFBK,Q<@'6L3O?8\95.&3(M9*M&!+SLQD,WI,DJ>1Y0M9DU]?DHXV+-O8@M]
M^&AD^EE6@,7&8_('L-%ZZZ$OJ0_A9G:U>]T<P%=#4LCXKG3?].$3R+QP>-I#
M-.1])>GK"JS`@B)-$`\]D]`E)H!/HJ3O#"P(/S;O@TQ=@5^3('H,1X@F&[!N
M+3TC)6)GG5:_.DS'U'+$'0>^.X[!*!B.PT'T;Q+6YM/86W''%S.C#P1;!B5M
MS7T#1@D2W_:#1CQVZ<%SBBV-N5H\@_UB&(UF;(^%$QWFN<7@L\=$/8*A:*^,
M:O<K>[!7]I7UJ3RW@7.9^+;,X']D/!@K,3[+_MIA"WH\P_RIP85#A-SOT(,;
MZ=YB%\%>[4LYC,:W76(7G4OY]AP,Q\'XKRUZ.E*_\5*VBV"!SV0GMV5'U[)1
M&-\AZS=>RG:12]GI&]EV/ML&5F!R^`!E:8G0.S][,;9D'^VOA67LN^9M?)`L
MF^N"]3]P7&N>PQ=N<EE94D*&E&'CQ;0#WRZ<KC%SG%KM<%*;SP+O9<"N#`,L
M7J:U.RU0F/4W_>(W````__\#`%!+`P04``8`"````"$`;+?^#G,'``!()```
M&0```'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R<6MN.VS80?2_0?Q#TGI5U
M]06V@TV#M`$:H"AZ>=;*LBW$L@Q)FTW^OL,A)7)(T:+[LE@/AW,Y,SQ#V=J^
M_UY?O&]EVU7-=>>'3PO?*Z]%<ZBNIYW_]U^?WJU\K^OSZR&_--=RY_\H.__]
M_N>?MF]-^[4[EV7O@85KM_//?7_;!$%7G,LZ[YZ:6WF%E6/3UGD/']M3T-W:
M,C_@IOH21(M%%M1Y=?6YA4WK8J,Y'JNB_-@4KW5Y[;F1MKSD/<3?G:M;-UBK
M"Q=S==Y^?;V]*YKZ!B9>JDO5_T"COE<7F\^G:]/F+Q?(^WN8Y,5@&S\8YNNJ
M:)NN.?9/8"[@@9HYKX-U`);VVT,%&3#8O;8\[OSG</,A6_G!?HL`_5.5;YWR
MO]>=F[=?V^KP>W4M`6VH$ZO`2]-\9:J?#TP$FP-C]R>LP!^M=RB/^>NE_[-Y
M^ZVL3N<>RIU"1BRQS>''Q[(K`%$P\Q2ES%+17"``^.O5%6L-0"3_OO,C<%P=
M^O/.C[.G=+F(0U#W7LJN_U0QD[Y7O'9]4__+E4(,BMO"T#[F?;[?MLV;!_4&
M[>Z6L^X)-V"8Q11#9MS"&*4M2(B.&7EF5G8^-"IL[P#9;_LT6FR#;X!&(70^
M<!WX.^J$HT8`T8PA01AJ2-/P#)Z9,O/,X&*A?.`"U4TT[29^Q`U3!HB6:O19
M.AKFKKE2HNADHP;)$%3<,V3*Z'I,44C`G812"8:X@LY076'/+=>LP2Q]-P#+
M-E*W0@(`*VXM&6;4[?T:,F4#W.4('0>7*SF`"S52,[[OFBG3+(6$@BN#(>`R
M9M8.3YC!F9S#ENVC7H6$8KL:(2!>UZ;7>`WPW,^4[:(^A83Z7$_[#($3]%2C
MV-9&<0H<()B!;:1^T1:($B0F]>2'C",40.]GA-J::4$R4`'9HTO)1`3'D%&%
MX@VY;[F8+Q]NU!PS6R`B8"XM!!<RHM`<1XOD:3G;.+A3\\Q91_-LX3S`G'B>
M`=BD'C0``5"`8TO3@):>YW)I:QJ@I+%IV$8M32&B`"<6QP_13SCRS\BP@XBF
M*?F>]I'&.*R/UM#V,^":U,/&B]E$%H8--?*9\392CGHP)*UQCD6;.]^!9$.-
MA&:\F^2#!J#$A&>7,B""<#3%/DX'!G?23AI$M),L7!MIC,1JZ]3"N%%S+,B)
M.K80;@1:ZMFY#S!JHS>EO"O)>[R\0LNAO)'&4#/>!04ME5N8$)'R*@'1\FJL
MY'Y)B4R&&D0$Y96%B=DUZ`&41UI24994*U#F6BXH/T13D4E3@XBB+`.B*$_0
M5!BM'.@X,JEJ$%&4+7,@TJ@*Z^MR3\*-VB&:NBFM+',@>HBE4-LX1)+T17DY
MESF4ESU'N3<7:M-<!Q$MKPR(E#?^OTR%&S7'4TRUL@RB6&,JK.X:A/=)`[=I
M;IDE$-&FLLR$F#&,<HF:\<:TT9MZ="7I\]JB3:?Y%VN4->/=I"DT``'1VLJ`
M:&TUFG*>0G`1UR]2@XB";)E"\4,,A=HZR&M]"@DMEP.D,=8,R"9+Q4)$0%8"
MHB!/L)3;K3P>+U?C!7(0$937EBD4:S2%)RAU>!S`C0BX="RN6IGQ<)5H=,2\
M1*O0@?]Q)W4SB&A^ELF3:-1TOXZH;721'"W\J`HMARY*($9WHD!M+5=F`$2T
MBV1`I(L21C0*+2'*3#B3--NFN14B"K%ETB4/\1%J&Q#+P2(@YJSE`K'&3S.Y
MFJ24"!&D+)_;US(@"K%&2GA<G+[32LPKU""B*%M&7?(0(:&V@;(<9P)ESE$N
M*&L$-8.R24J)$%&494`4Y2E2<D-94)#R.)`($479,NW2":*:?Y[&7?0$#2+J
MU3+JTH=("K6UVL+/*>/7$;RV0LNAMBG$J-+&_=JBMI8K,P`BM;9J0*2V*:,6
MG:2<GJ=QI^:9&0.1BG*TL(RZE'&*XGDF3Z:-WB0M1`LY903*7,L%98VGD)SA
M_,U$8?)5.L%7:F`4[0F^BE?6+T^5[\%2DZ\&$47;,HS2A_@*M0VTY<`1:#OS
M5?H07Z&VUED3?`4WLO&0492G^,KI\38U^6H0490M\RC3^.I^-Z&V@;(<.!QE
MH>70T]E#O(7:%.5!1)E#!D10SAC-*.<79V\:.]Q5<:?FF1D#$479,H\RC;-F
M4!:D!,TZ7BBBA1PX`F6NY8(RXQ@E[QGO3%O+58@HRC(@BO($3X6+R`5EDZLR
M(:(H6Z9@IG'53)XC/RDHA_H41)M.3]790WR%VAK*G)SH%%0"HBAK_.1X58=7
M!(SB"A&!.-1'('\Q@/_Z7I?MJ?REO%PZKVA>V8_^\-W[?CN*Q1L):;AYAI$+
M3W?&2@(K^)!GK"QA93VU)UMLGN$83EC+8EC!=PYT:UD&*_CSNKX2K3?/\"7.
MA+48K,'7#%,K8`T>'2=6$L@4'I.F5B!3N*5/K;!,)ZV!L>G(8,.4)0@+?GR9
M<!&NP!*^06&D'\$*_H1IK*2P@I`%XQ*\QW'+3^67O#U5U\Z[E$<H^0(/=,O?
M!.$?^N8&K0!O<S0]O,&!_Y[AC9T2WFS`'R:/3=,/'R#<8'P':/\?````__\#
M`%!+`P04``8`"````"$`!>:!<NH&``"K'```&0```'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6RL6=N.HT80?8^4?[!X7]N`+V-D>S6VN2J1HFB3/#,8VVB,
ML8"9V?W[5-/W+M]FM2_#^%!UBCY=U5TT\Z_?RV/O/:^;HCHM++L_M'KY*:NV
MQ6F_L/[Y%GQYLGI-FYZVZ;$ZY0OK1]Y87Y>__S;_J.K7YI#G;0\83LW".K3M
MV1L,FNR0EVG3K\[Y">[LJKI,6_A9[P?-N<[3;>=4'@?.<#@9E&EQLBB#5S_"
M4>UV199OJNRMS$\M):GS8]K"\S>'XMQPMC)[A*Y,Z]>W\Y>L*L]`\5(<B_9'
M1VKURLR+]Z>J3E^.,.[O]BC-.'?W`]&715973;5K^T`WH`^*QSP;S`;`M)QO
M"Q@!D;U7Y[N%]6Q[B3VS!LMY)]"_1?[1*/_WFD/U$=;%]H_BE(/:,$]D!EZJ
MZI68QEL"@?,`>0?=#/Q5][;Y+GT[MG]7'U%>[`\M3/<81D0&YFU_;/(F`T6!
MIN^,"5-6'>$!X&^O+$AJ@"+I]^[Z46S;P\)RP?LE;]J@(%16+WMKVJK\C]ZT
M&05U=I@S7+GSI#^>#ET;8CU*XC*2D2`!NAM!@;E[8KBRH).;]G"WLX<KLW?Z
M]F@X(8]X(\R4N<&5N=DP.3<<H**Z.'#E<6[:SY@]7!\:!PE/IXHD"9V.6R,9
MT)GN$F>3MNER7E<?/:A&F-/FG)+:MCU"RE.&CDTDT;4<@N0A+,^$9F'!:"%-
M&DC\]^78'<X'[Y"L&;-981M;MUAS"Y*9A'9C`KX)!"80FD!D`K$))`HP`%F$
M-I!ZOT(;0D.TX:-:<4"*Y1A"<`ONLC$!WP0"$PA-(#*!V`02!="$@*K\%4(0
M&L@S*"(E2XP<6%$C%^9$&$T,=82)D`<A/D("A(0(B1`2(R11$4TE6+.02LZX
M+U:6AXN)$'4Z\?&M*.)":"&*:QOUM19&W&V#$!\A`4)"A$0(B1&2J(@F"XP?
MR6*/^U/`+^]+?$TACKH,%'%'HI36"-D@Q$=(@)`0(1%"8H0D*J*-&;87;<RW
M!TJL]8$RQ)$#1<@&(3Y"`H2$"(D0$B,D41%MH%#+VD#I]M%-;GLHLM=5!0D+
MM7Q!`!>V";IY$!)]_`R1:^9:(+("'-M8&#;4R(5M3"D38X'QA1$ODP`A(4(B
MA,0(22AB=T^MJ43Z:[S)?E(E0J*KQ!!%)8%(`;!*U&AD=]NT,[1=?7GUQ7TA
MD*#E2(B02'B1S1]8C2TM%O<Y1Z)R:')!$Z3)=2%YH%_CV4.L=5T8`A<E#8SG
M65,C1\T5+-4E(W=FZ,6,2#Z3MF=D1`K8?75'0Y%"$8G+$PE$CL(Q8\=:[-'X
MR9C+Y$YL37;2_GU"]\Y<%YY!#NP%BO+&,ZVY(W0;P@H)LI%67!&?0>ZT4]JV
M1_I$!-SEMM+<2BZN$8;B.[$2[G(MEJXL6'U&66)N*,L@F$^AF6L*L+:IU9VD
MEE926>KH3IBR1HH'W`7,1'@T92&WZEY2NZ4]PE#,(!9K9F1'PCVNA=*%)1VK
MNK+>7BILVN!"!\I'OF*0D;)C/;/6W/%.RC)ZF5D^IR?+U?O2?AH:S`%GOC;<
M3L:06TGF"$,Q@UA]3,?&SI=PEVNQ=&E)GZM*^U-;NTV[94UQ!NFI;&SE:^9X
M+Y4I%UCQ"?69X_549B[71&""(^)(/A&/%>NQ'!L)?B>6+CCIH%7![^0R;;@U
M92GD3(0::UM`-PIWPZUD7?@8"C@DZ4,,11R27#&&$@YU7+H,I*G^A`RT!]=D
MH-#(561@5M!R7%^_-N2HC*R[LLI\!G7MQOMR.IJAE9'YW$DG$9_G3H2#Q7JP
M\71L=!()][D63!>2-.VJD*2`G0DY^>L]WIO;K/67T[GBD%[`4W/)I(ZN:H6V
MC`WCT@J8.<)%S)5K/^GT`7?4I!@9!1@R*W@(J3NE5R+&W$J/:,QT<B^B+CYY
M%U#%OU/,[-5!59E"6C$+2"IS05)F);E\J`Z2V(Z$`@ZIQ2SHI5C(,>:.DBOA
MT(5B)CV^*L//;2+L34&&7,%+5C<B6-Y$DIB-]YH9D8LPNJ`78]?V=K/1]GE`
MNI&[TPE*2$:C):3YAAK*1Y(:/Q(_-N*CTY^$,U^+KZ<G5.7->?E6G6$AO/C>
MKKQZP;<,U*A22$M;`=V<!F8EWV9]1N](*."0FK:"7DJ*N&+N*+G(EY@NAY2T
MI5]6Z`%YF=?[?)T?CTTOJ][(5Q/H^9=S`=-/.INI!R<!$-G$GSQXD<9X].3!
MJS#&X=/0<[?O&#PK\LGH@OW*\>"X]@*/ZSW#P/"-E>O!T>4%?.3!V=T%?.S!
M^1;@`_%$\*GHG.[S/]-Z7YR:WC'?@2C#[ABCIA^;Z(^6)<]+U<+'HBZ/#O!1
M,(<3_2$Y#MU55<M_D`#B,^/R?P```/__`P!02P,$%``&``@````A`.&4J\G3
M#0``8$8``!D```!X;"]W;W)K<VAE971S+W-H965T,C4N>&ULK)S;<N*Z$H;O
M=]5^!XK[%0(FD%"3K)IP!@,&C/<U0TA"30@I8`[K[5?+4KNE;J.0[+D9)A^_
M6FUUJRU+P)>_?V]?"C_7^\-F]WI;+%]<%@OKU]7N8?/Z=%M<Q)V_KHN%PW'Y
M^K!\V;VN;XO_K`_%O^_^^Y\OOW;[[X?G]?I8``NOA]OB\_'XUBB5#JOG]79Y
MN-B]K5_AG<?=?KL\PI_[I]+A;;]>/J2-MB^ERN5EK;1=;EZ+VD)C?XZ-W>/C
M9K5N[58_MNO7HS:R7[\LC^#_X7GS=D!KV]4YYK;+_?<?;W^M=MLW,/%M\[(Y
M_I,:+1:VJT;_Z76W7WY[@>O^7:XN5V@[_4.8WVY6^]UA]WB\`',E[:B\YIO2
M30DLW7UYV,`5J&$O[->/M\6OY492N2J6[KZD`Y1LUK\.UO\+A^?=K^Y^\Q!N
M7M<PVA`G%8%ON]UW)>T_*`2-2Z)U)XU`M"\\K!^7/UZ.L]VOWGKS]'R$<%_!
M%:D+:SS\TUH?5C"B8.9"N[':O8`#\&]ANU&I`2.R_)V^_MH\')]OBT'UHG)]
M5;ZJ@;[P;7TX=C;*9K&P^G$X[K;_TZJR\BJS4C%6X!6MU"ZNZI=!^0-&`F,$
M7HV1\L7UU56U=ET_WQ-0IM<#K\9(_>.74S-&ZIF13W@",RSU!%Z-)S`ZGC&\
M,7IX-7IK"#WMRI`S.H0T^I]PMXS#K_YC'`@NZN7+F^`#PU^NHC,4@,\X@Q$H
MPW^,,[89WW!`T/1P4/2LZ_"UQ(B5G9"=.P4P#!4UA\TDL?+7TW$%)Z'Z3Q;[
M<O4RG8*^AMF\^TSH2[H4I)6EM3PN[[[L=[\*4*[!B\/;4A7_<J,"EK&F:$^R
M*G.JR$!=4%:^*C.W11A+*!\'J(P_[ZXJP9?23ZAF*Z.YEYJRJVBB0I4;9;;%
M09N##@==#GH<]#D8<##D(.1@Q,&8@PD'$0=3#F8<S#F(.5APD%B@!"'.X@RA
M_1-Q5F94G#%"]P@H\!465%1@DQ8';0XZ''0YZ''0YV#`P9"#D(,1!V,.)AQ$
M'$PYF'$PYR#F8,%!8@$GJ%"]_T10E1F8_U!#K=E;=<-XKT4!Y%<FJKF29B;)
M0BU(6Y".(%U!>H+T!1D(,A0D%&0DR%B0B2"1(%-!9H+,!8D%60B2V,2)/MQ^
MG>CG+P.Q0BMU&F0,SKTF`=C/(EJI\)AF(FS6$J0M2$>0KB`]0?J"#`09"A(*
M,A)D+,A$D$B0J2`S0>:"Q((L!$ELXL045E).3/7M^$*MROSA50W=\&H25+-:
MW12D)4A;D(X@74%Z@O0%&0@R%"049"3(6)")()$@4T%F@LP%B059")+8Q(DE
M+&>=6/H#J-1N``VI4``%:0G2%J0C2%>0GB!]00:"#`4)!1D),A9D(D@DR%20
MF2!S06)!%H(D-G$""#=$)X#69#P^;U;?[W=0..&&F!/8`-;`>F6LC+AQ-806
M4<V,6)6XS"IQ2XLJ\,AHE>NZ>PMN9R(LUQU-JNG.0NI1]YS>>IDAN[<;M[=^
M)L+>!J*WX3F]A5H4P-,475O`G@Y&F0A[&PLR$2029"K(3!-X%$3+<T%B3=SA
M#]A:=Y&)T%"BB1Y^)[G@6>G_3RYEQ$TN30(H2M9(LK5<TS2#%Q*)?#.6G)A4
MKMT,:&<BO.".)G:^::(>M$_WULL,6:+@TNVMGXFPMX$F5F]#3?R]A::9O9BM
M!%=N;Z-,A+V-,]M()AFQW.8C&66&+%'`IO<T$Z'M668;R5R06!,V<=B#]R(3
MH:%$DYRLA.KB9&5.:8-=/JQM2NVFGR%.D0I8D6IJD=H[.9T0K4R$3K<U":!<
M4[.`)63'-',BRP/2S6Q;EKBHER<*>`4T(E7N?][581N'583!.?X,\[KB_H1Y
M(N[/2(M@C)0__-WQ.<Y,\OKASD1Y(M[=-'/&&N8JF].S/)^JK/3/L^XP&>*,
M6+:Y`PLCRJ+#+R/)Z]P2.05;[;U^8&ZD<G=R&%2!U3]E<)5E3!,;PD,_J2RG
MS,Z8\@;,T^JP;1H&<,NAAE56##IHWC]#4.5UHD<JC$O?H+1(_+PKEV%3V2VK
M`VSD=6"(*J\#(:KT"87:,AP9%$")HU$HLWD[IH:VBM7D":J\3D2H(B>F9SDQ
MDPWGB"BLL40+@TX/<H*-3@VRF]F@^DAF*SG+;(-@/M&@5_FRHZQ5[Q1^4F%2
MM0UR2W^5W:\[V!!Z(2?XQ.FBRGOWZ9$*G>@CTM6D=EEC.35`@;?_(:J\_8>D
MPOY'!IG:SJK&&!M0$DX0>7N*4$4-IXC<M&>7.T,5-9PCHH>-6*(%(AS(.JOV
M"0I.#:2;O."ED[SJ*:U24R>@A?.?TJ".BIS6B%5K5B*:V-`=*Z9JD0K#V3:(
M56N1T\:O4T.AG^C(O"?S>Z1")_H&F4)2O[P4Q?J<_H=DV=-_2"KL?V00#():
MK[`\&&,#[\5/4.6-0(0JRM8I=NZ]4\RHH>?:YJBRZ[89.D(+HZ+A9E><H)E3
M5^QFOMH9ML_N_(MU==;+R[9&E5KVX-LT*D">RVV1"D/9EJ@C49>0QWP/5?7,
MK[Y$`T3D_9"0QWR(*C(_DFB,B,Q/"'G,1Z@B\U.)9HC(_%RB&!'96DB4($IM
MN3FB=IKM'/G4'I8ZZ>>I8Y!]Q[]AU:MIV@6VJ,+OR"VC@F4!)9.V;J&.5'7/
M,M^CAE;0^*-"'U7ZIG13*U^SN3E`Q:FYF9;BX5D^A6C+N35SGT9H2S_-\0>%
M,1KQ.C1!(]X81&C+Z]`4;3G%03S1H2W'+_%(A[9NLJC'V-#KQ`)56:1NV!Y`
M@@K'`2OMW!FB]N]],R3>O<%B-W>7-RWD:=R_JL]A\2FBD5-=,V3EHN69>;;+
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MHV+G%6RE-2(5]CB6:")1)-%4HIE!\(+FYQ+%!KGA$`=^I$);B4$YARME6(/]
M@9Q35MBM0R/WU*_*4J>9=O]^&AI;SB),G/L96Q!(O.Z.0592=,_JL4>VK-01
M9W^DPAX'LL?A63V&V-!9((KS/U)ACV,RCVA"R/*>+^DBLF6IQ!D@J=#\C,PC
MFDL4&\3F%=OZ7Y`*;24&Y22KVJ5UDM5_XTOE;E8B@H2BDB`.`XU*O9"*CU^+
M5.AZVR"V*<RNN8,-G5!S\UU4>9WHY:KX4UL?5?KYI%J]YL\G`U1X?1JBRNM3
MF*OB/HV,RNP=L\(P1AM>?R:H\OH3Y:JX/U/RQPIZE3W'S="6XY=XD$05E:*8
MD&6>.[%`51:H*[9MFZ#"<<!*'F=%40'51R:,DK,)HQ';<68[_<VT'VCHW>]L
MD8HFC#;/=IS9[;Z##4%\>CYV4>5UHD<J=*)OD-D"K<$WR-CQ(+;Q]C]$E;?_
M$%6TZ3LRZ)WC0=EP@LC;8X0JZG%Z5H\SV7".B!X<8HD6!IT<T`3;G!I0-XGA
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MXD\SM(<J&OF^1`-$5)Z&A#SF0U21^9%$8T1D?D+(8SY"%9F?2C1#1.;G$L6(
MR-9"(O6C""JT^B:I<T?_R('^*O)VO7]:-]<O+X?":O=#_8!!4($/A&0X^W6%
MKVE]8_P>?G4A79)P7H%?8U#;4XQ_#1I?P2'YQGW0@"_;Y?!J`[ZPE<.O&O#E
MGQQ>KH%'Z;BQKF'_LZ%V)&4;V&YL+$Z\<P/OI*>DS!KL-$(_>>_`!E=CE/L.
M;$2!!WEM8/^YH7:7I6\M:-/.;0-;SPVU[R?;P-YR0^T<Y[US`^_DM8%MY8;:
MTY-MPGICFMZ^V0C$]09\Y4+J8QC,O+Z3>@,^^B[UX74#/NTO>03ARN.M>@.^
M:2/U+1C"/'VGWH#O14A]K]Z`[]#D<!B\//V@WH!O/("^E`T$_+['V_)I/5KN
MGS:OA\++^A&FSV7ZA<&]_H40_<?1G&)_VQWAASU@^P"^Z@^_Y+*&C\Q>7L#T
M?-SMCOB'ZB#[;9B[?P$``/__`P!02P,$%``&``@````A`"TIY%SP#P``NU4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C8N>&ULK)S;<N,X#H;OMVK?(>7[
M32*?DKB23'4LR3J?:G;WVITX'5<G<<IV=\^\_8(B(9*`S-BS<S.9_OP3A``(
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ME*W?5Q!MR)/(P-?-YKN0QD\"P>`+-CIL,U!MSYY6S\L?K_MF\RM:K;^]["'=
M$S@B<6"SIS_]U>X1(@IFSH<38>EQ\PH.P'_/WM:B-"`BRS_N!D.8>/VT?[D;
MC*;GDZO+D0?RLZ^KW3Y<"Y.#L\<?N_WF[;]2Y"E3TLA(&1EW1L;GP^N)-YD*
M(XZ!\&D[._Q5LWM3YP#XM!T`Y:L&'#G3C1H(?W&FT?GU9#*>7E^Y??0@)^V<
MGH[1D9-Z&!CQ/Z=."\&4T\(QGW:LWA4.A?\Y=5J(K)SVV!!?R(IJ"]1?[I?W
MM]O-KS,XZZ%F=A]+T4.\F0?6L#1E/73%>JA6H4B%E2_"S-T`QD,9[N`$^WD_
M&4YN+W["2?&H-`]<X]F*.2K$&2#,^A0$%(04+"B(*(@I2"A(*<@HR"DH*"@I
MJ"BH*6@,<`'IZ7($)?UWY$B8$3G"Z#X@T$D;DH2@`H?X%`04A!0L*(@HB"E(
M*$@IR"C(*2@H*"FH**@I:`Q@)00:Q=^1$&$&SCLX_XVS9FJGX$&*1E`;G8A(
MYIVD2Q,C`2,A(PM&(D9B1A)&4D8R1G)&"D9*1BI&:D8:DUA9@UYM9:W_ZHL=
M3:C;Y&!0'R09@?TN$\/)M9VN>2?"83XC`2,A(PM&(D9B1A)&4D8R1G)&"D9*
M1BI&:D8:DUBY@*NYE0MYV3D75WEW6L1`.RV2C,9=7YLSXC,2,!(RLF`D8B1F
M)&$D921C)&>D8*1DI&*D9J0QB94#6+)8.7`'7JCMP"LRU(%GQ&<D8"1D9,%(
MQ$C,2,)(RDC&2,Y(P4C)2,5(S4AC$BOPT/"MP!O%OW]9/WY_V$"#@8;?DY`1
MK*WDBDL8L?.AB+[`SSMB="R/7#U\*1K!`MIH:S=V6PLZ$;:UD)$%(Q$C,2,)
M(RDC&2,Y(P4C)2,5(S4CC22P%(8CM;(&B]O_/VO"B)TU18RL=<1(",N:%(W-
M9<$-67`'G:9+6F<:R:(CCLFBSI`AFE[:)1)W(K2==+:1I!TQ#-%#RSI#AFA*
M;A7R3H2VB\XVDK(CAB$Z6]49,D13L@ZN.Q':;CK;0*PR@7M7JTQZ3F*XW\:S
M6*CM>E`$_NC3<3JR8SV7HJ%USM(C\SL1.ATP$C*RZ(@Q/S4==2(T'3.2,))V
MQ&$ZZT1H.F>D8*3LB,-TU8G0=,U(8Q(KKV*'X83$MG([LPJ-85%DI'9,4HL#
MX=Y#JV@"_%[5B'9MI6KK[>>]=^5=D9,V1#MF'QG2V1:H<OH4]:JH3_&G/B5H
MQ^E3BBJG3QFJ+%O4IURI1G!2&S$GT2QZ;=%8E:AR^E6ARNE7?91?3:\MPR^[
MC&'&4\I8R$D92S2&=:4.UNB*EK%4?=*BO$Z%IV2`2*QT?MY?>6/C2-J53X@*
M&*L=H*H%JIP],D*5W"H5>TXQ(CN!I!@25#F=2%'E="+3*HQ"CNA@%`I4.!TH
M4>5TH$*5CD*-R!F%!E6'G+!+#VR=4GI"3DI/(KN#CLG%>BZV@,5`^'.X/GRM
MPJ`'"F&[A'[)VJ4R?>AXVP)=:-,.!R)4Z:#'"KG[4*('.LRGJ')&(=,JC$*N
MT.$H%#C(&84254X'*E3I*-0*N:/0Z(']4;!+3VP*T6WNX>0<>IA[?2:>"=`B
ME,CN?V-R5S57`S_K?](6J##\`0Y49_[E)5GYABAP1G^!*N>)'Z%*1S]&9*>-
MM3_EN-.)%&TYG<BT"H.0(SH4A`(%SOE+5#GGKU"E@U`C<@:A0=4A)^P2%'MA
MM`2]2;OE=?Q=OR=WU&#/&&/UH!!IBFQ9J0;:1T2JUD?S>D\G4$BU@^GE%:M'
M9?E0%%1//&;^".?7J8@5<G>#1`_L[P:M$RFJG$'(M`ICG"MT,`@%CG$&H425
M<_X*53H(M4+N(#1Z8'\0['H4^X)F/7[2".4VHE5X$@VG72W.Q4-M:)>`^CUH
MT^"C2A=QP%&(2)M?:.0P'Z%*FX\Y2A!I\ZE&#O,9JK3YG*,"D39?:N0P7Z%*
MFZ\Y:A"UYNV\BFW'$_*J=BGU=`_BZ3XD<:Q=GRLT@KMCUY)*#K2O>?1F*U"V
MAK*W>]YH-"4/44*4.,^FQ5%.16C+N@90IV)4*:?XG7*""J=/Z5$^96C+Z5..
M*NG3S=2[(7$J4.'TJ3S*IZK7%HU3C2J[@Y'508.J0W[9!2MV7$\H6+5!:Q:L
M1$.XQ.CJG)+=T+EXSBJ6<O9-/KL"*I5Y!60H1%M:M4#D-!^A2@^,.4HX2A$Y
MS6>HTN9SC@J.2D1.\Q6JM/F:H\9"=JK!_"FI%G)R!RB1O?B>DB3.18YAX&?M
M2JH^:U=*A>UJ>$6J/52S#0]5NUH`'>-3U&N+GH4QJIQG88(JIU^I4KECE?7:
MHG[EJ'+Z5:#*Z5=YE%\5VG)VTAI5!W/8H.*03W89BTWB$SJ6W%.&TP+7DP^>
M0OI$FBL$7R]`E<]1P%'(T8*CB*.8HX2CE*.,HYRC@J.2HXJCFJ/&0E8NQ-EK
MY>(O/4QMK=B=!I'Q8$XCXSI#-QY]I;(?J$[)_FB@59CND*,%1Q%',4<)1RE'
M&4<Y1P5')4<51S5'C4)PNL%AVXF$4^]O2*2P0A*ID)G(#CD3*57N9ZRBZ\.$
M(-)Y[*PC6BB5Z#)ZA4(K)]*V#!5=',=:A>83;1Y1JI%AB\Z8:5N&BCUKU2HT
M7VCSB$J-#%MTQDK;,E3L>:M6H?E&FP=D5PY<;JS*<=_)#H6<E(A"UNW-E&ZA
MJ(&BA`\GT>]5T2ME@"IY11K=C.@CWA`54$R'9UN@RNE3U*NB/L6H.NA3@@JG
M3RFJG#YEJ+)L49]R5+E7%*BR;-'2*U'E]*M"E66+^E6CRO)K2E:&#:HL6X9?
M=AF++=7C5Q5P_\S*6&W*6O=![,D<#K1<-YR2>S1:A6=@H)#:!!N/KR=DW1WB
MH$/'*U?"J'(Z$*%*-]98(?<N6*('.DZ<%%5.)S*MPBCD"AV.0H&#G%$H4>5T
MH$*5CD*MD#L*C1[8'P6[],3F[`FEI_9RC06MN/<63=7JH.S)G%)]UD&E+5!A
MT`,<*%O3%'Z^9#]N#E'@C/D"5<X.$*%*QSQ&9">+G.X)JIQ.I*AR.I%I%08A
M1W0H"`4*G/.7J'+.7Z%*!Z%&Y`Q"@ZI#3MB%1S>A_]KJG>]-P^DIZE$XHZ^>
M8W9%5P/M(R)=S5>VX($CIB)`\^*+7#_OI^,;\@PZQ#&'HJ`ZX3'S1]H6SA\K
MY.X!B1YH!(%V^A15SB!D6H5.Y`K!G_X@%#C&&8025<[Y*U29]2BCYPY"HP?V
M!\&NQ],VS\5S#KJ45'O@QN:Y4GWR4`15NJD&'(6(M/F%1OT'V)9:A"IM/N8H
M0:3-IQHYS&>HTN9SC@I$VGRID<-\A2IMON:H0=2:M_,JMG#-"]Q?ZS-J(UA[
M\3"4R'Q6HI![0\U7*OM22)>9`:IDR[^9WGCTZ2LJG.?8XBB?(K1E71FH3S&J
M'+<),BCBCDTW7]YWI,H=IPQG<_J4HTKZ-+F:C.FC$E0X?2J5RNU3U6N+QJE&
ME=W7R)JA0=4AO^PR%GO(KC+^??,!B[#/OM0RE%O1YH:D0G`&87N?:^3(HH\J
MO;L2<!0BTN87&CG,1ZC2YF..$D3:?*J1PWR&*FT^YZA`I,V7&CG,5ZC2YFN.
M&D2M>3O?8IO8S/<G.QMJ5]GL3Q+9ZR#V:&RH!CJWIWQ4F>L@.=#8M`Z5RD`+
MCB*.8HX2A8R55XK(Z6J&*NUJSLT7')4<51S5'#4*25>M)(J-X!.2V,KM[2F%
M/GGHI53NWN4KU2?7'53)?NI=>B.R=`Y1<:AOR07N43Y%O;9H/XU1Y>RG":J<
M?J5'^97UVJ)^Y:AR^E6@RNE7>91?%=IR7A-K5!W,88.*0S[990PJJXSE$@I?
M!''TFP+$+YGEFEEWSLF0/!YY4"KWSYZE)=#@-<O7PQ`%'(4<+3B*.(HY2CA*
M.<HXRCDJ."HYJCBJ.6HL9"<2"I4E4GX7]L27/HR$)=*J)+)_)$U_=3)7`XUK
MA,]1P%'(T8*CB*.8HX2CE*.,HYRC@J.2HXJCFJ/&0G;FZ`ZQ<1?C7AF(?-!,
M263^;EJI#.1S%'`4<K3@*.(HYBCA*.4HXRCGJ."HY*CBJ.:HL9"=%K%?>?PJ
M#<++<J&07J[,4:61SU'`46@AVT^Q7W*"GVISREA-CB0:ZYW9N4:ZG;,?D/E*
M)19)^HZ0?I,XT"KLWJ$V#\@^FM.V:D9\JT8AZVBDRD"^4A'7R7Y?H%7:==.6
M[;JX\STA$?)&V;Q=&TED^#GGR%>(N$Y^2QIHE7;=-&^[_MD=Z%&_71=;=K0=
M260=$4.^&B@6+D8=D;5IH%7ZB$Q;]A&)6Y@3DJ%NE<RS0B&[N.G7#\6Z'([9
M7GC331&_5T67G`&J#B[M0E2T:R/K>"'"]O&*B\AP*EX\=G;\[Q!:*_:E7R'[
M5O.*;*;/<:"]6B8J7ZLP@P&:E[O-GC<F`0YQS%&K6?&ECA.RWLK)X<K5I[EC
MHE1B&U)7)TLQJG0%!1R%B/BFP+AO_7;R#TE:*^2(U'+.KF.R,I^K@:+`7`<I
M;=G5SNI8V8)GE>()@N?Q[U:BXKBD.M9';6D?MST&;P*DW4DA*]E2]5FRE4KO
M``5H2Z,0D9%L^2Y!^:JVM]7VVVJ^>GW=G3UN?HCW!,+J_OZVP_(EA@^CX4PL
M'N&,89^,X)/VBX7D$[B^SD)HEWP,O!+Q2Z\M>%5BVU2(I0>8O$__933[`NV:
M3_`@?.KC8W@78Q^?S)KVW8ADXB\C\!0"V#<#^`J1ZOMD,GOH/6Q8S\SFO9_`
M&F8F5BC<&BP1X),V=\0WN`+#)^V)SCZYAD_Z`@_?'YR);\[US#/T9@%LJO-/
MX)MC,_&],/X)?,-KEO=^`M_$@GGZQ@3#&[!VTV,--M%@3-\G_M6L[CU..,R^
MHXRN9_#"D!Y_KV?P:@_.J^M9W<?A:[-0CZU'%UV(X=69'\MOJWRY_;9^WYV]
MKI[AE+EL?VFWE2_?E/_8J]WRKYL]O#03FB&\_A!>DKJ"7X%?BI^&/F\V>_P'
MN'31O7;U_G\```#__P,`4$L#!!0`!@`(````(0!"K(+WQP8``$$<```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*R9;9.B.!#'WU_5?0?+]ZL"/E(S
M;HT/"`K6U=7>W6M&<:1&Q0)F9O?;7X>D$Y)V.+=N]\4Z_NS^I]/="0$>OGX_
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MHZC]W2J.V<<J3_=A>DD@VU`G5H'G+'MEIL&>(7#N$F^OJL`?>6N?'.*W4_EG
M]N$GZ<NQA'(/8$9L8N[^QR(I=I!1D.G8`Z:TRTX0`/S?.J>L-2`C\??J\R/=
ME\?'MC/L#$8]QP+SUG-2E%[*)-NMW5M19N=_N)$EI+B(+43@\X9(@Z,C'.%3
M.-IJ\`:_OO"#3^%G@42#`\REFB9\HH/5L?J](9ME@]]0^(VDWWT!PO*JQH-/
M'*\YP(EP@$]TN"M`"SJ&%Q!*)#SO"]'"JK$_<,SF(%F2^6#P![K8G;X]&(VK
M?FG()"P"X:N*UAAHEW=JU?B+N(RG#WGVT8+=!"9:7&.V-UDN4\66YX/+1?#9
M&H#F9RI/3.:Q#06"]BY@X;Y/![;UT'V'Q;83-C-J8UC,T8*M+":[,,'2!)X)
M5B;P31"88&V"C0E"$T0FV-9`%U(K\POM\"ORRV18?C$S,P0JX;:>[CE:H,O"
M!$L3>"98F<`W06""M0DV)@A-$)E@6P-:,F&A_(ID,AGH=]B&:MUJI&_&C1RH
MJS0:&AF6)C+%A"P)\0A9$>(3$A"R)F1#2$A(1,BV3K1LPVY`LFT/.G*/OWMS
M8$)5OC%/,TX<&%HFU[8&1GJE$;HM"%D2XA&R(L0G)"!D3<B&D)"0B)!MG6CI
MA3R2]%J#S@CX[?,&[K7,44\G)TYU,JHVSCDA"T*6A'B$K`CQ"0D(61.R(20D
M)")D6R=:[N`DH>6N.6',6D^8(+;<3^>$+`A9$N(1LB+$)R0@9$W(AI"0D(B0
M;9UH"8.][B<2QJSUA`FB+D!S2>I+V-@A%]S(AG-8;9V/]'6^E$:XSCU"5H3X
MA`2$K`G9$!(2$A&RY<2J9J^EE=WXT=-3M8;+8[I[G64P;[B$W.A/!TY)_.S$
M1/1L"U++MB3U1)K9YD9.KSI_V3W+,1(M?Y>)EK)(5I(T#.1+(7;0@X&,:V<@
M?T?9M91%LI&D8:!0"HF!C`-C)']'V:V4!:*5"GI0*]6-DL#M"]:$6>LU$41O
MY;&>X3DWLN$VHM;O9IF$$;_K8\?<I2!P[*FY371MC[BM[AG-)V[!/:.MB=OF
MGM%":80%B01A[?X^M9SAA/W3I[:5@]7GK]*FU9'=H_U$(2MSO9("V7!E5NFV
M>WI,<W34BZ*"$C<H+!J05U>2)<JS9GJ?.D-G8H\,<0_%ZZ=+VS+$5VC5&(*O
MK##G@1Z"-1X[CF4LG36Z-8:P0:O&$$)EA2%$>@BVXXSM@9&%+;I]%H)>=[#2
MZL[O5']RK[68BM$.`D$3UMK!2-=<./['TE96F(@E(K$`^I8U'!C][Z'-9XFH
M>FV%5HV[BZ^L,(0`D5R#P]'8N`BOT:8QA`U:-880HI7:X2)$>A\9>=BBU6=!
MZ`T!6EI#-._H[,&,67F.[*$Z!@HK0+5F,!?F`JU&TG%)D8=(R:\4:I#WT4K)
M!Q2M$2GYC4(-\B%:*?F(HBVB2EY//+MC_-^G'O;XRZP'1]K&/#'O"M$/+O1J
MN=(*"?7ZOBS4^;X\Z`UZ$]MH0`_%/VM`L1"%>&,(/FJI$`*!JG,&7!I@1^Q-
MC"/$&MT:0]B@56,((5JI$"(]!&O8@XVY;Z1ABWZ?Q:"W`[O#;6J';]D5=MR;
MA^#:B8L]?#3[@2-M?4K46'UAI0[02R%O*^0A4@MHI5"#O(]62BN@:(U(R6\4
M:I`/T4K)1Q2Q]R`L7SPYO"#\O09_O'M.\I=DGIQ.16N7O;%W%K"Y3A\DYB]4
M9@,7;K+A0F'PQ<B%VZ`;?.PNJ[`,>W_LPJ&?VH=C%\[HE,.+G*>J*0V=&7O!
M<\-^9KOP4/"&CN,^02+H#S/'A0=;-WC?A2<RP+MR9'B!<XU?DBC.7])+T3HE
M!TA6KSI7Y/P5$/]2BC9^SDIX=5-U]!%>U25P@.^QAV*'+"OQ"QM`OOR;_@L`
M`/__`P!02P,$%``&``@````A`)4C?F,Q`0``0`(``!$`"`%D;V-0<F]P<R]C
M;W)E+GAM;""B!`$HH``!````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`)R104O#,!B&[X+_H>3>INF&C-!FH+*3`\&)LEM,OFW!)@U)M.V_-^NZ.M&3
MQ_"^>?)\7\IEI^OD$YQ7C:D0R7*4@!&-5&9?H>?-*EV@Q`=N)*\;`Q7JP:,E
MN[XJA:6B<?#H&@LN*/!))!E/A:W0(01+,?;B`)K[+#9,#'>-TSS$H]MCR\4[
MWP,N\OP&:PA<\L#Q$9C:B8A&I!03TGZX>@!(@:$&#29X3#*"O[L!G/9_7AB2
MBZ96H;=QIE'WDBW%*9S:G5=3L6W;K)T-&M&?X-?UP],P:JK,<5<"$#ONI^8^
MK.,J=PKD;<^Z-U<GWA]*_#LKI1CLJ'#``\@DOD=/=N?D979WOUDA5N1DGN9%
M6BPVA%!24#+?EOC<&N^S":A'@7\3SP`V>/_\<_8%``#__P,`4$L#!!0`!@`(
M````(0"EU<_FA00``!4/```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````)Q7VVXB.1!]7VG_`?$^
M@62C:#7J,"(0E$C)A`TD^VB9[@*LN.T>V\V&^?H][B9),Q0]HWGK2Y7K5-6I
MBY,OK[GN;,AY9<UE]_2DW^V026VFS.JR^S2??/J[V_%!FDQJ:^BRNR7?_3+X
M\X]DZFQ!+BCR'1QA_&5W'4+QN=?SZ9IRZ4_PV^#/TKI<!KRZ5<\NERJEL4W+
MG$SHG?7[%SUZ#60RRCX5[P=VZQ,_;\+O'IK9-.+SS_-M`<"#9%@46J4RP,O!
MO4J=]789.M>O*>FDU_R9`-V,TM*IL!WTDU[S-9FE4M,(!P^64GM*>A\?DAN2
M,6A3J9P?))OP>4-IL*[CU7>$[:S;64A/$<YE=R.=DB8`5A2K7ZIG7?C@!O]:
M]^+71,$G/0C4'ZO'IFSS69T/+LXK"3SM2\83:B3XL8]QKH(F_["<2A<8R!?G
M3<P5BAIQ#>@MBP+<$-<F(%[BUM395K:)_-V'*ZFE24G,#IP[(B(`#4194T#N
MD*AWL1BX&L8LR$"135[8I7@`):LD^PK6Z!=41M:`_D$M-(FIH^5OJ)S^BH[T
M:S'1]K^]I+Z[,5^3N"J],N2]N))>5>X`CX=KDCW_*P5Q9R$^)8>0(E*LV"W<
M\Z&*$/M_`L**9ZE+$O<D?>GJ:+*RLX#HTDJE8J@U*)S2+LY6:[E@579M8EO3
MY%NIB@A%&`JL^"V\-:LJ&4/O40)')4<VSU7M5YUK"PZ:%9H76A)[=C/37VT`
M]JG<2N3]I]*1%^0<96(6;/HB1CR_Q[1$`C/\-L&I11F[C9B"\ZR!6[39G,1<
MOA[!^T@:T<YB>6[%W$GC91J/Y+V;D4;#@?5_2BB0TULQ408Y4E*+,8M@5BX\
M?2MC/JXWL818J79J\MP_Y";\1*1Y"PV*MHD=86J;2CMA>>S'&1LML2%B6=N&
MJY6\@K719.\A'WE7FA1K@W.4:942"Z>=;CR<=B:=L7:F*%04MM3@\UAIU-0&
M`Z0>T(JO7(9\PRQ3L710"JR569GGTFWC")FMK0MS<CFFV:YSLBH--MXH3!V7
MKK<"XT]4?8M5>:34HA[1.:O.`&-W2B[P'K<H'EC#2K,[B]JA(U90R^CF2V=S
M]*L?.C:K<B"UU]?YQ#1"QE0,:X:1B[TGY@O^L"H-*X=%QG>U0[F=@8H!K)7V
M<N3)W$`V*0/&IA@:4X)@]\JH_(B9CU5C;P!5Z?RIRF'5\YF)WF#PU*/J$1N$
MVV`L1&I&H*R96O:AJ'@YQ)39Q'5N3$$J?NT"R<N\$O?BR>/X8,6U#PJK/HG)
M<1M8;:H!F>-RX.LR:+%R=*"V!2PO<%&)^^!']Q-79#";`U]CAV5Y_5K4LQ3;
M)>L+0OQF!54,F/5V@%D>RY]5^4"#XFKTHWIG9E5&:^Q"D%9&#'-;HE1@[,DX
MM)&54:Q*@Y6[7=BL1'3'^&,MIKV3\Q0[V!SV/&HBV[M__'#CN%/FQ3\5<SL&
M:]ZN5/L?DVJQS7#9>/O_\2&YP6W*Z7A(':GL3>;P1[P`/M>WW,'I^4G_KS[N
M=HUO26_7G-")!_\#``#__P,`4$L!`BT`%``&``@````A`.JM4E(]`@``/R8`
M`!,``````````````````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4
M``8`"````"$`M54P(_4```!,`@``"P````````````````!V!```7W)E;',O
M+G)E;'-02P$"+0`4``8`"````"$`C?RA+X,"``#>)0``&@``````````````
M``"<!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"```
M`"$`L)I$GL@%``!-$P``#P````````````````!?"P``>&PO=V]R:V)O;VLN
M>&UL4$L!`BT`%``&``@````A`"P;:B>3!0``%A@``!@`````````````````
M5!$``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(M`!0`!@`(````(0!K
M]J7'$P,``!H*```9`````````````````!T7``!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L!`BT`%``&``@````A``IVUU?2!```.14``!D`````````
M````````9QH``'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"+0`4``8`
M"````"$`/WJ/^=<"``"9!P``&0````````````````!P'P``>&PO=V]R:W-H
M965T<R]S:&5E=#0Y+GAM;%!+`0(M`!0`!@`(````(0!$01`/CP<``*8M```9
M`````````````````'XB``!X;"]W;W)K<VAE971S+W-H965T-3`N>&UL4$L!
M`BT`%``&``@````A`*5$76.'"P``G5,``!D`````````````````1"H``'AL
M+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"+0`4``8`"````"$`4254D%X#
M``#L"P``&0`````````````````"-@``>&PO=V]R:W-H965T<R]S:&5E=#4R
M+GAM;%!+`0(M`!0`!@`(````(0`BVWE;2P,``+P*```9````````````````
M`)<Y``!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L!`BT`%``&``@````A
M`('TZ'.5`@``4`8``!D`````````````````&3T``'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"+0`4``8`"````"$`^;;HD2<$``!G$```&0``````
M``````````#E/P``>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+`0(M`!0`
M!@`(````(0!ENK<+-08``.\@```9`````````````````$-$``!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L!`BT`%``&``@````A`.6>#OL)`P``!`D`
M`!D`````````````````KTH``'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"+0`4``8`"````"$`2#'&*VL#``"M"@``&0````````````````#O30``
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+`0(M`!0`!@`(````(0`E7@RO
M;P8``(PG```9`````````````````)%1``!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L!`BT`%``&``@````A`!N4R.O+%@``"\H``!D`````````````
M````-U@``'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"+0`4``8`"```
M`"$`SBG<3!($``#T#P``&0`````````````````Y;P``>&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+`0(M`!0`!@`(````(0!">%R>&@,``'T)```9````
M`````````````()S``!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L!`BT`
M%``&``@````A`!U+BZQ*`P``RPH``!D`````````````````TW8``'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6Q02P$"+0`4``8`"````"$`5OLY'U$#``#U
M"@``&0````````````````!4>@``>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM
M;%!+`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3`````````````````-Q]
M``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@````A`+6LW>&H"P``
M%&8```T`````````````````H80``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`
M"````"$`N0Q9.VYW``#HGP$`%`````````````````!TD```>&PO<VAA<F5D
M4W1R:6YG<RYX;6Q02P$"+0`4``8`"````"$`:_SAVVP"```S!@``&```````
M```````````4"`$`>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&
M``@````A`,$DX5E!!0``X!0``!@`````````````````M@H!`'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+`0(M`!0`!@`(````(0#`C52'T`<``"`C```9
M`````````````````"T0`0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L!
M`BT`%``&``@````A`*^!+%.P`@``$0<``!D`````````````````-!@!`'AL
M+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"+0`4``8`"````"$`CFCF3_T"
M``!T"```&0`````````````````;&P$`>&PO=V]R:W-H965T<R]S:&5E=#8Q
M+GAM;%!+`0(M`!0`!@`(````(0!+TFYG\0(``)L(```9````````````````
M`$\>`0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L!`BT`%``&``@````A
M``-PMBYA`P``6@L``!D`````````````````=R$!`'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"+0`4``8`"````"$`ZQZ79O\#``"C#0``&0``````
M```````````/)0$`>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+`0(M`!0`
M!@`(````(0!PR'WDD0,``$P+```9`````````````````$4I`0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L!`BT`%``&``@````A`!:,"*FG!```81,`
M`!D`````````````````#2T!`'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"+0`4``8`"````"$`<!B]@6`$``"0$0``&`````````````````#K,0$`
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`%``&``@````A`)@^_@$D
M!0``:!8``!D`````````````````@38!`'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"+0`4``8`"````"$`C0I;\;D#``!>#0``&0``````````````
M``#<.P$`>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(````
M(0"^I9Z*7P<``"`?```9`````````````````,P_`0!X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L!`BT`%``&``@````A`$J%`RN/!@``]QH``!D`````
M````````````8D<!`'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4
M``8`"````"$`3RS37,$%```+%P``&0`````````````````H3@$`>&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+`0(M`!0`!@`(````(0#E/QF.\0(``-<(
M```9`````````````````"!4`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L!`BT`%``&``@````A`.]3_JE_&```;(P``!D`````````````````2%<!
M`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"````"$`';9T
M^F$"``"X!0``&0````````````````#^;P$`>&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+`0(M`!0`!@`(````(0#>`ZDC=PP``(M$```9````````````
M`````)9R`0!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!`BT`%``&``@`
M```A`$V`C)J,$@``HF<``!D`````````````````1'\!`'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`E<6,RV\.```A2@``&0``
M```````````````'D@$`>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+`0(M
M`!0`!@`(````(0`J:!N\G`P``-]8```8`````````````````*V@`0!X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`2K>!9I4"```=
M!@``&`````````````````!_K0$`>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L!`BT`%``&``@````A`"W_W'K"!P``A",``!@`````````````````2K`!
M`'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0#-/W]Y
M$@8```$=```8`````````````````$*X`0!X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"+0`4``8`"````"$`.45W8($'``#'(```&```````````````
M``"*O@$`>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`BT`%``&``@````A
M`.K,QQOM`@``6`@``!D`````````````````0<8!`'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"+0`4``8`"````"$`#KPS]9P7```4@0``&0``````
M``````````!ER0$`>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(M`!0`
M!@`(````(0"$F5@VE@H``*,T```9`````````````````#CA`0!X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L!`BT`%``&``@````A`#J</(R=!```.1``
M`!D`````````````````!>P!`'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"+0`4``8`"````"$`'-'%OQH4```3:0``&0````````````````#9\`$`
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````(0#ZC.E-
MAA8``.9X```9`````````````````"H%`@!X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L!`BT`%``&``@````A`)U;H0O1!```31(``!D`````````````
M````YQL"`'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"+0`4``8`"```
M`"$`3;@#ZE8*``"0,@``&0````````````````#O(`(`>&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(````(0!^(I)&W`,``.$.```9````
M`````````````'PK`@!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L!`BT`
M%``&``@````A`(_,!\2-!0``ZQ8``!D`````````````````CR\"`'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`LW%6930&``"E
M&```&0````````````````!3-0(`>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM
M;%!+`0(M`!0`!@`(````(0`0<C&"Y@8``,D=```9`````````````````+X[
M`@!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`%``&``@````A`)9:
MLMM]`@``+@8``!D`````````````````VT("`'AL+W=O<FMS:&5E=',O<VAE
M970R,BYX;6Q02P$"+0`4``8`"````"$`;+?^#G,'``!()```&0``````````
M``````"/10(`>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(
M````(0`%YH%RZ@8``*L<```9`````````````````#E-`@!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L!`BT`%``&``@````A`.&4J\G3#0``8$8``!D`
M````````````````6E0"`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M+0`4``8`"````"$`+2GD7/`/``"[50``&0````````````````!D8@(`>&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0!"K(+WQP8`
M`$$<```9`````````````````(MR`@!X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L!`BT`%``&``@````A`)4C?F,Q`0``0`(``!$`````````````````
MB7D"`&1O8U!R;W!S+V-O<F4N>&UL4$L!`BT`%``&``@````A`*75S^:%!```
M%0\``!``````````````````\7L"`&1O8U!R;W!S+V%P<"YX;6Q02P4&````
/`$D`20#Q$P``K($"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
        <td class="nump">$ 3,422<span></span></td>
        <td class="nump">$ 1,550<span></span></td>
        <td class="nump">$ 825<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and development</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
        <td class="nump">2,246<span></span></td>
        <td class="nump">912<span></span></td>
        <td class="nump">557<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and administrative</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
        <td class="nump">$ 1,176<span></span></td>
        <td class="nump">$ 638<span></span></td>
        <td class="nump">$ 268<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Intangible Assets (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets, gross</a></td>
        <td class="nump">$ 1,364<span></span></td>
        <td class="nump">$ 1,317<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num">(236)<span></span></td>
        <td class="num">(163)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
        <td class="nump">1,128<span></span></td>
        <td class="nump">1,154<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Patents</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets, gross</a></td>
        <td class="nump">960<span></span></td>
        <td class="nump">913<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Licenses</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets, gross</a></td>
        <td class="nump">$ 404<span></span></td>
        <td class="nump">$ 404<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph ((a)(1),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Operating Expenses from Related Party Activities</a></td>
        <td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The following table summarizes the amounts included in our
 operating expenses as a result of costs incurred from services
 provided under the Services Agreement (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Years&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Services performed or out-of-pocket expenses paid to Alnylam</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">550</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EODAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Components Income Tax (Benefit) Expense (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 205<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit), Total</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">206<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
        <td class="num">(20)<span></span></td>
        <td class="num">(9)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
        <td class="num">(4)<span></span></td>
        <td class="num">(2)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense (Benefit), Total</a></td>
        <td class="num">(24)<span></span></td>
        <td class="num">(11)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
        <td class="num">$ (23)<span></span></td>
        <td class="num">$ (10)<span></span></td>
        <td class="nump">$ 206<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Paragraph Question 1-7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentFederalTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentStateAndLocalTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFederalIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Short-Term Investments</a></td>
        <td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following tables summarize our short-term investments (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Maturity<br />
 (in&#xA0;years)</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Amortized<br />
 cost</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>Unrealized</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Estimated<br />
 fair&#xA0;value</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman">
 <b>As of December&#xA0;31, 2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Losses</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2&#xA0;or&#xA0;less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,402</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(25</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,416</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,710</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,710</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,069</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,071</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Debt securities of U.S. government-sponsored agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,001</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,181</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">42</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(25</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,198</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="65%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Maturity<br />
 (in&#xA0;years)</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Amortized<br />
 cost</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>Unrealized</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Estimated<br />
 fair&#xA0;value</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman">
 <b>As of December&#xA0;31, 2012</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Losses</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">44,898</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(49</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">44,856</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1&#xA0;or&#xA0;less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,200</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,200</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,492</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,492</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,590</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(49</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,548</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2VAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Notes Payable - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="4">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Aug. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2010</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2008</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>April 2008</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>April 2008</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>April 2008

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>October 2012</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>October 2012

</div>
          <div>Convertible Debt

</div>
          <div>GSK</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_TermOfDebtInstrument', window );">Term of convertible note payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable', window );">Proceeds from issuance of convertible notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DebtInstrumentsAmendmentDate', window );">Convertible notes amendment date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2012-07<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage', window );">Voting securities percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,400,000<span></span></td>
        <td class="nump">5,400,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of convertible notes, converted number of common stock</a></td>
        <td class="nump">1,256,232<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,256,232<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,447,037<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per shares</a></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,400,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Outstanding principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Accrued interest on convertible notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity period of note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DebtInstrumentsMaturityDateMonthAndYear', window );">Conversion date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2015-10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible note payable, at fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,279,000<span></span></td>
        <td class="nump">10,134,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,700,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,738,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issued promissory note</a></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DebtInstrumentsAmendmentDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instruments, Amendment Date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_DebtInstrumentsAmendmentDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DebtInstrumentsMaturityDateMonthAndYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt Instruments Maturity Date Month and Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_DebtInstrumentsMaturityDateMonthAndYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minority Interest Ownership By Noncontrolling Owners Percentage</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_MinorityInterestOwnershipByNoncontrollingOwnersPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Proceeds From Issuance Of Convertible Notes Payable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_NetProceedsFromIssuanceOfConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_TermOfDebtInstrument">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term Of Debt Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_TermOfDebtInstrument</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Convertible Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtFairValueDisclosures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The after-tax amount of interest recognized in the period associated with any convertible debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestOnConvertibleDebtNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of notes issued in noncash investing and financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZCBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Revenue from Strategic Alliances (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">$ 5,454<span></span></td>
        <td class="nump">$ 6,118<span></span></td>
        <td class="nump">$ 4,759<span></span></td>
        <td class="nump">$ 3,238<span></span></td>
        <td class="nump">$ 3,238<span></span></td>
        <td class="nump">$ 2,809<span></span></td>
        <td class="nump">$ 3,309<span></span></td>
        <td class="nump">$ 3,344<span></span></td>
        <td class="nump">$ 19,569<span></span></td>
        <td class="nump">$ 12,700<span></span></td>
        <td class="nump">$ 13,789<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Strategic Alliances and Collaborations</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,569<span></span></td>
        <td class="nump">12,700<span></span></td>
        <td class="nump">13,767<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Strategic Alliances and Collaborations | Sanofi - Aventis</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,336<span></span></td>
        <td class="nump">10,030<span></span></td>
        <td class="nump">10,033<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Strategic Alliances and Collaborations | GSK</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,778<span></span></td>
        <td class="nump">1,996<span></span></td>
        <td class="nump">3,734<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Strategic Alliances and Collaborations | Astra Zeneca</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,859<span></span></td>
        <td class="nump">559<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Strategic Alliances and Collaborations | Biogen Idec</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 596<span></span></td>
        <td class="nump">$ 115<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail) (USD $)<br>In Millions, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems', window );"><strong>Schedule Of Earnings Per Share Basic And Diluted [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable outstanding</a></td>
        <td class="nump">$ 5.4<span></span></td>
        <td class="nump">$ 5.4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10.0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share of convertible notes payable</a></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Common Stock Reserved for Future Issuance (Detail)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock options outstanding</a></td>
        <td class="nump">5,598,000<span></span></td>
        <td class="nump">4,720,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance</a></td>
        <td class="nump">8,180,683<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Common stock options outstanding</a></td>
        <td class="nump">5,598,207<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock shares available for future grant</a></td>
        <td class="nump">710,534<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Employee Stock Purchase Plan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock shares available for future grant</a></td>
        <td class="nump">460,283<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Notes Payable</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance</a></td>
        <td class="nump">1,411,659<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_EquityLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_EquityLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>30
<FILENAME>0001193125-14-074001-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-14-074001-xbrl.zip
M4$L#!!0````(`&,P7$0+10.%/3`!`.\I#0`1`!P`<F=L<RTR,#$S,3(S,2YX
M;6Q55`D``^IL$%/J;!!3=7@+``$$)0X```0Y`0``W%U;;]M*DGY?8/^#U@^+
M'6#;[OLE.#D#7@?!Y@8G,SN[+P8CM6UB9,F'I!)[?OU64Y=(%&51E$@K.S@8
M.R(I]U=57?55=7?QMS\_/8P'WVV6I]/)VPMRB2\&=C*<CM+)W=N+68Z2?)BF
M%X.\2":C9#R=V+<7SS:_^//O__HOO_T;0H/KZT$XG4SL>&R?!W\?VK'-DL(.
MWDW<$T,+%X>S!SLI_G/P+<GM:#"=#/[N7[\?T$LR&-P7Q>.;JZL?/WY<VM%=
MDJ'I9)Q.[.5P^G`U0&CY-_XV']Z;P4!>4ACBVJ7KZ6PR>C.0:Q\%F4T*N'TP
M@H&\&5!,.,(44?65Z#=,O,'D?]?OGCX^9^G=?3'XC^&?X&8L$#S!!M>7UY=K
MR/Y]\&4ZR>'NA\=D\CSPQN/!M7LJ'US;W&;?[>AR\:5/W[+Q`(0ZR=]>K.%S
M'U].L[LK^!/L*EV(YV)^YQMW=?S"_2"5?SCYK>YW'VS<_X.5=Q-CS%5Y=7EK
MFD\Y)>JEP<SO6'UWGM9],]Q*KO[^X?V7X;U]2%`5`9C*79(\KIZ\3?)OY7.+
M"U=.J@@3Q,CRD9']^8?*$>5V>'DW_7X%%VINS^[&FR+-[-UL/,NSI])>W`.$
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M:A,2I85$6E*%N/8X\H/0(,\$<4P`5FCD#;T1@`_KB]\Y(U)CQG^[:H9B4[O!
M+"^F,,6]T7<7<_*@=&7%X5"IAE\5P8KB)T6XE`K^1:C13TIAS?B-$L9(_J2D
M!%6M"641(V_^^B5<EPSB6X*)?9\H7PLD0.N(!\`^/%])1(T0OO8UT21RIDY`
MZ+\36@KHIP7L0+HICB_)V'ZZ+07W&=R>_6RS4H`GD@=72CTI;"0U3>1Q`R9Z
MLVTT=%LR@1$>$0%B,=&(8^DCK7B$E"'2Q#X8U-P)D!L"$^-2JI]BV85X+A?G
M9=]<V^]V,K/7=CB]@U$"`?R0CB$0`67]8(O[Z2AZ>K3#PHY6'\.M-OV>?!L?
M*CBV\!(*O+H23UJ!B,125)HJJDD#TQ%;`E+$5SYA'DA$8<25+Y$?^QX*8D]+
MWQ##&;WA"]-Q7M)9SM'@*U-M"N$[*U*X\'%:V/QS\MQ"0N!3&-GP*LVE(%3`
M0A5P%`<Z1IQX!'DA#I$?AE0&PO"0AS=D(85R^FQ,H/KQ;X(,[;?"92A9F9H$
M298]@\_Q'ARSZA$I>`J/>)PAW_<YZ%L#2+`>4#JC,3&,@1TXI,Q-B"VD+X&H
M!HS/LV_C=!B/I\FA^!B6SDGLQX?;A0AV(QTL4_I"LH!8._`N0@*;:^_D0<`$
MH?1H`).8*[#A"-B`'T8285!YI'T>&M^XF4R=9ML%@8KZ?YK]_%>7,)>NDAQL
MT'JW03?V]8IZC'+P\%0HT'T<@RL#<2(9*"7\6),@CN:3F`(YN'S!KG<#Z\1Q
M$;PP""P$?5*,8ZY6!J&`#>I64UUB)47@:22%8P4QQ\ACP`P9YZ'F.%!<^VXF
M$$<*VSFU=X`3]%(L+BZ,QIN,/DXGPU:SX_6%`=F`KLBB`<S>#>.(F-](%LK)
M0K<UC)(I^:[ZYLI7=I*7Y3$ORY+)G75SS'_^>0M\@_O(^Y%DHP_)4_HP>X@@
M$YX^6_ME]BT?9NFC>_K:%?G:2A#X$[`F`O:SGD<^SC+[LE/Q8AQ'@8Q00(D`
M`DDC9&(5H#!61/B2>@9'*WZ$+XE8(Y`=R:`GG[P2'6<*PI10C/$C/;2G**&*
M.0[N0I3'($^1`N*4#F(9Z$A@0^;"%&?JH??*8L_4:RZ!.OK5AFAV91":,B[-
ML0:A(\U4I)#R!,RNP&4?/O60C(U4+`IC:NB\;L%/;Q#OIY.[KS9[.)UAO"23
M?8;16!+T9<.H0U450:4&\B[/9W;4%OHR'$DJR<$E'19)3T)ZA4P0A,#7E4"^
M%[M)$7J2!IZ'(>MEB_D@MTAK/9+J?+BU$*)'BWSUQ#";:[@Y5.?\V%;FM8'B
ME!`9-HO20EU"TIYR15QRWP>88-D$3#H@2'-.4!"%H=&8>RKPY@58T"T3AP#^
MZR2;EQW^:4=?DR??3NQM6N0'`L>N0MXHCV;;%0-L=.`S@U0$WIQ[`6B3AQ(9
M1D%LTL?^'%S)"ZC6&]AV#+]"H9Q9WT_'(W!FT1^S].#"\C'P0&T*;)`B#_X$
MXGX(NM,!<!\<N7@5*,'+7`K23J<V4"!RKD]LP-Q&4'%$27X/)-K]<)>_)V/P
MY+FWJBO\+1D?;,S'@/9$P$7,-3(^TP`Z]I$1#G0$>)D$=5,YURD#)PR!7&ZJ
MM1&>;I1\XVJGPA54L<9-Z@?M5;ZHGKAZ*28'Z?OT8`75W=JWN-$K^Q8<FU?&
M*SF6G>+E+N\K\1)V$-:O]N%QFB79\_SBL4M$*^2$$".=61MS^((1D7X(G,I#
M2DB(0+%BKJ++4*P])B)?:1[%FR9-N7'_^XE['ZX7I;!9(/6*(DN_S0K'R+Y.
M/R<MJB/[Q-+<()J+IC0(\'?S0NFZ31R,ME^3`4HA.C.9,DM;FLS+<CDWFZG(
MY?0V0^9+L&`S$#`-.:7-G(;XD:Z)7SEQ@/B!NWX%XG<,O$:!@JV(GX3`R`DW
M_##B=](DO#G<[1P%ASS6DC+$*#&0E$GJ5HY\Q&(#J@NY`3IX4ZIRV_T=EG1W
MP'6/T7,CKEN:L>.ZAJA-:O\:5)?T2W79BA>`D1.A#S/Q8Z/9%E@&_QT<S9H"
M742S$B@CFE>*V+N#U^F5VBVE9RM*7WHN!@/HE])OX>V6TK,5I7=XI3H([(D)
M&NF/T_^<N^SL.?T^L9R8G[$5I^?GS^FW9-,=I__I!=GY<_I]<CF]S2PX/>^`
MTW>W8/4"/6J\1-6((98E[!.M3YUF<:8*O>%R#/<%COP`A50!*_1,C+3Q(T0X
MU4))K@,:`5@J7<%>`U/`^L#5F-:+XI_*]>_U*???UIV&L2,/Q)G<V>C)9L,T
MMZ547\54`NR;.(@X,K&!B"R51#I6$5)A@#GC"O-0K3:;TDM"3K!7X#"Q=*:+
MC[.';S;KP$IK7!8P)T+#T*!`>!YDGX8A`VP'B3#TA<?#`#S72LQ<T4U'?G+0
M>^:O-RONIYE+^,]L#@NP05R3U.X<_TZ@X-0_95_<X8%1F?>UW!O>9A(>(P#N
M-NS`$&K![\*T*83/V6*5\C45SD&-D1?XCOY#A(H#@CQ.-`J4#(@O5.![^H;4
MUS!>!K#'M-OSNJYM6S6*3SOI6V7M^8C-C.T+-`VA$K>+62FQ66?<"6`3Y_LT
M^9:.TR)MNY>Y#X#*[596E:76[9%7SF8-A[.'V=A-WT_%O<V<K\_L/;C[]+M]
M-QE.'^S[:9Y_M,6GVZ_)T_G!IJ!7).@&Z`-!=5$Y/P9YT\HY+0]9R,VUUD:5
M\^6.R6M;"NF7,&_AEEKYIG7OQ;'3V$,+%C%,2TX#OX]M26XF(\C%(/OX9_GY
M\H3?YW%2;F)V6=OC0[_2"2"_Y%@0Q+`N#RMPY,?P?Y$G(;GB--:^.\HG72K.
M=\Z"H]!69#@:E6>8DO'G)!V]FP3)8UHDX_,S&*J=/Z2N3+HAE?KQ;QF*2\GS
MS7WLYX>1,(C?E<IL_=CKXS8X""_/;9$[ZC;G]^/Q]$?9'*(_L-Q7U`O=#C\C
M($\QD**8@,6(`%0F#(DB/YK[.Q?##56F-H:_`&83?1D3UGS%.=,6"BY>5<K1
MN\=_XAI\#_A8N5W5;:P\I.!^;8LDG=A1E&03(*7YAJN[38?I&6J28;>P@"$-
MWX"Z'\J+E/M\79-;(\-<D)?X]C[GM&;D9^F/@')36I]1;(Y^*[QDLU^$=D'R
M+X6N1ICZX7=[@J#CS0MS-LV/V;OP.N;:-)*X(A]\)G;EAYM8XA1&8M]#P@0D
M"9+_.R>">7Q=<U'K!+)/R#(P`A@QTGX`D*E4D"%Y!L4$5!E310)BG,L%%R0W
M(\OAL':YWTD1P,^TZ($];%LT9S$+`D*1!)>$./8BY#$2(PK&+(WQ8XP7*>+J
M>%2=$][&L+.2U6;?31]6[1BPW%69K=E=LS:AW<I3G*19>5>8YL/Q-)]EYSAW
MB<ME,*2_NWS3+B@[_1,D>+\$/2SWTS)!=E:U:H'4\/WY'#]GJF^6W08J3+\Z
M\CVIW*='U^4/J*0K<95+S+?3S*W+G">%`O^DJSGZ`9CV".,O&3QPEK@=/38"
MBY>!E^/?:B6P$;8^VB)Z&HYGKCK_E^ET]",=GV$UQCDP(C;]5Q,D>_0+CYP6
MZU.>OIFDX[<7!5#<8\P:;[5\VUE@Z]M(&]84!3`'5:FLOXRADN64&JJ)2M?6
M>;)3+(8UQUP>08LBB12-*.(A]UQ[@@BH$R0W`JB3"/`-<:>G@3]5*VI[@>QS
MR<Z-GZ47<B=HQ9YR6CGZAJ9\\OEX"M_C%CD9J:[G[D909\;GAXK@6FHT'V[W
M>^K[X/;N7(BH>*`V&^KO(9MSF?N[LONIT_(9ZI.5[K:RP%4W]#W.9KTPW.ML
M;.YU=*,R_B:0/:CAEWDJN\$.7?_G)!O>GZ447&IC-'M9""_CVB.4Y0?S)>^S
M%`)8O6*4OBR$31R-ZU1]\ZJ&52FG=T94T[)4#;/ZG-G')"W[1DYR"]YP+4\\
MVTHR4`U-324([\51%XO/%B+D=$:;"L@:.&5;T"TKWTE)X/>J49SE7';G).CB
M./SQ$-=$51<%%R5:MSLU[],4*`ZIST*&##<$\?*WB(:(2,XU]?V`J]AMJN5E
M_R%5DNNE//;BZ&;]MJ^#@&)YF&B^%6UKZT771P&WX'9W%%`L#\&0VAV471\&
MW(?T](J='VLIT<K#E'IRK-T>?!3+@X\.:\UZ??]XNSWX*)8''TN\E61K_XP]
M56;E>G=2(5UK<T;:^:BFGKFD(I)6%L5V9UI=AJ!>8=,UV*WBT>FU3:C"[1Q7
M4]BLU#8W])RTW0=LN@;[;+0-Y+A3V/.>@%Q7MOF_NKJ[QTU+W$:WUG=7Y7KW
M)@9,R5$NKE'Q?B&%+<]^:/F^'T'`OR`[<._R4%JT.Y+<5"SLUQ"+6W5ITD"S
MI2"6/2:9894]0><IB34#4;S#12^Z.$CR*\BE?=AL(HGR]#ZK80OG*8B^/$C9
M".,7$4OK.-M$$,MVX]O\XCPET9>!\,5;<(Z72S?%?-=UW##M_"IKV?VC46E_
M>23/D,9[3FN*^QW+0$IBFO3E;KN\L=C3Q3$_0@8=SH]^8JJKA9]U0.TG<C@Q
M;"]J'^P5EG>NK0A_L(E[8O1ILGK(3_(T__1MG-Z5^[;;3Y2Y;."':4='-?.I
M[Q&)A((YPOU`(8\(#X6QKP-?^#J6:DXV<-VVWI9P=V[U[=!^2AG!OZ0F!JQ)
M:ZRZLZ:R4BGK)-80;/?;\9Q@-*-NI87S=KENH\UYR_T#E6-SA^S.ZQB^:.E7
MFNU-7*PVTLI&O?/!+ZEI-Q,:X6?+G1/B3/%+HEF[1*T1_M7+^0@_2_P`OBW)
M:H1?+(@F%[J]`^@Z0O05$\@)8T)7'?98?QWVR)EUV-N&?L(.1J3LL,>)THI1
M>6"'O;6;%DT@YO>ZS749Y"GQ-(MG!1B+>[A%2X2VR(4'F500<V2(#,'P*44F
M(![R@/](@@U,*#'?JJZ)QE*S6MS-()VVS]VBA9X[&-NJSUT3B;7M<U<N#Y3G
MM7FE0?6I0?\*?1Q/XY`:]7$DBU4Y=BG-Z:3^2_9Q[-R^W9$=8:I;R#OMXWCL
MU__-YDYWD]5;T+].W4?_/\Q>EF9_0F4<)ZW.O/TOK"*W5?&2TD[B07-=>)E-
M/MU>VV0<Y:Z7YI+('^]@_K@M]A&.2,9>J"(?_$L(_L7S!-+:)R@RBG-!">;$
M7_F7RE[]70/OJMEKUW3R[)J]MID/QPC@!,U>NW=RYQE]W=OAF:YN-.M'%IUU
MH.UZPJE&^5OG'6A?G&:G.!U"R@ZT<L_;6W=U>?C9`,&"H>3S).Y#.G&O/U]8
M31ZV[09V#'9XW,0AB5%H/$A6510@+6,()9"I\DCQT'.ENOE"A]Q<'#X,TXD;
M\O:A;U4>T%5X5UWJ%1KR]@"[;,A+*OL`CFG(V]!.OL+WVN2V.$%<.*`C1$/[
MYUO=($[39O@8?39M,USNB2*XLOGG5?H,]S%K79]A:C:/9_X:?8:/D4ZS9<<R
MH55LJ^'LV?89[L/?N=/LBF[U86C29[BA:SN_>.YVV6-FVL3S#CHM]^$6G`\D
M:JO#]MY6RPVE\FX23V?9_]@DZS,$--2VV_Q)>1MEK\'JN@/U,7)H>L:9N"9M
M5+/*VVI?KP-U'_[-<?=JDZ#>6E#W`-"UH#:,B\/>^7CR%M1]('4MJ)7!>A/J
MJ[2@[L-GN[5AK>M["W;>@;H??P0YIE$[>\ATWH&Z#RVZK;2XLJ6Z80OJQE'J
MZX_IF<;><IL3T^V"[Q)6EXVYF\N@96-N\IJ-N?L(L.XEAT;BG2UNV]KT?6;M
MF5HU+5O%D)96O0)6[8PZA'O2[S;.I@_O;9Y/3UP*>M&68TQ#S\<>DLZ,>>B[
MEMS&1T9+3P8\]H@B<Y^]>L'<>BO4K:'WW([]*$-O=#K&I1&TTCWDC-JQ'Z/[
MINW82W=>?6-R;^W8^_!EH./*:ZCZ;L?>!R4INQE7&QB^=COV/A*(TF]#^KOS
M)1(]M6/O`:MQS=QJ7KST6NW8^\DG'-U47-9[J(/[L;_DWM=\^J(!X$<0QM<?
M=OS=?@#)W'<GH&T'#CK'H>#@N_T(B&BH*#($"R14")$M`O;IBY\"JCCPXU!V
MT,&^'U-Q[QS<W\6U[G3GHFRZ;/AX;8<V_>Y8NUL!/-M$%/+0"MA&0#KOWM\#
M]'F\TQ7*>FCW_L/FB2/XD+^>I1.@QSJ!!;B3O]W@J+7L`Z)$QV\WZ&$E4\!L
MYJ;:C[;Y\:G#]>U60L[2FODIK-FAZ_CT^C%683@U'O5]Y"L,V;D)0K#R($91
M'`O?):@2B_GZ-B&,R>,.K)_D!1#]!/&ZW0X]OP&BA_CEVI96WXS>_`T0+28#
MW'N64UV<9*K#O2=X1T8?B3JNS5?KWI'1_49=[^XNLW=)84',X#/R=-AW$<>7
ME`D5@:Q"#Z0FL$%^X$[8AJ&FW-"02F]%<&A9D.YW+_,.$77_-I,^2F,NL]9X
MT]6^SMM,^J@4N1<ID:VC:/V^S:2?$*H;;0EYO;>9]".%_R/ORI;;1I;LO\Q[
M.6I?7B8"ZQU'M"V%[3L=_:2@):C%&9ITD)2O/5\_F5@H$`3)(@2`L&Z_R*T5
MYR`KM\H%YX\:?L:1N&2;2:Y*OI[7-E_/]V'M:Y->F_=[T[A87R:L;.D>&82#
MP1IC?P/CQO+),;K?1IVC%+PZ!X*WG9-T)D4O61"$UUXU_CE;_YC?9^UOYN,J
MMR'@3^0ZY,MJ.UO4OXX#CC^NMG]E@+^J4Q^3Q9"%((B*P#\4F$DNB`ME0!2$
MFT&J9,JY+"H;3-/-&@S^D-NBQC$RN.S9N3,9YQ&W18UP:9YOB]*O&:;8_[:H
M$?Q''!A!73-B'W%=U`@8\V238;9MJN[AOJB\*@:=Y_FRU`!;T`ZWV7J^ZJS8
M.C>"@U3>Z@_EH/E33U8#4"\$R"NU^FJ(QM]VKAW5!$JY--6@8P(#IRWAQ`IA
M2!J(2,?2:)%GA?%VKT1U['&OM,)K'`6+J6#C],L2@:FN\'I5+M@(G`*1DC2F
M(;@Y(B$A>(C@ZZ26)EJ[.,B7*JA\Q*)FEEV\5"'_WB,M<E^>9ML_5\^+!S@G
M[[]]G]UOD\?'[!ZKO^"[/LVV8WI[.(Z4&U!57(%\2"M"$C*>$BJ8%$;PE.JX
M[-^M?+W78=O7T*T!(?#YW%5?WQEJ),41C%+EHTFIE1('W3*OW1,M97VQ2P/K
M)!$I.,$R-7"*5,1)'(#,*'#E6%!NX,#[\*8O=P+?=8B0X-G+X8@0U;`GW96(
MOLJ@QEIZYZJE=S@ZI*4/<.BE=P=PAUMZYVBY]`ZA'@YM&'KIW3FD_;_88NE=
MCO;"O6B]8QUVZ9VKEMXAUI8.H?'Q#KOTSE5+[W*\C6$%(RR]V\%]]?8W7U\F
M7WJ'T4;S2F?4Q5C7P,WKN*^T"*V)N_LB&U_<Q=H[:MB47O<8L''5%=5N6F^[
MZUH:7]A%.1.334UV[=<]/&Z>XZ9777-X@!O#C4%QR_Q]PU-,ZG6/`)OGL+OK
M\KZK\<<*,*M[*\6;@95O*;[G76RPV&9K3./]J%KO.@^9JG$CO#:I=.1&59.=
MC_15=4$\FM0,SPSN"9!-;GRE9J09Z4`(8TX?K@OH<V)Z=64I&=.J-HKZRD/3
M>QIKN:.P6P+`B\)JA2;.F.;43'_&=/'+;A[+H:T_9O,%UD+`&_T'_&QW@S<.
MTPQ]&ZJ$[('H,TS\'GPK;092#J(J8=*4UQ<JC,-W8R9)=YJXLS\-UTJK.Z.<
MTQ+W_4G5S3%Q4:P#'E$BI<D;*4(2QHDF-`Q98D,9N]#M=J;R8]:WQ#1.:T`/
MNZ;]&@4J6W*04+GZBK]6)GI8^.?+B_A->.F^;=J+B4J!,PR+?@,F>MB,Z<L+
M_UUXZ9ZM\F&BNBH[2-)-DXBQ5(@XEKN<("V=TUL^1,B7]%9SFO(DF1A+0&29
MY?T=>.F>$?-A0I45.P>)P&D2,9:`*!20U]"2)Q9+O[6LGD6O_\-\D6VVJV7V
M(=L^K79-3+M/OW3_=V=+&+6KV"@<>,L-MSY"U%+;$P1![*PFQF%M3PJ1CTU-
M0)(D"L%_YYJG<I=%SP?L[=*JKT$_#1(E2)[814'&<FWOK,*JII]6:.E5.="2
M=N,LU=QI$EBC",2/C%CF'(1((K5!)).@*H+!2KJB&NBMD@J4<MU-,BD/4F[#
MF(2AS*OC4Q):PXEFSD3,V$1%KI!,K/@V;XU&!6=/'9--8+!;@99+8V&%@N.N
M(H/QNB.!%()(J[2,4N9BEN[B=?5OQ>FPYUU6V8`W1ZKAS+H>+)%AH0F9",`2
M&4JD"34)TS`@41I8'3KFI."[T%"]+0ZMY(KW?MAQ'C=8=4:BF`*C#HZ]C24E
M23YGDT5QZO3NUE"^,;$\26GGL\Y#JFT:I"0*0VP14)2$.G9$)336:>3BA-5Z
M7=\:I6@YKD/I[E;I;3&*$XQY#VEX=+EHG!HB8LJ(#-.$.,X$`>6AX5>#'>*R
M,.OTQ02]419'=95D57/QI@5S5$])55GQ-\WIT(&1J`3SK9UU)>65PJ(JE:;?
MF`=OJ56L_[#(RZX/):9]WYJ71#FK^CC!(M&!=C(F+HIB$#)0AF&`K9<Z#C2/
M@H`*6H0Z^?Q4GUOS:\L0H\[U45#@Y<E45E>(-W82]UD<5;OI:J27^W?B=%A7
MIN+4FK?,Z="N3'7)B4/ZWAB-DG$Z5NI,E(U.;\NK!M:4M==)G>WJVMZ:0WB2
MTV$=0EDZV6^.4V&$D]>1TTJ!OK%8\#2EPXJIVK\B>S.4&J"2CN7&J\JPZZ'#
MO\$VK0!Q@C&%32G.J_F^8Y>.KLH%FJU=G=>N]%6U_@PO9-U]<-Z.0*$=KQ/H
M5[BON>2AA7.:*`O.=YHH"*)332AXD!!,,VV8W"U4&ZI18D?!I!FV#!2DNICA
M(*5I$NF$1!R'%%(.)SDU$8'#S52H>>!H4OB6<KC6B",,#S.I#PB33E@L>A:T
M6PV:W]R^4BQ=8Y/299/[!N9`PT'J5I[HQ4%5`B_I:Z87#EB;.$[!>S[F;\K5
M[N.4=2,-AQ/!+Z5A]YVU<=H?LAG^Q,/-<O=#H'/FFYNOB_G?N5+J?E`*;N"#
M5YON(3=6A#P$4T64@3,BP\B0@*D`-&QH(YR]EFKS4H)YL%*P(]RC:P8'E)^<
M(_@_;9D[[./M69HTS@)H7<+H"7;XW45(#'C$.'],RFZM:'Z;C';"TWV7T<#X
M54?%XH6?5][S9/%K[KH=!2_\5:**6:JF28!F5G3KH_(BH+HP8DQ.$C^`[^IF
M>>&OACQ`^,,[$S"TC1C+*K`>K,+5\C37N!HT5>&8E&_E\N`:MX$5C5+PGFGL
MN=IAG/H&40X<Y/1(2JMU*D`_Z\U'Q0BOG*LFR/:-YU<^#T/?Y.YF#3D[[7J?
M<6YD%4H'-B^]HL#G-;/]FSB[M`96KN4M_^OHRZQ/^3\^0/7C:IOEG_W\':QP
MA+M+UAOXZ4\8KUZPCPF;1!BGCIJ]<>??P8B?RW4**:E,14Q8B"--4@&(G4P)
MCX5B5`2&QJH8=$[?J5/#8$]C.?`K[[/L89.N5]^BU6(Q^[I:S[:K]04N)6>(
M65+.;3$XS'"<CRNU-KN)+^!8"=G#S4X:ALR$5A%E;4ADQ$#EA483[I0"L;#,
MLI<U\3M#=Q9L0SIFB^SF,6=P/Q.,X[4P)?AE/5MN9O<H77W1)(W!%)?3W!VE
MR2]EGD9.!4Q%1*3,$DEU2*R1"9PCIET:@D]5K<B@>4^M,+8^H?$"[$=9`Y';
MS!_RFZ#5LE"6V0.<PROQ=H%X>7.WVZ]-V\GSH*"F63]FV[IL5F/<;AZ+P[O%
M_//'?,7'[-=EAA9(X]ADGK/7B9,@58XKSG#'%@0VPH%M%7%$(D$EA#JI<$;>
M\<,RVDLQC4)'4=EJJ81_#$A'2U7Q*^C`X:$WCW'V=?M^N=FNG[]=M"NH`;D;
M'%`5MZ*RL6W/T[@+>/B?YV+4:;I:U]>J7?C8H)XT/O9^R-3IO<5::A,GACB1
MINA/0*2>Q)9HB#JIE$99:5[48G-KW%%`^[C_,9LO-WCUG6UNELE/O`A_GF^>
M\.<*PB[`SPI/PG1?G!*R@$$\#4YQ"!Z4L>`>@Z\%KJ#@$%L+`=[AG4"XI+C[
MJ>$]"Z3%GRHL1/R,>8K"Z2HLQ\?L7_F7+G`I"O#B`+SGJH@`(E^32!+%X/E*
M#6_9!2XA+*()<(>)*5;(M&)F/R7I!Z2Q##!WNJH#72UANG0SRC'(M?=]]SU;
MWQU2P+L2`#K*O5/UO7XGD!QW&^NJ;!=6]@K\[!01+[C8$ZN:ZV_.`NG=7=[#
M>YV1B*PLF#A,#'AZR+7P"M5!QZBWG8ENH8+LQL1N_T)!Q0L1IQ".)!)]Q4S^
M1-#N,1/:A)=(L_1I,%ZH'(1Z%'%!/%V90=O)$A@>""[!B^?*&##ZJ28A$$ET
M9(P*4\NB-"EWZG&EN>#U-,@E@$Z)Q,Z]Z^8`-)%?D`;R0T]KKJH'@H$-`6>T
M,V!-C591`$Z=PNQ`*BD)1*"(D#*VDD9&VA!?M]S-Z.]N"3HOOKY]7M\_P2=O
MU_/&'P"#>W^9:U]G[`XOKXS`V1-6ZJ-U=\U,U*'WX%5S5^58Z#NK&A5W@Y#R
MFY!O(98R;FCRJW*<*Y%_RD=^49E[D>UGO,#,;S<[$XQ5&KR\H=TE?H#E#BDR
M/SV!)#NPB(9BV;AGC'`6_Y2XA`].C,%E46B9YQNUP_^&87-@)V3'7FVX/K(G
MC(6#+Z1V%[,7V,1"Z&((;O\E,L*;FI`'1*=.&Y'$*7>\<-?SO1`29-'TXZ/D
MN:;7,R$U#L^47/**":.,$+*'C$U@..-&8`H6_=9`X/6F`N?51JF.;**H8[N,
MC9(-<U['=\&9VZVVS]5?I1@7LTLJ-)LDC5$`GU^#24M%\V;H<J"'9^I%H##U
MUYV(FGQT>]O5P,4\%WG\"?<1O(>G!<#;FV7#D_V8;6\>+UH>=!+04")>6?NF
MA)_%M;<'O,[1YL-LBPKT5SS;9A\`_%.P?/@KFUVPV&685YNW7H*<LY?EWE[/
M/48VLH9U:'.YFY5UD):X=G[R'`E=LI7^E&"KQCLZC83E!4ST$;56ZU^$.Y6@
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MWSM?/&\OZ>2'=X"X65&Q>])BM;3$*,:,B%)!DB0)"-[$D\`J@3=1,DJ3@*4Q
MO1-W''PY:Y7=[PWJ!JW?Q:?Y(L3-^U*\&D^4?Q$#T=V9ZX'7+GK/10+^X6*2
MA`ZL@`JQXL<PXC0->"Q-H&E4U/FP=ZR/`13=V&FD'[-M--L\@0GZ,7_('L)?
M_]Q@XG(W/R2`<_WCTB2W!ZMG1#90D52IM,2%PN+DF)`X%27$)9%10D>AX*#'
M[IC%HBF%Q6E[.4=O4(URN>5V_H`"//]1RVTG/^\7S_!KBCO8;Z#/9T4Y0C);
M+^&W;3J;8/]3W5I>14-PYVU`TD`P.,QA4G!D=)(J;9(PX2AO(I\7(RR7M6Q_
M+T@;;DGC>_I7=ET.I:_NP^H[J][5P]@S@!K>:7$N-U]6P3TX,>OL:$_E%,\1
MSQ?:FGVOU!M18P7Z]BE;H_2LLR=09B!@[Y?WJV_9/Y?K;+;`\2W_M5J@R<#:
M1BQMO%F^2&"PGF_@2_7(J$-V^/6\>8I-KG_LOC<_%'ZO`#G7\/G72N.0_,S6
M]_--W^?O#'VA448*RDD`?P3$+F;$6A0[FF#&&61/YD/^P&@B>3B5SOI$R<?A
M'<2*C_/M'Q=U9(]HM4!HC*8'/=CE(Y]1+)^?5NO\=N7]\D=6U$)/$B7/ZYET
MPS1[P6G>&^'Q06;**B@PX<\@$J4Y!RD(L\?5NCQF<%+0D&W7L]4:3MEL_>O]
M-ONV^;A:(D?KU6(!/UI=V4Q2IT@4#^%TXY)I,!+:;^EN9_-Q=8:G6`G<^*I:
M+^#PD9OUL7FAZ+CGP_,]HU\FC-T?/U`]\,$)`-NQR>*L^`B^_CK[#FBK@EB,
M3)>;#(QR;GV*64E3?'LLWQ]Y(-H=T#5?]/=2L=P\YM_TQVKY-VJ5"VL]Q]..
MX#G@W.?]EW\"Q#Y>=";RPNC_RX<^AMDR`^NQJ:C<?,HVSPL,=7)M\0PL+K>%
M"87OOEUMYA<.N^KC6%!G`;TC)A$0'@>1(J&,-7&".RTU1#-1<)?OZV5RWQ/M
M!^S!!(&F@S9I1]/E/D,C-W,"Q&$_5.%J3MQI,$4[YWX#U,&3-P*.*JQ_L9%3
M?(48*F"MVGZP</CL9]R_YB#$*;Y%GMLV=MKQ:P)I=T,JI5_P,\7WFI=3<M?J
MD>P_?9M;"T<56UR6]_/%//?CX!,1V+SYR&_6.FL"D$U")8N)%/".K6"&4,,3
MI5(CPR`IM+.VHL4S/8'C(.$X[7/*=%MXMO?8C:SA/=BA/&5;ZT>]><2I49@E
MVX`0@$/S;?[\;3-Q[8O(E6JL0N^$[E@;,A[_AX?<(,\6Z*^_7T:S[_/M;-%>
M-?\I`UT!!CS[G*U_S/,K03#KM::P`1+^_>8V0!5:OA^O#$V'EY[)]=+N4V"`
M,$"<HLK!TG_&?%1.*Z1SD5059-0&OTWQ:#*#7;/\3.#4`N8<_JK^^%.VF&VG
M3P,F1Q2W9W@X#JKA%T,HL9XM0(<%#]_FR_EFB][8CZR,.*=HGD!'"]WP(L_`
M\+KQ2^?+&9R;J=_X";RH$4KZW/>U0/)2C=$3WKR^G*;=5@74KL7E[&*Q^A>6
MJ$Q18:*$4'5P1%Z)U.=&?XH"8P_M;_O#-]MREO<@4C?KV]EZ6_Y/'K@4V81F
M\%+&-!>U\(Q&@<1^\GT+VA5>LR?E^QJ>KQ`44#[=!LQ<RD/KN"@7:<&(2%5"
M9&`L"0U/B8BU2WA@X>`D1>5%<^S$"02-?!$2M'S`#WCO^6.V0/>M\+^:]F>*
M,B#PT@D'XNT';Y?`\M*=($N@@9_O\R:8TOZTG[=H-?+]BZ?Z!(7!I9?VO`QK
M0YZ*-.7G+?@G\`+^6-W/%O`'RM]2ICC'%22J-65`B@R<!GIH0@(12Q([SI+8
MIM@46>9G]T7(!TFC5*3J>2NBF".<@4Q6`]LPL5M=]9:#W<H+X%'UC%0R"AB7
M1$D>$6F2A%@6&.+BD*K(42W"L+C?;<ZMZA%QJQRE&<ZX^STD""="-B;0GT%Q
M)-];?M,DLT@&03JNV[.]U9/[1^JUG,$4E:;`G)EWC%X#<X2!*TJQ;YHP'UK=
M=DE_1GR/1^V7#VX:+^[&U*#EK)GF/@/%2[YOP=E88_=HK79ABC)N<-6X5^Z[
M#5&_%=&5:=B5_7Y9;6<+<-O7\^5F?C]T5K2S::35I/?^RI]]J#AW`C')_3S]
MY)<J%[.?.H&'4-HOUB:<XL*F4F&;+OC>8WLIECV7=.+*!<,S*0[RNY?`\A#R
M_,;F\F&]XTDX^A%,R&9]UQDH7M)PQ#@'E=>)M#YO5^M?+S\//$]15C`%RA7W
M$I9NJ(]W7EZ_MMBW!L$=%!6?Q7$\NP7_7F3CIKFZIWK^XS]=X\+,!TKCRG;O
MMG?$HI-#U\)&G,9*@ID($T=D;#@.R59$F=@ID2A)0U7V536G19\$T1I(3R$"
M\8RCQ6$`<AI$XPTO%F!`MME#NP-V#?]`8*><P34C-@#T,DF)C=.$&(@[I+`J
M"&-5I*`.KM2]P#0VF:$M@4/P"1B;+8;'V^(TBU1$$>-$*P/B30-\T0PWC4BG
MG0M32H-"LIOC%%J?W>N>KRC2F/P]'Y<8;7&O>[X62,WJX+:6W@E[P`H7`?.#
MVO`3*$Y8[-DBJ^8U8:I_M5AD]X5&S'LOMK]!*PEN<9#*'JRM[`KR8%W4?(D*
M`V/&K\]Y!+^8Y4G[3[O"XW$OM,!Q"4T*[E\2X7J=V)&0)HKHA,4)Q-(!Q^;\
MO(7@X$++`TNM0?]<;77E<^\76><)CM^CGAP#JS)H[A_PWG*0Y0PL[[?OH)SR
MM,5U:@1\?<3<.]8OM!Q__'X[:G8#>BFCNMN&3R\="N<B=Q1XL\6BK;^F-U!,
M2^Z&`\41%,O[AAK-NNVX1FL2O</-3PK705%+NZVP]BVK%+B\=8"6T:G6J(Y/
M[=4K5D^.R!I(;G&&\.43&#R)97>RE%FF!+/RK-">@#I`-?T+"UA9.:B(J;N\
M`D==6&(_M9D"+XQI2?6@C,F[?$6"''O00#D+*:^?Q2*Q7[6)3_$<?*CMP6TV
M.DJU[]K\.=\^U7]#=[89TX:#S^"XZ<9V9$R4<!D3RJ,4(FV:DB#5X%_K2''&
M4ROSP>AT5R2V&P;5)P%C)F"`-`X6XZ>A./1QN'0,*WT2KNVK,S(C,<($E0,F
MJ'@I1DJ95S/R>L\4/AKU&L_41$9*R2R)I(T`.*@LIQ0G7*?6<2MC5KG;TM\S
M[1?7RY![T*D^0^X[HJS>+*(55T3I.<J_(TI1GFAAA/0`>=6A63E#-E]'XO9<
MEQY':%51%Q<"_>)!AVA-@\Q\'\E`\\BJ(W2P@&0`-CN7ENR&Y07@FG\K//!/
M\\W_INLLJRH17G,[7"VC.!#;YF*BPR,,)S75@>0DUI+A*KF`@.\8D3!((BNM
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MRR$X,-!$/J7SEU'Z@3VB8,4VD`7;?S'\Y??WOW_2/O]K>-$]'_[^^5W_D_;N
M0_],CF`=JLL#4;D$%WR.210P7,P4>G@HNXT!-4Y^_I,G5=37(U<.H0O2YM,U
MX2&;;@WG5G_8-7NCD=%O#6'Z9_<MP-Z%"*?GFK;5<#L00,EK3">@;5PB7$-E
MF<BC(.1Q'X1]*N*'KX]L@[:MDY^[GL=#7,K@OD8(52E=P[!$?R`\N@IH%"0>
M"S'7>01/MB<>]R0UY<!8CD1X`TZK2']>S+>GF??$E*:-QJ]U3!&15?3D<MPP
M\@>/<0E?B*<M*6I8MN%8=6QK>*V8"_@@QGQ4G]_\RI]'EM%)`=R&V6A8=LU<
MU)%;QOT/'H:_1N(Z^L19(B+NTXK\0V[AVMX8(+[Y(*JX;T"N'$-^>*J0^FU+
MSD/0QP3>JNQL0FZ3)9$R]BRV!"@_^G.=):G@M"PY$('#K)/%TDP^CW=L+DO,
M$E(K^?^U+,A1`+$B?X]G#L]%&'C;T]Q.W[8;#=LUAJZ#8Q@Z1L\R':/;'[FM
MD=-MCZRN-(P_AND;/[CZ<9J^`5SQK[F6I(N0OSV9L7@:1$8JYJ^M]CQ]HZD'
M8Y&F8O;:Q$<30-A(@G_X:ZO\>\)F0;AX_3F8\43[P*^U"S%CT4FECS'^QA\!
M_BCIDN"S5T'^]E7QW:OY'1@V-R"(Y#0",#Y1^MK]X5$(_P'J+/=9H1FP*$D3
M[?HR\"Z170F$<=H\#B(OF+,P7&ABHHDL32"4UD(^92$`D$U8Y&L3*HZC33CT
M$\O="2T5FABG+,`E%6T.CZ(T.<-.8WX5`"XBBQ%&@8&O/E)@YZ0A@4>=`RR?
M8\)5$'$MO60I_,,7T!SPP[4<U68BXAP(F\]!\F096]GBDEUQ;9*E,'W1KFC[
M'#%G$4!A(<".J+Y)_D66<$*67U'9BKR'RN#4D`@XP+@&>-`N$M`WY@QR0!NF
M2@E6U*6>KF-0"B#C!'%/%$#J@\F<8@Y0:B005^`PX..@&%4(<!-=&T.4'1%=
MKX/T$C_1?,01?A0P$D(GH'W@,^TS?'*MKG'0F+S'`08S4^P)@PFBI@#(1@6<
M:Y9HEJTMP-("T%0;<(_CC1T_LMG\S7<W7?.-8^D::NW9O43:LG<JTU+H8$B>
M/,D[B<4,!A;$.**8DE.1'1711_H1Q0%`A<$<UPEQ#[2$50K2>I%!.0".0/<S
M3/2:AUR;"Z1BP$+0)C&-V:S.\ZH"0.NBIPKO,1%U1DA!#Y,L5-R"UWC/C>2:
MQJ8QIRFRCCB0%J,V>-)7EG`#X*4I>;G*K5?*8M;.2-UNVE>21-?7\_\,K.V%
M#[M1ZW97,,)3@,-AR[#[KHGN;&1T3`?<L.5T!ZUFMVV/!@]Q!9L,[2.$$)5M
M(C#9#74KI9-1238#X``F0<,''?V-W`E90LR>H'`0Y5`V`00OKG8X!6%*+T66
MP(ODI]>;-:R"*"I896AF^6<YLL)M%5J\`EIB#A.Y,)DS+'KT]@3X@'_/F>_G
M?U\'?GKY]J35_.%$&XO8YS$]5ECU/EX,AA=&_^/[]]WS3\/7^8];";E,]1-0
MMV`:O3W!&^MY7/6X:5S]PR^P:?QP4OC8U*]_<Z6@26(4(VAO;K*MYYNZ;NVZ
MZU=U.L4UH;F;">V*O*P="/5:EZ0[AK[4XD%MP8B@2,*#YK)HY`.3DIC+NW5F
M@AAI"9@L7_M.7I974)R"L;5.;2E6>]B(OAH>V-OB`5K[[9)\&RUV,U![Q[(U
MG@+:`DSQ=_W^<#@:G3Q0VBQSH[B!2ZF^67:F(9^D1`,^JX=T1O[P$2[U/0,:
M,SQ46KK&U?!EA^*.+[^_E[BH/V,,MJE90W=<>VW32%S';/[V1/Y_LFU\GVR$
MKMYH.[L=X1<:SST39YEV`!%^&>?AG"01D_0:IFU/+MD/M(@K`F!9[LL0\+T?
MZ*$;\E$6PPP2I\MRW>@&?R<O4.`[7X?`=XYV_2%A"A[SNQ2AKP7EL;<7*-UZ
MVVQ\'?+=:EA'@_YEH4R4I'%&IQ.T()*KG#QY@4+_M9ATVWIJD5]=H9S?O+G'
M8L832,VRJJBI/.U3X#S^9MT\?O.2Z1YT^11"]752;O>QRKVY!6\0\*IFY:N$
M&W4"/WVD<CW.P>INYWD,ZT-H]!R4:>BMQH[7A0X]^'@/@8;&/"^;97+;UJ]4
M)9/[^Y5Z78\+25Z.JITZ>LMYM&__Z0!5[-36W<>OO=Y*D6.0L\^N^ACD[&^0
M\Y0.XKR25E$NMNM:Q!^Y??1TWN"1>S'@`YKM@XRW'DT0QS*?.,QZF;[`D>;%
M%QGF_3R-2=M*GWO@#0Z6=G79?D4Y8=4'*RF#=^<`+IV`]"ZYGX7\X^0+CVMO
M/\?0'([ZW8%K&9U6=V"X'?BG;5D-PS7;[7ZKU^RU+?-!Z>8[S'P]S_-,PX66
M$U%+"BI28K+*EO8URBG$W-/0PXD33I;$!(!00W@/[E$+L?P3<%*CH_K:F'LL
M2SBE8@L(0;1KD84^/`;7F@9&WB4`P:]9HC(@$TI@],1L!GWPXCXP"72?\QG;
M[C[E,S9NR1#<E%3H/E\^XR%W?:AI?):Y3BRQU1A__$GI_QROIP-@QW3)O<@B
M?.ITR3T8\I83)U_"D*T=*]:!+0KW170%`2@>6M'FL;H]##K&R!"/L*4L0F?_
MJ&C\WH+QL+GE(R"L3G3+X`=DQGU*5(^$>GI3\_#>UJ0\.'JST]$[N]Z@.ZPU
MQ;Z<S"B#(HO-[-:8[(#UP'FGH]NM':^,[=_`+;W=QB7!'>?`[-_`;=UQVKK=
M>.JUT`..+B*10H@A+XQ[<1;`TEW+TIN-Y\YZ>X:!.\VFWFJW]GK@!QL7'?X^
MRH'N#!]I>*3A/M#PL&83=+7TXX*'\,5DIC5TLV'J'7O_$T&?ETX.QN>ZV=G_
M!([GI9/5U$V<S+C/N7#Q<@*2@TU..%+Q2,5]H>*#$V6VG_ARSV)<@R#Q0I%D
MNTB9<9N=OMEN.<;`&CB&Z_9&1F<XL`UKY%J-EM/L]0>C9Z_0V#RK)X8.5Q-#
MR]VVQU9H/!8..Q8.VWFVR[%PV"/WYX^%PYZ?!R\Y$^;9!GHL''8L'+9_-0F.
MA<..A<,>M9!S+!QVW'<_%@X[0($_%@X[%@X[9/D^%@X[%@[[RDSZL7#85YUW
ML2TQ_/HH=RP<]A@'>RP<MG%=Z%@X[%@X;(L"=2P<MD*18^&PK]-5'X.<_0UR
MGM)!'`N''4Z\=2P<=LSIVUMO<+"TNR,?\JGK8PUN"_"7$^DJVZOPYGOKS`$(
M`#V$;W7M>_.L4XY</:9F\*:=?T?WYD*72':?+F.5M^LNRD(ZMURE2__:!!0K
M@."MKC%/YEQ=+7R?NUL?DO^Y5)(-LTK'+.$^[C?S*"$B=>.815/:F>@MRD_.
MV0(?=:]9['^4I^$_EE4V_E"7#G?EG<,7^97#?>!8S+PT8^%G'L_LK26@]IIM
MIS5L#`Q[8%F&V^CUC*[3=(U1KV&/AGV[W^Q@S3;KY.?SUI^6]9OM#"HIN4\_
M\#KE!WR\T_3<T:!O-_K#CC&TS+;A#@8=H]/N=XUVQVK:_5:_U^_UGCT]MW-6
M.V7]0:3P^7GEF/6X\'G/>'UZ-Z'[I.7%Z.BY8Y;R:>!!(!$&+/*XO)S[ET^_
MX@W.@'N07%+I/6P[CX.P5'K;--LZWB"N;MYF8"IBS@TT%<CZ^H%S@L!OO$L4
M2C(LWS?.S%6#=*H>@3CTJ0O"!:E9OAB\^>E,>X<`1WP<9RQ>H+DQR>Y0W;XH
MXG*'IKAI/,G&"9A'M(W\9LZBI*@>2+=CK]*A/C*O5IU'S.`%)F?=,C)MPX"L
MRIC7C^Q>(K)M$0[P-QGO+I@'/W<B2+HZ$Q"Y8!\D^5VD_3L+B?,V,8O-I'M"
M*8A1>.E&].4!X#WFT)IYGLBBM/1QZYL3@\$C,LT'&Z?-A!],`H_LZ]FW,O5]
M<SO<$@]\0@)$#/L`!8J\8,Y"]./0/8"8AUD"(I1R;*ME`$JB0Q"N089T+9L+
M*D8Y#WGN]E%W\5+S@(4(`R(B$%TQF?`8<_!!!^1EZD`5\.4<BVHR$,@HF&4S
M+>3@BU7LX''NXP7R=-U\!"0.0,Z35("O)[(`WH!7%J8)*1:H`-Y2KQ!0U[1#
M<ZHJ@XD`'!JF8LIA!+$FKM%U0'\)W4$?:0WSA[SME4CA'38M3H[H&LM`0("X
M'M4#53J'Q!&J\F;1<Z68#3)34E<19(4<0'4/^([,JFFF9!+07\I#G)&A4YQ0
MO<M'0K-TUVWIIM-:BTE.`LDJ*E(*OA#[KO-J':<^>JF`8`I`R-@I+<P-V2A"
MGN(Y%^+?LK3I'IH)L,`OU4P@CVH#('%!N5CW=>W+4LW1DC`MQJ,PP#TI-PQ@
MH%XM.0U=XR`"%!:C>5$DS(7&AU[P&3;^+X1<P60AA66]$)UBVZJ7.1=):KP[
M_X@X`H@USA-UH?J5'$E1'+=2\A;&(&<`;#J-^10QD[9+6I#"GN'<1.G0.$-#
M-F=!19UHD.1M-^LI#ENB5B>P1`M:1H`;JAJ8L1`"5BZR!.T$NNLP5$P2`'-*
M!AJ-#G2>ED5_L7^(7H,(N7A/!=KAY.Y=H?Q*.F7L\G<658*76ZR'KNBYAI%`
M[GKXMM;]2):`373+::)R'`A@60C`)01`!D1DU8^AA:H:5_)KMTD$RO<<U.(F
M`),/DT/$Q"PQV22CE^2-H0EZC46A*A1Z%O-4<F?DU*,H0$N*(6+Y*3P'6>9R
M;124ML*%!KKU;HK]E2K3>9.HDFGZ!H*#20Y#U)Q*H`B`EER75ZO!-M$N^#0C
M,F$^]$)+04R0M.AY<ZVK#Y0DHN8>.-J'G#__S<"K*I,,^"!7RJG=DK(6?(#I
M$EFO\6*-<A)CJVYTG2?">8^*!4`=EZ5V-3Z19K@(P)3^%DL:*\X$C`?:'QF"
M@=H!B`SDNL@C+Y8KF"S_K5SPTI>R5#B"D(LC+:VZ!L)#L,8J7IRP(,:UJ8PK
MKE?60598?X93*H!XVZ+(,M#)K8K[O66=.:5"$K,2>7@2@D\<)I*C:N^7JWLE
M>7DO'46K[+GJ!!25`-*8A33Q`TO!4^TTX;P<`R'E/N><Y$.E6AG*>2^`\#+2
MWOG<VZL@HYM-,]"F(LR@(U-Y],A4K)G%,$M,*N:'M`4`5$:EXV=)QJ39+>)X
M-16M?%B?EJ*:K4Q,-UG]FJDN(^-RN;",C>\1&=N-IFX[MC)TTA<L1^D/C8S)
M>-;<XQ=$QJNKC!M6K.K+6N]H+H1L.A>`VV+["UOMX=!QABW+<%NV8[A#>V!T
MVHYC=!KN8-#HF1UW8#_[PE:ABI\N19P:N/ZGE:1)EK1P+U:Y_L!;(F+0@X10
MQJ!/S6P)Y;HQU=@5"T*T+P;8>2.!D`=D#2?%I<F&KWPN8T?I*DGX$G(,`6**
M<U8,)2`V!5AQ;6*;ST_KAE9&NQ]Q$6XMD@`"Q"P)9*@$!+K4WM/,W2*7('_;
MV@0",E!OZ#V@S&0YP"`W[I4Q7`8\9F"`%K@$HIPF1&4QAPG&/S"J*4SM$X*-
M7A313F@&@BL/(E)AA:"9/3Z*.03D"4Y@R.FB(5,&AV9)$@]R=;B@KR)RA+ZF
M,<T>,*Y+^)SA2ERMTZ4%AFI<1D$J1$>G/I\$7I#^1&,K6$7HY`,$,'*(P"8U
M0HR35IE?X5Q&IHH&-><>KOV@82*&Y^M`VHRGE\)70145OZ";2#;3E18,"W,*
M;<3LMNG\]BL=K--&<X=KSA"U,?!BJ_(O(T$DREHM+!DAW0&+JO(JKWH!9T)<
MP!M>"K9?7\H5*&1<V0*`4!N(IDB,#5R4`KT#20/%D&I!*H=K<!/FT3*89"E(
MP6NE44DPC8CYD5=,)\`;A]@OX"AU#<67H?M7D;D'D1Z,'[09)VVTRA?2G#[O
M!CU*',`\B>1-4+1;P%1>W.-*H2H"BE314$A#2<A4VC89<\+<;8K!^$1.+?`1
M</@_'(U;'HI*X98`%S2[&G,(,,I%NP#M98E^3@75HCY)BCF&\:#5H/'`Q1G1
M"/TUKG&F>#$/_-:Q,0P:]!##^BK2_&8NPW")IG8E$%X8J/W-<@`R9@>BB=E"
MR@9$16!E0F`BKA-<UXT`A0Y+!"TM(\;`/!372T/=)">Z6E85(`?_X!03$0!V
M!S%%=%+$9!^T%5*LQM(4>@U`FI=(W(1'$RF_;L;*%>089!O_B03:U36P<D@%
M"@6?2R]#!"N=(;MC_I)OY]KW":PVQDR;KL\:97@D\C>Y-GT![5BHMBB3D8@_
M2M<13>FH6?(9[<,.PK!6M]]JNGVC978[AFO93:-M=P>&;;F]T;#9[G>=!^TO
M[M*6WCG9G&3JO&F$*P/EHC_..^:*LA@8H`)"\"%R"LM/DC47896]O(3*/,WV
M/E7F:3?WL#+/H>?)8R'H?<]W_/)#JV:S^8QY?B]1*!J'+Q26L^-LV*_`=C0/
M7TR>]U#L2Q2*UJ$+1=,^UGKYLIKH.#UC$X@+]TI4#O9*CH?9G)=S+N%XTNIP
MCI,_NL*<Z1R+Q!\/HE3^>D!A[B]84EMSHJ)W]\&"WH:#!;_`AVGR+CKG<2#\
MQR_795$@6\D=YA-<Y`QF+$S>GAC.RFJ>V6E:-IX1Z#>Z7<.U.H[1Z;<:1F,P
MZ#6Z[J#?=1I_67_9)S];[:8+K%LZ2;&U`2\?DIC@4FZ_6.@7$9YQ^8W=()NZ
MM%Q7?8F%TH>S>2@6G,-/7'':`@7G(!E5^MFKARW:IMEKC=I&>]CO&6X?"-DS
MAPVC.;0&0[/I=`&N))]Y9C:K6^I?/+XZP2[X%8\R?B%7V@G>KK;AVT.S:W<L
M8^"ZKN&:UL!HMUNF,1QT!MVNW6TX0V=_MN$57;0*8<@B[-D>/.YLQQ+5)-^=
MD5G=^9YV-I_$Z(;S56E:DP8.@][A3E=,6\<JDU-H8DRYY\7[?!N'C)V.R;D<
M=[=IM\+'S7%!Q\9PJ3N3"7#X!C#&_/:H7`M7.?=K3L(463JT:<<2[9J'(:V-
M*X`JM]Y7(*:8]AO1)M"4#$&QT4X[1=]^4]+C&C>I,&5P0FOP<A>N+*+OQ0%,
M(P)&B_$SGKZ&MJ=6I4##'/?4&&V@<TS?0W3E-A>`+<V5QF^`U@FRX]2N-/=Y
MB&F1B[SG>2S\S$MIE_H59C'P^(JV&W$_,-^3(BA.!8K<.01J%<F!08(U+C&?
M.BYVK]"_O%%U_D_=2G.8_&'2'1O+#;X`MP]9(K#!`K<%LW@?DG1_R\(TF(.?
MYZ$D:86\N)69H<@E&PY3H=@40B0S(S^Q2$P"7>OBU_\/:N$QK=NKGQ*JO*OE
M;2,XD.%?0G8C/LT`VJ^T:3@/O7K[6O(JM-/EID[$PL4_M"=-.X[K-LN58"#/
M:BD=9<*:Q_(L;)6J0<RNP%AH,TR$&_.E,S8ROT/N5*,[DEO9ZAMX?*8-JIV7
M)V&JR7(RR;8&6*IFD3B"H&5B1P%YZ2#.:5`10I8/F=(#0.MF)/-RUS3?O(?Q
MB!D>:*'-=LRG-5B(-H3VB0OA#JJ`@Z5$XSPW!*F@K*%&`3_B&G,P8A$9"+6!
MKKHND"/4=*U4W+BVQR[U^%N96E!M0JFC*J<!'@$EQK291O67LS$.!M/O0..*
ME"%*11!A;AO`8ODBEDF"\*'PBD3='*XZG3P3T31)%1#_+EX&F%$52^M)23:L
MEM(Z!BL-8.!?2@^G#>RJJ:FEL@*M)99%E@YXB[_E\0H$DEM(F4,0Q+Z!9R`7
MY0N`7DF4`M0BD98)*9@2_FZRQ(_<'/B"R\\OV16O"0<!R_,EJD8Y2.1AACOU
MHR+#NM+]6NJ!S"RI,F')(Q')RYZEJB@GE$MSS%`*#;(D,N^!3J^@0<NI[Z.L
M801/*EN1N_RX`.*?R82)2<KS]&N5RT&);86`;O+38,58=+\LJ/;39T%]20;S
M;WG(L9PJ^;P)DJ48Y0)!IR;6!$@4K`#3(+K7"UOZ[3=KK"DEZ!0`$"Q)>V%H
MKE3V#;0+R)5@B!>!\2&C?AEP%%TZIBZS9D2(ATZHSBH=6@8T`GFT,(OKDHB?
MJ01C%:\HO685FY"EF&JG3C3*)&,:,\IZ%1:E\F$T1"CE`0KFYJ.BEU$*Z1/%
M*>411(_/JP<9*@=-ZOX!,Y1$83B(#E-!YJTZJ,IA)G(-94:9(E?E!-ZWWU1H
MCT.`#FL>*54'H>3X\P":3,8\=\>^3Q,*3,A6[#_3NJM"L>16*@Q&+TJG3]9$
MM2*2T),BKKU%?)"_96>1B(R88^`MX\DZ,5>)48.SRKF[^59:S3?2MU?[JPHT
MGP"[",<@NA+AE621PJB.RAMEQ$^#JZ51EYGY=14J=)#-YWBRB0RH&@3ID@P8
M9/XC65V)#1I?/+>HETEG)5253;DTS"+#+A>T.$C^@W3Z'WOOVMNXD;0-?Q_`
M_X$8)(`#D`J/.DSN74`GYYV]DYEY,I/DV>?+@*9:-C<4J?!@C_?7OU75S9-.
MEF0=*)K`[L22R.ZNZNKJZNJJN@*L/\(F62X]66WK^0WRXC\)@J(5&U+9)L;X
MQ<E#:L.4MA80HPD^5A(O,F6)"VG.#]H14X8'E$R1I4E!I-XFQ3V/#G%7;])L
M:K:T]`LK[OQGCY_34[,LK="L/&C4IOA`3,K>X@3B!)@*,F%Y782T?G4AKUP<
M!E$]3UR,TLT2Q&.@DL5HB/'R"C)*'88;4O1[]OR:!W#'@#.M1U^&F/K&$6XH
M"_!!I*61880O!3.PN#&N712[21-R*6D](@L?SE[XYS1!\W7B1@X:+MR4Q)3;
MHG&1C0WM*%"XE$X;BZY%YBCN"3P5$2]"TG1>>&#JTO*^!SN)='[BBT1XROW"
M$^#B_.1;)P:L/M'FF6TUI-C"V&=AIC+(\DO#BL&F9#AE=##`-9BKDU9ZS0AC
MPZ40\0&6IRN;4X9V9A@D=_=I6/Y=&D&,NYOG3IGB/#D>-U++$<'+K68N'-(>
M3DC>XS,FAI&O51+.L$NPK`KN(10W.,8\4#8U,-9Y$AXCGMM7TL*IO4PJ/0W0
M='G")1?<5/5_BRE7]]XN.KW<*)/R-9IYK0JF8PO;K&KQ=.()X_",PC!*QU4Y
M>>@OLCM+\,7+A8AG]M-6?`MSE/$US)V[N%T5_8$;YR/=UQW*0/"?N)5;RKQ`
MBTX,"HVB_)P6H!E>V#=S_\\5%C'X%DN:+L$I/[[G0EC.HD(+360!+PUKF\CQ
M9]W]Y=N!(9B5'"4-N%JXH3DJ3.R-,33TP4CI&-:-8EJCL=(U;SJ*.6Z/NZHV
M[%OMT=GO":R6]#DS`_K"#.#Y1P6>@7U3G:N"+YL19',#.4W'R2V>U*..5CZY
M(OCA!GTJZ<ENV2A*\]`*W,`X=]*\U0]P[YI5"G!O;P!S71?@O@&M]E#?O\:N
MZXJXJJF'0B+]-^9CT<'XZLWJ))H%I?C"N,NZSL@E8^!6@.0#H^%>`LG:D1=6
MS6*)^2VQTD<_CWMZ<+$]PQ8U2S:,(R<E58=855:-(U=:KQ:Q#3;F+K[;S_][
M\F7[\KR@3N<\8`IG);K7NSB=]5*B$3JI2?=YT0(O!FE=WD+O6N>&_SPYT=9!
M2#XTH4UZUF4N_\4ZA)>T_*W7M^%IVB$0OIO%W^1FUC$WL^%AP\,J\+#N9X8O
M06Q[^YD+7M5SEK6>;+6K#WU]'M[H<D<]CZ^P^KQ!",_.<7E3$^NCMLGN#1<;
M+E:%B_L@@!XCCHM?`=(8\FO3BP!2*@=64>%KGK1]]68!^4#<<V+H(:'R\02$
M>8"!K%C2'/,6[#E+8JJ[;<_GGBBZG4$F(2,HSG/F.F%`/.))\A_Z>2(WCUN/
M>(3CU9LT,CS+2N!)O.G(>*IC$>H-.#IA122DC`:[E`9#N#08I^F57I>ST+2_
M$S<4J5.L2$Y*#8:MVTE\'X1NS/-`[Q)WPG.2)L$\YK7G$U%"_%^VGV(?:A2M
M/MN4J[RJI+`8B7A\H8C[^GSXXMQ!$]%]BAL5AXRD8',N(SSIV$G$RJFB>4YE
M)$W<R8:<2IP)WGF:%)`'#^:D8)GDO&D[Q[U<31VT4J#J73G=WDXEF&<ZSG$$
ME+F_0?R0MUSN?N))/WJIP2RN.VV9BR(V&C/GWH=CSQTEF(GQG3\;A12`SPJ8
M-AD>5$8,Y7K"4D8Q%\"%&8()SY(6*[X,C^*G0#NYB*T"08'7*4P>WA/-P)OL
MF^,E5`F!IU/#\SZ["V),6A(9LDJY'H0`(2CGEU!"<QG?$(CUG01#Q&C-;E(U
ME')ASZ(T1Y>D+QTK#\Y?'.75F\(XB\H01:P\YK4CAC;2,<_<WQ0=H2%B5X&_
M*;,J\!T2(WJ_[\V#,,Y]?UBO_?.3/PD1?:"LWPVY@!PYH;+[Y5(=A+JBMZP<
MI8C&PN?I.ZVE9[]0HB#PS^4AKC:!(<19D6H1U9OB^]P^Y1("\YBDJ>.(CB5>
MV88S91TML'A*$D72NR!RJ3*A0/9\R,BU3$6[4<H"N4RGC(3>,AYNOSKWC-*J
M"QV+G.H,JRQ#!$2=6,`J6UH:;F$AEC)\:.$59&.ILU::'[$JKT]:)OKJ349V
MVHX0@+040Q;ISQ-!7)ZJF.UK`@&QT#(H7C^R'9[2]=[/,DZY28$T3GC^%VX5
M5)M?Y.\6<V%$IJ^0^6SQ39(PS:8HDWU%A=/M-/-5,+;$KDT*C6NN`H3PXI2(
M]:(PW)\R.V@Q?9YS<S'1V*9R_H\ILGM*0)A";V<LOGI32&-<GKT42&GE4BV#
M.P'1E`1+HK>%*!4X>O4F$Z714MIEO`E%@*#-]):>C^/\6]J?C)L8^;R56<^E
M\(XJZ6`HGL)STPME]/-=>UN#210^2.VPJS=2`1Z89=F460KA#,%2>.V)J<L3
M8T1>>RGINIA_ZV""$%I?3W*>@L8A[*)2YGB4KN.RTG(YZ@<:X2&+T](@J<*B
M<@#E?$>70^B*!/XTN>+9XC[21X$FE'+YZLU*/A>J66SD,J\&PW>A<J)Z.HL9
M"EF*:@R<%`>MXL9X5:XM0$Q">W2IJ$V.#Y0S@^,!H<[YG.0#R5B]:7?@&2U"
M^J[>K"K`L90C#7LC!PFD>5GB^]6;E9SO1^NU8%GY\:-&;O@)*?8#"2SR.QCT
MO3WA1@T=L'CN;Z&0P#.6D["1.?B.S>M,4%9KOA1RUG*\4FTE<'PVM5/7$_AR
MT!S'(Q$IW=`6JH!1F-R5CY/E\DGO/XSRCZ.??L@@PJ,4)7(;LS^CR/:B((/A
M7I$C3)70D'7?&49)39,AN,0$;F.*-[1V$7.5RW\QM;ID'17:6+'UAF0GN;''
M=5(^Y#!XLCT"&^*KDNK&S'G%/ON.S!3$NT+$IB@UU5U"'Z7#)]]ENMBBIG^/
M)8RP-`'.4#9C#X&7S'B-'VSD/'FDY&1)HS:KXG'IST.PJA#`?A6HY`IE2!L-
MPHGR(E\B*5Y.71Y+]C+:'@@DMT&B%2[/J=\B=<C0:J<#/PQGZMFS&9<YZ),#
MR5SSXWUQ9;FS6>('2NGY=.BE)4?R><-NP]3!H<K\_$?USX`\[BX2&_8*/L#8
M4C"V>S:'11[#1C"$!A[<D/PG4UZAH+SR_[_A'^65CZABJWAX]6:!BQM57(EI
MQ$P4?[1>-5T7JQ;I(&ZF1AN,91G9&[]<SS#4TE=OECUTA+.Y@?7<_Q8S[G_+
M-%A>QR$[JPA%B+X/D+.RHR]5>_P4M<Y_MHWW;.'U1?_9!N\92LAV_K/UWC/<
M=[?TGZWSGEV]V<SOK3QF5V_6^,Q6>,SDU$17BB4RN60]X[=8J/4A/^-\XWL#
M+,'6ZB-5C+B.^9PL2E)V?N#ZC(0NG5%^`+)7"5S1*%K*>4==6$02EQBY6`@*
M/)>=.9HU/E=CN"#0U_J,?;41VYDO-$->47YFU>EL61P*SCU^.#**#I7<;1:F
MM=0$-&!>7@+5TM6;,H.>HVD)=UUJ7PG8]/.?QY9=C$6%1UQ*=1J:FC%W\<$Z
M_.UG15.UM$@>KW>$%">>N"[`;U@PE0N.B_0.@#0"KEB?FR:,8,R%#S#K.Y7$
MDHYVX,0,YAF.DAH0FTHK%Y0OZ#NA,=,[,$VBW@PZM,)R729>\I:;6T^EVE_!
M(Q\GW]A1@=D(J"B*A$2\AAK\P-F`1X\<DCV7P6P8&8)A.%DZ\GZGM;2"#0KJ
M9"OY7O`Z7+W)_5K%*9336JG/2>FCS0%P>9FF,U86><\7[ONB'D^K*N2Z]-RF
MXI?5*B87WZSZ*%7WM)TX*9\'KJC$)99M6UG]AQ?\*!=<RA;0"GMHDCF30.TJ
MPJW'3PCI9=PC^G)Y.3HZ9Q1]&(63/S_GF(;>LI;.?'*.SIH=B*R6M7"$6GF4
MC.3TC6YGU6F2;YV;WM,L=<V+A1-8D:CRP:V[]NU5[NSBR>U/OB?0L3(]L17/
M:W!4H]6:'=L$CG/YR";P(8NG-CRLII6=Q#A1&!`9%4W#S*6LJ?B3KG[/#WAU
MABX^I(-PX_HL.P4SXQ*GK2"^='K;VD,H?-9IH<+]/(1T+[KDN-K50XB[8[2W
MA_#JS7.,WN@A+%T'3:E:]4X>PBN>S5FZ.=O1/5A2;L)!N+-[<%=3;]D]2(S<
MANU%9URIB.>"0.9ZZ9WTG9K;KSD;\S,D.:WYR7$KGR"-^KNB?VM-HWE$1[G6
M'TT!(8]G,-?"?P>;$V-%UR,R)G75+1.]T@NWT#@NMI7-`V/,LH^N<%V3,^;3
MO4T!,EK>&55+_*G,@HVO2WIQSQ*O$Q=UM=`&2`4:DLY]$%"-P"`].&81+N)&
MK5B4Z9ZEUEC6)SP53!7X'RP?+)_*>SRCK8:69O5LLP]!C&8RG:135F+]1BKW
M*]-4W--*3VMY4IDK=/1%:9%>4A_<6Y1.#?P`Y/*EO1CD"_HM9@J6DF+O1.PL
M7VG41+Z[<DT2E:)]85Y+;IW<&U0H*9[&I*1ET9'QV<"B@ITHI^56"X;>:A-T
MP>0C/[]I;F?T62L>$Q;<,\:?WEMKA>552U>\MXWMMV#YH2W`7VYO;_HMN.RO
MWI2=]K1GK+7[UEEU8A_)[;I55AVZ^;EQ2`<Y/+"FIP(1.8:"6SH1E$X`^9:,
M&W]E@I@.9=`M^2;6&'"+YEM10>]TQ5LPWS":8?<KWK+Y=O5FYRO>DOFVM26Q
M>,5;9.O5FWVN>,OF&[<LG[GBW<I\@Y9VN=]=;;Y=/1O]L]%\NWJSZ_WN*J9S
M.=_B-G6-ZDQ9F-DTF4"NM+/*-YVI^73U9K,!Q>VBU7JP9-V@TN/V3?[P:BMI
M=6-E<^GJ3<%@RE_0U]M-RZUR`PJ7P!H3:CL#BAM:JTRH3$WY0<$/B(T+Z4"I
MN"J`:1#>4B$J#N/(7-H$$M_#<MFS!+=;E!'NBZ$IIG`[&JX=XL-GO'A=K*91
MF0O8Y`[1C+(KM84;V!U"W0L4MJ3?,VV'.T86BU$**+MZPV6@&!27]L:6VJ0;
M3R36G3[E:&C"(9[>7*(`@G:;%*\A^6%EFSCZS!2,L(@Q5F?-8(.DJ<N\"='A
MV+`Q!0]VY(`=%&;7P>B;!\T)PP<.Y9?$Y*X78:HMZ=-"B.8B/]*(VB+=Q1!@
M>"P(O<DCEKA/XZIY4P*9.3\JRB`S?C)%,S1D*Z[%/69/"OR:,"S0;O,;Q*M2
M]9>4!;!OA%$6M;D@&?F"%"&P8N4MY2A0U7G82NX3&%_QZACV(C0",\G!!E;*
M3GIIE%^7XHT!*]#G<=V1X4APT(BHI%^\/`A2EA8B;G$J,^91P?V</&"4$[JW
MW$=4BB9"@!\9@P1Y#7PGB&!:>=AHS$M6@P+,KJA\Z?V'D234=\%,+4@VDI]>
ME/&;Q*C0GKBCMGT?[THC.T>[*P37%I<IWV6Q7/]MX6:2P],\"04J/89NC`A'
M.;=I@TJX))?6^$U)]\.@/9=1X6\"J"D,8!7A6)0=QO(?O)>VP[_`/MR"%46A
M)'L$#8(9"1FQ.R+%,,<K=[(?W.QD4KQL0@E,[Z8*$[^T8!9\_KDS(A7IY5N$
M.KN*MU'IS\34XZ'7*#IJ?.FC$P>WT"YN0,L1".N"#S::T(<./N`7M4+=RAD@
M6KI]+440E`('Y%Q;<:N9XVJ2S7SU9A'T:(EEST&876T10\D5"$)7HI>>;L+S
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M^!PCW`J<XARZCNIGXE&*LAU^_M0O!:]>O5E:J?+*!-#"61C18+GV7C@,VG?P
MS)TP\2GS:7G;$,%=#A]UA*.^>L-M[A26"39Q1R`>+[&*;O-%NM4\`=/9(:_2
ME-#'Z(AC"T#L.6:7W]..\S<>'\0V4'XY>Y6V>9?N5<J6GTQC(]V21WEC0\A*
MVM00L6R!%VU9MU19554^@F@5U0MC17U*HT76F2U5A5,,/PG(67?PHCM/A%F&
M7NYBGV2(7+VAQ8HS)/-\ORDV,+/_8G2/``9HR'=1"2/R8!G3N9Y^$YEU>4RT
M>(Q^+(V<P[,9;4N9P+:7Q8L6SEPHIFE.97;H6YZ[C/U<?0N3-PT<)C?F,ZGU
M*1`?AV,#]3;C5(CM)<.F3B^^HCSS=Y)"KI<7%!WW?$2K$`:]/<,+GEEAZNDK
MLF.>>+IQL4T:B>W\A5:+R%[,K/Y\KRW:_84TV#^%H<XW8XI_3WCB-,9<Y]9X
M+E:EB9GDR-F@CA4TJ+FK,@8QXWF?`]IC:$=(OT>[EEZ/8K!#>;,1&"T>O3U)
M"CK)E@:P./]2/CL($,O!NC,'Z0R4+1Y0R=J"I_A9AI^A4ZV<DB2CD!N9'4KA
MI3&,YC;)SQSBHN,9K<A=X")GM1RDR]LH=41SG"%]B63,;`-Z]EI@I8MI8ZPR
M#ZB]6A$[O3(/>"NG)@%*H3X0B9WYL95[SEN]/)@9O0Y\'8)=E-D)SP<WK[B<
M$Q?'PN<A#)Z0NS4FV\4_<TDN1$!C)OLN$=#'<(`OUI.MGP.\0.&:S1W>+CRT
MV?\-O6WR6=^Z`:WY,,V"R!1XY'@L#-!)4#)*?OV\D$^SVI]3=A@^YD4>BM25
M7=)I0/<47B/A7^6BYMM2*>AC@;?X*]F67/I!?D&JL5GA&`26S@/N?RZ>AW%)
M8$6#S2F+XK`9+8>Y8SZ(?><3PSAL)1T3A!7UZV>QO6`7\*'DUX</5+M)Q*SB
MY>!J;I&'99%?"O%KF5MRKJ@*I30BVLKY[R]BYS7?89">O&;'PD3=PKYR%Z*+
M@ZS&O*&LF1^VF9:4Z<+$X)MMRFMB[C.,$PP@C39U0R`UM0%H>K+C?S$'M%!_
M06"*<\U[M56B4.KV2&*7;DE6$G]5K+!4J,FPL%\M7O:L7V9N20UM4YM$;75S
M!]-"R+3GWKE4B:*0XIJZ\E:@CZ<QZ$M'"ZUE+)TL4CL@S6D35NB*^DI;&!5%
M^PSO&#864MK*+RLL\P/Y9<66O=(QR^<@,PF6';48;5%RU6[OJ%W:O^/'8(7?
M=K/7MGPSFOMMSWXR+^=`%;(XMY4:6LN(^(M*DX>D/;B18`.7P=0@P^GCD:/:
M"OX@/T1U-W[<6W(L\VXPWR_B5=/*VW>>]Y1>"O"\SB?NL;%A`I,9_.;A13&O
M!9063\(#M2C&@@E]*]8LJ37?%]$I1)4@I>23*SBP2KHSUR[!:O&[6JS6<G[1
M>+FW=!OY63+6UA<LR>]V7X''M.R3,80"^0#Z:Y9^5[[C6]Y5<C[%6`F:NWQ`
M41KY5K5X6[$Z#+^X3!=C\%='06&ES4DI77JS19@9T-PM%@'#\48GSY%$!P39
MTRP6P5*+\?]7:;X"2$)Z5_Y<SX5^><`%GN5Y!"HTAQ5'7/0/8"D/=!30G3ZF
M]^<#PFQ(M$MYZ,23.!=?K<'[W"&'=]OE@\?API264WFSR\0=S[O%0E2[GG?Q
MJHG#=I]?A1W8[PQ;"IG8W-^\7H?E[N2K-Z4SIPNKFVH/`*]A`F+:96!7F\$/
M&,--':0J!2Q9QYW3>4'L5CR$4LV7+VZ"I80-/D(/`T0<)TSXT.E<0C-)G:;T
M:+)NM67=T#=Y;`O!F0AT+DK=;'!K+H81D,\WZYR2];D#.'7ZYE[K;7#;=P!B
M+R.X?W;NV23QV,?I9^R+?(+#8`;J)2(YH,N$C^1)C?H\P.CI"\8K'1[8O6W=
M#,?:S5#I]0:F8G8&;:5O##O*6!VIIJ7?]`?#P;/`[K_V?_OY_0=E\/'+EX^_
MOI-H1=Q\_/!%^?S^_XW?25K^Q4W_U_>__/N=M`1<()KX\O$3/$^K\,OX_WY1
MWG\8C3]\>2>9WQ?S?3<@IO-Z9,BAM%*=X%]N#5WQ.B'2)S3RTN/G4X:/O*F2
MVS6M!P&4+O/#.\:NYI<=?%-=4%ZP^]B;8-6?XQ_QH\BA7;#511\[SL<BICI7
M5/.(O=T6K+VG?[^$HIMCMQ>'N09>76O@U9NNU^$7%,2Y^YPT;X%N<+S:\F*\
M8CVE2UQ4<)>T%#YZ&;^J"$:]"`=17E8IY\AQ_B$IZZY@2C^%TH]B7%PO1@NN
M]H,#D6WQQJE9\R=5QV&3!8;`N3*T[]C"M^P;N@VCQ:_)7C@Q[RZ8BYE%O_!]
M88M<^`4WS(6O8-?->4#>KA]>]0ST4V?L`I_`D@:K-W*=A>_)QWE8CFVAEI^W
M,MXN@URM'M0ZP*K];,Q?QC=@46H(9%6R,17X*NU&&-]@3L99]O*F(K_Z\G&A
MXK"0IMS15^,R+;ZZ()FG'3C^N">\DM[2M#,3N!=HU5F>J_28#Z-M3J=;C(VZ
MY6=^H7EQ&D.3N^W5R.EUT1CMEJ4W&J,.8[Y\^V2S#AF+T\GE:9'KCK'W&ONA
MPKI#;74;:Z,68ZZ7M3'$JS"/37Z<!N&482;4CP*EZO)4AV[M;7]46748C=E1
MDS%OHSKFW[;P1Y^`&XLJ2+BOZ'XI]UT)V/-5"^*E\*8'[7"_!5M%&;I$N;_$
M,5_^$>&P+DQC/WO`*Q=@+-_+;1:#76'67VH_6++5ZYYEH]V)2?NP9F_+H]VK
M/D/.*S6=UB4(S5G$1]=DK7UDT[5N)I61P;B?RJ;:O\?&J&K&7&_?R683Z@\6
M$:)M6$BH"22$57SUEI31/8_+HL*6U'ENTR](:L"2N@"A.8\EI<I=]<@"U%A2
MC27U.JV22QQSW=U3X@:;4A1>MS&ER[IYGKB:JAI36DNOO:'P4JEIM[3:\VA?
M\3'DKMFXI1ICJC&FFC&O6*T_4F)D\8NEU-Z79^BNR_B]L=WP#TS(Z$<1BZ.^
M/_G%M=.:]+_R$GZ3C_YO#)/%7?]N@*5BCI3\.QKUNJ8QZBH]0[<4<W#34?KC
M\5@9]ZW!X$8?#;K&^-3)OX74UE6IO@++G"?Z3H&7*``)D^Y=%F)5"%X5S";>
M7KT1"?49?],:B1,T.0MO4Y&>,&6Y*,]#%2PW)`-CVY1(7,H*;O)\=\SSM7J[
MY_F:Y\MX;;H^2M=-GN];S=R8]7>3JRM[?;W3JS?YH?GV4.>19G(P0W/#W'S!
MFD:'Y7G%*?X%J\=)VBND67]]-!<TS,D5RT4[.;F-OVP17OZ)JAES,^:Z!($\
MET`3W2.&A0M#P)/GR1?SOE[0CJQUSIWAWQ"[RSBV(WY-I9"<&;FW`(X"YD%'
MV'#J]-<(U3:`GE&>03CGJ`43=HO`.$X2DB?N]";12X.7--G4VI>^;E[60@47
M4",HC:"<4--61J]BP5Z"%^6U<B=L'D1N?'%:5=/DCG;Q=EOM%DLC*(V@-/;K
M%5[_EJQ65+6_MSZWI#NL6>]CL6^%4.4#NE.^8[YSD;:MK*H75;SF5:RM1DX:
M.7F%EFT.V#:WYRR\.&7:EM5.LTBJMD@:.6GDY%#*])+BNE]1!:>&?PW_&OY5
MEG_G<15L/8]>]=.:-$,VVDTMHLI%`%2?.;VVK-6[BE43)%"=`_[FF,A"NM.>
M@9$G7&_G?*ZAL:'QW&.O@@EW2M]CCH2+Z+41HE93KFC5]=3>)J6L=VI=`;3.
M=D'#V7IRMN(+>G$7*'=S3_"0_WBKM==O-H5G"NF/ZUYHL@\/F1IZX/2U9G*:
MU-#-*8--CNBKH+F@:DZN82I^Z-CL#[G4_#*C)QMMXRQV6$-L8YY?&*?R435.
MY$,HS=KDE9FFW+6:=*%ZJYA&4&HK*+4W3VN2:=:6]6,7V&]63PW4;",G5923
MNEFO%Y_C8)X)RJ59))>E3!LYJ9Z<-#D.Y^IP=W%J^-?PK^'?I?"OR7%XX3U+
MKRWWM/-D15:?.6>\A*H^<ZR.;)E-BD-CDE9B2WM5<$H-!QL.-ARL.`?KY4&M
M71)9'FMG[6S3OVYZ+_\"MDE**AFCFBIKQ@4`XC:6?,/9U\/9BB_H%R!\'@"1
MLPSVB4"A(;MG?N0^L/>^$\S8I\!SG2?^[^%Q/(<CS1QUU([2[HP,Q>Q:0Z7;
M&7>5=E>WS/[(&O<ZG6=Q/&=V>.?Z"FQP[S1*V1%?\*EY1YL:"HP2N?]E[[3\
M\]2>N=[3NPVFXFTJ9"[^46*/]$L0\:!--Y/$[/'5*)J%@;;7C!.YJKC^A/GQ
M._/[O<9='J4'HY3<2)JPJ>MCJ==(BN^9Y-S;_AV37)\"^.,G:9(0@*@-#<Q9
MZ`83:1H&,RD.;3^R'8*+)=S0`-X.)?9`4*;PQ8]!*#ENZ"2S*+9]!P:$[T$K
M?N`KP:,/#T=!$L(/+>EC$DJ![SV!^,SF@0]-8%P6;]%9&C6T`>-._)#!4OLO
M#/W.=F$0U_@;BWX@Z-,'V_50GI5I$"J1C6"B64!M:XD7"PW<V_#=+6.^%+*I
MQYP8^B!`5(0DM6.&17)Q%#A&X(F=,V%YL/0U\-:&`<QMBN\M$@FME)O%1IV"
M?03-35F(M7@C!.C%YN`=^OL^\"8LC'(5WOLIG;1KG%7'C7_@V+&>)^8N2M%F
MV:2U;&PM:91ME_T",O!*?.%^&*)D$9&#I_R93_83?M=_M,.)@!_^&9Z,H_?^
M)QKSGY1:R29]X(E]Q\;?,,XD8I]"UV'[ZYO$=_E;;A28NM;Y^OOGT5=@TM<(
M1Q:]A77AN#/;BRA5:%$[J8/>S7!L*KV;GJF8[4Y;Z=YTQDIG-%1-P^RHH+M`
M.^EO_]EN67I!0Y^.,^4I&?%%#H9W'+JW";;UR;/]\6SN!4\L_-6.G7M8Y:7?
MH3&4T9=S>`Z[S69^WG15=="YZ2K=\7"@F,-13QFH8TMIC[716&T;?6@7^*F]
M_:?:TJV<G_N3569/ME]NL4W^[@>W$0L?4+N\]^<)T`@L<N`MFLPC0%H/V\-N
MYV:H:*,;$+9AIZOT^UU3&:G=@=H;:X.;L7%J2&O$=4ZWE8V8UH1!76`/JC=4
M>`4$:VAB$X;UWXD=QBR$S8%C6"<1=A.!C44QO#Y"6B>%.0%-#9,"VISG+1H_
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MN.V0JGIQIT&$YVMR@XH3MBRQ;PZ#`\P<7<3H#:-V7MW!NZ>_[.!M=78_>+>/
M?>YNNCYQUXVCX]E2@Z"?T"4IU%8D,1^7(@WFE*Z'ND^#OC8B88W_Z5<[=.Z+
M)O!AIV2O-T[$AHP'_TK\@M/-4%\/"XJ2\!G,@<4#T2MEQ:JCX<E5U46?LS-6
MHE'Z;H%W)_6&G>NY9J2O8J3U\G/_AJ%%R1G*X>V;VBCKQGF2]TY%H2EWK/,@
M+9R*PK:L:?6>0TLVK9/&L=;/GOC(0P#].XE]PYBN"ZS8V94[W0N1\Y>2VI/-
M8U\A5H=453]W@><3D8K!`MJ1*XG6RYSZP&**3[XX777=D75];[/CATN09B#1
MV+_PPV60J,M:>V_#XS)(U.2>WCD*B74WJ?#6UI%\H:+RBT#L/DI6#:!K??^3
M],?XMR_OA_U?E/XO[W_^\$Y*!WZM\4!">#4[*5_`"?):;>E[UVT]R1)I"%LB
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MU>^W3`0NZN;T]4(U+X]-XY*Z6S=/]/[B2Q^6E"U6Y<3:EJB+H1$L5@HG7:Q8
MZCU1%CBSG?NT`%R6;9D7I,1*<B&#!YF,CT`343);>!Y:@OX4WI]C>T[BB?*;
MCZ[G87D;V`4<%D5VZ'I/T`2#%SUJP?9]_#,?;N'UULY"5C\AT/<0@OY\[KD.
ML<)VG"#QR<-QE[@3+&4"C<S#X,&=,*PM:\>23>410MN)I>LH`6$016=U55.E
MGS__K_0AB-D/_%D7"P.&;!Z$,:].:_OP;P12!Y*4E@_D<E7H>IZ$\R""_F;V
M$[W_=^)BM0%X=_*?)(JQ7AEL\]2KG\S0)P,-"!E+[0AFASXT1J*-4K@H+;Q3
M_TD4RXVP^))+U5%I;+@HB(3'(/$F-(HH\8`BWDO&@GM[DE:9+5$I:KBZ?A2'
M"0X8FA!5>/%]7LFU)8F\Y2C])I(+-,)Z@+4$7)@P02XTLA7!*\B%!GC+V$:Z
M[.'+D,V"!T8M805=41BX5$3X(2U"Q4>P6(HJK435DOJ%H8OY`<T1S%R?!IQ1
M`XW0<";I%-XR(H>7;<7?;E$110F0E<QA\+S+**\]N6D8.ZN!356X=R@;LJ[R
MR&_,PX)>GZ"AIR^%BLM'*CK2'_2'_;%J*EJG:RAFNV\J`]7J*49[I/?:AFET
MQL.=JF[KQZMFO:KL:)06(>%JQ9ZA6L#EZ7C)A!=Q#A)<TL&2-Y;7:!8KE8JF
M1?S-A(HODVAC#1G7H8JE0J^!C`$1O'[`9_&KU+\+&15&W+YR:(%^9%F!A6K^
M,6?@UD;*+C4^\]UD(:\YVZ?2/S;.3W$RL;K4^GSF=05#F[HE5>EZG0MAA^D_
MKL]E-^]+7A%$?2[M/J64+XITZ6DM54V3^M,T_Z6`D7_#;AKE(T,+>))_7%G:
MC49_N^WT/\>UNL[:4L':'2<IFZ&LD-[!6'X)).NOC^1C5\98\HWNN-0T=>U:
M6^=/%;8`GL"(!^@B+5I32OKE'B959L&`=82&*I@W>%9(8B68*G,P-,'VS^RE
MN0V,!W.[[_E/GCU;,D`JZB.UK-6QNXO;P5E7PPOH6^UQJPMUJQVENU&WOV-Q
MTV%ONY/:NG/>,(6$B3Y..<[*%_O;F"^U`?/9U(V/=.0;=/JCM@6G/:,_5!73
ML#I*O]\>*;V.;O;-SDAMJ]TJU9G<XMB7X>L0F`X<^%+G3&Q_@Q:N;SE#?TAU
M60/P\#*`!^NBSFL;1GOQ73=5!K<XVI6,1#RL271$NUJ#`7.:L]DKFJ'="B">
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MV3CXX[XE%??'\ZW<5OP2-FCU<6*_@`U-H,:.NM8`73L)DEN/G4J[[]]CE3;%
MAF\-WUY0&F/GXA;E*AG9*Y_`3'*>#E\"P^KW!N.^>J/T5/-&,?6QI0STT5A1
M;_KC06>@CHWN;E4/NVNJ'NY1D@?[N$UUJ(M_"+L'^"$@9-Q,Q68/KJY>41AB
M^[AU&5?4@ETLU(H?$_@^C&W7IVJGHDH'-!$C;508V`G=6\8+,SK!G>_R<J3W
M\,M]X$VH^/N,V5$2\GJ+=AS#"TE,-3Y#-V:A:U-/6!9DFE;A!'[8,7^AV.QB
M8\&4#T6:!Y'+:PS']E_,QYI(:&<Z6#F5UQOEWP,)-KT0LC@)?:K0BDW<!Q&3
MA(F:5B@5'?^7363Q4MJ+-$NB&!^9!2&3//<O1G6,XWO;I_+&_/T('@+&I45.
MV3>;*J7B^[=/V![P&-ZR$^@=&.&RJ+658!RS8N>?3$HB7BXVK]\[8S#""19J
M61".O&8+C%WZ'<ML$AO<2+PC2Q,18D7\H]K`$<UBVKJ+HA-B(5F0A!ER"UJX
MM2.L:^6+`KA3:(*A?-ZR^!&+\99%A9?FQ3%AP_@;+R*3?P_MN51H9MT`X#,.
M0H@63%C$YP8;8[[-Q0BE!H12O&X_I@63X<4%60,I8S!H!XOQ/MZS13JBI7="
MAO5O60OY+\J62C:\#%M,PB7&QG(ZM$AMK.,;Q53E=Q5W$]]C421S)D(;)'Q4
M:O7!=CTJ8\.P`VA+EEPLXEP4XX(0(W&\%N^J;JB6-ZT2V`9AC2S+[O)^LVZ;
M*&\F-[8;_H$UB4=NY'@!SDAT^!VE:P[,3E>UE+9E#16SK6I81[>MC#LC4QL-
M+4OM=4Y=5$E;J.M(FX4)2@HX(A%+I%]S[1=MLZ&<L.P3R.Z]_8`%;6G#**S0
M-<L.%6R(!7I!T*9`HA!X!FO&=>YY8U1\V_&@!7?J\O+;O\!B\21-EG14\P9(
M(F@<H12*K=R[++1#Y_X)7YJ(C8H*#,?E_0_4M#^QPTE$2JW41F&SV:2=#RT'
M^@8V;Z[GCFL5M&A$9`@B1`5W]HW7_+["TLBNPPH%T,5VQ]P'K*-,E=/S0NYI
M%<$82Z:!(B#-E.\.UU@._1LH$FKTAY2_\`DF?PZS#TW,`E!8]N3!]F/[C@4)
MEF>&#0R+%:9;_XJZ\;A9XU8^(4R!.*_8EFX$>2MS&S0]=H<5Q>PH+9Y>M!4F
MH+M;TJ_+S^,>#/KO-GE"K`,4THAY'OZ]1(KH+=7[\.:U6W!7%.`49/BE^--?
M<++WV.2.X<31C\5?:3;C`'<<0:5,`[EV'PI/H<JEBFI!]A@!,N23GY;R1Y)@
M5B(\`K@1&/F%Q<`W[GF"6T7$UP-G$^WJF=1P>R8&DK^YLZQN&QH'6+#M%NML
MTZA%4V29N7[Y46@#'D[\Y<?!`.)U_WG%?+[3<#%9>A@-`L;'2IMIMH^UI(_+
MXPBS/\7P<<90Y(L2PH4>B1'U[]/"_2ND4!@'M`V"X@GF,([,0!$"`;)EP\"%
MN4>%R`NR($5!$L*VWX(V?E_!C,4QAVSJ@6E`9?%@0,ELSDU;^S9(8F&53&'R
M@[!$Y"XDXLP4B%P2(Y<LTG0JUXE+-I9,U<`Y@0,#Y/7_,LG;OVA?^Q)K]NV`
M_[%0>VX[1T<1+$1?`1:277#J^O8-:;L/8;%?L3VG%?VCW`ZX>E,`S.";+=_I
M_TX"-(13,0ZIP"WI*5P^L-DMOHHK)C=G<9^`?>&!B1:BW3$B&DFLK23JNTAB
MC/!&184<X#?\4"2DE(LGM2`@*X0!F@I^=BHL:/K4RLE[E1!<!_?IJ-PP/1K!
M/NK986F02U(NBQ=3>VYAR4CKVQ$-T,`Y*Y+I%'8.'-9#X"4<),?UI[A'$QI/
MH5JN=(WG2S&6S`*+?N!VWH1YRB2$7_S\\$I]<OY&,$-@R#NP115V/]R-<EY!
M._`[[OD@KV219@88@E3!YBK3,T$8!B#46-(7[`FYW$AA8VZT0:,-,FU@[*(-
MBH9-E$DCF7>9<*,-Q)Q[WX654A#TP&=\08`>6"OT1<M8%@-#DPEF&HY).)H\
M2JGW$RBC1[]H$!Y/L/>MDGRL`W&A]U7%I04^7406<V'2RH<>[H6@HU'9#Y&Y
M_80?0KR-7C<\%2=AF#L1;32=5Q:A180T@]K&PJ"OO&!U3W]9P6JKMWO!:O-\
M5:.;KH_2=5.)^:UF;BS&>U/R\@73U:H)!G3X&LW-Y"SCX)3FYDL0BVSF@_&\
MXA2+$]`KI+E:P$TGH;F@84ZN6"XZ*K9/=NBKK`;>C/G5CKE>M4J&=G1/(-`P
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MT>Z>Q62X`.Z<+P*@^LSIM66M5VO):8($JG/`WQP3^4N>CM.`L34T-C1>#HUU
MO^T9!OX#7JQC.IT?X-7ZW'ZBO,JJZZF]34I9[^R-J=;8!97T:3:<O7#.5GQ!
M+^X"Y6[N&0[F'V^U]OK-IO!,(?UQW0M-]N$A4T,/G+[63$Z3&KHY9;#)$7T5
M-!=4S<DU3,4/'9O](9>:7V;T9*.]-P#*N6[M7PVQK]`\KS*G\E$U3N1#*,W:
MY)69IMRUFG2A>JN81E!J*RBU-T]KDFG6EG6UR1^JVNIIY*21D]=HO5Y\CH/9
MTYM%4K%%TLA)(R>'4J9-CD,38][PK^%?P[]=^-?D.+SPGJ77EGO:>;(BJ\^<
M,UY"59\Y5D>VS";%H3%)*[&EU0EKON%@P\&&@Y?.P7IY4&N71);'VED[V_2O
MF][+OX!MDI)*QJBFRIIA-I;\95KR#6?KR=F*+^A#H6'NB%:)D(VI=&R$JR1X
MR<!WP&@A+%$,I4&4X`(X)32Q"9[R[\0.8Q9Z3P*>,HFPFP+@Z%49933%'[T6
M:*@_<#33M8"6NA0'5QL!+U\WSF77?!G.9<?8'>=2UQK<Q6?>/5)RB^C@%O_&
M]+I\%'_@DLP__LJ7["Q-W;@-I1]%`[_3"OV<K]#%WXNK]3VMUH4GLK5+I-_N
M9"A7[IKB=*?#@>W9OL-0BZY7=_N9SR_8J<^]>];<)3"\M_T[W/4D%L7NC+#B
MBWOH%%;\04]29XRKT63-M$YI4%V^1[ZY9*Z3]C9JZ_PX0P&'2U_:]773G_0<
MN[`D!>0[=/PG[)ZWL0T[ZSQT\9@$F^PT"&?\($NGRK^3`/?;F1W^Q6)Z#+-%
M0OX]GFSIJ=LP^(N%T8\39GOPWQ:V?,=\%MH>'&LG#(SOF>LS.AB7M^X@":$1
M%_;O*$93NXC)(0[",9Q*[7`B+9V`9?BOXR5XGH,V0C8/0AQK'-H3!C_R08DQ
MB0'#M^X$#NW^Y$<@(IA.<;3[GW</.1GO?>E?B?>4RQ#:LK+T"/H2&#-!WX$_
M`2J!'T0EL!*>4*6?/_^O]`%H@T?O7>>>.!$E'C[CHGN!\BC9MQBXE+C1/3$9
M)EFR'2=(?/Q:FB?A/(A8U.)>:9B`$)Z"F7MTXWOJ:44C-#3F,2<=#4XL-""F
M=LYE"#I:&FF+/"HKJ<+GH(WT21"XX,'%IVC$4HA>&##U@+(X@,\^\!D>F;E1
M%(1/9/MA-10&\^K$[D-:-05'X'@!B=,$<TOA._*[>.[TB8L]2!P&[</*=QUH
M@20#?[G&=W/WX/"G3T$4*^\_?<S&F/\X^NF'%D[C1R<.8&^CPP@.)YFC6R@)
M%[K).I%I@$L-2X\V+C!D#3P>W;.)3,Q:XB<^*$7N#";=]EF01#!S#NZTGL?Y
MBP1!$W>TKB-L(&3`OT?XC\27)C*?5BW-WJH^;'1#H8!RLG(Q_<SF,>WEW->$
M(X0-'AM8$#KD//:1RLAD#=G,=NY3IQB0A19#?&^7WD>76TC"(WVGM3K2S/4\
M%#>8XPB=:@L]4W8;"#!.)KP]<9'Q#!N^9?$C8SZ-)(#-&CCA2=]9+35KTK'#
MD&2$R[68`&@%_O4+RNP'7&T9?T@.H@0TUM\)CF`.$QU,0/TX=)B)X&'4G;DJ
MO+<?<#309$;;2N<@=.('OA)`@W;,%1^S0Q_^XEJWP!EB!JEG)SM!97J7T[!X
M<$K/3?@$,%;+N(!D?V<4V!+XH@E:N.0D(77.QX52AJ\XP6P>,F!4A(N1#TAH
MA"<8=B21"MCLG,1VB*754-/`XR2B986[3S`#D9B#"D*9=;D<X0[*-4R1O;<!
MK4.<`+Z]SH()\R18AGQ.\$T_4XZ+;_*G^8Q%H!!#L7I(K)%#0M_"3(<V:.30
MA:.RDRF_O.&_V!/MM^1!AL[Q5SZ2#06FRA,A]-)#X`$AGAL_2=?M]O?T<\?Z
M7D9E/N?JUWOZ`3ZZT5_*-&0@FZAZK]66H5O?"[6DMDQ=6WZ'9`=H=,$>``&R
M)])UIV7R/GHMZ(3O<ODKG+C"D`2%I.)@Y?#E=`]<@57NP!KGW;NSN>?";X47
M@0=S!HH'1=?VP0QI29]*GZG-=":B&%>WV"9A"^6R`4-^<+D>1G%/MU>NA[C"
MY4NWT"\^"*-S_E+X<+$_6#<D*YRZ!49R"J&1,HVTMESF30C2[+/T)20_YI/T
M.0[=>22FF70L5ZA?N"8H<7LE]VSQT".86?=@S46XQFWO"=52,.4:$3/@@$U/
M-%/":`PIPQCI(QZ&PMD?VG@V(@DFB81O$M(CRPO]QXG[@!__Y\<D4NYL>_X.
M/;?DKQVY$>[L"4C#%]#Z`P\X^$]X3?J?]-'/R0P&\O1Q^IZ6ZQ?[&Y@XJ#HY
MIEOV%DYH#!]^8]-_O&6!]_73N&MJ1D]5%,W05.5_555K?_W\9?35:%M?<45H
MNJ%]5=]*[N0?;]W)5T.SVJK:_MHV-+-O#53%&EH]Q>P,3*4_NE&5KF&UVZ-^
M6S?ZO:_XXC^1-D':.57:JONMB+CF_I=%W'K*MBWZ:,_0=,SM]\3'?>?.A^=!
M+]G?8"?SV=3%2ZKF:NDE5TOF[E=+UK%OEEYGU\U]VEM-W5@M[M]@T4GC308=
MC>N4EUUUGY'-Y?LR=^K!6%Y]@E]7@48@^,!5.&M_!\'@C(_6-]BU_#8"C)BU
MYLM^EQ&GOTJVVN>I]7YZ2DWUHBIEO8!2O7ODI+=Z10G`Z0Y/NDRZGC#^UP_\
M\!VZ\"]ZFVAE4XTK]$^=?&F_.#3`Z%R:Y+^49.NBZC4=@N)K?6]%_L-KWM:S
MU4]N)GY_58=%;W0O;KM[L9[3+JH<\T%(-H^LVNL6&%*?F*^&?PW_SLF_>AT"
M<DR6.D80RNJ9:NY5GS?G<H!4GS-'=YC4S;:H4]!IP\&&@^?FX#.!S\NQ'=L&
M;)3#//Y/&BAWX_JVCR68W^>QS(</\E!OC$YGT!\JHXYE*N9HV%?ZJFXIO9XU
M:O<UW=(M\]1!'L6("$_<$&EF2_J<1NEF/)(R)DDC.[:EZ]]].YFX\,QB0N(I
MXNW:6\>F3+-A%P/50S9%`B/8_#S8Q^!K#^,@DS#D45;VY#\)CRZ/1)"T9(=,
M3H-9@KGKB\1M&)I]QWATL\\<%D4@B.A3PE9XN&86[YC&UO%HZRS4SL5;.G>6
M1GP"]]-(&KP6S\,Y)\AW]%:58^M@8!BBQ4E>")^AT.9O#IM3/*D4W>/#V,ZK
MBZOIZ2^+J[$ZN\?5M,\7W-)TW83TK'KW^/BS(EA;J"V*UX:EN+!'-'$\!XCR
M6%.F9DWE@E_MT+DOQE8==DKV>N-$;,AX\*_$+Y1K,-37PX*B)&3I-PTK5L4<
MGEQ57?0U:L9*-$K?;3@*'/U&[5S/-2-]%2.MU[7';^R!^<D9,%+WK7<OZ\9Y
M*KJ?+$Q1[ECG#LD\+H5M6=/J/8>6;%HG+6Y8/WOB8YJF++%OF,UX@3#.7;ES
M[$#<$UGDSY+:D\UC%Y^J#JFJ?NXPLQ.1BF7FM`K<`5^..?6!Q52KX.)TU75'
MUH\40%P5:082C?W1@"Z#1%W6VGL;'I=!HB;W]+UC7E]UI/O`CEQ'\H6*RB\"
ML?LH636`KO7]3](?X]^^O!_V?U'ZO[S_^<,[*1WXM<9O?.'5[*1\`2?(:[6E
M[YT<<I(ETA"V1)BZMW'Y.@FKEU4U<KT$@U`.J;JN]49[56PMU)8P]3CVROD)
MVQ^6=2?M56[]GN$0_O&VN]Z1GS^2WPF:E_!XW4U0[":])=2;6\)FI'4=:;T,
ML,N[)33,\Z#%G9!"M=ZWA+K<K3F%)[C+KKL]48-;0DNV]%=R=6;)W?:Y*]&<
MB-0V[$!['XXNB]2.;!V;U'I94Y=[2:C+>OUOT*Q>S>]!+;G=K;8__<4DMN5N
M9^_`A>:2D)(*)T?PNA,'+\WEKAFM_2LA5-J#JZFM3K7U^=Z46:U>/2E36_K>
MI5QVT&S[PXQ=9%JPIJK?;YD(7-3-Z>N%8OT>F\8E=;=NGNC]Q9<^+"E;R8T(
M_0)U\16B74S8'+%O"&4+L\`)D$.DD&?9E@)D'*&9OB!F$SS(Y!1W)YDM/`\M
M07\*[\^Q/2?Q!!3/HTN)\7&6T^YZB`+#$`&+XSGX/OZ9#[?P>FMG(:N?$.A[
M"$%_/O=<AUA1@%J[2]P)EIV&1@2V6<31K0@M*$;P'NDZ2K!$0;2,PO4#?]9%
MV)<,[\Y&'!;X-P*I`TE*@>>?UJ&\23/[B=[_.W&QVH!?*)"00@+YR0Q],H21
MQX&&A!V1@DVAK*`4+DH+[]1_*B*&")PD'!LN"B+A,4B\R56*52>Y`J0M9<&]
M/4G1L$I4XI@)W2=%BX$F)@DAM>'[O.A"2Q)YRQ'+@;<*12`XKLW,GC!!+C2R
M%<$KR$48.FH9VTB7/7P9LEGPP%&=[A!@D7"X<B25';"X6E*_,'0Q/Z`Y`H)M
M@P%GU$`C-)Q).H4(R@;MTZCIU5M41!%"KQ$F'>\R$L4OGAG&SFI@N;++=C5:
MRG5=_J2+5S;IPZCL._:!J/HX_8PT?4QB0H>$^2&+M^]/TBB3O>N\)+[+W^)<
M>PNL=MR9[47_>*L82V5@+$WK&,,;0QF/QWW%U+6VTN]:AF+>W)C#FW%?NQFI
M7[6ONO;VGT;7[/1,LZ.J:LZ1_:A;`#A"U*C[P`-]%XUI?:"JR(&1#E_\9F0:
MZHT^ZBGFV!HH9J\S5GH]4U5N!OV!H6O&P++TDR,<=5=5OU%;"&B9"?0GV$-9
MB.!IQ#09X:IF(/WT26""%=DI+!U@1>\G:<2FKN/&)-JK[[N/6"!GB32\S0LC
MQC'#I`CVFC.-;&WIGH_`U^7D]([,`20)$/,V(&#7*6C;D#F@S"*.IO>`"A^:
M"'RF@()0XD?4J$L$"P`JM*QP%NF7%-`,-SZ"(BO7#2K`%>+QV">T>*%4LZ>N
M2K"&=XA=&+(80?X(5)3#BZ9O9>,JC(CT:#XFOBEZ7KH;%0R[D\W4RO6Q86U4
M3)@^41E_P?+"OB5J.*U!5L6?!1HKM)'+77&3FV=T\[E",%7'`W/*G;K<[@!!
M`"/$#H7-3"B!`@>M*&0IH$ATSU@<D8V"6'H@$03V&:W3*Z+)ZPG7+P0DB@V'
M9"@2N"#*<Q+?!Z$+8HDBF)J1&9QF.F*'FR4$OT?`?VFM*K*U)HS-N'&>H2RW
MI-_)%`!VH)V2FR=DBP6>A%$#,;?:K@388``[$UBN^?*C)PMPS&"$_HTCQ+'(
M4F0CHBC.`!AW?C3E5DG:OK"W!'"@+`D69;B]^521S5R>+`?-2##($EB`"#>'
M),[F^;'E['"A_<VHFB"/J!<^@[1"!_W%19AN2?SGP=+/:"8+!B%R35#6.B1V
M\/-_$M\AJ<C@G-<L%S2<TU)K!;QBY/LB8O$CJDL.+[P:R1D%BLLCX]*'IX`0
MUU%F-W.)_B\#CLM@%>'_4UN50'G@;`1'*IL?F1=F_LR*\Q/GQT?!CZABVG(1
MA!JG"S65QW!J-D!12X_H9[A]HI6>GA5P7B-8E9*FR;JU.$\ED:.#[#**-N'&
M$ZBPV8*7LZ.4+,Y_0E7[!#$?.(Q-HOQHED**XNM&KV7EBTB`$;?6@)8+BOGQ
M!H>S"8(;R"4:VVM)3'4XAU4'DAY0MN>>[;#TZ-Q'6-/_QWSFV"D(]GIH\8,Q
M12_@51/P-#I%N.HM05F3NL[.%+2F8%&Z<QR=ET2XZ80)P<;#(0W6,36NMKI9
M`[@DX?2&`[-7'17YR3Z3&Q@L.BZ`AC[TY($HJMVT`"/'$%ZI.8HXVC(T<L<0
ML)Q/*]*S-/_$U")ISQ*V.R$#%\;A2^_A-$@$)7=P)$\7%Z<EB0,\R3J@T)\*
M6IE.VD4$>K%KKA<,#FX/TWAW%[([@5>ORQW5D/5VKR"72[8OM/+[BNXVJ'R^
M_^1-EJ2K:*:0-\I7BES>8$5MX,=*ZC1#;O=Z<J]7(&_!B`9#!6?M$<P6-`_0
M\-FPH-%4^\9"QQ58W7"D"!482<#=7`(N&T8R3T*P><!\T&2SJ\J]KIXM'WX0
M6,MM7.'/+EWNY^.+%Y>3U;**2Q7L)8)&?V:2KMYPD17$E\U'0:9HPPW7T,I-
M"2?3E,L:C)1@:'.6`6]BFZRS[SIJ08F045'22?84QB3!,DX<(KPP4CC71>1_
MC&1B':RG%!L>!9[6=2;V:?!712RW]UP-Y=H&'2(+.ZF];O],MQ-HQY*UCO7,
MGOD=;&L%O9:[&CFCX&S,W`=QBUL2)]/*U;.\.!-%J<&QK9^,A:F@Q?/BR>CN
M=X5TRNK(1?=/Q4RX9PX.!MT#@830@<S4Y$ZW(QMZ>ZWZ+.Z/+6F,UTU<Q!;%
MT<4JG[$;>[3Q<2>,]!`(J/CEXUE1DE%BO2A8:$"(+\@?WG?X(+JP2GQTFTC3
M!#_B>Q[L!;A1V`^VZ_%;$Y!+?!!=_`S.M[BYP,I"-3Q(_4:CU&^TYNBRO+L>
M^.BBJZO.+J5]Z[PGE<]\4+^QB(6H0G#?O$GB!%C^'JP;=")43/++);_7*<V0
M*F_G-$V))IPL017JU?7+Y[55S&YW7U8QNZM7$(F^[F%<PY+^GO/+_((>WR_X
MRCL=9LT!PNI[75G?/_7V-48FKY2:?%O-E:5T%]I^7'LAZFBJ;!E-);\7"=48
MCCS!$V/"\?PI/35_\FR_]A)DME59[QZY7ES=E-#J,!+I^E,0Q<K[3Q_SH*;:
MRX\FFYHFMX]=$;9N2&P-RN:E[`Z$NYD=T/B);<7I+#N;U7[%=V6MJ\KM*NP9
ME[3B7Q'NW5E\VE^XQ^[6]<DWAXMV*4RTM&XS9PHYDL7M$`&5H>&'OD)A7:=O
MV\^X+=/PK-S!(_PB*4I:1.Z[XN%%HK`K#)')!D%#@%9H$&D(S!.S0XF[\];W
MOP6B&OH"TT!D"I!GX:R!6=O':=36*N@T:KJNGI>NP?<2G",O/(\"SP<53.FG
M4/I1C$LX=6BPM]O.]XN95`76I/'R"PRQ>?C\PK?IS?C"UQ1W<V+>73`70S:S
M75]XFPO?%[;(A5]PPUSX"G;=G`>X44>+0+.O:P;Z:?#+`I]<X*GK1ZZS\#WE
M"AV68W4_DWY<OB_9>"6H[W<H/6,E#U/N[%]M]2**:^DO*$YZ(`)W?_=<SU5Z
MS)?FW38VZI:?\>*,[Y\7I3$TN;L_LL1%:(QVR]J[L$*C,:HTYLNW3S;KD'$:
MGGQQ6N2Z8QRG>,F9=8?:ZC;61BW&7"]K8X@>>(]-?IP&X92Y8'C\R+[-W?`2
M58>^/Z1FE56'T9@=-1ESW:Y4ZQ-$<3"G8"/W-1GSY1\1#NO"-/:S![S+B:NA
M@/"S;+0[,6D?UNQM>;3/`[!P05+3>4$9T4OAT;X>=DW6VD<V7>MF4M4I2JTQ
MJIHQ7[;O9+,)]0>+J.1-2!GMCBB3](!%0%Z[)65TS^.RJ+`E=9[;]`N2&K"D
M+D!HSF-)J7)7/;(`-9948TF]3JOD$L=<=_>4N,'FQ5I>M3&%D%KGB:NIJC&E
MO0#@Y%(,A9=*3;NEU9Y'^XJ/(7?-QBW5&%.-,=6,><5JK4XZ[:/(I4FS9WA1
M'<P79=+4=D.D+F&%]-)@*C%13.4JK2B<5NFYXW'%14@;2I;9E-9Z]4;4`Z2T
M7$Q>A3\T*F/_G=G23%GZ3F_U.O3+=QI]$;((?6'N`_.>*E)M$UG)$Y*S%!C!
M.<Q,+C$IK^M*-%JM#KR?U<`L%2PFFM66GGVQFK'P_J9"BR7&+G!/&MK1?5:@
M$QK*@'Z*=5G+!."P">;BFSL#,?&><(SMC`1H!#YKBT3D7Q03GO<0C8/-_YXY
MS4<L\+E1O.PH2F9B"I*(.X)9%-,<</R/?+DNSADTD42IY`P\V_E+^>S<!QZF
MJ_,D=<PJQ`=FP81YO"JG'8DT]^BU)8YWS9<ECG<V)"4O&8#I.^=+H6[7N.LF
M>_NMIFZ3VREZO,6__PV:.1\6:>C\XTI534._/=3ILYFT[?)QBW.6CXA<5N7Q
M'6QF]GKCW-S0&VX4N*$=BQNU]Q>7:TB*Z,9EV^CR#ZLU<E]49J27%I>R.:?G
M-S?Z2YF&C.6@-*$H!W%1"3U::^_HT^]/X@!\(7UJS>G36WN7*-Q(W^7O9<]E
M[XIHLA340GIRF7=Y"7EJ:^^0E8N0[X:^<Z[?RJW6AP!QVSTW?KJXE=K16WN'
M&%R$*'>,NA.H'\F8>#6;+95BO2[4C[ND!=QNG;NZ1$/HA1%ZQDOOXA)W\>]-
M)U:W0)*N:N9/>-\6KGX!VLQOXK""]*V-EW&(3WLK*D^7GA=WI?/0I2OU(*U"
MS4I*0<#1E>I&TVWZB>$DE]BVZ:"PDFUL]0OKV<:O+ITX0ZV]MQ^8Q/'UYK:+
M\.@1(LCG\'MX$\P?"A"X-4(T4.2YGX&BVD_T5OY.5;BX8,!MYF#^<(%W5V]*
MW,N><3G*G"W-&3#N+@R2.5T#NS/7LPGY=6[[^-#C?1!1Z`:%<U`U60YAR+$&
MBQB&'#*QT"!>_4]@9KQ@3M$"V3#RYET^H[=N$#/GWH<=^>X)OIPD41R>.%IC
M_32D)5Z?F0!:FB$3,D80PA@)XP8$_PI+%D;`Q3;#J0I9*5/KEI6!*P?,L9,(
MPVZD"6)+^D',1?G>A;4/<Y''7=PR^,$-0D)\G#`<B^LS$9LA>O#<Z8)"RJ_Y
M8>;G\+L+C\U8?!],4NQJ-R+H2!'ODX$F+]6,%SHIQ]^57.!!$`(E=OA$26@$
M5DT,.?/,WO#20@G,U.IY_1/Q%B>)(W2LPB47Q9;Y$0?&%)BQ5V](2Z>A%00D
MD+:-,)W9!S[9V6,",)UD@F`W>205A^9\P(`?67*GH-A@O47`0!F72I3`IO%W
M0GC&Q,<(G^&SP`>2]39Q$0(T#="!-9SU717(X<_K..LB+,/4XS(K%`2!E7*`
M9P*W!_+M.`/TQ==#=@\M(/*J%T11(1SE:J$@<X:'\.H0#EX<J%)%6,S7V743
M\T"!*LL7V=A\%I4BC3<%/-*XFBB4@T8:;)B0+#?J=`$59R=8?VT$:R=?5!7W
M]6T.$D&@<CL$*QNM&'%40BOGY.Z^?=/`9=ULG]G]=2I:>V?*7SL]I9;50%#O
ML(A_9CZ<1CQ:P_8$CMUP.,?3R<,%!KC(6N?BUO.+'=O&>>JEG9%DO7UDDNN6
M;OJ*"LLV_&OXUZ!#OPP=>K^-WZM\I0)#-NM?Z6+?*@ZR9=6^I-J>O.GJ5F-O
M[*)^7U5YBX:##0=?*3X]KP)1NOYT`HP%8IXM@@+\P%<>>&%7^]$.)Q&%`3RQ
M^`KA:IW@SG?_FY:'Z!3+06P)3I_6]%#2.WY^M2P%&%+#8P#B>S=*+[PE\6<>
MLU`>A[M8[D%O&;QXPPGOG;OE2W_R1R\DY'U*0N?>!GH^>;9/(\N]UJ<88WN#
M9+SWI8].',"T43$+BNFP)\&<6`Y20Q4N-M$#;5SG\0Q#NHI8H#C[=?33#VFL
M!_-Q7432W`YCUW'G-H6Q8.0)A7NXMTG,I&2.TZY9WU/`4`*O%1[/F^W]!'("
M6L"%%JF!@HB+PB2V-&%3UP>BP@!D%KZ)W&_*#+JZS^(;,#Y+C!M:"1**38)'
M>&"&"#E*":/P)!Q6\1DI\2<LS/@&K908(3W">L'(&WP`B(_@V6#Z3KIV"Q!,
M74YM6C<#VIC9X5\L1D7'"V@LCBP-\'!]A_&0&/$^\Y%8=/)#*^E2"Z&[#?UM
MZ.WJ3;D_6'N>ZU"80<86+,_3DO[$I1LEP&VS*ZN&Q4.Z(AY0L8%A"^PJUF/9
MHJ!,2^H_HX<DLZW*>M<0X[EZLY*=5&,$(ZLH9A(',4TPTH5H0LBP/,[OEC%D
MBYW$]T%(.@D?S[BQB;IE%?7CQ'W`C__S8Q(I=[8]?T?+[3[PH)5H_'?BQD\?
M@IB-W,CQ@@A&](5]BP<>//-/:$+ZG_2U&YC'/W#^^GEEEA2:O,\U[Q]9!-]O
M&/V):P[:^HU-__&6!=[73^.NJ1D]55$T0U.5_U55K?WU\Y?15Z-M?45.:KJA
M?57?`H4N?PMH9F]AD3F@B[V(KN_<R3_>NI.OAF:U5;7]==#OFFUSU%,&G4%?
M,8WN6.F.1X8R[JOFN`]-CGO65VSTGVJKW<Z9L#,U:YCQWI\G<33V8WAL&+()
M#-R-_CH"Z<:^I.M(NMHQ5]"^>O!E2C^C4`\PR&E8T(#],+3].PIH&CSECWRR
MG_"K/F[S(F&<P'>C]_XGTA0++*8?1\#=;$@'X)P;!::N=;[^_GGT%?335[XL
M-XM1;VC`'[V1,A[T!HII#0QE,.AH2J^M]O61V>FWU2$7(RS255A+I^7.PM0X
M]VR2>.SC%,M:X?]Q.8..Q>C-OC_Y#.HC_L+"V7L?[2_L._J"FC5;X?MS>Y%_
MO;'>MZR!,NIH((L=S5)Z0Y!%LWL#_QNH_4ZOR_F'.DFHI$4#!3:).]=7XF#^
MCMN=X@MNA+\C^P3/^TH$2O&=EG^>VF`S/KU;<[^&.RP/I:-846XAP**'UJ$=
MTM01<DJA,%`WYQ6&W<'[6\7;%<:%0R^0HN8?<T*V#K7;,C).4]7OB[%P"X>4
M+.8N_6,CXQ:YO*'>QII`N[:Y>Z"=<;YHMZ;KNG6]SIVVI=0O'+].'NBT*7XI
M#![7Q#*E1'(UD&H;K:6J:614ZJ@HASW]:H,A*G(T;D/I1S&64M!Q(8MOZ^"H
MXE!KQ;#^#+8+-,P7.(:>C\MC4?M0;/G=#QFT)/ARYKI3IY6(<9H7L2`1>/C-
M!TK'W^,)R+&5WJK;C44[Z'G&_<0W@7==LZ4OF'3=+2VZ?"$^<S3?X!8[883+
M>=3>803[9]OUHQ,OYW/3_$L01>S41#^_FI<B!G9<WYJZ=H&OBS(0YQ:/36/B
M&P8.X'E1<?T)\/B=DGZYQ[%L&(3S`%.&X6!^"_/!'#1"7,'X2PHZ+!1<#`I*
M"'VQ*QM<K&98$>V!/^YY/=[19%-='5=1/V*-U65!ZD?H]9J@ARTH_>'8J_"%
MPJJM#A(^V!R^T!2KFJIF<-R9N@[5=P"#:\+F0>2>/LGCQ8H:+ZHN42V_."Q>
MDSO:ZMBNJE"]VSCV:&&9*[G_E7+FCS34AF4'&>HY?`9G64?UM_MG,ZSY87O2
MW)[#J?W2=A'MM>XB;5EM7YSM^_+#W3GT6:/XJZ7X0?0[JZO'-4>&E5I^5/;I
MX*GA]];GEG2'49D^7J\KT3SPHR#$L-`[YCN7Z/EYM5M!1U;7H*?7F.@C*X!F
M4SC+/!]J.9QS>^"Z>?[MI\T7>-3;*1;:N9Y[P9@7-T=Q:43!:'AC]&W5C5&Y
MEY=FE!RXRR,;H0T/&QZ>AH?5(*."G*N[J^APJ>C+42YKU^BN&<7G?.Y$).Y;
M<*HM:]WS&,V5YXUYGMORRO/EQ'?.N_#CQ"NGM[K"47.@N/P#A<%M`YXI?B)[
MY"!]5LH<;KC8</&\QXK:\F[;:A--UAO-8)KUMJ%J^M*>_PJ2L)JN3]QUD_76
M9+TU66_;L:C)>GLYZ4W66Q6SWA8Q&YJLMYT%N\EZ.Y<.J_N51HVRWBXU]FE?
MC[TI=X_MDZT,L:OQ,^I'Y[6Y=T!SE5/<4%:M)L7M%::X:7D#EYZ+_%)6M&6]
MXC&JM0W9;!AU^0D/1U\\]3?U+SS1[6(M_)<+O]FK=C6+1B&^=D9=Q!YR]&74
M!#$==\QK'-TUCJEN>-CP\")X6`TR*LBY>CFFFAR(:I"X+Q1U1[9ZY_%"59XW
MY[EDJ#Q;3GPGL0L_3KQPS"8%XOPJ]CA66VU#IQLN-ER\&"Y6A(XJ\NZ9%(@5
ML&HO1F-Z'F\-X;EN0L;>8Z07-'(DF#5K7ZPQC;#&5$.W-B.MK:*C3/VG,)BS
M,'Y"4+L8N(>\G"///L'1T7DZ/(*59=QT=*NK*=W.0%=,7>\J74T?*^-.OSNX
M:>N=7G>X$X)5]W`(5MC';;IIN_A'RAX"#<QX0X+I9KM[]LIJR*K"8-MKQEH\
MQ)K?[S7V/T%`[3!\(IRM>7'8+!TV0C]B$'F*X@E3&KE13'$8GGT+C62/RH3#
MF8#4%%^'QJ)@&C_:(9.E:1*"7".R(GX_=;_AWXC*B!\]9D<,L0\E=P:#>2",
MMJ@E?5H],#?"0)`0%@9&.4,;24088O<,F!C::*PJGNLS:<;B^Q1RED`RT\AH
M>(--$T_RW`<:Q/4=\UEH>]X3/`<K`/%!I_`;1YC]H27]LG*$$I"&)*0A^'E/
M&>(G?G+#O+\IDP329<AFMNO#P*$%8H"$2&<R0GMZR82`3/TG>,IGCWA7F0*7
MWL.T0+?``1A#$2K7C@+$605F18@7.6E)O[$YHGPB\["KF/F$:(F3*AJ:(`XP
M(H8*JB0$PD2PTWD`3\=X20JC!7%C.`$@`<',=3@5.`:!W3N!+K$-WTE"['A9
MRR^IY6T525G]H/J&AQ>T^+%T3V_0'QG=OJY871-TSTU[J'3;[9YBM$?P0'>D
M&WJ%=`\RA:::_BBPIZKJQP,Y=:>PX."1-+`K(@H"6!YA"?(OD_I[6-S>$ZX8
M%RB<Y.BL,YXW)(H:]E1I8C]%Z4UYBF*+B+4<F#:#;;4C4(3`,)8SC*/_DGJD
M53@+$EKK.?QTBM;[0-B8DX3T!:D?M"86Q@+?([RU#ZHIX7IMB_6QE:27%\<'
M%N/CL+(>W`F;#)Y^AY7YWO\(Z\R.@9"^$[L/?%0'1?,LFBC*,AYJWQJ:UHW9
M57H#HZN8@YN!TK.&8Z4W'G8LHST<&'H;;93NVW\J>M<PT&K,^;`]42OP46^?
M1P"]78,`^@<AHZ-B$ICD7P+\ZF,21S'('/2\@`KZ6ZK-APAI;3MQ8GMH5FH'
M4T>#=M?HC*V1HH\T#<%0!TK?:)O*S<#2;\9#?=CNJ1Q8]E/GWYKVJS9:`$2M
M!#O*TX3U2.$)>">";OA?,4YPNEAH5-%[`IA^`2LSN5U&G7W_X6:)U:/QT!RI
M74-I0_.*V>NVE4&_UU:Z@[&NCTS-TOMM;E=KNM6&?2#G]&X4E;DQMD-D6?2)
MA?34$<SI\:@W;-]T%(M@8*W>0.EV#1,,:\/H#MHWHX'1WF5+4X^PH^DM^#&6
M,/%%`DY(Q(KJ;%T#.P(3R(<1>CA"4$0<81RM4L?VG,0C`_/V20+VN9/4,,U>
MN,7="[]Y%"M&LOF2D?P$$\>*./,"23U?92E,^E6*\0[&N8M(N#$WSR>D%@,.
MIUX".B_M;R/72[CE_!(ZQ$!2.I3-=!1'L$B2X(B`K9\P-(3!?I\4#/L8#=PD
M?%(X.=RR%Y2`H7[U9BVY9#?@^21TT52E8=&J=`G-/F13AE;K589XCQ8(5WNE
M<7*`=\(EIN?X,](<\=VE&^`W'!^R>8FPX0A3OV"*T)PAOOH!,',*_3&TPUV?
M<S1C5X94GT3<LL_F0;HEJ<.A3?C<K1(.88C`$$LSBX85C'39[-@)XOD`2^=3
M>JCPGC@9+ITXLFK4<!01IQ^@3W`G90&RFBRWE/X5DGO+'#N)B`=PL(D"Z3%(
MX,1VBV?.V%4FN:S@TV#Y<?QI0I1.Q2<7','A"L-+=\TJU=FP.KO7V=@`2'VH
M[U]CUW6M.*&IJ\0RLQS^C<X:B8&.0FV^,A-[P8YXH5^^KGP^6/;R"K378\?$
M5H#DQ53_5T"R=N2%5;LDE!46:&I7YA;=7E=T31!^PZ@S,>H(V0J:(;=[/;G7
M.S+$5;W"4X?%L[`XS!Y7F1QAZF'FC9ZL=ZJ=+7P,F9>[74,VM&HCVQPCM5$V
MC*ZL6TV*Z\&L"S^(P<2PGRA0YM(T`$)":W+;>G7PAIILM-MRIUOM@B^UM8MJ
M$IR\J'/JGV34\+#A815X6*_3Q&4DN[UPR[5DU5+EGGX>6^-R^&2@?2ZK9ZJY
M=SE\TMJRBH>9_=/&7I5!4MN,A8:+#1>KPL5M`41.%`_RWI<^.G&`T2]X:R9C
M!,WJX!SAR732<#K)]:\PXL?_3^([%!N"85`4G./Z+L6MSX&1KB,%&&[C^G<\
M1`<C2C"D?_,E,8Y&DQZ9=&]/2N-!9TJ4>E.*%S704C"5OM/4EBH!Q1Z.B&*6
M'QD%'^5-N#[&]6P,0$KF`8]]"1P*J,=8(6C]P0[=((FD:4)I%`N\@;>G+L;W
M8R`0>^"!3S$\Y3HL*HP%8VS2`"NB(O%CUQ.A7.4.<0BB,]Y@2^I'4I0X]S)G
MS@-F`(APG?@^B'@4UCIV3<-@QD.YZ*-]&SRP\JP\<W>/TV)0#!1*2SH_]E*7
M:8](4"$ZBB3$1HX`D^8@(;>V9PM2O[-:YL+$44K#BIDK1N;!<]^9L'#S&"0Y
M#347T6$4LD117C@P3"!A(<:7`[.R1C`V+(UZFN[+CFV"RM?&ER[$3J,\\0#5
M48)KYQ.%M/'`5?I11`6/OV$A/8Q5.T9@[HI8<K77UO31J*<,K7Y?,;6>H?2&
M'4NQ1J.!U3='P[Z!^6[&VW]V#+T41[X[30N9)X&/E^0\NA+SY(:P\F#H\-?!
M@G-'-VWK9J2J2M<:]A3SICM6!D9'54S5[':-FX$UNAE5*-^DR!%*=.`LD9`G
M)'\5RSFYX>H1%GXA%X,O]GDA,#%*;O_#G%@"30OK/8(MG`H0^S%7!PLT.YSF
M4,@!)LBAA@$*8"3T@!V!NL1_K]Z4HU(Q/0[31114QL5LEQ:FQU#"%OP_SXRA
M+6_*)B)/#8C`+*]4ZPNRW#CA8X,W03=C[@L,(GOKZDWVGN?.7-$7:7+<&#"?
M*W11_T\H^<PC\`%L"[6^9#L.I<)<\:R]6^:YL#&@(K;#K(%`Q*X6.$?L*5/%
M8U07,V\V,(6K;YZ<EY',R<F(IB[X.V0*"`90+_FDB%A/7@,46J`JH#RT%FO_
M%X4#6;>2O9CPR!$#Z!.T\GOK<TNZP_P_']]5(MC$HP`9;=\!0S&\%;M`W4Z/
M?A'QS"UXMS^94(0NSA!MK4``;&!N=`^OWR7NA&$V8R2%[,X.>6;@G-+U)L2`
MG$<\TZ^8?%3X-<WCY,F#.#TT4=!$-BN1/64BVY+G5[GQTU;92NNU8UF-OH=^
M_#O<3OL@67$T<B,'A"PY1JY#I]T?FFUKH&C:6`,EJJN@3OLC93CN]4#/]K3V
M>'SN7(=.2\I9(G&>R!C:7!VUB;EP/$Z:0O')=HN2&2ZF_U+\>0@=_P?3#3"A
M+Y6ZE"94%405Q5ACID($TE7EH.I.NTI!U9T]@JHWO'*H[]=UW6XBF_>+Q3P8
M[ED3]5R)>-A31SV?C=`#QSK7/33GDQUG.?FGC,39&_'^W,%W1Z9/+-0FK'0K
MZ?W%=;#>Q^6%DIJJ>1ER7'E":W+=6-.XDT.)X>OCW#D,CZWGS[N<J`?9:)]'
MU>["HS-Q1CMR.&^]C(V^XR0S485"5%@C_^)^QL?E+*%KW=@;([**E:9?S`^M
MO;>1OI$?C2E3Y0VY,64NR90YY<:0WY@4[DHJO"'LZ9O09$VO?I#M:1EB-:?;
M5QW`>()-H;:\JUSP9W;O33?$)1N?8O+4EI;&Y,FE3QB@`"V4OGJT,3["09ZN
MC*);'4,'K>!EC<PC"D4LG29#2Q'6N70?F/?4DOH+(TLKNBY?<F?UGWU@4*&"
M-!9_8Z)T)B_97"PG2W$Y)6HP(@5?W";X8HN8BG(0QF^,#E6?[#!^^A+:?F13
M".U1@S&T[J`]:IL=93@<F8K9LVZ40?]FI'1TTU2'0]W4.^;98]LT`VMF$W,4
MXHY49`]QOQ(A&6G(%EW>43`TQELQ++_H2?9=R%@A9"KD!$ES(,CEP5PBV!=#
MB>SP">8X"2,*@[W%>HL8,@7M>=S7CXTSSV-4P;5<*9YBA^`;AZJZ3V:N[T84
M`_3`B[QC`40[=.Y%;!6LI8#7;X^2^1Q6%+PMRHVO*(E\AECT?G*71+%0"(\+
M[+5!Z\#@)T2`J/;<GW'5PM71;QBUA9P6MR2\&'?@>?:M"!23^NG<\*EY'[D\
M9JOO^4^>/8-&)M3"OVP_@9G)515%^ZH]&8L6VJ)7F,A_)3[#\:K4BHBEYSI-
MDZ[M*&]`O$2U*`L9U,.?^BE1^9>CGWYH2;]3M4LN*1B+EY:REK(7>%NI6)'8
M343Y22Q@2<&/("LVQ2T*"A74)R'PA+-UA6!1B"6%*5/S">?C%0:I^<D4"PF'
MU/3/MO>A[_`4@#L;X\ROBV3QGW/Z/X&8@F!#.U^8<^_#<>CNJ42QA-L*&)*^
M0B'M$0HQ%MWD086/H)>E'".`U\R_I8JE,S<62CVBC`.:>MA_J(CYHXOE*%&)
M3,7&(,:]:CR%VN>"7>DB7,<LLHVQ$5KDQ+-@B3,P?5D/:;%8FKG0A6$^ACA^
MD4V!!4N1N:)[.0N&Q<AW/I<\;A1&A,&5HDHJK^":DQ_Q!>*&7.O@I!97`7X'
MG.1UUD.6YB5<O2D$6W*12W47;R[*9>_\^N*9L#AD<%HXOEC2E,>]!FGY\A1!
M(:*%C1HS\6)>HC;B;Q*B`L^=2)4EU[I4#UT4I<7>/HM?"TKF4D+NCE7'M'NJ
MB+NCA[V]SJ[K&FB&94P7718O"L@J&K%4!#4?&6W[^<<F/+`247--4=370')3
M%'4GDRJS8,`Z`I,2T:W0CDYB)9@J\\#YB\6YO32W7;(+A:FZET?N#`&5UD%J
MVU67/KW6U)T4^'@+<,L=/'D+*;X9*N9X.N6.SO>^$\S8%_L;HC[^AEAOCNNY
M=&(KXV$>S"<XM-ICU;KI*R.U,U#,85]3>NK-C=*S]*[:M0;#D=%_UB?X:_^W
MG]]_4`8?OWSY^.L[B73-S<</7Y3/[__?^)VDY5_<]']]_\N_WTE+"E$T\>7C
M)WB>CHQ?QO_WB_+^PVC\X<L[253K7SKSN?S$5F14ZB/)7+WH$4KB('Q*4S"O
M""8/&`U'QF_\&!=1SCGWFW"@I-6/7),C9:OSW'-,(2*+9.]RJ!-][,CDQ<,<
M]PG,(_9VIU/BPMZ<'QJ?/]BU-YQ77F,J504/=@69ZCXG4F<]))0]%.DZ$W:@
MI*66X7)!RUV@+*J`9/&*9F3)\C_WH>U,9)[ZH'8F,H]].-MGFWR[?*3;[7BV
MG^7SR_@&[!P-CVTERT>!K])N4N#'HFURRWPV=0DH6I@W!8,''PC!E+R4D]EU
M6S8L:ZMW%PQ^?'B?P-N346;)/7UU".VE4Z;+EK[ZR/E2R@ZSGJNR>C_CS71A
MZ8K(R4)MF'0QGWRYOCP\7%9[JYTJ59'N0Y"HK<X)J`V)IE'E=5S=??D+;+.\
M"-7E9>6"^C;5NLMUQ7?>%Q/8[AZ'P'IMP#]GE<&DN]#V3[O-KN+]RUHX'##'
M;D,]MG@WC#JAYEB=#5L-O5'=#7]X;_MW!!X^M=T0!Y*P15#SBP9],JV]38++
M6@":K.V_=S9*\:",JI>U\4N`=5]]7M"4?<-(T\2-[BG,NS$\*KC&#J%.VKV]
M3]"-,JF@,KD$$P2M#Q[Y8&-8!);3OSA[HR>K^BNQ."S9Z+X24@U9M5:':U5L
MF5=E47^B="`"1XG#A"G)_.)6\K5N5/L"[\4$&NV]9?HB"#2,0QR(7MV&_%F@
M(\TP./H%1;+.N';;[;W=09>U,9EKJEG5CE#=;/;?'=;P1TS\O;AE>[V_/7D1
M&]+UZH)#=2%/%V%P9UVC\V]K%F&1T!.LA<6U+J(/*4`^#ST4Q=M6L?^E%8$.
MVN$I!*KA6L.U;;A6=_O[?1X3>RWBZ'Y(4Q7WV]*]<@F^<AC^9DUWHFI\UZ<-
M;-F)(:=D@W;2V,.JLD'?/X[K=1H21E;O[U3:??\>J[0I-GQK^+9SGO1+TIW+
MB=/D)>?8P?`2(AX2QBF^UI_\)^%0FR,6.:'+`:`/E2S=[QCM&WW84?2V.5+,
MKFDI`[VC*>WAL-U3^V-KH%4(''B1-SPVN6*`P$-1T8QCGL=4?@T+P*6?01QN
M02;2JHF\7MJ<YOZJ6*N,RO[QBHM4EO&6,1\3PP4'>!D+K*Z&IK6H9W9%]=:P
MRD5:3##ME7>`\.Y8C8VX1X72(E9H4W`56D$(=#^0W-G<=F*,^<`T\L*(@FE:
M;8Q@:TN_7+U91)'G`+SX%X<J3PL)@6#V?B*DWOA)NIZ`@>N@B<OKOI4Z([#=
MJ1<\KJCIN+PP=UU."U4,V!W^_AO#:I*(Z0T,=I[XOX<O5]#5^[W>L&\H0ZTW
M4,S^<*1TN[V1TNL/U9$YLKKC7KLZ*U#P1LJ84\45^#&K@Q?QX4:$3NQBFWSE
MV!%=:P1^*E^VS^MRPFJ,J/#N+=8SY,C&$9O;F'(H35R0&!:S$GHS+C8>JX"5
M&QYLU[-Y[5ZL%LSR2(;;)[X>[UTV+53J0V!ZK,.@S.R_6(@*`?Z`'Z"!]*<B
M0C,L7UB)#J/`"$?$2/@3*A0,4@Y/B"HW&#.!(-!?`BK^295'28T\N.P1=0>L
MYWP%"XAGW[X3/V4E6VW4!L"GE)6%H9>PKPF!VJ<2CI05MM4ZW6JEK2LQ<N-B
M=[_`ICM9K%5\I,HB9KM]T];,OF*VQX9BJD8;-TM3&8T&1F\P[AG#&V.7I=K`
M*S?PRJ^B)DA=:_<U\,KGGX-+KI]X-D(;>.4&7KD"L+0-O'(#K[PIIJF!5VX`
MJ-[6'UGO6`[[^G.N@5<^B/YIX)4W<*:!5V[@E;>*6VG@E1MXY=>^(3>FS"69
M,J?<&!IXY0LWI1IXY2-O";6%"#[!IE!;WKT@*&WK"_*%&_9[.V0#.V*382'S
MLQ^&6)T!K^L'3_DCG^PG_*K_:(>3CQRW\28(I\Q%0,VH[T_&W^:N"#)X[_.0
MG#\9*@<VZ2.R[!T;?V.AXT;L4^@Z;/^[^@2(I;?<*#!UK?/U]\^CKW,6?HUP
ML-%;"J>8V5Y$-RF+F"'JH'<S')M*[Z9G*F:[TU:Z-YVQTAD-5=,P.ZHYZGS5
MOIIO_VFT++W`['/R:EU@Q$C$7GVQO_'9AJ9_R8/.CA0<,>AV!MK`T!2UTS44
M<V0,E<%`'R@WHU%?:X_[UK#]?!S3@6%7U*U15U8B;4:@#"AP#';5<K@0Q]N<
MI$%NF*$A`B8PD*88X7?M^OGR;E!6BM>7NZ"L=,S=(RJZYXNH.'HP1P.LL1Q\
MD7+JW!$5KV@.&G"3NY/$4]0LL7&TO'$N;XA'OYT^UW,5'.FEU;PP-HK7!U8,
M4_:P:J5CA^$3%LN^F"`>K2.;:^)X#I;]>.8XGJYLK?&5G32_L]J:=+.H_\8B
M9H?./9T[)NR!><%\EF8=!5C[A73LI4(YF')'?R4%G#2Y=^RRS?72\ID1$8+8
M^\GE50@UY%ZO]SJ$NR,;^P-J-9I^X?Z,E/L\1!,G?J(/F$+)]?ZM';F1-'&G
ML#C8)=;-U>1.[Y44D]5D?4TD<\561576P&46LX-I[KT2(\:TCKRAU:U>2WV*
M<1WKDK?>7+M\J^49',$@MKU5%V7[:7'O=/7+7JH*]9ZL=\YCWN_$I7/P1NO)
MEKIW3?5Z6CX[KZ/"+7/M%]-UKU.OLH`O#S??'USDQ3AWC8'5&%B7PK6Z&UAX
MU[5L7M5^0]"[LG'LVJ"7NC=H)[`\ZV5=_7$HO+$+6D'7+UM"];2J7K9T&L/J
M(DV$QK!J#*M:&%:K=-)VH3D5`3^MQ$;28,E>X&Y4ISKDI]R/ZL2W%Z3*[90R
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M5+L<TP_M,*WQOXJ+*UF2-9);&[V?(DZ>Y&)I[Y`Y&!:/"HY(*C7-GPNFA<&P
M;PYCDTB*$N?^ZDV!P#5TR85W'UW/DVYA=*`Z8N;#-O#H(S6!Y`+_,TY+4^`B
M[[LE?0B*;'5`D]S!Q#RRD'`+,(,09V8"V@BS.*$KA)J&QD!R)]+*)#`)=0+]
MJY-TP1_:-L7*]U%6ZU)TQ[.Y%SPQT*/A@^NP-6G$68GWCU.$$KGS8?E->%[P
M,(CBZ/`Z\48?]L>JU5'ZPQ'HQ'ZOHPP&&ORC&6-+;9M#=4<P`OUXZH70B95;
MY%H)HQCK\(=LZG&Q%*7I,S0)CD^Q4/D>7P_9/;0`,\D31NQ(9`?C(MD]B??,
MY=`IW;8ZY=#UW9-WK?,E[]:YZ[I6`=?40U7'_C?L']+8Y_M*4Y=][QFYY+KL
M%2#YP!G%ET"R=N2%5;.":NM2__;RW+S$/[<OMJ>LFWN7S#Q06/RI:.UIJ[.?
MZD>I937E<G=8Q#\S'TXBWO_/WIOVN&TE"\/?`_@_$'XS@`.('>Y+<B<`M64\
MX\2&VYF\N5\,MD1U<T*1&I)RN^^O?ZKJG,--4C>ULSNZN)BT)?'P5)W:3RUL
MAM<4?/<PR]$S^?(<"[=4^]GQ\[Y`6_IYFCV>$63-.C+(+Z2=XPOM4WO!X06'
M7<#A2S?OJ>)C-R,@ZGJ39+UG;&@'T*4FR6=!C=HSS?-,[^H\:AQM?<G8Q?#X
MB_1"OF#Q@L6N8'&/9*,#7_[6[YA_R_`-_"H].UQWY^'(TX;PG#,<F++AF*KL
M]!5#]A1M8-NJ-72M?G>290`)F+50H(%.I&/9,>^7:66.?'$_S4;5+]*`I7N$
ML>1/,,T!:U)88LAO5]<XV/V618ZB!_Q!L*!Y2Q/*O^"SV6'A182)*MCIFBW(
M[L>+_M5K7Y]B]DT*.UY22@R.I2]2,S(Q:WXY9_W+7V$NBI]+_FP63'*Z:4]I
MF#N;_K3D[;)9UDZO6K+<$VV[<`UJ8?1U05,JZ1^X$*:31$FV3.DLD9`!,&IM
M5W3:AD>KO;8!6<E&K,8,/_.%'U-N2YS@D'I8P8OP1O^6,FZR&JSP9I9>D+"%
M_P0+(PJFMVQ#RS1ER44(1_$&EE1P'U#*T1(H),T1@SP-@64!]?!W2]@?H'D9
MY8@!^G7$W@Q'ROHW2;,TF:]NJWX$;5)7ZD*A+C#>I[=^S(=T#6`]]-F8!(JG
M'V"#`!L70V.!U^L"K</BC`Z?BZ*JCC*RO9'<[QN*;-B&*_==0Y5MPQJ-AHH[
M'KKJ07)1]A$Y*F.O_C(+XR`#JNY3_RV@CRKNZ,RNJ;G\`TM`N0[+UO)>R;:4
M/B0*^CLAICYB!A^(`H`2C.M@F8>33'H;3ZZD>Q\3Y$)X)TFA69+.D>N!0*5A
M$/GW/J6[1>$\1&D@^/1!XCS(F(.X(O;GP?H7O7LW@#4`@=<HX>HW\1;F<"EV
M#Y/=8N#B^"'RY]('T*9S?T+/^Q$<".X5UGA39L`-?N0_+C\:_O@=G=%;/+Q6
M2^`OZ\\CW:?AS1*AK4X."($=(LQ&0HXODAQA/10G\EUR3V\NA1;^ZVX)1R!-
M_$6(;1]`#"^6:;8,F%PLK_H0-S-IFBYO059C9AP14:$&Y^$D34K=]_%7+V,+
M^2Q?T(=3H='`7)925W\PI#C-WJ8!<?G5$T0`@'\)2.13<F)Y_/!-NA#+P?__
MTX^7P`'E$6ITA.Z5Y*&Z$=E:/"\1U4@/J`1T&!O'P`6+E"UO;T$<9JR_Z7V8
M@4"M'@U\"@L,&)GUJH=4^QE(],U?+FN'R_%3_<%]4/O!//!![&_$4RLN/F:R
MW.\!J3-?N@F318V^"WZ<)9,E5W:4R0EG2NFE!#HG.OQ@%J89;D>>1*"&!/6A
M%<!(\''Z8_FK:8!&@W23)OY4HF$I1,APE*!OP62![=X$40@O155ZYW]A*:1S
M,++).$#!$OA3LG22+&1I?TS%/O)VV'H037OP2\Q9QX?1Z$AS>"TL",\_]BP@
M+DIN6;M%D-*W2;R<1$&2AU.@S+M@CA=W#ST!%*VWAN]1CX/R[$E_!J`)`)^X
M<P0E2)EF1]2#W0;:A-`.R"U.XV&ER2^L.@'NX!A+L8@!^9I9#,Q,0H;,R'IY
M##A8:+H$`VX1^3D*\BM!,*C7;KFYN,T"+!V9=LJP,R$E,4_`L@F#*8H_7#D*
M9+SOI&3=!E(Y3=UC.G*$4C$/Y7GXD8&ZI!/C<(IOR%R%;>#PT<>)$/%X`U96
M@L!E"6`.S#),1>84.&5YEAR782K=!3Y8B0_,H"R00[*4E@@PA3IZ`D>,/;@!
MEP:,X3AZB4#2,,C10@AF@,(<[5E2?I,*X:7`O/%Z1GD48K0O;PAG@.T,3X@N
MF0N[%!E#Z)(&P3$#7R"9VZHWX)+.49[$`=-?<_\_22HQD5#H)/)7&)/GI4A$
MDEP`B3/W5IHO)W>@B,!(SN9XTO,$F&9)8P(9SZ$0I5<D<0+69DR(Q@W=`#4%
M:PS@B\-Y<3@O#N?I',[3\]M'=I02CXP5`Z8[R'*"ZBK\`Z2582T2'.IR`2A'
M3<YFPV'102JL<G2O4`$PM"-O)#>Y#P=;?-\XY'1#1B!R'I;G,&M.@AW#X29Q
M4+Z5^6*4>A2`O,4V*"$)@,()R'K,DK@/4!EGQ8)I,`FH#HTM<8MZ(R;CY!8K
MK(1EP@.89-AS?)#;A@)_AJ3.BXS*B6R3%/S&-/2)*^9!_@-Z8&JEQ0;84^#)
M4,5&\`4,!MPNUU627T[@8Z58&1['&ZWR^#3`.B[RQ^G-W((A<O\>#B%CT=D,
MK$\XB`EQWY16T2NK4&T)H(2+P`E658$\^(H\G!8%61@<%D[$&Z/R.'I<(,>$
M:TR5*WZ6X`,/Q'/PSO,[#[^@H`#1+@410VD%O2!7L11,&)FK)(1D4Q`14RC7
M?IS,PAYX??#K_P6VF/B2UV^XZ.5W-3>;"^^?(_]K<CV'U?Z%MC+8G9/Z\S]?
M_ZOV7(_Y/V`\//R?\%37U\MQPO"ITSKNEW-9`048I#$SIC*FX]AA5]8`0W<)
M_'T3"`V)16WP$PJ.,+N7"G=9+*C4HE?H.I<O+R,DY;M%#5UM8<::8C>T-%.#
M5?V<()-P<^Y-6"%"7X!,+@=PW9QHGA7_,1,8E`](C#GL!@,#J.;BJ>Q'*$.H
MX7Q!W&%UX7#6V#QSO%"E"&DHT?4N[K6PP=,@8K8I?W6Q.=I:3RH9%ZSF("5;
M%GF?\?$KJK"L/8)L12)W2A\!)FZHE@KI*%O>(#!Y2(*9G31%0N(\32(A&T!B
M39.4&39^<3'#K01:EX=,P$2]S7*^R/2IL\1&_2#B2'J2(^#70@PW(*51VW-%
MC*^KB9I:``)PS78I98M@@K$GT!98F@G+D\G`)20S=L)T*@.QH#\JOH#5R[I+
MW!K8*Y+_Q0\CJ@V%-7AU:(E<(0ZF2<!^3HYZE3AHL1['1U4HAQ32B9_FCPH-
M]SCOWU<4B@@,50ZAH9$(Y>6;&:MP)22H.?61"F62)&R``JHQ$FAE5>J"[MX8
MRU;HKL=+BG'_8,%2\!>+6_&]:&)2%2+*F9)`-^EI])[C1\1]170[ARDJ7*=)
ME,,:;F22_2),CJ9G=.[R=$%&@B#(`%YC()&Q`H<6!]->(4N%,U*3IGCNY0)D
MJB-1%()&.-WP7$BJA'S\Z($)]3MTY:?<"X#?W=^!-XR2#OY&AD6*#4+2,\RE
MJDE`$L^X`6ZO<+[V*S)AF9/CSAP!8"JT#1%FBD%4UJ*Z>[2&:$O"0,%P+S)Z
M::40/Y&=(OG,'P,A'RR$?*P)O%Y#/P`C3Y-"<!`>;BDD4P/J)@IO>:TNJ0;2
MWFQAAB[1%($Q5XE[!`%>6--(H$"3933E\`L#FD3&0JCCZ90<"HS:\>._DKQ5
MHFBHE<H!HQ:=D6F[:M4F,5L]*^S:1\@'S[=\69S$<AJ@X<WLR3HR5Y%16V?U
MY)X^MU)J_LAT>_5]58)F`2O<8QA_2:(O[(CXCNI;^9$+\3?AEP;493>(.@L5
M/.@O%EC;3P*4`T&\Q`P&I'Q&%GPWY-]/D5^)(XAGBE4S%O!M@%F$`@2AI6'V
MY[K.#&2U;<8WT$O\4,0C5A52W2;&D,OTB[!A:JH%R&B*/ZN1%YFRK[XI^A^@
M0ILVAF$1)(5XFU9U'CEQ9./,P:9'NZ+!^A6..[_O\;/PFGO2&LG*$EQ\C):+
M8,Q3'L@DP4#5-"B[;(`XAZ^SK`Q5%>%L$,]3O`XG>F'!$7;'`8980*&7'O4-
M`<N!W:6(WV_X`05@P=:D#UESE#S!..L"=0J__"/#"!]*YG,<]^Y'_'J>#-!7
MWXBP/QF$RPG^.5M&%,2I7-M09+9J7!1[0SL*!"[^"N0A>S62"+RZ$A'*DH@;
M9?B^64CL?0=V$LG\)>`U1<33W1UZ@,WS*54G"TVA\BQ4#0FV-(_QUH.+#++\
MREO3:8!'1HX!\F`I3M`2Q?NU`/:&K)"Q#=:/JSA3ND9(1;0-;5-L'T)R'K5;
M%,X">?(PB9B16F]XLKIJ$<(AZ3%)61#^+/$P,J%^IB8V'ROS[SIN657"0VR&
M6?@%\0J'$D\>>,0(CI3=[9126-C+9<@V)7U%,1G&,UST?\UQ;;2N*D&O,"NH
M?(-DWBB"R6T)'A>UZ)U$W#@\(S$4\Q`[1P]>$]UP[@G=5&*N8S9[$+U[_!LX
MHP*O:1G<1755C0<^>AY"KU>"[_#\C1_1^69W04`6'=\4&D6EGY:@&5[1FV7\
M!Y:(,?M`U?`B*K]C1$@77G2E*?G,0N-A^I5M=2%LSEKF4*ZI5$TV[6+L_/<B
MQD5:*-O4[8?+A*IO0+^M1,Y)KK"O`IY[RV\4*:4H$UK_)O%3=@L:`@E@(S&D
MFP<1`Q!46@F3P&\#T$OLC?Q]P@>;LI@-WIR1F&8A'OSF)O(!EFR"OEV&5]9!
M5`^35Z'EEMH*O.5R>!T7!2P..>>A6IGMA5VUI@GL\4KZK8R';'ZB^+WTQH\R
MC)+B)52,U(U/`BC`=O(71`F\'OR7NV3Z7:\>DZGN%V-/?,<44V%R_;_+,`O)
M2J(@NXBMX$$S?/)0)FE:\3*\NI[<E?W([O&T:%^%?F>?H:\#3,M-9A+B`DKV
M"[H,Y`XPO_$L\%'24R%]:.=<)XG-L!V?WSY>QR;K"!]%4T'\/&9%IB10=AK6
M+Z4:;)%-0M@@A0]`2889&JS$*FA(EF1888N2YJXW[`>E:75')$SAP/Y#M[H)
M1R^\$:1GT9Q?$%"85JDB2.>/V6#/,FC6O.VLQ`N'C4X?'1/;&P>23[!H@8Z9
M<QCQ;LV(X]<#38G'7%DFW6_``@=?!"B8="VV&=PL*WM%?N.,B)XG-R+]9DO,
M0"DOM[F#CTH#B.PN\-F.9OY$W/73_J^DM['$/1]I$J:3Y9R)F*S'_)P_`T[9
M9:"FL"P+CXCE<T[N8,M@$2=3MHOBPI%=Z+!+7<QT8C&.37/>,<+/=EA)[117
M&/S:OWI?1R"`R*1UJYOGV:8\J$X)5L).%L&$M!2/W,CB@END:G$+CZD*A`P1
MFK+H:0$?Y9LP$_M<!G.=O][&%!/]Y'_M9N;.I[N@>I5WNPQ9=@YYY^7G=`,A
M_/*<;K-"@@Q5%\*&23D9V-$W=`-757#@(P?9'7K\S"SR,3+(Z"OG2<U5$QS?
MQ-+&5A)?:LLV%R-K"'OIBZ1-3%O^$V@#]7[=!F>?HVZF!]CMX)4T3I@B1O(5
MLF#%:N_QAXK44'$;.T^`]##5C.R*'%/IT/QGSV?P(Q9)6B[(SO+QYIZ>!QL0
MUF-^A+^$M[/>QYW0_B@@\"S*!'MFE#7N?V=TAT!T3K3`S4%"`_C'[)G>NDF=
M=(K5K"?DW^+J?$JN%<]98EE48O0X(#6_#X*X02HL7TLDH^!W\*Y7WU0^OQ$U
M%)LVP!,H.6GQVU-NH`6QS\@(J:;(7XK\>YY0*C10A=:`R@+*)\,X^5W0A"-;
M>09=NC1CB:#\,DCRT299G2,D^;<^REEP'M?-D\AX@GM/$@J,B(]L67'W6MS1
M]B06A:N0<86([_SRXGGU-2)O(`U(Q'="[H[18OPW68SO%UWU0SV6JDJ*O)).
MP0MU4)'-X5300";:Q+CM79)@30+%H/C-&[LMIX`P.88918`Y`5=^A/D*&=[(
ME-8TNTUB-^^3D*+48,<LV:5-L6B8_2"IW['$6@IH97FZ)*%[PZ*5XM\]2?M.
M"H$\OB0$58_X0R\?Q5!K3`"E0>W)\XL[L%S^N02BQ_Z(9+/X<];HF1DHI(2F
MY+-\:UXI&(R.$#>\0`4;B+/H^3S,R(O!E,QJ#1-\O&31P'%PDV*M"KY*093\
M?/VO5XT2(/H*/J=E&LE&HLUXMB[#81K<4&+'5R0E\(3OJI=(8CNT*DF8("H$
MCR`8?H?$H2<PRFR':GQB4=P;K!',KQJ=Q&O1[]H^"E%=CWVLV<8]W325T3F?
MM5,FA=H$%_%0^H*\)S-69?#1`5<LT._/0-<@F3Y@_V^L%>'1WMIF.#"US83U
MO:`DEM[@?KYCX>B*:SEC)K.@$_8\6.S$^-Q_7K/##DC1`3I!>#[TQ^B_RQ#`
M0DN_B]+T]R)D"JH+?@(T0%8:T]+LDC:,T;?GKI)0V<7-4Q0"A(SC*=UH[N=\
M%`62E*N`>'V@SOU4-\;OMLM87.%X8>$:(BPH$<;XI-%8G]\=?&4Y6$AR7-'#
MJF5^'!C/:=[8"\NC+N5G)ZCE&C<J?\)\I+<EGKM**G@4#+<RI5!52:,>>B^L
M)1G$K)SYJ*[I#J@2E<HJ9BO:])1%QU*NT<!BY7`81`MA7SZ><U;,.1&45+M&
M(+JZHC3O]9MD0D7$U0!!=]([=-XEE0B8_:U5C.,*M939B!48[D(004#!#T7`
M.,6\`F'5D8CC%F]"MY^(&AX626(N=QF;K6EZ7\EVK50RM.V8'W.!7^2A5E^*
MR,1`#3J98#N7ZM+]D5@0_)8W8+>"495_1["5R;DL9,P`Q&@Z@8@,SB!$/V'U
M\"LG5X8H11H4FC53'M/D14C,9ZI$H<A@WXQ7JLW"$C\T.[AGU2X*>:!Y`-M$
M(0]A!N<L,K]*_\P00Z2LY<+R(`AA:%M6Z)4HI_#3-\XP*9]`#8#/A+S\5T8'
M"/ANCH7&*6,+D96%X3L:!U,4?/[`.:K,-"@2A]&ZI@10V"/CM<K,%9YFBE$$
M]$TI\(WV5D2*0KRFJ``G>DO(TBO69!D%)'`8-Y0$2E$.GO;*)J60;&,I":"9
M;D%LX"917U*2A9_^&>2%&N+[YPL^4/+V#?K=O'(:,![F677[`@O\B2HS9F7^
M=34G"/U=S&[-T>.!OWOX<(X)ARSYO++IPE%FVY2^)+@>12:$%<F_H2HL0%HR
M9RZ*R*^`0T0O_+XN!*ABN('0FI=T$X#/W0!U$YTT;JPH"[,R9X:1&'L'#I1A
MJ9AHTA>Y9(T%R>UF>Q/%(G4Q-BT\]#1@\VMBM'S7K256*K90G'.I90AAI3+T
M20YNGG<C)MUH7;!!!DF,W>*%/H&-#P!=X$5_#+,_NVB*C-?J9SK/18(9)ZQ\
M0-Q?L4+&2C83,P,:,$\8S)3>)(R$\CH.?P#F:8_^%YW%TDQEMP5K[0TBN3F&
M?]'5*6QK4E:S8,KKSP`("IO5S8XP7[*]83CLJT@P*YYBH0!ZCGIZL'>1"2Y2
M*-(0O<LI>6J%FN3E0<P+%K67E>)^/RT62#)^?U_)`T/TU*%BZ6--V_T1I(A,
M/\PG*T#FD0T!-+V"/</2_AD"Z"WEH>"E3Y&4A\Z$#T#S*YF;O$8<B+JUZ.U5
MNV*0)L'ZVDIFE)PML`T/78IA7I2(>*(@H)]^2BD*\$"UI$6R<L1D&@9!;B)P
MLM%H`4<I8((D#6[]E%4`\DRHI@"A&NZJ^U+Y5L0S6.07CT=<XA:GDOFS@$MX
MYJ&!O.^"K/D@&B_@SD9BL%P7A4SA[U2'X3$=*;:-3@CJ-G$>7&S0<8'9Q<7$
M@H7Y)C2-$>BS\CCR2#++L3E+3YHMTSBD2T;6@.8K_BTX-,+<1KH1`K6(!,/E
MRX?U&Z-2)O`(BFO4BM%=*Z\1EQ,B%Z2LKZE.U\-06UDORU@7!,,,S1(:\`8^
MPKNU.^2YT>"[ISE9F,6;T!H*1*%IF);OFU'E!/,RD)[970(A@+(+J@U#4+2E
ML+%[K`Z@N\]*C(*G:M.EPJM*EGI9RBE]#-#&X-R&[D-,YA6['*>%6$4$,T<0
MJC)'1F@:=EL&_Q#64SAA4#0NUXG#N2G2`4Y\6TQQ[&ZXH;@!9P=2XS+1XH!(
MDE)C<O0R@%!N21GP!`=B)2K2PZ2#:EH:J]ZFVP,_+[0U'XPIM)K8P93_B"\K
M\F$8/R1-PQB(E^<DD^O*GL&X!E^DTF^#DQDI;IYCP,,CZ+]3QE@$:\?,!RBS
M$%@HFD5,Q1LJP'&01.IM1;%3A@)>517M4JB(#^^2`8TB3,;3*WX/"M8E_5I!
M09G](SXG4=$#9@-R(+P6*?T4[V-.CM@8I0Q3?)^%^>X#%$K(*%BC>5MA?BX2
M1'B;7PJ(=3#`K6I\S"0@<K/-??[[DM^#E98!O,-#F$XI`U\8%_7D#X;Q5]]4
M#SC`0;\LVB/6*@EI/<D@';"(4I%^5PHQRM#WY_4SKS(`Q7I%(X3R[-<H#"[`
MRQK+2LD97>F*^DR1FULV4("S5-A9=D)$7H;\7H;\"M-Z'18O0WX/.N3W)26)
M#D0-VJ=4=)'\D`9R\?%UOIP^8*_1=.E'714EC>9/7&CXN.F@VK$I*S+O:_%H
M)!+4_(_U9:HE*V'D5C1VJJ5S\JQWH-HEO_K!_X%]L]N>E1VQG,VB#I"*_!H-
MG6I@T<LI[[DN$2@JR_,DBY8=-P^-E;EOSJLT$;Y0)#H-/KZG)E,?&JU],/&+
MOU=DAF9%;T62112GX38!13.Q?!8W+L+;HL]+67,(')@F4204%IA((6\)$^8L
M=R0$75^D`K*74]6I:)]1!ZLLS\4LU5??,#RS#GO,"6*)O/<ED;`$,HR,B_X,
M:"J(]/8"ET(J%7FGQ88BNH-#<F)EPRPE3!0/L[@T41K/^$?YN4BR+*3<F?O"
MP@ICWE6/6E#P:`NI@AMX=U#)[V75)=@RM^RV53AY[,S!')'^D=QCFEF/6=.L
MZ9YHEL8LL@H*RB4J%$ZQ98*@W%J954:T3>#<\^R1LM-(2F@4_Q:I%2S5F!JO
MK*-=:J6!0J;LGB11T/X6="F>YB()8U9S#^?5:^KEC2G.!9,!#BC,+\4!$B!&
MRF$Q;F]R;QSP!DHY29FKU&OT\.!\^ZK>QHV9L.4M_U2T2RN3G45$_WIYD\$1
M,(.#9:.P@&G!W'A097<!'X-J`1$WSUTI(I@^%\5=,#RO@UM"]4>1@]E%_?"^
M2+_)V':Y4\=O<ED>0''GS"Z&*9$M2,%U9PGME#C'S,/BFAI-FA0+X:L!VY)C
MPLJU)H;1T5XL$X<P-1C%VET8S*0R04BDZLFHT>CZ"/Y@`D%\50W*`L$`44QJ
MW85X90(6IM=;8E`%=%+>O1+YHN'-<]\:5_7P#+BW[*L;WJ><18>P3)NCLK+U
M6KB;@LXQ=?"FKN^=H-9!+?G@'0CC+I+K8#5%@J*D,[H,Y/5TI5#@21#<R,6<
M#5$41UH"V[:*9H]EJE39"1);UM4M&'SN%4^MNX_)!D`2RY@%0RUG6F6%4`AD
M-<?D#;OA^4ZJ*I5UU_Y7*[AH+$#T2Q?6:3#CN8XK62BOJ-7Y`;)05I);:FE_
MBU3D3K-*.F8:MLY<83F>41D;7K`I`-V(P'X,1,X4]V<[R3:BNHK':O!`JW75
MC?ZKK)2<H?O5A@ZS50*K9(TAQQ0#+X37#9^(_M7$G_RMG!<7E:$.%$9DA:)U
MK+["]AJX:7)J)[GHYEJGNI*4>RO)5FNH<`L:)%>D0>*%J]X1.@P:<R_2)$ZP
M=JFSV8B5U'.=A3O&WG5?!(<KH%QC^SNL,99^6TR9\?QK<E69>0`+R*K:*QLW
MU":%,*/EM[C2@^"3_U7JLUHG])*I;1YL,*\81*@#I0%&=(!XL<(92Z"N61HC
M/8\_Z"'%HV+!#WC&1?49:42=4DOL-SIR7O\F\<W7DMU90Q94$0O1>N4+]6\'
MZQF+)/*R8"UIU@(55,J(OHF&914-6,S"2[YX[UA*T2L,EU<\,VS20`//YJ3G
MHP(-]$^>@E%]`N]0"0U7#*AB[_`W*Q*BU*@TP5Q"?K&!0G\&1B0`1($IT:B0
MT@/#>:$,BO1*K%YCOZQ<7E":.SRY&L]231'/8FY6+#H-L'IYC+SZ4Y'J_SMS
MO.EZ$'/0\`M6XU6"$N-R!JO\X!W81$8&3^F?)I568-B^CE,U<Z29PU2Z-C4Y
M5Y/"1;\S47'?D'UX%N*2H9J;4=83EEVY6XTZ.O0XH_JPI'*(6SFUC4=:/*0>
M*G=GM4S9OX6/X)6]LS^AD73X44DC0[&'JJW*NJDILF%88]DS1J8\&KK6<*#I
M#OQGFU%)1\PC_<0"Q0(A;.Q+(YC1J#*I]32HI1;TJ9'&-6^DP4D6DRRI-P7V
MU6!!9.Q732WXLA].F:)+0P'9*`G@#]C3WU_#V>&_%]ADD/_[/ISF=W]_[1A_
M>RVQ*8;T,=]5__W'X>BC/'C_[IWWX7KT@_CC462OC#46PU0GY`W7)IC61IY.
MQ6YL\V^M1YD6SVQ^Y%"?;WJU]8)?_>A4VJ?/W]DXU7K]],\6H#>>V.I9'#(%
MW``?J$#DS=&]=3)MS/;DO$?#Q?,UP\6KMN8?H!;+C5$HM_SGVANCAJFY'0K^
M,H>F'?',ZC9R8X<'.YE#/'$&?&@7?-3PH1X+'RN<>W.+`YA`*?]_@\%H-!Z_
MWI*7564C,X-QL7:8,3<VHF"6$VJ">=WVDL6'.QA@8OHP;\W$C=55N^C80Z//
M]KO+3O?XW9YZ;4]>T`_,"UAO(L\PN;BHY,.0\>EY83MIR_])HS/H>?7*7?M@
M4Q2O>?7?CKW;0\"GO'#XM"O]*/!U39<=FG]'HM1P&E*+G*GT@(,,GQW_*E?*
MBZ;O"WP'XM^7P:UE1?"SXU1;NS)>-"G;^DL'4#N2,?&74;94:/&&E>$].P:V
MKM1=3_]TV[X`VB5`ZXS]/=WJ5#]8N8,\["UA_0:RTK3I;3P,;G(OGOY"[33P
MH1'E@EP7N5?P)<^G^93Z>./$"HG6W',>["Y2,SU3'YB:/'('MFR,#$_V=$N5
M%6?LC$9]<^B9ZC9WD4=)1=&O5KI?=2++9',3@EKK@4<:#[SZIFWK`7I<S/9^
MK/L`C?AYM+M(C]_[;^B_@-E0_FK!)6\W0,6T1:L:6"6_3[8JR=M40+GC[70Y
MK"UGHSN!+S$A]O_8I*P-,+X)63O%9)D!7K/ONGO1K"I*EVZ:+6/[FV;]?->]
MEU>_M%>_X*O:-+DO_M[K&JY0G+]PF4T?I-+W?"\@_<IM5CR#UK=RU:V^*(1Y
MHA%)`V-88?_\4&0="BV_%>4$VR'A)"[&<2EB)*K1&A2!26_E1BG[[7@$<FRA
MU_2^UME!3R/N1Z8$?G",*ZUATCG;FOQ/V;"/.`$GC&F<1^P=AK!_QK*>$[/S
MN6%^1S5,YY9A70L]'CIG9<#=UH"YNV5MV3E9M0W!K=[TE@LD%2&$[N_:!4\7
MK=OZV6]WPX"M]@Q%^XL`J^]\U?#,`'VCF;M"^MVQN7!/8E6MXY[A>2]Y#RZJ
ML9*62B%9HQ/>@_;Y"6HQ0N*Y,?#>N61JSU9W3F<X"=3;[6.'%5:Q4L9?L7+N
M6%N]H.P@6^W$M>0I^.CEV_WU&Z]GIT74OZH6L7J*]>QLW_V=NW/(LXO@[Y;@
M!]*W3YJ1\MQ=AF$]IH->P],C$2ZJX+E(1;NG*-WV)XYQVIT&^,4JA6>@'I`=
MSJD>F&Q>?/WQ\0L\>MLI&.U<O]MCSTWER"^-*!D-;XR^KKLQJK]E6\UUY%<>
MV0B]X/""P]/@L!M@=!!S+SU4]"G)_6@WIP"^P1>L:DF1Y;*11_&G9U5BW0-Q
MQXLVU^JISGF,YL[CQCC/;7GG\7+B.^=M\'%BSG&=BT-Q=AE['$-.9[;!-%EB
MB<=I[)&#O+-3YO`%BQ<LGM>M>+&X>Z(Z]E+U5C]!4?6V0W_5EUR$=7GUB5]]
MJ7J[5+U=JM[:H>A2];8_Z)>JMRY6O6D-7%^JWK8F[$O5V[EDV$N_TGA!56_/
M-?=IUXB]T7..'9/M#+#V7P3.-\;."<U=+G%#6C4O)6Y_P1*WR@B%YUZ+O"\J
MK)[6\1S5%YNR>4'4\R]X.#KSO'Q3_YD7NCU;"W]_XC?<;G>SN`C$OSJBGH4.
M.3H;79*8CKOG#8'N%YQ3?<'A!8?/`H?=`*.#F'M9@:E+#40W0-PQ$FO:/=,]
M3Q2J\[@YSR5#Y]%RXCN);?!Q8L8Q+B40YQ>QQ[':7FSJ]`6+%RP^&RQV!(XN
MXF[K`6''&N)5'Q4V\M,8?IU]"%(QARR<P&+#,%KB'*:=)WXMXY`]%6:)H:GV
MY]^NAY\70?HYP]=DKZ5I,`GG?I11REEC/IBIJK8^&.OR:#3R9'C<DCW'U&5C
M/#8&XY&GCH?*9Q7>]_HG6;DRW!)K3\!3![Z<O#9(YHL@SMB0M33UX]N`,-]_
M6#^=C0]F&WW%"YDL@!."%X;)]'<^O\ICXZO$]Q_2<!*<"9<#I>^.!R-#=L>N
M(1N6;<G.V![)]G"@&+IA*\;0!ESJKW]2KARU,J#NI,AI',SR)@O^NX0%1U_P
M38>?0-=7O($&7\G:L._(!E"4['H#%Y&D>J.QK9B#X9,3Z'[Q/O[\]E>Y__[3
MI_>__""1"SY^_^LG^?KM_XY^D-3R@['WR]MW?_P@K<0)^!*?WG^`WS=RAV_P
M;]6\DDIT2`P?)#%N"K-K[02Q`V^.!MI]&OW_G^2WOPY'OW[Z0>(SN>"];V-I
M'-RD2S]]P(1AHR?=!S0Y[MJ/DUDH42(I"),PSA/)QR3%!+[T@6"FV*TMGL(:
M0,>YSR1.%/DW?``=K1(!?<09K'B;!D1Y$BP#1("SO/E,N1Q3(&_#"=C]4>C'
MD^!*^@T63Z7\+J!9I)2$P^;EY?RU_)<]>)[O\SZ,(NG._Q)(R0*#+1*Y#QF^
M#A^=AQ]E3946:2!/HC`.)WXDS<*;-,E"'*FW2)/;U)]+N9_>!CG.AN,/S!*^
MCS3P2:#C7KQHD:2Y=/T03]-D'HCI>+!XL?:C"R8Q7F[?/@!2IYAFQ&;W,5SB
M9M<LE%56:KIIO__C[:>1?/W!&P!M5#+3Z8V:^KVF:35O;?,>X/V!/[E#&._O
M0O@C)`3>!%($6+]YD);9E?1V)G`^N4L2D!'L2)E`D$(VHI#$B$1$0//_`(?P
MI0"F5SNU-`CG-\L4OE]FM#<?R0*,`$K"`C@1V[3<;`4]2&/%/Z;!ER!*%GA,
MKU@M"AN"2&\!$9M("Q]A@`_%#HM]SX*`O1OVFRTG=R51]/`/'#\_Q0&&N?2M
M>J69<)Q`@VQ/2!_?:E?E9\O%+$UH#_PMN/C"#Z>(*7@]()+#3U,?XSB8T,_N
MP_R.5OOG,@YH:$VY1,E`!`T<R038,F0UDOXM)JGGM/$F9+`$O![G84I8-8G?
M$8^+90(PMT)<!/8&B`U"8*$J>HF_;Y>1GR<@(@!$8/8D1G@>V&3$I6#6R@$3
MVA<)L&L>`K,^T'$4*1"KBUSA9$PZ(5028;P,.-U5=D<;8?M+DP<_8KTD8V*'
MD-'[)$V(TNF?'W_U<%?`#<$R!_$">YLN)T2>Y5ZP5J=R'@6UD"3!HR`Q@IN9
M)#*L,`>87GU30DLK/C+'\M!J1GM<E#>)B:1FG*</3'XC0*L2O)#?A)FG)3BM
MS!!&E)0E$5LGS+(EK:+V=$7OV8XB,2M'<"[B'9;-<#XNXM1#C1B2[,-M@E4,
M#_NS60CB'?5)[4W`*SZ@//R"&?.+R)^PW0!'TL=@I.',5'KA*QJ2^JU]9=F<
MJ6'[L/];>G293NY\.CY\"'^H*E>*X-[5PUPS`'B3C=,PT.>+*'D(@NL@_0*O
M6F^5_9J0LP"F%=I?&<7XJ]\/0(S]FN1_!&`X31(0BD"QS"8;)RG_"'^G'LR^
M<OIJWQEZI@Q_F&!?:;KL]@U/-L=FWQN;QEC3C,_:9_7U3Q^T/_1?5&=8L>%/
M"G)S=#+05_#)_WK,\<=.W^U[(V<DFT-K"$Y-WY)=0S'ED3M6AXKC#D?&T^./
M3V)\:BCS$2,2H&2EFN?<=N>:2;SE(-Z,)!7L?0%*`G4,EQ\A@R?WO\(*;VZ"
M.)B%^7>@ZA8DHMZ`B&@UH?<I.$G*5B'9IF$!?\>6>&OV*6"2>)$%K]MV0'``
MN<WZK[(?0BVX78^X\.?M'5H66.>KH']DM\_^U9LN(RHTY3Q%4BVN*HX7=*TW
MWQ!\QL-SDBJJ#U<SZ(I:1E59J;9=TX2CD'9_!#Y:.E,R/]:6PS;DWY[!T<L)
M8;AJBP-:,X+S'(F*9P"[68/]%P%;/3G#/:UF7Z_6%:S?U*;LGMV,H7>C,=@^
M*F;]U*PA&3X2KQDLTQ3S@W:Z('GFE\F7G6[]N\.PP^F(7W^4^,<!6*F[IK;M
M2/OK>GFTRT_9(`?WS_IOL<,3EL)<\',N_&C*^L:WV\'_`E7HXU+D&H.89Y<A
M^ZW0=M),YUGA@H;GB(8V(F+QM1M9D$W!PIT;BM>5G@TO,#A&&M)!7W@4M^^"
MM0O6=L#:*9R+;5R?:K)#/<#VN!#9)CW]!0CO0R#P@K87@S9-6=_UZ6(LO'@!
M?E%[%ZP]+V.ANX'Y83`+TC28[AB9/Y'Y<N[?'4]5GOMWSQVRRTW!2W0EWFCK
M"\E;;.4`A<'/SQA^L[Z.^H*NCM[0/'^KXFAW%2])BAD7KMQ*Z%_0]=*$V"5`
M<G'U+UA[R5B[W*8<2QM>K(>M\*7N?)'RE\37Q7RXB/2+(KQ@[468#]V]7WE;
MU'2N5G3N=%JGLG'PRUW;.FKZBU'%^Z!!?3E![#W0<$G4V%+6ZD7'MU-)]]W?
MV"6E>,';!6]/]#(\2^.:>B^(,)-\[/23Q!/J`U/ILH1FP00;PV"_FB4U))JQ
M"V%8I6P.P1HV9?@@;__E3_*E'ZW_R9LP?O7-I6\$D>DN?2.L1YI`K.@PT6OB
M?,T;SMBRXNBOOG0EH+X1=6(6J+K!/RY](L[1)^*1`WE)?2$>!_/%](%X',Q+
MWX>MPA\C8=)4;!,>!L'6=MR\J1@\^(/TU(6N>WBW;ZR>;NY<S]SER=IOS)Y[
MVD#.R2#3>J9VG&23YY:.^CCW4AI7A76#K"?%`34)%IS+F?GD[+KE+=6:X%Q/
MV3"MJ"O4?0@0U9UC;\\#1$/O,A]W5R]_`C7+.BQGSX]UM9ZQ>TSYF=!UQS7O
MW@!:SG$`?%D*^.?D2Y#&U`CZ-O7CTZK9OT06RD'(^X*H$TJ.];,4NR$WNJOP
M!W<X'`>[S,_\,,6-+*DY_`2;E:<Y#2&(DYQF%M"ER7.S"@SSR-?,76$`M:?N
MKCLO0O'DJ0?/Q]IXEV0T<F0:W.0XC2B,;Y=A=H?FQ\7PZ"*/'4*<6.[.'O1%
MF'10F#P'$P2M#SZ"!],B<-;9L[,WW)ZB_44L#K.G.W\14/6>8JX?Q=TQ-N\*
M4W](PR25'C#O($^7@;Q</#M.?J/IW;[`VQM`W=J9II\%@+I^"(?H+Z>0KW,V
M.JP<3?;L>->R=@X'/2_%9%C/P.<_!*":<=&_6_#P>YP!^NS8]LWN]N2S4$BG
M[?QR>A[=O=;Z<#SZG$IZ7DZ]YJ%(\(*U"];^ZO;WI3;XZ*IQ*X2<$@V7VF`R
M)"ZUP=O)VI=4JWE*I7C!VP5OAZH-WK$,]EBUQ\I^8^@S.*1P%DY\4`\K(^EA
MB2EO$$]FBI]E`7SIQU,I"OV;,`KS$-9Y$\8EX)=28Z3ZG4;4&]N7&COGJ_<]
M>I7SI;KTM?5H/>*EPO<49W"I\+T]1H7O2_?NAZN*\S+^_)P[?6X7/X^WV/\5
MZS`70>ICFJ848>KFQ$_3!ZP8.7U-UX[^OVKW#&OG2,AI+S9W!-'IF=JSN-'L
M[C2)CT$6^.GDCOR.:?`EB)(%U43AOQ.\`"49^USK&8V>K?U%LAC4GGOLVH67
M)>4+(R(%LH^7SR]-5N^Y[L[#B9X7<=L]??>N$A=)CZ]Y&^=^?(O%:"S(M$C1
MQ,D?Z!_!?Y<AD_LW?A9FTC2<`7,$SS%Y7.W9[E\DHUKM:>I%Y&_!`\\SHPN.
MV?V+&#&&>62%]M(N+5].1LHECV<7K#U_J^6)9CI)[D?K+LIVD^+1"6<J[YL(
MZO8T^SSF_598.@=N5+=G*CL7%KU,RV=K/JK<,K]X9GKCVB\K-VYOA&B[5]CN
MW>SE8F!=#*SG@K67;F#A7=>J>?7B%8+F]/1C)\@^5]V@GL#R?%G6U;\/U73C
M&7'0F_U8Z&5:5?NQSL6P>I8FPL6PNAA6+\*P6B>3VJ7F=*0#6"<4R:6AVC/4
M1B^I&.>4^N@EX:V+`P['28H^A;0(TC"99M(B#3),(9_VI/M`NO._!*!D\B"=
MAS&JF3L_E\(<!R'.DS2`YZ/PSR!ZP"]B[$',?H%S#5=5DW0?PHOP1S>!E`9P
M.O\73*]@#6\R25(LR(D>RK?BF,5T"L_[>)!-[P>G)\Z6$;PYF<U@[5??4$%4
MO%8G8D'4MYISI9>',X>MP()7*V=ZED/PJ&9K;46(A#4*'"O38G(+IM0,`(&S
M)(U#GR"-"0GKLHKA1_=^.J5W?&L85]H*&FB];TWMRH(E^&<].($,!T"%7P(Z
ME[MP<@<G=QO2Z,K@ZR),J2&DIN@*+0!_J%>2A]MX#!1_L4B3K^'<SY%POE6O
M+/%*,4NS!2AI$.%X&]A(1HVPD@711_`U2"=A%F0]6(#MF(@.0%E&.>X6R#2,
M)T!]&3V-A6#X).!TX8=3&7XQ\1=ASG`,B_A`3_SG85P;IR.Z;>,L+-QU#L</
M[PQB]B^\`(%]PQ+UG?N`M64>,N)O=_)^E"6PSB,$D&[*LBUS:U<V@M2@7UD;
MB$&[<E:^0:16B>**U2CR+>VR!SJ<M32EN6SU-4#BJ6Q\Q1IL^U_\,,*3>H63
M6$$\A'&8T_;KV)=6D$XH_U:YTBH4BC*30^Q%(!AC'Y$A_0*+SI=S&LXR6+<3
M$HP^R<QB0_7M=$,6T9$N\V5!IL686Y3J&P]YPP'CS^(-U0XE:A(NQ?F+49C[
M7SF"B.'F_@,JC6QY\Q\@/F)<I-,8)^=&X1SXE:D'-I\7>1T%"&SY/@[2["Y<
M2!-J8,N/`9<C)9-,)DO2%:#VOH3),D.%DM+W]!51#/$SVQFC23SCCP%L?PZJ
MB[2+ZCJ6]`9_!Q]\Q[8$>T%T)/.%'S^4QK3[(WQ!]Z(/"`<7!=(D2',?W[6!
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M69X"4''^$IC^_).&3B_GCET?VT&0C2.+]I=V]?]R4JHN^+O@[YSX>UE.`)7,
M[:;DH\[WBE=[RIF&DW8?-^<*@'0?,T</F+PTV^(EI<==,'C!X+DQ^!?L,_\V
MGD3+:9GJT>:J0?*?RO(+,TSM4XO$*<R[@4]G4KEB3[I/EA'>OV).:#A?^!.6
M.EIFV8D78E).,)NQQ#/Z(L7T/S^3HB2^A?_"(AN23M-@[H=Q5LL=HM31,JT4
M'BX22Z^DWP.@+=H2CO.98*?*AUJG?9$_F.&N1/P6=X!Y3+")S5B[#_,[CN4X
M^)H#F4AS4*QW64=R:P!T3)BKH`KSL"BUBF_[-\Q5FTK7.:`_:V0A(NH0E?45
M*H<9?/7G8<S6NWE@9[3,[Y*432)@R3<9KO&?91IFTW!"<3`*DVF*XM+[>*93
M1S#VEG*A\=07*9!OR#*3B_,'F/(@#3)J=_H]!OB#V(\(6I;!.F5D4T'2W,_A
MD:R>;2HF2UU1OC8>!(8+,REX+(&!<R+>,_/\7%4M\ZN1P"MT"D3^ZIMRN^NV
M6M]HL(9HOY^&7_"?__/],I-O?7_Q`QN3]<G_.@RS291DRS3X!)3?CY+)GS_!
M4]+_B%]>WP'A](&3IH/*4%LO33&7"U,,^P_E3S[X#_B1AY3PGE)_,T#,+`@Q
M22_SXND(4TEIA>QM_(%RVZ4)L!J\^V,P^_OK((D^?Q@YAJJ[BBRKNJK(_U(4
MU?I\_6GX6;?,SX@[5=/5S\IK8.B0/97A!K+7R/3AW(^RO[^6]==2./W[ZW#Z
M65=-2U&LSXIKJ=IPZ,H#T_-D0W5UV1W8IFP.AWW3,X8#3S<_JY^-US]II@':
MK$36T5%0Q[AHS0N_'9:9G"-&:1_`?Y\\[(ZS!E+ZIFIXPY$KCX>6*QM#5T.D
M.+(R&H_[WEAQAD/E,S[X$](1)Z,F8\_]]#:,9?#4?R`>YO]FQ@/["/T4.0.*
M_D$M_ST#L1,]_/!('*#(2`CQCUK/X@IJB,3#POPOTQC6BJ'*;JT-NT74RI@#
M'.<_&'_;:?<;^RM/DBQG^<]<=DQ170+_LH17_'G(-/^K;VISI.DKP?)"=?5`
M7L3RQ,_N6,*]?(,TV'BR)P'-X*ND61#`(Y%_DP`%)BGHS^5B$85<98!B3B8A
MEW[8\_PN\-F.9OY$S*6A_5^!=5*DQD["=+*<9SFJZ8P$V=S_,R#S(9;38+:,
MIRP??_J%#)@%XQ#*+UXL`4=XY7*;)#PM.0O2+[!=4B^PB,AY9HG^&_.<4<A_
M83N$-;,E&@1Y0HB(<U0!F)+LERS+0""]!NM6-\_K#%!+@$`GM<<R53-^`EC_
M(@Y/Z%]6IL.RF.^I2"8@B^B.0X8(35D50@$?T@`\A_G*P1J]N2JT6PB&-;+[
MYFG!=;-!<(U8V0:>WN\!!@."J0=DX=\&'\EZ"^/;08G>3T$Z5P\GF2Q'MT?F
M4-:&JBH;9K\O>[IER..^J8U'`VU@N2B9]-<_?;#^4']1]6%#8)\6[CKB01Q@
M\100#?ST0YK$\.>$T1T[)_:_A<H]&-9LQ1V"2+=D1]=UD.=#579&?4T>C)S^
M2+4<S]'T;>2YZAQ7H&,^FE2B2JKCJHN"':3&/Y?1`S?BD,''WG4?K,UL"7*Y
M`@K8XB#X,/?_M\44A"H\^VMR55J"N(",EE^!C@^LQJ\H[/!CL.LKMB#6-_29
MX$>G`(6)3^7F[XO*@W=8>3"H5![TX"?7(0#DI_0\_J"'L@B+("I%,=5GI-'7
M,*MB7WI3UDD,?O2N?Y/XYLN/AS]^AR6#G^[`[%X2O-AH^DLX!1R"K`1JAY?<
M+L,I\V%Y\09X'3%HG`B.$)[`,X<U%JMHV.2Z,8GJU\LO8(F5`@Q$0\;1($K`
M&!HV57;`*@&AX8H!5>P=_BY=7H"QK+LBAV@&!C4`1'X`%F8QA0[F>S@OBCD+
M?Q.U#_LEJ[:BG$)_!K]>ZSRH9E$(!2L@8GA]';X8EH$M^%/V$7?Z\,WQE%74
MP1?PRAHH6-&E&CVF31->`PKV`%-=N'N^'"L!A&<S3M6L1(P\%A]](X`,H!;!
M@IB7=)0'#`*.5?3U>"$0&X?'S@R=R20MC)OB*5BA(`QI6G@JK3R<;45P0X`O
M$?/O9P5G70>WS&C9WUOA2U7=E;>_CE=$N65:KNZY-BC``2C`(3@M?=O3Y+ZE
MNT;?=-6!Q4USM0+UIGVW<>J8]@/K`KQ#>`9H^D/DQ]F!70Y#US5[H"GRT'3`
MY1BI(]FSG+ZL&D/-[6NV9FE&=U34-5G5A"JIBJLNJB8,$S&2)X%0<0CJCH2P
M72OQ`_HM&JG,`))NP53B7P7S190\!-Q'F)-($K,LI9L$90'\8QJ"A`:7`BW=
MFP<IR'*L)*92,!3T?IA27(_"EX$_N:O7!W-]0&J#2CGI_6#TBP5N(A]@R29W
M"8XQF"?3(**(8!G1V>S^%/"6RP&:@@@Y!$"<@S`*%U$@L[V@T,-*:-CC%:C?
M:9`^]43Q>^D-KPC^,T[NJ>J1[/_4GP93^0NB!%X_#T#L3[_K<3>![[ZZ7](\
M;,?HA-$B*0YJR$)`#W<?A,?!)#_B,UCX*=5NP_/B96"BQI.[0!1P^Z3=:5_)
M\O:N\MD]^:`8'V2N$*PAH&2_R(3<QF6Q7KN"CY*>"!QVHE](A^$;Q&;8CA\)
M$%:96CLMFZPC?'1?"^+GA?9DGH18U!B11,S"C"H8&VR134(4H+-P@EYOF*&K
M3:R"%D%)AA6V*&GN>L-^N$-=8<=Z0)>A%]Z8!F5C!D%`85JE"G!86NG0'=1$
M7<_`8_,P)P4$OT>?"=X?@&X/LC6!QX.I&-4P'6=H:/+0&MN@.E5/=EUW+)M]
MT^@[@Y&FZ>[958QS)570PV+V500=2*_LL\6*7X%W*9W2=!%EZB:S&0I#&IY<
MB6J!%0J_2"8DGOQ<TDW#E/Z9W,72/Y+%GV&,6FH`C)KWI'<^?!%%?J_:TH!*
MQJL^SY@%P!YJ#@^)#V;H3I)TD=#=%\;,_KOT4[HL8`$C'K+B0;0'L`11JY#U
M7G%9"![_-@V8N;NR!78$-8>+BJ[I<U0@<QS;@\X&K"9<5$6,_$%/C&F+>I\/
M3>OAS6V&6Z;X8,X4\".([;&&$%P1_',9!_@FFP)JOX+`04D(*^#]!NO8,*?K
M$))X[T2##UB")LV!L*RL3Q_1F]'TIU,$8Z*^8[NYX1X/F!;*G?<.88#X<>-Y
MO?9\DF!G&A";1"K5\.*K;VH!QG*75QR*(HXYH[L?<(XJ74MH\V@+!;>P@_=@
M&F$G"Y199+<PQZGPW_!&CWKYT.TI(&&"2CCB3E@DVIP@KFL!!!-\;7@\"[_R
M"\MJ/P/I/@US</_0K6,78/PV%J3U-$K2*>V$]]-`C^\^*=0.G1!S'>\$K[%X
M;+:<8$L"%MT$8I4I09Y[MN=7[AB73N(XH"M*YB8C!$`A0<61Y81(Y'D?I$6L
M@J[]@IC?)C/EQCJR*)4[<][`!DRF9<9,!;0$\G2)E]+BO,!2G:(_G")'P$K$
M'H)`5E_,PNS8.0DM!-Z'!J,3?#?E0I5F2Q@<J7?M4>JM@E9WBM'X*IVNW6MV
MQ0-=?@Q<\L!O*$O^Q04+KD[0^$G0_><A<V2,&Y^Y$]SN+'8<QOPR'@UU*15X
M`?S]!]SSVIE1W!W>,><=,\K7AZ6<*:5,$YL4O"C`W!J-]@8TBI-AH1.]0.EZ
M/+XJ^I3$P7W$FI<L0GB<Q,.5N-A/;J+P5KAB*1CR#S4^Y7;T8S#TI$6TS"K7
MVCEF4X1?4:853I7SMQYZ6CZ3%;`=-O.MXF3PX#8)HQK.2=64MS%SWE6'BT#>
MZ`-[P<!^Q/T5NW\7=(('_NH;.O*UK^3^#']I0QNVDRM'-#@&1;,6@@#/Z2:@
MUE0E+&S/A#K`ZDU`L3S@C!P)!ID!40]BPL<;!3D*XZ!Y`&O0_A'?QATLQ/]J
MFD'[)`.D8.'>UFB]I'04(%*MX91R94H;^TPU7"GRX8L)@H""_#[@?;<XQ13:
MK%">/M<Q=<3PWC"LX8V8U@ET\*HVOC,F0M\,OX!<8Q*K"C<L!*"YFV%=`REJ
M2N1-,4'QU3<LX:(G(1$3>W*3"2S,9<KXDLF.QGTOR05VX_L(:5?H%#5FXYI]
MA="WR6-K<65_`*YYNHL:ER>\9900*W42X62/PJ328HEE>E$?L8PW'J)&0>5;
M6G4,.CR.6;.@EKU]+.=OU68^C>3*HFF0^.-1K#>/:%W3!['']9V"'&O[3D'.
MR7OFK-2/ULZR)6[6P[:IV(33013,\A_4*T7!^I$J?\CBPQV8!&]@=LK(Q6^J
M=0/ENSLW,T#M*=;Z"H)FQ^.=\Z0W51`\6Z(P7SY1J/KZ[A3'(XJ7)SNLET\F
M&N]/=)$=;8G"?NE$86G&17+L0R3@SJ<!99ITBE2V.[\=5CC<2(4]M_JHS&%G
MN?CZ8S<K'IG#PF*Y0(*BK%S4@1VCW.S`K]SK=`["[.?FM`,6!_<4?7WA]&D4
M]/-A%IU1+BN1/!&W'.2=V['+YO+,8]^IO^-U#IX('!_J%OTP=]9TS29J,8K@
M=B:N/,)T*BW\E(H8J)*`LGZH^(%=WF%=1=E>G2U3#3W6@JH\M%9\AC>%_":!
MW^%A<(XO0W?$T^4DYV_F(7R,A@99GL0L^^M[N@%,DP=6@'95=-=OOJN(:%,Y
MY0S#YBQBC?&Z.,D)%I8SVB8/9;LTDGH*RM@/TW]CBLTO@8\_PU6.FX,_4G1'
MLT8CV1N/AK)A#TW9ZQLCN6^8KFNKJC4<=RC!$?%#<RP#B27VT!%T++/1PRJE
M":LB*C/L%WB`5/&#=^>YA/>UC'D2:7*7)'C!2P71&,@/9WCO%D3\9AA3#;,>
MN[TDNJC\*,R#.9925_*S,&#/[F4P:3>C&X.;9,DFC!2+AMD/DOH=7C1$M`Y=
M"M,%V0VKXA3_[DG:=U*8IL&7A*!B&=AZ^2B;I(``I4'MR4[<L(OLDGI^!T]V
MR>DB$Z/UWYI72G'!`MP%0B$/V;P/D#;S,*.\.!`'@92`.1'&/@X.XI4482R-
M@YM4W#\KB)*?K_\%S]:*$>@K^)R6J67'5*]M.=&(#)B,QL?<(&D`/H"4EF%V
M5[UG%MNA5>GRA\Y87'<S@JG<40=3!L:RR!>M9KSRA/Q/:V_'N$BFT@,DZB)+
M=F4?Q559/9MVS380Y').$T)+!1&4"ML$%_%09A>6%RP@KO%>ELH?A*O8HYI[
M/JL"<U::F^'`U#83UO=RBR6#;W`_WTDSH(*RW)\]7Z$3]KP8Y\,S,M?LL(4&
M::T%&GGRF(OYE@ARN,2,)U:O2RL!8]`WAR@)"+/$T%3[\V_7PR>JF/NV:1NZ
MHLD>O$0V^EC@Y0Q&LJN,/,OL#VS3&'U65?RI"X:>IK[^R3!MVZT7-+<!JXX)
M7B67?4J\"1DE'_@E*.9^YEC6#)^*"M?3H<,S!X8Y-AS9[>L.H&/<EUT3T3$"
M3.C6H*]K%NA:37O]DT.6;XF$]A`U2D.2N*#!G[&%!994G9@*3%6U]<%8ET>C
MD2?#0Y;L.:8N&^.Q,1B//'5,9=NJ_OHG654-LP;X!@#J4+X'/DXQZS<-[L!`
M!`N.M0S`@C3*])G^(XFF?`5<X'U\'4R6K&6$EX:8XUREK5^#_/T,Z\VZB";G
M]4^Z5</1L<!O+U[HNWH]:G"(7@E'$S6(1=,U6@N:M0#6\5-TJ0BR#YAJTT')
MHENO?U)K,#<VW1"C:3(+<ZK2["`P*HH+Q[*<NJ`L]OR$2KB^2](<JZ'?QEAJ
M<*AZN<-K`W"];$U1S,?UP3IPUM$G8F8,E@SS2Y=`Y>^+LL8^CB,+*B0Q^IJG
M/DW5!,/V+3H:((ZI1T$"=G)\^U9D\'513AJ,/MQU!'\4+-3170I?E+I5B7M2
M;+F`*\70QS)@I0]4IH-KKQG8/67L*"/+<H?>^+.)G0D,K8:HS?MODA6#OK,R
MSP1]:3=HH-QRLYO-ER`^M97<DJ#AB%37M.K&L=CP"JM3/[$A[ROV-OZ`B;KA
M5*0C\C8<8#>2[>!AD[-.2C\5;&%-<_0F#^\`7O.D1?SO_8Q^]"Z);U%^#M'%
M["`F-(?I[OKI/P+$JC@230E`JO'.#)E`9?91U$N26&3C!)C]`[_^(*8)G)8O
M%-<!Z%W9'ND@NKR!*?>-H26[NN9:AM57^@,/$0/\[5@KLFM_8%>J`YOV=:?=
M!)>I/[TNU1^!H@YNZ2ITW#ZRL05:#<:U6V\XC,*E+,V!+AZB@V=H.TK]#-=L
M_@E;%Q2>']]BE*J[DEX#_:8_8>0VX7A*Z_&>&IE0!!^ITQ4&Z#J)`A5<FD;P
M:RN8UAMFXH>,6KI(YBJX.)JKK;71ZKO?X'$##L`B#Z.0+'CX@/4).NTA.ZYC
M>V!HRHJA#F5#A^-V=-66%5L;F>;8-OK>B*DKS5"L]5[X)D":#;OR;LLMU5KK
MF]?V70<)J#H-J%*?U2"QVOT97I@*:@<;;QXNYUG']1&!;ECUT-)NX+6/OXUX
MGP7ZS0?>IA!#PUV.P6%D`V_$VL;@-@+9(*7I?Y8<@:`XBJI*=/;>Q@/6+W%]
MS[V/HF_)-6M;PM[]L6P4PFZ>.XQ2M/IT0ZN+TF,CI(Y^X8,5,HT[8]P(/RW+
M*I:EJ,"RAN=:()*5D>SI0T,>NIHZ&CH@L_K<A)2U.L,^`44K/234,_L(S#6Z
MJ>^@2D)7P6FED=:"])05)G#Y+O1ORL:LG1/<JDWW3T^87VN`>0I^(;<^L@Y6
M74<#QDW-I]"P&::&&PG\DOH1Z#=OB@636#B+5:J<G;IHO(`"MPVM;H8_`<:*
M>3;PL[L/O+R___!;AH)DS!H%QK=>V?VW@^>O@U8&\\4VFJ9;2YA:B<8!9664
MW`0_8![=OT5^A5<T/.B@P`02<16ME<3<`M(V70^[2#'.&IMC_>Y7<A.P%_C[
M](.?YOP?Y.BS^%O3V><Q@.D>79N/AP,#.UO6A>:NX#7-J44:3!@MH?BI^`]'
MQ(.Y@H?QP'4'EJ[*^M@<@3UE.W+?UL:R/K3<D>8YP#DCWN!3;T2I'P&A$6)%
M#,53_`^FLWSQ(VJ`2D9G4P5UD0ATO)+6-+N1PK(-6*VD)Q`3R.#EA/+.N`I:
MSW"#Y,27LRT%*(@,RVI>RAT`U@8]L<@^S9F!`WB73/SH63@D6C--HQ4D=>`+
M;YFY;AMP!C3)`HC!%.]"1&K+^UDUX>6D@L8PC8&G:H9L&MI`-NS12'94SY;=
M85\Q!ZYBZ?T^R_ZP&G+F@!!ONLIO)D]U\2K?6+D0V;S_#;<BG*XZ&5NT\3I?
MM]7U5R)BYRN)3),@F(J4#Y&R>^2KWE7:'HX&QE!Q=-F"5\B&ZUAR'P6!TQ]I
MVM!03<VSF!(UE68"Z&80-NB,,XJYMF%B$_7ERMU^JX#+!K><YT-TT3I@07'+
M49^ZX6G`TLHD^`#&1/I'X*>5O*4N*GX*M36N^;8`Z;#3OH3L+T9;T3!E,,S3
M,,["R;&CO3OK/I0/=D,^G`(7+:Y;TV7W`UPF^BCF"@T^"<SZZ]4.1[+P/EEO
M1BEJNVXE6VI69\?E"R4%*Z[21L!L@JMM5L$'7NO311K77_]$$?U6J00<D,TV
M$U[(883J_0R+6Q%S>Y6@'C&)Q,8*(M?9;#NM!:45&VRP3+Q\'$PQ.(SDM,26
MR^7SV,RT@TP"^D.VUDC`PT&]_DJ0/](%"[6E(TX&:C.:U0:8S;QT_E*9MKSD
MKI;(/`G(^H-?+VF[?_QHL:^_%VX#T>9`+OP=!:>-Z.X>U$1KR6KRP-.P-)(R
M:GDO)\Q'7#6RG8&F#$T#K*7^"(,GMB:[JF+*ICUT37UD&DK?Y)'LAHW].!!K
M8X_/B-CU#4''5M2-EU@TE6"]'W(.(QF(UM/LL2$;C@>P&Z.Q[`S'(]D&!]S0
M'=/K#TV>/KZ2,=,*FCH&J`4V\`#VP/:CXP.\QGO4Q_I@H&JR9=I`W8J'YZR.
M96UHN);K]L>*XC'";CJ/:_?>ZE*;9:MU_E);,TB2.TX]]M(>J"V&7G?1$S0Q
MP=9M5'@]"L4C!HP?!;^`T9>&^0,UN(EX1Y'W,RI"S)]!324ZQJK;R'+9`\@5
MLR>,`VK]DX8W2PIF13Y=4'TL)X.>]/86/**^/09W8#3HR\9@Z,I]963*UD@=
MCA1+]V#]4@4T#)ZG8=DA`;/,\Q0>V8!FC7<XN1+[,H!/M7UNY098&=;2VRAC
M`GB$@XI(P?P"2$"VQ.CGX3H]66-O:(_Z\L`<@JCP/!.@[:ORR+4-P]14\!EY
M<!%[LLJ*]3_?/[6W"@3%#0Q>,57G\Y9/'A2:\=`=>XYKR/H8;#<#?%L9F%^3
MAUY?,TQO;*K>^+-&V?:*KG!06FZR`A;>K[PM^AEEGICQ,MS+M6]*+6>$X\-M
MV?9,@`7,,;G?USS9&KN6K8^&8\W5BI/1P)OGX#RVN0H,GV@4R]MR$DN1<22B
M@>BR?P`/#M7_[2$4V&*9!E7FTU;/3]'@J!0`TK$TL,+[:*RX(*X=R[,&QMA3
M;2Z1E"O%X0!O"TD%"2,<$(6ML%ATNS)T]MU^Z22[<1G8(Q_T/SA83^RM`L7U
MY"Z8+B.\K4;+%`L9@Q1OLI-T3%WMA(#YA`&]PW>+4PQ;\SS#@,<,T"/62(=3
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MBBT[CJX.M('N6%HW`THL&,-&2<,R&6\E3OET8B`%]87'WO(I[]('J[`V[RDU
M($/IADW%\2>9P#B.R68HIQ;J(.C!\TI8<!I'QK["KN7=GQ7K&%V*/UEV!^-/
M?\U7[^FK.!LMEYT5\#ZZ"?D3N`$^4)4F63;T!N<U,ACS=09CQ*>=T#T9S21X
M]<WZV#/M[*;MT6YM7KZ0$]$.=2"HOPZ+\N<`LO;7`UD],F.],+_MVH^362A[
M7W#T3[:;5[:'3[#C!$#5[.GZD>=[=P=8I:?HRE\)V$NH=0L._OGZ7R=GV_U#
MHK9]Y$GL703:=9^=S-H7:+UG7Z[>]F-P#^,*_QO$P<1_AHSN'/O>HWM`FP<!
M^="`7B:=/T_V[X?);1!+;Z?!Y-FQO_G74WBJ:EZ8OZO,_WQNQ%[H-?@%AQ<<
M=@&'+]UGH'2,W<R%Z&0Y%KN&B-R>:9W'J>@^;K2>K9PG5MA]W.@]VSIG(OGS
ML3Y>;#[.!8L7+'8%B]OEAFV1V56K?5U;^IT=/@ML9/<5PQV.9<\Q#-DP35?N
MV[#,V#'ZCJGT34\=;I,%ICH;TL!VL(;P'70CK*I7$D>)5,5)6<907AROS<@Z
M39K:VUC2%,7M2?>!%&1(&&%V!UOV8RD0=1B&HK[Y\SLI\R,_?9"FU-/(CZ0%
M``(KO"E=[\&/_*<$8_'Q\,?OX.R_!#B@"?/5I``8A/+UQ2NR*XF:9V`I9?&9
M='^74,FEGTM1X&>YI#K20^"GF91$4TIWPV_C))<2'#1S'V;X_#3,_KL$%IR%
M`,82D)-2LAVV8*"*3OQ'99NT1K&A/($5%GZ:AY-P`91_552C9'``#T3"=)*!
MM%S`KR53^1M?-$SAT4EU^,("7HW[E=YDRYO_!),<'_!AG:_A?#F7HG`>YM(B
M#;()+`F;O7F`%6:L49B4^U^ER+__[DKZK8"ALFTZ,-Q1$/&%YWX^N9-\A@$^
M/PS/:U%6:L-&BT.=5&@2T/][(-WY7P*V'*42%4MJYM^J3V;EP;H_UI?A.+$$
M2JJG67NJP#>C*7K]W)\&TK?*E2H!O4:P7(_^!6OP?].)5W^`^9*T1:2K^D8P
M#1PQ1N2"V\#\J$<J<^E_-7H#)G;T,.5R$1!)1@]7J_*W+C"?%'VUS@>LYP/5
M:N/PW3!FC;&`VL[9R$&E=@%FV<BA[48KL/$FJ+PGS`?PJB</AQ?_UMCH]U7%
MDEUKK(#XMT=RWQUX\D"UO.%HI)FZHVXC_I4C2'_\(\0_!E$8AQ/@YT]I"/^+
M!/8A#>3BX^M\.7V0"'%^Q))BPD(O=$)#$&O^2=HA!&YC9?&8@^RSTY8"T?[=
MIZ\"'V3&#?`UEL.#+@ER%$G8`(.G-\_8%"``/L.V>*SM#PV3DX"GD6MG_B2G
M?&:4J&$Z6<ZQ"!ESG/\$MRE&&;/,4"WD=_@_L.\KZ?VZ'8$8P"4$LG,\@XPD
M?O&^&ECT\H!`R1+L6!=@3G!^!XMD;$Q`)BUX^R<0UXV5`4#J!'7K,\Z1<!8>
MR\L>?'R?7<$J8D8M5TP9CECE[R4!1H#?<UF,;Y:R):"3-!(EA$\#`(TVCDA*
M0!?2#WSZ+VPOFRU!O\9I$D7X(EP<]%B([^S1?F"-$*?Q,16%>V,OG_.^?-3T
MH`X64`>`E<2HIM^BRB<\4Y\$AA3"F3`A")M,Y<+!H/H)$]@PJ'^6S5[%Y3T(
M<NF&?@1'-0^FQ88B;#%%Y#2#;TC!P>_H8%FF*Q`341I;'S8&@"99AEJ%=I+<
MY'Z(*@(79L"FP:V?8N8Y/+Z,;^#=\,)B+],P!8$?/;`D>]A#%A3P\3-/`0'_
M2.YA:VD/UN`:^`:;0K!I/+C-*@K*)2H43L8*05!NK2R9)MHF<&!YHI)B0=!I
MB$;Q;]316$7`NHX]X-?K:!<LCHR$#'POX`&N\:5;4&YXFHLD!$(!7.%Y]22_
M[%&$FTEYVR\ZF6G9^*MD,L`!K`)8B`,D0+0Y8#%>A,6.!_$6`@FE2%710X_D
M@(!C*O@65HDJS<")!_P%X/YK\;L<I*1X,]9-8,]!./SKY4T&1P#;0G:G&5H9
M44C!W'A0K(P"/T<C#`Q")&[V:RZ;!&V#E'A2Z3^J["I*\8E)7V,_3/^-[=*Q
MQ7!1R8K5JIWLF&U@QV36)'Q/Z"HHPHDCHCD8+,5;1F:B!74F>E!CE1*<('`P
M^J;4\9]WG_>_?DC8H*P33R%17&?0UUW9'NE],*X&IMPWAF":Z)IK&59?Z0\\
M9ERINEUB[:``5Q#Y:Y!O;%KU#MT-UHPT_BVKM#UZ?Q^#9+L+%^S0?@'9C^[)
M*=HZ#0?ZR%$'0WFLV0IV(1R!43<TY/[`,13=ZVNCD<M,.>7*%,@[()!/AR^$
M^U?]/*LL.QMQ5^;`8_=:M,1JUZ2OCKM#0EFENR6Z5>]GO/D;[T]UN'E0M&Y6
MQ<?.?HX.?HX@I,=V775KBD9]FSN*G;8_8[MN:%K9NK4U'*T:P76Q2:?NOO[)
M,O42VJ=@+/N:LFK+78'Z;"N.8^M?'=4R-/=X;5DU16&*Q#6M>E]:`4'[`?#@
MY-$W^P#M6J;RU5851]&.VTY3_XSV!C9A!5^_,6BV%9#M\7+0;ONGQY'J8`]^
MO36&6O3D?^SQ8H(>_D:TZ:&8ZK/!F,:Z9+;&V$:0=^AIBW7W-\UFX1\#-O)5
MC"5D[^:]<_$'_]YGS-092-)=US#]R.AI1<*L[\$!):$._U]!*>M,4L7FVU_'
MNZ,3AP8S*6BJMMF&8!L`;H&4(XG!4R`(1:"M:X:CM\3/[C*0/;]1(CP7BL(!
M[HZBFRWQM1G>LY@?#10=08ZIGTW!>,_0]#@5?I#OVJO1%DP'7CZ++:&+OS\>
M3,TY<M=W\S/.$:/1$:IC64YS=$0)36.,+H:#4<>EP1UZH%\"]LMR#.\_D@BC
MUC_[8=R<R.NEH`WCVRJ",3PR^^1_W1]GEJ%8Q\69\1D=5$U?&3QX+*14W%LQ
MKT%TT:9!#9\.,XWB,QA8FFE]!53")[N-9M;H2A:C]E&09=RI;;/I3=.H$56'
MF$9=`*=JMK*;<&F%`)UB-36RV`S,J0^6P[X;7.C%=_M@W1TC&:T00$$XW=WJ
M9(\W7/UT4&\_:OV4]$S`[P98YP65K=CJ\4[66!V&UB%!Q6#?#:Z]!-4I!KT@
MF(YA?$4@URC:5F-?X.0TIFIT=9?)+Y6!4/`88`:<H=R+IZ/_+D.Z*O\M"V;+
MZ%TXVR-NHZJFHL%IJJJUADV=P=C5P,HR^W@+:9D#V37&G@R'W[=&VL`:NL9G
M,M45/DADBSU76SXF#WY$1\\OAFC6W?L8K"N<@+4/L5;`^VR;KFO!F5J686I;
MW8EI8$LJP[$MZT-%Q;L"L#DU59<=7;-@27WL:!P1]4DQ3P%V/AS8CF8YGQU3
M5PW]*X"AVL96&'''0]W134NVS8$M&Z.1*WN&KLN&8UK&8*RZ0W7,,&(B1E3E
MN6'$,FH.;HM[4TT=6YJ+5RPVR`1+!>=$=4'T(7EX`V/D><\+(X`/S5*WPH&B
M>6/-Z0_E?M\`''C:6.X[MB9;JFL/5-L9F0/W,XOA[H"#DPI$:YW<;R40Q87:
M![/#`A'!.[9`)$08=-!:%XF]AH.3"$3"")&^UDGV?PPCQQ&(SPDC1Q2(QAXX
M""),8OS@@W3YE/IQYM.$T"&EG18&)T\GI*FBE5]EOX?Y776%?3!FV=I71W$U
M>[?HWL"V!R/-&,J*-ACCP/.Q[(TM1W:L@:FIVM@Q4*YR:],T*PDHAT7!*4=*
M`]HTQ5'0SP`..^*`:9'DH=KU@.@N,Z9/A!)55XPCSMS6."5IFK$_2O9/]H'_
MVN8^R3[VP#8,0W7D@>$,`')%DUW3U&3-&CNNYAA#%6<P<Y7<-MGGL'"5JL6T
M#>=X4(JC54V]$?\_+92H0(\'I2YX&EYT-B!7=.*!@3002`V`=,SST:NCV9IS
M1"!-'CDPW3;4ZL5Y.`VC)181EO&_T5<V[`&U&XJK)4]7GHW\-`;MAVFW)-`\
MF@ZQ%X(<L(P4QU'L[9,(E#[H.<>3QYX.?L.X/V))E[8U&IN6/>J#$\6$%)ZY
M`3:%Z58D\R$@[R8RW=HU\@&1*;Q1W=+!,E..BLSU"M-+4TR-1V>W_U#^A)>L
M>1C^+,HYO"Q;SMG]_<<P^W.<!K69RGL@6@>+?A7130M^E8&!3\>69VCR$!P@
ML"5L3^X/U8'<]T8#!YP[U5#X585RI:@58CTZ,HZ(>[1QL%S[WPF8Q5@W]=!M
M[%/4U=:,(V%_/3K6X'\EKW#UA3?;O!#O/]1#H7TWU.*(<.L/]1=KV$#N46`]
M`4T/0RRYC*?=IFB-Y$DM[^G8R*C>((9Q@I=Q0MP454[]AU^3F"J*DR@"=<"^
M*,,4>R#4T&T'+"W=L-RM0BR>,W)T>V3+MF>:LC'H6W*_KWFR-78M6Q\-QYJK
M%5JP4K*T,XP5/(VQY#EX!QIT"LO`06`M$Z`YR+/?`^S:%4R]+T$*#WT,YGZ(
M"O0@,6K#U1V,UNO*:A&/TC?'ECHTY?Y(0>?7]&1/!S>X[XVUD649`\.K7-JI
MVA\<'WO!4N?;S4L=$'K+4MW5"VC--M2Q#5;VT!@.V"0WQQ@/Y9&B#G37&;OF
MR*Y`KU1"]&UVW<@E3.)$1)?P/C[#:]V]G`\3/&/,*K3=W1Q'1^]K?4^U9-.V
M;-GH#VS94X$"AN.^,^B;?9`]=B489-331C;`4Z]F#+`TFGLFE01Y=F^_.^AU
MG[E9@V=81K]OFS*P.@C-P4"%4P7Q.1@-AR"`#<_&<EAQJLX?957BH[M]##!.
MXMV#4".%O`G"3=M>N4&;!,$T8U:^&.V'71_VA*YU.&"-W&H9*B>31%=X`>*3
M$%7.N/P<>-S#0NB?<7C\/NG0&Z#V;L%61P7\>&GIV+/&AH?!`6^HR(;KC4!H
MNZ9LVWU0:M;04/N#@JQU?N0;H5@/*9@(\?1=.,&89;&M$>F\Z7`O$Z@.^\Z@
M@2#REK?++*=62:M`/@7`.9AX`]#ZR/(LUQC*[F`PE`V\]@*M:\B>-?0L;>!Y
MBJZPM"`;F%C[P_JELVS<,N"URL9]S_-`8EFR[6(`?JQILC,&(W<T&O2=O@&(
M&QO%P3O[<?'Q:9NA86<0E6=)VVN!MM6^W5=U#X#&E@HVFMGCOB</QIYC]5W5
M-72-T;9!AM6>I-TP.45)/7DX[Y<Y]FW"-'UP=L()X'"(@:SM!#DF,:C:2@'Y
M:NAMY\+JSUC<X\`K3+T>H-\-N(:-O<:K:ZR[>_1F`VZ>=L;ZG@.&#+:,L($V
M#-T9R<YH"'CR%`/0HJN@`P`QU#S"KI2&;0W-!F2\C1>`/^`@^-D`J`XV'F9;
MM8AK"?J:XI1VH#/'WET'^_K-'R@DPJNBR%;(WG*>:Z"8OD2Y4VSI`)BKJ([/
MX%Q\7F6P-<DT`QW^<,%MZ[M]V3#[.EB%MBJ[>+$[-&S/4@:,C+0KUSY`C&0W
M[#S-D?L&L5M2XSHUW(H:6=A:@0-ZG!>?CC__&N0#/[O[P+O8]1_`:08_NLB^
M\%@[L2W3[I^FJ4-T^0`\.*]_DL';4)O5=2UA.O.E4FM=MOLU$M768)F)ZQSU
M#JGYF\-K^%T$4EN%#Q))UBC=L24\#8.>MW'\E'@3ZORW,6VTBTRDX9VM:M9Y
MJ#U(!X^M[0UWRU-7=3QUMY%0\V@PK4M%NB=#$Y9RFR<LQSU)>?S>V&M5U,RL
M(G26;6SY5W<G]JR(+UHM!AEV2NFB9-$M+*.J0]W8]DID9!;FVY;XG\S:P%I^
MVV@`5.[Y":6P;SW?R?0!:$-+4XPG%,+3)9QEBP-F4H#5$6.?8&Z(`6GW@UF2
M!A62&'W-4S_!KKQ^^O`V#^99_5)/&+*=%)0&HP]U'<$?!0MU=%>TU?L8EH`?
M+L/L#@_F_6P8W'03:1HAK2$:GP3E&+7">X.L*4.MKX.WYAHN6.3TUT@;RJIE
M&([6[P\,FU<'VSL5NXMC[ZRX-UEHN$K[Y8[WS_@\%4UB^;9F-V+<ZY,Z18M>
MT:'W;?PA#18`K8B?\K1S,)C):&(7\UT\/&1$?557[P!=\Z`77'.\G]&/WB7Q
M+:J-DTNDMNH/[%VC<</^*!"KLNBQ7LZU%LX#;%@>Y_MUK=Z?+=ITK:80**:N
M-"77_L#6$;C&K^BT>^0R!=;HL_D(%*M:F[E('3<+P8/15K7TRM8;CK)PI7=K
MWG6J0\0PHJJ9C6ZR:S;_A(G?S,#JXCEB>RVMT3+R24#6&R)"[C/\=/%@52PG
M4I6U1DE]]QN<Z_H<`_B`W?"<]F1;#6,@`6UH^GIO>Q,<FX31,,P67#Z_GW67
MF%'X-FK%'H6A?82)2*/#$27T-E7%4=NW=R:(#M15\63\:ZV-N3S2/Q'GL-#D
M(F^>I'GX?_P.`VAA@K<6&7`]&+'S<#G/.JYP$?255LD[0=>>ZME4%II[4)W0
M<B:'>DN.P-:UFN6V[SOZ)+1UQ*&Q7S["'\";Q2Q/EW0G31=C6U5^G,PW=]:)
MB[80=;>=^:GC^'098M8-BM/V+Q>^=Z':N1/.G:_3$I]B6:")@.X\UP+#1,')
M(T-#'KJ:.AHZ8RSK8*Z#K*H-RGL4BE;6&"FTXB,PTS%2VD7##*T4HXU=MA:B
MIR).`I7O*L/2.BB!5*`"7;>?"#"M`>8I^$4+<MX,I.MH`+O-LI]"PV:8&@8[
ML$OJ1Z#VO>D\C,,L9PGF.S3S.)5)!V:-X>IUL^8),%JE+(W9'-&NIRSI"H;_
M#4=K&K0M86HE&<6\/<%-\`/F_Z`^8<EUNPQO.I6\!!(Q=<=J(S&W@+1-1F87
M*6:=R;%^]TU#89$&DU#DJU<]AB."N68\V<!U!Y:NROK8'(&E8#MRW];&LCZT
MW)'F.4`4(Y85ZC;N7!Z!H!$S!MZ!'^!_,"_IBQ^A,<:LJ:9P[>(1Z]CI0=4;
M:F$;J%J)A5\3G):[G)"7PV7K>DH:)">^8V\I&?!NQFH5XMH.U@8YL9N*:YQ'
MC94>R<2/GH6AK34;3[>"I)')*2:Z,)=D`\Z`)@'?`5;=XMV.R%%Z/ZMF+IU4
MS!BF,?!4S9!-0QO(ACT:R8[JV;([["OFP%4LO=]G23QJ0\P<$.)C=*<_55X"
MSO+=U(5_?3_ZE8L2T:NOBW8GWE^9VJ8K'K'S#7+TC*S?-E)JHI/=O.EHYUQO
M\,%XRD,7%2;&A8U5"_%Q0%KI2)JJC-W<*_E87=2$-MU\;,BM?!JDPY8G"6%8
MU.!\2G(_>HO3@^,LG!P[JK>S,E!6:UE/@8JG&)#/DN]Z)`,ECK8B<9Z$9?U=
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M-`VP#/LCG(IF:[*K*J9LVD/7U$>FH?1Y?XQF;.EQ(-:&'9\1L:\,NGL<A&//
M(]@;['83""C,NI($LL/X@7=H/0(/?,0.E='Q`5[C)^MC?3!0-1EL/:!NQ<-S
M5L>R-C1<RW7[8T7Q&&%;#<)>N_=6%[4L,:WS%[4TNEE7=*<>,6P/5+,.)@O\
M=((7.L/@2Q`E5#S?8:_7I!&(1EV7/0K%(P:,'P5B4B3>:"51%$R82*0RTOP9
M5,7B%9VN./IFXV8[(%?,GC!&D8&!HILEA>TBG^ZF/A8E-J>]M@77KV^/P?$9
M#?JR,<"F-,K(E*V1.APIENYIV-52J("&P?,T+)4>:1L<IC*1^^S%K"W=06`9
MR]7*`4<[`?8T8D3.0]'QIY:]^FN2=S.DA`GK*N>?/<&KX.BI$C01I*G7HE%(
M_'F4W:G<B>1(.RB\AZW)_8S316Q]GVE([703MBM4VQ?IGJR1""#`M4R<@:4X
MBK83`MJF(^N?K>.T%3E:3<S)D2,J9)36Z%E3(7.68HG3HXJ53C3RCPY8.M'5
MDH'3<^SY"P@>.]9?@WOZYD"DBUW_;=O^BA_NJ!%:H=<N")D&M]N&T9J0"XC/
MCR05"..(-.@42`+=:9B*9AX)242JV0FDHV[79MNV[)O8DE]5'&)'DE'5+1?_
M[TE<M01\"R0>2..>`E$&EI4K.$BZ)9[::UOV^R.9:B?`#9IIFFOHMM$2-=VP
MTQJ8.;Q*5'&$(E'.7E7,9[;13H4FE$3M]=HAI=`!%1XB:Z-5<$#>LPNYI&,W
MNV;Y1"MHSV(1/(J@PYM-G+9T%N`_GC5P+`PU;:8#DI!3D!"+->B*ZVC/CX:.
M;U5R&D(LM9?C&S!TD(X4)29,S=DM.-=6-IN(`&7[-A5=ZR!<HLPRE-TFVK=%
MF8%R1\'LT9.V%6;3`_G]#/L!OY@Y4$]6X#CPJ2R4VKJZVHN\514&BVM*22I%
M09:)D8<M-GUJ&#'VNF.EB8XP:CO#N%J<<JBFGQ7@W!W5;BL$J+NW`#U\1='I
M@-Z^ONB4Y$S`[P;80<CY7+$4555=1(#BNMO/H%"M_M`>V9YLFQ;.H+!UN3\$
M+(T=3S='?=LQ1N-*[).TI&:<*99"7UXOHCVZMYT672;K2KB%ZU(!L1,N\@9L
MM1<M[3%F%P2F-%-N3^4FGP"1NHFC@X]$=CQ8Q;ET&[KK+)N>`E_F]OCJ*I\V
MT'5X/F6N(I&8?HQ6;:1\>=.<#WZ:/WQ*_3CS*0UK&*;!)%^I^,7TB,JOLM_#
M_*ZZPCY8M6SMJZ.XFKV;1S6P[<%(,X:RH@W&V$%J+'MCRY$=:V#"6\:.@?,X
M,1L"1ZJ5.2*'1<`ILW8!:3@P!'PHV]%W0UJK'%Z5IY!8C>2)7;)X3X0155>,
M8V8U<S)R56UOC.R?2`3_M<U]$HGL@6T8!@XR-IP!`*YHLFN:FJQ98\?5'&.H
M#I5B[FG;1*+#PE6.%C=M8[>Y\:V@%"<+T.KGA)(-4#\6E+I("H.WG0W(UG/4
M=P320""UUS^9IGM&&%L.F=X11A-AU&DD70L8SSJSD1#D:%\Q[U&QCS/!4>5'
MKL*K;:<R-/4(0QR[@DS7V=ZW;C<.4P@)Q]%U53TJ,G=N)''L@;2`:(#=7$7T
MT\.2@4_'EF=H\M`R`,D&&/S]H3J0^]YHX!B.J1K*N!Q/6PWR'!L91\0]FC@3
M,(`.,Y?[^-C7:4JW;AP)^^O1L0;_*\F*JR^\V>:%&#[=N;=V$^V[H19LQ0_6
M'^HOUK"!W*/`>@*:'H98Q19/NTW1;/CZ0;KTM$7&2>_M3Y;MP1OELR39=@&K
M,R;)GBR!@:.%I<5N44ZQ`2VMTKG+9447"*R/>T;80C?$:;1@VP?R%O/$VR/'
M1;=7U17]`$/$^_W!4!D8ECP$<20;EC*4/47U9,]3E+[G:F/@6G:G*RM76K6O
MY#H8'@=SZW'I9P#4>!+0M4/2M_=&6\#V%$FW@TAY_9.N-?A^O;NY8WK2R2#!
M::JVIC5&FC^2AK1[Y\Z3P01BV6DVHGJB;^=:SL.:]:W92R49>Q#V,@=]!7Q1
M7=:!V&3#,739T31-'HPL!Q!@VP.SS^6(JE\IUA."I`1G;SY[&LBGRC;;@89\
MIC=J<P[+9Z>"!/E,TXSVZ7Y[\-FI8,)"8[-1%'1J/K-TY31\IC$^`T?9.3F?
M/0+D(4Y28WRFM`D1[\EG1X>$^,QT3Z+/3@43\IECV7OSV;:@Z0?AKE9*6SN7
M-7QZ0$]G#3\-VR'L+9(>AMWJ@FDOZ7$"2,@:UD^HI4\`$T@/MSF>_&1:6F,B
MTCV5EM:9EC:OW!-JZ:>!/(0>T"EGQSFJECX5),AGIN68I^"S4\%$R4&&>DHM
MK3$1<@CN:B5,=*ZE%?/$6OKT@#(MK=C'U])/PW8(/4#2PU+58\:L3@4)V?A8
M=G8JZ7$"F%!+*XV^X"?6TH]U)CNLEC:$M:^=6DGOTWVM'63'#PV?"A)D,\NQ
MK=,IZ>/#!&QFF^=0T@=AKE:RQ#BODCXEH$Q)5].RCJND]YD:W@XBD!ZF81XS
MX'TJ2%!ZJ*YFGTY)'Q\F&@6H-F;<;!`??/?TIBUV3P_#XT&<A[R2@OZ->29Y
M.`N#5,HF=\$\^/OKNSQ?_/#]]_?W]U=9,+FZ3;Y\/WC[K]<_4:V\8IHJ:-?R
M,;'P][65_V=!R0GE>[+<3_,AYK/@IF38J0+L57Y:_#``U5S^3)/U_]?>U3:G
MK6OKO\+T?KEWYM#(+_BET]T90IN6.>E.IJ3[P_W2<6T!VMM85+9I.+_^+-D8
M#"&)"9C(LF8Z+059EM?S6%I+6B\:[SHH-7I_4>K\_<5*("^2CBZB=/1JTM%K
METZAG@HE':.+[$K<06[70'5R1T3IZ-6DH]<IG:T-2*&D`Z0PJW''JE<ZNHC2
MT:M)1S^#=`P19V6D59..4=NLO.7H(I1TC&K2,6J4SI-NB'4+B\L#3[B_X8?W
M]S]9&)!W^'X>$I\D7_'L)W0?D!E/)42C/]ZL/3K3GS$)B,>6O&+#JGYS_Y[$
M;SX438:W-_GU[R_V=OL!)+ZZ;YV<KD_3>-(#N:FHW3*R`#G=AIZ?^8"W#,*R
M$[Z0$&8.^'?+.=Z&;5U^?9/TM&7(E>/>Q$3NN/"XR^7^#A0/'@\F;2\/!CO%
M7E9%=5O'A<<BKX5B1I9O9)0P$,>$^/TP)#R@8X5H]N,EH1,<#0/L/X-@91;R
M)>1F7`KV*MWM6U9LTPO[4?!@5/T)PVU4#!Y/5-`P*O5C^/7_<81]3W%)&"ZM
M,GLTC$N?XW\4AP3B4)8#IV$<&GD1'9/^@M\E5FQZ=3:)Q1\%Z`L!+:4[$Q+0
M_,P[*^?.K^3UW+/L`UM6S).5<EN):)[2K[F(?@;%,W]5^\&,1(0KH]R.;2>F
MY=R60F+Z2!+,^')9_J5L7831,O1F;<.QE/E52!S7;^4@].)X[\;_".0"BMDM
MRU93'&1-VHECEFF[V3A>MAK'<CT"(7'<5#!X>)0SH&Q.N1K+"YEO]G=;"B&O
MD-)`"&<S7G"09^T!X;02NKR`3_.@XZ<F8\*S-</\^A'/>9GW=@&X5<1*2`#7
MR^"G7RF,BI^7T0C^NW,(UO?]=)9F>NIC9;':B6Q6T:W)R'[#B4<B'!2'H^V$
M<4^)PB:#RE=-&E715Y6;VJG9([+3FLCL:;>[W%;UYG:01U($D8-TB9:21]*F
MJF7ES$QJ_K+R^DQ22TQ!JQ82238T'<<VA'8T6*,Y\G'D@0"4H\'C@(H5R"6$
M>'JER/66^!P?0^G*P7?GQTQNYUXI09/5BU8RL+2>W>-F9L]V!0.KT`+6%6XN
ME^N/7Z!/[HRVO.:N:-O*W;K1,)JG29RU,%H&JND:SKUM69HKV+2Y!HE$),'7
M9(%!_4Z\:,*CH_IQC)/X<OG5^YNRS*NB]&9>$S]+7]-*)#7-$-6=Z2`DUW8T
MB`VLLK9A:=@.*#.&:0EJ<%W3:))@-N/>+IOC^%R;F3,2WOVF=U.:QEX4?"*3
M:9WVE8CXJ8#TIB*G`M(5#U1`^NL%I(O)!160WL`(K\902>X]*\6E\W%)UJTT
MQ:%S<D@%I"LV'<LFL?BC`'TAH"H@74I$54"Z3)BJ@'1)<.PAG4=P:9JNC,-=
M"O$5>WL2^.K=DUFJ2+*R^GXX/4,SC7N8V4W1'/MS5A1*5(DIP]DLC>@P&L/;
M/O,2RI8%GXXESEG-3L7.ZNS4-=ML"#N_#/Y2=)2-CI9EBA8G4W5[0_&C/GZ(
MQ0B%U'ZDP-91!R=52`)&L2*)THT%5484.Y5NK.@H'AV5;JSXL8<?8C%"(;6#
M%'),DY_I"&O%Y&<Z=]Y]/TVFE)%BKS].YNS=H-\>H/+TB!PJ48%Z/,?>]]%G
MNL`LRL*LYS2**</!)Q`%FS,2X_ALB2\%1E;E+FT^A"IW:4.A4[E+FPJ@RETJ
M.[(J=ZD4,*J4@4U'4&7DD@)-E9%+)D#%RL@ECG@T%5!_$'):->2T<R*7!U)K
MJ.<*JCF<.Y#Z;#5^Q&6#R._Q.=B@9@45N]JLX+3&<$C%KBHV'<LFL?BC`'TA
MH"IV54I$5>RJ3)BJV%4I<%0G>+(CJT[PI(!1G>`U'4%U@B<%FNH$3TI`D88L
M03/&/@7HQK7W,^BXK8).K,-7$<2CY<6BD*JL4[6$%<BO4@DK=";,\D*.(F)6
MH82B0NZ>;W%9@I;Q>`ZY[U&`V6]&DEK=T(5%3N0RO*]?`%<\T'BE%;MG&X9@
M@=<5*JW<^`F%JTJU5D`?O_N-PT6=>U0"@IAYASD:K'>"SID[WF$9>EM.(+<I
M\Z=>S.L%1X!@E"S;B*-F6AK,H*9NZMNOIO(161&)SP+#"'2C=',"O,?'C#<[
MU2W5!%2!N)IKK3976UB]Z_`=B*S0VUX%Y#S;NP)2"``N_&0;H4MR;\<I#4'7
MCU?;O0^+][W4ZU5IM$<3*:M<)2.1#JA#I6CT<AJMMK/UGFZ[;=:P3[*[7GP%
MZVH+260[IF-:BD0G(M%-U";E6JS3&7&D@QP1I8.<2M*!9K5*QT!V89CIKG-O
MPT14VD-02>X>\2HN^9:#P@6C\9,[>HO9F++9%669/UQ\N=R9($L=;++0D/_D
MGJ]1<)U78S]37*]=*7`5FIV5?[#@63W%OWKXM[^O%M%,K$5`&.GH(DI'KR8=
MO4[IH)P[%GQ`LF^L'_F>6]68;'4-5!]6R$$FQTHH)G--SWQ>.GFSFJ2C.YS)
M".GP02SI<"M!K\"=K)GNU".=;!8T<^GP?4%;Y^[#IF5M]@61:^DJ^_/.3B#^
ME<+@/O%PW(<)/78:G'$'\I:1!8CA-O3\NA5I,V.O\QQ[S5=CKS+K&F;6O=8+
MV/2W(%=D762+ML"!9%Q0?"HHLM#,KD4X:"LE6N&F;.N.8"ZOS\\"EX1.<#0,
ML']:.I,(T('6Y6Q=Q7>U`R&>[_$K^HN_(A*J`I(8MJ5`%%!EAF3&7+,<S5UY
M@(B%\L;G@[+D[H$#VG'>'HV`I@<O'[R`AN8*MC9NK$P*3YTL^0EW`GH^=\G)
MC(`'!L*U]Y,7C8!)>=U&&H1L2P.0FHY0GJD0LR\>"WY[#/-H73I.^$=YD-(L
MW15TFJN$U-HG%WMQY@<WG,T9763KX(ES5+PJ3"!90;U^#H()UB;N?9_E`!I&
M<"GH++%4.)FF8+MH+\+I*F412=)LTKLB]_R3'"C9/>[/V[-=IPF:WI5'V%]>
MF.++Y?KC%^B3[U(NK_D6XPYL1:-A!$M7G+4P3K:WV%ZU<\.:]O*D04@AVQ%U
MM3P%4KI,2-FBYA<]!5*:#$B9KN'P\T%AC>XK`KH*OB8+'`PC$,:$KT'].,9)
M?+G\ZOU-62DF)C>^\^,W*52:'!Y-,Y"H4]XA\*RU52^1Q8)K;=Q&<]"Q#<O5
M!5V']J%3BC#.D<A#_X:1S^^XR("2!QR1ZYV\4MVBUX$C3_)ONY:)E-]0U=("
M$YX.F9^]1L$#3Z"O),1Q0B,Y-)&<'H9MN*8Z/1<EY<E3Y+SEBSJL)8,05#3?
M"^\8.74B66&9J`[Q%?7JHYYN]QQ'38*-8"*C=$S'`PJWGR=MXJ&:`A7QZB*>
M9FIZ6]R*3\(&GE2,)&E`(B\<P;_+F_$MV`C0:.2!-8GCF^AK?#?%S)LO):()
M<MU>6YR>3\*30F&2E`-*5Q)YR6H9^92"I-A6(]O4UFG+X$>NT].5MG,(!S;Y
M;(M#R/7L%P_BN0QQ9@4YG)ZFU*!&+$SEX&XO"D@`(Y*&B+;;,TVE$HG)O#:<
M(-HNLI!:)@_;2L2^;-K2-@W4@BCRM-0^_JEU4!&N7L*IW8'V,<!QC)ZEEKPF
MS$!7-&7)]"OQ&?T6>7<>FV`I`OA71#3UGM*]&D'$S)/J)L)R>E(]S42EA2GJ
MU4<]6]<<5_FP5.?#7U[(]T*A_<VX6!EA!#./_7/J:L:OR8N>J5MJI[X1,]0F
M_*(E]%,KHN+;B?EFZD@WU';\4:<T<I)!K7TBST42LU`S>ZZC-/-*7-C-;B\%
M"Y#.*]W;R-8:EO0GRWNQ)]_%]]%GNL`LXCV/YC2**</!)Y`.FS,2XYCGW!IA
M/V4D(<^>];]D8.W.1E0BE*)0TU#375Z%1XII8$#9G*<%QNI]/Q=S6L:51L%C
M(T.:%[M0QF^]^;.;H>J%/H(Q+>%(DV#1$'(:EO/Q49"\>,JS;2V\$#^?H.ZL
M+[(4V29+C&D)1QH$"W+A&UE69)ZL>DQ\4*#BF_%'/*=QT:,8K[-$ZW+&FU8Q
MI1'@Y'5`=:MGJ:#4FNJ`[N]+"O)HKL63XENVH,431@D0)H.+O])[BP)OY>F4
M"!3#%NT@[@!02C&_\D`B<)&12I!(6]L#.:;)55E#U-H>P\BG,WSGW??39$H9
M#&P;FR'?X8^\\!LL+U&*1Y@MB(^'WT8RH:.)JCX^ADZ<S-F[0;_ATM=[EM"G
M8D.8EN*$7_0P!W?[CL-6<(E[J/$47!*?9A2X"+LW_30NTFU*YW@(O"?Q)!Z2
M;D8@U^HA7H_41):8J*SUY+S8!B\/2R.^O[L-4-_WTQEW`L9!MB?`VS$\Y;TM
M<*XN2`173Q>U-$=%N+[AQ",1:`8>BT@TD6'!*;!IP"[`T]C(M1-0P((<).BZ
M4W6&"P+"_8FY2D""833PYB21(O`/V2;2U^[%*^O3[)F&8#$USUF?>80Z#C![
M%I;J[L7>_0`L*)(,/,:68\IXZ2-I78SW,D'"?0@%_Q[X:X=8I&?6UW:1\.6P
M!:M`K9\/FJRZO&,8PM9@K51=/B]TX/WD^SR4+==MI$'(MC0`J>D(<;TO33#[
M`C,\S/(8&H_H..$?Y4%*LW17T&FN$E)%XVOLQ7A*PV`XFS.ZR#,C2P032%90
M'[.#8(*U*4Y8ZG.[:1C!I1.&8ZEP,DU!5>.#<+I*6422-)OTKL@]_R0'2IG'
M)OR3F3/":WJG\)\T3F7YMECMW+"FO3QI$%+-\,@6T"/Z%9!J0A",@*$H9T3*
M=`V'.T0+:W1?$=!5\#59X&`8@3`F?`W*O-CCR^57[V_*2M[LN?%-?.A$#I4F
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MZ;>18YC;=7?%(NE9R]Z>,D-_J8,'%7.A_U7$S+J&<&VOD=%%;M=`=>Z*HWRF
M:T<E[Z/.)U#-YQ.HB&$R;`>0,$Q+4!>?:QI-D@>ASSD4<T;"N]_T;DK3V(N"
M3V0RK=5SX:R@V#W;$#7MVQ.@W/@)A:M*L,`<=O<;AXM:O13.!8VA:;U[1X.Y
M2]"-@CY/B[:#R5:5D=L4UBTOQCP;!>`2)4MYT`%)ZO>V82+35L79=W-(>"Q+
MTP,JR$I]WPG-W4TC(2DA6J^[MHH)8+4(9KGI7>34;+G96^75MBTW55Y-5N/-
MKIE5ENZ(]2;!,UM=W:ES]K`%G#UJQIGGL\A#<PP;5%T;9HV>4J9V<A'#)'`S
M+LT89:L4_A_@8$##,$\T>O:90--JW<8QD<YG`JY=V3K?L#8MR^96JVWSH#_7
MXMDVU&JS5K?2GS'^E?)=\P7>%X"QT^"4]R4!\=ARY(5X[Z'D+2,+$`-8@GZ]
MG#2[2*]UIGZ,DTH#:I@&]%JOE=C<1K986DCVS,BNTX+/M1#'-,!:YQO4\(^`
M[RRG77PSOO)\$F;AI>6=T/$8N,]?@77"\=$<9MHZK>EZ5_X=5/+"W0U#Y<SU
ML%^`21J1')#XUSA92W>&O3AE^$.:L'?\A_<7Q3=Y%_RJW>OY1D_\H(?\ZPK7
MDYB:NF;_^#[Z^*"3U6_OX+?#>OH!#_YC9V0!60#J&_GQZ_Y,82GA+\WZZRIW
MSV6[__JLVX\XHC,2/=;Q/MEL^GQX\?N+TMCW/OH<NGD@/?YE!;']19.'UV8L
MYK]4Z&"4TW9_'ZL?*W23I7A_2*0\H6/V6X5.UAK`_G[6/S_>%7\YPW=C2I.(
M\K2&T3^=^Q#^?L=HN#VY\)9O*9M<Z`@9%_SG"][PS:I]`O,#S'?W26:IK<>3
M]Q]2?]5LRO#XCS?_0X(?AM:S$+)^]`:7Z--5S^@:AFYT39@'NXZNZ]W!)\N!
M==JV![W+']H/H[@16(`X!/J_O(=\J#`F3KHW%R<>JG[T4/5S#=4X>JC&N89J
M'CU4\P1#O;P<?$0#T^I^A&Z[IH4^=OM(ZW?[?80N^ZY^Q>WT)[EZ:`]U#]4\
M>JCF>8;ZY&MU:`]U#_58J>KGDNJ3,\"A/=0]U&.E:IQ+JD].5H?V4/=0CY6J
M65&JA8ZQ?;?BVQ^Z@=P>6$96T5D5!:2X>GL`H&W2E/G\VQF(R(LFH)A$W>^C
M-Q_^Q$DGI''<F7,+BBNF'1)W_+PV4M`AH+O,N0(3)>&R,Z:L@SU_VJ'C3C+%
MG5^IQQ+,X&*X`S3!P=O.W12#X"G#_\J:Q.ELIS7T`_?JYO?RO=#G_O!@5L6=
MWR0,.S#Z3H1]',<>(]`6PV5A=KT71?SC9J"EB]_F5M5&J"\1M:W5*NK^G-M[
MO&A&Q_-]FH)U%TTZDY0$?!^NP^L:@9(?P[-Z2<?K^*O=L<[_QBF(W(LS(7"O
MW,[GT;\[_,S\__*V`!C#<\HX8-#,B^#O&'`%M$+B_>3F:8Y=Z;9@',PIZ-2=
MF;>$JW^EA.'LRN#O-$_BTTEH=L>HL'$*'`,29MS`*Z_X_8CD-XR6'7_*]_MB
MH!+\X1$.V;@XY;+!_Z9I&,`(XC2$)\GOL'[TJ1=T?F(<[3X?SCP*.B2K-I0-
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MZ??,0YV%?KM&%C]Z@A_RK^'#?P%02P,$%`````@`8S!<1.O-V,^>%```O24!
M`!4`'`!R9VQS+3(P,3,Q,C,Q7V-A;"YX;6Q55`D``^IL$%/J;!!3=7@+``$$
M)0X```0Y`0``[5UM<^.XD?Z>JOP'G5-U=5<5^6UVD^S43E+RVZZK[)%B>U)[
M]R4%4Y",&PK0`J1MY==?`Z1(2B)(4"0'@+)?9BP)+_TT&D!WH]'X\6_OBW#P
MBKD@C'XZ.CL^/1I@&K`IH?-/1U\>AZ/'R]O;H[_]]?>_^_$_AL/!P\/@BE&*
MPQ"O!K\$.,0<17CPA-X998O5X!*%01RB"%H;W!'Z]1D)_,>!_'<Z@*]^N7BX
M&YP?GPT&+U&T_'AR\O;V=HRG<\2'C(:$XN.`+4X&P^&ZOW\DE'T<_.GX'(@K
M_/+`8CJ%[PM?77*<]#P%FCX.SD_/OAN>G@_/__QT]I>/'[[_>'KVO\72;+GB
M9/X2#?XK^&\H?/K]$&I\&#P</QP70/[GX)%1`:472T17@U$8#AYD+3%XP`+S
M5SP]3AL-4[P#8"D5GXX*$-^?>7C,^/P$NOEPLBYX]/O?#9+"']\%V:CP]F%=
M_.SDE_N[Q^`%+]"04!$A&FQ4E(V553W[X8<?3M2O26E!/@K5RAT+%)<,"!QH
M2\A/PW6QH?QJ>'8^_'!V_"ZF1W^5'?[(68@?\&R@:/@8K9;XTY$@BV6(C]+O
M7CB>?3KB\U`HSI^=)_7_<,6">($I0)U>TXA$JULZ8WRAJ#X:R':_/-QND,_Q
M/`YCP=^5_$2I-)[(HB>5K9VTI?4!:O[S,0*!DWV,9S>$P@@1%$Z8(+*+RQ`)
M068$3YN3;MCNMP0Q01SO,0@-&H]><$0"%'8/ZQ86M@4>A1'F%(;_%;?"L=M:
M-P0'9%CHY?$%>/+"PBDLA->_QB"^(SH=`X^X7)'@)TP%])T0TPI/LYZL8VTO
MB,V[ZT\T+Y%XN0G9F[BE4\)Q$+5"MMM::X*OB`A")F*.GU[P12Q@KQ;B`@DB
MQK,)AYT0%E@YF8&%C_%B@?@*&$SF%.9U@&@T"@+8KR/0*B8L)`'!8C2=JMF/
MPG:K^[>AJT/^35@$1,'Z%ZZN2!C+E>,1!S&'7K'XS"*0MS">XNDM+2A3XYDJ
MBZ>?<73'A)A@KL2W#<.Z):1##FTUW;FD&+7?(9Y<\%X8CYXP7]S25RPB.5E%
M&R#5#7>(X`81_@\4QOAG`@H_#UY6-XR/A,"1@(EU1]`S"978W&,DRT]'459E
M3!^D5'&88VI>M@'<*1T=\@=:9J#3A"2=(W64_#U&'/2&<-6:(RU[[D-&TGZ5
M$'8^=QOTTNGXOF(:XQO.%H^1M'CG)`!+D$ACK.7P537<Y1JTTSI,F$L6ANB9
M<<6O[L=J[S[[6'LGG"TQ5SJ>5/:64G`Z67M+&^Y27RAI'W:PSD>K43]]C-"M
MM-'GY#G$R8K>R>CL--HAY=MM]S$JQGUTB`O,GP5)E`@U895^C&DO6GOCOOJ0
MO)LX@H\C2F,4WA-*%O'B#K87,/I6BC)0,L9+Z>D$VM0/W<CF'MUV.LJ@*_)(
MBA8H^UA`KTB*6?<CW*"??O"!(3C#'%2AQX@%7Z7(,:K^E%:A_#_U`EQAL`I)
M]Y.X:U(ZGNLI!6M_-HA=(IFW0L3*W=QR?M>VWZF>`SV-E\KD#\"D)=&JG0JS
MVUR'U,*:'B]4Z^*+P-,G=BTB`H.<J[E@V^4D0"%IO80H^/H8@*!@D7P_X2`K
M='[/ICAL@[8/<KH>VPMYEB0==)B*#C34TA8[I%G.8XK5QL;)<ZS8$R+:^1+3
MJ)]NUX\EHW*W2ORD3^C]`E,@)KI^EPQMNWC4--ZC#2^[""*Y4*,HCAA?W6!8
MF"4C4U)`87XE\G3RB<':$)?]TJ5EWPD]O8S\>':5;FK05YDWIAL9J.^F4]T^
MY5T/.F]MVUV.T@N8#QCFSV@A'=WCV1?*0;#FE/Q+\3&=3^V&R+2//G3W3$-.
MEP0A?2D/.(1=2YXG@CV;[-LMQ7"O_KK$BT,U^S/_77:,>H4BU`I9=<N=CMFS
MP+_&,)>O7WMQ#IIUT,WAG;)EGEC&K.SX38SY'('HJ\Y@/Q8L)-/U&53Q2*IP
M%)Y7+IQGX??H(@3]I#E'OB%MOC%S?<SG,E,S&OMF[C7B%%:R["2L%Y'3=V(-
MWI-T0'0J`G5=]0VU<.YW2Z_P<P2B=X_X5QS)_I/HAOQP5WK:,(\0H4\<R5"_
M1)OJ>>WIC49?F=N]&/9,:=^,SMP,.0FB%U&L[L@JS.Z%PJ2[OB$73OU>\8AS
M:3#('WI><IITZQ`+NI>!YIWWS8[U<:/T4D7%,\>>1:)1ORXQH7NAV*/W_K?:
MS>/.WE62^NX<@-R'HF#::?_+HO8`N/?-H5'/;C&BCRUBC_[[9HK487L6`UT7
M?4,KGO8FFKDLVS-8\TZ=@=^]I#?MNG\A+SV[Z\?TJ>^L_PTO/?[H?7.OZ,<F
MR#ZV\]K>^@9</`)Y`OM"H$#%"/0\R$VZ=8@%W8M`\\[[9L?N@5+A%*8783#L
MT0W@W8M`HWY[W]^WSN+Z46>TG:3P@OSFTAV`V8`)93&=RGNYR;>RKVYN%2=]
MGVQUWC-%AI>%%15`!W!IH^]07@MG?'/4TZ[5W>\9$L_J`G@LAG.$EB=2&DYP
M&(GU-TH^AJ=GZ3WP/Z1?_S.]9"?6URL?<(#)JQ+#SSBZC#E7L?A)QR%ZQN&G
MHV9U3RRB2N-9S6!L%;9$-X]Q,6ZFEG1->4O4QXM8;76ZJ[KR;A_(QG@&^I`>
M4Z-6K"#-@A<FB*A+F$L2H5"'2%/:"N7I]8UR0HO7,&S052/M&V5L4"DO;TL'
M#/PGC=-7%"J73'2).%\1.E='.1KJS>I:097'@5<"V"YFA]8L7%\ZA\K.S[3D
MU]>T@6@=.)E>-ZR>`IK"#M#]F=&@">F%\C:HOP8UFJTP3DTSXQVWOIX--"4W
MT:[?988`6%=^8FSZ1D+=YF14U0:FC1CE4M)WPXNM4;AU0RCQ7-:375[-,I;J
M">"(Q"O5,)78NI6GO*PUJ@L<-".]O((-^B<<+T&%3<.KUW:?B>YF4M,.(LTY
M.ZR#6B@556Q@>,`R3@Q/UX&.!0LJO:JH06)0T0:>\E0LI0@JDJM\8YI-5_^J
M];[@?QKQ3=(1#]8-PI\[SJ?-#(!IB1,A+T;(UH8DPHMU_1EGBQV;;]T9TYE;
M`\:!9)6&\OO3TZ/!&Y:9%M5G^+3DA''`\NGH_&@0"R".+1.3UU5TU1,_!_NG
M0P!KIA_FH/]\"*`U*D*.\B^^H=S:8HM@#3T3.?BS`P)?OF'D6,\/"*NAPSX'
M_^&`P!OIGSGT[_R!7F+M%H&7F6<9SC./AK@&IY%[+P=^.`-<X4W+X7JD>-7`
MK3*$<[P>Z5ZFOB#-I"ZB]DCYV@=U6:D,_+E'6[7>95:V7V\?1>>[U`\'"%EW
MBIU+^>FAH38X4<C1>Z1]FZ'7G6+ED#V:V68+V>ZQ:0[6(]/2#*PVXB''[-$Z
M9HBY:3Q+OHUYM+J9\<+$QYS#WV=Y<S,F;_-M`=N$[KYK82=<9'L:U(1T5=6P
MX:S_"419R*F+Q9A>O\O+5#$1+PF/I=VIP5%?SPH:3&6N,5#`1],%H41$R57B
M+,E;.9::6G;"&-9KJDS<E%QSBX'):5XG1L4%GK&-)%TP"AS!P@,SF*]N89XH
M4U)>H&$AT#>_I3!7L-"-:)\]VN,@T)D.8YK>JQ+];FE+(2R*;6NGWOK5'`WA
MI85MTET]V[9+V:`4EMQ<W#5T;I:Q0B7L?.LT;H7U5D>OIK25X([M['.ZF(Z=
M<E:IK96)LI+6@F=*5`F9T1"%,I_ASZ#%IH(@J1S30CX=3F1"W*M8OC$RP:",
M3FN4EMZZLQ,B(K!\DP46S"NPT$.FCKJKUZSJ.G90*.>"3E"SGZW:4P;J<=&P
MVEJ5O3S4:0BYOXGLY<G0-]!Z-[A?MO![&>_RC1FGTU"]#)NQQ+MLQ]%$X0Q_
MXQIKXF_P\QCI&[-1:U)X>1I5:L9MSK4>N>OE$98ARTK<)IKC*\>7*:TENNG1
MKS0)O`P@,P)>ZR_U,H"LPI[?'/6U">5E>*0ARA(YT(2OF\YDBX<^S1[_]HI:
MMT[7=I_FMI0"`JLYM6`\2C/7RY>=11;W.^%X0>*%J+\>LV=C[ERM3PQ\$!8N
MW]B[PLG_NF/&)DW8N3(-$R!('@V"O\-D:&`?*HR.!IM155MGJ8F/!J1JF9Z?
MCV>5>2:JZ]A%43^IRLO^=H[=P=GEQA2]I15W'?0GF@W:<`ME&B':&-FZGC-H
MMH(_FP#:KNH&IG5PXSZ@RNJZA2HU"1HC6M=S`XT^_-886$43;F!,KS^M!Z#T
M&I0Q6J/&+,4I2!5./8P(6OW%2KYW>DO3(#TZ+SX:IPMB,&W`(7R),M$"7UD#
M#N'+;/)]\94U\%N$2J-D%^GCY?(14C"0=E^PUV"HK^<$&NV5?E-8^@:<P-<@
M+X9974L)5P*,I^IL8OW(^'A6N$NA0U1;SQTT%:97107;]#^B$-^C2,99K-0K
M$Z%\?%19YDIZ(C/):]&B=0X4WD^_?L<\("+W*E;A+*UG"<V,1!7!?(4"=B*X
MENG*-)XE=X`9G<MEJ6+*5->QDZ`(<5SRV'TI^9K"=@.V]G"V;@6M&:MX7E[G
M[HE!I3I^NVM3A\6@4B,O9Y!'$M3<BMW*3J75*[R\+-\'.S:4QIPK'L4KM.-*
MS6::<^0[CV)7NA,4C3:7L\6C="K-?48;7#&S)#4I2/P4&%/6M#&`O+SOW[$H
M53A=-*D!#EN>ZEULFBP!?K*EPJN[-<TRN]3+'(3MX)L%?G@9D=>.,?6AV9OA
MIP<]21J%^Q^`3F?(EGTCXEI&?'K)*TT<D^9ZUT&S0N>D\_*Z5E=241JCY^==
MK'8L:1ALIKEF]6_&(K/X$\VMJG\S7NU$]?EZ<ZI3KE1%:7F9*K`'L=D)G_0R
M)T#7C-F)5O3RKG]?7-'(RSX>SF]]`:?P"/8+OH@%H5@(T-N(&,]@PQ'R(=_4
M7'Z4'.:K\>R1S"F9D4"ZG))U5B:#8"$)9(:(+%6E]7=_<VP3!LU$!(7AZHJ$
ML;QOF.>T^,SD_=0PGF*563,C1AHY4!;+#!=2?YM@KK1:VV"VR'&2X;FLE/FZ
M+1.7Y;7_F<#$Y\'+ZH:E^A.(>6$RW\,TA_+349X*?TP?I.#(]"=JEMC&`M0P
M&@"]J<C649^]A.X$]1EA*:U*/)P4Z'3C2TZV8+?`<Q*,0F`[#;!U-NY2E!Z@
MH&>6)AUPDJG9*K$^QM@XP;!S_3//JUOO-&X:\MI9\TZ]U?<3KPQXJZKD%(ZV
M;P[:T&A-P!B]NY8.HI>'($V9T-TL;WE.8E$A+EEP@5MN[Q([A[D65H\;0D$0
M[\"`F&Z34Q`K@ROE>S1D8[6L(+-JW:^M=M#O=-O)ZF4.KK@8U@^PEWM"#^S0
MSF]O=X$2)CFY`\A04Y+X#I1AHQQ.F#KK;LIVK)LX@H\C2F,4WH-D+>+%G70=
MKN.4;AC/G(_J!RM[VA8)"=$IN6M*K[17U$UK6TVS74U;]>/I#1MQ&.<MO6$Q
M_Q^,>&VV<?.&G,;[!+WB3@`76G(;\1OK!N^Z'8?1/KU@CM$LPKP=VD([;N37
M,UN(2W/N&:YT7H:!]L^?XOSQ4N_])BPJ+*I^)RKMD4F%G=;OC*:]\:BX>FNB
M19VWH`HO9G]F$5['&SEIE11HG?`T<D'=TBK<Y-MZ1SA]7-!1.!G5,IDR!XL=
MS*E$V-:W%&W36+@$E\:6K&R3!)9^O$BNY<GHER=V+2("(YJ?Q8YGQ;M[7^1[
M'Q<A"KX^!B`56"3?3SB1]P'OV11;2AV[Q>7=6&/+5,FY0['R5G#R'"NFA8BZ
M.I>6C,IU.<O%GB9A7Z?EMI&3-M%5;_!4)@PW?56OKI:5[+H)3<V>!ZRI9!&'
M2MHL(V6@IZ;C4E/73E[@9"],1:;9*!E6MHEK/T`N(MD0GOU@&35Q`&^'6LE*
M8K3,;3SB7K?$>^FFV)L/=0NKEQX)PV5H\\*NV8KLI6'=@A]FZU\[6]K:>6W3
MR6*`WR.7U![28,"`?3(VN1/++'$%42+V,6R[J^WU0%WD$%!6YGN(XK)?;!@N
M/C\#GM*R.127+XC."_==H$`2,"#]!<D\"4/VICPN-2#W;[@9/_@\%`KEV7F*
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MG1B+S/S<D!,9GBO3+)D.4DTK3B`U/OGJ_FBK<T3UK_5J"CL11U&^098=F!LM
MBEYZTEKPHF[*>NE(:\&/;871RVB2>OQ=;&%>NM7:+!N)IN&ET\Q0+:_$OY,/
MQ",'63O\Y0E>3WUZJ*G*FJD<]6U&>>GNVAM]M?=SKW3T-O.]9&Y+-Z\A*1^T
MN)5OC<32(_^%<ARP.27_4D.2>M_LY]M<YW?)%,G4/:@>,DNSJT^0S*^69Y2V
M33,.53!EE@`V?=,/A5<H0M:IBY\%_C4&3>/ZU;$<L.JH[(EE[%)GSLF[CWR.
M:)H%ZI)1P4(R3=8*]29.ECM[/"NI7$B\#>1=A/(9S0/'MTX1[AK.:\0IS.$L
MH[:S`Z(E]"EY*,4Q<@LIO^6YXK.T(NX1_XHC2:ZT+:)5GH9=9O8"VP,1^L21
M3-.6VF/NSY.^<+HYJEE`04ZQ<'9H*HEUD[^%O-VO>,2Y5(GD#QY,A`:DN\E[
MK?_#`^8WH=U-[F][F#Q@N@');O*Z(J6F!VQO1KV;(R`5!0]874P'E*@RLNPA
M$>ZJ>)2FCW%7U<J<2Q[(1A6M;HI#T:D$=@,5*)#=^[!8-R#=3=[ONLP*3BEG
MV6Y&M9L<WW8'&C#YQQ-)P#,2&#[\/U!+`P04````"`!C,%Q$^BK'&?].``!V
M"P8`%0`<`')G;',M,C`Q,S$R,S%?9&5F+GAM;%54"0`#ZFP04^IL$%-U>`L`
M`00E#@``!#D!``#M?6MSXT:2X/>-V/^@ZXVXN(NX=KN[[=D=QW@WJ%>/8M5-
MC:2V=_>+`P**9(U!@"X`:G%^_54!(`&0]00*S`*$^3!62_7(S"I4OC/_\A\O
MZ_#L&9$$Q]'/;]Y_]_V;,Q3Y<8"CY<]OOCZ\G3U<W-R\^8]__^=_^LO_>OOV
M[/[^[#*.(A2&:'OV7SX*$?%2=/;HO<11O-Z>7:(%CG!*%SN[Q='O3UZ"_M\9
M^__@C/[JO\[O;\\^?/?^[&R5IIN?WKW[]NW;=RA8>N1M'(4X0M_Y\?K=V=NW
MN^U^*0#[Z>Q/WWV@L-7^<A]G44!_7_O5!4%>OG-`0?KI[,/W[W]X^_V'MQ_^
M]?']O_WT\<>?OG__/_71\69+\'*5GOT?___2P=__^);.^'AV_]W]=S4<__?9
M0QPE=/1ZXT7;LUD8GMVS6<G9/4H0>4;!=^6B88GO&:5HE/S\IH;BRQ,)OXO)
M\AW=YN.[W<`W__Q/9\7@GUX2W)CP[>-N^/MW__7Y]L%?H;7W%D=)ZD5^8R);
MC#?U_9___.=W^5_KHRD<0;H?7@?KQW?%'XO1"?XIR?>\C?V<IAKHG`E'L'^]
MW0U[RW[U]OV'MQ_??_>2!&_^G6WX%Q*'Z!XMSG*(?TJW&_3SFP2O-R%Z4_YN
M1=#BYS=D&2;Y.;W_4,S_E\O8S]8HHH0)KJ(4I]N;:!&3=0[UFS.V[M?[FP;X
M!"VS,$O(2W[;TO+JOF-#WTE7>]<5UGLZ\[>'E%Y/ML=\<8TC>I[8"^_B)/]H
M+D(O2?`"H\`<=,UU3XG$G4=0BT,P6#Q=H13[7F@?K1OZ"J[1+$P1B>CQ/Z-.
M>!RO9@=@'[^M[?*PHC19Q6%`G\VK/S)Z?6=1,*<T(NS]HG]"44+W+H#IA(_9
M3N"X=K^(YMOU=S4OO&1U'<;?DILHP`3Y:2?,CE?K#/`E3OPP3C*"'E?H/$LH
M9T^2<R_!R7QQ1RC?I`\L^Y@I"1^R]=HC6TI@O(SH=^U[43KS?<K=4RJ"W,4A
M]C%*9D&0?_U>V.UU/PU<%NEW%Z<4*/K^A=M+'&;LY7A`?D;HKBCY$J?TOH59
M@(*;Z,(+_2S,`9@O\K$H^(+2VSA)[A#)KV\7@MD%Q"*%#I:V?E.TUK>(3W7Q
M5C%)'Q%9WT3/*$G9QYIT042^L$4,KCU,?O'"#/T54^V`^*OM=4QF28+2A'Y8
MM]A[PF%^;3XCCXT/9NE^RCRZ9[>*T&\L_RZ[(&P5#HOTH2O'5*8)<?F-J"#Y
M6^81*C>$V\X4Z;AS'W>DW#>_A-:_78-=K)[O,XHR=$WB]4/*U.,E]JG>B)GJ
MUO'X9`O;?(..5J<?S$4<AMY33')ZV3^KUGOV\?;>D7B#2"[C,6%OPRZ.E;>7
MN[!->8&S/N5@UD_+:)\^3NB&Z>A+_!2BXD6W<CI'BUJ$_'#M/DY%>P^+>%'U
M9XT+(2+_8'/Y&$6]2.W&>_5Q\ZZSE/YS%D69%W[&$5YGZUO*7JC2M\TAHT+&
M?,/,HA2V_`]V[F:+;:V>,I452<JN%A7V44)W]=@ULW_"!OOT@Q]5!!>(4%'H
M(8W]W]F5BZ/\1Z85LO^65@!FZO:Q_8_8-BB6O_42@IWUFUZ[XF;>)$F6&Z<[
M?M_*]:W*.72G^297^7VJTN)TVTV$.5[.(K3T3<_6^>K)UP0%C_%5DF)ZR)68
M2W6["@0ZB&DOH>?__N#3BX*2XO=WA-Z5:/DY#E#8!=L^P+%]MN?,\\0,="A*
M+$BHW!4MPIQ[SU#.V`A^RG+RA%YD_8DQVL?N^[&)(\:M"COIH_=RCB(*3'KU
MP@C:]?%0+-ZC#L^V\%/V4'MIEL9D>XWHP\P(68)"!>9GS'R9CS%]&S+>7VQJ
M]E;@Z>7DYXO+DJG1O7C6&#MW0+V-5=F^I%T/,J]R;9NGM*+J`Z+?SVS-#-WS
MQ=>(T(NUC/`_<CJ6WU.W(]+=HP_9?2\AET]"PFPI]RBD7(OY$ZD^6_#MCM>P
MU7XV\45A_O7O[7=[-^JEEWJ=,).O;/7,GA+T1T:_Y:OG7HR#>AO8<=[ENLQC
MO"?6WOV6S,G2HU<_WXSRXR0.<;#S0=5=4C57>#6YYL]"+^EY2.43<XJ<$+:A
M$7/GYG.9J'L8^R;NE4<B^I+M/6&]7#GQ)F#H/3(#A-4KH-JJ;U1K?K^;Z!(]
MI?3J??;([RAE^Q?1#95SEUG:$$D]'#T2C\4%%M)4SV]/;S`.E;CVKV'/D/9-
MZ+V9H0(AZ>4JRC<"1=/^I=#9KF^4:UZ_9S0CA"D,[`\]/SDFVSI$`OMWP'SS
MOLFQ<S<R*U5:]SGV?"6,]G6)"/8O18O=^V>U37=G[R*)>CL'4.Y#4-#=M/]G
M4>@`[ITY&.WL%B'Z8!$M]N^;*$R&[?D:B+;H&[6ZM[>0S-G8GI'5W]09].W?
M=-.M^[_D7-]=/ZJ/>K/^&5[I_NB=N4OV@42R#W:NW*UOA.LND$>J7R2>G\<(
M]'S()MLZ1`+[5\!\\[[)<>Q0JGEA>KD,FCNZ@;C]*V"T;^_\_<`7UX\X(]RD
M1,\COBZ&@ESG718U2W+^,4?<"\,W9^7"=33VLW"4O@OP^ETYYAV;T",\="N6
MJ1A';P.T\+(P-8/N>/II8(W7'HY:@UK,[A/2?(>W:[1^0L00S,;4'F%<T26(
MGSVAMWO*F$'*6Z"$-]B7?;BED#5@IA\9B@*6T%[\EBUE)QT_WYIN3C_AQHXA
MJUD0$RZ9<N02Y'^WC)_?!0B_8Z\4^R%_KMY^_[XL2_`O]%>_S>C6`=O^.O26
MN^5"[PF%/[\Y_ON[WN&YR`C+*[ZF3-H+_QMYY"H*+NGKQ@%-.+1_*'=G5NQ]
MAPB.@VOZNX0#IGCLJ>%D--*#LAIY.AAKUYY^8.B&<C09H-SAIX.V.$?QY>2/
M.QU\CW19"5CYG_N')G_0,)55F(C%`:?Y]Q/!L[V@!,CC1`/T\I]H*X+K:-S)
MX*M2!/+8B62>I:PJ#O-(BX&533H9Y,63?(\V,6'6TCPTE_<52X>?"MK+4N(2
M0'=9%ZGZA^8:AXA<L/S0F(CO9'/4J6"[RYY"[%^'L9<*(:N/.15<]VB)$_J-
M1ND7;RU\8`Z'G0JZ7^(PHW(=*0Y-_!D<CCL5?+^B,/S/*/X6/2`OB2,4L/PC
M1(1PBL;W#^\M6GIA`<3L!?,H>3BB?YC*$*&'[?HI#CD0-?^^AZ=2(V:D"1G5
M07;+E.J(GB9=SEF0>*TA(NVVC'D<^"PF`2(_OWG__????4__1T?G&M9/S&*&
M@I_?I"1#U2_C**6JSU68VQZHZH:611+YALH\A)[$SV\^O#G+$HI'O"G"CONB
MPX%RVH4B30EJ1Y#OOG_/R#%HS`YTO0JU#X-'32"65RA^'`V*1[I<A>0/(T.R
MH5A7:/XX>#0/>$>%VI\&CQI?,*LP_->18'BD1%8H_MO@411;X2HL_SQX+!52
M\![5]]^/!%61>EYA.GPA1Z!Z52@.7]CAV@LJ!(<OZNB8P2I\AR_U<(PL%7I`
MT@[7E7:()->^N\/J2&FO>`?4@WKD;#U$2&!H:![4SFYHBL]?WC5]B/WZ%35K
M9;>VDRR\Y"FG<I:\77K>IC"6H#!-=K\YM)J4O_ZMK#&;[*H+WR,?X><\"N,+
M2DLF=6!1,9O;WOK3':NRG),>&@>#@>`F&:J7C5""+A@/!'VVSO)(+U&E:E;:
MEMZ-^>+1>Q'C9+0*"*;[W/T[#^<UB#<X]0XMCZK1()"7U0OY@-:K$$+`-7MB
MBJHOO.[-07!P*K[*QAAP*+6(>C@6`FI6&9YE=]#_L,CW9R_,\SW2"X^0+14T
M\SQ1`19Z<T&PJD1G*0*'PV!@W=<"9)DGO.1<(?CJF1`8[:HRE;6,Y1^N8+`#
M<'^)(]\$]-IX".BOUILPWB)4QGUKRS/J>6.)1VA/6T[1W:L7U@R!OG*?XCCX
MAD.1(*(U=5P>Y/9T;I2(XY+SN+H;&(0'!5J+Q#$UV/QI+N*B$&*TIP/C)G_^
M'-'CCL'0I[X+<F2N-I8OG(IO\L>"05VCI![H_`D0\-\1M*'J;5EY<&<3TM&7
M=&;"8"0H04'YIA`5R10('.X1*Z&$@ET-L)IUI:SB+<!$8R($/OPN15P,)'V'
M3@SSSOI[Y'0XA/AX("B\O%!QP2`8.#4E'D=D'&.I1D>..9DC36ZI8UX9A?5I
M[Z+YX%YDC3YR<J90X>A>;(T^CGHJ9H6K>T$V^K@*A,4*.?=B:TR_Q!HV']T+
MG]&R6=>1TC03NQR48(PS7^P!#TRPB:*F)[K"V74NHH&SELY48>PZ3]$Y91%N
M4#P$-@P%XJQ,36WUXY.9AJJS=)=E=L%=RSE6R0WCO``2OU2%NGN1JS90EQGH
M*MS="VFU_-W7D74OO-4&LK+1%>[N2I66#EK@4ZHHX*[0J?9@\"3/PVA!EY/R
M6F,JBB]T.3VO';(:00@NI^NU0UH4[^)RQEX[3.7G":0<'N6`JWT`3<[3M+R/
M,`7<C""')BZ7<Q?-,--GTN#)C,KT$[GCR.$<%)W#-%,1#V,]7<[1;(>C,/;=
MY1S-EJB:)C2XG+S9C@0Z\0,NYW.VPUJJ]V@F=;J887;G,3EIA5+L4SAA@^$I
M+'.2@QWD;^6N.YW`%ZXS$SB\O\B,G67IBMZ,?U0'*<;D:(83&.1)]]K0EZ.=
M@%Q<G$]KREB"RWN`YK</4V#X:PSGZLW;MJL&/G!WFTWW(?W&X#&:+!AV]7PM
MB6<(EF9C=(_%H2'8F%NBN9.9AF!1;HDBO^0+E#W9%:,4F)I7V!]F88I(E'=.
M!=+G#BTBBO(.LAD@J:H'S='/O03[LRBXQ&&6"K4@U2RG9'<0NGZB&R?,.D8?
MCNCJA94XRW"R*NXNBY\14%8]#P0;%"'BA?2$9\&:?MG,=,2^N3)R3X2+8I89
M)L==CMAO?OL4/],7@-'G$ZOQ^+GQ\)<`20;"I##O3*?7]*DNNGEF]*#G]$G/
MJW,EYV@1$[3O'(<2>A.(1]]F''EDF_,L%G[#^@3&(85O>4,E1\JC1+>JSQWA
M*$CA+*_2.;UI"V$NEV@T4/IZ3K9=L&L!FQ!P[F!(N.5?_.&HR692T(6R^.H3
M%-"N.08$2BII%0]"M*SQ(1&\@M'0D!=$W,64RS/,U/-`4J%W()7`B$[@>)P3
MT"IH+AX/"KWR^^2-!$N45[ABBVKE]/<$>0FZ1,5_50?3?6&7Z/$UHK"%S/+R
MUS@,RD>*X3*/'I"?D2+VA."$_NF2_C-:%L@I%+C>MK,B#=_G\6^YS/W`I&VT
MI'H9E=>\R$>S)4&Y\BR6D4VFPZ3S)\@C/LM_NT3/*(SSU%.Y3"*?`X-%'IPH
M>FCV?X:$3?%6'`T#\>SXB"HG./X:)1ODYQY^KD%`/7[RHQG`NR,C1]Z6CQV<
M]^^$</Z*\'*5HF#V3*6,)?J2L3=VOLBM:S7+LYYYKN5B0W`2.N`BU'`Q:.LC
M!V4'N*:!(23`=D)XS[_ATV%[PE3#&CR$]-%6N`NM"D/(%54JM\U@4:ET.H0$
M42-\E5Z!(:2%&F',L<P,(1O4GLG@*"&X%\5["$4N1(I2\T'8*7J#B(M0J5,,
M-7,KPR"">[11%[@;P4-[IK@UN^$_QY\W>,B/-=PD+`\\@]0^DG7#_GCR)S5$
M<?#$26O(]AHP,8P417TR<:(BAI&:J'7MFX[T820<:CU7%D3T820B:@;?BN,J
M76XO:8:F,OAR"$4<]5!M:]^&K_$HM5YK.4<:@K98TP`W;+L24^XB8HJ#+E'\
MX'S8?/[!-1/!(V%V/U!'3E71`6[\@OE\"#>?H'J$'"/I'!@L_IZ557@?8P%X
M^45[HO))P$Z`DC\7U.\1O7,)3M$#(L_81X5(<X_\>%E<?%F/N-ZW!4GB9M4)
MZ'?)$HVDT0N<@<!)Y]);>SQN2@HI'EQV,>.(WF+I<?/'#A+J3LGS'4+6[^;2
M&UK]?0I3YVK77*K!AZF_SH!/6SV=\#,5C>Y"SQ>'@BH&N]#'20JW8#!(^)D7
MHI)G?_'6],='XE&9Q&<RASQ643T1!!]ZA>FMOB-EG4VU'"";`8?!N3$&_!DP
M/<#T:OW8+/!C(0"S+K_JA(X>C0>%_D"P270PX,Z90HW'$[0[R`YL1:F.ND12
M/!1%?P=F&YLO:KT>*EE&AEO[19VCPZYN=E&S)B/^RDN8#!2U(H!D-><P_X*^
MY7]JA6@UV3F\<@F^#4[%1.?PR?\XSPW*R=4+(CY.A*D`+19R$]^'38C%O4YU
MISN$6VYRM/SH:J[I&A6$CV0+[,5KN89UR^?V8*YK6+5X;&OS7,/&PE,K60<$
MV^PIP0'VR+9F8I!I,\+Q$-`_(JI,$0I,J5N5/2]G:];!9I:F!#]E*=,''N.B
MV+,`*_-U',!65_%73H,+%A%[NQI.=IF5:0@]ADW0%)BBAM!>6.H9$A13/,;/
MW2@N;?P4;OTA=$W3QU4_0&,(O=*T\1:Y(.#[NK^^_&I]MTHC/KIR"`^AOWD[
M)$4>/O@>Z&:!E")W08.M<-@L_/65%WDW\BPT@H7Y#Y5+^.J<:R=TIQ+Q(TRU
M4VLY@T@AU3Q\26>EP9>%U[?B#B(?NLWMU;%(C">3M(V;8CPIIBT,A^-)0.T_
M!GP\^:NM_<WCR4UMZ?X93^9JU]B+\:2Z=O2'CB?+53<88SP)KYKNT/&DO9ZB
M1M+0)0EA3O_@V;Y$DW6XRI^%QZL,`AA"Q;ON#]<1LD!\:4K?-DC?YILA3=.X
MG495'.A1HOEQ%&B*'08EFC^X;AI71>0TT-5P"@VFAY]1,0+PYNU:%H^*3[#_
M9P41+^)$&+?::<DIGWK*\#6._AM;/F)_^`!EK4^Y6H.)>YW">)P)XYG*[HXC
M%J";C`4>)S"IX#;T4CCU6S=V"UIC&X>FVB::"TQ7O?"2U748?TMNH@`3Y*=`
MQ?$(RL]\'9,4_R/WI\\7ESCQ6;A)0M7G.X+6.%M3,)]1^9**E,]VBX$7G&.1
M`I&/0]1P'#S&[(3N2/R,Z6F?;[]2AGD3[:N`S^B]>RZ\*O+.=KUL!5*HC<)(
MCY#]A]E6GNGGR`XUW44HR2KMZ<UU!RM^960CY`1+0.#(&D)5CO#2#<ZN&+U-
M&;N917#9>P%^VM-A<-O0QQ/G;PW].2P>H"BHOT%"O#2F3D:QRI-,7_)-G.#B
M69\E"1*R`OD<6"S4C(P_%@IJ19\W(0;R>2#FU:J=`E/`1$;6@U%`D#:>[9N(
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M2Y:V4D@*^9^H&"&RU[5>#@AW?C=W$6K<T2"E[[WMSJ]<4/"0L`(<U/.<P(8^
M"932Z9;ES:7T>V&F[<U:7`'-8`$G\'M8Q21]1&2MM@?JS85IOQ#["`5Y&]-=
M[`)+=-M7QQ)AI)SG#C82,Z=D`C3\S%O]V4M9YA4+0KZ(PQ#YA14\OSVIWLWK
ML"(X!0Q*7:KG`6&SP*FD=TUM`$P3DTWY,LT7N27A-HZ6[%F2?#+R.6#M)\X/
MD_I%493\P5-@[9@":S>;(@31"W=!,C?1(B;K_*P5DK[N;#/,R#),<GC??RBA
M9;_Y[1%1'2*]66^H^I3O.0OI=HP+'4"G&@T71MEG)$P]>DO/3S^$$AVGHIA0
M,QI"$8]3$4G#03Z$DA^G(E?;>+\A%`LYY97C1)(,H8S(J4@D$NF&4'CD]->(
M&U8UA)(EYE[A1MJ-68S-$.J7VR:(GA-Z"+6'^[HJ^T`E^'+$IR>"+,ZDHH>[
M'+N'2W$4[U71P5VV;)L.1]%4%1'<Y;M]$4%P&Z"XZNM+RFT?2](L0R_V#52G
MZF[]VSZIT/#W5,1PMQRN'6(HS-\5(=PM:&?_5JCJ!']T5WJV0PR3T+R**NY*
MSNU#MQI71,_]/80F2I8(TL57.X3^2SW=&TE8R!"Z,_5$E>/0'_@N3J<BADGL
M[!!Z[;6/K3QX7_:Q`T-H3F$'ZWZ,IT/H;V&'?B9*\!#Z7MBABDDT]Q`:8AA'
M,S<=Z;K)_'M2_."P<:`-*92Q%Q7F[AH_.UV"]A'C%6F`[*%3A3/KU>[;,]3W
M[C+43MA+1=@*>W<99R?LI1:3\?1Y,"O=,YXV$)J%F$;4&D(W(G0\_2$,I(.I
M3P3D:9H%*S=UO7KN/7BIT;Z1/2C]8UII][1U&EE`)!4@,X(>5^@\2^BGFB3G
M7H*3^>*.'AHC01G`_)"MUQ[9SA</>!GA!?:97;2(3F%M7>(0^XS_[DO/U@@&
M4?&QU@3M2YPB1:4?T>BI*MHUNW?H%C\S@:NI;9UO/WM_CTG>/T12$-QD!<<P
MK*!CE5BE=?%-5[&2ER'9]%>$EZL4!3-ZK[TEND=L5_JA4LEYD86W>,%-W>BV
MH%NG)\34:.KP*\$([LXM]EF09<)M!,(;`7&ZG[T7O,[6TF8ES3$@4-*+I(2R
M,0:D`D'&MIXO]A:3A\(J)*Q!(!QOY?[-R=*+RLP,;?'B2)>HW]>.*\)DZZ>,
MHM*;TQP#E!_,]X4KGUB=F2`9Q?2U1Q*9I?H[&'32.U$?8>5K?/!7*,A8X?E6
M7Q$OU=;>NJ"U^UL(P'6%T%BZ'((UH*7(O/=I'<H>0TB'[8"SX+6'3]@<69#V
MD<O-HJ"QO[MV7LH1NO,L$UMIR''9DM@3+;0$,?#>7J>CBPTCB,M!:SU=(SV;
MB<O1:#T11J(BPT>A:4FK1XI-(Y&DKE>`<VL-F8NC"-7Q.;"[#"$D3H51T]X%
M7@%%Z?*TKCRZZR6%H44K-12\'R`LK6J/8$F)CVZVR:O<KW<Q4PTQU6"VESC,
M4GK.#\AGF3H442KWWD1^F`4H;^89^EFX+VA#QZ+@"\HC\.\0R2N2@'38H]`'
M1Y!?O11@L^PC5B(E2TO`KSS"!+$]R$4PK\#:96=MD/Y[W2`_W_(7D%@N^]QQ
M@!04.0RL+^\.;92N:N6T$>$"U(Q>8+20VO3E<X"QN"-EF8D\[UH7#^XL"$QV
M%61J6>-2',3CQQ(1Y$IT@J5:JGM)LN.#+JT9:W>3_NT$LE;<)Y!,&@F3RN<=
M7+_3,[`X1K<VK<!/E^ID6WAK!,M;_N1'Z)$YQ3%8TOM<-C:;BJ@"[Q5?A'+9
MB]4%<8G$Y;*#RM)9\X1^>$?3R-S]^ODXO4B'`[94]T^8DXA+IF9N*./N@7G6
MQ1R974DYLUP9[BP(_8\5BZ@J0]0@K"I(W!'L(U$K.?WYD_YO5_]7QJ,>/0E>
M@OU9%)2N#Y&!M^TJIX5>(VY6:X5)8N@0(-C^KG&"`O4.?(3*I@52:O,EEY4F
MBW0PX&K@.I6IQ]_D8;0F:4,)@%4\`Z\:*83DQRX2BZN@7Q6K+IWWY9![=20S
M8'Q3ZS6K^NN%=QZ]>0J/%&\L#-1D$Q-*0_9I5^J,`GK9G+')HSC_,`J`BI\/
M82I^^UOU!8E$0,E`$#AYPIY@$,3=K,%`MY*$F'`&PL-[03^0)7W]BQ@RZ0>E
M,7%D^'2*@G!<4]P5M"[J80E8+$?#TIH'TR=6NV&W!9A%&BQGY;*7'FMVEAR&
MZFE.@J#GUX@@+V0@L%9D\ZABH0*J2B;`PE^T43.`_V@""/P/GV*JK43L.CQL
MXBB)68LO5A2*RNL)2@Q$H59+G<J6H)9+F!XCD@I&:!'0(XC!(^ZRVF^`K,;;
M"J[.=\94Y_6%]XC:Q_+XC78YM,$,2]57"909IS0]R36Q`?MQU8C)E#OP+"'-
M4$6Q8BK&D*\^@9^H7HRA+82="`[4:HFHJ_DVO0126]H0LD%;(BXSW@ZAE$K;
M\^9:?,%S9'M#N)WB]-JKRD#Y>*X]3/**Y'_%B%!:K+;7<=FZ>A;5N[-^1AX;
M'\S2_91Y=,_.D>!HF1??!4G@S$'=@U0AM@=-H)1K3`1QM33+QLM=+-RQ(%!/
MCCGH5+=!)^Q-[D7;--T_;&6MM_+U/GRROT;Q4X+(,[L!-]$F2W==X7#.Y<^W
M^?2\1H.\CG1?VTVT:[T=4!+Q'IUS+V3]OAY6"*6?2)QM*"9EEPPOW#>;N/"*
M;LA')AP1E=HN"TN+VNG(BLX+QP-#SR.Z+.E4:RHP3L>B[RUZ1J'>\<@F@^*5
M/PU)#LQ[*0>5S7`%@P_&&'QP#(./QAA\=`&#D@GEMO+CJZ['SK36>!58CB*0
MQ0[M:Q:%%DJ[[FS0`!BFD2ABT?ACG8!:>NM%HP<+.9",/-+@$IUZY#WK5H>=
M&#FVM"&X6$Y*)EV/E+NNF9.22\^/Y:Y;YY3$&JHSR"TJJGR([X'ZJ0HKZ-BR
M`35*R6I9(T88D-@G477<9RY'@O5)&VU5!3R43#,B26F-Y'YNUM\W^-@>O0Y*
M+E#+B5@H[<(L)@;C`<<OMD77U`8-'NEX2DH<?F.F)="'A[S`8%0B_H,+SZ,F
M-]'PI'!/7<_^"OX@&/.+/NGA!$<PD<A,C.Q<JO`\6B[GU/1*@0_'%'`OUZ97
M"GP\IL!4F?"4#[_4T2%E<"YB*GG1NR(ZE*=:X4EI4RSTO=ZS#!7UW%2[Y@M5
MG//?,H^DB(3;CG'.HXLN?`51-`.-X.!<Z4-KQ/PIQ,O\"U`>E>%JKF.NL,,<
MF04[D$5[JX'33"L:T-8VKR)J:(H9*JGVA?+P76M3EHZ?L&QU81T1T>C78!QP
M0-Y4^P1[>)^Y!+/VIKT&GZ)#A](02P9EYNB9B,)W$-P28FXKMRQPC,F;U`-I
M!N=Y<LBX"&5@?N7YZ/53=:;UQ$%I:X^0+?TDI5V`I5.F/-6#P`E^S8':\T<'
M4#9(&J\AFU^\>\A?1?B/#.EG$_:U[8AHJ:79][$E-`VS=1$E=H^3WZ\)HGPB
M100EZ;V7ZM!#.MT5W'Y%>+E*43![IOQRB7Z)68]V>GQ;0R3EZSA@RRU>N@MZ
M'7'*3D3/GGLT"P*3FJP_CZY>F/B?X63%^`D+0'\2L1[UO,G"-``+D]JBTC/O
ME`0Z6N8QK\'2<L+#TG@XX/4<-TDGE_0'994Z(=7<M5`Y2K`6(MF@TC&`2<F7
MW.'S-1RGH$AB!L^<-3>F]J@*NVMS?J6VPWOTC*(,L?:\#RE+:%YB?Q:&F(7D
MPQ2G),2+EJ4-,[]A7O6;1_I3XOGY.R4-,3)=!4*!`L'4N'B#H&O,C(IYWO^@
M"/D>%SS!("M[G^-XB:*;`/GBK8_&3&;C`H!?<8!J'H':]T^5'43HBW21)6F\
M1D1E#VZ_GI5;\"GY77S\U1^';ZX1X'^/%HA^Z2']Z(]>[MF2"G#L`1!3R&0Z
MQ&TM+Y+H\NW_;*<'EA?%"TR5!WI&_.=6.`RDC$_56]7P&TS.MW<D#C(_9Q8/
MB#QC7^ZMZ&<O.Z=V)+!POC_9R)Z@X+(`^5B(6\2R%N:+FOP@B3_GCX53]5K*
M3OO&3$:/)[CN*[1F=V;IC8R<?EZ5$=NGK9*_8GC@)H.Q)>EIFT!Z9:SNVC[<
MH8^"-X''V+E#*:D$!%X(0OZ":$AO$A2=>58D'$)+,JQPY*D?%7I`E<JLH5?3
MU%UVG9HAQ3&`N>SA-$/NV,(&[XS42[27*C6-*FZF&@3\<Z.5-=47`=HDYD,Y
M-3BL)0HNXI`JM:QH*T/*F?#H6?#WK&@8QYJ(%;V!"V`$]G[A>#MV_9WR*S*E
M-`?8W5-L.#D<`K2O->_).K_FC2N9^UM]^H7K6&_-%G@UWJW)M]5^YPLZ!/M>
M*-[W8(2=714W.*][C(++X\AJX^FVX7U&,X*\Y!.]A6G%L@30'0R&:1G7@.;P
MP_(%?ZY_94<&K*,.<Q:WL'1>NS+0W":LS=/B#^T)#APBJO!'@E8%FI.LP19'
M#VGL_WZ7$7_EU3Z@Y"+92%Y!W:E0[2E+V!Y6'D')39)D1Q^J:K1M"M?N^CT]
M2X+S'^\0E:4%;XC>5&`*YX%C:M(6PT!@+<UKL^`YUP@N,D*0,`-1-!H"<A96
M7=008\I?64T,!56D=?V^OA<@9+@(%)ZU\/&J:EH%]QV]\TB&HMY\&.R8QQ$%
MI>57B$-SE)77YV!1EO>^+!1P\;.CG-,/9$S)PM&R'8C"R99@?49AO"E2&Z(`
M!U2F%#-&R6CKT!Q*"4::9+N%IF@ZUB0IW;+WDC$(>M'R!U2:UBZ=8N56'$2C
MB[\=_D`[,,0925>?L4_B^\A[],@22:Z?9+2[48*"O?YZ\<O.X"C>\WB0E;UO
MUNLLBF^B1>BMUVS65@V*<LYH8R=OXVB)TRS`$6MPD@7;^>*.OGA,#/+6FY"E
M_GU.'E>(>)NMF'XM5H%XJ3Y[+WB=K:5VMN88$"@I[U9"V1ACY2;<,95U'J&=
M;>N18)D)3#;<'CR/WV(3>`3#[<!#D*\T#!X/@KA!=R3V$0H2%E11&:)B(C)6
MB<?#0[_7722E"F0S+)U]'"_B!5W;1YM4=1.%@T&BQYEI41+/6OT=##KI2U<?
MX3R$0`UA:WH>R\S74:^E4RQE92RSL)"EF,NYA='7<`7+4.O`!9H5DB!6HHZ2
MIJ:XUEP)]/U)B>>GCS'5:9AC_SHF\W25A]4=MB,XNAPVUAX858Y;%]BC2FWM
MB2J<M6U%$_"!D7W)DO$]0G07>M'5RP;Y*0I8ZPQ]V(YF0MXG.5ML#K)$S4,;
M[)X+?$;I*@YVI-G_F@Y%^)F3U=5]O9XP$INJ^K5`W\=;+TRW=$F?WC-OB<ZI
M0A7,HR^(*O'A4?JAWAR+.8FJ9$0GLA`MN/WU4A"M;33E'XXJ_[`+_7ZALG50
M]C3:V:'/,24+^;UJ&WY,2IUI,*'0XCC.*GC],/+1\>!F<Y1<[R,F"T#=X\1Q
M*.QQ^@"5&]@1)[6C8H_B1_<27VSE'W/,JM7)NEONK2O:AS&F%<Y_'BW.Q[:5
MZH*[ER=D[:35IJ^*#.Z6E.M`!I':6*'MW@MN_\[K64$KFOS;:&DBC$2ND!_O
M(R@+"MGC_X-[8IHM_&7!8Q7^(Y9W9&[VB@#N)05;)8#(KU\18+P"@<297*$_
M8LE7-\>B(H:[I8J[$L,P_;$BR2@%17TK5$6(\8J.;4+S*KH`B8_"`EU]Y-SQ
M:W;9L\&/N&!7W\<A"4%SN?+)J<@CS,%RN7+*J8@C#V>"K[\"3R$)4=R5E?HB
MBH7(`/"ZEN#D4SK_X4LQ`I-(G3M8D<A=V]UI221.8JQHY:ZIK^]77%+P:$^>
M]^Y:`GN]2I+J(A5MW+42GHHVZDHQ%;5>G[1M%(%9$>KU2M['92PJJKQ>:5M8
M/J4BSNN3NO6RORL*O5+!6KO>346I5RI?"S+V*[J\4J%:0]]X_WIE:&FR:!54
M]?JDZ+8UDRJ:O3[IND7]I8I<4.+UR#I4:%:WOC],:VX8D.LYNRYA)*E6K8N0
MZ^'<DKSI.D8'12ZJS\A=25J%4;.X2!7+!G_MI!^2S3QB7K1GQZ13^+NN]_DZ
M3<;!/!HV$Y6Y(8<&%>*J-\E=@U`_!).G45=T`=+(6K0>LIV7.:H.5GT01YH6
M.L3F5;T1Z2"9#[QAE2.TL<Q82[+^,)%5FG)<DNG'B4Q'6EE)FC\Y*HAJY.&_
MJDYRO%9K']QS0I@A)6NU]M$]_ZX9<I)6:Q_=<SZ:X=8L85+A!67M`&V@-J#V
M:=EZ[1$6>$]BRI=2EL3)')ZY#`+2(\WWLS5+*$54&MH01#59AC_].42E.EL/
M)-J!S:(=T@;L)6P'Q46L+6^K5\@F2Q'YJT>";\RI'`4/\2)E/XJKD:@GP?0'
MR=T)^5=PP^A&A?Y$WO!+.F6J.G^=$?KM9_D!7^,7]I.<GI()=BII[U(<MOO/
M0'Q+Q8,A:'F+O`2MXC"X66](_%P\Y%)BRF8,OU:ZM3K&_-=167]39Z93&'TB
M<6*,3#')*3R.O,*ZN-RV[-76,SY?D*1DMGB*4S@H*Y#JS!P=1D"5IBNKBQA&
MK?J%BNE3L(1-'Z\!)SJ(K5)?8)=H(-%E^R.!$[Y58=JU/JOC)U.K/O,1ITBW
M(YU*1AI"'ET[S.W9)H:02&?Y=N22VA"2X@RDFJJ2A5@U'D(Q@#8H:]BNAI#J
M;XBZCG%F"/G[+=&6VE&&D*+?$F^Y=1,\N;Z%3UE/NQE5%)`^RD8RM6FL#Y2K
MA^?AH4QY%@2X@.\F8L$E17XV@.9=%ZD.)"F!LBV;,1;_P2NQ&`_4+CE9BYRR
M%DU&`E?40.EC#JX2N2\O@<>#W$2I%RU92N`L25":M)<(W.*G'?SQC/3H%C^S
MW-(F<6J&(0VQI<5"CN%[OOWL_3TF%Z&7\/H@M5G!,0QE_E[E-,=P4<E66E,=
MPZFZ/5^\M=S7:+K*J\$4R,-Z"!K50:]>_)"5`5Y^BN/@&ZZDN`,$M:8.7]<2
MQ5\5:7R2?L('(T`T/,J[5+%5S3&P>IODF]'3W)0+P'K&6W#QAIW;]&$"UP'U
MO.6G)8O;'G03T8&O'JL_HA$KR&W)IY8^A^!(Z@%[H38U!`=36WKH247@GJ9N
M%)#)L@V_2U.(`+<7]8LU5[B#]YV/S#;<PN:G*QN.RDMJ@G0K:6HH_E+.B^R,
MK[3.%SFV6K[.HI@T%H]I/Q;>&NU8567Z5'^A]^SQ&PJ?T6<JKZY:6-=T%G6?
M#O^-/')-QUK!?[_80/".,V$V7KO%AH'W(]W>WH$7JPT$\V^Q/;SI6E8L@\76
M(7=K5O[+>\(A95Q(Z`IHN\KP;:V3/5%D'NIXLR9+41^45`E^+JO*%LG055*#
MUZX=)-.>O;EL=X2E3B'VN&R'!*5/(0Z[;*2$)4^N)<'GQTV6O9-;]J",6*P<
M,$YW=:M8)4D<+5'DT\MMP9@E4$>JE1]1Y$5I+5EH%H;Q-U9'C*>`:,V#$.]9
M>[;YXA[1.Y"D7KI/I1`9VD3#;16-$AUI=>Y21<]PA=-!S=.03&=#W(^J+624
M7M#_XI25Y=QU/.;>$>F4(9MB!>=_Q=ZSO*](WMMGOIC33\)CQYCG%/(.734%
M)GB-M8^E?(.UX[E%21*+['^\D6"EK^A'PRX:?9`*:40`,W^LG>`UMC1=$1=-
M'7-%C.[$Q")N))MDN#UX6%]$'.4[?(E3G'=WRQM/"0`2C1^^&4Q`I2\9$Z'G
MB_(XRN]QGLLV7-8BGV`%IOEB02G/!/5]TOW#QO,E%1,5,^Q`5<I[A_>$]2A5
M77;MN58@E?<^.(9..MX*1&92HC79T!B:F[SM;)+>,YENWTC<#$;!&G8@IS,2
MJMQX?JF_<IX*R<!^8.#*&-*ACL!1#X\_A:F]G5S?Z,.I*V"/U<;>D812&<5Y
MRWI'Y/49F//&<QO70"@:.F\<[XB]0N1SWO;=$7VEGNJ\=;L]`=3F+GC;=>_(
M<S5\E^NUV;CU,@G<Y9IM-G#7LU97K:@=[1O3VPT0:3T51=SKHVSI+1#8SBK,
M1R<*ZEFT*P(`28!*EU]+G\.`(_D[8"PS'H!W,AR;MUJ1MZLVY(A/S$4<18W<
M.J'H1#ZMZA%66*`JQ5MASZX>6T<53EU$-9ONOM=3+,$K)%UG1?W7*//"LME[
M+B_<>=O\`69=.ANZXZ!K*,G<:$E!BI((._R/Y(LC=YIJ7M\0"L,-E'.&[_"S
MXUP^N.!<BEUF(G>S[FR',;N0!GD8+N(PGC<1B^UD]E]1GEN+A9S&-X_UM8)P
M;26W,?X6V\%WMX[#V#ZN$$'>(A76*#)?YZ3.0A.^VW1L2%GA6!V#IN1JRP4J
MI<11FUC/A*@_(LX[3/NG18V%..\T[9T:-0'">1]JS\2H<Q_G':H]T\(!CZJ>
M;557D737A@QL2H7+@8F>$4E9BL^7.$4)/35V7CWFOU!2A)01/J[B+/&BX`HO
M5Y(`2]EP"!$ZK]4S7SRDL?^[M-XL9R`(O/%Z'4<Y%(I^XX?C8*#=W\9+])1>
M>YC\XH49JNZK2`'3F>D`1JJ>[YRQP%#?QM&2Q7O57P<U_-Q9P)B880`..;L"
M!3R,*Y60L91,UFR+<=:'E4=O]4V29"AX+T#(<!$H/"MX)!7S.0/AX:W=F(K.
M=P3[2'8D>O/AL1.Y*52CX2%7UH,7#A\P[,9%ZP4R6G/]9$;_/V`_L7!GGI`F
M'=\'1)\]JF@P:5LC@4AW*ORYRVH@\48Z`#%E\7H`LX%#SMRU0[U/=./D-DZH
MKCR/KEZ8`2##R8I1:+Y@%!,04SW/RE?V*>$K"0=_!&J,D0=:SJ,#*?D+HB1X
M]%X$E%//F]S593PG%=DIK=:,."QJ12*)<8>Z`+.4:PH&#Q1N6[S^,XYRR]3^
M0_D642%TA3?G6Q;52CDDB4.ZS++X@SRUL_UB=C*R47I'8A^A(&$)"DRK84':
M\X6>%MAN#8C[DP,@U_P:0^QD<?MI3)__FC&.BDYEZ3AQ>KER$D@CGMH)'_`%
M`3EE,T"*:K+<HUR!K-D9)4^V>+R5N_&0$KK^$OLS^GFS[T687BT8V1,4XL1F
MX5AG(+'UPC/9NY`2*WF<!P=W'%S3"+&EO=E\_LB^707+0N6CZ76?$AN^FLDF
M(M.`XRXS.V@Z$<TN[`ZEL):)$1QO2)$!:22OD\OQ,:88FDNE+L?#F&(OMR6Z
M'.QBBFD'3<KE.)<6;YW2?0@>U6(77U-7G<N5`CJS-JE'S.5:`2TP;^KA+A<#
MZ/85"[Y>!]/]6^"I85IV.9V_NRR:.W%<SMOO*'.(O87@N?J]?;'B\"F74V9;
MX*SA4C/-GG4<8ZGQLL)U*)*5O-NI('ZN0A.(U6K7U9>X^-T-AK:%G=RW"%X^
MPS::$J-\B>O'T>#*,^N52/XP>"2E/HT2RQ\=M;N.KNJ+3H""[+%Q$4^)O;P;
MFD[8RS5D`'D$1%5_3I8M4@D![II1-/'4\*WOL?T`I8-J75^E8[HAW7%\?/"W
M5Z,(E=S?+6$A+F(I*D/5$4G7GR(M1_T>RUIL9/4E#B:W[XZ4-0OS3ZWF-*?/
M3/[?51Q2I))+"I2/;?1R%Z7_49G+^Q\4(=^3)/T=#8((L9E]\TB@B(1LCK$2
MKG&.XR6*;@+DBPET-`8Z%?+(8"')AKP%31.IW?W"*S/+TA7]?O^!#EO;Z,QP
M`H-YEB8I%1EPM-1%H3[%RJVM[?!+[BQ`)-^)=WN%8RU!TG1;B+\BP<@I3=$"
MY+J)KIPYP%@T6:4N'MQ9$)A<K3=AO$7H`9%G[*/\PSKW$A30KXZ5:,Y9^867
MK.Z1CUB/3V9&OGI!Q,<)*E]H?@^K/G9PED)?V-$F*0IR#I\\QJD7-O"+DY3>
MW?]&*<4R7D82_M'??J.B7M%3XCHFY:_8.%%P^XF!L,*7]C"S^W^7$7_%ZJ&&
M7D35_"C=J@+I3:9/B797?V0L$JL,M=L)&+-UG`GK44JG0."P=]^>;W-02A6M
M@#,7J*5I0]K31XR;K1#Z`21&EC)466V/JO7*+KLZ,T$PNIM+I:[J[U/JYBXB
MH"Y\:JJUBDG0:5GU,.F]NBA$134/)$7+"W?B+HMQF"\>B4=%#Y_)%-+736.B
MG20E'T4>E7?FD43N.!YD=>_';[%Z[VH0R#F64'R-D@WR\0*C0'Y\PO&#AMZ8
ME]J"?X6";/]!G!?L758J0S8#!`.N=C(C]*->YIZR4HC)AY15$W.5Y;/WP@HI
M[B7_["GQ"<XUY_OC2BR];S<HVNTZ-6HR0_O[#(I:I3EF9Z1);LH.C[G.3.5$
M@J,$^[G$;9N`)EL/D::?Z,!TC]6OB`4PH&#VC(BW1/D?65CR7J'IB;RF4(!1
M^DF-X],ACGMK"$LR:<A]98Z5C*C];.CD34U$EZ3R8D8!,RDI"Y#ULA48S8ZM
M![)""I(9H(4@=H*;3A&(QE@8J*N8@X**S!%4:**;$->RZ>[9U1+9@8V7`<.U
M2!*[S"@[6Q:/<"$Q5!`V\H$?D,]25K"PWFW'19VC@]"\W8H`DM6<P_P+^I;_
MJ16BU>2IC$N7,BZ6SIFJ3#C`'MG63#BR]U@XWD[AERJ:M'`/E2Z.71-O]D&(
MC2\&LZU`^S6BK_@W^CXA(@;J>!!HL"LW1*R1$=*+3`8>52DLB"*-"6L01F;6
M&7%9%'T"&4M(0ZB9HHV^RJ4QA!(I9F>M(1\,H5J*-M)R%_T0*J(87&:E7VL(
M%5&T\=4H;.1NQHXVEEJ>]R$4/+'S3FEHLD,HD&)PR65AV$.HD:)$51'9/82J
M*.V/DRMM.%P<1?\KMN]3&T(=E?[IT];C,X2*+">CGIX/<@@E7?0E89LA^T,H
M`&.7,NU"]8>0/`Y/)T%0/GR)91=>+&5\#GB5(NMDZLD];YI1[3:AVOJYX"L\
MJ*E@&KA?4R/X:9D5TNZ*CFV05MA"CM%W]XFPA#X_L7)/@(]0JM78JBFI#U0_
M,KUA[ZKR,JI;ZZX^;(:DJ#A%A:F[8F(+3#G.UNI#=/<A5@:S5T5ICG,;JJ-T
M5S,R1["60%&=()#\H%U^3R.H?P3%,36Q%`03#*<ZIB&>@HC%X53(-,57'!4T
MG(*9FCB[73BSMQ.611&76/_):8&PQ]#QJM./03A:Q:O=M>^>A&A&52,J`0"^
MJ*"LDJM&U'W]\]+7/\%E`\T:F?W@[T;!1<TK($M;:`8*"B5BEW#5J8C:&E77
M#K:G@J$N(-EKN5#WW+MF2!V7IJQP@^^U*?L$58'YC<]0PYQB>E'A2L#NG2WW
M*$&$.8]C<IVE]&^[2$2SNJ[V:X=*,PTY`Z%KG1K""U0WH7;R%]X&IUY8.*#$
MUT"`D/$ZP-@J*C8>CIMJ9G:N!*BD.F_DD&O4B2K\Y0+YK:`4,G>(Q7UY)5&.
M_CQ5S+(;`_GLX9`1EKZ">62?X`/H;;M!T:Z,4:O%21?HV2::<!_0_'Q1/PQ1
MCO[1>#="7V2N_B,>/+24-#%R7&8WM"2T[E$J4(EG1PFG,H9;&4_KC'&$2:4J
M(O3X8KN<G]<[691"@,O9?+K4::%`@J?W*1U\(GEYP-$&,I0TA!#P,(/1Q=\9
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MJV\V<+H!\`[=W4=,67:!%J>ZK;J`#%&V%Z,IDJ@_]"3;MX%DB#?\EZ)$3R[T
M(9_^^!BS7]70%]B">KKH[>$9)_5[%1NTMQ\G;0&894>@AOBF&Z-\:C..10"=
M\!=H0MNG_\`4!"??%Z&O3%0ZLH_WQ"X0@Z2SM,#I28AL`(%S_7[JY3IWH`JU
M%/.%IBB=WDI!V(D5<#?43-C5Q5Y$@*`%3%?*CC"VMV?:]V09'$+9>S<IJJ]Y
M#J'LOILTYD1,#*&ROYO$;&.*'4*?`#>IW=5X,H0>`VY27CMP:`@]">R2&,8Z
M,H0.!P[261FUZG)'A%/&[?;$)(4M3!PL?#Y4<G=PGKE?I0GH.'J*\!Y%A<=.
M\3.O.$-W>`0^#$]T.<,7@+HM#-[@R<)N4;#WT.Q!M"*%BP\#,(T,HX_60([$
MIM-R"'V[1G(LAC[[(30*&\C)])L5XW(O,\B@'IOJ5:O@W$H*F`ZFKX.Q&6'G
M<@FUL9Q7JPQ6T^)O4%5)9E0M6Q=X?DW85;Q*4KRN=Z!NMA#^FE!TST//__W!
M7]&EDN+W[%VG?_@<!RB$J!A]T!V)&R[5'`->$[<@G'YEW,;X(=?''7'EF+:/
MW?YCJWV.E$%\1NDJ#N(P7FX%X;^GW'GP%-WQVTO\C`/Z>!9MF/NG)W??0>4&
MR+#J)=9?O>%H;N,O<4B7">F[=>K[>+`S;#8$#]#B%6)RR9'CVTKZ@^Z>+E-&
M6-B]U_T&__7=X^3W:X*8YQ$1JGV=ZMOC[NLD-3OTI[.6T"'9:J*9\5;U7C,@
M54VY6IH=@[&,P."I$WJU4$&H,X#F<<-+'^K3#6"N*EJQ^^OS4)=-DF.B/E^;
M'4+3B3%1_U![`^^%X3C]>[(^@(>S\5N0G$H;[AX&KJ5DCC"1\N3'=-*/$#R*
M3J\_Q2E,(^XF5KM%(X$V`M\(Q`)?ZZ">"[M]-=UXIH&_H,THCD@%XKD-\\51
MP#\]QN>C1&2:TYP,ZNM%Y!G[2'`W"_CI3_/%/?+C983_06]F'D%U$2=I(K)[
M][7+6/S*[<_M$XH0\4+Z$,R"-?T*&2M-\3,J[Y+47Z\W%P*KFXB^!FC?;>>V
MO`^2:`G9#(<PD!I1Y7-&@46G_N'CBKY@K>>HM+"BG]\E>D9AO&'DTOEN=6;"
M=B*R\\[K=26RN=>I:Q'UQ'7YA8FL'LH(=>L3'HJN%`EOG-;SE&GPZSKZ"K8"
MKN+J.<!L(NV&7TO];6@)!'6LM;C<$+P`QIAK2N;P%OB1>3-;%$/L05P9L/WN
M9/31>DA-+7E0)JI+M@.C"*L-\92QK9AI;A8$N(#O)EK$9`UFN"KA.Z>OT@*G
M#+0*=I791F\NA,HAH#J[;]4=E&.EF&LEF%*PU>Z[JO\^H5^,3[\";\D^O!`O
M,?UJ&E;/)C;VUW?H'$L$R&<O]5>[Q*7=WPL\S`Y79T&'\/_LO>!UMIY%4>:%
MAZ>X.]U6A#!:>2QFUG$9D"K^?/P^)]4#K6E&T5GCU.81(Y[%-WIHD6;$Q@QC
M$O;`K^"M&#W0R0;G&H+>:YLP9BP-7CL^/84.A5?P8+')0F#"8:UI_E":+'N\
MXPCE!8:88O[HO91X[^S2-E2B:I?Y8K]/N4&YG4@M-9]O18G3V%&8W:8]%T*0
MO,@(H:!=HX`9+(\`$XB.JEF`F`@H+$=$-,D]/!C#P%%&I8HY?<B*0D:*A/L.
M"P+BGYL$9U'`+(*F]U(Q%TC)1Q2VH/QDS&ZIYF1(O-HA-"!,6GQX75:$I$#C
M\VEWL%I+C,6TU#7&2I>X<'3L8!0[1>Y*&WER;^_0%^U&:"KJ1#X;$HO+M7RM
M$*<36ZFHXU[]5BO4$3Z`X/W7]%)=3/5"=T,#-(Q=W343SJLAUCR'8#KNA20J
MU6<(IN->"*-^+=PV%7?5+WA\1:50PEN0P4BCI\<,H0%&3P32H`E42PM8MP.4
M^9VY?B(?A[B,I=N5#F`W.:.:W/;P:[\C\3-F='J,9WE-W^._M`\XF[3L]EJV
MP(^P7YR5X&B>MM3CH36O;PB%'@[E'-!3;P)TL6(IUC?1[@VD`V9)@M*$)9[O
M@UF_>9$OBINQL+#ED^+"4:N*3?G#,R(IB\[X$J=(<<.,5^L3FT_TT;B-DV0>
M7;U0'K?,<+)B=A3FEGTZ_(0[+.30#14\0+.=JK1G!HW/SNRRMMS#(2I]B1F_
MS?S\'I98\(/364R%&74,UW:(*O-TA<@L^'N6I'D5"3.\CV:[AMG^5]%2%K-N
MM(1#.-XQN?2_D4?V?S]ZJ]NLX!"&?)7,%$OA*@YA2G]Q0:4`;/H-UN:]>K^.
MB;2\]^>H!=BQ^G%,R=63'.*RW;8/.HG?-)<-M7U0HO[FN6R2[0/W8\G+9<NK
MC>?57.MTV=1JG2(JS17>QGK:#\3(\.)\6(!EXO`E?^?=_Y:I8*K3@P<)0/"8
M8QVX(H.CG3`[DT$<'0(D8NI%A^C:TAV."GF=?KAZ6,\1OV*B/O:>6"5U3%]I
MP$#=/4A-AZXB-E<T"S+D>`_3)T)%)ET$BL'NP*T9#RZ8Y`0>M9O]!6DC<C#+
M"4P,P'<&YC)\(UHRQ>'"(V1;-D;7_B0D*[B!(1-AM)')!]NJPM)<^X[$E%3I
MEN5SIJS#]1\9SNN3T9]OHI3J*DP(+<;RW(S=%G3B+/;FFL8]V55MTSTDQ2I.
M8*KMV[?OO+>.45WV4")1'SR6=!M7*KF(FF?6$\=EDN.1ZM-HB6F^RFFA%S?S
M-%L!/JA2+L/QXB:U^+7+;A"+)%`Q$9=](!;)<*B!N>S^,$?;A@CELCO$YI-0
M"+@NNSHL8ENJZR[[,JQ@VQ"Z7'9.6#S;0U.`R]X(BVA+W5$..AHLHMX\9C!O
MPLA*3@GZ+;96$ZH.BH:R^ECCGKJ14O?[&8C/J9T"-_C"936_N3-EM[E=T@_;
MPC7&=#>*).F&,`C?YS\QR-[7(&._^^UB=@#+[K=.F.K&XX`8OS&?K_O/PA21
M*.]W\9E^]>ML3<=ULR;SEP3ME7C<4).+H'C\D,VQ`N-A&1C,)0AG`&BT_BQ+
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M0B3=>Z?:?`7:MB"7HP-MW6V]@W<O%K`E_E*%V^5H0%OG;>0,=#E@L,V7;]7J
M[7)\81OB=%#2P6,.38-N1.95=U.\;6*H4D1+9#^,"MD#^TN)X\=1X2@QQI;X
M_N"RN:!/#T*=3)+H$)?":F7F,J7977DM7#422@QG-I$>B@E-TZY?Q_S0J6H:
M$@M6SB.7KY*;J)#'YPN!1#*5RM_S@J*EQ!)%_O9(L!/%ZW#GN((%S]FM'C_\
M,!T[%!5],'QZBD;WZ?*C9T@0Y=[))2I_H*\5Y7+T.*_INY<76*.J%X[9I+LX
MR1\<;CR&W0T<.JT]!@W`R]Y*2MI87OQ4UFRCEXVKPQP_(B.T:+<FD_!E<-F6
M;8QM'R^/R]9OV]?!^.D!MY`KM6AM8<-=T\\KK>[WD*W7'MG.%WN3;5E?,F&7
M\AZ%7LJ,`(3BS*R1+<K\"42761AM0V\MSH]H#AARALAX1>'Z_9"&P'$&#@Q>
M6U%Z]94?B1<EGL^^[TM,>47*_0AKHY)?<;JJK\#[<"SO`'U.->!4VK=RFD.X
M).?;QNLJ#N8U6``D(GUO/-<#5&9\:+?6."4""!%7_#[N!?\#O@TNN`N57-TW
MI!$=W.XNCU@'-J%B+_P-7G76\Q69/_--;\+QAP?_8&CYBVPC[H3/2%OC[<3]
MW-6&3X=_FVMD&CH!IERC,&]9_;>,PHY(N+W&D1?YV`LOO=2#*,-RY9&(/K_)
M'2(['S_V!<(8?RQ(H0D>)+,HN,1AEE:GI`-_;98+F)AAT!WRR1C2W]E^06EA
M_[P5MVUHC@%-9M^)8`)(C\?!*,]YGI)8-2[_;"<Q7/I<BXP/1E-/`*<XDUUC
MVJ1*=\D3,KL_5<*0SGF.4,=L2[3CQZ&Z$(YV_>J`)>?!AM>)^T/W@(N"VY=Z
M1%4@C(.[>T^-<EV2=S\;RA[R'*2!4J(TP^3UY8[!UU!]R)X2]$=&F>;5,XN)
M=Z:0ZD66I/1U)+/@F=7C3LJX$8&`+!IMJ8_4,PKCO,O!1;RFN["K@/]1Y!.P
M^KH^XU>S)4&Y&")V];=;:-*"7=2"[PA^]E)T%WJ^^-05@V'@CGV$@MPC<1&'
M%-"8L+U$JJ=X/&2)-\9*JX^IEM3#`K)8[>['F'(?]H!=QR1OSY&<;Q5EF>VL
M/3"J,+@5$2(VU@9QV'O,7)^G95$8$QR@(AW_'OD(/Z.`@ELSP(L\]6:+`./)
M4GGFB[H[4EKX3CT1&I^,O9/T'TR,3&Z2)&/=EHQ.3;T$,(Z4-_AH)RJK\6D.
MMV-G\Z)X@<5B2^/O=G:D+T:*EE0E"D.<"VR<=UDVLB<HN)^+?"S([6D*[2*+
MK7*X`[!+Q2;^6`>@EL9V\8:Z`+-<^A&-=@1R.2,3CA\T]$#%SQD\.,`>V=;8
MCN+F\,=/7A:K\4<651]>AG='[0&>C#I1?A85I5J3S%;V(9=+_ICK%O4;);*-
MP!?=E'YI&J)IY<L4RHXN?P=:8F^%8T,O`"_+)(R`5HG#C<AGKB`W0J=S&^((
M;>XN.V+;("HQ@KKLB&UUX8VL*2[[9#MB?V!G<=D!VQ%3+6NG^[Y8'=U[#)'E
M"O24ZKS[!?9T494*8.[7V#,]44L:'7@QOEZNNL`"42+[HPO*NBQ-2F%\4WS8
M[N@26J8)&\@ZD0YESI/Y9@&%L1N^$K+VL4H-@2(Y4V0I<#LHZDN<HN0QW@=[
M/:24#^6%0N=DZ46E08<)5W&(@YUUYXZ*TG1,4>MYP9E<Q5H]4O#.0TJ@L=0<
M'%=$C_53YIO+K6\#XB/80:3T/1X/!(57ZKEK#IJ\%QW-<L([TN`;!R<S9E.<
M%D'L/T/@UCM]!8'[F0XTR/IT\L0=7<"W5K#,]^DG%I19./G26Q%/TY@`\=I?
M>`E3JME_KO[(\#,532GAY*B8S07!*EYO"%JQ[^<9%;E#!5B:B.E.A\$M8@U2
M2I,E3GXORI2SGX3HB&>,)6*^/3VO/4Q^\<(,?48>>RK8RV%R6?3G@]3Z7F\H
M?`RF.:'/X29.O'"^N(VCY2TS=1>]B?00;;44:'US3;Q$PV%@3[UHB2E++^AY
MS?@MR@E<@"=$0C4/!IMGE*35%Z$^"M'X2?,N*/0%?:-"!&O3@*/E':$R5!85
MD2.)R:-EO`Q0WM"N-/0]\D,O2?`"^X7T%_P]*R[*)4I\@C>2"'?C98!RC:C@
MGVY9$YV4"E5,H-KH?SC:T]W)N6D(P0*T=&8"UB"Y+VIYLTNC=TSJ>2`6G\(4
M<(\V,<G?`X.'1&\N"%;<IE9%UREZGVYRF9CR1_;))-);V&:ER=+8LZ7QA'!^
M3=!\<96D>$U!$?;]:`Z:+**3113`(GIX5<'MF=8PTV"Y@XA'U+O7;7C7(`(2
M-<]:0V`<1%2B%KIB>P5XY*$U'`VL;/`A'[:0UC2N#R*[1?,F"^T]X#D1]DY5
M9H"'S]NQA::^10*^=Z^]^ZNTOIHV=748V5:N@0K_H0I9.J[;"LNARU*:QIT*
MX:%+4_J^WPKGH4M7YI;R"O>A"UGF'I$*=R!Y:PKR:<;I'%;!M!#]:Z\>O\H"
M+AX_EMB*<7E07Y65?+(^3];GT[%BR=,);HB>>*XFS\W1-HR/G7C7B7C!OK76
MC`(2L&+A5,EY0'Y&\C;,5R]^F-&[4A1K6&^R77"TJ5#3PT83KY]X_<3K1\/K
M^WB*)B'!,2&A\N?0'R_1$_,#?/;([RAE:#./0+JMCIRYNA!)Z?UZ)%Y`S[@P
M(8\XJ]=&9+1ERO)Y1F_;39+9)&E,DL8D:9PDJ,#V4SG)&Z]$WIAL&@YSSKTB
MP>*D#F*EZ!$_K&*2/B*RKEV._#SU;1BM%YXDB4F2F"2)T4@2-IZ:269P3&;8
M1Q97?#^9#`W'Y0VXY.&_UO(YD^`R,>J)44^,^A39(OQ':^+!0^+!XU*^+7#B
M6^P]X3`W89394,&<%9_/",'1DO4_3[Y&\5."R#,CW4VTR5*6]TB)'N+<BZ;-
MP&UN-?']0RUB3^;"\)0W,%+2V]!V86./23J:I*-).AJ-=&3Y`0*7INR+C58Y
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MYCWU@3)Z9"<^/F@^/BGI#G.Y2J[.4GIHG^E-6F?K>WJT7GCG;?,SOH[)G'X`
M'COE6^0EBK!SNVM/O'_B_1/O'PWOM_3@3"*!8R(!*PGLB`XO`H7_+(I&3UJY
MD_+*Q)DGSCQQYCXXL_#9G'BM8[SV(:7GLHI#"GU25-YG8T<<NC;QL,'RL)/"
MJ?M9B%#0G3]QZ(E#0^C.^A=\XME#Y=F3M=QASKTW7EVM-V&\1>@!D6?LH[Q=
MYKE'GR'64)->][Q2X2S,8<&LMR:K8;B,\#]0<(?HG:7CDE19[;^__6"IQP<_
M_T3F^>>;S/P4/].C-G0TM%[8%7J4%M#9-X\$=;!9[<SBC),D6Q>_:TV;#IM8
MJ6AT`%-RCUBY3Q1<QZ0P"M_0_5F=$G5UH[9+37+_9+N:)./!2\;=GA-P(;D'
MKUI[U@I>3+E7:G1AK!5E?A@-9:P+L!61?IPT3A<TSDNV(\JCLPA^RMC6+#6]
M;0<V@2RGWH4CM:DG3=Y7)_7?28*=)-A)@K4NP6H\HN"RZL1>#[.3Z6BJ4KR,
MV._:I62(A#K\=U@Z9>+`$P>>./#$@7LM$B)[LB;^.R#^._E0'>9@>Q,4LS3%
M$3O+^6)_FE<OS/J$SE%$;U1JZ.(R7Q&6`E3N1X2@@$+):Q-HB+W9:L#^\\4"
M,3LTVA_3/?VP#QK]F:'?8LE)@AM1]%^V7GMD6_OP&WFIRGND.WV23B?I%-1S
MTX)M@@NO?3BP6G"0,;HX#66($?DRM1_\R37IF.YVCT+Z8W#GD73[2+PH\?S<
M\3YB4^JXE#B3`^3+6R8K3&+Z9&B=1-G1B+)&CP>XZ#KQ[M:\>S+#NLO!*P5"
M=*"&YC?-929>/O'RB9>/AI>;/R,30W>,H?\MHT>&2+C=_^TF6L1D75C0)CW<
M92ZN>79\#J(Y>>+8$\>>./9H.+;NDS'QZ4'RZ4GG=I=;5\*R_"S-%&^3M29>
M/O'RB9>/AI>W?%`FUNX8:W_(GA+T1T9_O'IF_YZT;K?Y^&OB:"<-X11]!@*0
MA>,G?CSQ8Y"0-.$%GGBNF.?^Y1W;XLE+$/W'_P=02P,$%`````@`8S!<1+N@
M1)B\D```E4`(`!4`'`!R9VQS+3(P,3,Q,C,Q7VQA8BYX;6Q55`D``^IL$%/J
M;!!3=7@+``$$)0X```0Y`0``[;U[<^0XDB?X_YKM=\#UGMU4F2FK@HQWW\RN
M*969/;)1IC0I5?7.EIVU41$(B5,,,IID*#/ZTQ\>?!,`008((&IW;:=+*9$.
M_SG]YW@Y'/_\/[[O`_`&X\2/PG_YD_/3Y$\`AIMHZX<O__*G7Q[?73_>W-[^
MZ7_\]__Z7_[Y_WKW#GS]"CY$80B#`)[`_]S``,9>"L&3]ST*H_T)W'G/,$C`
MG1_^_NPE\`K@_]V"*`3_\_W7.^#^Y`#PFJ:'/__\\[=OWWZ"VQ<O?A>%@1_"
MGS;1_F?P[EW>U*]4J3^#Q4\NTJOREZ_1,=RBWU=^=1-#+T5/@RU2Y\_`G3BS
M=Q/WG;M\<E9_GL[_/''^5_7IZ'"*_9?7%/RP^1$]/)F_0V],P=>?OOY4P??_
M@,<H3-#3^X,7GL!U$("O^*T$?(4)C-_@]J=,:)#A!<B:8?(O?ZI`_/X<!S]%
M\<O/J)GIS_F#?_JO_P70A__\/?%K+WR;YH\[/__/SW>/FU>X]][Y89)ZX:;V
M(A;&>M59K]<_D[_2IQ/_SPF1<A=MB)4D%`3<)_"_WN6/O<._>N>X[Z;.3]^3
M[9_^.V[PG^,H@%_A#A`=_IR>#O!?_I3X^T,`_Y3][C6&.[8601S_C-__.80O
MZ%MN<0MKW(*SP"W\M^S7Q-'^!/"3OWR]Y0):UV31EWZF2@;X']A1:VK"[RD,
MMW";*XI?%YB+2">6)D*QV&A3$QA@FT<Q$SB1M?.29R+PF+Q[\;S#S]@5?X9!
MFN2_(<[Y;N)D1OYOV:__=KW9(":DB*H/4>!O?)A</R=I[&W2O#6"\5_^)/'"
MSX7^^)4:@A@FT3'>P%XFH9^GIQ9_"Y[Q2_L`O8+C#PS?_?+X)^!O_^5/_O9O
M4V>^F$P6?ULZT\E\^C?G;\Z?_GLI"^3"P&^YN/_OGZD>:J&E*"[!N_'QN</P
M7<=U__/B3:XG^K$#8/;$SYL(A9I#^J[V&7=QM)?RI;S]2-HF/YMC3W(=;N_3
M5QA_A1OHOWG/`4R^P/3F&,<P["!2Q[OZ.2562-+]7&?FK&KT2@"2"XA@4)$,
MD&B0R39*-86P">MNHI#X9@(\A#LBN.-2M`6TD_-:!@,E3&62C`_>":LDQ[[&
MPP;H5M=`-KROW%F37YD@.]AT!BJWANI`!=G`%[9CL0C"0&^($3'$@_7K?12G
M_C_(P/U^]\%/"AX_Q'#O'_?);?@&DW2/M$WX7W:(,+V,&J"A;&A'XRFG8!QM
M!U0;`O<[4#1%.KN\,5!I32TK65,3<[:9$>-431+MP(%*Q=-WOQ1\!4+(C%`:
M.7T&-1J<'VK9?C$A?@D2PG3'S7B.?T/:/\+MQ^\'&":0#(U/3V@*^AX)^;WA
M#1(O*.;K-MH<,6!BE=[:R/G?RG%7R_7?ICDWD3B0R0._48D`BP1$YC@S.E9<
M4HS/8>'+X/TV-CYNQZ\8)!T[HP;\C1>`I]A'_^O16/JN^/5C>MR>`&G4"XP,
MI>69AT.%I(U,#1&05G>^]^P'?HHFU9WC9L[SFCMZIA*RX\SU=+FL\ZDBR_@`
M6@$VMXHM*&69[G*%KM;L5?EF,,24X_X8X('6!XA&-1N?]&GHYX!V_^&V.@)X
MB*,#C-/3`_I:*?K;Q[\?_<->2"PUXO7R4(G.LJZ]7,_=@K9YRZ#:-"C:)B/P
MVF`T;QZ0]LG?"PT,#LL-6)`,U.]@D@"O8L=MU8ZXS_4J+1L.'$J9UX@SZCZ`
MX;!$UN3P3F,,7]$8PW^#M^$FVL.[*,'K<_>[)^][MQ]*23$39&14DV;"?.VT
M8PE=GZXU`6@;`#="5JO1/!^U8VQT,)HQW*8QZ*+UIF:,`$FW)!;T<7<.Y:5M
M:"FS/\/],XR'^TKVOEULIDK)NNYBAO[3A\>_4?GF-G9'P"]%79_B_P%3^$?+
M.5QW[)[LK1C0"&^W6Q^/%;S@P?.WM^&-=_!3C^L0G*=U<I*M@O2FC;/.&5@(
M`E@28AS(9!DBFP)@;@/8`4EZYX=@PP>FC4=B1ZNQ1F`)BS@B[L^$[YCG2[^X
M/5E-W"[6F.ZKE.&\/!().J!.JZC9UBF:>8(AFFS>HFXN>H-XKGD=!-$WDLC)
M6HJ7>4_[)H^$4I+;!+.E.UUE>SVE0U&QH"(7%((U[_>HAMJ,$=JA=FS]J,;;
MC!5MO.8V?'IPLMSWD360F7[X/X]T1_I3%%<7NKA=`N]YK?TO1PG9=`5WN2YX
ME8L"2%9MO=A4GZL"6SX?I&<KLDR,&.X]/\1IP%XC1^-X0$Z.3'#P3J;X)>V0
M]:Y89"RS?$J>(LY(X?'5BR$YTX+GKFCB2E3^"O]^]!,_A8\P?O,W\`'&?K3]
M"C?12TBD_.H%QV:/KZU9(^P>!XMT3M-RT0H2"7B*@&"\7NH%JHJ!0C.0J0:H
M;J"B'"#:F8XZ%MB<!*_'--K\_HZ:<E,U):3Y$W;$J'%)S@YU(WXA:R,F=H;;
M)#G"+?Y?/&*ZB1)^INHY(FV+=!P]91DU0Z/JWE$,MPEHHR!O%9!F+0Y/*@Q%
M0D^!&(V,4.C9HZ"38.%7T6Z'N(/&3QN>*:R*0!VDZ1U=1`8V'CEP/`LW?@"_
MP+3<PWN*;KSD]0'-M_PMW+X__8)BXVUX?R"CXO#E>I/Z;R2YJ.O0XQA-F8HT
MBO2770"<N\Z<&8$*/<BN>G67'?T1*P-R;<#[$\#ZX"!5:`1*E<P?US1M7[=I
MWS3"I\TR^X;(OGC7#_\6_[S!QCUB@_IH_E<8U"MT^+,UP4TQK[E!3^5'4[/^
M^Q)#NDCTW6\.=!@/:%_1K;8NN;XWGSJS:;9TF[^.J(L$Z,[)'ZR\HTWYCE77
MP0A<601Z5E197EXNG;90JJ76APBOB`GMFSUBC%ZT??DOO%JU"$9%F*+8``!-
MDHT)0))F`U`TB29`H9=J=:]ODZV"U<BP/B#"X98L9[QO+F=DYV=X`S&YEW4.
MO:4TDIVE3M>3?#"=RZ6+CN!]>]7Q(W^I3,.06#UNJ85!L_/R7KY;&XS*FTM-
M'QB$I\#;,Q-N&`]H[_^JK4N&W<G:72ZRWH^^/F[^#+_O&ZR\HTWYCGYO,`*W
M@L!<5\=R[K*C:X%3PZ@]*?IU$P5(K8ANNUZ'VSM_@YE;]*X"QO42H)V1?;23
M=)GE>C&;9XREXD%-/CF%E+4`*D,I,ZP>S0`.WP#7^@W0$1E&LX+;TPW,19<A
M1"^C3V\##A^$)W#STTOT]O,6^G3\C7YH#KO1KZA.)(TB\%X:7[W]=PV#YU:C
MDN/$R7R]=BM\HHD]Z'V]3#E/?5=._;%]G>L8V)79"(U,%VM55VY1#Q:^^,\!
MO$X2R-\A%K^D<WHHU$1Z>K0L]E@:%8E*B8"*-#0;5`?39549\DN8'A9I=!(H
MY9&UR5^W=8Q0*TS]K1\<4_\-/L+-,29;'1^_;X(CZL$^(=!XBGI,,[T_>C'.
M+DP>8$PFL0C5D5_N0(ELG415H;#LGMYL621^5YH%9;L@;QC@ED&E:4SZO'&<
M998M#]'V#9%?N^E(C'B(4M0Y^5X0G$!APJ0T81BE^$PD-2,YC!)L\,'"+*20
M5]!?BLW3`S)F@A4R&EQ4<K(6@Y1]I`L,5>]/;`&,O5<=+5Y.6!/!D&6L.UVY
M:H/=^Q/@B3*Q8VN;K5V1K<UM"&ODLL+`U_E5+C`<WODAO$WA?J385XJ_G$!7
MZ"Q?EV$^4QO5?L,Z`*+$90:P83841JO"AKNF#:-!-KR0&-<BJ,*`5O]*]D2O
M+]X>,A-VI%\S'FU*7607!-?S6<?8",LTE"(S"E@1W:^ZT9HE<-M'NXG9L).:
MO<A#[`=/WZ*GU^B8>.'V([YR2K#S*'A<^SXC7Q?)[21W.EODU:"Q,("D@5P<
M(/(T[QPJ@N2((!G=%%0$T"T!HJ97YG;XNNE3[N=U8#?2@<;0N]]]A5[P,4%,
M@WG52E[\YCVNL\/DZ"!]W=6TV/A#DO`(&LL"5%A1^M50_Z@"FUM@0R/;G;?!
M59%/X!ANT=BV/,(10,_PV=@.UZOUAR*[F.%-C#X$V7_'US9\B4*O_,T3^BG!
M1V2B,!'7J>HI12O+>JDF[:#+V20G7]D`25ZI-P&J;9BN;C6B+=R6+3QJBW=\
M8]@PJ!WF_W5.][>J$:H+TP/TIP'TV@=W%\4IB1'W]*/4"X0$ZJ_S`NO\A`73
M;7JSR=K\_7C#^^ZD^:XCR?6'M/MJWV.J[MQ=5GW6_)G=X3!<,?7T.K#PB&L;
MHSF'[KA8IO:,=G?N><_G;#UQ:MX\ZITQ<I%X"(1*0-[0UZT)S*++85IXC7NU
M5+1N/FO*RWL&O<G*F:U9WFY)##\'%;UOK.;Z9HL?B)R*RP%+(OPGSX])-2E\
M^6$0)<<8?L7KW+AHCO`+"E_4SA*1-M+#7:?106"AM,0;*,6"0JY)_BC#6QD7
M@3WTL*`M\%*PP]C?"'9\F@-7)J'2P;.7^!;T-3*.VR9?I]W4[.5@:O\O&,*-
M)]C!:3VD?=^FJ8'LRO_"73C9;@T6`:@,S3LT9RGO-)4WNA=S%A17YCOHV8/A
MN7VY\\)$:J3W^^;%VR?4BBA?M/:,SCZMVK#T*J93'"C!KP/\OMG<R<$H7&D4
MVOH<EKO4NI<66"4]R7L_>H'A[19N^!U)ZQG=_4A3`=GPM71763=")0`L0F\O
M<I;J3D-UDWW(64!<B6^@I0?AN7O1@3!AGG_:-DD/,>X['/(3YJ%3Z3/P[_YV
M<]TP>_Y;#?U"UI3L+'GI.-G&^@VXUNN+0S2E\WDO\'=1'/I&AB^-+XS=K8K$
MQ``%5S&\#K?X/_C&4C05(_MSZ8T7QR<T6Q'5EI=[5^.`1DHA^>L25ME`AU0<
MQ5O6Y(>*9'"=@ESVB$7:#Z0N]\=0>%^P>NRS`CO>HB:506$%.YJ]0_3[:`>H
M?B-"?TR].-4+?MX)_AF^^"&Y-&-<$W0.@-6#=X7@30Z0>X6KZL!9WDCV1&%:
MC_\VW,0X=^L#I/_MY04<$<9C,ELO62=UENM95VC.KM'(FP!Y&V;VX4:S`MFF
MPU6R?]AFK_^(CRY3S.3H\L6P6.SNW6066-,B3D>!OSD]P>_I>]3V[_W<I?&N
M>1;7%9+.E%C.UYWT):+!;U@X(-(-+2^I1U[O79O(+>0EVV4E",DPDBDF5M02
MINBRG]7,M)8"LO[E3":K"K.JA#*;4GL^*I>%RC19N%[5)`<;NQ$RP#CU=SZN
M*)O<[S[`0Y3X[`-@,F_H)`9?#>ECA--BQ:HB#!\)R<299HDBB&X+8E1`-$J9
M;M^K$:?#'$;H$W@)4H;4FA:>.68\J),LK=9[W,J=G=@@,C`YZ*U?9D\2GPG(
M+0%%,H"T,8+K3C4BL,&;]O^[CF(@[&<-L>"N9XF)R7)1C*4:1+@S76WC?%Q,
M/G3@,L&)EHOQ:'%W1FT*SJ;X#7H$=3X!?TN\\83N#?%Z\Y);L<YDO<XJ:^?O
MZ]T+/T-KIZJUR6WP,S"X79;7L@/.]NUB_YN!3PVE.FI;?PR1W>'V`QKQ,<W>
MXW7M9)373=9?IGCD0IDJ4?L^:P#@%C0S>B3H3ALZN^K]Z-`[HL%(^%WVIP\R
M_%Z!?\O!K2>4].=T&6=Z6DYU$'J#N-)`\I?80PUM.[YMXV&#`::NB>3`;[9:
MSV>M</*&>(1E@4R8L<AQ!J9FG-""23HDG`&,!(`O1]P'TRNGJQ`]`O&%#U$W
M^]ED8G&=81(C<]FZ1D4Q@O+01N<^70\).N>]\FI)'XF;YG><-HE65JVHG%ZR
M8-]N)!MD5\TAN?#%WX#K(/#QA>>TCD>M/S.[.]'?MVM3ZY[6LXF^6761#>?/
MU5(CG2M8*INP(``,T5NZ).MZMNJ($$7AGPTWAM0KWYA?:3-ER.;8OVG(O&J0
M(DN:#DOG<%8F;@W^7HIF'/L]C#>^%V17N0B6%#F/ZI]M,/60';ZZ$W>:SS4:
M@G3/,,['X3!Q&%U_5(#*E?XZFB820HY4IA%\Z".1U0]@DD8A9&<.2;YDGL`-
MC22=!<U#\YLXVQ0H99IF]3G@./PN9=I%]7.@LDG?\1T-\9]#.T$D8%G&S,PD
MU^S!.\!8G%W%?%;K7(&A@'Q"ZZ35/P(BQW0JU=FH7!8JLV-G@5?5!\$\[*;(
MX*?Y(/PF"G$Y8AAN?)B4JPD=1;+ZR=!,'FG%I">`919O*9ZFR5<;J*VW&2ZW
M-9X=W*8=O.%VT,G4WB[?9'`_<RH;^G8VRULS&R+!Q*!87CW)S=K)8C)URA&R
MG)^.O;(E'#J/9(*>(<O8XM[8=N@9L@POS9W!_-I0O*<Q]06L)^\YX*032;]M
M9:`BJDEVIJNYNUST#5*D`1OC4W_D/6/3B,@5A*7^\'N&)#Y\>Z)1C=;](E%I
M/VLG1-V9![V$V#8EZGUR=K%>N+U);#X'8313=!/:^@E01P)";].9XG(4DA,(
M-][!3[V`W)29?(4)C-_@]E,4?SJF2-7;)#GB/!&!I_23HYG1O923/HJR6E56
M#Z,P.XB2-4(O9DU`W@Q`[0#:$,A;,L?K\0SB5BKO4[,DU!!Q;H@=,L2.&L(7
M&$(GVP>1H$GX_C8US/G.E?WZ<V8XV_>6*H?%2?.K^</1N$TTEI!%O(+?QFO8
MV1^\^#Y^Q-?Q;4FUK/Q:Z.YOQGW3#"%XZL@ZU6SE.`R*(+'@/@94<%;0O[A?
MW#AOE("N,BG!4J_`P<L*^%M"JBXOY=!,:!YE:U5Y8^A#OWJ5<R[)37(0U/"7
M?=7$*I6$7K*+I^O5W"V7J$I>9:++`U\)P,+'[9.$"U2J03."B1'0W6M3JI&W
M^F8N<J.K43V(6UN*DC67X:Z=#K6OC^EK%/O_:)V$DWG#3%?>5*/'7:P+!NNR
M&6<ISWBW?19`1G>=324](4(#W3;/`SG=-=,L5I`(3T_E"90];9(\5`7I%8KE
M8LDG#I5E"6D&`&L1AJROC(3H#<;/T?B8''X4X(,S%@'J]!&ROV(+*YA_?TR3
MU`NW_"OMA*^8C`$5/:1W(=`/_$!0$6A)-!@*D<^>2(S1&(48?BCD4=,RJF>[
ME<-57V&2QC[YD59K[IAF"%\U.-L5Z27I7<LY]J[V;+<B&E1D9_7,C4UUE2%N
MAPP#B*7GN<I@-THY;+U3`K9'<M/EMU=_\PHJ=]:!370,MB",4I#`(+@"*=9B
M!^,KL/=^A\`+3R@&13'ZLQ=`).X*1#&M!$'^%AV(_?`N4?H*\X?(GS:50&;#
MA%HF-K`FU)W?Q?"(0'AM3O,Q,SU_KVM!)O/)FD'=\>Z\Z=/!]T?"&>=;,,P?
M\%48(Y3_>_+39.*4:_/_+T#Z7$WH_[77`/!U-A_@ABQ'@:ES!;"#DXP2](-[
M!6;.U7*UO)JZ"_++Z?QJA9Y:35;UB03Y8V54U"46O7F`&WP4.SA9,H+BWQ_#
M^D2J1TJ_1BE,.-MJXF<-CH5JBLCVB0MWOFX/?JX`$89O4Z*>96RX,QP4(T@2
M3(9V`M4!:XQ@WJ*LKCCTT.B%?"U:H\JN`0:34JP11=LPJMA]B$*\XG^_NPV1
M=>"3]_WC]P,N<_<>C?9V?GK7<:!&_GT#44!:.4E?6Z#Q<CDMRJ3CVLM4/D`-
M@*P%D#5A]C#-.`9P[#)`9W@9QPJN4BOH"CV]^5X-1_T,J2M$B8[0R+UK86CJ
M<XIB-EDN9WW#DJ'C,^IQ]XQ&)@_/J`??,PB9/SK3B\Q]8H_Q8S.'&+XB?="$
MD6KX!:;W.Z0F?UK-?4/OF@M/#=F=B/5B4NZZEL)R1\3W/R*W1`(-W6ZI".&B
MC3"($M,G6;J\KK%,(+2$)<2A-_-)WD4I^[I92C%UDKXURW$6`GYEEU':<R?E
M&/#=-OP[^\@G]-P.)O)MI&P<?43?[E^]>/O-B^%UN'V,=BG^49C:V_&2B9&S
M4"/9*9RSFI8U((E(D,LD!S=SJ?H'R.K@.=WP#&?L*@3KUL#B*RT/I-*LU_$Q
MM0U\I=A7&_%V&\=,CXVPABDM(_[53WZ_B>'63_%/W!Z!_X;6?IFKAG3BZJK<
M::P(`U@&H.+(SZ9Z7C4`W19`LI;>@4]?O]OI?_6N5FP40Q1*TOA(T@)NPX<X
M>D'^T''UL^@5O23BZB%]Z>5\7M0U+:6A\2S(Y1D_T:D(I-L"Z9<@#9.HTP,;
M+!);Q!"-WO`MO,\!_`"?TT^>'Y/M[[(&`__JA.XW]9*J2QWYK(MIL1A3"`58
M*L!BLY.?%<'&&*84L=M$'$8I!`?OA%<%KW"NQPZCYYX%/1NQ5"*-XJ_,!)WT
M0*TQVL@2M1%TI`QF0>SIZKL9SYJ++_TZLID[<SD1Q7@O?2:J%H&P'(N((NR/
M.=@-D^$N"E^>8+S_0C)6:"3J_G[,M\P0A*6*]#[!:L&@"I8(L$CPA29;4:'&
M27,V4G'_8T$W>_ZW%$.TYY2-%/\X`81K)44+ST5#I`'1:C/S2?U+S"PU)-UF
M.IO,EOFZ<NDUE/BF2D*<C:<5TC3@Z5H[/AM4B]I$D,$E8A%/*NO"7."&>_Y^
M/;X%/?V07F$Y6:UY=+"E7Q^,BS"B<N`2'&(_W/@'+P#>/CJ&M@R->_1M9_9I
MHY)$=L[(>,<\87H%W,EJ->'V(IE`>R:39\)D]RNBZ&"80E*S3(Y1#-/I`8F%
M<0RW,@4OQ6^9H11+%?D=AO6T3:I"HB6U,=5!;1&K`=42:HE\DD,NKFG,T"L^
MX$MHR<+2(]P<8S_U.?,VN7>T4DN@B/0-:VNW&.1EXNAZ9RG0.*U4P72%,,U2
M2L(/ZX3J,HH1.AT1L</T$]S"V`M::>N\#]SQEDY*B561W;)RW4E^5H,*!)E$
MUDD%0ZQ2B)3P*I-DE$5R[E?CD809AC,I@9N?7J*WG[?0IR1"/S2Y@WY5:.$G
M&R_X#^C%'\/M!T3NQK<3/JJ!):+V9:<-B\ELW:`&$06P+("$`2Q-+R>4X7*'
MX!J;'3(.ABG1:06#/0KG')0XMO%>TM^?<#21#;+3Y7Q9YPS_W)NA<T?J<"XZ
M</Z0"?WQ"I"K.2SH<#J\D]'?B`QE'\WHI3]'/WRY/\`L2;;KGN#A`JVAITA+
MV7G'?.ZL9*D+R@9!V:+Y&X7U&*G:=_[97E++<$&>\)W6,Q@,R!T,U^'V#K74
M=R[7\:Y^BHL5DNV@G/6LP68BEYPR(I*MF]\IQ$T(2N19P$XYYV004<(@9CB7
MI"A`Q-?;-WRE5I)IR_VX[*>U\HJI0H^">063J""02P*9*%.\.1\78<HO!^2X
M*$(<O!,YF[<A1W'([I_WXOEADN8WQWF;#=YPQM?*;:#_AA\QNQ@I]L4ZJ?C6
M,D$CO!I*]QH2U)5FNPYP>TL.=.#/<$WV]AW.QY=^72/19'62]M#E-#N01-:_
M2]&@D`U*X8!*!XX9-HX"OK*W1G!'NT:F8QH9KYXWU*&KY.QE/"O96KU>8#!G
MZT)L8FY-,^E3J_.\0H84?VOW@5A+X^&68)!YTTQAOLI_A2P0%G4SNRA^MEDD
M\K?'=)&F92XIJC&)WRNVM0UG*L*5)[@ZULPX#VN.6&T-I/?85_E:%XE,U0O@
M#2]A*<#E]L>EDTU\)VNRAF,'\^SH*G_%>]H8/WI7=UJN9S,.08Q7LE(!S=YL
MT`Y/XW/DG.I4ZDA2&;)_]WGG_!D/:J9&O779\.K,%DZ%%96QZV]8C$$^G(''
M[8=')P_8SM2D``.[>>^_\>+XY(<O=.(J]>4:KQAC1%T/^6*<LSF;&[F\;('&
M!I*<`;&KNL,F1VN\O(.,0_*YQ#"1!:PJ[5Y.J1YB?P-%:RYR[YOC&U\IZ3'-
M;,;IF*J>6IEA$_$CK;$<HL3'%_3TH*,B"TR;"PFQ]@2]<0$V\1W(9RRNOF$N
M*9D^^#^2LW>8PNBV5.^@)0C#'?8R'Y/O.%?1=#UM+-[>];Q79+)&C7"&_7>F
M+E%1"8T]`^B`9H9++6?C,^?NC%M/QN#)%V\//T1[SV^6M^A\W!A32AWDZS>M
M)VRJ8%G@-RK-"JX,!,<BRU4W.C-T:?L<GR\->RBI,E-O(;E&_[O%/S%.C'0_
MK[OBC$@9V=M@9LMI=F=APV62*U`('.\<"8OJ:K&QN)[H@"8N1*,,'V>Z[Q4`
MMX:R#*7Y5=2HZ;3)&)3_[*7XP.<)-_(Y"M/7ZW"+3^M(?#3NJX8#`4\OV<R>
MQ62Y8L<$D(LFM`%$.*F4C\4;#1!*,+-C!0OS]9B8>T4.)<";<U6;8D8707GA
M0V@8\Z-MUNV#HB>-C;'[7"XW6;DN9Y'=R`5ZJA#1?/W-*]P>`[*(A6L?ODMQ
M;<Y6N#!X69Z$I_&'UV8OPFOH@BPK]RGQ@^:H@5J7]J/)DK,"CJ5808N^:`@K
MBM[Q`&,_VN89P!:Y?\67!-Z?@S?C_+2,3U8ZH=\);<F7M9)$1B/ID\R.4\SB
MLK)->040W4>WN_FD'+@M]4#ZN6B=9])&,<F]8:2SB&UG>IOCS&<-FME6&4$E
MTD474IMJ(TCZ*(MU%T:W`>41SI%H#TT5G/V?K)>+A32%+:V0H,M,;M5,1FLD
M*&!$#^);624AU_DKSB<@9WN_(+L)CVT+7S%`:Y8>TB<I9VNGP=NO)#6*7IQ8
M"C1+R;,AUC@'>(!T\T[D="QB<<U@ECEO,#SRUQ/K3QGA!VE:=B=[M9Y/6Y0@
M$DQSH#^,IMMS8>CW_)K3L)V]Q&N!?XM+>7`>-N?M_0I>.&N'Y_1FZW@H0%6K
MYGB(XC0[7[RUEQ:"4AT"@UA`DAYCI^;SYJC2>TCAH(&\RV&+/2.F<[`Q^XTK
M$.![CC=U*EE$&]E!%,LRBO([:DU\A9OH)?2QE1[(#@5[3[WC'?T9'6*%Y!QI
M-9V[TUF>RM$@244FH$)U)W`HA,B.`YH@=N5K*,3)C`FXV%6!\\#%J2EY0XY]
ME:P-"?.,$QAP*JD?O@R+$-R7C8<*GF:2CK::+O.K")N$N@*%=/O"AQ+8O#BB
M&77/B*($.B^TY-!M#C)=3.9'&Z'I3`[F:\4UAVU.2HDP,.27T4MZDWSF-.?,
MS3JRMF8)*#>#'55EAS@P:XH@;1Z3+$4:72<)3)/ZMDO'E^>]98"+'%5D_6XV
M64T:],,\HR)!8QO2+-U4(+5V*;?##UG\$MG#"DK])8X2_IE=YL,F"40TD,Y!
M04;@\X:(,IMC<P8LDEI#<F;*Y=T4@?.(/*O84G,Q(4E*,]C##<G$&,Y+QKG2
M.V_#679QQIKT%05(ZWU-22`KDE7$CMC-)&M23@JU[GSOV0_(S8]?H#2E&F^9
MY%1=%>E+!]>N@%05F0`)M8139R`EI$(O,7HF2_K;,\`M^H$S%C/85!,&#895
MK(@:/4*%Z?C0QYLF9:F\=E`8+1#TYDI?2)="$%E66$6%+)\T?+E#_3LISK>+
MXF]>O)6>PPDDF"0.7RWI[,>UB$^%?(`;`+46+.EQ%9F@Z'VC`G*`(6]&ARQ5
M!FZD[RY$'>$C]U8%GVX>"V-2A]7L"%7I*VP6^.AXV&@`PAK(WR(^%ZS($E&V
M!)7>L`B3N!#,,:;J3F)R%)"59C04\A]B'&/2TP,R9GH=;C_^_>@?2.'I<'L;
MILC"N$00?5:TLSQ,H*G,AT':2NZ-(VT6BT8V1(5/>8N`-$DV'8M&R;_*9K-7
MS&1)C&\B;LBQQ$1R*17CVXG$L%)"0LHG'7(;X7_`PCK/7N(G8.OOD'(0Q27C
M"1=G!9I6$L9P8ULQBD`_T'-`M5'.=8`\+?1P?>G/?NCOCWOTG&R7V$>DR1%)
M#SVE._CY5#!NP3]FQ^%J38)*FR!K%#]LR1!G+#N1(%*%OL^@X_6,#;T>U:HA
MT@"N"`=2?0UK<<#X"A.(3/MZGD\54NP+"[EJTKE,DV4S$5,F$N3-6$W]0;8@
M;,_?)$.$+7R#040'"?C?$9Y74/*3-NU:49#S^P%\KUG3"HK_Z@5',E^Y#H+H
M&[['6=9?&&^:I');'>DSKW/1;*"0"PK!:@F[IF!#^.*E<-N+LN=BGF'0)4!/
M!-`8&?D>*B0@QS:&25?9%NS^R-6'S5"KHH'TZ5EWVLQOQFRJ2+*`/H-QS3BI
M8H$8G@'R,#R-PY>F,0Q1Q`_A-LN2QM/J\AK&N\[K4&3>U4N@;H5D_6[NN.7@
M$HL%>3TD++AVC^B=^:M35`-W50#7R#YY)VZ04=)N!KF)"S'%_O.1'#E"*MY$
M29J=0OH';!Y![/>N?FZ*%9).L5]-W3HWJW*IGV+)H!1ME)@*41-B?MP?@NB$
M)G*;*NPT`K.)`W[XMQ_!`4FR@)%RKLM@I(3!5.V+L9K+[`NKOT\>(/*.,/5>
MX/WN8^"_T(O,]OB4D6CC29U\`[MFRI27/;N^=M=.L8G&9O85R#6H_2VY`J42
MN&),K@:HZJ%]4\V,!3MB(]N`5?O=Z[1?YXZ;&2-F5<N_D_7R:F2MAUU\,V<"
MO`2?=:ZX'\ST2]#38OOIVIA3'NFJ^W1J/Y%%PZV\K_WLI9M7/WRI_9UBZ=?Y
MRP@T/S"3T%+ZD,IZ,9&,2#'(VVL\0UNT:A"GVD)T\1Z?2*=WWS8'=D7T0:'&
M$P2;\D4+1X`]V"0Q+)3]!!:%DZP_N0[#HQ<T`V,>,`?%E5Z2S0>8/NI*7S;B
MK#K'/GF'3AMNCX#*P9&-06<TJY'H\\`,*O^4`.C%N/A)`M)72,8S7G@">^]4
MAAN(HQ3^:R5261A_AM!/(A#U_BQCSEZ3)_@]?8\$_=YC.%UYR9)Y9JF1I".O
M76>=UZ,J%RF1(V.WW,)D$_N'O)PH_M6!3";Q3S1];A?%Z#%\5Q>M8U3M2M'L
M$F^?XX>]?73$UW<U>ND$',,MWEM_I3,FQ!!$G&T6AVK].6[X)RMFH@-M+`ZQ
M^&8S)!80N9I7Q$<`ZPK!VC:A:Y._:Y;6,(N9L=(AAAN?;AN'V^L]+E;Z#U;`
MD'E#Z]B&JX9T)8SEO%C++H61?.>J.%.C$#7XW!8^'$V]#GSZQ@J=[E<?`XB-
M8II!Z.<`#J,2]U5#G.+ITZ/:V8)!KD*LA313`KF;;P#2^FBV\*[+:7D$%)I+
MT2B[2*&\05;T\97'G^'^N74PL.MI_>-JGBJRYU!6<V>>[\:4>:2%,-U#6"5P
M'"X<\!L59V;(J@2<V^M;:1JG=M&G,D`5&D$YFZ/]'DW)?2_(8@:N(>EO<%2\
M?HDAQ,_($5U>D,D8(*VE9%>SG*S*FO$5EVNV0RNLTI9`T=2X;).*(N,8I!U@
M;#"(?/@9QRKMR"1G%2OB5N]`P0QI_0QK9!91+)O=[ZI[LE]A@)-\<19.\OCJ
MQ?#92^#VP3N1B^R[J@N>)U3GS.,L367S*Z>+5;Z"5JY2WN]J:18@:Y)DL26@
M;!3DK9HO8*C/6&Y[29=OK"MJK7>]S*5MQJ.$8+6YT/F?0<VX*AN)X$/98>JG
MI]MP%\5[&NC8`4+^/>VC)@FE)#UXNEY,)]D@*9-**QL0N:`B>&Q&\X=$JM$Z
M%J#M&.^HANR>#UG/J*8'3<M!C*RUAH]9$KCYZ25Z^WD+?3I<03\T1RGH5X4J
MGU#8\P)Z`\<G]+OF&17QLQK&%$(%9'?F%Y/%K,$F*BN[4@80:7KYHPZ8.P38
MV"R1<C+,C&X[Z&;#?T`OEN-"^:01)A3-R[N+LV;S`(NR@P7#0#$Y(`:EGP$M
MQV+[?]T"^KR_TAO=<8XL=CZNF0<L'63]9KY>-,E0&V3<F3J-J!2@.QB@3GZ(
M7*])$JY)]#&%]E`?P^T'-#<4?+WZ<YJY46M</IA.FR.E;"2!!($/8VU627%A
M.""W+R"=OL]TIJ;3M['K\_8G)%;P6<B?-?LV;E/>`]QFG,>OF_/CWLJ[4LKK
M]-FJ2S1=M8!G8N7]8Y9@C?A"5NLZUM2YCVM<+>?I(%UG8+G*$M]R223]GL@R
MOKJM!)P[")RNM>@NEZNN,@O-80-?WGN)OY'\EO19@TPA"LA&TN7"G7-I0B39
MP9#^H`@]R&L@A"DM=7]`T!(LSB9FU)Q+1(O2!M9PXAH-O?S@F'(KA72]99HG
MI2KR!6S6*S%CR`)])M4B]@R$6N$1*?E(14ARZFRH$A=F*/VNQ249=6Q7Y!!/
MS0+6A9`V%SN#2<-*-H25?N'$@C#2S\TFJ]ERS0T?5@6-(<"R7(H^(<(49WIP
MQ3:.\$Y@=C]OD"=]C\<YTZ7C\&=PQLX`JL57]#?DSJT"GTU$81[YD[."$;)D
MYZ&S%*5*&<R;8QSSZQYTOZ>3/%W*R#K9<C7+ZK86A0?R?+;JI:J95$-,4@J6
MWDFPV<1'<C#:;'&DWDY9XY:474QR[!'&;_X&Y@-*G!!8VAM7:-Z0G^YW974]
MNF1/$@=YVZECM6*`OXI4ER6`XZS=!MLS#<KY*<EDK:2WEEK@-.%2CWQ#B.8(
MFZ]":]*D+M^D629P58FKJDVCX3;5'9P4LYD5RE1^/&L#WXV7O"+]H?\&MY^0
MI3]^QP<S$GB_>TS1R.B>E`DY*^A)MF!;P)-36_H&(B??E)</=E@#D*L`L`X@
M5P)'/Z(&R/2P.,R-8$@2XHAYXMP\.$H`F)N'%*39[Y$1$V*EB&\EJP)7/S;V
M#EH]/H6U`>M+%+[!!`TQK\EU-N0BA!I&%'R_1.E_P.[*X..U9ULP&P)"NLK"
M<C7O&]H*?0!5"-#[+.KA#U<M1TH!I)7QZN5V6)G&O:J1-MA(<39)3B,01N&[
MS+(>M6R(+'B"^"&1!:V*@N=0O'=,'/S1_E`1,D_8C[-?X><<W5Q@*_%'B*5,
M9-*;??/^8\<S`FQY[B0&%76!\P>+O.=_$Q*._PK]EU?4\COO#<:X7&A<L=F!
MFI(.1_]/U.X7=K2$<KX7&(WO>#C.++@B>M)$I"R;EZ;.(K^JM`QG9))FINB'
M*D0N`]$#TO(5>:FQ\I@2?L5D6<,&QJE`9Z;RA*@];XH6526D$Q/6JPF3'%28
M31P9#"^?Q=BY/,-S-RY/6G904D2BUD0>1W`8>?H&P_2$_C=X$]3>Z_.Z[I(2
M/723K/CFK-Q%5IU/%($!;0#0%O16EA@+-"M6"$";K*PUE@E(/$$,<LWWMT.I
M6]27Z&NC\8^0D3(7/DR>O.>`=8:L_G=-A\AJC<H?IEWG?6OV.OB-"#!P.'@X
M`%<6@([#9$SGR$^3M3%J\M;3#>)*[`6WX19^_S=XXMF_]9Q.[VTV+G^<<.96
MO/@$,CF`"`)(DB%O/@N0VQ>0-N_F.5/-RYG8M7D[&4J3'H.LBR3WQS1)<=78
M\(7_L40OZ>6!0!-Y'\H+">8^1*<7=#Q$Q8**7&,44875Y6"]D@2KD3X2WMG@
M4I>1M!&+9BY^A0=<3#U\>41S&F9)(>'C>LG$U$%^@-&D$14'"GF`"C3&G_/A
MN0/A:62,T.T:7.$;1!=+/D1[SV].]%M_ULH"VF:/ZE/SFM?_1M\W-2T8HKXK
MJ;X^+ZZ[1=UK*P!U>>DG/X#QC9?"ERCF3PCJ3VGUV5K3\M]^,JFY+I$"<C&F
M''@X%K<7%GW>S'2?NE.W0>OR[8?C<^!O/@61USPOQ'Y&JU]7&NY1\&E5\VHJ
M`Q`AIGQZ*`ZW!PY]_LQPF;HW-^'J\N6O\,7'!57"](NWYZXW-A_3ZM'UMGL,
M/NOK-J48@.68\NLST+C]T.CS;K83U1V<@5N7C_\:!<<P]6+:9?`GE,WGM'IY
MHW'YF+>LNWDAA_;GQJ:.Y^!Q>^+1Y^D<5ZJ[.@NZ+E__*PR"?PNC;^$C])(H
MA-O;)#FV]JR[G]?J^QPE>JQHU\<O6!X@`D$N$5"1IMB@`J';0/CN=UF$^OC1
MX7YUGHB,8B0%BFKE;V&E8.Y7^`;#(Z3'=]"7#KW@YIBDT1[&=UUGE`?+TYE"
M-51)6=]=.^M%G9VHK5I9Y:RU_,@=;0_D#=IPO%B+C0B_<UOLAME"6_K6N52I
MI7>=95XCD>+O1Z1Q5Z74^D,Z.5UK63:M=C)?Y>5`R/OF*Z$.A^%*P]#&&*;+
MU&C0AFO.MW$>/^J2PY2YW2!^5KNG-Q20CKK3AL,7<@QM2:A#Y?9&I9<''/=J
MTX%E!'.LP`-4#T$LBA'OHR._:)3H%>T<8>LA&U1G:V=5HTHNKE)VC4HTR1@%
M&`EQ'F)\V,^.RH02?M=FC<`0:K+E22N\^0_S$>U9[_7V)9U@L9I-\\SV;/0P
M]NR#1=VS$3@Z$72DH9\!P^T!0T^N.=OQRWQR!EB%C&,EA;?^;(9I?3*KU^OU
M<EUGV8B)X1T$ZZ^XHTEQ&5[UU]Z5TUXCG5K9[$Q\:FCT/85A@AR9GD.^W]VC
M7M[#F5QWT$O8U.IX13O=Q/K(QE?TWUE&P5Q@7HG@?@<*F8`(U<Q+A0@=DP@[
M"*P0)B%U"2G``K)CGEX`8(&?%D@PQW<Y^I4Q0,)$)F:#GSP__M4+CO`Z26":
M7(?5`JR?D6K'&&[OPZ]P<XQCI"UZX$L4QOD_<7W]!+]/2/X$-Z^A__<C["QZ
M.GJS&F>E8V.1KN$YG67;$U@C0%0"5"=R5T>U$G*N%KC'FQ:9)N2IJFKDHH\$
M%,J!4CL+]C*LLKO;L'O6/N[_DJN*B;V&B:^&65?7I%U7>*A._+5\US]0K&5-
MI;0T>?DQML^<PYDNW9G&^&IB.F:=N56'57.S1)U!0$,T57$T6UDD9<`@>O\2
M1L\)C-^PKK?AX4BJ=X4;!)Z@>7\BK]\$7I((-P=':\Y<!%6&07HS>[U8\:(G
M.UK2X%A5"!"-0%TE\/Y$Y0"BE>$-3RO,3"\'D;2)H<"GG+."H*?V*Y@.>,<]
M+7KUU4]^_Q1#I#GR2IBD7]OWT?=^W5!`$NDDZ_GNPF$&F%PVP,(!E@YR\>"K
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M!+@!`G9Z,(>+8K,9IF7QX[_Z:)`?;UY/=_`-F5>J1Q.];(::`HVDKX98SI<L
M<E;^50@'1+HM79\J\"V&EGBMZA$E?)=#R2Y+&28E.7#Q&@5;]/&S,TSR6V5=
MKYLAIE`GZ3T6=\GL-ZO"07YDS:8]*97XFSOSSW7\_R1O``.4E?)L#FF[36B4
MMA_\9!-$>+LKZ3C5+7S%!#T9>D@GBZR6[26BBCSC)\"5@6SR3AZD=IX)7)')
M+9YI;.'3$_R>OD=M_M[C&Y?O&&94H8A\6NNTG4Y<\S8L$A"9%I%J&$Y1GIEM
M7&JY81>9ZB8QRB:299%D%:ACN/53O'O;]7DY;YE@%%L5^?V\M=OB%!4)\LKB
M1"A)5C!,*@5015N7&PHT.<30,WI'J:1S,EDFL)$%/".S24=X^:'H#7/\JJHA
MO>6UG$UXW*+K(X[A2Q!5@6PMC%!Y5SE,B\C$\D`!D5HFL85$;F\2N7:0R.WI
M7ZOY7$PBUT(2#0'902+7-A*Y_4CD6DBB:6\23>T@T;3GK<[+=7LQHD:BJ84D
M&@*R@T13VT@T[4>BJ>J[>1N-T+/@C6\D>%!W@0:F%K*G^5T$GY9E:+/@@7MX
M?Q1N*P+#H?2(8,1E%\Y'E!5J3=+8WY!R"YOJY=IO^;$OL"^70TP77A!2J"BW
MP#>-T<Y0?/2.G$FY?P[\%V+USIWOGM),=*+]5)3M>];+17NJUWW\EAXHJ[0W
M"F<I/SZ&6ZD.>$0#S;"!\I06+P4?X(9T9V#J7`'LJ2/"?TR].#5M@'F'`>P8
MXP^+"<RARP!;VAX..X[HW<FFTZMLRM)`*JN_]#396:\'1]GN8[L6)>.;,FYK
M^L2T;M2R[I4"\]H8Y_J2?6@0[/4Q+SQ"2B4WJVKF,B-CG^3AR;JXZ7B<J&A%
MDK4)FXX:#"W*X%9,Z9%BH"69X0J`R";MJ&SJ0N-@W]29R60^?!XNPUIK$HQ,
M&3=;H*N9)=JQ;8QFN)7/@![\]R.:A,,X.%&+_U&BGU3ZD^H/9C0*5K+1'J+`
MWYSH_TJ'ML[W3<2K+J5D>;*<N.TMZXIP0.7F_[$HJ"BU0#.#\9ZD65G!>5GW
M91)9RDBVL#-IG^B1.RTC)<,P2[F*2>>OSQ@EX*H-L`^W67)X1KDEFHR50VR2
MO9WNW<5@L>'4;+'#+9(<,%--&`]HWU*OMB[I+K/Y;)K=<)"]/F[Z"'\+?;#R
MCC;E.[;,!R-P*PC,;7ZSG+O<]&Z!,](O^J&?HO'W&]S>(B*$+SX:7V?%9S>(
M'<?`P\6<]E&<^O]@\>0,03I[R-[:2;J;.YDM\A5&T@8@C8"RE:+H=-D.J#:D
MEE=K:HL0ON"&A%WER"8A&]I5T%X':&U]Y6"7KW68P\QG&\<K^GW\?H!A`K^@
ML?K3-QB\P<]1F+YR]VK/$VH)][LUE7;Z]6(J%P<J;8*L48!;!;190-LU-'[6
M9RO215?,XY%6KFIA`D#:T!4(L8%2:J`]UT`VA!!Y1LF&$TG#VQ]:_@-Z\2?T
MK!+G*X19&TIR#65IX<ZGZ^$A!+<&<'.7$#D&F:9?Q#AA>^PX]K`S4#3Y,3Q`
MU.Q[(8$!^:0ZW\+"[`X,J'UI[Y\L%^<&!M3<Q02&OJ89$A@X]K`X,%3X<69@
MR.U[&8'A"36O;LA`I5D=&HB*L@28+N>S,V,#:>]2@D-_XPR(#BG/(O:&AQI+
MSHL/I8DO)$!\B]2Y%Y)E=W#X%LEZO[->3<X-#=^BBPD,/0TS)"RPK6%Q4"B9
M<69(R(RK9M./-!\PFZ]=>'?'.2\R5(KV[</>*DIZ\'(UF4^S/4;2QCLNM1M7
M78Y^CH._'3FN,2IQ+K#%%AV[F^,:Q!W!._1LFPX.#^7>ZC#36C;<>7_Z[/UG
M%'?>%M%#@AU#FZ9:LHDXL_5T)36@>7\"I`4;;ID8R0PR]'ZNF<'2H0O/RR4'
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M8:<CM5/`L9/&%;\SHTYC\>\<V]LU=N(&V%ZO6C%*ZNWCCN/,YA*AP!S=1P/=
M3>PK`)/4WY/#%06-WZ"E:PQLQO8VGYIA#OK^Z>MG'\'Z&GI/7OP"4\$91/[3
MV@<H7%4D?6NUFLX7V>B#R`)$&$#2`!6G>3RA!I`C`&3T!*,:>&X;WI?K#)X1
MNDNRJ.R3Q78PTN$>8Q1RCC&\#K>?_._XIT1<\I[_@L[.E:N%=*F:V2Q?;<AE
MD8W@7)KI:O=J`+IU@%X%H-'^L=/K:KVBV!8F:/,7-&*^BY+D/OS@)X<H\7%7
M=;^CXVO.)Q6_HY$\0D6D3Z]-<OY@<0#+PQ6S*A+!_2Z;H9HZW*L0*#G'2T`B
M8%LBS0MP6:L@"E_>(3KOLVFF25I)>6656=T&,DNNVQ`-Y%-2A:/S$U>?-4*F
MB@+2);\7SII!HHHD\]09#&M6X$*4\<60]#.$X5IL9C3QFV)$@M6!2*&/W_&U
M%T<_><5*W>\^P&?>=<G=[VEFBE`96?=:K:JL20"5B8E3EXH[("S7S`A.+5RW
MVO_`.DS4"VV5P^P7*A1^U]DPI#HCB!05F]&DVT1&(@L,<?T=-+*^WN[]T,=7
M6*?^&\RRWGF?O.,MG5%%K(KT88C9(A_.4H%D,E@7F1\*,11/%`)UJT#QI-"K
MB33*+SF'K+%+PC(6<DNXS"+WKCT\ZWN;97Y/>S?;#"_$J,=]N>3C+]'(6\D(
M$:-H^\T/L'K-O=#RROGK9ZSTACN4[B5#)S'[*":]>.@LLPW'7#QA:#OWH&P"
M_)8W8HJIHQG"K1G".\\0VK@\Q.EKG.YM3R6[DG^)WF`<XJ'Q7V(O%&Q(LA_4
MO1?)U$+.NU839[+(DJ!*,8#(,50M]7PTCGXTXLW'\R&Y+$C&]AN%_"BV&OFH
MU9`T^5U`S.*/VLF8MRQ]1M1=K#(")K]KIMH@79U,5Z.,&J0Y9='COYDC3M-G
M2[+4`"DAR+_>_'H=!#Z^QI-/E/9#N@G3TD`R,$Y=9YF5]T8B0"Y#+X/.4YXP
MZ5_!#2C5-TFJ\\"X,E]""\NXCE^PC8U4">MN]_MC&-V&N\#;[_%;IVX2=KZC
MFY-="LDZQF+F9-4QJ,1W59&&**L4FU-B`TQL)OFL%*D[Y"MJH;LLXPKV2]G%
MQ"+1[?[@^3'9DHD_9`D>][N[*'PA^;ATXBMWB=4@41J7C(;H)UV6H3C%5[8"
M[F.0MX,W97%+60I[MGIBS457HYO&;9@FHN9X5S6'R66C<VA073T:;$@CW$=F
M"?%Z]2=DBSN8)!%O7X;UI$[FMIN7SF.;KK+I8R$$8"F`BC%$MS/Q$#8]P1"O
M,?FY+*/TX7M2C1T<W(:</]I#G)V`E;F)D%[AT0]?[@\P)H/4Y#W<13&DSSUY
MWV'R\7L:>U&\]4,O/I'3]E^0:=";R$Q(OY?;$'UYF/#V4L9L42\9QX(AG3(S
M<9R"U*@1FD)(:%WJ`TJ%`-4(9$\3G4!-*5H5`M35`KE>XT2)*/6"CBAAA:$7
M16K2,S6C3\V8XA8-1YVQ*=R(7J-^#W-1\!%-R\FM?QV[P;RGM4>?E@KR]]=/
M5K7(44@ROI&K`ID[`)E>MG)=K<TTMBDL8,D=;@GQ75"74?2&.;94U9#M`MQ)
M7DBZY5>Y.*,U%E5!9%-'`J(A_K"<4,"AEETLXI&P(I3X'?-<ZG>=\&R]=#K9
M9+2NDSJ878RRH%R3E$-*L&IP*2:5O$(CSNMC^AK%?GKJ[)I:#VMG4E,#Z=RT
MU6Q6HQ`2!`I)%O1%9P%S!P#3RQ:>F[5IPC2$'?R0Z'(8CQOE2,][ZQUG(F*)
M!7W,F>`$3+&F9^&[G)@MMO0G=)'C!8:;TUU'85WQ.R:8PU)$?C;MKEKTJ0BT
MH(2N.IQ-)O7!J9U/(I=DDHIK'EN8]>0]![PCA_SG#3.**"$]P5[E=UCRO(R(
MLXA(_>$)2<2'9Y(_-<?KXDYI$:.\D3ZY)'K#!'?..(PSG[;[(HM.(*F"V&20
M=6>+))R0R2(EYX9&XU%G6I?H%;-,ZIV+-%_FY9LX?F8^$TL5R@:;;-BI%;M=
M!W6L2)?*]W4?/'_;]0&SITPPA#8MZR[+Y6K:)`5,`!9AF`,#<%3=GB0H@`,'
MAW;?K[L-T]TK@(UZ>':`_3T,X<[O'&$UGC;A\745I"^0GS&6DO,"#)DLPQ0X
M`UB#"N"'9RKDQ_QF6Y-I3>=!6PR!IIWP;!8QB<^PA=$`()GQSWO<1`@8F)X^
M6:[;0T)[$O-5H+-S*"B332]"K^;H7-["5R^%7R'6WP]\LJ?+6_"6?T_[$3H)
MI63O%UDOIEFI^`HML%Q0%VSP4FGE<)M1P`C<CO-UJC$W%UV&8-9SY*X'4\MC
M=[+F&CN8L-;XY=ZQ*(CT611WU^O52BZ`C+CV/R1V]$<I%3=,['"HARH5+LSM
M=O2BH4R4L&37HZ[4S2OZ4/`V_`!W,([A%F<.D(.%OWK!D69Y!D'T#9\N[AI6
M#A=L8H@_6%OI,J'S)8/.=?>FS8+;$.0-T_03>J2W:!L4C1N>.>@Q&@D,F6G\
M$+P59O!$9M`^Z3B;2,SIR7DF5CSV8.KRR?-CW#R\W]U$X1N,4US6[DN4PH[I
M36]IYL8K?565K$7ANM,U8R3##`K(\W&#)`I`?,B]TB8@C9H:YHQJ'.F(63'.
MO2[CR(Z.1K50(SSNL!W><B?95.P0(M'@X)WPN,."$=308,(86PVR[YBQL;SL
M0N)NB3,$61(1Q5I*=O:+V60^[PJ&Y:TN4>MRBFC$RRGZAD&%%NF(@+5[;FRX
MKD.366KW=^`[+!I76]@6X>1"0E=PDS"@1;-)SA[4=?H);G%U<WS8Z8@K5M6F
MR?UF'0/;,#_''*:X[,QI.EDS5IWKH8._,PVN4Y"I`0H]JL]C5:R:?&JP)HDX
M6/PF);<F%UO$V0XQ\%*PRXR6%$;##\0<:QF>HYY'3XGIZAD?Q:(H]B4*MW![
MW)#Q8X;D\=6+X7LO@=N;:(]_0X>>44>%GG-EFX]:_1267N=9-<XN,Z)5K>4B
M8)&V`6D<5%L'N'FK(M2(EB.1Z3&--K^C"5\IQ\*0,XQ+$J%F@'4M"C'WZ2N,
MK[?_>13?S2G[MODPT51)/@7+Z9SQ$-F@(MPJFI^%O'DQPHNIBQ$&^JL$49GV
ML8V*Q:_"%ZF#J3(B+"%E4R_ICL9U)9E9:8%F=MC'S[.,0$A*Q-C*3)[[RM*3
M:1Z+./H0^U'\']"+*]GM_;R`*<$\0UEJ27<@RUGGC)_(![B!6L%*JPAZM@T(
M/RG2$T::QD?X[GBPD*PB/Y;@*M=2%E&5U#.Z#K>XG%$PF*Y<*>8IRU--?FFI
MF[:D#7)?(&G%7NXJ,48VF\60RT4VF%R!$))-GGR-[9E_BL8PK[N<7H+;0DM:
MQ&_TBYL8;OV^<];*>^8Y7"HC>_AAO>IF+?Y5)M;43?**\9*;Y#&L#1^68>JU
M_5&";`U[&*)7#+T$?H#TO[?A]683'=$$&06!?%`._3><O"&@6@\9>FDGKYBT
M2RZ=\FPQ$0MR^3@?*&^!=)O%Q#1OQ"`AQ[($(><-+@#N;1!L?*EN1&#'8M@:
M"=O?PQOD[6D[NXC\0%.O>GM&_IX5A,V4D1_0S1T9DC[PT]*T#&85HB7#UP*8
MP7R[WAXI1[:J3:PA&)KB;^]\[QGUZ*G?KX-LOFJ:9@U]I)<^UJNYF&E8,*A(
MMHALYV#.^4;@!6)X1BG'\=%.UK&,8P?Q\F,(0YC'>M<H]1@*R6\+S$3<*P[S
M6$B^<U$3]A4`8[QI68X\K66CP''%=.29RRX^?H5O,#S*CS2;[UG!PTP9Z;Y@
MX:QE.)B)M8U_0]`VN<<%9IYH#8^4(UG5)G80[./^$$0G"+_"@,ST!_1[`A%&
M:<?72[H_F%4J(+89F#<`LA9L[`T5&:$V)+4H(Z^W-XMYVF$M.RB;7:$7OMQX
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MTD=ZI60Q6?-(AN2"0C#()=O!L[,Q-WLU3]RKG8^PNVRZ8H2+1C"QKL<645`4
M5+B6,117(/*'-!^YT^1&_C=F/:PW=C`TD$]`G1;K551.9:)*11D+#^?"<FNP
MRFFHSX6ED3<"%VLPA6<&D]S()K<=WRY_R@`;LJ9[9+PL&C3X.,:-&WV6:<X`
M,JLAL>*"#:;?L#R]"MBDB]^'E?)VN`H4ZJ3N=T_>]XX/QG_/``VXRLCZTV2R
M;/8/]V&M#"262@:6]SM\-,-L;Z$&;VV?T<]Q1V&K[*/IZ9R<H[)8)C:42=X)
M+VJK/&*`37VN-ENMYVZ#.":O9QL(H#Z$,G\O6]M%6,YM^$:V7`F2SWUSC''V
M'AJ_?4$`Z3\ZOQ+_32->SU5'.JI.W76+#$0JR,2264<IV#1-U""^K'Y$PF'9
M9!,;RQ@'0R_(,MT>8?SF;^#MU\?/</\,8]'G%[REFWM\5>27H,M2WU1@GJ<)
M,I'@%GP%C^`W*M?<_I8RM*X0[0](Z(_&R=;MF2VB=5AG.,D2N/GI)7K[V4<1
M*4DIQ>C/37+1WR)U\']PC:D[SG5K@@<U4(C?NK0?31;%OG`NQ.`M8HH`N3T!
MC<V(;G?").@`;Z9SR761O7*3][S6#H6CA+0/K<O"QX4/673II@IXM$+*:Q2G
M[YY@O`>E5,,#M`Z'J_<6(DN8Y4N"%QK0"/'CWX]^>GJ$:)A(LC\[<X>E!1AA
M5)=6LC/NV7+1HEA"U]?P[(B*!Z5\"W*'1S%!HZ=*KJ@-O`$VT$]161]G<U;*
MCH9)C`\2$24_>_'O,,63OY:ZX?8&S6\]/WR*/;RIVS_I<*3FS`0(I1ADN32O
MW')2AA-R9B^+**4V#&+A!S*-0*:2I<F1%IBY&;(LB46C4)43N=0;W\BDEG7M
M+^<A$Y/9/O>_HGG?>MF>R)JXUE8!CM;\U=R=M6*G84Y;3=]*6^B!FKK^[O,/
M][0>--)CYJW+!N&).V_/3K$0-#Y$8HQW38/P-#V^`X_^_J7I3.R>H8;=O/??
M>"E\B6+_'^3D<,>&0.>+QMC!TD;:NU9N:V1(O:LNU?BV@%+`S3$:^.U#M$=C
M$8O()/)-/KFXEC%"MH=[,:>*O^ND3MZHK,,X\R)[`SR`>]-$&*1^YN]HY.T%
MX.'X'/@;<+_;P1@-O(VZ?--#:IY=@ZKD+EEDV2C&3Y_P?.2`6</TT(Z'==\)
MR]5$\A;CZ=19._3>UU(4*&3IO<Y5#1B'!\80/Q5"<_M\I[&9*D>;XDY5L05,
M=$)W^$3V=;C]B@D6B)/5V<]J[)R8"DB71ETOLFH$1`Q9M:."QDE@E^VRS@=%
M&(%?S_/7C2ZJ"3VJVH'Q@:OIS+!X)-6/Z6`O"M-7U!J^K809G`2/:^_0^+I(
M.L9T/G5F69=&O+V4=@6(/+))A"5J[MX407-8T#)DUV,BZ^CB%,&C-WP5I8`"
M`A260+=H(G-%+Q?"WW&/VS'7_W4SK>P!.PQDK`]\C8+M[?X01V^0S'F%4S/1
M&[K[0[8:LO.?A9LO?!?"0%6:X?F<*H0N'Z'QOE+L>:T>4V`-=?UF\NF8'F/X
MV0_]_7'_X)U(4W><-$;Y]XSTI!U*R8ZU%NOUI-*E)H"*!9E<D`L>/P%2W+NJ
MA.O8`%>BRU6)V56`65^_*\G4>@<L8ZZQ@PEK^UCN'8N"2)_-V36N]R@70$;<
M>!X2._JCE(H;)K;7U4.5"A?F=N![T5`F2@S=GQ=%")Q#[(>$@%^BU-_`!QC[
M4?-P:_?S1B(#1QG9^=YJNJS-U"OB`)4'J$`#X4`%-,<4-(D8H`(?<ZH>';!,
M+P!I!7)((1^XD/7%@@["U>.`R$KG9YYMH4^GZNB'Y@P=_0JI\.(%'\/43T^,
M=!S6$QIFX(QF95.TYNOU.B?%"UY\)A*,9-^<B\+M@6)LWQ:X"O9F'E0CZTV=
MES88NI-AP&T#$]?)UX_&ODRAJXC<4.U)K;@G+-V6ZX(Z[D&PX9J#B@[7X?8Q
MC3:_XX4I%&EH*G/W-V*_9L;;F;I(.]%BXK8H0#8AJC*S<P/&J7$^5#9?R#Y$
M4I'\3P!R$1L@DM!+.>SBV\I&RG6<#91^W2(*]KY08[:<2%/1^*'`4="[3?27
MR$O1$<!>5C/,TQMA%2/&@V:X=].K8H^SG"_6;9;=C%F/J$<'-P1,I4O+"O)8
M.!2\X5<8XL"WP_OE^Z7F"T;9T/=`]GPYGW%985-?<PX^>EE5FR)&;Z7J=CDQ
M5VSJ,3YY?ORK%QQA>=3S*SX5BE/1NS^M\&TS;!*I)%VC>IY75*E2"TL&1'3U
MF'4AW#C/E"%O#>GVT,/2ML!+P0Y;X8U8(0J!!^*\"?#L);XM?9>,6W-(VFE&
M-=M0_H9DS@K..]2?T+[55&M>TG\6B_)D0_:^YEVDX5H[5:V-'EL8CL'MLKR>
M'1^F;Y=[/&U\:B@5A2]^BF^J\()']-_3_>X!N3=R\D=O?PA@<A]^3IY>8>P=
M3@+:]9>BG9J]590\\.+,'#=/.:NT`4@CN(IXU@S(VL$%QS\G(&M*,]/'-8(S
MT`A&`\>X)G$5^H6>.#0X()2Q:IA)C0SJD:IX]Q_7>NFH)<%\5.=PG=&^=!VR
MZ7)5LA-+H563C)>4.!M4P:]W!:HK6RI+B)RK-H[F&<$&1M"B`I*?+WO8("NH
M!O)E,E<3/B\$]13T,V,`,`$W+"@5(78T$3\JIE`R!O[LI;BBUXEF3-WO2,E4
MG$]5J:[!&CI(O:=[G"NCE.P(9CUS5G1DFTO-4@'Q\(4(!C*%9<<;SRH'ZY@'
M*QZN*D?L5A$;&W7VH6`QSI2VA8E^]+/W'2=D"T\HUI_1V&O6&I8^H^<X;DX0
M\KKA8X?#0;@5$":[0*:/5'N^-D0CKDS/%HA=N?:,3E>N-BQ=4,C)-\?S4R"&
M77DP"+<"PJ@KLWRDYLHMB&K&;GX8X3Z@N`CN6XB,_>H?WI_PQ3U1F"($2,P+
M_0/J*C9X]/3"/-0V7)CV4=Y0327'!I/%?#[-AGY94Z"\,3%O#+P_@7ISV=]`
MV:#F`:$6NSBVVJ5C[*C%."0B_1J1<S9)67_[($2N9Y!Y;JPH1YYG6=)$'_X%
MIC=>\OH01V_^%F[?GWY)X/8V_.2'7KC!I:LWJ?\F.NW00X#&WE]>*^F;Z>>3
M[*P$O@06"P>Y=$QK+!\7G2]:`&439K+J1C+!(C?!!IO@D)O@^01^.";D_K\?
MP:XP@B<T@JY!2'\GKXY0>AK2;A9WY/,-$&0EJWMG7R]6[D!V&\\.'-DJI-_^
M=+&,%F43#K2<10RG*UIG]-,L`>89S=!*MI.:.?.U!).+%FSMI\\U0;V?+OOF
M:H_M%T:PFM4")Y=@,\^0=K-X6#\M$F0EJWOW2'*C<!:[;>VG55FE4O?_$AD]
MH)_NLIQ%#"]*C`SMIUD"S#.:H97L*K6[GBPDF%S69K&TGS[7!/5^.NNF053`
MMIK'`K>6X"_/=';S=EC/+!)D)8_[GC";KI<RXVX6GVWMF559I5%DZM(8/:!G
M[K*<(8;?AIMH#^^B1-#Y5I[1R\NR8>F"'K/\4@1,.?H^P`*,L6@@!C?'$(RF
MO$3O/E#Y19?R&AG==O`&61L8E6RU([$%W['D&R^.3[LH_N;%VSM_[]/=ZOL0
MA89RPZO8&;MY12;.RU2R=B=5BM>]':]0=]EK=F:+>7;J"/MDV>O@YD&U?5`J
M@(^8(!4JN]"5/6NJ!1#DDHRW;6_*?LYEV4^\O6_*B-GYR<)(T0Z@X'/PPM,_
M)8">$#Z!-`+'%/WX#P@VV2W<J?<=;&*X]?&<J%25%L,)T4<I)T<XY-8?N@+[
M+'.K3"S`+4?%]]@00,:2#4:(ED7Z@>HOK:I[0,/##83;Y!,RPVV2'#UDHOO=
M312^H4_N/P?P2Y3"Y,$[\:J*]Y9A(-#W4E"V2+4SG<[+:)XW`7`;(&\$YZ%7
MF@&D'9`UI#U>CV<&QS8S=(;=\6Q!8FMA!QQ>@)_;@<39T@XAL<.!;P==86]0
M%*C&MO[F-#//_':]V43'$$=AI'*(?MS0VUX>HL#?G.C_/L'OZ7NDQN_<"4E/
M,5IGJ_UTDT["GZUG.<V_@;()4&\#4/'Y?W[#[0#2D+'UHQ'MD5T0B'MKODG,
MSCN'.7Q]:CK`@D;8C>SA):_EUE.X+=)%R/4K7<O#TN_KY+.L4M(7D<_S<^69
MZ.J.+!K%E^E$1+SY!>!1#$"8^W@\'`+BR5X`MD45I`1WTV$4OB/6J21B(.M8
MES[9U^=KS.YE6H.4OH\?O#C-_G&]^?O13WP\W+]%7RY\P<.+ZR2!:4+^A*:G
MCMB7^HO33_C>.DIG"B]GTSK_[V.`VP+YORNM@;(Y0-L#>8/`,1H/QK4/"0_7
M>]SI)8CIF_B(`*/9.AJKI\5]P%L?W^)C`_T'\X,1#889UE!P*):;_N+Y88+7
M5?C)&YRG]5*;I8)T15VWV%.J"`)$$J"B1J'D(<(>\-;%RK.A3;/B%TDV:\;%
M%RO+DSVFS5JBT-EX:<U7N@3MAP#WP7L47K:UTI.ZD:.FGJ/QL3N-;[TIS,#%
M/0[L-84=PA=L^M%ASY3"UMC-B")MHQ?A6LET)T%W6#_BOCN!W9/!CO<,=1Q,
M962S4=?SO)9VK0O)\A,RH39,^13"I2D^Z2N,$<\(SA\@%?>CT>K:TI[)HQ??
M-&:(AKHFO/0KFGY5'M%*G[)=Z?P19U4LD^`^E[YN;M(S$`$=8[1&$#X19=;[
MV^Y2=_0&8C4;GD=<RN)^1ZY?_/@=S>42O.M*+I5DU@L3OZ!]*U.DC6P"P'JQ
MSFY+IN+PYAR]1K20"#*1FG<HE:%SS*'KV'A4!M&M0,0Y%%0$SMF`6.RVFHF!
M&S.WNRA#N7(KL=-`1OJV3*LB@^,1OK!*#'8_K[/7XRDAO<6UF#M-*I5)5[DT
M0QVB$G`M$N7@$@$X;3UDE]/5NDNA/93TG?>;-$)M/'V+GEZC8^*%V^MP^_0-
M!F^07V6^^R7=?6BG1I(>-%].I]G]XIE(@&2"7"C92Z-BQRU4QNU.U0)UC`,5
M]ZQJT;I5M(@*KK'N4YIU11<J9PDU(6&W\S<0B4>?)8KQ:Z?'@[<1Q0/Q&]J#
M@5`=R0&9.UVYBRP2$'EDI[B4"(A(4U%`'4*G@O!:.\(.^JN#Z79\2'.A0(IM
M91SH-HF)L70Q0LD6KGACZ/9S&L?.K<9E%UU<=YTM&Y4CY5R&F9'R>5`:YR/A
MJ%"Z#H*=!Z5R%VDD!4C70)_+B.H`GXW="@)W[*3PGS=)Z-Y;">O%DD=LXQLF
M:M!QN&YTDZ33V80<,;XI<E_?JQ$<;V8]:8(?O4_:.NM%?HEHZ3NC'WB6[BH&
MXEG4]^FS#H.S:*R=#.*SQ#SL1@E`%G233T><,I>=8WOP3F2)ZL.Q>;"L[]LF
MB")62=;95NYDWB0/E0RHZ/QP*LB%`R3=,*<40E^PH%^)L%\!,H:S@H=R3LWD
MIH0-+>9K=L'W>8Z2"[&/O9EFTJE=,[<U-NPF<7Z%O>$AHWI+D'$D\J_9!7"T
MX<@#J%JUD,6,O0T_(2?Z#^C%G2-0>4'V,;>BG70_-,^K2O1B+RXYC9H"I"VK
M.3S4)CF/EQ?`8X9[#^!RTU)6\_D)M0J5$+HBR49&E^I)I[ZYL_4P2I.V+H+3
M`ZV2DWIQ$:1N^_@@5C=L93>MOT5J2)W+L9+2F7+2:S)S9S:0T-^BRZ#S$(OD
M9)Y?!ID;GCV,RE4[64SDIU<80V^7<F]?["_'/B*7RDE/$!>3Z0`BEPU93>.!
M]B`T%D.TC,QM[QY`YH:UU&0D\6JL??Q^\.D2/@X?S!02R5>UYRC)Z27I<3/'
M<9TL68E?0/$*E,))]ZDY:6D$R,V@TZH9J0-Q1Q+3"+`;F[JMJHQXFS>'?>+`
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M51;`*NT1PF8MXL.$E39KY3.S5L%ON%U:AE#WJ0E]5G*LMU)')-1G*G=L4^F)
MEDI"4!E#S[>_D6E11>V;*$R08ML<PP/RTCR&W>^RDI1>\(A^0^O.=F6<*Y&M
M<[*E0F'I7._5:LJ(.K5V";&J+6-V%6V#LG'SJ>_:3=>*0E<-VWE-VT6#;*=M
MCJB2B;7II+)/<W$!ZD-13+BKEKSR9BXE;#%TE]TTF:U=UKAI8`0K%;&@7+U1
MD^;[4.#],4$#A"2Y`N^]Q"?UL&NF]"K#KJASV'6QP4W`8F5QCO?-C(0\7"2/
M5O?%]7_%.=[,9W4&'Y8"TJE0JV*EB10&S&I;EX(,L?]L3)5BAQZ18Y1\(G^J
M,8B+VQ@-;J+](8:ON/[4&RP/4N%KO'9/WO<'&/O1%OT^QDM7'R#];]>\Y'S!
MN@EVEK;2P^II<0B*>&ZMT>I90D#N_=L!U#*@38.\;9`W;GY&HM=N%<9O:G;#
M.U%FS^XJXU$K5IQO7IL"RR\AT@_?L[C]URC89H63,9[[\!&B:$@O:8Y]-"A[
M^8#^&;Y0@#G<GHYX=G,6!*%S,<@?:%HM.D-3J0S(M"%%^6G(N@]!J1'(5`)4
MISR(E6'-KI"EU<HDD%5,^8)-^`..8C\"-.=(7J,X?8<WP;(K><CP^0K?.FJJ
M$+X59G.:=B,9"&*#X4E;RG8VTYV#JE@HTV4H^4[&.I([GU[4BW24FZVQ7]`=
MS)E:2)]+6\QJX;@BS([)V_GH*N.Y(`I?*(&#4JQQT@K]KD4[OD%,$.>!7-^4
M,.L3LI_12(]:P[(^XQ1SI^QU0U7XS@?A5D"8='*FCU3]N@W1C"O31/JG*+N)
MJWE!%_<#=;VGU>4[E)$^#K6<K'(:9.=&GJ+\KKKV+7:F[A!2C)?<)E2]K@^-
MZ_Q"HF$62;IGG5DRYK&";0\QSOE-3P\!3K`(MQ_1;P][_@BLAP"3_.-J)7_-
M59[US2)B+AX0^62/KFC!&DXJL@$AYP-2^)4<;T/4/.3H\?X9%.$VQM).MQ;2
M56PY*WC[B&?%.-7TMIP3RSH&\UV3;&4I).VDZ_F43U0BF>1=@XIL:RAZ/O`V
M.]GK)5:Q4^2\0F)R[:4DJ?H!V_`^A#?H47_C!4^Q[P7\&O"BQW6G0PMTD?2G
MU0Q'>Y+K3(0!)`WDX@"1IS=W614D1P3)9*UW50#=OM],2WJP!)F*W-\N2ZAC
M]].WJ`^[.8\;83=;%]G+MI;3]:S*;EQ/Q#B[%4!R1)",LUL!0+?O-]/';C&9
MZNP66$(-NV.XR>0+.-UZ2#N3FQK('AR9+"9Y[UR*T$S9LW1W&KH;Y>992%R)
MKZ"'A#R?+ZG'!&ID`HMDP3B&V\<TVOS^^.JAKWI]3-%X'N];\N9+XI=T3EF%
MFLA.V>;SR;(@`I4'B$!`)8)2I*%=#W4PW3K,!`N\0I-3@M,3XM0V+Y7RR=J$
MM-L^ALAU\/QM?H5VN*TDHHI+7,N\J9=F7>K(IA'/9HNRT\%"BVOA\6IM+5W:
M:`%KU9#=*F2\0!O1G$HJRH)LZA[.VJ">E)W,\,^/8II3\Q5UN,C&Y!@).3NQ
M_<\C7:CZ`)--[!\8(\/!8K0RLY]NLGW%=+4HND340IY)V&P#E(V`2BNF*#NB
M+0A_FV(-$W:8=]?9.\!DAJC\YJ7P(?`VY&"3.,6&_;!>6C(TD$Z\+PK59')`
M(<AT^LWYN%PF+L-$$OA6@RX\^&9($6T@W":?$)R;*`CRBSBY.X[<Y[52@Z.$
M]&V+"Z?HFJ@H@&6!FC!3]%"!C3#D-O13O%1Z/"!G#=.L3A,XT*TWLW3I\+HZ
M8T06,4^:\`W&*4X`^@"?^9,Q_AO&B%-30]J]9K,)FSJ%.(#EV<">X0`I?Y+D
M"+<X)V;O)PF^73F,4B.7*_=P/#YSVM8PS1UL8`^!OM_=1/M]%)*E%XDORW[/
M$(^8RDC7Z)PLF&S*A>(S5U0L74TTSZKSX;HUN.3R2C^'&^WP$5$,-QD-KL2Q
M*<7?MP=B[FDQ$R%&R$]>H.';RYYP(]E3-UXP'F#Z=&-3I]A"YT86._KI,_!U
M$JL<D^"N.\%C7P__JUP]+4\P1<^!_V+#FDR7QW8SSYH>_M$+X&<OQ0<53]?A
M%@_?X896FB$)?ZE<FNL9$@V1MJ>:TOL`E6W&*JMQ<R!OCVR#E"V2LI-YF^/E
MR@ZA_IA6(K$A$XX/7V+*)Z@]6S-ISV<-+RX,L;+QP(%'#;3X<O+Q.XPW?B+(
M)>AZSU008"DCW<%-W2F3ZB2K(),*"K$6D/ELM(SN'&:"FN/D;#'+'LJ*_)5+
M3*[%#-%OYZ>XN`#_8^</Z"54UJKT\8G5O-C[P.^2*B?&^#%$^>+6CH"CN487
M;_A$PY>KZ!1E>T;1+D)S1Z);5R8W]V']V9\<320S@MWE?+7*LT"1J'?H_V?"
MC.1P*X'C%'`BO(Q506,V150%-K??I]*4-=K!G4KVJ,@&AGH?]L',CHJ%W>_I
M[:O$RLCV`NYZ6M*'>Q[9>"%!M7C=*MZK#+#7`[#&7E'.5QN=I82MK*+>^],3
M:OOZNR\8$7:^:0/]2G6D$YU74U>"@.]/`$M&?HEDVT;"@:B[:7C5!=HX$=N>
M*T7%AL6L(J-\P?Y>(FR@Y_"J\)/ELLQS$_#4J@KZH]FAQMPF9<WO*_;V:RG.
MVE2>GJOD7V+ALHKH)1L(2C213J"9S&0H261:1L#^.-N4@R7E7G@0C9.NYH]2
M-"M-8Q6Q[C@7'_9XT0:"W?6\;6ZRG*ZF,A/$.U,W[XT$66:.V('9./E:/BM%
MP#OC%^)Q5?L">Z_.X%=L(![20SXQ=+F0H-R7D:I]#V=:7XS"/FVL8N9IE'J!
M%GB+`?",QXP*Q:2B16X4J^($N6[K-'CZVGS=AOC1T$EZO7.Q7DK$$BK=YBGK
M.?@%TU4K.<AQ7RD^LNQD%3<'L](N/O9?.)DM'9F!M+T4'`:9D*]R0^(%\7`8
M`VWF'FKY0[3W?'[Y@.XWK6!?H8[TP?BY,Y>@']UOH**MX]\PT/+;+`+8YKG8
M<ETY,M9M9A4;?TG@[AC<^3O8UQ,J;]K`QE(=Z6'9?";3&5+!`$NVC(L#(0MG
MO#!)_3VN_PR.%'?@OQF^N4#>=:78V+":"3;^^]&+T6</3L4%Q+?A+HKW).&N
MW.+I2`;J*T4C2WNJ)MV53&99GD+10.4.\4H3M2U0PVE#8]K"56H+78P>Z/Y5
M=@\QJG5,[YJ%2KYL"Z][KXLXZ_E$CL[F)Z0C(*>34HB/)Z'NEF6"#U[J64M4
MX<2TA[E,T/(K^CJB5+_R[QK)530J[47SO!XQ>=5H7MXPY5T9Y75Y>\LIJ@Y=
MQV?,9X5EW*I/Z/;;?A<,3E?Y@8GLXQLMTC840-5[+5BV8#A(RX,-GWOX"C?1
M2^C3X[@?LAK$7^$;#(^\]0?A*SJ]7*"']"V!:R</V*4T6ILB*R^="33$`U40
MZ17862&VK`(;"*/PW08)]%-2E.(0Q01]3!LU7$);QC%K9.HRE9+C@5^)8"^X
M#K>/:!Z3PA=_<QT$/JY[<?T20WYES]ZOZSY"V$,WR9-JSF+FKNFAPEPX6<DK
MQ(-</B@:T'O.<"S,3B_,)D\CCF4!.I5J@:9U,,HRBJ;.T`\E<W&"L:_=%$6?
MEV.`GZ9U-/9[?&;?"_Q_$$-^]@.8I%$(V;=W#Y&@/P;U44_2(9?KQ6R2AZ%<
M?N:'C19`V<2XI!1$I-$LX#0L<&W4`EUA:30SN#T=P6!X&L+V2H3J;4+%04HF
M#!D/-+UFF?.9NY@W0XFI`#%`\V8(L(+A`W"XW5]`,T4[26A\GA_@/>0'+TY/
MPEP?QH-:Y_3-UF6GN9-I7K(@DP&($,-9.V?B<?OAT3<WYSE3?4;.Q*ZHDREE
M/\5>F'@;NL\8PTUZ?X!X:A&^9%?ZD&)7E:>2O_KI:U4".SXI;4%_!Z=2?<D!
MUL1Q9K.\>ZPZ;44VH"J`0H?\]JRLOEQ5#8#U`#51NCM;8U9DA#++K=C5WQLS
M9;:M&[_Y>`$"-87W/9$IHAA$QQ373SI$F]]A"F!N0W+%61J!ZR`\!=[>X/AB
MC#!7&9TH_R:FQS85!>\ZSN9VOF9HW,/217K4,)DX7:'#_*%<I6@98Z0^:$V,
MF41.RAM!<>UD$>.2COS(SM?,,R[I73IL-5UV,"XQGO&H%*R8<%U@#?.MY:(2
M?$N,)RWR%'M_JOY%E#XE+\`"#K:UDLYA6BS=3C:^/]5'PV;3M,:Q`6OEP'P^
M5V\WEF$GQU(V\52^>%H?"18P=7C),&>Z<KN&JHE=A=/&,D*5J^_:1K"1L9)5
MT_I:S`QGLWRHY'Y';OZ^B\*7)QCO!;<TB=_1RDN!(M(98O-YD;*2B\,Y</0J
M>RP18)$CW->TI@A#^(+=1,P]94!GV?6]X<8_>`$H$*/)HJ5W,DFY:)UW7=8R
MP[0$(M2OU^'V`WR#043K#\<QSH/%/]Y$(1EG/T4/=)'N4Q03]9/.4L!J9&ME
MK@*%I8>$[KK8'*/-DNR/2L.@TC+(FP9/$<@:!ZAU&A`2*ZH.ZS>?6S.?QS??
M56F_M+3?KK"?->6+E?*Q'GY4?9P+"U.=E334R+Z,,-6[,,5D-9T[ZL*4!44[
M]%M/>92R(MU`(2$5Q2D+*HBPM<]VZWHY9/Z.\;B2*2)]T:*[G'7$BTRB3?0?
M`K)-ZVTIT#YN-IRPFW-5FUC')?$13XDW;>%5SQ.5DS)I7,PNTZ=%%6.^3+()
MSIE*VL<ZXM&JE4.^>O:F+<2CZLA?@S.;2A*/"K:0=@,0"X>NUM*N[J/2M*O8
M1U%"+*LQT0D,P?/ZDU7YRL@.DQ;S\F0&AS2F3G0I`B>."$:/<BA":%T$D*96
M):6RPQ8CLAT7UL/A!5<OPHO]\M^J]:8=$:"IENP)Y-5ZY31B07,E!(N^`KEP
MLK]E0U@X"[$X0&#1&@`/"15GH29!H\!%M^UV(.8,W\$!B;0LE/!XVQ%4F%8S
M.8:7FB>;FQ+WFPG.YJTM,SMFN0-@U/O5)^\[N"%E7\"-%\>G711_\V+#Q5Y8
M'L0:3!N?KJ:>'\+M1R\._?`EN=Z@CNU(DEP^P)V_\?D9(YTO:J5$ES;2*165
MLTI4)LB%@HI4D(DU11VE<`F=JN"V?'#Z&"3KF'5621G&!J9U="[,APTRJE^4
MGKNK"8]%IGN=LW%=`EU$'0_7`(JF<J1$&3Y<URHDE#SAPFR\E.'>K^N?U$GK
M)NE0J\5L71PP)L(!_JZ,ZEH)(`WHGM.-`]BI`OXD!&PP37I4$[@RW]S@O*XW
MB2N3NWX64QEU*D43BX)`GV'Z&FWSB67Q:_0H]-^P.H+//DR>H;@T2%G)I8G%
M:NXLZH&JTMQ565X*T!8K2U'EG\I6C82Q\>WC<.S3,H\!ZTB%N?%-5(M[Z6L<
M'5]>P;XP0I[F;3KRG15(FJ%PN%5'BHT/,/:CK9P?9,^:CVE4$>FR6NNU*%Y1
M8:;#T`!(W!`S(J*^H6,`K%I8B"NP#EQ8AL)!G3L"JE>L8&:]H:60U'7!W>]I
M787H4$8^EWCF"+ACR[W`:O&Z'+QF%RHDW;*^9B%C%H,LXY_BROZLGS/2AX'6
MT]6T1@WFX$N;[_?3VQU=[S<8/T<C:.X0U9^BU`M0A\<'H)F8G/-/%8`F:=99
MCZ?QF`':]2U!,W>=29U^%E37.0-*C9%_ML&CQ15R&%#5S+JBDQ>D)S0*W.!Y
MS@M\[R5P>Q]^@>FC%[1Z#+EWM,_".A22](SU<CG+DQFI1%"*!$0FN`\!D@J(
M6,WS,I4@';,@.Z9J*I&Z)5(?!:UG`I#.V'+0T0Z$"&["@ZMG"B=)Q'(J)V,E
M$[T@;OU^]YBB`>]-%";^%M(;1^BB$=PBC2M%23C!O:<0C3UH/\UD$W&=:5Y!
M"\O'94!("Z#6!,C;P)2M%JLQTP&/:`FZ>?WR$I,2)>"`=']%[@T.L;]A+CSK
MZJV'.7>U+Q]@-<,L_N+MT8_52K6BL_82+YIA*T<;Z92^Q6+"8B@6B_]5JWYJ
M]/B[8LQN@3G*,%]1T)$\:`/T[/!:#B5%!C--PR-.@4'_>/60V]PFR1%N;\->
M76FW"$/4[-)+>FXWF;!)2AH@_R9-`-H&N`VMZD;5VJ$D+L[&]Y$T<@$>HNTF
MVN\18Q/<IBUTE?5N'G&E3&>8P@]X^((Z>*)DMSO4'S=#S9H.\NZW6K-H2(21
MP2L19YQOP\&Y634[!`?-)$'"@V.`24PGX["F;0`EJTJ/7ACM_.LW-#'U!=<B
MLA[3O7;$T$'2$9;SY6Q%EXNH$)!)T;LN="X`IPW`Y*G6<^&X%3CO1%]$RZJ.
M@`C%0@X/L4(F=E'0*/=Z?>3%8C9WJZ0S0;8!&E=99IQ=`_1WQ1;72"8ABY33
M9P-#+_:C^Y!=CHCSD'8B-3603?*>K699_EDN`CB:&766ZDY-=23#*+G.@D*7
M/%/@$Q+@!14T44M?(8`A:CN@IZC-IIEQV5"RD&D"I51\^A9U4[%\R!05"PTD
M\X[=N;M<-ZCHFJ'B,-7K5$0R;*#B,"@Y%;W#(?`WY'Q/L0.Q]5(C$STQ!UH$
MK`,WLNR1:?)+F!S@QM_Y<"O>-^`^KW/A@Z>$="6[]<)I4*$BR_3&@!)T;A7=
ME30\;2LA77Y76PH16L0,;5[A]H@7:*[1?'#K!\?4?X./<'.,?9S!\/'[)CAN
MX18?7+N)]H<C[8KN=_E)V7PUYXEQ:&RD1K025*7FTA>PN>MYSFK:/E[3K&H`
M2A5`K@,],UK1`K]4'#`O5D'!;T078S'!F$'=FD$C"8/NF@:-^AI47Q0:@\;U
MT*7\PUUVO.LX,3)"0Q<9]_J>T5@N)Z/&/M.'60Q;EFXD12E>_?6"X`0^,*SZ
M)4K!;9A9U@_!C1=L<%6/+`225]!?<-+F7920R[;Y.VR7%P)%AVY&^GQF0^&-
ME[SB__OX]Z/_Y@7XJ/%UN'U\C>(4EYR[#=]@DI(3R,)2)0H%&PEU0[65'H4L
MG$4[M.$6Z?]4VB5U'4G+]%*V2MO&*X`8,AP=OAWW>R\^D=0P+/Y=TSIV1*!S
M"<6..&>9V7"$B0)DN`BGGK[!RM4K&,`79%G.GZNW2<I-,)4U9"8"*=)>.N'2
MF2\9$:G:3/4V(1J6FHK4;FNJWQ%NQTS3B%5;LTV!53UJU7?GF]5`J%/,;$[H
M4_D)38?"_2$*(;FU$PVRHSV:$7_/[@MX#T.X\].^HZS>$@T%MYYJRO)M,B\.
ML]2B6-X<_A=MD%3%S6_5R-JT<3PUJJ5(9*I8IV*:'S+I/XINU#(18P92AA=,
MAIA7T:YRKL0'N(-Q#+>HZ>LD@222W?G>LQ^0>>2='\+;%.Z9)V('2-&_+]U7
M14D?GB&;YAE9E=XU;X6X,6V'=*N5EL!ON"U`&M-\.\C(UFC%/I8UKG5;HVO+
M?%23M(9?*AQ$TZ;[T!!1V94?9%N]$8XUGQLBP=K(UF?.,)M/YO.!46W$2=;Y
M`:V_$88%,Q,SS;$M,2R&F9L<GL'__J'+ENF<C)KR4[E^THQ,XWJI*+UD,LOO
M^.W+?/MF;^,9J#ESDPL)=LSA!O&$/7_K;V#C(0+?+9!-+?&%3LD'/]D$47*,
MV>.@83),A8,NQ:33_=P)8W\L:Z!8KB%-@$H;MBPSJ[8$J_L?;@DCC)=U>R[/
MI0RJ>-[2W*E_[R7^!E_*1M,>)%=FI*68F[_(JBA[(-*=NDYC#L/.PB$-T:L+
MLU02&Y9F1C%'*YS980[9.<TH-G%'L8GFV4W?*,&8X?0RKMX@)[$X(R7!VN#6
MISM>S6=.<W%&VFO-KLXHM\+`>&;!\HQR4PP,8]:LS_0)`?VCERWK,Q]W.[C!
M:0'%3M]7+R5%T\,-FC"22-)SD6:`2"-3L_YZ2L]/5M,U(Q3D[56WE'&3H-ZF
MA6LV(YLJ*_]<,P(^2Y+?=_2(>K0CHL()?(*X0&-0M>!#'+WY"7XEC<#U)CUR
M_FS'K&\XW]B3P(%?QG#0V1^"Z`3A(XS?_`W,XR/<XL4[&"9$Z^N`Z$*RP[-+
M'/Y!ZG'Z$7HN2257AE2V929,J0,@?11BP5IIRA4!F29E'XXH6E4&E-K@]TI]
MLON&`-'(EG4I4_9MK5^Q[?ONN67?JZJ!HT$&-A#XU'.>$Q$5?\\_1*B4'[PI
M;N^20V;O3:C52DO8M&A<:-#0-'[BLHGOVK;\0\4\R9'@"-_"<.P+4S\]_=7?
MHL'M+HKW66'VXJ;@C]^1JX9><'-,4C3VC9/W)S3:WQXW].`/M8/L,%%A6V9B
MGCH`LC1T5FO6-)<H`K`FH*(*J%W=G6L#"G7`^Q/(%:+'^S*5K!DG&C)P^])O
MAO&>*\;S)(UG(!ZJ)S0G%BK^5F;CX"?/CW_U@B-DI7-\AA[>[]W>XRLKCG'L
MAR]XJ;%O9I6*-HS$/06*RT[;UI,%(]YA!0#1@)>#E6N!;W(J]"!KWS;F9^DV
M*(EO%2/^JP]C%%U>3P`QEY?&69C42ZL?(&H9V([`IY#![("GZJ,9#G1^Z*?P
M#M^[<QNFR'5\I"!%)#>*ZQ1@)D1U:"6]5CY9KQCQAT@'1#PHY>?,L63TI-0&
MK:4S*OW=`!L8B`623LXANHP=[69QCT&)M"0K>=U_,VR]G/0FN(4CB%'LTBQP
MTK+$9=!;MD/O94/#A#^F:'CQ&6F\/^Z_XORCX,$[D?H#GZ+X_D"NU`M?[M`P
MI/>)CW-DFPD*PQ66'3:O'-;V'&T89"T#VC3(VP:H<5"T#FCS-L8.3>9K1I/,
M>M=AB/,'<B.29DH;[A@VM"3JG$]!3APZ\WLHSLLLLARD2P`PWS"7=\E21_;J
MC]5ROFCG69:Y+I:<X3\;8BNTZ84HFS%Y-LY6AF0OG)K3(47,8Z0_<HTS7D"0
M2,IN/6U%(.@Q`5XYZ]5RU14$S"95GX6L@_L6)$J?!:^#\M8D/_-H)6;Z:&?.
M[N,7+_3_0;>PPVTV;KO?/?HOH;_S-UZ87F\VT3'$8Y&'*/`W<A4TSI!K+G(,
M5UK25:>NLV0,-*KMTAW:;/B,+Q0MVP9EXR!OW71(TF2R5O"RU62RL4Z3W5I1
M<22[:0ZBYT<M1K@]\Y.872EZB",T8TQ/^+!RBK3'I7H/I!*EU/9.Q^M&UGO$
M.DEGM+D.8^4WETV.LJ>$"(5X6S9V%.+/;G&F\JXRT)XL:/V++G+>S%Y7D3";
M6:K^^]&+D1L$IT]^Z(4;WPLJJ30]%W'[R#)"XAX*2M<2G;#V<HJ&0-%2+4G.
MO@79L4Q#^WP8T!->++M\\%+/#J(/X`*;]7V-:38$?(6!AS[.`]+Y5"T5_?Y4
M^XM4U]U'EI$0T$-!:3]?S1@A(!,'B+QZY?+WI\9?+>GCQ[)-*X^#;YLKG.(J
M;1S](6(`5]@AHJ^M[0P1/0<(DF*L"@P#^[[IFE')3Q`3[!L1C&"0YFYLN<F:
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ME&D$/B:IO\=%S:K'\G8-L_Z2D`-Z@;?Y_1T"@<`F>61[B/T-_N/G:`L#V\+;
M^6SN"G5G?C[%>3=$K^0K3&#\!K>?HIBF`]\B'3QD0&'`.DN4N>R:7GI*U_5=
M+6;MA!K:%,C;(BGZ61YZWAP--:;29L:S!3L@R]C"8-C59IW\(HM],1(N[+)K
MV\6"3)=!<8*1W-+?I(;'>?CCO#_=!%XB>4*Y_8:9$5A3#=G.?[Y:L.9QQ$G?
MGP`1:,TRTED@VPM#!.2S!$@#0Q2>(W+&&TS+&.$2?,$=\U=XB.(B8^U$_[=S
M*B3UKDY^R2@D?^AUEC.-B@6%7)KL>,K_8\%$1#EPEPG<*-GZ>&J-=M+&43-Z
MSW)JVKDF.*'F3GAJ3O)5[:-S.;TD'6R.YJ_K;#3>E7]D\D#="*`=2T!W#+%'
M0"Z7;F;)H;M^#"['T3WLIB'4\,_?2+QF5XCI,WI<NZZ[D`XO1L[%*,8J&U7,
M'6A1#%@VF)@^B2)/3\D88GJN$/LPN7Z(LPLNR2SF,]P_P[CQU67>T#HOX*HA
M/2B>3XK9`!8&KD$A+IN9_D8E&IL"J,'HUC#>1.$;1*-FO/#7P&MV+M#IB?49
M@-@VYLCTOC>9V&]H)Q-3#>F<P_5Z4B/3>RO)=#Y&5X31/(&$WM<F$-\>1@C$
M3$_@?5#VPSIIP]1`TIM<9U$L^W)2=@P1Y7Q4E7L$:"[?QI9[!(0.5J,'WPKV
M,*.2%,C+":Q6L<TWN:_#[6>8OD;;*(A>3M?/21I[F[27.ZAMV3AGE<*1+T4_
M6X@#0#4_5IQE7*^87620X./-%0W!;[F.ICIARZQ/`E5YFTPUH>;/]L6I4>C>
M'?34?YZ+CZ#Y-8H?_#=_"\,MOB!0A\LSV[W4Z,D"(\M>=^EV#)[.CIW%59FY
M?N1BT3]`W#S;[C1JYN;9YN8Y^3#8_F&BIHCBH\5,[J<Q%C&?NY$]]T'V!..]
M(_+R<1K4'2-'02$]M)G-II7@*#YW5<1&UJFKKM"(U0*.P9AHWL[U8)AB@_QP
M@EZ<_&@\%([*W58,'.]3_&&&B[]&`1(3^.E)]X"QT?*E#QGK<*3O1G)J<7'4
M06.IX1]MV'B&[>NQ\JT09#Q2ZB'ZZ,-&QJ=1DY2B4EFZ*(#/-K72;FH)!F.W
MJ3T=9F1`LBOT\_G2S7)I2'3K&![FI_(!8WQXQ0F#5]FB(SW!9C#?SR:3C]OQ
M:#5X1VJ0359W+7)T/1E*FF)UF=ZDXW/;W(WQDS+';.\/TGWUJ6R-E"UN:]'$
M:".YI+986F./92Z/U19C:^VH3&?1:@C$8_=/AO-V58+ZZB>_?XHAO`T15V"2
MZEJ<8K9[J4M3+##2%8G<^7KD:(O5`U@_D"OX1UF7.MOP)/)B*>]VV#Y^;I^8
M8Y^+7)D2<7RT=2GNI[FHD,E;IE(H^!*"7M_YMX-^4+;<;FY)PY#=RN%@1]W,
MCK*9AI<DU)-/2;`Z9W'!<#3Z['W']\;F28N/Q^=D$_LDWHXQ;NMJ[A(B5P<&
MZ>,?"G/.,I5`F7M:4>H21V8J;4PO+8((6YAZ+Z10S,&+4W_C'SQ<*!@&/KVD
MWNYC!>K(K"3FR7RABXJ$7X[XL%)>X>KZB&;FL?\/N%7MVMQV+B'V\927KMOD
MKI>J@A[5I5*:KE3GPJ*=$JM62](EY.A!0LT25RO3[6AE.C^OV(<O;_.*!LDC
M!V285Z3B18;`+A8KB7W"[W7)0>_-\P.\$/DIBO^"WE5^B*NKN0L,@4T,TD,3
M=ZIL2Z0="7.M2)5.HM=EA\2SK,R-C%YAIDIH?.%9Z])B'X_,8X1`YO<QN\N>
M5Z!_>8GA"QJ1WH9I[(>)OZ'+BNQCJEJ:O)B]=CD\LE6^',==5;;;SUF(NLJ/
M55Z!0CE0:)?M5XQ\.E7]AOL(YE;4P137?)@R]DB[[B-8G);=+^SD%W9ZPR(O
M;X^\7Q@]?YN\QR>YJ%-L]WEN-8PW?H+[RCHRY:?8NAN\A%-LG2ADTS>GCN.H
M.<66!\.*3JUP>&F'V-2:.3N849K'2\$'N"'5@,#4N0*87,:'V*.R6,EY-KFO
M<E$+#FU(=":A>O[(;><2EAAXRDOGH<P<90E`K&A'M;FP%04E1KV,R#8&,96L
M&@B_P87'L;]"_^4UA=OK-QA[+S#["\2W92G?1N_9^F7&/!$DZ8*E4W6;[*Q(
MF.L(,B7S/T)R2]JE[;J/^`W^=PJ<,I%@I'#:^;TN?,[<P/<5[CT_],.7FR@D
MZP)'+QBE),P9FESF+%L6GFP06$S6\_&FWZTP7.@+*@I?9GT93=_F,@*TF2@R
MTF2^UW>\X-$Q3&[#!QC[T?8I2KV@OH8Q[AA&W/3EC8N%>&37Z-QU;2E4Y:`8
M)N`V!%1#0%1L+HU>])!8G?E)N'UZA2`E1FIL$^$<59JI$&7VA9D"EUD1<4`\
M&&&`W/WU+C'(?HKB'?1QZDIR'6X_?C_X,9%0@!V)$MWM7E!X[00C?S&I,U,=
M6RO*D1+<%?7*:*LVKJZIR4.R!;L=,[(JMOR,Y'KAU-8`;G_>4>'H)X@%7W;T
ME":ZRM`I]WG^D''3P(+N>3K]D>*MBH7'&?I_1F+Q'W-96-\W<_\W#N*Z%X_/
M_ZJ7&/Q)DO+8(^1&(Q<4GNN:2^^0.POE&:=4D[&&N;I"YQGV)+&0O'_9@8_-
M.)61C&'DRP]-C>A+_O@!S<F*^BA:/+9;BXL-;IW0I.\RF4V5CS:;T:\]L"1/
MX,N,8:54TQ\A2*K]+B2*%L;S,N.1HUY@BXVWP\8SEJ)O.':,%X7EON(EANG[
M8YJD7KCUPQ<M&UK\]BXH]')!2*>73Z?*2E_G0;:BU!]CLTJ-E4G(S&T456QD
M96+`F$Q6&1[%W^;"`^&HJ?SM=BXS\/7*.G<FSDIY`FLUX(V8RG\@(X"/X:C;
M1^<9=G9NC%-DI,?4BU-[S33O82;WXOO,`09J5YB(VM;Z@_21XQT+87^#"^\3
MOT9!\"F*\1_'=]UJ8Y?9.U802!<XG4Z4+[Q4N\C?L$X@4^K2RL6JLS")<5FE
MH6B7![@_2%!CL'2DR-8T_X6'-P-)$K*M7V8`5+")/EDOU5T0QHJ()M(;=,\F
ME'V'_QWG&,J,=_;,XP+[(MT9('V^VQ^XM\(=\T[70%U6D3]>'U9!)YT',5TJ
M+V?1HSL#%94O?O0_QJ=A;Z[F)U;`@3<F^(/%9D8`,1"FFQ_Q$@]\\Z'RSDBZ
M(YVZ':+)!1WX'@!/-C(L5[.)V@/?PI`M./!M<D7:XF]S6?N[9J*)RH/?0[_G
M)0ZY?X4)AD?RR>$&_?@4X5]53,"I[SG2`&BX/A<T`!\,4OK@\G*I[`:V//!0
MI?.C-$1M\!217]<"/K?R\&6.R/5\*Q+B,PM',1J19P9.(_"&#6QEI#<9=E2.
MU\_[Q'_,J#]J@I!T\W^HF-XO6V&^FBM/)Y(-X9=<-724[_!_PK,X/NB-QA>>
M<M(-T,!6[9E*_:$"M8K3T:Z[4KX2+AN^_Y!GVC5^MO\3[8<$)+U]@+W[GV<L
M//6&K;NJJD(%+VCM71UJZ4+,,]=5NR0_N._XX]5G-?0Y+[)7L<+,8ZSQ*W8"
M*RY0E-1XS`L5^ZIP:1<L]L0G>Q_=W)VZZB]<[!/++_4*QC$_B.+IFT6?8]Q+
M&L?\)NP,IKBP).K8TLR0".3^8F]Q'!C+E=WJ..0;7M24ZP%QYM7+9HSW.WHD
M\!&?"'Q`4TDHOE%]G`8O84K4B4(Z:7RZF*J9XN0J93F@]SN0G>\D:H%,KPN;
MJZBU,XF:V8LX7D8[6D9G[\6_P[2L9+ZI'(R]R+F'-*N5S"7D/I*5>Q0)+_Z3
M_WE"^J&YT0-RK2_>'GZ(</0?NK`[I"F;]A,&Z"^]W+Q83N2'F8EXG$G_%^M#
MEGFP1@"K!'ZC2MEZ('9L^]+[<OY^]--39B.10:Q9M#^#H;V6XH>:_[+"&N]^
MB3&V6M4J<1&A<`@RZ0R,F=LCF;$C2(INP;G,?5-SWZ1Z$9GE)6]'B0MJPNS@
MSW21`5A8=%)+].VAP26%7GE8\C/'68_+QR3C;G>=W#]$T!WI:UQ,B7'U84!I
ML.WY>>R)M%1_-""_#?'Z@O\&\<@\>8@"?W/JY<QB2<8CGU`]Z>M2UTY7#C5M
MATR8BY;(U#D!M"V;`I`ZHY!`0E:JWK6-8E]DD7+[[@C1;3]C3'^-@BUR"KI,
M<1-X27+]W4]$WL%Y0S=SV6I(UV2<SZO[K)DPD*W6$''@-RS0Y.*5`HAN$^(_
MR6+42CRQ%[8()C",,2)53^^*/FKM.=VDJ38N';<7Z^J=/;53]H;K>`V&0RIN
M?:29A^^]`-\C!G[P0Y`0J3\:YP/+F5HL:*$WX_M1G.(=^0_P.26+MJ+N@_6L
M5@XP%)!VG)53G*Q`8FB^#!9$MS[,]A;GXG(+7._2'-=5%S!]E!#X6)T6/#M8
M08V.[4SVTR;IT6_3:[&:"0EB>#?P?&PBDEBQLR?T-R%1C.^O9?K<AC@GG2RE
M='W(ZJ,F2%)I7[KDPFHU:S&D(L<P-88BHOLQ2>KO\57@'1=EG8WG#<;/T<B(
MG";5??%'TDYQ!D^8_&X:0-%Y@;;TZSWZG?\/O.Z1<#+\NU[2GY/?H9&<RZS<
MZ7HVI5GT3Z]^`OP4[D$,#TAILC^1OD*P0>)PHENE*?#MU=^\`KP^Z(<I#+?T
M3,XS!`F:WJ+?D1<3$BB(#_YP3(Y>$)Q``!,LU0M!%$)P@EZ,#_;@I\,HWGL!
MB-`4"L'&:<FG30"O:%,0,0<@_8(H?('QCZB%37`D4Z`T]LA_$[@YQG[JP^0*
M>&^>CZP5P'>[*'Z7>`&L_?D5!MMW:?0.41[_[E1_-]R"".D34_5;%$)ZIO2!
M;WC#)?#)X:0,,41C-J)[ZGV/PFA_^DGWR0"5;B&(]J"0"K!8(PGW*J&2F%EB
MVG`P:4J#EPQ1E<1U&5L8&1RA$$9VE\A*U_V.+)^+IMG<YW4.DWA*2-\HX:P7
M&7MR4=F:Y?TNR[`V.N56@H_>"D1011DJH\.++D^KC3&$%C!*E&QA.-H?4`>)
M>2Q!%N8[)@C#4D1ZLWXQGS1)DZ_W%P+MX,W9,*OIM5+@M+-(Y(9,)G%M8I1-
M=WX(;]&/G10J'S3!FZ)UZ0B\F,Z;9/D-2P%$C&F"#,/C]L.CG1,M9V(2H8[=
MJ/??[VZ\Y/53$'U+.`?8I5XQP0B&'M*;Q^OB?J#"E_`!-R0/$('&3@HK1]E@
M3-0#I7;V")R1R2.>;0PSZI,?>N'&]X*'*/%):HPTL_BOFF$85Q_I^S&6RU8O
MA)A6R`6Y8)L8IP9UFWF]41M@8*?S<I@HMIEA1I+)6RVM1IZ2@G?-<)*OD/QU
MEO,9@Y15P?F\RB)6*L+=IF55\#_)`3=`S&X?YC"SPVY&J?FX@:$7^Y',$D;M
M61/4JRH@W1.LBBL#"I?+Y=BQ4C$8%252-Q;M7&$Y%9,;+>A&N?"$MZ.ZOA9]
MR(3WDY:E(^UJVEK>_HU(,.WN_6$TUQSX,+1[>LUEF"Y>PC7CV\VNA_MY6@]J
M]?%FZ[(.LEHNBNE-:_!D,'WX/$",_&&C]_*>AX9<H?L>OOAA.#:@-$J]8$0H
M"Y*%@1NAQ82*02OD.IR^F,2C>CTN,?';$9LZYX1V3`3/G`5-ELYZPHU9%DSX
ME.!SF_ARCOS9+I*(YW`63MR:*GV)4OC!3S9!E!QC^`2_I^]1^[]+?UW>^T8I
MQ5%*NCZ2LW;Y#,/"02D=#2B1?$`:L(9S*@Q`LS^B\`W&J8]&H>`!.2*,8[BE
M*RY7]8*".*NN3M@/<.=O?"-95H/]7<Q?D5GMH3/Y[>,A\%/Z]1(_"K_B/%/N
M_0=]Q1@G-U\W61>?+=?\D3_E./5KT@HHFP&D'6-5_L<T!V'\5YR(FT`Z0`4)
M06]3#<R!+M]-[`XC&N/W;9(<X?;#,4:S'UJ9@YZO++7$-3:+,/U89#J+7&BX
M4-W<'ZRI_*["9%J)!(`V"&B+>3V>['!Q)0R0@KIEYUBV:S`PZ+%5-C`HXP'P
MJ<F.!_2;36DB$C9*$X6(9.-81^;0C49?JHR<<CO0H]OXIT,QBJ*V2Z-:;+7F
MH+>2T-.*NN=]`>MB\,?](8A.D/8=1=UC7#UEB!L*I-D2=?DJ2M=(G"[6LN$V
M;RVO65Z4-,<-6AAG%5FG'6"S\)''V1"-7,`AM\8!B;0RK*IR%F(/W`BIA-$8
MC&;6$+G*1<34[E`B'4P[[&Y=%/T"OY$_#0J:Y<NVQ,A"(^E1PV0E'1*1</IW
M&^/?,.2\<'>5Q3LK8]O`CRP.99<0IUIDE0Y+=9-9%X7N\8G?(:Y`7[0E^A!M
M>ESLNY"-/$2PA4&G/V#&_(S,3<'!.^%\BXN<D]7<5YJ3I?&LXR/Y8Z,,^':(
M@[`%V<)7IG;25Z@NIRM9_M(GFI7^Q^E=SV/T^2;IF#'@=2J8%]1&?XTRHW3P
M?+A9UM0L(7S!-6@,&L:9V7,[P6#R2T<WOKWLC'9D]V'0+*CZNE61C>HD7<AL
MZB[[Q3,JW]8@-@`]/3B^V\$-V7=S28$;)]^("P4KR9<P2F&X>3\V5RQJ$8=_
MQ?7$%&_(2<HTSW8Y164KG$T6"Z<S!)`F+V\W;@1+G;/79&&4Z$<DB=#1P^2V
MQ1/N,NX`I^/+LB1^<!649\.R>RF#Q@W17H%]\4*-9<[=0[$U5G221#9&B,UL
M6VP8N&72>-<2[O=>2U^Z\XDDURW=+SD#MY#)MM)TR*X!PT:VT7#`GD'E/4OH
MUV<!W9W,G.X9.J6>?1L&`^'VW2^PE81]MP@:YK*-?`HV"`1R+"'G64N^RZ7;
MG=I*R7H)NP.*##)L<\!64I^[4MYA5#4EV=/82^&+O[D.`A];G57S5/2D]N+K
M3#4DO6R^7B]FM.)Z(0<4@L:L&L(*,JKP.`;P=-0'/Q^4VQ^4G@+A0L*45<'Y
M%AB)M\Q+@L3/FN=NK\MTILOU<B%@[YCW!/7@[P!,?`8;N?M('3`^BPW>>R1%
M(`&33=]Y='Q.X-^/N.SSFTR59=[C.H?1'!VD!X>38E6ID`2(*!L*+ZL`YPX"
MIVV4V^%RM<&LR!P6\.4SW#_S5X:8SYIC"E5`^JCP8K'DT81*LH,B`U`Q^6$1
M)>I>)>!#!;L%9.@L3<Y[W!PE^A;KGBR7RQF;%184(U>!C<D-:TJ0=SB<@"H6
ME!YO*-19A(?[O$&^]*XQ,Y\51P_:3F6^I(X2>&S.V$04<0$<H1$LH(JPY"KK
M47,$Z56W=+I<37E#+*-56,_%Q)F`6%"25>!8`DH8+L_:4.8DOM^>\[1!3ISZ
MW04_6;J\"3H69;8>MP)H;'9T0#/%D)/@HGN!+2SAB?BR>^[S9KG2[U+X^6HF
M9HO9&^^5P!,QQH8[[[L<KX,U%JP!^UO?BT^/7@`EKG;E/J^9-TPEY$OA+2OK
M6U04P+(LN=I5"3ZWCN^*`HRZ`>JDCM#WFM3AV\0,=?9[I,[][C;<1'OXY'V_
MB4)\;S@,-SZ4F.)+OJZ56'(Z21?$0!$\YQF1C/E%90,D'-2D6[$D,`)^FEKX
MBA[$Y9U"?.GZD=YJ]$L8PTWT$I+;RK$]WL,0[CAG'?6QLI];UTG:PWYF.'LX
M!.36#2_(+R:\#7=1O/=D;@&4?%LK8Z54DI[!SYW\9%Y%<'D?):C(MF#-6SUV
MMX5]6Y8!QWF$V!([;`F_;,DL77MY=)VM\O8S058</F*X]=,;+XY/2*]O7KRE
MT9/C$:(W-))2H(9L4KH[FV=5/T@_2:2!JKBL&S'#/%4`LVK4"40._TK*RV_A
M&PRB`[G&*47(-Q3YIM*.2;9)N&2585UVLH=5_!D?_WGCC.IQ'=YR-G'%?#(Y
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MQ-$;68>[#H+H&[9?X\MU/:W[_!U?%3G?6<V6"V=.3^!16:`B#!32])[`4X3*
M,8)*?`9/$30R%2I>!6C&`%(*U"]%:[__2>G'<RM?KP(*>**OI^6@87>T*(X:
M=AACY.!U&R)GA$GZU4OA`T3?&462EYXAC2/#GD#'5E#V9/IJ,IMTA[\KD+>"
M;Z1$_RP;LB4R*C!#9[RL6V%L(PP-I`HLT1E[KH"?FP*?);8P%(FY+Q&@!&94
M%+;B_?WN`WQ.;\,DC0G]V1^:\9S^\--60K([FT[6<R</,?$>)]Y@.:`4I#N$
MG`G%T0VE*Q"<B<<M\##NT,S+CAED.)\F%19S;&!FO25++NI(XFD_IW5%I=&X
M=$:GN\SW+XLD.>,)..>A<7NAT;=BP'&C^A(!"_APKT_@YJ>7Z.WG+?2IPZ,?
MFGZ.?O6WI]C#*Q"/I_USU/PH[;]K\.M6H[)K1_-UX<_T=4#?U^O(YZGORJD_
MMN=R'0-[+!NAFI'4M^CI-3HF7KA]^@:#-TC7RVY#/&;SWTAA96:-C+YO:Q]U
M2:LF6\)HL7;SZ=ZW".3"`96>+X47\L<K4LX?G8T#V>D%V5!MD3$-0$($HHYK
MK,#Z0*J68[Q^AC$R\D,-W.^NXQBGV)/)I"";C?FLSA$@2P'IJPVGRWQ]&9]_
M0Q.ABB"S&6QGPW(+6%$=%@X;7Z+PG5?Y'>K2P@2-NT@E6PM2VT0>6!LX<LVD
MIDM&;R3WNT_>Q@_(I2>\&JSL![5WM"PM9)?KIRLWJ^%(Q&`RE(*,5&`]'XYC
M`$Y'OW@V)K<_)CU]HH@K9??'Q3\.8?G%5WF/&B=MKY3*Q62^6@EH:Z3TJ@I(
M?.J:J[RJ`A>?OJ8+KW9PAT_AP=FM'!+_$FYP8=<HQN<X.:N/@@=U$YBIA>RQ
MG?ELYE+ZUL2,O13)I>[Y8!SM8,2D/1^1VQ>1%KH*65*0E8]>$56W,/X6^^@3
M\)>FV@_IIVA#`\GOOYHN%O.<GH6(<==5!-0\!X2C%407)<]!XC:0&&0@Q_DK
M[&,!-;&F@TLC>`$.`G]!??5]V'G#KN`%C:L[?"VDD_?7LW7N_+DL@(6!^]#X
MG;>*X+D,>$9K7G1[6W41I\,*9NER%R5)+[JT7C!"EZ86TL?(G;*O*/P)"QN3
M+FN*+(0O:*PB/%*@"N",@9"-2C]E>!['I@S3#J8HDQ??>?*^YZ5W!!^2];1F
MLC!4D+X=8C6M,$6Z[-#9D*2.WJC`1CCR%*7>.$D$DH=K5"!IG*EYSL[41#MP
MK'XZ7!_CV8**41U,:L8!GG443?"8#=R&&Q2`4,C\`+,?OL+D&.#25)\0E@?T
M:6-Z5QYZZ2%*?+*SQ)X+J&Q`_\12H?:2VP"NNYHM\DDI)_+@3/>L9?!#H<2/
MH%`#8)<#1)'\4DO\?J&+[JFM*3.*`WC%BH4*%1M^,F##KIFU*4/2&T*S=L`/
MVZRA'\FAI@.QT0EZ,0FR!Y&%-$W=1PAKE6F_ZJ]@T8"N0%%3_N88X]/AG3%?
ML7#SP\6>&LN.6];SY50^.#5"4M:Z!4')H/'J`0E'H4UF%COBT#@TDQ@<#C'Z
MF&/)IU<O_6MT#+9?(GR"R=ND'W<[N,')<.@I?&ZI1T\G(<R2,6*WIK+][V+E
M3#O&@R!%K0'2'$#M`=H@*%HD#W_E'('3/NY3;)J.,/IDTC2#AG.*[>.V[%.=
M"1/7N0+^#I0/7(%OQ%YA1`Y68GOYM`IUY4V`0BXLK(C_8/2,Y=G1IVMX)_E5
MC`SE$GB_^YBD_AYIP1V2U1_2.;2JM2Q]Z&GMY@MP"<G=+208&N,,1^'F**(.
M%-H&)4R'J0TNVFB->/;C7Z(W&(>X!WX\H.%*%,/M1WSF&<TYR53K.2T7QX57
MS`X2I9,E`_23O^IXF9T(_@4\@K(=4#0$*BW1X\)E6X8OL1W=,(2>!'-28L;W
M#?ST^!-X*=I^EQ3&\K(*_48Y?`8U:DP?:EXEDX9?O<#?DK'U_>ZSC\!_#;WW
M?K3WXM]%.4<RK^F>"$CH).F62]=9K>F0OQ2*NT`B%B"YH!"L=T2O&J,CA=%D
M,I-JQ.[@KZIE&-V#C\6`6=9$)@80?X7^RVL*M]<HQ*&H_>6(M;G?D2IUE2)U
M[[W$WUR'VP]^<$1/<WJB@<(T#B*&:2A]\,Q99)3-VP%90X"V1.X#PVU5*U0"
MTAI`S8&L/3/C"`VVH=>AT!J=QP3/M".`YLT')`@\$RN02QNH9!#"%`0X]^:`
M+$>J/YH<3YS'E.J(X@Q#4ZID9KA#@M&_T;_0#\A\$/WC_P=02P,$%`````@`
M8S!<1#=+;X3R4@``F!`'`!4`'`!R9VQS+3(P,3,Q,C,Q7W!R92YX;6Q55`D`
M`^IL$%/J;!!3=7@+``$$)0X```0Y`0``[7U;<^,XEN;[1,Q_R,V)V-B-V*RL
MS*R>F:KHG@GYENT8I^6VG573\U)!DY"$+HI4@:32JE^_`$F)I(@K"0H4B'[H
M<MJXG/,1EW/'G__S=1V^V0*4P#CZR]L/WWW_]@V(_#B`T?(O;[\^O9L]7=[>
MOOW/__CG?_KS_WKW[LWCXYNK.(I`&(+=F__V00B0EX(WS]YK',7KW9L'!!(0
MI5Z*AWMS!Z/?7KP$_+\WY/^#-_A7_WWQ>/?FXW<?WKQ9I>GFI_?OOWW[]AT(
MEAYZ%T<AC,!W?KQ^_^;=N_V$/Q>D_?3F7[_[B*FK_>4QSJ(`_[[VJTL$BID#
M3-1/;SY^_^&'=]]_?/?QWYX__/M/G_[TT_<?_J?>.M[L$%RNTC?_Q_^_N/'W
M?WJ'>WQZ\_C=XW<U+O_WFZ<X2G#K]<:+=F]F8?CFD?1*WCQB7M$6!-^5@X8E
MOV\PIE'RE[<U%E]?4/A=C);O\32?WN\;OOWG?WI3-/[I-8&-#M\^[9M_>/_?
M7^Z>_!58>^]@E*1>Y#<ZDL%H73_\^../[_._%JT3^%.2CW(7^SE*$@2^8;8@
M_WJW;_:._.K=AX_O/GWX[C4)WOX'F?#/*`[!(UB\R6GX*=UMP%_>)G"]"<';
M\G<K!!9_>8N689(C_^%CT?]?KF(_6Y-E%`7740K3W6VTB-$ZI_KM&S+NU\?;
M!OD(++,P2]!KOG[2<CF^)TW?<T=[WY?61]SSUR>\X@&98[ZX@1'^0M`+'^($
MDBDN0R])X`*"0)UTR7%/R<2#AT"'CZ`P>+H"*?2]4#];M_AD6X-9F`(4X<^_
M!;WX:(^FAV`?OJO-\K3"F*SB,,`'X?7O&5Z^LRB88XP0.9'PGT"4X+D+8GKQ
MHS:3<5[[+T3UZ89;FI=>LKH)XV_);11`!/RT%V?MT7H3?`43/XR3#('G%;C(
M$GQ7)\F%E\!DOJC?^AC"IVR]]M`.`PR7$=[7OA>E,]_']W6*Q8J'.(0^!,DL
M"/+=[X7]3O?3T*41OX<XQ43A\R_<7<$P(R?'$_`SA&<%R7V<XO469@$(;J-+
M+_2S,"=@OLC;@N`>I'=QDCP`E"_?/H#I)40C0D=#:U\I4N-KY*=:>*L8I<\`
MK6^C+4A2LEF3/HSP!];(P8T'T<]>F(&_0BSQ(W^UNXG1+$E`FN"-=0>]%QCF
MR^8+\$C[8)8>NLRC1[*J$-YC^;[LP[!6.C3B@T>.L4P3PG*/B"CY6^8A+#>$
MN]Z(])QYB#52SILO0NU[5V$6K=]W"Z(,W*!X_902E7<)?:P)0J*,]?Q\O(%U
MGD&MT?&&N8S#T'N)48Z7_F_5><XASMX'%&\`RF4\(NQMR,+1<O92!]8I+U#&
MQS>8]J^E-,\07^B6Z.A+^!*"XD37\G5:@VJD_'CL(;Z*]!P:^<+JSQH60D2^
M87/Y&$2#2.W*<PVQ\FZR%/]S%D69%WZ!$5QGZSM\O6"E;Y=3AH6,^8:8.C%M
M^1_TK,T.TVK]REA61"E96EC8!PF>U2/+3/\75IAG&/ZP(K@`"(M"3VGL_T:6
M7!SE/Q*MD/RWM`)<`:P50OV;6#<IFO=Z2<'>GHV77;$R;Y,DR\W-/?>W<'RM
M<@Z>:;[)57X?J[0PW?438=K#::06G^G9.A\]^9J`X#F^3E*(/W(EYF+=KB(!
M-R+:2^CYOSWY>*&`I/C]`\)K)5I^B0,0]N%V"')T?]L+XDLB!CH0)1HD5.J(
M&FDF^S@"^<6&X$N6PQ-ZD?8C1FD>O>?')H[(;57829^]UPL086+2ZU<":-_#
M0S#X@#H\F<)/R4'MI5D:H]T-P`<S`;(D!0O,6TB\D\\Q/ALRVE]T:O9:Z!GD
MR\\75^6EAN>B66/TK`'Q-%IE^Q*[`61>X=@ZO](*JP\`[Y_9FABZYXNO$<(+
M:QG!/W(<R_W4[Q/)SC&$['Z0D,LC(2&VE$<0XEN+^!.Q/EO<VSV78:?Y=/(+
MPGSW'^QW!S?JE9=ZO3CCCZSUF[TDX/<,[^7K[2#&0;D)]#CO<EWF.3Z`=7"_
M)7.T]/#2SR?#]W$2AS#8^Z#J+JF:*[SJ7/-G@=?T(L3RB3HB)Z3MW,#<N_G&
M#.J!QJ'!O?90A$^R@R=LD"7'GL08>\_$`*%U"8BF&IK5FM_O-KH"+RE>>E\\
M]!M(R?Q%=$/EW"66-H!2#T;/R".Q?H4T-?#9,QB-YPJN_F4X,*5#`WTP,U0D
M)(,L1?Y$1MG4ORADIAN:Y9K7;PMF"!&%@?QAX"-'9=H10:!_#:A//C0<>W<C
ML5*E=9_CP$M":=XQ@:!_4728??BKMNGN'%PD$4\W`I:'$!1D)QW^6&0Z@`>_
M')1F'A<00UP1'>8?&A0BPPZ\#%A3#,U:W=M;2.:D[<#,RD\Z&O;UKW35J8=?
MY%3?W3"JCWBRX2^\TOTQ^.7.F<<DDT-<Y\+9AF:X[@)YQOI%XOEYC,#`'UEE
MVA%!H'\)J$\^-!QMAU+-"S/(8I"<<1R,ZU\"2O,.?K\?^>*&$6>8DY3L;6KN
MESO,38-/W!A$`4G,+7Y+)M.35IQ/CJ?'I#1F#$GN=8R:T)83Y@G6"?"_6\;;
M]P&`[PG:Y(<<]G???RC3J_\%_^K7&9XZ(-/?A-YR/USHO8#P+V_;?W\_.#V7
M&2+YD3?XL/'"OP,/74?!%?Y*%-*83=6H;"](\IM?]Y]E1ODLLY<D11[)K6P0
M)=]O>!SW9!3H/``$X^`&_RZA`,EN>VHZR5>4H[)J>3H::U\2'P'@%I\=/$*I
MS4]';?$=V=N'WNYT]#WC83EDY7\>GII\CT)\*Y#+C$).\^\GHF=WB0'((_("
M\/I?8,>BJ]7N9/15P=BYESJ99RFI*$)\?VQB>9U.1GEQ:3R"38R(72H/@J3M
M8F[S4U%[%:\]&#&I*_]\*FIN8`C0)<G$BQ%[339;G8JVA^PEA/Y-&'O'MS*]
MS:GH>@1+2"[]*+WWULP#YKC9J:C[.0XS+'FBXJ.QM\%QNU/1]PL(P_^*XF_1
M$_"2.`(!R?0`B$DGJ_WP]-Z!I1<61,Q>(0W)XQ;#TU0&8SSMUB]Q2*&H^?<#
M/7559X::M'G(WP^$?VSI.<W:3F6+]YN\Y,D[?P7#@XJT0/%:16+>4Q'3KN4W
M,0H`RLN.X?^]?;/9YT;=%<PR*<S)PYIN`O*6I">,$2;A+V\_OGV3)9B[>%,$
M?AK!1U;ZW,/2E*TJ5#Y,&I4C';>"Y>.D86$H"A4\GQP\-,VT`N@'!Q#=Q%!!
M]*=)0W1T`U>P_.ND8:&+QA4Z_^;0:9L`*GC^?=+PL"W$%4(_3AHA@>YT@.G#
MM(5EOD&H0FG:PC/#4%#!,VTAFFH9J\"9M@@M8RRNL)JV-$TQ8U;0V"=%4_TN
M>RQ:QC2;[3M<)/@K:`_+]]_;"`S#I-K<,'L/R>E6R)_?'\>"#!TA(EF]O;,]
M>>$E+SDB6?)NZ7F;PJ@,PC39_^;8NES^^M>RZG&RKW?]"'P`MWE<T#U(2]'J
MR/*LUK>[E;P_5V6!,3DVCAH;HAMEH%[(1$@ZH[TAZK-UEL<>LFJGDV++>&W,
M%\_>*YLGI5&,<'JH)O'@P;PJ]@:FWK&'1M3:".5E/4TZH?6ZF";H8H1E,1J9
MHU.P*QMMC%,I!>IQ6Q-4D[<*2+X1_@_)Q=AZ(2"W2WKI(;3#JD:>N<S@0JZO
M$:XJY8G+P'$S,[0>JE.27"A:NCB3?'%/$QSMZX25U;7Y&Y?1>`1TW\>1KT)Z
MK;T)ZJ_7FS#>`5!F(DC+,^)^ML1M=<>64@;Z^I4\SX%/N<]Q''R#(4L0D>IJ
M5Z1-=YP;10NI<+;K#1JC\*AD<)'**":;WFV,O`B$&.GNAGGC'W\CT>/:9,BC
M/P8Y,E<;RQ-.=&_2VQJCNH:D'.GT#B;H?T!@@]7;LA;FWB8DHR_)]#3#$:,H
M"KXWF:QPNIC@X1&0HEX@V%>EJUE7RKKR#$XD.IK@A_YN%I4#SDM8)Z9Y;_UM
MN8Z.*6XW-$HOQ5HMN`FDNAKEB98FQ&ADADY)*6XD<INRI"8CFYW03<6W/Q)/
ME<"F=G!;?;0K(E`>&/XU6>%C5TR@/#YR"GN%DUW!@?(X,<3V"AB[8@)53YX:
M$I^Z>,CCU`O/`0F&RED'1-)18&M@DC)>=*&Y5W#2%J"7V!J`)*,@*L1LONLE
M\)+2]2NT;+[Y9587"Y<N-_UXC_$11WR962"J-NWZFN'98*L%9*=$U`<W*0]V
M)5)V6'AG<?/U@9#C>JZ`LRNE0@=L//M]A9M=N1::3[HZ4%WR+L9[-^H`BM>Z
MPLU.54?3`F.XR2OTNJ1IG-6J4U"&CH.G;:VZT!DE5JBVK?47N@$E$0MF:SV&
M;H"Q0A9M+<G0#27^.NIBGQG_.<YV)+?-#139P+*J#&JHR$L0MI9IZ.+>;\J?
M31>Z[>8;>LC`Y#)<Q7#P-J*]":[R$1!-^]1Q-DBOFB=G88Q20XB96V=KU9..
M,*DF6]I:#J4;?#)QD;962.F&&-=PTJE,BHK`/=:<_8<<Y15(H8]I-9M>B&F9
MHYSL(+];]B]0,R+Q9'H:3I@LJLW,LG2%5\<?U8=D<]+J,0H.\L)=TM27K4=!
M.;LLO%076]+U[$IM<P'I9QZ0[J(Z1J`'<\U-4M>R[1X59:C:][WMOI2.$.T%
MBEZ>DS,Q'G0"B%ZAT%+/B;/H.HNNE19=HUI_842;A9CB",^T!8;4^V.SGJ!^
M&J^'D5HPI85M+_9<>`GT9U%P!<,L92K%HEZV*);=<?V,)TZ(B1=?=M'U*ZE\
MG<%D5:Q=$OO*0%;<SP@W(`+("_$7G@5K&.7/"I`]5Z88L'@1]-+RCNCG&`M*
M$<'G,WGJX`M8O[0>L.(T-%,C:&__O\$G/GG@'489_M#S#4#YH9E<@$6,P.&Q
M<)#@E8`\?+9C^0'M\J.>!+"2I^'C$-.WO(WP.0@2UJH:<D9S"!YN`X&5@=7:
M'.48X7(37.`]LF"6>6"U-E39*O_@^WRB@C8FX=3&)NGFGU7'K9PQLL`%"R?5
MX<'`KMG&")581BR.LFA9NT%9]#):FZ:\`'&?ML<_T\3]C%1)VI-4$L/Z`NUV
MHZ!6@#F[O5'JA?N3UM)8#2U!)$3QS!G^/0)>`JY`\5_1A^D_\)CP^!IAVD)B
M8?UK'`;E(45XF4=/P,]0$2:)8(+_=(7_&2T+Y@2JYV#3:9'C'W,S1:XM/!$]
M`2RQ1HDE32_RP6R)0"ZZL:5[E>YF*GTEP$,^*8QP!;8@C/,:+'R9A-_'#!=Y
MT#OKH#G\V21M@K.BU<R(>]$'6*V"\=<HV0`_#U6AFC+$[9V#6H'>/8P4>9O?
M]NQ<T">D\Q<`EZL4!+,MEC*6X#XC9^Q\D=L%:WX>.<-BQ\%,VND%MH@I>G1<
M5,+1&I'6\HXJDU$-+K97;ND%UD&BZE;'Y<<"I0@OWK1L:Q=.$GX)VPN8=,*-
M:6&ROUJ)T$S2C-SGZCFVERA1PDKH5;.],(D26A3;HNWU2/09S%JE<`8Q.]E>
M@8]E8F@>@'L3R02B_T1F#`*,NG7/^L!;:=@8P0TN[):^&R<32<K%A7.K]BO!
M81U`=<]9OSH<XY<EY*"1T(TF4X"#"]2@,5R]B@Y8LQ:9H5+VEQJ0VJK-R)Q^
M!01L63,Z-";["PM(YNRP0]M/5UE@S!`)8^=[/7%P'AJ@%%!=782]WD`XIYU(
M<TPW'(=LC=%VUYG+"NN:%=9<5(?$,(?,)//E\L.V64XH8M:F,I%+)U$RBQK^
MI][?1)0,HVX:GR-N'S-<_",K7RAZCAGDY0OM!4O4`?D"&/Y\73\"O.82F((G
M@+;0!X40_@C\>!GEHY3U]AA`##RMD6(^I$H5WI<D*YX;_$=I:+CX$'?5MMNY
M;-#BP"4+,X[P*N9^;GI;(YE3#W/NEZ[^[K*EJ#89*FKFLZ6FF7>@![L'!+=8
MQ'@(/9^=D2!H/(:7QKET,QH;B8+V0E#>???>&O_XC#Q\M_OD[N:'S(L[&N$'
M+V&\JA_V6H;X/N7U,,?!A3(']!Y&.)"LG:BS8**&/("Z'"B3P=!J;Y3Z([$F
MD>&`VL=EO"B59.SP!+Q,7Y<1PZ.S78N906NKX9G1^^M'<Q075?;JDF%Q8!>/
M3";XGI\O:@].5C(EC[ON@XX.A_W33D69RPSY*R\ALFC4"0#.:*/C_!Y\R__4
MB=&J\^CXRC6I+CP5'4?'3_['>6XD3ZY?`?)APLP,[##0./E]VH0P[;0RZ]U'
MQ%MN0M5\Z$J..384F(=D!^[98XV-ZX['[5'?L7'5X;"M]1L;-QJ.6LXX1KC-
M7A(80`_M:J8>GE;);&^"^F>`E5J$B2EU7`^A'49ZMB:/N\[2%,&7+"4:S'-<
M/&+"X$I]G$EQ:T@_.:)3UN`D[&81+_4O8R!:A.U];42,\*RU5?:AG7GX*A`Q
MS,$51';F"G#]NHP*^&UL[$SBDL9&$!I3X63G\]/R.,D'2%68V1DX*XT9R^U9
M`617(IRKO',<%2KM/VZD'E61+]5*L;,:2C>`6&$0![0^6;J<1,[8QJ5/$:"L
MWV\R_MY&$@W]*)\,3BV/<AT<L>[5JU;"IC`NIQY*;4"+^P9NEU()-N(CY9OH
M5;K$UMTG8[7J58%B<LNM;8]V!2HZ&O+[E:^P!;CA\U-<]8M><2>]*EM8E!'=
MT8GL*E_HB/[J52IC(HM0"<8IU\F0#43K53)C(HN."I?30+A.U'Y%,@J5XSH:
M>:GK@?2U)GP=-`ZKX#M%7=@.RHE%9Q^S9->D=0F.4;-+!7JK]B0UXZ)?S7G[
M\!&$R]M><[Z_W-4"RG*!7B8K;HKO]K#X;080N)I;[`5"]WJ6`'V<,$#L8&U7
MF(P75;!'QVTN8V7;#.$B2F]H0"01Q'.Z4_I\ZMP59H`52*&/J1]K0;5*<B/_
M3Y[,N(P39@IAKR%=J2Y7]$HY$<NV$CVNV(<K]F$R#='%BY];.#0M7GS2;S/U
MDVNL?P#,&:*<(<J0G>6'"8/C#`G.D"!M2+CTDM5-&']+;J,`(H`/9#-%\1'(
M%\LZ1BG\(V=YOKB"B4^"&I)9%#P@L(;9&I.Y!>65R[(,=!O,>*%Y$H4;^3`$
M#?_Y<TR^T`.*MQ!_[8O=UP3+$='A;;\97K/;(C2!KP(-,I61`NV81OP)R7^(
M)+'%6YE\U'0?!\.KL"_7UTJN#)4(H=-&?YM,B3W&$"9XO`(O:15(6H:1DJV#
M=TE&=EP1FO6!P9]T=S.\X5O(A_D9BG\.BX,U"NIG*Y,OB:[.$EN%F>$;:A,G
ML+BN9DD"F%<<OX]9+L07-+VM*:H30@K`Q%R_DELN@\FJD(S(ON1PP.]GQ*9?
M/<)*+!`LR_Y1*T.4-H[MVP@+;7OA+/=B80D%X*,>JSBL5:0VQKBX?/!V''.O
MN-]HN$$95HB@]P)#7O5+J:[CX.EJK^5U8(K6=UQ<E6_)*W.T[S<.;O:98X\@
MKQ+4Y5-QAA@'CP>MJ[0B"[0[A0'&P1_6P#?X]MDOL/WSZ^7)S15^.@YFAN_B
MK7/N=5QKXGSM!2CW(*69(FY@Y$5^PQ3!0%5A@''S)]CW'08:$;^%^-_C>](&
M&#=_W;XG;Z`1\4LQ%:KQ21M@W/QU^YYCLZG>QY&/R:R6610<CI#<@R1B4[J_
M0>[FZ,%#:?F/F5\4PH`QWERI%RU)VG<A*>1_PF($RU[7>3A#O,?[Q5:S6K!9
MH[8V\@2AM]L'5A0('@/+X$'<;Q3<X",!(YWN2,6+%.\78MK>D":R;+$'&`5_
M3ZL8I<\`K<7V0+F^9I[!C'T`@N0&Q>M]\`XI%'&H<LSB2-AO/-QPS)R<#J;I
M)Q[\+UY*TK))Y/ME'(;`+ZS@^>I)Y59>CQ&-(Z#PU(6XGR%N%C#EO"%<:V#F
M,=E->3+-%[DEX2Z.EN18XFP9?A]CSX!>'!<"8X7MTAN[^'2E^/1#3(U\6'J[
MBXM&YT6C;S9A3H,7[I&[C18Q6A<A9P+8)7NK<8:689+3^^%C22WYS:_/`.M!
MZ>UZ@U7`?,Y9B*<C-^D1=:+6)H/KAHQ3JL?ER44;V%Z<\%1H,W7#;N4+?RP`
MCL`R=ZDXB.4"#+H5.W1@M\'N&D7:K5"B^P+TY4Z)`NI60M$!W`:8)<SW*KOH
MKD3)P+J.Y1K/:2&K1R(T$@35XKJZO9LV93CEPB:Z/>8S95Q;@7FVO_"C&T!>
M3%:%I9V5Z098C*VXR@I#.W.%=6/8BGBL`+130AH*0,8JM*M<M:L/<;2:N@>H
M-9_/8SL<JZ5DY]N=0R+8<$!70':H['T65:?U0"GPYE4PJA3O/B>96?^*%#W2
M],E.^[P>(%5BG"M$N[S.&N/+_RP1E8B?;2Q-N1BD;B^26[#35>'L$VYC^W/F
M`ZU83E1@M\?.)[ALQ7&CW9Y%GQZ4*FD;%:9=7F8\VRM*T;]0#WFS_?59/8@-
MX_GI]8#M9+!7L2G9_J2M'D15$J?ZO75[!B>J:M)1,U),MN;.`<8?+#75=8%1
M&)I8H6:GSZ;7XNN>4%;!:J<;1_J!N.XW=I?W'VU'CBO7]WKZT7;DN$:[7@\Z
M6H.<6@F_?J\]CE]JZ8-9JYRCAA<@,3THG0QD[EG(9AELR308]S:DHLPWH3<B
MF<EJKB+_<2*<J\COBLX?%9U7RD-LVM;JI<&L?PJD#U!'54U/]_3,Z0OSDURE
M,$XR!)Y7X")+\&9*D@LO@<E\\5#_;%'PE*W7'MK-%T]P&<$%](G'L`AC)L\>
MQR'TB3)S>)2F!K>)$O^EB8Y81>[C%`A*H+):NW+16&*!*;B#6Z*]-NU,%[LO
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M!J]KM,H"KNWFI8X2_R&0X5ATLKU`4`^\&!==MR(TXT?,)?:50&@4\1I..Y95
MQU:#YD`X2DETMKZYK1E3'9886V.S!UJ^<D8?6X.N!P*58Q^P/=BZI0XV$GGK
MVIBM]S5']:QC<63IZA<R?OYH-*V3W<I8CA\-[0:"R<4U#()@)^O`(4;"0:P`
M<>U^V`/HUJ@,@%I$%7OC>L2&R0.(>K[,Z0Y8D[$L#S$Q-D$O#'=7,,Q2?#0^
M`9\4$\!(W,<DE3/,`G)<7GJAGX6'PKVX+0CN09XP^P!07OW41/#*#%,?M"B_
M?BW()@422#G6+"T)O_8042@/)!>Y:`S7@9ZQ3;A%>E)^L:,/P'$##3GC&2+(
M\KYJ'WX\V`CC?H3=3/#",)-R78K\/H:Y>-A?5'D)*%D^J+U,<-(Z1/D/AC";
M&Z&]K+1:*[[%Q9_=WI9@RK$$=NGYOI5@V?/XYK[AHW<2HZ7AAY="&O5(A->2
MK4:3H806,;K*@K:MG@95V8CAJJ7?WK:Z;/N`QKEL;?7&:EIC-#G75J^JK%C9
M2)C3?,W;>NNX")[C5+I!Y,/)N8"&A_,D`JJU_J.S^3Z&'",F[?E'%ODQYICN
MB[NKY9I2>YDP`I#R=E4MNQJ%5<V[!P1]\('!DWS_:9K?G`&K4RY*ZV[R$NC/
MHJ#TU+'\$5U'.2WU$CDS4B.,70/IA(JM8J!3+^CA)JH[G6$%H%_#O2Q-HWZR
M1B.*"B*`K::H'N?WY/39GEAU7KA3T7FJL"[:HS(FE!UR')#P,GRRDD?5\M>*
M^9YX3@\S\03K-7DTR@L?O`U`@B@"6ELS5*--C#"&Y("N[`4"ZGE];%-C8+XQ
M"H**GX]I*G[[:[6#6)H#IZ&);U_;\N1+EHEZZ:YFE>.KL@H#&/D.-!V(T<@L
M_L]X*DZ@(*6A>7HO]V'%GC!H1Z*CM>:&_3MC185IQH5+4=.E^AF)Z!$SP&VJ
MQPQ"&7FVQK\C4>Z7<4(MO2'N9`+/KQ$"7DA(^(POK'E4'9X,5#D=S-)/K.A*
M]+<Z&*'_Z7.,-="(+(>G31PE,9;VKTD]4RS!)R!1$(PZ#65"O1)++`<M2N[\
MLC7:1@$HB2/)5LN&'$HR!YZM,35=$6H?J=V"`<_AM4<UC$3GD)VE!-15-H(9
M2S&RU7K(5P0G9TP5P\'32*V-R1'#PCN1[$T;%ILGV$N&;A2P=6.I&T::CD6N
MZ=7VZB<=0>/Y"6ROE-AUG5$=$[;6D^D'5C=K@"LX>?)X$I/>TQL/HOP!M[]"
M@#"*J]U-C,K74:/@#GHO,"S7AT?:![/TT&4>/9+E@V"TS%]",5(`(B?U0%+%
MV($TAH%+HJ,1)V;SE3V^\Y+:U@C5SN5M.O'_K,L7.,>];DP/!UM9?;H\O8^/
M[*]1_)(`M"4KX#;:9"G^<QSY^,S/;YV+7=X]+XO&?]1GJ.F,8G?AA>31]:<5
M`.EG%&<;S$?Y,*47'A[6N_3RZYSYY(:V8<UB4?LVO#>LF.T-4T\#G5>(0:JK
M89[:PML=V()0[O/P.AOEJQ+%1$$[W"Y&><@/MR0']`/W'N/U&`L''Y4Y^#@R
M#CXI<_!I#!R4UVCN(VEO5[D+66J,\P]9TH-\3=_MH%+*]C8:ZD3D94&,'KWM
M**CFKGE6:Q>*<^)7<`;6/1H68;J]Q':/PTDAEG7NV.FI."G4<BXA.[T<IP3:
M^49,?P&1*^_#![LA[FE;:M1)D?"!V%YX;PA<I;4!VT/UA$;`QBL;@QTBML?>
MJ%@K)Q?YUQ4D5;.IM3&"&@$\/@2L?>JE+V8,J\L>KX\.+]8:ZWJ+VQ_+JN;_
MH:(K9U>>S$W"<3@Q#D#.HIX,:BK."2J,-!^9K<EW@Z+WL8V>74EY@Z+WJ8V>
M70E[(XY\-52YEN<+XXIODT6H?V7Y#T,?Z":CJ)NVB_E"%#?]M\Q#F+EPUS-N
MVKIH11?3=!8Q36<:3T/9EL=FR?E+")?Y+A8N-\71)LOYKQ]'S[O`&-WR$O0`
M1GJJ,\=,*K96US0N2F]*47KW6`;;8&C(L\VD[DI"2HLP:S2Q6H]"D74V/$,V
M/&T'W&00'N`:[?IE&J)*+Z/7)B\%]I1B=<Q]!N[9:JMU[$S6.1:B^\7P%"O]
M.AIIQ:RA)5`7+S$`H"ZVPB386@^J"?G-!W8>V>6X'+'S:!1E4^J+:33/[1V]
M4.,AM,,GPOX-;JJ6S.WBRBD<!;722^/43E_<`$O2J'$8D_[%T0[\501_SX!\
MR8"AIK4(2RF#XQ!3FL8P6Q=1<(\P^>T&`7P]X6,4).FCE\K@P>T^%MY^`7"Y
M2D$PV^)K>@E^CD/\*?#GVRDRR1_'N0BUN`B+T_H2;RF8DE4EYR9L]3+!2<WD
M,8^N7XD5)(/)BMR))!_OA?5)Q/V<\=XZX_W`LD!=]Y!8E[9J("9AYPO2DPFW
M/"'BP]B?\SQJN'5XLXT:\L+69%))#7\&NCP_F5Q3$^BSY->)E1,91"5W'IB!
MP3W=#IJ0LT`UKF20;VSK#G'.!48VP19$&;C!&#VEI/#2$OJS,(0DY=!,D76$
MO&A9.CGRE>M5OWG&/R5X6Q"1A1L6KCJ*EM<U9V3/_@^(@.]1B6,TTC+W!8R7
M(+H-@,^>NM7&^5H*`GZ!`:BYT6I[XAKO,H1WZF66I/$:()$3I?MX6E;!Y^0W
M]N>O_GC^]D$&_X_Y&>V%>,NW3K/9$NLW9/NS$5+I;F*U/H*0O$/XX*%T5S_$
M!#9\83<SO.2;@K61#G_6\^ZQ%\4+.,-#II!^<3";&2E%ZJ]`D(5@OE`]3Y*+
MW0.*@\S/K[TG@+;0Y[LKAYE+SU=K"224LX37<B`JJ-<9OZV)541R:>>+FB3$
MR6NDMS6I%764`P_O"BM=!;8;NGJ+.77]LSJY>YFJM@"]Q&,%;L3:HID5)"MZ
M-$H:#'.-V0[UH+?_9"VC@Z,JN':MCT<?'&"N3&A]6<"3K=\>LH*]MGH)?82S
M1&T7$J3TI`H?FC)>06-7+6XU:&KV.UM#K-0`H9C4;8V$4@.F;>^W/6F6:\YH
ME*A7M1Q,P]-'N;VBX#(.0^^%O+B2*W-C22J:^3X)>X31\B$.H0^%8>J<#B9,
M;[/@'UGQB#IYX7H=H[1\09U%/K.]'L?DWM[%LI\V&^B=DVTM/6ZB9]YUOED:
M"SL/D?!!E,@X@=0&,+*ZG(M\I"YRQLR7N`GTO9`][U$+/;,*5O!U'NL97+6S
MFI2[ZZ9W"V8(>,EGO`K3ZN)C4'?4V,RKX@UJCC>6S_AS?9>U3.Y'VU7K%)J^
MU_Y5I?*RXBQO1M.!Z(`A2-(X8KQU*-E)&VUQ])3&_F\/&?)77FT#)9?)AG,*
MRG8UL]X/M#VML.2>W"9)UMJHHM:Z$:ZM]4?\+1',?WS(B]$($.9V-8QP'NLI
MAK9H9H36TA(X"[:Y7G&9(:+,L4AFM#9!.<FY*HI*)_ASE^6E05"E8=77ZP<&
M0XJ#F.*SEEM6E=&NZ'[`:Q[P6)3K;X:[0E\OC=1,'IJMM)P^1X.2DC?+"/*/
M'6&?82@C*A;6C[N1R.RLB=8M".--D?<8!3#`,B7[8N2TUD[-L92@I$EV&\@%
MY9(WEM,=.2_)!8$76GZ`<DO*<+MH615'>5OLO4-OJ(>&.$/IZ@OT4?P8><\>
M6@+.\N.T'F^P,6.NOU[^O#=;LN=L-](R]^UZG47Q;;0(O?6:]-J)21'VL38$
M^RZ.EC#-`AB1Q].R8#=?/.`3CXA!WGH3DIH"7Y+G%4#>9L?&K\,H)DZJ+]XK
M7&=KKIVMV<8(E?CN%E+9:*-E)3P0E74>@;UMZQE!G@F,UUP?/<_?8A5Z&,WU
MT(.`+S0,MAN96$$/*/8!"!(2_U$9HF+$,E:QVYNG_J"[<$KL\'IH^O9QO(@7
M>&P?;%+12F0V-I*X04R+G%#RZN_&J..>=/469A)?#CH4*:<CH[IRNVA*G%IF
M82&G$*=P!X.JX@B:J9:AR^@W3P"I^(JAJ2F%-3,]WMNYM_HYQOH"<;W?Q&B>
MKO+@/1+XP-MO6L8^,U0(W=S73O2,K6F5TDCAK5A.^P$I>@B]Z/IU`_P4!.0]
M/GG:6CU-KB;^X=]LI`G-8SO>X;3[`M)5'.RA.?P:-P5P2TG*ZS_>0!RQS1W#
M6C$?XYT7ICL\I$_BHY;@`@OEP3RZ!U@1#%O9HW)]-*:4BG))1Y%$JL%U+)=!
MJFTBESYJ5?IH'_Q^QC)D4#YUNK=E7D`,"_H-(/;VD^EF-+U5&.%(SZ33MY>M
M3D:@1CQ64>7'L8G3P((12DZQK1_P^&A7#3HI/,3V_@,\G^Q*5M&5>T^Q;%8K
MRL[LA+Z0'8>(5GC]Z/"BEG<X-OU4F]*NO"!M*TQLU:L@M+,,1@\(65:&"C*[
M;DK]^U3.L%SA^>\.3ZE=W`+.71@TX'BQ,P?L?K!+_->%'2\^K\+.R<)469@7
M!5&!9U>2MU;P6"$;%7A.X*-K8<P8@PHZIXVQ;EFIM)T*2#O?I^@+I&(V;@6G
M4T!H<$H9PRL0G4I"`[%+A&J%J9UJR1`)K'6UF1-`:&NAFU-!R\R^L[50SJF`
MY0?JV5YN9VAT.8#:*4H-!:B&&"3;RQ\/"[TP1,GV%[T&A5><85O!ZV2S_O"R
MTX0KG.VT,`]]XW&*@AV@_6"G`7K0)<RI&U3A:J=Q^E2XBNM'54@[+:Z#]"87
MCU^![#2Z3JIRJZA.A:C3XGHBVBP$50'KM+DNP/)K8%3H.H6MP[TF63&L0MGI
M;<HH,^JE5)@Z94V#E:<-J]/-^OLGCDH$5+&X3COK9NI5J[)7X=U!:QOULV*G
M1%RRWE\%=@?%;1,GD-`X3K3=(V['C[@=E^YHN+OJE3,F@00[RONH8E*U1^Q4
M9D1H-*M<59'&EJX-G<4Z:+D#/>M=6+\W=98%H<8P*U3UK+:^G2:W8<#FESRI
M,+53!QRN\H)[O7,02+GE(B;T<.=@V!ZEXT_HL<XA(-4LJ.R_QD?W-?I\#4:]
ME#VZGQRZO=9ZI;KN$?W!(=H'4;TV*/?T+[_8DZT"FE2-*^[[MA_M<F&J`<)[
MW_:379$T:L!PWK?]9%>HAAHNS;*#%29V&B:Y->C<F[_B-W^S]=I#),$-Q1N`
M4E*$@T26Y(J"H8=]LS4I"`*PRH(1\&'./_XY!*4EKAX9NR>;A,*E#=I+VL)F
M'4)MP^MZFFZ3X;7R5P\%WTCT3A0\Q8N4_,A]]D_0R<QS=+DW,=]#MP0WK-`G
M_/=EN5W<(T<W&8I@FN4?^`:^DI_X>'(ZZ'FX99^3N3ML`\[[+,S&)K"\`UX"
M5G$8W*XW*-X6UP`73%Z/\W^:1P^JS--1\!:[N-^HN!$6V)?I.2J./J,X46:F
MZ#0J/EHA+K*\W'5\Z'A@?NZ!\I8A74;%@_#A!9F>9LNALRF4*G(NZ.X"G4:@
M-TI?7?0BVZ(5,EGX^/$M4H?&9+%KW692T)5WN>TIY-U0TV=-Z)9#_F.!;X2/
MWK1L:QG"?%FF7T9XG'KAF6+&"7WBJ-&V5SKJ`I>$C<SV.D:*L,D8D&PO3M01
M,JZ=R/;Z0QTQXUM^;:\<I*HUN@!-!:"4U(T)A6%J1/#.3(2.29\GS=6)I=59
M$,""QMN(A$(6E7<,&*+JFLJ1@L*P/?%ZV.)(<ZZ3,W2=G*F!WIF"G2G8F8*'
M-!MQ[SC;S2!.9W`2[TDEWD.4WRV>*%J2.@^S)`%ITEV\'9=PV"/*"D8P!7=P
M2\J--,&I.0\D9/`.`XV,WXO=%^\?,;H,O83V$':7$4;&(2_N1=AM9+R(1&NI
MKB/CJ5H]]]Z:'T6B.HH)3C_'<?`-AB&^?8YIK,YF@<*G-H8)+H_)N@?I]:L?
MDN=3EGOJ&<Q)=3U_DP$KGK:H*$&/0Z6U,*+:XUM+%"O;;&-68>><"W(JNW``
MDP)QA]N[X1%4/7IM5S!4[E=)(%OQ.'8Z6`=`CBEO=W.\GE/L35<TY>[>?C[8
M\4?A=)0H&]:"YC5GNP6J!V)4T<7V")Q.DCS=7BP64&R]=)WG@6G>E)5:G258
M":I.8O.$XD@T8SE!RSI%`!M-'$E=B*:8_NF*L*"3+=$DPS@,:MB1=WFPA'2/
MU]GS-Q!NP9<X2E<=C+4R@XX?A[\##]W@MEKX/PQV)GS'&3-EO]M@Y\'W,YY>
MWP<O1CL3SK_%^OC&8VDQ-Q=3A]2I27EC[P6&^.("3,]2UU&<Z^4\W!3.%"]=
MC:O[7FID)PH$-%NM4!HA["N-V6JX,@;QX?JSU0%B%ME"I+(U$\THMH68;FN^
MFEEH<\W/]A(%SDG@G`1CL=8Z)X$T5)U/QJG8N,EK2##=5\XE3T;`:`DB'Z.A
MP=;-L%94(S^#R(O26D+^+`SC;Z0$,LT^(=7/A%X\0\";+QX!WI()_EZ'+%26
M'9[5W$QQ5^8*D+:FJ(VAJ[RN>$JNM4MQA--133.@J/8VL9*NRA/R$1-XB?\+
M4_*21(;(T<Y8.-PNY^R/8GS_:W)JYP^PYD\WSQ=SO/$]\AGSZB2TCR[J8B8L
MW,<?"%^HY,7D.Y`D,<L)0FMIK$@PWC1DH>%CMU!?&#33V^H)"R=#XQ$ARF_3
MW%*%9R)Z%#5&G--<'SW/`*UAE,]P'Z?0!_MWQ1D$L=J?OY6<@=)]1B+AYHOR
M<Y3[<9Y+<=2KA=]!"TWSQ0(C3^370\FQIXWG<VK+"WKHH:J4;(_7R166<D2+
M7;JO%DKYCU2VJ>.VUT*1FBRL30)6I@;K4`!K)NDCD5P!(N>[MU2DD3&&'LIQ
MCP2KB9Y?JG64HX+3<!@:J#(&MZG9%^H[Z`3UJG[20JZM9HL>.DH5B,T3%JSV
M'_8$3OX6LMI%J&/Y,65#JUV`/9$3R(M6>_AZ0B=4D*WVX74'3VR)M-5#IPDX
MJDFC6V%PZS$3JBN]2H-O`7J);49.SOUQP/"#DXSEUQY+.:W0_.#0;)]^#/-H
MA9I3,BBH\1T>%7A3U2VF';G0`R>>'<O:%,:^>*GN9WL?K7=Q5O4EQ;4'LW?;
M-+%AU(00>9NJN\Y":Y`L2'R74@71T%:?450CO<F*UVFBS`N_P`BNLW4N9#YX
MN_R(OHE1T[33HUZIO<%/9Q'44GR^XH.7GWK_E5OB<RN80-1O:`J9P5;"/N<?
M[J!G#QUM8RIB5QDKV$:V]X@YN^2&N"D.,F(^;R.21D,<9ZQ2!QT&&C6_>4J6
M%H9K(XV;XV^Q'G[WXXR8V^<50,!;I,S:I^KCG&_0AOB*M%H14I%AZB9`U2NB
M`M%"._3`(-9/)ZO#7X;'L7:O61T",SB2-8G(ZHB8@8&L7\56A\<,C*.]]8"5
M]/AI^II4T%%8C,Y/8L!/8C8G.-H"E)(LZ?LX!0E>$V3Y#)@/C.$(L6SWO(JS
MQ(N":[A<<5(Q>,V-9-"2^K+SQ5,:^[]QW[6A-#25\1M'.17<IS_:[<Q0>UB-
M5^`EO?$@^MD+,U"M5Y:Q0J;G"#@2?`-:6\-4W\71D@2&UT\',?W47H8Y4>/`
M..5D"13TD!#IDC)2U2))44;N[:<5ONR2VR3)0/"!P9#B(*;XK.CAO%=':6B>
MWMJ*J7!^0-`'O$\BU]\\=RR7GJBU><J%[\XQFVMQ0C9'3V;X_P/R$\E*HHDY
MW/9#4/3%PXH`D78EDG5ENYK_ZKQRI+26(Z`87Y)R!).&YQQ0H*F&,T6P$\1L
M<+L8J6F,P4ONX@3KX_/H^I58>C*8K,A7GB_(5V<P(NZGY:3XG-!5A:,_&GJB
M,H_XGT='LO(]P!`\>Z\,Y,3]7(!'F1R`!7>,U9J`0V+A./(8M>D8:.;>^XS&
M6G;.%QCEEI[#<OL688%N!3<7.Y(L@.]*%(=XF&7Q!WY!A>Z#Z:F#`M('%/L`
M!`G)DB,:`LFYF2_D-*IN8YA8/3D!?"VJT41/[10_C?$A6C-L82&JK&C-+NHB
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M>?VC1XMK]JUPFH+,WHXUX6S#MHUO"J+4M"/V)3'A^V"MK06EB`['6[.':.H+
MB&9?WV/S<:+8<%UK>W`^310<X?UO;UZ02F`91UNS.VU^Q,E39E8++TR*=Y5/
M%1]&%35N,E@E(=MIO9;$2")4Z(#41SN-:,(`G8:^18FZL'6[2<0+<62?B:+#
MV&>UL.=J/TTD]?=ASV&^:VH12?BHR?^[BD,,27(%%M"'Z8#9P43@^A\0`=_C
MY`2W&AEY!_B;AP)!B'2SC99HN`L8+T%T&P"?#5"KC>E,Z98ED9,L?6<TBZRV
M]@MG^BQ+5W@/_U%M-W;F=*O'*#B89VF28K$!1DM9%NI=M*S:V@P_Y]Y2@/*9
M:*N7V583)4V_+7L7,5JZ+&8-E,OFP5/Z&.:B>57*\D'M98*3Z_4FC'<`/`&T
MA3[(-]:%EX``[SKR$$A^E5]ZR>H1^`!N04#\.]>O`/DP`>4)37\,=X@91HO0
M/?FT20J"_(9/GDDMI09_<9+BM?MWD&(NXV7$N3^&F\\J](HWXFYB5/Z*M&/E
MZYR8""WWTH%FLOX?,N2O2`'UT(NPJA^E.U%ND$IWET5\_7M&`G?+B/"]@#%;
MQQFSM#.WB]%,Z(M=3DJIHA5TY@(U-P]2NOM4<HI+*:.LWHH5W_K[3E0(97H:
MX>AASI5+JK^[K.=],$M=/)-4_`2=3.=BUO-=#@H5DQ51/R-YF5ZX%PA)B,U\
M\8P\?#G[Y-;EGFT2'?7D2/H@\K!$,(\X-W.[D=:YG[_%XKFK1D:^8TG%URC9
M`!\N(`CXGX_9W@SU*Q!DAP5U45R.O$HSO!Y&.*#*OS.$-\4R=ZN4(D#>I"P*
MF@O%7[Q74B?T(%MF+XF/8*Z;/;8+&0T^W5EAMW\77/(RT3_/6:%5*OQ[,T!R
M6[X)GFME6,Y",$J@G\NKN@%4F?H<,?V,&Z8'KGX!Q,6.E=XM0-X2Y'\D4?0'
M=6`@>%6I,(;TBYC'EV,>#_HVR2!KR$UETB</U&$F'.5*35B+I/*310$Q6@BK
M]PTRE3',VKHWK_H(IX?1ZBE[L4VF<DJCK1FJ*Z]V@2)Q-12:W":$M33;1[*T
M6)9&Y6&,\5KD<%YE^#I;%H=P(3%4%#8*(SP!GV1806;!Y9Z#C@X'I@&U$P"<
MT4;'^3WXEO^I$Z-59U?[J$_M(TW?&:M,,(`>VM5,(+SSF-E>3^6F*F:Q<$"4
M1O2(B"APFV\(MO%"H;<6:K]&/OF2A?K$J"G*::B)!GR3?,-G)$!L8-J-3`9G
M4N.@&@D[@XB%M@8M2H5/-?.A5"49VPM$24,G,OO;7@]*;8U)R`^VEX:2!HSO
M8+:]_)/"!A3ZJVPO_R2-E435.COS9*01DO+D]ZKN9!-:?:T"MM>"4MB8O(!K
MV\M!"6$2Q'_;7@"J^S*B2J*6UH&2/[7T^V-M+QDU/+9=/8VV%Y\Z&?)R?G/;
MJU?):V<ZDR!LKW6E%]5NB1.VEP(PCS$CO<+VEPB&/Z&%,72V%X)3@WB@\)O3
M9?2/'>2N/G#;:XRHIM/45%MZ0G$%F)UJ11?`!+;,-G1V'HF:H*.G(A_`^V27
MJ<#5(#NNBB2='M,PDE?)8=4VLVNE=`.(57^F0LE.W:,#2I0HE>K4L?.V$^8P
M576VVDEAU1*RTT2@#DXM:ZU:.78*EA+Y8Y,MB"V)#2/4S/J*V(KP,"+QK:^*
MK0H3.TC6^B+9DE!-NUBVZGKBI?#LP?K!@<4S5-E?7WS(Y+CJ05B%@/M**+73
M&W@2P)6J-E62KL5+G)_+6#\*Y*U@UHO!O!3*QE7#5K1LQ<B5N!ZXQ+5=H3=J
M@+2+*5>XV.GP%F8(-HX;"=.@U3N+FQ+8/)@Y4O#I(#);3O[@=G_$LR$2-A6C
MFRS%?]OG=JC5B-=?AYQ;4X+2T'#][DMO`U,O+)SS;%`9["B/8YA;02WEXW:N
MFG7O&KU"U&DMS[EZ+*OV;JYRM.)FZCG7QTTTSDLK)=?ZLZO4J3?^?^O!D`"+
M3\$\,IVQ`0:;[JRP*V.=:WE-!7NZ06/.8[2N$>O1*59MHU;[456G,!R<R`ML
M:DD"4RI4P`:&>EU/J31!_SA"R\H1\(06G6E%E`/?UM(%@T,JE#]L+70@BVP'
MO=?6R@<LY6!R<4(\("3D-&L#A'BXT/>;O0YV%Q?N7LO5:=)O[ZUIV.]K6<TS
M/X5;3*<)<WU%4)[)=Q"Q'D&(OUM`<E>35AI@PE"(-0UZSB9/BTV!E<^M<ZB/
MY#,>/<<_*V,?RPRN<6`]17I[*K>SY1(?C'C[-\MD\$QK0T]Y5H\>-$N/D'7>
MY(I9,GVX"<]JG[79&=2HWI[GS-$ZJB^T+\^2%P$8'D/N[&>^CX]X>P1$[(#1
M\C*.\G,J\\)G@-8GV.#2E)SC6KZ)T0)`8M%*9E%P_;J!*!_A4,1IH%4LGM=*
M-`V<%_UH.L>OT"P!-Q"L1Y.<(TXUS\I)7C=CSW?FZ$TA$.%<T?KUX[GC]1B'
M(3[$R1^'!ZT^V9GC9N"NE9W=(3O0[.>_VWG<D<VY.-5)($O(.>J9;#99VMW'
M@?3,+I2<XPK_N:@%FBL@P,<_/L?D5S7V&7;)@19Z=WKL1']0H4QZ>CNQ-7!=
M]B3J',]T999/;5+42.`H?%>2U`[IRU(E893G"]-ORZJK/\1YHI>(L\29^W+$
M24!6H&!T#_C6WR/8D\K44M0',AG+IB<:B)&IW3=JQ-8X.1=1R:YQI2?2:'*!
MW(,BJ3/DR=XX:?V!80.E&C6,[K8_GS?.KR%OM+#]^;YQ?A]*T)CM+P2.\T-T
M\1[8_M[@.+]47UNA[6\5CO.K2<=[VOZVH=[/8\8(:?M+B2/\1L(D!UM?5CQE
MBLA``@7S^5;+'A0[UT_5PZ]N=_550Y]23\I!*XEI\G72>X5+CKD<S:9P?:0>
M2MTG&B;^W]:B-@:^3`</8+?Z.#\6Z$?Y&1PX_$^6[55]+I7:X^YSG>2N^?5C
M_0-U>)>VN&VNH^E\(L5X:@-VV9X/W$]1@!CRH^H,$ZH^K)UO2%OR214C["IE
MS+F#QWOZ]LS%KCZR\RF/]R/+IX7U>VA\Y'*3R7ANG2:P3GE9E4!LUTZUY:/J
M3,RPM1B[+=^Z4P&?TY61-UG:<I8DV;I`Z6M"-L%UDL*UEX+#$Y1E!=3YOA$&
MZR+T_-^>_!4>*BE^3^XS_(<O<8`Y-I`$</3\.36^O]G&1*J"704\-;VR5"P@
M^;>6&NU=^=%C@D91?K3KE7$X=&K'$KZBOX!T%0=Q&"]W@LUPBIG/'M&]Q',%
MMS#`E\@C/B=.@2=UWK-*ZN5Q-4B2KGA":U;CSS&^KV"(SZU3K\>CF<VF,=,(
M+4XA(I^UPN&TY"W+SCEF9)A/!0XZW]GOOD>8_':#`(GM`5C=2$^U]ZCSCA)-
MIIF^TB>BX"'T(O(.-/<5W4&F,FFMI6I=>GP@/'!MSP35E]E]@@/7UH_A,KUU
MN6;4E3HMOACYV\Y6\ZU-7XZNL]K^U*=-7^Y8O[/U!=(Q?+N!;!M6OW!Z*HU]
ML(W&6B-6/P5Z"FO"Y$K2G!19AC)I]P.EIP+W1">;*PW4QTS$?-&^Z1H]7<*0
M\;<V6T`;B2D(\\%!0/_V1#:*$I:Q5+*SBT(8010"0%OH`\8.+[XC_FF^>`1^
MO(S(X[A%J&[.%,LC,]0LMD0\=/]NGT$$D!?BXW06K&$$R1)*X1:4>XH;22+7
MUP17MQ$^%<'A@>J[<CUPXIEX/4;$`=<EPN_CXFD*E![QM8M%E15>ME=@"\)X
M0\"26>\R/<T^4*SG?)1[K%CG7'8XB`;^'K8JR`.+$`VU6%(*M=V)(7$_UF$3
M7$:V+TRIN[B.E]058[N[11DU25'45E>'\Y$S:W@/(-9,S@Q],E2E[AAK#=(G
MAUF[U'1*\[-)V^@56&"F@SQ7#;YD9"IB49X%`2QHO(T6,5H;LYB6]%W@6W$!
M4T):1;O(3B;7UXB]E(XZ6835PN1S)>BK):Z:,=5^L]5_G^!MY)/%NB2;/81+
MB'=JP]S>Y$;_^"/ZCB4#Z(N7XL.QS`3=_[W@0^WCR@PX(OZ_>*]PG:UG491Y
MX?%7W'_=3D`HC>P\(7T](>.R[]ME@:UDH_8]E51?7-(.*3.&4?NBRCU^"#/0
M>P'9;L]2QEC'-6:[`4<WJ&IWHZUFGJ'0/9:@;0TO/87;1NI:LM50Y.R03%..
M@KCB[(NJ:"D>C%,Q4Y&S+8Y`7H^4&%2?O=<2FKVW4H>]HYIEOCC,4TY03L>R
M.:GWUV*AD9B1F<4NW=>$=G29(;+';D!`O&$MPACZD*B704X8"/,9874:'Q]$
M$(-1AK6$^0:4]4<%5HT>`QKD/W?ES**`>')4UZ6@KR$+7GY=E%M&;95*=C;)
M5S>&SHB3#ANOSX@F$6ALGVX?5FH(6^RE?>-N,3*UJH[\-<7K890#J>5A;B7T
ML%6?.L&LBW1<5VGZ"!#='FL9O[ZH!=A>-T2O5U9L1Y9YBE3O7731NN/4"\\;
MM6E;>3JCU&%1VI\'VU^QI-PR;,.![5[`0>`4:;VV>P$'`55\NW3R^HWW=M&H
MTM+D'Y$-PWIGX#"PRJG=MK\].A"X$GAV*;$S_C-`PL2@(C$Y=[0I=[1)MR`)
M]8A\&,(RJG]?7(P<65D:H]WQE?"`XBU,<-OG>):_S-+^2_<H=V?]F[+UC^&A
M/0Q.2A0VURO7ERS5;V@*F;YC81^C7[U)T.6*%%2ZC?97+FXP2Q*0)J0.U2$Q
MZ)L7^:PP6PT#:_Y25#IJ[RMA<60+4$IB8._C%`A6F/)H0W+S&1][=W&2S*/K
M5RQ2+3.8K$C4&@FE>3G>PCT&&M$*91Q`L[T5XW"=-;:=VF+M.,>(4+J/B<20
M^?DZ++F@)_J1L$<U=!3''A$J\W0%T"SX1Y:D>6RG&M^MWF/C[/"K:,E+]5,:
M8D0\/A#I^N_`0X>_M\[J+B.,B$.Z]4"52^8H(^(4_^(22P%0=0_6^CE_<W<C
M@5B,M=4XH*QG4%V<>D026[TK0V#,/AIM=:<,@6+]V.WF./FQP"W"!U\*QOSP
MN6;DVJ*CK1Z23NCU5KEM=8EH1U.D\EO]W(#F3:UD[;(ZK$XSL'15S>KP.<T(
MJAIP^@7930M;AK&D@O"#@U`AJK.+\C)>G[N2FV>:T9PJZ"@L/GNC-UU$@B!1
M.4_];HI@1->'W@MYL0YBX<%@*M6!I&8<DB![BM7+9%+8@:;/"&L0L@P4C<=#
MMV3&'J/3*/BHK>Q[(,W(4:]1<*)`_FAH+J,.HR71HR\]A':+&)%GHJ2W!&>$
M<7!()%QI9O+&NHI@-L=^0#&&*MV1HAPI/M*O?\]@7MH<_WR+KY<H+SU6M*6%
M*_0;<!3?XF!S;:R3?<%WV8\D&&44G$K'".D/`M+.45WV$#)1;^P2HL<2$CF6
M$IB,L[)1]H@G^[;T\_H!V6&4TU+/#(M4'&$,^0Q\.926LB`E<_3R`V\!>HG'
MJOAJ!%!TC=KJ!M8(X;'^.H&"F9*0Z1!>;?4'ZSP$"[7$5E^O1J1*`XWMB6V]
MD&J(Z-V\L^<0S:)Q51V;G?HY9"U?7A*1`$J^UHFMM>8"Z^12'?\"4XFY5=68
M;'4ACM@99L"7VMT*()8?*(6K.CGK;8'0N>Y[8-5YM4ZE['8MU&TT+\+-B)'D
M&<_"><>^V::_N35)-XA0^"'_B5#VH489^=VOE[,C6O:_'84;PQ[GK/V.3KI5
M<!;B4R/RR%/`7V!$GI#![?IYVNA#FL#@\'QG&ON_S?/S;__0,95!=OMS=E4Q
MW!)EQA45$$H#H^ZQ69:N\NN,<S@S&H^#;NIW%3:?LDNR#P?Y^1,^@BV(LOW;
MO;>/3]R]+^IEK7,57\',J^L.KF$A"LZCKPFHO87W+<+"Y@INBKR0\IRGG2(Z
MA]?"+Y.:Z]<-+$JLD70,&B^R74VL>F4!9F3RRMX]R=VD1XTTN^=K:HED(`&U
MQW!4200(M%H;>8.4_DXZ0F0SYSFA%[NJ3?E\7*Y<51I6%!!?XKVW!MR[<Y"I
M3&!&E:5GZSACOF7,ZS$>#M@"&[O]:*@7+C]1+RUGP=<('=Z>?#Z\4)8\K[ST
MES@+@_LXO5UOL+AUO5@`G^A=A[H)[:.B^V`FO0=4ZTSC?<E!CAQ;#9QR"A8U
MN:VETDP/H^:)T$1)H'K8FGNJ`M;!KEF!86<<F@P8-%-,A8N=P6;=7,%M.=C6
MD\>Y?>E^.)Y^UC&8QVH?KRQ><@'7=IW1BE"I68YLC1;6M1_E%IQ=L<$=L>.:
M!6R-#M:USI1<GE97@U(\Z;3Z!*RN!J4(;`]3CM4EH<3F[JD'H?%P$9ES#G%E
M#J-C2^(>&K=\N`;\/4P?)PR3U'EO;V6F4SCWZJN1$[QE:_DY:4^:<-=.R8DA
MZ;FK8W8<;'"ZH'^C1<1RN3RYC0K]<;Y@2*/NJ;+#V5Z\O[@$D;]K"?6L,#AJ
MG[%P00LA$;>?<B#B6,+W]*#*VO)T1%FMSY;R7S\.&I*!5R`"6.Q)KD#Y`[YI
MLI!LIAM\9^6UGA\`_G_2Z2%.\M07:HR9W@E&]+T.'#0(+Y^N%F*C>?!1>$%Y
M=TQ=:&%N@%[NK$V.RE/JH73<8IXT7D-L4%O=8+H7H_+NMM55IAM8?''U<XT5
M^_PZ&GDY!:',.CD[L!(RDLO.?BN59(R1!+BVKJL11QF9-)(\9>NUAW;SQ<$!
M6C[GD)";[!&$I"3-`Y:6=C/BG^M0<IVA4LS":!=Z:W8^9K/!.6>DVJM>U]<'
M-W&`TE"+8EH?]QEY48(//+Q;KB"6*E+JDJZU2GZ!Z:H^`FT9:I[!]%>J$2>R
M\`F[C8@74>E_8;<Q\7*Q:YR[[)0BA0&,Y,4=G(=RA/*,M=W&<H+&"&13]B5Q
M,%\<"0.VFQ]D#^0#/KJO.5LCPE5OB49*7;?3:DJ[5^Z2:GJ>VWO?=L1Z77N3
MM??T1JW+@K4V4O!4J!HRLAFUF(`07[H@^%N&L0`HW-W`R(M\Z(577NJ9J.5W
M[:$(7__)`T#[2#3H,^1H>ELCU<IHE,RBX`J&65I])1GZ:[W&P(D:!_TI'Y>%
MJV\(S!/>OGE@I53X2[NUL\T5^-R#M(#HCOVB8[.-T3I.>^6%06F[G1F+35[H
M@&V/*?^LIR82]Z)A6>^4NIZ`3G81)XENYEUJS-.H"I&78=]6Z=T9NQJ)%6H[
MMBE?[T^6"B&[HOW[(D2Y*6PU8_6%ZNCJM]6<VA<FAMYD:XS6('#5%3:[:QGH
M`XX"F(T%#>3%PLD9/;L`I+8*)V.-RUX2\'N&I[G>DF3,T3RP<9DE*;Z!T2S8
MDK?!DC(HF*$YLEIK>GM]"\(X?Y_R,E[C6<AZ@7\4"YT\SN(3>6JV1"#7=-@A
M6=T&LL6P99=YZ`'!+59M'T+/9W]U06,S=,<^`$'NY+Z,0TQHC,A<+)L,N[W)
MLM]$;*HV4RV;G`3D$C/#<XRE!7*`W<0H?QPUN=@)GNO1,_:9H4+H%D0>ZAC;
M2/B41_QV>3T`3&,"`U`477L$/H!;$&!R:YXX5MR4VB"&^21I[/-%/<*%6PQ=
MW-$T/QDY)_$_B-B?W"9)1M[85OIJXB$,\XCO!A_L51LQ/\WF>@S07A0O(%ML
M:?Q=SXSXQ$C!$JN_80AS@8UR+O-:#D0%=;OPVQI9/4VAG>7*$#8?`>U<L8G>
M=@14B\*EF<U'0#LW2IC6=`PT\R4W5NN14,Z_A)GM35$/`^BA7>W*$2!/;^^\
M:2,(7].J+M$J(O74.!S^"HK9P8C9T1YE:V%5=3VHOI)9=AQ;G]Z0D+\K:SE3
M0+9UXTKI!14^#<7)UHJ[LEI'?5<QK?>VAAQT`8ECBK4UY*`+3&KV(%NC#WHB
M=V1ELC74H"=*4G9B6Z,.9&T=#>RHM@5;I0,9B\KD8C%D01&:=NQ/)A,@Q!7-
MK:T\K[I^--DTK"U1WV4_,DQ^>XP^.8Q8XH3]I=$$IGC!T6Z[P4#:[,_!J6U`
ML.M)*6GG`DOK8UGS;"XQ=Q^G('F.#_&IAT2J9(Z67E2:>XG"$H<PV-M^'VKT
MS!>4SE7DYS,F[R+$\)J([ISY/GE3`$;+!TR^#X'(H\KIX.(CCPD:0WRD]E5*
M7Q?:IS'B==U3U+)3'+M;VPV-TLN-)6@V,GGQB$^;QLUSQ)VMHHOSEA_+)\QM
MV,BCU'ZP6>\3H1X7TS64,>'@+42[$Y).)^WN;X!I2;VL(M*^CS(0E!GA^1P[
MEL0ET<&$+'+I)<042/YS_7L&MUAMQ!^>SXI:7R-<Q6N\V5889+@%12YZ098D
M8[+=S?`6D2>@2R<;3'XKGN,C/S'98?>P1?OKCN>-!]'/7IB!+\`C1QTY^506
MBWQ_(T6MUAM,'Z%ICO!QOHD3+YPO[N)H>4><L\7+[7*,=AK*Z%MVDGRQFINA
M/?6B)<2238$GOI5A"G*`"_*83(CZF>%F"Y*TVA'B3\%J[^Q"!4+WX%M-JD%8
M!LRB(O(R43FTE(<QE".\?Q_L$?BAER1P`?U">@W^D14+Y0HD/H(;3C:;\C"&
M\HHW`*4[\E)SBH4J(E!MY#>.=/?QY-<VA&`&6S(]#1;B>RS>#B.+1NXSB?L9
ML4>")8'U$6QB=%"6)`\2N;Y&N**^G%X\;8[7TVTN$^/[D6R9A+L*NXSD[.`#
MV\%/2.?7!,P7UTD*UY@4YANIS4;.7C\V^Z&SUW>RUQ\O_LE8V[FH2`@`UN<@
M2`'5Z1:V/@E!<HU)B,W69R)(0<6V^%B?;2"%CX*-T_HH.BG`)-TBUN<$2^X^
MII7/^J1.N=7$<]G8FBFM!I&\_:O"RZX"Y:I[3N@GJ(":LJ3>S0%683=%X5TF
MN*%":,HRNJ3IM`)KRE*Z?%1&A=>4I79U_U>%VY2%=W4?:86;Y7*\"R%U(:2J
M(:3'[T<8S7PZ)D80`<IL/H:'&D6^579[6Z+V[(K-F93_U<"Q+=K[SJOIO)J2
M(B+G*)Z,@]/)@DX6U"8+YN@9R0HR+Q$ZF6I`&<5?@2`CM2QFF)"`/%T'M^`)
M^!G>,Q`DUZ]^F.%U7A2!7&^R?3J;JK`]P$1.!G4RJ)-!G0S*\AT,<+0YX=4)
MKTYX90BO59P*_O$*O)`X@R\>^@VD!#T2<9#NJNU'PG\`2O&!]8R\`.^WPE6L
MM0+4N"1''7E^28EK"TV^5*XP@&'^]*X<(1IZIW-:A9.23W$OJ9\'3FYV<K-R
MN*GNP]A)STYZ=M+SB:7GOI9C)T.?4H:V3`X\F&!(IL=1M@<&\&D5H_09H'4-
MVWR]REN3.P_LY&(G%SNYV,G%'>S)W0\S)P$["=A)P`P)^)!%6TFQB3,"MPLI
MUN`1B*S<+F/A0;H`)+6/$[6=:'F*HUQF]SEAT@F3JA4CZ`>ADQ.=G.CDQ"YR
MHC-W6B@MWD'O!8:Y`:>LL!/,R0/(&4(P6EYX"4R^1O%+`M"6?/[;:).EI'88
M7C@AS->FM)"I<RHGFQY;3@XP%^Z*611(X*UH$=8QAY/@G03O)'@GP4N9@[4<
M:I.1^.74(JTW_F1*A3IMRFE3JMK491SB.SLFQ?.VH/9._4B>XE4ACRZ"J(S@
MDA3'J#_,^SRR)U!Z]8SM]`5[]`4G#Q_=IUJWWQ0U+#496.G&FXS:X$1;)]H.
M*-K:Y39PXM^8Q3_&:\?EFR<D'?V)U#('2^C/PA#B60'?!J[<W8FK3ERU]HYT
MXNKIBI@KG5E.5G6RJI-5&;(J\X$.BPMBV"6F,K^@0`05]QL5-_*&=Z4AG$CJ
M1%)KKT+IH\&)FR+KJ-JYY$1.)W(ZD5.#R.GLHT[P-,Q-9W'3"9E.R'1"IA,R
M-0B93K1THJ43+66*F36?S[78B-G]IOT<Q\$W&(;X@&'C)9#AU,8P4W=-O!3H
MO,GT=#J`DS)/<?QWVJM3%+2<6*[EO7EGS70BIQ,Y-8N<=ADQIR%X6B:F54G#
M,((IN(-;T,)/M=Z!]$A.,'6"J1-,G6"J(IAV.K&<H.H$52>H,K.2UFM8E(<F
MKSC$>*%$2X`;`;UFTCXY]Q(4"N1#M3%,W/2*WZ$'FZZ^P,BE<B>C#GH_=#I/
MG(SJ9%3IC'FUD]R)ITX\=>*I%O&TKTEU&D*J$]Y.8E+-4ORYOL`(KK/U(]DW
MX8.WR[_N38SF&T`*043+.^`E@H1ZO6,[D=:)M$ZD=2)M1[-KGU/-2;I.TG62
M+D/2)4]$CL3BVB1%(+4R&INXMED0RA#NK*(C%ZR="#GH8<W?\TY6=+*BI*S(
M/(2=].>D/R?],:2_IQ3OD54<8NZ3XI5PTM8E*E%NU@(>@51ZU,A)41.4HDY*
MI^SV9;$@V]_DD4[?>4XV=+*AK!U1?ILX:=%)BTY:["LMNAPC)S/J<VE?KS=A
MO`/@":`M],'3"F_K"R\!P66\WH`H*0Z,,*<E+VE-WL!;1O`/$#P`O+]PNR1-
MY-W<NN<SBQZ=_'PKS_.C)IGY*=SB3ZT8#=!YX+'@47H09]\\%-3))F\O%M\X
M2;)U\;O.V/281,N#"D<T)8^`/!<)@IL8%4[56SP_J50N?ERAZU!.X[3/;N]T
M,J>3=7\QH?.A-!GUC*_/:KC<)_,<L#*2?<2""M4?'*I#B.X5P'^R&V!GGW'V
M&?58K@4&(0_$1?`E(U.3XIU)1R\>0Z,0ST+1'<2=7/S3**TP4]*C3DCG8=T+
MC(/M=D['&=.]Q-9Q)([)R6@S3I@Y#V'&#"[,LW`<YJ0Q27BW$6X-GKU7%Z)%
MK;+<0D=PO?)ZC(0#<8%H3A<GQDY0C#5PA$OLO'$<YDYN'H<(Q+4?\D]!)S4[
MJ7E44O.Y"(@N*FM<8J)E(M;!Z4-\.W%$5N-\<4#N^I7X>\`%B,`"IHKA-.HC
MFD7@JCQK,)5%;=A9%-Q![P6&,(7*95?41C,<J[=8`.)Q!H?/](B/)N+5PP=5
M"/.S4)']#D,Z%<,>2_E3MEY[:%?;^(U",\)U)-O=J4^C$P&=^M0S_*+#33P9
M[4H2PBX7FHNMZB4.N2`JM7O/Q40Y@X@SB#`,(H\@Q#\&#QY*=\_(BQ(L4Y'(
M38L=:';9%5@?4&"R$78;$R_RWCZ5$9P6;(^CS:E"1[>@[+$P1;U93=!4.I0F
MHQXZ6=/)F@/*FG;YXIS$.5:)LS+"L,A3],9(#N-D3R=[6GLK.ME3OXU8]GAR
M`J@30)T`RA!`_Y;A[0-0N#O\[39:Q&A=>*F<G7/,4B?WVTE'JJF.,CI.19*H
M9&<G?SKYT]I+L>-1X<11D3@J>S(Y(=0)H4X([26$.@.H$T7-BZ*5_8&_:M5L
MI"IC.4'5":K67IQ.4!W<;JIT;CFYU<FM3FYEO6Z0O23@]PS_>+TE_W;VTE$+
MJ9,28DZ:;]?<!@(IG]E\#+2+DP-9[9WX.*;[BR\+L3^ZDW><O#,J><<0+H(C
M?1SZ%E46_/-[0N&+EP#\C_\/4$L#!!0````(`&,P7$3>16SP;18```GV```1
M`!P`<F=L<RTR,#$S,3(S,2YX<V155`D``^IL$%/J;!!3=7@+``$$)0X```0Y
M`0``[3U=<]NVLN]GYOP'7#_<F\Y4EF4W:>-)>L:QG=8S=N1C*VW/>>G`)"1A
M0@$J"-K6^?5W`7X((DB(U(>#G.%+(I.[BUWL8K'8!<!W_WB>1>B1B)AR]OY@
M<'AT@`@+>$C9Y/W!Y_O>V?WYU=7!/W[^^]_>_4^OA^[NT`5GC$016:`_`A(1
M@25!(_S,&9\MT'TP)3/\/7K`,0D19^B/#W?7Z/AP@-!4ROEIO__T]'1(P@D6
M/<XBRLAAP&=]U.OE+?R6\G**WAP>`SO&FSN>L!">&X_.!<$2H%$(7)RBXZ/!
M#[VCX][QCZ/!3Z<GKT^/!O\VH?E\(>AD*M&KX#L`/GK=`XP3='=X=VB(];_H
MGK,8H&=SS!;H+(K0G<**T1V)B7@DX6%&--;2(NA"%K\_,`1\.CGD8M*')@;]
M/VZNTUXY^/O?4`I[^OP@(KJ"H9[D."=]RF*)64`,%.BK+PX,]5IUNMF(A9*Q
M-7C[]FU?OS6@D[@WP7A>P(]Q_*"ALQ=]U56]HT'O9+"*)1=S$E>BZ3?5>&(2
MK?:8(),D2F+QK.U!X0R.5S`8Z">95?=`*$5?-=8'H!Y`$4$#$W4]GH6C8$)9
MH)F=_;J?OC2@`S!-*1:KX#$)#B?\L9^]K.Z((!$"!EP=:O96X1Y;N"&AU6CP
MHKHU\AQ,JU'4FVH<RAY)+*NQTG?5>+&<BVHL]4;A#`P<B<6$R$]X1N(Y#DA3
MVP`'-"-,?N1B=D'&.(F`T;\2'-$Q)>$!PE(*^I!(L@*0L"7(SXK*.\P8E]J3
MZ+_5D_F<LC'/_H0':KB<"AZ1$1@,4C\^WUTYV)292^PKT/X%#Q+%*&;A)9-4
M+JZ`N)CI)@\0#=\?."$*-G)&0C*FC&J&!T<#U$,YNOD32*&4%C*(O>N7*92)
M)^"[A^QG_3O`49!$&O$:_LZ0,P@7XER`LV1R`\PE9_5XV=-<'[M2TSWPJPUJ
M./Y(&7A@BJ-;'FMFSB,<QYE=*87=`<*?#1'<^CL!I16$X/<''"GGC^ZGA,BX
MT]>V^KK%X$3EE$@*O=-:>1I[C09_<&H0O5KAX+M.HXTT>@5QZ(R<19((!D(\
MDFK5V6!N7;TNZ:KX'2,^1L.YBFBI"@"5^U1!H"!3PF(@C*YYW`W'9LJ[GX+)
M3WD40CA_^5<"<]`9"X<P!,1*EZ;*,Q0;T-[&5-QZ?^/4^SF'4$9(^A`1="O(
MF$#@%0(,#[YH0]"_,D[^#Z6\H%<04M"`RFY$[\$HZKSV%A;2Q)7_N$<SZ2:"
MC<SF',?3CQ%_BJ]82`4)9/5$8(.Y-?V36]-`#6ERG9;JM?2)2Q*/>!$^+?MP
M*":8T?]H<6#4Q#RBH?X#QN>M(:H1>RV1+V@<1#Q.!!F19_DA@D%EZ/P%&W5;
MT%NUVBJPX(_1E*`/24P9B>/O(0J,J;8EL^G4322S&18+]>Z>3AC$F0$&&SP+
M=*Z`L@FZ!=8#2CKCV\CX+K%@T(OQ+1%Z@FAG1?783G,8')7-X1.1.F9$0`EI
M4ITZ-U'GE4XS93\OR(.$X7R#Q1<B,4S$Z2Q[3X)$`.,DAI?G,$=CRD8"JT3V
M61R3S7W*WAIW&].@;$P&'YT5;6)%'S$5O^$H(<MNC=N9@IN"6Y_'97TJ8DA3
M0S<$JX>=;C?6[3F/(OS`A4X`G`F!V42_V'30MZ'GUOM)6>_W4I7,)C10E26J
MTD1YJJ%H$B*7S@PV,8-;P>?@?1>W$813X(J5=YYO8P>M"+H-X8>R(>2TTSQ]
M3OA[Q(CLM+]9F"!AG*JU^;8S_GHZ;EV_MB?OG"1*:79JWL+7SV8T#814M,7U
M@HDPM5K:W-VW(NE6_INR\@WJF:<WZ'<VL(D-J#A\4V77X;JU^J.MU64J4#>&
M;O%"+0DZC6ZB43-SFBZJ%.RF.FY.S:WUGUQ:+R6`O]<#G;/:='"6!N[L8[,1
M#TP1[9OUE@[@3@5E+5=PZZFX[<'*^&4$D4D1*9*=EC<+X52=9H2?-X_='`2<
MNCVVTG<I+;6YL9NF-U/G'8%.T%LHY&($B^@8!WIUNZEVV]!S*]M*KV6D>YHV
M,HEWJM]$]?],H".)B!;%.V,/6CNM-R3E5KB5?[LG$0E`XZ@@CPKZZ`)+W.E]
MHS@N>8C)7PG\O'Q4?[>,VVJQW=JULVP%(912ZK3I0Q4W+VM^E6INT;C;EJQ$
MW>ZKNNA5_JO;`[+;`N](K<";F=<Z&FXKL5)\=K$7O4HI=3KVJNK;PD3VS(+;
MPJP\HL%-9UK[*P6WL(\F=-Q*MM**-67A3N$O51]NH?[V5-W&8&4;F]6*.]MX
ML:)Q"^/8@*S;.JS<HZ.`W)G$OBO)K:*(IM2<!G!2D:"LJBIWNG_!\G*KV6(#
MPFZ+L+*8SE)S9Q@O4Z%L81-M:;K-P<IQ[J!:V1G-W@I:K::0M63<IF$E2,WB
M5J?CEZIRM5!Y>ZIN"[#2FO45K\X>7J#TU<(46A%T6X&5MEQ;!NN,H<G]'LM!
M.25YK4!7"H9CLTX`@5]6)1B.C1K!LD20UP7.PE!+LJ+J[*:0EVG+;4=6<G(/
M19(>6G)FWF"B#M1*3+OSL\TL\A;\"O0LCJ+%!8T2E:M:YJS!Z4`D$"4A":_8
M^;*'AF,-2\)/1*JJ1EXD*9O@;HF[;<[*E1J-H[QUM&Q>;<M$.0.(,F2PH.PO
M8V)9N9DO*S>=A;6PL)(:&_FN1CAN>[#2I14EN,Z'[$3#RXEDRH4<$3$SBE%E
MU;J!W3JUDISF?*'(]12]U5)8I\D6FBQ*5K]2(K`(IHN/7*390P@8KBE^H)'V
MGEGU*3R3!<J0W2GG*F"6UA-\6?$[I>VTDQ^L7*A1-RM:1S#<L\RHCCT,#O+B
M6HBP-''!,Q1\9%%,9U]M[`MZC\/B(:+93+].Z\6RH]*BMJ3FMJ&*/:!F:\KE
M-+.8Y=*ILY@M/))9[VX40[3`=%M"T\/973BQ*R?Q2%A"/@H^*TK<187;]@$N
M8+=BK;1G1@R-@5IE>;U39*NXT%*(+FV9NQ,:C>2-Z;C5;^4\&VZHZ(;Y;E<-
M^4X%<QM$[:JA$MBM9SNKN5PU5.^2Z#39+H=4H1-8;3<:VZUPW7JVLHYU6V!4
M)J`;Q+L=Q.5M++4#V`)T*]5*ZQF#U]KATBFOE?+*JF@Z9AOCN55K9>@J=BQU
M0W5GVG;L,&JD]=;X;NU;N3SW[J3."';KKS\F$OX\8RS!T0WP-4MFU["6);=X
MD6Y>YR*[[9I-](MZC[X!*:=IO+;2=X;/3QM#:6LH:PYILBAO4&?VBB;3E]W<
MT-9;%)O#]-:#[/J2AIZB!:[;%"KV,-9<K-)YB)TKOM@4J/?^I3L"]4^U><#8
M#IAM!FQK&SLA[S:?O>QY[`QM9_%(IO#\TUDP4Z3^_2J.$_V)JXH89"V.VR2L
MI-^*UG.J>@K)YIJ<<*??EMD_Z-#A7'%Q%DCZ2.7"3NS9(&[M5>3LE-I2&B@G
MTFFJE:9@L97,=`_&GZ'I$;^,)06?MBRA#,>&J@!(U6$C''RY#\`[DCA]?BO`
M/;+)#0])5-;T/IIP6XJ5]3-80(H')#G*N5@IV8U7C$H!ZW*O8J:7<9,;7,8/
MT@QU5M?>/WQ0GX)4'^,@+*[)_5="N75O90(UE9XF@TPZG<I:J:SF@K1&@5\K
M7+=ZK9Q@[3UK7:RVLUAMSMG*69,/A`%G\O)9#::J0&T-@EO%%5<KY@2-PRGH
M54;T.Y21[?2ZU7X<U8MJO[\Z79!(+A8?":Q]U-C,E'@K^"-5G^`=<0BVDJHW
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M]^KMJLVV9C9"<FNV8G]>Z7K6;K:&Q^J?!QS#>FJ,GO43"4#O#V(ZFT>P`$^?
M81$H_!7]/YT<<C'I#]Z^?=O74/UYNC,.'%X_)YL3L+"?'T2D\8^/CDY2HRGU
M7\953F$JR/C]@9A$<>_X:'`R.#X9_`D8A\^S*`>15*I6S".7BE#\/<)1=-#W
M5_)5-380'!`J!+\HR'PC<D?X@40-10;8"I&O%85O1-KR,&\@-*!4"+URP+U"
M]G=]/)]3\&?Z;_B+,9Y"IP]`="XD8GA&XCD.7(Q3%LNT9!H'4S+#USS0A!PH
MZJ]>CM=3CWJ#X][)X/`Y#C,6VW"P[.EV'.1X;3DP2;W6?X6R<=LY@FKT=:/F
MQCA^T-A)W%.6&?>5\GM'`^"WMEG=I(DYP7BN$?LDDG%!J[>DU;[W0RGZBDJ?
M)3,B:-"L$\I8JB?>JNX?O-F&!<YZ&[+!V:?-.*GLW^T5HYZTU8LF&Y/@<,(?
M^_K2"K%HS$X57O['=HPD0A`6:(K'K3@Q$8N_>DLR[7D)"6W=(3F.^K%51Y#G
M8-JZ]0))_]JJ?:I/IK?FP$#+?F_%12SG0A$;M.&A0-*_>DMTLWU8DNGS,XJ!
M]P=G02`2$F8K;WUSRZ+TQ0<UB?ZY!BX-`\`]@%\YE?GS*TEF*DH^0/@AE@('
M\OW!&$=ZH@>^Z2D$`)2'(XT<)B);OC"JSG*IN5E"FR`ZK#5@LM8EPU\$3^;O
M#U)T"O1KQ"J6(B,"ZTUY-8-PXU%#G$41?UIN7$JE:P2>"IDV/>,,5C5BL:&(
MZ;L''"G*\((\4+D;P2>"I'P_YX>Q4PE7GYNB`-N43:H$2;G8@:I">1I2:%W5
M8:[6\W[!9YBR*N[S-ROV%NJ'>Q7`V>416T1X=D-F#T283*\^]XIE^!V2U?.9
MNC`3J-%=]+8M4CL\KT2>"QJ-GOAHRI,8L_"23J85`KJ@O!)'M?9OPDB`;2'L
M=SZQ_H'R"6%7(0DLSNU7/C%^#JL@&N#(8KO\PBNFUXS52R:)(.$%EN:$V`HK
M%3=?)IV&\/"^=DYYF?F_=+$_P?$O`N9U$E;+6(8QIT<*CR9$?$U99K#D4BGS
M[%-*MOW50?AEB&4F:011,L11<0.!+%C?1%M[,?@U941Q&)?D;(/XPF';UC+K
MBT?;RILAO7R(.@5,$20/I#Y$-0XWW"8BF&+#)\;GL)ZK-.5&&+X9=,:T<:WP
M'5%ZT#]O=<O58KHQ3+7F/']=WYJQ_9L^!K=R2V99LA+(BB@DH#,<M9(D3>ON
M9MUG[KDJ-N5DJ_5L*T6-`VJ!YI?[6<=XA?-IB.*KZYDG$'7]BD7XI"[<9.$]
M'TOUL\KIK(/UR]VL'D:MD*<:P"<AU-?EKF!$BR2=W]126:<L5B-K-YB'H72)
MX1LLU>V\"\7O#4S@4["M?Q$LZD6LQS#'V40]TJ^_IJCI?M+LCK&[=$=:Y7RW
M'M2OB<[B5XT5L*M6,M;C^"ELL>FX]E->\+OZ5IR5#MB0SM;YXB)`V%NZN.;$
MS^5L'O$%(>9S%?@$JE`^(</Q942UJ/:QL+SC=D@V\_+@XN<I[%>UK"K!RA_)
M=G5"[''9Y`)&>L2U19]C%JJO-=O!A0O(KPEYR6<YG]`DV;TAOE==P(,D<T^7
ML-:6"V-?WEG&BBEQ(W"/5@&Y0UE97JM!-GH"H`7\&SW:!MP*RR=UIA\8JUK'
M66]\4I+FK;P:6WGJY8+K\EFF%<LTR#&VP^O;BDQ9UD'Z%1X5Y_FO&*P28RON
MJWGOF1#I24!K<)>>^S1\/ZK]I"2BC\0*%E=/Q56-\$V0/7("*?O75>S_3E21
ME81GL,2'*+!89GR.R3B)KNF86-VP,1W/;)@G0DYO:"#X'<,C+";$#D-<0#Y9
M]R\<^IVI![J,9LE1\]XK$>(O-MO+9SZQ^NOY;_D%V!;+%>]\8OUJ-DL8A]`R
MPC.(+;E8U$JR'M0KP?*D\AVLB%:/LU=Y]&;@'OEP!\/EZ&X]J)<AWY+M%9;3
M$ZM7S+@(J9R1KI2]/9&M4T8OL,6P1KY?8.BI;W<-&83#H,Z$QE.%I>X`>)#K
M^V<=_K?0-=?I?A+P4T5FT/)I#AB?G)E>N5P^SVE*LR;5[X3R+;V?7C*;WAB8
MW4J;7T=;Y9^;@7ODGQT,E_WS>E`O_;-F6WT_CC)-'KPF#8BU@'6#;;T&V&7=
M/LLBVB7/\@NO?`.'=9=,0NC>Z![^5]_\`.H`<(_504#PX3?Q:`K+L/G"%FP#
M9)^$S\N9>:ZG_H.*6MQFX.6Z;\;PUZ[]@FO@0N>!U7;/6`Z?&!'QE,X_+#[!
MU*TJ&QP"<C9)7RQ+.68';$[#H\+/)R*723V(4LZQ$(LQ%T]8A-=T1M,3H4/V
M.29&02L7-8W],D=K],U.J?K56[>"!X2$^LJ0_'9>.^+-+@9?[9*6J/L+#`-!
MPAU%AI\2Y<F&XRQ@RO+%V?6EIOAN.%/6K[XQ>1A(#LP:QR4@]*NIN32`]<G)
M#\=CF']58K6(UN_583U;KC6`7@E5YVJ6`7PIO&^,887Z7]$J]5C!43D(=&Q8
M:H[BVY)F*":8+6O2RP\WTPFC8)EJFTJ@CR>#$O6IS9KRPK:$/%H&W:IR[I"1
M_%3.2-"*.I$3RJ=1JQD%O]E`G#HHK\01)*@[1U7QSB_6.1]S%8@$9"YK]%`/
MXY,H=WIG&X[T9SQ*7^ZLWQ'3"LLO<2?J#B-5/U#'3IH?1&J+Z*?0#K'\9'QY
MPZ!QF.2"@GN0E7<2&E#Q[U1.30HK8N^6\+>0DE9?2\$B4"&,L:&MPB)<8'Y9
M1Q6G>GMI=E^TBN#6BF8C^+4WP/G1;)VCK=ISV@IK1:L>[#ZU]](7#O:&R"D/
M<WT5CP&4T,=2!F$[,EN/Z?UOVFYP/&&/QQ)VF?V^XPL<Z=QHEMO2G_\8LD]$
MWN-HI:JZ'M2C_-<]9GQ,S]3%F-0.*BK?^N1B4P9K^/:285`W!MI#9F=H*M[Y
MR#JLW6I9-][YQ?J4A$E$UM[R7Y5PV`39HR1#8_;+E=>VB%[689="7&*A]E@6
MIZ+!*T/$`9$6C1*88MV:;X[LI>;7L%^O^6:(GFO>^/2#6\O5@%YJU&"U7GLV
MD.>:VBBW6R__-N0\[RD]&N/:SY;6+KLVIN#;$LQ]_7_E.&^*X=.`=_)L67X3
M:#\-.YM<5C_,>":$VC>@X#XLEB#9_J\S5=XK]J@:'^1,U\[JJYR59K#WIGRR
MG_T(:QG>7IOY[[+8;(?$V60BR`1+<J4.73,(J])^>+#.NNZ]I?\&>\UDK3M9
MI8^V8_W)/95"W4,OMV[9JUZW=_J=S>"9^L;5.8]7^VDM[#>0F+13SJ5;B.L`
M7MX7-;B.V&;6NI>X'L2G/$VC*["_]8NOZ_G/-YZJHTB5.U3;HWJ4:E9.(STB
ML[QR:46VJM=^E;J,38'ICL#T;@!89ZL,^:.^FL'*C;9!\FHP`LEX./Z(@RS/
M5W*1->^]])`6KY:#K(7P226?6:"\.!=JLJT(8FK>>Q1J?&8A$4\"`(0U4"K>
M^=7YE1\5A7$L]!FE"Y+]N"-Q$JF4DBINWP(W(BUIJF].\UC7..,5L7=*=W]3
MX`XWF=?(/)IB^3M/HO`35[,<\'DY'A/U/<W\A.[Z?FM"8V\1Z@Z["!9IZL(J
MJKYRGM^I\('"$!!?*L9.(^BO.)K>]=//PL#/_P=02P$"'@,4````"`!C,%Q$
M"T4#A3TP`0#O*0T`$0`8```````!````I($`````<F=L<RTR,#$S,3(S,2YX
M;6Q55`4``^IL$%-U>`L``00E#@``!#D!``!02P$"'@,4````"`!C,%Q$Z\W8
MSYX4``"])0$`%0`8```````!````I(&(,`$`<F=L<RTR,#$S,3(S,5]C86PN
M>&UL550%``/J;!!3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`8S!<1/HJ
MQQG_3@``=@L&`!4`&````````0```*2!=44!`')G;',M,C`Q,S$R,S%?9&5F
M+GAM;%54!0`#ZFP04W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`&,P7$2[
MH$28O)```)5`"``5`!@```````$```"D@<.4`0!R9VQS+3(P,3,Q,C,Q7VQA
M8BYX;6Q55`4``^IL$%-U>`L``00E#@``!#D!``!02P$"'@,4````"`!C,%Q$
M-TMOA/)2``"8$`<`%0`8```````!````I('.)0(`<F=L<RTR,#$S,3(S,5]P
M<F4N>&UL550%``/J;!!3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`8S!<
M1-Y%;/!M%@``"?8``!$`&````````0```*2!#WD"`')G;',M,C`Q,S$R,S$N
M>'-D550%``/J;!!3=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``,>/
$`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Changes in Amount of Unrecognized Tax Benefits (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
        <td class="nump">$ 569<span></span></td>
        <td class="nump">$ 406<span></span></td>
        <td class="nump">$ 288<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Increase (decrease) for prior year tax positions</a></td>
        <td class="nump">137<span></span></td>
        <td class="nump">50<span></span></td>
        <td class="num">(29)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase for current year tax positions</a></td>
        <td class="nump">386<span></span></td>
        <td class="nump">113<span></span></td>
        <td class="nump">147<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Total</a></td>
        <td class="nump">$ 1,092<span></span></td>
        <td class="nump">$ 569<span></span></td>
        <td class="nump">$ 406<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized Tax Benefits, Increases (Decreases) Resulting from Prior Period Tax Positions</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxContingencyLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Unrecognized Tax Benefit<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems', window );"><strong>Finite-Lived Intangible Assets And Liabilities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible asset</a></td>
        <td class="nump">$ 0.1<span></span></td>
        <td class="nump">$ 0.1<span></span></td>
        <td class="nump">$ 0.1<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Intangible assets, amortization expense, next twelve months</a></td>
        <td class="nump">0.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Intangible assets, amortization expense, year two</a></td>
        <td class="nump">0.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Intangible assets, amortization expense, year three</a></td>
        <td class="nump">0.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Intangible assets, amortization expense, year four</a></td>
        <td class="nump">0.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Intangible assets, amortization expense, year five</a></td>
        <td class="nump">$ 0.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_FinitelivedIntangibleAssetsAndLiabilitiesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>2. Net Loss Per Share</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Basic net loss per share is calculated by dividing the net loss by
 the weighted average number of common shares outstanding for the
 period, without consideration for common stock equivalents. Diluted
 net loss per share is calculated by dividing the net loss by the
 weighted-average number of common share equivalents outstanding for
 the period determined using the treasury-stock method. Dilutive
 common stock equivalents are comprised of convertible preferred
 stock and options outstanding under our stock option plan. For all
 periods presented, there is no difference in the number of shares
 used to calculate basic and diluted shares outstanding due to our
 net loss position.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Potentially dilutive securities not included in the calculation of
 diluted net loss per share because to do so would be anti-dilutive
 are as follows (in common equivalent shares):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>Years ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Convertible preferred stock outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,699,999</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Common stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,639,270</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,883,311</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,338,250</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Convertible note payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,411,659</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,366,787</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,050,929</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,250,098</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,038,249</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In October 2012, all convertible preferred stock converted in
 conjunction with our initial public offering. For the year ended
 December&#xA0;31, 2011 we had convertible notes payable outstanding
 of $10.0 million that were convertible into convertible preferred
 stock upon the occurrence of various future preferred stock
 financing events at prices that were not determinable until the
 occurrence of the future events. As such, we have excluded those
 convertible notes payable from the table above. For the years ended
 December&#xA0;31, 2013 and 2012 we had a convertible note payable
 outstanding with a principal balance of $5.4 million that was
 convertible into common shares at $4.00 per share, at the option of
 the note holder. Those shares are included for the years ended
 December&#xA0;31, 2013 and 2012.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Operating Expenses From Related Party Activities (Detail) (Alnylam, USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Alnylam</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty', window );">Services performed or out-of-pocket expenses paid to Alnylam</a></td>
        <td class="nump">$ 550<span></span></td>
        <td class="nump">$ 2<span></span></td>
        <td class="nump">$ 8<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Related Party Transaction Direct Operating Expenses From Transactions With Related Party</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_RelatedPartyTransactionDirectOperatingExpensesFromTransactionsWithRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>35
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A
M,V,U.#8T.&8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A
M,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X
M,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0F%L86YC95]3:&5E
M=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"86QA
M;F-E7U-H965T<U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT<U]O9E]/<&5R871I;VYS7V%N
M9%]#/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1A
M=&5M96YT<U]O9E]#;VYV97)T:6)L95]0<F5F/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT<U]O9E]#;VYV97)T:6)L
M95]0<F5F,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-T871E;65N='-?;V9?0V%S:%]&;&]W<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E1H95]"=7-I;F5S<U]"87-I<U]O9E]0<F5S
M96YT83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYE
M=%],;W-S7U!E<E]3:&%R93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DEN=F5S=&UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N=',\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=')A=&5G:6-?06QL
M:6%N8V5S7V%N9%]#;VQL86(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M96YT7VYE=#PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?07-S
M971S7VYE=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N=F5R=&EB;&5?3F]T97-?4&%Y
M86)L93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O
M;G9E<G1I8FQE7U!R969E<G)E9%]3=&]C:U]#;SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E9FEN961?0V]N=')I8G5T:6]N7U!L
M86X\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O
M;65?5&%X97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y296QA=&5D4&%R='E?5')A;G-A8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4V5L96-T961?475A<G1E<FQY7T9I;F%N
M8VEA;%]$/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4W5B<V5Q=65N=%]%=F5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y4:&5?0G5S:6YE<W-?0F%S:7-?;V9?4')E<V5N=&$Q/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F5T7TQO<W-?
M4&5R7U-H87)E7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DEN=F5S=&UE;G1S7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S
M7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-T<F%T96=I8U]!;&QI86YC97-?86YD7T-O;&QA8C$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M
M96YT7VYE=%]486(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y);G1A;F=I8FQE7T%S<V5T<U]N971?5&%B;&5S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O
M;G1I;F=E;F-I97-?/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0V]N=F5R=&EB;&5?4')E9F5R<F5D7U-T;V-K7T-O,3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]4
M86)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y2
M96QA=&5D4&%R='E?5')A;G-A8W1I;VYS7U1A8FP\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S,N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y396QE8W1E9%]1=6%R=&5R;'E?1FEN
M86YC:6%L7T0Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^5&AE7T)U<VEN97-S7T)A<VES7V]F7U!R97-E;G1A,CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!O=&5N=&EA;&QY7T1I;'5T
M:79E7U-E8W5R:71I93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DYE=%],;W-S7U!E<E]3:&%R95]!9&1I=&EO;F%L7SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VAO
M<G1497)M7TEN=F5S=&UE;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D9A:7)?5F%L=65?2&EE<F%R8VAY7V9O<E]!<W-E=#PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970S.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E8V]N8VEL:6%T
M:6]N7V]F7TQI86)I;&ET:65S7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,"YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S7T%D9&ET:3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970T,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E=F5N=65?
M9G)O;5]3=')A=&5G:6-?06QL:6%N8SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-T<F%T96=I8U]!;&QI86YC97-?86YD7T-O;&QA
M8C(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM
M87)Y7V]F7U!R;W!E<G1Y7V%N9%]%<75I<&T\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#0N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M96YT7TYE
M=%]!9&0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=6UM87)Y7V]F7TEN=&%N9VEB;&5?07-S971S7T0\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#8N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G1A;F=I8FQE7T%S<V5T<U].971?
M061D:71I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T-#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#0X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]&=71U<F5?
M06YN=6%L7TUI;FEM/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#0Y+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0V]N=F5R=&EB;&5?3F]T97-?4&%Y86)L95]!9&1I/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#4P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N=F5R=&EB;&5?4')E
M9F5R<F5D7U-T;V-K7T-O,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D-O;6UO;E]3=&]C:U]297-E<G9E9%]F;W)?1G5T=3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970U,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K7T]P=&EO
M;E]!8W1I=FET>5]$971A:6P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3,N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y!<W-U;7!T:6]N<U]5<V5D7W1O7T5S=&EM871E7T8\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D
M7T-O;7!E;G-A=&EO;E]$971A:6P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-34N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y$969I;F5D7T-O;G1R:6)U=&EO;E]0;&%N7T%D9&D\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUP;VYE
M;G1S7TEN8V]M95]487A?0F5N969I=%\\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3<N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y296-O;F-I;&EA=&EO;E]O9E]%>'!E8W1E9%]3
M=&$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUP
M;VYE;G1S7V]F7T1E9F5R<F5D7U1A>%]!<W,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3DN:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?061D:71I;VYA;%])
M;F9O<FT\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-C`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#
M:&%N9V5S7VEN7T%M;W5N=%]O9E]5;G)E8V]G;FD\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C$N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7T]P97)A=&EN9U]%
M>'!E;G-E<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T-C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y396QE8W1E9%]1=6%R=&5R;'E?1FEN86YC:6%L7T0R/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#8S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N='-?
M061D:71I;VYA;%])/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#8T+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z
M4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*
M("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T
M96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX
M.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO
M>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^
M#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@
M=VET:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS
M8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X
M9B]7;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5654%%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M
M871I;VX@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&
M96(N(#`W+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,C@L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@26YF;W)M871I;VX@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<Q,"U+/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$
M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y$96,@,S$L#0H)
M"3(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<R,#$S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A
M;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B=&63QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4<F%D:6YG(%-Y;6)O;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)U)'3%,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U)%1U5,55,@5$A%4D%01554
M24-3($E.0RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,#`P,34P-34Q,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT
M($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!396%S;VYE
M9"!)<W-U97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=.;SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@0W5R<F5N="!297!O<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG665S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!6;VQU;G1A<GD@
M1FEL97)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3F\\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG06-C96QE<F%T960@1FEL97(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3
M=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#,L,38X+#`S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!0=6)L:6,@1FQO870\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,C4L,3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X
M,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P
M,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$51
M0T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D)A;&%N8V4@4VAE971S("A5
M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W
M+#@P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-#`L-34R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&]R="UT97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-BPQ.3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPU-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1R86-T
M<R!A;F0@;W1H97(@<F5C96EV86)L97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E<&%I9"!A;F0@;W1H97(@8W5R<F5N="!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#DX/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#(Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q-RPQ.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY."PY,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPW-C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,Q
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT86YG:6)L92!A<W-E=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PQ,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#$U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,RPP-C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#,L-3$X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-R=65D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!P;W)T
M:6]N(&]F(&1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L.#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`L-#4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,S<P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L
M-S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)T:6)L92!N;W1E<R!P87EA8FQE+"!A="!F86ER('9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PR-SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ,S0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E9F5R<F5D(')E=F5N=64L(&QE<W,@8W5R<F5N="!P;W)T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#<U-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M;&]N9RUT97)M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#0U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PV,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,2PT,C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W1O8VMH;VQD97)S)R!E<75I='DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,#$@<&%R
M('9A;'5E.R`R,#`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9"!A="!$96-E
M;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@-#$L-S@W+#,R-B!A;F0@,S4L.#,Q
M+#@P."!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!$96-E;6)E
M<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@
M8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<R+#4Q
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R,BPU,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U
M;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@W.2PP.#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-C`L-#$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@97%U:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,RPT-3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BPP.3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)S)R!E<75I='D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(S+#`V-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`S
M+#4Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T
M7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5#14%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D)A;&%N8V4@4VAE971S
M("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P
M87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#<X-RPS,C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PX,S$L.#`X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#$L-S@W+#,R-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#@S,2PX,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4R.#)B9#@R7S(Y
M,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T
M.&8O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2C-!1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@
M86YD($-O;7!R96AE;G-I=F4@3&]S<R`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P
M96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY2979E;G5E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5V96YU97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL-38Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPW,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S+#<X
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/<&5R871I;F<@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D
M979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL
M.30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`L,S0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3<L,C@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT,CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#DS,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C,W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-RPS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-2PR-S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PY,C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@
M;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L
M.#`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$R+#4W-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@W+#$S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@:6YC;VUE("AE>'!E
M;G-E*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT97)E<W0@86YD(&]T:&5R(&EN8V]M93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,CDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-#<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S@X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&]S<R!O;B!E>'1I;F=U:7-H;65N="!O9B!D96)T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PW,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M(&-H86YG92!I
M;B!V86QU92!O9B!C;VYV97)T:6)L92!N;W1E('!A>6%B;&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,30U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.38Y*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&)E
M9F]R92!I;F-O;64@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$X+#8Y,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q-RPT,3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-RPS.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@=&%X("AB96YE9FET
M*2!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3@L-C8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$W+#0P."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@W+#8P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@8V]M<')E
M:&5N<VEV92!L;W-S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5;G)E86QI>F5D(&=A:6X@*&QO<W,I(&]N('-H;W)T
M+71E<FT@:6YV97-T;65N=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#@P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!R96AE;G-I=F4@;&]S<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@L-C,R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W+#,Y,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#8X,BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!L;W-S('!E<B!S:&%R92P@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XT.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(N,3(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X-2XX
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E<R!U<V5D('1O(&-O;7!U=&4@8F%S:6,@86YD(&1I;'5T960@
M;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS."PT-SDL-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^."PR,3(L-3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#@L-3@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=')A=&5G:6,@06QL
M:6%N8V5S(&%N9"!#;VQL86)O<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=65S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E
M;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-38Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L
M-S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3,L-S8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y';W9E<FYM96YT($=R86YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V96YU97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E
M=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4R.#)B
M9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A
M,V,U.#8T.&8O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%459&
M2SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY3=&%T96UE;G1S(&]F($-O;G9E
M<G1I8FQE(%!R969E<G)E9"!3=&]C:R!A;F0@4W1O8VMH;VQD97)S)R!%<75I
M='D@*$1E9FEC:70I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@
M4VAA<F4@9&%T83PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E1O=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<FEE<R!!($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397)I97,@0B!0<F5F97)R960@4W1O
M8VL\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^26YI=&EA;"!0
M=6)L:6,@3V9F97)I;F<\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4')I=F%T92!0;&%C96UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB<CY);FET:6%L(%!U8FQI8R!/9F9E
M<FEN9SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@
M4W1O8VL\8G(^4')I=F%T92!0;&%C96UE;G0\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!P86ED
M+6EN(&-A<&ET86P\8G(^26YI=&EA;"!0=6)L:6,@3V9F97)I;F<\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!P86ED+6EN
M(&-A<&ET86P\8G(^4')I=F%T92!0;&%C96UE;G0\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^06-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N
M<VEV92!I;F-O;64@*&QO<W,I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D%C8W5M=6QA=&5D(&1E9FEC:70\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E(&%T($1E8RX@
M,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,R
M+#8Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4@870@
M1&5C+B`S,2P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,S0L-CDU*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S4L-#`Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N
M8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@,C`Q,#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(T+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0Y.2PY.3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O
M9B!O<'1I;VYS("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U,RPQ.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM
M;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A
M<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!L;W-S
M(&]N('-H;W)T+71E<FT@:6YV97-T;65N=',L(&YE="!O9B!T87@\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPV,#(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@W+#8P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T($1E8RX@,S$L
M(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0Q+#0Y-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PU.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0S+#`Q,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E("AI;B!S
M:&%R97,I(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34S+#$X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA
M;F-E(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,BPV.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L
M86YC92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L.3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#DY+#DY.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5F9F5C="!O9B`R+69O<BTQ('-P;&ET(&]N('-H87)E<R!O9B!P
M<F5F97)R960@<W1O8VL@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,BPT-3`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,C4P+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!O
M<'1I;VYS("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Y-"PS-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@=7!O;B!E>&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-34P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O
M9B!S:&%R97,@;V8@<')E9F5R<F5D('-T;V-K('1O(&-O;6UO;B!S=&]C:R`H
M:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R
M+#0U,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PR-#DL.3DY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-CDY+#DY.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G-I;VX@;V8@<VAA<F5S(&]F('!R969E<G)E9"!S=&]C:R!T;R!C;VUM;VX@
M<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#8Y,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,R
M+#8Y,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#(L-C<W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M
M;6]N('-T;V-K("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,BPW,S`L.3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#4L,#,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C`L-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PP,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PW-#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR
M96%L:7IE9"!L;W-S(&]N('-H;W)T+71E<FT@:6YV97-T;65N=',L(&YE="!O
M9B!T87@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$W+#0P."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$W+#0P."D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@
M;F]T97,@<&%Y86)L92!T;R!C;VUM;VX@<W1O8VL@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW,#,L,C8Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N=F5R<VEO;B!O9B!N;W1E<R!P87EA8FQE('1O(&-O;6UO;B!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L.#$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#@Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P
M,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#`Y,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(R+#4R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-C`L-#$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@*&EN('-H
M87)E<RD@870@1&5C+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-2PX,S$L.#`X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M;6]N('-T;V-K('5P;VX@97AE<F-I<V4@;V8@;W!T:6]N<R`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,R+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW,S(L-#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P
M;VX@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#0R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#0R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!U;F1E<B!%;7!L;WEE92!3=&]C:R!0=7)C:&%S92!0;&%N("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X
M+#`S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U;F1E<B!%
M;7!L;WEE92!3=&]C:R!0=7)C:&%S92!0;&%N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M;6]N('-T;V-K("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,3<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#4L-S<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0U+#<W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@;&]S<R!O;B!S
M:&]R="UT97)M(&EN=F5S=&UE;G1S+"!N970@;V8@=&%X/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q."PV-C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q."PV-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92!A="!$96,N(#,Q+"`R,#$S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DS+#0U-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$W,BPU,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@W.2PP.#<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC
M92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#<X-RPS,C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R
M.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V
M-#AF+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13%&/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T871E;65N=',@;V8@0V]N=F5R=&EB;&4@
M4')E9F5R<F5D(%-T;V-K(&%N9"!3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5F
M:6-I="D@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S
M+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^26YI=&EA;"!0=6)L
M:6,@3V9F97)I;F<\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:RQO9F9E<FEN9R!C;W-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,S0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L.#@V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X
M,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C
M-3@V-#AF+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14950D<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1A=&5M96YT<R!O9B!#87-H($9L
M;W=S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY/<&5R871I;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q."PV-C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-RPT
M,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@W+#8P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE
M(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S8P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQO<W,@9G)O;2!C:&%N9V4@:6X@=F%L=64@;V8@8V]N=F5R=&EB;&4@;F]T
M92!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$T
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L.38Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]S<R!O;B!E>'1I;F=U:7-H;65N="!O9B!D96)T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I
M;VX@;V8@<')E;6EU;2!O;B!I;G9E<W1M96YT<RP@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0V-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!I;G9E
M<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPT,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!D:7-P;W-A
M;"!O9B!L;VYG+71E<FT@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG92!I;B!O<&5R871I;F<@87-S
M971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')A8W1S(&%N9"!O=&AE<B!R96-E
M:79A8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-SDI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R97!A:60@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,BPR.#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$S-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@V,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,T-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8W)U960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@U,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,U-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPX
M,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH."PR,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R96YT(&%N9"!O=&AE<B!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@L,S,P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L-S(Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U+#`V
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^26YV97-T:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5S(&]F
M('-H;W)T+71E<FT@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<R+#`P-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V,BPP-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3`L-C8S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%T=7)I=&EE<R!A
M;F0@<V%L97,@;V8@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L.34Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L,#@S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L-3@U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C
M:&%S97,@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,34Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0V-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<75I<VET:6]N
M(&]F(&EN=&%N9VEB;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R-S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H("AU<V5D(&EN*2!P<F]V:61E9"!B
M>2!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-#`L.#@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,P+#,X-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,R-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&:6YA;F-I
M;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;G9E
M<G1I8FQE(&YO=&5S('!A>6%B;&4@86YD(&]T:&5R(&QO;F<M=&5R;2!O8FQI
M9V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&YE
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4L.3@P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4L-S@X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')I;F-I<&%L('!A>6UE;G1S(&]N(&]T:&5R(&QO;F<M=&5R;2!O8FQI
M9V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0T
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@T,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C:7-E(&]F(&-O;6UO;B!S=&]C
M:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!F:6YA;F-I
M;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#8L-#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S`L-#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,S4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="`H9&5C<F5A<V4I(&EN8W)E87-E(&EN
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(R+#<T-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,2PS-S<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPP.3,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C
M87-H(&5Q=6EV86QE;G1S(&%T(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#4U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,C8X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&%T(&5N9"!O9B!P97)I;V0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#@P-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#4U,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3<U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E(&]F(&-A<V@@9FQO
M=R!I;F9O<FUA=&EO;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G1E<F5S="!P86ED/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S('!A:60\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L
M96UE;G1A;"!D:7-C;&]S=7)E<R!O9B!N;VXM8V%S:"!I;G9E<W1I;F<@86YD
M(&9I;F%N8VEN9R!A8W1I=FET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@;F]T97,@<&%Y
M86)L92!T;R!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,"PX,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@9F]R('1E;F%N="!I;7!R;W9E
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8U,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M;W5N=',@86-C<G5E9"!F;W(@<&%T96YT(&5X<&5N9&ET=7)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B
M7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF
M+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E1H92!"=7-I;F5S<RP@0F%S:7,@;V8@4')E<V5N
M=&%T:6]N(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@
M4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1H92!"=7-I;F5S<RP@0F%S:7,@;V8@4')E<V5N=&%T:6]N(&%N9"!3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M
M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB
M/C$N(%1H92!"=7-I;F5S<RP@0F%S:7,@;V8@4')E<V5N=&%T:6]N(&%N9"!3
M=6UM87)Y(&]F#0H@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB
M;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@4F5G=6QU<R!4:&5R87!E
M=71I8W,@26YC+B!W87,@;W)I9VEN86QL>2!F;W)M960@87,@82!$96QA=V%R
M90T*(&QI;6ET960@;&EA8FEL:71Y(&-O;7!A;GD@=6YD97(@=&AE(&YA;64@
M4F5G=6QU<R!4:&5R87!E=71I8W,@3$Q##0H@;VX@4V5P=&5M8F5R)B-X03`[
M-BP@,C`P-RP@=VAE;B!!;&YY;&%M(%!H87)M86-E=71I8V%L<RP@26YC+@T*
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M8W)O/"]I/E).07,@<'5R<W5A;G0@=&\@82!L:6-E;G-E(&%N9`T*(&-O;&QA
M8F]R871I;VX@86=R965M96YT+B!296=U;'5S(%1H97)A<&5U=&EC<R!);F,N
M('=A<R!C;VYV97)T960@=&\-"B!A($1E;&%W87)E(&-O<G!O<F%T:6]N(&]N
M($IA;G5A<GDF(WA!,#LR+"`R,#`Y+B!!<R!U<V5D(&EN('1H:7,-"B!R97!O
M<G0L('5N;&5S<R!T:&4@8V]N=&5X="!S=6=G97-T<R!O=&AE<G=I<V4L("8C
M>#(P,4,[=&AE#0H@0V]M<&%N>2PF(W@R,#%$.R`F(W@R,#%#.V]U<BPF(W@R
M,#%$.R`F(W@R,#%#.W5S)B-X,C`Q1#L@86YD#0H@)B-X,C`Q0SMW928C>#(P
M,40[(&UE86YS(%)E9W5L=7,@5&AE<F%P975T:6-S($EN8RX\+W`^#0H@/'`@
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M<VEN9R!O=7(-"B`\:3YM:6-R;SPO:3Y23D$@<')O9'5C="!P;&%T9F]R;2!T
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M97,L(&)I;VQO9VEC<R!A;F0@;6]N;V-L;VYA;`T*(&%N=&EB;V1I97,N/"]P
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O
M;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*(#QB/CQI/E5S92!O9B!%<W1I;6%T97,\+VD^/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP
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M(&]N(&]U<B!K;F]W;&5D9V4@;V8@8W5R<F5N=`T*(&5V96YT<R!A;F0@86-T
M:6]N<R!W92!M87D@=6YD97)T86ME(&EN('1H92!F=71U<F4L(&%C='5A;"!R
M97-U;'1S#0H@;6%Y('5L=&EM871E;'D@9&EF9F5R(&9R;VT@=&AE<V4@97-T
M:6UA=&5S(&%N9"!A<W-U;7!T:6]N<RX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P
M<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^4F5V
M96YU92!296-O9VYI=&EO;CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z
M-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86XG/@T*($]U<B!R979E;G5E<R!G96YE<F%L;'D@8V]N<VES="!O9B!U<&9R
M;VYT('!A>6UE;G1S(&9O<B!L:6-E;G-E<R!O<@T*(&]P=&EO;G,@=&\@;V)T
M86EN(&QI8V5N<V5S(&EN('1H92!F=71U<F4L(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N=`T*(&9U;F1I;F<@86YD(&UI;&5S=&]N92!P87EM96YT<R!U;F1E
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M)B-X03`[9&5L:79E<GD@;V8@=&AE('!R;V1U8W1S(&%N9"]O<B!S97)V:6-E
M<R!H87,@;V-C=7)R960[#0H@*#,I)B-X03`[=&AE('-E;&QI;F<@<')I8V4@
M:7,@9FEX960@;W(@9&5T97)M:6YA8FQE.R!A;F0-"B`H-"DF(WA!,#MC;VQL
M96-T86)I;&ET>2!I<R!R96%S;VYA8FQY(&%S<W5R960N/"]P/@T*(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E
M>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B!-=6QT:7!L92!E;&5M96YT(&%R<F%N9V5M96YT
M<RP@<W5C:"!A<R!O=7(@<W1R871E9VEC(&%L;&EA;F-E#0H@86=R965M96YT
M<R!W:71H(%-A;F]F:2P@07-T<F%:96YE8V$@04(@*"8C>#(P,4,[07-T<F%:
M96YE8V$F(W@R,#%$.RD-"B!A;F0@1VQA>&]3;6ET:$ML:6YE('!L8R`H)B-X
M,C`Q0SM'4TLF(W@R,#%$.RDL(&%R92!A;F%L>7IE9"!T;PT*(&1E=&5R;6EN
M92!W:&5T:&5R('1H92!D96QI=F5R86)L97,@=VET:&EN('1H92!A9W)E96UE
M;G0@8V%N(&)E#0H@<V5P87)A=&5D(&]R('=H971H97(@=&AE>2!M=7-T(&)E
M(&%C8V]U;G1E9"!F;W(@87,@82!S:6YG;&4@=6YI="!O9@T*(&%C8V]U;G1I
M;F<N($1E;&EV97)A8FQE<R!U;F1E<B!T:&4@86=R965M96YT('=I;&P@8F4@
M86-C;W5N=&5D(&9O<@T*(&%S('-E<&%R871E('5N:71S(&]F(&%C8V]U;G1I
M;F<@<')O=FED960@=&AA="`H:2DF(WA!,#MA(&1E;&EV97)E9`T*(&ET96T@
M:&%S('9A;'5E('1O('1H92!C=7-T;VUE<B!O;B!A('-T86YD+6%L;VYE(&)A
M<VES.R!A;F0-"B`H:6DI)B-X03`[:68@=&AE(&%G<F5E;65N="!I;F-L=61E
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M:79E9"!U<VEN9R!A("8C>#(P,4,[8F5S=`T*(&5S=&EM871E(&]F('-E;&QI
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M;VYS:61E<F%T:6]N(')E8V5I=F5D('5N9&5R('1H92!A<G)A;F=E;65N=`T*
M(&%S(')E=F5N=64@;VX@82!S=')A:6=H="UL:6YE(&)A<VES(&]V97(@;W5R
M(&5S=&EM871E9"!P97)I;V0@;V8-"B!P97)F;W)M86YC92P@=VAI8V@@9F]R
M('5S(&ES(&]F=&5N('1H92!E>'!E8W1E9"!T97)M(&]F('1H90T*(')E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!P;&%N+CPO<#X-"B`\<"!S='EL93TS1&9O
M;G0M<VEZ93HQ.'!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#L@
M;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*(#QI/DUI;&5S=&]N97,\+VD^/"]P/@T*
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*(%=E(')E8V]G;FEZ92!R979E;G5E(&9R
M;VT@;6EL97-T;VYE('!A>6UE;G1S('=H96X@96%R;F5D+"!P<F]V:61E9`T*
M('1H870@*&DI)B-X03`[=&AE(&UI;&5S=&]N92!E=F5N="!I<R!S=6)S=&%N
M=&EV92!I;B!T:&%T(&ET(&-A;@T*(&]N;'D@8F4@86-H:65V960@8F%S960@
M:6X@=VAO;&4@;W(@:6X@<&%R="!O;B!E:71H97(@;W5R#0H@<&5R9F]R;6%N
M8V4@;W(@;VX@=&AE(&]C8W5R<F5N8V4@;V8@82!S<&5C:69I8R!O=71C;VUE
M(')E<W5L=&EN9PT*(&9R;VT@;W5R('!E<F9O<FUA;F-E(&%N9"!I=',@86-H
M:65V86)I;&ET>2!W87,@;F]T(')E87-O;F%B;'D-"B!A<W-U<F5D(&%T('1H
M92!I;F-E<'1I;VX@;V8@=&AE(&%G<F5E;65N="P@*&EI*28C>$$P.W=E(&1O
M(&YO="!H879E#0H@;VYG;VEN9R!P97)F;W)M86YC92!O8FQI9V%T:6]N<R!R
M96QA=&5D('1O('1H92!A8VAI979E;65N="!O9B!T:&4-"B!M:6QE<W1O;F4@
M86YD("AI:6DI)B-X03`[:70@=V]U;&0@<F5S=6QT(&EN('1H92!R96-E:7!T
M(&]F#0H@861D:71I;VYA;"!P87EM96YT<RX@02!M:6QE<W1O;F4@<&%Y;65N
M="!I<R!C;VYS:61E<F5D('-U8G-T86YT:79E#0H@:68@86QL(&]F('1H92!F
M;VQL;W=I;F<@8V]N9&ET:6]N<R!A<F4@;65T.B`H:2DF(WA!,#MT:&4@;6EL
M97-T;VYE#0H@<&%Y;65N="!I<R!N;VXM<F5F=6YD86)L93L@*&EI*28C>$$P
M.V%C:&EE=F5M96YT(&]F('1H92!M:6QE<W1O;F4-"B!W87,@;F]T(')E87-O
M;F%B;'D@87-S=7)E9"!A="!T:&4@:6YC97!T:6]N(&]F('1H92!A<G)A;F=E
M;65N=#L-"B`H:6EI*28C>$$P.W-U8G-T86YT:79E(&5F9F]R="!I<R!I;G9O
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M=&EO;G,N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R
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M:6]N+"!T;R!C;&EN:6-A;`T*('1R:6%L+"!T;R!R96=U;&%T;W)Y(&%P<')O
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M8W0@8V%N9&ED871E(&=E;F5R86QL>0T*(&EN8W)E87-E<RX\+W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@
M9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^
M#0H@/&D^1W)A;G0@4F5V96YU93PO:3X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R
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M=&AA=`T*(&9U;F1I;F<@:7,@87!P<F]V960N($%N>2!A;6]U;G1S(')E8V5I
M=F5D(&EN(&%D=F%N8V4@;V8@<&5R9F]R;6%N8V4-"B!A<F4@<F5C;W)D960@
M87,@9&5F97)R960@<F5V96YU92!U;G1I;"!E87)N960N/"]P/@T*(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*
M(#QI/D1E9F5R<F5D(%)E=F5N=64\+VD^/"]P/@T*(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z
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M8F4@<F5C;V=N:7IE9"!W:71H:6X@=&AE#0H@;F5X="`Q,B!M;VYT:',@87)E
M(&-L87-S:69I960@87,@;F]N+6-U<G)E;G0@9&5F97)R960@<F5V96YU92X\
M+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T
M=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;B<^#0H@/&(^/&D^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]I
M/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I
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M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[
M('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N)SX-"B!792!A8V-O=6YT(&9O<B!S=&]C:R!O<'1I
M;VYS(&=R86YT960@=&\@;F]N+65M<&QO>65E<RP@=VAI8V@-"B!P<FEM87)I
M;'D@8V]N<VES="!O9B!M96UB97)S(&]F(&]U<B!S8VEE;G1I9FEC(&%D=FES
M;W)Y(&)O87)D+`T*('5S:6YG('1H92!F86ER('9A;'5E(&%P<')O86-H+B!3
M=&]C:R!O<'1I;VYS(&=R86YT960@=&\-"B!N;VXM96UP;&]Y965S(&%R92!S
M=6)J96-T('1O('!E<FEO9&EC(')E=F%L=6%T:6]N(&]V97(@=&AE:7(-"B!V
M97-T:6YG('1E<FUS+CPO<#X-"B`\<"!S='EL93TS1&9O;G0M<VEZ93HQ.'!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T/@T*("8C>$$P.SPO
M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#L@;6%R9VEN+6)O='1O
M;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*(#QB/CQI/E)E<V5A<F-H(&%N9"!$979E;&]P;65N=#PO:3X\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM
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M9F]R;65D+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA
M<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y);F-O;64@5&%X97,\+VD^/"]B
M/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O
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M>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E
M>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B!792!U<V4@=&AE(&QI86)I;&ET>2!M971H;V0@
M;V8@86-C;W5N=&EN9R!F;W(@:6YC;VUE('1A>&5S+B!5;F1E<@T*('1H:7,@
M;65T:&]D+"!D969E<G)E9"!T87@@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A
M<F4@9&5T97)M:6YE9`T*(&)A<V5D(&]N('1H92!D:69F97)E;F-E(&)E='=E
M96X@=&AE(&9I;F%N8VEA;"!R97!O<G1I;F<@86YD('1H92!T87@-"B!R97!O
M<G1I;F<@8F%S:7,@;V8@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A;F0@87)E
M(&UE87-U<F5D('5S:6YG#0H@=&AE(&5N86-T960@=&%X(')A=&5S(&%N9"!L
M87=S('1H870@87)E(&5X<&5C=&5D('1O(&)E(&EN(&5F9F5C=`T*('=H96X@
M=&AE(&1I9F9E<F5N8V5S(&%R92!E>'!E8W1E9"!T;R!R979E<G-E+B!792!P
M<F]V:61E(&$-"B!V86QU871I;VX@86QL;W=A;F-E(&%G86EN<W0@;F5T(&1E
M9F5R<F5D('1A>"!A<W-E=',@=6YL97-S+"!B87-E9`T*('5P;VX@=&AE(&%V
M86EL86)L92!E=FED96YC92P@:70@:7,@;6]R92!L:6ME;'D@=&AA;B!N;W0@
M=&AA="!T:&4-"B!D969E<G)E9"!T87@@87-S971S('=I;&P@8F4@<F5A;&EZ
M960N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN
M+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*(#QB/CQI/D9A:7(@5F%L=64@3W!T:6]N/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB
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M#0H@:6YS=')U;65N="P@,BD@:7)R979O8V%B;&4L(&%N9"`S*2!A<'!L:65D
M('1O(&%N(&5N=&ER90T*(&EN<W1R=6UE;G0N/"]P/@T*(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD
M96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N)SX-"B!);B!*=6QY(#(P,3(L('=E(&%M96YD960@86YD(')E<W1A
M=&5D(&]U<B`D-2XP(&UI;&QI;VX@8V]N=F5R=&EB;&4-"B!P<F]M:7-S;W)Y
M(&YO=&4@;W)I9VEN86QL>2!I<W-U960@:6X@1F5B<G5A<GD@,C`Q,"!T;R!'
M4TL-"B`H)B-X,C`Q0SLR,#$P($=32R!N;W1E)B-X,C`Q1#LI+"!W:&EC:"!W
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M86)L92!T;R!N;VXM;W!E<F%T:6YG(&5A<FYI;F=S+CPO<#X-"B`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT
M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\
M8CX\:3Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]I/CPO8CX\+W`^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T
M.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;B<^#0H@5V4@8VQA<W-I9GD@=&EM92!D97!O<VET
M<R!A;F0@;W1H97(@:6YV97-T;65N=',@=&AA="!A<F4@:&EG:&QY#0H@;&EQ
M=6ED(&%N9"!H879E(&UA='5R:71I97,@;V8@.3`@9&%Y<R!O<B!L97-S(&%T
M('1H92!D871E(&]F#0H@<'5R8VAA<V4@87,@8V%S:"!E<75I=F%L96YT<RX@
M5&AE(&-A<G)Y:6YG(&%M;W5N=',@87!P<F]X:6UA=&4@9F%I<@T*('9A;'5E
M(&1U92!T;R!T:&4@<VAO<G0@;6%T=7)I=&EE<R!O9B!T:&5S92!I;G-T<G5M
M96YT<RX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G
M:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^4VAO<G0M5&5R;2!);G9E<W1M96YT
M<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M
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M="!O9@T*('-T;V-K:&]L9&5R<R8C>#(P,3D[(&5Q=6ET>2`H9&5F:6-I="DN
M(%=E(&1E=&5R;6EN92!T:&4@<F5A;&EZ960-"B!G86EN<R!O<B!L;W-S97,@
M;V8@879A:6QA8FQE+69O<BUS86QE('-E8W5R:71I97,@=7-I;F<@=&AE('-P
M96-I9FEC#0H@:61E;G1I9FEC871I;VX@;65T:&]D(&%N9"!I;F-L=61E(&YE
M="!R96%L:7IE9"!G86EN<R!A;F0@;&]S<V5S(&EN#0H@:6YT97)E<W0@:6YC
M;VUE+CPO<#X-"B`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!T.VUA<F=I;BUT
M;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T/@T*("8C>$$P.SPO<#X-"B`\<"!S
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M($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@86YD(#(P,3(N/"]P/@T*(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*
M(#QB/CQI/D-O;F-E;G1R871I;VYS(&]F($-R961I="!2:7-K/"]I/CPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T
M;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@1FEN86YC:6%L(&EN<W1R=6UE
M;G1S('1H870@<&]T96YT:6%L;'D@<W5B:F5C="!U<R!T;R!S:6=N:69I8V%N
M=`T*(&-O;F-E;G1R871I;VYS(&]F(&-R961I="!R:7-K(&-O;G-I<W0@<')I
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M9"!G=6ED96QI;F5S(')E9V%R9&EN9R!A<'!R;W9E9`T*(&EN=F5S=&UE;G1S
M(&%N9"!M871U<FET:65S(&]F(&EN=F5S=&UE;G1S+"!W:&EC:"!A<F4@9&5S
M:6=N960@=&\-"B!M86EN=&%I;B!S869E='D@86YD(&QI<75I9&ET>2X\+W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M
M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@/&(^/&D^4')O<&5R='D@86YD($5Q=6EP;65N=#PO:3X\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T
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M=&AE(&5S=&EM871E9"!U<V5F=6P@;&EV97,-"B`H9V5N97)A;&QY('1H<F5E
M('1O(&9I=F4@>65A<G,I+B!,96%S96AO;&0@:6UP<F]V96UE;G1S(&%R90T*
M(&%M;W)T:7IE9"!O=F5R('1H92!L97-S97(@;V8@=&AE:7(@=7-E9G5L(&QI
M9F4@;W(@=&AE(')E;6%I;FEN9PT*(&QE87-E('1E<FTL(&EN8VQU9&EN9R!A
M;GD@<F5N97=A;"!P97)I;V1S('1H870@87)E(&1E96UE9"!T;R!B90T*(')E
M87-O;F%B;'D@87-S=7)E9"X@4F5P86ER(&%N9"!M86EN=&5N86YC92!C;W-T
M<R!T:&%T(&1O(&YO=`T*(&EM<')O=F4@<V5R=FEC92!P;W1E;G1I86P@;W(@
M97AT96YD(&5C;VYO;6EC(&QI9F4@87)E(&5X<&5N<V5D(&%S#0H@:6YC=7)R
M960N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN
M+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*(#QB/CQI/DEN=&%N9VEB;&5S/"]I/CPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ
M,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5V4@8V%P:71A;&EZ92!C;W-T<R!W
M:&EC:"!C;VYS:7-T('!R:6YC:7!A;&QY(&]F(&]U='-I9&4@;&5G86P-"B!C
M;W-T<R!A;F0@9FEL:6YG(&9E97,@<F5L871E9"!T;R!O8G1A:6YI;F<@<&%T
M96YT<RX@5V4@<F5V:65W(&]U<@T*(&-A<&ET86QI>F5D('!A=&5N="!C;W-T
M<R!P97)I;V1I8V%L;'D@=&\@9&5T97)M:6YE('1H870@=&AE>0T*(&EN8VQU
M9&4@8V]S=',@9F]R('!A=&5N="!A<'!L:6-A=&EO;G,@=&AA="!H879E(&9U
M='5R92!V86QU92!A;F0@86X-"B!A;'1E<FYA=&EV92!F=71U<F4@=7-E+B!7
M92!E=F%L=6%T92!C;W-T<R!R96QA=&5D('1O('!A=&5N=',@=&AA=`T*('=E
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M87)S(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3,N/"]P/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M
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M;G0L#0H@=VAI8V@@9F]R(&-U<G)E;G0@;&EC96YS97,@:7,@,3`@>65A<G,N
M/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O
M='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86XG/@T*(#QB/CQI/DEM<&%I<FUE;G0@;V8@3&]N9RU,:79E9"!!
M<W-E=',\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
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M;F<@=F%L=65S(&]R(&5S=&EM871E9`T*('5S969U;"!L:79E<RX@268@:6YD
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M9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L(#(P,3(@86YD(#(P,3$N/"]P
M/@T*(#QP('-T>6QE/3-$9F]N="US:7IE.C$X<'0[;6%R9VEN+71O<#HP<'0[
M;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^
M0VQI;FEC86P@5')I86P@86YD(%!R92U#;&EN:6-A;"!3='5D>2!!8V-R=6%L
M<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M
M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ
M,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%=E(&UA:V4@
M97-T:6UA=&5S(&]F(&]U<B!A8V-R=65D(&5X<&5N<V5S(&%S(&]F(&5A8V@@
M8F%L86YC92!S:&5E=`T*(&1A=&4@:6X@;W5R(&9I;F%N8VEA;"!S=&%T96UE
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M(&5F9F]R="!T;R!B92!E>'!E;F1E9`T*(&EN(&5A8V@@<&5R:6]D+B!)9B!P
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M86QS+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I
M;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y396=M96YT(%)E<&]R=&EN9SPO:3X\
M+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM
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M92!5;FET960@4W1A=&5S+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y#;VUP<F5H96YS
M:79E($QO<W,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P
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M<')E:&5N<VEV92!G86EN<R`H;&]S<V5S*2!H879E(&)E96X@<F5F;&5C=&5D
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M)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ
M93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/CQI
M/E)E8VQA<W-I9FEC871I;VYS/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
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M>2`H9&5F:6-I="D@;W(-"B!S=&%T96UE;G1S(&]F(&-A<V@@9FQO=W,N/"]P
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O
M;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*(#QB/CQI/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE
M;G1S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[
M(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@26X@2G5L
M>2`R,#$S+"!T:&4@1D%30B!I<W-U960@06-C;W5N=&EN9R!3=&%N9&%R9',@
M57!D871E#0H@3F\N)B-X03`[,C`Q,RTQ,2P@/&D^4')E<V5N=&%T:6]N(&]F
M(&%N(%5N<F5C;V=N:7IE9"!487@@0F5N969I=`T*(%=H96X@82!.970@3W!E
M<F%T:6YG($QO<W,@0V%R<GEF;W)W87)D+"!A(%-I;6EL87(@5&%X($QO<W,L
M(&]R(&$-"B!487@@0W)E9&ET($-A<G)Y9F]R=V%R9"!%>&ES=',\+VD^("@F
M(W@R,#%#.T%352`R,#$S+3$Q)B-X,C`Q1#LI+@T*(%1H:7,@=7!D871E('!R
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M#0H@1&5C96UB97(F(WA!,#LQ-2P@,C`Q,RP@=VET:"!A;B!O<'1I;VX@9F]R
M(&5A<FQY(&%D;W!T:6]N+B!790T*(&EN=&5N9"!T;R!A9&]P="!T:&ES(&=U
M:61A;F-E(&EN(#(P,30L(&%N9"!D;R!N;W0@8F5L:65V92!T:&4-"B!A9&]P
M=&EO;B!O9B!T:&ES('-T86YD87)D('=I;&P@:&%V92!A(&UA=&5R:6%L(&EM
M<&%C="!O;B!O=7(-"B!F:6YA;F-I86P@8V]N9&ET:6]N+"!R97-U;'1S(&]F
M(&]P97)A=&EO;G,@;W(@<F5L871E9"!F:6YA;F-I86P-"B!S=&%T96UE;G0@
M9&ES8VQO<W5R97,N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?
M83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R
M.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S
M+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY.970@3&]S<R!097(@4VAA<F4\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S(%!E<B!3:&%R93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HP<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z
M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CXR+B!.
M970@3&]S<R!097(@4VAA<F4\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[
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M)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD
M96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N)SX-"B!0;W1E;G1I86QL>2!D:6QU=&EV92!S96-U<FET:65S(&YO
M="!I;F-L=61E9"!I;B!T:&4@8V%L8W5L871I;VX@;V8-"B!D:6QU=&5D(&YE
M="!L;W-S('!E<B!S:&%R92!B96-A=7-E('1O(&1O('-O('=O=6QD(&)E(&%N
M=&DM9&EL=71I=F4-"B!A<F4@87,@9F]L;&]W<R`H:6X@8V]M;6]N(&5Q=6EV
M86QE;G0@<VAA<F5S*3H\+W`^#0H@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P
M=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#X-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0X-"4@8F]R9&5R/3-$,"!S='EL93TS1"="3U)$15(M0T],3$%0
M4T4Z0T],3$%04T4[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N
M="US:7IE.C$P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0U-R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HX<'0G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(^/&(^665A<G,@96YD960-"B!$
M96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HX<'0G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CXR,#$S/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/C(P,3(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,3PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS1"=F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@0V]N=F5R=&EB;&4@<')E9F5R
M<F5D('-T;V-K(&]U='-T86YD:6YG/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/@T*("8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$S+#8Y.2PY.3D\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z
M,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ
M93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($-O;6UO
M;B!S=&]C:R!O<'1I;VYS/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,RPV,SDL,C<P/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$L.#@S+#,Q,3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR+#,S."PR-3`\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*($-O;G9E<G1I8FQE(&YO=&4@<&%Y86)L93PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-#$Q+#8U.3PO=&0^#0H@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,V-BPW.#<\+W1D/@T*
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@[/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P
M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP
M,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P
M<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[
M(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5&]T86P\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N
M="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C4L,#4P+#DR.3PO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP
M=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C,L,C4P+#`Y.#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V
M+#`S."PR-#D\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS
M+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P
M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P
M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@
M;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z
M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);B!/8W1O
M8F5R(#(P,3(L(&%L;"!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@8V]N
M=F5R=&5D(&EN#0H@8V]N:G5N8W1I;VX@=VET:"!O=7(@:6YI=&EA;"!P=6)L
M:6,@;V9F97)I;F<N($9O<B!T:&4@>65A<B!E;F1E9`T*($1E8V5M8F5R)B-X
M03`[,S$L(#(P,3$@=V4@:&%D(&-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4@
M;W5T<W1A;F1I;F<-"B!O9B`D,3`N,"!M:6QL:6]N('1H870@=V5R92!C;VYV
M97)T:6)L92!I;G1O(&-O;G9E<G1I8FQE('!R969E<G)E9`T*('-T;V-K('5P
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M.S,Q+"`R,#$S(&%N9"`R,#$R('=E(&AA9"!A(&-O;G9E<G1I8FQE(&YO=&4@
M<&%Y86)L90T*(&]U='-T86YD:6YG('=I=&@@82!P<FEN8VEP86P@8F%L86YC
M92!O9B`D-2XT(&UI;&QI;VX@=&AA="!W87,-"B!C;VYV97)T:6)L92!I;G1O
M(&-O;6UO;B!S:&%R97,@870@)#0N,#`@<&5R('-H87)E+"!A="!T:&4@;W!T
M:6]N(&]F#0H@=&AE(&YO=&4@:&]L9&5R+B!4:&]S92!S:&%R97,@87)E(&EN
M8VQU9&5D(&9O<B!T:&4@>65A<G,@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$S(&%N9"`R,#$R+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^26YV97-T;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CXS+B!);G9E<W1M96YT
M<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I
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M97,N($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L(&]U<@T*('-H;W)T
M+71E<FT@:6YV97-T;65N=',@:&%D(&$@=V5I9VAT960@879E<F%G92!M871U
M<FET>2!O9B!L97-S('1H86X-"B!T=V\@>65A<G,N/"]P/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M
M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%1H
M92!F;VQL;W=I;F<@=&%B;&5S('-U;6UA<FEZ92!O=7(@<VAO<G0M=&5R;2!I
M;G9E<W1M96YT<R`H:6X-"B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS
M1&9O;G0M<VEZ93HQ,G!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
M,'!T/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,"!S='EL93TS
M1"="3U)$15(M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G(&%L:6=N/3-$8V5N=&5R/@T*
M(#QT<CX-"B`\=&0@=VED=&@],T0V-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[(&9O;G0M<VEZ93HX<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!R;W=S
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CY-871U<FET>3QB<B`O/@T*("AI
M;B8C>$$P.WEE87)S*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M<F]W<W!A;CTS1#(^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!R;W=S<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CY!;6]R=&EZ
M960\8G(@+SX-"B!C;W-T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!R;W=S<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/E5N<F5A;&EZ960\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@<F]W<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^
M17-T:6UA=&5D/&)R("\^#0H@9F%I<B8C>$$P.W9A;'5E/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,CXF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M+C`P<'0@<V]L:60@(S`P,#`P,#L@=VED=&@Z.#0N,C!P=#L@9F]N="US:7IE
M.CAP=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CY!<R!O
M9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S/"]B/CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^1V%I;G,\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^3&]S<V5S
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;B<^#0H@0V]R<&]R871E(&1E8G0@<V5C=7)I=&EE<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(F(WA!,#MO<B8C>$$P
M.VQE<W,\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<Q+#0P,CPO
M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,SD\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
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M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[
M(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@0V5R=&EF:6-A=&5S
M(&]F(&1E<&]S:70\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M(&]R(&QE<W,\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3$L-S$P/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PW,3`\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I
M>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M
M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M
M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($-O
M;6UE<F-I86P@<&%P97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ(&]R(&QE<W,\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-BPP-CD\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,#<Q/"]T9#X-"B`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N)SX-"B!$96)T('-E8W5R:71I97,@;V8@52Y3+B!G;W9E<FYM96YT
M+7-P;VYS;W)E9"!A9V5N8VEE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$@;W(@;&5S<SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XW+#`P,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RPP,#$\
M+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I
M>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L
M:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI
M9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#
M0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F
M;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[
M(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG
M/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ
M93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^.38L,3@Q/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0R/"]T9#X-"B`\
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M='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.38L,3DX/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#L^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P
M,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P
M,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X
M(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X
M(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE
M/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O
M;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P('-T>6QE
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M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(')O
M=W-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/DUA='5R:71Y/&)R("\^#0H@
M*&EN)B-X03`[>65A<G,I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!R;W=S<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(')O=W-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/D%M;W)T
M:7IE9#QB<B`O/@T*(&-O<W0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(')O=W-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^56YR96%L:7IE9#PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!R;W=S<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\
M8CY%<W1I;6%T960\8G(@+SX-"B!F86ER)B-X03`[=F%L=64\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.R!F;VYT+7-I>F4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X-"B`\<"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C$N,#!P="!S;VQI9"`C,#`P,#`P.R!W:61T:#HX-"XR,'!T.R!F;VYT+7-I
M>F4Z.'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/D%S
M(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+V(^/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CY'86EN<SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CY,;W-S
M97,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N)SX-"B!#;W)P;W)A=&4@9&5B="!S96-U<FET:65S
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,B!O<B!L97-S/"]T
M9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-"PX.3@\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C<\+W1D/@T*(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
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M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@0V5R=&EF:6-A=&5S(&]F(&1E<&]S
M:70\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ)B-X03`[;W(F
M(WA!,#ML97-S/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C8L,C`P/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#(P,#PO=&0^#0H@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS
M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P
M<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@0V]M;65R8VEA
M;"!P87!E<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(@;W(@
M;&5S<SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#0Y
M,CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPT.3(\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P
M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S
M;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O
M;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP
M,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P
M<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3<L-3DP/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I
M>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C<\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#0Y/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE
M.CAP=#XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU
M-RPU-#@\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F
M;VYT+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N
M,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N
M,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T
M.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS
M8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9A:7(@
M5F%L=64@365A<W5R96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB
M/C0N($9A:7(@5F%L=64@365A<W5R96UE;G1S/"]B/CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!4
M15A4+4E.1$5.5#H@-"4G/@T*(%=E(&AA=F4@8V5R=&%I;B!F:6YA;F-I86P@
M87-S971S(&%N9"!L:6%B:6QI=&EE<R!R96-O<F1E9"!A="!F86ER#0H@=F%L
M=64@=VAI8V@@:&%V92!B965N(&-L87-S:69I960@87,@3&5V96P@,2P@,B!O
M<B`S('=I=&AI;B!T:&4@9F%I<@T*('9A;'5E(&AI97)A<F-H>2!A<R!D97-C
M<FEB960@:6X@=&AE(&%C8V]U;G1I;F<@<W1A;F1A<F1S(&9O<B!F86ER#0H@
M=F%L=64@;65A<W5R96UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!!<'!L:6-A8FQE(&%C8V]U;G1I;F<@9W5I9&%N8V4@9&5F:6YE
M<R!F86ER('9A;'5E(&%S('1H92!E>&-H86YG90T*('!R:6-E('1H870@=V]U
M;&0@8F4@<F5C96EV960@9F]R(&%N(&%S<V5T(&]R('!A:60@=&\@=')A;G-F
M97(@80T*(&QI86)I;&ET>2`H86X@97AI="!P<FEC92D@:6X@=&AE('!R:6YC
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M("AI*28C>$$P.VEN9&5P96YD96YT+"`H:6DI)B-X03`[:VYO=VQE9&=E86)L
M92P@*&EI:2DF(WA!,#MA8FQE('1O#0H@=')A;G-A8W0L(&%N9"`H:78I)B-X
M03`[=VEL;&EN9R!T;R!T<F%N<V%C="X@5&AE(&=U:61A;F-E('!R;W9I9&5S
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M96-T(&]U<B!A<W-U;7!T:6]N<R!A8F]U=`T*('1H92!F86-T;W)S('1H870@
M;6%R:V5T('!A<G1I8VEP86YT<R!W;W5L9"!U<V4@:6X@=F%L=6EN9R!T:&4@
M87-S970-"B!O<B!L:6%B:6QI='DN(%1H92!G=6ED86YC92!P<FEO<FET:7IE
M<R!T:&4@:6YP=71S('5S960@:6X@;65A<W5R:6YG#0H@=&AE(&9A:7(@=F%L
M=64@:6YT;R!T:&4@9F]L;&]W:6YG(&AI97)A<F-H>3H\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#9P=#L@34%2
M1TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\
M='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y,979E;"`Q(&EN8VQU9&5S
M(&9I;F%N8VEA;`T*(&EN<W1R=6UE;G1S(&9O<B!W:&EC:"!Q=6]T960@;6%R
M:V5T('!R:6-E<R!F;W(@:61E;G1I8V%L#0H@:6YS=')U;65N=',@87)E(&%V
M86EL86)L92!I;B!A8W1I=F4@;6%R:V5T<RX\+W1D/@T*(#PO='(^#0H@/"]T
M86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@-G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B
M;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^
M)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/DQE
M=F5L(#(@:6YC;'5D97,@9FEN86YC:6%L#0H@:6YS=')U;65N=',@9F]R('=H
M:6-H('1H97)E(&%R92!I;G!U=',@;W1H97(@=&AA;B!Q=6]T960@<')I8V5S
M#0H@:6YC;'5D960@=VET:&EN($QE=F5L(#$@=&AA="!A<F4@;V)S97)V86)L
M92!F;W(@=&AE(&EN<W1R=6UE;G0@<W5C:`T*(&%S('%U;W1E9"!P<FEC97,@
M9F]R('-I;6EL87(@:6YS=')U;65N=',@:6X@86-T:79E(&UA<FME=',L('%U
M;W1E9`T*('!R:6-E<R!F;W(@:61E;G1I8V%L(&]R('-I;6EL87(@:6YS=')U
M;65N=',@:6X@;6%R:V5T<R!W:71H#0H@:6YS=69F:6-I96YT('9O;'5M92!O
M<B!I;F9R97%U96YT('1R86YS86-T:6]N<R`H;&5S<R!A8W1I=F4-"B!M87)K
M971S*2!O<B!M;V1E;"UD<FEV96X@=F%L=6%T:6]N<R!I;B!W:&EC:"!S:6=N
M:69I8V%N="!I;G!U=',@87)E#0H@;V)S97)V86)L92!O<B!C86X@8F4@9&5R
M:79E9"!P<FEN8VEP86QL>2!F<F]M+"!O<B!C;W)R;V)O<F%T960@8GDL#0H@
M;V)S97)V86)L92!M87)K970@9&%T82X\+W1D/@T*(#PO='(^#0H@/"]T86)L
M93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@-G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D
M97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X
M,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/DQE=F5L
M(#,@:6YC;'5D97,@9FEN86YC:6%L#0H@:6YS=')U;65N=',@9F]R('=H:6-H
M(&9A:7(@=F%L=64@:7,@9&5R:79E9"!F<F]M('9A;'5A=&EO;@T*('1E8VAN
M:7%U97,@:6X@=VAI8V@@;VYE(&]R(&UO<F4@<VEG;FEF:6-A;G0@:6YP=71S
M(&%R90T*('5N;V)S97)V86)L92P@:6YC;'5D:6YG(&UA;F%G96UE;G0F(W@R
M,#$Y.W,@;W=N(&%S<W5M<'1I;VYS+CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T
M)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE('!R97-E;G1S(&]U<B!F86ER('9A
M;'5E(&AI97)A<F-H>2!F;W(@87-S971S#0H@86YD(&QI86)I;&ET:65S(&UE
M87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,@870-
M"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S(&%N9"`R,#$R("AI;B!T:&]U<V%N
M9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR
M)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0U.24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI
M9VX],T1C96YT97(^/&(^1F%I<B!V86QU92!A<R!O9B!$96-E;6)E<B8C>$$P
M.S,Q+`T*(#(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&(^5&]T86P\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#$\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#(\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L
M)B-X03`[,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@07-S971S.CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V%S:"!E<75I=F%L96YT<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-RPQ-S`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$W+#$W,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@0V]R<&]R871E(&1E8G0@<V5C=7)I=&EE<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<Q+#0Q-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<Q+#0Q-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#97)T:69I8V%T97,@;V8@9&5P;W-I
M=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+#<Q,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+#<Q,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$
M96)T('-E8W5R:71I97,@;V8@52Y3+B!G;W9E<FYM96YT+7-P;VYS;W)E9"!A
M9V5N8VEE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<L,#`Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RPP,#$\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V]M;65R8VEA;"!P87!E
M<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,#<Q/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPP-S$\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ,3,L,S8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+#$W,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XY-BPQ.3@\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@3&EA8FEL:71I97,Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;G9E<G1I8FQE(&YO
M=&5S('!A>6%B;&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PR-SD\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q
M+#(W.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T
M9#X-"B`\=&0@8V]L<W!A;CTS1#$V/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQB/D9A
M:7(@=F%L=64@87,@;V8@1&5C96UB97(F(WA!,#LS,2P-"B`R,#$R/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CY,979E;"8C>$$P.S$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#(\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L)B-X03`[,SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V%S:"!E<75I=F%L96YT<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
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M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(WA!
M,#LF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@0V]R<&]R871E(&1E8G0@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C0T+#@U-CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C0T+#@U-CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#97)T:69I8V%T97,@;V8@
M9&5P;W-I=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,C`P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPR,#`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V]M;65R8VEA;"!P87!E
M<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-#DR/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPT.3(\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XY-BPY,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,SDL,S8S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4W+#4T.#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($QI86)I;&ET:65S.CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0U
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0U/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!#;VYV97)T:6)L92!N;W1E<R!P87EA8FQE/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,3`L,3,T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PQ,S0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!4:&4@9F]L;&]W
M:6YG('1A8FQE('!R97-E;G1S(&$@<F5C;VYC:6QI871I;VX@;V8@=&AE(&QI
M86)I;&ET:65S#0H@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A('%U87)T
M97)L>2!B87-I<R!U<VEN9R!S:6=N:69I8V%N=`T*('5N;V)S97)V86)L92!I
M;G!U=',@*$QE=F5L(#,I(&9R;VT@1&5C96UB97(F(WA!,#LS,2P@,C`Q,B!T
M;PT*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@*&EN('1H;W5S86YD<RDZ/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N
M/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<S
M)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,24^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX-"B`\8CY&86ER)B-X03`[5F%L=64F(WA!,#M-96%S=7)E;65N=',\
M8G(@+SX-"B!5<VEN9R!3:6=N:69I8V%N=#QB<B`O/@T*(%5N;V)S97)V86)L
M92!);G!U=',\8G(@+SX-"B`H3&5V96P@,RD\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($)A;&%N8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PQ,S0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
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M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PQ-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($)A;&%N8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$Q+#(W.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M8FED<R!A;F0O;W(@;V9F97)S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!);B!*=6QY)B-X03`[,C`Q,BP@=V4@86UE;F1E9"!A;F0@<F5S
M=&%T960@=&AE(#(P,3`@1U-+($YO=&4L('=H:6-H#0H@<F5S=6QT960@:6X@
M82!D96)T(&5X=&EN9W5I<VAM96YT(&9O<B!A8V-O=6YT:6YG('!U<G!O<V5S
M+@T*($-O;F-U<G)E;G1L>2!W:71H('1H92!D96)T(&5X=&EN9W5I<VAM96YT
M+"!W92!E;&5C=&5D('1H92!F86ER#0H@=F%L=64@;W!T:6]N(&9O<B!T:&4@
M,C`Q,"!'4TL@3F]T92X@5&AE(&%M96YD960@86YD(')E<W1A=&5D(#(P,3`-
M"B!'4TL@3F]T92!P<F]V:61E9"!F;W(@82!R;VQL;W9E<B!I;G1O(&$@;F5W
M('!R;VUI<W-O<GD@;F]T92P-"B!E9F9E8W1I=F4@87,@;V8@=&AE(&-L;W-I
M;F<@9&%T92!O9B!A('%U86QI9GEI;F<@:6YI=&EA;"!P=6)L:6,-"B!O9F9E
M<FEN9R`H=&AE("8C>#(P,4,[4&]S="U)4$\@1U-+($YO=&4F(W@R,#%$.RDN
M($EN($]C=&]B97(@,C`Q,BP-"B!U<&]N(&]U<B!I;FET:6%L('!U8FQI8R!O
M9F9E<FEN9RP@=&AE(%!O<W0M25!/($=32R!.;W1E('=A<PT*(&5S=&%B;&ES
M:&5D+"!A;F0@=&AE(#(P,3`@1U-+($YO=&4@=V%S('-I;75L=&%N96]U<VQY
M(&-A;F-E;&QE9"!A;F0-"B!O8FQI9V%T:6]N<R!T:&5R971O('=E<F4@=&5R
M;6EN871E9"X@5V4@=F%L=65D('1H92`R,#$P($=32R!.;W1E(&%T#0H@2G5L
M>2`R,#$R+"8C>$$P.U-E<'1E;6)E<B`R,#$R(&%N9"!A="!T:&4@97AT:6YG
M=6ES:&UE;G0@9&%T92X@5V4-"B!V86QU960@=&AE(%!O<W0M25!/($=32R!.
M;W1E(&5A8V@@<75A<G1E<B!S:6YC92!T:&%T(&1A=&4N(%=E#0H@<F5C;W)D
M960@82`D,2XW(&UI;&QI;VX@;&]S<R!O;B!E>'1I;F=U:7-H;65N="!O9B!D
M96)T("AT:&4-"B!D:69F97)E;F-E(&)E='=E96X@=&AE(&]R:6=I;F%L("0U
M+C`@;6EL;&EO;B!C87)R>6EN9R!V86QU92!A;F0@=&AE#0H@=&AE;B!F86ER
M('9A;'5E*2!I;B!*=6QY(#(P,3(N($EN('-U8G-E<75E;G0@<&5R:6]D<RP@
M8VAA;F=E<R!I;@T*(&9A:7(@=F%L=64@:&%V92!B965N(')E8V]R9&5D(&]N
M(&$@<75A<G1E<FQY(&)A<VES(&EN(&YO;BUO<&5R871I;F<-"B!E87)N:6YG
M<RX@5V4@<F5C;W)D960@82!L;W-S(&9R;VT@8VAA;F=E(&EN('9A;'5E(&]F
M('1H90T*(&-O;G9E<G1I8FQE(&YO=&4@<&%Y86)L92!O9B`D,2XQ(&UI;&QI
M;VX@86YD("0S+C`@;6EL;&EO;B!O;B!T:&4-"B!S=&%T96UE;G1S(&]F(&]P
M97)A=&EO;G,@86YD(&-O;7!R96AE;G-I=F4@;&]S<R!F;W(@=&AE('EE87)S
M(&5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!A;F0@,C`Q,BX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU4
M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5V4@=7-E9"!A;B!I;F-O
M;64@87!P<F]A8V@@:6X@=&AE(&9O<FT@;V8@82!C;VYV97)T:6)L92!B;VYD
M#0H@=F%L=6%T:6]N(&UO9&5L('1O('9A;'5E('1H92!N;W1E+B!4:&4@8V]N
M=F5R=&EB;&4@8F]N9"!M;V1E;`T*(&-O;G-I9&5R960@=&AE(&1E8G0@86YD
M(&]P=&EO;B!C:&%R86-T97)I<W1I8W,@;V8@=&AE(&YO=&4N(%1H92!K97D-
M"B!I;G!U=',@=&\@=&AE(&UO9&5L(&%S(&]F($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3,@86YD(#(P,3(@=V%S#0H@=F]L871I;&ET>2`H-C8E(&%N9"`W-24L
M(')E<W!E8W1I=F5L>2DL(')I<VLM9G)E92!R871E("@P+C,R-24@86YD#0H@
M,"XT,C$E+"!R97-P96-T:79E;'DI+"!A;F0@8W)E9&ET('-P<F5A9"`H-RXT
M)2!A;F0@.2XU)2P-"B!R97-P96-T:79E;'DI+B!4:&4@=F]L871I;&ET>2!I
M;G!U=',@=V5R92!B87-E9"!O;B!H:7-T;W)I8V%L(&%N9`T*(&EM<&QI960@
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M;VUP87)A8FQE('-T<F%I9VAT(&1E8G0-"B!I;G-T<G5M96YT<RX\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E
M,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T<F%T96=I8R!!;&QI
M86YC97,@86YD($-O;&QA8F]R871I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=')A=&5G:6,@06QL:6%N8V5S(&%N9"!#
M;VQL86)O<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM
M8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@/&(^-2X@4W1R871E9VEC($%L;&EA;F-E<R!A;F0@
M0V]L;&%B;W)A=&EO;G,\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O
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M<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[
M/"]P/@T*(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$.#0E(&)O<F1E<CTS1#`@<W1Y;&4],T0G0D]21$52+4-/3$Q!
M4%-%.D-/3$Q!4%-%.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O
M;G0M<VEZ93HQ,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I
M9'1H/3-$-C<E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z.'!T)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/EEE87(@96YD960-"B!$
M96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HX<'0G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CXR,#$S/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/C(P,3(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,3PO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS1"=F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@4V%N;V9I+4%V96YT:7,\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34L,S,V/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ,"PP,S`\+W1D/@T*(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$P+#`S,SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M
M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N
M="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@
M1U-+/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PW-S@\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PY.38\+W1D/@T*
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPW,S0\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P
M="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ
M,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($%S=')A6F5N
M96-A/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PX-3D\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-34Y/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ
M+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*($)I;V=E;B!)9&5C/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-3DV/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$Q-3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US:7IE
M.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED
M(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@
M(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N
M,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(]
M,T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Y+#4V.3PO=&0^#0H@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ,BPW,#`\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3,L
M-S8W/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N
M="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X
M(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X
M(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/"]T86)L93X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I
M;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B`\8CY386YO9FD\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI
M;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86XG/@T*($EN($IU;'D@,C`Q,BP@=V4@86UE;F1E9"!A;F0@<F5S
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M+"!W:&EC:"!R97%U:7)E9`T*('1H92!A<'!L:6-A=&EO;B!O9B!T:&4@;F5W
M(&%U=&AO<FET871I=F4@9W5I9&%N8V4@861O<'1E9"!B>2!U<R!I;@T*($IA
M;G5A<GD@,C`Q,2!F;W(@;75L=&EP;&4@96QE;65N="!A<G)A;F=E;65N=',N
M(%=E(&1E=&5R;6EN960@=&AA=`T*('1H92!E;&5M96YT<R!W:71H:6X@=&AE
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M<F%T96=I8R!A;&QI86YC90T*('=I=&@@4V%N;V9I.B`H,2DF(WA!,#MA(&QI
M8V5N<V4@9F]R('5P('1O(&9O=7(@/&D^;6EC<F\\+VD^4DY!#0H@=&%R9V5T
M<SL@86YD("@R*28C>$$P.V$@<F5S96%R8V@@;&EC96YS92!U;F1E<B!O=7(@
M=&5C:&YO;&]G>0T*(&%L;&EA;F-E+CPO<#X-"B`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT
M)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;B<^#0H@26X@2G5N92`R,#$S+"!T:&4@;W)I9VEN86P@<F5S96%R8V@@=&5R
M;2!E>'!I<F5D+"!U<&]N('=H:6-H('=E(&%N9`T*(%-A;F]F:2!E;G1E<F5D
M(&EN=&\@86X@;W!T:6]N(&%G<F5E;65N="!P=7)S=6%N="!T;R!W:&EC:"!W
M90T*(&=R86YT960@4V%N;V9I(&%N(&5X8VQU<VEV92!R:6=H="!T;R!N96=O
M=&EA=&4@=&AE(&-O+61E=F5L;W!M96YT#0H@86YD(&-O;6UE<F-I86QI>F%T
M:6]N(&]F(&-E<G1A:6X@;V8@;W5R('5N96YC=6UB97)E9`T*(#QI/FUI8W)O
M/"]I/E).02!P<F]G<F%M<R!A;F0@=V4@=V5R92!G<F%N=&5D('1H92!E>&-L
M=7-I=F4@<FEG:'0@=&\-"B!N96=O=&EA=&4@=VET:"!386YO9FD@9F]R(&-O
M+61E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9@T*(&-E<G1A
M:6X@;6E2+3(Q(&%N=&DM;6E2<R!I;B!O;F-O;&]G>2!A;F0@06QP;W)T)B-X
M,C`Q.3MS(%-Y;F1R;VUE+@T*($EN($IU;'D@,C`Q,RP@=V4@<F5C96EV960@
M86X@=7!F<F]N="!P87EM96YT(&]F("0R+C4@;6EL;&EO;BP@;V8-"B!W:&EC
M:"`D,2XR-2!M:6QL:6]N(&ES(&-R961I=&%B;&4@86=A:6YS="!F=71U<F4@
M86UO=6YT<R!P87EA8FQE(&)Y#0H@4V%N;V9I('1O('5S('5N9&5R(&%N>2!F
M=71U<F4@8V\M9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N#0H@
M86=R965M96YT('=E(&5N=&5R('!U<G-U86YT('1O('1H92!O<'1I;VX@86=R
M965M96YT+B!4:&4-"B!N;VXM8W)E9&ET86)L92!P;W)T:6]N(&]F('1H:7,@
M<&%Y;65N="P@)#$N,C4@;6EL;&EO;BP@:7,@8F5I;F<-"B!R96-O9VYI>F5D
M(&%S(')E=F5N=64@;W9E<B!T:&4@;W!T:6]N('!E<FEO9"!F<F]M('1H92!E
M9F9E8W1I=F4-"B!D871E(&]F('1H92!O<'1I;VX@86=R965M96YT(&EN($IU
M;F4@,C`Q,R!T:')O=6=H('1H92!E>'!I<F%T:6]N(&]F#0H@=&AE(&]P=&EO
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M97)M(&%N9`T*('-U8G-E<75E;G0@;W!T:6]N(&%G<F5E;65N="P@=V4@<F4M
M979A;'5A=&5D(&]U<B!E<W1I;6%T960@<&5R:6]D#0H@;V8@<&5R9F]R;6%N
M8V4@86YD(&%R92!N;W<@86UO<G1I>FEN9R!T:&4@<F5M86EN:6YG(&1E9F5R
M<F5D#0H@<F5V96YU92!A<W-O8VEA=&5D('=I=&@@=&AE(&EN:71I86P@=7!F
M<F]N="!P87EM96YT(&]F("0R-2XP#0H@;6EL;&EO;B!R871A8FQY(&9R;VT@
M2G5N92`R,#$S('1H<F]U9V@@=&AE(&5X<&ER871I;VX@;V8@=&AE(&]P=&EO
M;@T*('!E<FEO9"X@1&5F97)R960@<F5V96YU92!A="!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$S('=A<R`D,BXR#0H@;6EL;&EO;BX\+W`^#0H@/'`@<W1Y;&4]
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M<R!T;R!S96QE8W0@861D:71I;VYA;`T*(#QI/FUI8W)O/"]I/E).02!T87)G
M971S+B!792!C86X@96%R;B!A('!R96-L:6YI8V%L(&UI;&5S=&]N92!O9@T*
M("0Q-2XP)B-X03`[;6EL;&EO;B!U<&]N('1H92!F:6QI;F<@;V8@86X@26YV
M97-T:6=A=&EO;F%L($YE=R!$<G5G#0H@87!P;&EC871I;VX@*"8C>#(P,4,[
M24Y$)B-X,C`Q1#LI(&9O<B!T:&4@<V5L96-T960@/&D^;6EC<F\\+VD^4DY!
M#0H@=&%R9V5T+B!792!C86X@86QS;R!R96-E:79E(&UI;&5S=&]N92!P87EM
M96YT<R!O9B!U<"!T;R`D,S,N,`T*(&UI;&QI;VX@9F]R(&-L:6YI8V%L(&UI
M;&5S=&]N97,@86YD('5P('1O("0Q-C4N,"!M:6QL:6]N(&9O<@T*(')E9W5L
M871O<GD@86YD(&-O;6UE<F-I86P@;6EL97-T;VYE<RX@26X@861D:71I;VXL
M('=E(&%R92!E;G1I=&QE9`T*('1O(')E8V5I=F4@<F]Y86QT:65S(&)A<V5D
M(&]N(&$@<&5R8V5N=&%G92!O9B!N970@<V%L97,@=VAI8V@@=VEL;`T*(')A
M;F=E(&9R;VT@."!T;R`Q,B4L(&1E<&5N9&EN9R!U<&]N('1H92!V;VQU;64@
M;V8@<V%L97,N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@
M;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/D=32SPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT
M+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@26X@07!R:6P@,C`P."P@=V4@96YT97)E9"!I;G1O
M(&$@<W1R871E9VEC(&%L;&EA;F-E('=I=&@@1U-+('1O#0H@9&ES8V]V97(L
M(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@;F]V96P@/&D^;6EC<F\\+VD^
M4DY!+71A<F=E=&5D#0H@=&AE<F%P975T:6-S('1O('1R96%T(&EN9FQA;6UA
M=&]R>2!D:7-E87-E<R`H=&AE#0H@)B-X,C`Q0SMI;6UU;F\M:6YF;&%M;6%T
M;W)Y(&%L;&EA;F-E)B-X,C`Q1#LI+B!);B!&96)R=6%R>2`R,#$P+"!W90T*
M(&%N9"!'4TL@97AP86YD960@=&AE('-T<F%T96=I8R!A;&QI86YC92!T;R!I
M;F-L=61E(&AE<&%T:71I<R!##0H@=FER=7,@:6YF96-T:6]N("@F(W@R,#%#
M.TA#5B8C>#(P,40[*2!T;R!D:7-C;W9E<BP@9&5V96QO<"!A;F0-"B!C;VUM
M97)C:6%L:7IE(#QI/FUI8W)O/"]I/E).02!T:&5R87!E=71I8W,@=&%R9V5T
M:6YG(&UI4BTQ,C(@9F]R#0H@=&AE('1R96%T;65N="!O9B!(0U8@*'1H92`F
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M92!A9&]P=&5D(&)Y('5S(&EN($IA;G5A<GD@,C`Q,2!F;W(@;75L=&EP;&4-
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M;V8@<&5R9F]R;6%N8V4N($%S(&]F($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q
M,RP@9&5F97)R960@<F5V96YU92!A<W-O8VEA=&5D('=I=&@@=&AE(&EM;75N
M;RUI;F9L86UM871O<GD-"B!A;&QI86YC92!W87,@)#,N-2!M:6QL:6]N+"!W
M:&EC:"!W92!A<F4@97AP96-T:6YG('1O(')E8V]G;FEZ92!O=F5R#0H@=&AE
M(')E;6%I;FEN9R!E<W1I;6%T960@<&5R:6]D(&]F('!E<F9O<FUA;F-E(&]F
M(&%P<')O>&EM871E;'D@-@T*('EE87)S+CPO<#X-"B`\<"!S='EL93TS1"=M
M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N
M=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@26X@2G5N92`R,#$S+"!T:&4@2$-6(&%L;&EA;F-E('=A<R!A
M;65N9&5D('1O('-T871E('1H870@4D<M,3`Q+`T*(&%N9"!O=&AE<B!F;W)M
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M;65N="P@=V4@<F5C;W)D960@=&AE(')E;6%I;FEN9R`D,2XQ#0H@;6EL;&EO
M;B!I;B!D969E<G)E9"!R979E;G5E(&%S<V]C:6%T960@=VET:"!T:&4@=7!F
M<F]N="!P87EM96YT#0H@9G)O;2!T:&4@2$-6(&%L;&EA;F-E+"!A<R!O=7(@
M97-T:6UA=&5D('!E<FEO9"!O9B!P97)F;W)M86YC92!W87,-"B!C;VUP;&5T
M92X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM
M8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@/&D^26UM=6YO+4EN9FQA;6UA=&]R>2!!;&QI86YC
M93PO:3X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I
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M;&QI;VXL(&EN8VQU9&EN9R!U<"!T;R`D,34N-0T*(&UI;&QI;VX@9F]R('!R
M96-L:6YI8V%L(&UI;&5S=&]N97,L('5P('1O("0X-RXP)B-X03`[;6EL;&EO
M;B!F;W(-"B!C;&EN:6-A;"!M:6QE<W1O;F5S+"!U<"!T;R`D,34P+C`F(WA!
M,#MM:6QL:6]N(&9O<B!R96=U;&%T;W)Y#0H@;6EL97-T;VYE<R!A;F0@=7`@
M=&\@)#$X,"XP)B-X03`[;6EL;&EO;B!F;W(@8V]M;65R8VEA;&EZ871I;VX-
M"B!M:6QE<W1O;F5S+B!792!A<F4@86QS;R!E;G1I=&QE9"!T;R!R96-E:79E
M('1I97)E9"!R;WEA;'1I97,@87,@80T*('!E<F-E;G1A9V4@;V8@86YN=6%L
M('-A;&5S('=H:6-H(&-A;B!I;F-R96%S92!U<"!T;R!T:&4@;&]W(&5N9"!O
M9@T*('1H92`Q,"!T;R`R,"4@<F%N9V4N/"]P/@T*(#QP('-T>6QE/3-$9F]N
M="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0^
M#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.R!M
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M;VQL;W=I;F<-"B!P<F5C;&EN:6-A;"!M:6QE<W1O;F5S.B`D,"XU(&UI;&QI
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M(&]F('1H90T*('-E;&5C=&5D('1H<F5E('1A<F=E=',Z("0T+C`@;6EL;&EO
M;B!F;W(@=&AE(&EN:71I871I;VX@;V8@82!0:&%S90T*(#$@8VQI;FEC86P@
M=')I86P[("0U+C`@;6EL;&EO;B!F;W(@=&AE(&EN:71I871I;VX@;V8@82!0
M:&%S92`R#0H@8VQI;FEC86P@=')I86P[(&%N9"`D,C`N,"!M:6QL:6]N(&EF
M($=32R!C:&]O<V5S('1O(&]P="UI;B!T;R!T:&4-"B!P<F]G<F%M(&9O;&QO
M=VEN9R!T:&4@8V]M<&QE=&EO;B!O9B!A('!R;V]F+6]F+6-O;F-E<'0@=')I
M86PN/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN
M+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*(#QI/DA#5B!!;&QI86YC93PO:3X\+W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T
M97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;B<^#0H@3F]T=VET:'-T86YD:6YG('1H92!F;W)E9V]I
M;F<L($=32R!H87,@<F5T86EN960@:71S(&EN=&5R97-T(&EN('1H90T*(&UI
M4BTQ,C(@<')O9W)A;2!I;B!(0U8L(&%N9"`\9F]N="!S='EL93TS1'=H:71E
M+7-P86-E.FYO=W)A<#YM:5(M,3(R)B-X03`[<F5M86EN<SPO9F]N=#X@82!C
M;VQL86)O<F%T:6]N#0H@=&%R9V5T('5N9&5R('1H92!A;&QI86YC92X@268@
M=&AE($A#5B!P<F]G<F%M(&ES('-U8V-E<W-F=6PL('=E#0H@8V]U;&0@<F5C
M96EV92!C;VYT<F%C='5A;"!M:6QE<W1O;F4@<&%Y;65N=',@=7`@=&\-"B`D
M,30T+C4F(WA!,#MM:6QL:6]N+"!I;F-L=61I;F<@=7`@=&\@)#4N-28C>$$P
M.VUI;&QI;VX@9F]R#0H@<')E8VQI;FEC86P@;6EL97-T;VYE<RP@=7`@=&\@
M)#(Y+C`F(WA!,#MM:6QL:6]N(&9O<B!C;&EN:6-A;`T*(&UI;&5S=&]N97,L
M('5P('1O("0U,"XP)B-X03`[;6EL;&EO;B!F;W(@<F5G=6QA=&]R>2!M:6QE
M<W1O;F5S(&%N9`T*('5P('1O("0V,"XP)B-X03`[;6EL;&EO;B!F;W(@8V]M
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M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O
M;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!792!H879E(&5V86QU871E9"!T
M:&4@<F5M86EN:6YG(&-O;G1I;F=E;G0@979E;G0M8F%S960@<&%Y;65N=',-
M"B!U;F1E<B!T:&4@2$-6(&%L;&EA;F-E(&%N9"!D971E<FUI;F5D('1H870@
M=&AE('!R96-L:6YI8V%L(&%N9`T*(&-L:6YI8V%L('!A>6UE;G1S(&UE970@
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M<R!C;VYT:6YG96YT('5P;VX@=&AE(')E<W5L=',@;V8@1U-+)B-X,C`Q.3MS
M('!E<F9O<FUA;F-E('=I;&P@;F]T#0H@8F4@86-C;W5N=&5D(&9O<B!U<VEN
M9R!T:&4@;6EL97-T;VYE(&UE=&AO9"X@4W5C:"!P87EM96YT<R!W:6QL(&)E
M#0H@<F5C;V=N:7IE9"!A<R!R979E;G5E(&]V97(@=&AE(')E;6%I;FEN9R!E
M<W1I;6%T960@<&5R:6]D(&]F#0H@<&5R9F]R;6%N8V4L(&EF(&%N>2P@86YD
M('=H96X@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D+@T*
M(%=E(&-A;B!E87)N(&$@<')E8VQI;FEC86P@;6EL97-T;VYE(&]F("0U+C4F
M(WA!,#MM:6QL:6]N('5P;VX@=&AE#0H@<V5L96-T:6]N(&]F(&$@9&5V96QO
M<&UE;G0@8V%N9&ED871E+B!792!C86X@86QS;R!E87)N('1H90T*(&9O;&QO
M=VEN9R!C;&EN:6-A;"!M:6QE<W1O;F5S.B`D-"XP)B-X03`[;6EL;&EO;B!F
M;W(@:6YI=&EA=&EO;B!O9@T*(&$@4&AA<V4F(WA!,#LQ(&-L:6YI8V%L('1R
M:6%L.R`D-2XP)B-X03`[;6EL;&EO;B!F;W(@=&AE(&EN:71I871I;VX-"B!O
M9B!A(%!H87-E)B-X03`[,B!C;&EN:6-A;"!T<FEA;#L@86YD("0R,"XP)B-X
M03`[;6EL;&EO;B!I9B!'4TL-"B!C:&]O<V5S('1O(&]P="UI;B!T;R!T:&4@
M<')O9W)A;2!F;VQL;W=I;F<@=&AE(&-O;7!L971I;VX@;V8@80T*('!R;V]F
M+6]F+6-O;F-E<'0@=')I86PN(%=E(&AA=F4@;F\@;V)L:6=A=&EO;B!T;R!P
M97)F;W)M(&%N>0T*(')E<V5A<F-H(&]R(&1E=F5L;W!M96YT(&%C=&EV:71I
M97,@=6YL97-S(&UU='5A;&QY(&%G<F5E9"!U<&]N(&)Y#0H@=&AE('!A<G1I
M97,N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN
M+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*(#QB/D%S=')A6F5N96-A/"]B/CPO<#X-"B`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E
M>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B!);B!!=6=U<W0@,C`Q,BP@=V4@96YT97)E9"!I
M;G1O(&$@8V]L;&%B;W)A=&EO;B!A;F0@;&EC96YS90T*(&%G<F5E;65N="!W
M:71H($%S=')A6F5N96-A+B!5;F1E<B!T:&4@=&5R;7,@;V8@=&AE(&%G<F5E
M;65N="P@=V4-"B!H879E(&%G<F5E9"!T;R!C;VQL86)O<F%T92!W:71H($%S
M=')A6F5N96-A('1O(&ED96YT:69Y+"!R97-E87)C:`T*(&%N9"!D979E;&]P
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M86-T=7)E(&%N9`T*(&-O;6UE<F-I86QI>F%T:6]N(&]F(&%L;&EA;F-E('!R
M;V1U8W0@8V%N9&ED871E<RX\+W`^#0H@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z
M,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#X-"B`F(WA!
M,#L\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[(&UA<F=I;BUB
M;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@56YD97(@=&AE('1E<FUS
M(&]F('1H92!A9W)E96UE;G0L('=E(')E8V5I=F5D(&%N('5P9G)O;G0@<&%Y
M;65N="!O9@T*("0S+C`@;6EL;&EO;B!I;B!/8W1O8F5R(#(P,3(N(%=E(&1E
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M;W5G:`T*('!R92UA9W)E960@<V%L97,@=&%R9V5T<RP@=V4@8V]U;&0@<F5C
M96EV92!M:6QE<W1O;F4@<&%Y;65N=',@=7`@=&\-"B`D-#DX+C`F(WA!,#MM
M:6QL:6]N+"!I;F-L=61I;F<@<')E8VQI;FEC86P@;6EL97-T;VYE<R!O9B!U
M<"!T;PT*("0U+C`F(WA!,#MM:6QL:6]N('5P;VX@;&5A9"!C;VUP;W5N9"!I
M9&5N=&EF:6-A=&EO;BP@=7`@=&\@)#$R,RXP#0H@;6EL;&EO;B!F;W(@8VQI
M;FEC86P@;6EL97-T;VYE<RP@86YD('5P('1O("0S-S`N,"8C>$$P.VUI;&QI
M;VX@9F]R#0H@8V]M;65R8VEA;&EZ871I;VX@;6EL97-T;VYE<RX@26X@861D
M:71I;VXL('=E(&%R92!E;G1I=&QE9"!T;PT*(')E8V5I=F4@<F]Y86QT:65S
M(&)A<V5D(&]N(&$@<&5R8V5N=&%G92!O9B!N970@<V%L97,@=VAI8V@@=VEL
M;`T*(')A;F=E(&9R;VT@=&AE(&UI9"US:6YG;&4@9&EG:71S('1O('1H92!L
M;W<@96YD(&]F(#$P('1O(#(P)2P-"B!D97!E;F1I;F<@=7!O;B!T:&4@<')O
M9'5C="!A;F0@=&AE('9O;'5M92!O9B!S86QE<RP@=VAI8V@@<F]Y86QT:65S
M#0H@;6%Y(&)E(')E9'5C960@:6X@8V5R=&%I;BP@;&EM:71E9"!C:7)C=6US
M=&%N8V5S+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA
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M87-S=7)E9"X@3W1H97(@8V]N=&EN9V5N=`T*(&5V96YT+6)A<V5D('!A>6UE
M;G1S('5N9&5R('1H92!S=')A=&5G:6,@86QL:6%N8V4@86=R965M96YT(&9O
M<@T*('=H:6-H('!A>6UE;G0@:7,@8V]N=&EN9V5N="!U<&]N('1H92!R97-U
M;'1S(&]F($%S=')A6F5N96-A)B-X,C`Q.3MS#0H@<&5R9F]R;6%N8V4@=VEL
M;"!N;W0@8F4@86-C;W5N=&5D(&9O<B!U<VEN9R!T:&4@;6EL97-T;VYE(&UE
M=&AO9"X-"B!3=6-H('!A>6UE;G1S('=I;&P@8F4@<F5C;V=N:7IE9"!A<R!R
M979E;G5E(&]V97(@=&AE(')E;6%I;FEN9PT*(&5S=&EM871E9"!P97)I;V0@
M;V8@<&5R9F]R;6%N8V4L(&EF(&%N>2P@86YD('=H96X@8V]L;&5C=&%B:6QI
M='D@:7,-"B!R96%S;VYA8FQY(&%S<W5R960N/"]P/@T*(#QP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD
M96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N)SX-"B!#;VYC=7)R96YT;'D@=VET:"!T:&4@8V]L;&%B;W)A=&EO
M;B!A;F0@;&EC96YS92!A9W)E96UE;G0L('=E#0H@96YT97)E9"!I;G1O(&$@
M0V]M;6]N(%-T;V-K(%!U<F-H87-E($%G<F5E;65N="`H)B-X,C`Q0SM#4U!!
M)B-X,C`Q1#LI#0H@=VET:"!!<W1R85IE;F5C82P@<'5R<W5A;G0@=&\@=VAI
M8V@@=V4@86=R965D('1O('-E;&P@=&\-"B!!<W1R85IE;F5C82!A;B!A9V=R
M96=A=&4@;V8@)#(U+C`F(WA!,#MM:6QL:6]N(&]F(&]U<B!C;VUM;VX@<W1O
M8VL-"B!I;B!A('!R:79A=&4@<&QA8V5M96YT(&-O;F-U<G)E;G1L>2!W:71H
M(&]U<B!I;FET:6%L('!U8FQI8PT*(&]F9F5R:6YG+"!A="!A('!R:6-E('!E
M<B!S:&%R92!E<75A;"!T;R!T:&4@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<-
M"B!P<FEC92X@26X@3V-T;V)E<B`R,#$R+"!I;B!A8V-O<F1A;F-E('=I=&@@
M=&AE($-34$$L('=E('-O;&0-"B!!<W1R85IE;F5C82`V+#(U,"PP,#`@<VAA
M<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@870@82!P<FEC92!P97(-"B!S:&%R
M92!O9B`D-"XP,"X@1G5R=&AE<BP@=&AE($-34$$@<W1I<'5L871E9"!T:&%T
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M"B!M87)K971A8FEL:71Y(&1I<V-O=6YT+"`D-"XS(&UI;&QI;VX@=V%S(&%T
M=')I8G5T960@=&\@=&AE#0H@8V]L;&%B;W)A=&EO;B!A;F0@;&EC96YS92!A
M9W)E96UE;G0N(%=E(&-O;G1I;G5E('1O(')E8V]G;FEZ92!T:&4-"B`D-"XS
M(&UI;&QI;VX@:6YT;R!R979E;G5E(')A=&%B;'D@;W9E<B!T:&4@97-T:6UA
M=&5D('!E<FEO9"!O9@T*('!E<F9O<FUA;F-E(&]F('1H92!C;VQL86)O<F%T
M:6]N+B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+`T*(&1E9F5R<F5D
M(')E=F5N=64@87-S;V-I871E9"!W:71H('1H92!C;VQL86)O<F%T:6]N(&%N
M9"!L:6-E;G-E#0H@86=R965M96YT(&%N9"!#4U!!('=A<R`D,BXP(&UI;&QI
M;VX@86YD("0R+CD@;6EL;&EO;BP@<F5S<&5C=&EV96QY+`T*('=H:6-H('=E
M(&%R92!E>'!E8W1I;F<@=&\@<F5C;V=N:7IE(&]V97(@=&AE(')E;6%I;FEN
M9R!C;VYT<F%C='5A;`T*('1E<FT@86YD(&-O<G)E<W!O;F1I;F<@97-T:6UA
M=&5D('!E<FEO9"!O9B!P97)F;W)M86YC92!O9@T*(&%P<')O>&EM871E;'D@
M,BXU('EE87)S+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[
M(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CY":6]G96X@261E8SPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ
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M;B`\:3YM:6-R;SPO:3Y23D$@8FEO;6%R:V5R<R!F;W(-"B!M=6QT:7!L92!S
M8VQE<F]S:7,@*"8C>#(P,4,[35,F(W@R,#%$.RDN(%5N9&5R('1H92!T97)M
M<R!O9B!T:&4-"B!A9W)E96UE;G0L('=E(&=R86YT960@0FEO9V5N($ED96,@
M86X@97AC;'5S:79E+"!R;WEA;'1Y(&9R964L#0H@=V]R;&1W:61E(&QI8V5N
M<V4@=&\@;W5R(&EN=&5R97-T(&EN('1H92!C;VQL86)O<F%T:6]N(&EN=&5L
M;&5C='5A;`T*('!R;W!E<G1Y(&9O<B!T:&4@<'5R<&]S92!O9B!C;VUM97)C
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M=F4@;&EC96YS92!T;R!O=7(@8F%C:V=R;W5N9`T*(&EN=&5L;&5C='5A;"!P
M<F]P97)T>2D@9F]R('1H92!P=7)P;W-E(&]F(&-O;6UE<F-I86QI>FEN9R!P
M<F]D=6-T<PT*(&9O<B!T:&4@9&EA9VYO<VES(&]F($U3+B!792!A;'-O(&=R
M86YT960@0FEO9V5N($ED96,@82!R:6=H="!O9@T*(&9I<G-T(&YE9V]T:6%T
M:6]N(&]N(&-E<G1A:6X@8V]M;65R8VEA;"!T<F%N<V%C=&EO;G,@<F5L871I
M;F<@=&\-"B`\:3YM:6-R;SPO:3Y23D$@<')O9'5C=',@=VAI8V@@=71I;&EZ
M92!I;G1E;&QE8W1U86P@<')O<&5R='D-"B!D979E;&]P960@9'5R:6YG('1H
M92!C;VQL86)O<F%T:6]N+B!0=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@=&AE
M#0H@86=R965M96YT+"!I;B!!=6=U<W0@,C`Q,B!W92!R96-E:79E9"!A;B!U
M<&9R;VYT('!A>6UE;G0@;V8@)#`N.`T*(&UI;&QI;VXN(%=E(&%R92!A;'-O
M(&5L:6=I8FQE('1O(')E8V5I=F4@<F5S96%R8V@@;6EL97-T;VYE#0H@<&%Y
M;65N=',@=7`@=&\@86X@86=G<F5G871E(&]F("0Q+C,F(WA!,#MM:6QL:6]N
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M96YU90T*(')E;&%T:6YG('1O('1H92!U<&9R;VYT('!A>6UE;G0@;V8@)#`N
M."!M:6QL:6]N(&]N(&$@<W1R86EG:'0M;&EN90T*(&)A<VES(&]V97(@;W5R
M(&5S=&EM871E9"!P97)I;V0@;V8@<&5R9F]R;6%N8V4L('=H:6-H(&ES#0H@
M87!P<F]X:6UA=&5L>2!T=V\@>65A<G,@8F%S960@;VX@=&AE(&5X<&5C=&5D
M('1E<FT@;V8@=&AE(')E<V5A<F-H#0H@86YD(&1E=F5L;W!M96YT('!L86XN
M/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O
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M;R!R96-E:79E(&EN(&-O;FYE8W1I;VX@=VET:"!0:&%S92`Q#0H@;6EL97-T
M;VYE<R!U;F1E<B!T:&4@0FEO9V5N($ED96,@86=R965M96YT+"!O<B!O=7(@
M97-T:6UA=&5D('!E<FEO9`T*(&]F('!E<F9O<FUA;F-E+CPO<#X-"B`\<"!S
M='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T
M97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;B<^#0H@5V4@:&%V92!E=F%L=6%T960@=&AE(&-O;G1I
M;F=E;G0@979E;G0M8F%S960@<&%Y;65N=',@=6YD97(@;W5R#0H@8V]L;&%B
M;W)A=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G0@=VET:"!":6]G96X@261E
M8R!A;F0@9&5T97)M:6YE9`T*('1H870@=&AE(')E<V5A<F-H('!A>6UE;G1S
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M=&]B97(@,C`Q,PT*(&%N9"!.;W9E;6)E<B`R,#$S+"!W92!R96-E:79E9"!R
M97-E87)C:"!M:6QE<W1O;F4@<&%Y;65N=',@=&]T86QI;F<-"B`D,"XS(&UI
M;&QI;VXN($EN(&%D9&ET:6]N+"!W92!C86X@96%R;B!T:&4@9F]L;&]W:6YG
M(')E<V5A<F-H#0H@;6EL97-T;VYE<SH@)#`N-28C>$$P.VUI;&QI;VX@9F]R
M('9A;&ED871I;VX@;V8@=&AE(#QI/FUI8W)O/"]I/E).00T*(&)I;VUA<FME
M<B!I;B!A('-E8V]N9"!I;F1E<&5N9&5N="!S86UP;&4@<V5T.R!A;F0@)#`N
M-2!M:6QL:6]N('5P;VX-"B!T:&4@<F5F:6YE;65N="!O9B!T:&4@/&D^;6EC
M<F\\+VD^4DY!(&)I;VUA<FME<B!S:6=N871U<F4@9G)O;2!A#0H@;&]N9VET
M=61I;F%L('-T=61Y(&]F('!A=&EE;G0@<V%M<&QE<R!O;B!-4R!T:&5R87!Y
M+B!!<R!O9@T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L(&1E9F5R<F5D(')E
M=F5N=64@87-S;V-I871E9"!W:71H('1H90T*(&-O;&QA8F]R871I;VX@86YD
M(&QI8V5N<V4@86=R965M96YT('=A<R`D,"XS(&UI;&QI;VXL('=H:6-H('=E
M(&%R90T*(&5X<&5C=&EN9R!T;R!R96-O9VYI>F4@;W9E<B!T:&4@<F5M86EN
M:6YG(&-O;G1R86-T=6%L('1E<FT@86YD#0H@8V]R<F5S<&]N9&EN9R!E<W1I
M;6%T960@<&5R:6]D(&]F('!E<F9O<FUA;F-E(&]F(#$P(&UO;G1H<RX\+W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M
M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($-O;F-U<G)E;G1L>2!W:71H('1H
M92!C;VQL86)O<F%T:6]N(&%N9"!L:6-E;G-E(&%G<F5E;65N="P@=V4-"B!E
M;G1E<F5D(&EN=&\@82!N;W1E('!U<F-H87-E(&%G<F5E;65N="!W:71H($)I
M;V=E;B!)9&5C+"!P=7)S=6%N=`T*('1O('=H:6-H('=E(&ES<W5E9"!A(&-O
M;G9E<G1I8FQE('!R;VUI<W-O<GD@;F]T92!I;B!T:&4@<')I;F-I<&%L#0H@
M86UO=6YT(&]F("0U+C`@;6EL;&EO;BX@5&AE("0U+C`@;6EL;&EO;B!N;W1E
M('!L=7,@86-C<G5E9"!I;G1E<F5S=`T*(&-O;G9E<G1E9"!I;G1O(#$L,C4V
M+#(S,B!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!U<&]N('1H90T*(&-L
M;W-I;F<@;V8@;W5R(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG(&EN($]C=&]B
M97(@,C`Q,B!A="!A#0H@8V]N=F5R<VEO;B!P<FEC92!O9B`D-"XP,"!P97(@
M<VAA<F4N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C
M-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R
M7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T
M,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0
M<F]P97)T>2!A;F0@17%U:7!M96YT+"!N970\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0L
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;B<^#0H@/&(^-BX@4')O<&5R='D@86YD($5Q=6EP;65N="P@;F5T/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O
M;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!O=7(@
M;6%J;W(@8VQA<W-E<R!O9B!P<F]P97)T>2!A;F0-"B!E<75I<&UE;G0@*&EN
M('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'0[
M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P
M/@T*(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$-S8E(&)O<F1E<CTS1#`@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%
M.D-/3$Q!4%-%.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M
M<VEZ93HQ,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H
M/3-$-S4E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z
M.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^1&5C
M96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z.'!T)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G
M8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N)SX-"B!,86)O<F%T;W)Y(&5Q=6EP;65N=#PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XU+#,T,CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-"PU.#,\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P
M="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ
M,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($-O;7!U=&5R
M(&5Q=6EP;65N="!A;F0@<V]F='=A<F4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,30\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3$T/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C
M0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M)SX-"B!&=7)N:71U<F4@86YD(&9I>'1U<F5S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,3$Y/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CDS/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!,96%S96AO;&0@
M:6UP<F]V96UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,2PX,#4\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S4Q/"]T9#X-
M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE
M.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!#;VYS
M=')U8W1I;VX@:6X@<')O9W)E<W,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ,3D\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$Q
M/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US
M:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O
M;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L
M:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P
M<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P
M>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#0Y.3PO=&0^#0H@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE
M.CAP=#XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C4L-S4R/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L
M;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N)SX-"B!,97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@
M86UO<G1I>F%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RPW,S$\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/BDF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F
M;VYT+7-I>F4Z.'!T/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#(L-#0R/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1&9O;G0M<VEZ93HQ<'@[/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T
M.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%!R;W!E<G1Y(&%N
M9"!E<75I<&UE;G0L(&YE=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-S8X/"]T9#X-
M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T1F;VYT+7-I>F4Z.'!T/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C,L,S$P/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O
M;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!$97!R96-I871I;VX@86YD(&%M
M;W)T:7IA=&EO;B!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT(&]F("0Q+C,-
M"B!M:6QL:6]N+"`D,"XY)B-X03`[;6EL;&EO;B!A;F0@)#`N."!M:6QL:6]N
M('=A<R!R96-O<F1E9"!F;W(@=&AE#0H@>65A<G,@96YD960@1&5C96UB97(F
M(WA!,#LS,2P@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P-"B!R97-P96-T:79E;'DN
M/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?
M-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T,30N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1A;F=I
M8FQE($%S<V5T<RP@;F5T/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G1A;F=I8FQE($%S<V5T<RP@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C!P=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T
M.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/C<N($EN=&%N
M9VEB;&4@07-S971S+"!N970\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[
M(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG
M/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!O=7(@;6%J;W(@
M8VQA<W-E<R!O9B!I;G1A;F=I8FQE#0H@87-S971S("AI;B!T:&]U<V%N9',I
M.CPO<#X-"B`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!T.VUA<F=I;BUT;W`Z
M,'!T.VUA<F=I;BUB;W1T;VTZ,'!T/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@
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M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/D1E8V5M8F5R)B-X03`[
M,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O
M;&ED(",P,#`P,#`G/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L
M:60@(S`P,#`P,"<^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#
M145&1B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O
M;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@
M9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^
M#0H@4&%T96YT<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY-C`\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CDQ,SPO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@3&EC96YS97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XT,#0\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`T/"]T
M9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US:7IE
M.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED
M(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@
M(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@
M<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S
M;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS
M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,V-#PO
M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$L,S$W/"]T9#X-"B`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!!8V-U;75L871E9"!A;6]R=&EZ871I;VX\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE
M.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@R,S8\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$V,SPO=&0^#0H@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^*28C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);G1A;F=I8FQE<RP@;F5T/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O
M;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PQ,C@\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PQ-30\+W1D/@T*
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X
M.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P
M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P
M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O
M=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O
M=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[
M(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG
M/@T*($EN=&%N9VEB;&4@87-S970@86UO<G1I>F%T:6]N(&]F("0P+C$@;6EL
M;&EO;BP@)#`N,2!M:6QL:6]N(&%N9`T*("0P+C$@;6EL;&EO;B!W87,@<F5C
M;W)D960@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+`T*
M(#(P,3,L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L>2X@06UO<G1I>F%T
M:6]N(&]F('1H97-E(&EN=&%N9VEB;&4-"B!A<W-E=',@;W9E<B!T:&4@;F5X
M="!F:79E('EE87)S(&ES(&5X<&5C=&5D('1O(&)E(&%P<')O>&EM871E;'D-
M"B`D,"XQ(&UI;&QI;VX@<&5R('EE87(N/"]P/@T*(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS
M8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X
M9B]7;W)K<VAE971S+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE
M<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/C@N($-O;6UI=&UE;G1S
M(&%N9"!#;VYT:6YG96YC:65S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T
M.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/D]P97)A=&EN
M9R!,96%S93PO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[
M(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5V4@;&5A
M<V4@;V9F:6-E(&%N9"!L86)O<F%T;W)Y('-P86-E(&QO8V%T960@870@,S4T
M-2!*;VAN($AO<&MI;G,-"B!#;W5R="P@3&$@2F]L;&$L($-A;&EF;W)N:6$@
M*'1H92`F(W@R,#%#.T9A8VEL:71Y)B-X,C`Q1#LI(&9O<B!O=7(-"B!C;W)P
M;W)A=&4@:&5A9'%U87)T97)S(&%N9"!R97-E87)C:"!F86-I;&ET>2!U;F1E
M<B!A;B!O<&5R871I;F<-"B!L96%S92!A9W)E96UE;G0@*'1H92`F(W@R,#%#
M.TQE87-E)B-X,C`Q1#LI+B!4:&4@3&5A<V4@8V]M;65N8V5D(&EN#0H@2G5L
M>2`R,#$P(&%N9"!P<F]V:61E9"!F;W(@87!P<F]X:6UA=&5L>2`R,BPP,#`@
M<W%U87)E(&9E970@;V8-"B!O9F9I8V4@86YD(&QA8F]R871O<GD@<W!A8V4L
M(&5X<&ER:6YG(&EN($IU;F4@,C`Q-RX@26X@3F]V96UB97(-"B`R,#$R+"!W
M92!A;65N9&5D('1H92!,96%S92!T;R!E>'!A;F0@;W5R(&QA8F]R871O<GD@
M86YD(&]F9FEC90T*('-P86-E(&)Y(&%P<')O>&EM871E;'D@-RPP,#`@<W%U
M87)E(&9E970L(&EN8VQU9&EN9R!T:&4@861D:71I;VX@;V8-"B!A;B!A<'!R
M;WAI;6%T96QY(#,L,#`P('-Q=6%R92!F;V]T(&1E9&EC871E9"!R97-E87)C
M:"!A;F0-"B!D979E;&]P;65N="!L86)O<F%T;W)Y+B!,96%S92!P87EM96YT
M<R!F;W(@=&AI<R!A9&1I=&EO;F%L('-P86-E#0H@8F5G86X@3V-T;V)E<B`R
M,#$S+B!792!H879E(&%N(&]P=&EO;B!T;R!T97)M:6YA=&4@86YD(&-A;F-E
M;"!T:&4-"B!L96%S92!I;B!*=6YE)B-X03`[,C`Q-2!U<&]N('-I>"!M;VYT
M:',F(W@R,#$Y.R!W<FET=&5N(&YO=&EC92!T;PT*(&]U<B!L86YD;&]R9"X@
M5V4@86QS;R!H879E('1W;R!O<'1I;VYS('1O(&5X=&5N9"!T:&4@;&5A<V4@
M9F]R#0H@<W5C8V5S<VEV92!T:')E92UY96%R('!E<FEO9',N/"]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@;6%R9VEN+6)O='1O;3HP<'0[
M('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N)SX-"B!);B!C;VYN96-T:6]N('=I=&@@=&AE(&EN
M8V5P=&EO;B!O9B!T:&4@3&5A<V4L('=E('=E<F4@<')O=FED960-"B!T96YA
M;G0@:6YC96YT:79E<R!O9B`D,"XQ(&UI;&QI;VX@=VAI8V@@=V%S('5S960@
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M:&4@3&5A<V4@:6X@3F]V96UB97(@,C`Q,BP@=V4@=V5R92!P<F]V:61E9"!A
M;@T*(&%D9&ET:6]N86P@=&5N86YT(&EM<')O=F5M96YT(&%L;&]W86YC92!O
M9B!A<'!R;WAI;6%T96QY("0P+C<-"B!M:6QL:6]N+"!W:&EC:"!W87,@=71I
M;&EZ960@:6X@,C`Q,R!T;R!F=6YD(&QE87-E:&]L9"!I;7!R;W9E;65N=',-
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M<V4@86=R965M96YT+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
M=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!#=6UU
M;&%T:79E(')E;G0@=&\@8F4@<&%I9"!O=F5R('1H92!L96%S92!T97)M(&ES
M(&)E:6YG(&%M;W)T:7IE9`T*(&]N(&$@<W1R86EG:'0M;&EN92!B87-I<R!O
M=F5R('1H92!T97)M(&]F('1H92!,96%S92X@4F5N="!E>'!E;G-E#0H@9F]R
M('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"`R,#$R
M(&%N9"`R,#$Q('=A<PT*(&%P<')O>&EM871E;'D@)#`N-R!M:6QL:6]N+"`D
M,"XV(&UI;&QI;VX@86YD("0P+C4@;6EL;&EO;BP-"B!R97-P96-T:79E;'DN
M(%=E(&%C8V]U;G0@9F]R('1H92!D:69F97)E;F-E(&)E='=E96X@=&AE(&UI
M;FEM=6T-"B!L96%S92!P87EM96YT<R!A;F0@=&AE('-T<F%I9VAT+6QI;F4@
M86UO=6YT(&%S(&1E9F5R<F5D(')E;G0N#0H@1&5F97)R960@<F5N="!A="!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$S(&%N9"`R,#$R('=A<R!A<'!R;WAI;6%T
M96QY#0H@)#`N.2!M:6QL:6]N(&%N9"`D,"XU(&UI;&QI;VXL(')E<W!E8W1I
M=F5L>2X@5V4@86QS;R!P87D@<')O<&5R='D-"B!T87AE<RP@;6%I;G1E;F%N
M8V4@86YD(&EN<W5R86YC92P@=VAI8V@@87)E(&5X<&5N<V5D(&%S#0H@:6YC
M=7)R960N/"]P/@T*(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN
M+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@
M=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86XG/@T*($%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P
M,3,L(&9U='5R92!A;FYU86P@;6EN:6UU;2!L96%S92!P87EM96YT<PT*(&9O
M<B!O=7(@;W!E<F%T:6YG(&QE87-E<R!A<F4@87,@9F]L;&]W<R`H:6XF(WA!
M,#MT:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!T
M.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
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M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`R,#$T/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ
M93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ+#`V-CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M
M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N
M="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@
M,C`Q-3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PQ,S@\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T
M.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#(P,38\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N
M="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L,C$Q/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M)SX-"B`R,#$W/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,C0\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P
M="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ
M,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%1H97)E869T
M97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M
M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PP
M,SD\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT
M+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@
M9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@
M9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CY,:6-E;G-E
M($%G<F5E;65N=',\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
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M871E<FEA;"X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A
M,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D
M.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE
M970Q-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B
M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[
M(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG
M/@T*(#QB/CDN($-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4\+V(^/"]P/@T*
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($%S('!A<G0@;V8@;W5R('-T<F%T96=I
M8R!A;&QI86YC92!W:71H($=32R!E<W1A8FQI<VAE9"!I;@T*($%P<FEL)B-X
M03`[,C`P."P@=V4@:7-S=65D(&$@=&AR964M>65A<B!C;VYV97)T:6)L92!N
M;W1E(&EN#0H@97AC:&%N9V4@9F]R("0U+C`F(WA!,#MM:6QL:6]N("@F(W@R
M,#%#.S(P,#@@1U-+($YO=&4F(W@R,#%$.RDN($EN#0H@1F5B<G5A<GD@,C`Q
M,"!A;F0@:6X@8V]N;F5C=&EO;B!W:71H('1H92!S=6)S97%U96YT(&5X<&%N
M<VEO;B!O9@T*('1H870@<W1R871E9VEC(&%L;&EA;F-E+"!W92!I<W-U960@
M82!C;VYV97)T:6)L92!P<F]M:7-S;W)Y(&YO=&4@:6X-"B!E>&-H86YG92!F
M;W(@)#4N,"!M:6QL:6]N("@F(W@R,#%#.S(P,3`F(WA!,#M'4TL@3F]T928C
M>#(P,40[*2X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M
M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;B<^#0H@/&D^,C`Q,B!!;65N9&UE;G0@;V8@=&AE
M(#(P,#@@1U-+($YO=&4\+VD^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*
M($EN($IU;'D@,C`Q,BP@=V4@86UE;F1E9"!A;F0@<F5S=&%T960@=&AE(#(P
M,#@@1U-+($YO=&4N(%=E#0H@86-C;W5N=&5D(&9O<B!T:&4@86UE;F1E9"!A
M;F0@<F5S=&%T960@;F]T92!A<R!A(&1E8G0@;6]D:69I8V%T:6]N+@T*(%1H
M92!A;65N9&5D(&%N9"!R97-T871E9"!N;W1E('!R;W9I9&5D('1H870@=&AE
M('!R:6YC:7!A;"!A;6]U;G0-"B!P;'5S(&EN=&5R97-T('5N9&5R('1H92!N
M;W1E('=I;&PL('5P;VX@8V]M<&QE=&EO;B!O9B!O=7(@:6YI=&EA;`T*('!U
M8FQI8R!O9F9E<FEN9R!I;B!W:&EC:"!W92!R96-E:79E(&$@;6EN:6UU;2!L
M979E;"!O9B!P<F]C965D<PT*(&9R;VT@;F5W(&EN=F5S=&]R<R!O<B!T:&%T
M(')E<W5L=',@:6X@8V5R=&%I;B!O9B!O=7(@8W5R<F5N=`T*('-T;V-K:&]L
M9&5R<R!T;V=E=&AE<B!O=VYI;F<@;&5S<R!T:&%N(#4P)2!O9B!O=7(@=F]T
M:6YG#0H@<V5C=7)I=&EE<RP@875T;VUA=&EC86QL>2!C;VYV97)T(&EN=&\@
M<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL-"B!A="!T:&4@:6YI=&EA;"!P
M=6)L:6,@;V9F97)I;F<@<')I8V4N(%1H92`D-2XP(&UI;&QI;VX@;F]T92!P
M;'5S#0H@86-C<G5E9"!I;G1E<F5S="!C;VYV97)T960@:6YT;R`Q+#0T-RPP
M,S<@<VAA<F5S(&]F(&]U<B!C;VUM;VX-"B!S=&]C:R!U<&]N('1H92!C;&]S
M:6YG(&]F(&]U<B!I;FET:6%L('!U8FQI8R!O9F9E<FEN9R!I;B!/8W1O8F5R
M#0H@,C`Q,B!A="!A(&-O;G9E<G-I;VX@<')I8V4@;V8@)#0N,#`@<&5R('-H
M87)E+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I
M;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B`\:3XR,#$R($%M96YD;65N="!O9B!T:&4@,C`Q
M,"!'4TL@3F]T93PO:3X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV
M<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US
M:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@26X@
M2G5L>2`R,#$R+"!W92!A;65N9&5D(&%N9"!R97-T871E9"!O=7(@,C`Q,"!'
M4TL@3F]T92X@5&AE#0H@86UE;F1E9"!A;F0@<F5S=&%T960@,C`Q,"!'4TL@
M3F]T92!P<F]V:61E9"!F;W(@82!R;VQL;W9E<B!I;G1O(&$-"B!N97<@<')O
M;6ES<V]R>2!N;W1E+"!E9F9E8W1I=F4@87,@;V8@=&AE(&-L;W-I;F<@9&%T
M92!O9B!A#0H@<75A;&EF>6EN9R!I;FET:6%L('!U8FQI8R!O9F9E<FEN9R`H
M=&AE("8C>#(P,4,[4&]S="U)4$\@1U-+#0H@3F]T928C>#(P,40[*2X@5&AE
M(%!O<W0M25!/($=32R!.;W1E('=O=6QD(&)E(&5Q=6EV86QE;G0@=&\@=&AE
M#0H@86=G<F5G871E(&%M;W5N="!O9B!P<FEN8VEP86P@86YD(&%C8W)U960@
M8G5T('5N<&%I9"!I;G1E<F5S="!A<R!O9@T*('1H92!I;FET:6%L('!U8FQI
M8R!O9F9E<FEN9R!D871E+B!4:&4@,C`Q,"!'4TL@3F]T92!W;W5L9"!T:&5N
M(&)E#0H@<VEM=6QT86YE;W5S;'D@8V%N8V5L;&5D(&%N9"!O8FQI9V%T:6]N
M<R!T:&5R971O('=O=6QD(&)E#0H@=&5R;6EN871E9"X\+W`^#0H@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X
M="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*($EN($]C=&]B97(@,C`Q,BP@:6X@8V]N:G5N8W1I
M;VX@=VET:"!O=7(@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<L#0H@=&AE(%!O
M<W0M25!/($=32R!.;W1E('=A<R!E<W1A8FQI<VAE9"!I;B!T:&4@<')I;F-I
M<&%L(&%M;W5N="!O9@T*("0U+C0@;6EL;&EO;BP@=VAI8V@@=V%S(&5Q=6EV
M86QE;G0@=&\@=&AE(&]R:6=I;F%L('!R:6YC:7!A;"!A;6]U;G0-"B!O9B`D
M-2XP(&UI;&QI;VX@<&QU<R!A8V-R=65D(&)U="!U;G!A:60@:6YT97)E<W0@
M;V8@87!P<F]X:6UA=&5L>0T*("0P+C0@;6EL;&EO;BX@5&AE(%!O<W0M25!/
M($=32R!.;W1E(&AA<R!A(&UA='5R:71Y(&1A=&4@;V8@=&AR964-"B!Y96%R
M<R!F<F]M('1H92!A;FYI=F5R<V%R>2!D871E(&]F('1H92!A9W)E96UE;G0L
M(&]R($]C=&]B97(@,C`Q-2X-"B!!="!'4TLF(W@R,#$Y.W,@;W!T:6]N+"!T
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M:71I86P@<'5B;&EC#0H@;V9F97)I;F<@<')I8V4@;V8@)#0N,#`@<&5R('-H
M87)E+B!#;VYC=7)R96YT;'D@=VET:"!O=7(@:6YI=&EA;`T*('!U8FQI8R!O
M9F9E<FEN9RP@=V4@86-C;W5N=&5D(&-A;F-E;&QA=&EO;B!O9B!T:&4@,C`Q
M,"!'4TL@3F]T92!A<PT*(&$@9&5B="!E>'1I;F=U:7-H;65N="!A;F0@<F5C
M;W)D960@82!L;W-S(&]N('1H92!E>'1I;F=U:7-H;65N="!O9@T*(&1E8G0@
M;V8@)#$N-R!M:6QL:6]N(&%N9"!E;&5C=&5D('1H92!F86ER('9A;'5E(&]P
M=&EO;B!F;W(@=&AE#0H@4&]S="U)4$\@1U-+($YO=&4N($%S(&]F($1E8V5M
M8F5R)B-X03`[,S$L(#(P,3,L('1H92!F86ER('9A;'5E(&]F#0H@=&AE(%!O
M<W0M25!/($=32R!.;W1E('=A<R`D,3$N,R!M:6QL:6]N+"!A;F0@:7,@8VQA
M<W-I9FEE9"!A<PT*("8C>#(P,4,[0V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L
M92P@870@9F%I<B!V86QU928C>#(P,40[(&]N('1H90T*(&)A;&%N8V4@<VAE
M970@*'-E928C>$$P.TYO=&4@-"DN/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I
M;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T
M.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QI/DYO=&4@<&%Y
M86)L92!T;R!":6]G96X@261E8SPO:3X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R
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M;V8@)#4N,"!M:6QL:6]N+B!4:&4@)#4N,`T*(&UI;&QI;VX@;F]T92!P;'5S
M(&%C8W)U960@:6YT97)E<W0@8V]N=F5R=&5D(&EN=&\@,2PR-38L,C,R('-H
M87)E<PT*(&]F(&]U<B!C;VUM;VX@<W1O8VL@=7!O;B!T:&4@8VQO<VEN9R!O
M9B!O=7(@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<-"B!I;B!/8W1O8F5R(#(P
M,3(@870@82!C;VYV97)S:6]N('!R:6-E(&]F("0T+C`P('!E<B!S:&%R92X\
M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T
M.3EF7V%E,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE970Q-RYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G9E<G1I
M8FQE(%!R969E<G)E9"!3=&]C:RP@0V]M;6]N(%-T;V-K(&%N9"!3=&]C:VAO
M;&1E<G,G($1E9FEC:70\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:RP@0V]M;6]N
M(%-T;V-K(&%N9"!3=&]C:VAO;&1E<G,G($1E9FEC:70\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CXQ,"X@
M0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K+"!#;VUM;VX@4W1O8VL@86YD
M#0H@4W1O8VMH;VQD97)S)B-X,C`Q.3L@1&5F:6-I=#PO8CX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P
M="<^#0H@/&(^4F5V97)S92!S=&]C:R!S<&QI=#PO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!/;B!397!T96UB97(F(WA!,#LW+"`R,#$R
M+"!O=7(@8F]A<F0@;V8@9&ER96-T;W)S(&%P<')O=F5D(&$-"B!O;F4M9F]R
M+71W;R!R979E<G-E('-T;V-K('-P;&ET(&]F(&]U<B!C;VUM;VX@<W1O8VLN
M(%1H90T*(&%C8V]M<&%N>6EN9R!F:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@
M;F]T97,@=&\@=&AE(&9I;F%N8VEA;`T*('-T871E;65N=',@9VEV92!R971R
M;V%C=&EV92!E9F9E8W0@=&\@=&AE(')E=F5R<V4@<W!L:70@;V8@;W5R#0H@
M8V]M;6]N('-T;V-K(&9O<B!A;&P@<&5R:6]D<R!P<F5S96YT960N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q.'!T)SX-"B`\8CY#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4')I;W(@=&\@=&AE
M(&-O;G9E<G-I;VX@:6X@=&AE(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG(&EN
M($]C=&]B97(-"B`R,#$R+"!O=7(@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T
M;V-K('=A<R!C;&%S<VEF:65D(&%S('1E;7!O<F%R>0T*(&5Q=6ET>2!O;B!T
M:&4@86-C;VUP86YY:6YG(&)A;&%N8V4@<VAE971S(&EN<W1E860@;V8@:6X-
M"B!S=&]C:VAO;&1E<G,F(W@R,#$Y.R!E<75I='D@*&1E9FEC:70I(&EN(&%C
M8V]R9&%N8V4@=VET:`T*(&%U=&AO<FET871I=F4@9W5I9&%N8V4@9F]R('1H
M92!C;&%S<VEF:6-A=&EO;B!A;F0@;65A<W5R96UE;G0@;V8-"B!R961E96UA
M8FQE('-E8W5R:71I97,N(%5P;VX@8V5R=&%I;B!C:&%N9V4@:6X@8V]N=')O
M;"!E=F5N=',@=&AA=`T*('=E<F4@;W5T<VED92!O9B!O=7(@8V]N=')O;"P@
M:6YC;'5D:6YG(&QI<75I9&%T:6]N+"!S86QE(&]R#0H@=')A;G-F97(@;V8@
M8V]N=')O;"!O9B!T:&4@0V]M<&%N>2P@:&]L9&5R<R!O9B!T:&4@8V]N=F5R
M=&EB;&4-"B!P<F5F97)R960@<W1O8VL@8V]U;&0@8V%U<V4@:71S(')E9&5M
M<'1I;VXN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%S(&]F
M($1E8V5M8F5R)B-X03`[,S$L(#(P,3(L(&%L;"!397)I97,@02!0<F5F97)R
M960@4W1O8VL@86YD#0H@4V5R:65S($(@4')E9F5R<F5D(%-T;V-K(&AA9"!C
M;VYV97)T960@=&\@8V]M;6]N('-T;V-K(&EN#0H@8V]N:G5N8W1I;VX@=VET
M:"!T:&4@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<N($9O;&QO=VEN9R!O=7(@
M:6YI=&EA;`T*('!U8FQI8R!O9F9E<FEN9RP@=V4@9FEL960@86X@86UE;F1E
M9"!A;F0@<F5S=&%T960@8V5R=&EF:6-A=&4@;V8-"B!I;F-O<G!O<F%T:6]N
M('1O(&%U=&AO<FEZ92`Q,"PP,#`L,#`P('-H87)E<R!O9B!U;F1E<VEG;F%T
M960-"B!P<F5F97)R960@<W1O8VLN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY0=6)L
M:6,@3V9F97)I;F=S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G
M/@T*($EN($]C=&]B97(@,C`Q,BP@=V4@8V]M<&QE=&5D(&]U<B!I;FET:6%L
M('!U8FQI8R!O9F9E<FEN9R!W:&5R96)Y#0H@=V4@:7-S=65D(&%N9"!S;VQD
M(#$Q+#(U,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A="!A('!U8FQI
M8PT*(&]F9F5R:6YG('!R:6-E(&]F("0T+C`P('!E<B!S:&%R92P@<F5S=6QT
M:6YG(&EN(&YE="!P<F]C965D<R!T;R!T:&4-"B!#;VUP86YY(&]F("0S.2XU
M)B-X03`[;6EL;&EO;BX@0V]N8W5R<F5N=&QY('=I=&@@=&AE(&-O;7!L971I
M;VX@;V8-"B!O=7(@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<L('=E('-O;&0@
M-BPR-3`L,#`P('-H87)E<R!O9B!C;VUM;VX-"B!S=&]C:R!I;B!A('!R:79A
M=&4@<&QA8V5M96YT('1O($%S=')A6F5N96-A(&%T('1H92!I;FET:6%L('!U
M8FQI8PT*(&]F9F5R:6YG('!R:6-E(&]F("0T+C`P('!E<B!S:&%R92P@<F5S
M=6QT:6YG(&EN(&YE="!P<F]C965D<R!T;R!T:&4-"B!#;VUP86YY(&]F("0R
M-2XP(&UI;&QI;VXN($EN(&%D9&ET:6]N+"`D-2XP(&UI;&QI;VX@;V8@;W5T
M<W1A;F1I;F<-"B!P<FEN8VEP86P@<&QU<R!A8V-R=65D(&EN=&5R97-T(&]F
M("0P+C@@;6EL;&EO;B!U;F1E<FQY:6YG(&$-"B!C;VYV97)T:6)L92!N;W1E
M('1H870@=V4@:7-S=65D('1O($=32R!I;B!!<')I;"`R,#`X+"!W:&EC:"!W
M87,-"B!A;65N9&5D(&%N9"!R97-T871E9"!I;B!*=6QY(#(P,3(L('1O9V5T
M:&5R('=I=&@@)#4N,"8C>$$P.VUI;&QI;VX-"B!O9B!O=71S=&%N9&EN9R!P
M<FEN8VEP86P@<&QU<R!A8V-R=65D(&EN=&5R97-T('5N9&5R;'EI;F<@80T*
M(&-O;G9E<G1I8FQE(&YO=&4@=&AA="!W92!I<W-U960@=&\@0FEO9V5N($ED
M96,@:6X@075G=7-T(#(P,3(L('=A<PT*(&%U=&]M871I8V%L;'D@8V]N=F5R
M=&5D('5P;VX@=&AE(&-L;W-I;F<@;V8@;W5R(&EN:71I86P@<'5B;&EC#0H@
M;V9F97)I;F<@:6YT;R!A;B!A9V=R96=A=&4@;V8@,BPW,#,L,C8Y('-H87)E
M<R!O9B!O=7(@8V]M;6]N('-T;V-K+@T*(%5P;VX@=&AE(&-L;W-I;F<@;V8@
M=&AE(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG+"!A;&P@<VAA<F5S(&]F('1H
M90T*($-O;7!A;GDF(W@R,#$Y.W,@=&AE;BUO=71S=&%N9&EN9R!C;VYV97)T
M:6)L92!P<F5F97)R960@<W1O8VL-"B!A=71O;6%T:6-A;&QY(&-O;G9E<G1E
M9"!I;G1O(&%N(&%G9W)E9V%T92!O9B`Q,RPV.3DL.3DY('-H87)E<R!O9@T*
M(&-O;6UO;B!S=&]C:RX@56YD97)W<FET97)S(&9O<B!O=7(@:6YI=&EA;"!P
M=6)L:6,@;V9F97)I;F<-"B!E>&5R8VES960@86X@;W9E<BUA;&QO=&UE;G0@
M;W!T:6]N('1O('!U<F-H87-E(#$L-#@P+#DX,B!A9&1I=&EO;F%L#0H@<VAA
M<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@870@)#0N,#`@<&5R('-H87)E+"!R
M97-U;'1I;F<@:6X@;F5T#0H@<')O8V5E9',@;V8@)#4N-2!M:6QL:6]N+B!)
M;F-L=7-I=F4@;V8@=&AE(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG+`T*('5N
M9&5R=W)I=&5R<R8C>#(P,3D[(&5X97)C:7-E(&]F('1H96ER(&]V97(M86QL
M;W1M96YT(&]P=&EO;B!A;F0-"B!C;VYC=7)R96YT('!R:79A=&4@<&QA8V5M
M96YT+"!W92!R86ES960@82!T;W1A;"!O9B`D-S`N,"!M:6QL:6]N(&EN#0H@
M;F5T('!R;V-E961S(&%F=&5R(&1E9'5C=&EN9R!U;F1E<G=R:71E<B!D:7-C
M;W5N=',L(&-O;6UI<W-I;VYS(&%N9`T*(&]T:&5R(&]F9F5R:6YG(&5X<&5N
M<V5S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!*=6QY
M)B-X03`[,C`Q,RP@=V4@8V]M<&QE=&5D(&$@<'5B;&EC(&]F9F5R:6YG('=H
M97)E8GD@=V4@<V]L9`T*(#4L,3<U+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K(&%T("0Y+C4P)B-X03`[<&5R('-H87)E(&%N9`T*(')E8V5I=F5D(&YE
M="!P<F]C965D<R!O9B`D-#4N."!M:6QL:6]N+"!A9G1E<B!D961U8W1I;F<-
M"B!U;F1E<G=R:71I;F<@9&ES8V]U;G1S+"!C;VUM:7-S:6]N<R!A;F0@;W1H
M97(@;V9F97)I;F<-"B!E>'!E;G-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$X<'0[($U!4D=)3BU43U`Z
M(#!P="<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/D-O;6UO;B!3=&]C
M:SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!!<R!O9B!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"!T:&5R92!W97)E(#0Q+#<X-RPS,C8@
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M:&]R:7IE(#(P,"PP,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q.'!T)SX-"B`\8CY3:&%R97,@4F5S97)V960@9F]R($9U='5R92!)
M<W-U86YC93PO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4
M:&4@9F]L;&]W:6YG('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@87)E(')E<V5R
M=F5D(&9O<B!F=71U<F4-"B!I<W-U86YC92!A="!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#8X)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@
M=VED=&@],T0X,B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V]M;6]N('-T;V-K
M(&]P=&EO;G,@;W5T<W1A;F1I;F<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C4L-3DX+#(P-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V]M;6]N
M('-T;V-K(&]P=&EO;G,@879A:6QA8FQE(&9O<B!F=71U<F4@9W)A;G0\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C<Q,"PU,S0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5M<&QO>65E(%-T;V-K
M(%!U<F-H87-E(%!L86X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0V,"PR
M.#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;G9E<G1I8FQE(&YO
M=&4@<&%Y86)L92`H4&]S="U)4$\@1U-+($YO=&4I/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ+#0Q,2PV-3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*(%1O=&%L(&-O;6UO;B!S:&%R97,@<F5S97)V960@9F]R(&9U='5R
M92!I<W-U86YC93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PQ.#`L-C@S
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4G/@T*(%1H92!C;VUB:6YE9"!T;W1A;"!N=6UB97(@;V8@<VAA<F5S(')E
M<V5R=F5D(&9O<B!I<W-U86YC92!U;F1E<B!T:&4-"B`R,#$R(%!L86X@:7,@
M-S$P+#4S-"!S:&%R97,@87,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RX@
M5&AE#0H@9F]L;&]W:6YG('1A8FQE('-U;6UA<FEZ97,@;W5R('-T;V-K(&]P
M=&EO;B!A8W1I=FET>2!U;F1E<B!T:&4@,C`Q,@T*(%!L86X@9F]R('1H92!Y
M96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@*&EN('1H;W5S86YD
M<RP-"B!E>&-E<'0@<&5R('-H87)E(&%N9"!C;VYT<F%C='5A;"!T97)M(&1A
M=&$I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR
M)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0V,24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&(^3G5M8F5R)B-X03`[;V8\
M8G(@+SX-"B!O<'1I;VYS/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(^/&(^5V5I9VAT960\8G(@+SX-"B!A=F5R
M86=E/&)R("\^#0H@97AE<F-I<V4\8G(@+SX-"B!P<FEC93PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M/CQB/E=E:6=H=&5D/&)R("\^#0H@879E<F%G93QB<B`O/@T*(')E;6%I;FEN
M9SQB<B`O/@T*(&-O;G1R86-T=6%L/&)R("\^#0H@=&5R;3QB<B`O/@T*("AI
M;B8C>$$P.WEE87)S*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQB/D%G9W)E9V%T93QB<B`O/@T*
M(&EN=')I;G-I8SQB<B`O/@T*('9A;'5E/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!/<'1I;VYS(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[
M,S$L(#(P,3(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#<R
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BXQ,3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!'<F%N=&5D
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
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M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@17AE<F-I<V5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#<S,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N.#$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V%N8V5L960O
M9F]R9F5I=&5D+V5X<&ER960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH,C4T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RXU,CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M
M)SX-"B!/<'1I;VYS(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-3DX/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C,N-CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW
M+CDX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#$V,CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!697-T960@;W(@97AP96-T960@=&\@=F5S="!A="!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU
M+#,X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C8P/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-RXY,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,"PX
M,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17AE
M<F-I<V%B;&4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,BPR-#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XR,CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,3(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3,L.#0R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!W96EG:'1E9"!A
M=F5R86=E(&=R86YT(&1A=&4@9F%I<B!V86QU92!P97(@<VAA<F4@;V8@96UP
M;&]Y964-"B!S=&]C:R!O<'1I;VYS(&=R86YT960@9'5R:6YG('1H92!Y96%R
M<R!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+`T*(#(P,3,L(#(P,3(@86YD(#(P
M,3$@=V%S("0T+C$T+"`D,BXY-R!A;F0@)#$N,30L(')E<W!E8W1I=F5L>2X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE('1O=&%L(&EN
M=')I;G-I8R!V86QU92!O9B!S=&]C:R!O<'1I;VYS(&5X97)C:7-E9"!W87,@
M)#4N-PT*(&UI;&QI;VXL("0P+C@@;6EL;&EO;B!A;F0@)#`N,B!M:6QL:6]N
M(&1U<FEN9R!T:&4@>65A<G,@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$S+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN($-A<V@@<F5C96EV
M960-"B!F<F]M('1H92!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS('=A<R!A
M<'!R;WAI;6%T96QY("0P+C8@;6EL;&EO;BP-"B`D,"XQ(&UI;&QI;VX@86YD
M("0P+C$@;6EL;&EO;B!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B-X
M03`[,S$L#0H@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P
M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@87-S=6UP=&EO;G,@=7-E9"!T
M;R!E<W1I;6%T92!T:&4@9F%I<B!V86QU92!O9B!S=&]C:R!O<'1I;VYS#0H@
M=7-I;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I;F<@;6]D96P@
M=V5R92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-
M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT
M<CX-"B`\=&0@=VED=&@],T0W-24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$8V5N=&5R/@T*(#QB/EEE87(F(WA!,#ME;F1E9"8C>$$P.T1E8V5M8F5R
M)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX-"B`\8CXF(WA!
M,#LR,#$S)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(^#0H@/&(^)B-X03`[,C`Q,B8C>$$P.SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M/@T*(#QB/B8C>$$P.S(P,3$F(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($5M<&QO>65E(%-T;V-K($]P=&EO;G,Z/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*(%)I<VLM9G)E92!I;G1E<F5S="!R871E/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XY/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XP+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C=&5D(&1I
M=FED96YD('EI96QD/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,"XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C`N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X<&5C
M=&5D('9O;&%T:6QI='D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XW,BXT/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,RXT/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XW,BXY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@17AP96-T960@=&5R;2`H>65A<G,I/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BXQ/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C8N,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XV+C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T)SX-"B`\:3Y2:7-K+69R964@:6YT97)E<W0@<F%T93PO:3XF(W@R
M,#$T.U1H92!R:7-K+69R964@:6YT97)E<W0@<F%T90T*(&%S<W5M<'1I;VX@
M:7,@8F%S960@;VX@;V)S97)V960@:6YT97)E<W0@<F%T97,@87!P<F]P<FEA
M=&4@9F]R('1H90T*(&5X<&5C=&5D('1E<FT@;V8@=&AE('-T;V-K(&]P=&EO
M;B!G<F%N=',N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\:3Y%>'!E8W1E9"!D:79I9&5N
M9"!Y:65L9#PO:3XF(W@R,#$T.U1H92!E>'!E8W1E9"!D:79I9&5N9"!Y:65L
M9`T*(&%S<W5M<'1I;VX@:7,@8F%S960@;VX@=&AE(&9A8W0@=&AA="!W92!H
M879E(&YE=F5R('!A:60@8V%S:`T*(&1I=FED96YD<R!A;F0@:&%V92!N;R!P
M<F5S96YT(&EN=&5N=&EO;B!T;R!P87D@8V%S:"!D:79I9&5N9',N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T)SX-"B`\:3Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]I/B8C>#(P,30[
M5&AE(&5X<&5C=&5D('9O;&%T:6QI='D@87-S=6UP=&EO;@T*(&ES(&)A<V5D
M(&]N('9O;&%T:6QI=&EE<R!O9B!A('!E97(@9W)O=7`@;V8@<VEM:6QA<B!C
M;VUP86YI97,@=VAO<V4-"B!S:&%R92!P<FEC97,@87)E('!U8FQI8VQY(&%V
M86EL86)L92X@5&AE('!E97(@9W)O=7`@=V%S(&1E=F5L;W!E9`T*(&)A<V5D
M(&]N(&-O;7!A;FEE<R!I;B!T:&4@8FEO=&5C:&YO;&]G>2!I;F1U<W1R>2X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU43U`Z(#$R<'0G/@T*(#QI/D5X<&5C=&5D('1E<FT\+VD^)B-X,C`Q-#M4
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M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M5$]0.B`Q,G!T)SX-"B`\:3Y&;W)F96ET=7)E<SPO:3XF(W@R,#$T.U=E(')E
M9'5C92!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS90T*(&9O<B!E
M<W1I;6%T960@9F]R9F5I='5R97,N($9O<F9E:71U<F5S(&%R92!E<W1I;6%T
M960@870@=&AE('1I;64@;V8-"B!G<F%N="!A;F0@<F5V:7-E9"P@:68@;F5C
M97-S87)Y+"!I;B!S=6)S97%U96YT('!E<FEO9',@:68@86-T=6%L#0H@9F]R
M9F5I='5R97,@9&EF9F5R(&9R;VT@=&AO<V4@97-T:6UA=&5S+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS1#`^#0H@
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M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\8CY9
M96%R($5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q
M,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L
M,C0V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
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M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#$W-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,S@\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,C8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,RPT,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PU-3`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^.#(U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M(%1H92!T;W1A;"!C;VUP96YS871I;VX@8V]S="!R96QA=&5D('1O(&YO;BUV
M97-T960@87=A<F1S(&YO="!Y970-"B!R96-O9VYI>F5D('=A<R`D-RXX(&UI
M;&QI;VX@87,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RX@5&AE#0H@=V5I
M9VAT960M879E<F%G92!P97)I;V0@;W9E<B!W:&EC:"!T:&ES(&5X<&5N<V4@
M:7,@97AP96-T960@=&\@8F4-"B!R96-O9VYI>F5D(&ES(&%P<')O>&EM871E
M;'D@,BXS('EE87)S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^16UP;&]Y964@4W1O
M8VL@4'5R8VAA<V4@4&QA;CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
M(#0E)SX-"B!);B!/8W1O8F5R(#(P,3(L('=E(&%D;W!T960@=&AE(#(P,3(@
M16UP;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;@T*("@F(W@R,#%#.S(P,3(@
M4'5R8VAA<V4@4&QA;B8C>#(P,40[*2P@=VAI8V@@96YA8FQE<R!P87)T:6-I
M<&%N=',@=&\-"B!C;VYT<FEB=71E('5P('1O(#$U)2!O9B!S=6-H('!A<G1I
M8VEP86YT)B-X,C`Q.3MS(&5L:6=I8FQE#0H@8V]M<&5N<V%T:6]N(&1U<FEN
M9R!A(&1E9FEN960@<F]L;&EN9R!S:7@M;6]N=&@@<&5R:6]D<R!T;R!P=7)C
M:&%S90T*(&]U<B!C;VUM;VX@<W1O8VLN(%1H92!P=7)C:&%S92!P<FEC92!O
M9B!C;VUM;VX@<W1O8VL@=6YD97(@=&AE(#(P,3(-"B!0=7)C:&%S92!0;&%N
M('=I;&P@8F4@=&AE(&QE<W-E<B!O9CH@*&DI)B-X03`[.#4E(&]F('1H92!F
M86ER#0H@;6%R:V5T('9A;'5E(&]F(&]U<B!C;VUM;VX@<W1O8VL@870@=&AE
M(&EN8V5P=&EO;B!O9B!T:&4@96YR;VQL;65N=`T*('!E<FEO9"!O<B`H:6DI
M)B-X03`[.#4E(&]F('1H92!F86ER(&UA<FME="!V86QU92!O9B!O=7(@8V]M
M;6]N#0H@<W1O8VL@870@=&AE(&%P<&QI8V%B;&4@<'5R8VAA<V4@9&%T92X@
M5V4@:7-S=65D(#0X+#`S-2!S:&%R97,@;V8-"B!C;VUM;VX@<W1O8VL@=6YD
M97(@=&AE(#(P,3(@4'5R8VAA<V4@4&QA;B!F;W(@=&AE('EE87(@96YD960-
M"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S+B!!<R!O9B!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$S(#0V,"PR.#,@<VAA<F5S#0H@;V8@;W5R(&-O;6UO;B!S=&]C
M:R!W97)E(')E<V5R=F5D(&9O<B!F=71U<F4@:7-S=6%N8V4@86YD(&AA=F4@
M8F5E;@T*(&%U=&AO<FEZ960@9F]R('!U<F-H87-E('5N9&5R('1H92`R,#$R
M(%!U<F-H87-E(%!L86XN/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E
M,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE
M971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY$969I;F5D($-O;G1R:6)U=&EO;B!0;&%N/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969I;F5D($-O;G1R:6)U
M=&EO;B!0;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T
M;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N)SX-"B`\8CXQ,2X@1&5F:6YE9"!#;VYT<FEB=71I;VX@4&QA;CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB
M;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@26X@,C`P.2P@=V4@97-T
M86)L:7-H960@86X@96UP;&]Y964@-#`Q*&LI('-A;&%R>2!D969E<G)A;"!P
M;&%N#0H@*"8C>#(P,4,[-#`Q*&LI(%!L86XF(W@R,#%$.RD@8V]V97)I;F<@
M86QL(&5L:6=I8FQE(&5M<&QO>65E<RX@06-T:79E#0H@96UP;&]Y965S('=H
M;R!A<F4@870@;&5A<W0@,3@@>65A<G,@;VQD(&%N9"!A<F4@;F]T(&]T:&5R
M=VES90T*(&1I<W%U86QI9FEE9"!U;F1E<B!T:&4@=&5R;7,@;V8@=&AE(#0P
M,2AK*2!0;&%N(&%R92!E;&EG:6)L92!T;PT*('!A<G1I8VEP871E+B!%;7!L
M;WEE97,@;6%Y(&-O;G1R:6)U=&4@=7`@=&\@-3`E(&]F('1H96ER#0H@8V]M
M<&5N<V%T:6]N('!E<B!Y96%R("AS=6)J96-T('1O(&$@;6%X:6UU;2!L:6UI
M="!P<F5S8W)I8F5D(&)Y#0H@9F5D97)A;"!T87@@;&%W*2X@56YD97(@=&AE
M(#0P,2AK*2!0;&%N+"!W92!M87D@96QE8W0@=&\@;6%T8V@@80T*(&1I<V-R
M971I;VYA<GD@<&5R8V5N=&%G92!O9B!E;7!L;WEE92!C;VYT<FEB=71I;VYS
M+B!792!H879E(&5L96-T960-"B!T;R!M871C:"`R-24@;V8@96UP;&]Y965S
M)B-X,C`Q.3L@8V]N=')I8G5T:6]N<R!U<"!T;R`V)2!O9B!T:&4-"B!E;7!L
M;WEE97,F(W@R,#$Y.R!E;&EG:6)L92!S86QA<GDN(%=E(&UA9&4@)#`N,2!M
M:6QL:6]N+"`D,"XQ#0H@;6EL;&EO;B!A;F0@)#`N,2!M:6QL:6]N(&EN(&UA
M=&-H:6YG(&-O;G1R:6)U=&EO;G,@9F]R('1H92!Y96%R<PT*(&5N9&5D($1E
M8V5M8F5R)B-X03`[,S$L(#(P,3,L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I
M=F5L>2X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U
M.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?
M,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE970Q
M.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN
M8V]M92!487AE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YC;VUE(%1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^,3(N($EN8V]M92!487AE<SPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W
M:6YG('1A8FQE('-U;6UA<FEZ97,@=&AE(&-O;7!O;F5N=',@;V8@;W5R(&EN
M8V]M92!T87@-"B`H8F5N969I="D@97AP96YS92`H:6X@=&AO=7-A;F1S*3H\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI
M9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-S4E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#$P(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\8CY996%R
M(&5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&(^,C`Q,3PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0W5R<F5N=#H\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@1F5D97)A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1')I9VAT/C(P-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@4W1A=&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/C$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#XQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^,3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#XQ
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#XQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1R:6=H=#XR,#8\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@1&5F97)R960Z/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9E9&5R86P\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG
M:'0^*#(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^*#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M4W1A=&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$<FEG:'0^*#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#XH,CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1')I9VAT/B@R-#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/B@Q,3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C
M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($EN8V]M92!T87@@*&)E;F5F:70I(&5X<&5N<V4\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH,C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,C`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@:7,@82!R96-O;F-I;&EA
M=&EO;B!O9B!T:&4@97AP96-T960@<W1A='5T;W)Y(&9E9&5R86P-"B!I;F-O
M;64@=&%X('!R;W9I<VEO;B!T;R!O=7(@86-T=6%L(&EN8V]M92!T87@@<')O
M=FES:6]N("AI;@T*('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0
M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O<F1E<CTS
M1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8V)3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E
M<CX\8CY996%R(&5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q
M,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@U+#DR,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#4R,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*(%-T871E(&EN8V]M92!T87AE<RP@;F5T(&]F
M(&9E9&5R86P@8F5N969I=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@Q+#`Y,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$L,#$V/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-#,R/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@5&%X(&-R961I=',\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPT,#8\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@T,C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V.#,\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!';W9E<FYM96YT(&=R86YT/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@8V]N
M=F5R=&EB;&4@;F]T92!P87EA8FQE/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-#4V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M,3@S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QO<W,@;VX@9&5B="!E>'1I
M;F=U:7-H;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-CDR/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-H86YG
M92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^.2PP,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-2PS.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPP-3@\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R:6]R('EE87(@=')U92UU
M<#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,S4\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@S-C@\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C,S,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@4W1O8VL@8V]M<&5N<V%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-C8W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0V
M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-#@\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#@V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C$Q/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($EN8V]M92!T87@@*&)E;F5F:70I(&5X<&5N<V4\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XH,C,\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,C`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T
M.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4
M+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE
M<R!T:&4@<VEG;FEF:6-A;G0@8V]M<&]N96YT<R!O9B!O=7(-"B!D969E<G)E
M9"!T87@@87-S971S(&%N9"!L:6%B:6QI=&EE<R`H:6XF(WA!,#MT:&]U<V%N
M9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T
M)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0W-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX\8CY$
M96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!$969E<G)E9"!T87@@87-S971S.CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
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M+#0V,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PU,C@\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E<V5A<F-H
M(&%N9"!D979E;&]P;65N="!A;F0@;W1H97(@=&%X(&-R961I=',\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#<R-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ+#DX,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@1&5F97)R960@<F5V96YU93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C,L.3DY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C<L,S(R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!);G1A;F=I8FQE<R!A;F0@<')O<&5R='D@86YD(&5Q=6EP;65N
M="!B87-I<R!D:69F97)E;F-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2PW.38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PR
M,3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PR.3<\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-#4Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@5&]T86P@9&5F97)R960@=&%X(&%S<V5T<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,CDL,C<Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3DL
M-3`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;"!D969E<G)E
M9"!T87@@;&EA8FEL:71I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Y
M-S,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(R-CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!.970@9&5F97)R960@=&%X(&%S<V5T/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR."PS,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.2PR
M-SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%9A;'5A=&EO;B!A;&QO
M=V%N8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R."PS,#8\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#$Y+#(W.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!.970@9&5F97)R960@=&%X(&%S<V5T/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)2<^
M#0H@1F]R(&%L;"!P97)I;V1S('!R97-E;G1E9"P@=V4@:&%V92!D971E<FUI
M;F5D('1H870@:70@:7,@;6]R90T*(&QI:V5L>2!T:&%N(&YO="!T:&%T(&]U
M<B!D969E<G)E9"!T87@@87-S970@=VEL;"!N;W0@8F4@<F5A;&EZ960N#0H@
M06-C;W)D:6YG;'DL('=E(&AA=F4@<F5C;W)D960@82!V86QU871I;VX@86QL
M;W=A;F-E('1O(&9U;&QY(&]F9G-E=`T*('1H92!N970@9&5F97)R960@=&%X
M(&%S<V5T(&]F("0R."XS)B-X03`[;6EL;&EO;BX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q
M,RP@=V4@:&%D(&9E9&5R86P@86YD($-A;&EF;W)N:6$@=&%X(&YE=`T*(&]P
M97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@;V8@)#0T+C(F(WA!,#MM:6QL
M:6]N(&%N9"`D-3(N-@T*(&UI;&QI;VXL(')E<W!E8W1I=F5L>2P@=VAI8V@@
M8F5G:6X@=&\@97AP:7)E(&EN(#(P,S`@86YD(#(P,S$N($%T#0H@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,RP@87!P<F]X:6UA=&5L>2`D,2XV(&UI;&QI;VX@
M;V8@=&AE(&YE=`T*(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@<F5L
M871E('1O('-T;V-K(&]P=&EO;B!E>&5R8VES97,L#0H@=VAI8V@@=VEL;"!R
M97-U;'0@:6X@86X@:6YC<F5A<V4@=&\@861D:71I;VYA;"!P86ED+6EN(&-A
M<&ET86P@86YD#0H@82!D96-R96%S92!I;B!I;F-O;64@=&%X97,@<&%Y86)L
M92!A="!T:&4@=&EM92!W:&5N('1H92!T87@@;&]S<PT*(&-A<G)Y9F]R=V%R
M9',@87)E('5T:6QI>F5D+B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S
M+"!W92!A;'-O#0H@:&%D(&9E9&5R86P@86YD($-A;&EF;W)N:6$@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT('1A>"!C<F5D:70-"B!C87)R>69O<G=A<F1S
M(&]F("0S+C8F(WA!,#MM:6QL:6]N(&%N9"`D,BXX)B-X03`[;6EL;&EO;BP-
M"B!R97-P96-T:79E;'DN(%1H92!F961E<F%L(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!T87@@8W)E9&ET#0H@8V%R<GEF;W)W87)D<R!W:6QL(&)E9VEN
M('1O(&5X<&ER92!I;B`R,#(Y+B!4:&4@0V%L:69O<FYI82!R97-E87)C:`T*
M(&%N9"!D979E;&]P;65N="!T87@@8W)E9&ET(&-A<G)Y9F]R=V%R9',@87)E
M(&%V86EL86)L90T*(&EN9&5F:6YI=&5L>2X@07,@;V8@1&5C96UB97(@,S$L
M(#(P,3,L('=E(&%L<V\@:&%D("0P+C(@;6EL;&EO;B!O9@T*($9E9&5R86P@
M06QT97)N871I=F4@36EN:6UU;2!487@@0W)E9&ET(&-A<G)Y9F]R=V%R9',@
M=&AA="!A<F4-"B!A=F%I;&%B;&4@:6YD969I;FET96QY+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@
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M87@@4F5F;W)M($%C="!O9B`Q.3@V("AT:&4@06-T*2!L:6UI=',@80T*(&-O
M;7!A;GDF(W@R,#$Y.W,@86)I;&ET>2!T;R!U=&EL:7IE(&-E<G1A:6X@=&%X
M(&-R961I="!C87)R>69O<G=A<F1S#0H@86YD(&YE="!O<&5R871I;F<@;&]S
M<R!C87)R>69O<G=A<F1S(&EN('1H92!E=F5N="!O9B!A(&-U;75L871I=F4-
M"B!C:&%N9V4@:6X@;W=N97)S:&EP<R!I;B!E>&-E<W,@;V8@-3`E(&%S(&1E
M9FEN960@:6X@=&AE($%C="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)2<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('1H92!C:&%N
M9V5S(&EN('1H92!A;6]U;G0@;V8@;W5R#0H@=6YR96-O9VYI>F5D('1A>"!B
M96YE9FET<R`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z
M(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$
M,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-S0E/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R
M/CQB/EEE87(@16YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"96=I
M;FYI;F<@8F%L86YC92!O9B!U;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4V.3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-#`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR.#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($EN8W)E87-E
M("AD96-R96%S92D@9F]R('!R:6]R('EE87(@=&%X('!O<VET:6]N<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
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M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!);F-R96%S92!F;W(@8W5R<F5N="!Y96%R('1A
M>"!P;W-I=&EO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS
M.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L,#DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4V.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@26YC;'5D960@:6X@
M=&AE(&)A;&%N8V4@;V8@=6YR96-O9VYI>F5D('1A>"!B96YE9FET<R!A=`T*
M($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L(&ES("0Q+C$@;6EL;&EO;B!T:&%T
M+"!I9B!R96-O9VYI>F5D+"!W;W5L9`T*(&YO="!I;7!A8W0@;W5R(&EN8V]M
M92!T87@@8F5N969I="!O<B!E9F9E8W1I=F4@=&%X(')A=&4@87,@;&]N9R!A
M<PT*(&]U<B!D969E<G)E9"!T87@@87-S970@<F5M86EN<R!S=6)J96-T('1O
M(&$@9G5L;"!V86QU871I;VX-"B!A;&QO=V%N8V4N(%=E(&1O(&YO="!E>'!E
M8W0@86YY('-I9VYI9FEC86YT(&EN8W)E87-E<R!O<B!D96-R96%S97,-"B!T
M;R!O=7(@=6YR96-O9VYI>F5D('1A>"!B96YE9FET<R!W:71H:6X@=&AE(&YE
M>'0@,3(@;6]N=&AS+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-
M"B!792!A<F4@<W5B:F5C="!T;R!T87AA=&EO;B!I;B!T:&4@56YI=&5D(%-T
M871E<R!A;F0@0V%L:69O<FYI82X@5V4-"B!A<F4@<W5B:F5C="!T;R!I;F-O
M;64@=&%X(&5X86UI;F%T:6]N(&)Y('1A>"!A=71H;W)I=&EE<R!I;B!T:&]S
M90T*(&IU<FES9&EC=&EO;G,@9F]R(#(P,#D@86YD(&9O<G=A<F0N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($ET(&ES(&]U<B!P<F%C=&EC
M92!T;R!R96-O9VYI>F4@:6YT97)E<W0@86YD+V]R('!E;F%L=&EE<R!R96QA
M=&5D#0H@=&\@:6YC;VUE('1A>"!M871T97)S(&EN(&EN8V]M92!T87@@97AP
M96YS92X@1F]R('1H92!Y96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3,L(#(P,3(@86YD(#(P,3$L('=E(&AA=F4@;F]T(')E8V]G;FEZ960@
M86YY#0H@:6YT97)E<W0@;W(@<&5N86QT:65S(')E;&%T960@=&\@:6YC;VUE
M('1A>&5S+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4F5L871E9"U087)T>2!4<F%N<V%C=&EO;G,\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;&%T960M4&%R='D@5')A;G-A8W1I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M)SX-"B`\8CXQ,RX@4F5L871E9"U087)T>2!4<F%N<V%C=&EO;G,\+V(^/"]P
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M
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M"B!S97)V:6-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T
M.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ
M93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*($EN($%U
M9W5S="`R,#$S+"!W92!E;G1E<F5D(&EN=&\@86X@86UE;F1M96YT('1O('1H
M92!!;65N9&5D(&%N9`T*(%)E<W1A=&5D($QI8V5N<V4@86YD($-O;&QA8F]R
M871I;VX@06=R965M96YT('=I=&@@27-I<R!A;F0@06QN>6QA;0T*(&1A=&5D
M($IA;G5A<GDF(WA!,#LQ+"`R,#`Y+"!A<R!A;65N9&5D(&EN($IU;F4@,C`Q
M,"!A;F0@3V-T;V)E<@T*(#(P,3$@*&%S)B-X03`[86UE;F1E9"P@=&AE("8C
M>#(P,4,[06UE;F1M96YT)B-X,C`Q1#LI+B!5;F1E<B!T:&4-"B!T97)M<R!O
M9B!T:&4@06UE;F1M96YT+"!T:&4@<&%R=&EE<R!A9W)E960@=&\@;W5R('5S
M92!O9B!C97)T86EN#0H@06QN>6QA;2UC;VYT<F]L;&5D(&EN=&5L;&5C='5A
M;"!P<F]P97)T>2!C;VYC97)N:6YG('1H92!U<V4@86YD#0H@;6%N=69A8W1U
M<F4@;V8@1V%L3D%C(&-O;FIU9V%T97,@*"8C>#(P,4,[1V%L3D%C)B-X03`[
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M06UE;F1M96YT+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[
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M=&AE(%-E<G9I8V5S($%G<F5E;65N="`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@
M/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G
M:6XM8F]T=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@8F]R9&5R/3-$
M,"!S='EL93TS1"="3U)$15(M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<@86QI9VX],T1C
M96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<W)3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M+C`P<'0@<V]L:60@(S`P,#`P,"<^#0H@/&(^665A<G,F(WA!,#ME;F1E9"8C
M>$$P.T1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/C(P,3,\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,CPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CXR
M,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!397)V:6-E<R!P97)F
M;W)M960@;W(@;W5T+6]F+7!O8VME="!E>'!E;G-E<R!P86ED('1O($%L;GEL
M86T\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-34P/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XR/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX/"]T
M9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4V5L96-T960@475A<G1E<FQY($9I;F%N
M8VEA;"!$871A/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y396QE8W1E9"!1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB
M/C$T+B!396QE8W1E9"!1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$@*%5N875D
M:71E9"D\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE
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M>&-E<'0@<&5R('-H87)E(&1A=&$I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@
M,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U-R4^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^1F]R('1H92!Q=6%R
M=&5R<R!E;F1I;F<\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/@T*(#QB/DUA
M<F-H)B-X03`[,S$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<CX\8CY*=6YE)B-X03`[,S`\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX-"B`\8CY3
M97!T96UB97(F(WA!,#LS,#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R/@T*(#QB/D1E8V5M8F5R)B-X03`[,S$\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#QB/C(P,3,Z/"]B/CPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@4F5V96YU97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR,S@\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L-S4Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XV+#$Q.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PT
M-30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($]P97)A=&EN9R!E>'!E;G-E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C@L-S@X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CDL-#0U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL,#(S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#$Q-CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@3F5T(&QO<W,\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH-RPR,CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@W+#,T.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(L,38T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
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M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"87-I8R!N970@;&]S<R!P97(@<VAA
M<F4\<W5P('-T>6QE/3-$)T9/3E0M4TE:13H@.#4E.R!615)424-!3"U!3$E'
M3CH@=&]P)SXH,2D\+W-U<#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#`N,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XR,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@P+C`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,#4\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!$:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93QS
M=7`@<W1Y;&4],T0G1D].5"U325I%.B`X-24[(%9%4E1)0T%,+4%,24=..B!T
M;W`G/B@Q*2@R*3PO<W5P/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH
M,"XR,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C(P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#`N,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XQ,3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X]
M,T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P
M86X],T0T/CPO=&0^#0H@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*(#QB/C(P,3(Z/"]B/CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4F5V
M96YU97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS-#0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,L,S`Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR+#@P.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR,S@\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]P
M97)A=&EN9R!E>'!E;G-E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C4L-3(U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L.#8W
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,S0Q/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C<L-30Q/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4
M.B`M,65M)SX-"B!.970@;&]S<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@R+#(T.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(L-3DY
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-2PV.#4\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B@V+#@W-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E
M<B!S:&%R93QS=7`@<W1Y;&4],T0G1D].5"U325I%.B`X-24[(%9%4E1)0T%,
M+4%,24=..B!T;W`G/B@Q*3PO<W5P/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH,3,N,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,3`N-S@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,34N.3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XR
M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!B;W)D97(],T0P/@T*(#QT<CX-
M"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T/B@Q
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M"B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)2!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-"4@86QI9VX],T1L969T/B@R*3PO=&0^#0H@/'1D('9A;&EG;CTS1'1O
M<"!A;&EG;CTS1&QE9G0^07!P;&EC86)L92!A8V-O=6YT:6YG(&=U:61A;F-E
M#0H@<')O=FED97,@=&AA="!A(&-O;G1R86-T("AS=6-H(&%S('1H92`R,#$P
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M='D@:6YS=')U;65N=`T*(&1U<FEN9R!T:&4@<&5R:6]D+B!&;W(@=&AE<V4@
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M92!N;W1E('!A>6%B;&4N/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E
M,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?
M83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE970R,BYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S
M97%U96YT($5V96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#$X<'0G/@T*(#QB/C$U+B!3=6)S97%U96YT($5V96YT<SPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!);B!&96)R=6%R
M>2`R,#$T+"!W92!A;F0@4V%N;V9I(&5N=&5R960@:6YT;R!A('-E8V]N9"!A
M;65N9&5D(&%N9`T*(')E<W1A=&5D(&-O;&QA8F]R871I;VX@86YD(&QI8V5N
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M('!R;V=R86US('1A<F=E=&EN9R`\9F]N="!S='EL93TS1"=72$E412U34$%#
M13H@;F]W<F%P)SYM:5(M,C(Q+S(R,CPO9F]N=#X@9F]R(&]N8V]L;V=Y(&EN
M9&EC871I;VYS+`T*(&5A8V@@;V8@=VAI8V@@:7,@=&\@8F4@;&5D(&)Y('5S
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M;GD@<W5C:`T*('!R;V=R86TL('!R;W9I9&5D('1H870@)#$N,C4@;6EL;&EO
M;B!O9B!T:&4@)#(N-2!M:6QL:6]N('5P9G)O;G0-"B!O<'1I;VX@9F5E('!A
M:60@=&\@=7,@8GD@4V%N;V9I(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@2G5N
M92`R,#$S#0H@;W!T:6]N(&%G<F5E;65N="!W:6QL(&)E(&-R961I=&%B;&4@
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M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*
M($EN(&-O;FYE8W1I;VX@=VET:"!O=7(@96YT<GD@:6YT;R!T:&4@<V5C;VYD
M(&%M96YD960@86YD(')E<W1A=&5D#0H@8V]L;&%B;W)A=&EO;B!A;F0@;&EC
M96YS92!A9W)E96UE;G0@=VET:"!386YO9FDL('=E('-O;&0@86YD(&ES<W5E
M9`T*(#$L,S`S+#<X,"!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!T;R!!
M=F5N=&ES+"!A;B!E;G1I='D-"B!A9F9I;&EA=&5D('=I=&@@4V%N;V9I+"!I
M;B!A('!R:79A=&4@<&QA8V5M96YT(&%T(&$@<')I8V4@<&5R('-H87)E#0H@
M;V8@)#<N-C<@9F]R(&%N(&%G9W)E9V%T92!P=7)C:&%S92!P<FEC92!O9B`D
M,3`N,"!M:6QL:6]N+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%4T-!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY4:&4@0G5S:6YE<W,L($)A<VES(&]F(%!R97-E;G1A=&EO;B!A
M;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M("A0;VQI8VEE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E5S92!O9B!%<W1I;6%T97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP
M=#L@;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(#QB/CQI/E5S92!O9B!%<W1I;6%T
M97,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@
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M;6%T97,@87)E(&)A<V5D(&]N(&]U<B!K;F]W;&5D9V4@;V8@8W5R<F5N=`T*
M(&5V96YT<R!A;F0@86-T:6]N<R!W92!M87D@=6YD97)T86ME(&EN('1H92!F
M=71U<F4L(&%C='5A;"!R97-U;'1S#0H@;6%Y('5L=&EM871E;'D@9&EF9F5R
M(&9R;VT@=&AE<V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<RX\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2979E;G5E(%)E8V]G;FET:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y2979E;G5E(%)E
M8V]G;FET:6]N/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M96=I8R!A;&QI86YC92!A9W)E96UE;G1S+`T*(&%S('=E;&P@87,@9G5N9&EN
M9R!R96-E:79E9"!U;F1E<B!G;W9E<FYM96YT(&=R86YT<RX@5V4@<F5C;V=N
M:7IE#0H@<F5V96YU97,@=VAE;B!A;&P@9F]U<B!O9B!T:&4@9F]L;&]W:6YG
M(&-R:71E<FEA(&%R92!M970Z#0H@*#$I)B-X03`[<&5R<W5A<VEV92!E=FED
M96YC92!T:&%T(&%N(&%R<F%N9V5M96YT(&5X:7-T<SL-"B`H,BDF(WA!,#MD
M96QI=F5R>2!O9B!T:&4@<')O9'5C=',@86YD+V]R('-E<G9I8V5S(&AA<R!O
M8V-U<G)E9#L-"B`H,RDF(WA!,#MT:&4@<V5L;&EN9R!P<FEC92!I<R!F:7AE
M9"!O<B!D971E<FUI;F%B;&4[(&%N9`T*("@T*28C>$$P.V-O;&QE8W1A8FEL
M:71Y(&ES(')E87-O;F%B;'D@87-S=7)E9"X\+W`^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E
M;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*($UU;'1I<&QE(&5L96UE;G0@87)R86YG96UE;G1S+"!S=6-H
M(&%S(&]U<B!S=')A=&5G:6,@86QL:6%N8V4-"B!A9W)E96UE;G1S('=I=&@@
M4V%N;V9I+"!!<W1R85IE;F5C82!!0B`H)B-X,C`Q0SM!<W1R85IE;F5C828C
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M9`T*("AI:2DF(WA!,#MI9B!T:&4@86=R965M96YT(&EN8VQU9&5S(&$@9V5N
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M:6YG(&$@)B-X,C`Q0SMB97-T#0H@97-T:6UA=&4@;V8@<V5L;&EN9R!P<FEC
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M9B!A8V-O=6YT:6YG+`T*(&%N9"!W92!R96-O9VYI>F4@=&AE(&-O;G-I9&5R
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M03`[/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.R!M87)G:6XM
M8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@/&D^36EL97-T;VYE<SPO:3X\+W`^#0H@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!T97AT
M+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@5V4@<F5C;V=N:7IE(')E=F5N=64@9G)O;2!M:6QE
M<W1O;F4@<&%Y;65N=',@=VAE;B!E87)N960L('!R;W9I9&5D#0H@=&AA="`H
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M=&EO;B!O9B!T:&4@86=R965M96YT+"`H:6DI)B-X03`[=V4@9&\@;F]T(&AA
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M"B!P87EM96YT(&ES(&YO;BUR969U;F1A8FQE.R`H:6DI)B-X03`[86-H:65V
M96UE;G0@;V8@=&AE(&UI;&5S=&]N90T*('=A<R!N;W0@<F5A<V]N86)L>2!A
M<W-U<F5D(&%T('1H92!I;F-E<'1I;VX@;V8@=&AE(&%R<F%N9V5M96YT.PT*
M("AI:6DI)B-X03`[<W5B<W1A;G1I=F4@969F;W)T(&ES(&EN=F]L=F5D('1O
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M+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T
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M:61A=&4@9V5N97)A;&QY#0H@:6YC<F5A<V5S+CPO<#X-"B`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\:3Y'
M<F%N="!2979E;G5E/"]I/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P
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M<G)E9"!R979E;G5E('5N=&EL(&5A<FYE9"X\+W`^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&D^1&5F
M97)R960@4F5V96YU93PO:3X\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M9FEE9"!A<R!N;VXM8W5R<F5N="!D969E<G)E9"!R979E;G5E+CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[
M(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^4W1O8VLM
M0F%S960@0V]M<&5N<V%T:6]N/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
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M=&EN9R!P97)I;V0N/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P
M=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!792!A
M8V-O=6YT(&9O<B!S=&]C:R!O<'1I;VYS(&=R86YT960@=&\@;F]N+65M<&QO
M>65E<RP@=VAI8V@-"B!P<FEM87)I;'D@8V]N<VES="!O9B!M96UB97)S(&]F
M(&]U<B!S8VEE;G1I9FEC(&%D=FES;W)Y(&)O87)D+`T*('5S:6YG('1H92!F
M86ER('9A;'5E(&%P<')O86-H+B!3=&]C:R!O<'1I;VYS(&=R86YT960@=&\-
M"B!N;VXM96UP;&]Y965S(&%R92!S=6)J96-T('1O('!E<FEO9&EC(')E=F%L
M=6%T:6]N(&]V97(@=&AE:7(-"B!V97-T:6YG('1E<FUS+CPO<#X-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#HP<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y297-E87)C:"!A
M;F0@1&5V96QO<&UE;G0\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M)SX-"B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@87)E(&5X<&5N
M<V5D(&%S(&EN8W5R<F5D(&%N9"!I;F-L=61E#0H@8V]M<&5N<V%T:6]N(&%N
M9"!R96QA=&5D(&)E;F5F:71S+"!N;VXM8V%S:"!S=&]C:RUB87-E9`T*(&-O
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M96X@<V5R=FEC97,@87)E('!E<F9O<FUE9"X\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O
M;64@5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O
M;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*(#QB/CQI/DEN8V]M92!487AE<SPO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@
M=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86XG/@T*(%1H92!A8V-O=6YT:6YG(&=U:61A;F-E(&9O
M<B!A8V-O=6YT:6YG(&9O<B!U;F-E<G1A:6YT>2!I;B!I;F-O;64-"B!T87AE
M<R!P<F5S8W)I8F5S(&$@<F5C;V=N:71I;VX@=&AR97-H;VQD(&%N9"!M96%S
M=7)E;65N="!A='1R:6)U=&4-"B!C<FET97)I82!F;W(@=&AE(&9I;F%N8VEA
M;"!S=&%T96UE;G0@<F5C;V=N:71I;VX@86YD(&UE87-U<F5M96YT(&]F#0H@
M=&%X('!O<VET:6]N<R!T86ME;B!O<B!E>'!E8W1E9"!T;R!B92!T86ME;B!I
M;B!A('1A>"!R971U<FXN($9O<@T*('1H;W-E(&)E;F5F:71S('1O(&)E(')E
M8V]G;FEZ960L(&$@=&%X('!O<VET:6]N(&UU<W0@8F4@;6]R92!L:6ME;'D-
M"B!T:&%N(&YO="!T;R!B92!S=7-T86EN960@=7!O;B!E>&%M:6YA=&EO;B!B
M>2!T87AI;F<-"B!A=71H;W)I=&EE<RX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R
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M86YC:6%L(')E<&]R=&EN9R!A;F0@=&AE('1A>`T*(')E<&]R=&EN9R!B87-I
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M(&1E9F5R<F5D('1A>"!A<W-E=',@=VEL;"!B92!R96%L:7IE9"X\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER(%9A;'5E($]P=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ
M.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^1F%I<B!686QU92!/
M<'1I;VX\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P
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M9&5C:7-I;VX@86)O=70@=&AE(&5L96-T:6]N(&ES.B`Q*2!A<'!L:65D(&EN
M<W1R=6UE;G0@8GD-"B!I;G-T<G5M96YT+"`R*2!I<G)E=F]C86)L92P@86YD
M(#,I(&%P<&QI960@=&\@86X@96YT:7)E#0H@:6YS=')U;65N="X\+W`^#0H@
M/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P
M=#L@=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($EN($IU;'D@,C`Q,BP@=V4@86UE;F1E
M9"!A;F0@<F5S=&%T960@;W5R("0U+C`@;6EL;&EO;B!C;VYV97)T:6)L90T*
M('!R;VUI<W-O<GD@;F]T92!O<FEG:6YA;&QY(&ES<W5E9"!I;B!&96)R=6%R
M>2`R,#$P('1O($=32PT*("@F(W@R,#%#.S(P,3`@1U-+(&YO=&4F(W@R,#%$
M.RDL('=H:6-H('=A<R!A8V-O=6YT960@9F]R(&%S(&$@9&5B=`T*(&5X=&EN
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M/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^
M0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X
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M/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAO<G0M5&5R;2!);G9E<W1M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^
M4VAO<G0M5&5R;2!);G9E<W1M96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI
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M,3D[(&5Q=6ET>2`H9&5F:6-I="DN(%=E(&1E=&5R;6EN92!T:&4@<F5A;&EZ
M960-"B!G86EN<R!O<B!L;W-S97,@;V8@879A:6QA8FQE+69O<BUS86QE('-E
M8W5R:71I97,@=7-I;F<@=&AE('-P96-I9FEC#0H@:61E;G1I9FEC871I;VX@
M;65T:&]D(&%N9"!I;F-L=61E(&YE="!R96%L:7IE9"!G86EN<R!A;F0@;&]S
M<V5S(&EN#0H@:6YT97)E<W0@:6YC;VUE+CPO<#X-"B`\<"!S='EL93TS1&9O
M;G0M<VEZ93HQ,G!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T
M/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#L@
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M;0T*(&EN=F5S=&UE;G1S(&%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@
M86YD(#(P,3(N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N8V5N=')A=&EO;G,@;V8@0W)E
M9&ET(%)I<VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP=#L@;6%R9VEN+6)O='1O
M;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86XG/@T*(#QB/CQI/D-O;F-E;G1R871I;VYS(&]F($-R961I="!2:7-K
M/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA
M<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P
M<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@1FEN86YC:6%L
M(&EN<W1R=6UE;G1S('1H870@<&]T96YT:6%L;'D@<W5B:F5C="!U<R!T;R!S
M:6=N:69I8V%N=`T*(&-O;F-E;G1R871I;VYS(&]F(&-R961I="!R:7-K(&-O
M;G-I<W0@<')I;6%R:6QY(&]F(&-A<V@L(&-A<V@-"B!E<75I=F%L96YT<R!A
M;F0@<VAO<G0M=&5R;2!I;G9E<W1M96YT<RX@5V4@;6%I;G1A:6X@9&5P;W-I
M=',@:6X-"B!F961E<F%L;'D@:6YS=7)E9"!F:6YA;F-I86P@:6YS=&ET=71I
M;VYS(&EN(&5X8V5S<R!O9B!F961E<F%L;'D-"B!I;G-U<F5D(&QI;6ET<RX@
M5V4@:&%V92!N;W0@97AP97)I96YC960@86YY(&QO<W-E<R!I;B!S=6-H(&%C
M8V]U;G1S#0H@86YD(&)E;&EE=F4@=V4@87)E(&YO="!E>'!O<V5D('1O('-I
M9VYI9FEC86YT(')I<VLN(%=E(&UA:6YT86EN(&]U<@T*(&-A<V@@97%U:79A
M;&5N=',@86YD('-H;W)T+71E<FT@:6YV97-T;65N=',@=VET:"!T:')E92!F
M:6YA;F-I86P-"B!I;G-T:71U=&EO;G,N(%=E(&EN=F5S="!O=7(@97AC97-S
M(&-A<V@@<')I;6%R:6QY(&EN(&-O;6UE<F-I86P-"B!P87!E<B!A;F0@9&5B
M="!I;G-T<G5M96YT<R!O9B!F:6YA;F-I86P@:6YS=&ET=71I;VYS+"!C;W)P
M;W)A=&EO;G,L#0H@52Y3+B!G;W9E<FYM96YT+7-P;VYS;W)E9"!A9V5N8VEE
M<R!A;F0@=&AE(%4N4RX@5')E87-U<GDN#0H@061D:71I;VYA;&QY+"!W92!E
M<W1A8FQI<VAE9"!G=6ED96QI;F5S(')E9V%R9&EN9R!A<'!R;W9E9`T*(&EN
M=F5S=&UE;G1S(&%N9"!M871U<FET:65S(&]F(&EN=F5S=&UE;G1S+"!W:&EC
M:"!A<F4@9&5S:6=N960@=&\-"B!M86EN=&%I;B!S869E='D@86YD(&QI<75I
M9&ET>2X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT
M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\
M8CX\:3Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]I/CPO8CX\+W`^#0H@/'`@
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M;F]M:6,@;&EF92!A<F4@97AP96YS960@87,-"B!I;F-U<G)E9"X\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1A;F=I8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!T.R!M
M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^/&D^26YT86YG:6)L97,\+VD^/"]B
M/CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O
M='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!792!C87!I=&%L:7IE(&-O
M<W1S('=H:6-H(&-O;G-I<W0@<')I;F-I<&%L;'D@;V8@;W5T<VED92!L96=A
M;`T*(&-O<W1S(&%N9"!F:6QI;F<@9F5E<R!R96QA=&5D('1O(&]B=&%I;FEN
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M,3(@>65A<G,@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RX\+W`^#0H@/'`@
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M86US+B!792!A;6]R=&EZ92!C87!I=&%L:7IE9`T*(&QI8V5N<V5S(&]V97(@
M=&AE:7(@97-T:6UA=&5D('5S969U;"!L:69E(&]R('1E<FT@;V8@=&AE(&%G
M<F5E;65N="P-"B!W:&EC:"!F;W(@8W5R<F5N="!L:6-E;G-E<R!I<R`Q,"!Y
M96%R<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@
M07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-
M"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T;VTZ
M,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B`\8CX\:3Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S
M/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'0[(&UA
M<F=I;BUB;W1T;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P
M<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5V4@<F5G=6QA
M<FQY(')E=FEE=R!T:&4@8V%R<GEI;F<@86UO=6YT(&]F(&]U<B!P<F]P97)T
M>2P@97%U:7!M96YT#0H@86YD(&EN=&%N9VEB;&4@87-S971S('1O(&1E=&5R
M;6EN92!W:&5T:&5R(&EN9&EC871O<G,@;V8@:6UP86ER;65N=`T*(&UA>2!E
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M9&5T97)M:6YE('=H971H97(@=&AE(&%S<V5T)B-X,C`Q.3MS('9A;'5E(&ES
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M96-E;6)E<B8C>$$P.S,Q+"`R,#$S+"`R,#$R(&%N9"`R,#$Q+CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-L:6YI8V%L(%1R:6%L(&%N9"!0<F4M0VQI;FEC86P@4W1U9'D@
M06-C<G5A;',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,'!T.R!M87)G:6XM8F]T=&]M
M.C!P=#L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@/&(^/&D^0VQI;FEC86P@5')I86P@86YD(%!R92U#;&EN:6-A
M;"!3='5D>2!!8V-R=6%L<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z
M-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86XG/@T*(%=E(&UA:V4@97-T:6UA=&5S(&]F(&]U<B!A8V-R=65D(&5X<&5N
M<V5S(&%S(&]F(&5A8V@@8F%L86YC92!S:&5E=`T*(&1A=&4@:6X@;W5R(&9I
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M;F0@=&AE(&QE=F5L(&]F(&5F9F]R="!T;R!B92!E>'!E;F1E9`T*(&EN(&5A
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M(&EN(&]U<@T*(&%C8W)U86QS+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E9VUE;G0@4F5P
M;W)T:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-
M"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T;VTZ
M,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B`\8CX\:3Y396=M96YT(%)E<&]R=&EN9SPO:3X\+V(^/"]P/@T*
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P
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M4W1A=&5S+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!R96AE;G-I=F4@3&]S<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4]
M,T0G;6%R9VEN+71O<#HQ.'!T.R!M87)G:6XM8F]T=&]M.C!P=#L@9F]N="US
M:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@/&(^
M/&D^0V]M<')E:&5N<VEV92!,;W-S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4]
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M<F5F97)R960@<W1O8VL@86YD#0H@<W1O8VMH;VQD97)S)B-X,C`Q.3L@97%U
M:71Y("AD969I8VET*2!F;W(@86QL('!E<FEO9',@<')E<V5N=&5D+CPO<#X-
M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E8VQA<W-I9FEC871I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y296-L87-S:69I
M8V%T:6]N<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
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M(&]R#0H@<W1A=&5M96YT<R!O9B!C87-H(&9L;W=S+CPO<#X-"B`\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C$X<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y296-E
M;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@
M=&5X="UI;F1E;G0Z-"4[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86XG/@T*($EN($IU;'D@,C`Q,RP@=&AE($9!4T(@:7-S
M=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T90T*($YO+B8C>$$P.S(P
M,3,M,3$L(#QI/E!R97-E;G1A=&EO;B!O9B!A;B!5;G)E8V]G;FEZ960@5&%X
M($)E;F5F:70-"B!7:&5N(&$@3F5T($]P97)A=&EN9R!,;W-S($-A<G)Y9F]R
M=V%R9"P@82!3:6UI;&%R(%1A>"!,;W-S+"!O<B!A#0H@5&%X($-R961I="!#
M87)R>69O<G=A<F0@17AI<W1S/"]I/B`H)B-X,C`Q0SM!4U4@,C`Q,RTQ,28C
M>#(P,40[*2X-"B!4:&ES('5P9&%T92!P<F]V:61E<R!E>'!L:6-I="!G=6ED
M86YC92!O;B!T:&4@9FEN86YC:6%L('-T871E;65N=`T*('!R97-E;G1A=&EO
M;B!O9B!A;B!U;G)E8V]G;FEZ960@=&%X(&)E;F5F:70@=VAE;B!A(&YE="!O
M<&5R871I;F<-"B!L;W-S(&-A<G)Y9F]R=V%R9"P@82!S:6UI;&%R('1A>"!L
M;W-S+"!O<B!A('1A>"!C<F5D:70@8V%R<GEF;W)W87)D#0H@97AI<W1S+B!4
M:&ES(&=U:61A;F-E(&ES(&5F9F5C=&EV92!P<F]S<&5C=&EV96QY(&9O<B!F
M:7-C86P@>65A<G,L#0H@86YD(&EN=&5R:6T@<&5R:6]D<R!W:71H:6X@=&AO
M<V4@>65A<G,L(&)E9VEN;FEN9R!A9G1E<@T*($1E8V5M8F5R)B-X03`[,34L
M(#(P,3,L('=I=&@@86X@;W!T:6]N(&9O<B!E87)L>2!A9&]P=&EO;BX@5V4-
M"B!I;G1E;F0@=&\@861O<'0@=&AI<R!G=6ED86YC92!I;B`R,#$T+"!A;F0@
M9&\@;F]T(&)E;&EE=F4@=&AE#0H@861O<'1I;VX@;V8@=&AI<R!S=&%N9&%R
M9"!W:6QL(&AA=F4@82!M871E<FEA;"!I;7!A8W0@;VX@;W5R#0H@9FEN86YC
M:6%L(&-O;F1I=&EO;BP@<F5S=6QT<R!O9B!O<&5R871I;VYS(&]R(')E;&%T
M960@9FEN86YC:6%L#0H@<W1A=&5M96YT(&1I<V-L;W-U<F5S+CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F5T($QO<W,@4&5R(%-H
M87)E("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0;W1E;G1I86QL>2!$:6QU=&EV92!396-U<FET:65S($YO="!)
M;F-L=61E9"!I;B!#86QC=6QA=&EO;B!O9B!$:6QU=&5D($YE="!,;W-S('!E
M<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M
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M;B!C;VUM;VX@97%U:79A;&5N="!S:&%R97,I.CPO<#X-"B`\<"!S='EL93TS
M1&9O;G0M<VEZ93HQ,G!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ
M,'!T/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
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M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E<CX\8CY9
M96%R<R!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE
M.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/C(P
M,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^
M/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P
M,#`P)SX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE
M.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!#;VYV
M97)T:6)L92!P<F5F97)R960@<W1O8VL@;W5T<W1A;F1I;F<\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,3,L-CDY+#DY.3PO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@0V]M;6]N('-T;V-K(&]P=&EO;G,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XS+#8S.2PR-S`\+W1D/@T*(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,2PX.#,L,S$Q/"]T9#X-"B`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C(L,S,X+#(U,#PO=&0^#0H@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS1"=F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@0V]N=F5R=&EB;&4@;F]T
M92!P87EA8FQE/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PT
M,3$L-C4Y/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M,S8V+#<X-SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z
M,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N
M="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F
M;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-
M"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PP-3`L.3(Y/"]T9#X-
M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR-3`L,#DX/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I
M>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,38L,#,X+#(T.3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@[/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P
M,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P
M,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X
M(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X
M(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B
M7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF
M+U=O<FMS:&5E=',O4VAE970R-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DEN=F5S=&UE;G1S("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-H
M;W)T+51E<FT@26YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P=#L@
M;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*(%1H92!F;VQL;W=I;F<@=&%B;&5S('-U
M;6UA<FEZ92!O=7(@<VAO<G0M=&5R;2!I;G9E<W1M96YT<R`H:6X-"B!T:&]U
M<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!T.VUA<F=I
M;BUT;W`Z,'!T.VUA<F=I;BUB;W1T;VTZ,'!T/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#$P,"4@8F]R9&5R/3-$,"!S='EL93TS1"="3U)$15(M0T],3$%04T4Z0T],
M3$%04T4[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE
M.C$P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V
M-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HX<'0G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!R;W=S<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P
M)SX\8CY-871U<FET>3QB<B`O/@T*("AI;B8C>$$P.WEE87)S*3PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@<F]W<W!A;CTS1#(^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!R;W=S<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S
M;VQI9"`C,#`P,#`P)SX\8CY!;6]R=&EZ960\8G(@+SX-"B!C;W-T/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,CXF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P
M,#`G/CQB/E5N<F5A;&EZ960\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@<F]W<W!A
M;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^17-T:6UA=&5D/&)R("\^#0H@9F%I
M<B8C>$$P.W9A;'5E/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!R
M;W=S<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H@/'`@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,#L@
M=VED=&@Z.#0N,C!P=#L@9F]N="US:7IE.CAP=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B`\8CY!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R
M,#$S/"]B/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@
M(S`P,#`P,"<^/&(^1V%I;G,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@
M<V]L:60@(S`P,#`P,"<^/&(^3&]S<V5S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S
M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ
M93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US
M:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@0V]R
M<&]R871E(&1E8G0@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(F(WA!,#MO<B8C>$$P.VQE<W,\+W1D/@T*(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C<Q+#0P,CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,SD\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
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M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;B<^#0H@0V5R=&EF:6-A=&5S(&]F(&1E<&]S:70\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR(&]R(&QE<W,\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$L-S$P/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ,2PW,3`\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($-O;6UE<F-I86P@<&%P97(\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ(&]R(&QE<W,\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPP-CD\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,CPO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/@T*
M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C8L,#<Q/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!$96)T('-E8W5R
M:71I97,@;V8@52Y3+B!G;W9E<FYM96YT+7-P;VYS;W)E9"!A9V5N8VEE<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$@;W(@;&5S<SPO=&0^
M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#`P,#PO=&0^#0H@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-RPP,#$\+W1D/@T*(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P
M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P
M,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P
M96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%1O=&%L/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ
M93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.38L,3@Q/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F
M;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C0R/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
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M;G0M<VEZ93HX<'0^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^.38L,3DX/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D
M;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D
M;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P
M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P
M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'0[;6%R
M9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*
M(#QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)2!B;W)D97(],T0P('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313I#
M3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I
M>F4Z,3!P="<@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS
M1#8U)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP
M="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(')O=W-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P
M,#`G/CQB/DUA='5R:71Y/&)R("\^#0H@*&EN)B-X03`[>65A<G,I/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,CXF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(')O=W-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T
M('-O;&ED(",P,#`P,#`G/CQB/D%M;W)T:7IE9#QB<B`O/@T*(&-O<W0\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P
M,#`P,"<^/&(^56YR96%L:7IE9#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!R;W=S
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CY%<W1I;6%T960\8G(@+SX-"B!F
M86ER)B-X03`[=F%L=64\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(')O=W-P86X],T0R/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z.'!T
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"B`\
M<"!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P
M.R!W:61T:#HX-"XR,'!T.R!F;VYT+7-I>F4Z.'!T.R!F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86XG/@T*(#QB/D%S(&]F($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3(\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI
M9"`C,#`P,#`P)SX\8CY'86EN<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P
M="!S;VQI9"`C,#`P,#`P)SX\8CY,;W-S97,\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US
M:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT
M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!#
M;W)P;W)A=&4@9&5B="!S96-U<FET:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,B!O<B!L97-S/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XT-"PX.3@\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C<\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
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M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O
M;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@
M9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^
M#0H@0V5R=&EF:6-A=&5S(&]F(&1E<&]S:70\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ)B-X03`[;W(F(WA!,#ML97-S/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,C`P/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XV+#(P,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B
M9V-O;&]R/3-$(T-#145&1B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@0V]M;65R8VEA;"!P87!E<CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C(@;W(@;&5S<SPO=&0^#0H@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XV+#0Y,CPO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-BPT.3(\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X
M('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@
M<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT
M+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*
M(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX
M<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-3<L-3DP/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M
M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#0Y/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-RPU-#@\+W1D/@T*(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U
M8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U
M8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP
M,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP
M,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R
M.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V
M-#AF+U=O<FMS:&5E=',O4VAE970R-BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R96UE;G1S("A4
M86)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&86ER(%9A;'5E($AI97)A<F-H>2!F;W(@07-S971S(&%N9"!,:6%B:6QI
M=&EE<R!-96%S=7)E9"!A="!&86ER(%9A;'5E(&]N(%)E8W5R<FEN9R!"87-I
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#!P
M="<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!P<F5S96YT<R!O=7(@9F%I<B!V
M86QU92!H:65R87)C:'D@9F]R(&%S<V5T<PT*(&%N9"!L:6%B:6QI=&EE<R!M
M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES(&%T
M#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!A;F0@,C`Q,B`H:6X@=&AO=7-A
M;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P
M/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y
M,B4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I
M9'1H/3-$-3DE/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L
M:6=N/3-$8V5N=&5R/CQB/D9A:7(@=F%L=64@87,@;V8@1&5C96UB97(F(WA!
M,#LS,2P-"B`R,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`Q/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`R/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E
M;"8C>$$P.S,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S<V5T<SH\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A<V@@97%U:79A;&5N=',\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3<L,3<P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ-RPQ-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($-O<G!O<F%T92!D96)T('-E8W5R:71I97,\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
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M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
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M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V5R=&EF:6-A=&5S(&]F(&1E<&]S
M:70\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PW,3`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PW,3`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@
M1&5B="!S96-U<FET:65S(&]F(%4N4RX@9V]V97)N;65N="US<&]N<V]R960@
M86=E;F-I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#`P
M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<L,#`Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;6UE<F-I86P@<&%P
M97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#`W,3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,#<Q/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,3$S+#,V.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-RPQ-S`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.38L,3DX/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*($QI86)I;&ET:65S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#;VYV97)T:6)L92!N
M;W1E<R!P87EA8FQE/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$L,C<Y/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,2PR-SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(^#0H@/'1D/CPO
M=&0^#0H@/'1D(&-O;'-P86X],T0Q-CX\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&
M86ER('9A;'5E(&%S(&]F($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,CPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY4;W1A;#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^3&5V96PF(WA!,#LQ/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"8C>$$P.S,\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A<V@@97%U:79A;&5N=',\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,SDL,S8S/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
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M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X
M03`[)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ
M96TG/@T*($-O<G!O<F%T92!D96)T('-E8W5R:71I97,\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
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M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R
M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V5R=&EF:6-A=&5S(&]F
M(&1E<&]S:70\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#(P
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,C`P
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;6UE<F-I86P@<&%P
M97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#0Y,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-#DR/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^.38L.3$Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Y+#,V,SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-RPU-#@\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M
M24Y$14Y4.B`M,65M)SX-"B!,:6%B:6QI=&EE<SH\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M-3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@0V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L93PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$P+#$S-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`L,3,T/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]N8VEL:6%T
M:6]N(&]F($QI86)I;&ET:65S($UE87-U<F5D(&%T($9A:7(@5F%L=64@;VX@
M475A<G1E<FQY($)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P="<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!P<F5S
M96YT<R!A(')E8V]N8VEL:6%T:6]N(&]F('1H92!L:6%B:6QI=&EE<PT*(&UE
M87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!Q=6%R=&5R;'D@8F%S:7,@=7-I
M;F<@<VEG;FEF:6-A;G0-"B!U;F]B<V5R=F%B;&4@:6YP=71S("A,979E;"`S
M*2!F<F]M($1E8V5M8F5R)B-X03`[,S$L(#(P,3(@=&\-"B!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$S("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.
M+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D
M97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W,R4^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C$E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^#0H@/&(^1F%I
M<B8C>$$P.U9A;'5E)B-X03`[365A<W5R96UE;G1S/&)R("\^#0H@57-I;F<@
M4VEG;FEF:6-A;G0\8G(@+SX-"B!5;F]B<V5R=F%B;&4@26YP=71S/&)R("\^
M#0H@*$QE=F5L(#,I/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"86QA
M;F-E(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3`L,3,T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!#:&%N
M9V4@:6X@97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@8V]N=F5R=&EB;&4@;F]T
M97,@<&%Y86)L93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M,30U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!"86QA;F-E(&%T
M($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,2PR-SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B
M7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF
M+U=O<FMS:&5E=',O4VAE970R-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-T<F%T96=I8R!!;&QI86YC97,@86YD($-O;&QA
M8F]R871I;VYS("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2979E;G5E(&9R;VT@4W1R871E9VEC($%L;&EA;F-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@
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M(&-O;&QA8F]R871I;VX@*&EN#0H@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T
M=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@8F]R9&5R/3-$,"!S='EL
M93TS1"="3U)$15(M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G(&%L:6=N/3-$8V5N=&5R
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V-R4^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M
M<VEZ93HX<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^
M/&(^665A<B!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US
M:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB
M/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P
M,"<^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C
M,#`P,#`P)SX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US
M:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT
M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!3
M86YO9FDM079E;G1I<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PS
M,S8\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#`S,#PO=&0^
M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`L,#,S/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B!'4TL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ+#<W.#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ+#DY-CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XS+#<S-#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R
M/3-$(T-#145&1B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;B<^#0H@07-T<F%:96YE8V$\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ+#@U.3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XU-3D\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@
M=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@0FEO9V5N($ED96,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU.38\+W1D/@T*(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$U/"]T9#X-"B`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^#0H@
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P
M,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P
M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX
M<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3DL-38Y/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+#<P,#PO=&0^#0H@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ,RPW-C<\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D
M;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D
M;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T
M.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7
M;W)K<VAE971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M96YT+"!N970@*%1A
M8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-U;6UA<GD@;V8@4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HV<'0[(&UA<F=I;BUB;W1T;VTZ,'!T.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@9F]L;&]W
M:6YG('1A8FQE('-U;6UA<FEZ97,@;W5R(&UA:F]R(&-L87-S97,@;V8@<')O
M<&5R='D@86YD#0H@97%U:7!M96YT("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\
M<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I
M;BUB;W1T;VTZ,'!T/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I
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M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP
M,'!T('-O;&ED(",P,#`P,#`G/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P
M,#`G/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P
M,"<^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL
M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ
M,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@3&%B;W)A
M=&]R>2!E<75I<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PS
M-#(\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L-3@S/"]T9#X-"B`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN
M9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N)SX-"B!#;VUP=71E<B!E<75I<&UE;G0@86YD('-O9G1W
M87)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$T/"]T9#X-
M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q-#PO=&0^#0H@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS1"=F;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@1G5R;FET=7)E(&%N9"!F
M:7AT=7)E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q.3PO
M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,SPO=&0^#0H@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;B<^#0H@3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.#`U/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C<U,3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS1"=F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;B<^#0H@0V]N<W1R=6-T:6]N(&EN('!R;V=R97-S
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$Y/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q,3PO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@[/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT
M+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-RPT.3D\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#<U,CPO=&0^#0H@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S='EL93TS
M1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P
M<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@3&5S<R!A8V-U
M;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT
M+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#,L-S,Q/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#0T,CPO
M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^*28C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X
M.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P
M,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P
M,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI
M9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED
M(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+#<V.#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#,Q,#PO=&0^
M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@[/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@
M(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@
M(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@
M9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@
M9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^26YT86YG:6)L92!!<W-E=',L(&YE="`H5&%B;&5S
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M
M;6%R>2!O9B!);G1A;F=I8FQE($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV
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M9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&)O<F1E<CTS
M1#`@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.D-/3$Q!4%-%.R!F;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)R!A;&EG;CTS
M1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-S<E/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z.'!T)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#8@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ
M+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^1&5C96UB97(F(WA!,#LS,2P\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.R!F;VYT+7-I>F4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P
M,#`P,"<^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P
M,#`P)SX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE
M.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!0871E
M;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDV,#PO=&0^#0H@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^.3$S/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N
M="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F
M;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-
M"B!,:6-E;G-E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P
M-#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,#0\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.SX-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P
M,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P
M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,S8T/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F
M;VYT+7-I>F4Z.'!T/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PS,3<\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT
M+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG/@T*
M($%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#(S-CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,38S/"]T9#X-"B`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XI)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@[/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*($EN=&%N9VEB;&5S+"!N970\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE
M.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ+#$R.#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#$U-#PO=&0^#0H@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@[/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P
M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P
M,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T
M7V$P,V$S8S4X-C0X9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8O5V]R:W-H965T
M<R]3:&5E=#,P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@1G5T=7)E($%N;G5A;"!-:6YI;75M($QE87-E(%!A>6UE;G1S(&9O
M<B!/<&5R871I;F<@3&5A<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C!P=#L@;6%R
M9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!!<R!O9B!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$S+"!F=71U<F4@86YN=6%L(&UI;FEM=6T@;&5A
M<V4@<&%Y;65N=',-"B!F;W(@;W5R(&]P97)A=&EN9R!L96%S97,@87)E(&%S
M(&9O;&QO=W,@*&EN)B-X03`[=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4]
M,T1F;VYT+7-I>F4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M
M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@8F]R9&5R/3-$,"!S='EL93TS
M1"="3U)$15(M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G(&%L:6=N/3-$8V5N=&5R/@T*
M(#QT<CX-"B`\=&0@=VED=&@],T0X-B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&
M1B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M
M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N
M="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@
M,C`Q-#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP-C8\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*(#(P,34\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M,3,X/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C
M0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M)SX-"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(Q,3PO=&0^#0H@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;B<^#0H@,C`Q-SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-C(T/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(]
M,T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!4:&5R96%F=&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US
M:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O
M;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L
M:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F
M;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C0L,#,Y/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E
M,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14Y(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G9E<G1I8FQE(%!R
M969E<G)E9"!3=&]C:RP@0V]M;6]N(%-T;V-K(&%N9"!3=&]C:VAO;&1E<G,G
M($1E9FEC:70@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!297-E<G9E9"!F;W(@1G5T=7)E
M($ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O
M;3HP<'0[('1E>'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@9F]L;&]W:6YG('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL@87)E(')E<V5R=F5D(&9O<B!F=71U<F4-"B!I
M<W-U86YC92!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$S.CPO<#X-"B`\<"!S
M='EL93TS1&9O;G0M<VEZ93HQ,G!T.VUA<F=I;BUT;W`Z,'!T.VUA<F=I;BUB
M;W1T;VTZ,'!T/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<]
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M9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M)SX-"B!#;VUM;VX@<W1O8VL@;W!T:6]N<R!O=71S=&%N9&EN9SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT
M+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-2PU.3@L,C`W/"]T9#X-"B`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!#;VUM;VX@<W1O8VL@;W!T:6]N<R!A=F%I;&%B;&4@9F]R(&9U
M='5R92!G<F%N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S$P+#4S-#PO=&0^
M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!B9V-O;&]R/3-$(T-#145&1B!S
M='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ
M93HQ,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US
M:7IE.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@16UP
M;&]Y964@4W1O8VL@4'5R8VAA<V4@4&QA;CPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T1F;VYT+7-I>F4Z.'!T/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-#8P+#(X,SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HQ
M,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)VUA<F=I
M;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;3L@9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@0V]N=F5R
M=&EB;&4@;F]T92!P87EA8FQE("A0;W-T+4E03R!'4TL@3F]T92D\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N
M="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$L-#$Q+#8U.3PO=&0^#0H@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@[/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G
M8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N)SX-"B!4;W1A;"!C;VUM;VX@<VAA<F5S(')E<V5R=F5D(&9O
M<B!F=71U<F4@:7-S=6%N8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,3@P
M+#8X,SPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1&9O
M;G0M<VEZ93HQ<'@[/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P
M>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N,#!P
M>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M3W!T:6]N($%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L
M;&]W:6YG('1A8FQE('-U;6UA<FEZ97,@;W5R('-T;V-K(&]P=&EO;B!A8W1I
M=FET>2!U;F1E<B!T:&4-"B`R,#$R(%!L86X@9F]R('1H92!Y96%R(&5N9&5D
M($1E8V5M8F5R)B-X03`[,S$L(#(P,3,@*&EN('1H;W5S86YD<RP-"B!E>&-E
M<'0@<&5R('-H87)E(&%N9"!C;VYT<F%C='5A;"!T97)M(&1A=&$I.CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS
M1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V,24^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(^/&(^3G5M8F5R)B-X03`[;V8\8G(@+SX-"B!O
M<'1I;VYS/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(^/&(^5V5I9VAT960\8G(@+SX-"B!A=F5R86=E/&)R("\^
M#0H@97AE<F-I<V4\8G(@+SX-"B!P<FEC93PO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQB/E=E:6=H
M=&5D/&)R("\^#0H@879E<F%G93QB<B`O/@T*(')E;6%I;FEN9SQB<B`O/@T*
M(&-O;G1R86-T=6%L/&)R("\^#0H@=&5R;3QB<B`O/@T*("AI;B8C>$$P.WEE
M87)S*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M(&%L:6=N/3-$8V5N=&5R/CQB/D%G9W)E9V%T93QB<B`O/@T*(&EN=')I;G-I
M8SQB<B`O/@T*('9A;'5E/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!/
M<'1I;VYS(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#<R,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,BXQ,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!'<F%N=&5D/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17AE<F-I
M<V5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#<S,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C`N.#$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,V5M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0V%N8V5L960O9F]R9F5I=&5D
M+V5X<&ER960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,C4T
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RXU,CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!/<'1I
M;VYS(&]U='-T86YD:6YG(&%T($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-3DX/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C,N-CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+CDX/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C(Q+#$V,CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!697-T960@;W(@97AP96-T960@=&\@=F5S="!A="!$96-E;6)E<B8C>$$P
M.S,Q+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#,X,CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+C8P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-RXY,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,"PX,#`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@17AE<F-I<V%B;&4@
M870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,BPR-#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XR,CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C8N,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,3,L.#0R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^07-S=6UP=&EO;G,@57-E9"!T;R!%<W1I;6%T92!&86ER(%9A;'5E(&]F
M(%-T;V-K($]P=&EO;G,@57-I;F<@0FQA8VLM4V-H;VQE<R!/<'1I;VX@4')I
M8VEN9R!-;V1E;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HP<'0[(&UA<F=I;BUB;W1T
M;VTZ,'!T.R!T97AT+6EN9&5N=#HT)3L@9F]N="US:7IE.C$P<'0[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<^#0H@5&AE(&%S<W5M<'1I;VYS('5S
M960@=&\@97-T:6UA=&4@=&AE(&9A:7(@=F%L=64@;V8@<W1O8VL@;W!T:6]N
M<PT*('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO
M9&5L('=E<F4@87,@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T1F;VYT+7-I
M>F4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#X-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0X-"4@8F]R9&5R/3-$,"!S='EL93TS1"="3U)$15(M
M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\
M=&0@=VED=&@],T0W-24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=F
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[(&9O;G0M<VEZ93HX<'0G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,3`@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P,#`P
M,#`G/@T*(#QB/EEE87(F(WA!,#ME;F1E9"8C>$$P.T1E8V5M8F5R)B-X03`[
M,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX-"B`\8CXF(WA!,#LR,#$S
M)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S
M;VQI9"`C,#`P,#`P)SX-"B`\8CXF(WA!,#LR,#$R)B-X03`[/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX-
M"B`\8CXF(WA!,#LR,#$Q)B-X03`[/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C
M0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@
M9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M)SX-"B!%;7!L;WEE92!3=&]C:R!/<'1I;VYS.CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!2:7-K+69R964@:6YT97)E<W0@<F%T93PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$N.3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,"XY/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+C,\+W1D/@T*(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B4F(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!%>'!E8W1E9"!D:79I
M9&5N9"!Y:65L9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N
M,#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XP/"]T9#X-"B`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XE)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XP+C`\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/B4F(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P
M<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z
M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!%>'!E8W1E
M9"!V;VQA=&EL:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-S(N-#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S,N-#PO=&0^#0H@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-S(N.3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M8F=C;VQO<CTS1"-#0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD
M96YT.BTQ+C`P96T[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86XG/@T*($5X<&5C=&5D('1E<FT@*'EE87)S*3PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,3PO=&0^#0H@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XV+C$\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-BXQ/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ,G!T.R!M87)G:6XM8F]T=&]M.C!P=#L@=&5X="UI;F1E;G0Z-"4[
M(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG
M/@T*(%-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!I<R!R969L96-T960@:6X@
M=&AE('-T871E;65N="!O9@T*(&]P97)A=&EO;G,@86YD(&-O;7!R96AE;G-I
M=F4@;&]S<R!A<R!F;VQL;W=S#0H@*&EN)B-X03`[=&AO=7-A;F1S*3H\+W`^
M#0H@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM
M87)G:6XM8F]T=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@8F]R9&5R
M/3-$,"!S='EL93TS1"="3U)$15(M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G(&%L:6=N
M/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W,B4^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[(&9O;G0M<VEZ93HX<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L:60@
M(S`P,#`P,"<^/&(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,2XP,'!T('-O;&ED(",P
M,#`P,#`G/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@<V]L
M:60@(S`P,#`P,"<^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C$N,#!P
M="!S;VQI9"`C,#`P,#`P)SX\8CXR,#$Q/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(]
M,T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N)SX-"B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,BPR-#8\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CDQ,CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-34W
M/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP
M,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!'96YE<F%L(&%N9"!A9&UI
M;FES=')A=&EV93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L
M,3<V/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8S.#PO
M=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-C@\+W1D/@T*
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X
M.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ+C`P<'@@<V]L:60@(S`P
M,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P
M,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P
M>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,2XP,'!X
M('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,2XP,'!X('-O;&ED(",P,#`P,#`G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HQ+C`P<'@@<V]L:60@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@8F=C;VQO<CTS1"-#
M0T5%1D8@<W1Y;&4],T0G9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F
M;VYT+7-I>F4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96T[
M(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86XG
M/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPT,C(\+W1D/@T*(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M
M<VEZ93HX<'0^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,2PU-3`\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M<VEZ93HX<'0^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.#(U/"]T9#X-
M"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P
M>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,RXP,'!X(&1O=6)L92`C
M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N
M,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N
M,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS+C`P<'@@9&]U8FQE(",P,#`P,#`G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-
M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S
M("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUP;VYE;G1S($EN8V]M92!487@@*$)E;F5F:70I($5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[
M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM
M87)I>F5S('1H92!C;VUP;VYE;G1S(&]F(&]U<B!I;F-O;64@=&%X#0H@*&)E
M;F5F:70I(&5X<&5N<V4@*&EN('1H;W5S86YD<RDZ/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'
M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&%L:6=N/3-$8V5N=&5R(&)O
M<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<U)3X\+W1D/@T*(#QT
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M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(^/&(^665A<B!E;F1E9`T*($1E8V5M
M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($-U<G)E;G0Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9E
M9&5R86P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H
M=#XR,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M(%-T871E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#XQ/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^
M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1')I9VAT/C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^,3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^,3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$<FEG:'0^,C`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*
M($1E9F5R<F5D.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!&961E<F%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/B@R,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/B@Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-T871E/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I
M9VAT/B@T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L
M:6=N/3-$<FEG:'0^*#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1R:6=H=#XH,C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#XH,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!);F-O;64@
M=&%X("AB96YE9FET*2!E>'!E;G-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(S
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P-CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]N8VEL:6%T:6]N(&]F
M($5X<&5C=&5D(%-T871U=&]R>2!&961E<F%L($EN8V]M92!487@@4')O=FES
M:6]N('1O($%C='5A;"!);F-O;64@5&%X(%!R;W9I<VEO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)2<^#0H@5&AE(&9O;&QO=VEN9R!I<R!A(')E8V]N8VEL:6%T:6]N
M(&]F('1H92!E>'!E8W1E9"!S=&%T=71O<GD@9F5D97)A;`T*(&EN8V]M92!T
M87@@<')O=FES:6]N('1O(&]U<B!A8W1U86P@:6YC;VUE('1A>"!P<F]V:7-I
M;VX@*&EN#0H@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!4D=)3BU43U`Z(#!P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,#X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$-C8E/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P(&%L:6=N/3-$8V5N=&5R/CQB
M/EEE87(@96YD960-"B!$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR
M,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$Q/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!%>'!E8W1E9"!I;F-O;64@=&%X
M(&)E;F5F:70@870@9F5D97)A;"!S=&%T=71O<GD@=&%X(')A=&4\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8L,S4U/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#4L.3(S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(L-3(R/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@4W1A=&4@:6YC;VUE('1A>&5S+"!N970@;V8@9F5D
M97)A;"!B96YE9FET/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#$L,#DP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,2PP,38\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
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M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!487@@8W)E9&ET<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@R+#0P-CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#0R,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8X,SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58
M5"U)3D1%3E0Z("TQ96TG/@T*($=O=F5R;FUE;G0@9W)A;G0\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!C;VYV97)T
M:6)L92!N;W1E('!A>6%B;&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XT-38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PQ.#,\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
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M87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
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M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@0VAA;F=E(&EN
M('9A;'5A=&EO;B!A;&QO=V%N8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XY+#`R-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU
M+#,X-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#`U.#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@4')I;W(@>65A<B!T<G5E+75P/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(S-3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#,V.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,S,S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!3
M=&]C:R!C;VUP96YS871I;VX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XV-C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#8S/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T.#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.
M1$5.5#H@+3%E;2<^#0H@3W1H97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XH.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XR,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.
M5#H@+3%E;2<^#0H@26YC;VUE('1A>"`H8F5N969I="D@97AP96YS93PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@R,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$P/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUP;VYE;G1S(&]F($1E9F5R<F5D(%1A>"!!<W-E=',@86YD($QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-
M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/
M4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@=&%B
M;&4@<W5M;6%R:7IE<R!T:&4@<VEG;FEF:6-A;G0@8V]M<&]N96YT<R!O9B!O
M=7(-"B!D969E<G)E9"!T87@@87-S971S(&%N9"!L:6%B:6QI=&EE<R`H:6XF
M(WA!,#MT:&]U<V%N9',I.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-
M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P/@T*(#QT
M<CX-"B`\=&0@=VED=&@],T0W-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$."4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-R4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS
M1&-E;G1E<CX\8CY$96-E;6)E<B8C>$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!$969E<G)E9"!T87@@87-S971S
M.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
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M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^."PU
M,C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG
M/@T*(%)E<V5A<F-H(&%N9"!D979E;&]P;65N="!A;F0@;W1H97(@=&%X(&-R
M961I=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#<R-SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#DX,SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@1&5F97)R960@<F5V96YU93PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L.3DY/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C<L,S(R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!);G1A;F=I8FQE<R!A;F0@<')O<&5R='D@
M86YD(&5Q=6EP;65N="!B87-I<R!D:69F97)E;F-E/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,2PW.38\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,2PR,3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]T
M:&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PR.3<\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#4Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4
M+4E.1$5.5#H@+3%E;2<^#0H@5&]T86P@9&5F97)R960@=&%X(&%S<V5T<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,CDL,C<Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3DL-3`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!4
M;W1A;"!D969E<G)E9"!T87@@;&EA8FEL:71I97,\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@Y-S,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(R-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%
M6%0M24Y$14Y4.B`M,65M)SX-"B!.970@9&5F97)R960@=&%X(&%S<V5T/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR."PS,#8\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ.2PR-SD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%9A
M;'5A=&EO;B!A;&QO=V%N8V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R
M."PS,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$Y+#(W.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$
M14Y4.B`M,65M)SX-"B!.970@9&5F97)R960@=&%X(&%S<V5T/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-
M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$<FEG:'0^#0H@)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N
M9V5S(&EN($%M;W5N="!O9B!5;G)E8V]G;FEZ960@5&%X($)E;F5F:71S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA
M<FEZ97,@=&AE(&-H86YG97,@:6X@=&AE(&%M;W5N="!O9B!O=7(-"B!U;G)E
M8V]G;FEZ960@=&%X(&)E;F5F:71S("AI;B!T:&]U<V%N9',I.CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P
M=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E
M;G1E<B!B;W)D97(],T0P/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W-"4^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`@
M86QI9VX],T1C96YT97(^/&(^665A<B!%;F1E9`T*($1E8V5M8F5R)B-X03`[
M,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z
M("TQ96TG/@T*($)E9VEN;FEN9R!B86QA;F-E(&]F('5N<F5C;V=N:7IE9"!T
M87@@8F5N969I=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-38Y/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
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M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E
M;2<^#0H@26YC<F5A<V4@*&1E8W)E87-E*2!F;W(@<')I;W(@>65A<B!T87@@
M<&]S:71I;VYS/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3,W
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($EN8W)E87-E(&9O<B!C
M=7)R96YT('EE87(@=&%X('!O<VET:6]N<SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C,X-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,30W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,2PP.3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-38Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4F5L871E9"U087)T>2!4<F%N<V%C=&EO;G,@*%1A
M8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-U;6UA<GD@;V8@3W!E<F%T:6YG($5X<&5N<V5S(&9R;VT@4F5L871E9"!0
M87)T>2!!8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA<F=I
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M<G9I8V5S($%G<F5E;65N="`H:6X@=&AO=7-A;F1S*3H\+W`^#0H@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T
M=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@8F]R9&5R/3-$,"!S='EL
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M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ+C`P<'0@
M<V]L:60@(S`P,#`P,"<^#0H@/&(^665A<G,F(WA!,#ME;F1E9"8C>$$P.T1E
M8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,2XP,'!T('-O;&ED(",P,#`P,#`G/CQB/C(P,3,\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3HQ+C`P<'0@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,CPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.C$N,#!P="!S;VQI9"`C,#`P,#`P)SX\8CXR,#$Q/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M
M.R!T97AT+6EN9&5N=#HM,2XP,&5M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!397)V:6-E<R!P97)F;W)M960@
M;W(@;W5T+6]F+7!O8VME="!E>'!E;G-E<R!P86ED('1O($%L;GEL86T\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-34P/"]T9#X-"B`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR/"]T9#X-"B`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX/"]T9#X-"B`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4R.#)B9#@R7S(Y,V)?
M-#DY9E]A93(T7V$P,V$S8S4X-C0X9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8O
M5V]R:W-H965T<R]3:&5E=#,T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4V5L96-T960@475A<G1E<FQY($9I;F%N8VEA;"!$
M871A("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y396QE8W1E9"!1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%
M6%0M24Y$14Y4.B`T)2<^#0H@4W5M;6%R:7IE9"!Q=6%R=&5R;'D@9&%T82!F
M;W(@,C`Q,R!A;F0@,C`Q,B!A<F4@87,@9F]L;&]W<R`H:6X-"B!T:&]U<V%N
M9',L(&5X8V5P="!P97(@<VAA<F4@9&%T82DZ/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM
M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R(&)O<F1E
M<CTS1#`^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#4W)3X\+W1D/@T*(#QT9"!V
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M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&;W(@=&AE
M('%U87)T97)S(&5N9&EN9SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^#0H@
M/&(^36%R8V@F(WA!,#LS,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQB/DIU;F4F(WA!,#LS,#PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/@T*
M(#QB/E-E<'1E;6)E<B8C>$$P.S,P/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(^#0H@/&(^1&5C96UB97(F(WA!
M,#LS,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@/&(^,C`Q,SH\+V(^
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M
M,65M)SX-"B!2979E;G5E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS
M+#(S.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PW-3D\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C8L,3$X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU+#0U-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@
M+3%E;2<^#0H@3W!E<F%T:6YG(&5X<&5N<V5S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^."PW.#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^.2PT-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.2PP
M,C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`L,3$V/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M(%1%6%0M24Y$14Y4.B`M,65M)SX-"B!.970@;&]S<SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@W+#(R.3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^*#<L,S0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPQ-C0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#DR-SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A<VEC(&YE="!L;W-S('!E
M<B!S:&%R93QS=7`@<W1Y;&4],T0G1D].5"U325I%.B`X-24[(%9%4E1)0T%,
M+4%,24=..B!T;W`G/B@Q*3PO<W5P/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH,"XR,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C(P/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#`N,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,"XP-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M5$585"U)3D1%3E0Z("TQ96TG/@T*($1I;'5T960@;F5T(&QO<W,@<&5R('-H
M87)E/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z(#@U)3L@5D525$E#04PM04Q)
M1TXZ('1O<"<^*#$I*#(I/"]S=7`^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@P+C(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#`N,C`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH,"XP-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@P+C$Q/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<CX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L
M<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@
M8V]L<W!A;CTS1#0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@
M,65M.R!415A4+4E.1$5.5#H@+3%E;2<^#0H@/&(^,C`Q,CH\+V(^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX-
M"B!2979E;G5E<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#,T-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS,#D\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(L.#`Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#(S
M.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!415A4+4E.1$5.5#H@+3%E;2<^
M#0H@3W!E<F%T:6YG(&5X<&5N<V5S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-2PU,C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-2PX-C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-BPS-#$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RPU-#$\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)
M3D1%3E0Z("TQ96TG/@T*($YE="!L;W-S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#(L,C0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH
M,BPU.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U+#8X-3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#8L.#<V/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!4
M15A4+4E.1$5.5#H@+3%E;2<^#0H@0F%S:6,@86YD(&1I;'5T960@;F5T(&QO
M<W,@<&5R('-H87)E/'-U<"!S='EL93TS1"=&3TY4+5-)6D4Z(#@U)3L@5D52
M5$E#04PM04Q)1TXZ('1O<"<^*#$I/"]S=7`^/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@Q,RXP-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,"XW.#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@Q-2XY.#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B@P+C(R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0[($U!
M4D=)3BU43U`Z(#!P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&)O<F1E<CTS1#`^#0H@
M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0T)2!A;&EG;CTS1&QE
M9G0^*#$I/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y.
M970@;&]S<R!P97(@<VAA<F4@:7,@8V]M<'5T960-"B!I;F1E<&5N9&5N=&QY
M(&9O<B!E86-H(&]F('1H92!Q=6%R=&5R<R!P<F5S96YT960N(%1H97)E9F]R
M92P@=&AE#0H@<W5M(&]F('1H92!Q=6%R=&5R;'D@<&5R+7-H87)E(&-A;&-U
M;&%T:6]N<R!W:6QL(&YO="!N96-E<W-A<FEL>0T*(&5Q=6%L('1H92!A;FYU
M86P@<&5R('-H87)E(&-A;&-U;&%T:6]N+CPO=&0^#0H@/"]T<CX-"B`\+W1A
M8FQE/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E(&)O<F1E<CTS1#`^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0T)2!A;&EG;CTS1&QE9G0^*#(I/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$=&]P(&%L:6=N/3-$;&5F=#Y!<'!L:6-A8FQE(&%C8V]U;G1I;F<@9W5I
M9&%N8V4-"B!P<F]V:61E<R!T:&%T(&$@8V]N=')A8W0@*'-U8V@@87,@=&AE
M(#(P,3`@1U-+($YO=&4I('1H870@:7,-"B!R97!O<G1E9"!A<R!A;B!A<W-E
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M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%4%%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY4:&4@0G5S:6YE
M<W,L($)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N
M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("T@061D:71I;VYA;"!);F9O
M<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E-E9VUE;G0\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VX@
M06YD(%-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!P<FEN8VEP86P@86UO=6YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M;W!E<F%T:6YG('-E9VUE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N($%N9"!3=6UM87)Y($]F(%-I
M9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M<&5R='D@86YD(&5Q=6EP;65N="P@97-T:6UA=&5D('5S969U;"!L:79E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI
M;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/<F=A;FEZ871I;VX@06YD(%-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U
M:7!M96YT+"!E<W1I;6%T960@=7-E9G5L(&QI=F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I
M;VX@06YD(%-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI
M8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&:6YI=&4@;&EV960@:6YT86YG:6)L92!A<W-E
M="P@97-T:6UA=&5D('5S969U;"!L:79E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%T96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N($%N
M9"!3=6UM87)Y($]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1FEN:71E(&QI=F5D(&EN=&%N9VEB;&4@87-S971S+"!W
M96EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!U<V5F=6P@;&EF93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$R('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T
M.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7
M;W)K<VAE971S+U-H965T,S8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.4T%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E!O=&5N=&EA;&QY($1I;'5T:79E(%-E8W5R:71I
M97,@3F]T($EN8VQU9&5D(&EN($-A;&-U;&%T:6]N(&]F($1I;'5T960@3F5T
M($QO<W,@<&5R(%-H87)E("A$971A:6PI/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I=F4@
M4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI
M;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&]T96YT:6%L;'D@9&EL=71I
M=F4@<V5C=7)I=&EE<R!N;W0@:6YC;'5D960@:6X@8V%L8W5L871I;VX@;V8@
M9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L,#4P+#DR.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C4P+#`Y.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#`S."PR-#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET
M:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R
M(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0;W1E;G1I86QL>2!D:6QU=&EV92!S96-U
M<FET:65S(&YO="!I;F-L=61E9"!I;B!C86QC=6QA=&EO;B!O9B!D:6QU=&5D
M(&YE="!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,RPV.3DL.3DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED
M:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@
M;V8@16%R;FEN9W,@4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;W1E;G1I86QL
M>2!D:6QU=&EV92!S96-U<FET:65S(&YO="!I;F-L=61E9"!I;B!C86QC=6QA
M=&EO;B!O9B!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV,SDL,C<P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX.#,L,S$Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS,S@L
M,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)T:6)L92!.;W1E<R!087EA8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E
M8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG
M<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;&QY(&1I;'5T:79E
M('-E8W5R:71I97,@;F]T(&EN8VQU9&5D(&EN(&-A;&-U;&%T:6]N(&]F(&1I
M;'5T960@;F5T(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#0Q,2PV-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,V-BPW.#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?
M864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF+U=O<FMS
M:&5E=',O4VAE970S-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%)04,^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0Q/CQS=')O;F<^3F5T($QO<W,@4&5R(%-H87)E("T@061D:71I;VYA;"!)
M;F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!E
M>&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D%U9RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!/9B!%87)N:6YG<R!097(@4VAA
M<F4@0F%S:6,@06YD($1I;'5T960@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L
M92!N;W1E<R!P87EA8FQE(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-2XT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@<')I
M8V4@<&5R('-H87)E(&]F(&-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,U%!1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-H;W)T+51E<FT@26YV
M97-T;65N=',@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G9E<W1M96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%M;W)T:7IE9"!C;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#DV+#$X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-3<L-3DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E86QI>F5D($=A:6YS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@3&]S
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S
M=&EM871E9"!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY-BPQ.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-RPU-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O<G!O<F%T92!$96)T(%-E8W5R:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN
M=F5S=&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36%T=7)I='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<R(&]R(&QE<W,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,B!O<B!L97-S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ
M960@8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$L-#`R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#0L.#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@3&]S<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!F86ER('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,2PT,38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PX
M-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-E<G1I9FEC871E<R!O9B!$97!O<VET/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G9E<W1M96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUA='5R:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M,B!O<B!L97-S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S$@;W(@;&5S<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F5D(&-O<W0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#<Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,C`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@
M9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L
M-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-BPR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UE<F-I86P@4&%P97(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN=F5S=&UE;G0@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^36%T=7)I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q
M(&]R(&QE<W,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG,B!O<B!L97-S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ960@8V]S=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP-CD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#0Y,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR96%L:7IE9"!'
M86EN<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM
M871E9"!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#`W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8L-#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$96)T('-E8W5R:71I97,@;V8@52Y3+B!G;W9E<FYM
M96YT+7-P;VYS;W)E9"!A9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV97-T;65N="!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-
M871U<FET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$@;W(@
M;&5S<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%M;W)T:7IE9"!C;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5N<F5A;&EZ960@1V%I;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@9F%I<B!V86QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+#`P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,DM!23X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY&86ER(%9A;'5E($AI97)A<F-H>2!F;W(@
M07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S=7)E9"!A="!&86ER(%9A;'5E
M(&]N(%)E8W5R<FEN9R!"87-I<R`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H
M;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L
M(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E=',@;65A<W5R
M960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,3,L,S8X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y-BPY,3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE
M970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU92!O
M;B!A(')E8W5R<FEN9R!B87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$L,C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`L,3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E
M+"!"86QA;F-E(%-H965T($=R;W5P:6YG+"!&:6YA;F-I86P@4W1A=&5M96YT
M($-A<'1I;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T<R!M96%S=7)E9"!A="!F86ER
M('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-RPQ-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS.2PS-C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<G!O<F%T92!$96)T(%-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I
M;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S
M(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Q+#0Q-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#@U-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V5R=&EF:6-A=&5S(&]F($1E<&]S:70\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE
M970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^07-S971S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R
M96-U<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Q+#<Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8L,C`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$96)T('-E8W5R:71I97,@;V8@52Y3+B!G;W9E<FYM
M96YT+7-P;VYS;W)E9"!A9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E
M="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!<W-E=',@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E
M8W5R<FEN9R!B87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM97)C:6%L(%!A<&5R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!"86QA;F-E(%-H
M965T($=R;W5P:6YG+"!&:6YA;F-I86P@4W1A=&5M96YT($-A<'1I;VYS(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%S<V5T<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@
M<F5C=7)R:6YG(&)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#`W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8L-#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E+"!);G!U=',L($QE=F5L(#$\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@
M5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T
M96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S(&UE87-U<F5D(&%T
M(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$W+#$W,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#,V,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92P@
M26YP=71S+"!,979E;"`Q('P@0V%S:"!%<75I=F%L96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@
M0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#
M87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E=',@;65A<W5R960@870@9F%I<B!V
M86QU92!O;B!A(')E8W5R<FEN9R!B87-I<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<L,3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,SDL,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E+"!);G!U=',L
M($QE=F5L(#(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I
M;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S
M(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV+#$Y.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W+#4T.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1F%I<B!686QU92P@26YP=71S+"!,979E;"`R('P@0V]R<&]R871E($1E8G0@
M4V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@
M1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E
M=',@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$L-#$V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L.#4V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&86ER(%9A;'5E+"!);G!U=',L($QE=F5L(#(@?"!#97)T:69I8V%T97,@
M;V8@1&5P;W-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@
M1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W-E
M=',@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-S$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9A:7(@5F%L=64L($EN<'5T<RP@3&5V96P@,B!\($1E8G0@<V5C=7)I=&EE
M<R!O9B!5+E,N(&=O=F5R;FUE;G0M<W!O;G-O<F5D(&%G96YC:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A
M;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG+"!&:6YA;F-I86P@4W1A=&5M
M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T<R!M96%S=7)E9"!A="!F
M86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64L($EN<'5T<RP@
M3&5V96P@,B!\($-O;6UE<F-I86P@4&%P97(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@
M4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^07-S971S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@
M82!R96-U<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L,#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPT.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64L($EN<'5T<RP@3&5V96P@,R!\
M($-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@
M4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU
M92!O;B!A(')E8W5R<FEN9R!B87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q,2PR-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P+#$S-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?
M83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R
M.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S
M+U-H965T-#`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5+3D%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E)E8V]N8VEL:6%T:6]N(&]F($QI86)I;&ET:65S($UE87-U<F5D
M(&%T($9A:7(@5F%L=64@;VX@475A<G1E<FQY($)A<VES("A$971A:6PI("A5
M4T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1F%I<B!686QU92P@3&EA8FEL:71I97,@365A<W5R960@;VX@4F5C
M=7)R:6YG($)A<VES+"!5;F]B<V5R=F%B;&4@26YP=70@4F5C;VYC:6QI871I
M;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN(&5S=&EM871E9"!F86ER('9A;'5E
M(&]F(&-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,2PQ-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R+#DV.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64L
M($EN<'5T<RP@3&5V96P@,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@3&EA8FEL:71I97,@365A<W5R
M960@;VX@4F5C=7)R:6YG($)A<VES+"!5;F]B<V5R=F%B;&4@26YP=70@4F5C
M;VYC:6QI871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96-E;6)E<B`S
M,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3,T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VAA;F=E(&EN(&5S=&EM871E9"!F86ER('9A;'5E(&]F(&-O;G9E<G1I
M8FQE(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PR-SD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B
M7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF
M+U=O<FMS:&5E=',O4VAE970T,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14)004,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',@+2!!
M9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',L(%)E8W5R<FEN
M9R!A;F0@3F]N<F5C=7)R:6YG+"!686QU871I;VX@5&5C:&YI<75E<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]S<R!O;B!E>'1I;F=U:7-H;65N="!O9B!D96)T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L-S`P+#`P,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#<S
M."PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VYV97)T:6)L92!N;W1E<R!P87EA8FQE+"!C87)R>6EN9R!V
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO<W,@9G)O;2!V86QU871I;VX@;V8@8V]N=F5R=&EB;&4@;F]T97,@
M<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PQ
M-#4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,BPY-CDL,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!A<W-U;7!T:6]N+"!V
M;VQA=&EL:71Y(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@87-S=6UP=&EO;BP@<FES:R!F
M<F5E(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C,S
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`N-#(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER('9A;'5E(&%S<W5M<'1I;VXL(&-R961I="!S<')E860\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C0P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDN-3`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X
M,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C
M-3@V-#AF+U=O<FMS:&5E=',O4VAE970T,BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I#0DD^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5V96YU92!F<F]M(%-T<F%T96=I
M8R!!;&QI86YC97,@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#@^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E)E=F5N=64@9G)O;2!%>'1E<FYA;"!#=7-T;VUE<B!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E;G5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#0U-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BPQ,3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L-S4Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M+#(S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,RPR,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(L.#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`S+#,P.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPS-#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y+#4V.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(L
M-S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,RPW.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T<F%T96=I8R!!;&QI86YC97,@86YD($-O;&QA8F]R
M871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY2979E;G5E(&9R;VT@17AT97)N86P@0W5S=&]M97(@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5V96YU97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL-38Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-S`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L
M-S8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=')A=&5G:6,@06QL:6%N8V5S(&%N9"!#;VQL86)O<F%T:6]N<R!\
M(%-A;F]F:2`M($%V96YT:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=64@9G)O;2!%>'1E<FYA
M;"!#=7-T;VUE<B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E;G5E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PS
M,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,"PP,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,"PP,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T<F%T96=I8R!!;&QI86YC97,@86YD($-O;&QA
M8F]R871I;VYS('P@1U-+/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2979E;G5E(&9R;VT@17AT97)N86P@
M0W5S=&]M97(@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5V96YU97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW-S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#DY-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=')A=&5G:6,@06QL:6%N8V5S(&%N9"!#;VQL86)O<F%T
M:6]N<R!\($%S=')A(%IE;F5C83PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V96YU92!F<F]M($5X=&5R
M;F%L($-U<W1O;65R(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N
M=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M.#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1R871E9VEC($%L;&EA;F-E<R!A;F0@0V]L;&%B;W)A=&EO
M;G,@?"!":6]G96X@261E8SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V96YU92!F<F]M($5X=&5R;F%L
M($-U<W1O;65R(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3DV
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E
M,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE970T,RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P13%&2$T^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1R871E9VEC($%L
M;&EA;F-E<R!A;F0@0V]L;&%B;W)A=&EO;G,@+2!!9&1I=&EO;F%L($EN9F]R
M;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0X/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Y
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#0^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5L+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y!=6<N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/D=32SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D=32SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/D=32SQB<CY$979E;&]P;65N="!#;VUM97)C:6%L:7IA=&EO;B!!;F0@
M3&EC96YS92!!9W)E96UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY'4TL\8G(^2$-6($%L;&EA;F-E/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^1U-+/&)R/DA#5B!!;&QI86YC93QB<CY-:6YI;75M/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^1U-+/&)R
M/DA#5B!!;&QI86YC93QB<CY-87AI;75M/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^1U-+/&)R/DA#5B!!;&QI
M86YC93QB<CY0<F5C;&EN:6-A;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D=32SQB<CY(0U8@06QL:6%N8V4\
M8G(^0VQI;FEC86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CY'4TL\8G(^2$-6($%L;&EA;F-E/&)R/E)E9W5L
M871O<GD\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CY'4TL\8G(^2$-6($%L;&EA;F-E/&)R/D-O;6UE<F-I86QI
M>F%T:6]N($UI;&5S=&]N97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY'4TL\8G(^2$-6($%L;&EA;F-E/&)R
M/E!H87-E($]N92!#;&EN:6-A;"!4<FEA;#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D=32SQB<CY(0U8@06QL
M:6%N8V4\8G(^4&AA<V4@5'=O($-L:6YI8V%L(%1R:6%L/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^1U-+/&)R
M/DA#5B!!;&QI86YC93QB<CY0<F]O9BUO9BU#;VYC97!T(%1R:6%L/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M1U-+/&)R/DEM;75N;RU);F9L86UM871O<GD@06QL:6%N8V4\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY'4TL\
M8G(^26UM=6YO+4EN9FQA;6UA=&]R>2!!;&QI86YC93QB<CY-:6YI;75M/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^1U-+/&)R/DEM;75N;RU);F9L86UM871O<GD@06QL:6%N8V4\8G(^36%X
M:6UU;3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/D=32SQB<CY);6UU;F\M26YF;&%M;6%T;W)Y($%L;&EA;F-E
M/&)R/E!R96-L:6YI8V%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^1U-+/&)R/DEM;75N;RU);F9L86UM871O
M<GD@06QL:6%N8V4\8G(^0VQI;FEC86P\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY'4TL\8G(^26UM=6YO+4EN
M9FQA;6UA=&]R>2!!;&QI86YC93QB<CY296=U;&%T;W)Y/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^1U-+/&)R
M/DEM;75N;RU);F9L86UM871O<GD@06QL:6%N8V4\8G(^0V]M;65R8VEA;&EZ
M871I;VX\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CY'4TL\8G(^26UM=6YO+4EN9FQA;6UA=&]R>2!!;&QI86YC
M93QB<CY&;W5R=&@@36EC<F\@4DY!(%1A<F=E=',\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY'4TL\8G(^26UM
M=6YO+4EN9FQA;6UA=&]R>2!!;&QI86YC93QB<CY$979E;&]P;65N="!#86YD
M:61A=&4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CY'4TL\8G(^26UM=6YO+4EN9FQA;6UA=&]R>2!!;&QI86YC
M93QB<CY0:&%S92!/;F4@0VQI;FEC86P@5')I86P\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY'4TL\8G(^26UM
M=6YO+4EN9FQA;6UA=&]R>2!!;&QI86YC93QB<CY0:&%S92!4=V\@0VQI;FEC
M86P@5')I86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CY'4TL\8G(^26UM=6YO+4EN9FQA;6UA=&]R>2!!;&QI
M86YC93QB<CY0<F]O9BUO9BU#;VYC97!T(%1R:6%L/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,3(\8G(^07-T<F$@6F5N
M96-A/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^07-T<F$@6F5N96-A/&)R/D%G<F5E;65N=#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D%S=')A
M(%IE;F5C83QB<CY-:6YI;75M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^07-T<F$@6F5N96-A/&)R/DUA>&EM
M=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CY!<W1R82!:96YE8V$\8G(^4')E8VQI;FEC86P\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY!<W1R
M82!:96YE8V$\8G(^0VQI;FEC86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY!<W1R82!:96YE8V$\8G(^0V]M
M;65R8VEA;&EZ871I;VX\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CY!<W1R82!:96YE8V$\8G(^0V]M;6]N(%-T
M;V-K(%!U<F-H87-E($%G<F5E;65N=',@0W-P83QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D)I;V=E;B!)9&5C
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^0FEO9V5N($ED96,\8G(^4F5S96%R8V@@5&%X($-R961I="!#87)R
M>69O<G=A<F0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V
M+B`S,"P@,C`Q,SQB<CY":6]G96X@261E8SQB<CY!;65N9&5D($-O;&QA8F]R
M871I;VX@86YD($QI8V5N<V4@06=R965M96YT/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^0FEO9V5N($ED96,\
M8G(^5F%L:61A=&EO;B!/9B!-:6-R;R!2;F$@0FEO;6%R:V5R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^0FEO
M9V5N($ED96,\8G(^3&]N9VET=61I;F%L(%-T=61Y($]F(%!A=&EE;G0@4V%M
M<&QE<R!/;B!-<R!4:&5R87!Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^4V%N;V9I/&)R/DUI;FEM=6T\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CY386YO9FD\8G(^36%X:6UU;3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E-A;F]F:3QB<CY0<F5C;&EN:6-A
M;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/E-A;F]F:3QB<CY#;&EN:6-A;#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E-A;F]F:3QB<CY296=U
M;&%T;W)Y(&%N9"!#;VUM97)C:6%L:7IA=&EO;B!-:6QE<W1O;F5S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3,\8G(^
M4V%N;V9I/&)R/D1E=F5L;W!M96YT($-O;6UE<F-I86QI>F%T:6]N($%N9"!,
M:6-E;G-E($%G<F5E;65N=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6PN(#,Q+"`R,#$S/&)R/E-A;F]F:3QB<CY297-E87)C:"!A;F0@
M1&5V96QO<&UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CY386YO9FD\8G(^4F5S96%R8V@@86YD($1E=F5L
M;W!M96YT/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-O;&QA8F]R871I=F4@07)R86YG96UE;G1S(&%N9"!.;VXM8V]L
M;&%B;W)A=&EV92!!<G)A;F=E;65N="!4<F%N<V%C=&EO;G,@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YI=&EA;"!U<&9R;VYT(&]P=&EO;B!P87EM96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^57!F<F]N="!P87EM96YT(&-R961I
M=&%B;&4@86=A:6YS="!F=71U<F4@86-C;W5N=',@<F5C96EV86)L97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5P
M9G)O;G0@<&%Y;65N="!N;VXM8W)E9&ET86)L92!P;W)T:6]N(')E8V]G;FEZ
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5V96YU92!T:')O=6=H(&UI;&5S=&]N92!P87EM
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M-"PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR.2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,R+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX-RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y
M."PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,C,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W,"PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,38U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L=&EE<R!B87-E9"!O;B!P97)C
M96YT86=E(&]F(&YE="!S86QE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E9F5R<F5D(')E=F5N=64@<F5C;V=N:71I;VX@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<X('EE87)S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M9F5R<F5D(')E=F5N=64@<F5M86EN:6YG(')E8V]G;FET:6]N('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-B!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<R('EE87)S(#8@;6]N=&AS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S$P(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C96QE<F%T:6]N(&]F(')E;6%I
M;FEN9R!A;6]R=&EZ871I;VX@;V8@=7!F<F]N="!P87EM96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@8V]L;&%B;W)A=&EV92!A<F5A<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A;F0@;&EC
M96YS92!A9W)E96UE;G0@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%U9W5S="`R
M,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)T%U9W5S="`R,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!T
M97)M(&]F(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!P;&%N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<T('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:R!I<W-U93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#<X-RPS,C8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PX
M,S$L.#`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,C4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@.2XU/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@9&%Y
M<R!D=7)I;F<@=VAI8V@@07-T<F%:96YE8V$@8V]U;&0@;F]T('-E;&PL('1R
M86YS9F5R+"!M86ME(&%N>2!S:&]R="!S86QE(&]F+"!O<B!G<F%N="!A;GD@
M;W!T:6]N(&9O<B!T:&4@<V%L92!O9B!A;GD@8V]M;6]N('-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<S-C4@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T
M<FEC=&EN9R!C;VUM;VX@<W1O8VL@=F%L=6%T:6]N(&UE87-U<F5M96YT('!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E=F5N=64@<F5C;V=N:71I;VX@<&5R:6]D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S(@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5E9"!P<F]M:7-S
M;W)Y(&YO=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@=&\@8V]M;6]N('-T
M;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-38L,C,R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR-38L,C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@<F%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%1#9!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY3=6UM87)Y(&]F(%!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@*$1E
M=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U
M:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&=R
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<L-#DY/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M+#<U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&5S<R!A8V-U;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T
M:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPW,S$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,BPT-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<V.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S$P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,86)O<F%T;W)Y
M($5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@9W)O<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,S0R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU.#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!U=&5R($5Q
M=6EP;65N="!A;F0@4V]F='=A<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M
M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&=R;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,30\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI
M='5R92!A;F0@1FEX='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&=R;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD
M($EM<')O=F5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@9W)O<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#`U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS=')U8W1I
M;VX@:6X@4')O9W)E<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&=R;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B
M7S0Y.69?864R-%]A,#-A,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF
M+U=O<FMS:&5E=',O4VAE970T-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15E"04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="P@3F5T
M("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R
M/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0
M<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P
M<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E
M,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE
M971S+U-H965T-#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$541D%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/E-U;6UA<GD@;V8@26YT86YG:6)L92!!<W-E=',@*$1E=&%I
M;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@
M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9I;FET92U,:79E9"!);G1A;F=I8FQE($%S
M<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&:6YI=&4@;&EV960@:6YT86YG:6)L92!A<W-E
M=',L(&=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M,S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+#,Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C=6UU;&%T960@86UO<G1I>F%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,S8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&5S
M+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3(X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ
M-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!A=&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D9I;FET92U,:79E9"!);G1A;F=I8FQE($%S<V5T<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&:6YI=&4@;&EV960@:6YT86YG:6)L92!A<W-E=',L(&=R;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY&:6YI=&4M3&EV960@26YT86YG:6)L92!!<W-E=',@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1FEN:71E(&QI=F5D(&EN=&%N9VEB;&4@87-S971S+"!G<F]S<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0P-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T
M.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7
M;W)K<VAE971S+U-H965T-#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.3T%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DEN=&%N9VEB;&4@07-S971S+"!.970@+2!!9&1I
M=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^26X@36EL
M;&EO;G,L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I;FET92U,
M:79E9"!);G1A;F=I8FQE($%S<V5T<R!!;F0@3&EA8FEL:71I97,@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!I;G1A;F=I8FQE(&%S<V5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=&%N9VEB;&4@87-S971S+"!A;6]R=&EZ871I;VX@97AP96YS92P@;F5X="!T
M=V5L=F4@;6]N=&AS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT86YG:6)L92!A<W-E=',L(&%M;W)T:7IA=&EO;B!E>'!E;G-E
M+"!Y96%R('1W;SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&%N9VEB;&4@87-S971S+"!A;6]R=&EZ871I;VX@97AP96YS92P@
M>65A<B!T:')E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=&%N9VEB;&4@87-S971S+"!A;6]R=&EZ871I;VX@97AP96YS92P@
M>65A<B!F;W5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT86YG:6)L92!A<W-E=',L(&%M;W)T:7IA=&EO;B!E>'!E;G-E+"!Y
M96%R(&9I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4R
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M5$%!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@
M0V]N=&EN9V5N8VEE<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I
M;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CY,96%S97,\8G(^<W%F=#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`S,"P@,C`Q,CQB<CY/9F9I8V4@
M86YD($QA8F]R871O<GD@4W!A8V4\8G(^<W%F=#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y.;W8N(#,P+"`R,#$R/&)R/E)E<V5A<F-H(&%N
M9"!$979E;&]P;65N=#QB<CYS<69T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG
M96YC:65S($1I<V-L;W-U<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&QE
M87-E(&5X<&ER871I;VX@9&%T92P@>65A<B!A;F0@;6]N=&@\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<R,#$W+3`V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG
M(&QE87-E(&]P=&EO;F%L('1E<FUI;F%T:6]N+"!D871E+"!Y96%R(&%N9"!M
M;VYT:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,34M,#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<&5R871I;F<@;&5A<V4@;W!T:6]N86P@=&5R;6EN871I;VX@;F]T
M:6-E('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@
M;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO;G,@=&\@97AT96YD(&]P97)A
M=&EN9R!L96%S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P97)A=&EN9R!L96%S92!O<'1I;VYA;"!E>'1E;G-I;VX@<&5R:6]D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%R96$@;V8@9F%C:6QI='D@=6YD97(@;W!E<F%T:6YG(&QE87-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1E;F%N="!I;F-E;G1I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1E;F%N="!I;7!R;W9E;65N="!A;&QO=V%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8U,RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@V
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!9&1I=&EO;F%L(%1E;F%N="!);7!R;W9E;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1E;F%N="!I
M;7!R;W9E;65N="!A;&QO=V%N8V4L(&EN=&5R97-T(')A=&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@N,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5N="!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T
M.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7
M;W)K<VAE971S+U-H965T-#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V1$%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/E-U;6UA<GD@;V8@1G5T=7)E($%N;G5A;"!-:6YI
M;75M($QE87-E(%!A>6UE;G1S(&9O<B!/<&5R871I;F<@3&5A<V5S("A$971A
M:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3&5A<V5S($9U='5R92!-:6YI;75M(%!A>6UE
M;G1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#`V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PQ,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#XR,#$W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1H97)E869T97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@3&5A<V5S+"!&=71U<F4@
M36EN:6UU;2!087EM96YT<R!$=64L(%1O=&%L/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0L,#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A
M,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D
M.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE
M970U,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P13)604D^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L92`M($%D9&ET:6]N86P@26YF
M;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-#XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U
M9RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5L+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y&96(N(#(X+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D%P<BX@,S`L(#(P,#@\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY!<')I;"`R,#`X/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,3(\8G(^
M07!R:6P@,C`P.#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/
M8W0N(#,Q+"`R,#$R/&)R/D%P<FEL(#(P,#@\8G(^0V]M;6]N(%-T;V-K/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,3(\
M8G(^3V-T;V)E<B`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D]C="X@,S$L(#(P,3(\8G(^3V-T;V)E<B`R,#$R/&)R/D-O;G9E<G1I
M8FQE($1E8G0\8G(^1U-+/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1E8G0@26YS=')U;65N="!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&5R;2!O9B!C;VYV97)T:6)L92!N;W1E('!A>6%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]N=F5R=&EB;&4@;F]T
M97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO
M=&5S(&%M96YD;65N="!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S(P,3(M,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6;W1I;F<@<V5C=7)I=&EE<R!P
M97)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F(&-O
M;G9E<G1I8FQE(&YO=&5S+"!C;VYV97)T960@;G5M8F5R(&]F(&-O;6UO;B!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-38L,C,R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PR-38L,C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-#0W+#`S-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N('!R:6-E
M('!E<B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO=&5S(&ES<W5E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]U='-T86YD:6YG('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@:6YT97)E<W0@;VX@8V]N=F5R=&EB;&4@;F]T
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36%T=7)I='D@<&5R:6]D(&]F(&YO=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G-I;VX@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<R,#$U+3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@;F]T92!P87EA8FQE+"!A
M="!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$L,C<Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#$S-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@97AT:6YG
M=6ES:&UE;G0@;V8@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L-S`P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#<S."PP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U960@<')O
M;6ES<V]R>2!N;W1E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF
M7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K
M<VAE971S+U-H965T-3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5244-+/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:RP@0V]M
M;6]N(%-T;V-K(&%N9"!3=&]C:VAO;&1E<G,G($1E9FEC:70@+2!!9&1I=&EO
M;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#`W+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;"X@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M3V-T+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/E9O=&4\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2979E<G-E('-T;V-K('-P;&ET(&]F(&-O;6UO
M;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XU/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VL@<VAA<F5S+"!I<W-U960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#$W-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I8V4@<&5R('-H87)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0U+#@P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0U+#DX,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#8U+#<X."PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@
M<')I;F-I<&%L(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O=71S
M=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L
M-S@W+#,R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,U+#@S,2PX,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('9O=&5S(&]F(&5A8V@@
M<VAA<F4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@9W)A;G0@9&%T
M92!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0N,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(N.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$N,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4:&4@=&]T86P@:6YT<FEN<VEC('9A
M;'5E(&]F('-T;V-K(&]P=&EO;G,@97AE<F-I<V5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<V@@<F5C96EV960@9G)O;2!E>&5R8VES92!O9B!C;VUM;VX@<W1O8VL@
M;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<&5N<V%T:6]N(&-O<W0@<F5L871E
M9"!T;R!N;VXM=F5S=&5D(&%W87)D<R!N;W0@>65T(')E8V]G;FEZ960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960M879E<F%G92!R96-O9VYI=&EO;B!P97)I;V0@;V8@8V]M<&5N
M<V%T:6]N(&-O<W0@<F5L871E9"!T;R!N;VXM=F5S=&5D(&%W87)D<R!N;W0@
M>65T(')E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<R('EE87)S(#,@;6]N=&AS(#$X(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=32R!\($-O;G9E
M<G1I8FQE($YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W5T<W1A;F1I;F<@<')I;F-I<&%L(&%M;W5N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN
M=&5R97-T(&]N(&-O;G9E<G1I8FQE(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y":6]G96X@261E8R!\($-O
M;G9E<G1I8FQE($YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W5T<W1A;F1I;F<@<')I;F-I<&%L(&%M;W5N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L
M(%!U8FQI8R!/9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:R!S:&%R97,L(&ES<W5E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PR-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I8V4@
M<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);FET:6%L(%!U8FQI8R!/9F9E<FEN9R!\($-O;G9E<G1I8FQE($YO
M=&5S(%!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VL@:7-S=65D('5P;VX@8V]N=F5R<VEO;B!O9B!C;VYV
M97)T:6)L92!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#<P,RPR-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L(%!U8FQI8R!/9F9E<FEN9R!\($-O
M;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@=7!O;B!C;VYV
M97)S:6]N(&]F(&-O;G9E<G1I8FQE(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S+#8Y.2PY.3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!<W1R82!:96YE8V$\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@<VAA<F5S+"!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPR-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')I8V4@<&5R('-H87)E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R
M;VT@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F1E<G=R:71E<CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!S:&%R97,L(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#0X,"PY.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEC92!P97(@<VAA<F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$R(%!L86X\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@
M<VAA<F5S(')E<V5R=F5D(&9O<B!F=71U<F4@:7-S=6%N8V4@86YD(&%U=&AO
M<FEZ960@9F]R('!U<F-H87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW,3`L-3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XR,#$R(%!U<F-H87-E(%!L86X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA
M<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<VAA
M<F5S(')E<V5R=F5D(&9O<B!F=71U<F4@:7-S=6%N8V4@86YD(&%U=&AO<FEZ
M960@9F]R('!U<F-H87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-C`L,C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F('!A<G1I8VEP86YT<R!E
M;&EG:6)L92!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('-H87)E<R!I<W-U
M960@=6YD97(@<'5R8VAA<V4@<&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT."PP,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$R(%!U<F-H87-E(%!L86X@?"!!
M="!I;F-E<'1I;VX@;V8@=&AE(&5N<F]L;&UE;G0@<&5R:6]D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S
M(&]F(%-T;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!F86ER
M(&UA<FME="!V86QU92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,B!0=7)C:&%S92!0
M;&%N('P@070@87!P;&EC86)L92!P=7)C:&%S92!D871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F
M(%-T;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!F86ER(&UA
M<FME="!V86QU92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?
M83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R
M.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S
M+U-H965T-3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5$3T%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/D-O;6UO;B!3=&]C:R!297-E<G9E9"!F;W(@1G5T=7)E($ES<W5A
M;F-E("A$971A:6PI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K(&]P=&EO;G,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L-3DX+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S(P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M8V]M;6]N('-H87)E<R!R97-E<G9E9"!F;W(@9G5T=7)E(&ES<W5A;F-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$X,"PV.#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D5Q=6ET>2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@;W!T:6]N
M<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PU.3@L,C`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('-H87)E<R!A=F%I;&%B;&4@9F]R
M(&9U='5R92!G<F%N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S$P+#4S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K(%!U<F-H87-E(%!L86X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<VAA<F5S(&%V86EL86)L92!F;W(@
M9G5T=7)E(&=R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-C`L,C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&-O;6UO;B!S:&%R97,@<F5S97)V960@9F]R(&9U='5R
M92!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT
M,3$L-C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A
M93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T-3,N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$583D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K($]P=&EO
M;B!!8W1I=FET>2`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@
M97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DYU;6)E<B!O9B!O<'1I;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&]U='-T86YD:6YG(&%T($1E
M8V5M8F5R(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#<R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PX-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-S,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%N8V5L960O9F]R9F5I=&5D+V5X<&ER960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@;W5T<W1A
M;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L-3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y697-T960@;W(@97AP96-T960@=&\@=F5S
M="!A="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PS.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE(&%T($1E8V5M8F5R(#,Q+"`R
M,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(T-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY796EG:'1E9"!A=F5R86=E(&5X97)C:7-E('!R:6-E/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&]U
M='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(N,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-BXU,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A;F-E;&5D+V9O<F9E
M:71E9"]E>'!I<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,N-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P=&EO;G,@;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P
M,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXV.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S
M=&5D(&]R(&5X<&5C=&5D('1O('9E<W0@870@1&5C96UB97(@,S$L(#(P,3,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXV/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES
M86)L92!A="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D(&%V97)A9V4@
M<F5M86EN:6YG(&-O;G1A8W1U86P@=&5R;3PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O=71S=&%N9&EN9R!A
M="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S<@>65A<G,@,3$@;6]N=&AS(#(S(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1E9"!O<B!E
M>'!E8W1E9"!T;R!V97-T(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<R`Q,2!M;VYT:',@,2!D
M87D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X97)C:7-A8FQE(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-B!Y96%R<R`Q(&UO;G1H(#$S(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^06=G<F5G871E(&EN=')I;G-I8R!V86QU93PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O
M=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R,2PQ-C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1E9"!O<B!E>'!E8W1E
M9"!T;R!V97-T(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,"PX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-A8FQE(&%T($1E8V5M
M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$S+#@T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A
M93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T-30N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5704%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%S<W5M<'1I;VYS
M(%5S960@=&\@17-T:6UA=&4@1F%I<B!686QU92!O9B!3=&]C:R!/<'1I;VYS
M(%5S:6YG($)L86-K+5-C:&]L97,@3W!T:6]N(%!R:6-I;F<@36]D96P@*$1E
M=&%I;"D@*$-O;6UO;B!S=&]C:R!O<'1I;VYS*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!O<'1I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^16UP;&]Y964@4W1O8VL@3W!T:6]N<SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T
M(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N.3`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XY
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+C,P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AP96-T960@9&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@
M=F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(N
M-#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S,N-#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S(N.3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!T97)M("AY96%R<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S(#$@;6]N=&@@-B!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S8@>65A<G,@,2!M;VYT:"`V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-B!Y96%R<R`Q(&UO;G1H(#8@
M9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T
M7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T-34N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5+24%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O
M;7!E;G-A=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@4V5R=FEC
M92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L;&]C871I;VX@;V8@4F5C
M;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S+#0R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PU-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E
M=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS
M871I;VXL($%L;&]C871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@4V5R=FEC92!3
M:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L;&]C871I;VX@;V8@4F5C;V=N
M:7IE9"!097)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;B!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#$W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%5DI!0SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY$969I;F5D($-O;G1R:6)U=&EO;B!0;&%N("T@061D:71I;VYA;"!)
M;F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969I;F5D($)E;F5F:70@
M4&QA;B!$:7-C;&]S=7)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(#0P,2`H2RD@
M<&QA;B!C;VYT<FEB=71I;VX@<F%T97,@87,@<&5R8V5N=&%G92!O9B!E;7!L
M;WEE97,@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F%T92!O9B!C;VYT<FEB=71I;VX@=&\@-#`Q*$LI
M('!L86X@87,@82!P97)C96YT86=E(&]F(&5M<&QO>65E<R!C;VYT<FEB=71I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M97)C96YT86=E(&]F(&5M<&QO>65E)W,@96%R;FEN9W,@=&AE(&-O;7!A;GD@
M;6%Y(&-O;G1R:6)U=&4@=&\@=&AE(#0P,2A+*2!P;&%N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE<B!C;VYT<FEB
M=71I;VX@=&\@-#`Q("A+*2!P;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3T1!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VUP;VYE;G1S($EN8V]M92!487@@*$)E;F5F:70I($5X<&5N<V4@
M*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9E9&5R86P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($EN8V]M92!4
M87@@17AP96YS92`H0F5N969I="DL(%1O=&%L/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9#H\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F5D97)A
M;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%T
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!);F-O;64@5&%X($5X<&5N<V4@*$)E;F5F:70I+"!4;W1A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!T
M87@@*&)E;F5F:70I(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S
M83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B
M9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H
M965T-3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5$3$%%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E)E8V]N8VEL:6%T:6]N(&]F($5X<&5C=&5D(%-T871U=&]R>2!&961E
M<F%L($EN8V]M92!487@@4')O=FES:6]N('1O($%C='5A;"!);F-O;64@5&%X
M(%!R;W9I<VEO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!2871E
M(%)E8V]N8VEL:6%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!I;F-O;64@
M=&%X(&)E;F5F:70@870@9F5D97)A;"!S=&%T=71O<GD@=&%X(')A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-BPS-34I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#DR,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(L-3(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1A=&4@:6YC;VUE('1A>&5S+"!N970@;V8@9F5D97)A;"!B
M96YE9FET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`Y,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#`Q-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T,S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y487@@8W)E9&ET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,BPT,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#8X,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O=F5R;FUE;G0@9W)A;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F
M86ER('9A;'5E(&]F(&-O;G9E<G1I8FQE(&YO=&4@<&%Y86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&1E
M8G0@97AT:6YG=6ES:&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#:&%N9V4@:6X@=F%L=6%T:6]N(&%L;&]W86YC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PP,C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,X-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#4X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<FEO<B!Y96%R('1R=64M=7`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(S-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@S-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!C;VUP96YS871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8V-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A
M>"`H8F5N969I="D@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@R,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]E,C@R8F0X,E\R.3-B7S0Y.69?864R-%]A,#-A
M,V,U.#8T.&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO93(X,F)D
M.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF+U=O<FMS:&5E=',O4VAE
M970U.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14)"044^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^0V]M<&]N96YT<R!O9B!$969E<G)E9"!487@@07-S971S(&%N9"!,:6%B
M:6QI=&EE<R`H1&5T86EL*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R960@=&%X
M(&%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W,@8V%R<GEO=F5R<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPT-C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L-3(X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@86YD(&]T:&5R('1A>"!C<F5D:71S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<R-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#DY.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L,S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G1A;F=I8FQE<R!A;F0@<')O<&5R='D@86YD(&5Q=6EP
M;65N="!B87-I<R!D:69F97)E;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#<Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PR.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!D969E<G)E9"!T87@@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PR-SD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PU
M,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&1E9F5R<F5D('1A>"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH.3<S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(R-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@9&5F97)R960@
M=&%X(&%S<V5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR."PS
M,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.2PR-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(X+#,P-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.2PR-SDI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&1E9F5R<F5D
M('1A>"!A<W-E=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3DI!1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY);F-O;64@5&%X97,@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$
M971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!/9B!);F-O;64@5&%X97,@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&1E9F5R<F5D('1A>"!A<W-E=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R."PS,#8L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.2PR-SDL,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F0@97AP:7)A=&EO;B!Y96%R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`S,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R
M871I;F<@;&]S<R!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-RPT-C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^."PU,C@L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6UI=&%T:6]N(&]F
M(&-O;7!A;GDG<R!A8FEL:71Y('1O('5T:6QI>F4@8V5R=&%I;B!T87@@8W)E
M9&ET(&-A<G)Y9F]R=V%R9',@86YD(&YE="!O<&5R871I;F<@;&]S<R!C87)R
M>69O<G=A<F1S+"!M:6YI;75M('!E<F-E;G1A9V4@;V8@;W=N97)S:&EP(&-H
M86YG93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M56YR96-O9VYI>F5D('1A>"!B96YE9FET<R!T:&%T+"!I9B!R96-O9VYI>F5D
M+"!W;W5L9"!N;W0@:6UP86-T(&EN8V]M92!T87@@8F5N969I="!O<B!E9F9E
M8W1I=F4@=&%X(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!/9B!)
M;F-O;64@5&%X97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A
M<G)Y9F]R=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=&5R;F%L(%)E=F5N=64@4V5R=FEC92`H25)3*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V-H961U
M;&4@3V8@26YC;VUE(%1A>&5S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!O<&5R871I;F<@
M;&]S<R!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-"PR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06QT97)N871I=F4@;6EN:6UU;2!T87@@8V-R
M961I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A;&EF;W)N:6$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-C:&5D=6QE($]F($EN8V]M92!487AE<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3(L-C`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!L
M;W-S(&-A<G)Y9F]R=V%R9"!E>'!I<F%T:6]N('EE87(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<R,#,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%L:69O<FYI82!\(%)E<V5A
M<F-H(%1A>"!#<F5D:70@0V%R<GEF;W)W87)D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!/9B!);F-O;64@
M5&%X97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT('1A
M>"!C<F5D:70@8V%R<GEF;W)W87)D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L('P@4F5S96%R8V@@5&%X($-R
M961I="!#87)R>69O<G=A<F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE($]F($EN8V]M92!487AE<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@=&%X(&-R961I="!C
M87)R>69O<G=A<F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,RPV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY
M9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T-C$N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5,2D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-H86YG97,@
M:6X@06UO=6YT(&]F(%5N<F5C;V=N:7IE9"!487@@0F5N969I=',@*$1E=&%I
M;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@
M<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DEN8V]M92!487@@0V]N=&EN9V5N8WD@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)E9VEN;FEN9R!B86QA;F-E(&]F('5N<F5C;V=N:7IE9"!T87@@8F5N
M969I=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-38Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YC<F5A<V4@*&1E8W)E87-E*2!F;W(@<')I;W(@>65A<B!T
M87@@<&]S:71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YC<F5A<V4@9F]R(&-U<G)E;G0@>65A<B!T87@@<&]S:71I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#DR
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`U-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?93(X,F)D.#)?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY
M9E]A93(T7V$P,V$S8S4X-C0X9B]7;W)K<VAE971S+U-H965T-C(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5#2D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@
M;V8@3W!E<F%T:6YG($5X<&5N<V5S($9R;VT@4F5L871E9"!087)T>2!!8W1I
M=FET:65S("A$971A:6PI("A!;&YY;&%M+"!54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QN>6QA;3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R
M='D@5')A;G-A8W1I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<G9I8V5S('!E<F9O<FUE
M9"!O<B!O=70M;V8M<&]C:V5T(&5X<&5N<V5S('!A:60@=&\@06QN>6QA;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3DY!1SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY396QE8W1E9"!1=6%R=&5R;'D@1FEN
M86YC:6%L($1A=&$@*$1E=&%I;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M(&5X8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,38^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/DIU
M;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/E-E<"X@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY-87(N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-E
M;&5C=&5D(%%U87)T97)L>2!&:6YA;F-I86P@1&%T82!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U+#0U-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-BPQ,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0L-S4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#(S
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPR,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L.#`Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S+#,P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPS-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$Y+#4V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3(L-S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q,RPW.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!E>'!E;G-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3$V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.2PP,C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#0T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L-S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPU-#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#,T,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L.#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PU,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RPS
M-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2PR-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,"PY,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#$L.3(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,BPQ-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@W
M+#,T."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#<L,C(Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-BPX-S8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#8X-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(L-3DY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,BPR-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q."PV-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@Q-RPT,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@W+#8P,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&YE="!L;W-S('!E
M<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@P+C`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#`N,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,34N.3@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S
M=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$P+C<X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P
M/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q
M,RXP-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,"XT.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#(N,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@X-2XX,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I;'5T960@;F5T(&QO<W,@
M<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N
M,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CQS=7`^6S%=+%LR73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\<W5P/ELQ72Q;,ET\+W-U<#X\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ72Q;,ET\+W-U<#X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ72Q;,ET\+W-U
M<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT9"!C;VQS<&%N
M/3-$,C`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I
M;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELQ73PO
M=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$,3D@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S('!E<B!S:&%R92!I<R!C;VUP=71E9"!I;F1E<&5N9&5N=&QY(&9O
M<B!E86-H(&]F('1H92!Q=6%R=&5R<R!P<F5S96YT960N(%1H97)E9F]R92P@
M=&AE('-U;2!O9B!T:&4@<75A<G1E<FQY('!E<BUS:&%R92!C86QC=6QA=&EO
M;G,@=VEL;"!N;W0@;F5C97-S87)I;'D@97%U86P@=&AE(&%N;G5A;"!P97(@
M<VAA<F4@8V%L8W5L871I;VXN/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N
M/3-$=&]P/ELR73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$,3D@=F%L
M:6=N/3-$=&]P/D%P<&QI8V%B;&4@86-C;W5N=&EN9R!G=6ED86YC92!P<F]V
M:61E<R!T:&%T(&$@8V]N=')A8W0@*'-U8V@@87,@=&AE(#(P,3`@1U-+($YO
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M(&]F('1H92!C;VYV97)T:6)L92!N;W1E('!A>6%B;&4N/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%5$%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=6)S97%U96YT($5V96YT<R`M($%D9&ET:6]N86P@26YF;W)M871I;VX@
M*$1E=&%I;"D@*%-A;F]F:2P@55-$("0I/&)R/DEN($UI;&QI;VYS+"!E>&-E
M<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,SXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$S/&)R/D1E
M=F5L;W!M96YT($-O;6UE<F-I86QI>F%T:6]N($%N9"!,:6-E;G-E($%G<F5E
M;65N=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(X
M+"`R,#$T/&)R/E-U8G-E<75E;G0@179E;G0\8G(^4')I=F%T92!0;&%C96UE
M;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R."P@
M,C`Q-#QB<CY3=6)S97%U96YT($5V96YT/&)R/D1E=F5L;W!M96YT($-O;6UE
M<F-I86QI>F%T:6]N($%N9"!,:6-E;G-E($%G<F5E;65N=#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT
M($5V96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5<&9R;VYT('!A>6UE;G0@8W)E9&ET86)L
M92!A9V%I;G-T(&9U='5R92!A8V-O=6YT<R!R96-E:79A8FQE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XR-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YI=&EA
M;"!U<&9R;VYT(&]P=&EO;B!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BXU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&%N9"!I<W-U86YC92!O9B!C;VUM
M;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P
M,RPW.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#<N-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@<'5R8VAA<V4@<')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?,CDS
M8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V4R.#)B9#@R7S(Y,V)?-#DY9E]A93(T7V$P,V$S8S4X-C0X
M9B]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B
M=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\
M;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,V+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#$N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#0R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970T,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#0N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0U+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970T-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0X+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T.2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#4Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U,BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3,N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#4T+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970U-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-38N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4W+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970U."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T-3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8P
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970V,2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T-C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#8S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970V
M-"YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?93(X,F)D.#)?
?,CDS8E\T.3EF7V%E,C1?83`S83-C-3@V-#AF+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1FHM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Strategic Alliances and Collaborations - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="8"></th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="9"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="4"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2013</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>GSK</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>GSK

</div>
          <div>Development Commercialization And License Agreement</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Preclinical</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Clinical</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Regulatory</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Commercialization Milestones</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Phase One Clinical Trial</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Phase Two Clinical Trial</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>HCV Alliance

</div>
          <div>Proof-of-Concept Trial</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Preclinical</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Clinical</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Regulatory</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Commercialization</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Fourth Micro RNA Targets</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Development Candidate</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Phase One Clinical Trial</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Phase Two Clinical Trial</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>GSK

</div>
          <div>Immuno-Inflammatory Alliance

</div>
          <div>Proof-of-Concept Trial</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Astra Zeneca</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Astra Zeneca

</div>
          <div>Agreement</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Astra Zeneca

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Astra Zeneca

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Astra Zeneca

</div>
          <div>Preclinical</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Astra Zeneca

</div>
          <div>Clinical</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Astra Zeneca

</div>
          <div>Commercialization</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Astra Zeneca

</div>
          <div>Common Stock Purchase Agreements Cspa</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Biogen Idec</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Biogen Idec

</div>
          <div>Research Tax Credit Carryforward</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2013

</div>
          <div>Biogen Idec

</div>
          <div>Amended Collaboration and License Agreement</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Biogen Idec

</div>
          <div>Validation Of Micro Rna Biomarker</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Biogen Idec

</div>
          <div>Longitudinal Study Of Patient Samples On Ms Therapy</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sanofi

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sanofi

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sanofi

</div>
          <div>Preclinical</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sanofi

</div>
          <div>Clinical</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sanofi

</div>
          <div>Regulatory and Commercialization Milestones</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>Sanofi

</div>
          <div>Development Commercialization And License Agreement</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>Sanofi

</div>
          <div>Research and Development</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sanofi

</div>
          <div>Research and Development</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Initial upfront option payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,500,000<span></span></td>
        <td class="nump">$ 25,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerAdvancesCurrent', window );">Upfront payment creditable against future accounts receivables</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Upfront payment non-creditable portion recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,300,000<span></span></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,900,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Revenue through milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">144,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,500,000<span></span></td>
        <td class="nump">29,000,000<span></span></td>
        <td class="nump">50,000,000<span></span></td>
        <td class="nump">60,000,000<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="nump">432,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,500,000<span></span></td>
        <td class="nump">87,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">180,000,000<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">498,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">123,000,000<span></span></td>
        <td class="nump">370,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,000,000<span></span></td>
        <td class="nump">33,000,000<span></span></td>
        <td class="nump">165,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RoyaltyPercentageBasedOnNetSales', window );">Royalties based on percentage of net sales</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="nump">20.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="nump">20.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10.00%<span></span></td>
        <td class="nump">20.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8.00%<span></span></td>
        <td class="nump">12.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DeferredRevenueRecognitionPeriod', window );">Deferred revenue recognition period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">8 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DeferredRevenueRemainingRecognitionPeriod', window );">Deferred revenue remaining recognition period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Acceleration of remaining amortization of upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_CollaborativeAreasGranted', window );">Number of collaborative areas granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration and license agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">August 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">August 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ResearchAndDevelopmentPlanExpectedTerm', window );">Expected term of research and development plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42,000<span></span></td>
        <td class="nump">36,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41,787,326<span></span></td>
        <td class="nump">35,831,808<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Price per share</a></td>
        <td class="nump">$ 9.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_CommonStockTransactionRestrictionPeriod', window );">Number of days during which AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">365 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_FairValueInputsPeriod', window );">Restricting common stock valuation measurement period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueRecognitionPeriod', window );">Revenue recognition period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issued promissory note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion to common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,256,232<span></span></td>
        <td class="nump">1,256,232<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and License Agreement Entered Date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_CollaborationAndLicenseAgreementEnteredDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_CollaborativeAreasGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative Areas Granted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_CollaborativeAreasGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_CommonStockTransactionRestrictionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock Transaction Restriction Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_CommonStockTransactionRestrictionPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DeferredRevenueRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Revenue Recognition Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_DeferredRevenueRecognitionPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DeferredRevenueRemainingRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Revenue, Remaining Recognition Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_DeferredRevenueRemainingRecognitionPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_FairValueInputsPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Inputs Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_FairValueInputsPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ResearchAndDevelopmentPlanExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and Development Plan, Expected Term</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_ResearchAndDevelopmentPlanExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue Recognition, Milestone Method, Expected Milestone Receivable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_RevenueRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue Recognition, Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_RevenueRecognitionPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_RoyaltyPercentageBasedOnNetSales">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty Percentage Based On Net Sales</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_RoyaltyPercentageBasedOnNetSales</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentForAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current portion of prepayments received from customers for goods or services to be provided in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CustomerAdvancesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RecognitionOfDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets, net (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets</a></td>
        <td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The following table summarizes our major classes of intangible
 assets (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Patents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">960</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">913</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Licenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,364</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,317</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accumulated amortization</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(236</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(163</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Intangibles, net</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,128</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,154</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
        <td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following table summarizes our major classes of property and
 equipment (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,342</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,583</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Computer equipment and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">114</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">114</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">119</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">93</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,805</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">751</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Construction in progress</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">119</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">211</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,499</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,752</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less accumulated depreciation and amortization</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,731</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,442</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,768</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,310</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation', window );">Maximum 401 (K) plan contribution rates as percentage of employees compensation</a></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Rate of contribution to 401(K) plan as a percentage of employees contribution</a></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee's earnings the company may contribute to the 401(K) plan</a></td>
        <td class="nump">6.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contribution to 401 (K) plan</a></td>
        <td class="nump">$ 0.1<span></span></td>
        <td class="nump">$ 0.1<span></span></td>
        <td class="nump">$ 0.1<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Defined Contribution Plan, Employee Contributions, Percentage of Eligible Compensation</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_DefinedContributionPlanEmployeeContributionsPercentageOfEligibleCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanDisclosureLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the cost recognized during the period for defined contribution plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanCostRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ED6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Property and Equipment (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">$ 7,499<span></span></td>
        <td class="nump">$ 5,752<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
        <td class="num">(3,731)<span></span></td>
        <td class="num">(2,442)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">3,768<span></span></td>
        <td class="nump">3,310<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory Equipment</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">5,342<span></span></td>
        <td class="nump">4,583<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer Equipment and Software</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">114<span></span></td>
        <td class="nump">114<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture and Fixtures</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">119<span></span></td>
        <td class="nump">93<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold Improvements</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">1,805<span></span></td>
        <td class="nump">751<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Construction in Progress</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
        <td class="nump">$ 119<span></span></td>
        <td class="nump">$ 211<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Annual Minimum Lease Payments for Operating Leases</a></td>
        <td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As of December&#xA0;31, 2013, future annual minimum lease payments
 for our operating leases are as follows (in&#xA0;thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2014</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,066</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2015</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,138</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2016</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,211</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2017</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">624</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Thereafter</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,039</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders' Deficit (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Future Issuance</a></td>
        <td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The following shares of common stock are reserved for future
 issuance at December&#xA0;31, 2013:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Common stock options outstanding</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,598,207</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Common stock options available for future grant</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710,534</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Employee Stock Purchase Plan</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">460,283</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Convertible note payable (Post-IPO GSK Note)</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,411,659</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total common shares reserved for future issuance</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,180,683</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table summarizes our stock option activity under the
 2012 Plan for the year ended December&#xA0;31, 2013 (in thousands,
 except per share and contractual term data):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Number&#xA0;of<br />
 options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Weighted<br />
 average<br />
 exercise<br />
 price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Weighted<br />
 average<br />
 remaining<br />
 contractual<br />
 term<br />
 (in&#xA0;years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Aggregate<br />
 intrinsic<br />
 value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options outstanding at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,720</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.11</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,864</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(732</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.81</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Canceled/forfeited/expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(254</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options outstanding at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,598</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.98</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,162</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Vested or expected to vest at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,382</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,800</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,244</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.22</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,842</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model</a></td>
        <td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The assumptions used to estimate the fair value of stock options
 using the Black-Scholes option pricing model were as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Year&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">
 <b>&#xA0;2013&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">
 <b>&#xA0;2012&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">
 <b>&#xA0;2011&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Employee Stock Options:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.9</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.3</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72.4</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73.4</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72.9</td>
 <td nowrap="nowrap" valign="bottom">%&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Expected term (years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.1</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.1</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.1</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Stock-based compensation is reflected in the statement of
 operations and comprehensive loss as follows
 (in&#xA0;thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,246</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">912</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">557</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,176</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">638</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">268</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,422</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,550</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">825</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Shares Reserved For Future Issuance Table</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Business, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Business, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>1. The Business, Basis of Presentation and Summary of
 Significant Accounting Policies</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Regulus Therapeutics Inc. was originally formed as a Delaware
 limited liability company under the name Regulus Therapeutics LLC
 on September&#xA0;6, 2007, when Alnylam Pharmaceuticals, Inc.
 (&#x201C;Alnylam&#x201D;) and Isis Pharmaceuticals, Inc.
 (&#x201C;Isis&#x201D;) contributed significant intellectual property,
 know-how and financial and human capital to pursue the development
 of drugs targeting <i>micro</i>RNAs pursuant to a license and
 collaboration agreement. Regulus Therapeutics Inc. was converted to
 a Delaware corporation on January&#xA0;2, 2009. As used in this
 report, unless the context suggests otherwise, &#x201C;the
 Company,&#x201D; &#x201C;our,&#x201D; &#x201C;us&#x201D; and
 &#x201C;we&#x201D; means Regulus Therapeutics Inc.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We are a biopharmaceutical company focused on discovering and
 developing first-in-class drugs that target <i>micro</i>RNAs to
 treat a broad range of diseases. We believe we have assembled the
 leading position in the <i>micro</i>RNA field, including expertise
 in <i>micro</i>RNA biology and oligonucleotide chemistry, a broad
 intellectual property estate, key opinion leaders and disciplined
 drug discovery and development processes. We refer to these assets
 as our <i>micro</i>RNA product platform. We are using our
 <i>micro</i>RNA product platform to develop chemically modified,
 single-stranded oligonucleotides that we call anti-miRs. We use
 these anti-miRs to modulate <i>micro</i>RNAs and by doing so return
 diseased cells to their healthy state. We are pursuing several
 <i>micro</i>RNA targets and are focusing our proprietary efforts in
 oncology and orphan diseases. We believe <i>micro</i>RNAs may be
 transformative in the field of drug discovery and that anti-miRs
 may become a new and major class of drugs with broad therapeutic
 application much like small molecules, biologics and monoclonal
 antibodies.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Use of Estimates</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Our financial statements are prepared in accordance with U.S.
 generally accepted accounting principles. The preparation of our
 financial statements requires us to make estimates and assumptions
 that affect the reported amounts of assets, liabilities, revenues
 and expenses and the disclosure of contingent assets and
 liabilities in our financial statements and accompanying notes.
 Although these estimates are based on our knowledge of current
 events and actions we may undertake in the future, actual results
 may ultimately differ from these estimates and assumptions.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Revenue Recognition</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Our revenues generally consist of upfront payments for licenses or
 options to obtain licenses in the future, research and development
 funding and milestone payments under strategic alliance agreements,
 as well as funding received under government grants. We recognize
 revenues when all four of the following criteria are met:
 (1)&#xA0;persuasive evidence that an arrangement exists;
 (2)&#xA0;delivery of the products and/or services has occurred;
 (3)&#xA0;the selling price is fixed or determinable; and
 (4)&#xA0;collectability is reasonably assured.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Multiple element arrangements, such as our strategic alliance
 agreements with Sanofi, AstraZeneca AB (&#x201C;AstraZeneca&#x201D;)
 and GlaxoSmithKline plc (&#x201C;GSK&#x201D;), are analyzed to
 determine whether the deliverables within the agreement can be
 separated or whether they must be accounted for as a single unit of
 accounting. Deliverables under the agreement will be accounted for
 as separate units of accounting provided that (i)&#xA0;a delivered
 item has value to the customer on a stand-alone basis; and
 (ii)&#xA0;if the agreement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially in the
 control of the vendor. The allocation of consideration amongst the
 deliverables under the agreement is derived using a &#x201C;best
 estimate of selling price&#x201D; if vendor specific objective
 evidence and third-party evidence of fair value is not available.
 If the delivered element does not have stand-alone value, the
 arrangement is then accounted for as a single unit of accounting,
 and we recognize the consideration received under the arrangement
 as revenue on a straight-line basis over our estimated period of
 performance, which for us is often the expected term of the
 research and development plan.</p>
 <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Milestones</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We recognize revenue from milestone payments when earned, provided
 that (i)&#xA0;the milestone event is substantive in that it can
 only be achieved based in whole or in part on either our
 performance or on the occurrence of a specific outcome resulting
 from our performance and its achievability was not reasonably
 assured at the inception of the agreement, (ii)&#xA0;we do not have
 ongoing performance obligations related to the achievement of the
 milestone and (iii)&#xA0;it would result in the receipt of
 additional payments. A milestone payment is considered substantive
 if all of the following conditions are met: (i)&#xA0;the milestone
 payment is non-refundable; (ii)&#xA0;achievement of the milestone
 was not reasonably assured at the inception of the arrangement;
 (iii)&#xA0;substantive effort is involved to achieve the milestone;
 and (iv)&#xA0;the amount of the milestone payments appears
 reasonable in relation to the effort expended, the other milestones
 in the arrangement and the related risk associated with the
 achievement of the milestone. Any amounts received under the
 agreements in advance of performance, if deemed substantive, are
 recorded as deferred revenue and recognized as revenue as we
 complete our performance obligations.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Generally, the milestone events contained in our strategic alliance
 agreements coincide with the progression of our product candidates
 from target selection, to clinical candidate selection, to clinical
 trial, to regulatory approval and then to commercialization. The
 process of successfully discovering a new development candidate,
 having it approved and ultimately sold for a profit is highly
 uncertain. As such, the milestone payments we may earn from our
 partners involve a significant degree of risk to achieve.
 Therefore, as a product candidate progresses through the stages of
 its life-cycle, the value of the product candidate generally
 increases.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Grant Revenue</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We recognize revenue from government and private agency grants as
 the related research expenses are incurred and to the extent that
 funding is approved. Any amounts received in advance of performance
 are recorded as deferred revenue until earned.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Deferred Revenue</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Amounts received prior to satisfying the above revenue recognition
 criteria are recorded as deferred revenue in the accompanying
 balance sheets. Amounts not expected to be recognized within the
 next 12 months are classified as non-current deferred revenue.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Stock-Based Compensation</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We account for stock-based compensation expense related to stock
 options granted to employees and members of our board of directors
 by estimating the fair value of each stock option on the date of
 grant using the black-scholes model. We recognize stock-based
 compensation expense using the accelerated multiple-option
 approach. Under the accelerated multiple-option approach (also
 known as the graded-vesting method), we recognize compensation
 expense over the requisite service period for each separately
 vesting tranche of the award as though the award was in substance
 multiple awards, resulting in accelerated expense recognition over
 the vesting period.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We account for stock options granted to non-employees, which
 primarily consist of members of our scientific advisory board,
 using the fair value approach. Stock options granted to
 non-employees are subject to periodic revaluation over their
 vesting terms.</p>
 <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Research and Development</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Research and development costs are expensed as incurred and include
 compensation and related benefits, non-cash stock-based
 compensation, license fees, laboratory supplies and associated
 overhead and facilities costs. In certain circumstances, we make
 non-refundable advance payments to purchase goods and services for
 future use in research and development activities pursuant to
 contractual arrangements. In those instances, we capitalize these
 amounts and record expense in the period that we receive the goods
 or when services are performed.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Income Taxes</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The accounting guidance for accounting for uncertainty in income
 taxes prescribes a recognition threshold and measurement attribute
 criteria for the financial statement recognition and measurement of
 tax positions taken or expected to be taken in a tax return. For
 those benefits to be recognized, a tax position must be more likely
 than not to be sustained upon examination by taxing
 authorities.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We use the liability method of accounting for income taxes. Under
 this method, deferred tax assets and liabilities are determined
 based on the difference between the financial reporting and the tax
 reporting basis of assets and liabilities and are measured using
 the enacted tax rates and laws that are expected to be in effect
 when the differences are expected to reverse. We provide a
 valuation allowance against net deferred tax assets unless, based
 upon the available evidence, it is more likely than not that the
 deferred tax assets will be realized.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Fair Value Option</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Applicable accounting policies permit entities to choose, at
 specified election dates, to measure specified items at fair value
 if the decision about the election is: 1) applied instrument by
 instrument, 2) irrevocable, and 3) applied to an entire
 instrument.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In July 2012, we amended and restated our $5.0 million convertible
 promissory note originally issued in February 2010 to GSK
 (&#x201C;2010 GSK note&#x201D;), which was accounted for as a debt
 extinguishment of the original note. We elected to measure the
 amended note under the fair value option. The difference between
 the carrying value of the original note and the fair value of the
 amended note was recorded as a loss on extinguishment of debt to
 non-operating earnings. Thereafter, any change to the fair value of
 the amended note is recorded as gain (loss) from valuation of
 convertible note payable to non-operating earnings.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We classify time deposits and other investments that are highly
 liquid and have maturities of 90 days or less at the date of
 purchase as cash equivalents. The carrying amounts approximate fair
 value due to the short maturities of these instruments.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Short-Term Investments</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We carry short-term investments classified as available-for-sale at
 fair value as determined by prices for identical or similar
 securities at the balance sheet date. Our short-term investments
 consist of both Level 1 and Level 2 financial instruments in the
 fair value hierarchy. We record unrealized gains and losses as a
 component of other comprehensive loss within the statements of
 operations and comprehensive loss and as a separate component of
 stockholders&#x2019; equity (deficit). We determine the realized
 gains or losses of available-for-sale securities using the specific
 identification method and include net realized gains and losses in
 interest income.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 At each balance sheet date, we assess available-for-sale securities
 in an unrealized loss position to determine whether the unrealized
 loss is other-than-temporary. We consider factors including: the
 significance of the decline in value compared to the cost basis,
 underlying factors contributing to a decline in the prices of
 securities in a single asset class, the length of time the market
 value of the security has been less than its cost basis, the
 security&#x2019;s relative performance versus its peers, sector or
 asset class, expected market volatility and the market and economy
 in general. When we determine that a decline in the fair value
 below its cost basis is other-than-temporary, we recognize an
 impairment loss in the year in which the other-than-temporary
 decline occurred. We determined that there were no
 other-than-temporary declines in the value of short-term
 investments as of December&#xA0;31, 2013 and 2012.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Concentrations of Credit Risk</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Financial instruments that potentially subject us to significant
 concentrations of credit risk consist primarily of cash, cash
 equivalents and short-term investments. We maintain deposits in
 federally insured financial institutions in excess of federally
 insured limits. We have not experienced any losses in such accounts
 and believe we are not exposed to significant risk. We maintain our
 cash equivalents and short-term investments with three financial
 institutions. We invest our excess cash primarily in commercial
 paper and debt instruments of financial institutions, corporations,
 U.S. government-sponsored agencies and the U.S. Treasury.
 Additionally, we established guidelines regarding approved
 investments and maturities of investments, which are designed to
 maintain safety and liquidity.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Property and Equipment</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We carry our property and equipment at cost, which consists of lab
 equipment, computer equipment and software, furniture and fixtures
 and leasehold improvements. Property and equipment is depreciated
 using the straight-line method over the estimated useful lives
 (generally three to five years). Leasehold improvements are
 amortized over the lesser of their useful life or the remaining
 lease term, including any renewal periods that are deemed to be
 reasonably assured. Repair and maintenance costs that do not
 improve service potential or extend economic life are expensed as
 incurred.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Intangibles</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We capitalize costs which consist principally of outside legal
 costs and filing fees related to obtaining patents. We review our
 capitalized patent costs periodically to determine that they
 include costs for patent applications that have future value and an
 alternative future use. We evaluate costs related to patents that
 we are not actively pursuing and write off these costs. We amortize
 patent costs over their patent lives, beginning with the date the
 patents are issued. The weighted average remaining life of the
 issued patents was 12 years at December&#xA0;31, 2013.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We obtain licenses from third parties and capitalize the costs
 related to exclusive licenses that have alternative future use
 within multiple potential programs. We amortize capitalized
 licenses over their estimated useful life or term of the agreement,
 which for current licenses is 10 years.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We regularly review the carrying amount of our property, equipment
 and intangible assets to determine whether indicators of impairment
 may exist which warrant adjustments to carrying values or estimated
 useful lives. If indications of impairment exist, projected future
 undiscounted cash flows associated with the asset are compared to
 the carrying amount to determine whether the asset&#x2019;s value is
 recoverable. If the carrying value of the asset exceeds such
 projected undiscounted cash flows, the asset will be written down
 to its estimated fair value. No impairment charges were recorded
 during the years ended December&#xA0;31, 2013, 2012 and 2011.</p>
 <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Clinical Trial and Pre-Clinical Study Accruals</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We make estimates of our accrued expenses as of each balance sheet
 date in our financial statements based on the facts and
 circumstances known to us at that time. Our accrued expenses for
 clinical trials are based on estimates of the fees associated with
 services provided by clinical trial investigational sites and CROs.
 Payments under some of the contracts we have with such parties
 depend on factors such as successful enrollment of patients, site
 initiation and the completion of clinical trial milestones. In
 accruing service fees, we estimate the time period over which
 services will be performed and the level of effort to be expended
 in each period. If possible, we obtain information regarding
 unbilled services directly from these service providers. However,
 we may be required to estimate these services based on other
 information available to us. If we underestimate or overestimate
 the activity or fees associated with a study or service at a given
 point in time, adjustments to research and development expenses may
 be necessary in future periods. Historically, our estimated accrued
 liabilities have approximated actual expense incurred. Subsequent
 changes in estimates may result in a material change in our
 accruals.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Segment Reporting</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Operating segments are identified as components of an enterprise
 about which separate discrete financial information is available
 for evaluation by the chief operating decision-maker in making
 decisions regarding resource allocation and assessing performance.
 To date, we have viewed our operations and managed our business as
 one segment operating primarily in the United States.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Comprehensive Loss</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Comprehensive loss is defined as the change in equity during a
 period from transactions and other events and/or circumstances from
 non-owner sources. Our only component of other comprehensive loss
 is unrealized gains (losses) on available-for-sale securities.
 Comprehensive gains (losses) have been reflected in the statements
 of operations and comprehensive loss and as a separate component of
 the statements of convertible preferred stock and
 stockholders&#x2019; equity (deficit) for all periods presented.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Reclassifications</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Certain current and non-current liabilities in prior period
 financial statements have been reclassified or consolidated to
 conform to the current period presentation. These reclassifications
 had no impact on our statements of operations, statements of
 preferred stock and stockholders&#x2019; equity (deficit) or
 statements of cash flows.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In July 2013, the FASB issued Accounting Standards Update
 No.&#xA0;2013-11, <i>Presentation of an Unrecognized Tax Benefit
 When a Net Operating Loss Carryforward, a Similar Tax Loss, or a
 Tax Credit Carryforward Exists</i> (&#x201C;ASU 2013-11&#x201D;).
 This update provides explicit guidance on the financial statement
 presentation of an unrecognized tax benefit when a net operating
 loss carryforward, a similar tax loss, or a tax credit carryforward
 exists. This guidance is effective prospectively for fiscal years,
 and interim periods within those years, beginning after
 December&#xA0;15, 2013, with an option for early adoption. We
 intend to adopt this guidance in 2014, and do not believe the
 adoption of this standard will have a material impact on our
 financial condition, results of operations or related financial
 statement disclosures.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components Income Tax (Benefit) Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table summarizes the components of our income tax
 (benefit) expense (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"><b>Year ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Current:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(9</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(4</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(2</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(11</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Income tax (benefit) expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(23</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following is a reconciliation of the expected statutory federal
 income tax provision to our actual income tax provision (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected income tax benefit at federal statutory tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,355</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,923</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2,522</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State income taxes, net of federal benefit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,090</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,016</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(432</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Tax credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,406</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(423</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(683</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Government grant</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in fair value of convertible note payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">456</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Loss on debt extinguishment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">692</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,026</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,386</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,058</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Prior year true-up</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(235</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(368</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">333</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">463</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">248</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(86</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">211</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Income tax (benefit) expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(23</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table summarizes the significant components of our
 deferred tax assets and liabilities (in&#xA0;thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net operating loss carryovers</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,460</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,528</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development and other tax credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,727</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,983</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,999</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Intangibles and property and equipment basis difference</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,213</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,297</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">459</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred tax assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,505</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred tax liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(973</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred tax asset</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,306</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,306</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,279</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred tax asset</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Changes in Amount of Unrecognized Tax Benefits</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table summarizes the changes in the amount of our
 unrecognized tax benefits (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Beginning balance of unrecognized tax benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">569</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">406</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Increase (decrease) for prior year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">137</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(29</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Increase for current year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">386</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">113</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">147</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,092</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">569</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">406</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Reconciliation of Liabilities Measured at Fair Value on Quarterly Basis (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Change in estimated fair value of convertible notes payable</a></td>
        <td class="num">$ (1,145)<span></span></td>
        <td class="num">$ (2,969)<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 3</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations', window );">Balance at December 31, 2012</a></td>
        <td class="nump">10,134<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Change in estimated fair value of convertible notes payable</a></td>
        <td class="nump">1,145<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations', window );">Balance at December 31, 2013</a></td>
        <td class="nump">$ 11,279<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of obligations measured on a recurring basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7,9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXNAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Option Activity (Detail) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at December 31, 2012</a></td>
        <td class="nump">4,720<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
        <td class="nump">1,864<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(732)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled/forfeited/expired</a></td>
        <td class="num">(254)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at December 31, 2013</a></td>
        <td class="nump">5,598<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at December 31, 2013</a></td>
        <td class="nump">5,382<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2013</a></td>
        <td class="nump">2,244<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at December 31, 2012</a></td>
        <td class="nump">$ 2.11<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 6.52<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="nump">$ 0.81<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled/forfeited/expired</a></td>
        <td class="nump">$ 3.52<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at December 31, 2013</a></td>
        <td class="nump">$ 3.69<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at December 31, 2013</a></td>
        <td class="nump">$ 3.60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2013</a></td>
        <td class="nump">$ 1.22<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contactual term</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at December 31, 2013</a></td>
        <td class="text">7 years 11 months 23 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest at December 31, 2013</a></td>
        <td class="text">7 years 11 months 1 day<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at December 31, 2013</a></td>
        <td class="text">6 years 1 month 13 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at December 31, 2013</a></td>
        <td class="nump">$ 21,162<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested or expected to vest at December 31, 2013</a></td>
        <td class="nump">20,800<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2013</a></td>
        <td class="nump">$ 13,842<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 17,807<span></span></td>
        <td class="nump">$ 40,552<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
        <td class="nump">96,198<span></span></td>
        <td class="nump">57,548<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Contracts and other receivables</a></td>
        <td class="nump">79<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
        <td class="nump">3,098<span></span></td>
        <td class="nump">829<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">117,182<span></span></td>
        <td class="nump">98,929<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">3,768<span></span></td>
        <td class="nump">3,310<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
        <td class="nump">1,128<span></span></td>
        <td class="nump">1,154<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">987<span></span></td>
        <td class="nump">125<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">123,065<span></span></td>
        <td class="nump">103,518<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">1,172<span></span></td>
        <td class="nump">311<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">3,013<span></span></td>
        <td class="nump">658<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
        <td class="nump">1,297<span></span></td>
        <td class="nump">1,348<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
        <td class="nump">4,888<span></span></td>
        <td class="nump">10,451<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">10,370<span></span></td>
        <td class="nump">12,768<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes payable, at fair value</a></td>
        <td class="nump">11,279<span></span></td>
        <td class="nump">10,134<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, less current portion</a></td>
        <td class="nump">6,500<span></span></td>
        <td class="nump">17,756<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump">1,459<span></span></td>
        <td class="nump">767<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">29,608<span></span></td>
        <td class="nump">41,425<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2013 and 2012, 41,787,326 and 35,831,808 shares issued and outstanding at December 31, 2013 and 2012, respectively</a></td>
        <td class="nump">42<span></span></td>
        <td class="nump">36<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">172,518<span></span></td>
        <td class="nump">122,528<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
        <td class="num">(16)<span></span></td>
        <td class="num">(52)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(79,087)<span></span></td>
        <td class="num">(60,419)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">93,457<span></span></td>
        <td class="nump">62,093<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 123,065<span></span></td>
        <td class="nump">$ 103,518<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsAndOtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Convertible Security<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtFairValueDisclosures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph g<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">$ 1.3<span></span></td>
        <td class="nump">$ 0.9<span></span></td>
        <td class="nump">$ 0.8<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Initial Public Offering</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock,offering costs</a></td>
        <td class="nump">$ 434<span></span></td>
        <td class="nump">$ 5,886<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Components of Deferred Tax Assets and Liabilities (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryovers</a></td>
        <td class="nump">$ 17,460<span></span></td>
        <td class="nump">$ 8,528<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development and other tax credits</a></td>
        <td class="nump">4,727<span></span></td>
        <td class="nump">1,983<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
        <td class="nump">3,999<span></span></td>
        <td class="nump">7,322<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets', window );">Intangibles and property and equipment basis difference</a></td>
        <td class="nump">1,796<span></span></td>
        <td class="nump">1,213<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
        <td class="nump">1,297<span></span></td>
        <td class="nump">459<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
        <td class="nump">29,279<span></span></td>
        <td class="nump">19,505<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
        <td class="num">(973)<span></span></td>
        <td class="num">(226)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
        <td class="nump">28,306<span></span></td>
        <td class="nump">19,279<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num">(28,306)<span></span></td>
        <td class="num">(19,279)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Tax Assets Property Plant And Equipment And Intangible Assets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsDeferredIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsGrossAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsLiabilitiesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax liability attributable to taxable temporary differences net of deferred tax asset attributable to deductible temporary differences and carryforwards after valuation allowances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e31931-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Segment</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Outstanding principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Licenses</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, estimated useful lives</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Patents</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife', window );">Finite lived intangible assets, weighted average remaining useful life</a></td>
        <td class="text">12 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Finite Lived Intangible Assets Weighted Average Remaining Useful Life</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_FiniteLivedIntangibleAssetsWeightedAverageRemainingUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NumberOfOperatingSegments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>15. Subsequent Events</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In February 2014, we and Sanofi entered into a second amended and
 restated collaboration and license agreement to extend our
 strategic alliance. Under the terms of our extended alliance,
 Sanofi will have opt-in rights to our miR-21 pre-clinical fibrosis
 program targeting miR-21 for the treatment of Alport Syndrome, our
 preclinical program targeting miR-21 for oncology indications, and
 our preclinical programs targeting <font style="WHITE-SPACE: nowrap">miR-221/222</font> for oncology indications,
 each of which is to be led by us. If Sanofi chooses to exercise its
 option on any of these programs, Sanofi will reimburse us for a
 significant portion of our preclinical and clinical development
 costs and will also pay us an option exercise fee for any such
 program, provided that $1.25 million of the $2.5 million upfront
 option fee paid to us by Sanofi in connection with the June 2013
 option agreement will be creditable against such option exercise
 fee. In addition, we will be eligible to receive clinical and
 regulatory milestone payments under these programs and potentially
 commercial milestone payments. We also continue to be eligible to
 receive royalties on <i>micro</i>RNA therapeutic products
 commercialized by Sanofi and will have the right to co-promote
 these products.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In connection with our entry into the second amended and restated
 collaboration and license agreement with Sanofi, we sold and issued
 1,303,780 shares of our common stock to Aventis, an entity
 affiliated with Sanofi, in a private placement at a price per share
 of $7.67 for an aggregate purchase price of $10.0 million.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of diluted net loss per share</a></td>
        <td class="nump">5,050,929<span></span></td>
        <td class="nump">3,250,098<span></span></td>
        <td class="nump">16,038,249<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Preferred Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of diluted net loss per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,699,999<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of diluted net loss per share</a></td>
        <td class="nump">3,639,270<span></span></td>
        <td class="nump">1,883,311<span></span></td>
        <td class="nump">2,338,250<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Notes Payable</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities not included in calculation of diluted net loss per share</a></td>
        <td class="nump">1,411,659<span></span></td>
        <td class="nump">1,366,787<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
        <td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Potentially dilutive securities not included in the calculation of
 diluted net loss per share because to do so would be anti-dilutive
 are as follows (in common equivalent shares):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>Years ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Convertible preferred stock outstanding</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,699,999</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Common stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,639,270</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,883,311</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,338,250</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Convertible note payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,411,659</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,366,787</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,050,929</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,250,098</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,038,249</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EFUBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
        <td class="num">$ (18,668)<span></span></td>
        <td class="num">$ (17,408)<span></span></td>
        <td class="num">$ (7,602)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump">1,360<span></span></td>
        <td class="nump">1,017<span></span></td>
        <td class="nump">911<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Loss from change in value of convertible note payable</a></td>
        <td class="nump">1,145<span></span></td>
        <td class="nump">2,969<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,738<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on investments, net</a></td>
        <td class="nump">1,464<span></span></td>
        <td class="nump">422<span></span></td>
        <td class="nump">551<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on investments</a></td>
        <td class="num">(25)<span></span></td>
        <td class="num">(28)<span></span></td>
        <td class="num">(1)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">3,422<span></span></td>
        <td class="nump">1,550<span></span></td>
        <td class="nump">825<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of long-term assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Contracts and other receivables</a></td>
        <td class="num">(79)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
        <td class="num">(2,283)<span></span></td>
        <td class="num">(308)<span></span></td>
        <td class="num">(136)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">860<span></span></td>
        <td class="num">(189)<span></span></td>
        <td class="num">(1,345)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
        <td class="num">(51)<span></span></td>
        <td class="nump">677<span></span></td>
        <td class="num">(528)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="nump">1,355<span></span></td>
        <td class="num">(20)<span></span></td>
        <td class="nump">29<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(16,819)<span></span></td>
        <td class="nump">486<span></span></td>
        <td class="num">(8,219)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent and other liabilities</a></td>
        <td class="num">(11)<span></span></td>
        <td class="nump">337<span></span></td>
        <td class="nump">452<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(28,330)<span></span></td>
        <td class="num">(8,721)<span></span></td>
        <td class="num">(15,063)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
        <td class="num">(72,005)<span></span></td>
        <td class="num">(62,041)<span></span></td>
        <td class="num">(50,663)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Maturities and sales of short-term investments</a></td>
        <td class="nump">31,951<span></span></td>
        <td class="nump">33,083<span></span></td>
        <td class="nump">54,585<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(800)<span></span></td>
        <td class="num">(1,151)<span></span></td>
        <td class="num">(467)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangibles</a></td>
        <td class="num">(35)<span></span></td>
        <td class="num">(275)<span></span></td>
        <td class="num">(131)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
        <td class="num">(40,889)<span></span></td>
        <td class="num">(30,384)<span></span></td>
        <td class="nump">3,324<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of convertible notes payable and other long-term obligations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
        <td class="nump">45,980<span></span></td>
        <td class="nump">65,788<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Principal payments on other long-term obligations</a></td>
        <td class="num">(100)<span></span></td>
        <td class="num">(445)<span></span></td>
        <td class="num">(412)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
        <td class="nump">594<span></span></td>
        <td class="nump">139<span></span></td>
        <td class="nump">58<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="nump">46,474<span></span></td>
        <td class="nump">70,482<span></span></td>
        <td class="num">(354)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
        <td class="num">(22,745)<span></span></td>
        <td class="nump">31,377<span></span></td>
        <td class="num">(12,093)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">40,552<span></span></td>
        <td class="nump">9,175<span></span></td>
        <td class="nump">21,268<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">17,807<span></span></td>
        <td class="nump">40,552<span></span></td>
        <td class="nump">9,175<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
        <td class="nump">37<span></span></td>
        <td class="nump">8<span></span></td>
        <td class="nump">65<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">208<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of notes payable to common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,813<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_TenantImprovementAllowance', window );">Allowance for tenant improvements</a></td>
        <td class="nump">653<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">586<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Amounts accrued for patent expenditures</a></td>
        <td class="nump">$ 11<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 21<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_TenantImprovementAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tenant Improvement Allowance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_TenantImprovementAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(c),9(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (c)-(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashInvestingAndFinancingItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7,9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591552-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4591551-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow attributable to repayments of borrowings not otherwise defined in the taxonomy (with maturities initially due after one year or beyond the operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfOtherLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">41,787,326<span></span></td>
        <td class="nump">35,831,808<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">41,787,326<span></span></td>
        <td class="nump">35,831,808<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders' Deficit<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock, Common Stock and Stockholders' Deficit</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>10. Convertible Preferred Stock, Common Stock and
 Stockholders&#x2019; Deficit</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Reverse stock split</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 On September&#xA0;7, 2012, our board of directors approved a
 one-for-two reverse stock split of our common stock. The
 accompanying financial statements and notes to the financial
 statements give retroactive effect to the reverse split of our
 common stock for all periods presented.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Convertible Preferred Stock</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Prior to the conversion in the initial public offering in October
 2012, our convertible preferred stock was classified as temporary
 equity on the accompanying balance sheets instead of in
 stockholders&#x2019; equity (deficit) in accordance with
 authoritative guidance for the classification and measurement of
 redeemable securities. Upon certain change in control events that
 were outside of our control, including liquidation, sale or
 transfer of control of the Company, holders of the convertible
 preferred stock could cause its redemption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2012, all Series A Preferred Stock and
 Series B Preferred Stock had converted to common stock in
 conjunction with the initial public offering. Following our initial
 public offering, we filed an amended and restated certificate of
 incorporation to authorize 10,000,000 shares of undesignated
 preferred stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Public Offerings</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In October 2012, we completed our initial public offering whereby
 we issued and sold 11,250,000 shares of common stock at a public
 offering price of $4.00 per share, resulting in net proceeds to the
 Company of $39.5&#xA0;million. Concurrently with the completion of
 our initial public offering, we sold 6,250,000 shares of common
 stock in a private placement to AstraZeneca at the initial public
 offering price of $4.00 per share, resulting in net proceeds to the
 Company of $25.0 million. In addition, $5.0 million of outstanding
 principal plus accrued interest of $0.8 million underlying a
 convertible note that we issued to GSK in April 2008, which was
 amended and restated in July 2012, together with $5.0&#xA0;million
 of outstanding principal plus accrued interest underlying a
 convertible note that we issued to Biogen Idec in August 2012, was
 automatically converted upon the closing of our initial public
 offering into an aggregate of 2,703,269 shares of our common stock.
 Upon the closing of the initial public offering, all shares of the
 Company&#x2019;s then-outstanding convertible preferred stock
 automatically converted into an aggregate of 13,699,999 shares of
 common stock. Underwriters for our initial public offering
 exercised an over-allotment option to purchase 1,480,982 additional
 shares of our common stock at $4.00 per share, resulting in net
 proceeds of $5.5 million. Inclusive of the initial public offering,
 underwriters&#x2019; exercise of their over-allotment option and
 concurrent private placement, we raised a total of $70.0 million in
 net proceeds after deducting underwriter discounts, commissions and
 other offering expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In July&#xA0;2013, we completed a public offering whereby we sold
 5,175,000 shares of common stock at $9.50&#xA0;per share and
 received net proceeds of $45.8 million, after deducting
 underwriting discounts, commissions and other offering
 expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Common Stock</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2013, there were 41,787,326 shares of
 common stock outstanding. Each share of common stock is entitled to
 one vote. The holders of the common stock are also entitled to
 receive dividends whenever funds are legally available and when
 declared by our Board of Directors. Following our initial public
 offering, we filed an amended and restated certificate of
 incorporation to authorize 200,000,000 shares of common stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Shares Reserved for Future Issuance</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following shares of common stock are reserved for future
 issuance at December&#xA0;31, 2013:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Common stock options outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,598,207</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Common stock options available for future grant</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710,534</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Employee Stock Purchase Plan</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">460,283</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Convertible note payable (Post-IPO GSK Note)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,411,659</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total common shares reserved for future issuance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,180,683</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The combined total number of shares reserved for issuance under the
 2012 Plan is 710,534 shares as of December&#xA0;31, 2013. The
 following table summarizes our stock option activity under the 2012
 Plan for the year ended December&#xA0;31, 2013 (in thousands,
 except per share and contractual term data):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Number&#xA0;of<br />
 options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Weighted<br />
 average<br />
 exercise<br />
 price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Weighted<br />
 average<br />
 remaining<br />
 contractual<br />
 term<br />
 (in&#xA0;years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>Aggregate<br />
 intrinsic<br />
 value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options outstanding at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,720</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2.11</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,864</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(732</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.81</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Canceled/forfeited/expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(254</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Options outstanding at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,598</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.98</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,162</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Vested or expected to vest at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,382</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3.60</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,800</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,244</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.22</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,842</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The weighted average grant date fair value per share of employee
 stock options granted during the years ended December&#xA0;31,
 2013, 2012 and 2011 was $4.14, $2.97 and $1.14, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The total intrinsic value of stock options exercised was $5.7
 million, $0.8 million and $0.2 million during the years ended
 December&#xA0;31, 2013, 2012 and 2011, respectively. Cash received
 from the exercise of stock options was approximately $0.6 million,
 $0.1 million and $0.1 million for the years ended December&#xA0;31,
 2013, 2012 and 2011, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The assumptions used to estimate the fair value of stock options
 using the Black-Scholes option pricing model were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center">
 <b>Year&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>&#xA0;2013&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>&#xA0;2012&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>&#xA0;2011&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Employee Stock Options:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">73.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Expected term (years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <i>Risk-free interest rate</i>&#x2014;The risk-free interest rate
 assumption is based on observed interest rates appropriate for the
 expected term of the stock option grants.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <i>Expected dividend yield</i>&#x2014;The expected dividend yield
 assumption is based on the fact that we have never paid cash
 dividends and have no present intention to pay cash dividends.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <i>Expected volatility</i>&#x2014;The expected volatility assumption
 is based on volatilities of a peer group of similar companies whose
 share prices are publicly available. The peer group was developed
 based on companies in the biotechnology industry.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <i>Expected term</i>&#x2014;The expected term represents the period
 of time that options are expected to be outstanding. Because we do
 not have historic exercise behavior, we determine the expected life
 assumption using the simplified method, which is an average of the
 contractual term of the option and its ordinary vesting period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 <i>Forfeitures</i>&#x2014;We reduce stock-based compensation expense
 for estimated forfeitures. Forfeitures are estimated at the time of
 grant and revised, if necessary, in subsequent periods if actual
 forfeitures differ from those estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Stock-based compensation is reflected in the statement of
 operations and comprehensive loss as follows
 (in&#xA0;thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,246</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">912</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">557</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,176</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">268</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,422</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,550</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">825</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The total compensation cost related to non-vested awards not yet
 recognized was $7.8 million as of December&#xA0;31, 2013. The
 weighted-average period over which this expense is expected to be
 recognized is approximately 2.3 years.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Employee Stock Purchase Plan</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 In October 2012, we adopted the 2012 Employee Stock Purchase Plan
 (&#x201C;2012 Purchase Plan&#x201D;), which enables participants to
 contribute up to 15% of such participant&#x2019;s eligible
 compensation during a defined rolling six-month periods to purchase
 our common stock. The purchase price of common stock under the 2012
 Purchase Plan will be the lesser of: (i)&#xA0;85% of the fair
 market value of our common stock at the inception of the enrollment
 period or (ii)&#xA0;85% of the fair market value of our common
 stock at the applicable purchase date. We issued 48,035 shares of
 common stock under the 2012 Purchase Plan for the year ended
 December&#xA0;31, 2013. As of December&#xA0;31, 2013 460,283 shares
 of our common stock were reserved for future issuance and have been
 authorized for purchase under the 2012 Purchase Plan.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 07, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 28, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">RGLS<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">REGULUS THERAPEUTICS INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001505512<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">43,168,034<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 125,100,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_DefinedContributionPlansTextBlock', window );">Defined Contribution Plan</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>11. Defined Contribution Plan</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In 2009, we established an employee 401(k) salary deferral plan
 (&#x201C;401(k) Plan&#x201D;) covering all eligible employees. Active
 employees who are at least 18 years old and are not otherwise
 disqualified under the terms of the 401(k) Plan are eligible to
 participate. Employees may contribute up to 50% of their
 compensation per year (subject to a maximum limit prescribed by
 federal tax law). Under the 401(k) Plan, we may elect to match a
 discretionary percentage of employee contributions. We have elected
 to match 25% of employees&#x2019; contributions up to 6% of the
 employees&#x2019; eligible salary. We made $0.1 million, $0.1
 million and $0.1 million in matching contributions for the years
 ended December&#xA0;31, 2013, 2012 and 2011, respectively.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_DefinedContributionPlansTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the description of the plan, the basis for determining contributions, and the amounts of contributions under the Company's defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_DefinedContributionPlansTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJ3AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">$ 19,569<span></span></td>
        <td class="nump">$ 12,700<span></span></td>
        <td class="nump">$ 13,789<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">29,942<span></span></td>
        <td class="nump">20,342<span></span></td>
        <td class="nump">17,289<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">7,429<span></span></td>
        <td class="nump">4,932<span></span></td>
        <td class="nump">3,637<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">37,371<span></span></td>
        <td class="nump">25,274<span></span></td>
        <td class="nump">20,926<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(17,802)<span></span></td>
        <td class="num">(12,574)<span></span></td>
        <td class="num">(7,137)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
        <td class="nump">292<span></span></td>
        <td class="nump">110<span></span></td>
        <td class="nump">129<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(36)<span></span></td>
        <td class="num">(247)<span></span></td>
        <td class="num">(388)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,738)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Loss from change in value of convertible note payable</a></td>
        <td class="num">(1,145)<span></span></td>
        <td class="num">(2,969)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
        <td class="num">(18,691)<span></span></td>
        <td class="num">(17,418)<span></span></td>
        <td class="num">(7,396)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
        <td class="num">(23)<span></span></td>
        <td class="num">(10)<span></span></td>
        <td class="nump">206<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(18,668)<span></span></td>
        <td class="num">(17,408)<span></span></td>
        <td class="num">(7,602)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net</a></td>
        <td class="nump">36<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="num">(80)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">(18,632)<span></span></td>
        <td class="num">(17,393)<span></span></td>
        <td class="num">(7,682)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
        <td class="num">$ (0.49)<span></span></td>
        <td class="num">$ (2.12)<span></span></td>
        <td class="num">$ (85.82)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute basic and diluted net loss per share</a></td>
        <td class="nump">38,479,447<span></span></td>
        <td class="nump">8,212,538<span></span></td>
        <td class="nump">88,582<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Strategic Alliances and Collaborations</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">19,569<span></span></td>
        <td class="nump">12,700<span></span></td>
        <td class="nump">13,767<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Government Grant</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 22<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestAndOtherIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7,9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669646-108580<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Strategic Alliances and Collaborations<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Strategic Alliances and Collaborations</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>5. Strategic Alliances and Collaborations</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The following table summarizes the amounts included in our revenues
 which resulted from our strategic alliances and collaboration (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"><b>Year ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Sanofi-Aventis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,336</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,030</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,033</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 GSK</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,778</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,996</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,734</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 AstraZeneca</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,859</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">559</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Biogen Idec</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">596</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">115</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,569</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,700</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,767</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Sanofi</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In July 2012, we amended and restated our collaboration and license
 agreement with Sanofi to expand the potential therapeutic
 applications of the <i>micro</i>RNA alliance targets to be
 developed under such agreement. The modification made to the
 agreement was considered a material modification, which required
 the application of the new authoritative guidance adopted by us in
 January 2011 for multiple element arrangements. We determined that
 the elements within the strategic alliance agreement with Sanofi
 should be treated as a single unit of accounting because the
 delivered elements did not have stand-alone value to Sanofi. The
 following elements were delivered as part of the strategic alliance
 with Sanofi: (1)&#xA0;a license for up to four <i>micro</i>RNA
 targets; and (2)&#xA0;a research license under our technology
 alliance.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In June 2013, the original research term expired, upon which we and
 Sanofi entered into an option agreement pursuant to which we
 granted Sanofi an exclusive right to negotiate the co-development
 and commercialization of certain of our unencumbered
 <i>micro</i>RNA programs and we were granted the exclusive right to
 negotiate with Sanofi for co-development and commercialization of
 certain miR-21 anti-miRs in oncology and Alport&#x2019;s Syndrome.
 In July 2013, we received an upfront payment of $2.5 million, of
 which $1.25 million is creditable against future amounts payable by
 Sanofi to us under any future co-development and commercialization
 agreement we enter pursuant to the option agreement. The
 non-creditable portion of this payment, $1.25 million, is being
 recognized as revenue over the option period from the effective
 date of the option agreement in June 2013 through the expiration of
 the option period. Revenue associated with the creditable portion
 of this option payment will be deferred until its application to a
 creditable transaction. In addition, we agreed to continue
 specified research on the miR-21 programs during the option period.
 As a result of the expiration of the original research term and
 subsequent option agreement, we re-evaluated our estimated period
 of performance and are now amortizing the remaining deferred
 revenue associated with the initial upfront payment of $25.0
 million ratably from June 2013 through the expiration of the option
 period. Deferred revenue at December&#xA0;31, 2013 was $2.2
 million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We have evaluated the remaining contingent event-based payments
 under our strategic alliance agreement with Sanofi and determined
 that the preclinical payments meet the definition of a substantive
 milestone. Accordingly, revenue for these achievements will be
 recognized in its entirety in the period when the milestone is
 achieved and collectability is reasonably assured. Other contingent
 event-based payments under the strategic alliance agreement for
 which payment is contingent upon the results of Sanofi&#x2019;s
 performance will not be accounted for using the milestone method.
 Such payments will be recognized as revenue over our remaining
 estimated period of performance, if any, and when collectability is
 reasonably assured. As of the expiration of the research term in
 June 2013, Sanofi no longer had rights to select additional
 <i>micro</i>RNA targets. We can earn a preclinical milestone of
 $15.0&#xA0;million upon the filing of an Investigational New Drug
 application (&#x201C;IND&#x201D;) for the selected <i>micro</i>RNA
 target. We can also receive milestone payments of up to $33.0
 million for clinical milestones and up to $165.0 million for
 regulatory and commercial milestones. In addition, we are entitled
 to receive royalties based on a percentage of net sales which will
 range from 8 to 12%, depending upon the volume of sales.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>GSK</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In April 2008, we entered into a strategic alliance with GSK to
 discover, develop and commercialize novel <i>micro</i>RNA-targeted
 therapeutics to treat inflammatory diseases (the
 &#x201C;immuno-inflammatory alliance&#x201D;). In February 2010, we
 and GSK expanded the strategic alliance to include hepatitis C
 virus infection (&#x201C;HCV&#x201D;) to discover, develop and
 commercialize <i>micro</i>RNA therapeutics targeting miR-122 for
 the treatment of HCV (the &#x201C;HCV alliance&#x201D;). In June
 2012, we amended our immuno-inflammatory alliance to extend the
 target selection period for the fourth collaboration target. The
 modification made to the agreement was considered a material
 modification, which required the application of the new
 authoritative guidance adopted by us in January 2011 for multiple
 element arrangements. We determined that the elements within the
 immuno-inflammatory alliance should be treated as a single unit of
 accounting because the delivered elements, the opt-in licenses for
 <i>micro</i>RNA product candidates, did not have stand-alone value
 to GSK. As a result of the extension of the target selection
 period, we extended the amortization period for the remaining
 deferred revenue to approximately eight years, which represented
 our new estimated period of performance. As of December&#xA0;31,
 2013, deferred revenue associated with the immuno-inflammatory
 alliance was $3.5 million, which we are expecting to recognize over
 the remaining estimated period of performance of approximately 6
 years.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In June 2013, the HCV alliance was amended to state that RG-101,
 and other formulations thereof, will be developed by us
 independently of our alliance for the treatment of chronic HCV
 infection.&#xA0;This amendment removed any further milestone or
 royalty obligations owed by GSK to us as it relates only to RG-101.
 Concurrent with the amendment, we recorded the remaining $1.1
 million in deferred revenue associated with the upfront payment
 from the HCV alliance, as our estimated period of performance was
 complete.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Immuno-Inflammatory Alliance</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The immuno-inflammatory alliance includes contractual milestones.
 If all the product candidates are successfully developed and
 commercialized through pre-agreed sales targets we could receive
 milestone payments up to $432.5&#xA0;million, including up to $15.5
 million for preclinical milestones, up to $87.0&#xA0;million for
 clinical milestones, up to $150.0&#xA0;million for regulatory
 milestones and up to $180.0&#xA0;million for commercialization
 milestones. We are also entitled to receive tiered royalties as a
 percentage of annual sales which can increase up to the low end of
 the 10 to 20% range.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We have evaluated the remaining contingent event-based payments
 under our immuno-inflammatory alliance and determined that the
 preclinical and clinical payments meet the definition of a
 substantive milestone. Accordingly, revenue for these achievements
 will be recognized in its entirety in the period when the milestone
 is achieved and collectability is reasonably assured. Other
 contingent event-based payments under the strategic alliance
 agreement for which payment is contingent upon the results of
 GSK&#x2019;s performance will not be accounted for using the
 milestone method. Such payments will be recognized as revenue over
 the remaining estimated period of performance, if any, and when
 collectability is reasonably assured. We can earn the following
 preclinical milestones: $0.5 million upon the selection of a fourth
 <i>micro</i>RNA target and $5.0 million upon the selection of a
 development candidate for each of the selected three targets. We
 can also earn the following clinical milestones for each of the
 selected three targets: $4.0 million for the initiation of a Phase
 1 clinical trial; $5.0 million for the initiation of a Phase 2
 clinical trial; and $20.0 million if GSK chooses to opt-in to the
 program following the completion of a proof-of-concept trial.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>HCV Alliance</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Notwithstanding the foregoing, GSK has retained its interest in the
 miR-122 program in HCV, and <font style="white-space:nowrap">miR-122&#xA0;remains</font> a collaboration
 target under the alliance. If the HCV program is successful, we
 could receive contractual milestone payments up to
 $144.5&#xA0;million, including up to $5.5&#xA0;million for
 preclinical milestones, up to $29.0&#xA0;million for clinical
 milestones, up to $50.0&#xA0;million for regulatory milestones and
 up to $60.0&#xA0;million for commercialization milestones. In
 addition, we will receive tiered royalties which can increase up to
 the low end of the 10 to 20% range on sales from any product that
 GSK successfully commercializes under this alliance.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We have evaluated the remaining contingent event-based payments
 under the HCV alliance and determined that the preclinical and
 clinical payments meet the definition of a substantive milestone.
 Accordingly, revenue for these achievements will be recognized in
 its entirety in the period when the milestone is achieved and
 collectability is reasonably assured. Other contingent event-based
 payments under the strategic alliance agreement for which payment
 is contingent upon the results of GSK&#x2019;s performance will not
 be accounted for using the milestone method. Such payments will be
 recognized as revenue over the remaining estimated period of
 performance, if any, and when collectability is reasonably assured.
 We can earn a preclinical milestone of $5.5&#xA0;million upon the
 selection of a development candidate. We can also earn the
 following clinical milestones: $4.0&#xA0;million for initiation of
 a Phase&#xA0;1 clinical trial; $5.0&#xA0;million for the initiation
 of a Phase&#xA0;2 clinical trial; and $20.0&#xA0;million if GSK
 chooses to opt-in to the program following the completion of a
 proof-of-concept trial. We have no obligation to perform any
 research or development activities unless mutually agreed upon by
 the parties.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>AstraZeneca</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In August 2012, we entered into a collaboration and license
 agreement with AstraZeneca. Under the terms of the agreement, we
 have agreed to collaborate with AstraZeneca to identify, research
 and develop compounds targeting three <i>micro</i>RNA alliance
 targets primarily in the fields of cardiovascular diseases,
 metabolic diseases and oncology. Pursuant to the agreement, we
 granted AstraZeneca an exclusive, worldwide license to thereafter
 develop, manufacture and commercialize lead compounds designated by
 AstraZeneca in the course of the collaboration activities against
 the alliance targets for all human therapeutic uses. Under the
 terms of the agreement we are required to use commercially
 reasonable efforts to perform all research, development and
 manufacturing activities described in the research plan, at our
 cost, until the acceptance of an IND or the end of the research
 term, which extends until the fourth anniversary of the date of the
 agreement, and may be extended only by mutual written agreement of
 us and AstraZeneca. Following the earlier to occur of the
 acceptance of an IND in a major market or the end of the research
 term, AstraZeneca will assume all costs, responsibilities and
 obligations for further development, manufacture and
 commercialization of alliance product candidates.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Under the terms of the agreement, we received an upfront payment of
 $3.0 million in October 2012. We determined the elements within the
 strategic alliance agreement should be treated as a single unit of
 accounting because the delivered element, the license, does not
 have stand-alone value. As a result, we are recognizing revenue
 related to the upfront payment on a straight-line basis over our
 estimated period of performance, which is four years based on the
 expected term of the research and development plan. If all three
 targets are successfully developed and commercialized through
 pre-agreed sales targets, we could receive milestone payments up to
 $498.0&#xA0;million, including preclinical milestones of up to
 $5.0&#xA0;million upon lead compound identification, up to $123.0
 million for clinical milestones, and up to $370.0&#xA0;million for
 commercialization milestones. In addition, we are entitled to
 receive royalties based on a percentage of net sales which will
 range from the mid-single digits to the low end of 10 to 20%,
 depending upon the product and the volume of sales, which royalties
 may be reduced in certain, limited circumstances.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We have evaluated the contingent event-based payments under our
 strategic alliance agreement with AstraZeneca and determined that
 the preclinical payments meet the definition of substantive
 milestones. Accordingly, revenue for these achievements will be
 recognized in its entirety in the period when the milestone is
 achieved and collectability is reasonably assured. Other contingent
 event-based payments under the strategic alliance agreement for
 which payment is contingent upon the results of AstraZeneca&#x2019;s
 performance will not be accounted for using the milestone method.
 Such payments will be recognized as revenue over the remaining
 estimated period of performance, if any, and when collectability is
 reasonably assured.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Concurrently with the collaboration and license agreement, we
 entered into a Common Stock Purchase Agreement (&#x201C;CSPA&#x201D;)
 with AstraZeneca, pursuant to which we agreed to sell to
 AstraZeneca an aggregate of $25.0&#xA0;million of our common stock
 in a private placement concurrently with our initial public
 offering, at a price per share equal to the initial public offering
 price. In October 2012, in accordance with the CSPA, we sold
 AstraZeneca 6,250,000 shares of our common stock at a price per
 share of $4.00. Further, the CSPA stipulated that AstraZeneca could
 not sell, transfer, make any short sale of, or grant any option for
 the sale of any common stock for a 365-day period following the
 effective date of our initial public offering. Accounting guidance
 for multiple element arrangements contains a presumption that
 separate contracts negotiated and/or entered into at or near the
 same time with the same entity were negotiated as a package and
 should be evaluated as a single agreement. We valued the discount
 applied to the shares of common stock due to the one-year
 restriction. Based upon restricted stock studies of similar
 duration and a Black-Scholes valuation to measure the lack of
 marketability discount, $4.3 million was attributed to the
 collaboration and license agreement. We continue to recognize the
 $4.3 million into revenue ratably over the estimated period of
 performance of the collaboration. As of December&#xA0;31, 2013,
 deferred revenue associated with the collaboration and license
 agreement and CSPA was $2.0 million and $2.9 million, respectively,
 which we are expecting to recognize over the remaining contractual
 term and corresponding estimated period of performance of
 approximately 2.5 years.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Biogen Idec</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In August 2012, we entered into a collaboration and license
 agreement with Biogen Idec pursuant to which we and Biogen Idec
 have agreed to collaborate on <i>micro</i>RNA biomarkers for
 multiple sclerosis (&#x201C;MS&#x201D;). Under the terms of the
 agreement, we granted Biogen Idec an exclusive, royalty free,
 worldwide license to our interest in the collaboration intellectual
 property for the purpose of commercializing non-<i>micro</i>RNA
 products for the treatment, diagnosis and prevention of MS and
 non-MS diseases and disorders. We also granted Biogen Idec an
 exclusive, royalty-free, worldwide license, with the right to
 sublicense, to our interest in the collaboration intellectual
 property (and a non-exclusive license to our background
 intellectual property) for the purpose of commercializing products
 for the diagnosis of MS. We also granted Biogen Idec a right of
 first negotiation on certain commercial transactions relating to
 <i>micro</i>RNA products which utilize intellectual property
 developed during the collaboration. Pursuant to the terms of the
 agreement, in August 2012 we received an upfront payment of $0.8
 million. We are also eligible to receive research milestone
 payments up to an aggregate of $1.3&#xA0;million. We considered the
 elements within the collaboration and license agreement as a single
 unit of accounting because the delivered element, the license, does
 not have stand-alone value. As a result, we are recognizing revenue
 relating to the upfront payment of $0.8 million on a straight-line
 basis over our estimated period of performance, which is
 approximately two years based on the expected term of the research
 and development plan.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In June 2013, we amended the collaboration and license agreement to
 provide for revised terms with respect to Phase 1 of the research
 plan and related milestone payment provisions. The Biogen Idec
 amendment does not modify the maximum dollar amount we were
 originally eligible to receive in connection with Phase 1
 milestones under the Biogen Idec agreement, or our estimated period
 of performance.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We have evaluated the contingent event-based payments under our
 collaboration and license agreement with Biogen Idec and determined
 that the research payments meet the definition of substantive
 milestones. Accordingly, revenue for these achievements will be
 recognized in its entirety in the period when the milestone is
 achieved and collectability is reasonably assured. In October 2013
 and November 2013, we received research milestone payments totaling
 $0.3 million. In addition, we can earn the following research
 milestones: $0.5&#xA0;million for validation of the <i>micro</i>RNA
 biomarker in a second independent sample set; and $0.5 million upon
 the refinement of the <i>micro</i>RNA biomarker signature from a
 longitudinal study of patient samples on MS therapy. As of
 December&#xA0;31, 2013, deferred revenue associated with the
 collaboration and license agreement was $0.3 million, which we are
 expecting to recognize over the remaining contractual term and
 corresponding estimated period of performance of 10 months.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Concurrently with the collaboration and license agreement, we
 entered into a note purchase agreement with Biogen Idec, pursuant
 to which we issued a convertible promissory note in the principal
 amount of $5.0 million. The $5.0 million note plus accrued interest
 converted into 1,256,232 shares of our common stock upon the
 closing of our initial public offering in October 2012 at a
 conversion price of $4.00 per share.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>4. Fair Value Measurements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We have certain financial assets and liabilities recorded at fair
 value which have been classified as Level 1, 2 or 3 within the fair
 value hierarchy as described in the accounting standards for fair
 value measurements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Applicable accounting guidance defines fair value as the exchange
 price that would be received for an asset or paid to transfer a
 liability (an exit price) in the principal or most advantageous
 market for the asset or liability in an orderly transaction between
 market participants as of the measurement date. Market participants
 are buyers and sellers in the principal market that are
 (i)&#xA0;independent, (ii)&#xA0;knowledgeable, (iii)&#xA0;able to
 transact, and (iv)&#xA0;willing to transact. The guidance provides
 an established hierarchy for inputs used in measuring fair value
 that maximizes the use of observable inputs and minimizes the use
 of unobservable inputs by requiring that the most observable inputs
 be used when available. Observable inputs are inputs that market
 participants would use in valuing the asset or liability and are
 developed based on market data obtained from independent sources.
 Unobservable inputs are inputs that reflect our assumptions about
 the factors that market participants would use in valuing the asset
 or liability. The guidance prioritizes the inputs used in measuring
 the fair value into the following hierarchy:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 1 includes financial
 instruments for which quoted market prices for identical
 instruments are available in active markets.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 2 includes financial
 instruments for which there are inputs other than quoted prices
 included within Level 1 that are observable for the instrument such
 as quoted prices for similar instruments in active markets, quoted
 prices for identical or similar instruments in markets with
 insufficient volume or infrequent transactions (less active
 markets) or model-driven valuations in which significant inputs are
 observable or can be derived principally from, or corroborated by,
 observable market data.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 3 includes financial
 instruments for which fair value is derived from valuation
 techniques in which one or more significant inputs are
 unobservable, including management&#x2019;s own assumptions.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The following table presents our fair value hierarchy for assets
 and liabilities measured at fair value on a recurring basis at
 December&#xA0;31, 2013 and 2012 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair value as of December&#xA0;31,
 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Corporate debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,416</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,416</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Debt securities of U.S. government-sponsored agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,001</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,001</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,071</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,071</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">113,368</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,198</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Convertible notes payable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair value as of December&#xA0;31,
 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,363</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,363</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Corporate debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,911</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,363</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,548</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom" colspan="5"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom" colspan="5"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Convertible notes payable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,134</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,134</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents a reconciliation of the liabilities
 measured at fair value on a quarterly basis using significant
 unobservable inputs (Level 3) from December&#xA0;31, 2012 to
 December&#xA0;31, 2013 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="21%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Fair&#xA0;Value&#xA0;Measurements<br />
 Using Significant<br />
 Unobservable Inputs<br />
 (Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,134</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in estimated fair value of convertible notes payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We obtain pricing information from quoted market prices or quotes
 from brokers/dealers. We generally determine the fair value of our
 investment securities using standard observable inputs, including
 reported trades, broker/dealer quotes, bids and/or offers.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In July&#xA0;2012, we amended and restated the 2010 GSK Note, which
 resulted in a debt extinguishment for accounting purposes.
 Concurrently with the debt extinguishment, we elected the fair
 value option for the 2010 GSK Note. The amended and restated 2010
 GSK Note provided for a rollover into a new promissory note,
 effective as of the closing date of a qualifying initial public
 offering (the &#x201C;Post-IPO GSK Note&#x201D;). In October 2012,
 upon our initial public offering, the Post-IPO GSK Note was
 established, and the 2010 GSK Note was simultaneously cancelled and
 obligations thereto were terminated. We valued the 2010 GSK Note at
 July 2012,&#xA0;September 2012 and at the extinguishment date. We
 valued the Post-IPO GSK Note each quarter since that date. We
 recorded a $1.7 million loss on extinguishment of debt (the
 difference between the original $5.0 million carrying value and the
 then fair value) in July 2012. In subsequent periods, changes in
 fair value have been recorded on a quarterly basis in non-operating
 earnings. We recorded a loss from change in value of the
 convertible note payable of $1.1 million and $3.0 million on the
 statements of operations and comprehensive loss for the years ended
 December&#xA0;31, 2013 and 2012.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We used an income approach in the form of a convertible bond
 valuation model to value the note. The convertible bond model
 considered the debt and option characteristics of the note. The key
 inputs to the model as of December&#xA0;31, 2013 and 2012 was
 volatility (66% and 75%, respectively), risk-free rate (0.325% and
 0.421%, respectively), and credit spread (7.4% and 9.5%,
 respectively). The volatility inputs were based on historical and
 implied volatility of peer companies. Peer companies were
 consistent with those used previously for purposes of determining
 volatility for stock-based compensation. The risk-free rate inputs
 were based on the yield of US Treasury Strips as of each date. The
 credit spread inputs were based on a creditworthiness analysis of
 the Company and market rates for comparable straight debt
 instruments.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Use of Estimates</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Our financial statements are prepared in accordance with U.S.
 generally accepted accounting principles. The preparation of our
 financial statements requires us to make estimates and assumptions
 that affect the reported amounts of assets, liabilities, revenues
 and expenses and the disclosure of contingent assets and
 liabilities in our financial statements and accompanying notes.
 Although these estimates are based on our knowledge of current
 events and actions we may undertake in the future, actual results
 may ultimately differ from these estimates and assumptions.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Revenue Recognition</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Our revenues generally consist of upfront payments for licenses or
 options to obtain licenses in the future, research and development
 funding and milestone payments under strategic alliance agreements,
 as well as funding received under government grants. We recognize
 revenues when all four of the following criteria are met:
 (1)&#xA0;persuasive evidence that an arrangement exists;
 (2)&#xA0;delivery of the products and/or services has occurred;
 (3)&#xA0;the selling price is fixed or determinable; and
 (4)&#xA0;collectability is reasonably assured.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Multiple element arrangements, such as our strategic alliance
 agreements with Sanofi, AstraZeneca AB (&#x201C;AstraZeneca&#x201D;)
 and GlaxoSmithKline plc (&#x201C;GSK&#x201D;), are analyzed to
 determine whether the deliverables within the agreement can be
 separated or whether they must be accounted for as a single unit of
 accounting. Deliverables under the agreement will be accounted for
 as separate units of accounting provided that (i)&#xA0;a delivered
 item has value to the customer on a stand-alone basis; and
 (ii)&#xA0;if the agreement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially in the
 control of the vendor. The allocation of consideration amongst the
 deliverables under the agreement is derived using a &#x201C;best
 estimate of selling price&#x201D; if vendor specific objective
 evidence and third-party evidence of fair value is not available.
 If the delivered element does not have stand-alone value, the
 arrangement is then accounted for as a single unit of accounting,
 and we recognize the consideration received under the arrangement
 as revenue on a straight-line basis over our estimated period of
 performance, which for us is often the expected term of the
 research and development plan.</p>
 <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Milestones</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We recognize revenue from milestone payments when earned, provided
 that (i)&#xA0;the milestone event is substantive in that it can
 only be achieved based in whole or in part on either our
 performance or on the occurrence of a specific outcome resulting
 from our performance and its achievability was not reasonably
 assured at the inception of the agreement, (ii)&#xA0;we do not have
 ongoing performance obligations related to the achievement of the
 milestone and (iii)&#xA0;it would result in the receipt of
 additional payments. A milestone payment is considered substantive
 if all of the following conditions are met: (i)&#xA0;the milestone
 payment is non-refundable; (ii)&#xA0;achievement of the milestone
 was not reasonably assured at the inception of the arrangement;
 (iii)&#xA0;substantive effort is involved to achieve the milestone;
 and (iv)&#xA0;the amount of the milestone payments appears
 reasonable in relation to the effort expended, the other milestones
 in the arrangement and the related risk associated with the
 achievement of the milestone. Any amounts received under the
 agreements in advance of performance, if deemed substantive, are
 recorded as deferred revenue and recognized as revenue as we
 complete our performance obligations.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Generally, the milestone events contained in our strategic alliance
 agreements coincide with the progression of our product candidates
 from target selection, to clinical candidate selection, to clinical
 trial, to regulatory approval and then to commercialization. The
 process of successfully discovering a new development candidate,
 having it approved and ultimately sold for a profit is highly
 uncertain. As such, the milestone payments we may earn from our
 partners involve a significant degree of risk to achieve.
 Therefore, as a product candidate progresses through the stages of
 its life-cycle, the value of the product candidate generally
 increases.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Grant Revenue</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We recognize revenue from government and private agency grants as
 the related research expenses are incurred and to the extent that
 funding is approved. Any amounts received in advance of performance
 are recorded as deferred revenue until earned.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Deferred Revenue</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Amounts received prior to satisfying the above revenue recognition
 criteria are recorded as deferred revenue in the accompanying
 balance sheets. Amounts not expected to be recognized within the
 next 12 months are classified as non-current deferred revenue.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Stock-Based Compensation</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We account for stock-based compensation expense related to stock
 options granted to employees and members of our board of directors
 by estimating the fair value of each stock option on the date of
 grant using the black-scholes model. We recognize stock-based
 compensation expense using the accelerated multiple-option
 approach. Under the accelerated multiple-option approach (also
 known as the graded-vesting method), we recognize compensation
 expense over the requisite service period for each separately
 vesting tranche of the award as though the award was in substance
 multiple awards, resulting in accelerated expense recognition over
 the vesting period.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We account for stock options granted to non-employees, which
 primarily consist of members of our scientific advisory board,
 using the fair value approach. Stock options granted to
 non-employees are subject to periodic revaluation over their
 vesting terms.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
        <td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Research and Development</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Research and development costs are expensed as incurred and include
 compensation and related benefits, non-cash stock-based
 compensation, license fees, laboratory supplies and associated
 overhead and facilities costs. In certain circumstances, we make
 non-refundable advance payments to purchase goods and services for
 future use in research and development activities pursuant to
 contractual arrangements. In those instances, we capitalize these
 amounts and record expense in the period that we receive the goods
 or when services are performed.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Income Taxes</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The accounting guidance for accounting for uncertainty in income
 taxes prescribes a recognition threshold and measurement attribute
 criteria for the financial statement recognition and measurement of
 tax positions taken or expected to be taken in a tax return. For
 those benefits to be recognized, a tax position must be more likely
 than not to be sustained upon examination by taxing
 authorities.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We use the liability method of accounting for income taxes. Under
 this method, deferred tax assets and liabilities are determined
 based on the difference between the financial reporting and the tax
 reporting basis of assets and liabilities and are measured using
 the enacted tax rates and laws that are expected to be in effect
 when the differences are expected to reverse. We provide a
 valuation allowance against net deferred tax assets unless, based
 upon the available evidence, it is more likely than not that the
 deferred tax assets will be realized.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Option</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Fair Value Option</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Applicable accounting policies permit entities to choose, at
 specified election dates, to measure specified items at fair value
 if the decision about the election is: 1) applied instrument by
 instrument, 2) irrevocable, and 3) applied to an entire
 instrument.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In July 2012, we amended and restated our $5.0 million convertible
 promissory note originally issued in February 2010 to GSK
 (&#x201C;2010 GSK note&#x201D;), which was accounted for as a debt
 extinguishment of the original note. We elected to measure the
 amended note under the fair value option. The difference between
 the carrying value of the original note and the fair value of the
 amended note was recorded as a loss on extinguishment of debt to
 non-operating earnings. Thereafter, any change to the fair value of
 the amended note is recorded as gain (loss) from valuation of
 convertible note payable to non-operating earnings.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We classify time deposits and other investments that are highly
 liquid and have maturities of 90 days or less at the date of
 purchase as cash equivalents. The carrying amounts approximate fair
 value due to the short maturities of these instruments.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Short-Term Investments</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We carry short-term investments classified as available-for-sale at
 fair value as determined by prices for identical or similar
 securities at the balance sheet date. Our short-term investments
 consist of both Level 1 and Level 2 financial instruments in the
 fair value hierarchy. We record unrealized gains and losses as a
 component of other comprehensive loss within the statements of
 operations and comprehensive loss and as a separate component of
 stockholders&#x2019; equity (deficit). We determine the realized
 gains or losses of available-for-sale securities using the specific
 identification method and include net realized gains and losses in
 interest income.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 At each balance sheet date, we assess available-for-sale securities
 in an unrealized loss position to determine whether the unrealized
 loss is other-than-temporary. We consider factors including: the
 significance of the decline in value compared to the cost basis,
 underlying factors contributing to a decline in the prices of
 securities in a single asset class, the length of time the market
 value of the security has been less than its cost basis, the
 security&#x2019;s relative performance versus its peers, sector or
 asset class, expected market volatility and the market and economy
 in general. When we determine that a decline in the fair value
 below its cost basis is other-than-temporary, we recognize an
 impairment loss in the year in which the other-than-temporary
 decline occurred. We determined that there were no
 other-than-temporary declines in the value of short-term
 investments as of December&#xA0;31, 2013 and 2012.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Concentrations of Credit Risk</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Financial instruments that potentially subject us to significant
 concentrations of credit risk consist primarily of cash, cash
 equivalents and short-term investments. We maintain deposits in
 federally insured financial institutions in excess of federally
 insured limits. We have not experienced any losses in such accounts
 and believe we are not exposed to significant risk. We maintain our
 cash equivalents and short-term investments with three financial
 institutions. We invest our excess cash primarily in commercial
 paper and debt instruments of financial institutions, corporations,
 U.S. government-sponsored agencies and the U.S. Treasury.
 Additionally, we established guidelines regarding approved
 investments and maturities of investments, which are designed to
 maintain safety and liquidity.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Property and Equipment</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We carry our property and equipment at cost, which consists of lab
 equipment, computer equipment and software, furniture and fixtures
 and leasehold improvements. Property and equipment is depreciated
 using the straight-line method over the estimated useful lives
 (generally three to five years). Leasehold improvements are
 amortized over the lesser of their useful life or the remaining
 lease term, including any renewal periods that are deemed to be
 reasonably assured. Repair and maintenance costs that do not
 improve service potential or extend economic life are expensed as
 incurred.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangibles</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Intangibles</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We capitalize costs which consist principally of outside legal
 costs and filing fees related to obtaining patents. We review our
 capitalized patent costs periodically to determine that they
 include costs for patent applications that have future value and an
 alternative future use. We evaluate costs related to patents that
 we are not actively pursuing and write off these costs. We amortize
 patent costs over their patent lives, beginning with the date the
 patents are issued. The weighted average remaining life of the
 issued patents was 12 years at December&#xA0;31, 2013.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We obtain licenses from third parties and capitalize the costs
 related to exclusive licenses that have alternative future use
 within multiple potential programs. We amortize capitalized
 licenses over their estimated useful life or term of the agreement,
 which for current licenses is 10 years.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We regularly review the carrying amount of our property, equipment
 and intangible assets to determine whether indicators of impairment
 may exist which warrant adjustments to carrying values or estimated
 useful lives. If indications of impairment exist, projected future
 undiscounted cash flows associated with the asset are compared to
 the carrying amount to determine whether the asset&#x2019;s value is
 recoverable. If the carrying value of the asset exceeds such
 projected undiscounted cash flows, the asset will be written down
 to its estimated fair value. No impairment charges were recorded
 during the years ended December&#xA0;31, 2013, 2012 and 2011.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_AccruedExpensePolicyTextBlock', window );">Clinical Trial and Pre-Clinical Study Accruals</a></td>
        <td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Clinical Trial and Pre-Clinical Study Accruals</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We make estimates of our accrued expenses as of each balance sheet
 date in our financial statements based on the facts and
 circumstances known to us at that time. Our accrued expenses for
 clinical trials are based on estimates of the fees associated with
 services provided by clinical trial investigational sites and CROs.
 Payments under some of the contracts we have with such parties
 depend on factors such as successful enrollment of patients, site
 initiation and the completion of clinical trial milestones. In
 accruing service fees, we estimate the time period over which
 services will be performed and the level of effort to be expended
 in each period. If possible, we obtain information regarding
 unbilled services directly from these service providers. However,
 we may be required to estimate these services based on other
 information available to us. If we underestimate or overestimate
 the activity or fees associated with a study or service at a given
 point in time, adjustments to research and development expenses may
 be necessary in future periods. Historically, our estimated accrued
 liabilities have approximated actual expense incurred. Subsequent
 changes in estimates may result in a material change in our
 accruals.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Segment Reporting</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Operating segments are identified as components of an enterprise
 about which separate discrete financial information is available
 for evaluation by the chief operating decision-maker in making
 decisions regarding resource allocation and assessing performance.
 To date, we have viewed our operations and managed our business as
 one segment operating primarily in the United States.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Comprehensive Loss</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Comprehensive loss is defined as the change in equity during a
 period from transactions and other events and/or circumstances from
 non-owner sources. Our only component of other comprehensive loss
 is unrealized gains (losses) on available-for-sale securities.
 Comprehensive gains (losses) have been reflected in the statements
 of operations and comprehensive loss and as a separate component of
 the statements of convertible preferred stock and
 stockholders&#x2019; equity (deficit) for all periods presented.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Reclassifications</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Certain current and non-current liabilities in prior period
 financial statements have been reclassified or consolidated to
 conform to the current period presentation. These reclassifications
 had no impact on our statements of operations, statements of
 preferred stock and stockholders&#x2019; equity (deficit) or
 statements of cash flows.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In July 2013, the FASB issued Accounting Standards Update
 No.&#xA0;2013-11, <i>Presentation of an Unrecognized Tax Benefit
 When a Net Operating Loss Carryforward, a Similar Tax Loss, or a
 Tax Credit Carryforward Exists</i> (&#x201C;ASU 2013-11&#x201D;).
 This update provides explicit guidance on the financial statement
 presentation of an unrecognized tax benefit when a net operating
 loss carryforward, a similar tax loss, or a tax credit carryforward
 exists. This guidance is effective prospectively for fiscal years,
 and interim periods within those years, beginning after
 December&#xA0;15, 2013, with an option for early adoption. We
 intend to adopt this guidance in 2014, and do not believe the
 adoption of this standard will have a material impact on our
 financial condition, results of operations or related financial
 statement disclosures.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_AccruedExpensePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued Expense [Policy Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_AccruedExpensePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144471<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsFiniteLivedPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section M<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2,12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2, 12<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PriorPeriodReclassificationAdjustmentDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for segment reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>12. Income Taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following table summarizes the components of our income tax
 (benefit) expense (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" nowrap="nowrap" align="center"><b>Year ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Current:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">1</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Federal</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(9</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 State</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(4</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(2</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(24</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">(11</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Income tax (benefit) expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(23</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following is a reconciliation of the expected statutory federal
 income tax provision to our actual income tax provision (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Expected income tax benefit at federal statutory tax rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(6,355</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(5,923</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2,522</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 State income taxes, net of federal benefit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,090</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,016</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(432</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Tax credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,406</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(423</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(683</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Government grant</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in fair value of convertible note payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">456</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Loss on debt extinguishment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">692</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,026</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,386</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,058</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Prior year true-up</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(235</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(368</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">333</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Stock compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">667</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">463</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">248</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(86</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">211</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Income tax (benefit) expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(23</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 The following table summarizes the significant components of our
 deferred tax assets and liabilities (in&#xA0;thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Deferred tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Net operating loss carryovers</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,460</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,528</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Research and development and other tax credits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,727</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,983</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,999</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Intangibles and property and equipment basis difference</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,213</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,297</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">459</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred tax assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,505</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total deferred tax liabilities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(973</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred tax asset</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,306</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(28,306</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,279</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net deferred tax asset</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 For all periods presented, we have determined that it is more
 likely than not that our deferred tax asset will not be realized.
 Accordingly, we have recorded a valuation allowance to fully offset
 the net deferred tax asset of $28.3&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 As of December&#xA0;31, 2013, we had federal and California tax net
 operating loss carryforwards of $44.2&#xA0;million and $52.6
 million, respectively, which begin to expire in 2030 and 2031. At
 December&#xA0;31, 2013, approximately $1.6 million of the net
 operating loss carryforwards relate to stock option exercises,
 which will result in an increase to additional paid-in capital and
 a decrease in income taxes payable at the time when the tax loss
 carryforwards are utilized. As of December&#xA0;31, 2013, we also
 had federal and California research and development tax credit
 carryforwards of $3.6&#xA0;million and $2.8&#xA0;million,
 respectively. The federal research and development tax credit
 carryforwards will begin to expire in 2029. The California research
 and development tax credit carryforwards are available
 indefinitely. As of December 31, 2013, we also had $0.2 million of
 Federal Alternative Minimum Tax Credit carryforwards that are
 available indefinitely.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The future utilization of our research and development credit
 carryforwards and net operating loss carryforwards to offset future
 taxable income may be subject to an annual limitation as a result
 of ownership changes that may have occurred previously or may occur
 in the future. The Tax Reform Act of 1986 (the Act) limits a
 company&#x2019;s ability to utilize certain tax credit carryforwards
 and net operating loss carryforwards in the event of a cumulative
 change in ownerships in excess of 50% as defined in the Act.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The following table summarizes the changes in the amount of our
 unrecognized tax benefits (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Beginning balance of unrecognized tax benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">569</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">406</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">288</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Increase (decrease) for prior year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">137</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(29</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Increase for current year tax positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">386</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">113</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">147</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,092</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">569</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">406</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 Included in the balance of unrecognized tax benefits at
 December&#xA0;31, 2013, is $1.1 million that, if recognized, would
 not impact our income tax benefit or effective tax rate as long as
 our deferred tax asset remains subject to a full valuation
 allowance. We do not expect any significant increases or decreases
 to our unrecognized tax benefits within the next 12 months.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We are subject to taxation in the United States and California. We
 are subject to income tax examination by tax authorities in those
 jurisdictions for 2009 and forward.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 It is our practice to recognize interest and/or penalties related
 to income tax matters in income tax expense. For the years ended
 December&#xA0;31, 2013, 2012 and 2011, we have not recognized any
 interest or penalties related to income taxes.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>8. Commitments and Contingencies</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Operating Lease</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We lease office and laboratory space located at 3545 John Hopkins
 Court, La Jolla, California (the &#x201C;Facility&#x201D;) for our
 corporate headquarters and research facility under an operating
 lease agreement (the &#x201C;Lease&#x201D;). The Lease commenced in
 July 2010 and provided for approximately 22,000 square feet of
 office and laboratory space, expiring in June 2017. In November
 2012, we amended the Lease to expand our laboratory and office
 space by approximately 7,000 square feet, including the addition of
 an approximately 3,000 square foot dedicated research and
 development laboratory. Lease payments for this additional space
 began October 2013. We have an option to terminate and cancel the
 lease in June&#xA0;2015 upon six months&#x2019; written notice to
 our landlord. We also have two options to extend the lease for
 successive three-year periods.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In connection with the inception of the Lease, we were provided
 tenant incentives of $0.1 million which was used to construct a
 leasehold improvement. In addition, we were provided and fully
 utilized a tenant improvement allowance of approximately $0.6
 million, which was used to fund additional leasehold improvements.
 In January 2011, the Lease was amended to memorialize the payback
 of the allowance into our base rent. In conjunction with the
 amendment of the Lease in November 2012, we were provided an
 additional tenant improvement allowance of approximately $0.7
 million, which was utilized in 2013 to fund leasehold improvements
 in the newly occupied space. We are obligated to repay our landlord
 the tenant improvement allowance, plus interest at a fixed rate of
 8%, on a monthly basis over the remaining term of the Lease. The
 future minimum payment summary below includes our amended base
 rents over the remaining period of the lease agreement.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Cumulative rent to be paid over the lease term is being amortized
 on a straight-line basis over the term of the Lease. Rent expense
 for the years ended December&#xA0;31, 2013, 2012 and 2011 was
 approximately $0.7 million, $0.6 million and $0.5 million,
 respectively. We account for the difference between the minimum
 lease payments and the straight-line amount as deferred rent.
 Deferred rent at December&#xA0;31, 2013 and 2012 was approximately
 $0.9 million and $0.5 million, respectively. We also pay property
 taxes, maintenance and insurance, which are expensed as
 incurred.</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As of December&#xA0;31, 2013, future annual minimum lease payments
 for our operating leases are as follows (in&#xA0;thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2014</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,066</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2015</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,138</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2016</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,211</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2017</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">624</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Thereafter</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,039</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>License Agreements</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We have license agreements with third parties that require us to
 make annual license maintenance payments and future payments upon
 the success of licensed products that include milestones and/or
 royalties. Minimum future payments over the next five years are not
 material.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfIncomeTaxesLineItems', window );"><strong>Schedule Of Income Taxes [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
        <td class="nump">$ 28,306,000<span></span></td>
        <td class="nump">$ 19,279,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OperatingLossCarryforwardExpirationYear', window );">Operating loss carryforward expiration year</a></td>
        <td class="text">2030<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">17,460,000<span></span></td>
        <td class="nump">8,528,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum', window );">Limitation of company's ability to utilize certain tax credit carryforwards and net operating loss carryforwards, minimum percentage of ownership change</a></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate', window );">Unrecognized tax benefits that, if recognized, would not impact income tax benefit or effective tax rate</a></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfIncomeTaxesLineItems', window );"><strong>Schedule Of Income Taxes [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">1,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Internal Revenue Service (IRS)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfIncomeTaxesLineItems', window );"><strong>Schedule Of Income Taxes [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">44,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax', window );">Alternative minimum tax ccredit</a></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">California</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfIncomeTaxesLineItems', window );"><strong>Schedule Of Income Taxes [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">52,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_OperatingLossCarryforwardExpirationYear', window );">Operating loss carryforward expiration year</a></td>
        <td class="text">2031<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">California | Research Tax Credit Carryforward</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfIncomeTaxesLineItems', window );"><strong>Schedule Of Income Taxes [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforward</a></td>
        <td class="nump">2,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Federal | Research Tax Credit Carryforward</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ScheduleOfIncomeTaxesLineItems', window );"><strong>Schedule Of Income Taxes [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforward</a></td>
        <td class="nump">$ 3,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Operating Loss Carryforward Limitation On Use Percentage Ownership Change Minimum</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_NetOperatingLossCarryforwardLimitationOnUsePercentageOwnershipChangeMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_OperatingLossCarryforwardExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating Loss Carryforward, Expiration Year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_OperatingLossCarryforwardExpirationYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ScheduleOfIncomeTaxesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_ScheduleOfIncomeTaxesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsLiabilitiesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Alternative Minimum Tax<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6504908<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Carryforwards<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TaxCreditCarryforwardAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>6. Property and Equipment, net</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following table summarizes our major classes of property and
 equipment (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,342</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,583</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Computer equipment and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">114</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">114</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">119</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">93</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,805</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">751</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Construction in progress</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">119</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">211</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,499</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,752</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less accumulated depreciation and amortization</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,731</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,442</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,768</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,310</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Depreciation and amortization of property and equipment of $1.3
 million, $0.9&#xA0;million and $0.8 million was recorded for the
 years ended December&#xA0;31, 2013, 2012 and 2011,
 respectively.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets, net<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, net</a></td>
        <td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>7. Intangible Assets, net</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The following table summarizes our major classes of intangible
 assets (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Patents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">960</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">913</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Licenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,364</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,317</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accumulated amortization</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(236</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(163</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Intangibles, net</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,128</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,154</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 Intangible asset amortization of $0.1 million, $0.1 million and
 $0.1 million was recorded for the years ended December&#xA0;31,
 2013, 2012 and 2011, respectively. Amortization of these intangible
 assets over the next five years is expected to be approximately
 $0.1 million per year.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>9. Convertible Notes Payable</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As part of our strategic alliance with GSK established in
 April&#xA0;2008, we issued a three-year convertible note in
 exchange for $5.0&#xA0;million (&#x201C;2008 GSK Note&#x201D;). In
 February 2010 and in connection with the subsequent expansion of
 that strategic alliance, we issued a convertible promissory note in
 exchange for $5.0 million (&#x201C;2010&#xA0;GSK Note&#x201D;).</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>2012 Amendment of the 2008 GSK Note</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In July 2012, we amended and restated the 2008 GSK Note. We
 accounted for the amended and restated note as a debt modification.
 The amended and restated note provided that the principal amount
 plus interest under the note will, upon completion of our initial
 public offering in which we receive a minimum level of proceeds
 from new investors or that results in certain of our current
 stockholders together owning less than 50% of our voting
 securities, automatically convert into shares of our common stock
 at the initial public offering price. The $5.0 million note plus
 accrued interest converted into 1,447,037 shares of our common
 stock upon the closing of our initial public offering in October
 2012 at a conversion price of $4.00 per share.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>2012 Amendment of the 2010 GSK Note</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In July 2012, we amended and restated our 2010 GSK Note. The
 amended and restated 2010 GSK Note provided for a rollover into a
 new promissory note, effective as of the closing date of a
 qualifying initial public offering (the &#x201C;Post-IPO GSK
 Note&#x201D;). The Post-IPO GSK Note would be equivalent to the
 aggregate amount of principal and accrued but unpaid interest as of
 the initial public offering date. The 2010 GSK Note would then be
 simultaneously cancelled and obligations thereto would be
 terminated.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In October 2012, in conjunction with our initial public offering,
 the Post-IPO GSK Note was established in the principal amount of
 $5.4 million, which was equivalent to the original principal amount
 of $5.0 million plus accrued but unpaid interest of approximately
 $0.4 million. The Post-IPO GSK Note has a maturity date of three
 years from the anniversary date of the agreement, or October 2015.
 At GSK&#x2019;s option, the Post-IPO GSK Note shall be convertible
 into shares of common stock of Regulus at any time prior to the
 maturity date with a conversion equal to the quotient of all
 outstanding principal and interest divided by the initial public
 offering price of $4.00 per share. Concurrently with our initial
 public offering, we accounted cancellation of the 2010 GSK Note as
 a debt extinguishment and recorded a loss on the extinguishment of
 debt of $1.7 million and elected the fair value option for the
 Post-IPO GSK Note. As of December&#xA0;31, 2013, the fair value of
 the Post-IPO GSK Note was $11.3 million, and is classified as
 &#x201C;Convertible notes payable, at fair value&#x201D; on the
 balance sheet (see&#xA0;Note 4).</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <i>Note payable to Biogen Idec</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In August 2012, we entered into a note purchase agreement with
 Biogen Idec, pursuant to which we issued Biogen Idec a convertible
 promissory note in the principal amount of $5.0 million. The $5.0
 million note plus accrued interest converted into 1,256,232 shares
 of our common stock upon the closing of our initial public offering
 in October 2012 at a conversion price of $4.00 per share.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) (Sanofi, USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>Development Commercialization And License Agreement</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014

</div>
          <div>Subsequent Event

</div>
          <div>Private Placement</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014

</div>
          <div>Subsequent Event

</div>
          <div>Development Commercialization And License Agreement</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerAdvancesCurrent', window );">Upfront payment creditable against future accounts receivables</a></td>
        <td class="nump">$ 1.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.25<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Initial upfront option payment</a></td>
        <td class="nump">2.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.5<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale and issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,303,780<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.67<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate purchase price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current portion of prepayments received from customers for goods or services to be provided in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CustomerAdvancesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockConsiderationReceivedPerTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENNAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data (Detail) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="16">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_SelectedQuarterlyFinancialDataLineItems', window );"><strong>Selected Quarterly Financial Data [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump">$ 5,454<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 6,118<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 4,759<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 3,238<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 3,238<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 2,809<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 3,309<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 3,344<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 19,569<span></span></td>
        <td class="nump">$ 12,700<span></span></td>
        <td class="nump">$ 13,789<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
        <td class="nump">10,116<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">9,023<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">9,445<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">8,788<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">7,541<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">6,341<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,867<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,525<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">37,371<span></span></td>
        <td class="nump">25,274<span></span></td>
        <td class="nump">20,926<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,927)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (2,164)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (7,348)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (7,229)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (6,876)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (5,685)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (2,599)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (2,248)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (18,668)<span></span></td>
        <td class="num">$ (17,408)<span></span></td>
        <td class="num">$ (7,602)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
        <td class="num">$ (0.05)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">$ (0.05)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">$ (0.20)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">$ (0.20)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (0.22)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">$ (15.98)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">$ (10.78)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">$ (13.06)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">$ (0.49)<span></span></td>
        <td class="num">$ (2.12)<span></span></td>
        <td class="num">$ (85.82)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
        <td class="num">$ (0.11)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
        <td class="num">$ (0.07)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
        <td class="num">$ (0.20)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
        <td class="num">$ (0.20)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr>
        <td colspan="20"></td>
      </tr>
      <tr>
        <td colspan="20">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Net loss per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly per-share calculations will not necessarily equal the annual per share calculation.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">Applicable accounting guidance provides that a contract (such as the 2010 GSK Note) that is reported as an asset or liability for accounting purposes may require an adjustment to the numerator of the diluted earnings per share calculation for any changes in income or loss that would result if the contract had been reported as an equity instrument during the period. For these periods, adjustments were made to the numerator of the diluted earnings per share calculation to adjust net loss to remove the gain from the change in value of the convertible note payable. Adjustments to the denominator were made to add the number of shares to be issued upon conversion of the convertible note payable.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_SelectedQuarterlyFinancialDataLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_SelectedQuarterlyFinancialDataLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Selected Quarterly Financial Data</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Summarized quarterly data for 2013 and 2012 are as follows (in
 thousands, except per share data):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>For the quarters ending</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>March&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>June&#xA0;30</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>September&#xA0;30</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>December&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2013:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,759</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,118</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,454</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,788</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,445</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,023</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,116</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,229</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,348</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,164</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,927</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic net loss per share<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(1)</sup></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.05</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.05</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted net loss per share<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(1)(2)</sup></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.07</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.11</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2012:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,809</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,525</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,867</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,341</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,541</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,248</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,599</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,685</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,876</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic and diluted net loss per share<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(1)</sup></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13.06</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10.78</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(15.98</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.22</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(1)</td>
 <td valign="top" align="left">Net loss per share is computed
 independently for each of the quarters presented. Therefore, the
 sum of the quarterly per-share calculations will not necessarily
 equal the annual per share calculation.</td>
 </tr>
 </table>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(2)</td>
 <td valign="top" align="left">Applicable accounting guidance
 provides that a contract (such as the 2010 GSK Note) that is
 reported as an asset or liability for accounting purposes may
 require an adjustment to the numerator of the diluted earnings per
 share calculation for any changes in income or loss that would
 result if the contract had been reported as an equity instrument
 during the period. For these periods, adjustments were made to the
 numerator of the diluted earnings per share calculation to adjust
 net loss to remove the gain from the change in value of the
 convertible note payable. Adjustments to the denominator were made
 to add the number of shares to be issued upon conversion of the
 convertible note payable.</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25249566&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERQCK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 07, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Vote</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split of common stock</a></td>
        <td class="nump">0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares, issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 45,800,000<span></span></td>
        <td class="nump">$ 70,000,000<span></span></td>
        <td class="nump">$ 45,980,000<span></span></td>
        <td class="nump">$ 65,788,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Outstanding principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41,787,326<span></span></td>
        <td class="nump">35,831,808<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_CommonStockVotesPerShare', window );">Number of votes of each share of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.14<span></span></td>
        <td class="nump">$ 2.97<span></span></td>
        <td class="nump">$ 1.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">The total intrinsic value of stock options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,700,000<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions', window );">Cash received from exercise of common stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost related to non-vested awards not yet recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period of compensation cost related to non-vested awards not yet recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 3 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">GSK | Convertible Notes</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Outstanding principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest on convertible notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Biogen Idec | Convertible Notes</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Outstanding principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial Public Offering</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares, issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial Public Offering | Convertible Notes Payable</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,703,269<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial Public Offering | Convertible Preferred Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,699,999<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Astra Zeneca</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares, issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Underwriter</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares, issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,480,982<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2012 Plan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock shares reserved for future issuance and authorized for purchase</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">710,534<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2012 Purchase Plan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock shares reserved for future issuance and authorized for purchase</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">460,283<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of participants eligible compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock shares issued under purchase plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">48,035<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2012 Purchase Plan | At inception of the enrollment period</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair market value of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2012 Purchase Plan | At applicable purchase date</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair market value of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_CommonStockVotesPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock, Votes per share</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_CommonStockVotesPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of interest payable on debt, including, but not limited to, trade payables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase price of common stock expressed as a percentage of its fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Quarterly Financial Data<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>14. Selected Quarterly Financial Data (Unaudited)</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The following financial information reflects all normal recurring
 adjustments, which are, in the opinion of management, necessary for
 a fair statement of the results of the interim periods. Summarized
 quarterly data for 2013 and 2012 are as follows (in thousands,
 except per share data):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>For the quarters ending</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>March&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><b>June&#xA0;30</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>September&#xA0;30</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <b>December&#xA0;31</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2013:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,759</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,118</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,454</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,788</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,445</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,023</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,116</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,229</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,348</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,164</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,927</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic net loss per share<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(1)</sup></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.05</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.05</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Diluted net loss per share<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(1)(2)</sup></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.20</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.07</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.11</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr>
 <td height="8"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 <td height="8" colspan="4"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <b>2012:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Revenues</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,309</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,809</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,525</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,867</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,341</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,541</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,248</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,599</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,685</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,876</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Basic and diluted net loss per share<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">(1)</sup></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13.06</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(10.78</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(15.98</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.22</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(1)</td>
 <td valign="top" align="left">Net loss per share is computed
 independently for each of the quarters presented. Therefore, the
 sum of the quarterly per-share calculations will not necessarily
 equal the annual per share calculation.</td>
 </tr>
 </table>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left">(2)</td>
 <td valign="top" align="left">Applicable accounting guidance
 provides that a contract (such as the 2010 GSK Note) that is
 reported as an asset or liability for accounting purposes may
 require an adjustment to the numerator of the diluted earnings per
 share calculation for any changes in income or loss that would
 result if the contract had been reported as an equity instrument
 during the period. For these periods, adjustments were made to the
 numerator of the diluted earnings per share calculation to adjust
 net loss to remove the gain from the change in value of the
 convertible note payable. Adjustments to the denominator were made
 to add the number of shares to be issued upon conversion of the
 convertible note payable.</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25249566&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The following table presents our fair value hierarchy for assets
 and liabilities measured at fair value on a recurring basis at
 December&#xA0;31, 2013 and 2012 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair value as of December&#xA0;31,
 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Corporate debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,416</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71,416</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Debt securities of U.S. government-sponsored agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,001</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,001</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,071</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,071</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">113,368</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,198</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Convertible notes payable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair value as of December&#xA0;31,
 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,363</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,363</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#xA0;&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Corporate debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,911</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39,363</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,548</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom" colspan="5"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom" colspan="5"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Convertible notes payable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,134</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,134</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value on Quarterly Basis</a></td>
        <td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents a reconciliation of the liabilities
 measured at fair value on a quarterly basis using significant
 unobservable inputs (Level 3) from December&#xA0;31, 2012 to
 December&#xA0;31, 2013 (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="21%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Fair&#xA0;Value&#xA0;Measurements<br />
 Using Significant<br />
 Unobservable Inputs<br />
 (Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,134</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Change in estimated fair value of convertible notes payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Balance at December&#xA0;31, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,279</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6DAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Future Annual Minimum Lease Payments for Operating Leases (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_LeasesFutureMinimumPaymentsLineItems', window );"><strong>Leases Future Minimum Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">$ 1,066<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">1,138<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">1,211<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">624<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due, Total</a></td>
        <td class="nump">$ 4,039<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_LeasesFutureMinimumPaymentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_LeasesFutureMinimumPaymentsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
        <td class="num">$ (1,700,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (1,738,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes payable, carrying value</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Loss from valuation of convertible notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (1,145,000)<span></span></td>
        <td class="num">$ (2,969,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate', window );">Fair value assumption, volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">66.00%<span></span></td>
        <td class="nump">75.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumption, risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.325%<span></span></td>
        <td class="nump">0.421%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsEntityCreditRisk', window );">Fair value assumption, credit spread</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7.40%<span></span></td>
        <td class="nump">9.50%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentCarryingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average expected volatility of stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsEntityCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk associated with risk of default, credit spread risk and downgrade risk, expressed as a percentage, used as an input to measure fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bbb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueInputsEntityCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7,9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQVFK">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Series A Convertible Preferred Stock</div>
        </th>
        <th class="th">
          <div>Series B Preferred Stock</div>
        </th>
        <th class="th">
          <div>Initial Public Offering</div>
        </th>
        <th class="th">
          <div>Private Placement</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Initial Public Offering</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Private Placement</div>
        </th>
        <th class="th">
          <div>Additional paid-in capital</div>
        </th>
        <th class="th">
          <div>Additional paid-in capital

</div>
          <div>Initial Public Offering</div>
        </th>
        <th class="th">
          <div>Additional paid-in capital

</div>
          <div>Private Placement</div>
        </th>
        <th class="th">
          <div>Accumulated other comprehensive income (loss)</div>
        </th>
        <th class="th">
          <div>Accumulated deficit</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 32,691<span></span></td>
        <td class="nump">$ 10,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2010</a></td>
        <td class="num">(34,695)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">701<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13<span></span></td>
        <td class="num">(35,409)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,900,000<span></span></td>
        <td class="nump">2,499,999<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">153,184<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
        <td class="nump">58<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
        <td class="nump">825<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">825<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
        <td class="num">(80)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(80)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(7,602)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(7,602)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2011</a></td>
        <td class="num">(41,494)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,584<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(67)<span></span></td>
        <td class="num">(43,011)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">153,184<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">32,691<span></span></td>
        <td class="nump">10,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,900,000<span></span></td>
        <td class="nump">2,499,999<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Effect of 2-for-1 split on shares of preferred stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(12,450,000)<span></span></td>
        <td class="num">(1,250,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">294,374<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
        <td class="nump">138<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">138<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
        <td class="nump">1,550<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,550<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of shares of preferred stock to common stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(12,450,000)<span></span></td>
        <td class="num">(1,249,999)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,699,999<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of shares of preferred stock to common stock</a></td>
        <td class="nump">42,691<span></span></td>
        <td class="num">(32,691)<span></span></td>
        <td class="num">(10,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42,677<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,730,982<span></span></td>
        <td class="nump">6,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,038<span></span></td>
        <td class="nump">20,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13<span></span></td>
        <td class="nump">6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,025<span></span></td>
        <td class="nump">20,744<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(17,408)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(17,408)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Conversion of notes payable to common stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,703,269<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Conversion of notes payable to common stock</a></td>
        <td class="nump">10,813<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,810<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2012</a></td>
        <td class="nump">62,093<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">122,528<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(52)<span></span></td>
        <td class="num">(60,419)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">35,831,808<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
        <td class="nump">732,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">732,483<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
        <td class="nump">594<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">593<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
        <td class="nump">3,422<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,422<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">48,035<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
        <td class="nump">201<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">201<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
        <td class="nump">45,779<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,774<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
        <td class="nump">36<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(18,668)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(18,668)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2013</a></td>
        <td class="nump">$ 93,457<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 42<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 172,518<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (16)<span></span></td>
        <td class="num">$ (79,087)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41,787,326<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of a stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockSplits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityCarryingAmountAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.27(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>3. Investments</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We invest our excess cash in commercial paper and debt instruments
 of financial institutions, corporations and U.S.
 government-sponsored agencies. As of December&#xA0;31, 2013, our
 short-term investments had a weighted average maturity of less than
 two years.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following tables summarize our short-term investments (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Maturity<br />
 (in&#xA0;years)</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Amortized<br />
 cost</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>Unrealized</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Estimated<br />
 fair&#xA0;value</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman">
 <b>As of December&#xA0;31, 2013</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Losses</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2&#xA0;or&#xA0;less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,402</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">39</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(25</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71,416</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,710</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,710</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,069</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,071</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Debt securities of U.S. government-sponsored agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,001</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,181</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">42</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(25</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">96,198</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="65%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Maturity<br />
 (in&#xA0;years)</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Amortized<br />
 cost</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>Unrealized</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Estimated<br />
 fair&#xA0;value</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style="border-bottom:1.00pt solid #000000; width:84.20pt; font-size:8pt; font-family:Times New Roman">
 <b>As of December&#xA0;31, 2012</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Gains</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Losses</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Corporate debt securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">44,898</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(49</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">44,856</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Certificates of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1&#xA0;or&#xA0;less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,200</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,200</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2 or less</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,492</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,492</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,590</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(49</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">57,548</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for  investments in certain debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Debt Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Equity Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_IncomeTaxRateReconciliationLineItems', window );"><strong>Income Tax Rate Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at federal statutory tax rate</a></td>
        <td class="num">$ (6,355)<span></span></td>
        <td class="num">$ (5,923)<span></span></td>
        <td class="num">$ (2,522)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
        <td class="num">(1,090)<span></span></td>
        <td class="num">(1,016)<span></span></td>
        <td class="num">(432)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
        <td class="num">(2,406)<span></span></td>
        <td class="num">(423)<span></span></td>
        <td class="num">(683)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Government grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(7)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes', window );">Change in fair value of convertible note payable</a></td>
        <td class="nump">456<span></span></td>
        <td class="nump">1,183<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">692<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
        <td class="nump">9,026<span></span></td>
        <td class="nump">5,386<span></span></td>
        <td class="nump">3,058<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior year true-up</a></td>
        <td class="num">(235)<span></span></td>
        <td class="num">(368)<span></span></td>
        <td class="nump">333<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
        <td class="nump">667<span></span></td>
        <td class="nump">463<span></span></td>
        <td class="nump">248<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
        <td class="num">(86)<span></span></td>
        <td class="num">(4)<span></span></td>
        <td class="nump">211<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
        <td class="num">$ (23)<span></span></td>
        <td class="num">$ (10)<span></span></td>
        <td class="nump">$ 206<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_IncomeTaxRateReconciliationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_IncomeTaxRateReconciliationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income Tax Reconciliation Change in Fair Value of Convertible Notes</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_IncomeTaxReconciliationChangeInFairValueOfConvertibleNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income Tax Reconciliation Gain Loss on Extinguishment of Debt</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_IncomeTaxReconciliationGainLossOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationOtherAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationOtherReconcilingItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationTaxCredits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Strategic Alliances and Collaborations (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_RevenueFromStrategicAlliancesTableTextBlock', window );">Revenue from Strategic Alliances</a></td>
        <td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The following table summarizes the amounts included in our revenues
 which resulted from our strategic alliances and collaboration (in
 thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center" style="border-bottom:1.00pt solid #000000"><b>Year ended
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Sanofi-Aventis</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">15,336</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,030</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,033</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 GSK</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,778</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,996</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,734</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 AstraZeneca</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,859</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">559</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Biogen Idec</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">596</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">115</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:1.00px solid #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19,569</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,700</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="font-size:8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,767</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="border-top:3.00px double #000000">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_RevenueFromStrategicAlliancesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from Strategic Alliances Table</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_RevenueFromStrategicAlliancesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>245</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - The Business, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>The Business, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>Net Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</Role>
      <ShortName>Investments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Strategic Alliances and Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>Strategic Alliances and Collaborations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property and Equipment, net</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Intangible Assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock</Role>
      <ShortName>Intangible Assets, net</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Convertible Notes Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders' Deficit</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDefinedContributionPlansTextBlock</Role>
      <ShortName>Defined Contribution Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related-Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Selected Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock</Role>
      <ShortName>Selected Quarterly Financial Data</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - The Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies</Role>
      <ShortName>The Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables</Role>
      <ShortName>Investments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Strategic Alliances and Collaborations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables</Role>
      <ShortName>Strategic Alliances and Collaborations (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Intangible Assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables</Role>
      <ShortName>Intangible Assets, net (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders' Deficit (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Selected Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables</Role>
      <ShortName>Selected Quarterly Financial Data (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - The Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureTheBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>The Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare</Role>
      <ShortName>Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Summary of Short-Term Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments</Role>
      <ShortName>Summary of Short-Term Investments (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis</Role>
      <ShortName>Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Reconciliation of Liabilities Measured at Fair Value on Quarterly Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfLiabilitiesMeasuredAtFairValueOnQuarterlyBasis</Role>
      <ShortName>Reconciliation of Liabilities Measured at Fair Value on Quarterly Basis (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Revenue from Strategic Alliances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliances</Role>
      <ShortName>Revenue from Strategic Alliances (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Strategic Alliances and Collaborations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation</Role>
      <ShortName>Strategic Alliances and Collaborations - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfPropertyAndEquipment</Role>
      <ShortName>Summary of Property and Equipment (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformation</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Summary of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfIntangibleAssets</Role>
      <ShortName>Summary of Intangible Assets (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Intangible Assets, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformation</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Summary of Future Annual Minimum Lease Payments for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfFutureAnnualMinimumLeasePaymentsForOperatingLeases</Role>
      <ShortName>Summary of Future Annual Minimum Lease Payments for Operating Leases (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Convertible Notes Payable - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation</Role>
      <ShortName>Convertible Notes Payable - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureConvertiblePreferredStockCommonStockAndStockholdersDeficitAdditionalInformation</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance</Role>
      <ShortName>Common Stock Reserved for Future Issuance (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity</Role>
      <ShortName>Stock Option Activity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel</Role>
      <ShortName>Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Stock-Based Compensation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Defined Contribution Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformation</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Components Income Tax (Benefit) Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureComponentsIncomeTaxBenefitExpense</Role>
      <ShortName>Components Income Tax (Benefit) Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvision</Role>
      <ShortName>Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Components of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureComponentsOfDeferredTaxAssetsAndLiabilities</Role>
      <ShortName>Components of Deferred Tax Assets and Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Changes in Amount of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureChangesInAmountOfUnrecognizedTaxBenefits</Role>
      <ShortName>Changes in Amount of Unrecognized Tax Benefits (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>163 - Disclosure - Summary of Operating Expenses From Related Party Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfOperatingExpensesFromRelatedPartyActivities</Role>
      <ShortName>Summary of Operating Expenses From Related Party Activities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>164 - Disclosure - Selected Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialData</Role>
      <ShortName>Selected Quarterly Financial Data (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>165 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_CommonStockValue had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_DeferredTaxAssetsOperatingLossCarryforwards had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">'Monetary' elements on report '142 - Disclosure - Fair Value Measurements - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '144 - Disclosure - Strategic Alliances and Collaborations - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '149 - Disclosure - Commitments and Contingencies - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '151 - Disclosure - Convertible Notes Payable - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '152 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders' Deficit - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '161 - Disclosure - Income Taxes - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Statements of Operations and Comprehensive Loss</Log>
    <Log type="Info">	Process Flow-Through: Removing column '1 Months Ended
Jul. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 108 - Statement - Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>rgls-20131231.xml</File>
    <File>rgls-20131231.xsd</File>
    <File>rgls-20131231_cal.xml</File>
    <File>rgls-20131231_def.xml</File>
    <File>rgls-20131231_lab.xml</File>
    <File>rgls-20131231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3QAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Short-Term Investments (Detail) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ShortTermInvestmentsAmortizedCost', window );">Amortized cost</a></td>
        <td class="nump">$ 96,181<span></span></td>
        <td class="nump">$ 57,590<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainOnSecurities', window );">Unrealized Gains</a></td>
        <td class="nump">42<span></span></td>
        <td class="nump">7<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedLossOnSecurities', window );">Unrealized Losses</a></td>
        <td class="num">(25)<span></span></td>
        <td class="num">(49)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Estimated fair value</a></td>
        <td class="nump">96,198<span></span></td>
        <td class="nump">57,548<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Corporate Debt Securities</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_MaturityPeriodOfShortTermInvestments', window );">Maturity</a></td>
        <td class="text">2 or less<span></span></td>
        <td class="text">2 or less<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ShortTermInvestmentsAmortizedCost', window );">Amortized cost</a></td>
        <td class="nump">71,402<span></span></td>
        <td class="nump">44,898<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainOnSecurities', window );">Unrealized Gains</a></td>
        <td class="nump">39<span></span></td>
        <td class="nump">7<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedLossOnSecurities', window );">Unrealized Losses</a></td>
        <td class="num">(25)<span></span></td>
        <td class="num">(49)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Estimated fair value</a></td>
        <td class="nump">71,416<span></span></td>
        <td class="nump">44,856<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Certificates of Deposit</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_MaturityPeriodOfShortTermInvestments', window );">Maturity</a></td>
        <td class="text">2 or less<span></span></td>
        <td class="text">1 or less<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ShortTermInvestmentsAmortizedCost', window );">Amortized cost</a></td>
        <td class="nump">11,710<span></span></td>
        <td class="nump">6,200<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Estimated fair value</a></td>
        <td class="nump">11,710<span></span></td>
        <td class="nump">6,200<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Commercial Paper</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_MaturityPeriodOfShortTermInvestments', window );">Maturity</a></td>
        <td class="text">1 or less<span></span></td>
        <td class="text">2 or less<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ShortTermInvestmentsAmortizedCost', window );">Amortized cost</a></td>
        <td class="nump">6,069<span></span></td>
        <td class="nump">6,492<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainOnSecurities', window );">Unrealized Gains</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Estimated fair value</a></td>
        <td class="nump">6,071<span></span></td>
        <td class="nump">6,492<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Debt securities of U.S. government-sponsored agencies</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_MaturityPeriodOfShortTermInvestments', window );">Maturity</a></td>
        <td class="text">1 or less<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rgls_ShortTermInvestmentsAmortizedCost', window );">Amortized cost</a></td>
        <td class="nump">7,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainOnSecurities', window );">Unrealized Gains</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Estimated fair value</a></td>
        <td class="nump">$ 7,001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_MaturityPeriodOfShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maturity Period Of Short Term Investments</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_MaturityPeriodOfShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:durationStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rgls_ShortTermInvestmentsAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>rgls_ShortTermInvestmentsAmortizedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>rgls_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph g<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainOnSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease), resulting in a gain, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedGainOnSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedLossOnSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrealizedLossOnSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
        <td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>13. Related-Party Transactions</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 We have entered into several agreements with related parties in the
 ordinary course of business to license intellectual property and to
 procure administrative and research and development support
 services.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 In August 2013, we entered into an amendment to the Amended and
 Restated License and Collaboration Agreement with Isis and Alnylam
 dated January&#xA0;1, 2009, as amended in June 2010 and October
 2011 (as&#xA0;amended, the &#x201C;Amendment&#x201D;). Under the
 terms of the Amendment, the parties agreed to our use of certain
 Alnylam-controlled intellectual property concerning the use and
 manufacture of GalNAc conjugates (&#x201C;GalNAc&#xA0;Process
 Technology&#x201D;) on a non-exclusive basis. We will generally not
 be permitted to sublicense or otherwise transfer the GalNAc Process
 Technology and other Alnylam licensed intellectual property rights
 relating to GalNAc conjugate technology without the prior written
 consent of Alnylam, subject to certain limited exceptions for
 sublicenses to third party collaboration partners. There were no
 financial terms related to this Amendment.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 The following table summarizes the amounts included in our
 operating expenses as a result of costs incurred from services
 provided under the Services Agreement (in thousands):</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" nowrap="nowrap" align="center" style="border-bottom:1.00pt solid #000000">
 <b>Years&#xA0;ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2011</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Services performed or out-of-pocket expenses paid to Alnylam</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">550</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
